<SEC-DOCUMENT>0000875045-22-000031.txt : 20221025
<SEC-HEADER>0000875045-22-000031.hdr.sgml : 20221025
<ACCEPTANCE-DATETIME>20221025161118
ACCESSION NUMBER:		0000875045-22-000031
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		123
CONFORMED PERIOD OF REPORT:	20220930
FILED AS OF DATE:		20221025
DATE AS OF CHANGE:		20221025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		221329622

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20220930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:6f409836-83df-4817-b8b9-7a5ff0648b96,g:f22c5c21-a910-4760-9b39-9695772d8988,d:f1c5ef17491f4c2cbb98c8f67b203f36--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:biib="http://www.biogenidec.com/20220930" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:currency="http://xbrl.sec.gov/currency/2021" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20220930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY18xLTEtMS0xLTEzNDY5Mw_f4a006ba-2eff-4377-bab3-7718401026bf">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY18yLTEtMS0xLTEzNDY5Mw_6069d453-f9ab-4996-aa33-bfcfb0b7eb91">12/31</ix:nonNumeric><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY18zLTEtMS0xLTEzNDY5Mw_a73b190d-cbb4-4b46-8e48-38f517be2e43">2022</ix:nonNumeric><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY180LTEtMS0xLTEzNDY5Mw_0b9f2483-031b-4320-9553-b589943ad514">Q3</ix:nonNumeric><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY181LTEtMS0xLTEzNDY5Mw_2cb0a1a1-6680-4077-87b9-667e4a0ebf78">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="i8b9473308ccd44839cb2a3b16f056f1e_I20221024" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY182LTItMS0xLTEzNDY5Mw_90f9a363-3604-4181-8b62-0b2cb3b32abd">144,001,404</ix:nonFraction><ix:nonNumeric contextRef="i5fe5cd2bc5bd45a7a679664aecb0fb65_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81OC9mcmFnOjgxZTA4OGY5MTZmNjRiNTNhOTg3ODBiMDdiYjcyMWJmL3RhYmxlOjM2MWFkNGRmNjQ0MTQ1NDJiNWRhYTdhZjBiNGQyNjJhL3RhYmxlcmFuZ2U6MzYxYWQ0ZGY2NDQxNDU0MmI1ZGFhN2FmMGI0ZDI2MmFfMS0xLTEtMS0xMzQ2OTM_9b000636-ef02-4f72-bf1a-3ccdaec35b98">4</ix:nonNumeric><ix:nonNumeric contextRef="i4d5087bb8d414f3a9c0ece6a6b58e9c7_D20220101-20220930" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81OC9mcmFnOjgxZTA4OGY5MTZmNjRiNTNhOTg3ODBiMDdiYjcyMWJmL3RhYmxlOjM2MWFkNGRmNjQ0MTQ1NDJiNWRhYTdhZjBiNGQyNjJhL3RhYmxlcmFuZ2U6MzYxYWQ0ZGY2NDQxNDU0MmI1ZGFhN2FmMGI0ZDI2MmFfMi0xLTEtMS0xMzQ2OTM_3cfb99bc-9ad4-4423-bdf5-83d2051a6b07">28</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="i5b184b88aa274ec19c0f59ff28afb452_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfNS0xLTEtMS0xMzQ2OTM_ce9bc511-0464-4b71-a185-e17efa3c2ab2">3.625</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfNi0xLTEtMS0xMzQ2OTM_bc4f4706-227a-4633-9197-789ec8cf7a7e">4.050</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i286147027fd848569c362d90f20b6f37_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfNy0xLTEtMS0xMzQ2OTM_0ea18eb9-905f-4d47-9587-c1ddb62424f3">5.200</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i314cc95227f74e429b94104786b26357_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfOC0xLTEtMS0xMzQ2OTM_1b6235de-5180-4ef3-b2b4-ebe76a3ad1b2">2.250</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id8657f446214427d9d8b9bd45a3d47e5_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfOS0xLTEtMS0xMzQ2OTM_160112df-ffb6-4fd9-bc12-8e76b9edc175">3.150</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i8278526fab9042518d7f4accd2d4a217_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfMTAtMS0xLTEtMTM0Njkz_78f9bc5c-b1cb-4569-8c1e-56e67755044f">3.250</ix:nonFraction><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="0" name="us-gaap:AssetImpairmentCharges" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RleHRyZWdpb246OTNmMDExMTkxYTMzNDBkMmFlMjE3NDYzZTRiNWEzNTBfOQ_6b83c6c3-2715-455a-8840-ab5fe53fd934">0</ix:nonFraction><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDYvZnJhZzpmYWYyYzEzODQyNjU0ZWE0OTA3OGQ2MzExOThhOTA5Ny90ZXh0cmVnaW9uOmZhZjJjMTM4NDI2NTRlYTQ5MDc4ZDYzMTE5OGE5MDk3XzEy_7b0e9c35-c94f-42d1-bff6-e329c3eb5f2b" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20220930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b9473308ccd44839cb2a3b16f056f1e_I20221024"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-10-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="if8b5bc83e8644cd983699f6fb8858208_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="if551793810f14521aa422baeecc3bfbf_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64c2a0bb31734409bb0e29d39fc13bae_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2765e6631dd6439f847c09bcca089302_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id677ff3bfec54adbaa112244fd4799d4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31f777fcba294e1981f4bbec61fe6842_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bc6e1753ff4db990730bfcea938673_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07dd344004654602b840c7084123794f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599788f95f5d42d1afd8d372967a5f5d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c6c0f5fe10b475babd385cc9a5f1933_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01501338195d4d64b3297f4c712b4a35_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76bd2bb0d53b471685923452d6735342_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e041e2494c45019e324230082e286e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="id7caa4287cd44462b9d9cd33c1545d15_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cac6a36cb7544188ce0dee2256caca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia953e5a0fc224c8c9f234d2c963d4105_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i957729f8711844ff89317163bd3b28ee_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1aee04605d242bfb83b7fe9c6cb1edc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i835d8ccc4e79473b96d3739d3fc0f451_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id36ae3eeb09d4b00b8023ee15c29a104_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i385b6988b4664d52a88f8aaf055e4153_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df7f5528d01483d85bf88ee051bf26a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie99add0e88f54844bcc4c75b8cdd5670_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibedabc034ea240c0b3ac08428570bb02_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a2bd09b86954ad5a4bee8091dd95fdf_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd70f96bb3774f148eea2bb8f9432dc4_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i239d15fce1e540cea5ec4ef251ea8908_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92b65c6517c4a3480678a0a31182921_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66f984c3b15d4a31acd93e52732606cb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic367eb9333f6492b83e15ec443ce582f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i702681f6e9854a2c9237a3f37fa30d3a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i759633f59042448b81434c16a76b3557_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47eb6434b4184bf1862e2d8683e198b4_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfdf3c77bb8d4707b6431886367684a2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52b178fd120d412a861501afee397e6e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47664e2a665d414a81f45b227301ee8b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaef22786954a47d5be08054078b6dbc6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5068c3b18e94e8eaaf2091ea3cf9695_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e0fa57a6c3f4fa4942ba9c62ac16a53_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b3d30bc29ae41cb9335a4b23f385945_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3caac96ac07546cc86bfb686908d7b3e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a2cbbf2a9947cc889f57763f6fb24a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ac4673c093c48e281f08d7e26c19005_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id54e452525014575861abb8575bfa40f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6150f5ddab6c45c9aa1fbef55937177e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i06a5ef7f9cda42e78d300b36e9338315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7cee2e97b0274d3aa6084ff72dceb5e3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibfaaee5621ff405286fd6056576cd59b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if66f99b3393445feb052472c42d6ea59_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e74df0a4fa34fa7b4d9f15ccfa2ccce_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3990a5fbd8c6491e91e119ed2fdea887_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i823c7f9f43d342ba884251bf9f5bd146_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic891f4015650489eb42c53e2bfc38c39_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e12504ff04743d888a4e88d3bff71b4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia0e15bd993a74d7398c821d849b6ea3c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7258ddc589f4c9088e286caf7f6e0b7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4495699cfde945d2a01834b568e58db0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i016bab72022342ff94ff7761ad5e759f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40f04ec35e4e4acb994f1e07cc20f981_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6ecf9467f994f5599b5246c048da7f0_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if30d21aaea274bffaf4cb30ef1f8e3dc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fb9684f2f3649a1bffccb6af71ea857_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i49fb8433ee7144e590c0de93a2924ac6_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8eac1696a0f401e8764ac4f1f27de37_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4194d914ec04ff093919ddd1c085893_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55ef7924a674515889fe70f6b17eb7f_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71feb4d0055c4b68bbe964b0257e980a_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5de6cf32968c4297a40eb09bdeb942bc_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21588e5af69246eb8bf060b182d4cef9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e1be32983094b30a756db2fdf7ba492_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830fd3fe92594ddca8ffd711b4e954ed_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i142a8abed9f24909ac2458987495c92a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied6c3cb168af4d3f93e74f6073e0a218_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d3c54dd7e9843cea195c454def9d2ee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5351af1a8e574e448a3647a4f7afd7b0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i940fb720af7649c3b174e6131bd6809b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacd07c7062014cc6810ba0fe03987501_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3a55df4cbc94d0f84173632a99327a0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i654c8bf1e47f4749b94d94eb9db91cad_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i986fcf8b728f45a5aade17658c08c927_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7fcd64658864191b6d0041174b23749_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7543833405d140a9b03a3c2c4959f28c_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i97905b3b54ce40cb912f87e63e0db92d_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2e04c673b4ba4bfeb809934ced292e5b_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id028a6bff3b24d2f9b0854cfb01e2f33_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddcd0ac5de004c8584ccf204981e3c5a_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if91d142efb024f1784dcfc0a7ba633de_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1ae20d5729dc44e2bbeb4f64c73911df_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85003cc1f8c04f36b4ffbbf6882c9e1e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e6a8dcb7c44e968654b2542e3eba4c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ida229f85edf14616bba475cf65eab0e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide8a35ebfa6c49c4940e18829274b634_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i672dd8e6f6974a0681e2532e151fe07d_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7764d2904f084d0487b1c7d0a1c60a98_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d65d2e85cb14209a4f5a5f72eaf1a06_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id80ceaef197d43efbe8a7cb665f36bd3_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a8c604e337a41529c5ebe37e6e83167_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7dcf494036c4e47bb9cb906a08568a5_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66de57d0942e46cfb25b1d0f1fd008d1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idbd356e38fd146938c9d48f464ee5866_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07d6d89e16864773a22d6d824c32ffd4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac062867190e40d291330b2582dde77d_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i316ee61fce71448090e9e99d3e03605f_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i607186b7dfc843688ebf32e0578fc19b_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8da0e6904f247e0a072f97c4201c43b_I20220131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i30e4e1687d1446f2a418d8e2edce385e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="krw"><xbrli:measure>iso4217:KRW</xbrli:measure></xbrli:unit><xbrli:context id="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f7ed163c5b4dc1a6bbd9abf449fa0f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f5bb12cf4d14733835facacabb3cc9b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iba57778587524c7389b5d85413395030_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50d36a66d9ab43cdb58d18874e1a3785_D20230101-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ca34953d844cb0860dc038de00e235_D20230101-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1f37877cc204468be6364c936821118_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d680499749847fbb5726594897a6967_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea6f6f793edc47d08a4cb4fbe2bea78d_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f41754e9d7e480eb6a52dc448c1e2bc_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe53d000d3d24ab085f9e7a60f3038fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i50e9ef276762476587698a382951d243_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75d90b3006f344218e928d1ad4dfdd95_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieae68b14dd844654b97d8e0821a7d63d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia678bb0bdba34f6d8468b6ea458c7c67_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idee5f0f1a0fc412eac579e1d0b56f5c0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i524a5a89350540a3bc0f4b10a71bb6aa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94cd8b6ab6a24b2d8c28a1fef87c6153_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia14b4c4bce6a4909a76b690dbb1dda86_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i052a675de8aa4e5d9832465ff8570284_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibada012125344986aaa29e2b44e3995b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc52be6137340a5b547b2482e77071b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30f15676d39144d6be62e0983a2c677d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d433d159ae4a1ab0cd0e666f0067b5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86dce0a14ccd4ac7b68ee2512c78b229_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5d02c3121d046fa80f33ce0ea159f1b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id90d2fa8645d41c59b47948a99c4c9a8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb6cdfb945042ec929ed76602fc0d41_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic82f6ca075b24e908f242a5f756da00b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0112f1abc12545e994f30a836d2cb12f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a4811b664994d1a81bade00a2863057_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2775701ccced4d349950476cf4ac935f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9e8c8756b2146eca09944df5c248397_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5abd26923c541018c31b313875f2f0a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54d1f43c44b042958f27d4875e2c518e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c9d7081eeb3425aaab5ae1f08229ad0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e3fe4bcdeb74d82a40d4194dfecf8e0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a55754206442b9ad7d2a15bb0c2ed8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1539f85dca834b21b083a5841069d1f9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i413272e3f9254d67a44927e69cdc2477_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1260db1e62944da8c762971630a803f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a6c9354a1594ed984122907bfaf64d9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd1a7dde2606420ab2beaa988524cc5e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67dbc5422bc347699fed7d1ba9192ef3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib54b6aedfcba481d9b05a81e2c49254c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a3f69c1b08b48a7ad41ca04403e0c5c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c8b237efb1e4c6bb345fa501d512b04_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35666f9afdf94c86b0dadb5d20099aa4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2eff75aba234462e895ad96c0ec0c13c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieca6a0988c1143f78d17d64f36bd59d0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f4ebfef6a604efa9a0c65992472c0d7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4b9ad0869ff4c3fb817b4710e10a630_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i15a90a6d21554cd3b7fbe3e029fbaac9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9fe0b10bf3a4a2fbaac7c18a2d43b48_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe746589d79e42be854dd4cb784c05e9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id00b404c1c0143a69096eacb3dc9e10c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifebf0d8ca7134f8a863034f1a0b81573_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a04530193ba4b518e49e6435d62ee0e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied70d0ff45d4458aa25726112c8513dd_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41cbc8191ce24bd3873905bcb5a73840_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d3ea9011ece4aec9bbf5dd07e371b5f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e67a47e02e64b21801d078a6891829d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cb20e8bd6614d08aae2157a736ee0bc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id05eb883732b498a834f089684813866_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iabd90fb1abfc4a8fb6a417188bd3b333_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d6326e426354c5cab099ca0de375d35_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8812745790a446cbad04fb159242ad1f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e033d68ed2c41b3ad7632aa89aec9a8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2af6c017ace04a208fed42ce9a986242_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a5b99981159460c97cd042e3a67f70d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i25429e48c15549dd9fd5d52789bdf66e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i152fc65157fa4362b32c7674d4f3af52_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0c5c8cd61c24cfabd4664c10261b0e5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i757c59aeb42e4b328db5739cfaf1d0cc_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib31ea0e171e14113bef79d2f5da80f7b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9438c78c688a4bfeadfaaa6784905992_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12c8a988b4e0420e89ff703030bbadfa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d0a194344841dba3b5f8ff6d1c4f81_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1908a95691ba4679b174a8dfdd916a93_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibcc0686d78a742bd8fdd73944fe180e7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ad6d7a35eac421397e8362b9656f4b8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b05c62014347fab4835789f107cfe0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b466566e8754a25a7bfeab1a81a2cea_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idec7cc8cd0034b3eb2562e8018818d3c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e4f384abac34bae9d5bf87acf30d4ee_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8c9122746944d3f9095dbb7cc11377a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2516de1ac60a4e90831421c900ff396e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac6ccbe24af4deaa5a62b863311b57c_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib50af91715af4a78bba950701876534e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i657478733d8d43ed87decbb8c4f5d541_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i51f276f171e54d29894f040aa5ab5443_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a905ec064574da2bf8cee1f4d8bd703_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6a59839d59b407ea4068c5b93d2ba34_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0e0989aaba247af8dc5f027f0f887ef_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i613b7926acf54b98ac70428273633e52_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6cfc69fc6c34480b827a3877c93ab58_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6e2e5b23e04f37a8291ce446990fd4_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26ce3d87d7074b3db7e594727ab76ac8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icad85b2a32a540c2be8bee5055609f06_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i308866a912504314ad0566776705f1fa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia643249264394743951818a9aa78ae5d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c11e3688c394fb189088fdb0469db74_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i08acc85b03b14f00a2f9ca0f2979648e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50c2970d6269468d9f534821befd3de2_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30db570b4e794739ac24a66ec8692dae_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia02964d914cc47388a24d99a47433421_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife378d865970465ba0ce74157101a61f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3319dce269e41ad92a3ddcfe5bf5189_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1c72b384af94d18b63dff491dca9a24_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d798d15c7984659815575140f16c70b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb65596c915c406cbc7bf9acd98622e5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dfead640e914b38b2696de5407f84ba_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6470a08268ef4de99f119d927d1a4d2f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b19835c69324505bc3bbe38750f529b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ecbaf37433b4d40b16bc5671b74f060_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f24d1c8c3584b7c8926aeeea29cd96b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6345900a23346efb313425848fb28e9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i093cbce56499494f8d57067e66f44ff9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i652da0112b604ae891ebdd50c297d7b5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f5a9325fee04e2cba98e5d937adfc74_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia413a1e58ac1484aa3e51cdfe63a6c21_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5164cd322f6648be8b5b9b79fc0d4cf2_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic152d3b856314bd5bbd4d922f5b1f015_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29dd87c31a2a4a4eae9d3aae32da4d82_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8300e4d26c6147549e8368f3079a0031_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a97f7fa27df49c584d3adb23745a423_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i502d3aeb3a4d41ef97ee7cc08116a94c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic67b3715c36b42269427fe5c63da86f8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i66c8c948a5be433c868d626d7809cd82_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i755ecabb947b4b71a2c01fa25760d3d7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45d4b0e30bae4689bf949adfac85bab6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i659ebe25d6134f28930cc20ef43b65ef_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a9d2d82af3f46eab21badf9ac3a6981_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27be45bcbe624d5980096e1785112fdc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib82aa5e2bd524a66bc66939217047a6d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac5d67fc3dd24634b8a4e9c26b4458f1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6770d7e189d34ca88257ea5c55b40ebf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i937b847996cd4321b4854f84342ab7a3_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide726508c8b14430a7064d271b9e7f5d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bca8925482a46e2bc9ec6966695df2a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68aced51bea449ccb43e7ba29ae949ae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59833a1a99db458b86c073d840320416_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61ca7ff7f1294b878f3affcec832bf63_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1357d813e6fc4d059c8f9d8460edabad_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86b062cf2b8e4fcba6125d3f43aba52c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f6299f5a6b94d23a99157b0a82cf59d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1053bcff8b284ac390b5229c577c0a2f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bc39363344843769eab66bc91bcd94b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbb1af036ea24e969a66a5344c047fac_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56fe58d06e354206ac06d6c22f264c16_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if01198d0ed2345ce9da3494a19010f80_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17c1f93f7995494ba74ed1cbfe9a5453_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0324cb7d71b14d358a44ddaf249e9c3b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8592dfe9d1b04943b8d47d4fe572c054_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9c613ef03654592a30cd87dad818832_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f69bddf17d545ee8a128bacba69d2ff_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06c6cf6db10348b4bf28c5a5845cf749_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib41052befcfa4e75b65cfb241f1f0da7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7782237c1c694b6a815faeed508e0178_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icab523ef9fd74083a6a33e39224832dd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e3216e6a74f4785916f831d67d9d956_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e3d7bbc24a94e268d3446995f65a4cd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78ef0131528e441a8a6df4550ce7e43c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea2d09427bd04c80941fbfc24a9f7d03_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0b3afb1cd4f478a818eb6239991e0c1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7441a70014540ecb01931d60471c8db_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie32ae0d4377945619a0b004bca44e643_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ee7d380900c45aabe38933fa9737ca5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i023eec0df3f048a9b3e4824e8ed3ab2a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7abe78fd6cf4342a3cc9da64b09d5b4_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia3d5d9ecb0104bb3a06537378655c966_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i969d874254604c79af7ddf89bcd68f38_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10e1787100a84bd8bffa4619e4984d73_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a0a6d1a5b414021b5171c6b7d9fb15d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieec166a2d8374cc7abab4547af3faf08_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7cdc5646c6548bd8cc644b73018859b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9531b1a6d294f8ea6c46caa9162ea5c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c012248699d44a19bf1b3ad593025f7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if879beacfc67428891a4ad60e8881285_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic18416d266bc4669a44779b7ea401676_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d74fbbf09504685acefcb2a4557aa87_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i730101ba7e3344f3a767d6b2aad9f3cc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5506665c921446e28905adb32f532db9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7afa8b191c2a4834a01ef669ef46770c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea3cff758de541ed88b25aac322f9445_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53a426a19b4043ba8a16122036b18ddd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60eeb012b13c4da095da075b0f10d9cc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab47af987094aeab2253c68b0b4781a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8fc23920c4547298b885029056b0d73_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i078e0ac095bc447c9134a911525da50b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia01a554c2ebb48d39f052bebdba83ffd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6b844bf5cc94564a2ea1dc24656006a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72d549b89a0d4280b7cbec3d16492a8d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b356d5dccac4dc0a67e6486ae9004c6_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9f59cd8393d427894d27c27f376c119_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d01410013b84b008e63a03d34b48335_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3823cd2bfc3c42808394d87cf2b96174_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9d72c66352d4e0ab7a43307ebcfaab7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd11875ea0ab4093a2da88d3dbb08434_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37bc23335780472587bf9311eee7023d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61a94521878b432cb2e9c5db2c9a03d9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d932603e9c9416bb175281368f58803_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1305265f23d04121a22583b545fe9bef_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9573b057d440c3a41440888f9bc519_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8008ca07420f4639a1bee2e6a25b83b1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3b600d7fd8d42519eb7d5e81b59a62c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d991b8372b64a33973a4e1e72f10d14_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a74210ccbe44871b085a79bdcf8b0ab_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie61b19d0952c468285e72114e0c815fa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6aeb83f9ea074f7ca098ec2277b76dcf_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfbcb20de8de4987b63b10487fe1503f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i455d14ea6c564470b68cf17c79c8b1ec_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c1038b4167343c2894ae361d7838cf6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b33b1754e9a4fd8861a165f689594b7_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if31045dd949540548e6be6125e1e8384_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7037c9ec74674577a86a47384437b333_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6998a8488a944245ac8b554c781cd12e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1722b2d0cc7645f1a42a9c8bb59390c0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0c5dd5e3cf24dbc93e12d0785e49cc2_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a195ea9682417d82da6447b85f8eb4_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d77cc63bd804d2195547eeb78d38213_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d2601de96ae48c0893072540afa20be_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf5eb57f75b949ddb446686c65bd2b5d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if382ab28a2c14f67953b81e1f8e224a6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0599c4c9cd214ece84111681c4bd49cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:context id="i4508c31bb9b042d2bf4dcb1d266392a0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2e3e533c0e2443196830784733320d3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i382decd071794d58a8eb96ab53eaa0fb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a124abe85aa4a19a264079c46a16e9f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ada2bf116084c4fa8e8e98e14a03495_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2424282c7e6f49e1a4c067b8194f126f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic979c424773c4abda7b0f080e9803dfa_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354359e6eb63451598deb6430cb7b015_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if28aa7d47b4e4774b232d953458d1d70_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95ce0946ae03453e9adefffc884e3e56_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04d9b2bdab044462bcfd071d9cae87fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f1f736cf0c848ceb0338e6ef724d11d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2aa9db267e8b405ebe94ed94f54a1041_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e630e38d8e4abc913f03bb50be1f22_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85e08dba5a5d46c48d1d0ba4950b19c1_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4789aad763454e5aa2bf7c06207aaf14_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i809babb0c0c0499093a3c1b393fd910b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ide348a94f52a4b6fbe470e76039c8fd9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13532228d6b4faa9945313be54cbe8a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia83d6b8be2f94d1ca6fdeb88a1fd79be_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie57145cefb184ed0a3414659db9ff24a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idc4ea9a082274af0bbf9b1541950118d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21ebca31e894acc847e9662f2798865_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83428f933f704288a217da35a25533ab_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic58515149d05482e8c241be729c7cebb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf1edb54ce2347b69f028201a0598732_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d47538d8dcd446ca3b4284f191efc96_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaefd6081d97b42989d5b2062fea0e2c0_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cee8c4809cc43778d9d5dd7095222d0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4883b5a7fdb64564a053bc40e6173d46_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib12491491b0e466ebdc29adb36c32405_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16bb558d82d1463380f6b8863e69e26a_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17597137521d4e01a99df9202a256434_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i294799e924cb4e7fb31a94d1eb9af81b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45f788f2e9604cf7abd1e93ae4f8f733_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LecanemabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf9a5892d99e44d8b1534f84205aaefe_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2837cc88485b432d98238003fed8b676_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib904f98f905e4ad3953b630e2bca4280_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47ad44653f43466cbe8c8233fd37d1a4_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia350432a960f43db838c5d34090e798f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if99a29e320c44befaad6c64343facc66_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i085d08ca766f453bb0b1ed59eda80c1d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaeafe70f44754eb2a753ad330c4edea3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a922c6b9d0648949c052b847de903cf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4df75de89f2a48e1ac98377bbeff106a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf245f7c03b94d219b053513a7037afe_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13c845f22a44a8bbbd7ebeccf43f5e8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f3a6e8db3344edcb5ed43acaf59842c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7d41aebda1d4947b30b143badbf9555_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7948b4b0b9c44243a39e812b8fbbcdae_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fd374623fbf4e19a6f32d3cc68790b9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cfeace678454dfeafaf48a68a2f8986_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c5d0bb749664bab88044a8c3f5fed55_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fe5cd2bc5bd45a7a679664aecb0fb65_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d5087bb8d414f3a9c0ece6a6b58e9c7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c435e88eff34c74b9a309271c43e352_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic329b49057fa46bba58db3d0c2daed85_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id00f8990c87c4edab48f9433250dcf28_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bd688a827a34b67a0e784b5fb549597_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaad538ee04e34626a6eea7c18b5170f0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ab6e798443f48349a275b2f127d63aa_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i320468fceb194a22b349781516794d96_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4229dbf5c29146898a310730f9f2a556_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i21935cd1c743479b8b352f61a8406ef3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ed4059cc532499cb0d947b46e8c2790_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i508e95abdda94a41920a1c67a004ec92_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff6e063c1a884b0e80c8af000019a9b2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b7cf9a8189c4e4badbd47fc34b589a4_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13cda5e55cec4e3aba7217644a62e136_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1977ca3896f4eba933be81acfc29491_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ice735e68404d4fb58b4cc4f43fa85a6a_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i349975b3917d48bb8801949ca1421861_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79b9cb96a23b4137a822345574780176_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebbfb14f37df42ada487358aa320ac59_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a82f9151b54f9ebfe04551807803e2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4631e2214cef421b815632fdba8b8cf5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i126cacdb6c3e45eb94667935f595ce8a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22a9faf176f64839888f1c73d5604d08_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id599ac01e6414ccd9716756cd0c865de_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4a5207e2c6849eda81b356e237635cb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bfd0daf2c604315aee2e5514037add9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f9583d6da0848eaadca5e7997e92ab7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3747bdadb44befa911a3d96310ff13_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib5fbb5c6be6b4e50a17ab9ebfa5c3d3d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i58730b06ccbb4aa3b96956a5848ff476_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieb48448825914249a3d6d269e0343fed_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icbe4b913116b4794b2827d45ad900e88_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id29abbf0715a4be1a4a2755996712479_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7487b639fa246688caae909a985fa49_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ccf4f8b82f4fda959e8343a1d3dde5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6033459c5bd84004a95df092bb16d49d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0b72d88f82114d2580cad7720faae9d6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67936f8313184aba9a6a811874849e9e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a9350f33f340dfac40b834b36fbee2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f224e8cb20d4247baed59ca9186ca70_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8d22419e65e4acdb11df2fd6d50ab7e_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b184b88aa274ec19c0f59ff28afb452_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb58e5595fd8416d9ad9613922e40315_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f54baa0a0034028959f4f1dd23cf711_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i286147027fd848569c362d90f20b6f37_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i93f9683196184871a6a8088e9b6526da_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i314cc95227f74e429b94104786b26357_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56a4148355e345a48fcfef9143a41e51_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id8657f446214427d9d8b9bd45a3d47e5_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ddc68c90fa6433c864fb720db1a4975_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8278526fab9042518d7f4accd2d4a217_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i205e68692a474c17b451db6c94fec530_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i981abb5814734c34b5ba0e1cfe305f9d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib07f093c1bcb4f10bfd6b343935a270d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6606034d42124a12b44cdb4c5fba6c23_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a78bdbf8e24900b4b8c65ca0447bcf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f61cc110f204304ba8ab5bbe034f465_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3600b20cbb584539b04e82e09e3dc634_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3d3e200523fc4be9bb17d504c77c4dee_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8f54474067a24bd5b888172e5b16c777_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id0679777b7204048a91c984d68574247_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecab3d1c123b45d38c30c5bec136d009_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62fe1e7bda30406db87fea2368ed0582_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i169651b95d8845368e7d477cb953ff71_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa04c9b7320b461cba254a374d51bda4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i200d118e7ed64bf5af0105a017c0fece_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1d995ddecf64fadbaf96fe1384500ac_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib271e1f2e84443bca4859f128d33db6b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c07337e773d46e6ad996880dd86a2fe_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0caa15f7fec549d5b6d3e7a3c8450b9e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff043d96d6794a88b3666b1deedfcd35_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83d8b0ff4a59482aa6bdc802c56365fc_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22a07047b8e84600ba3373e7735d13ac_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ac3efa6755547028b1585766ed0d6a8_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1e84a127d4d438c93f97cacfe5c9ceb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia1b944b88e544c5aacd839481cf31357_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iafa20a7bcf2748dcbeac35d8a0e0ca7a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5e498c8f45242b3a2d9e70d2c42a503_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bd633e40e1e41b1b9c1ae520b9468ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id52d6723b04d4723a146148f91d54d4d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i61daafc34b6c4be389482539c0515d29_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc378ef82c4040a2a4ab36fe9ca4766b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8335794299174638814a89b8c49ff4e9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5e6a6220363429f80e31efa34a52864_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95bf11f05e341b19847e153ea08fdc7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i120d294420ac4cc5a5287c7acc20fa00_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8996f46ad23e477a8251393d59e34875_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5fa5a40f0ac14aa19a149832f0cf7187_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32243243b47a43fb8c6ba0eb85b30fd8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7855fb3a8a984c0abaab370eeac02ee2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie45b0d8165e24b5a9fbc05c247e52911_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic258686cd3a6456ebc2c9b09e2ff27be_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea016b088d845d98937c3a05df5d947_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97bd4991354c4a15ac876c71524967c5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96b8241173c4299901100e5efed591a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b8795f0fecd44bc833219a58dfaee62_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec630ea085d14b79a6702770f05c54fc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b690018155f45cdb7f208616597334e_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c24c29444b548aca4187e271cfa886b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d5d2ca68e014dc3922d00d93a88be43_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5e7ec03b8354dbab75b233556df07d5_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88cbc69efa06413895dfc1180ad985c9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib29380d2bf674aeb8ea8724965b1f6b8_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d977c21aa234f7f99392c7a1a2c212c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i52fa7dd299c7425bbc3bba8fd21f9067_I20180531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89423fcf9d5d4c26a6860a1d370bc9f4_D20181101-20181130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-11-01</xbrli:startDate><xbrli:endDate>2018-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if414410918334d9bb8c6e78f27e2bd55_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic2f87e0409bf4de6bbfb65f1f00e2861_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22be7e941fc4472097793c58bfe13c85_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd0cd6a0501e4513abdff115c36b8a4c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff7a68233a6346a3b41b5ba48c00eb25_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9172dc7ebd564a448d1ab478d505ac9e_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i507cb74104cc4af691f7ec53fa51daf0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f4b8580bdd4045984ea773c64855bd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e7d3a50e8e24a18a4f3bebf9a25ee71_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idecbeb6a787b45e999586e7f179ad321_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib88cc97bd13d40ac90880007f88756da_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41dae46b1004553a798193cc1c16ae9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c0575de61ec44b4950ffd44163cfc4e_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53ce27e2d1834006bccaafc6efdf9bff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac791a4319614586b5fa4b20e746145d_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia15c5a492bc341798bf62fd3955ff770_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6a5fda462c643bdb69ff40ab7f9019c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib019b33e0733407486645ee0e3dba238_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5aa0d743936f4ed9aafcdf381a12a281_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ec860c976745568331c92c49c8ddbb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27638e932c864367ae3db51bb6a4e81f_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31b779d2d9c44b8e902c134c0f3a5def_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3c6767b12f4843b4be545567280f6604_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i034507e9f9464a29a0c701e02ba11b39_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i15cf3398e090470b836590f86a9494e7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="iff59169dbc0c45b4897fff451d70d7df_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaa1ea81bcf844509d4e9629d0129c76_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a75cf0ee8a497393ba39d608afef91_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a57d1b2e861499fab173d2ef85a3b1e_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia758334f8b3d4c2bb05db550ef70a7a0_D20220901-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24f4a773df0340cc9dcea4430ac7f361_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b979e0fcbd45a49408dd1c5807f36c_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52ed0ad90e1a409da68a677b1a180bed_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0993033b50e4a51badc996a38d9d905_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0974435913f44b15b34152a1fee687d0_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7037a7c948b64786be2cf157e66fc0cb_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i737aacf58c3f4d9b8d3e88a3953abda7_I20150915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec0813dbc2c649b99fb2b393fca060b6_I20220915"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a76584efadd4ffb99238713fd21af42_D20220701-20220731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43b8001bd67d4407bc0ad37c6a818891_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97bfc367938746ae877a3fe76a5d66e2_D20210201-20210228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6619831da50241829e986aa29f5743ad_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaec7e30533b342c590bb4d7ffe633982_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0abcd53e74c94a7c833bb12a8fd01cfe_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f65dc8cba414b409a0f8978d6ed6d6a_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ae9f957d5c456c9db2d0b8de63c577_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc7da9d0cf1d468abb521a902e87c1d0_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cdd7aef8328422d92318a8fb44162a7_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i566fa85dece64a33ba2afa4c152f1217_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica81c533dc694911997333f2bdba6785_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if562d93e14c149bf85526ac1ea39f925_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a801c0708314316ba9f6b3812a045ba_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d5210f96b74598bfeb245483674c64_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e94d3bedc394a18ac6119d2d5a633ef_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f0d8ba0521942b4b77b6c16befe6648_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i225e191ffa7842e98d83316aa99374a1_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8ffee1d6cf8a41c9a6241f4cc1056e1b_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4ea7c38a0a34d079a17eefda9d0a994_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i62ec65b1ad2d4bc99e0fe80385ecaee2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29b15de8609a499c99c1288814cbddff_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a62332cc2dd41a7b9a9be9081dd2307_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f60ecb887d4be79a4bb68b4285b869_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5733cabf96334e7ab886168311c47ed0_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f2f649fd1a74126a144c38bb92e1623_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie69a59bf2fb143128c5de3ed05732a32_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i849dd4a8f4c64ed988e7ed27a7acc5aa_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71a1afa58f84476abfee908e733759f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27ac905d40cc4c0b8cfce80524bd7f9f_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied4f63161aa64b41b8e31012f313c41d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie529a3e858834552a0a5634398d18674_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic83040f816404800a727b532e6017bb0_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23f5a5169ebd42aba57956e30523887b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9cf20ed80544d3aa60312bf7249ea5b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if299c0d105f14cf986a61dc16c3cb70c_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9019b680c6754477845629fe912cca42_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee1e133f85df4fcda4b5fbf47287ab83_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a8c74397f6e462ca3d0a16f7d7d1724_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21633472081e499f84d2d8a16c51f6c1_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8e3376c311a4ab1ba9f36f3d6388b0b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69bc310b2d7d4bdda29eb1089e137559_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93992c5f9dc945f6b4d933f8893cab02_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0310cfc482e54baf860e1cc61e2cb08b_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7af590a969ea4209b99c133a0dbaa97d_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9385ae1537df4bc4b697a93604cec286_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ec20c3acd4e4e87afaf283b335fcd61_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i87a19de3dc2c48cc83fa43e9c9f68324_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe4a1ed6e5af4242b0dd4a5d99cdd5d3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i86189fb69f0b4545b7c8c310762bef0d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b2c0753f0cd4a10bc3da9507bfdac2d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i423847116cc5490a9bdce5eb39edf6cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5726a88b7bb7444385b56260f3916f3a_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19e2ef680f084dee982a474253928b22_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia84ab3f48f3942d2a12b2e1aa732dcf0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e38e0479cb74c8fa5f98e9890ca19cc_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ab96fe04b24b54881a9fb26fd5d9e9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i020a6d175274414c85d5892faf01ae3b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2916810b28d34baab3e072744e15d7f9_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie280a8f5fb6f4a64a937ed98bf711fcd_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc5c47cebcd646a29a4d500a8101cb83_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1200447817a47ce88c12b9b2d542734_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0d2d23ef6a94bc2ab3418e068cdf65a_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i643e3738705a431185c23ad01faf0241_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ea82c65b64d4a08b32f42941f129ccd_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia985ab3c9c6947ce9bbddd4486e39ab2_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if43e265e90d84abea2ec20efefd5e160_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a056e0535b44f73a14fb5b5866c995f_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic363356bb33f48c5be8d5bb4b72a7bf6_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f4a133d037248e49ca85fc0d7750a92_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48833179911f4b4da985ff177df33255_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bd91ba74efe415d96d36566a8533af0_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4971fa532f65444a849a4efe193ef3b9_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fdb74af71e2435d84ec8c2691f9906f_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia28cefc2251e4aaabc62eda2e1948a43_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if71aa78fc18748d9bfdd023c98e48b21_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28eda3a32b1a4782908d9192bc909c52_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29a060d008f4427d9936c693dd36d7d5_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d36468b37944b318ad8e33e0eb69a3d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21f7cf90b35a4e9cadd33e5ac5864d7a_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f2b501618744c89aa413dcc343decd8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i815aa12c57884893ade8be8bae2934ae_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10042e38a8a542d693db8947e7136f70_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7db73a71288148e78f2f4ecd84931f93_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie29a14310e7041918de391cbb7abc267_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4441454a34d345f9842e1c241d644d60_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i893566fba033473daa38c35e9da2c3eb_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c02e6a550e94385bd647008ae2d2a57_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54de034401784154b4ba0d3eb7e3d450_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12b0509f87024db39c961704c8e7c7e0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c37ed99d794477582d69045529410a5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70546cdb486b478dbb121a7e30415292_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i514b2ba420f64268a1d2daffdaab5268_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78a6bb2bc10a4e3c91f961981fa702e8_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3443044069b84a6e88b9b3cc9b330446_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb735cebf0af4abd9050e30bb5f39f33_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c76958e4cf140f8ad08dea4b3f1ab5f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcac94427f544cbbae306a72b2a5e7ad_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6031c646c1504c3086d61ab2593a7c25_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddb4c4c4dd53404e8de0fcbf8e7d9a10_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6f9bec593be4e5d91def662f86f3734_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide22393d682f495894e1b5ec178709c1_D20230101-20230630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1f8e21b88c804c23b9bfcb582dae16ce_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i348dea4c284f4a53bb11bb12aec530fa_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i141e695e78b143d688d46ac172f1b598_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i179603334c294ba3b273f1bedccca3c9_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id03c149483b744869649d8b1d34aa36b_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591976370b814e62bd8c8b9ed758f611_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02b6a4d48c4a4334acaae1eb260e0b13_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i505f65ad62c3405996f7fb81bba9d4cb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19a6d0acc3304bb9aa01590e1e7460fb_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6511e416082b49b9a364fc869d30a213_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21152c4b7a304de9aeb9f9105783865d_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd4b5749a9a44fab753be0fde81fae7_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0b2780de2c442749c94a8cf029cc0bc_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4b772a8ed2c4a2aac06ce78bbdaec90_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if842e4daa2c44c5aaad2b10260a4d9ba_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5edddd85627f4628a01d57ff448a161b_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9708e37fa77451aadd22d8e388458e8_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68bdd3eb1eb14260abcb70364529e312_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3154c9870f64f398d5ee5795b0ed8a9_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib0000607651b4c2da18c5e8d251aa79d_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97091bfe16ce48fa8f91049acef10017_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19c19ba4f7294ef3b3f1a8cc3f9e7a51_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9bddd0739a28443f9a5addc1d0165587_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6280e0f3e31e4892b76bcf7697d7da8c_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9dca4a205fd04aff8770a8d6c0648246_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637a39c4b67547449f9bb69b9022b010_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6be2070a42f4a50adbcea4041c3995b_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6514e9099d749e2a24676b1e0964505_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie96ed8937b44437397b52545c683f8ca_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i63077c7ccbc64b09ba57ccfcb24dc699_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i67337d92701149d7a5ac303a93defa2c_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac8df81074864fdca6b0580aa1c815e0_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4853d9b210a44032a2de85b0f2c6b1bb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6a86bf51ac541cab63587970a524ba7_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94f98a47df764e30ba42983d8f26f8ff_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b59abb400d4439985bc8aede1323697_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i442b682326924c119499dfef30296ddd_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06a34504b754441cb3200ef36b1270d9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64fbcbfb69f64e4bad4eaf9e2feb10e6_D20210801-20210831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2688c6f795fe495b87c7088b9af08f05_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb2ae5cb50394082889ddf96ebccf655_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43982e8c28374e20a8abf7ff9c154d4d_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c00ebed6f7d4754af195586caa15662_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecc1e7ba25054542bf09508f1c307e7e_I20181107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-11-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54f716cdfda745bd9304e51b2b5d7a59_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic158a58579df49b6bfc1555e6b8983da_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1c25ceefcea49b9827a310222a5b592_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i534cd99ae2f945f4b8b88984e7158822_D20191201-20191231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:context id="ib960c5c895e446e0acbf3a757df2ab49_D20200101-20200331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92a4535230f44352ba473e29091c1ed5_I20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie2a1da015b744d1bad39bd303d279f1e_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifbc42c348d684b9cbcdd1bfb3d7628c9_I20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9c991d99f95e47928b97d145d5eb1271_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a682c52ea24aa381955c02cfe12e06_D20220101-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476cf962e66248c3a8819cbb993cf272_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b8287024d7d445698e5003d95aef21d_D20211001-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA4_33d64726-8450-4fd4-9806-931674c83ea6">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6OTI3NWU4ZTY4MGY4NDI2Njk1ZGVjNDk5M2QwNjAzYzMvdGFibGVyYW5nZTo5Mjc1ZThlNjgwZjg0MjY2OTVkZWM0OTkzZDA2MDNjM18wLTAtMS0xLTEzNDY5Mw_7d846037-6c51-4c27-a32a-c687d8fff1bb">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8xMjM_98b79c02-fcba-412b-a91b-f021a3dcc5ac">September 30, 2022</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:4.756%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.044%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6ODhlYWFjOWVmY2FlNDgzZGI2OWU0NTI1YjJkNmU0NDkvdGFibGVyYW5nZTo4OGVhYWM5ZWZjYWU0ODNkYjY5ZTQ1MjViMmQ2ZTQ0OV8wLTAtMS0xLTEzNDY5Mw_76395e99-1c19-4e80-9ee4-ffe038dc63eb">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA5_87387673-053c-489f-a047-0eec4fe96f1c">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20220930_g1.jpg" alt="biib-20220930_g1.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEw_c0cc26b6-437a-41b7-a2c0-2b9016d8b6d5">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6MmVkNDFmN2MyYmIyNDg0YjkyODFlZTBiMGM4NjMxY2IvdGFibGVyYW5nZToyZWQ0MWY3YzJiYjI0ODRiOTI4MWVlMGIwYzg2MzFjYl8wLTAtMS0xLTEzNDY5Mw_7e79dbd0-7666-44c1-99c5-5ea79872aaf7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6MmVkNDFmN2MyYmIyNDg0YjkyODFlZTBiMGM4NjMxY2IvdGFibGVyYW5nZToyZWQ0MWY3YzJiYjI0ODRiOTI4MWVlMGIwYzg2MzFjYl8wLTItMS0xLTEzNDY5Mw_d60f258e-e033-46b9-9bc8-ff9ccdcfb997">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEx_4b376543-6040-4be3-b7c7-cea0671447c5">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEz_9b589aae-3c30-4d0d-bb85-062d6aa471de">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE0_bf2fbf33-0b93-40b3-a861-f259d9371e28">MA</ix:nonNumeric> <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE1_eb9626e0-5272-456d-84cc-3c1dbca4b788">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEy_0c0fed8a-f82b-438d-9b84-23cdff709487">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE2_bb0e7f3b-b105-4073-98a1-133dc1aac404">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:11pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:35.463%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.080%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.619%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.970%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NzUyMDZlN2RiZjczNDdiYmE4N2ZhNzc2NDc0ZDZkNzUvdGFibGVyYW5nZTo3NTIwNmU3ZGJmNzM0N2JiYTg3ZmE3NzY0NzRkNmQ3NV8xLTAtMS0xLTEzNDY5Mw_5744d0ec-0d3c-4191-841e-0efc1f808c65">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NzUyMDZlN2RiZjczNDdiYmE4N2ZhNzc2NDc0ZDZkNzUvdGFibGVyYW5nZTo3NTIwNmU3ZGJmNzM0N2JiYTg3ZmE3NzY0NzRkNmQ3NV8xLTItMS0xLTEzNDY5Mw_8725c0dc-9d81-4d09-a379-68e03818ca9b">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NzUyMDZlN2RiZjczNDdiYmE4N2ZhNzc2NDc0ZDZkNzUvdGFibGVyYW5nZTo3NTIwNmU3ZGJmNzM0N2JiYTg3ZmE3NzY0NzRkNmQ3NV8xLTQtMS0xLTEzNDY5Mw_1944e02e-4878-4400-95f6-d7070f449f8a">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA2_925b06dd-4361-43cd-b3d1-4e4b06b52105">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA3_f03dbb77-4fd6-4ac1-a084-06b974e7261b">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:21.920%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.979%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.568%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.052%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.981%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NDNkNGFlZTI0MTI5NDJlZmEyMGYyNGMzYmE2ZDRmNmIvdGFibGVyYW5nZTo0M2Q0YWVlMjQxMjk0MmVmYTIwZjI0YzNiYTZkNGY2Yl8wLTAtMS0xLTEzNDY5Mw_7bdba093-d46b-4083-a78d-c41cbbd9b697">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NDNkNGFlZTI0MTI5NDJlZmEyMGYyNGMzYmE2ZDRmNmIvdGFibGVyYW5nZTo0M2Q0YWVlMjQxMjk0MmVmYTIwZjI0YzNiYTZkNGY2Yl8xLTQtMS0xLTEzNDY5Mw_1763f61f-d545-46ac-aa62-080221f449b3">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NDNkNGFlZTI0MTI5NDJlZmEyMGYyNGMzYmE2ZDRmNmIvdGFibGVyYW5nZTo0M2Q0YWVlMjQxMjk0MmVmYTIwZjI0YzNiYTZkNGY2Yl8yLTQtMS0xLTEzNDY5Mw_2de5aa3e-cfaa-4e6e-8f4c-d0b607e24dca">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE3_ec19768b-de55-47fd-93a8-3c2b1ef175e7">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of October&#160;24, 2022, was <ix:nonFraction unitRef="shares" contextRef="i8b9473308ccd44839cb2a3b16f056f1e_I20221024" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8xOTk1_90f9a363-3604-4181-8b62-0b2cb3b32abd">144,001,404</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"></td></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended September 30, 2022 </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:8.124%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:79.866%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.710%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_13">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_16">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_19">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_19">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_22">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_22">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_25">Condensed Consolidated Balance Sheets&#160;&#8212; As of September 30, 2022 and December&#160;31, 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_25">7</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_28">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_28">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_31">Condensed Consolidated Statements of Equity &#8212; For the Three and Nine Months Ended September 30, 2022 and 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_31">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_34">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_34">13</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_109">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_109">47</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_193">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_193">81</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_196">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_196">83</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_199">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_202">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_202">84</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_205">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_205">84</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_208">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_208">99</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_211">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_211">100</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_217">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_217">101</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the Act) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the Act. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; "goal," &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potential,&#8221; &#8220;possible,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other words and terms of similar meaning. Reference is made in particular to forward-looking statements regarding:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of revenue; contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans and prospects relating to sales, pricing, growth, reimbursement and launch of our marketed and pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic or biosimilar versions of our products or competing products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and period of regulatory exclusivity;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our plans and investments in our portfolio as well as implementation of our corporate strategy;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions and cost-reduction measures;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, filings and approvals, of our products, drug candidates and pipeline programs, including collaborations with third-parties, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our operations and business initiatives and obtain funding for such activities;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of the COVID-19 pandemic on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, cyber-attacks or other privacy or data security incidents, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of the conflict in Ukraine, including impacts on our operations, sales and the possible disruptions or delays in our plans to conduct clinical trial activities in affected regions;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the United States (U.S.), including the Inflation Reduction Act of 2022 (the IRA), and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, use of third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, activities in new or existing manufacturing facilities and the expected timeline for the remaining portion of the Solothurn manufacturing facility to begin manufacturing products or product candidates and for the gene therapy manufacturing facility in Research Triangle Park (RTP), North Carolina to be operational;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our collection of accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws (including tax), regulatory requirements, judicial decisions and accounting standards.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. You should not place undue reliance on these statements. Forward-looking statements speak only as of the date of this report. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AVONEX&#174;, PLEGRIDY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#8482;, BENEPALI&#8482;, BYOOVIZ&#8482;, FLIXABI&#8482;, FUMADERM&#8482; and IMRALDI&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACTEMRA&#174;, ENBREL&#174;, EYLEA&#174;, FAMPYRA&#8482;, GAZYVA&#174;, HUMIRA&#174;, LUCENTIS&#174;, OCREVUS&#174;, REMICADE&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_16"></div><div style="text-align:center"><span><br/></span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_19"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.578%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.576%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b5bc83e8644cd983699f6fb8858208_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy0xLTEtMS0xMzQ2OTM_7a8f9712-82c2-4468-afca-7fc1e3284956">1,962.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if551793810f14521aa422baeecc3bfbf_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy0zLTEtMS0xMzQ2OTM_d1d1d8cd-6c54-4525-8b1d-484110dcb038">2,205.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c2a0bb31734409bb0e29d39fc13bae_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy01LTEtMS0xMzQ2OTM_09f0586c-6faf-4923-b7fc-3b5ccf00be15">6,083.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2765e6631dd6439f847c09bcca089302_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy03LTEtMS0xMzQ2OTM_5d5b7238-224d-4e59-ad02-8dfc63ceea61">6,653.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677ff3bfec54adbaa112244fd4799d4_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC0xLTEtMS0xMzQ2OTM_896d1a2e-746f-4200-8993-adbb088c5153">416.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f777fcba294e1981f4bbec61fe6842_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC0zLTEtMS0xMzQ2OTM_3e06e4bc-6e9f-4ac5-b062-6fb0edbadc28">415.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bc6e1753ff4db990730bfcea938673_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC01LTEtMS0xMzQ2OTM_7700f9a2-7180-4c09-8458-8509bce45c31">1,252.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07dd344004654602b840c7084123794f_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC03LTEtMS0xMzQ2OTM_2941d478-a712-402a-bde2-e4483e2a41c8">1,244.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599788f95f5d42d1afd8d372967a5f5d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS0xLTEtMS0xMzQ2OTM_43fccec4-8ddf-491c-ad9b-2cbe8b737ecb">129.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6c0f5fe10b475babd385cc9a5f1933_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS0zLTEtMS0xMzQ2OTM_0d739d5f-b3b6-4ef3-8983-89fce613c406">157.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01501338195d4d64b3297f4c712b4a35_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS01LTEtMS0xMzQ2OTM_f936bf42-74db-442e-a966-4e78c5d3a5e9">293.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76bd2bb0d53b471685923452d6735342_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS03LTEtMS0xMzQ2OTM_929d2ac8-a5a7-4075-b9db-eda41ae0232c">350.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi0xLTEtMS0xMzQ2OTM_2835aed2-ab3b-4cb6-80d7-ecb793512d8f">2,508.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi0zLTEtMS0xMzQ2OTM_969a7569-0cef-49c1-916c-aec2e139b9ac">2,778.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi01LTEtMS0xMzQ2OTM_10d45364-1707-4684-a6dd-8806203fab85">7,629.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi03LTEtMS0xMzQ2OTM_0118ba70-d560-4a46-866c-1f2c31491460">8,247.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC0xLTEtMS0xMzQ2OTM_9d580152-6754-4c6b-bf33-db0acb09be7b">469.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC0zLTEtMS0xMzQ2OTM_b337444a-9554-455d-b77b-9e3768dfaaab">511.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC01LTEtMS0xMzQ2OTM_c4a2815d-38eb-4a06-bf71-13ab9864c030">1,707.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC03LTEtMS0xMzQ2OTM_09e80e2a-b849-4e4a-8e46-2cb05aaec672">1,449.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS0xLTEtMS0xMzQ2OTM_d6398ae3-36cb-4ac3-ae77-8f711d0942fb">549.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS0zLTEtMS0xMzQ2OTM_d76b35a6-0979-4456-9c9d-aa2a6c2a85b1">702.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS01LTEtMS0xMzQ2OTM_38662257-c59f-48e9-9971-450b891dacdd">1,629.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS03LTEtMS0xMzQ2OTM_97e338f7-53cf-42c9-ac55-507c75f02a64">1,801.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtMS0xLTEtMTM0Njkz_b0dd5fcd-7ec4-41a1-8fe3-82e2ca2a7e0b">563.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtMy0xLTEtMTM0Njkz_7247576e-b42e-47c3-82d1-37f2603a982f">654.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtNS0xLTEtMTM0Njkz_348f78f2-fc77-4795-a03d-be4e84f41410">1,770.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtNy0xLTEtMTM0Njkz_9a3fd9fe-35c2-4bae-a70a-e4dcf64ccba8">1,886.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtMS0xLTEtMTM0Njkz_e5ba969c-3df7-42b0-8a25-957f4d379a25">56.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtMy0xLTEtMTM0Njkz_51878a2c-b45c-4a8d-a324-ff802eba20af">111.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtNS0xLTEtMTM0Njkz_2d74b9c6-2d45-44e0-958f-bb849c979d23">190.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtNy0xLTEtMTM0Njkz_0c91072a-4963-459b-a2b0-a7a8b18336c4">813.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItMS0xLTEtMTM0Njkz_6938e702-c608-455d-be77-588258f45084">45.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItMy0xLTEtMTM0Njkz_5f7567ea-f026-45e4-a242-8906aff1ee81">21.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItNS0xLTEtMTM0Njkz_f4abe252-1994-4472-95ea-467a54412e7c">42.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItNy0xLTEtMTM0Njkz_41d2d8b8-bf78-4455-9d6f-acb31e780373">74.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtMS0xLTEtMTM0Njkz_10d2c144-f019-4bcf-961d-39622ed682e0">2.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtMy0xLTEtMTM0Njkz_998a309b-2cc8-485b-a40d-802cb44ccc11">15.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtNS0xLTEtMTM0Njkz_7dc5ca20-b0b0-440f-90e7-2e75f0f7a598">13.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtNy0xLTEtMTM0Njkz_765826da-8da9-469a-8da4-90f74cf4603e">49.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtMS0xLTEtMTM0Njkz_1166dfed-acc9-41f3-a3c5-baa77dadfb29">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtMy0xLTEtMTM0Njkz_d50970b2-6ae6-4f3d-a3c4-ce3d6923cd0f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtNS0xLTEtMTM0Njkz_b116edba-6f09-4563-a240-9ae75fb00e11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtNy0xLTEtMTM0Njkz_2b39fe1a-02c3-4e47-86c1-2618d50be74d">18.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtMS0xLTEtMTM0Njkz_f5a7aa6b-b3a8-443b-852a-3452784325ea">15.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtMy0xLTEtMTM0Njkz_cce5ddf4-3e24-4677-b2e7-f125b5d1a6e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtNS0xLTEtMTM0Njkz_aea80e3e-4dc5-4806-abd1-3e26089ac6ac">124.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtNy0xLTEtMTM0Njkz_0d533e17-4f3e-4fe2-a4c7-1792f8147ac2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMS0xLTEtMTQzNDI4_1cbfa3a3-3b23-4da7-b1c8-8dcc6bc8a290">503.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMy0xLTEtMTQzNDI4_e7465133-c1e3-4588-993d-d96c0e7cdd0a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNS0xLTEtMTQzNDI4_2e3a7de9-9c31-4efb-8594-7ab783e83cba">503.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNy0xLTEtMTQzNDI4_7172091c-611a-4b7c-8159-1efbff9ee607">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMS0xLTEtMTM0Njkz_4809d55f-1ece-47d4-b5c6-f4717a81993e">56.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMy0xLTEtMTM0Njkz_9648949e-5129-4ccd-ae80-7202b5ddd583">502.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNS0xLTEtMTM0Njkz_efaf69dd-e59d-4dfd-bb25-85fac390b6e0">221.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNy0xLTEtMTM0Njkz_590de148-93ff-4bdd-beea-7118bf33073a">913.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctMS0xLTEtMTM0Njkz_cb0c6410-b72f-4a2b-a5a2-1a85f1bd22d1">1,137.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctMy0xLTEtMTM0Njkz_996906fb-8354-4d16-974a-0be4e9ccc685">2,487.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctNS0xLTEtMTM0Njkz_883eae6d-089a-4e02-8b78-a10d7d90d29f">4,641.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctNy0xLTEtMTM0Njkz_393553ca-f608-41a0-ab37-83077c800980">6,907.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax expense and equity in loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtMS0xLTEtMTM0Njkz_a37967a1-4c72-469b-ad05-4d14f1c7a837">1,371.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtMy0xLTEtMTM0Njkz_42faed2b-952c-4481-9b20-8334eac13cd6">291.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtNS0xLTEtMTM0Njkz_fc7b9a91-0536-4820-b5d4-87cad8736eb2">2,988.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtNy0xLTEtMTM0Njkz_a19fe433-d0c4-4a9b-9d75-2c11ee0b66ea">1,340.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktMS0xLTEtMTM0Njkz_1ccd4d0e-6d13-4e76-a42c-078b7099dbdb">236.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktMy0xLTEtMTM0Njkz_cb48ef51-faca-44e9-b125-893054b581c9">25.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktNS0xLTEtMTM0Njkz_a750c141-aaf4-4815-9ec6-39c2356bb7a9">578.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktNy0xLTEtMTM0Njkz_06cfe8c2-b000-4585-bed4-363b2c6cc837">390.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity in (income) loss of investee, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtMS0xLTEtMTM0Njkz_07a30522-571f-4269-86e3-b4c0fa09c638">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtMy0xLTEtMTM0Njkz_d548aea7-7813-45aa-ab2f-9cdf4af1cd38">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtNS0xLTEtMTM0Njkz_7ba9af7d-b285-4da2-ae21-588e52f65e3e">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:IncomeLossFromEquityMethodInvestmentsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtNy0xLTEtMTM0Njkz_7936eb59-cb28-4f49-bd67-7988e0636f63">17.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtMS0xLTEtMTM0Njkz_8fd8d9be-6ad2-4780-8369-948a753042bf">1,134.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtMy0xLTEtMTM0Njkz_80caf3c8-bf75-4fa5-bdbf-1274d5f042a3">318.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtNS0xLTEtMTM0Njkz_5e90d360-1a87-440c-b93e-a704864d3e77">2,412.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtNy0xLTEtMTM0Njkz_75631a91-6b0d-4228-be35-0dae561a452b">1,748.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItMS0xLTEtMTM0Njkz_8218b95d-916c-4055-8470-1282e87f01c6">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItMy0xLTEtMTM0Njkz_66468bac-2766-483d-a833-d8dd8bdb4168">11.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItNS0xLTEtMTM0Njkz_72c0cd04-a470-47d2-8ba3-5a20e9a680f5">84.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItNy0xLTEtMTM0Njkz_8498941d-e20e-4f06-801b-f724aa80d934">560.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtMS0xLTEtMTM0Njkz_88c50014-8324-4d3a-aa83-47cddb07997d">1,134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtMy0xLTEtMTM0Njkz_12f3a7f3-0154-4c5a-b687-8d1674fdde27">329.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtNS0xLTEtMTM0Njkz_6f5b464c-1a54-4223-bd59-9ec16a977632">2,496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtNy0xLTEtMTM0Njkz_f61f3b11-0239-4ba7-90c1-1c2ab4c804e9">1,187.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtMS0xLTEtMTM0Njkz_524c8197-9bae-461a-8cc3-dd2ad9f788a0">7.86</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtMy0xLTEtMTM0Njkz_53853d3c-1029-4e5c-8035-65ad204fcf15">2.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtNS0xLTEtMTM0Njkz_ca552457-2705-48e5-b347-4fd22989b316">17.12</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtNy0xLTEtMTM0Njkz_a58264f0-8807-4e95-9f4b-b3b8c14a147f">7.93</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctMS0xLTEtMTM0Njkz_ea38b6ff-c6e4-4892-948f-9d1eafe94ac0">7.84</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctMy0xLTEtMTM0Njkz_229ae766-10f0-423e-a017-67b29306f82d">2.22</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctNS0xLTEtMTM0Njkz_b258822d-3ed0-4e0d-b671-8d9efe2049e7">17.07</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctNy0xLTEtMTM0Njkz_75937a43-1ebb-4e05-9321-965d63f109a8">7.90</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtMS0xLTEtMTM0Njkz_c5a78c91-cbe6-4364-8124-deb3564e88da">144.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtMy0xLTEtMTM0Njkz_e2972d91-c8ba-44a9-b9b6-6dcbed242dbf">148.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtNS0xLTEtMTM0Njkz_d4494750-2b7d-42de-9848-5af3211a1e3a">145.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtNy0xLTEtMTM0Njkz_c34116dd-d6cf-4568-bba3-c6e2142d9f7a">149.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtMS0xLTEtMTM0Njkz_9a853797-afdf-4160-b2ab-07de8009c686">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtMy0xLTEtMTM0Njkz_4a5cb506-44c9-4df4-a209-ffaa0429920e">148.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtNS0xLTEtMTM0Njkz_57258ac9-cd31-48a1-8ccb-80b4d6298d6e">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtNy0xLTEtMTM0Njkz_5d7cf22f-276a-436c-9f0f-70142470799d">150.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.577%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi0xLTEtMS0xMzQ2OTM_48167aca-252e-4de3-a8e3-31e56dc7f205">1,134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi0zLTEtMS0xMzQ2OTM_cf580c98-4cd3-44f6-afeb-0bb21e85885a">329.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi01LTEtMS0xMzQ2OTM_58d09195-b381-431e-b06d-59e4fd7a3487">2,496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi03LTEtMS0xMzQ2OTM_195dbac8-b3a4-49ac-a10f-af43e62cf04a">1,187.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on securities available for sale, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC0xLTEtMS0xMzQ2OTM_23f5947c-30d0-4cd2-9814-45a2f08c0022">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC0zLTEtMS0xMzQ2OTM_d95d6d5f-37d8-415d-8661-23bc0a9a2d4d">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC01LTEtMS0xMzQ2OTM_1de46930-17bd-4e02-a293-3fde497b8011">19.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC03LTEtMS0xMzQ2OTM_feead1f0-e261-4c04-94e7-6cbc56c62b19">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS0xLTEtMS0xMzQ2OTM_253ea4e1-d792-42c7-8d99-3596f02ea48c">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS0zLTEtMS0xMzQ2OTM_611a3d55-f185-49a5-a9f0-0d237c518178">66.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS01LTEtMS0xMzQ2OTM_77c5d34d-f583-4e75-994e-6e0b253f0978">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS03LTEtMS0xMzQ2OTM_1edd3c59-4f05-4fc1-92aa-34d38e666248">205.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi0xLTEtMS0xMzQ2OTM_80d0e3e8-2131-4530-a2e4-6f65c8542834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi0zLTEtMS0xMzQ2OTM_70c5a620-378e-478d-818e-8131e919922e">15.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi01LTEtMS0xMzQ2OTM_8f788ef9-fcb6-408e-a890-d4e7ba6fee37">25.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi03LTEtMS0xMzQ2OTM_e7ed165d-dbc3-4888-b909-4f13701ea3c3">35.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy0xLTEtMS0xMzQ2OTM_713bfb80-e9f6-4c59-b55c-d9ff36d926fd">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy0zLTEtMS0xMzQ2OTM_d8a4036b-a186-4708-9bf6-c0558ab2a91d">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy01LTEtMS0xMzQ2OTM_155c897b-a670-4623-b706-4c2c4de55ddd">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy03LTEtMS0xMzQ2OTM_62783f4e-3a22-4daa-bee6-f2e6d44addec">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustment</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC0xLTEtMS0xMzQ2OTM_5e9dce82-a0aa-4a3a-8d5b-ab6e31b77363">59.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC0zLTEtMS0xMzQ2OTM_0842b85d-8fc8-4e44-b4eb-d368717b92f8">47.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC01LTEtMS0xMzQ2OTM_8533b29b-9131-4e8f-8626-4f3a3a8f4d48">95.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC03LTEtMS0xMzQ2OTM_f1688502-c8b0-4e82-a20d-f59ad877dcbb">80.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS0xLTEtMS0xMzQ2OTM_2b0b7b6e-441a-4f1b-b051-8945707d8af0">53.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS0zLTEtMS0xMzQ2OTM_f40bc51f-0629-42ad-8810-4443ef30eac7">35.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS01LTEtMS0xMzQ2OTM_facd7ab9-4301-4ccc-ac9b-2f186704d3ff">56.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS03LTEtMS0xMzQ2OTM_a1292bd9-5969-42e9-8bb2-c499bf2a5ee5">162.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtMS0xLTEtMTM0Njkz_f2e70150-85e5-4eeb-a5de-4694afb3c7c2">1,081.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtMy0xLTEtMTM0Njkz_9d7629fc-0477-4727-9fd2-86a7396f42b0">364.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtNS0xLTEtMTM0Njkz_20e289d6-bbe5-4afb-bfe4-c5eb1335c5d8">2,439.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtNy0xLTEtMTM0Njkz_a2b0599d-accc-4c7a-968c-f8de1bdde1dd">1,350.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtMS0xLTEtMTM0Njkz_5ac3da47-ec48-413e-8039-eefedc0dc120">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtMy0xLTEtMTM0Njkz_caa6bb4f-3aae-4dd0-881d-63f0e0866d82">11.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtNS0xLTEtMTM0Njkz_2202ebcc-ccf1-4a88-82c0-3831bec375f8">84.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtNy0xLTEtMTM0Njkz_041f9f69-eef7-4033-af28-cc38fca3ca80">560.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItMS0xLTEtMTM0Njkz_f38fd29b-31d8-4941-bb9b-543b7a8350e3">1,081.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItMy0xLTEtMTM0Njkz_2862f09b-c70f-4057-b437-c128c11cb37b">353.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItNS0xLTEtMTM0Njkz_c5c4d869-1aca-4dce-b7e5-8046df648710">2,355.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItNy0xLTEtMTM0Njkz_c7efe3a4-2ac7-4684-988e-b3e721ed7a58">1,911.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.250%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.861%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMy0xLTEtMS0xMzQ2OTM_14c26c12-0673-454c-8943-849e8f6f5203">3,675.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMy0zLTEtMS0xMzQ2OTM_2f537028-1a70-454c-9ccd-c515479e006a">2,261.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNC0xLTEtMS0xMzQ2OTM_d3266221-5a74-435e-adfb-a1449f743987">1,235.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNC0zLTEtMS0xMzQ2OTM_16a508ca-d5bb-42a7-82c2-12f19ac295f9">1,541.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNS0xLTEtMS0xMzQ2OTM_5935179f-efc9-49f9-a643-0374dcbab9a7">1,568.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNS0zLTEtMS0xMzQ2OTM_728e12c0-07aa-4755-9aec-bed5b148d50e">1,549.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNi0xLTEtMS0xMzQ2OTM_abf2b209-e603-4b5c-a529-7f60e68fed76">415.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:DuefromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNi0zLTEtMS0xMzQ2OTM_ab6107e3-6a14-4ced-b5e8-722f2d67fffc">412.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNy0xLTEtMS0xMzQ2OTM_e1d4b5a3-1e61-47f4-a99b-d86c6454d060">1,375.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNy0zLTEtMS0xMzQ2OTM_4039e541-aceb-480a-a7a8-e609b26214c7">1,351.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOC0xLTEtMS0xMzQ2OTM_e67fd6f9-f493-4cb6-b5ca-1c00c33e6d2d">1,495.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOC0zLTEtMS0xMzQ2OTM_f0195a09-1bb4-41c4-bb5d-fcf5f94e3b28">740.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOS0xLTEtMS0xMzQ2OTM_447acece-bfa5-4076-8ad9-3756509082dc">9,765.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOS0zLTEtMS0xMzQ2OTM_3f8bb207-0894-4d34-abf8-ebda683d0aaa">7,856.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTAtMS0xLTEtMTM0Njkz_aefe1342-5353-4f1d-b208-2e617a325d90">860.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTAtMy0xLTEtMTM0Njkz_6cd9a13e-97c8-4843-b946-ec9ff0c63474">892.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTEtMS0xLTEtMTM0Njkz_e2f099af-86bf-47df-a8de-24ecbabf2dc2">3,266.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTEtMy0xLTEtMTM0Njkz_54fc54a5-38c6-40e2-a390-b15340c90d7a">3,416.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTItMS0xLTEtMTM0Njkz_e3221085-c6da-43dc-a5b7-3d82233a7c78">424.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTItMy0xLTEtMTM0Njkz_dd7b688a-2654-4ea7-aadd-d2e14df53fcc">375.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTMtMS0xLTEtMTM0Njkz_cda00772-0bfa-458f-bbaf-4970f6e47bd7">2,008.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTMtMy0xLTEtMTM0Njkz_7c971a40-29ac-4772-a383-39f243964e96">2,221.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTQtMS0xLTEtMTM0Njkz_c5c77256-abdd-43d5-b872-296db7b2e7ae">5,741.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTQtMy0xLTEtMTM0Njkz_b2ae8372-c72b-4407-b308-798a5a96852d">5,761.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTUtMS0xLTEtMTM0Njkz_d6175e91-760f-488f-8ac1-3c147cae158a">1,174.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTUtMy0xLTEtMTM0Njkz_7cf79015-9c28-4509-a8ef-c3f4f2eaf71c">1,415.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTYtMS0xLTEtMTM0Njkz_2fc31f80-7ec6-457e-878d-81b9d81a376c">1,612.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTYtMy0xLTEtMTM0Njkz_6af4e389-6735-4a40-aace-451ad2cd8129">1,939.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTctMS0xLTEtMTM0Njkz_b0dc9b0f-1b3f-4a6f-b419-e6a7f87c9e05">24,854.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTctMy0xLTEtMTM0Njkz_b79dd895-3f84-48fb-a16d-af03e704cc58">23,877.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjAtMS0xLTEtMTM0Njkz_02561168-a402-4bd7-8d65-035510fb96be">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjAtMy0xLTEtMTM0Njkz_2340b03b-8388-450f-b4d4-ec5a3fd367c9">999.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjEtMS0xLTEtMTM0Njkz_50e36a84-d13f-448b-a08e-2390b09f609c">237.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjEtMy0xLTEtMTM0Njkz_31993e4b-9b32-4839-bd26-5e5a02b7a98c">174.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjItMS0xLTEtMTM0Njkz_ff3ad1d1-52f3-49dd-a9d3-4860e4323d12">383.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjItMy0xLTEtMTM0Njkz_3bf8b24c-ab93-4e11-a61f-c358ee7444df">589.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjMtMS0xLTEtMTM0Njkz_cf5878a9-845b-4943-aa87-8825d971681e">3,305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjMtMy0xLTEtMTM0Njkz_79a1135a-0b10-4f87-a470-73066ac36b10">2,535.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjQtMS0xLTEtMTM0Njkz_ca709c37-d21f-4c64-8f15-4d4031f8ab26">3,926.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjQtMy0xLTEtMTM0Njkz_e5d0f1ff-0917-4439-a6ba-399066b4654e">4,298.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjUtMS0xLTEtMTM0Njkz_277c52ef-8419-460e-9f86-ba72b758c0c5">6,279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjUtMy0xLTEtMTM0Njkz_ac3fa771-36a5-4848-9b6a-8fb92d8c66f9">6,274.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjYtMS0xLTEtMTM0Njkz_6e3a73eb-94fa-4081-a938-f0019196b7ea">328.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjYtMy0xLTEtMTM0Njkz_76a55d38-4a5c-4d22-8cc9-9abe385b04ce">694.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjctMS0xLTEtMTM0Njkz_d4889af5-9f4f-42f0-9ccf-ad3c930bfd69">354.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjctMy0xLTEtMTM0Njkz_1f2af86c-6b43-4be3-aedb-2c955d9f84ab">330.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjgtMS0xLTEtMTM0Njkz_caa622a0-64e6-4f0a-89ff-632b41453167">1,198.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjgtMy0xLTEtMTM0Njkz_53d78308-8b66-487c-bde4-907a3cb6e11b">1,320.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjktMS0xLTEtMTM0Njkz_caf1988d-8c45-4550-b9cc-1d04260cb0cf">12,087.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjktMy0xLTEtMTM0Njkz_a179907e-f777-4150-9356-c51becb94b2c">12,917.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzAtMS0xLTEtMTM0Njkz_ac7928ee-075d-4509-ae40-8e3536dc736e"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzAtMy0xLTEtMTM0Njkz_be24c4aa-92d2-4590-b947-152dd4c8e591"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $0.001 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzMtMS0xLTEtMTM0Njkz_c08e0e97-0722-480f-842a-e6bb98433a62">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzMtMy0xLTEtMTM0Njkz_b5f0982e-9bb7-4541-a51f-7143cbf68c38">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $0.0005 per share</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzQtMS0xLTEtMTM0Njkz_4626de38-403b-45cd-a492-8e9d6a17fbb4">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzQtMy0xLTEtMTM0Njkz_f377be43-e6c0-41f9-bb0e-7deff2f76742">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzUtMS0xLTEtMTM0Njkz_d36a0c2b-a7d6-4c4b-b355-c560d426fd87">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzUtMy0xLTEtMTM0Njkz_a521925f-d7c7-450a-a6d1-dd4bff809e5c">68.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzYtMS0xLTEtMTM0Njkz_001ed8ea-25d3-4d96-8bab-383fba2bf1ef">163.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzYtMy0xLTEtMTM0Njkz_2fa412ab-05c2-4604-90c1-6f0fae8d678e">106.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzctMS0xLTEtMTM0Njkz_53ddca5d-4770-4317-9d91-6d2aeb3fdb5c">15,916.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzctMy0xLTEtMTM0Njkz_bac97810-f889-476d-a96f-fae83b373fa7">13,911.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzgtMS0xLTEtMTM0Njkz_a3bcd732-0a13-4f7d-b83d-cf4a0d058c80">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzgtMy0xLTEtMTM0Njkz_710d4362-ca83-46da-9e71-a697b3b16857">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Biogen Inc. shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzktMS0xLTEtMTM0Njkz_1e6bff31-aaac-48f5-a172-1e3921fa6b62">12,775.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzktMy0xLTEtMTM0Njkz_95ac500b-59e1-4a59-88c9-22fb4d1e42a7">10,896.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interests</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" sign="-" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDAtMS0xLTEtMTM0Njkz_8f78c770-9530-47c8-b54f-d045dd47ce92">8.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:MinorityInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDAtMy0xLTEtMTM0Njkz_88532913-6a63-4ef0-9168-54ff9782432c">63.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDEtMS0xLTEtMTM0Njkz_5077589a-9954-4c8c-be83-c1bdd226d4e1">12,766.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDEtMy0xLTEtMTM0Njkz_d9f85c3a-514a-4778-b96f-ccd492d5db2d">10,959.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDItMS0xLTEtMTM0Njkz_740dc726-9ca8-4e9b-8f2c-80c38630d26c">24,854.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDItMy0xLTEtMTM0Njkz_66871b1c-bb8a-40b0-9fd1-b3a388894fb3">23,877.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_28"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.736%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.691%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMy0xLTEtMS0xMzQ2OTM_e1bf3e03-a01d-4657-ac2f-ebbb87f53a94">2,412.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMy0zLTEtMS0xMzQ2OTM_ad853939-bced-447a-8137-748a7816917a">1,748.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNS0xLTEtMS0xMzQ2OTM_70080dd9-aa24-4f13-93b4-6902ed3fec93">398.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNS0zLTEtMS0xMzQ2OTM_a6337bb7-502f-47dc-abab-2c703105dd83">353.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNi0xLTEtMS0xMzQ2OTM_1e135023-b39c-44c2-a8cf-57456b73153c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNi0zLTEtMS0xMzQ2OTM_d25105ca-d1cd-45be-a83a-b1e9c0fcc454">629.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNy0xLTEtMS0xMzQ2OTM_d3bbad86-c278-4646-a44e-3b47d6e59be0">321.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNy0zLTEtMS0xMzQ2OTM_aeea4c7b-3369-44a4-879f-0cdc02c7c714">36.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOC0xLTEtMS0xMzQ2OTM_4857c29b-ec35-4a7e-9282-6eaa100f7121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOC0zLTEtMS0xMzQ2OTM_323f4c36-6cf4-4f73-8b26-51251881b3c8">18.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOS0xLTEtMS0xMzQ2OTM_18eca0d5-c766-4a95-866f-45ac17c22900">186.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOS0zLTEtMS0xMzQ2OTM_fc692072-09a2-4466-9ab6-de5b33f8c4e2">179.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTAtMS0xLTEtMTM0Njkz_d61c1fa0-b78a-42ad-b221-dfa5fc3a5282">13.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTAtMy0xLTEtMTM0Njkz_03cef0d6-a0e2-4c84-b6de-943589f30c7e">49.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTEtMS0xLTEtMTM0Njkz_f744018d-d873-4127-963d-751ee72819d7">139.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTEtMy0xLTEtMTM0Njkz_86605106-6814-4f9e-98d5-9252bff79ed5">750.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTItMS0xLTEtMTM0Njkz_1e35380c-3236-4e73-8f73-95ec845eec54">160.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTItMy0xLTEtMTM0Njkz_1cfcea87-7f09-4d73-b50d-188bb699fca4">710.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on equity method investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTMtMS0xLTEtMTM0Njkz_584b0062-0c10-4e16-9cfe-8bc4c1f4fc0a">2.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTMtMy0xLTEtMTM0Njkz_d2ca92e0-c7a3-4b19-b98c-6d0554e29f3f">17.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTQtMS0xLTEtMTM0Njkz_7e129a48-c38c-40db-a134-67a2332888e9">1,505.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTQtMy0xLTEtMTM0Njkz_3b57b893-e76a-4fd3-89aa-17533b2a502e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMS0xLTEtMTQwMjU5_de6fa2d2-e762-4d54-a9b7-8b55f94f3066">503.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMy0xLTEtMTQwMjU5_15f496aa-a949-487e-919a-9f2b6eee39de">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMS0xLTEtMTM0Njkz_ae912c20-90a2-4866-bd6b-d8ab1af66872">147.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMy0xLTEtMTM0Njkz_0299335b-012b-492b-b088-d0c46381b228">164.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTctMS0xLTEtMTM0Njkz_14cc37e4-c94e-4490-b807-7b5c134b0b52">109.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTctMy0xLTEtMTM0Njkz_3944c16d-01cc-4e37-a775-8c3297bd87e2">157.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTgtMS0xLTEtMTM0Njkz_2a020938-bd0c-4d0f-b87d-72590c36782b">3.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInDueFromRelatedParties" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTgtMy0xLTEtMTM0Njkz_dfa342f0-8124-4579-8240-14b1ca23461d">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTktMS0xLTEtMTM0Njkz_7714ab06-8bc4-4dda-8bd1-cad83fd0b55b">338.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTktMy0xLTEtMTM0Njkz_0ef4293d-79a2-4465-8b3c-c52ad4acb0c1">322.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjAtMS0xLTEtMTM0Njkz_8686af22-c1e6-494e-a770-f69da89a0657">632.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjAtMy0xLTEtMTM0Njkz_281e3fe1-ab6f-43d7-9d54-8d6f22eb9846">243.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjEtMS0xLTEtMTM0Njkz_81e8a614-d108-4bc5-8e9b-b2db77940b07">100.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjEtMy0xLTEtMTM0Njkz_82aa8e1d-f97b-4e33-aa14-7e6db098f215">260.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjItMS0xLTEtMTM0Njkz_62aaca8a-a8d4-4900-abd1-69039f6eabd3">15.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjItMy0xLTEtMTM0Njkz_0ec2c985-3787-445a-806f-ecccbed4b852">87.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjMtMS0xLTEtMTM0Njkz_1e692244-31e7-4b8b-ab27-ee8cb444b0d1">1,559.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjMtMy0xLTEtMTM0Njkz_a8bdf586-9884-4e39-87e0-d53fc88e89b5">2,801.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjUtMS0xLTEtMTM0Njkz_d3258cd8-147f-4ccd-b0dc-56089bb661e3">153.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjUtMy0xLTEtMTM0Njkz_d82e6f8d-3418-43e2-afb3-67072d48ff4f">206.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjYtMS0xLTEtMTM0Njkz_0604243c-44c0-47c4-bc84-dacfa93d5d8c">3,104.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjYtMy0xLTEtMTM0Njkz_b7bc709b-559f-4b37-9c4d-838b27c0c5b5">2,028.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjctMS0xLTEtMTM0Njkz_9ff31b76-8987-4a79-b5b3-e8cd744e5693">2,805.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjctMy0xLTEtMTM0Njkz_ea8ac102-1b03-4aa3-9599-499640c57654">2,372.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjgtMS0xLTEtMTM0Njkz_bff6ebc0-a9ad-4e94-82cd-b5ef9539b5d9">990.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjgtMy0xLTEtMTM0Njkz_50436ed2-5c7a-4a14-9144-2f388fb1ee37">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of building</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMS0xLTEtMTQwMjg1_8e85be88-9892-47b1-b55d-469f0e449ea4">582.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMy0xLTEtMTQwMjg1_eba9a21f-3f3b-4ca3-86a3-8d63504f7958">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjktMS0xLTEtMTM0Njkz_1721cce2-0224-4b37-83e5-b2fa05277b11">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromDivestitureOfBusinesses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjktMy0xLTEtMTM0Njkz_6746700e-647d-49ad-9d21-10561a0e31d2">28.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMS0xLTEtMTM0Njkz_40e2f5d0-b53a-429e-99ed-f545d8920375">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMy0xLTEtMTM0Njkz_c82ebae4-36e2-4ac7-b68a-7b6a1ea42075">18.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzEtMS0xLTEtMTM0Njkz_99e0994a-b8cd-46a3-a408-b38dee6a556d">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzEtMy0xLTEtMTM0Njkz_65191059-44e3-4c80-a6a5-40e73bfe90ec">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzItMS0xLTEtMTM0Njkz_29a9d420-da38-4470-8801-b873156e7faf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzItMy0xLTEtMTM0Njkz_0eb133ef-bf93-4c49-9a1a-c621241909c7">91.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzMtMS0xLTEtMTM0Njkz_a4bacbc8-5943-4443-99e3-39efd03f0c64">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzMtMy0xLTEtMTM0Njkz_0b972873-cc98-40ce-adb3-4e0b2c1b4048">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzQtMS0xLTEtMTM0Njkz_07dba1ff-916d-4412-a9eb-937d294b94bb">1,717.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzQtMy0xLTEtMTM0Njkz_d7c0d8f3-0797-43ca-8ce5-9d2abcf4452a">451.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzYtMS0xLTEtMTM0Njkz_6f4f489b-7c00-45d0-a2ff-5b541c853df9">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzYtMy0xLTEtMTM0Njkz_16eee98c-17ee-4020-b1e4-7a5c3416fa40">1,800.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzctMS0xLTEtMTM0Njkz_6a8c1c11-18fa-48f7-8a88-fded6f8ded72">5.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzctMy0xLTEtMTM0Njkz_c7c0a737-5e49-46b2-9334-b299ba03c0ad">8.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Repayment of borrowings and premiums paid</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzgtMS0xLTEtMTM0Njkz_167ccc7f-9d53-420f-a94f-bd9ed6bbc2d8">1,002.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzgtMy0xLTEtMTM0Njkz_280c4221-9ee4-43ac-917f-e6263d114229">170.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net (distribution) contribution to noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDEtMS0xLTEtMTM0Njkz_46796b44-2ea4-499f-9834-9749e00ba4c1">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsToMinorityShareholders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDEtMy0xLTEtMTM0Njkz_08a1eab1-07c6-4e44-abb2-9e2abe3d1950">94.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDItMS0xLTEtMTM0Njkz_c9a278b0-adc1-4acf-8206-89ed901e051f">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDItMy0xLTEtMTM0Njkz_574d7bfa-99cd-4bb2-9f11-1f07edfb1ce4">22.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDMtMS0xLTEtMTM0Njkz_d5bc6295-90ed-4b34-afef-eb213d8dd90c">1,739.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDMtMy0xLTEtMTM0Njkz_71280bbf-fe60-4082-8ff5-06b029e12224">2,096.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDQtMS0xLTEtMTM0Njkz_48d317ef-2467-48d0-9956-c317877f8277">1,537.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDQtMy0xLTEtMTM0Njkz_047eb0d0-6339-4b3b-af30-1f0d6495e700">254.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDUtMS0xLTEtMTM0Njkz_b4e92392-cfa3-42ed-8aee-f9311c3d3094">122.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDUtMy0xLTEtMTM0Njkz_6d56e111-f79c-4945-931f-4090490a5286">44.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDYtMS0xLTEtMTM0Njkz_8b595b62-9a45-4045-8b51-1e9be19a5594">2,261.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDYtMy0xLTEtMTM0Njkz_8cb9462f-a49c-453a-98cc-95d848e1ef55">1,331.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDctMS0xLTEtMTM0Njkz_347f3155-88f4-49cd-a580-80082ef52787">3,675.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957729f8711844ff89317163bd3b28ee_I20210930" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDctMy0xLTEtMTM0Njkz_e06f4a7c-4232-4558-a63a-23cc5bf89634">1,541.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_31"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1aee04605d242bfb83b7fe9c6cb1edc_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xLTEtMS0xMzQ2OTM_dc0369ea-c870-4763-94e3-375ccb7ea4b7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1aee04605d242bfb83b7fe9c6cb1edc_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0zLTEtMS0xMzQ2OTM_da0db8db-6c7a-4fbb-8f09-f6c55ff8e8ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i835d8ccc4e79473b96d3739d3fc0f451_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi01LTEtMS0xMzQ2OTM_7d42588f-3cc7-40b0-9f99-1f7ca99b55ab">169.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i835d8ccc4e79473b96d3739d3fc0f451_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi03LTEtMS0xMzQ2OTM_96371406-f757-47e6-a117-96872e9134d3">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id36ae3eeb09d4b00b8023ee15c29a104_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi05LTEtMS0xMzQ2OTM_f1f67500-2e38-47e9-81b3-02c9a1b965c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i385b6988b4664d52a88f8aaf055e4153_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xMS0xLTEtMTM0Njkz_4e906cdd-e479-4b1d-a3f0-859ada4d917d">110.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df7f5528d01483d85bf88ee051bf26a_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xMy0xLTEtMTM0Njkz_768c8ec1-17eb-4dba-9a27-413b5c14a7e9">14,959.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie99add0e88f54844bcc4c75b8cdd5670_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xNS0xLTEtMTM0Njkz_b3b89059-d73f-43bc-aa8d-27af526722d5">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie99add0e88f54844bcc4c75b8cdd5670_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xNy0xLTEtMTM0Njkz_7b98d6db-fbc6-4e09-942b-67500ee0a1d6">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibedabc034ea240c0b3ac08428570bb02_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xOS0xLTEtMTM0Njkz_d528d69c-394e-48ee-961f-63d8a7f4de97">11,872.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2a2bd09b86954ad5a4bee8091dd95fdf_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0yMS0xLTEtMTM0Njkz_48c59b77-8ee1-4615-ac9a-553905c40fe1">9.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd70f96bb3774f148eea2bb8f9432dc4_I20220630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0yMy0xLTEtMTM0Njkz_96e5ebdb-a24b-4655-aacf-307949182f9a">11,863.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i239d15fce1e540cea5ec4ef251ea8908_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0xMy0xLTEtMTM0Njkz_a6352eee-2af4-4c53-809f-2238efb11cb4">1,134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0xOS0xLTEtMTM0Njkz_f5c193fb-1a97-4368-b591-447800462c6e">1,134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92b65c6517c4a3480678a0a31182921_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0yMS0xLTEtMTM0Njkz_9c38e793-f309-451d-8acb-01f5e96ce6b5">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0yMy0xLTEtMTM0Njkz_40173ff8-cf56-4f06-a5a9-749302c16b2f">1,134.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66f984c3b15d4a31acd93e52732606cb_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNC0xMS0xLTEtMTM0Njkz_4c9766b1-b431-4ca3-a8bd-482157cdf969">53.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNC0xOS0xLTEtMTM0Njkz_efa048cb-5c64-406e-9030-950e9397abea">53.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNC0yMy0xLTEtMTM0Njkz_a43abb8c-5baf-44e3-aa28-a5e474413147">53.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92b65c6517c4a3480678a0a31182921_D20220701-20220930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNi0yMS0xLTEtMTM0Njkz_ac26a8d1-60cc-4dee-bc04-fd8738eff133">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNi0yMy0xLTEtMTM0Njkz_6b0ebd29-b312-4945-827f-24e75694fb4c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0xNS0xLTEtMTM0Njkz_cb33d586-d70f-44e6-900e-9fcf31788e14">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0xNy0xLTEtMTM0Njkz_70fcff13-c663-4fa2-9277-bb965167fd39">250.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic367eb9333f6492b83e15ec443ce582f_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0xOS0xLTEtMTM0Njkz_e5f25a87-1bfb-4d0b-966d-69661ba8bbd9">250.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0yMy0xLTEtMTM0Njkz_6d464d13-0a99-4ef2-aded-057c54cc3786">250.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i702681f6e9854a2c9237a3f37fa30d3a_D20220701-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC01LTEtMS0xMzQ2OTM_5c5dd55b-9945-498b-90e1-ef7dc323c0e1">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i759633f59042448b81434c16a76b3557_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC05LTEtMS0xMzQ2OTM_b1ae31df-efc0-4e0f-8689-1dc406ffbc8b">71.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47eb6434b4184bf1862e2d8683e198b4_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0xMy0xLTEtMTM0Njkz_dd991cbb-1012-4bd1-a613-5b418faff1f1">178.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0xNS0xLTEtMTM0Njkz_17edee35-b107-4536-8d03-68a15a32dd84">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0xNy0xLTEtMTM0Njkz_c1895a35-4205-40e3-a5f7-a7de4831dd7d">250.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0yMy0xLTEtMTM0Njkz_0527283e-9bba-475c-b51a-b2764e02e086">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfdf3c77bb8d4707b6431886367684a2_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS01LTEtMS0xMzQ2OTM_74dfd0ce-3478-4ea3-ae11-ca93e01eeca0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS05LTEtMS0xMzQ2OTM_2c1bd277-3a8b-4cc4-aaab-87b62778a416">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS0xOS0xLTEtMTM0Njkz_8164ff14-8b69-4ba5-ab85-86ac62624fa0">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS0yMy0xLTEtMTM0Njkz_5687cdef-99ba-4856-9d0b-0f0abd9f18a3">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="icfdf3c77bb8d4707b6431886367684a2_D20220701-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtNS0xLTEtMTM0Njkz_30253854-a761-4be4-9b48-b01664b0a4f4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtOS0xLTEtMTM0Njkz_d93944d8-14cf-4bd6-95a6-117c140eb45a">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtMTktMS0xLTEzNDY5Mw_fb36c7f4-27f8-4d3b-86db-8f3608cabd02">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtMjMtMS0xLTEzNDY5Mw_869a6654-b148-4f9d-b51a-73e2aabfb5e3">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTEtOS0xLTEtMTM0Njkz_a6ae6a7f-d8a6-4bb5-97eb-0b2622b2c82b">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTEtMTktMS0xLTEzNDY5Mw_f095c8a7-e45c-43b1-943b-1680045fbd25">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTEtMjMtMS0xLTEzNDY5Mw_96284f5c-79d4-425a-b881-23b662723d7d">65.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTItOS0xLTEtMTM0Njkz_d6724bfa-dfdf-41dc-8539-63d106117f13">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTItMTktMS0xLTEzNDY5Mw_584245fe-e37f-423e-91aa-7b46c5c8aa63">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:StockholdersEquityOther" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTItMjMtMS0xLTEzNDY5Mw_e3144e0e-565e-4551-9cdd-5fa8543b1831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMS0xLTEtMTM0Njkz_dd33648a-661c-4adf-ba81-aeda4ffb9b3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMy0xLTEtMTM0Njkz_12e9d805-657c-4302-9105-9f377a8eddc3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtNS0xLTEtMTM0Njkz_5613e90d-e003-47b5-a8a9-bedd34c8a75a">167.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtNy0xLTEtMTM0Njkz_1f0c8c63-61be-4ad1-8790-cb184e3e9cd9">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5068c3b18e94e8eaaf2091ea3cf9695_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtOS0xLTEtMTM0Njkz_b4c8c9ea-ad52-4447-b402-ebe831adeb48">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e0fa57a6c3f4fa4942ba9c62ac16a53_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTEtMS0xLTEzNDY5Mw_76ab45e1-72b7-4ec4-bf83-968db0f2742a">163.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b3d30bc29ae41cb9335a4b23f385945_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTMtMS0xLTEzNDY5Mw_c99ae88f-4ea7-4d6f-990a-777b09fcb231">15,916.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTUtMS0xLTEzNDY5Mw_e2747741-0944-4d9b-8cd7-e999762d5574">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTctMS0xLTEzNDY5Mw_bfa18b41-4ddb-46a3-8c66-60366c5b6676">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2a2cbbf2a9947cc889f57763f6fb24a_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTktMS0xLTEzNDY5Mw_2f425ccf-a938-4d86-b7f1-3eec8748af9d">12,775.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac4673c093c48e281f08d7e26c19005_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMjEtMS0xLTEzNDY5Mw_76368d41-dd27-4bbd-8090-5156e4a54c76">8.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMjMtMS0xLTEzNDY5Mw_6e38e77b-e993-42d3-af11-dc11e3e6ba68">12,766.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.675%"><tr><td style="width:1.0%"></td><td style="width:19.638%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.351%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.677%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.871%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.694%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.523%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.654%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.586%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.342%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.105%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id54e452525014575861abb8575bfa40f_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xLTEtMS0xMzQ2OTM_8252b7be-adad-485d-b062-33f67dc5da99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id54e452525014575861abb8575bfa40f_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0zLTEtMS0xMzQ2OTM_41f277cc-f207-4be3-ac67-9a093eb60974">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6150f5ddab6c45c9aa1fbef55937177e_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi01LTEtMS0xMzQ2OTM_f3a56749-9fb0-4a3d-b17f-d38c7ebfcb2c">170.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6150f5ddab6c45c9aa1fbef55937177e_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi03LTEtMS0xMzQ2OTM_53d0b5f3-de8c-4e68-8fa0-22a2af5c88bc">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a5ef7f9cda42e78d300b36e9338315_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi05LTEtMS0xMzQ2OTM_6e5f08e5-9982-4e42-ab25-8de073a01562">68.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7cee2e97b0274d3aa6084ff72dceb5e3_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xMS0xLTEtMTM0Njkz_6bf4d663-dfa8-446f-8af1-4e8586710b72">106.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfaaee5621ff405286fd6056576cd59b_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xMy0xLTEtMTM0Njkz_f4d5e2c1-e3ae-4a96-93d7-05a2874bea94">13,911.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="if66f99b3393445feb052472c42d6ea59_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xNS0xLTEtMTM0Njkz_11d29300-137b-4e10-882c-cd4f6b3bd8b7">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if66f99b3393445feb052472c42d6ea59_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xNy0xLTEtMTM0Njkz_7b29d961-4087-4ffc-91f2-4af652b0e3b1">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e74df0a4fa34fa7b4d9f15ccfa2ccce_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xOS0xLTEtMTM0Njkz_b712a86e-3dd9-44e0-b0c3-f0f7779e1332">10,896.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3990a5fbd8c6491e91e119ed2fdea887_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0yMS0xLTEtMTM0Njkz_9348c71a-6067-46e6-8d6e-bf2cfebc269b">63.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0yMy0xLTEtMTM0Njkz_94536c04-4745-46ed-a9e9-e71c62a5d5e6">10,959.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i823c7f9f43d342ba884251bf9f5bd146_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0xMy0xLTEtMTM0Njkz_2e7d7f12-a1c0-422c-83c8-8d40d40fef52">2,496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0xOS0xLTEtMTM0Njkz_31080d92-4412-4206-90e3-86856b3f8ea0">2,496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic891f4015650489eb42c53e2bfc38c39_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0yMS0xLTEtMTM0Njkz_7fd1a309-044f-4ab1-af25-e096a7893542">84.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0yMy0xLTEtMTM0Njkz_e534237c-aa22-41ff-9720-7a525a4e8683">2,412.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e12504ff04743d888a4e88d3bff71b4_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNC0xMS0xLTEtMTM0Njkz_42e4466b-cc49-43c0-8490-e99fa7f0472a">56.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNC0xOS0xLTEtMTM0Njkz_8cc35c85-6a95-4977-811b-db640fc59eed">56.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNC0yMy0xLTEtMTM0Njkz_0443836c-4dad-4423-9afc-2793174c1049">56.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic891f4015650489eb42c53e2bfc38c39_D20220101-20220930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNi0yMS0xLTEtMTM0Njkz_536ebe55-ea23-4cf9-a421-9fff5ae76e34">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNi0yMy0xLTEtMTM0Njkz_de9d9be8-c46b-4d5a-b630-40120d9cf621">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0xNS0xLTEtMTM0Njkz_d479f211-79f9-4138-87c2-7d27ea00c1a0">3.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0xNy0xLTEtMTM0Njkz_77e55f0e-c134-4723-9366-9f6339b7397c">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia0e15bd993a74d7398c821d849b6ea3c_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0xOS0xLTEtMTM0Njkz_592440a3-3ea0-4b2c-847d-67b9be20d251">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0yMy0xLTEtMTM0Njkz_65f81ae8-acf3-40ef-a699-339c9d1752b4">750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ia7258ddc589f4c9088e286caf7f6e0b7_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC01LTEtMS0xMzQ2OTM_71135029-edf3-4f0b-a51a-045979b50d5d">3.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4495699cfde945d2a01834b568e58db0_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC05LTEtMS0xMzQ2OTM_874d64fc-6ba9-46b3-8d68-d9299a68966c">257.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i016bab72022342ff94ff7761ad5e759f_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC0xMy0xLTEtMTM0Njkz_9e2cc628-b472-4032-93e5-17e06ddc1d17">492.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC0xNS0xLTEtMTM0Njkz_f4b7530a-fe04-48e6-8ec9-dd4ba0d002d7">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC0xNy0xLTEtMTM0Njkz_1049199c-cf20-4133-9115-23c3db8a1c78">750.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40f04ec35e4e4acb994f1e07cc20f981_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS01LTEtMS0xMzQ2OTM_512c5783-4c78-42ed-a57f-148f85e17aee">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS05LTEtMS0xMzQ2OTM_8ebb0583-26d3-4289-8904-df7ae7aa620d">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS0xOS0xLTEtMTM0Njkz_e21b41b8-0e16-48fa-ae42-1d668caf9a88">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS0yMy0xLTEtMTM0Njkz_ea2cb4ec-019a-4df0-844a-b28654c963b6">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i40f04ec35e4e4acb994f1e07cc20f981_D20220101-20220930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtNS0xLTEtMTM0Njkz_c3b23c27-f36e-41d6-87a9-65a7ff35012c">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtOS0xLTEtMTM0Njkz_20d0a6a9-ef6c-4347-b636-e3de1a1760d3">43.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtMTktMS0xLTEzNDY5Mw_4a065699-f9b2-4240-8971-cefb22f45ac3">43.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtMjMtMS0xLTEzNDY5Mw_4ff269e8-c453-4950-bf27-a1cc5c7172e2">43.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTEtOS0xLTEtMTM0Njkz_b701e2cf-0f0b-4e88-a133-6ca8e79ab276">194.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTEtMTktMS0xLTEzNDY5Mw_e062eaf8-80d8-4d77-a476-3094b252ddb9">194.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTEtMjMtMS0xLTEzNDY5Mw_b6f61b33-92c8-41f4-9b8e-5549b48a8e34">194.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTItOS0xLTEtMTM0Njkz_7594154a-3079-4689-9762-581f32cea37f">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTItMTktMS0xLTEzNDY5Mw_9e876f53-6266-435f-960a-0230f08f966b">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTItMjMtMS0xLTEzNDY5Mw_be2b3afc-b8d7-4101-9bfe-2fd0d42b678f">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2022</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMS0xLTEtMTM0Njkz_d258d0e5-f948-4456-b55f-05bd02606b3a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMy0xLTEtMTM0Njkz_b96f9fed-b0a5-44ba-bab5-ee4d27f1fdfd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtNS0xLTEtMTM0Njkz_9a5e022d-eeb0-45e2-ad4e-73bdd381627b">167.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtNy0xLTEtMTM0Njkz_76e2915f-b251-4d02-bdf7-24d487095ff0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5068c3b18e94e8eaaf2091ea3cf9695_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtOS0xLTEtMTM0Njkz_bd142849-6190-4f4f-8d65-d929e830f444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e0fa57a6c3f4fa4942ba9c62ac16a53_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTEtMS0xLTEzNDY5Mw_63386bcd-7a3b-4e6d-bd46-a29a9df37135">163.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b3d30bc29ae41cb9335a4b23f385945_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTMtMS0xLTEzNDY5Mw_122bf409-ae23-4be7-a539-e3580dc8effb">15,916.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTUtMS0xLTEzNDY5Mw_7ff89596-2930-4d0d-b9b4-07ebd0bdeda4">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTctMS0xLTEzNDY5Mw_99a5d0c8-842c-40cb-af2d-bf6ea3f1a8a8">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie2a2cbbf2a9947cc889f57763f6fb24a_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTktMS0xLTEzNDY5Mw_cedde628-84cc-470a-a6a0-206ffa736ff3">12,775.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7ac4673c093c48e281f08d7e26c19005_I20220930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMjEtMS0xLTEzNDY5Mw_dab81fa2-9d0e-4faf-b14d-417e68cc1994">8.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMjMtMS0xLTEzNDY5Mw_c0c269b2-122d-4e95-950f-02e7bc7c529d">12,766.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span><br/></span></div><div style="padding-left:54pt;padding-right:54pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2021</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia6ecf9467f994f5599b5246c048da7f0_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xLTEtMS0xMzQ2OTM_b59a38fb-7c47-40fc-865b-07907ec6be31">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6ecf9467f994f5599b5246c048da7f0_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0zLTEtMS0xMzQ2OTM_7df46929-ba91-4bcf-845a-5a3b4ec71eec">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if30d21aaea274bffaf4cb30ef1f8e3dc_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi01LTEtMS0xMzQ2OTM_46dd246c-eb6a-416c-a5f1-d9c4f75cf012">172.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if30d21aaea274bffaf4cb30ef1f8e3dc_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi03LTEtMS0xMzQ2OTM_2a81111d-9ec9-495f-a1fb-25052de64e30">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fb9684f2f3649a1bffccb6af71ea857_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi05LTEtMS0xMzQ2OTM_4bbae366-45a5-4310-b6c1-5991e94654ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i49fb8433ee7144e590c0de93a2924ac6_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xMS0xLTEtMTM0Njkz_3bb30992-075d-49f4-9077-e9b8631e5f30">171.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8eac1696a0f401e8764ac4f1f27de37_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xMy0xLTEtMTM0Njkz_a2e3ffbf-19fc-4137-beb3-24334e91dd17">13,900.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib4194d914ec04ff093919ddd1c085893_I20210630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xNS0xLTEtMTM0Njkz_5698ada5-520a-4494-bbf9-6a5c9aa3b4c7">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4194d914ec04ff093919ddd1c085893_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xNy0xLTEtMTM0Njkz_fd8afcdc-efc4-40e0-9f03-d37776328eb0">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib55ef7924a674515889fe70f6b17eb7f_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xOS0xLTEtMTM0Njkz_dd1321f1-2318-4751-a637-113d29668a8d">10,751.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71feb4d0055c4b68bbe964b0257e980a_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0yMS0xLTEtMTM0Njkz_4f4fab2b-6f2a-44ea-9ea3-eab413a0528e">462.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5de6cf32968c4297a40eb09bdeb942bc_I20210630" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0yMy0xLTEtMTM0Njkz_3c384ca8-2d58-455c-bb73-ecde9749bc07">11,214.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21588e5af69246eb8bf060b182d4cef9_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0xMy0xLTEtMTM0Njkz_1c5ee336-204e-4e04-a81e-af9031440a1e">329.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0xOS0xLTEtMTM0Njkz_dcd2d547-6ce7-44e8-8c86-5bd54d091429">329.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e1be32983094b30a756db2fdf7ba492_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0yMS0xLTEtMTM0Njkz_e608146a-7528-4126-90a9-c441f7b122e1">11.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0yMy0xLTEtMTM0Njkz_4caa5633-aad2-49d0-bfed-fcc0b1616ecd">318.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i830fd3fe92594ddca8ffd711b4e954ed_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0xMS0xLTEtMTM0Njkz_bba3845e-797e-4579-aa2a-c7e579e345ce">35.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0xOS0xLTEtMTM0Njkz_130eb89d-c0ec-4eb6-b8df-ef5a657488be">35.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e1be32983094b30a756db2fdf7ba492_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0yMS0xLTEtMTM0Njkz_8e546ced-95d7-49df-b27b-df6e452e86b9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0yMy0xLTEtMTM0Njkz_cbf57e7d-12f4-4bad-b940-4fed83f4ce20">35.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0xNS0xLTEtMTM0Njkz_569ef62a-562c-4806-9573-963673da75dd">2.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0xNy0xLTEtMTM0Njkz_66234a46-d525-4872-b5ac-8425e41d4547">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied6c3cb168af4d3f93e74f6073e0a218_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0xOS0xLTEtMTM0Njkz_a171a753-1ece-42d4-8bf1-c9b12445f639">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0yMy0xLTEtMTM0Njkz_54413991-2afc-4dc5-bd56-2a04f6962e8c">750.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4d3c54dd7e9843cea195c454def9d2ee_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC01LTEtMS0xMzQ2OTM_320ef945-bd99-434c-bcb1-990a2671dbb4">2.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5351af1a8e574e448a3647a4f7afd7b0_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC05LTEtMS0xMzQ2OTM_9dfbd1f8-d40c-4b70-99b0-6dd0393b070f">68.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i940fb720af7649c3b174e6131bd6809b_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC0xMy0xLTEtMTM0Njkz_76e35260-e558-4259-8ed2-afc8408f8310">681.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC0xNS0xLTEtMTM0Njkz_2d550f02-08fd-4e84-82b5-b7fea9f11ace">2.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC0xNy0xLTEtMTM0Njkz_08c5d949-cedc-41c7-88e7-1f68d0b4078f">750.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacd07c7062014cc6810ba0fe03987501_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS01LTEtMS0xMzQ2OTM_545a0747-163d-4df9-8ead-23118df5c359">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a55df4cbc94d0f84173632a99327a0_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS05LTEtMS0xMzQ2OTM_962f0926-4251-42ec-bb4a-5d6dcca866a5">11.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS0xOS0xLTEtMTM0Njkz_4a7edf9e-a2b2-4df1-ab17-ce28903c10b9">11.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS0yMy0xLTEtMTM0Njkz_10a0e76c-557b-43bb-8f09-90dc90203024">11.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iacd07c7062014cc6810ba0fe03987501_D20210701-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtNS0xLTEtMTM0Njkz_029a22f9-7a4c-47ec-96ba-f4485c929998">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i21588e5af69246eb8bf060b182d4cef9_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtMTMtMS0xLTEzNDY5Mw_6356457d-adcf-49bb-ab69-1427fbf9026b">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtMTktMS0xLTEzNDY5Mw_0a61b24e-887b-4915-a366-e5da10ea2a49">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtMjMtMS0xLTEzNDY5Mw_b50ace79-c759-4079-87dd-0126c4bd5092">5.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3a55df4cbc94d0f84173632a99327a0_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTEtOS0xLTEtMTM0Njkz_fdd27bd2-6d6b-4675-956c-cdf47eca7cd1">57.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTEtMTktMS0xLTEzNDY5Mw_64bb3de4-6c6c-46fa-bc0b-94431e9335ca">57.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTEtMjMtMS0xLTEzNDY5Mw_c4bb591a-d222-4cf7-b930-4db53ad1f937">57.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMS0xLTEtMTM0Njkz_691ce58a-2deb-4898-b7e4-72b30520451f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMy0xLTEtMTM0Njkz_5db7fea1-6d3d-4233-9b7c-8adcf50cee33">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtNS0xLTEtMTM0Njkz_b82e98af-dfa9-401a-9e3a-eaa732623bfe">170.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtNy0xLTEtMTM0Njkz_2a127830-935f-47cd-be2d-22621351cfdc">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7fcd64658864191b6d0041174b23749_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtOS0xLTEtMTM0Njkz_18813ea4-a0c1-41ee-8bf4-90b30fed9715">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7543833405d140a9b03a3c2c4959f28c_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTEtMS0xLTEzNDY5Mw_217924a2-f085-44d1-9996-28c935337f64">136.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97905b3b54ce40cb912f87e63e0db92d_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTMtMS0xLTEzNDY5Mw_c4118969-a54b-427a-a06b-c4f1734a8d14">13,543.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTUtMS0xLTEzNDY5Mw_32456f19-6793-446f-a2ad-2ecf342fe962">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTctMS0xLTEzNDY5Mw_a4f68d6f-5654-4b1b-b411-1e531140f7ba">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id028a6bff3b24d2f9b0854cfb01e2f33_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTktMS0xLTEzNDY5Mw_ba6cae48-d1ea-4171-a423-993b0a54a0d3">10,429.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcd0ac5de004c8584ccf204981e3c5a_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMjEtMS0xLTEzNDY5Mw_98353f05-1977-4d14-85db-68535656b161">451.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957729f8711844ff89317163bd3b28ee_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMjMtMS0xLTEzNDY5Mw_3d792f45-cffd-48f6-a26b-85a760bfc2c7">10,881.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.458%"><tr><td style="width:1.0%"></td><td style="width:19.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.361%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.578%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.558%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.755%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.408%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.061%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.872%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Noncontrolling<br/>interests</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2020</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if91d142efb024f1784dcfc0a7ba633de_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xLTEtMS0xMzQ2OTM_4ca1c897-4427-4a08-9865-65ab17a596cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if91d142efb024f1784dcfc0a7ba633de_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0zLTEtMS0xMzQ2OTM_e78890bc-a40a-4226-8f7e-a2cb86db086f">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1ae20d5729dc44e2bbeb4f64c73911df_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi01LTEtMS0xMzQ2OTM_a4a6a1ed-8729-4137-8ea5-59681e59f07c">176.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ae20d5729dc44e2bbeb4f64c73911df_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi03LTEtMS0xMzQ2OTM_2c2f9ac8-e98a-4e19-858d-ba676c1ef08c">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85003cc1f8c04f36b4ffbbf6882c9e1e_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi05LTEtMS0xMzQ2OTM_75b1abe9-9af7-4da5-a6d9-df418b4bab76">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9e6a8dcb7c44e968654b2542e3eba4c_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xMS0xLTEtMTM0Njkz_760c716b-6b4e-453d-a3fb-cd8c88dd6669">299.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida229f85edf14616bba475cf65eab0e5_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xMy0xLTEtMTM0Njkz_4f0dcded-fada-43e0-9a5c-7ffe6d5a7b07">13,976.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ide8a35ebfa6c49c4940e18829274b634_I20201231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xNS0xLTEtMTM0Njkz_3755262f-fcf5-43e1-86e3-4a258144b259">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ide8a35ebfa6c49c4940e18829274b634_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xNy0xLTEtMTM0Njkz_9c767e48-bbe8-4f7b-a4ed-fb590760b26f">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i672dd8e6f6974a0681e2532e151fe07d_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xOS0xLTEtMTM0Njkz_e5bfa0d8-8b89-4e97-8fb6-1d02a5870d20">10,700.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7764d2904f084d0487b1c7d0a1c60a98_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0yMS0xLTEtMTM0Njkz_93654d06-e616-482a-91dc-13ad721e61c1">14.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0yMy0xLTEtMTM0Njkz_06d8efff-9d8a-4320-b972-567dc0a1d2d0">10,686.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d65d2e85cb14209a4f5a5f72eaf1a06_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0xMy0xLTEtMTM0Njkz_6178df7f-d9e7-4256-8dba-f6ea35b2aefc">1,187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0xOS0xLTEtMTM0Njkz_1a7849d2-dfe5-4099-aa48-8f0dc4e82b32">1,187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0yMS0xLTEtMTM0Njkz_c1d75c88-6551-419a-9e46-e4cfa8658f27">560.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0yMy0xLTEtMTM0Njkz_6543431b-07e3-4fe9-8077-ad9694b0ee04">1,748.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id80ceaef197d43efbe8a7cb665f36bd3_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0xMS0xLTEtMTM0Njkz_b49fa3cd-6ce3-40d1-a230-96dba3c5cb52">162.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0xOS0xLTEtMTM0Njkz_3ba3b3f7-8144-41b0-beda-d232f5a5f542">162.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0yMS0xLTEtMTM0Njkz_d71164a5-aa4d-4ce8-99be-51d6acb28b1e">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0yMy0xLTEtMTM0Njkz_29b835cc-0876-47f6-a83e-b505b5b397cd">163.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Distribution to noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNS0yMS0xLTEtMTM0Njkz_40c61a8c-00c3-4d2a-839d-fbe11b51b815">100.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNS0yMy0xLTEtMTM0Njkz_190d0de2-a3db-4279-ae40-e02064733332">100.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capital contribution from noncontrolling interest</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNi0yMS0xLTEtMTM0Njkz_8c325ba3-1300-4844-9845-fcc46f708a7d">5.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:NoncontrollingInterestCapitalContribution" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNi0yMy0xLTEtMTM0Njkz_e2a6d02c-6796-40f6-b196-f548234c1fbf">5.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Repurchase of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0xNS0xLTEtMTM0Njkz_4f7da10b-0a91-4658-9363-dcd156b626a8">6.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0xNy0xLTEtMTM0Njkz_fcde60e4-27c6-4145-933b-edaa8857806c">1,800.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5a8c604e337a41529c5ebe37e6e83167_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0xOS0xLTEtMTM0Njkz_54ff4269-5331-4a17-97c1-e14aa52f5e2f">1,800.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0yMy0xLTEtMTM0Njkz_a9d83a6b-eb18-4ca3-a97e-ad37712c82a1">1,800.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Retirement of common stock pursuant to the 2020 Share Repurchase Program, at cost</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib7dcf494036c4e47bb9cb906a08568a5_D20210101-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC01LTEtMS0xMzQ2OTM_57e13171-96b4-41f2-b751-dac3bbc601af">6.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i66de57d0942e46cfb25b1d0f1fd008d1_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC05LTEtMS0xMzQ2OTM_b14a921d-da23-438e-b529-4cd8f0c905af">231.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idbd356e38fd146938c9d48f464ee5866_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC0xMy0xLTEtMTM0Njkz_cdfc34ad-07d8-410c-a827-259aeaa149c3">1,568.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC0xNS0xLTEtMTM0Njkz_c45e453f-58bf-4d9d-acfb-3de4fada30c8">6.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC0xNy0xLTEtMTM0Njkz_06d3d72c-1cac-4923-87ed-e64b77aef2a0">1,800.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07d6d89e16864773a22d6d824c32ffd4_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS01LTEtMS0xMzQ2OTM_d7564d3a-6917-4b70-839e-95e24aae0c60">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS05LTEtMS0xMzQ2OTM_681534a7-6fb2-4c15-b6d7-eb38ada839df">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS0xOS0xLTEtMTM0Njkz_b2b8871e-5a8a-4a65-a685-a189df05233f">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS0yMy0xLTEtMTM0Njkz_9daf1d87-1197-47cd-8edd-9231cfb3d8fa">44.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07d6d89e16864773a22d6d824c32ffd4_D20210101-20210930" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtNS0xLTEtMTM0Njkz_bf9898fd-7177-4408-b017-357383513c71">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9d65d2e85cb14209a4f5a5f72eaf1a06_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtMTMtMS0xLTEzNDY5Mw_4d1602cf-ccd4-4343-a174-f811fa0307d6">52.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtMTktMS0xLTEzNDY5Mw_36bbc237-f6dd-4ccc-b21c-5132d82f9103">52.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtMjMtMS0xLTEzNDY5Mw_fe51e5ff-06a9-4744-a0de-72b546f5a607">52.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTEtOS0xLTEtMTM0Njkz_bc56b8e7-6244-400d-ab5c-76ae970708e3">186.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTEtMTktMS0xLTEzNDY5Mw_05bde443-94da-4f1d-87f6-0b8c5176c75d">186.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTEtMjMtMS0xLTEzNDY5Mw_15a966d2-ad35-4a77-99b9-d12196bda391">186.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTItOS0xLTEtMTM0Njkz_81df3628-5223-4e54-8b09-4f7fce401f87">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTItMTktMS0xLTEzNDY5Mw_c378bfed-e201-4e44-82ff-a0498b92e96b">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTItMjMtMS0xLTEzNDY5Mw_22913fda-c522-48e7-bf38-15272fb91f7c">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2021</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMS0xLTEtMTM0Njkz_bd537360-b8f9-482c-8698-f2bcc1d8fc87">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMy0xLTEtMTM0Njkz_48027d77-4d99-4626-8234-79487bd62cf5">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtNS0xLTEtMTM0Njkz_2c35bbc4-cd14-42ad-8aa4-a7e03c469808">170.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtNy0xLTEtMTM0Njkz_2dbe8b97-fc4d-4911-9a79-a1625f1cce1d">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7fcd64658864191b6d0041174b23749_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtOS0xLTEtMTM0Njkz_a5932d76-ce62-45b3-8cfc-6ba8c8490799">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7543833405d140a9b03a3c2c4959f28c_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTEtMS0xLTEzNDY5Mw_f376177b-7969-4005-a4db-fef57ab71f57">136.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97905b3b54ce40cb912f87e63e0db92d_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTMtMS0xLTEzNDY5Mw_6b30bbc9-6c50-4789-bee7-4d09336bbb1e">13,543.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTUtMS0xLTEzNDY5Mw_126e9e9a-75e2-4e5a-bcdd-d61d1fb09df8">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTctMS0xLTEzNDY5Mw_fcc93f4d-2747-445f-a2ee-395e3bf11ffd">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id028a6bff3b24d2f9b0854cfb01e2f33_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTktMS0xLTEzNDY5Mw_8f2a55d3-1c5e-498c-a9c5-ddf17349b9d6">10,429.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcd0ac5de004c8584ccf204981e3c5a_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMjEtMS0xLTEzNDY5Mw_e6afb7b8-0653-4073-a77d-8c984b965975">451.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i957729f8711844ff89317163bd3b28ee_I20210930" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMjMtMS0xLTEzNDY5Mw_acf13bf2-22c1-4037-9457-f1f747b732af">10,881.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_34"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_37"></div><div style="padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUyMA_aa407ce3-0285-49d5-a2d1-4a9d781a80c1" continuedAt="ib31f7943444f4c04a9323dd0bccd43a6" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:BusinessOverviewPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUwNw_00e936f1-c86f-4da6-a1d2-cfd28db56b0a" continuedAt="ia14a767f9aea4349b394ec50700722ce" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="ia14a767f9aea4349b394ec50700722ce" continuedAt="icfaa4d992c364eefb96509d677f44142"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="icfaa4d992c364eefb96509d677f44142"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</ix:continuation> </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUyOA_472664b1-1a9c-4807-98e9-76f169741563" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfNDExMA_7fd3f8e8-d545-4e07-a3ed-9fdd0a44f2a9">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ib31f7943444f4c04a9323dd0bccd43a6" continuedAt="i33c45d8e179d496ea05b5a9696f9bca4"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUzNg_1b2ab6c3-207d-4177-b5ab-58f5fa588750" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfNDYyMA_50e57475-eccc-4fdc-83d9-fa3abfc6bbd4">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUzMw_62c1246b-0610-495b-872a-2b0d90ec73de" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUyMg_054964a2-6c2f-41b4-967b-fcb402aef3aa" continuedAt="if2fb638ed81b4292819a581576d530f9" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="i33c45d8e179d496ea05b5a9696f9bca4"><ix:continuation id="if2fb638ed81b4292819a581576d530f9">In June 2022 the FASB issued Accounting Standards Update (ASU) No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022.</ix:continuation></ix:continuation> Upon adoption, we recorded an immaterial amount in other (income) expense as a result of removing the impact of the remaining contractual sale restrictions from the fair value measurement of certain shares in Sage Therapeutics, Inc. (Sage). </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_43"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjgzMg_bd1a19f3-bee3-4be0-85af-36841002142b" continuedAt="i017bdc07ab24459d9e8bf407ecac460c" escape="true">DISPOSITIONS </ix:nonNumeric></span></div><ix:continuation id="i017bdc07ab24459d9e8bf407ecac460c"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTEz_87489fb2-69a4-4e3a-922d-19880424e2d7">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics). Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjY1_192d59ff-ed91-4d07-9503-7ea9bcb0fdf6">1.0</ix:nonFraction>&#160;billion in cash at closing and expect to receive approximately $<ix:nonFraction unitRef="usd" contextRef="i316ee61fce71448090e9e99d3e03605f_I20220131" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMzIz_0fcfce3c-0a3a-4d42-8efc-11d188235b8c">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i607186b7dfc843688ebf32e0578fc19b_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMzg0_f667ce64-0313-4cfb-9416-315c9efa1b7f">812.5</ix:nonFraction>&#160;million due at the first anniversary and approximately $<ix:nonFraction unitRef="usd" contextRef="ie8da0e6904f247e0a072f97c4201c43b_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNDM0_a92fa58f-a17f-4dc0-bb3c-41f9b74f1baa">437.5</ix:nonFraction>&#160;million due at the second anniversary of the closing of this transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale, the carrying value</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our investment in Samsung Bioepis totaled $<ix:nonFraction unitRef="krw" contextRef="i30e4e1687d1446f2a418d8e2edce385e_I20220630" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNTg2_fa54f23b-700e-42c9-ae65-a3c09436456f">581.6</ix:nonFraction>&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized a pre-tax gain of approximately $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-8" sign="-" name="us-gaap:GainLossOnSaleOfInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNjcx_ea2f9c94-9f2f-4d5b-af1e-9707bfddc082">1.5</ix:nonFraction>&#160;billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to net income of approximately $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfOTMx_ce8967d6-690b-49f9-b468-9818a46427b3">58.9</ix:nonFraction>&#160;million in cumulative translation losses, partially offset by approximately $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTAwMg_879562a8-55d4-4f73-8dbc-91be6cf85ccb">57.0</ix:nonFraction>&#160;million in gains resulting from the termination of our net investment hedge.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our condensed consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of September 30, 2022, the estimated fair values of the first and second payments using risk-adjusted discount rates of <ix:nonFraction unitRef="number" contextRef="ic1f7ed163c5b4dc1a6bbd9abf449fa0f_I20220930" decimals="3" name="biib:OtherAssetsMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNTQ5NzU1ODE4NTYz_e3f8e5d8-6f69-45dd-8bfb-6c9566550125">4.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0f5bb12cf4d14733835facacabb3cc9b_I20220930" decimals="3" name="biib:OtherAssetsMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNTQ5NzU1ODE4NTcx_673d48bc-2550-4bac-808a-526ba49307bb">5.3</ix:nonFraction>%, respectively, were approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTcwMw_0b7ee53a-ccdc-4672-b67c-3c0a7052eb6e">790.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTcxMA_2e1d8a79-b1b6-4f87-8013-e2abfb52c0cc">402.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, respectively. These payments have been classified as level 3 measurements and are reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">months ended September 30, 2022, we recognized a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="iba57778587524c7389b5d85413395030_D20220701-20220930" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjE5OTAyMzI1OTIwMg_2b7df0c5-7463-434b-ac1c-eb48f3aef2df">2.7</ix:nonFraction>&#160;million and a loss of approximately $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjE5OTAyMzI1OTIzOQ_bd89af3d-cde4-481d-bf04-e2d8184ec7eb">4.0</ix:nonFraction>&#160;million to reflect the changes in fair value related to our first and second payments, respectively. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTk4NQ_96136127-4524-4f39-b718-e6b4699c4026">50.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any payments due to us remain outstanding after the second anniversary of the closing of this transaction, we may elect to receive shares of Samsung BioLogics common stock at a <ix:nonFraction unitRef="number" contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430" decimals="INF" name="biib:PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjM5Nw_90a0f5d6-350b-48f9-878b-a09900461392">5.0</ix:nonFraction>% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for the nine months ended September 30, 2022, we recorded a discrete tax expense of approximately $<ix:nonFraction unitRef="usd" contextRef="iba57778587524c7389b5d85413395030_D20220701-20220930" decimals="-5" name="biib:DiscreteIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjY5OA_7a4e25a4-fae7-4178-beb1-2a3efb7b0fe1"><ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" name="biib:DiscreteIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjY5OA_ea0ab306-cfe3-4f95-b1e1-cb381a806ed3">258.3</ix:nonFraction></ix:nonFraction>&#160;million related to this transaction, which is reflected in income tax (benefit) expense in our condensed consolidated statements of income.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_46"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjQyMw_29faf7d6-6c18-457e-ad11-0fbbf4553c3b" continuedAt="i5c1bef11697044009f773ce035898730" escape="true">RESTRUCTURING </ix:nonNumeric></span></div><ix:continuation id="i5c1bef11697044009f773ce035898730" continuedAt="i69c79e3223da4e7aa98f2670871e5dc3"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $<ix:nonFraction unitRef="usd" contextRef="i50d36a66d9ab43cdb58d18874e1a3785_D20230101-20230630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNTk0_1f24a0d7-63cf-447b-9bec-cba1f44abbd1">130.0</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="i61ca34953d844cb0860dc038de00e235_D20230101-20230630" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNjAw_a3a9a711-ca43-4fc3-876e-5b9fba4e3a80">150.0</ix:nonFraction>&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i69c79e3223da4e7aa98f2670871e5dc3"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNzkx_f5a7aa6b-b3a8-443b-852a-3452784325ea">15.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNzk4_aea80e3e-4dc5-4806-abd1-3e26089ac6ac">124.1</ix:nonFraction> million, respectively, of net pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfOTE3_18cef8ef-1a65-4cc5-9b41-fa546f107d2e">21.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfOTI0_8c9f148d-5894-4ea7-bf8b-6e1a6d5c8618">110.2</ix:nonFraction>&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets. In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge, MA (300 Binney Street), as well as to reduce the lease term for the majority of the remaining space.  This resulted in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930" decimals="-5" name="biib:GainLossOnRestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjc0ODc3OTA3MzgzMQ_0e597dce-283b-4818-902c-285225afb820">5.3</ix:nonFraction>&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. For additional information on our 300 Binney Street lease modification, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the nine months ended September 30, 2022, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:RestructuringReserveAcceleratedDepreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMTU1NQ_4d4cfa08-7506-468b-ba3e-d7df631decd9">10.4</ix:nonFraction>&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized other restructuring costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjA0Mw_6a81fee7-5228-4d9c-8dc3-ea9187f5f2d6">8.8</ix:nonFraction>&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjQzMw_11edc2d5-3b89-40bd-8e21-adc3887cddfb" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:82.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.545%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1f37877cc204468be6364c936821118_I20211231" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMS0yLTEtMS0xMzQ2OTM_4e4ccf0c-1c6a-4eb6-b8bb-a39783d24480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d680499749847fbb5726594897a6967_D20220101-20220331" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMi0yLTEtMS0xMzQ2OTM_b1daa9e3-6a2b-4a4a-a555-f0b085145902">27.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d680499749847fbb5726594897a6967_D20220101-20220331" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMy0yLTEtMS0xMzQ2OTM_c16a5c86-ca15-411a-9fb7-83cde36ac890">6.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea6f6f793edc47d08a4cb4fbe2bea78d_I20220331" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfNS0yLTEtMS0xMzQ2OTM_da952152-08ec-46a4-b94c-46b1a38708fa">21.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f41754e9d7e480eb6a52dc448c1e2bc_D20220401-20220630" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfNi0yLTEtMS0xMzQ2OTM_be2d9295-6fc3-468d-8de6-79eab03552ab">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f41754e9d7e480eb6a52dc448c1e2bc_D20220401-20220630" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfNy0yLTEtMS0xMzQ2OTM_4b2e4620-b765-4bf6-93d8-d34af60c54c9">29.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfOC0yLTEtMS0xMzQ2OTM_5ad27e26-290c-494f-b383-be240ea18012">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe53d000d3d24ab085f9e7a60f3038fc_I20220630" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfOS0yLTEtMS0xMzQ2OTM_7b435f89-61ee-48fc-84d5-f13ca9dff087">52.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50e9ef276762476587698a382951d243_D20220701-20220930" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTAtMi0xLTEtMTM3MDQz_e8c4e125-b0a7-4f41-841e-c3114539f9c3">21.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i50e9ef276762476587698a382951d243_D20220701-20220930" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTEtMi0xLTEtMTM3MDQz_0a3ab7d2-d52a-4fd6-bdb1-8c503105a8a4">32.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:RestructuringReserveAccrualAdjustment1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTItMi0xLTEtMTQ4OTAx_3171f6d2-633b-4dc7-8e58-bf56fe07272d">1.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75d90b3006f344218e928d1ad4dfdd95_I20220930" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTItMi0xLTEtMTM3MDQz_e9d29ccb-f250-416b-b9b6-cc939e72104d">40.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_49"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;REVENUE </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYwNw_0ccad4ec-57e4-414f-b2c1-d866cea9208f" continuedAt="i24f503b293024349b32f2754cb0aa670" escape="true"><div style="margin-top:6pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYyMQ_c3c15d9b-f532-47e2-9a50-380c28589e34" continuedAt="iedc630483d404ab3a17392d50f7bb0cf" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieae68b14dd844654b97d8e0821a7d63d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC0yLTEtMS0xMzQ2OTM_b9d0744d-159d-402a-8459-d5c56c9ade13">92.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia678bb0bdba34f6d8468b6ea458c7c67_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC00LTEtMS0xMzQ2OTM_0a8b2ff9-aba0-408c-b16b-d321056abb10">246.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idee5f0f1a0fc412eac579e1d0b56f5c0_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC02LTEtMS0xMzQ2OTM_f2a17845-582e-46ed-bb5f-e381bd7770e8">339.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i524a5a89350540a3bc0f4b10a71bb6aa_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC04LTEtMS0xMzQ2OTM_a9eb5344-359f-4f74-8677-494fb09ee471">179.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94cd8b6ab6a24b2d8c28a1fef87c6153_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC0xMC0xLTEtMTM0Njkz_b8c1f727-4ef7-453c-8fd8-586533fcbb21">319.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia14b4c4bce6a4909a76b690dbb1dda86_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC0xMi0xLTEtMTM0Njkz_fc660a28-8b48-46aa-bbb4-0619fd4e5de2">498.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i052a675de8aa4e5d9832465ff8570284_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS0yLTEtMS0xMzQ2OTM_f2a9ee85-f935-4a44-b89f-2649d7ac60f2">127.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibada012125344986aaa29e2b44e3995b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS00LTEtMS0xMzQ2OTM_a5ae98b3-c669-4901-8308-6cc6848905be">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecc52be6137340a5b547b2482e77071b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS02LTEtMS0xMzQ2OTM_0f56269d-f6da-4f34-949b-6bbbf662c06e">137.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30f15676d39144d6be62e0983a2c677d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS04LTEtMS0xMzQ2OTM_8e3aad25-b29a-4aad-881d-c37e7edb24de">120.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d433d159ae4a1ab0cd0e666f0067b5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS0xMC0xLTEtMTM0Njkz_5bb3ce1f-ac6b-4519-a929-d7a3402a1c29">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86dce0a14ccd4ac7b68ee2512c78b229_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS0xMi0xLTEtMTM0Njkz_96542bbb-48c3-4cf4-83da-2ce7549bc461">120.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5d02c3121d046fa80f33ce0ea159f1b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi0yLTEtMS0xMzQ2OTM_10bdc958-8861-4425-bffa-76aa4387d1a5">220.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id90d2fa8645d41c59b47948a99c4c9a8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi00LTEtMS0xMzQ2OTM_82833f0d-8191-4f9d-b030-ad26ac005f9f">256.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb6cdfb945042ec929ed76602fc0d41_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi02LTEtMS0xMzQ2OTM_f5c6cbe1-7a20-4039-a88d-53a73be650ca">476.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic82f6ca075b24e908f242a5f756da00b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi04LTEtMS0xMzQ2OTM_14f50696-deae-43d9-97ce-3bfff6c5d445">299.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0112f1abc12545e994f30a836d2cb12f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi0xMC0xLTEtMTM0Njkz_301f7ba2-0057-42b0-9d97-447941b97e00">319.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a4811b664994d1a81bade00a2863057_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi0xMi0xLTEtMTM0Njkz_5b3df34e-f762-4b57-b150-1fd2cad8a743">619.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2775701ccced4d349950476cf4ac935f_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy0yLTEtMS0xMzQ2OTM_19cf4c31-4bad-4f4a-9b50-984a4637ed40">174.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9e8c8756b2146eca09944df5c248397_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy00LTEtMS0xMzQ2OTM_ec60fdaa-6c43-46d5-afbc-946f1382c61a">80.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5abd26923c541018c31b313875f2f0a_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy02LTEtMS0xMzQ2OTM_b5bdd1f3-9397-425a-b323-d17b7aee4e7e">255.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54d1f43c44b042958f27d4875e2c518e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy04LTEtMS0xMzQ2OTM_e00ef1ca-94d6-4115-9e6f-813b699dc513">213.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c9d7081eeb3425aaab5ae1f08229ad0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy0xMC0xLTEtMTM0Njkz_b00fc718-979b-4324-84fb-9e1ed28045ab">88.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e3fe4bcdeb74d82a40d4194dfecf8e0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy0xMi0xLTEtMTM0Njkz_058d8f49-dec6-46cb-a324-895b9187e837">301.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a55754206442b9ad7d2a15bb0c2ed8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC0yLTEtMS0xMzQ2OTM_b71bc96e-475e-4245-afa0-9393a69c9781">39.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1539f85dca834b21b083a5841069d1f9_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC00LTEtMS0xMzQ2OTM_f0a67707-1e47-44d1-9556-a412b39d995f">41.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i413272e3f9254d67a44927e69cdc2477_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC02LTEtMS0xMzQ2OTM_546779fc-bd11-4e5a-b9d4-d5bd09d5273d">80.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1260db1e62944da8c762971630a803f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC04LTEtMS0xMzQ2OTM_c30b7d44-ad3a-4f08-a9b1-126254c3167d">39.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a6c9354a1594ed984122907bfaf64d9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC0xMC0xLTEtMTM0Njkz_d1d81940-d6c5-4243-865c-5ef486fffe67">47.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd1a7dde2606420ab2beaa988524cc5e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC0xMi0xLTEtMTM0Njkz_3ffacbad-ad9e-4d71-b8b8-a4e1f26d2682">86.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67dbc5422bc347699fed7d1ba9192ef3_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS0yLTEtMS0xMzQ2OTM_40c16178-0b3f-4cb6-8d72-943bdc0e47cf">214.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54b6aedfcba481d9b05a81e2c49254c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS00LTEtMS0xMzQ2OTM_5c1a6002-0cff-442e-8d2e-834126e29cc3">121.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a3f69c1b08b48a7ad41ca04403e0c5c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS02LTEtMS0xMzQ2OTM_2e8ead92-a868-4009-8461-3ee26160fa8c">336.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c8b237efb1e4c6bb345fa501d512b04_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS04LTEtMS0xMzQ2OTM_ba0c2ef8-2244-49e0-985d-935bd513eab1">252.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35666f9afdf94c86b0dadb5d20099aa4_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS0xMC0xLTEtMTM0Njkz_df020e1c-f079-408a-b0a7-89dc5562911d">135.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2eff75aba234462e895ad96c0ec0c13c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS0xMi0xLTEtMTM0Njkz_401d30e2-da18-40d3-86f5-23db840ada99">387.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca6a0988c1143f78d17d64f36bd59d0_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtMi0xLTEtMTM0Njkz_088db5b5-59a0-49d3-a627-baa5c352d983">273.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f4ebfef6a604efa9a0c65992472c0d7_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtNC0xLTEtMTM0Njkz_cb84f924-cb89-4ca9-841b-fe18e7606688">232.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4b9ad0869ff4c3fb817b4710e10a630_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtNi0xLTEtMTM0Njkz_ad5a9f1c-e53c-4143-a7e1-2eca07812ab9">505.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i15a90a6d21554cd3b7fbe3e029fbaac9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtOC0xLTEtMTM0Njkz_8212042f-7569-44af-a06d-d6fc4c57c9d1">281.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9fe0b10bf3a4a2fbaac7c18a2d43b48_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtMTAtMS0xLTEzNDY5Mw_3b0bf920-2fa3-4fa8-8c2d-394dca9b91b2">241.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe746589d79e42be854dd4cb784c05e9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtMTItMS0xLTEzNDY5Mw_53fdb895-a0fb-4a56-a231-711a58afc75e">522.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00b404c1c0143a69096eacb3dc9e10c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtMi0xLTEtMTM0Njkz_ad065d86-c6cd-46a4-b74b-d2dfa701aa6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifebf0d8ca7134f8a863034f1a0b81573_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtNC0xLTEtMTM0Njkz_11b1099b-a7e0-4e97-b896-31c94c68f1f6">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a04530193ba4b518e49e6435d62ee0e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtNi0xLTEtMTM0Njkz_abd2e8ed-6a26-4a1a-877d-d608ce9b136f">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied70d0ff45d4458aa25726112c8513dd_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtOC0xLTEtMTM0Njkz_246c93a8-70b7-4e7c-a9c4-72c5ce4c53bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41cbc8191ce24bd3873905bcb5a73840_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtMTAtMS0xLTEzNDY5Mw_67cd9a9f-f6e7-421a-aeb5-6b2c5b9855a1">26.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d3ea9011ece4aec9bbf5dd07e371b5f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtMTItMS0xLTEzNDY5Mw_46954681-c839-4699-abaf-b8b2a327e0d1">26.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e67a47e02e64b21801d078a6891829d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItMi0xLTEtMTM0Njkz_184fcc33-ca97-49c1-838b-eb355c246b7c">707.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cb20e8bd6614d08aae2157a736ee0bc_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItNC0xLTEtMTM0Njkz_4b742bfb-9092-4dbd-83e4-79f55ddfb19e">632.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id05eb883732b498a834f089684813866_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItNi0xLTEtMTM0Njkz_46d9e19d-0beb-48a2-9f38-4bf988dc61fe">1,340.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iabd90fb1abfc4a8fb6a417188bd3b333_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItOC0xLTEtMTM0Njkz_5fb8dc3b-ca54-4e4d-9435-7cf5e81769ed">833.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d6326e426354c5cab099ca0de375d35_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItMTAtMS0xLTEzNDY5Mw_8fbb0460-dee4-4317-84fb-10177339849b">722.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8812745790a446cbad04fb159242ad1f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItMTItMS0xLTEzNDY5Mw_c4ba032a-a0d8-4883-8c00-451f3b6e3043">1,556.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e033d68ed2c41b3ad7632aa89aec9a8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtMi0xLTEtMTM0Njkz_fbca9a80-f3c2-4eeb-ae63-1c739928725a">140.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2af6c017ace04a208fed42ce9a986242_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtNC0xLTEtMTM0Njkz_384fc30e-93c3-4ec5-aa0c-60e1741934d1">290.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a5b99981159460c97cd042e3a67f70d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtNi0xLTEtMTM0Njkz_70d5d90f-452e-4c15-93d2-0fdbe261baeb">431.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i25429e48c15549dd9fd5d52789bdf66e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtOC0xLTEtMTM0Njkz_38bb225e-2680-4fe2-a241-209b893cceff">139.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i152fc65157fa4362b32c7674d4f3af52_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtMTAtMS0xLTEzNDY5Mw_2b0a8234-0698-4315-8797-fc31bfcbea25">304.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0c5c8cd61c24cfabd4664c10261b0e5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtMTItMS0xLTEzNDY5Mw_157c183a-e7ac-4702-bac5-0bb0fc518ab7">444.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i757c59aeb42e4b328db5739cfaf1d0cc_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtMi0xLTEtMTM0Njkz_84bab073-bf65-4339-9229-00f1f31a7449">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31ea0e171e14113bef79d2f5da80f7b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtNC0xLTEtMTM0Njkz_2e7cc5f8-daaf-488e-8ea2-4ea7e10b97ed">110.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9438c78c688a4bfeadfaaa6784905992_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtNi0xLTEtMTM0Njkz_dde6f406-a64b-42e1-8625-aec432a4a8f2">110.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12c8a988b4e0420e89ff703030bbadfa_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtOC0xLTEtMTM0Njkz_1bee3f8f-e128-4c34-929a-c03fc0912374">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d0a194344841dba3b5f8ff6d1c4f81_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtMTAtMS0xLTEzNDY5Mw_ac69ec18-1507-4d30-9319-550aac19cc63">120.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1908a95691ba4679b174a8dfdd916a93_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtMTItMS0xLTEzNDY5Mw_95030db3-24d1-4962-9fc2-8a21e27f7ba7">120.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcc0686d78a742bd8fdd73944fe180e7_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktMi0xLTEtMTM0Njkz_7124d24a-277f-45dd-8561-fded033e81ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ad6d7a35eac421397e8362b9656f4b8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktNC0xLTEtMTM0Njkz_3d35be2d-ba52-4f28-8340-0c86e955bd70">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b05c62014347fab4835789f107cfe0_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktNi0xLTEtMTM0Njkz_40c6609e-f0c9-4b38-a2f1-5b67cc5f78a0">57.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b466566e8754a25a7bfeab1a81a2cea_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktOC0xLTEtMTM0Njkz_2a965771-7aa6-4f0d-8345-6bb59c0db3d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idec7cc8cd0034b3eb2562e8018818d3c_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktMTAtMS0xLTEzNDY5Mw_510093f5-bdd2-41fc-b8c5-bf7dcc1dd244">57.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e4f384abac34bae9d5bf87acf30d4ee_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktMTItMS0xLTEzNDY5Mw_21228dc5-a389-41ca-9e94-54866a126623">57.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8c9122746944d3f9095dbb7cc11377a_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtMi0xLTEtMTM0Njkz_91ba91fc-c2f8-4e3a-bb83-c33e9af556d0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2516de1ac60a4e90831421c900ff396e_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtNC0xLTEtMTM0Njkz_12d4ed11-06e8-498c-ad87-de2943f2692f">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac6ccbe24af4deaa5a62b863311b57c_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtNi0xLTEtMTM0Njkz_367ef11c-74c0-4963-b160-98d6a0adf774">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib50af91715af4a78bba950701876534e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtOC0xLTEtMTM0Njkz_1312e581-d16b-4183-a31b-ee5026745390">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i657478733d8d43ed87decbb8c4f5d541_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtMTAtMS0xLTEzNDY5Mw_7efac3a7-695b-43a4-ae87-10f3b62a1d4e">24.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i51f276f171e54d29894f040aa5ab5443_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtMTItMS0xLTEzNDY5Mw_c23d468c-10c6-4fb7-8a2d-9e894c73d7b5">24.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a905ec064574da2bf8cee1f4d8bd703_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtMi0xLTEtMTM0Njkz_83ddbe94-d670-4d9b-bec7-19105dc35ce6">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6a59839d59b407ea4068c5b93d2ba34_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtNC0xLTEtMTM0Njkz_6c7b970f-6116-4e18-b694-e60ded2b04cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0e0989aaba247af8dc5f027f0f887ef_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtNi0xLTEtMTM0Njkz_5d955713-f0fd-409e-8fd1-d1c8169c5aed">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613b7926acf54b98ac70428273633e52_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtOC0xLTEtMTM0Njkz_18205cee-451e-4f5d-b6db-02726dc00df5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6cfc69fc6c34480b827a3877c93ab58_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtMTAtMS0xLTEzNDY5Mw_166cee1e-5cf2-44d4-b405-f0ae390dbb6c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6e2e5b23e04f37a8291ce446990fd4_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtMTItMS0xLTEzNDY5Mw_b8a9e2ee-4060-46e6-8ce8-55960bb25594">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26ce3d87d7074b3db7e594727ab76ac8_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItMi0xLTEtMTM0Njkz_bb0ce573-2ad6-4d1b-b5ca-f8220c064b12">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icad85b2a32a540c2be8bee5055609f06_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItNC0xLTEtMTM0Njkz_35ce3df4-5cfd-4843-a8e5-fd4400f0bbae">186.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i308866a912504314ad0566776705f1fa_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItNi0xLTEtMTM0Njkz_ae9425f5-df9c-4f52-9ec7-aa66422169c3">187.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia643249264394743951818a9aa78ae5d_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItOC0xLTEtMTM0Njkz_1dbabdd8-ec37-4938-820d-67322e1b0367">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c11e3688c394fb189088fdb0469db74_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItMTAtMS0xLTEzNDY5Mw_6505f83c-556a-4212-8e11-ca2f62e8f467">202.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08acc85b03b14f00a2f9ca0f2979648e_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItMTItMS0xLTEzNDY5Mw_cb3a765b-c1ad-4cb3-9f9a-6bdaa4a49142">202.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50c2970d6269468d9f534821befd3de2_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtMi0xLTEtMTM0Njkz_c60aaf92-d482-4216-87cf-60be6faf87c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30db570b4e794739ac24a66ec8692dae_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtNC0xLTEtMTM0Njkz_cd19a715-9d2c-4546-8f79-279fe4f9f314">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia02964d914cc47388a24d99a47433421_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtNi0xLTEtMTM0Njkz_2171b387-1626-4bc4-90c9-42216e7d4c80">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife378d865970465ba0ce74157101a61f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtOC0xLTEtMTM0Njkz_bbd5af98-836c-4fbd-8906-535834457987">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie3319dce269e41ad92a3ddcfe5bf5189_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtMTAtMS0xLTEzNDY5Mw_d09401da-44e7-4952-a930-571426f354e0">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1c72b384af94d18b63dff491dca9a24_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtMTItMS0xLTEzNDY5Mw_05540bd5-f64c-4c67-9afc-e992812c9631">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d798d15c7984659815575140f16c70b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtMi0xLTEtMTM0Njkz_9f28d9a3-a79d-47e4-a3e1-f1fdc1a1d97d">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb65596c915c406cbc7bf9acd98622e5_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtNC0xLTEtMTM0Njkz_b196ee65-3947-4739-8c60-92b7a00894b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5dfead640e914b38b2696de5407f84ba_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtNi0xLTEtMTM0Njkz_ff939415-da74-4705-a735-d614d3f5c8bc">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6470a08268ef4de99f119d927d1a4d2f_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtOC0xLTEtMTM0Njkz_bc53a88b-17a3-4469-bebe-4563416af073">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b19835c69324505bc3bbe38750f529b_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtMTAtMS0xLTEzNDY5Mw_7f7fec5c-9af3-4877-baab-dde7b2d54dfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ecbaf37433b4d40b16bc5671b74f060_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtMTItMS0xLTEzNDY5Mw_dc0698ba-b698-4582-984a-d7a97912ba24">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f24d1c8c3584b7c8926aeeea29cd96b_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctMi0xLTEtMTM0Njkz_28b2636f-7f74-4fab-861a-d28ac3ad56df">850.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6345900a23346efb313425848fb28e9_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctNC0xLTEtMTM0Njkz_d4bf6d65-66f9-4f5e-a0ea-0a5ffe7f7633">1,111.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8b5bc83e8644cd983699f6fb8858208_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctNi0xLTEtMTM0Njkz_afb42f76-e1b7-47e8-bd5a-7573b0fec55b">1,962.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i093cbce56499494f8d57067e66f44ff9_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctOC0xLTEtMTM0Njkz_6ff8999c-71dc-47ea-a7ab-9b2c6d1d08a0">973.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i652da0112b604ae891ebdd50c297d7b5_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctMTAtMS0xLTEzNDY5Mw_a28dcb93-8b65-483b-9e91-8c6a43e765b7">1,232.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if551793810f14521aa422baeecc3bfbf_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctMTItMS0xLTEzNDY5Mw_7171bf11-f854-4cee-9bfc-37bc5cbd5fcb">2,205.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the United States (U.S.) in June 2022 and became commercially available during the third quarter of 2022.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i24f503b293024349b32f2754cb0aa670" continuedAt="i136a7891ddc545d69576e1964aaca139"><ix:continuation id="iedc630483d404ab3a17392d50f7bb0cf"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5a9325fee04e2cba98e5d937adfc74_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC0yLTEtMS0xMzQ2OTM_11f2bc79-947c-46fb-84bf-3a4114c8185d">330.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia413a1e58ac1484aa3e51cdfe63a6c21_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC00LTEtMS0xMzQ2OTM_042ce583-b321-4d2d-bb00-bdb0a29b445e">816.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5164cd322f6648be8b5b9b79fc0d4cf2_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC02LTEtMS0xMzQ2OTM_3411fe0a-bce8-4e17-86ac-9219f5b74997">1,146.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic152d3b856314bd5bbd4d922f5b1f015_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC04LTEtMS0xMzQ2OTM_b8506bda-1182-4cd3-8d6f-a0a8c0ecb931">520.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29dd87c31a2a4a4eae9d3aae32da4d82_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC0xMC0xLTEtMTM0Njkz_9199108b-9210-4211-8c76-4f78f8f49624">945.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8300e4d26c6147549e8368f3079a0031_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC0xMi0xLTEtMTM0Njkz_bfe99a9c-130c-4f5f-bffb-a23cf84aa87a">1,465.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a97f7fa27df49c584d3adb23745a423_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS0yLTEtMS0xMzQ2OTM_a8dad4e8-f4a7-45c7-8de2-3ddedfc6a6a7">383.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i502d3aeb3a4d41ef97ee7cc08116a94c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS00LTEtMS0xMzQ2OTM_f7a363b4-daef-478b-a5a3-14f6ed90a554">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67b3715c36b42269427fe5c63da86f8_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS02LTEtMS0xMzQ2OTM_47ccb513-6260-4bc9-b610-d1080ac11f42">402.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66c8c948a5be433c868d626d7809cd82_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS04LTEtMS0xMzQ2OTM_ef44294c-a8ae-41df-93e2-ff69fcc5cef1">285.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i755ecabb947b4b71a2c01fa25760d3d7_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS0xMC0xLTEtMTM0Njkz_e00bec2b-8760-4afe-acd2-550db8b9a45c">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45d4b0e30bae4689bf949adfac85bab6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS0xMi0xLTEtMTM0Njkz_11fc89f1-144e-4b60-a8d5-5432b4b1e8f4">285.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i659ebe25d6134f28930cc20ef43b65ef_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi0yLTEtMS0xMzQ2OTM_52a1ca5f-bfcb-4044-b8cc-8c72fe54e564">713.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a9d2d82af3f46eab21badf9ac3a6981_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi00LTEtMS0xMzQ2OTM_9ae36f20-46ce-4725-9b3c-5e899f4ab5b5">836.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27be45bcbe624d5980096e1785112fdc_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi02LTEtMS0xMzQ2OTM_21a75889-3343-450f-8f85-c9a3477e9185">1,549.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib82aa5e2bd524a66bc66939217047a6d_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi04LTEtMS0xMzQ2OTM_fa43ad5e-87d5-4d34-8053-b49198364980">805.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac5d67fc3dd24634b8a4e9c26b4458f1_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi0xMC0xLTEtMTM0Njkz_74ddc967-150f-49f0-a600-1f825233e9ac">945.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6770d7e189d34ca88257ea5c55b40ebf_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi0xMi0xLTEtMTM0Njkz_46279d75-45f3-4221-b249-8e9f3c06b41e">1,750.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i937b847996cd4321b4854f84342ab7a3_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy0yLTEtMS0xMzQ2OTM_020a2551-3900-48ac-b4da-355dc2009fbf">493.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide726508c8b14430a7064d271b9e7f5d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy00LTEtMS0xMzQ2OTM_97e8fb3f-793d-49fe-b219-b8e646a3ea17">249.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca8925482a46e2bc9ec6966695df2a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy02LTEtMS0xMzQ2OTM_38fb52f6-82a0-4c86-9cc9-73d28c9e05d4">743.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68aced51bea449ccb43e7ba29ae949ae_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy04LTEtMS0xMzQ2OTM_fd5d1ec0-702d-436d-ae10-9ff0cbe867b0">636.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59833a1a99db458b86c073d840320416_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy0xMC0xLTEtMTM0Njkz_a6a2f360-fae3-463a-b42f-734d1cc22bea">286.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61ca7ff7f1294b878f3affcec832bf63_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy0xMi0xLTEtMTM0Njkz_7f75e8be-1e85-473a-82b2-6fc23a1f4bef">923.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1357d813e6fc4d059c8f9d8460edabad_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC0yLTEtMS0xMzQ2OTM_19569cfa-0b3f-4ff2-9e6a-154ea2e29fb9">114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86b062cf2b8e4fcba6125d3f43aba52c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC00LTEtMS0xMzQ2OTM_b526704b-3081-4f0b-af6f-71a5ffd62f18">138.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f6299f5a6b94d23a99157b0a82cf59d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC02LTEtMS0xMzQ2OTM_94813097-47cc-4ed3-bf52-714c7e182e7e">252.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1053bcff8b284ac390b5229c577c0a2f_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC04LTEtMS0xMzQ2OTM_82062324-de19-410b-b2b8-fbd1308cb241">115.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bc39363344843769eab66bc91bcd94b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC0xMC0xLTEtMTM0Njkz_1cd05935-45f0-4ea6-bf06-801f4508cea8">149.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbb1af036ea24e969a66a5344c047fac_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC0xMi0xLTEtMTM0Njkz_9b747ab8-8d7b-465f-afba-81400cbfda15">265.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56fe58d06e354206ac06d6c22f264c16_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS0yLTEtMS0xMzQ2OTM_8356ff96-d45e-4870-abc9-4db370ed91df">608.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if01198d0ed2345ce9da3494a19010f80_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS00LTEtMS0xMzQ2OTM_76048b4e-9ebb-499e-9741-286b03310013">387.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17c1f93f7995494ba74ed1cbfe9a5453_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS02LTEtMS0xMzQ2OTM_0904a12a-2d5c-4b4e-b14c-331c1676faba">995.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0324cb7d71b14d358a44ddaf249e9c3b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS04LTEtMS0xMzQ2OTM_836e93ba-fd57-44fd-bfa7-26a71d2dba4f">751.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8592dfe9d1b04943b8d47d4fe572c054_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS0xMC0xLTEtMTM0Njkz_a67c1839-54f4-428f-863d-ea9f19922c13">436.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9c613ef03654592a30cd87dad818832_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS0xMi0xLTEtMTM0Njkz_2395baca-4cca-4321-973c-9dd92bd68a0e">1,188.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f69bddf17d545ee8a128bacba69d2ff_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtMi0xLTEtMTM0Njkz_3febb137-c559-4912-b64a-8eb9b252f524">849.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06c6cf6db10348b4bf28c5a5845cf749_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtNC0xLTEtMTM0Njkz_d41a92ac-d8b1-46d1-a1e9-fe012badd5e3">693.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib41052befcfa4e75b65cfb241f1f0da7_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtNi0xLTEtMTM0Njkz_21b8b898-43c9-4c46-9051-83aef5196f5e">1,542.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7782237c1c694b6a815faeed508e0178_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtOC0xLTEtMTM0Njkz_1f1d19cf-a92d-4364-9a6f-d31088dbf92e">854.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icab523ef9fd74083a6a33e39224832dd_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtMTAtMS0xLTEzNDY5Mw_87a12b19-5a6f-4345-a9d3-25fbe8014357">696.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e3216e6a74f4785916f831d67d9d956_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtMTItMS0xLTEzNDY5Mw_a4f32083-3520-4dbf-9352-be9d36429297">1,550.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e3d7bbc24a94e268d3446995f65a4cd_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtMi0xLTEtMTM0Njkz_2a2d1a0e-cf99-4a86-8f49-d85a317104f2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78ef0131528e441a8a6df4550ce7e43c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtNC0xLTEtMTM0Njkz_67b3ada0-ac91-44f3-bbba-da31465fb47e">73.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea2d09427bd04c80941fbfc24a9f7d03_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtNi0xLTEtMTM0Njkz_7356ca85-88d9-41be-ab03-b252f399a511">73.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0b3afb1cd4f478a818eb6239991e0c1_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtOC0xLTEtMTM0Njkz_5a212928-cb6c-46f5-8cd7-a8faf7d39cd2">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7441a70014540ecb01931d60471c8db_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtMTAtMS0xLTEzNDY5Mw_3854bff5-5631-4ca5-baa3-93b2004cbc29">78.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie32ae0d4377945619a0b004bca44e643_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtMTItMS0xLTEzNDY5Mw_bc672254-a000-4bdd-ac17-2bce22ef451e">78.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ee7d380900c45aabe38933fa9737ca5_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItMi0xLTEtMTM0Njkz_2b92a61a-79f4-46f5-a4e6-76bf42455cb8">2,170.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i023eec0df3f048a9b3e4824e8ed3ab2a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItNC0xLTEtMTM0Njkz_72745010-62e4-4911-8404-86715c47feb2">1,990.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7abe78fd6cf4342a3cc9da64b09d5b4_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItNi0xLTEtMTM0Njkz_20f56ccb-81ea-45ea-a7c0-c3244bbf85ff">4,161.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3d5d9ecb0104bb3a06537378655c966_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItOC0xLTEtMTM0Njkz_7fea7672-94f0-4834-841b-57df1bb94477">2,410.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i969d874254604c79af7ddf89bcd68f38_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItMTAtMS0xLTEzNDY5Mw_fcf5773f-5688-4368-a251-8d93ad0743ec">2,157.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10e1787100a84bd8bffa4619e4984d73_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItMTItMS0xLTEzNDY5Mw_1189f480-9fa4-45bc-b5cc-d6fc5e1e9503">4,568.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a0a6d1a5b414021b5171c6b7d9fb15d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtMi0xLTEtMTM0Njkz_e9ee6cfd-e24c-452e-bbfe-7647e6e2fe1e">443.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieec166a2d8374cc7abab4547af3faf08_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtNC0xLTEtMTM0Njkz_3db0194b-1f51-48ea-b7e1-54798fb55bc0">891.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7cdc5646c6548bd8cc644b73018859b_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtNi0xLTEtMTM0Njkz_0ad15d26-b868-43cc-8513-75bda8758c9c">1,334.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9531b1a6d294f8ea6c46caa9162ea5c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtOC0xLTEtMTM0Njkz_aee5ca7e-45ab-4b31-b2c6-759a07970538">437.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c012248699d44a19bf1b3ad593025f7_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtMTAtMS0xLTEzNDY5Mw_275bc203-35c3-482c-8aee-90ecf50d880a">1,026.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if879beacfc67428891a4ad60e8881285_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtMTItMS0xLTEzNDY5Mw_d986d80a-dae2-4f74-a253-16a7fc58afe5">1,464.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic18416d266bc4669a44779b7ea401676_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtMi0xLTEtMTM0Njkz_2a8aa883-958a-42cf-9b6c-5a14297b248b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d74fbbf09504685acefcb2a4557aa87_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtNC0xLTEtMTM0Njkz_262bca43-f538-44c3-9b08-743d7f044cbc">340.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i730101ba7e3344f3a767d6b2aad9f3cc_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtNi0xLTEtMTM0Njkz_2e61a270-ae8d-4507-a5d2-0fcb63702179">340.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5506665c921446e28905adb32f532db9_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtOC0xLTEtMTM0Njkz_1b88794c-3d07-4dbe-bb05-cac992cab5a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7afa8b191c2a4834a01ef669ef46770c_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtMTAtMS0xLTEzNDY5Mw_742234a1-8d9c-4695-86a8-6260fdb24635">363.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea3cff758de541ed88b25aac322f9445_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtMTItMS0xLTEzNDY5Mw_1e052d35-3897-4611-990d-0870caa74667">363.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53a426a19b4043ba8a16122036b18ddd_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktMi0xLTEtMTM0Njkz_4cb029aa-3e42-4b86-a2d5-a61a5f3f87fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60eeb012b13c4da095da075b0f10d9cc_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktNC0xLTEtMTM0Njkz_92253704-be72-4997-adca-53be69db1e4a">172.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab47af987094aeab2253c68b0b4781a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktNi0xLTEtMTM0Njkz_45ee53f3-2997-4e46-9020-b517fdb73d06">172.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8fc23920c4547298b885029056b0d73_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktOC0xLTEtMTM0Njkz_1588b6b9-ab85-4cde-81f6-d8f6b20f66fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i078e0ac095bc447c9134a911525da50b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktMTAtMS0xLTEzNDY5Mw_f5fd622f-6213-4ec0-933e-6b818c360a93">170.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia01a554c2ebb48d39f052bebdba83ffd_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktMTItMS0xLTEzNDY5Mw_ea857cd8-1353-4747-9370-d4b4c1a5f5fe">170.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6b844bf5cc94564a2ea1dc24656006a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtMi0xLTEtMTM0Njkz_71115405-f897-4940-889d-f43928d80d18">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72d549b89a0d4280b7cbec3d16492a8d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtNC0xLTEtMTM0Njkz_48127b07-576d-4c31-a69a-b9f541d33625">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b356d5dccac4dc0a67e6486ae9004c6_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtNi0xLTEtMTM0Njkz_24d29e41-f95e-4e46-b582-69f8a2c4dbd0">62.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9f59cd8393d427894d27c27f376c119_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtOC0xLTEtMTM0Njkz_2006ba2b-7c51-469a-aaea-129364cc2e46">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d01410013b84b008e63a03d34b48335_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtMTAtMS0xLTEzNDY5Mw_28752cda-a28a-45c0-8e6d-8890c74ed29f">75.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3823cd2bfc3c42808394d87cf2b96174_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtMTItMS0xLTEzNDY5Mw_77cf0bc9-7753-456e-aca5-96a21239de5a">75.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9d72c66352d4e0ab7a43307ebcfaab7_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtMi0xLTEtMTM0Njkz_3a427931-1101-4027-8198-5e6bb195653c">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd11875ea0ab4093a2da88d3dbb08434_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtNC0xLTEtMTM0Njkz_e97eeee3-4153-43eb-acb4-91902d3ecc7d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37bc23335780472587bf9311eee7023d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtNi0xLTEtMTM0Njkz_f42bf99d-a407-46c6-ade7-f43795a91fd3">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61a94521878b432cb2e9c5db2c9a03d9_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtOC0xLTEtMTM0Njkz_e69792a6-c19b-4633-90cb-0d2c41a65842">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d932603e9c9416bb175281368f58803_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtMTAtMS0xLTEzNDY5Mw_d58deeb3-4a6d-439b-a7ff-6863ac5901a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1305265f23d04121a22583b545fe9bef_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtMTItMS0xLTEzNDY5Mw_46c928ad-a3ca-4d4b-ac00-21998910c6c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a9573b057d440c3a41440888f9bc519_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItMi0xLTEtMTM0Njkz_f4f7b7c0-efe5-4ed6-9f7e-46725bce232b">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8008ca07420f4639a1bee2e6a25b83b1_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItNC0xLTEtMTM0Njkz_fd6ad83a-63ee-476d-ad12-47ba31439e22">575.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3b600d7fd8d42519eb7d5e81b59a62c_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItNi0xLTEtMTM0Njkz_b89b97a1-4500-4bf7-a032-4d1691456528">576.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d991b8372b64a33973a4e1e72f10d14_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItOC0xLTEtMTM0Njkz_ac889482-c35b-4c4e-bd70-f4a491f7bd64">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a74210ccbe44871b085a79bdcf8b0ab_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItMTAtMS0xLTEzNDY5Mw_a3749a06-c2ed-4419-8302-cd73f38c5e5e">610.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie61b19d0952c468285e72114e0c815fa_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItMTItMS0xLTEzNDY5Mw_4b9889c1-cf18-43ca-be1a-28bd35afef25">610.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6aeb83f9ea074f7ca098ec2277b76dcf_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtMi0xLTEtMTM0Njkz_5e3f6085-c908-401a-92cc-af52709f6032">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibfbcb20de8de4987b63b10487fe1503f_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtNC0xLTEtMTM0Njkz_ddf02da2-2a0b-44c2-aadd-83fd97deba7a">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i455d14ea6c564470b68cf17c79c8b1ec_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtNi0xLTEtMTM0Njkz_fc051439-8669-4986-b94c-c2403a4d4446">6.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c1038b4167343c2894ae361d7838cf6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtOC0xLTEtMTM0Njkz_5a25fdb5-52ca-48ff-8b72-43641f299844">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b33b1754e9a4fd8861a165f689594b7_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtMTAtMS0xLTEzNDY5Mw_fc78f9e0-91ee-441d-8b80-c95dfe1520b9">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if31045dd949540548e6be6125e1e8384_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtMTItMS0xLTEzNDY5Mw_da6718e5-389c-4ee3-a46a-9ed6e71679a5">8.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7037c9ec74674577a86a47384437b333_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtMi0xLTEtMTM0Njkz_9ea0d34e-f8e2-4a56-b416-bebd16277ba3">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6998a8488a944245ac8b554c781cd12e_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtNC0xLTEtMTM0Njkz_ac3d22cf-1224-46cb-ac54-ccd2388e1122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1722b2d0cc7645f1a42a9c8bb59390c0_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtNi0xLTEtMTM0Njkz_34158212-6fa7-4d81-a7fa-71edf1121446">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0c5dd5e3cf24dbc93e12d0785e49cc2_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtOC0xLTEtMTM0Njkz_01b0a1ef-2467-473c-9d1b-da7bf844cc85">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a195ea9682417d82da6447b85f8eb4_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtMTAtMS0xLTEzNDY5Mw_51156ea3-3fe4-4b74-8779-0d074414c7a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d77cc63bd804d2195547eeb78d38213_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtMTItMS0xLTEzNDY5Mw_eae4e3c2-dad5-4b0c-81f5-4963df6a4497">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d2601de96ae48c0893072540afa20be_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctMi0xLTEtMTM0Njkz_ec0a9233-ec4c-419b-9d1c-097d10a1701a">2,619.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf5eb57f75b949ddb446686c65bd2b5d_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctNC0xLTEtMTM0Njkz_b966ce12-ae94-4250-a3e1-14ff7b6ec2f6">3,463.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64c2a0bb31734409bb0e29d39fc13bae_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctNi0xLTEtMTM0Njkz_d4cb5883-ff4d-4d7e-8f63-1f7ec0c1e848">6,083.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if382ab28a2c14f67953b81e1f8e224a6_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctOC0xLTEtMTM0Njkz_dea63954-23f1-4f00-b994-da0ef4289698">2,850.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0599c4c9cd214ece84111681c4bd49cc_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctMTAtMS0xLTEzNDY5Mw_d39dd150-8d7a-4173-aa59-e7ba95c26a76">3,802.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2765e6631dd6439f847c09bcca089302_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctMTItMS0xLTEzNDY5Mw_b74792b0-b162-4dea-8ab2-45da29956f36">6,653.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzU3_4cb837a2-0ca0-4a24-a398-93a59107fe1a"><ix:nonFraction unitRef="wholesaler" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzU3_dbab42d1-cb95-4790-a2bb-7c5590f399c7">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i4508c31bb9b042d2bf4dcb1d266392a0_D20220701-20220930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzg3_0f8c4b85-c2a6-489c-aea3-63aa9e6635b6">26.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="ie2e3e533c0e2443196830784733320d3_D20220701-20220930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzk0_41d8f787-8331-4454-a2e7-065ee43d8d62">10.5</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2022, and <ix:nonFraction unitRef="number" contextRef="i382decd071794d58a8eb96ab53eaa0fb_D20220101-20220930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNDU0_34b4b80d-f673-41f9-9a9f-bad2aab2f7e3">26.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i0a124abe85aa4a19a264079c46a16e9f_D20220101-20220930" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNDYx_2506403c-dd1d-4a3c-834e-7e04d11e63d9">10.7</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTQ0_4cb837a2-0ca0-4a24-a398-93a59107fe1a"><ix:nonFraction unitRef="wholesaler" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTQ0_dbab42d1-cb95-4790-a2bb-7c5590f399c7">two</ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="i1ada2bf116084c4fa8e8e98e14a03495_D20210701-20210930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTc0_b2b0c753-6bb9-485c-ae7d-4ad8bed82394">26.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i2424282c7e6f49e1a4c067b8194f126f_D20210701-20210930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTgx_28165f8e-3ed0-4ec9-9536-23a8e5b49d87">10.8</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2021, and <ix:nonFraction unitRef="number" contextRef="ic979c424773c4abda7b0f080e9803dfa_D20210101-20210930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNjQx_b7a79f86-de88-4cf7-8c92-b6d0fe6e944a">29.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i354359e6eb63451598deb6430cb7b015_D20210101-20210930" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNjQ4_c6d79efb-f36e-408e-9d1a-235fce9626ea">10.0</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2021.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTY0OQ_408d15f4-c797-4cba-876c-73ac049d367f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if28aa7d47b4e4774b232d953458d1d70_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS0yLTEtMS0xMzQ2OTM_2fc4d7bd-b604-401c-aa6f-0bdc092281c8">137.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95ce0946ae03453e9adefffc884e3e56_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS00LTEtMS0xMzQ2OTM_badfee55-c423-43a2-8057-c0cb48b0a71c">759.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04d9b2bdab044462bcfd071d9cae87fb_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS02LTEtMS0xMzQ2OTM_000c93fc-40fb-4e0c-a6bf-c89866171998">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS04LTEtMS0xMzQ2OTM_2ff01fcb-f438-40cd-bb43-aa2b0c7da56f">935.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi0yLTEtMS0xMzQ2OTM_c4be572a-be56-4652-8bf3-ed779b080387">499.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi00LTEtMS0xMzQ2OTM_bcc9c69c-72df-4fda-a0d9-8c4ce038d5c0">1,993.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi02LTEtMS0xMzQ2OTM_3c8ea97b-d904-4d7d-bfbd-fcb3a4e327bd">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi04LTEtMS0xMzQ2OTM_cc9d4f9c-37ef-41fb-9d5c-0f9d5e95aa81">2,501.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy0yLTEtMS0xMzQ2OTM_55d83d9b-56dd-4d25-8fef-02cae6c0686b">2.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy00LTEtMS0xMzQ2OTM_c9c662a2-2da9-414e-b39a-d944913fe3f1">18.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy02LTEtMS0xMzQ2OTM_935c8ec7-34ec-4831-8909-628403be743b">7.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy04LTEtMS0xMzQ2OTM_2d4c2f83-4c05-45cf-94d9-56977aed8861">28.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC0yLTEtMS0xMzQ2OTM_40d23121-f4ec-4d49-aa92-170ce7420e34">379.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC00LTEtMS0xMzQ2OTM_fa87315d-6e4b-4dbe-a71f-ed4edd162b08">1,442.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC02LTEtMS0xMzQ2OTM_3152709e-8f32-4752-8b75-0744537b9f14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC04LTEtMS0xMzQ2OTM_2067a586-21df-43ee-a599-728de2ba8bd4">1,821.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS0yLTEtMS0xMzQ2OTM_9fce3bf2-53ee-44ef-aa74-3066fb1d43af">124.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS00LTEtMS0xMzQ2OTM_32628624-c93a-4e89-8af6-eb2f47613be4">463.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS02LTEtMS0xMzQ2OTM_199ebf1c-332c-4269-ad27-452b294cfa3c">14.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS04LTEtMS0xMzQ2OTM_5d58d095-0f12-4ff9-9577-51fd73f755c8">602.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f1f736cf0c848ceb0338e6ef724d11d_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi0yLTEtMS0xMzQ2OTM_553aed40-40e5-41ce-82dc-62beb47fba9f">130.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2aa9db267e8b405ebe94ed94f54a1041_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi00LTEtMS0xMzQ2OTM_7a65f7fb-836b-4249-b117-6a0482f2802f">829.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e630e38d8e4abc913f03bb50be1f22_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi02LTEtMS0xMzQ2OTM_cfa7b651-26a7-4d80-a407-ff5d05e89b56">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi04LTEtMS0xMzQ2OTM_1322724a-2d97-4fc5-9a1c-e796aa20e4ec">983.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i136a7891ddc545d69576e1964aaca139"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYxNQ_a1b2f7a6-2f32-4b44-b7cb-db26e40e9a28" escape="true"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85e08dba5a5d46c48d1d0ba4950b19c1_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMS0yLTEtMS0xMzQ2OTM_c17f63b6-8198-4ee8-b924-9d403c2a72c3">129.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4789aad763454e5aa2bf7c06207aaf14_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMS00LTEtMS0xMzQ2OTM_9adbcf05-0142-4903-aef0-b971599b4038">133.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809babb0c0c0499093a3c1b393fd910b_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMi0yLTEtMS0xMzQ2OTM_4dbc6e9e-8707-4051-aed4-60c0276ab844">854.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide348a94f52a4b6fbe470e76039c8fd9_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMi00LTEtMS0xMzQ2OTM_fc252cb6-1b93-4224-ae2b-e3edcec729f3">802.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMy0yLTEtMS0xMzQ2OTM_ac488276-c8cb-496d-915e-2c779578fadb">983.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMy00LTEtMS0xMzQ2OTM_5a9b5cf3-886b-41b1-b39e-41c6d933f417">935.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYxOA_760caae5-5e91-4053-a118-0e218aaaa9d3" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13532228d6b4faa9945313be54cbe8a_D20220701-20220930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi0yLTEtMS0xMzQ2OTM_f8c5a1f7-4d77-4a25-88ac-f8a46bc16cba">131.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d6b8be2f94d1ca6fdeb88a1fd79be_D20210701-20210930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi00LTEtMS0xMzQ2OTM_447ce461-bcbb-4808-bb72-bd7686d62eda">145.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie57145cefb184ed0a3414659db9ff24a_D20220101-20220930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi02LTEtMS0xMzQ2OTM_8fb99ea7-7bfd-4f32-9f97-c45a71d26d43">414.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4ea9a082274af0bbf9b1541950118d_D20210101-20210930" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi04LTEtMS0xMzQ2OTM_df87946e-9bc6-4b70-bf32-2f9926e86f69">498.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13532228d6b4faa9945313be54cbe8a_D20220701-20220930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy0yLTEtMS0xMzQ2OTM_38c61db2-c546-4f20-8272-4724dcf32c89">285.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia83d6b8be2f94d1ca6fdeb88a1fd79be_D20210701-20210930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy00LTEtMS0xMzQ2OTM_83eb9b81-ee7f-47ba-baab-ffed54d3e9a0">269.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie57145cefb184ed0a3414659db9ff24a_D20220101-20220930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy02LTEtMS0xMzQ2OTM_8e02f824-68b6-4937-ad89-a7c71332368f">838.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc4ea9a082274af0bbf9b1541950118d_D20210101-20210930" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy04LTEtMS0xMzQ2OTM_e2bd37d0-ba78-4764-b5f8-a0ee8fa7cb4d">745.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id677ff3bfec54adbaa112244fd4799d4_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC0yLTEtMS0xMzQ2OTM_482264c3-363a-4bc5-9c2d-139ef6d255b7">416.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31f777fcba294e1981f4bbec61fe6842_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC00LTEtMS0xMzQ2OTM_2f9c4612-b23b-4a76-8049-e733bd39dafd">415.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bc6e1753ff4db990730bfcea938673_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC02LTEtMS0xMzQ2OTM_04f95b60-3724-408a-a01e-d16d651f207e">1,252.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07dd344004654602b840c7084123794f_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC04LTEtMS0xMzQ2OTM_23b2c57d-8fca-4455-9172-1e10cd1ad1a8">1,244.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:OtherrevenuesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYzOA_a46d3710-0f3f-43df-a20d-526b3cfeb897" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.286%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21ebca31e894acc847e9662f2798865_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy0yLTEtMS0xMzQ2OTM_f09dd5e9-8d40-492b-a7d1-f069575e312e">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83428f933f704288a217da35a25533ab_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy00LTEtMS0xMzQ2OTM_a074d7e4-05fa-4a2a-9506-c410a6a727c1">6.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic58515149d05482e8c241be729c7cebb_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy02LTEtMS0xMzQ2OTM_1144525b-d78a-4e1b-a88d-224f2a2ff7d2">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icf1edb54ce2347b69f028201a0598732_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy04LTEtMS0xMzQ2OTM_87b43007-beab-4d61-bebc-19482059ccac">15.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d47538d8dcd446ca3b4284f191efc96_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi0yLTEtMS0xMzQ2OTM_77ca20a2-ff88-4e31-ac6d-dafb67df30af">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaefd6081d97b42989d5b2062fea0e2c0_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi00LTEtMS0xMzQ2OTM_1c36ac37-af5e-4dc1-8053-c322ff62259a">7.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cee8c4809cc43778d9d5dd7095222d0_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi02LTEtMS0xMzQ2OTM_5001c522-5a5a-4334-b92a-bc1bcfc24a97">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4883b5a7fdb64564a053bc40e6173d46_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi04LTEtMS0xMzQ2OTM_1b4dc579-e5cb-4480-b791-cb0c89285dfa">20.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib12491491b0e466ebdc29adb36c32405_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy0yLTEtMS0xMzQ2OTM_aa808aab-7b80-4ed7-b5a3-a567fffaa115">114.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16bb558d82d1463380f6b8863e69e26a_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy00LTEtMS0xMzQ2OTM_ff638f8d-1fa2-4e46-8142-859865d872f9">143.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17597137521d4e01a99df9202a256434_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy02LTEtMS0xMzQ2OTM_1ba321bd-589b-429a-92eb-f8d7166dea86">242.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i294799e924cb4e7fb31a94d1eb9af81b_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy04LTEtMS0xMzQ2OTM_0449860b-028c-4e11-be89-ddd40e07c72e">314.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599788f95f5d42d1afd8d372967a5f5d_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC0yLTEtMS0xMzQ2OTM_4baf1912-a14a-4c1b-a541-d4fb4ae6b5ba">129.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c6c0f5fe10b475babd385cc9a5f1933_D20210701-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC00LTEtMS0xMzQ2OTM_c5da674a-db93-4d5c-b0e2-b7e7eca36036">157.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01501338195d4d64b3297f4c712b4a35_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC02LTEtMS0xMzQ2OTM_5ca904c7-ef7b-44d0-ba10-2e1d9182f22c">293.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76bd2bb0d53b471685923452d6735342_D20210101-20210930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC04LTEtMS0xMzQ2OTM_a9206ee0-18c2-4ccf-b7d0-4a55c47bb7b2">350.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_52"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;INVENTORY </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTUyNA_4c412007-72ff-49a6-9001-81663df3c205" continuedAt="i30072ec5356d4a35bfa60dc3f70cd7dd" escape="true"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTUyMQ_947e97e9-ed39-4ad1-82d7-d0d84c5c2c95" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMS0yLTEtMS0xMzQ2OTM_5f4b8d16-b205-43f0-abea-8eb9b960a66e">394.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMS00LTEtMS0xMzQ2OTM_8004b425-8e5b-4fe1-b2a0-d7a4b790cc39">349.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMi0yLTEtMS0xMzQ2OTM_c19a4d23-6d3b-4f89-ada6-9e4b78ed6167">771.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMi00LTEtMS0xMzQ2OTM_38fc377d-90df-4584-9fa3-3e9d3b8ce93d">814.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMy0yLTEtMS0xMzQ2OTM_2e805e9f-9ff9-4f76-9c44-6109f397ebb9">209.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMy00LTEtMS0xMzQ2OTM_35dd1f86-0a54-4de2-b29a-b0d70edb5052">187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfNC0yLTEtMS0xMzQ2OTM_869203ec-c7e3-4c22-a577-93130def1303">1,375.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:Inventorynetcurrentandnoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfNC00LTEtMS0xMzQ2OTM_e4800b63-a3cc-4a50-9aed-73f65994e364">1,351.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work in process inventory as of September 30, 2022, includes approximately $<ix:nonFraction unitRef="usd" contextRef="i45f788f2e9604cf7abd1e93ae4f8f733_I20220930" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTM1_a9f245e3-68e5-404f-876a-b48611b1c035">118.0</ix:nonFraction>&#160;million related to lecanemab.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="ibf9a5892d99e44d8b1534f84205aaefe_D20220401-20220630" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfNjc3_5da037ce-728e-416d-a13f-29911fbaac92">275.0</ix:nonFraction>&#160;million of inventory related to </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i30072ec5356d4a35bfa60dc3f70cd7dd"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i2837cc88485b432d98238003fed8b676_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfODcx_ce676874-9255-4d5c-b03e-3822eced0af2">136.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfODc3_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of 2021 we wrote-off approximately $<ix:nonFraction unitRef="usd" contextRef="ib904f98f905e4ad3953b630e2bca4280_D20220101-20220331" decimals="-5" name="us-gaap:InventoryWriteDown" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfOTcy_d3744cb7-4d6f-4f41-abdf-5654b1f14d01">120.0</ix:nonFraction>&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income for the year ended December 31, 2021. We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i47ad44653f43466cbe8c8233fd37d1a4_D20220101-20220331" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTE2Ng_6c723216-2f6c-4819-8605-9c5994f5f98a">59.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTE3Mg_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2022, the carrying value of our ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="ia350432a960f43db838c5d34090e798f_I20211231" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTQwMA_10ab7435-dde2-4b80-899f-ff30f2ddba36">223.0</ix:nonFraction>&#160;million of ADUHELM inventory. For additional information please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_55"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;INTANGIBLE ASSETS AND GOODWILL </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDkwNA_ade22aca-a03f-4017-9076-a8ae30745be0" continuedAt="i10e06f22774f49f3b8ac088b41f7025a" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDkwNQ_754d5f2d-eb48-4bc8-8cce-a6fdd30c116d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.257%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.383%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.396%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.659%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.972%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.669%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a29e320c44befaad6c64343facc66_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi00LTEtMS0xMzQ2OTM_d62a0126-4446-494c-93d4-fc4624c954bd">7,415.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if99a29e320c44befaad6c64343facc66_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi02LTEtMS0xMzQ2OTM_8e9b5c0c-b524-4f1a-a5f2-cd73b32f064e">5,579.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if99a29e320c44befaad6c64343facc66_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi04LTEtMS0xMzQ2OTM_612735d2-220d-4cdd-81b6-3e3354768a22">1,835.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085d08ca766f453bb0b1ed59eda80c1d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi0xMC0xLTEtMTM0Njkz_d1dfd2f3-1f14-47dc-bf69-d34e295618ee">7,413.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i085d08ca766f453bb0b1ed59eda80c1d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi0xMi0xLTEtMTM0Njkz_ee34e788-e818-461e-b8b8-87decc45d729">5,388.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i085d08ca766f453bb0b1ed59eda80c1d_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi0xNC0xLTEtMTM0Njkz_85b1e92f-4d62-4f14-bb4f-a0bfb7e7592c">2,024.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeafe70f44754eb2a753ad330c4edea3_I20220930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy00LTEtMS0xMzQ2OTM_3b9b7313-e404-4d35-80a4-e07b96570d6e">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeafe70f44754eb2a753ad330c4edea3_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy02LTEtMS0xMzQ2OTM_d716aad5-0590-4287-b0dc-ba864244eb37">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaeafe70f44754eb2a753ad330c4edea3_I20220930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy04LTEtMS0xMzQ2OTM_a8731991-3197-4337-a949-41859a8e91f0">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a922c6b9d0648949c052b847de903cf_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy0xMC0xLTEtMTM0Njkz_55c618f5-5fee-4507-b4c1-6ae862eec051">132.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a922c6b9d0648949c052b847de903cf_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy0xMi0xLTEtMTM0Njkz_6205a2be-7d18-4417-bfce-2fe244fafce3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a922c6b9d0648949c052b847de903cf_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy0xNC0xLTEtMTM0Njkz_15d88cb6-8dac-42cf-80cc-e6fdf1c56092">132.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df75de89f2a48e1ac98377bbeff106a_I20220930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC00LTEtMS0xMzQ2OTM_33ec4150-6a30-4d44-8490-2a14058f9eea">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df75de89f2a48e1ac98377bbeff106a_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC02LTEtMS0xMzQ2OTM_f1d1e5aa-122e-43ec-a3c2-acf90722bd94">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4df75de89f2a48e1ac98377bbeff106a_I20220930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC04LTEtMS0xMzQ2OTM_d05182a9-f0c4-43d8-ba28-8f3b2fb9422c">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf245f7c03b94d219b053513a7037afe_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC0xMC0xLTEtMTM0Njkz_c2aef57f-240f-4659-b293-6f400d08dcb9">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf245f7c03b94d219b053513a7037afe_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC0xMi0xLTEtMTM0Njkz_84aa87c9-7bed-4f20-95ae-6f584aaf8bed">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf245f7c03b94d219b053513a7037afe_I20211231" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC0xNC0xLTEtMTM0Njkz_f43f3453-9883-4bec-b73b-6da15d7e8f17">64.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS00LTEtMS0xMzQ2OTM_98859968-d983-4436-a2ad-6dd1bdc976de">7,588.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS02LTEtMS0xMzQ2OTM_db8f0ec6-a0a0-4b77-b9c3-29f44b143153">5,579.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS04LTEtMS0xMzQ2OTM_8d825465-6c70-4124-aed6-b5879ccc31ec">2,008.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS0xMC0xLTEtMTM0Njkz_7b0d8b1f-1362-4b62-87df-d2e158b60832">7,609.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS0xMi0xLTEtMTM0Njkz_1215bf5c-e0eb-4cf1-b2e1-2002775d7182">5,388.5</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS0xNC0xLTEtMTM0Njkz_7c971a40-29ac-4772-a383-39f243964e96">2,221.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, amortization and impairment of acquired intangible assets totaled $<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjc3_e5ba969c-3df7-42b0-8a25-957f4d379a25">56.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjg0_2d74b9c6-2d45-44e0-958f-bb849c979d23">190.9</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMzE0_51878a2c-b45c-4a8d-a324-ff802eba20af">111.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMzIx_0c91072a-4963-459b-a2b0-a7a8b18336c4">813.2</ix:nonFraction> million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2022, we had no impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $<ix:nonFraction unitRef="usd" contextRef="if13c845f22a44a8bbbd7ebeccf43f5e8_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNTQ4_5295b8fe-e921-4fee-a5b7-2f2313f89729">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f3a6e8db3344edcb5ed43acaf59842c_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMjc1OA_710a2a5e-3bc3-4c8f-933d-e4e93859f0bf">365.0</ix:nonFraction>&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ia7d41aebda1d4947b30b143badbf9555_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNjY0_54a1120f-c177-42ee-abeb-804908f8832b">28.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7948b4b0b9c44243a39e812b8fbbcdae_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMjg4OQ_6a47bb18-cc83-4cf3-bc82-fcb988844df1">220.0</ix:nonFraction>&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets also reflects a $<ix:nonFraction unitRef="usd" contextRef="i0fd374623fbf4e19a6f32d3cc68790b9_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfODk2_b0544a52-b0dd-46ac-b3c0-4f5bb075c0fb">44.3</ix:nonFraction>&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of September 30, 2022, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i10e06f22774f49f3b8ac088b41f7025a" continuedAt="i40494b8049534a0eb40d5099544ffbd8"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $<ix:nonFraction unitRef="usd" contextRef="i0fd374623fbf4e19a6f32d3cc68790b9_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjc1OA_b0544a52-b0dd-46ac-b3c0-4f5bb075c0fb">44.3</ix:nonFraction>&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value associated with the remaining vixotrigine IPR&amp;D intangible asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $<ix:nonFraction unitRef="usd" contextRef="i2cfeace678454dfeafaf48a68a2f8986_I20220930" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjk0OA_7ab22d06-2f27-4725-b04c-9fda80a6234e">109.3</ix:nonFraction>&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial, or sooner if there is a reevaluation event, and may record an impairment charge related to this asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recognized impairment charges of $<ix:nonFraction unitRef="usd" contextRef="if13c845f22a44a8bbbd7ebeccf43f5e8_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMzUxNg_5295b8fe-e921-4fee-a5b7-2f2313f89729">15.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i9f3a6e8db3344edcb5ed43acaf59842c_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMzMzMQ_710a2a5e-3bc3-4c8f-933d-e4e93859f0bf">365.0</ix:nonFraction>&#160;million, respectively, related to BIIB111, and impairment charges of $<ix:nonFraction unitRef="usd" contextRef="ia7d41aebda1d4947b30b143badbf9555_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMzM5OA_54a1120f-c177-42ee-abeb-804908f8832b">28.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7948b4b0b9c44243a39e812b8fbbcdae_D20210101-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMzQwNg_6a47bb18-cc83-4cf3-bc82-fcb988844df1">220.0</ix:nonFraction>&#160;million, respectively, related to BIIB112, reducing the remaining book values of these IPR&amp;D intangible assets to zero.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $<ix:nonFraction unitRef="usd" contextRef="i8c5d0bb749664bab88044a8c3f5fed55_D20210701-20210930" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzNjA1MQ_94dcb7fd-04c5-44f3-8ece-f30b894813e8">39.1</ix:nonFraction>&#160;million during the third quarter of 2021 related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDkwMQ_35edab7e-14ce-4411-b064-8b1e2790d2f7" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfMS0yLTEtMS0xMzQ2OTM_89a5c169-2bb2-45cc-8850-701ab17a3639">55.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfMi0yLTEtMS0xMzQ2OTM_3d049be2-60c4-42ae-b835-086500a8e0a3">215.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfMy0yLTEtMS0xMzQ2OTM_882cf862-4637-4762-a0c3-16534264bf58">195.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfNC0yLTEtMS0xMzQ2OTM_2f70faa8-9d94-4698-a7be-4ba4712dd17e">190.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfNS0yLTEtMS0xMzQ2OTM_2984ca9b-c0ce-4676-ba32-a5d14427d7bd">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfNi0yLTEtMS0xMzQ2OTM_99ea6788-6adf-485e-91b0-aca8889ca3d8">165.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDg2NQ_0efd6fbc-a495-400b-8233-268a285a9375" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmUzYTUyNzAyNTU3OTQwZDQ5YmRlMTFkZDhiODk4OTNjL3RhYmxlcmFuZ2U6ZTNhNTI3MDI1NTc5NDBkNDliZGUxMWRkOGI4OTg5M2NfMS0yLTEtMS0xMzQ2OTM_b2ae8372-c72b-4407-b308-798a5a96852d">5,761.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmUzYTUyNzAyNTU3OTQwZDQ5YmRlMTFkZDhiODk4OTNjL3RhYmxlcmFuZ2U6ZTNhNTI3MDI1NTc5NDBkNDliZGUxMWRkOGI4OTg5M2NfMy0yLTEtMS0xMzQ2OTM_7ec9894c-19cd-4b1c-8d33-5c4f14b97c48">19.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmUzYTUyNzAyNTU3OTQwZDQ5YmRlMTFkZDhiODk4OTNjL3RhYmxlcmFuZ2U6ZTNhNTI3MDI1NTc5NDBkNDliZGUxMWRkOGI4OTg5M2NfNC0yLTEtMS0xMzQ2OTM_edb39dd1-d6af-4d9f-be56-836e4a28c4a1">5,741.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i40494b8049534a0eb40d5099544ffbd8" continuedAt="i15b2a2666bac4058b361b55a574d565d"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDcxMw_e5e77e42-cd7c-462b-a85e-e0f8bd18f407">no</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i15b2a2666bac4058b361b55a574d565d">cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_61"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;FAIR VALUE MEASUREMENTS </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk0Mw_b8a74a42-21e9-4927-b7de-b485f94a8cb4" continuedAt="i48c3e653fdb446d9942564df4a85c2e0" escape="true"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk2MQ_9e783143-c2d0-4a41-a8ae-79d7e5f46514" continuedAt="i2b240583fd8c44deae071a696ae7e63f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC0yLTEtMS0xMzQ2OTM_6f8dd9c3-f839-492a-93c7-488236bff6b0">3,191.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC00LTEtMS0xMzQ2OTM_2adbe613-ba73-4a30-b5ac-b6920da6d82f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC02LTEtMS0xMzQ2OTM_86ae6c9e-3926-4e11-bff5-413eb7ec848f">3,191.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC04LTEtMS0xMzQ2OTM_a50b1519-66fa-498e-b3ee-1acd3aae6af6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaad538ee04e34626a6eea7c18b5170f0_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi0yLTEtMS0xMzQ2OTM_57ca058e-0eb9-474a-a2f2-574215d5d279">1,219.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0ab6e798443f48349a275b2f127d63aa_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi00LTEtMS0xMzQ2OTM_c824ca95-a190-44cd-9ad5-6095ee1f7d03">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i320468fceb194a22b349781516794d96_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi02LTEtMS0xMzQ2OTM_009c49cb-7013-4ae6-92c9-fb622effef1c">1,219.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4229dbf5c29146898a310730f9f2a556_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi04LTEtMS0xMzQ2OTM_b862e677-e609-44af-bab1-a2840ddc9a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21935cd1c743479b8b352f61a8406ef3_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy0yLTEtMS0xMzQ2OTM_4dc3a411-57bf-43ab-87b2-f07bf98097b0">702.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ed4059cc532499cb0d947b46e8c2790_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy00LTEtMS0xMzQ2OTM_73081339-7cba-4b3e-bd92-f0f1b1367512">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i508e95abdda94a41920a1c67a004ec92_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy02LTEtMS0xMzQ2OTM_5aa57105-9e4d-4a88-a829-e85d65544117">702.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff6e063c1a884b0e80c8af000019a9b2_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy04LTEtMS0xMzQ2OTM_87e1a757-56ea-4eda-8582-50ca574637d3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b7cf9a8189c4e4badbd47fc34b589a4_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC0yLTEtMS0xMzQ2OTM_289905e8-c859-4bf1-90c6-e9cee883bf8e">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13cda5e55cec4e3aba7217644a62e136_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC00LTEtMS0xMzQ2OTM_f56dba93-a7a8-46f7-8ebe-1f7cfa5b1829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1977ca3896f4eba933be81acfc29491_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC02LTEtMS0xMzQ2OTM_b6ad824e-6e40-43bf-aefa-bda99494534a">174.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice735e68404d4fb58b4cc4f43fa85a6a_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC04LTEtMS0xMzQ2OTM_136a806a-fc8b-4674-8f28-607de5653044">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS0yLTEtMS0xMzQ2OTM_78a0d714-d73f-43cf-bcd9-ab295612620c">896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS00LTEtMS0xMzQ2OTM_cb23fba4-c34c-4059-a63a-d0ac0e45cc61">896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS02LTEtMS0xMzQ2OTM_ccc3d8a6-bde2-4df7-a730-902efbaf9324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS04LTEtMS0xMzQ2OTM_2d77362a-bf51-4abd-afc6-dc88432a8776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtMi0xLTEtMTM0Njkz_0b7ee53a-ccdc-4672-b67c-3c0a7052eb6e">790.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349975b3917d48bb8801949ca1421861_I20220930" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtNC0xLTEtMTM0Njkz_d285a2bd-85b2-442a-a8cf-b8210977352f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b9cb96a23b4137a822345574780176_I20220930" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtNi0xLTEtMTM0Njkz_216064c3-7f7b-4185-b20d-86465cb81e34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbfb14f37df42ada487358aa320ac59_I20220930" decimals="-5" name="biib:OtherAssetsCurrentFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtOC0xLTEtMTM0Njkz_c85647a3-5fc1-4745-87e8-6d5be942b0a0">790.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtMi0xLTEtMTM0Njkz_f345fe43-61ab-403d-9395-99b879864a83">195.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtNC0xLTEtMTM0Njkz_b51bc230-c170-470b-b40e-93dbd216de58">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtNi0xLTEtMTM0Njkz_546d1b3e-dba3-40c1-a4e4-eb3c36b3c810">195.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtOC0xLTEtMTM0Njkz_482bce55-1e0f-4296-ac5b-7d1f9e126cbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtMi0xLTEtMTM0Njkz_ffdd6c63-46f8-46f9-9b00-c40ab3f803bc">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtNC0xLTEtMTM0Njkz_3adec600-e6cd-451e-8d0b-17cc0266fd6e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtNi0xLTEtMTM0Njkz_c76c487c-b6ca-4422-88fd-4c660aea107a">32.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtOC0xLTEtMTM0Njkz_af45267a-dd8e-4626-8e54-122235608474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtMi0xLTEtMTM0Njkz_2e1d8a79-b1b6-4f87-8013-e2abfb52c0cc">402.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i349975b3917d48bb8801949ca1421861_I20220930" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtNC0xLTEtMTM0Njkz_432b338a-ea67-4dba-b902-beafe4476d23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79b9cb96a23b4137a822345574780176_I20220930" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtNi0xLTEtMTM0Njkz_567d46ef-ed2d-4cb2-9eae-c489f54dcece">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iebbfb14f37df42ada487358aa320ac59_I20220930" decimals="-5" name="us-gaap:OtherAssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtOC0xLTEtMTM0Njkz_6239395e-b105-48a5-8f81-6f300f4f4d8c">402.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtMi0xLTEtMTM0Njkz_e4bdf468-9f4e-4d8b-b329-30f611b9aab2">7,605.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtNC0xLTEtMTM0Njkz_be0d5730-615e-4de3-8765-e216429628a1">896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtNi0xLTEtMTM0Njkz_9cef61ae-cc2c-4788-b002-afa99a166ebb">5,515.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtOC0xLTEtMTM0Njkz_d6392618-7e39-406f-b2b9-51e8f62c2700">1,193.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtMi0xLTEtMTM0Njkz_4fbd57f6-f39e-4724-8709-c0c0e67db297">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtNC0xLTEtMTM0Njkz_8e9dba36-11af-4e29-9f06-05912c67c6b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtNi0xLTEtMTM0Njkz_d5f029f8-e283-4ecf-83e9-aa957fae34d9">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtOC0xLTEtMTM0Njkz_442bedb7-d5c2-42bc-b5d3-b806d22dbd59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktMi0xLTEtMTM0Njkz_58b34ba3-ac58-4e97-85d6-fc37d28363a0">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktNC0xLTEtMTM0Njkz_fef50f06-5bdb-41ce-a722-4b1973901156">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktNi0xLTEtMTM0Njkz_f11127f9-2995-45ba-90d3-4a052bb8c4f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktOC0xLTEtMTM0Njkz_16e59426-8386-41ce-8580-c7bbcfb0f4ab">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtMi0xLTEtMTM0Njkz_4aac545b-d523-4926-a7cb-c8ad3ad81eca">218.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtNC0xLTEtMTM0Njkz_1317eb86-8cec-4fac-bd8e-7908a0222ebf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtNi0xLTEtMTM0Njkz_be5ca0c3-a3ff-4cd0-9845-2188391b7bfe">22.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtOC0xLTEtMTM0Njkz_f619a7b9-edcd-48d6-b859-23f43c422b64">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzk0_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i48c3e653fdb446d9942564df4a85c2e0" continuedAt="i3a55cca6e2e94ad3bcf938ae0d90bff9"><div><ix:continuation id="i2b240583fd8c44deae071a696ae7e63f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC0yLTEtMS0xMzQ2OTM_888f2028-b352-432d-8674-5e8ff3d8e189">1,632.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC00LTEtMS0xMzQ2OTM_b91df0a7-6f36-4c7f-abc5-7b9264a71d1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC02LTEtMS0xMzQ2OTM_9cbfbb02-6807-4edb-a695-6d0ee66f5c34">1,632.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC04LTEtMS0xMzQ2OTM_a0380635-90b6-439c-9cb4-4d74cd9b3a7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22a9faf176f64839888f1c73d5604d08_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi0yLTEtMS0xMzQ2OTM_c14f9edf-6806-42cf-b2dc-0d9457c2159c">1,108.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id599ac01e6414ccd9716756cd0c865de_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi00LTEtMS0xMzQ2OTM_3578c9d9-5b99-49b4-ae1f-c3cf05dba578">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4a5207e2c6849eda81b356e237635cb_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi02LTEtMS0xMzQ2OTM_5e0fc747-913b-4b3c-a8d7-e45896f9dc35">1,108.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bfd0daf2c604315aee2e5514037add9_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi04LTEtMS0xMzQ2OTM_df6363c0-8b3b-494b-9dc3-d705f981a2f5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f9583d6da0848eaadca5e7997e92ab7_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy0yLTEtMS0xMzQ2OTM_5a837945-205a-43a7-a0ae-568c2e43e2f3">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf3747bdadb44befa911a3d96310ff13_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy00LTEtMS0xMzQ2OTM_06dbafb2-81f1-4753-85b6-d140b9da5de7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5fbb5c6be6b4e50a17ab9ebfa5c3d3d_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy02LTEtMS0xMzQ2OTM_40e3de6a-0423-4d88-825f-35ce962df20e">1,192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58730b06ccbb4aa3b96956a5848ff476_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy04LTEtMS0xMzQ2OTM_ad3414aa-4d97-4ba7-940f-bf6dd6874203">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb48448825914249a3d6d269e0343fed_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC0yLTEtMS0xMzQ2OTM_febc2733-de3d-4c4e-9da6-fd339d2cdde9">132.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbe4b913116b4794b2827d45ad900e88_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC00LTEtMS0xMzQ2OTM_16445e3b-726b-470a-99a1-d291371123dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id29abbf0715a4be1a4a2755996712479_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC02LTEtMS0xMzQ2OTM_0a89e670-de04-417e-8799-efcbdb0d0a74">132.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7487b639fa246688caae909a985fa49_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC04LTEtMS0xMzQ2OTM_2cfa1889-acae-4a70-a714-16ab219d4c9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS0yLTEtMS0xMzQ2OTM_f0153cbb-6bbf-404a-a679-326eff3c0427">1,048.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS00LTEtMS0xMzQ2OTM_92cb8822-68e8-4325-871d-41092a768933">181.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS02LTEtMS0xMzQ2OTM_46330dbc-fab8-4861-b1f7-e2146c246e5f">866.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS04LTEtMS0xMzQ2OTM_d810df73-9325-4db9-90c9-201ee28b7ab5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtMi0xLTEtMTM0Njkz_ab95725d-5d00-4ebe-bcdb-122d96c47b72">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtNC0xLTEtMTM0Njkz_cea6bf4a-de81-4da5-94cb-89be801d6f71">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtNi0xLTEtMTM0Njkz_b51325b4-12b8-4b8b-8bf6-e0a040178fd4">80.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtOC0xLTEtMTM0Njkz_d7f6feff-6f5a-4a6a-aaf2-6936f995f2e5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtMi0xLTEtMTM0Njkz_6102e575-1e25-402f-a5c3-d8487a57519a">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtNC0xLTEtMTM0Njkz_ce02ae55-1a35-4a9d-8578-a40bb9e1068a">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtNi0xLTEtMTM0Njkz_f879db67-06b1-4cf0-9df3-c8c83049a678">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtOC0xLTEtMTM0Njkz_52e7a894-eb91-4361-9521-a61f5d7d3662">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItMi0xLTEtMTM0Njkz_cdc6d599-2a78-4338-9dc7-df71d834ee87">5,228.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItNC0xLTEtMTM0Njkz_6833e7ab-d708-45a6-ba62-6ea5bd6cc69e">181.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItNi0xLTEtMTM0Njkz_c482cad4-65a8-4c43-904f-9d5858e1f6b8">5,046.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItOC0xLTEtMTM0Njkz_df1a36a2-7731-4962-a9ea-7a1eca245357">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtMi0xLTEtMTM0Njkz_8d6445e2-fa10-4cd6-b0c4-ccf5ce776d7e">10.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtNC0xLTEtMTM0Njkz_e56903ab-a568-4361-83b6-1c62e2ed5d36">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtNi0xLTEtMTM0Njkz_3ba5cf70-9691-43a0-a25b-87f887b36113">10.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtOC0xLTEtMTM0Njkz_50fe3a80-2a43-4a5a-a9d2-dfd27d3f84a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtMi0xLTEtMTM0Njkz_cf734bbd-80bb-4fb1-aeb5-6d2c9ff01009">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtNC0xLTEtMTM0Njkz_724ba349-b2ac-48fd-bde5-e0b64a0beeea">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtNi0xLTEtMTM0Njkz_83faf02f-9017-4120-b77c-ec8f95883015">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtOC0xLTEtMTM0Njkz_591aeb41-b63f-4648-8ff3-683c5c1d5989">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtMi0xLTEtMTM0Njkz_02907934-81c3-4db4-8108-d7fcc0ae84fc">219.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtNC0xLTEtMTM0Njkz_d983e9c7-b2b7-4738-bb5c-dd21003663f3">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtNi0xLTEtMTM0Njkz_c1af3c33-2a83-4137-be32-f7635670fc6e">10.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtOC0xLTEtMTM0Njkz_405f3e4f-f556-4fe4-a7cc-171a3dd69ad6">209.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. As of September 30, 2022, we elected to early adopt ASU 2022-03 on a prospective basis, which resulted in removing the impact of contractual sale restrictions from the fair value measurement of our remaining Sage common stock subject to certain holding period restrictions. As of September 30, 2022, our entire investment in the common stock of Sage was classified as a Level 1 measurement. Prior to the adoption of this standard, the fair value of Level 2 instruments classified as marketable equity securities represented a portion of our investment in the common stock of Sage and was valued using an option pricing valuation model. The initial holding period restriction for a portion of our investment in the common stock of Sage expired during the second quarter of 2022 with the remaining holding period restriction set to expire in the fourth quarter of 2022. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Denali Therapeutics Inc. (Denali) had holding period restrictions that expired during 2022. As of September 30, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as Level 2 measurements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTQ5NzU1ODI0MDg4_4f0b3282-a3ec-486c-b0c3-bd280319ec04"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTQ5NzU1ODI0MDg4_89ee227a-f3f6-4126-b9e3-b12b4ec7513b">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of September 30, 2022 and December 31, 2021. There have been no significant changes to our valuation techniques as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i3a55cca6e2e94ad3bcf938ae0d90bff9" continuedAt="ic093e231da3c42fdab88f67e76a3eb86"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk1Ng_fdceced8-3d94-42b9-96a2-bed5ed2bfbdb" continuedAt="i7cdf270de63e4844b04e0fe2e3c4df98" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.040%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0yLTEtMS0xMzQ2OTM_58b34ba3-ac58-4e97-85d6-fc37d28363a0">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC00LTEtMS0xMzQ2OTM_cf734bbd-80bb-4fb1-aeb5-6d2c9ff01009">209.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic2ccf4f8b82f4fda959e8343a1d3dde5_I20220930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0xMC0xLTEtMTM0Njkz_e9649c05-5547-4b09-ab03-3cd0d31099c9">4.50</ix:nonFraction>%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6033459c5bd84004a95df092bb16d49d_I20220930" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0xMi0xLTEtMTM0Njkz_0c3c42ab-2faf-443d-aa87-864bf9329900">4.50</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b72d88f82114d2580cad7720faae9d6_I20211231" decimals="4" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0xNC0xLTEtMTM0Njkz_5f7aa5b0-1706-4c0f-a30e-235fb1bb5c75">1.30</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 to 2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="biib:TechnologicalAndRegulatorySuccessProbability" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzMxOA_3ea3ac87-769b-4d64-8fab-dddbc6e956cf">10.9</ix:nonFraction>% to certain probability as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration Obligations</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk2Nw_bff7a3a1-05dc-4692-ab51-eb9c016ed26c" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.412%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67936f8313184aba9a6a811874849e9e_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi0yLTEtMS0xMzQ2OTM_66eaf166-f3ca-4746-950d-5f7e6fc98b3d">197.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a9350f33f340dfac40b834b36fbee2_I20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi00LTEtMS0xMzQ2OTM_156591a5-557e-475e-8f01-23f714493b32">226.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi02LTEtMS0xMzQ2OTM_f87dd8bc-cf3d-41b6-ab66-4362347ce4ab">209.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f224e8cb20d4247baed59ca9186ca70_I20201231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi04LTEtMS0xMzQ2OTM_325e8dc0-aa91-407b-836d-f6bb3be19c37">259.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy0yLTEtMS0xMzQ2OTM_10d2c144-f019-4bcf-961d-39622ed682e0">2.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy00LTEtMS0xMzQ2OTM_998a309b-2cc8-485b-a40d-802cb44ccc11">15.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy02LTEtMS0xMzQ2OTM_7dc5ca20-b0b0-440f-90e7-2e75f0f7a598">13.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy04LTEtMS0xMzQ2OTM_765826da-8da9-469a-8da4-90f74cf4603e">49.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS0yLTEtMS0xMzQ2OTM_bd461e5f-1fa6-460d-8306-efa5e12cd5ab">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d22419e65e4acdb11df2fd6d50ab7e_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS00LTEtMS0xMzQ2OTM_b3111101-007c-444d-8b89-effb6b0c0d0b">210.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS02LTEtMS0xMzQ2OTM_58c55fa0-0be9-4719-a3d1-b81fa9480a99">195.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d22419e65e4acdb11df2fd6d50ab7e_I20210930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS04LTEtMS0xMzQ2OTM_c48b69d2-1951-4ceb-a9cb-c608b212de5f">210.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzg2Mw_4d619c8d-1918-481e-8627-704fe8795ebe">195.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzg3MA_0303cbb6-c77a-4e02-84ad-3677a066c1f6">209.1</ix:nonFraction> million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, the changes in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, the changes in the fair value of our contingent consideration obligations were primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ic093e231da3c42fdab88f67e76a3eb86"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Instruments</span></div><ix:continuation id="i7cdf270de63e4844b04e0fe2e3c4df98"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b184b88aa274ec19c0f59ff28afb452_I20220930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy0yLTEtMS0xMzQ2OTM_845a15c6-cdfd-462c-827d-f377a9745a34">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b184b88aa274ec19c0f59ff28afb452_I20220930" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy00LTEtMS0xMzQ2OTM_87d8265b-bd22-4a22-b1af-857c3f349c6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb58e5595fd8416d9ad9613922e40315_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy02LTEtMS0xMzQ2OTM_467e9df6-3a4e-44a6-b6e8-65c22dfc4b44">1,020.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb58e5595fd8416d9ad9613922e40315_I20211231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy04LTEtMS0xMzQ2OTM_e468f961-7a9e-4807-8bcf-fe9cb98ec57f">999.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC0yLTEtMS0xMzQ2OTM_c3ca0fcf-3ee4-4462-9e74-ce471282dbeb">1,697.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC00LTEtMS0xMzQ2OTM_ddc8bfbc-0aec-4702-904f-8b84e05eab73">1,744.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f54baa0a0034028959f4f1dd23cf711_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC02LTEtMS0xMzQ2OTM_f2a4a152-10c3-4957-8108-18c62553b8af">1,895.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f54baa0a0034028959f4f1dd23cf711_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC04LTEtMS0xMzQ2OTM_94809878-9bda-4944-8801-566bb24b8e31">1,742.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286147027fd848569c362d90f20b6f37_I20220930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS0yLTEtMS0xMzQ2OTM_c95e932e-90d6-44a3-b222-eb9f9ad94a56">1,183.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i286147027fd848569c362d90f20b6f37_I20220930" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS00LTEtMS0xMzQ2OTM_b2f78851-1911-4118-a796-c65ff9e7df9f">1,492.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f9683196184871a6a8088e9b6526da_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS02LTEtMS0xMzQ2OTM_d90665aa-fd85-4a6e-8bd6-0e714a1fb7f9">1,475.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93f9683196184871a6a8088e9b6526da_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS04LTEtMS0xMzQ2OTM_8f50b24b-02ba-4269-9b67-9485df8e21c8">1,492.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314cc95227f74e429b94104786b26357_I20220930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi0yLTEtMS0xMzQ2OTM_c854d3ef-7b95-466c-a2a1-26deaf34360c">997.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i314cc95227f74e429b94104786b26357_I20220930" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi00LTEtMS0xMzQ2OTM_97f31017-f4d5-44e0-af11-ddc4ed8f167a">1,100.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a4148355e345a48fcfef9143a41e51_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi02LTEtMS0xMzQ2OTM_82e1d218-ad78-418f-a070-848f6f569388">1,463.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56a4148355e345a48fcfef9143a41e51_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi04LTEtMS0xMzQ2OTM_c9a4217c-acea-4146-9b4e-40c168d2ef62">1,099.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8657f446214427d9d8b9bd45a3d47e5_I20220930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy0yLTEtMS0xMzQ2OTM_dc573971-ba7e-42c3-b527-01aea414949f">965.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id8657f446214427d9d8b9bd45a3d47e5_I20220930" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy00LTEtMS0xMzQ2OTM_610516b0-a5b9-4d4e-8831-a706117d76cb">1,473.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddc68c90fa6433c864fb720db1a4975_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy02LTEtMS0xMzQ2OTM_82510187-62e9-4305-97a1-dedd7cbc1922">1,457.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ddc68c90fa6433c864fb720db1a4975_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy04LTEtMS0xMzQ2OTM_5fb0a050-1365-4371-87d5-bdfe2027a095">1,473.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278526fab9042518d7f4accd2d4a217_I20220930" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC0yLTEtMS0xMzQ2OTM_06e36f3b-9ceb-43cd-9d3c-13707c239e85">452.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8278526fab9042518d7f4accd2d4a217_I20220930" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC00LTEtMS0xMzQ2OTM_fc67f157-3161-4128-a67f-869d2eddda2a">468.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205e68692a474c17b451db6c94fec530_I20211231" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC02LTEtMS0xMzQ2OTM_61909fe7-6c45-487f-96f7-f4d386eeb39f">692.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i205e68692a474c17b451db6c94fec530_I20211231" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC04LTEtMS0xMzQ2OTM_f34944ba-60f8-4964-92e4-94be19069021">466.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS0yLTEtMS0xMzQ2OTM_a710b6a5-ae1c-40a0-b83a-27697eb3014a">5,296.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS00LTEtMS0xMzQ2OTM_6f0c5f20-4fe9-4537-af68-4a9e0a97b561">6,279.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DebtInstrumentFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS02LTEtMS0xMzQ2OTM_283d4252-a8db-43aa-b934-f55aec5ad7de">8,004.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS04LTEtMS0xMzQ2OTM_bba5dd13-8785-453c-80ba-dc744f626cfc">7,273.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 3.625% Senior Notes due September 15, 2022, were redeemed in full in July 2022. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2022, compared to December 31, 2021, are related to increases in U.S. treasury yields and wider credit spreads used to value our Senior Notes since December 31, 2021. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_67"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;FINANCIAL INSTRUMENTS </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjQ5MQ_7e12d4db-7f22-4c5b-8e86-b2782a968aec" continuedAt="icb2943414da148939ff97a00092ae303" escape="true"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjUwNg_cf09169a-c169-462b-8932-474504bef87b" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i981abb5814734c34b5ba0e1cfe305f9d_I20220930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMS0yLTEtMS0xMzQ2OTM_0b36c8f8-e483-4adb-8961-c258c61cad8f">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07f093c1bcb4f10bfd6b343935a270d_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMS00LTEtMS0xMzQ2OTM_f0c548e7-59d9-4889-94f9-9e60cacba0e4">247.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6606034d42124a12b44cdb4c5fba6c23_I20220930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMi0yLTEtMS0xMzQ2OTM_7fbbdcb8-8a5a-44f6-bbe4-39a155ef1bd2">115.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a78bdbf8e24900b4b8c65ca0447bcf_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMi00LTEtMS0xMzQ2OTM_9e97c94b-5d70-414b-bf3e-39c376e37be3">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f61cc110f204304ba8ab5bbe034f465_I20220930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMy0yLTEtMS0xMzQ2OTM_55271916-a8a6-48f6-b703-5e7dbd7a56a6">3,070.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3600b20cbb584539b04e82e09e3dc634_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMy00LTEtMS0xMzQ2OTM_a24f6c42-d1ae-4858-9155-65fdf29dfe75">901.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d3e200523fc4be9bb17d504c77c4dee_I20220930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNC0yLTEtMS0xMzQ2OTM_e193ee0b-1959-40ae-a4d8-aa3589ae496c">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f54474067a24bd5b888172e5b16c777_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNC00LTEtMS0xMzQ2OTM_ff9ba06e-6138-498f-bd16-a75f654183c5">283.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNS0yLTEtMS0xMzQ2OTM_7954e6fe-3bc4-4e0e-9303-2278c783b518">3,191.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNS00LTEtMS0xMzQ2OTM_ebbafcc6-f84e-46df-b435-5490eb25de03">1,632.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="icb2943414da148939ff97a00092ae303" continuedAt="iced23461a44c49d0a3f3739cf30db30f"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities (gains) losses are recorded in other (income) expense, net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjQ4Mw_ca0f4a8e-9c22-41e7-9fa6-655b38f101cc" continuedAt="ibabd10d629f642df8b9dc485f5dbe046" escape="true">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><ix:continuation id="ibabd10d629f642df8b9dc485f5dbe046"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0679777b7204048a91c984d68574247_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC0yLTEtMS0xMzQ2OTM_fd1dab9c-6a3e-483b-9ed3-fcabb03ec4db">833.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0679777b7204048a91c984d68574247_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC00LTEtMS0xMzQ2OTM_28e76790-de1f-4841-8c44-c06009ad8779">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0679777b7204048a91c984d68574247_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC02LTEtMS0xMzQ2OTM_780e3a4f-a172-4bd5-b969-bde9557e1db1">6.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0679777b7204048a91c984d68574247_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC04LTEtMS0xMzQ2OTM_132fcecc-8ffa-42eb-bb6e-d6d9b1dfeb2c">826.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS0yLTEtMS0xMzQ2OTM_ea33487b-8f27-462f-a1cc-2265013fb762">400.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS00LTEtMS0xMzQ2OTM_e890876f-62f5-4772-8961-f486125d253a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS02LTEtMS0xMzQ2OTM_69c9e28b-ef0b-457d-b74d-c3f760a58864">8.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS04LTEtMS0xMzQ2OTM_43ef640b-ee6d-42c7-90bf-d05e097a68c0">392.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy0yLTEtMS0xMzQ2OTM_97710078-8274-4e40-8a8d-665fa0f2c83e">412.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy00LTEtMS0xMzQ2OTM_48c93b6d-bec2-49c8-9844-a3c9e4c36bd0">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy02LTEtMS0xMzQ2OTM_90ac96ee-34b2-403b-a692-4fcd29d695c5">3.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy04LTEtMS0xMzQ2OTM_5eaf192f-b257-4c8d-8c33-29c0f8a2aa58">408.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169651b95d8845368e7d477cb953ff71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC0yLTEtMS0xMzQ2OTM_3137d971-40b7-4d03-ad38-7114d3641795">298.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169651b95d8845368e7d477cb953ff71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC00LTEtMS0xMzQ2OTM_56d79581-061c-4d14-8dd2-2bddf856ab82">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i169651b95d8845368e7d477cb953ff71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC02LTEtMS0xMzQ2OTM_7e8c4937-e710-4ca9-af01-29d46570da4a">5.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i169651b95d8845368e7d477cb953ff71_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC04LTEtMS0xMzQ2OTM_ed30cf88-80eb-4fa7-9c17-6ace12d493e3">293.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtMi0xLTEtMTM0Njkz_eea8db12-6926-4b67-8684-5c28b812bc4d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtNC0xLTEtMTM0Njkz_6360fe46-5648-4c7c-9086-88af935aa6dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtNi0xLTEtMTM0Njkz_a17ff3ac-9d5c-42a6-bc96-9b691a232a19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtOC0xLTEtMTM0Njkz_11f0bffa-52ee-455d-8154-20183223626d">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtMi0xLTEtMTM0Njkz_7d81e498-3414-4fd9-82a1-e5b7a646e14d">177.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtNC0xLTEtMTM0Njkz_f24a00c8-1af7-4d1b-9602-f829bdb619b6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtNi0xLTEtMTM0Njkz_990a7223-6cd4-4f84-9606-36546e431ce4">3.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtOC0xLTEtMTM0Njkz_5864864e-cbbf-45a2-89f7-f42878719e1d">174.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItMi0xLTEtMTM0Njkz_551f6efb-d0f9-4eb2-919c-f2704109d9c7">2,122.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItNC0xLTEtMTM0Njkz_0aa8b4d9-af20-4215-81de-2a2b6c496aa7">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItNi0xLTEtMTM0Njkz_7dd431fe-4e06-4d2a-b6ea-a666e94b59de">27.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItOC0xLTEtMTM0Njkz_27246b43-5b2b-4fa7-90f1-51d2f72de88e">2,095.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtMi0xLTEtMTM0Njkz_06f5c84f-6415-4fdb-9934-48a340d2a163">1,133.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtNC0xLTEtMTM0Njkz_c140f274-65c3-47ac-8704-afcbb547c46d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtNi0xLTEtMTM0Njkz_020a3da0-62a8-43d0-9d35-ce5a556acf51">237.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtOC0xLTEtMTM0Njkz_a7f27771-e708-4744-a729-74d7ce5fd48e">896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctMi0xLTEtMTM0Njkz_196b8358-00a9-45a2-a220-37ee53c467e1">1,133.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctNC0xLTEtMTM0Njkz_959f8cef-3adc-450c-8f2b-b772da6d9656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctNi0xLTEtMTM0Njkz_7f869d19-bc0f-491d-8e5d-693f63026a5c">237.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctOC0xLTEtMTM0Njkz_ab591357-d38b-45d7-82b7-055c20dfe671">896.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC0yLTEtMS0xMzQ2OTM_68cb7933-5c65-4f94-b155-5ac6a2d6e3e9">723.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC00LTEtMS0xMzQ2OTM_a9f56bc8-24ae-468a-b3a2-367c296df072">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC02LTEtMS0xMzQ2OTM_f197f351-25e5-416d-a7c3-f515313795be">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC04LTEtMS0xMzQ2OTM_2a782928-aebc-4864-afeb-7c6ba4175993">723.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS0yLTEtMS0xMzQ2OTM_20092e10-a48f-4eac-a6b3-39e9f0d71111">385.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS00LTEtMS0xMzQ2OTM_0fbfa6dc-77ec-4ebc-a61d-b3052ad10bc4">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS02LTEtMS0xMzQ2OTM_955ad030-f14e-4bae-87c6-c7132386c933">0.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS04LTEtMS0xMzQ2OTM_9a4f02d4-68c8-4d94-b042-cd07bc7e2012">384.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy0yLTEtMS0xMzQ2OTM_9dc94139-f78a-460c-9b8c-9ac7248f20af">817.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy00LTEtMS0xMzQ2OTM_9e85bce4-ade1-4748-bed7-a95ec0845255">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy02LTEtMS0xMzQ2OTM_e184546b-88e0-46ed-8fc1-9cc91b085f2f">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy04LTEtMS0xMzQ2OTM_0c984b9d-7663-489e-bf12-e8440b5e150e">816.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC0yLTEtMS0xMzQ2OTM_7e51429b-edfe-4ae5-9518-acf47f85b492">377.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC00LTEtMS0xMzQ2OTM_fccdc4e9-a567-40cb-a555-ede65b668141">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC02LTEtMS0xMzQ2OTM_60571d99-21fc-437f-a83f-b791f8be8c7c">1.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC04LTEtMS0xMzQ2OTM_45713e2b-bbc9-44e1-9743-a141a36c1ed6">376.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtMi0xLTEtMTM0Njkz_dcd3b5cf-c63e-40dd-bb5e-4cef14d9d6ff">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtNC0xLTEtMTM0Njkz_aefbcadc-d054-429a-a9b5-9929dfdff3c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtNi0xLTEtMTM0Njkz_f3cd14b6-c67d-4399-9198-19caf7e35ac6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtOC0xLTEtMTM0Njkz_b1e75002-d5ec-4586-b8f8-6dbbfbc37706">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtMi0xLTEtMTM0Njkz_f60246ce-fb18-4975-bc5e-cbc997ccdd0c">131.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtNC0xLTEtMTM0Njkz_05b8ce68-3e2d-4139-97e7-854e40ea58cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtNi0xLTEtMTM0Njkz_ca382f6e-14dd-4d82-a1b2-1d4388be981e">0.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtOC0xLTEtMTM0Njkz_f34c518a-adb0-4ad4-a2d1-cc3a06233c6c">131.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItMi0xLTEtMTM0Njkz_0cb0724f-5ea4-4904-bc47-295b268b4a5a">2,435.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItNC0xLTEtMTM0Njkz_22e83e5f-08d0-4ed1-9d57-b9f207728ed8">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItNi0xLTEtMTM0Njkz_b8232b21-1a88-4c85-8b72-e5a891c83f1a">3.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItOC0xLTEtMTM0Njkz_ca043627-01ce-4723-bed8-be3c931cdc4a">2,433.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtMi0xLTEtMTM0Njkz_475e3d74-48ee-4966-b9fd-390d9c4b5513">33.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtNC0xLTEtMTM0Njkz_4463b92d-3b5a-4e14-9f2d-3997097f18b8">9.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtNi0xLTEtMTM0Njkz_057c179e-d71f-4821-9e78-5d96e0ad67a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtOC0xLTEtMTM0Njkz_750323b5-6467-43a6-8748-6a9097c54e90">43.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtMi0xLTEtMTM0Njkz_6e50ea45-3e57-4eec-b981-704f17c3b276">1,133.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtNC0xLTEtMTM0Njkz_c78092c9-2104-45a8-a3dc-468f60c33d21">151.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtNi0xLTEtMTM0Njkz_9f6e3586-482f-4569-9fbd-46c2fc650b4f">279.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtOC0xLTEtMTM0Njkz_388f8ade-f73c-4977-b78c-7493afa8488d">1,004.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctMi0xLTEtMTM0Njkz_f94503c1-ad01-47c3-abc7-613f11d8daac">1,167.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctNC0xLTEtMTM0Njkz_28aedbaa-3198-4fb9-be3b-83bdab8d12da">160.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctNi0xLTEtMTM0Njkz_87242655-d8fa-48e7-9f8d-93afae50d87b">279.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctOC0xLTEtMTM0Njkz_120c3483-0bb5-4758-bdda-9d3ee0742c0b">1,048.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iced23461a44c49d0a3f3739cf30db30f"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjUyMQ_657180cf-9727-4b96-82e2-102e287ae90e" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:41.924%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi0yLTEtMS0xMzQ2OTM_65e79962-cda7-4d10-85eb-9a9434f65806">1,235.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi00LTEtMS0xMzQ2OTM_73159623-905f-44c6-a4ec-b3c682207fd3">1,245.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi02LTEtMS0xMzQ2OTM_0f37a28b-410e-4525-9c61-e914da938b85">1,541.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi04LTEtMS0xMzQ2OTM_74c5c97d-5b6b-48ee-8c51-c5c344f0d7bb">1,541.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy0yLTEtMS0xMzQ2OTM_ea79b3a5-e88c-4a92-bd78-90bb4b65d457">848.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy00LTEtMS0xMzQ2OTM_4d83573e-30b9-4286-b4ad-3f58187712e9">864.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy02LTEtMS0xMzQ2OTM_c94e74f5-ace3-4c55-92b8-15871262d033">868.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy04LTEtMS0xMzQ2OTM_12d4e830-ad77-4612-b0bf-1d7a1dc238f6">870.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC0yLTEtMS0xMzQ2OTM_dba50666-10d4-48f8-9f5d-53feeaa2cc9b">12.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC00LTEtMS0xMzQ2OTM_67813f6d-d729-4822-b0b3-787a81c4b60f">12.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC02LTEtMS0xMzQ2OTM_e8e2bbec-ff52-44b5-8483-49cb157d38b7">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC04LTEtMS0xMzQ2OTM_a32c1d3b-6043-4941-8b3b-74c94708932c">24.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS0yLTEtMS0xMzQ2OTM_01f0474e-713d-4add-91ab-2846cc0880a5">2,095.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS00LTEtMS0xMzQ2OTM_66d8384d-073b-4d97-84fb-a37c587a06cb">2,122.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS02LTEtMS0xMzQ2OTM_7821b441-4e0c-4875-98c6-74216fa4fd75">2,433.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS04LTEtMS0xMzQ2OTM_de053e22-4dee-4c46-8389-e45452c81c60">2,435.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2022 and December 31, 2021, was approximately <ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTA1MQ_e73ec821-ffbc-4bf0-a7f5-4595fb4b0456">9</ix:nonNumeric> months and <ix:nonNumeric contextRef="i2c07337e773d46e6ad996880dd86a2fe_D20220101-20220331" name="biib:AverageMaturityOfMarketableSecurities" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTA1OA_7ef1128c-edf4-481b-a6d1-0d822304d6e1">10</ix:nonNumeric> months, respectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:RealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjQ4Ng_d5e7b914-5cc4-45bb-906a-be65ba418536" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi0yLTEtMS0xMzQ2OTM_fa9d405e-8d95-443c-8ce0-d3dcb658ac15">1,643.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi00LTEtMS0xMzQ2OTM_6a61941b-31a1-4e6d-b4ae-2ddec683f8da">575.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi02LTEtMS0xMzQ2OTM_68d34573-24f4-4e66-aebe-d4116001a057">3,104.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi04LTEtMS0xMzQ2OTM_5a8d4bf9-18cb-4cee-bd1f-099d0dc22e57">2,028.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy0yLTEtMS0xMzQ2OTM_c04d59d3-8091-4757-a40a-656d33d76526">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy00LTEtMS0xMzQ2OTM_35fc20dd-062e-4a8e-89fd-93f53137d885">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy02LTEtMS0xMzQ2OTM_94178896-8d91-48cf-8183-d13fb2fd74b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy04LTEtMS0xMzQ2OTM_4e707904-862e-4343-9757-c302701ca5c8">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC0yLTEtMS0xMzQ2OTM_afba7124-f405-41b3-82a3-373813dfe662">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC00LTEtMS0xMzQ2OTM_0485030c-a053-4798-b8a6-8c86c35fa5c4">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC02LTEtMS0xMzQ2OTM_9055a0aa-49eb-466a-9a4b-b1e46ea4c9ef">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC04LTEtMS0xMzQ2OTM_21ea13ef-f5ed-472f-b829-6f13e4cbc563">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="i0caa15f7fec549d5b6d3e7a3c8450b9e_I20220930" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTU0MA_77c9f0a9-a1e0-4055-b64e-4b6f2c301a3e">948.5</ix:nonFraction> million which are included in investments and other assets in our condensed consolidated balance sheets. As of  December 31, 2021, our strategic investment portfolio totaled $<ix:nonFraction unitRef="usd" contextRef="iff043d96d6794a88b3666b1deedfcd35_I20211231" decimals="-5" name="biib:StrategicInvestmentPortfolio" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTU0Nw_0354103f-ba22-4870-a567-83f407d321fa">1,110.3</ix:nonFraction> million and was included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2022, was primarily due to a decrease in the fair value of our investments in Denali and Sangamo common stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sage and Sangamo common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_70"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;DERIVATIVE INSTRUMENTS </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcwNg_7c0a8248-8f9f-4248-8b97-c4edcc36a97c" continuedAt="i194e76b31cba4e4597b20fb1335f0c7e" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2022 and December 31, 2021, had durations of <ix:nonNumeric contextRef="i83d8b0ff4a59482aa6bdc802c56365fc_D20210101-20211231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNzE0_36f687bb-0261-4e26-99cc-3992e2445a0c">1</ix:nonNumeric> to <ix:nonNumeric contextRef="i22a07047b8e84600ba3373e7735d13ac_D20210101-20211231" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNzIw_f522ebf5-2439-4bfb-bbba-a1155be9be6e">15</ix:nonNumeric> months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i194e76b31cba4e4597b20fb1335f0c7e" continuedAt="icc61826d5fcf45b9aebc847e985ea72a"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjczMQ_6b49306c-ac57-4258-a44a-d604edebdfaf" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ac3efa6755547028b1585766ed0d6a8_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMi0yLTEtMS0xMzQ2OTM_51cdd283-682c-4f51-b28f-e668d51eae47">1,089.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1e84a127d4d438c93f97cacfe5c9ceb_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMi00LTEtMS0xMzQ2OTM_699e8ddf-187f-42e5-96e2-5750874b4c95">1,828.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1b944b88e544c5aacd839481cf31357_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMy0yLTEtMS0xMzQ2OTM_3d4c12e4-cc89-43df-b583-8debc9028b60">43.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa20a7bcf2748dcbeac35d8a0e0ca7a_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMy00LTEtMS0xMzQ2OTM_97edf1d5-0faf-4212-a2c5-9ab3ca713651">166.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5e498c8f45242b3a2d9e70d2c42a503_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNC0yLTEtMS0xMzQ2OTM_117e8d22-d7ba-479c-ae68-317b8c964f1d">37.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bd633e40e1e41b1b9c1ae520b9468ff_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNC00LTEtMS0xMzQ2OTM_7d628865-c291-4098-a335-df5a07b9af54">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id52d6723b04d4723a146148f91d54d4d_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNS0yLTEtMS0xMzQ2OTM_5e93d58b-26bc-4804-bbe5-7a2d1a5edd66">23.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61daafc34b6c4be389482539c0515d29_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNS00LTEtMS0xMzQ2OTM_7dc07837-b1b8-4fc4-a91a-1d08ce7cc78d">72.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc378ef82c4040a2a4ab36fe9ca4766b_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNi0yLTEtMS0xMzQ2OTM_9cb1cedb-0042-414f-939e-37f4d6d0882a">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8335794299174638814a89b8c49ff4e9_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNi00LTEtMS0xMzQ2OTM_69856b9d-4c3c-41db-9e97-f921d3c5b84a">59.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e6a6220363429f80e31efa34a52864_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNy0yLTEtMS0xMzQ2OTM_c0a471f8-5f4f-4f3b-ba32-d498683d5a44">1,208.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if95bf11f05e341b19847e153ea08fdc7_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNy00LTEtMS0xMzQ2OTM_4c624297-2457-4d34-a17d-6b7a3734d6de">2,126.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcyNA_b03c6290-6bad-4ceb-9edd-7d09e484027d" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMi0yLTEtMS0xMzQ2OTM_7548d7f2-b096-469f-8325-ff227e92c762">146.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMi00LTEtMS0xMzQ2OTM_1947e05c-4bd5-4cfe-a70f-6d2dece01b3f">60.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMy0yLTEtMS0xMzQ2OTM_9ae6cb28-6b20-4b90-aa92-56e276f50d28">2.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMy00LTEtMS0xMzQ2OTM_e9b76a87-d8af-4f04-8189-298b7d63ec81">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfNC0yLTEtMS0xMzQ2OTM_b63cd0c9-ebf4-405b-ba64-5d28b258cbf0">144.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfNC00LTEtMS0xMzQ2OTM_e0acbe3f-0ec2-4ed7-9fda-f18b7f074736">53.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $<ix:nonFraction unitRef="usd" contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMTkxMA_b63cd0c9-ebf4-405b-ba64-5d28b258cbf0">144.3</ix:nonFraction>&#160;million to be settled over the next <ix:nonNumeric contextRef="i120d294420ac4cc5a5287c7acc20fa00_D20220101-20220930" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMTk0MQ_3f9206b1-3126-412e-9d08-00e99c241ea0">15</ix:nonNumeric> months, of which approximately $<ix:nonFraction unitRef="usd" contextRef="i8996f46ad23e477a8251393d59e34875_I20220930" decimals="-5" name="biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMTk2OA_bd93d137-755c-44e6-b5bf-721483a2fb72">142.6</ix:nonFraction> million of these net unrealized gains are expected to be settled over the next <ix:nonNumeric contextRef="i5fa5a40f0ac14aa19a149832f0cf7187_D20220101-20220930" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMjA0Mg_2fb0fce7-a9ec-4093-84f2-9bac1c3aa611">12</ix:nonNumeric> months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcxMQ_e1a0cfe1-11e7-43a1-801a-c99dbfe98f13" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32243243b47a43fb8c6ba0eb85b30fd8_D20220701-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy0yLTEtMS0xMzQ2OTM_3163f4d3-a686-4df0-943b-7a97d426de7a">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7855fb3a8a984c0abaab370eeac02ee2_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy00LTEtMS0xMzQ2OTM_e3760ae6-bf44-4688-be65-0908e0496dc2">14.9</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie45b0d8165e24b5a9fbc05c247e52911_D20220701-20220930" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy04LTEtMS0xMzQ2OTM_9a5bbd7a-63a7-41c8-ae3b-315696ca7fe6">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic258686cd3a6456ebc2c9b09e2ff27be_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy0xMC0xLTEtMTM0Njkz_cd13d4b8-2a03-4f0a-94cb-bc8c21a4a577">0.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idea016b088d845d98937c3a05df5d947_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC0yLTEtMS0xMzQ2OTM_bcb5aa40-d101-4fcd-8021-a11c4032db05">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i97bd4991354c4a15ac876c71524967c5_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC00LTEtMS0xMzQ2OTM_7d686793-26db-4254-bb27-9994219d6888">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie96b8241173c4299901100e5efed591a_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC04LTEtMS0xMzQ2OTM_946d9583-4bee-46fb-8d2b-db9afb616b92">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b8795f0fecd44bc833219a58dfaee62_D20210701-20210930" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC0xMC0xLTEtMTM0Njkz_cb6889ac-accb-49cc-9040-031b30651952">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec630ea085d14b79a6702770f05c54fc_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS0yLTEtMS0xMzQ2OTM_4b3bf447-7468-48cf-bba5-5b20ae09e0f8">143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1b690018155f45cdb7f208616597334e_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS00LTEtMS0xMzQ2OTM_7709393b-fb51-4735-84d6-ca62ae6151a4">68.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5c24c29444b548aca4187e271cfa886b_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS04LTEtMS0xMzQ2OTM_b8635668-77af-4edc-ab2b-3a2d46540ef4">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3d5d2ca68e014dc3922d00d93a88be43_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS0xMC0xLTEtMTM0Njkz_f457ee94-563d-4dd5-ba07-a068079182c5">4.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id5e7ec03b8354dbab75b233556df07d5_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtMi0xLTEtMTM0Njkz_c0a886e2-ac81-4d31-8797-eeb7859fff0f">3.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88cbc69efa06413895dfc1180ad985c9_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtNC0xLTEtMTM0Njkz_24b4ad4b-e5eb-4f5a-819b-bc80f583ff78">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib29380d2bf674aeb8ea8724965b1f6b8_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtOC0xLTEtMTM0Njkz_23a06140-b5ae-4504-942a-7e5c99e25be3">0.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1d977c21aa234f7f99392c7a1a2c212c_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtMTAtMS0xLTEzNDY5Mw_d9ee66f3-a803-4e44-8e82-fc149b9b6a73">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately <ix:nonFraction unitRef="number" contextRef="i52fa7dd299c7425bbc3bba8fd21f9067_I20180531" decimals="3" name="biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzAwNA_75a37485-7efa-42e1-8c8d-5b957d1d7006">5.0</ix:nonFraction>% to approximately <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzAyNA_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb">49.9</ix:nonFraction>%. The share purchase transaction was completed in November 2018 and, upon closing, </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="icc61826d5fcf45b9aebc847e985ea72a" continuedAt="i739e646753fc437cb49c9e99a5dfd78b"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we paid <ix:nonFraction unitRef="krw" contextRef="i89423fcf9d5d4c26a6860a1d370bc9f4_D20181101-20181130" decimals="-8" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzExNw_3000ef82-0296-4ff9-845b-8cdfc4ea059e">759.5</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="i89423fcf9d5d4c26a6860a1d370bc9f4_D20181101-20181130" decimals="-5" name="us-gaap:PaymentsToAcquireEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzEzOA_76d06682-4fc2-49f7-8f10-b9db8aab9d40">676.6</ix:nonFraction> million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzUxMw_87489fb2-69a4-4e3a-922d-19880424e2d7">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzY1Mg_d473323a-ca4f-414a-8561-f8cef95181a0">57.0</ix:nonFraction>&#160;million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTQ5NzU1ODIwNjk4_87489fb2-69a4-4e3a-922d-19880424e2d7">49.9</ix:nonFraction>% </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity interest in Samsung Bioepis, we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $<ix:nonFraction unitRef="usd" contextRef="if414410918334d9bb8c6e78f27e2bd55_D20220101-20220331" decimals="-5" name="us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNDQzOQ_88228e69-efe2-4ec4-abac-238ac4d3d8fb">10.6</ix:nonFraction> million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $<ix:nonFraction unitRef="usd" contextRef="ic2f87e0409bf4de6bbfb65f1f00e2861_I20211231" decimals="-5" name="us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNDg1NQ_6ab6a5d3-91cf-41a7-9551-7ae586f1a836">3.6</ix:nonFraction> million as of December 31, 2021.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcyOQ_80c345c5-f24c-4391-b798-2c3737d7936a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.980%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22be7e941fc4472097793c58bfe13c85_D20220701-20220930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0yLTEtMS0xMzQ2OTM_2cb088c2-f927-4781-93a3-25b8fa542190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0cd6a0501e4513abdff115c36b8a4c_D20210701-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy00LTEtMS0xMzQ2OTM_d0fd4d21-c930-47dd-8881-fac1925f237c">24.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22be7e941fc4472097793c58bfe13c85_D20220701-20220930" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy04LTEtMS0xMzQ2OTM_7fcaba36-66ea-45e1-ab7d-1fa102709153">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd0cd6a0501e4513abdff115c36b8a4c_D20210701-20210930" decimals="-5" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0xMC0xLTEtMTM0Njkz_e10dbbd3-1cc0-47b1-8614-a76a5a6c8527">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff7a68233a6346a3b41b5ba48c00eb25_D20220701-20220930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0xNC0xLTEtMTM0Njkz_fbb92690-0f98-4c23-b448-f4113acdbb69">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9172dc7ebd564a448d1ab478d505ac9e_D20210701-20210930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0xNi0xLTEtMTM0Njkz_fd672ec1-1b15-4512-9492-29fe601c6ab9">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i507cb74104cc4af691f7ec53fa51daf0_D20220101-20220930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0yLTEtMS0xMzQ2OTM_eaf78794-2a9f-4347-9995-23f7e2b583b0">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f4b8580bdd4045984ea773c64855bd_D20210101-20210930" decimals="-5" name="us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC00LTEtMS0xMzQ2OTM_113366ff-9dce-4fa6-b692-075e5395b285">46.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i507cb74104cc4af691f7ec53fa51daf0_D20220101-20220930" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC04LTEtMS0xMzQ2OTM_22692ab3-95e0-4136-a2aa-ba5fe68a296f">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id6f4b8580bdd4045984ea773c64855bd_D20210101-20210930" decimals="-5" sign="-" name="biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0xMC0xLTEtMTM0Njkz_cb8a3e30-d8bb-48f6-9ef0-f4a98b2c8a44">1.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e7d3a50e8e24a18a4f3bebf9a25ee71_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0xNC0xLTEtMTM0Njkz_ffeacdb3-3864-4421-bc7c-05d4df67f09b">4.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idecbeb6a787b45e999586e7f179ad321_D20210101-20210930" decimals="-5" name="us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0xNi0xLTEtMTM0Njkz_57967d39-ecf0-45a8-8302-723604303f4f">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTEyMA_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="ib88cc97bd13d40ac90880007f88756da_I20220930" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTc0MQ_e0d0d6b7-3dc8-423e-b22f-6b44789b3547">1,285.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="if41dae46b1004553a798193cc1c16ae9_I20211231" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTc0OA_74d5c3f2-5862-4e6b-a18b-16739f731f79">1,268.0</ix:nonFraction> million as of September 30, 2022 and December 31, 2021, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTc5Ng_481e5928-6a52-4f2a-8a81-5625517823c8">36.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTgwMw_fa75af62-a2c7-410b-851d-8fb7db8cdf84">85.8</ix:nonFraction>&#160;million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2022, respectively, compared to net losses of $<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTk2Nw_7831dbd8-8108-46ca-a24a-d6a755698a83">13.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTk4OA_039aea07-f959-436e-88fe-6e7fba1a3fdb">26.1</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i739e646753fc437cb49c9e99a5dfd78b"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcwNA_52ac17ff-91bc-4257-8318-1b812962b114" escape="true"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c0575de61ec44b4950ffd44163cfc4e_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMi00LTEtMS0xMzQ2OTM_a578b8b4-cd2a-4fb0-bc3c-251632ccbd99">158.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53ce27e2d1834006bccaafc6efdf9bff_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMi02LTEtMS0xMzQ2OTM_a6629ff5-b065-4023-bf27-fac53a61475f">66.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac791a4319614586b5fa4b20e746145d_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMy00LTEtMS0xMzQ2OTM_f19cc1c1-27e5-4cde-a3b2-c2f88d7f2e65">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia15c5a492bc341798bf62fd3955ff770_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMy02LTEtMS0xMzQ2OTM_afcb4e91-9230-4331-bc5a-470ce3dc2c63">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6a5fda462c643bdb69ff40ab7f9019c_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfNC00LTEtMS0xMzQ2OTM_366c01a4-6a4e-4375-b736-d7b691fd5389">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib019b33e0733407486645ee0e3dba238_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfNC02LTEtMS0xMzQ2OTM_3098f8ef-a8de-4a7a-99db-73d75785d2f1">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5aa0d743936f4ed9aafcdf381a12a281_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfOC00LTEtMS0xMzQ2OTM_8b4ed538-b0ac-402d-8640-06877d4ca388">21.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ec860c976745568331c92c49c8ddbb_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfOC02LTEtMS0xMzQ2OTM_74d80106-e125-4253-ba3c-58d7d5992eed">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27638e932c864367ae3db51bb6a4e81f_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTYtNC0xLTEtMTM0Njkz_793ff9f1-2b45-43a1-9633-c20c50b427ea">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31b779d2d9c44b8e902c134c0f3a5def_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTYtNi0xLTEtMTM0Njkz_f7cd2501-9211-4237-b611-84e070ee168e">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6767b12f4843b4be545567280f6604_I20220930" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTctNC0xLTEtMTM0Njkz_d4fff806-0eb4-4bbf-8906-6b7d2354e53d">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i034507e9f9464a29a0c701e02ba11b39_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTctNi0xLTEtMTM0Njkz_56efb6f9-bb05-40c5-b131-5570c2e05cbd">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjYxNg_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_73"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;PROPERTY, PLANT AND EQUIPMENT </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTIxMw_d5ec51bb-99c0-4f52-9da4-f56153aa92ad" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTcx_5f6e0a22-6abf-4e6d-b9cc-ec789b19dce3">2,098.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTc4_521e100e-bbbd-4118-b0a3-0a4041f8f7a0">2,006.6</ix:nonFraction> million as of September 30, 2022 and December 31, 2021, respectively. For the three and nine months ended September 30, 2022, depreciation expense totaled $<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc2_9afbf7fb-6a57-438b-8d59-4244c2bebb40">64.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjgz_fbb782a7-5d12-4eaf-baee-1170f99f62a2">207.7</ix:nonFraction>&#160;million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMzEz_4180efb0-4e75-4950-aa9e-b1755d5c6a96">65.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMzIw_2e90787f-aba5-4eac-8cd4-d4ff765ddca7">168.7</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include <ix:nonFraction unitRef="sqft" contextRef="i15cf3398e090470b836590f86a9494e7_D20220101-20220930" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNjI2_dbe34b08-5c69-4bd2-af6f-6108d44d72c2">393,000</ix:nonFraction> square feet related to a large-scale biologics manufacturing facility, <ix:nonFraction unitRef="sqft" contextRef="iff59169dbc0c45b4897fff451d70d7df_D20220101-20220930" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNzAw_923a58a6-fba8-443d-a62b-b806dcd33c31">290,000</ix:nonFraction> square feet of warehouse, utilities and support space and <ix:nonFraction unitRef="sqft" contextRef="ieaa1ea81bcf844509d4e9629d0129c76_D20220101-20220930" decimals="INF" name="biib:NumberOfSquareFeet" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNzYx_777707ac-68d3-492c-b592-5c7bf4f3aae3">51,000</ix:nonFraction> square feet of administrative space. As of September 30, 2022 and December 31, 2021, we had approximately $<ix:nonFraction unitRef="usd" contextRef="i92a75cf0ee8a497393ba39d608afef91_I20220930" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfODM5_306cecb5-44b5-461f-acf8-96d9580ef9f0">701.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a57d1b2e861499fab173d2ef85a3b1e_I20211231" decimals="-6" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfODQ2_d60c507d-923a-45f7-9529-831a1ee54d79">677.0</ix:nonFraction> million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $<ix:nonFraction unitRef="usd" contextRef="i92a75cf0ee8a497393ba39d608afef91_I20220930" decimals="-8" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTEyMw_ee984e2b-35c8-407b-b8aa-794a1a86e163">1.2</ix:nonFraction>&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite at the Solothurn facility will be operational during the second half of 2023.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">125 Broadway Building Sale</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway, Cambridge, MA (125 Broadway) for an aggregate sales price of approximately $<ix:nonFraction unitRef="usd" contextRef="ia758334f8b3d4c2bb05db550ef70a7a0_D20220901-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc3OA_d9f25a8e-024e-4f6b-8f81-6e2eaf5df490">603.0</ix:nonFraction>&#160;million, which is inclusive of a $<ix:nonFraction unitRef="usd" contextRef="i24f4a773df0340cc9dcea4430ac7f361_D20220101-20220930" decimals="-5" name="biib:GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc4Ng_2b4b7d1e-2240-413d-b51a-3de79a44a8da">10.8</ix:nonFraction>&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $<ix:nonFraction unitRef="usd" contextRef="ia758334f8b3d4c2bb05db550ef70a7a0_D20220901-20220930" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc4Mg_0131dd63-4ce9-4de8-9764-10ebae20a435">503.7</ix:nonFraction>&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. This transaction included approximately $<ix:nonFraction unitRef="usd" contextRef="i41b979e0fcbd45a49408dd1c5807f36c_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNTQ5NzU1ODE1NzI4_e82113aa-4d54-423a-acb6-641c863e8a34">79.2</ix:nonFraction>&#160;million of property, plant and equipment, net, which comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="i52ed0ad90e1a409da68a677b1a180bed_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNTQ5NzU1ODE1NzQ3_3a87d891-924b-4711-872f-331984f27fba">72.6</ix:nonFraction>&#160;million for buildings, approximately $<ix:nonFraction unitRef="usd" contextRef="ie0993033b50e4a51badc996a38d9d905_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTA5OTUxMTYzMTAxMw_6b5b42aa-7602-4b98-9118-8dcd41fd5f63">1.6</ix:nonFraction>&#160;million for land and approximately $<ix:nonFraction unitRef="usd" contextRef="i0974435913f44b15b34152a1fee687d0_I20220930" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTA5OTUxMTYzMDk5OQ_93ccc35e-88f7-44b1-9ae9-942b7bef63bb">5.0</ix:nonFraction>&#160;million for machinery and equipment.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_79"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfMzI5ODUzNDg5NjExOA_ee510e60-7148-46a5-a4aa-018222e3c87c" continuedAt="i42f3a6a74c8a49b2bd868a2dff8aa228" escape="true">LEASES </ix:nonNumeric></span></div><ix:continuation id="i42f3a6a74c8a49b2bd868a2dff8aa228"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">125 Broadway Building Sale and Leaseback Transaction</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the sale of our building at 125 Broadway, we simultaneously leased back the building for a term of approximately <ix:nonNumeric contextRef="i7037a7c948b64786be2cf157e66fc0cb_I20220930" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIwODY1_a54d1ca8-4763-43da-9454-075123168828">5.5</ix:nonNumeric> years, which resulted in the recognition of approximately $<ix:nonFraction unitRef="usd" contextRef="i7037a7c948b64786be2cf157e66fc0cb_I20220930" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIwNTgw_47f408d6-9f4c-4357-bdda-a122ad54a4ad"><ix:nonFraction unitRef="usd" contextRef="i7037a7c948b64786be2cf157e66fc0cb_I20220930" decimals="-5" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIwNTgw_7029747c-9e43-40f4-ae9b-74ec89c1a8c6">168.2</ix:nonFraction></ix:nonFraction>&#160;million in new lease liabilities and right-of-use assets recorded within our condensed consolidated balance sheets as of September 30, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">300 Binney Street Lease Modification</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge MA, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of right of use assets of approximately $<ix:nonFraction unitRef="usd" contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930" decimals="-5" name="biib:OperatingLeaseRightOfUseAssetDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIyMTAz_2d289e6a-4609-4a9c-a622-3f42e1d0eede">47.4</ix:nonFraction>&#160;million and lease liabilities of approximately $<ix:nonFraction unitRef="usd" contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930" decimals="-5" name="biib:OperatingLeaseLiabilityDerecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIyMDg3_f67a9869-f5ca-4e21-8a1e-0e4d623242b1">52.7</ix:nonFraction>&#160;million, which resulted in a gain of approximately $<ix:nonFraction unitRef="usd" contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930" decimals="-5" name="biib:GainLossOnRestructuringCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIyMTE5_0e597dce-283b-4818-902c-285225afb820">5.3</ix:nonFraction>&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_76"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12.</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INDEBTEDNESS</span><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjUwNg_cb8793e3-9c0e-4249-9323-d61c81d78aec" escape="true"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.625% Senior Notes due September 15, 2022</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="i737aacf58c3f4d9b8d3e88a3953abda7_I20150915" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfODk_4d8e912b-bb44-4812-a4c2-efdf3f6fd28c">1.0</ix:nonFraction>&#160;billion aggregate principal amount of our <ix:nonFraction unitRef="number" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTI2_0fdddac2-a010-456c-a958-02225367e494"><ix:nonFraction unitRef="number" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTI2_e7da9044-1357-4730-9c18-bcdb767b56d2">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes due September 15, 2022, at <ix:nonFraction unitRef="number" contextRef="iec0813dbc2c649b99fb2b393fca060b6_I20220915" decimals="INF" name="biib:DebtInstrumentRedemptionRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTY5_98a85924-b8b0-4c3a-a715-d10dc040fdd2">99.920</ix:nonFraction>% of par. Our <ix:nonFraction unitRef="number" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTg0_0fdddac2-a010-456c-a958-02225367e494"><ix:nonFraction unitRef="number" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTg0_e7da9044-1357-4730-9c18-bcdb767b56d2">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our <ix:nonFraction unitRef="number" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjY0_0fdddac2-a010-456c-a958-02225367e494"><ix:nonFraction unitRef="number" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjY0_e7da9044-1357-4730-9c18-bcdb767b56d2">3.625</ix:nonFraction></ix:nonFraction>% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i9a76584efadd4ffb99238713fd21af42_D20220701-20220731" decimals="-5" name="us-gaap:ExtinguishmentOfDebtAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMzYx_977b0fb2-205f-40d8-9a48-a028088ea7ee">2.4</ix:nonFraction>&#160;million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges were recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228" decimals="-5" name="biib:LongTermDebtExchangedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfOTg1_54f9ff41-75ae-41e4-a9de-5a803761f165">624.6</ix:nonFraction>&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i43b8001bd67d4407bc0ad37c6a818891_D20210201-20210228" decimals="-5" name="biib:LongTermDebtExchangedAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTA3OA_21cd800e-a685-4ad2-8615-7c65560ff3ad">700.7</ix:nonFraction>&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i97bfc367938746ae877a3fe76a5d66e2_D20210201-20210228" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTE1MQ_a3719f9d-85a3-4842-9dbc-82f5b897766e">151.8</ix:nonFraction>&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228" decimals="-5" name="biib:DebtInstrumentRedemptionAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTQ2Mg_3907a91b-4a39-48fc-9a02-f62a83b98441">8.9</ix:nonFraction>&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228" decimals="-5" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTUzNQ_ab2eaf35-f0e4-40f1-8def-42b0412c4179">12.1</ix:nonFraction>&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i6619831da50241829e986aa29f5743ad_D20220701-20220930" decimals="-5" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTY4NQ_d10c57d8-8258-49f9-bae7-807790cb9786">3.2</ix:nonFraction>&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i6619831da50241829e986aa29f5743ad_D20220701-20220930" decimals="-5" name="us-gaap:RepaymentsOfDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjE1MQ_d78a0354-0eed-4253-8777-5be95a35b5c8">13.8</ix:nonFraction>&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="i6619831da50241829e986aa29f5743ad_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjMxNg_54a5c053-22ff-4a0c-bfa6-1897b7f92976">6.1</ix:nonFraction>&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2021.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_82"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;EQUITY </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA3Ng_dfd38f97-a109-4cc6-b1d6-ac3cd7c78846" continuedAt="iba1043e4dba848da90848803cb8ae8c3" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="iaec7e30533b342c590bb4d7ffe633982_I20201031" decimals="INF" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTEx_ee93976c-30c9-4722-a61d-8a1dc7d45096">5.0</ix:nonFraction> billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMzk2_265ee65b-a64e-4d5a-bcb2-4be67a1906a7">1.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930" decimals="-5" name="us-gaap:StockRepurchasedAndRetiredDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5OTUxMTYyODg4Mg_aa1516ab-54b4-4fd4-9602-a34b181599da">3.6</ix:nonFraction> million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNDUz_858c4041-bbed-4417-ae95-24d9540bddee">250.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930" decimals="-5" name="us-gaap:TreasuryStockRetiredCostMethodAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5OTUxMTYyODg5NA_1f29ae66-858b-432a-8695-cd95268ce926">750.0</ix:nonFraction> million during the three and nine months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2021, we repurchased and retired approximately <ix:nonFraction unitRef="shares" contextRef="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNTcz_e56a9e8d-de7a-48ca-905c-73b052096a0b">2.2</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNTgw_da62eba4-1c12-4670-bc95-dbdf2e2df9a2">6.0</ix:nonFraction>&#160;million shares of our common stock at a cost of approximately $<ix:nonFraction unitRef="usd" contextRef="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNjM3_227eaf19-0d15-4e35-a70f-93f4452108f7">750.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNjQ0_72b6df88-022f-4673-a1cb-e6a326fff1bc">1.8</ix:nonFraction>&#160;billion, respectively. Approximately $<ix:nonFraction unitRef="usd" contextRef="i0abcd53e74c94a7c833bb12a8fd01cfe_I20220930" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNTQ5NzU1ODE1NDA2_b0a276c3-3317-4fef-8433-068a0ef1b2bc">2.1</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5Mw_462c89e3-a167-48a1-a175-e4aed52608bc" escape="true"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f65dc8cba414b409a0f8978d6ed6d6a_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS0yLTEtMS0xMzQ2OTM_75d85915-5c9b-41cb-986f-ebcad68bed00">2.2</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ae9f957d5c456c9db2d0b8de63c577_I20211231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS00LTEtMS0xMzQ2OTM_fe867dfe-cd40-4d0d-81ae-d26518a7912d">53.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc7da9d0cf1d468abb521a902e87c1d0_I20211231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS02LTEtMS0xMzQ2OTM_8d9d7949-e3a4-4534-9f83-9f6acde3e5dd">25.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cdd7aef8328422d92318a8fb44162a7_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS04LTEtMS0xMzQ2OTM_dee971fe-629b-4167-a0f4-19711c056139">44.8</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i566fa85dece64a33ba2afa4c152f1217_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS0xMC0xLTEtMTM0Njkz_f194c7ba-e132-4a08-8d9f-e1ce6d27c0cb">139.0</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS0xMi0xLTEtMTM0Njkz_2fa412ab-05c2-4604-90c1-6f0fae8d678e">106.7</ix:nonFraction>)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi0yLTEtMS0xMzQ2OTM_5e77ffa7-a549-48a7-af8e-823431357fe6">26.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi00LTEtMS0xMzQ2OTM_58464a77-686a-4d2e-9752-45d336a64907">204.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi02LTEtMS0xMzQ2OTM_51d8fc72-a9a8-4291-95b2-9fd825e1995f">12.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi04LTEtMS0xMzQ2OTM_57ea4def-58a9-491b-a3f9-873f80894dce">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi0xMC0xLTEtMTM0Njkz_8e60cc80-a79b-4de6-9801-78e8c3dd17d8">154.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi0xMi0xLTEtMTM0Njkz_fdbf0e6e-bb8a-4676-af44-e9c15ee4d5a3">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy0yLTEtMS0xMzQ2OTM_5b9fb7a7-decc-4ba9-8205-9116ac94574e">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy00LTEtMS0xMzQ2OTM_2cf938ee-1108-4a21-a9b2-46627e72f787">125.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy02LTEtMS0xMzQ2OTM_832f82b0-6800-475a-b135-06ce5827f694">38.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy04LTEtMS0xMzQ2OTM_5f120540-5c40-4fcd-acc8-6df51b16ec81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy0xMC0xLTEtMTM0Njkz_ac5a2a46-348e-4716-a2b9-15b39455948b">58.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy0xMi0xLTEtMTM0Njkz_228c6a4e-b4c9-4e72-b203-a68c01380d97">97.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC0yLTEtMS0xMzQ2OTM_6a4c1f9f-021b-4528-a89b-86ebfb42e73d">19.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC00LTEtMS0xMzQ2OTM_b05e7607-d3bc-4375-8c25-8f9aeef07f04">79.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC02LTEtMS0xMzQ2OTM_2b4bfa7e-4dff-44d7-8374-9832eaa582cd">25.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC04LTEtMS0xMzQ2OTM_dc510cde-1ab6-491d-a50b-228034ca1a71">4.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC0xMC0xLTEtMTM0Njkz_192f7cee-9176-427f-bbfe-23e3e27303ed">95.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC0xMi0xLTEtMTM0Njkz_646894dc-a31a-4b76-bbd4-378898001a7b">56.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica81c533dc694911997333f2bdba6785_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS0yLTEtMS0xMzQ2OTM_c3b232a1-f2ef-487b-b77c-ecd8288acf1a">21.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if562d93e14c149bf85526ac1ea39f925_I20220930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS00LTEtMS0xMzQ2OTM_c3a5e180-023b-4d81-bc9e-38a2c8f2e6b0">132.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a801c0708314316ba9f6b3812a045ba_I20220930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS02LTEtMS0xMzQ2OTM_0c2ef2fe-16be-4d51-bbe5-b9aa685f97f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie0d5210f96b74598bfeb245483674c64_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS04LTEtMS0xMzQ2OTM_b3f9e24b-a797-4a72-8e67-76070bf4525f">40.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e94d3bedc394a18ac6119d2d5a633ef_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS0xMC0xLTEtMTM0Njkz_d66b2505-9889-4f92-986a-ba19f286b882">234.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS0xMi0xLTEtMTM0Njkz_981225dc-8f21-4c05-92c3-51846885f3f4">163.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfOTIz_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.696%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.859%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f0d8ba0521942b4b77b6c16befe6648_I20201231" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS0yLTEtMS0xMzQ2OTM_4e739b17-befe-4a7b-9d7a-d2a9589fefa8">1.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i225e191ffa7842e98d83316aa99374a1_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS00LTEtMS0xMzQ2OTM_280687e6-e565-4f67-bce5-88c1c67f4c6a">179.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ffee1d6cf8a41c9a6241f4cc1056e1b_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS02LTEtMS0xMzQ2OTM_0fff098e-bf53-479c-bfeb-f4dbc5ea3edb">8.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic4ea7c38a0a34d079a17eefda9d0a994_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS04LTEtMS0xMzQ2OTM_62d7c57e-c507-44b0-ba1f-6ae12ed09034">66.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i62ec65b1ad2d4bc99e0fe80385ecaee2_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS0xMC0xLTEtMTM0Njkz_0bf48957-ec1c-49f8-a604-1f2d02c28aeb">46.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS0xMi0xLTEtMTM0Njkz_5bf5bac5-0b5f-4aec-bbb8-16d9849796fc">299.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi0yLTEtMS0xMzQ2OTM_1b4859e6-b01a-4b18-a5cf-074e61c21ad5">2.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi00LTEtMS0xMzQ2OTM_c3d86312-f89c-4038-b382-bee77583039a">143.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi02LTEtMS0xMzQ2OTM_9e6c5258-0da2-4f7a-bffe-c05f6ffa9099">35.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b15de8609a499c99c1288814cbddff_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi04LTEtMS0xMzQ2OTM_d599edb5-b56a-4a7f-9953-517d2311c23c">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi0xMC0xLTEtMTM0Njkz_7f6d6610-625f-437f-a95f-bbd48f4e7b77">80.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi0xMi0xLTEtMTM0Njkz_30ec659e-1396-4b9c-be7b-531330a8a357">99.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy0yLTEtMS0xMzQ2OTM_adda5353-3195-4432-8d0b-c5277c52c766">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy00LTEtMS0xMzQ2OTM_3d722675-96ae-4174-9dd1-a59406788f7d">62.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy02LTEtMS0xMzQ2OTM_1a30473c-1fba-4d30-b714-f9190ff74967">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b15de8609a499c99c1288814cbddff_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy04LTEtMS0xMzQ2OTM_be913447-605d-47b1-95c7-7d2a053ba378">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy0xMC0xLTEtMTM0Njkz_42a52ee8-c4ff-47c5-bcdd-ae85df9daedb">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy0xMi0xLTEtMTM0Njkz_f6d1c418-e65e-4aa1-935b-5b807f4d84a6">63.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC0yLTEtMS0xMzQ2OTM_178e2150-1899-4ad1-bb4f-910747f2f68a">1.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC00LTEtMS0xMzQ2OTM_61d9ccd2-b11f-407f-8d91-4ee2a5ef2408">205.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC02LTEtMS0xMzQ2OTM_81666358-923b-4ab4-8e4f-4e278c776daa">35.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29b15de8609a499c99c1288814cbddff_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC04LTEtMS0xMzQ2OTM_3299e4a3-8997-4a91-99d4-5cfc5c3b0880">3.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC0xMC0xLTEtMTM0Njkz_1cfe7bf7-b240-4f94-be9f-8d4dcf3429d1">80.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC0xMi0xLTEtMTM0Njkz_e405f56b-dbaa-4c48-986c-220e31c62d18">162.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a62332cc2dd41a7b9a9be9081dd2307_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS0yLTEtMS0xMzQ2OTM_5ebe48ba-4491-4a98-a8b9-89c975c2a982">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f60ecb887d4be79a4bb68b4285b869_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS00LTEtMS0xMzQ2OTM_4ebd5bfa-2d72-402c-921b-ce6b7d673111">26.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5733cabf96334e7ab886168311c47ed0_I20210930" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS02LTEtMS0xMzQ2OTM_ba40da7c-553c-4816-861b-d110841fad58">26.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f2f649fd1a74126a144c38bb92e1623_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS04LTEtMS0xMzQ2OTM_132d4852-d96c-4019-bad8-eba01dc64f4f">62.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie69a59bf2fb143128c5de3ed05732a32_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS0xMC0xLTEtMTM0Njkz_da06a6d0-d8bf-4e51-a38f-96c906c15477">126.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i957729f8711844ff89317163bd3b28ee_I20210930" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS0xMi0xLTEtMTM0Njkz_94150102-7479-4fdf-b703-54870e5f026a">136.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iba1043e4dba848da90848803cb8ae8c3"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5MQ_9db3caa4-b3db-4dc6-9a49-db044da8ed16" escape="true"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.730%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i849dd4a8f4c64ed988e7ed27a7acc5aa_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy0zLTEtMS0xMzQ2OTM_9d9eab81-c552-4cc2-9996-e5ed9988dae9">8.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if71a1afa58f84476abfee908e733759f_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy01LTEtMS0xMzQ2OTM_1dc6d1f4-7b23-415c-96e5-4fc24b61ea0b">0.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i27ac905d40cc4c0b8cfce80524bd7f9f_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy03LTEtMS0xMzQ2OTM_288fd501-92b2-407f-b72c-6013dae81e7b">9.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ied4f63161aa64b41b8e31012f313c41d_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy05LTEtMS0xMzQ2OTM_59248eae-7645-4c08-808e-c1b271c4389b">1.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i849dd4a8f4c64ed988e7ed27a7acc5aa_D20220701-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC0zLTEtMS0xMzQ2OTM_7c3d27a4-cdec-4973-97d1-94e3b2d9eb54">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71a1afa58f84476abfee908e733759f_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC01LTEtMS0xMzQ2OTM_ccba09e3-fcbd-4f3f-9e24-db8dd89c0f18">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27ac905d40cc4c0b8cfce80524bd7f9f_D20220101-20220930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC03LTEtMS0xMzQ2OTM_2eccb747-7d8b-457f-bf05-4aabc650f5e9">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied4f63161aa64b41b8e31012f313c41d_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC05LTEtMS0xMzQ2OTM_6372fded-72c0-4d21-96b5-9b29024c9b2c">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi0zLTEtMS0xMzQ2OTM_b78802bd-b4d8-4ed8-aac2-b4fca80776a0">77.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi01LTEtMS0xMzQ2OTM_dfa323ca-fbbe-43c7-a797-448d6b5dd078">14.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi03LTEtMS0xMzQ2OTM_d000b733-2635-4d51-8ce7-554fa9ce0cb7">143.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi05LTEtMS0xMzQ2OTM_d5a58598-ecb2-457b-b968-7abade2d4197">68.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy0zLTEtMS0xMzQ2OTM_6bc865ab-46bb-4517-93f1-76f39189dc19">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy01LTEtMS0xMzQ2OTM_7751508c-39f4-4c03-87bd-b5e531da9a06">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy03LTEtMS0xMzQ2OTM_3bbd8065-5012-4238-b8a8-3f4b77fe6cf7">3.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy05LTEtMS0xMzQ2OTM_7f753467-cda8-4c3f-b38e-dc86a07e1482">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC0zLTEtMS0xMzQ2OTM_5a048733-6c3b-4fdf-a692-94b1e56ccf5f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC01LTEtMS0xMzQ2OTM_4d1f454e-85ea-4499-ac09-f7a54de21003">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC03LTEtMS0xMzQ2OTM_585f2c38-52e9-4ed5-b2b9-3b47691b34bf">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC05LTEtMS0xMzQ2OTM_d042824d-7510-46a2-8501-8c3e10956672">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS0zLTEtMS0xMzQ2OTM_496b5f1f-7b0f-42e0-a53e-947a27b760b1">7.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS01LTEtMS0xMzQ2OTM_07b202fa-04e2-4cb4-8481-235898931692">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS03LTEtMS0xMzQ2OTM_fa9b0e33-e998-45e8-a411-3053d748c70e">14.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS05LTEtMS0xMzQ2OTM_9e5f338c-3ce5-47dd-a977-2fea2ff316f3">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic83040f816404800a727b532e6017bb0_D20220701-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtMy0xLTEtMTM0Njkz_bce8d3fe-c542-4cf2-9a83-e439a0b69f33">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23f5a5169ebd42aba57956e30523887b_D20210701-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtNS0xLTEtMTM0Njkz_fcdec070-ffb3-461b-a4f0-ca233e3f194d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9cf20ed80544d3aa60312bf7249ea5b_D20220101-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtNy0xLTEtMTM0Njkz_4b175e1a-dbf3-469b-94b0-50fe536a994d">38.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if299c0d105f14cf986a61dc16c3cb70c_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtOS0xLTEtMTM0Njkz_e28274bd-1c76-4356-857e-53e5c2c32ff1">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9019b680c6754477845629fe912cca42_D20220701-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtMy0xLTEtMTM0Njkz_e96a708d-dff7-43de-9ce0-f493b8614f09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee1e133f85df4fcda4b5fbf47287ab83_D20210701-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtNS0xLTEtMTM0Njkz_dde421b6-25fb-4f94-98a4-c65d81f428ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9a8c74397f6e462ca3d0a16f7d7d1724_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtNy0xLTEtMTM0Njkz_98e84979-be25-4bcb-a17c-82162680f357">58.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21633472081e499f84d2d8a16c51f6c1_D20210101-20210930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtOS0xLTEtMTM0Njkz_4ec3e64f-dd9e-4005-87ef-d17a00ea5590">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8e3376c311a4ab1ba9f36f3d6388b0b_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtMy0xLTEtMTM0Njkz_9d1d79f8-ad8b-4539-93b1-4c5ccc15a4fa">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i69bc310b2d7d4bdda29eb1089e137559_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtNS0xLTEtMTM0Njkz_3b11df72-164f-4b4a-a1c9-5697522b4f99">14.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i93992c5f9dc945f6b4d933f8893cab02_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtNy0xLTEtMTM0Njkz_f38e4c05-6f8e-4732-90fe-b4f3c84f6b9c">97.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0310cfc482e54baf860e1cc61e2cb08b_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtOS0xLTEtMTM0Njkz_61fb981f-e44c-4a1d-8b5a-378b13786cf3">63.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA2MA_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb">49.9</ix:nonFraction>% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_85"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;EARNINGS PER SHARE </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RleHRyZWdpb246YWRhOGJjNzdhODVhNDg4Njk5NjIxNWJlODAwODJjMjhfMjY3_aa2260b8-797a-4c93-be3d-e7225fa9ab55" escape="true"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RleHRyZWdpb246YWRhOGJjNzdhODVhNDg4Njk5NjIxNWJlODAwODJjMjhfMjU4_ffa13da3-c098-4f35-87da-44936f07b07f" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy0yLTEtMS0xMzQ2OTM_88c50014-8324-4d3a-aa83-47cddb07997d">1,134.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy00LTEtMS0xMzQ2OTM_12f3a7f3-0154-4c5a-b687-8d1674fdde27">329.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy02LTEtMS0xMzQ2OTM_6f5b464c-1a54-4223-bd59-9ec16a977632">2,496.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy04LTEtMS0xMzQ2OTM_f61f3b11-0239-4ba7-90c1-1c2ab4c804e9">1,187.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS0yLTEtMS0xMzQ2OTM_ee88fb6e-d1e7-41ee-940c-ada8ec830541">144.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS00LTEtMS0xMzQ2OTM_f5cd5dfd-e5b7-474f-aee7-f6e2ec03ba3d">148.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS02LTEtMS0xMzQ2OTM_9f2c6120-d671-4f1d-a350-9308770f79f6">145.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS04LTEtMS0xMzQ2OTM_7ab33c1c-d06b-45fa-baa5-c446125a5dcc">149.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7af590a969ea4209b99c133a0dbaa97d_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC0yLTEtMS0xMzQ2OTM_0a722133-8289-4a88-81ac-bf3deee72a4a">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9385ae1537df4bc4b697a93604cec286_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC00LTEtMS0xMzQ2OTM_76f65194-2689-425e-9b88-ba6f9c9cee5f">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6ec20c3acd4e4e87afaf283b335fcd61_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC02LTEtMS0xMzQ2OTM_d7b8221b-fe19-4220-aa17-058d5ba6eb06">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i87a19de3dc2c48cc83fa43e9c9f68324_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC04LTEtMS0xMzQ2OTM_ccdd780a-3c4e-4ac8-a763-bd2881c7fb98">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe4a1ed6e5af4242b0dd4a5d99cdd5d3_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS0yLTEtMS0xMzQ2OTM_22bc323c-86e6-4009-ba11-a52c88ad9fa5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86189fb69f0b4545b7c8c310762bef0d_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS00LTEtMS0xMzQ2OTM_9ed55095-c5d9-4b8c-b91c-64c68ec81f9a">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2b2c0753f0cd4a10bc3da9507bfdac2d_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS02LTEtMS0xMzQ2OTM_a4d06435-7dc4-49f1-9bed-cb4bb03282cc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i423847116cc5490a9bdce5eb39edf6cc_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS04LTEtMS0xMzQ2OTM_caba9970-34fd-4377-bacb-ab00f45548b4">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5726a88b7bb7444385b56260f3916f3a_D20220701-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtMi0xLTEtMTM0Njkz_584a3444-be2f-4345-acea-d0d33d45d0da">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i19e2ef680f084dee982a474253928b22_D20210701-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtNC0xLTEtMTM0Njkz_a3282c05-f48b-4714-9665-6603d1c1572e">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia84ab3f48f3942d2a12b2e1aa732dcf0_D20220101-20220930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtNi0xLTEtMTM0Njkz_a7304b3e-76b1-4670-8f88-1e4f5f8d0a36">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e38e0479cb74c8fa5f98e9890ca19cc_D20210101-20210930" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtOC0xLTEtMTM0Njkz_3550fc55-b29f-4fdf-a94a-69b8c2649a99">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtMi0xLTEtMTM0Njkz_5f6d5e89-0685-4aca-bed0-e518226af25b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtNC0xLTEtMTM0Njkz_a0419be8-036b-4f1e-9a39-61752ad1c4a4">0.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtNi0xLTEtMTM0Njkz_6c9d234d-afa5-4937-b897-ed0ee3f96fb7">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtOC0xLTEtMTM0Njkz_a2c6c43b-2de1-4fb7-ac8f-d4d2c773f5fb">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItMi0xLTEtMTM0Njkz_ff6e5ace-29ac-4ca0-8eb4-58c29b3d685e">144.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItNC0xLTEtMTM0Njkz_b79df29c-8738-4758-a291-14238f99b82d">148.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItNi0xLTEtMTM0Njkz_fc2339ae-9f63-4675-941a-36d7a525296a">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItOC0xLTEtMTM0Njkz_0b2fbae0-14a8-404a-aff3-52f91d76fafd">150.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_88"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15.&#160;&#160;&#160;&#160;SHARE-BASED PAYMENTS </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RleHRyZWdpb246NTYyZjg4OTIxNWJjNDA2ZmE3MDZmMTBkNTI4ZTQ5MzJfNjQy_3a166681-eead-4a6d-bee9-86e605eb3ca2" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RleHRyZWdpb246NTYyZjg4OTIxNWJjNDA2ZmE3MDZmMTBkNTI4ZTQ5MzJfNjY3_c9c10dd0-ccdb-4068-882b-cf9ded625270" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ab96fe04b24b54881a9fb26fd5d9e9_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi0yLTEtMS0xMzQ2OTM_f2c4932f-7759-44c4-8448-a457d60d13d0">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i020a6d175274414c85d5892faf01ae3b_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi00LTEtMS0xMzQ2OTM_62afcd6d-b76d-48a2-9d18-d9fc683c79c3">19.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2916810b28d34baab3e072744e15d7f9_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi02LTEtMS0xMzQ2OTM_b89d5b5d-0690-4634-9bfb-dfc7cc156f3b">72.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie280a8f5fb6f4a64a937ed98bf711fcd_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi04LTEtMS0xMzQ2OTM_1c43df84-0201-4abf-b2de-db7d86863896">72.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc5c47cebcd646a29a4d500a8101cb83_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy0yLTEtMS0xMzQ2OTM_31028dcf-db2f-442b-92de-b8b9ed756832">46.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1200447817a47ce88c12b9b2d542734_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy00LTEtMS0xMzQ2OTM_f2ac8901-d21f-4651-824a-b8bd0d178b73">42.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0d2d23ef6a94bc2ab3418e068cdf65a_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy02LTEtMS0xMzQ2OTM_d69715f3-6ecc-4346-8ae8-c3faa96e0010">129.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i643e3738705a431185c23ad01faf0241_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy04LTEtMS0xMzQ2OTM_f0dced47-c5e8-4287-854a-c5abb3d86e55">127.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS0yLTEtMS0xMzQ2OTM_e3c93f6f-b742-41e3-814c-fc34f6eed055">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS00LTEtMS0xMzQ2OTM_c58660c4-1901-49ae-9afc-81851bc47ad0">62.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS02LTEtMS0xMzQ2OTM_c96aade7-7c71-4001-bbeb-85a7029bed3c">201.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS04LTEtMS0xMzQ2OTM_77b1794d-e2a6-443e-9731-c78de1296a2c">200.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi0yLTEtMS0xMzQ2OTM_76a066b5-cd8c-47cc-9122-089b1ba4d0c2">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi00LTEtMS0xMzQ2OTM_6bfd2a10-bd5f-4366-82a4-1c502a974761">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi02LTEtMS0xMzQ2OTM_6250adef-4afc-4588-b212-9b22001e42dd">7.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi04LTEtMS0xMzQ2OTM_f246eb0a-7fb5-4be2-a10b-c58b611272ac">6.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy0yLTEtMS0xMzQ2OTM_63c2cf7b-5aec-4150-82cd-34acb6b6eaf8">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy00LTEtMS0xMzQ2OTM_61ee3738-8e18-45b1-a9a4-ed183f60a20f">60.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy02LTEtMS0xMzQ2OTM_e75b17c7-def6-4fde-80a1-186c33301e71">194.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy04LTEtMS0xMzQ2OTM_023fccb3-7792-4fa7-ad1e-2ba56bfdc3b0">193.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC0yLTEtMS0xMzQ2OTM_9c3c4722-1cad-4b89-969c-efe9f8020d75">13.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC00LTEtMS0xMzQ2OTM_10d7a62c-3b91-4e71-a5ad-c7a1f5115933">10.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC02LTEtMS0xMzQ2OTM_f42720fe-1d21-4d27-9228-22fc94a849ff">36.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC04LTEtMS0xMzQ2OTM_7800e131-f7d1-4756-aa96-66478a742e33">35.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ea82c65b64d4a08b32f42941f129ccd_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS0yLTEtMS0xMzQ2OTM_7bfa8114-aab0-4034-997b-321131ec8c3c">56.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia985ab3c9c6947ce9bbddd4486e39ab2_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS00LTEtMS0xMzQ2OTM_53b2651a-55ec-4df6-b7bb-1b8e558e4bc6">49.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if43e265e90d84abea2ec20efefd5e160_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS02LTEtMS0xMzQ2OTM_22c6b07f-a2e0-4814-9349-92d55b00514c">158.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a056e0535b44f73a14fb5b5866c995f_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS04LTEtMS0xMzQ2OTM_058ba0f4-c6b9-467c-b639-541917d7f83f">157.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RleHRyZWdpb246NTYyZjg4OTIxNWJjNDA2ZmE3MDZmMTBkNTI4ZTQ5MzJfNjQ5_3e224d1a-af3f-4c56-a507-c045af51ca21" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic363356bb33f48c5be8d5bb4b72a7bf6_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi0yLTEtMS0xMzQ2OTM_d6741a15-9f98-4025-af7f-70155f71a033">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f4a133d037248e49ca85fc0d7750a92_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi00LTEtMS0xMzQ2OTM_2fefea61-9fd9-4f67-b6c0-2cafa4472385">9.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48833179911f4b4da985ff177df33255_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi02LTEtMS0xMzQ2OTM_1e7c0356-20dd-4355-90d7-42a2c4cbf3b6">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bd91ba74efe415d96d36566a8533af0_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi04LTEtMS0xMzQ2OTM_4ce9e56f-cd62-4d42-9bdf-4e51cfd2ed1a">35.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4971fa532f65444a849a4efe193ef3b9_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy0yLTEtMS0xMzQ2OTM_906dfe64-fe3c-4e98-88f9-660dcbe64b2e">48.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5fdb74af71e2435d84ec8c2691f9906f_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy00LTEtMS0xMzQ2OTM_aba9bc81-ba5e-4186-b49d-d8e7ae0ea3f8">38.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia28cefc2251e4aaabc62eda2e1948a43_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy02LTEtMS0xMzQ2OTM_49f33081-4477-4893-afb7-c76831b1aad3">150.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if71aa78fc18748d9bfdd023c98e48b21_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy04LTEtMS0xMzQ2OTM_adecadf6-645f-4732-8089-bbdb87109766">121.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28eda3a32b1a4782908d9192bc909c52_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi0yLTEtMS0xMzQ2OTM_fedfa53e-2b13-4d6f-9f8c-5c468f4d2778">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a060d008f4427d9936c693dd36d7d5_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi00LTEtMS0xMzQ2OTM_8f85d89f-7956-4a21-8496-0bcc3d182d30">4.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d36468b37944b318ad8e33e0eb69a3d_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi02LTEtMS0xMzQ2OTM_c0bc1cb7-d3b7-472b-b985-dece1172aa83">22.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21f7cf90b35a4e9cadd33e5ac5864d7a_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi04LTEtMS0xMzQ2OTM_d6b302de-c638-43d8-b331-3b6e9f6a0b56">14.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f2b501618744c89aa413dcc343decd8_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy0yLTEtMS0xMzQ2OTM_a3899c11-b3cb-4ecb-9588-e0c264010819">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i815aa12c57884893ade8be8bae2934ae_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy00LTEtMS0xMzQ2OTM_d420fb7f-ee63-4e80-854e-37db2d1719c5">4.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10042e38a8a542d693db8947e7136f70_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy02LTEtMS0xMzQ2OTM_c8e5828f-f0c6-4e30-965c-6ae17c6afc0a">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7db73a71288148e78f2f4ecd84931f93_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy04LTEtMS0xMzQ2OTM_efb48100-4757-4a27-9a09-a8079bedd990">13.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie29a14310e7041918de391cbb7abc267_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC0yLTEtMS0xMzQ2OTM_a796686a-3036-42e5-818d-962b9dcdd82a">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4441454a34d345f9842e1c241d644d60_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC00LTEtMS0xMzQ2OTM_9e6f24a1-d469-42fd-9958-d009b192880b">4.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i893566fba033473daa38c35e9da2c3eb_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC02LTEtMS0xMzQ2OTM_1962aead-6d09-48b7-a56c-cb3ebf9d8fb1">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c02e6a550e94385bd647008ae2d2a57_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC04LTEtMS0xMzQ2OTM_b064e46f-7f74-4ce6-84a1-90742a4c0d16">14.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtMi0xLTEtMTM0Njkz_8592e00b-81bb-478f-88f8-52c62c737c29">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtNC0xLTEtMTM0Njkz_0abea6ea-fcda-4386-86bf-44f5fc8af5e4">62.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtNi0xLTEtMTM0Njkz_5da8a4df-2957-4fa2-b506-433712f8f603">201.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtOC0xLTEtMTM0Njkz_47af49a4-c893-408f-a9b2-46f4ff215aaa">200.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtMi0xLTEtMTM0Njkz_3d8684f4-2400-429d-af0b-462e690c6c11">2.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtNC0xLTEtMTM0Njkz_ecd6b5cc-b1b9-4e2e-942c-450af366142d">1.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtNi0xLTEtMTM0Njkz_6887523f-012e-4a56-9027-2174535a0a55">7.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtOC0xLTEtMTM0Njkz_ba81a876-6d26-4588-8979-746f27b80df8">6.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItMi0xLTEtMTM0Njkz_f44a2383-9672-4185-ba79-e3e8a65ddfad">69.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItNC0xLTEtMTM0Njkz_a8a9bffb-0c39-4bbe-b1e5-ace8507de21e">60.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItNi0xLTEtMTM0Njkz_8c5322ec-6423-4d59-84b4-ef313e917ec0">194.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItOC0xLTEtMTM0Njkz_6ec580d1-5ad9-46e2-ad4f-ec85ff055f69">193.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_91"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16.&#160;&#160;&#160;&#160;INCOME TAXES</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Reduction Act</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the Inflation Reduction Act of 2022 (the IRA) was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA will be effective for periods after December 31, 2022. The enactment of the IRA did not result in any material adjustments to our income tax provision or net deferred tax assets as of  September 30, 2022.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzkyMw_ff68ac6b-6173-4b33-94bf-36de32a6fc86" continuedAt="i3955d96d46aa4d2db4719b90945825ba" escape="true"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzkzNw_b38900f0-156c-4560-a15a-bdd6e247151a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.671%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi0xLTEtMS0xMzQ2OTM_2f367f5d-fbb3-4994-b95f-1d319fdfb3fd">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi0zLTEtMS0xMzQ2OTM_0df5c547-51be-4850-b5d9-6f983fcf1391">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi01LTEtMS0xMzQ2OTM_d1fe6e61-3717-4f2f-a836-825b4f21fb2b">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi03LTEtMS0xMzQ2OTM_ab56a7b6-2dc7-4d56-ae9f-109b61350017">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy0xLTEtMS0xMzQ2OTM_c8255fe2-67c4-42ed-90b2-ced6293ea4f4">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy0zLTEtMS0xMzQ2OTM_4ff63802-89f7-4360-be18-0cf9fe476a25">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy01LTEtMS0xMzQ2OTM_0807f31b-7402-43f9-ad7c-b5c75890809b">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy03LTEtMS0xMzQ2OTM_4e9f0ad9-70c3-4592-8d22-c701e7410e06">0.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC0xLTEtMS0xMzQ2OTM_ebb4c58d-bac5-447c-b93c-bffd8bd656a3">3.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC0zLTEtMS0xMzQ2OTM_42bbbe9c-e3b5-4a5f-91e0-fc7476091281">20.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC01LTEtMS0xMzQ2OTM_e3c4bbd7-2e19-4023-987a-1e55f7f6f595">4.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC03LTEtMS0xMzQ2OTM_1445b755-467e-4aaa-9574-86d4857ba3e0">11.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS0xLTEtMS0xMzQ2OTM_f9d00fb2-ed65-4c23-8985-aac9e72137dd">1.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS0zLTEtMS0xMzQ2OTM_20994cfe-d1c9-4ac7-ba98-e8b45ed4f3e0">7.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS01LTEtMS0xMzQ2OTM_0e5afb94-bf41-4114-82a1-b17cb166ce67">1.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS03LTEtMS0xMzQ2OTM_b032934a-63ca-4312-9320-0d4b1980d925">4.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi0xLTEtMS0xMzQ2OTM_032d98b5-094a-46ed-8232-e4fa9c12e67c">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi0zLTEtMS0xMzQ2OTM_aff0fe2e-9fcd-45da-a733-4db009a47ef9">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi01LTEtMS0xMzQ2OTM_fe1fe5a3-edb5-46be-ade4-b0234f54d11f">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi03LTEtMS0xMzQ2OTM_fb3e1330-8ce2-4dcd-b9c2-2a83f5409b08">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtMS0xLTEtMTM0Njkz_dd1b6249-f970-4c39-9a62-cd9aa4470e57">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtMy0xLTEtMTM0Njkz_ec232e05-895d-48f2-a7da-466b418efaf7">2.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtNS0xLTEtMTM0Njkz_7b6287d6-85af-483b-971c-99c988d3bccd">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationGILTItax" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtNy0xLTEtMTM0Njkz_a315b215-18b9-4946-94ed-4e6142f3d81f">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtMS0xLTEtMTM0Njkz_bb7dc61c-f793-49d8-ab3e-d88fd75df5c3">0.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtMy0xLTEtMTM0Njkz_13613c91-abe8-4d26-87fc-d50e77c646bc">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtNS0xLTEtMTM0Njkz_cdbf5aeb-e7ae-482a-b370-44616fe3f656">1.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtNy0xLTEtMTM0Njkz_0ef27f46-cb4e-4011-bc5e-c028288161ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtMS0xLTEtMTM0Njkz_0bad6bd6-2202-4522-89ab-ac4de6a6d962">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtMy0xLTEtMTM0Njkz_0cca9a5e-9b87-4364-b12a-c0e06f53751b">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtNS0xLTEtMTM0Njkz_d17b076d-ab99-4dd8-b233-ef899d1d93cd">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationLitigationAgreement" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtNy0xLTEtMTM0Njkz_1269547c-10e6-43d3-8fe8-696acce4b581">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtMS0xLTEtMTM0Njkz_368b4067-5b3c-4de8-b7c4-0120b16f925d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtMy0xLTEtMTM0Njkz_a9484bb3-5309-451a-8d81-02dcc018120f">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtNS0xLTEtMTM0Njkz_8c6ba6de-cc1f-4313-b8c8-5e6903c043a0">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtNy0xLTEtMTM0Njkz_46a92880-e0c6-42a2-9e19-171f0c8f3dcc">36.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctMS0xLTEtMTM0Njkz_51ca3314-018e-4c32-8db5-18186d48574a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctMy0xLTEtMTM0Njkz_2e77ba7c-e246-421a-81d5-efde8433c882">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctNS0xLTEtMTM0Njkz_807fad74-0c1c-47d3-86cb-102aafe38276">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="biib:EffectiveTaxRateReconciliationInternationalReorganization" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctNy0xLTEtMTM0Njkz_87c4f90d-2076-40d9-bf5d-998e9a196302">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtMS0xLTEtMTM0Njkz_ec807687-9e94-400f-84d5-d25c9870453c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtMy0xLTEtMTM0Njkz_fcc94e17-3299-4140-92aa-ab5fef29a4b1">1.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtNS0xLTEtMTM0Njkz_cf967dc3-8dfa-4fa9-bc99-f83bdf024e61">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtNy0xLTEtMTM0Njkz_141370fb-f356-447a-86fc-35d4af244772">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktMS0xLTEtMTM0Njkz_0f967e28-ad15-4c27-9747-f9aaccf275e9">17.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktMy0xLTEtMTM0Njkz_e2839e95-2c45-4f62-91c6-d3bf26c8ff14">8.9</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktNS0xLTEtMTM0Njkz_1a724f0a-7716-4cdf-8321-362ec2b7496a">19.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktNy0xLTEtMTM0Njkz_ae4133b9-c4e6-403c-a923-fce9747ed31e">29.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the increases in our effective tax rates include the tax impacts on the sale of one of our buildings and the favorable prior year tax effects of changes in the value of our equity investments, where we recorded unrealized losses, and the BIIB111 and BIIIB112 impairment charges. The tax effects of this change in value of our equity investments were recorded discretely as changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in our effective tax rate also reflects the net effects of the Neurimmune SubOne AG (Neurimmune) matters, as discussed below, and the litigation settlement agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTE5MA_2818e4df-91bd-4daf-8322-5d5d7a14f603"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTE5MA_8cf5f050-5d42-4eff-9f2f-d405a5389dd1">490.0</ix:nonFraction></ix:nonFraction>&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTQ0Nw_7a30d501-5942-4bf9-a8f9-51eee8593f9b">390.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTU5OQ_bbf0a272-4e14-40b5-bd14-57bf5c11721a">85.0</ix:nonFraction>&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i3955d96d46aa4d2db4719b90945825ba" continuedAt="ice330360baa54a20bff449945192476f"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="i54de034401784154b4ba0d3eb7e3d450_I20221231" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzQxNA_a2b82ef8-2ce9-4cee-93d0-77465ab77829">500.0</ix:nonFraction>&#160;million, including approximately $<ix:nonFraction unitRef="usd" contextRef="i12b0509f87024db39c961704c8e7c7e0_I20221231" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzQ0Mg_e0153141-7146-42b9-99ec-9d67d85bd096">455.0</ix:nonFraction>&#160;million related to the unrecognized</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax benefits related to Neurimmune's tax basis in ADUHELM, in the next 12 months as a result of various audit</span></div></ix:continuation><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ice330360baa54a20bff449945192476f">closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as w</ix:continuation>e have recorded a full valuation allowance against the relevant deferred tax assets.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_94"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17.&#160;&#160;&#160;&#160;OTHER CONSOLIDATED FINANCIAL STATEMENT DETAIL </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEzNg_f062740f-19a7-438e-b9d1-63303580583f" continuedAt="i215f2e46f4fe44c0bfd8588e874c606e" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjE1Ng_38c4a728-3e71-40b1-9465-d428a4dcc51c" continuedAt="i267d9aa0d2cc4a05b531933555215e69" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi0yLTEtMS0xMzQ2OTM_a858eca6-4fdf-459c-8a68-8c05578884cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi00LTEtMS0xMzQ2OTM_237c08fb-38d1-455f-8815-bd95e3e8aba0">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi02LTEtMS0xMzQ2OTM_d967ba19-7996-4a5e-8d19-cc9657de7009">1,505.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi04LTEtMS0xMzQ2OTM_5b508020-97e2-46ef-a5b6-5e1b0da22a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy0yLTEtMS0xMzQ2OTM_986aef38-4be5-41c4-abb2-d468fa5f29ab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy00LTEtMS0xMzQ2OTM_bf2a9657-fe96-49d4-8cde-886981d19cc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:LitigationSettlementExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy02LTEtMS0xMzQ2OTM_d2b51264-f7c8-419c-99a5-c9baf9c6b399">900.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy04LTEtMS0xMzQ2OTM_25984229-ad05-4c96-8519-178778f5fc92">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC0yLTEtMS0xMzQ2OTM_7d051cbd-9043-4d16-87c7-8cedc012449c">23.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC00LTEtMS0xMzQ2OTM_7cded189-5673-4e13-9306-5d1612e5f8ad">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC02LTEtMS0xMzQ2OTM_727f65f3-4490-4233-b9dc-7eb600e5c79a">39.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC04LTEtMS0xMzQ2OTM_e2079e33-e26e-405d-a66f-2e6cf16c4097">8.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS0yLTEtMS0xMzQ2OTM_f19aee7b-1520-46b9-9ff5-b6a164741197">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS00LTEtMS0xMzQ2OTM_186fc4db-a0f0-4bbd-94e9-e64df37dedd2">66.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS02LTEtMS0xMzQ2OTM_d2262101-9dfa-491e-9736-c32e0eaabd69">191.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS04LTEtMS0xMzQ2OTM_837737dc-5a88-44d6-825b-a712c5ff23d4">187.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi0yLTEtMS0xMzQ2OTM_ccdd9ab0-19dc-4c72-817c-721d03005a20">101.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi00LTEtMS0xMzQ2OTM_d9ae792c-b4cc-419a-9324-515dc1e42ad3">424.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi02LTEtMS0xMzQ2OTM_3e6826e7-c68d-4215-968a-dce240ea31f2">167.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi04LTEtMS0xMzQ2OTM_9ef0d08a-bf3b-4f2d-98de-5dba87890e9c">707.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy0yLTEtMS0xMzQ2OTM_a4d2e92c-8d1e-4f55-ac17-b457ebf9338c">11.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy00LTEtMS0xMzQ2OTM_db0ea26d-3d80-4bb7-a59b-d97898c002e6">13.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy02LTEtMS0xMzQ2OTM_13f70789-4099-4e71-bc1d-c9476958c36d">39.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy04LTEtMS0xMzQ2OTM_11fe9ce7-6406-4333-a90c-bb6f8c8f25ff">23.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC0yLTEtMS0xMzQ2OTM_4161e3af-ff07-4ed6-812c-1f862813e7d0">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC00LTEtMS0xMzQ2OTM_0ad63534-c030-4801-9f6d-c3ed96bffea7">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC02LTEtMS0xMzQ2OTM_1a78b72f-6bc4-4782-a4bc-7c4afa038c14">25.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC04LTEtMS0xMzQ2OTM_3ca8a998-af21-49cb-a4e4-afdbbbfa0ee2">4.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS0yLTEtMS0xMzQ2OTM_4040abda-725b-4f65-bb27-f24f896021eb">56.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS00LTEtMS0xMzQ2OTM_7db4cfb1-13e1-412d-b5a6-c036fe6e9b25">502.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS02LTEtMS0xMzQ2OTM_0ed282fc-4467-42e7-a348-1d0f93244e53">221.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS04LTEtMS0xMzQ2OTM_88b46d2b-78d2-4f57-828f-9a4d9705c698">913.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjA0_87489fb2-69a4-4e3a-922d-19880424e2d7">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i267d9aa0d2cc4a05b531933555215e69">(</ix:continuation>Gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022 we recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfNjA0_d5d84396-b933-4f48-8a55-b611efd76617">900.0</ix:nonFraction>&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i215f2e46f4fe44c0bfd8588e874c606e"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:GainLossOnInvestmentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEyOQ_87985f6a-73e6-4f66-8a04-faf670bc7455" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi0yLTEtMS0xMzQ2OTM_e191d6a0-a1b1-422d-82d3-d8558c956c80">109.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi00LTEtMS0xMzQ2OTM_953f24f1-b242-4ce9-b154-8cf76444170c">424.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi02LTEtMS0xMzQ2OTM_a0c9d852-8744-4d5a-97ab-cefea1daf447">158.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi04LTEtMS0xMzQ2OTM_3369fa62-c139-4cc4-98c2-d238d27165e2">705.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy0yLTEtMS0xMzQ2OTM_e3342d2a-bd37-4990-9ca4-cac4f223bc75">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy00LTEtMS0xMzQ2OTM_422e2648-e631-48c3-95c5-84d2616b60bb">2.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy02LTEtMS0xMzQ2OTM_8dd7da3b-0c10-43d4-b2be-ef0926e76be1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy04LTEtMS0xMzQ2OTM_eb383203-e63a-4fdc-8568-3c70af756774">9.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC0yLTEtMS0xMzQ2OTM_55cfa1f3-b243-4940-ab34-ca80551fd868">109.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC00LTEtMS0xMzQ2OTM_9b19b78f-5ff0-4297-b42a-549f83e4509d">426.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC02LTEtMS0xMzQ2OTM_1571007a-5d14-4f3c-93f5-39fd45c960c3">158.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC04LTEtMS0xMzQ2OTM_f8fa043d-62fd-41b7-a9ba-fc44656cf1c7">715.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis Pharmaceuticals, Inc. (Ionis), Sangamo and Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i6c37ed99d794477582d69045529410a5_D20220701-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMTM3MA_943969d7-000d-4531-864a-2644636f2a28">112.5</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="i70546cdb486b478dbb121a7e30415292_D20220101-20220930" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMTU3Ng_55e968dc-92d3-4169-ab2f-3c5d9c86f438">198.0</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEzNA_0bf2201a-d7e1-4583-9ba6-36403b028305" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMS0yLTEtMS0xMzQ2OTM_25bcf630-c9b9-41fe-ac30-270ecda8fc39">900.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:SettlementLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMS00LTEtMS0xMzQ2OTM_2a0f6ec6-4778-4b6b-95fd-4ffac07e2e35">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i809babb0c0c0499093a3c1b393fd910b_I20220930" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMi0yLTEtMS0xMzQ2OTM_74807629-e79d-41a6-b2fd-f75f605928a9">854.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide348a94f52a4b6fbe470e76039c8fd9_I20211231" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMi00LTEtMS0xMzQ2OTM_1e33985d-158a-4828-a825-f60dbed88e50">802.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMy0yLTEtMS0xMzQ2OTM_9fcb1ab4-6f7a-451a-8e73-67141b437e3e">260.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMy00LTEtMS0xMzQ2OTM_07922185-817a-4c5b-b07c-d913241021b6">324.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNC0yLTEtMS0xMzQ2OTM_652c1f80-df0f-4d9c-bf1a-e94742717d5c">208.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNC00LTEtMS0xMzQ2OTM_77e0686c-f46d-4a79-9b31-13278842ed0e">234.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNS0yLTEtMS0xMzQ2OTM_b3051390-1be6-4123-9d5a-80c9d745fc0d">313.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNS00LTEtMS0xMzQ2OTM_b631bcb8-2589-4d78-a56a-78ddef763856">345.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOC0yLTEtMS0xMzQ2OTM_8f7b7f3b-b097-4d93-a3cd-03349128a353">769.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOC00LTEtMS0xMzQ2OTM_9e8ee3ec-4474-4115-ada6-de1d02991625">828.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOS0yLTEtMS0xMzQ2OTM_43ba9d90-c8cd-43bf-93cd-3aa05acc7a3e">3,305.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOS00LTEtMS0xMzQ2OTM_fc007af8-3e8f-4c3e-8f90-7ae19794dc0a">2,535.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630" decimals="-5" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMTY3Mg_f83b00ce-0eb3-439b-84b6-04d08a28f032">900.0</ix:nonFraction>&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjAxNA_caa622a0-64e6-4f0a-89ff-632b41453167">1,198.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjAyMQ_53d78308-8b66-487c-bde4-907a3cb6e11b">1,320.5</ix:nonFraction> million as of September 30, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjA5OA_a7aaccb4-8e79-42ad-bb19-35063d3e7de4">559.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEwNQ_8effc5fb-6bdb-466c-abbf-365702fa0eb9">664.5</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_97"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18.&#160;&#160;&#160;&#160;COLLABORATIVE AND OTHER RELATIONSHIPS </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NDI_51d60405-94bd-4b5c-9700-995968c89a93" continuedAt="iec021f9a2a9c4e54b98593ede8ab36da" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits or losses equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years for the manufacture of lecanemab drug substance and drug product.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iec021f9a2a9c4e54b98593ede8ab36da" continuedAt="i7061c99184f34b6896b249ec566de7f8"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022 Eisai completed the submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date of January 6, 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NjQ_2ca0cd47-3b05-4a69-b32b-50fa0c403b74" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514b2ba420f64268a1d2daffdaab5268_D20220701-20220930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi0yLTEtMS0xMzQ2OTM_847bcd78-5cb1-4bb7-b07b-c0bb0af97388">109.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a6bb2bc10a4e3c91f961981fa702e8_D20210701-20210930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi00LTEtMS0xMzQ2OTM_eb6ed0ef-e1cd-4bc6-b068-a0a4f69cd9d5">118.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3443044069b84a6e88b9b3cc9b330446_D20220101-20220930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi02LTEtMS0xMzQ2OTM_cc21c31d-f3e5-420e-9b75-a5b7ba9174ae">264.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb735cebf0af4abd9050e30bb5f39f33_D20210101-20210930" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi04LTEtMS0xMzQ2OTM_51070550-58d8-4974-a6c7-2d176da53db3">236.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i514b2ba420f64268a1d2daffdaab5268_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy0yLTEtMS0xMzQ2OTM_cf7726d5-97c2-4081-94e5-65237f490e8a">54.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a6bb2bc10a4e3c91f961981fa702e8_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy00LTEtMS0xMzQ2OTM_c182bd93-4533-46fb-9dd4-3b3fead83785">59.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3443044069b84a6e88b9b3cc9b330446_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy02LTEtMS0xMzQ2OTM_a11d5992-cea2-4e6c-8f59-f708dd3e6520">132.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb735cebf0af4abd9050e30bb5f39f33_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy04LTEtMS0xMzQ2OTM_cd7995e4-419b-424c-90a9-28554828f0c1">118.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c76958e4cf140f8ad08dea4b3f1ab5f_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC0yLTEtMS0xMzQ2OTM_86a44b37-d1b3-4b36-9304-1e11e91e4884">29.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcac94427f544cbbae306a72b2a5e7ad_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC00LTEtMS0xMzQ2OTM_1a22bedc-0f85-40cf-ba2b-7b2e307ad729">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6031c646c1504c3086d61ab2593a7c25_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC02LTEtMS0xMzQ2OTM_fef18e0d-f4bd-4146-b787-e9b180b84f28">68.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb4c4c4dd53404e8de0fcbf8e7d9a10_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC04LTEtMS0xMzQ2OTM_2dfe5d3d-51db-48f4-8d97-bd54227f037f">15.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c76958e4cf140f8ad08dea4b3f1ab5f_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS0yLTEtMS0xMzQ2OTM_cb2510d8-1730-4146-9263-2a8383da9c5a">14.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcac94427f544cbbae306a72b2a5e7ad_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS00LTEtMS0xMzQ2OTM_3045dfde-426d-42c7-8a37-f9c25d7f509c">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6031c646c1504c3086d61ab2593a7c25_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS02LTEtMS0xMzQ2OTM_3b23bb27-7382-4799-ae21-dd0787da979f">34.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddb4c4c4dd53404e8de0fcbf8e7d9a10_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS04LTEtMS0xMzQ2OTM_38c78130-3a01-4871-a25f-7fe910bf440a">7.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;<ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjI0Ng_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $<ix:nonFraction unitRef="usd" contextRef="id6f9bec593be4e5d91def662f86f3734_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjU2NA_f11c2a40-3c9c-4d7f-9b0e-2514fe3bcf8b">100.0</ix:nonFraction>&#160;million milestone payment to Neurimmune. For the nine months ended September 30, 2021, we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjY3OA_d6cb4bf9-72ce-472b-9cac-3dd6c62351a3">45.0</ix:nonFraction>&#160;million to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjcwMA_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>% share of the $<ix:nonFraction unitRef="usd" contextRef="id6f9bec593be4e5d91def662f86f3734_D20210601-20210630" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjcxNg_f11c2a40-3c9c-4d7f-9b0e-2514fe3bcf8b">100.0</ix:nonFraction>&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022, we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $<ix:nonFraction unitRef="usd" contextRef="ide22393d682f495894e1b5ec178709c1_D20230101-20230630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMzI1NA_83befbc3-b4a6-467d-8c5d-12a39f236b24">335.0</ix:nonFraction>&#160;million for the period from January 1, 2022 to December 31, 2022. As of September 30, 2022, Eisai's portion of these expenses was approximately $<ix:nonFraction unitRef="usd" contextRef="i1722b2d0cc7645f1a42a9c8bb59390c0_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMzM3Nw_73efc2cf-9d06-44cd-ae1e-4593a46ce50a">300.0</ix:nonFraction>&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NTA_49940b90-c6f9-4a43-89dc-27b72031cb3d" continuedAt="ifbe3059d037e48a69ab6500041080603" escape="true">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</ix:nonNumeric></span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i7061c99184f34b6896b249ec566de7f8" continuedAt="iead7d97d0f5f47d89f6725758e87d0fa"><div><ix:continuation id="ifbe3059d037e48a69ab6500041080603"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8e21b88c804c23b9bfcb582dae16ce_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi0yLTEtMS0xMzQ2OTM_ace33cdc-eaad-4d67-b6f0-6aa7b3ad386a">34.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348dea4c284f4a53bb11bb12aec530fa_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi00LTEtMS0xMzQ2OTM_a43a8dd8-e6a9-4e39-bb6e-609d3e3df20c">43.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141e695e78b143d688d46ac172f1b598_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi02LTEtMS0xMzQ2OTM_5148364d-e11a-4599-84c9-5e919ee0c97e">116.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179603334c294ba3b273f1bedccca3c9_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi04LTEtMS0xMzQ2OTM_0fa017d8-de7a-4481-9128-e98c205bf5b3">132.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f8e21b88c804c23b9bfcb582dae16ce_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy0yLTEtMS0xMzQ2OTM_24ffea17-4999-495e-95f8-23e8d1fc6035">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i348dea4c284f4a53bb11bb12aec530fa_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy00LTEtMS0xMzQ2OTM_aea79f3f-c78a-4411-b0a3-1a2a9336aae7">24.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i141e695e78b143d688d46ac172f1b598_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy02LTEtMS0xMzQ2OTM_29049ae9-5e61-4d59-9cde-2b17b49eb751">63.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i179603334c294ba3b273f1bedccca3c9_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy04LTEtMS0xMzQ2OTM_57d43fa3-0e50-449b-84db-183a281bf103">73.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c149483b744869649d8b1d34aa36b_D20220701-20220930" decimals="-5" sign="-" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC0yLTEtMS0xMzQ2OTM_fe2fc959-e3b2-45b6-a956-bf0721ce4955">8.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591976370b814e62bd8c8b9ed758f611_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC00LTEtMS0xMzQ2OTM_2ddd01fd-4a77-4373-a3ee-95513f4b63bf">154.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b6a4d48c4a4334acaae1eb260e0b13_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC02LTEtMS0xMzQ2OTM_596afe37-a350-4503-876d-5f69751106cd">127.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505f65ad62c3405996f7fb81bba9d4cb_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC04LTEtMS0xMzQ2OTM_649803bd-a722-4240-a4fd-1d1879edb6fe">391.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id03c149483b744869649d8b1d34aa36b_D20220701-20220930" decimals="-5" sign="-" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS0yLTEtMS0xMzQ2OTM_1ec1fd5a-cee9-4a91-897e-65c40ced432e">3.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i591976370b814e62bd8c8b9ed758f611_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS00LTEtMS0xMzQ2OTM_07ade190-a60e-4ac3-8602-25363dc2ae8a">83.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02b6a4d48c4a4334acaae1eb260e0b13_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS02LTEtMS0xMzQ2OTM_23e4e826-c67a-4649-bbf6-20ba8d064a84">68.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i505f65ad62c3405996f7fb81bba9d4cb_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS04LTEtMS0xMzQ2OTM_9224687b-4ea6-43cf-8344-7342d3abdbe5">211.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a6d0acc3304bb9aa01590e1e7460fb_D20220701-20220930" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi0yLTEtMS0xMzQ2OTM_b4cb3ab6-4a8c-444f-aa5a-c7fd608991cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi00LTEtMS0xMzQ2OTM_6a5b8376-9d0b-4601-a871-e1c48818bac7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6511e416082b49b9a364fc869d30a213_D20220101-20220930" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi02LTEtMS0xMzQ2OTM_e4a49f52-efb0-45ae-a34a-24732dc03bd7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21152c4b7a304de9aeb9f9105783865d_D20210101-20210930" decimals="-5" name="biib:AdditionalMilestonePayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi04LTEtMS0xMzQ2OTM_a5b34c2c-c9f0-48a4-a4c7-a340ccc288bf">100.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19a6d0acc3304bb9aa01590e1e7460fb_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy0yLTEtMS0xMzQ2OTM_6e8f00d2-14d8-4c66-9d25-d43d3ecd3a68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy00LTEtMS0xMzQ2OTM_8575ee36-76b2-4a0a-afcf-6d1b34df304c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6511e416082b49b9a364fc869d30a213_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy02LTEtMS0xMzQ2OTM_cc8e2fcb-66eb-4cf1-80e8-fe608e452db1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21152c4b7a304de9aeb9f9105783865d_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy04LTEtMS0xMzQ2OTM_0d4cbae8-85b8-4b34-abec-3d097fd86458">45.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDE0Ng_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i2dd4b5749a9a44fab753be0fde81fae7_D20220701-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDQwNA_d482ee32-b02b-4c93-8a4f-3ff31a14e969">3.4</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ic0b2780de2c442749c94a8cf029cc0bc_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDQxMQ_e7bf9551-a1df-4e68-a037-559a6170c405">214.0</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, to reflect Eisai's <ix:nonFraction unitRef="number" contextRef="id4b772a8ed2c4a2aac06ce78bbdaec90_D20210701-20210930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDQ0OA_6be04980-eeef-4284-8ba1-1dc6e2a8df55">45.0</ix:nonFraction>% share of net collaboration losses in the U.S.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to $<ix:nonFraction unitRef="usd" contextRef="id4b772a8ed2c4a2aac06ce78bbdaec90_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDUxMA_cb9a5bf8-4b31-4cb9-8b3b-b744339f5029">50.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="if842e4daa2c44c5aaad2b10260a4d9ba_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA5OTUxMTY0NTI4Mw_1fd35a78-cb70-4d8e-89b1-5631c63ccec4">90.7</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $<ix:nonFraction unitRef="usd" contextRef="ib904f98f905e4ad3953b630e2bca4280_D20220101-20220331" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDgzNQ_3ae7b598-ad06-4400-9541-21e1a81f1204">275.0</ix:nonFraction>&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM. F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we have also recorded approximately $76.0&#160;million of aggregate gross idle capacity charges related to ADUHELM.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recognized approximately $<ix:nonFraction unitRef="usd" contextRef="i6511e416082b49b9a364fc869d30a213_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjc0ODc3OTA5MjQ4OQ_66c53d9a-e9f1-49e3-9996-e4f347ff63c5">177.0</ix:nonFraction>&#160;million related to Eisai's <ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTE5NA_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>% share of inventory and idle capacity charges in collaboration profit (loss) sharing within our condensed consolidated statements of income</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5edddd85627f4628a01d57ff448a161b_I20220930" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTQxOQ_4b8b7987-24ba-4dee-9920-5ca629e6db2e">110.6</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="id9708e37fa77451aadd22d8e388458e8_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTQyNg_5196ae57-ea3a-49a1-aac5-35813075cfb3">285.4</ix:nonFraction>&#160;million as of September 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Amounts payable to Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5edddd85627f4628a01d57ff448a161b_I20220930" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTUzMg_e9c7dd89-1000-4d40-8b08-87b024cf263a">81.7</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $<ix:nonFraction unitRef="usd" contextRef="id9708e37fa77451aadd22d8e388458e8_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTUzOQ_07628d30-9a84-4be1-9f5c-3b2b2fbd77f0">46.5</ix:nonFraction>&#160;million as of September 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, we and UCB will co-promote dapirolizumab pegol and share profits equally.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="iead7d97d0f5f47d89f6725758e87d0fa" continuedAt="ia387c9ef620346d59e31ac009a6d379c"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bdd3eb1eb14260abcb70364529e312_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi0yLTEtMS0xMzQ2OTM_2c99f72b-21db-403e-a2b5-90569d5e4138">18.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3154c9870f64f398d5ee5795b0ed8a9_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi00LTEtMS0xMzQ2OTM_c9cd4ecc-065c-4dd8-a336-daa4b77821bf">16.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0000607651b4c2da18c5e8d251aa79d_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi02LTEtMS0xMzQ2OTM_44ab4112-103c-4990-a5e2-3e0c07ff35ab">51.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97091bfe16ce48fa8f91049acef10017_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi04LTEtMS0xMzQ2OTM_44e15115-2995-41f1-8ef9-f1c3c9ef1f07">49.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68bdd3eb1eb14260abcb70364529e312_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy0yLTEtMS0xMzQ2OTM_9f12948b-1b5a-4ba6-8d6a-c5fa027528c6">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3154c9870f64f398d5ee5795b0ed8a9_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy00LTEtMS0xMzQ2OTM_8d62c734-dfef-4207-8142-ef35798ba1a5">8.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0000607651b4c2da18c5e8d251aa79d_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy02LTEtMS0xMzQ2OTM_b7d67d52-08fa-4d5f-a83e-252a69bdd9e9">25.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97091bfe16ce48fa8f91049acef10017_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy04LTEtMS0xMzQ2OTM_3042be36-b0aa-420f-b5a2-be48c4c70ab6">24.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c19ba4f7294ef3b3f1a8cc3f9e7a51_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi0yLTEtMS0xMzQ2OTM_217d28ab-25ab-4afb-b0aa-d31bbab2a4e9">40.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bddd0739a28443f9a5addc1d0165587_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi00LTEtMS0xMzQ2OTM_288fd6fb-59a3-4996-a304-d812995038c4">40.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6280e0f3e31e4892b76bcf7697d7da8c_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi02LTEtMS0xMzQ2OTM_d1f38176-d050-4ca7-b75a-d298cde791c6">130.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dca4a205fd04aff8770a8d6c0648246_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi04LTEtMS0xMzQ2OTM_30624e1b-0ef6-4195-b345-cf3a7da86e4b">134.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19c19ba4f7294ef3b3f1a8cc3f9e7a51_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy0yLTEtMS0xMzQ2OTM_5ec6ab43-26a7-4e47-be2f-6276af4d01f4">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9bddd0739a28443f9a5addc1d0165587_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy00LTEtMS0xMzQ2OTM_3abafc13-134d-42cc-8790-579547eb3a0e">20.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6280e0f3e31e4892b76bcf7697d7da8c_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy02LTEtMS0xMzQ2OTM_e89139d7-d4bc-402c-9380-9fc3e0b81529">65.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dca4a205fd04aff8770a8d6c0648246_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy04LTEtMS0xMzQ2OTM_35df9a27-ca67-4912-bc54-18af95e81fe9">67.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637a39c4b67547449f9bb69b9022b010_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC0yLTEtMS0xMzQ2OTM_282d2cdc-96f0-404a-898c-f3e05a4931b0">28.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6be2070a42f4a50adbcea4041c3995b_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC00LTEtMS0xMzQ2OTM_b7488148-e161-4f2d-948f-cc73b749b6d8">7.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6514e9099d749e2a24676b1e0964505_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC02LTEtMS0xMzQ2OTM_21f33f70-532a-4bfd-acbd-4621abedc142">69.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96ed8937b44437397b52545c683f8ca_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC04LTEtMS0xMzQ2OTM_31f41353-6f49-4f5c-b21a-5bcea2c0f8b4">23.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637a39c4b67547449f9bb69b9022b010_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS0yLTEtMS0xMzQ2OTM_03b8daf9-b396-4fe2-b7fd-c4630d92dfcb">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6be2070a42f4a50adbcea4041c3995b_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS00LTEtMS0xMzQ2OTM_7815e107-f778-4a83-8360-a22d50bc991b">3.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia6514e9099d749e2a24676b1e0964505_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS02LTEtMS0xMzQ2OTM_8e963649-3002-45d4-ae61-eaa8e244f343">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie96ed8937b44437397b52545c683f8ca_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS04LTEtMS0xMzQ2OTM_dff28dce-f13b-4a70-b7fa-c2f1ababda93">11.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022 we and Denali announced the initiation of the Phase 3 LIGHTHOUSE study for BIIB122 (DNL151), a small molecule inhibitor of LRRK2 for the potential treatment of Parkinson's disease.</span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NjY_7020b927-7c28-4a04-9ab6-1c0f5d42412a" escape="true"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63077c7ccbc64b09ba57ccfcb24dc699_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi0yLTEtMS0xMzQ2OTM_b254b3ae-d62b-481f-b068-18ad27bb82ff">19.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67337d92701149d7a5ac303a93defa2c_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi00LTEtMS0xMzQ2OTM_a8fbc311-511f-4f61-8fd2-edb36551b6b4">8.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8df81074864fdca6b0580aa1c815e0_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi02LTEtMS0xMzQ2OTM_b56bf162-a54c-40b4-9bdf-c56f97594d1e">58.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4853d9b210a44032a2de85b0f2c6b1bb_D20210101-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi04LTEtMS0xMzQ2OTM_2f6e98da-b643-4514-9400-bb2fcadc4a1b">27.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i63077c7ccbc64b09ba57ccfcb24dc699_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy0yLTEtMS0xMzQ2OTM_3d17c593-e727-44b6-a043-0b5752890e72">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67337d92701149d7a5ac303a93defa2c_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy00LTEtMS0xMzQ2OTM_f9396929-3aaa-4fcf-99c0-72c84b7323d2">5.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac8df81074864fdca6b0580aa1c815e0_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy02LTEtMS0xMzQ2OTM_e5326077-ff17-4424-8270-5019be5f51ce">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4853d9b210a44032a2de85b0f2c6b1bb_D20210101-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy04LTEtMS0xMzQ2OTM_16fcb8af-e602-4baf-a5f4-c53c9c36ce32">16.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a <ix:nonNumeric contextRef="if6a86bf51ac541cab63587970a524ba7_D20220101-20220930" name="biib:Termofcollaborationagreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NTM_c76616cf-d5d9-4075-95e6-a1a7bc513dd2">five-year</ix:nonNumeric> period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ia387c9ef620346d59e31ac009a6d379c" continuedAt="i146aaf134f9e41b48a81e66437758401"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.794%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.701%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sangamo collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f98a47df764e30ba42983d8f26f8ff_D20220701-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi0yLTEtMS0xMzQ2OTM_218f8a88-4487-4ef9-a148-37d84988a26c">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b59abb400d4439985bc8aede1323697_D20210701-20210930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi00LTEtMS0xMzQ2OTM_15e7ab5d-25b5-4e28-a9d5-076fd2627bc0">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442b682326924c119499dfef30296ddd_D20220101-20220930" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi02LTEtMS0xMzQ2OTM_ac813efe-9ccc-4d60-8341-0e6d1580035d">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a34504b754441cb3200ef36b1270d9_D20220101-20220630" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi04LTEtMS0xMzQ2OTM_4bd2b0cd-d9a6-4337-8d3a-d6330bd041be">16.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f98a47df764e30ba42983d8f26f8ff_D20220701-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy0yLTEtMS0xMzQ2OTM_c8ef007d-6f74-4028-8713-c6030300ffcf">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b59abb400d4439985bc8aede1323697_D20210701-20210930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy00LTEtMS0xMzQ2OTM_8af95f25-f7bd-4550-93c5-1f4fa3515ea0">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i442b682326924c119499dfef30296ddd_D20220101-20220930" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy02LTEtMS0xMzQ2OTM_d4f4f570-afaa-461d-9e02-7a4e270cc34d">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06a34504b754441cb3200ef36b1270d9_D20220101-20220630" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy04LTEtMS0xMzQ2OTM_f85ecb6e-e531-4f1a-aeec-bcd281ee5bab">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021 we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="i64fbcbfb69f64e4bad4eaf9e2feb10e6_D20210801-20210831" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA0NDI_e06be5b2-dd57-43ae-8993-b0a4f20da5e8">125.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense in our condensed consolidated statements of income. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $<ix:nonFraction unitRef="usd" contextRef="i64fbcbfb69f64e4bad4eaf9e2feb10e6_D20210801-20210831" decimals="-5" name="biib:ContingentMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA1OTY_f6f1e124-1e42-415a-be51-5e1fdaa89dd6">812.5</ix:nonFraction>&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recorded $<ix:nonFraction unitRef="usd" contextRef="i2688c6f795fe495b87c7088b9af08f05_D20220701-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTEyMTE_bb416fdc-3809-4c67-90e1-0a1ed5bdb698">14.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="icb2ae5cb50394082889ddf96ebccf655_D20220101-20220930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTEyMTg_c41cee66-f3ea-48ef-b2d3-2d408ade1a54">51.5</ix:nonFraction>&#160;million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i43982e8c28374e20a8abf7ff9c154d4d_D20210701-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTEzOTc_4fdfc887-57e5-4d05-9c4f-85ed5a6571d7">7.7</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i5c00ebed6f7d4754af195586caa15662_D20210101-20210930" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA5OTUxMTY0NTM0Nw_68c4cefa-2aa6-46a1-b100-e396a8df7536">84.9</ix:nonFraction>&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE2Nzk_87489fb2-69a4-4e3a-922d-19880424e2d7">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE2ODk_192d59ff-ed91-4d07-9503-7ea9bcb0fdf6">1.0</ix:nonFraction>&#160;billion in cash at closing and expect to receive approximately $<ix:nonFraction unitRef="usd" contextRef="i316ee61fce71448090e9e99d3e03605f_I20220131" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE2OTU_0fcfce3c-0a3a-4d42-8efc-11d188235b8c">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments of approximately $<ix:nonFraction unitRef="usd" contextRef="i607186b7dfc843688ebf32e0578fc19b_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE3MDE_f667ce64-0313-4cfb-9416-315c9efa1b7f">812.5</ix:nonFraction>&#160;million due at the first anniversary and approximately $<ix:nonFraction unitRef="usd" contextRef="ie8da0e6904f247e0a072f97c4201c43b_I20220131" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE3MDc_a92fa58f-a17f-4dc0-bb3c-41f9b74f1baa">437.5</ix:nonFraction>&#160;million due at the second anniversary of the closing of this transaction.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, we are also eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430" decimals="-5" name="biib:AdditionalMilestonePayment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE3NDc_96136127-4524-4f39-b718-e6b4699c4026">50.0</ix:nonFraction>&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i146aaf134f9e41b48a81e66437758401" continuedAt="i265cf275279349fa8afcf911b6c86578"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $<ix:nonFraction unitRef="usd" contextRef="iecc1e7ba25054542bf09508f1c307e7e_I20181107" decimals="-5" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI1MTU_35f6a334-0a96-4a33-9d82-d141f551f15c">675.0</ix:nonFraction> million and related to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="i54f716cdfda745bd9304e51b2b5d7a59_D20220101-20220930" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI3MDc_83052180-f3e9-4aac-8f54-359c877df399">1.5</ix:nonNumeric> years, and the basis differences related to developed technology and IPR&amp;D for marketed products were being amortized, net of tax, over their estimated useful lives of <ix:nonNumeric contextRef="ic158a58579df49b6bfc1555e6b8983da_D20220101-20220930" name="biib:Equitymethodinvestmentbasisdifferenceamortizationperiod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI4Nzg_940242c7-6ea4-41c1-93ff-7a58e59bba8a">15</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI5NzY_cd357630-1c8c-4f3f-88ad-73a98bb36690">2.6</ix:nonFraction> million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $<ix:nonFraction unitRef="usd" contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTMwODE_ae2fee6f-b092-4ee3-a780-272ed6446d13">17.0</ix:nonFraction>&#160;million, offset by amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTMxNTk_9d144360-bb12-4bab-bb13-11f29439ed0b">14.4</ix:nonFraction>&#160;million. This amount reflects our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized net income on our investment of $<ix:nonFraction unitRef="usd" contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM1NzE_59329f45-430b-4ba1-8511-374e4e1c1590">1.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM1Nzg_ade37fd0-e4e6-4c93-9880-32218901b49b">17.2</ix:nonFraction> million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax to</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taling $<ix:nonFraction unitRef="usd" contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM2NzU_cce3ea6e-5ab5-47ea-bfde-754c310257b6">8.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM2ODI_6629f95e-72d0-43d2-bf36-f2436f2494e5">39.5</ix:nonFraction>&#160;million, respectively, offset by amortization of basis differences totaling $<ix:nonFraction unitRef="usd" contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM3NDc_468b5af1-02d6-4c27-be8a-b03d581c21db">7.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930" decimals="-5" name="us-gaap:AdjustmentForAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM3NTQ_0640ea20-a189-45e7-aaf6-c53b3c14b641">22.3</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled <ix:nonFraction unitRef="krw" contextRef="if1c25ceefcea49b9827a310222a5b592_I20211231" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM4NDY_cffb97e6-ba2f-4051-ab57-8882f9861577">713.3</ix:nonFraction> billion South Korean won ($<ix:nonFraction unitRef="usd" contextRef="if1c25ceefcea49b9827a310222a5b592_I20211231" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM4Njc_cb39c2e4-ca73-4013-a858-3b9e79727397">599.9</ix:nonFraction> million), which is classified as a component of investments and other assets in our condensed consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to <ix:nonFraction unitRef="krw" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="-8" name="us-gaap:EquityMethodInvestments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0MTg_decd90de-6961-4c55-97ad-75aa5ad71e35">zero</ix:nonFraction>.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="i534cd99ae2f945f4b8b88984e7158822_D20191201-20191231" decimals="INF" name="biib:ContingentCommercializedRightsNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQyNjU_1d5403e9-4732-42f3-b3e3-4892549e6ad5">two</ix:nonFraction> potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately <ix:nonFraction unitRef="number" contextRef="i534cd99ae2f945f4b8b88984e7158822_D20191201-20191231" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ2NzM_94ce2111-524d-4a5a-ad75-58e6df71e925">45.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ib960c5c895e446e0acbf3a757df2ab49_D20200101-20200331" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ3NDQ_28245301-1c32-4d1b-a361-2e394658089d">100.0</ix:nonFraction> million to Samsung Bioepis in January 2020, of which $<ix:nonFraction unitRef="usd" contextRef="ib960c5c895e446e0acbf3a757df2ab49_D20200101-20200331" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ3OTI_71c170c9-588d-4bc6-81f5-f0966fc72ae8">63.0</ix:nonFraction> million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $<ix:nonFraction unitRef="usd" contextRef="i92a4535230f44352ba473e29091c1ed5_I20200131" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ5MDc_5c131347-f2fb-447c-9ef8-ef1ad78fb8aa">37.0</ix:nonFraction> million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 we accrued $<ix:nonFraction unitRef="usd" contextRef="iba57778587524c7389b5d85413395030_D20220701-20220930" decimals="-5" name="biib:AccruedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTUwNDg_c510ba21-48d8-4470-91ad-1ceaf77d823a">15.0</ix:nonFraction>&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the United Kingdom (U.K.), that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTUzMTE_74507743-6abb-465e-a0d5-592a3fb7d8f9">180.0</ix:nonFraction> million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional <ix:nonNumeric contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" name="biib:CollaborationAgreementTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTU1MTA_730626d1-f281-4cd6-9bac-d1c2d1fa887f">five years</ix:nonNumeric>, subject to payment of an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="-5" name="biib:ContractOptionExerciseFee" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTU1NjI_9ccd19ec-2ccc-456a-b8ff-a9089665c175">60.0</ix:nonFraction> million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYwMzI_332c330b-9609-427a-a94e-c5b7c653ed8e">50.0</ix:nonFraction>% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2022, we recognized net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="ie2a1da015b744d1bad39bd303d279f1e_D20220701-20220930" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYzMDU_227f5020-3069-4a6d-8b69-9720263361e5">48.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYzMTI_76da47e0-3e3a-4516-ab57-5c089a587742">171.4</ix:nonFraction> million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYzNTg_332c330b-9609-427a-a94e-c5b7c653ed8e">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to a net profit-sharing expense of $<ix:nonFraction unitRef="usd" contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY0NDc_2e7886f4-e036-4a6f-992a-4b657fc11476">71.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY0NTQ_07472e58-4690-492c-8e36-db0a763b7c99">210.2</ix:nonFraction> million, respectively, in the prior year comparative periods. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i265cf275279349fa8afcf911b6c86578" continuedAt="i9626e89091b94d61aadddfe603942dd3"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ifbc42c348d684b9cbcdd1bfb3d7628c9_I20220930" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY5ODg_ea4a5c52-ca65-446c-8c8f-e26b95a2e41e">1.8</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $<ix:nonFraction unitRef="usd" contextRef="i9c991d99f95e47928b97d145d5eb1271_I20211231" decimals="-5" name="us-gaap:DueFromRelatedParties" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY5OTU_b6756e10-dba6-4d32-9395-2f11ef6a7e3e">4.1</ix:nonFraction>&#160;million as of September 30, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed abo</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ve were $<ix:nonFraction unitRef="usd" contextRef="ifbc42c348d684b9cbcdd1bfb3d7628c9_I20220930" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTcxMTE_f69c2645-0828-464c-8c30-0abf5c88a7e2">53.8</ix:nonFraction>&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i9c991d99f95e47928b97d145d5eb1271_I20211231" decimals="-5" name="us-gaap:DueToRelatedPartiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTcxMTg_3ad41ec9-d125-4496-8314-b30822157321">148.7</ix:nonFraction>&#160;million as of September 30, 2022 and December 31, 2021, respectively.</span></div></ix:continuation><div style="margin-top:6pt;text-indent:24.75pt"><ix:continuation id="i9626e89091b94d61aadddfe603942dd3" continuedAt="i145ea4ed2fca4cc384a486f3381fd8a0"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i145ea4ed2fca4cc384a486f3381fd8a0"> to our consolidated financial statements included in our 2021 Form 10-K.</ix:continuation> </span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_100"></div><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19.&#160;&#160;&#160;&#160;INVESTMENTS IN VARIABLE INTEREST ENTITIES </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzM3MjI_7fc998a6-c0b6-499c-ae0f-c5f0531c9cd0" continuedAt="i4ee36c6533d44c9bae8201d7507828fc" escape="true"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or <ix:nonNumeric contextRef="if7a682c52ea24aa381955c02cfe12e06_D20220101-20220930" name="biib:CollaborationAgreementTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzc0Mg_04065fa3-798d-4871-9adc-cb3fe79b8956">12</ix:nonNumeric> years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund <ix:nonFraction unitRef="number" contextRef="if7a682c52ea24aa381955c02cfe12e06_D20220101-20220930" decimals="INF" name="biib:ResearchAndDevelopmentCostsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzEwODU_3c56855a-2d47-4518-80be-1844b6029653">100.0</ix:nonFraction>% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $<ix:nonFraction unitRef="usd" contextRef="i476cf962e66248c3a8819cbb993cf272_I20211231" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzEzMzg_f21d2bfd-7de5-4ff2-bff9-65275baec0bc">100.0</ix:nonFraction>&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $<ix:nonFraction unitRef="usd" contextRef="i476cf962e66248c3a8819cbb993cf272_I20211231" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE0MzM_f21d2bfd-7de5-4ff2-bff9-65275baec0bc">100.0</ix:nonFraction>&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $<ix:nonFraction unitRef="usd" contextRef="i1b8287024d7d445698e5003d95aef21d_D20211001-20211231" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE2OTQ_9cb5c657-0a9e-45a8-898f-082101186eec">45.0</ix:nonFraction>&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="INF" name="biib:PercentageoffuturedevelopmentcostsrelatedtoEisai" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE3MTY_05d7c961-0c8a-4566-93f4-4aca444902ea">45.0</ix:nonFraction>%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $<ix:nonFraction unitRef="usd" contextRef="i476cf962e66248c3a8819cbb993cf272_I20211231" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE3MzI_f21d2bfd-7de5-4ff2-bff9-65275baec0bc">100.0</ix:nonFraction>&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE4Njk_2818e4df-91bd-4daf-8322-5d5d7a14f603"><ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE4Njk_8cf5f050-5d42-4eff-9f2f-d405a5389dd1">490.0</ix:nonFraction></ix:nonFraction>&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE4OTQ_7a30d501-5942-4bf9-a8f9-51eee8593f9b">390.0</ix:nonFraction>&#160;million related to this deferred tax asset. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE5MDE_bbf0a272-4e14-40b5-bd14-57bf5c11721a">85.0</ix:nonFraction>&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i4ee36c6533d44c9bae8201d7507828fc"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzI5MDU_b973788f-af3d-4fc1-82a3-5925f3529a8c">25.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzI5MTI_7ed69936-b362-40cb-993b-440c433faa5f">24.6</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></ix:continuation><div id="if1c5ef17491f4c2cbb98c8f67b203f36_103"></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20.&#160;&#160;&#160;&#160;LITIGATION </span></div><ix:nonNumeric contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDMvZnJhZzpiNTI5OWUwODAwNDY0NDYyYTU3NGFjOGE3Y2U3ZGYyYy90ZXh0cmVnaW9uOmI1Mjk5ZTA4MDA0NjQ0NjJhNTc0YWM4YTdjZTdkZjJjXzEyOTU0_44cbc55a-7e2f-485b-b6e8-277e032e235d" continuedAt="i9d0f34e7dca04fb58a91c02f3d80000f" escape="true"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in actions filed by shareholders in November 2020 (the November 2020 Securities Action) and February 2022 (the February 2022 Securities Action) and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. In September 2022, the court dismissed the November 2020 Securities Action, and the plaintiff has appealed to the U.S. Court of Appeals for the First Circuit. Our motion to dismiss the February 2022 Securities Action is pending. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Action</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders on February 9 and July 21, 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The court has stayed both cases. An estimate of the possible loss or range of loss cannot be made at this time.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="i9d0f34e7dca04fb58a91c02f3d80000f" continuedAt="ie94be23fc53b42b2883b01155e930781"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris and proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent). In June 2022 Fresenius Kabi amended both actions to assert claims under European Patent 3 145 488 (the EP &#8216;488 Patent), which expires in May 2035. No hearing has been set in either action.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a corresponding Danish utility model, DK 2020 00038 Y3. In September 2021 the Court refused Fresenius Kabi's request for a preliminary injunction, finding that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark, and a hearing is scheduled for January 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP '510 Patent, which resolves all pending infringement claims under the EP '510 Patent. The EPO has scheduled a hearing on the validity of the EP '488 Patent for October 26, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court, alleging infringement of the German counterpart of European Patent No. 3 212 667 (EP '667 Patent), which expires in October 2035. The case has been stayed pending proceedings in the EPO to invalidate the EP '667 Patent.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the Opposition Division of the EPO revoked the EP '667 Patent. Gedeon Richter Nyrt have appealed that decision to the TBA of the EPO. No hearing has been set in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Gedeon Richter Nyrt commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model corresponding to EP '667. The proceeding has been stayed pending the outcome of proceedings that Biogen has filed in the German Patent and Trademark Office to cancel the utility model. No hearing has been set in the cancellation proceedings.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, without admitting any liability, we agreed to pay $900.0 million to settle previously disclosed litigation unsealed in July 2015 and filed by Michael Bawduniak on behalf of the U.S. and certain states in the U.S. District Court for the District of Massachusetts alleging violations of the federal False Claims Act and state law counterparts. In October 2022 the court dismissed the case with prejudice.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $<ix:nonFraction unitRef="usd" contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDMvZnJhZzpiNTI5OWUwODAwNDY0NDYyYTU3NGFjOGE3Y2U3ZGYyYy90ZXh0cmVnaW9uOmI1Mjk5ZTA4MDA0NjQ0NjJhNTc0YWM4YTdjZTdkZjJjXzYyNDI_d4915250-960c-4891-84dc-137cb152a607">200.0</ix:nonFraction> million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan, alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts, alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="ie94be23fc53b42b2883b01155e930781"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. The Company also received a civil investigative demand from the Federal Trade Commission (FTC) and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#8217;s approval and ADUHELM&#8217;s marketing. In July 2022 the FTC informed us that it had closed its investigation.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 the U.S. Supreme Court denied our petition for writ of certiorari for review of the previously disclosed decision of the U.S. Court of Appeals for the Federal Circuit holding that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid. Thereafter, we moved to dismiss our appeals from the judgments in the previously disclosed Delaware Actions, and we and Mylan Pharmaceuticals, Inc. (Mylan) agreed that the judgment in our favor in the previously reported </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review filed by Mylan in 2018 should be vacated.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc. and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement, following our receipt of Sandoz inc.'s notice of intent to commercially market a biosimilar version of TYSABRI (natalizumab). No trial date has been set.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent), which covers administration of natalizumab to treat MS and expires in February 2023. A hearing has been set for November 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A. brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has not been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the EPO revoked the EP &#8216;967 Patent. A hearing on our appeal to the TBA of the EPO is set for December 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#8216;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#8217;s proposed natalizumab biosimilar. A hearing has been set for February 2023.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_109"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;5 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_112"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Executive Summary</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Introduction</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we continually review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland. In the second quarter of 2021 a portion of the facility received a Good Manufacturing Practice (GMP) multi-product license from the Swiss Agency for Therapeutic Products (SWISSMEDIC). In April 2022 the United States (U.S.) Food and Drug Administration (FDA) approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite at the Solothurn facility will be operational during the second half of 2023. We believe that the Solothurn facility will support our anticipated near-term needs for the manufacturing of biologic assets. If we are unable to fully utilize our manufacturing facilities, due to lower than forecasted demand for our products, we will incur excess capacity charges which will have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs, and, unless we develop, acquire rights to and/or commercialize new products and technologies, we will be substantially dependent on sales from our products and our financial rights in our anti-CD20 therapeutic programs for many years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Environment</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market or are developing and have considerable experience in undertaking clinical trials and in obtaining regulatory approval to market pharmaceutical products. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from generic versions, prodrugs and biosimilars of existing products as well as products approved under abbreviated regulatory pathways. Such products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed, for example the Inflation Reduction Act of 2022 (the IRA) has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments, geopolitical events, supply chain disruptions, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2021 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM (aducanumab)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">U.S.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM, which we are collaborating on with Eisai Co., Ltd. (Eisai), based on reduction in amyloid beta plaques observed in patients treated with ADUHELM. As part of the accelerated approval, we are required to conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer&#8217;s disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit of ADUHELM, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. ADUHELM product label states that treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population which was studied in clinical trials.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In January 2022 the Centers for Medicare and Medicaid Services (CMS) released a proposed National Coverage Determination (NCD) decision memorandum, stating the proposed NCD would cover FDA approved monoclonal antibodies that target amyloid for the treatment of Alzheimer's disease for people with Medicare only if they are enrolled in qualifying clinical trials.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 CMS released the final NCD for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with the write-off of inventory and purchase commitments in excess of forecasted demand related to ADUHELM. For the nine months ended September 30, 2022, we have also recorded approximately $76.0&#160;million of aggregate gross idle capacity charges related to ADUHELM.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We have recognized approximately $177.0&#160;million related to Eisai's 45.0% share of inventory and idle capacity charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We expect to continue funding certain regulatory and research and development activities for ADUHELM, including the continuation of the EMBARK re-dosing study and the initiation of the Phase 4 post-marketing requirement study, ENVISION. Additional actions regarding ADUHELM may be informed by upcoming data readouts expected for this class of antibodies, as well as further engagement with the FDA and CMS.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022, we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of September 30, 2022, Eisai's portion of these expenses was approximately $300.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for aducanumab and in December 2020 the Ministry of Health, Labor and Welfare accepted for review the Japanese New Drug Application (NDA) for aducanumab.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 the Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a negative opinion on the MAA for aducanumab in Europe. We sought re-examination of the opinion by the CHMP. In April 2022 we announced our decision to withdraw our MAA for aducanumab in Europe.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. and European Union (E.U.) markets and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to continue to have a substantial and increasing negative impact on our TECFIDERA revenue in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the U.S. Supreme Court declined in October 2022 to review the appellate decision holding that claims of our U.S. Patent No. 8,399,514, related to TECFIDERA, are invalid.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the E.U., we are seeking to enforce a patent granted in June 2022 that relates to TECFIDERA and expires in 2028. In addition, we are litigating to affirm that TECFIDERA is entitled to regulatory data and market protection until at least February 2024. Our Company, the EMA and the European Commission (EC) have each appealed the May 2021 decision of the European General Court, which annulled the EMA's decision not to validate an application for approval of a TECFIDERA generic on the basis that the EMA and EC conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the EC have each appealed the General Court&#8217;s decision as wrongly decided and the appeal is pending. On October 6, 2022, the Advocate General of the Court of Justice of the European Union (CJEU) issued a nonbinding advisory opinion in Biogen's favor. This opinion recommends that the CJEU set aside the judgment of the European General Court. We are awaiting the decision of the CJEU.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report and the discussion under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations - Product Revenue - Multiple Sclerosis (MS) - Fumarate</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business Update Regarding COVID-19 and Other Disruptions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COVID-19</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to present a substantial public health and economic challenge around the world. The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are monitoring the demand for our products, including the duration and degree to which we may see delays in starting new patients on a product due to hospitals diverting the resources that are necessary to administer certain of our products to care for COVID-19 patients, including products, such as TYSABRI and SPINRAZA, that are administered in a physician's office or hospital setting. We may also see reduced demand for immunosuppressant therapies during the COVID-19 pandemic.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we are currently continuing the clinical trials we have underway in sites across the globe, COVID-19 precautions have impacted the timeline for some of our clinical trials and these precautions may, directly or indirectly, have a further impact on timing in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Conflict in Ukraine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine have resulted in global business disruptions and economic volatility, including sanctions and other restrictions levied on the government and businesses in Russia. Although we do not have affiliates or employees, in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor and are currently involved in clinical trials with sites in Ukraine and Russia. The timing and costs of these trials may be impacted as a result of the conflict. For example, the development of orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS, that we are developing with InnoCare Pharma Limited (InnoCare) has been delayed and will require the establishment of new clinical sites in other geographies. In addition, new government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia. Revenue generated from sales in these regions represented less than 2.0% of total product revenue for the three and nine months ended September 30, 2022 and the year ended December 31, 2021.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors such as the COVID-19 pandemic, adverse weather events, geopolitical events, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the various risks posed by the COVID-19 pandemic and the conflict in Ukraine, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation Reduction Act of 2022</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA will be effective for periods after December 31, 2022. The enactment of the IRA did not result in any material adjustments to our income tax provision or net deferred tax assets as of September 30, 2022. We expect additional guidance and regulations to be issued in future periods and will continue to assess its potential impact on our business and results of operations as further information becomes available.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA also contains substantial drug pricing reforms that may have a significant impact on the pharmaceutical industry in the U.S. This includes allowing CMS to negotiate a maximum fair price for certain high-priced single source Medicare drugs, as well as redesigning Medicare Part D to reduce out-of-pocket prescription drug costs for beneficiaries, potentially resulting in higher contributions from plans and manufacturers. The IRA also establishes drug inflationary rebate requirements to penalize manufacturers from raising the prices of Medicare covered single-source drugs and biologics beyond the inflation-adjusted rate. Further, to incentivize biosimilar development, the IRA provides an 8.0% Medicare Part B add-on payment for qualifying biosimilar products for a five-year period.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The overall impact that the IRA will have on our business, results of operations and financial condition, and the impact on the pharmaceutical industry as a whole is not yet known. We will continue to assess as further information becomes available.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Diluted earnings per share attributable to Biogen Inc. was $7.84 for the three months ended September 30, 2022, representing an increase of 253.2% compared to $2.22 in the same period in 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended September 30, 2022, compared to the three months ended September 30, 2021, reflects the following:</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total revenue was $2,508.5 million for the third quarter of 2022, representing a $270.4 million, or 9.7%, decrease compared to $2,778.9 million in the same period in 2021.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Product revenue, net totaled $1,962.1 million for the third quarter of 2022, representing a $243.6 million, or 11.0%, decrease compared to $2,205.7 million in the same period in 2021. This decrease was primarily due to a $215.7 million, or 13.9%, decrease in MS product revenue and a $13.0 million, or 2.9%, decrease in SPINRAZA product revenue.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in MS product revenue was primarily due to a decrease in U.S. TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market and a decrease in Interferon demand due to competition.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease in SPINRAZA revenue was primarily due to the unfavorable impact of foreign currency exchange, as well as a decrease in demand as a result of increased competition in certain established markets, particularly Germany and Japan, and the timing of shipments.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">The decrease was also due to a decrease in biosimilar revenue primarily due to unfavorable pricing and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Revenue from anti-CD20 therapeutic programs totaled $416.9 million for the third quarter of 2022, representing a $1.5 million, or 0.4%, increase compared to $415.4 million in the same period in 2021. T</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hi</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s increase wa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s primarily due t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o a $16.9&#160;million, or 6.4%, increase </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in royalty revenue on sales of OCREVUS, partially offset by a </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, or </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11.8%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, decrease in RITUXAN revenue. Sales of RITUXAN have been a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">dversely </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">affected by the onset of biosimilars competition.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Other revenue totaled $129.5 million for the third quarter of 2022, representing a $28.3 million, or 17.9%, decrease compared to $157.8 million in the same period in 2021.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expense</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Total cost and expense was $1,137.4 million for the third quarter of 2022, representing a $1,350.4 million, or 54.3%, decrease compared to $2,487.8 million in the same period in 2021.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">Research and development expense for the third quarter of 2021 included a </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$125.0&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> upfront payment to InnoCare and $39.1&#160;million of estimated clinical trial closeout costs and manufacturing commitments associated with BIIB111 (timrepigene emparvovec) and BIIB112 (cotoretigene toliparvovec).</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">Selling, general and administrative expense for the third quarter of 2022 decreased $90.8 million, or 13.9%, compared to the same period in 2021, primarily driven by cost savings initiatives, including the substantial elimination of the ADUHELM commercial infrastructure.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.59pt">A pre-tax gain of approximately $503.7&#160;million recognized during the third quarter of 2022 related to the sale of one of our buildings.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Condition, Liquidity and Capital Resources:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We generated $1,559.3 million of net cash flow from operations for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Cash, cash equivalents and marketable securities totaled approximately $5,771.4 million as of September 30, 2022.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We repurchased and retired approximately 1.2&#160;million shares of our common stock at a cost of approximately $250.0&#160;million during the third quarter of 2022 under a program authorized by our Board of Directors in October 2020 to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaborative and Other Relationships</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative and other relationships discussed below, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Samsung Bioepis - Biogen's Joint Venture with Samsung BioLogics</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0&#160;billion</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash at closing and expect to receive approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.3&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash to be deferred over two payments of approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $812.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the first anniversary and approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $437.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the second anniversary of the closing of this transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Eisai Collaboration Agreements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022, we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of September 30, 2022, Eisai's portion of these expenses was approximately $300.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In March 2022 we extended our supply agreement related to lecanemab from five years to ten years for the manufacture of lecanemab drug substance and drug product.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Key Developments</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are expected to be achieved through a number of initiatives, including reductions to our workforce, primarily within our global Alzheimer's infrastructure, the consolidation of certain real estate locations and operating efficiency gains across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our 2022 cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 3, Restructuring</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB125 (zuranolone)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022 we and our collaboration partner Sage Therapeutics, Inc. (Sage) initiated a rolling submission of a NDA to the FDA for BIIB125 (zuranolone) for the potential treatment of major depressive disorder (MDD).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 we and Sage announced that the Phase 3 SKYLARK study of zuranolone, which is being evaluated in women with postpartum depression (PPD), met its primary and all key secondary endpoints. Subsequently, we decided to submit a single NDA seeking approval of zuranolone for the treatment of both MDD and PPD. We expect to complete the submission of this single NDA by the end of 2022, and to seek priority review of the filing.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2022 we and our collaboration partner Eisai announced the completed submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab, an anti-amyloid antibody candidate for the potential treatment of Alzheimer's disease. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act (PDUFA) action date of January 6, 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022 we and Eisai announced that the Phase 3 Clarity AD confirmatory study for lecanemab met its primary and all key secondary endpoints.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Mosunetuzumab</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In June 2022 our collaboration partner Genentech announced that mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas, was approved in the E.U.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022 Genentech announced that the FDA accepted the company's BLA and granted Priority Review for mosunetuzumab, with a PDUFA action date of December 29, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">BIIB067 (tofersen)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022 we announced that the FDA accepted our NDA and granted Priority Review for BIIB067 (tofersen), an investigational antisense drug being evaluated for people with superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS), with a PDUFA action date of April 25, 2023.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Senior Note Redemption</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2022 we redeemed our 3.625% Senior Notes totaling $1.0&#160;billion in aggregate principal amount prior to their maturity on September 15, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our Senior Note redemption, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">125 Broadway Sale and Leaseback Transaction</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cambridge, MA (125 Broadway) for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneously, with the close of this transaction we immediately leased back the building for a term of approximately 5.5 years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">BIIB800</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022 we and our collaboration partner Bio-Thera Solutions announced that the EMA accepted the MAA for BIIB800, a biosimilar referencing ACTEMRA, an anti-interleukin-6 receptor monoclonal antibody, for the treatment of severe, active and progressive rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">BIIB122 (DNL151)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022 we and our collaboration partner</span><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Denali Therapeutics Inc. (Denali) announced the initiation of the Phase 3 LIGHTHOUSE study for BIIB122 (DNL151), a small molecule inhibitor of leucine-rich repeat kinase 2 (LRRK2) for the potential treatment of Parkinson's disease.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Denali, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_118"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(120.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,508.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,778.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(270.4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,850.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(231.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,802.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(339.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(570.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,244.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,629.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,247.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(618.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Product Revenue</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(159.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(142.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(51.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(215.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(243.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(318.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">117.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(201.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(192.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,161.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,568.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(407.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(129.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(570.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Multiple Sclerosis (MS)</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fumarate</span></div><div><img src="biib-20220930_g2.jpg" alt="biib-20220930_g2.jpg" style="height:549px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fumarate revenue includes sales from TECFIDERA and VUMERITY. During the fourth quarter of 2021 VUMERITY was approved for the treatment of relapsing-remitting MS (RRMS) in the E.U., Switzerland and the United Kingdom (U.K.).</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases of 26.5% and 11.4%, respectively, in U.S. Fumarate revenue were primarily due to decreases in TECFIDERA demand as a result of multiple TECFIDERA generic entrants in the U.S. market, partially offset by increases in VUMERITY sales volumes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases of 19.8% and 11.6%, respectively, in rest of world Fumarate revenue were primarily due to TECFIDERA pricing reductions in certain European countries, the unfavorable impact of foreign currency exchange and decreases in TECFIDERA demand as </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">multiple TECFIDERA generic entrants entered into markets such as Germany and Canada, partially offset by increases in VUMERITY sales volumes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in the U.S. and European Union (E.U.) markets and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and is expected to continue to have a substantial and increasing negative impact on our TECFIDERA revenue in the future.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the U.S. Supreme Court declined in October 2022 to review the appellate decision holding that claims of our U.S. Patent No. 8,399,514, related to TECFIDERA, are invalid.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the E.U., we are seeking to enforce a patent granted in June 2022 that relates to TECFIDERA and expires in 2028. In addition, we are litigating to affirm that TECFIDERA is entitled to regulatory data and market protection until at least February 2024. Our Company, the EMA and the European Commission (EC) have each appealed the May 2021 decision of the European General Court, which annulled the EMA's decision not to validate an application for approval of a TECFIDERA generic on the basis that the EMA and EC conducted the wrong assessment when determining TECFIDERA's entitlement to regulatory data and marketing protection. Our Company, the EMA and the EC have each appealed the General Court&#8217;s decision as wrongly decided and the appeal is pending. On October 6, 2022, the Advocate General of the Court of Justice of the European Union (CJEU) issued a nonbinding advisory opinion in Biogen's favor. This opinion recommends that the CJEU set aside the judgment of the European General Court. We are awaiting the decision of the CJEU.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that TECFIDERA revenue will continue to decline in 2022, compared to 2021, as a result of generic competition.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect an increase in VUMERITY sales volumes in 2022, compared to 2021, mostly due to demand growth in the U.S. and 14 other markets. We continue to work with our contract manufacturing supplier to address potential supply constraints for VUMERITY. We do not anticipate a supply shortage in 2022 and are currently focused on rebuilding adequate inventory with the goal of re-initiating new country launches in 2023. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Interferon</span></div><div><img src="biib-20220930_g3.jpg" alt="biib-20220930_g3.jpg" style="height:525px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases of 15.0% and 19.1%, respectively, in U.S. Interferon revenue were primarily due to decreases in Interferon sales volumes of 15.5% and 15.2%, respectively. The net declines in sales volumes reflect the continued decline of the Interferon market as patients transition to other higher efficacy and oral MS therapies.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases of 10.1% and 11.2%, respectively, in rest of world Interferon revenue were primarily due to decreases in Interferon sales volumes resulting from the continued decline of the Interferon market and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that Interferon revenue will continue to decline in both the U.S. and rest of world markets in 2022, compared to 2021, as a result of increasing competition from other MS products, including biosimilars, and further pricing reductions in certain European markets.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div><img src="biib-20220930_g4.jpg" alt="biib-20220930_g4.jpg" style="height:333px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases in U.S. TYSABRI revenue were primarily due to decreases in sales volumes.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases in rest of world TYSABRI revenue were primarily due to decreases in pricing and the unfavorable impact of foreign currency exchange, partially offset by increases in sales volumes.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate TYSABRI revenue to be relatively flat on a global basis in 2022, compared to 2021, despite increasing competition from additional treatments for MS. We expect to continue to face price reductions in certain European markets. We are also aware of a potential biosimilar entrant of TYSABRI that may enter the U.S. and European markets as early as 2023.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Spinal Muscular Atrophy</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div><img src="biib-20220930_g5.jpg" alt="biib-20220930_g5.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, compared to the same period in 2021, U.S. SPINRAZA revenue remained flat.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase of 1.3% in U.S. SPINRAZA revenue was primarily due to an increase in sales volumes resulting from favorable channel dynamics, partially offset by a decrease in net pricing.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, compared to the same period in 2021, the decrease of 4.4% in rest of world SPINRAZA revenue was primarily due to the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same periods in 2021, the decrease of 13.2% in rest of world SPINRAZA revenue was primarily due to a decrease in pricing and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, rest of world SPINRAZA reflects decreases in demand as a result of increased competition in certain established markets, particularly Germany and Japan, and the timing of shipments, partially offset by sales volume growth in certain Asian markets.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face competition from a gene therapy product and an oral product. In 2022 we expect that SPINRAZA revenue will be subject to increased competition likely resulting in continued patient discontinuations and a lower rate of new patient starts combined with the impact of loading dose dynamics as patients transition to dosing once every four months and lower prices in certain rest of world countries.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis Pharmaceuticals, Inc. (Ionis), please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Alzheimer's Disease</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM</span></div><div style="margin-top:6pt"><img src="biib-20220930_g6.jpg" alt="biib-20220930_g6.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In June 2021 the FDA granted accelerated approval of ADUHELM, which became commercially available in the U.S. during the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the CMS released the final NCD for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, as a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">to</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:107%">our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Biosimilars</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BENEPALI, IMRALDI, FLIXABI and BYOOVIZ</span></div><div><img src="biib-20220930_g7.jpg" alt="biib-20220930_g7.jpg" style="height:600px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 BYOOVIZ, a biosimilar referencing LUCENTIS, was approved in the U.S., the E.U. and the U.K. BYOOVIZ launched in the U.S. in June 2022 and became commercially available in July 2022 through major distributors in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases of 7.5% and 5.6%, respectively, in biosimilar revenue were primarily due to unfavorable pricing and the unfavorable impact of foreign currency exchange, partially offset by increases in sales volumes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate a slight decline in revenue from our biosimilars business in 2022, despite the launch of BYOOVIZ in the U.S., and an anticipated modest </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increase in sales volumes as we continue to face price reductions in certain markets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently working with our contract manufacturer for IMRALDI to address facility regulatory inspection deficiencies at two filling locations, which could impact supply and have an adverse impact on 2023 IMRALDI sales, if not resolved. Manufacturing of BENEPALI also utilizes one of these facilities and therefore could have an adverse impact on 2023 BENEPALI sales. We are working with our existing secondary supplier for BENEPALI with the aim to secure additional capacity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_124"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech (Roche Group)</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, and GAZYVA collaboration operating profits in the U.S. and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><img src="biib-20220930_g8.jpg" alt="biib-20220930_g8.jpg" style="height:346px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Biogen&#8217;s Share of Pre-tax Profits in the U.S. for RITUXAN and GAZYVA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables provide a summary of amounts comprising our share of pre-tax profits in the U.S. for RITUXAN and GAZYVA:</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.371%"><tr><td style="width:1.0%"></td><td style="width:52.064%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.735%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.382%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.737%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">409.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">457.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,307.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,562.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">222.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Pre-tax profits in the U.S.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,121.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of pre-tax profits</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases in U.S.&#160;product revenue, net were primarily due to decreases in</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> sales volumes of RITUXAN in the U.S. of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26.1%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29.3%</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, primarily due to the onset of competition from multiple biosimilar products</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same pe</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">riods in 2021, the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decreases in collaboration costs and expense were primarily due to lower cost of sales, selling and marketing expense, distribution costs and other expenses related to RITUXAN.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are aware of several other anti-CD20 molecules, including biosimilar products, that have been approved and are competing with RITUXAN and GAZYVA in the oncology and other markets. Biosimilar products referencing RITUXAN have launched in the U.S. and are being offered at lower prices. This </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competition has had a significant adverse impact on the pre-tax profits of our collaboration arrangements with Genentech, as the sales of RITUXAN have decreased substantially compared to prior periods. We expect that biosimilar competition will continue to increase as these products capture additional market share and that this will have a significant adverse impact on our co-promotion profits in the U.S. in future years.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of royalty revenue on sales of OCREVUS and our share of pre-tax co-promotion profits from RITUXAN in Canada. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, compared to the same periods in 2021, the increases in other revenue from anti-CD20 therapeutic programs were primarily due to sales growth of OCREVUS. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty revenue recognized on sales of OCREVUS for the three and nine months ended September 30, 2022, totaled $281.1 million and $825.2&#160;million, respectively, compared to $264.2&#160;million and $730.5&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note&#160;18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_127"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.556%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">96.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">272.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">334.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">95.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(61.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.6)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Collaborative and Other Relationships</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from collaborative and other relationships primarily includes royalty revenue on biosimilar products from Samsung Bioepis.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaborative arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Royalty and Corporate Revenue</span></div><div><img src="biib-20220930_g9.jpg" alt="biib-20220930_g9.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the decreases in other corporate revenue were primarily due to lower contract manufacturing revenue related to the timing of batch releases.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_130"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Reserves for Discounts and Allowances</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are based on estimates of the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable (if the amount is payable to our customer) or a liability (if the amount is payable to a party other than our customer). These estimates reflect our historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Actual amounts may ultimately differ from our estimates. If actual results vary, we adjust these estimates, which could have an effect on earnings in the period of adjustment.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><img src="biib-20220930_g10.jpg" alt="biib-20220930_g10.jpg" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, reserves for discounts and allowances as a percentage of gross product revenue were 31.2% and 29.1%, respectively, compared to 26.5% and 27.9%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Discounts</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts and wholesaler incentives.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the decreases in discounts were primarily driven by decreases in gross sales, primarily driven by lower TECFIDERA sales.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Adjustments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, Veterans Administration, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, compared to the same period in 2021, the increase in contractual adjustments was primarily driven by higher co-pay assistance in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the decrease in contractual adjustments was primarily driven by lower TECFIDERA sales in the U.S., resulting in lower pharmacy rebates, Medicaid rebates and managed care rebates, as well as lower Medicaid rebates in the U.S. driven by a favorable change in estimates for VUMERITY.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Returns</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, return reserves were relatively consistent.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Cost and Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">469.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">511.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">549.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">563.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">654.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(90.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">111.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">113.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(503.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(503.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(558.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,487.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(54.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,350.4)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,707.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,449.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">257.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,629.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,801.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(172.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,770.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,886.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(115.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(622.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit (loss) sharing</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(157.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(117.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(72.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of building</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(503.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(503.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">913.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,134.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,641.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,907.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.8)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,266.3)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Sales, Excluding Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20220930_g11.jpg" alt="biib-20220930_g11.jpg" style="height:325px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Cost of Sales</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in product cost of sales was primarily due to the write-off of ADUHELM inventory during the first quarter of 2022. During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM. For the nine months ended September 30, 2022, we have also recorded approximately $83.0&#160;million of aggregate gross idle capacity charges.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recognized approximately $177.0&#160;million related to Eisai's 45.0% share of inventory and idle capacity charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases in royalty cost of sales were primarily due to lower royalties payable on lower sales of SPINRAZA, TYSABRI and AVONEX, partially offset by higher royalties payable on higher sales of VUMERITY.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="if1c5ef17491f4c2cbb98c8f67b203f36_139"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development</span></div><div><img src="biib-20220930_g12.jpg" alt="biib-20220930_g12.jpg" style="height:350px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20220930_g13.jpg" alt="biib-20220930_g13.jpg" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant amount of our research and development costs consists of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense incurred in support of our marketed products includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products. Late stage programs are programs in Phase 3 development or in registration stage. Early stage programs are programs in Phase 1 or Phase 2 development. Research and discovery represents costs incurred to support our discovery research and translational science efforts. Costs are reflected in the development stage based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, compared to the same period in 2021, the decrease in research and development expense was primarily due to higher milestone payments in 2021 and a decrease in spending in late stage programs, primarily due to the discontinuation of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the decrease in research and development expense was primarily due to higher milestone payments in 2021, partially offset by the advancement of BIIB059 (anti-BDCA2) for the potential treatment of systemic lupus erytheatosus (SLE), the development of mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas, the development of BIIB124 (SAGE-324) for the potential treatment of essential tremor, which we are developing in collaboration with Sage, the development of BIIB122 (DNL151) for the potential treatment of Parkinson's disease, which we are developing in collaboration with Denali, and the development of BIIB135 (orelabrutinib) for the potential treatment of MS.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2021 we recorded significant upfront payments related to our new collaborations as part of research and development expense. Excluding upfront payments, we expect our core research and development expense in 2022 to be consistent with 2021 as we continue to invest in our pipeline. We intend to continue committing significant resources to targeted research and development opportunities where there is a significant unmet need and where a </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug candidate has the potential to be highly differentiated.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Early Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, compared to the same period in 2021, the decrease in spending related to our early stage programs was primarily due to a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB054 (cinpanemab) in Parkinson's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB112 (cotoretigene toliparvovec) in X-linked retinitis pigmentosa.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB059 for the potential treatment of cutaneous lupus erythematosus (CLE); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB113 for the potential treatment of Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the decrease in spending related to our early stage programs was primarily due to a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB054 (cinpanemab) in Parkinson's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of gosuranemab (BIIB092) in Alzheimer's disease;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB112 (cotoretigene toliparvovec) in X-linked retinitis pigmentosa; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage, which had the first patient dosed in a phase 3 study in the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB124 for the potential treatment of essential tremor;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB135 for the potential treatment of MS;</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB059 for the potential treatment of cutaneous lupus erythematosus (CLE); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending in the development of BIIB113 for the potential treatment of Alzheimer's disease.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Late Stage Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, compared to the same period in 2021, the decrease in spending associated with our late stage programs was primarily due to a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the decrease in spending related to lecanemab; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to mosunetuzumab, a late-stage bispecific antibody in development for B-cell non-Hodgkin's lymphoma and other therapeutic areas; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB122 for the potential treatment of Parkinson's disease into late stage.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the decrease in spending associated with our late stage programs was primarily due to a decrease in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the discontinuation of BIIB111 (timrepigene emparvovec) in choroideremia.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB059 for the potential treatment of SLE into late stage;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an increase in spending related to mosunetuzumab; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of BIIB122 for the potential treatment of Parkinson's disease into late stage.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Marketed Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in spending associated with our marketed programs was primarily due to an increase in costs associated with:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the advancement of ADUHELM from late stage to marketed upon the accelerated approval of ADUHELM in the U.S.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Research and Development</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019 Eisai initiated a global Phase 3 trial for the development of lecanemab in early Alzheimer's disease. Under our collaboration arrangement, Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. In July 2022 Eisai completed the submission of a BLA to the FDA for the accelerated approval of lecanemab.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had approximately $118.0&#160;million of work-in-process inventory related to lecanemab. We plan to continue producing inventory and are also procuring raw materials associated with this production. If the program does not receive regulatory approval, we would expect to expense inventory on hand at that time as research and development expense and, under the terms of the collaboration arrangement with Eisai to jointly develop and commercialize lecanemab, we and Eisai would share the costs equally.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="if1c5ef17491f4c2cbb98c8f67b203f36_142"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative</span></div><div><img src="biib-20220930_g14.jpg" alt="biib-20220930_g14.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, selling, general and administrative expense decreased by approximately 13.9% and 6.1%, respectively, primarily due to cost-reduction measures realized during 2022, partially offset by gross ADUHELM commercialization expense of approximately $4.0&#160;million and $111.0&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the final NCD we have substantially eliminated our commercial infrastructure supporting ADUHELM, retaining minimal resources to manage patient access programs, including a continued free drug program for patients currently on treatment in the U.S.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in the second quarter of 2021 reimbursement from Eisai for its share of U.S. ADUHELM selling, general and administrative expense is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect selling, general and administrative costs to decline in 2022, compared to 2021, primarily driven by the implementation of our cost savings initiatives, which include the substantial elimination of our commercial infrastructure supporting ADUHELM as well as other cost-reduction measures.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amortization and Impairment of Acquired Intangible Assets</span></div><div><img src="biib-20220930_g15.jpg" alt="biib-20220930_g15.jpg" style="height:330px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to our TYSABRI, AVONEX, SPINRAZA, VUMERITY and TECFIDERA (rest of world) products and other programs acquired through business combinations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the decreases in amortization and impairment of acquired intangible assets were primarily related to impairment charges of approximately $629.3&#160;million recorded in 2021. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we had </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We monitor events and expectations regarding product performance. If new information indicates that the assumptions underlying our most recent analysis </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">are substantially different than those utilized in our current estimates, our analysis would be updated and may result in a significant change in the anticipated lifetime revenue of the relevant products. The occurrence of an adverse event could substantially increase the amount of amortization expense related to our acquired intangible assets as compared to previous periods or our current expectations, which may result in a significant negative impact on our future results of operations.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Overall, the value of our acquired IPR&amp;D assets is dependent upon several variables, including estimates of future revenue and the effects of competition, our ability to secure sufficient pricing in a competitive market, our ability to confirm safety and efficacy based on data from clinical trials and regulatory feedback, the level of anticipated development costs and the probability and timing of successfully advancing a particular research program from one clinical trial phase to the next. We are continually reevaluating our estimates concerning these and other variables, including our life cycle management strategies, research and development priorities and development risk, changes in program and portfolio economics and related impact of foreign currency exchange rates and economic trends and evaluating industry and company data regarding the productivity of clinical research and the development process. Changes in our estimates may result in a significant change to our valuation of our IPR&amp;D assets.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the FDA regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value associated with the remaining vixotrigine IPR&amp;D intangible asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $109.3&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial, or sooner if there is a reevaluation event, and may record an impairment charge related to this asset.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recognized impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111, and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112, reducing the remaining book values of these IPR&amp;D intangible assets to zero.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1&#160;million during the third quarter of 2021 related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 6, Intangible Assets and Goodwill,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="if1c5ef17491f4c2cbb98c8f67b203f36_148"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Profit (Loss) Sharing</span></div><div><img src="biib-20220930_g16.jpg" alt="biib-20220930_g16.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit (loss) sharing primarily includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars commercial agreement with Samsung Bioepis and, beginning in the second quarter of 2021, Eisai's 45.0% share of income and expense in the U.S. related to the ADUHELM Collaboration Agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, we recognized net profit-sharing expense of $48.7 million and $171.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits compared to a net profit-sharing expense of $71.8 million and $210.2 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$214.0&#160;million, respectively, to refl</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ect Eisai's 45.0% share of net collaboration losses in the U.S., </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to $50.6&#160;million and $90.7&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> nine months ended September 30, 2021, we also recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.0%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $100.0&#160;million milestone payment made to Neurimmune related to the launch of ADUHELM in the U.S. during the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_154"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(Gain) Loss on Fair Value Remeasurement of Contingent Consideration</span></div><div><img src="biib-20220930_g17.jpg" alt="biib-20220930_g17.jpg" style="height:330px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations includes future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, the changes in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, the changes in the fair value of our contingent consideration obligations were primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="if1c5ef17491f4c2cbb98c8f67b203f36_160"></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restructuring Charges</span></div><div><img src="biib-20220930_g18.jpg" alt="biib-20220930_g18.jpg" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized approximately $15.4 million and $124.1 million, respectively, of net pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $21.6&#160;million and $110.2&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge, MA (300 Binney Street), as well as to reduce the lease term for the majority of the remaining space. This resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 300 Binney Street lease modification, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the nine months ended September 30, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized other restructuring costs of approximately $8.8&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.113%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.057%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.430%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="if1c5ef17491f4c2cbb98c8f67b203f36_1925"></div><div><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Gain on Sale of Building</span></div><div><img src="biib-20220930_g19.jpg" alt="biib-20220930_g19.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. Simultaneously, with the close of this transaction we immediately leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2&#160;million in new lease liabilities and right-of-use assets recorded within our condensed consolidated balance sheets as of September 30, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 300 Binney Street lease modification, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div><img src="biib-20220930_g20.jpg" alt="biib-20220930_g20.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the change in other (income) expense, net primarily reflects a pre-tax gain of approximately $1.5&#160;billion related to the sale of our 49.9%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity interest in Samsung Bioepis during the second quarter of 2022, partially offset by a pre-tax charge of $900.0&#160;million in connection with a litigation settlement agreement, as discussed below.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2022, net unrealized gains and realized gains on our holdings in equity securities were approximately $109.3 million and $0.5 million, respectively, compared to net unrealized losses and realized gains of approximately $426.9 million and $2.7 million, respectively, in the prior year comparative period. The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis, Sangamo Therapeutics, Inc. (Sangamo) and Denali common stock of approximately $112.5&#160;million.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, net unrealized losses and realized (gains) losses on our holdings in equity securities were approximately $158.1 million and zero, respectively, compared to net unrealized losses and realized gains </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of $715.2 million and $9.3 million, respectively, in the prior year comparative period. The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately  $198.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_166"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Income Tax Provision</span></div><div><img src="biib-20220930_g21.jpg" alt="biib-20220930_g21.jpg" style="height:500px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the increases in our effective tax rates include the tax </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impacts on the sale of one of our buildings and the favorable prior year tax effects of changes in the value of our equity investments, where we recorded unrealized losses, and the BIIB111 and BIIIB112 impairment charges. The tax effects of this change in value of our equity investments were recorded discretely as changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in our effective tax rate also reflects the net effects of the Neurimmune SubOne AG (Neurimmune) matters, as discussed below, and the litigation settlement agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inflation Reduction Act</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA will be effective for periods after December 31, 2022. The enactment of the IRA did not result in any material adjustments to our income tax provision or net deferred tax assets as of  September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 16, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to our condensed consolidated financial statements included in this report.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div id="if1c5ef17491f4c2cbb98c8f67b203f36_169"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Equity in (Income) Loss of Investee, Net of Tax</span></div><div><img src="biib-20220930_g22.jpg" alt="biib-20220930_g22.jpg" style="height:266px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. We recognized amortization on certain basis differences resulting from our November 2018 investment.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022, we recognized net income on our investment of $2.6 million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $17.0&#160;million, offset by amortization of basis differences totaling $14.4&#160;million. This amount reflects our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized net income on our investment of $1.1 million and $17.2 million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax to</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taling $8.9&#160;million and $39.5&#160;million, respectively, offset by amortization of basis differences totaling $7.8&#160;million and $22.3&#160;million, respectively.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_172"></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Noncontrolling Interests, Net of Tax</span><img src="biib-20220930_g23.jpg" alt="biib-20220930_g23.jpg" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:317px"/></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of our variable interest entity, Neurimmune, as we determined that we are the primary beneficiary.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the change in net income (loss) attributable to noncontrolling interests, net of tax was primarily due to a deferred tax benefit recorded in the second quarter of 2021, as discussed below.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million related to this deferred tax asset.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2021, the change in net income (loss) attributable to noncontrolling interests, net of tax was also due to the $100.0&#160;million milestone payment to Neurimmune related to the launch of ADUHELM in the U.S. during the second quarter of 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration agreement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our income taxes please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 16, Income Taxes,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_175"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.578%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,675.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,261.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,414.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,235.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(305.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">860.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">892.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,771.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,694.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,076.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(999.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,279.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,274.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,279.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(993.9)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,765.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,856.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,909.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,926.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4,298.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">371.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,839.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,558.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,281.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_178"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, certain significant cash flows were as follows:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1,559.3 million in net cash flow provided by operating activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$990.3 million in net proceeds received from the sale of our equity interest in Samsung Bioepis;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$582.6 million in net proceeds received from the sale of one of our buildings;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.0 billion payment made for the redemption of our 3.625% Senior Notes due September 15, 2022;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$806.5&#160;million in total net payments for income taxes; </span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$750.0 million used for share repurchases; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$153.9 million used for purchases of property, plant and equipment.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations as well as our existing cash resources. We believe generic competition for TECFIDERA in the U.S. and other key markets will continue to reduce our cash flow from operations in 2022 and will have a significant adverse impact on our future cash flow from operations. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. In October 2022 we made the $900.0&#160;million payment related to the litigation settlement agreement. In July 2022 we redeemed our </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3.625% Senior Notes due September 15, 2022, with an aggregate principal amount of $1.0 billion. In September 2022 we received $582.6 million in net proceeds from the sale of one of our buildings.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may, from time to time, also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash, Cash Equivalents and Marketable Securities</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had cash, cash equivalents and marketable securities totaling approximately $5.8 billion compared to approximately $4.7 billion as of December 31, 2021. The change in cash, cash equivalents and marketable securities at September 30, 2022, from December 31, 2021, was primarily due to net cash flow provided by operating activities and $990.3 million in net proceeds received from the sale of our equity interest in Samsung Bioepis and $582.6 million in net proceeds received from the sale of one of our buildings, partially offset by $1.0 billion of cash used for the redemption of our 3.625% Senior Notes due September 15, 2022, and share repurchases.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and other assets in our condensed consolidated balance sheets as of December 31, 2021, include the carrying value of our investment in Samsung Bioepis of $599.9 million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.0&#160;billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in cash at closing and expect to receive approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $1.3&#160;billion </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in cash to be deferred over two payments of approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $812.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the first anniversary and approximately</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $437.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due at the second anniversary of the closing of this transaction.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. If any payments due to us remain outstanding after the second anniversary of the closing of this transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.742%"><tr><td style="width:1.0%"></td><td style="width:34.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.473%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.073%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">173.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">244.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Ionis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,043.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, Sangamo, Denali and Sage, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Expenditures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In March 2021 we announced our plans to build a new gene therapy manufacturing facility in RTP, North Carolina to support our gene therapy pipeline across multiple therapeutic areas. The new facility is expected to be operational by the end of 2023, with an estimated total investment of approximately $200.0&#160;million. Construction for this new facility began during the fourth quarter of 2021.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$624.6&#160;million aggregate principal amount of our 2045 Senior Notes was exchanged for $700.7&#160;million aggregate principal amount of our 2051 Senior Notes and approximately $151.8&#160;million of aggregate cash payments; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$8.9&#160;million aggregate principal amount of our 2045 Senior Notes was redeemed for approximately $12.1&#160;million of aggregate cash payments, excluding accrued and unpaid interest.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior unsecured notes issued in 2020 (2020 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 2.25% Senior Notes due May 1, 2030; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.5 billion aggregate principal amount of 3.15% Senior Notes due May 1, 2050.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our currently outstanding senior unsecured notes issued in 2015 (2015 Senior Notes):</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.75 billion aggregate principal amount of 4.05% Senior Notes due September 15, 2025; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$1.12 billion aggregate principal amount of 5.20% Senior Notes due September 15,&#160;2045.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2020 Senior Notes and our 2015 Senior Notes were issued at a discount, which are amortized </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">as additional interest expense over the period from issuance through maturity.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022 we redeemed our 3.625% Senior Notes due September 15, 2022, with an aggregate principal amount of $1.0 billion.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of September 30, 2022 and December 31, 2021, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Facility</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020 we entered into a $1.0 billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. As of September 30, 2022 and December 31, 2021, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Working Capital</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Working capital was $5.8 billion and $3.6 billion as of September 30, 2022 and December 31, 2021, respectively. The change in working capital reflects an increase in total current assets of approximately $1.9 billion and a decrease in total current liabilities of approximately $371.8 million.</span></div><div style="margin-top:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in total current assets was primarily driven by the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">net increase in cash, cash equivalents and marketable securities due to net cash flow provided by operating activities;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">receipt of approximately $990.3 million in cash, net of expenses, from the sale of our equity interest in Samsung Bioepis;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">recording of a receivable from Samsung BioLogics for approximately $790.8 million as part of the sale of our equity interest in Samsung Bioepis; and </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">cash receipt of approximately $582.6 million related to the sale of one of our buildings. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase was partially offset by cash used for the redemption of our 3.625% Senior Notes due September 15, 2022, of approximately $1.0 billion and for share repurchases of $750.0 million.</span></div><div style="margin-top:9pt"><span style="color:#348839;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in current liabilities was primarily due to the following:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">redemption of our 3.625% Senior Notes due September 15, 2022, of approximately $1.0 billion, which were classified within current liabilities as of December 31, 2021; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">a reduction in our accounts payable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in accrued expense and other resulting from an accrual recorded during the second quarter of 2022 for a pre-tax charge of $900.0&#160;million in connection with a litigation settlement agreement reached during 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2&#160;million and 3.6 million shares of our common stock at a cost of approximately $250.0&#160;million and $750.0 million during the three and nine months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2021, we repurchased and retired approximately 2.2&#160;million and 6.0&#160;million shares of our common stock at a cost of approximately $750.0&#160;million and $1.8&#160;billion, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_181"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flow</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:55.728%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.558%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,559.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,801.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.3)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,717.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(451.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">480.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,739.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2,096.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operating activities represents the cash receipts and disbursements related to all of our activities other than investing and financing activities. We expect cash provided from operating activities will continue to be our primary source of funds to finance operating needs and capital expenditures for the foreseeable future.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized gain (loss) on strategic investments, acquired IPR&amp;D and share-based compensation;</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent payments associated with our acquisitions of businesses and payments related to collaborations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the decrease in net cash flow provided by operating activities was primarily due to lower revenue in 2022, timing of payments and higher net income tax payments in 2022 as compared to the same period in 2021.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in net cash flow provided by investing activities was primarily due to proceeds received from the sale of our <ix:nonFraction unitRef="number" contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xODEvZnJhZzo1ZDExZjhkMzA1ZjA0MjEyYTFlODJkZTU4ZjUzNWJmNi90ZXh0cmVnaW9uOjVkMTFmOGQzMDVmMDQyMTJhMWU4MmRlNThmNTM1YmY2XzU0OTc1NTgxNjM5OA_87489fb2-69a4-4e3a-922d-19880424e2d7">49.9</ix:nonFraction>% equity interest in Samsung Bioepis of $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xODEvZnJhZzo1ZDExZjhkMzA1ZjA0MjEyYTFlODJkZTU4ZjUzNWJmNi90ZXh0cmVnaW9uOjVkMTFmOGQzMDVmMDQyMTJhMWU4MmRlNThmNTM1YmY2XzE1MzQ_bff6ebc0-a9ad-4e94-82cd-b5ef9539b5d9">990.3</ix:nonFraction> million, net of expenses, during the second quarter of 2022 as well as $<ix:nonFraction unitRef="usd" contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xODEvZnJhZzo1ZDExZjhkMzA1ZjA0MjEyYTFlODJkZTU4ZjUzNWJmNi90ZXh0cmVnaW9uOjVkMTFmOGQzMDVmMDQyMTJhMWU4MmRlNThmNTM1YmY2XzU0OTc1NTgxNzcyOA_8e85be88-9892-47b1-b55d-469f0e449ea4">582.6</ix:nonFraction> million in net proceeds received from the sale of one of our buildings during the third quarter of 2022.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the decrease in net cash flow used in financing activities was primarily due to $1.1&#160;billion in lower share </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">repurchases in 2022, partially offset by $832.2&#160;million in higher debt repayments in 2022.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_184"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Contractual Obligations and Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, contingent development, regulatory and commercial milestone payments, contingent payments and contingent consideration related to our business combinations, as described below.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes in our contractual obligations since December 31, 2021, aside from our new lease commitment as a result of our sale-leaseback transaction during the third quarter of 2022. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Payments</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are obligated to make contingent payments of 18.0% on annual worldwide net sales of TYSABRI up to $2.0 billion and 25.0% on annual worldwide net sales of TYSABRI that exceed $2.0 billion. Royalty payments are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPINRAZA</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make royalty payments on annual worldwide net sales of SPINRAZA using a tiered royalty rate between 11.0% and 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">VUMERITY</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 the FDA approved VUMERITY for the treatment of RMS. During the fourth quarter of 2021 VUMERITY was approved for the treatment of RRMS in the E.U., Switzerland and the U.K. Under our agreement with Alkermes Pharma Ireland Limited, a </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiary of Alkermes plc (Alkermes), we make royalty payments to Alkermes on worldwide net sales of VUMERITY using a royalty rate of 15.0%, which are recognized as cost of sales in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019 we entered into a new supply agreement and amended our license and collaboration agreement with Alkermes. We have elected to initiate a technology transfer and, following a transition period, to manufacture VUMERITY or have VUMERITY manufactured by a third party we have engaged in exchange for paying an increased royalty rate to Alkermes on any portion of future worldwide net sales of VUMERITY that is manufactured by us or our designee. For additional information on our collaboration arrangement with Alkermes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. we agreed to make additional payments based upon the achievement of certain milestone events.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized the contingent consideration liabilities associated with this acquisition at their fair value on the acquisition date and revalue these obligations each reporting period. We may pay up to approximately $400.0 million in remaining milestones related to this acquisition.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Development, Regulatory and Commercial Milestone Payments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of September 30, 2022, we could trigger potential future milestone payments to third parties of up to approximately $9.5 billion, including approximately $1.9 billion in development milestones, approximately $700.0 million in regulatory milestones and approximately $6.9 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of September 30, 2022, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain clinical and commercial milestones are met, we may pay up to approximately $24.3&#160;million in milestones in 2022 under our current agreements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Funding Commitments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to contract research organizations (CROs). The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $15.8 million in our condensed consolidated balance sheets for expenditures incurred by CROs as of September 30, 2022. We have approximately $943.5 million in cancellable future commitments based on existing CRO contracts as of September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the sale of our Hiller&#248;d, Denmark manufacturing operations to FUJIFILM Corporation (FUJIFILM), we provided FUJIFILM with certain minimum batch production commitment guarantees. There is a risk that the minimum contractual batch production commitments will not be met. Based upon current estimates we do not expect to incur an adverse commitment obligation associated with such guarantees. We developed this estimate using a probability-weighted estimate of future manufacturing activity and may further adjust this estimate based upon changes in business conditions, which may result in the increase or reduction of this adverse commitment obligation in subsequent periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the divestiture of our Hiller&#248;d, Denmark manufacturing operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Divestitures</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Related Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of September 30, 2022, we have approximately $155.1 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, we have accrued income tax liabilities of approximately $558.0&#160;million and $633.0&#160;million, respectively, under a one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings (the Transition Toll Tax). Of the amounts accrued as of September 30, 2022, approximately $137.8&#160;million is expected to be paid within one year. The Transition Toll Tax will be paid in installments over an eight-year period, which started in 2018, and will not accrue interest.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Off-Balance Sheet Arrangements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any relationships with entities often referred to as structured finance or special purpose entities that were established for the purpose of facilitating off-balance sheet arrangements. As such, we are not exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in such relationships. We consolidate variable interest entities if we are the primary beneficiary.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_187"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_190"></div><div style="margin-top:14pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Critical Accounting Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of our critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K. There have been no material changes to our critical accounting estimates since our 2021 Form&#160;10-K.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_193"></div><div style="margin-top:14pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the COVID-19 pandemic and the conflict in Ukraine. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, interest rate lock contracts and interest rate swap contracts. </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Exchange Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar, Swiss franc, Japanese yen and South Korean won.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of September 30, 2022, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue and Operating Expense Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts and options used to hedge certain forecasted revenue and operating </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expense transactions denominated in foreign currencies in the next 15 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Balance Sheet Risk Management Hedging Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of September 30, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $227.2 million and $333.1 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions. </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Investment Hedge Program</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net investment hedging program was designed to mitigate currency fluctuations between the U.S. dollar and the South Korean won as a result of our approximately 49.9% ownership interest in Samsung Bioepis. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interest Rate Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investment portfolio includes cash equivalents and short-term investments. The fair value of our marketable securities is subject to change as a result of potential changes in market interest rates. The potential change in fair value for interest rate sensitive instruments has been assessed on a hypothetical 100 basis point adverse movement across all maturities. As of September 30, 2022 and December 31, 2021, we estimate that such hypothetical 100 basis point adverse movement would result in a hypothetical loss in fair value of approximately $12.7 million and $14.3 million, respectively, to our interest rate sensitive instruments. The fair values of our investments were determined using third-party pricing services or other market observable data.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Credit Risk</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the COVID-19 pandemic and the conflict in Ukraine, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of September 30, 2022 and December 31, 2021.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Equity Price Risk</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. We may sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in the fair value of these equity securities are impacted by the volatility of the stock market and changes in general economic conditions, among other factors. The potential change in fair value for equity price sensitive instruments has been assessed on a hypothetical 10.0% adverse movement. As of September 30, 2022 and December 31, 2021, a hypothetical adverse 10.0% movement would result in a hypothetical decrease in fair value of approximately $89.6&#160;million and $104.8&#160;million, respectively.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_196"></div><div style="margin-top:12pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:8pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Disclosure Controls and Procedures and Internal Control over Financial Reporting</span></div><div style="margin-top:8pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2022. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well </span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:8pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_199"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_202"></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of September 30, 2022, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_205"></div><div style="margin-top:6pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets and in markets affected directly and indirectly by the COVID-19 pandemic. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or could cause a decline in our stock price: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those resulting from governmental or regulatory requirements; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third-parties;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, regulatory or legislative developments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability or reluctance of patients to receive a diagnosis, prescription or administration of our products or a decision to prescribe and administer competitive therapies as a direct or indirect result of the COVID-19 pandemic.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 the FDA granted accelerated approval of ADUHELM in the U.S. In addition to risks associated with new products and the other factors described in these Risk Factors, our ability to successfully commercialize ADUHELM may be adversely affected due to:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">concern regarding the accelerated approval of ADUHELM and its data;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain reimbursement for ADUHELM;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the final NCD by CMS for the class of anti-amyloid treatments in Alzheimer's disease, including ADUHELM; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the lack of market acceptance of ADUHELM.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the accelerated approval, we are required to conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The FDA may withdraw approval if, among other things, the confirmatory trial fails to verify clinical benefit, ADUHELM's benefit-risk is no longer positive or we fail to comply with the conditions of the accelerated approval.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success will depend upon the successful development of new products from our research and development activities or our licenses or acquisitions from third-parties, including our commercialization agreements with Samsung Bioepis, as well as additional indications for our existing products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Product development is very expensive and involves a high degree of uncertainty and risk and may not be successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the antisense oligonucleotide platform and gene therapy, may present additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of an investigational therapy, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use and safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or indications, we may make a strategic decision to discontinue development of a product candidate or indication if, for example, we believe commercialization will be difficult relative to the standard of care or we prefer to pursue other opportunities in our pipeline. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of new products or products with additional indications may not meet investor expectations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt;text-indent:13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with biotechnology and pharmaceutical companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources and other technological or competitive advantages. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has reduced, and may in the future, significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which will negatively impact our revenue. For instance, demand and price for TECFIDERA declined significantly as a result of multiple TECFIDERA generic entrants entering the U.S. market in 2020. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may also be adversely affected due to a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain appropriate pricing and reimbursement for our products compared to our competitors in key international markets; or</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt;padding-left:4.5pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives may depend upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies and companies or the entry into strategic alliances and collaborations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business. We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity for their acquisition is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or if we will be able to reach agreement.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on adequate coverage, pricing and reimbursement from third-party payors. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of payors seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the Inflation Reduction Act of 2022 (the IRA) has certain provisions related to drug pricing. We expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country may not only limit the revenue from our products within that country but may also adversely affect our ability to secure acceptable </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prices in existing and potential new markets, which may limit market growth. This may create the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue. Additionally and in part due to the impact of the COVID-19 pandemic, in certain jurisdictions governmental health agencies may adjust, retroactively and/or prospectively, reimbursement rates for our products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition from current and future competitors may negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors could cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways may significantly reduce the price that we are able to charge for our products and the volume of products we sell.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators, joint venture partners and other third-parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative, joint venture and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third-parties. Reliance on third-parties subjects us to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators, joint venture partners or third-parties devote to our programs, products or product candidates;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators, joint ventures partners or third-parties fail to perform; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators, joint venture partners or third-parties may not always be aligned with our interests, and such parties may not pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">third-party relationships require the parties to cooperate, and failure to do so effectively could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators, joint venture partners or third-parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue as well as involve us in possible legal proceedings; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators, joint venture partners or third-parties could subject us to civil or criminal investigations and monetary and injunctive penalties, impact the accuracy and timing of our financial reporting and/or adversely impact our ability to conduct business, our operating results and our reputation.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on containing the cost of health care. Legislative and regulatory proposals, enactments to reform health care insurance programs (including those contained in the IRA) and increasing pressure from social sources could significantly influence the manner in which our products are prescribed and purchased. For example, provisions of the Patient Protection and Affordable Care Act (PPACA) have resulted in changes in the way health care is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and the expansion of the number of hospitals eligible for discounts under Section 340B of the Public Health Service Act. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is increasing public attention on the costs of prescription drugs and we expect drug pricing and other health care costs to continue to be subject to intense political and societal pressures on a global basis. For example, two committees of the U.S. House of Representatives are investigating the approval and price of ADUHELM. In addition, there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing. Some of these proposals could have significant effects on our business, including an executive order issued in September 2020 to test a &#8220;most favored nation&#8221; model for Part B and Part D drugs that tie reimbursement rates to international drug pricing metrics. These actions and the uncertainty about the future of the PPACA and healthcare laws may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, including as a result of the COVID-19 pandemic, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. In recent years, some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are increasingly requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the E.U. and some other international markets, the government provides health care at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored health care system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce health care costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third-Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of Samsung Bioepis, collaboration partners and other third-parties over whom we have limited or no control in the development and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing of biosimilars products. If these third-parties fail to perform successfully, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive patent clearances, patent infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any manufacturing or supply chain difficulties we may be unable to meet demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success and/or the success of Samsung Bioepis in this business area.</span></div><div style="margin-top:6pt;padding-left:4.5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third-parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:4pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by negative publicity or if adverse information concerning us is posted on social media platforms or similar mediums, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative bodies and lawmakers in these countries. We may fail to obtain or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of patent and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third-parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third-parties to be pertinent to the manufacture, use or sale of our products.&#160;Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain would reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in a clinical trial may not be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies or disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities may grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. For example, as part of the accelerated approval, we will conduct a confirmatory trial to verify the clinical benefit of ADUHELM in patients with Alzheimer's disease. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third-parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third-parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be affected. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our marketed products, generic or biosimilar versions of our marketed products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or our stock price to experience periods of volatility.</span></div><div style="margin-top:6pt;text-indent:22.3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products and require significant expense and management time.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our technology systems could subject us to liability or interrupt the operation of our business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon technology systems and data to operate our business. The COVID-19 pandemic has caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with a number of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our technology systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our technology systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches of our technology systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to liability, negatively impact our business operations, and/or require replacement of technology and/or ransom payments. Our technology systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, when they impact vendors, customers or companies, including vendors, suppliers and other companies in our supply chain. They are often carried out by motivated, well-resourced, skilled and persistent actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and employees or contractors acting with careless or malicious intent. Geopolitical instability, including that related to Russia's invasion of Ukraine may increase cyber-attacks. Cyber-attacks include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our technology systems and data. Cyber-attacks also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will prevent breakdowns or breaches in our systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are considering new cyber security regulations. For example, the SEC has proposed amendments to its disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These proposed regulations may impact the manner in which we operate.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators are imposing new data privacy and security requirements, including new and greater monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. New U.S. data privacy and security laws, such as the California Consumer Privacy Act (CCPA), and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause our customers to lose trust in us, which could have a material adverse effect on our business and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Risks of Reliance on Third-Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates including VUMERITY. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third-parties are independent entities subject to their own unique operational and financial risks that are outside of our control. These third-parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives. Furthermore, factors such as the COVID-19 pandemic, weather events, labor or raw material shortages and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results in operations or result in product shortages.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, public health epidemics, natural disasters, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are generally required to maintain compliance with cGMP and other stringent requirements and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third-parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk Relating to Government Actions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We and/or our third-party providers may be required by the U.S. federal government to manufacture medical supplies needed to treat COVID-19 patients under the Defense Production Act or other acts or orders of government entities, which may result in delays in the manufacturing and supply of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management and other personnel changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management (including our CEO), other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and key personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, the underperformance or discontinuation of one or more marketed or late stage programs, recruitment by competitors or changes in the overall labor market. In addition, changes in our organizational structure or in our flexible working arrangements could impact employees' productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the health care industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other health care providers that prescribe or purchase our products are also subject to government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of health care companies. Health care companies are facing heightened scrutiny of their relationships with health care providers and have been the target of lawsuits and investigations alleging violations of government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of health care business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the health care industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to health care availability, pricing or marketing practices, compliance with employment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">practices, method of delivery, payment for health care products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the FDA and foreign regulatory approval processes or perspectives that may delay or prevent the approval of new products and result in lost market opportunity; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns or relocations may result in delays to the review and approval process, slowing the time necessary for new drug candidates to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing internationally;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the far-reaching anti-bribery and anti-corruption legislation in the U.K., including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or embargoes and other trade restrictions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our international operations are subject to regulation under U.S. law. For example, the U.S. Foreign Corrupt Practices Act (FCPA) prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the health care professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are building a large-scale biologics manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are expanding our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may continue to occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:4pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for ADUHELM, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The ongoing COVID-19 pandemic may, directly or indirectly, adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business has and could continue to be adversely affected, directly or indirectly, by the ongoing COVID-19 pandemic. National, state and local governments have implemented and may continue to implement safety precautions. These measures may disrupt normal business operations and may have significant negative impacts on businesses and financial markets worldwide.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to monitor our operations and applicable government recommendations, and we have made modifications to our normal operations because of the COVID-19 pandemic, including limiting travel and working from home. Customer-facing professionals interactions in healthcare settings have changed as a result of the COVID-19 pandemic. This limits our ability to market our products and educate physicians, which, in turn, could have an adverse effect on our ability to compete in the marketing and sales of our products.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in flexible working arrangements could impact employee retention, employees' productivity and morale, strain our technology resources and introduce operational risks. Additionally, the risk of cyber-attacks or other privacy or data security incidents may be heightened as a result of our moving increasingly towards a remote working environment, which may be less secure and more susceptible to hacking attacks.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic could affect the health and availability of our workforce as well as those of the third-parties we rely on. Furthermore, delays and disruptions experienced by our collaborators, joint venture partners or other third-parties due to the COVID-19 pandemic could adversely impact the ability of such parties to fulfill their obligations, which could affect product sales or the clinical development or regulatory approvals of product candidates under joint control.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to continue our existing clinical trials or to initiate new clinical trials has been and may continue to be adversely affected, directly or indirectly, by the COVID-19 pandemic. Restrictions on travel and/or transport of clinical materials as well as diversion of hospital staff and resources to COVID-19 infected patients could disrupt trial operations and recruitment, possibly resulting in a slowdown in enrollment and/or deviations from or disruptions in key clinical trial activities, such as clinical trial site monitoring. These challenges may lead to difficulties in meeting protocol-specified procedures. We may need to make certain adjustments to the operation of clinical trials in an effort to minimize risks to trial data integrity during the COVID-19 pandemic. In addition, the impact of the COVID-19 pandemic on the operations of the FDA and other health authorities may delay potential approvals of our product candidates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, legislation has been enacted aimed at providing emergency assistance and health care for individuals, families and businesses and broadly supporting the U.S. economy. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products or additional pricing pressures and have a financial impact on our business that we cannot predict.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While it is not possible at this time to estimate the entirety of the impact that the COVID-19 pandemic will continue to have on our business, operations, employees, customers, suppliers or collaboration partners, continued spread of COVID-19, measures taken by governments, actions taken to protect employees and the broad impact of the pandemic on all business activities may materially and adversely affect our business, supply chain and distribution systems, results of operations and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income (loss) have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may be required to record, charges that include:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including in-process research and development (IPR&amp;D) and other intangible assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, recurring charges for excess or obsolete inventory and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics, such as the COVID-19 pandemic, on employees, the global economy and the delivery of healthcare treatments.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the anticipated results of future periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio could adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will continue to repurchase shares or that we will repurchase shares at favorable prices.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on terms that are favorable to us.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure and debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect our business and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third-party from attempting to acquire us.</span></div><div style="margin-top:6pt;text-indent:11.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could trigger reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global biopharmaceutical company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings (including those related to the impact of the Tax Cuts and Jobs Act of 2017), adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws and regulations either prospectively or retrospectively (including those related to the IRA). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the Organization for Economic Cooperation and Development&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; (BEPS) by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. These initiatives focus on common international principles for the entitlement to taxation of global corporate profits and minimum global tax rates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the third quarter of 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:21.988%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.282%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.726%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.94&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">300,000&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,237.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,002&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.96&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870,002&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,170,002&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.67&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2&#160;million and 3.6 million shares of our common stock at a cost of approximately $250.0&#160;million and $750.0 million during the three and nine months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2021, we repurchased and retired approximately 2.2&#160;million and 6.0&#160;million shares of our common stock at a cost of approximately $750.0&#160;million and $1.8&#160;billion, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_214"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:19pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:15.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.024%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:77.232%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022930xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022930xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2022930xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2022, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><div id="if1c5ef17491f4c2cbb98c8f67b203f36_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#if1c5ef17491f4c2cbb98c8f67b203f36_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</span></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;25, 2022 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2022930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7a79262949064b388f6db827d1548930_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michel Vounatsos, certify that&#58;</font></div><div style="margin-top:9pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 25, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2022930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i4d63e394e8314813a563368ff36ededf_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael R. McDonnell, certify that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="padding-left:36pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 25, 2022</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2022930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i093abd881cd34300bc4e5d71815c64d0_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 25, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michel Vounatsos</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October 25, 2022</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Michael R. McDonnell</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20220930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6f409836-83df-4817-b8b9-7a5ff0648b96,g:f22c5c21-a910-4760-9b39-9695772d8988-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20220930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20220930">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20220930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1">
        <link:definition>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnauditedParenthetical" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>1004005 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>2108103 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>2116104 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>2120105 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>2124106 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>2131107 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>2139108 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>2142109 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>2144110 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>2146111 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>2148112 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>2153113 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>2156114 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>2160115 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>2164116 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>2168117 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>2172118 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>2174119 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>2176120 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Dispositions" roleURI="http://www.biogenidec.com/role/Dispositions">
        <link:definition>2177121 - Disclosure - Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>2309302 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>2317303 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>2321304 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>2325305 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>2332306 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>2340307 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>2349308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>2354309 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>2357310 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>2361311 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>2365312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>2369313 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>2410404 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>2414408 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>2415409 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>2418410 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>2419411 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails">
        <link:definition>2422412 - Disclosure - Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillDetails1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1">
        <link:definition>2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails">
        <link:definition>2426414 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetailsTextual" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual">
        <link:definition>2427415 - Disclosure - Fair Value Measurements (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
        <link:definition>2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails1" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1">
        <link:definition>2429417 - Disclosure - Fair Value Measurements (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails2" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2">
        <link:definition>2430418 - Disclosure - Fair Value Measurements (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails">
        <link:definition>2433419 - Disclosure - Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails1" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1">
        <link:definition>2434420 - Disclosure - Financial Instruments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2">
        <link:definition>2435421 - Disclosure - Financial Instruments (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetails3" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3">
        <link:definition>2436422 - Disclosure - Financial Instruments (Details 3)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDetailsTextual" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual">
        <link:definition>2437423 - Disclosure - Financial Instruments (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialInstrumentsDetailsTextual2" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
        <link:definition>2438424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails">
        <link:definition>2441425 - Disclosure - Derivative Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>2443426 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesDetailsTextual" roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual">
        <link:definition>2445427 - Disclosure - Leases (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessDetails" roleURI="http://www.biogenidec.com/role/IndebtednessDetails">
        <link:definition>2447428 - Disclosure - Indebtedness (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareRepurchasesDetails" roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails">
        <link:definition>2450429 - Disclosure - Share Repurchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2451430 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>2452431 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>2455432 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails">
        <link:definition>2458433 - Disclosure - Share-Based Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDetails1" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1">
        <link:definition>2459434 - Disclosure - Share-Based Payments (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetailsTextual" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual">
        <link:definition>2462435 - Disclosure - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails">
        <link:definition>2463436 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails">
        <link:definition>2466437 - Disclosure - Other Consolidated Financial Statement Detail (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailsTextual" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual">
        <link:definition>2467438 - Disclosure - Other Consolidated Financial Statement (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCollaborationsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails">
        <link:definition>2470439 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
        <link:definition>2471440 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>2473441 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>2475442 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DispositionsDetailsTextual" roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual">
        <link:definition>2478443 - Disclosure - Dispositions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" abstract="false" name="EffectiveTaxRateReconciliationSaleOfSamsungBioepis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationInternationalReorganization" abstract="false" name="EffectiveTaxRateReconciliationInternationalReorganization" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" abstract="false" name="Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DiscreteIncomeTaxExpenseBenefit" abstract="false" name="DiscreteIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherAssetsMeasurementInput" abstract="false" name="OtherAssetsMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_TechnologicalAndRegulatorySuccessProbability" abstract="false" name="TechnologicalAndRegulatorySuccessProbability" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_DuefromantiCD20therapeuticprograms" abstract="false" name="DuefromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" abstract="false" name="PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CollaborationAgreementTerm" abstract="false" name="CollaborationAgreementTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_FacilityTypeDomain" abstract="true" name="FacilityTypeDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesNonCurrentMember" abstract="true" name="CorporateDebtSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CentersForMedicareAndMedicaidServiceMember" abstract="true" name="CentersForMedicareAndMedicaidServiceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A3250SeniorNotesDueFebruary152051Member" abstract="true" name="A3250SeniorNotesDueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionRate" abstract="false" name="DebtInstrumentRedemptionRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A125BroadwayBuildingMember" abstract="true" name="A125BroadwayBuildingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BIIB111AndBIIB112Member" abstract="true" name="BIIB111AndBIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UCBPharmaS.A.Member" abstract="true" name="UCBPharmaS.A.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesNonCurrentMember" abstract="true" name="GovernmentSecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationGILTItax" abstract="false" name="EffectiveTaxRateReconciliationGILTItax" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_FUMADERMMember" abstract="true" name="FUMADERMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LecanemabMember" abstract="true" name="LecanemabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BIIB111Member" abstract="true" name="BIIB111Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" abstract="true" name="MortgageAndOtherAssetBackedSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_FacilityLocationAxis" abstract="true" name="FacilityLocationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_LongTermDebtExchangedAmount" abstract="false" name="LongTermDebtExchangedAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccruedMilestonePayments" abstract="false" name="AccruedMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" abstract="false" name="EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BYOOVIZMember" abstract="true" name="BYOOVIZMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_SolothurnSwitzerlandMember" abstract="true" name="SolothurnSwitzerlandMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GainLossOnRestructuringCharges" abstract="false" name="GainLossOnRestructuringCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TGNMember" abstract="true" name="TGNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_VixotrigineMember" abstract="true" name="VixotrigineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_WarehouseUtilitiesAndSupportSpaceMember" abstract="true" name="WarehouseUtilitiesAndSupportSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContingentCommercializedRightsNumberOfProducts" abstract="false" name="ContingentCommercializedRightsNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ShorttermderivativeMember" abstract="true" name="ShorttermderivativeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherresearchanddiscoveryMember" abstract="true" name="OtherresearchanddiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" abstract="false" name="EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_AdministrativeSpaceMember" abstract="true" name="AdministrativeSpaceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesCurrentMember" abstract="true" name="EquitySecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ZINBRYTAMember" abstract="true" name="ZINBRYTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherAssetsCurrentFairValueDisclosure" abstract="false" name="OtherAssetsCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OperatingLeaseRightOfUseAssetDerecognized" abstract="false" name="OperatingLeaseRightOfUseAssetDerecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentCostsPercentage" abstract="false" name="ResearchAndDevelopmentCostsPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_WorkforceReductionMember" abstract="true" name="WorkforceReductionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityLocationDomain" abstract="true" name="FacilityLocationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" abstract="false" name="PercentageoffuturedevelopmentcostsrelatedtoEisai" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_InnoCarePharmaLimitedInnoCareAgreementMember" abstract="true" name="InnoCarePharmaLimitedInnoCareAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NeurimmuneMember" abstract="true" name="NeurimmuneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Inventorynetcurrentandnoncurrent" abstract="false" name="Inventorynetcurrentandnoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OthercorporaterevenuesMember" abstract="true" name="OthercorporaterevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BIIB112Member" abstract="true" name="BIIB112Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BiologicsManufacturingMember" abstract="true" name="BiologicsManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContingentMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="ContingentMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ResearchanddevelopmentassetAxis" abstract="true" name="ResearchanddevelopmentassetAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_FacilityTypeAxis" abstract="true" name="FacilityTypeAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationLitigationAgreement" abstract="false" name="EffectiveTaxRateReconciliationLitigationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityDomain" abstract="true" name="DerivativeMaturityDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OperatingLeaseLiabilityDerecognized" abstract="false" name="OperatingLeaseLiabilityDerecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_NoncontrollingInterestCapitalContribution" abstract="false" name="NoncontrollingInterestCapitalContribution" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_AverageMaturityOfMarketableSecurities" abstract="false" name="AverageMaturityOfMarketableSecurities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentAssetDomain" abstract="true" name="ResearchAndDevelopmentAssetDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" abstract="true" name="SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DebtInstrumentRedemptionAmount" abstract="false" name="DebtInstrumentRedemptionAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" abstract="false" name="UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CostOfGoodsSoldCapacityCharges" abstract="false" name="CostOfGoodsSoldCapacityCharges" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdditionalMilestonePayment" abstract="false" name="AdditionalMilestonePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ADUHELMMember" abstract="true" name="ADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" abstract="false" name="Equitymethodinvestmentbasisdifferenceamortizationperiod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_OutLicensedPatentsMember" abstract="true" name="OutLicensedPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DerivativeMaturityAxis" abstract="true" name="DerivativeMaturityAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" abstract="false" name="IncomeLossFromEquityMethodInvestmentsNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" abstract="false" name="GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SangamoTherapeuticsInc.AgreementMember" abstract="true" name="SangamoTherapeuticsInc.AgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_Termofcollaborationagreement" abstract="false" name="Termofcollaborationagreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" abstract="false" name="AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IonisSangamoDenaliAndSageMember" abstract="true" name="IonisSangamoDenaliAndSageMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PLEGRIDYMember" abstract="true" name="PLEGRIDYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_NumberOfSquareFeet" abstract="false" name="NumberOfSquareFeet" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20220930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6f409836-83df-4817-b8b9-7a5ff0648b96,g:f22c5c21-a910-4760-9b39-9695772d8988-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2c3ca578-9c1a-4ff8-b860-ea3418ea8740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_831dfc16-4964-4ec3-80ce-33255b137bba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2c3ca578-9c1a-4ff8-b860-ea3418ea8740" xlink:to="loc_us-gaap_ProfitLoss_831dfc16-4964-4ec3-80ce-33255b137bba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2ae355f8-3cd1-4669-94b9-07591f8f1c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_2c3ca578-9c1a-4ff8-b860-ea3418ea8740" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_2ae355f8-3cd1-4669-94b9-07591f8f1c69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_476bec47-1ba4-405a-b200-42d58d30efe4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_476bec47-1ba4-405a-b200-42d58d30efe4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_43a2634a-245c-4e3e-ac8e-615cf958d671" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_43a2634a-245c-4e3e-ac8e-615cf958d671" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b75d3351-2b86-47f2-bd06-d2a6cf1b9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b75d3351-2b86-47f2-bd06-d2a6cf1b9ee9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b7a6bba8-5f32-4662-9b37-e5cf96a07430" xlink:href="biib-20220930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_b7a6bba8-5f32-4662-9b37-e5cf96a07430" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_66536b07-3fa8-4ba6-96dd-8977d351e76c" xlink:href="biib-20220930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_biib_Collaborationprofitlosssharing_66536b07-3fa8-4ba6-96dd-8977d351e76c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_3cf89ed0-6689-4e94-a3c3-8b813f39eaea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_3cf89ed0-6689-4e94-a3c3-8b813f39eaea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_10c06769-c6cb-4bf2-b5aa-916f1e504f90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_10c06769-c6cb-4bf2-b5aa-916f1e504f90" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d248b2fb-6276-42c9-9303-7f5dd39e3291" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_d248b2fb-6276-42c9-9303-7f5dd39e3291" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c2a2e1bf-bd74-4d15-8efa-5e599ddf7274" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c2a2e1bf-bd74-4d15-8efa-5e599ddf7274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_570b4a79-0888-47ee-9102-23fe537e717b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_960bdf5b-b071-44be-b454-dcc328ccea45" xlink:to="loc_us-gaap_RestructuringCharges_570b4a79-0888-47ee-9102-23fe537e717b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_ab65883c-f560-446e-ba16-711d801fa023" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64ebd6dd-c337-4935-aa59-95f3e4c06f3e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ab65883c-f560-446e-ba16-711d801fa023" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_64ebd6dd-c337-4935-aa59-95f3e4c06f3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1bb31b73-4d29-41be-89d6-f619e16d4d13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ab65883c-f560-446e-ba16-711d801fa023" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1bb31b73-4d29-41be-89d6-f619e16d4d13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_a29b04d8-266c-4167-acac-356ee727a07e" xlink:href="biib-20220930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_ab65883c-f560-446e-ba16-711d801fa023" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_a29b04d8-266c-4167-acac-356ee727a07e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3cea0491-b558-462e-bae9-ee6c30a697f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_73b65864-b31f-43cd-9e35-e65c0c1f95b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3cea0491-b558-462e-bae9-ee6c30a697f0" xlink:to="loc_us-gaap_Revenues_73b65864-b31f-43cd-9e35-e65c0c1f95b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_b943657a-af7b-482c-8cde-3853ee096cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_3cea0491-b558-462e-bae9-ee6c30a697f0" xlink:to="loc_us-gaap_CostsAndExpenses_b943657a-af7b-482c-8cde-3853ee096cf5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4a03ce8-332d-4fe2-99f3-36a7acbdc563" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_17af8b21-3488-42ed-863c-e965ed5d3249" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4a03ce8-332d-4fe2-99f3-36a7acbdc563" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_17af8b21-3488-42ed-863c-e965ed5d3249" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_97830d1b-0f03-45e3-ad86-fc30dbe18ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4a03ce8-332d-4fe2-99f3-36a7acbdc563" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_97830d1b-0f03-45e3-ad86-fc30dbe18ddc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_01a0f16f-43cc-42b9-abb2-542e9bcb4adb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4a03ce8-332d-4fe2-99f3-36a7acbdc563" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_01a0f16f-43cc-42b9-abb2-542e9bcb4adb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_514167ca-9af7-4c45-b0e4-4fc980cc1341" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4a03ce8-332d-4fe2-99f3-36a7acbdc563" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_514167ca-9af7-4c45-b0e4-4fc980cc1341" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_586aee7d-e09a-4ba3-ad30-4f63854775af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e4a03ce8-332d-4fe2-99f3-36a7acbdc563" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_586aee7d-e09a-4ba3-ad30-4f63854775af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_067ecf0e-c739-42ca-8e2b-00d2e478ce5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_798893b8-4dde-4f5b-b2bc-aff5f8833507" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_067ecf0e-c739-42ca-8e2b-00d2e478ce5b" xlink:to="loc_us-gaap_NetIncomeLoss_798893b8-4dde-4f5b-b2bc-aff5f8833507" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_485c1910-20bb-4f2a-a2d8-2e7c37de97f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_067ecf0e-c739-42ca-8e2b-00d2e478ce5b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_485c1910-20bb-4f2a-a2d8-2e7c37de97f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_96e096d9-2ece-4402-b62d-6bccedba51d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1ea9cc91-f56d-4509-afe8-86cfc7a0106a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_96e096d9-2ece-4402-b62d-6bccedba51d2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1ea9cc91-f56d-4509-afe8-86cfc7a0106a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08b89ef1-c1a6-4903-8b8e-daa215c19cbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_96e096d9-2ece-4402-b62d-6bccedba51d2" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_08b89ef1-c1a6-4903-8b8e-daa215c19cbf" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_b84a4a98-55e0-4c91-8195-55d8ab78b69a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4039ecf6-b39b-403a-b16b-ffffa6cd1de9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b84a4a98-55e0-4c91-8195-55d8ab78b69a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_4039ecf6-b39b-403a-b16b-ffffa6cd1de9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_c60987ac-21e1-407f-944f-aafa5cebce3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b84a4a98-55e0-4c91-8195-55d8ab78b69a" xlink:to="loc_us-gaap_Liabilities_c60987ac-21e1-407f-944f-aafa5cebce3f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_27cfba8d-e0fc-43cb-a38d-bdd13e4aec28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_b84a4a98-55e0-4c91-8195-55d8ab78b69a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_27cfba8d-e0fc-43cb-a38d-bdd13e4aec28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_310cf474-8b4c-4b0c-9a72-bfc4bbc6a7ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_52a17a22-a70f-4e4b-ac4c-199e06e80573" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_310cf474-8b4c-4b0c-9a72-bfc4bbc6a7ab" xlink:to="loc_us-gaap_AccountsPayableCurrent_52a17a22-a70f-4e4b-ac4c-199e06e80573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_96fddb48-bf25-4d21-9c18-7f5ddaa2d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_310cf474-8b4c-4b0c-9a72-bfc4bbc6a7ab" xlink:to="loc_us-gaap_TaxesPayableCurrent_96fddb48-bf25-4d21-9c18-7f5ddaa2d6db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_dce7d54c-7a42-47d5-b7ad-f10174c2a229" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_310cf474-8b4c-4b0c-9a72-bfc4bbc6a7ab" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_dce7d54c-7a42-47d5-b7ad-f10174c2a229" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_0263eaf7-e65e-4742-8aa4-71a20dba4dbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_310cf474-8b4c-4b0c-9a72-bfc4bbc6a7ab" xlink:to="loc_us-gaap_NotesPayableCurrent_0263eaf7-e65e-4742-8aa4-71a20dba4dbe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a03bf741-ee0c-4b37-bbdc-5b2891cdefc1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a03bf741-ee0c-4b37-bbdc-5b2891cdefc1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f4f44afe-44d8-436f-a9fe-625dd7c3d9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f4f44afe-44d8-436f-a9fe-625dd7c3d9c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_30fc08ba-ba9e-4dfa-8433-a4e438a497df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_30fc08ba-ba9e-4dfa-8433-a4e438a497df" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_1e854d7e-6b44-4919-89e4-1af6bda687a4" xlink:href="biib-20220930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_1e854d7e-6b44-4919-89e4-1af6bda687a4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_e8018877-3a28-4ba7-ac58-c4701be6cad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:to="loc_us-gaap_InventoryNet_e8018877-3a28-4ba7-ac58-c4701be6cad4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_07d13c42-fee4-44be-8511-0240ec123f73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5cff558b-171f-4d66-95a0-7d0edf5e8f19" xlink:to="loc_us-gaap_OtherAssetsCurrent_07d13c42-fee4-44be-8511-0240ec123f73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41176a8b-b0ce-460c-9d53-45a4a750eaa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cbac8014-15c3-460c-b896-626f42ed76ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41176a8b-b0ce-460c-9d53-45a4a750eaa5" xlink:to="loc_us-gaap_StockholdersEquity_cbac8014-15c3-460c-b896-626f42ed76ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_327fbcaa-b36a-4bf6-b1b8-9b6e55efd184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_41176a8b-b0ce-460c-9d53-45a4a750eaa5" xlink:to="loc_us-gaap_MinorityInterest_327fbcaa-b36a-4bf6-b1b8-9b6e55efd184" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_dfac84bb-7389-4505-8c30-e0771bd0e4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_AssetsCurrent_dfac84bb-7389-4505-8c30-e0771bd0e4ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9f724ebb-52d8-4003-b6ee-ee459119d80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_9f724ebb-52d8-4003-b6ee-ee459119d80c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b0b201da-146c-4688-ab49-fe23f4e32b6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b0b201da-146c-4688-ab49-fe23f4e32b6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84148340-29c6-4ec9-8fd9-0c703e889dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_84148340-29c6-4ec9-8fd9-0c703e889dc8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4b1fa386-538f-4281-a3a6-ba3a5333fd7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_4b1fa386-538f-4281-a3a6-ba3a5333fd7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ddd175ca-8b22-4b54-992e-d159c1093068" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_Goodwill_ddd175ca-8b22-4b54-992e-d159c1093068" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_ede1d678-a416-449e-b646-5817624b4667" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_ede1d678-a416-449e-b646-5817624b4667" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_62f74809-150d-49b0-a094-1ac64cfa3d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_8d386267-a5f0-4e62-b8d3-921f60e17f4e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_62f74809-150d-49b0-a094-1ac64cfa3d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_ed1eed16-83e1-4eed-94bb-ada78cdda222" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:to="loc_us-gaap_PreferredStockValue_ed1eed16-83e1-4eed-94bb-ada78cdda222" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2c28d6d2-7f73-47dd-870c-b02283286d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:to="loc_us-gaap_CommonStockValue_2c28d6d2-7f73-47dd-870c-b02283286d6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_44b7a368-16e7-48e8-8a22-e02e64468b58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:to="loc_us-gaap_AdditionalPaidInCapital_44b7a368-16e7-48e8-8a22-e02e64468b58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f1f36e1-f7fd-4cc4-bef6-9abf3754618c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4f1f36e1-f7fd-4cc4-bef6-9abf3754618c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b30baa3d-025d-44aa-a6f7-bf0f8f2eb77f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b30baa3d-025d-44aa-a6f7-bf0f8f2eb77f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b2f58b66-d536-46af-b7a0-0ad09f194d08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_65019034-a7bb-454b-98a7-8ea873ad4e86" xlink:to="loc_us-gaap_TreasuryStockValue_b2f58b66-d536-46af-b7a0-0ad09f194d08" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_268289a4-6275-4382-aae6-17f6397b736d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_aacc221c-98ba-4b2e-8d05-f54bea942510" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_268289a4-6275-4382-aae6-17f6397b736d" xlink:to="loc_us-gaap_LiabilitiesCurrent_aacc221c-98ba-4b2e-8d05-f54bea942510" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_32013d90-d81f-4b89-b9bb-5024b3f02e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_268289a4-6275-4382-aae6-17f6397b736d" xlink:to="loc_us-gaap_LongTermDebt_32013d90-d81f-4b89-b9bb-5024b3f02e4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3eb28981-e85d-49e7-b915-2edab2658bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_268289a4-6275-4382-aae6-17f6397b736d" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_3eb28981-e85d-49e7-b915-2edab2658bd4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_58e23ecc-72a6-4d46-8045-9793e7f159f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_268289a4-6275-4382-aae6-17f6397b736d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_58e23ecc-72a6-4d46-8045-9793e7f159f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_46040628-1a6e-4f01-8cac-f5bf6f7668b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_268289a4-6275-4382-aae6-17f6397b736d" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_46040628-1a6e-4f01-8cac-f5bf6f7668b0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca091666-b074-41dc-9d08-b66d22354c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3a4842c8-06cf-4217-b1a5-f312ca4d3db3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca091666-b074-41dc-9d08-b66d22354c6a" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_3a4842c8-06cf-4217-b1a5-f312ca4d3db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_af15b8e2-5e99-4e15-9181-6e8cc67ed8a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca091666-b074-41dc-9d08-b66d22354c6a" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_af15b8e2-5e99-4e15-9181-6e8cc67ed8a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_cea26790-bf72-438d-9cfa-cf861827e160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca091666-b074-41dc-9d08-b66d22354c6a" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_cea26790-bf72-438d-9cfa-cf861827e160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_4d306d7c-b9a5-4597-9b73-37e202053dee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca091666-b074-41dc-9d08-b66d22354c6a" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_4d306d7c-b9a5-4597-9b73-37e202053dee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_29282e2e-b469-439c-8974-47aad6bb9a7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ca091666-b074-41dc-9d08-b66d22354c6a" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_29282e2e-b469-439c-8974-47aad6bb9a7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_526cb622-8116-424a-844c-6dfe3a440777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_526cb622-8116-424a-844c-6dfe3a440777" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c5281d03-d825-44d0-bb76-ba6a01d6684c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_c5281d03-d825-44d0-bb76-ba6a01d6684c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4c5603ca-04e8-46d2-b248-64a4df20d95d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4c5603ca-04e8-46d2-b248-64a4df20d95d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_aac0e4d7-c584-44e5-b502-8fe7a7aa7554" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_aac0e4d7-c584-44e5-b502-8fe7a7aa7554" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4f57e992-1015-4a1e-9153-162027b5826e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_4f57e992-1015-4a1e-9153-162027b5826e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_635e5d19-3fac-496d-b2f1-4f4f2002d15f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_635e5d19-3fac-496d-b2f1-4f4f2002d15f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ef8beb77-f10c-491a-a046-dd8c2ebe4931" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_ef8beb77-f10c-491a-a046-dd8c2ebe4931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f6175795-813a-4c59-b1bc-7ff55b904e47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f6175795-813a-4c59-b1bc-7ff55b904e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1aac2112-89e5-43ef-93e8-18bec682c93e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_1aac2112-89e5-43ef-93e8-18bec682c93e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_f0558b20-0b11-42f2-9410-c62149677680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ddcd85-0407-41b4-969c-c38b0f8c690d" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_f0558b20-0b11-42f2-9410-c62149677680" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a30a53ad-8d81-4202-8bd5-34a2f4237e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f31e3d63-60ae-480c-8b2d-38694da80de0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a30a53ad-8d81-4202-8bd5-34a2f4237e98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_f31e3d63-60ae-480c-8b2d-38694da80de0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f613a1c6-2150-4146-9a59-3a3ef856db97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a30a53ad-8d81-4202-8bd5-34a2f4237e98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f613a1c6-2150-4146-9a59-3a3ef856db97" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a99e30e-2de2-402d-8691-21e016155947" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_a30a53ad-8d81-4202-8bd5-34a2f4237e98" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_3a99e30e-2de2-402d-8691-21e016155947" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e1e2330e-c98d-47c0-a10f-71b4bfc3273d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_e1e2330e-c98d-47c0-a10f-71b4bfc3273d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ffc91bcc-452a-4dc5-8c8c-5355bca7a2f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_ffc91bcc-452a-4dc5-8c8c-5355bca7a2f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_38819314-a05b-4e5a-a91a-40a687aa76d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_ShareBasedCompensation_38819314-a05b-4e5a-a91a-40a687aa76d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f042701d-7680-442d-b085-28649a9395bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_f042701d-7680-442d-b085-28649a9395bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8af16ee3-5335-43c3-9e70-2c9ce64c0d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_8af16ee3-5335-43c3-9e70-2c9ce64c0d3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6d6a4386-5297-437e-a89f-e315c9d78a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_6d6a4386-5297-437e-a89f-e315c9d78a50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_89073808-88d4-4659-a986-aa788a05fa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_89073808-88d4-4659-a986-aa788a05fa0f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e9000cd1-cc60-40ae-8e02-5b8b94a457c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_ProfitLoss_e9000cd1-cc60-40ae-8e02-5b8b94a457c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_43abd782-8b2e-4a7a-b1b2-6bb427cb5071" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_43abd782-8b2e-4a7a-b1b2-6bb427cb5071" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_cf5dafe1-847b-4e26-a5fc-8fab00360f63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_cf5dafe1-847b-4e26-a5fc-8fab00360f63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_8329c4e1-34a1-49f6-8639-9426c5bd6ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_8329c4e1-34a1-49f6-8639-9426c5bd6ac0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_202709d5-81fc-40e7-a165-7def28d4c39d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_202709d5-81fc-40e7-a165-7def28d4c39d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_b6c4247a-57ae-4168-ba2d-ef5982c344ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_b6c4247a-57ae-4168-ba2d-ef5982c344ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f84f96f3-f8bb-4bab-b5f6-50a38980e49f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f84f96f3-f8bb-4bab-b5f6-50a38980e49f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_9b8a5aca-9d58-4f1f-a2c0-b011e60100dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:calculationArc order="15" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_9b8a5aca-9d58-4f1f-a2c0-b011e60100dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cdf5fe3f-809b-4170-b52a-c1e3a7f068b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="16" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_cdf5fe3f-809b-4170-b52a-c1e3a7f068b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_17eb16b9-8456-4a33-a969-d7a96d693f37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="17" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_InventoryWriteDown_17eb16b9-8456-4a33-a969-d7a96d693f37" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0487dbc6-a63a-41a1-8c3f-5e3cc354def8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="18" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_0487dbc6-a63a-41a1-8c3f-5e3cc354def8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_bbc69424-06d1-42bb-8622-6875425294f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="19" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3a8061b1-db4f-489c-b3e6-137853f64130" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_bbc69424-06d1-42bb-8622-6875425294f2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9dab5523-8675-4185-8ef6-e000f8a44bbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_81d9f881-a4a2-49ad-8e90-09cf94d2ff92" xlink:href="biib-20220930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_9dab5523-8675-4185-8ef6-e000f8a44bbc" xlink:to="loc_biib_ShareOfCoPromotionProfits_81d9f881-a4a2-49ad-8e90-09cf94d2ff92" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_13a006e2-db27-4431-95b6-21c809c35c98" xlink:href="biib-20220930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7599547a-28d3-46ec-9cc8-8babdee9f785" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_13a006e2-db27-4431-95b6-21c809c35c98" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_7599547a-28d3-46ec-9cc8-8babdee9f785" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4dd43310-b0ac-4a6d-a5c5-c874851e5755" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_13a006e2-db27-4431-95b6-21c809c35c98" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_4dd43310-b0ac-4a6d-a5c5-c874851e5755" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b9c262cc-228a-418c-bb9e-d43701f06d31" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent_13a006e2-db27-4431-95b6-21c809c35c98" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b9c262cc-228a-418c-bb9e-d43701f06d31" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03af881b-9c88-488a-97d7-2339cb66084e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d892f13e-23a5-4fb9-98bc-70d9bb0903e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03af881b-9c88-488a-97d7-2339cb66084e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_d892f13e-23a5-4fb9-98bc-70d9bb0903e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2134381e-3b37-487e-a68f-9a8ef14ee8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_03af881b-9c88-488a-97d7-2339cb66084e" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_2134381e-3b37-487e-a68f-9a8ef14ee8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_163f5a6e-bcfc-4b1e-b4e0-6a3eff444a28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e1a16060-5227-4ceb-9398-0c31cf40634c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_163f5a6e-bcfc-4b1e-b4e0-6a3eff444a28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e1a16060-5227-4ceb-9398-0c31cf40634c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_35f37711-27b8-40fb-b3a7-e89b28e63ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_163f5a6e-bcfc-4b1e-b4e0-6a3eff444a28" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_35f37711-27b8-40fb-b3a7-e89b28e63ef7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_3a565465-cd57-41d8-b810-79fc17792340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9de0bc1-3f23-48f1-8594-01b02106e330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3a565465-cd57-41d8-b810-79fc17792340" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f9de0bc1-3f23-48f1-8594-01b02106e330" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_091098de-9162-4bc3-9a0e-ab7a4b59d635" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_3a565465-cd57-41d8-b810-79fc17792340" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_091098de-9162-4bc3-9a0e-ab7a4b59d635" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af18a057-0eaf-4aa0-8e77-a392b143e63b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_64c111c9-97b0-4d06-9148-5ea89b66d08b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af18a057-0eaf-4aa0-8e77-a392b143e63b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_64c111c9-97b0-4d06-9148-5ea89b66d08b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f00ce52-4841-4b5f-af7e-4abc3f8bfa55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af18a057-0eaf-4aa0-8e77-a392b143e63b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7f00ce52-4841-4b5f-af7e-4abc3f8bfa55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f34badcf-151c-4cec-b3a1-1020ff7af107" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_af18a057-0eaf-4aa0-8e77-a392b143e63b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f34badcf-151c-4cec-b3a1-1020ff7af107" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_32545b92-af24-4cbc-8709-dbc6b61f00ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_303a4758-646a-4f06-9cb4-ef42c7eb1f78" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_32545b92-af24-4cbc-8709-dbc6b61f00ad" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_303a4758-646a-4f06-9cb4-ef42c7eb1f78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b35a116a-6cec-423b-9444-c228d84e66f3" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_32545b92-af24-4cbc-8709-dbc6b61f00ad" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_b35a116a-6cec-423b-9444-c228d84e66f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_d7a12a06-6632-4a55-8e85-f56c7078cfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost_32545b92-af24-4cbc-8709-dbc6b61f00ad" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_d7a12a06-6632-4a55-8e85-f56c7078cfa4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails2"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e3a3f838-f47e-4275-a020-e43e6ef42d39" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8d5df586-5f39-470d-a510-e895e8997a42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e3a3f838-f47e-4275-a020-e43e6ef42d39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8d5df586-5f39-470d-a510-e895e8997a42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f2ff1484-7ae0-41a7-a160-863c56e25b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e3a3f838-f47e-4275-a020-e43e6ef42d39" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_f2ff1484-7ae0-41a7-a160-863c56e25b9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_4bafbfc4-ac86-4cc6-8641-e3c016cc00ff" xlink:href="biib-20220930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e3a3f838-f47e-4275-a020-e43e6ef42d39" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_4bafbfc4-ac86-4cc6-8641-e3c016cc00ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e4725-d698-4ac6-9515-47240b9a078f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_eee30197-7351-4697-8aa5-100c640c7c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e4725-d698-4ac6-9515-47240b9a078f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_eee30197-7351-4697-8aa5-100c640c7c5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_c31aac17-f308-44ad-98ec-23b9c8862480" xlink:href="biib-20220930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e4725-d698-4ac6-9515-47240b9a078f" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_c31aac17-f308-44ad-98ec-23b9c8862480" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2cd85dce-1790-4e7e-b64f-ee298f83635c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_922e4725-d698-4ac6-9515-47240b9a078f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_2cd85dce-1790-4e7e-b64f-ee298f83635c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9ee0e8b5-732e-4a3a-bdfb-0aa0d9839ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2fe2724b-3bf6-4416-9a67-68355f78e340" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9ee0e8b5-732e-4a3a-bdfb-0aa0d9839ca5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2fe2724b-3bf6-4416-9a67-68355f78e340" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_94bbaad5-41dd-41db-8a27-168abc8dff17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9ee0e8b5-732e-4a3a-bdfb-0aa0d9839ca5" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_94bbaad5-41dd-41db-8a27-168abc8dff17" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_eed947ce-eb4d-434e-ace8-938f4a80eedd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_41500eff-0393-4dba-be9c-67a10592ad7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_eed947ce-eb4d-434e-ace8-938f4a80eedd" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_41500eff-0393-4dba-be9c-67a10592ad7f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareBasedPaymentsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f76d0a29-aa8d-4746-b934-859c94b6e059" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_17726f4e-d85a-4f34-a891-b817aa1154e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f76d0a29-aa8d-4746-b934-859c94b6e059" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_17726f4e-d85a-4f34-a891-b817aa1154e3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2dcb0a2c-4ed2-486e-9e26-7b2cc28c53cc" xlink:href="biib-20220930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_f76d0a29-aa8d-4746-b934-859c94b6e059" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_2dcb0a2c-4ed2-486e-9e26-7b2cc28c53cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7b8b29c8-8b45-42cc-bf97-dcd98b05fdb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_7b8b29c8-8b45-42cc-bf97-dcd98b05fdb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_b88256cd-80b8-41c0-88d5-95ba602c120b" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_b88256cd-80b8-41c0-88d5-95ba602c120b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9d163b71-aa69-4814-bfa9-5c2cb6ac1b05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_9d163b71-aa69-4814-bfa9-5c2cb6ac1b05" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_7db94c39-ed81-4e84-8738-28c7819d5b20" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_7db94c39-ed81-4e84-8738-28c7819d5b20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_cef201bc-edbe-4d41-a588-38d190b82865" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_cef201bc-edbe-4d41-a588-38d190b82865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_394d9979-c8b1-4053-85ac-295011cdb56a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_394d9979-c8b1-4053-85ac-295011cdb56a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_8c8af712-f8a9-4237-84d7-134bd26f10f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_8c8af712-f8a9-4237-84d7-134bd26f10f7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c72ed3c6-2867-43d6-a1f9-0d68e0a7d365" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_c72ed3c6-2867-43d6-a1f9-0d68e0a7d365" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_958cfc72-da2c-4c6b-b0e2-47e47bdb6e03" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_958cfc72-da2c-4c6b-b0e2-47e47bdb6e03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_bbe4bac3-36d4-4694-8d89-c8fcfc78b85d" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_bbe4bac3-36d4-4694-8d89-c8fcfc78b85d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b0bf4dea-e8d8-4210-a07b-02c5bcf9c8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_c8995a2b-e6a1-428e-b438-d3cc8552567c" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_b0bf4dea-e8d8-4210-a07b-02c5bcf9c8d0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_07bc0e7c-e518-420a-99e8-e9505ef451ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_87b7f2a9-2f03-4a50-9181-5697af1fc508" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_07bc0e7c-e518-420a-99e8-e9505ef451ca" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_87b7f2a9-2f03-4a50-9181-5697af1fc508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cc50cb66-5810-4401-b568-cf749151fb01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_07bc0e7c-e518-420a-99e8-e9505ef451ca" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_cc50cb66-5810-4401-b568-cf749151fb01" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20220930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6f409836-83df-4817-b8b9-7a5ff0648b96,g:f22c5c21-a910-4760-9b39-9695772d8988-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended" id="ic0f0173a262e4f6399a768e1e98f8a31_CondensedConsolidatedStatementsofIncomeUnaudited">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a207e8ac-47cc-428c-b257-56d47bbfb67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_Revenues_a207e8ac-47cc-428c-b257-56d47bbfb67c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ab4a0e45-ca88-4519-a3f6-65f8ff4b57b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ab4a0e45-ca88-4519-a3f6-65f8ff4b57b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b4b14fed-cbe3-4808-92da-13ef4abffc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b4b14fed-cbe3-4808-92da-13ef4abffc07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f32837ae-3f0b-4e1c-ba0a-c1818cd315fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f32837ae-3f0b-4e1c-ba0a-c1818cd315fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9d7fe0dc-0f67-4cf5-8581-698084f3587b" xlink:href="biib-20220930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9d7fe0dc-0f67-4cf5-8581-698084f3587b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_8729707b-9da3-4ef9-8a0d-fa21c80abc0b" xlink:href="biib-20220930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_biib_Collaborationprofitlosssharing_8729707b-9da3-4ef9-8a0d-fa21c80abc0b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_61082ee0-71c4-4420-ba62-3f040c3863aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_61082ee0-71c4-4420-ba62-3f040c3863aa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_53cec308-82cd-416f-ae23-03c6b8014df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_53cec308-82cd-416f-ae23-03c6b8014df8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b68a3402-4e3c-4eac-a506-1bdf046df3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_RestructuringCharges_b68a3402-4e3c-4eac-a506-1bdf046df3d8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dbaa79be-fbdf-4757-b4a4-37503c80f711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dbaa79be-fbdf-4757-b4a4-37503c80f711" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_51885926-06e4-4782-83d4-63d8a37bd7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_51885926-06e4-4782-83d4-63d8a37bd7ae" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_15ad937f-9f39-4d56-802c-3e1f09b92320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_CostsAndExpenses_15ad937f-9f39-4d56-802c-3e1f09b92320" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_18cbebb4-304e-435f-9db4-6846cfe9f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_18cbebb4-304e-435f-9db4-6846cfe9f5cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09ce45a0-d032-4012-aa95-73e78ef0ef49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09ce45a0-d032-4012-aa95-73e78ef0ef49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_f8bbc448-1cf0-45ba-956a-e56fac7ee93a" xlink:href="biib-20220930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_f8bbc448-1cf0-45ba-956a-e56fac7ee93a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bf172330-b3c7-4231-9ef8-8dd6760f33c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_ProfitLoss_bf172330-b3c7-4231-9ef8-8dd6760f33c9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a377518-a97b-4ca2-935d-3fcd105cadc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a377518-a97b-4ca2-935d-3fcd105cadc9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25e617f0-90c6-439d-b8a7-7318b806f553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_NetIncomeLoss_25e617f0-90c6-439d-b8a7-7318b806f553" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e3e6e40a-2893-449b-ab44-c903168d79aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_e3e6e40a-2893-449b-ab44-c903168d79aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bf8e172a-d3ae-4867-a79e-b6fe71a5e1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bf8e172a-d3ae-4867-a79e-b6fe71a5e1e5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c664817-5068-425f-815b-5df8b3561175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c664817-5068-425f-815b-5df8b3561175" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0e1db96d-d1e9-447e-bb61-cf5847f9c2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0e1db96d-d1e9-447e-bb61-cf5847f9c2e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:to="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5ffbc990-aa1e-460b-8d06-added229c557_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:to="loc_srt_ProductsAndServicesDomain_5ffbc990-aa1e-460b-8d06-added229c557_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:to="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_056d59b5-a3a3-4ff2-ad96-193e7a4dd002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:to="loc_us-gaap_ProductMember_056d59b5-a3a3-4ff2-ad96-193e7a4dd002" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8160d633-2b80-4bff-b151-5eb0f0a2e7dc" xlink:href="biib-20220930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8160d633-2b80-4bff-b151-5eb0f0a2e7dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_bff54b18-7f83-4f3b-89a2-305183ea05ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_bff54b18-7f83-4f3b-89a2-305183ea05ee" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended" id="iedcd9733a3554c5c975bfe8bcb5d59b2_CondensedConsolidatedStatementofEquityStatement">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_83ce1887-9278-4bc9-8db7-73129b03ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_83ce1887-9278-4bc9-8db7-73129b03ce09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3977d541-d67e-4950-8627-f4641cd31aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3977d541-d67e-4950-8627-f4641cd31aef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13bad6a6-c529-49d1-a2e2-aa4388fd4da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_ProfitLoss_13bad6a6-c529-49d1-a2e2-aa4388fd4da0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38b7eda4-2c53-4d12-99a4-04b5445c5d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38b7eda4-2c53-4d12-99a4-04b5445c5d29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_1b46cc14-d625-425e-aee8-01902aa01dd5" xlink:href="biib-20220930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_1b46cc14-d625-425e-aee8-01902aa01dd5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2c407afc-facf-483e-a3ca-92b9c6a6f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2c407afc-facf-483e-a3ca-92b9c6a6f8c5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_eecab5c4-9d65-4aa5-a086-7ca1d5a02827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_eecab5c4-9d65-4aa5-a086-7ca1d5a02827" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_760ce08b-cafe-4571-97fd-a4db07af0eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_760ce08b-cafe-4571-97fd-a4db07af0eaa" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_41b8db8e-2c26-4c5d-859e-debccf972b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_41b8db8e-2c26-4c5d-859e-debccf972b26" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_fb166a5c-60e3-4580-8bbc-b2901518eb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_fb166a5c-60e3-4580-8bbc-b2901518eb35" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5d2c41d7-4c96-4c71-8144-c4c4f7d05ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5d2c41d7-4c96-4c71-8144-c4c4f7d05ab1" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_84a7cddb-9a6b-4b6c-857f-4cc6e16d927d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_84a7cddb-9a6b-4b6c-857f-4cc6e16d927d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75d5841b-4242-49f8-bfc1-9540bd170f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75d5841b-4242-49f8-bfc1-9540bd170f44" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_eba810b5-6a54-4e94-9b35-1c997c129e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_eba810b5-6a54-4e94-9b35-1c997c129e44" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33c20b02-fab3-4d0e-bdb4-a8307d643c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33c20b02-fab3-4d0e-bdb4-a8307d643c08" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_8494caa9-c86f-4c0c-842d-8cac2d3a2765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockholdersEquityOther_8494caa9-c86f-4c0c-842d-8cac2d3a2765" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b261a4b1-beba-4d57-ac0d-324ce5640948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_010cc79f-8d0b-4451-8a65-9a872055852a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_37635add-66eb-4580-819b-49dff0ee3752_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_37635add-66eb-4580-819b-49dff0ee3752_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7331b443-5d3f-43de-8923-56ad61648595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7331b443-5d3f-43de-8923-56ad61648595" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_4ec13e03-f4df-4b28-952b-1cfbbb7397e2" xlink:href="biib-20220930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7331b443-5d3f-43de-8923-56ad61648595" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_4ec13e03-f4df-4b28-952b-1cfbbb7397e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:to="loc_us-gaap_EquityComponentDomain_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:to="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b5113d48-ca7e-4712-bff7-7aabe17714c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_PreferredStockMember_b5113d48-ca7e-4712-bff7-7aabe17714c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3eabe72b-6afd-4f88-9d39-ab2f2d999253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_CommonStockMember_3eabe72b-6afd-4f88-9d39-ab2f2d999253" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b246cdcc-caaa-4ccd-869f-cd9d830634ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b246cdcc-caaa-4ccd-869f-cd9d830634ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_941b1f85-bb72-47c2-ad07-0918b6cd59ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_941b1f85-bb72-47c2-ad07-0918b6cd59ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d69d61a8-51e4-482d-a7a9-ac69319e429b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_RetainedEarningsMember_d69d61a8-51e4-482d-a7a9-ac69319e429b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_049f65fc-18d0-4e3a-a4a4-29aad2b972c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_TreasuryStockMember_049f65fc-18d0-4e3a-a4a4-29aad2b972c1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_46d04cac-47a8-4b51-b672-4ca47742d16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_ParentMember_46d04cac-47a8-4b51-b672-4ca47742d16f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_bea418fe-27c0-467f-8ae3-f21b7ee1937d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_bea418fe-27c0-467f-8ae3-f21b7ee1937d" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended" id="ie18c89569bb94c0e81d5fa6f6754a1aa_RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_94d54e81-4dd3-406b-8e21-fafd139646a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_RestructuringCharges_94d54e81-4dd3-406b-8e21-fafd139646a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_74933093-0409-455b-8c87-8ae114fb502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_SeveranceCosts1_74933093-0409-455b-8c87-8ae114fb502a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges_50c08cb4-9e14-4c02-bfb0-3a8e890ac22c" xlink:href="biib-20220930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_biib_GainLossOnRestructuringCharges_50c08cb4-9e14-4c02-bfb0-3a8e890ac22c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_225a297c-27a6-4eee-b497-141cdfadd55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_225a297c-27a6-4eee-b497-141cdfadd55b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_7c315325-4f94-4d06-b3b7-4711fcc4cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_OtherRestructuringCosts_7c315325-4f94-4d06-b3b7-4711fcc4cd0e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:to="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_9471be22-a881-41de-b5ea-e60fd3a8b2f9_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:to="loc_srt_RangeMember_9471be22-a881-41de-b5ea-e60fd3a8b2f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:to="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_303fdf98-1075-441f-8d92-b034cac01fb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:to="loc_srt_MinimumMember_303fdf98-1075-441f-8d92-b034cac01fb8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bba8ef9a-d6df-4afc-8d4d-621660716579" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:to="loc_srt_MaximumMember_bba8ef9a-d6df-4afc-8d4d-621660716579" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:to="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_a6ed653e-324a-47a3-a1fa-238574d20f3b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_a6ed653e-324a-47a3-a1fa-238574d20f3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8863b9b0-915f-45a4-a8a8-20f039571bcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8863b9b0-915f-45a4-a8a8-20f039571bcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_943c1acc-ae42-4d4a-8d22-58f17afab29b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8863b9b0-915f-45a4-a8a8-20f039571bcd" xlink:to="loc_srt_ScenarioForecastMember_943c1acc-ae42-4d4a-8d22-58f17afab29b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended" id="i5aad48a71aea415a8a658a13edaf11a3_RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_83019400-760e-4439-a1b2-ebe19c130427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringReserve_83019400-760e-4439-a1b2-ebe19c130427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a43511ec-c6c0-4c65-b774-df27de73db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringCharges_a43511ec-c6c0-4c65-b774-df27de73db6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_15c9f812-f5cc-4ded-8931-635594b68af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_PaymentsForRestructuring_15c9f812-f5cc-4ded-8931-635594b68af7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_4ef15b38-a700-45ea-9a6a-d91bf4205032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_4ef15b38-a700-45ea-9a6a-d91bf4205032" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_01b42a0f-58ac-488b-bacb-629d4ffbee15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_2525207d-3058-45b0-b7ae-3ad137459afe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_2525207d-3058-45b0-b7ae-3ad137459afe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d163a1ee-8136-4f71-a41b-6ca03fc7dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d163a1ee-8136-4f71-a41b-6ca03fc7dc90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_69cfe4f0-4097-416f-90ff-5c90f77cd627" xlink:href="biib-20220930.xsd#biib_WorkforceReductionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d163a1ee-8136-4f71-a41b-6ca03fc7dc90" xlink:to="loc_biib_WorkforceReductionMember_69cfe4f0-4097-416f-90ff-5c90f77cd627" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended" id="i2ad0518b340c46699b968e39c69b4a44_RevenuesRevenuesbyproductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9ffd56d3-8dd0-4a1d-94f3-abe5e8638deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a5f2cd46-cf68-4edb-96f4-a94e0b21427a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9ffd56d3-8dd0-4a1d-94f3-abe5e8638deb" xlink:to="loc_us-gaap_Revenues_a5f2cd46-cf68-4edb-96f4-a94e0b21427a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9ffd56d3-8dd0-4a1d-94f3-abe5e8638deb" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:to="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_337ba005-c220-4bc9-baac-08847beeee59_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:to="loc_srt_ProductsAndServicesDomain_337ba005-c220-4bc9-baac-08847beeee59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:to="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:href="biib-20220930.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:href="biib-20220930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:to="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_c0c7b6c2-0fbf-469e-9ed8-4e76472c31a2" xlink:href="biib-20220930.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:to="loc_biib_TECFIDERAMember_c0c7b6c2-0fbf-469e-9ed8-4e76472c31a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_d1d17084-e401-4202-a49e-f201f3f80d78" xlink:href="biib-20220930.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:to="loc_biib_VUMERITYMember_d1d17084-e401-4202-a49e-f201f3f80d78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:href="biib-20220930.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:to="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_3d844738-767a-4874-a859-5c0a44354ebf" xlink:href="biib-20220930.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:to="loc_biib_AVONEXMember_3d844738-767a-4874-a859-5c0a44354ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_3b386a4d-ca4b-4a92-9a6b-03e182176d5e" xlink:href="biib-20220930.xsd#biib_PLEGRIDYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:to="loc_biib_PLEGRIDYMember_3b386a4d-ca4b-4a92-9a6b-03e182176d5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_b1972fad-501b-4902-9e6b-3933df8da9f4" xlink:href="biib-20220930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_TysabriProductMember_b1972fad-501b-4902-9e6b-3933df8da9f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_20e1fc2b-198a-4f00-83e6-45d5e20812d1" xlink:href="biib-20220930.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_FAMPYRAMember_20e1fc2b-198a-4f00-83e6-45d5e20812d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_bfabdb81-9322-4aec-9057-e1b8f98ea008" xlink:href="biib-20220930.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_SPINRAZAMember_bfabdb81-9322-4aec-9057-e1b8f98ea008" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:href="biib-20220930.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_a75b574c-81de-4b98-9071-4fb81cf6ecd0" xlink:href="biib-20220930.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_BENEPALIMember_a75b574c-81de-4b98-9071-4fb81cf6ecd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_68d0f57a-c871-4850-bdea-99a3d6cfb668" xlink:href="biib-20220930.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_IMRALDIMember_68d0f57a-c871-4850-bdea-99a3d6cfb668" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_412afa96-dded-4a1e-b42c-f0b173673f08" xlink:href="biib-20220930.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_FLIXABIMember_412afa96-dded-4a1e-b42c-f0b173673f08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_46c31841-f4d1-48db-9ecc-49826d6e983d" xlink:href="biib-20220930.xsd#biib_BYOOVIZMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_BYOOVIZMember_46c31841-f4d1-48db-9ecc-49826d6e983d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_4b31f63c-664f-49b0-a468-a618e1091662" xlink:href="biib-20220930.xsd#biib_FUMADERMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_FUMADERMMember_4b31f63c-664f-49b0-a468-a618e1091662" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_f4ea0a66-0f0c-4f21-94cd-60b23b9b4fc7" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_ADUHELMMember_f4ea0a66-0f0c-4f21-94cd-60b23b9b4fc7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_56d0f879-2f40-4a4c-9493-6f8ffcc560e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_us-gaap_ProductMember_56d0f879-2f40-4a4c-9493-6f8ffcc560e4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:to="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_fa840e52-634e-4705-8163-26f2af9cc54f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:to="loc_srt_SegmentGeographicalDomain_fa840e52-634e-4705-8163-26f2af9cc54f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:to="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2fb76b6b-e45a-4aff-b495-e513854e2217" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:to="loc_country_US_2fb76b6b-e45a-4aff-b495-e513854e2217" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a79d708d-6ec8-40db-850d-28259213d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:to="loc_us-gaap_NonUsMember_a79d708d-6ec8-40db-850d-28259213d9f2" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended" id="i2efef3dc84a24ebbbe9e28e89ec0cc2c_RevenuesReservesforDiscountsandAllowancesDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_73760b20-085f-4479-bec1-cb3906de258f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_73760b20-085f-4479-bec1-cb3906de258f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_eba93b4c-329b-41a1-8c90-827764d46a42" xlink:href="biib-20220930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_eba93b4c-329b-41a1-8c90-827764d46a42" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_97f991f4-0223-47a8-a4b2-fd901c012b46" xlink:href="biib-20220930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_97f991f4-0223-47a8-a4b2-fd901c012b46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_71285022-9c6f-4047-a38b-204eeff4284b" xlink:href="biib-20220930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_71285022-9c6f-4047-a38b-204eeff4284b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_f6915f57-3469-4642-b960-33d5ec7660ee" xlink:href="biib-20220930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_f6915f57-3469-4642-b960-33d5ec7660ee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3f575d4d-abc3-4ae6-896e-b0105c4768a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_66ff0fdc-8895-4c8f-83f0-f447164f0740_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_66ff0fdc-8895-4c8f-83f0-f447164f0740_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_cf79947c-caf6-4eef-aa36-e919ea947b20" xlink:href="biib-20220930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:to="loc_biib_ReserveforCashDiscountsMember_cf79947c-caf6-4eef-aa36-e919ea947b20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_3c66b25c-7b52-408d-9007-f51233821519" xlink:href="biib-20220930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:to="loc_biib_ContractualAdjustmentsMember_3c66b25c-7b52-408d-9007-f51233821519" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_acced657-1382-490f-b24c-5841dfe0897d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_acced657-1382-490f-b24c-5841dfe0897d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended" id="ib7397495fd0d4ef3932737b4175e7d79_RevenuesReservesforDiscountsandAllowancesDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fcf88e11-b915-45d7-8572-9d9ebf6e7f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b9b9e0-b3aa-4e3d-ba05-3e710716280a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_fcf88e11-b915-45d7-8572-9d9ebf6e7f2a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b9b9e0-b3aa-4e3d-ba05-3e710716280a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_fcf88e11-b915-45d7-8572-9d9ebf6e7f2a" xlink:to="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_10dea709-3de8-4006-b7ad-71ddc91ea475_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_10dea709-3de8-4006-b7ad-71ddc91ea475_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_57394697-3652-455d-b11a-44fa3f74a0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:to="loc_us-gaap_AccountsReceivableMember_57394697-3652-455d-b11a-44fa3f74a0f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_58ab37e9-adbe-48fc-9824-7cdf4bfc5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_58ab37e9-adbe-48fc-9824-7cdf4bfc5b2f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended" id="id8c6ea3a9c164627b252a50f2189d5dc_RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_f41f1452-af11-476d-adef-eac6ea896102" xlink:href="biib-20220930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_biib_ShareOfCoPromotionProfits_f41f1452-af11-476d-adef-eac6ea896102" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_910ecae6-a9f7-4fb1-bf14-583122d7e10c" xlink:href="biib-20220930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_910ecae6-a9f7-4fb1-bf14-583122d7e10c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a7f19dc-a132-4c62-938f-232acd60151b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_us-gaap_Revenues_4a7f19dc-a132-4c62-938f-232acd60151b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:to="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9b29803b-0c0b-403a-9601-eab7bd43730e_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:to="loc_srt_ProductsAndServicesDomain_9b29803b-0c0b-403a-9601-eab7bd43730e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_804d0ee0-6da3-4ab3-a0c1-0790c9cbec5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:to="loc_srt_ProductsAndServicesDomain_804d0ee0-6da3-4ab3-a0c1-0790c9cbec5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a1ddb780-d59e-460d-b996-b6ce763c7b53" xlink:href="biib-20220930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_804d0ee0-6da3-4ab3-a0c1-0790c9cbec5d" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a1ddb780-d59e-460d-b996-b6ce763c7b53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:to="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7612794e-4f50-4109-8534-1c7d41ba3b07_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:to="loc_srt_NameOfMajorCustomerDomain_7612794e-4f50-4109-8534-1c7d41ba3b07_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1198c3b5-7531-48e1-bdec-ffa0dcccb0ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:to="loc_srt_NameOfMajorCustomerDomain_1198c3b5-7531-48e1-bdec-ffa0dcccb0ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_475187b2-462c-47ab-b627-6d8e55309037" xlink:href="biib-20220930.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1198c3b5-7531-48e1-bdec-ffa0dcccb0ff" xlink:to="loc_biib_RocheGroupGenentechMember_475187b2-462c-47ab-b627-6d8e55309037" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended" id="ia90845510dea41729ca1d85f7d4f92f9_RevenuesOtherRevenuesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bdc35500-f307-440f-bb03-fd3ee920482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_88befec2-c7f5-4cdf-be27-3b8aa0624770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bdc35500-f307-440f-bb03-fd3ee920482f" xlink:to="loc_us-gaap_Revenues_88befec2-c7f5-4cdf-be27-3b8aa0624770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bdc35500-f307-440f-bb03-fd3ee920482f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6901dfe8-b991-4b3f-80ee-63a5f958973e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6901dfe8-b991-4b3f-80ee-63a5f958973e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_55361568-2144-488b-b0bb-86977aa06287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6901dfe8-b991-4b3f-80ee-63a5f958973e" xlink:to="loc_us-gaap_CollaborativeArrangementMember_55361568-2144-488b-b0bb-86977aa06287" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_29e4741f-bfb1-409a-8b07-1b946fa83a6f_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:to="loc_srt_ProductsAndServicesDomain_29e4741f-bfb1-409a-8b07-1b946fa83a6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:to="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_32fe920a-b574-4970-8b72-e909a3fc7c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:to="loc_us-gaap_RoyaltyMember_32fe920a-b574-4970-8b72-e909a3fc7c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_61ad31ed-4c02-4d11-bec9-ba7fc00892cf" xlink:href="biib-20220930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:to="loc_biib_OthercorporaterevenuesMember_61ad31ed-4c02-4d11-bec9-ba7fc00892cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_c3a0213a-190d-4711-be6d-85fff0cec49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_c3a0213a-190d-4711-be6d-85fff0cec49d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_09793fbf-8ae5-4153-84c7-21623347b91b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:to="loc_srt_NameOfMajorCustomerDomain_09793fbf-8ae5-4153-84c7-21623347b91b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:to="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_4379c015-dbec-4fd8-9287-a1ede70e6d15" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_4379c015-dbec-4fd8-9287-a1ede70e6d15" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_d154f913-c412-4070-9e8c-11bc37bb4ab9" xlink:href="biib-20220930.xsd#biib_ZINBRYTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:to="loc_biib_ZINBRYTAMember_d154f913-c412-4070-9e8c-11bc37bb4ab9" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended" id="i33aa12b4634347ef8faed8f222d914a0_RevenuesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_28efe549-4b65-4694-a39b-1302b614bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_us-gaap_Revenues_28efe549-4b65-4694-a39b-1302b614bf0c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_3c4de6e8-528e-45a3-a2ce-3bd5e146534f" xlink:href="biib-20220930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_3c4de6e8-528e-45a3-a2ce-3bd5e146534f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_039bda5f-696f-4620-9461-d5077ae58979" xlink:href="biib-20220930.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_biib_NumberOfWholesalers_039bda5f-696f-4620-9461-d5077ae58979" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:to="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c444fdae-1707-4242-9fca-7140da3c5632_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:to="loc_srt_ProductsAndServicesDomain_c444fdae-1707-4242-9fca-7140da3c5632_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:to="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_c16f682e-df61-4dc6-8592-02b9667eb4a7" xlink:href="biib-20220930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:to="loc_biib_OthercorporaterevenuesMember_c16f682e-df61-4dc6-8592-02b9667eb4a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_856c8ec9-8150-47b3-9a40-87bcbd3be108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_856c8ec9-8150-47b3-9a40-87bcbd3be108" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:to="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7c7e0106-f1cb-4364-bd86-c12bdb23ae93_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:to="loc_srt_NameOfMajorCustomerDomain_7c7e0106-f1cb-4364-bd86-c12bdb23ae93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:to="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_014015af-78d9-4a3e-89ba-d0924a7c3b13" xlink:href="biib-20220930.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:to="loc_biib_DistributorOneMember_014015af-78d9-4a3e-89ba-d0924a7c3b13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_8e051a5f-2e58-4ed1-b313-665086032877" xlink:href="biib-20220930.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:to="loc_biib_DistributorTwoMember_8e051a5f-2e58-4ed1-b313-665086032877" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended" id="i426992d60b1342d9bbff6c1bb66c65b3_InventoryComponentsofInventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a692a20-ff0b-4eee-bd9f-e00dbb7a0c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a692a20-ff0b-4eee-bd9f-e00dbb7a0c91" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd2d3552-e3b7-4414-b0a7-061fdb6284f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd2d3552-e3b7-4414-b0a7-061fdb6284f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_840e36f4-d052-4f0c-ba52-f9d72090d141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_840e36f4-d052-4f0c-ba52-f9d72090d141" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_0ad07b00-940f-4122-a96a-ca18abb35cfd" xlink:href="biib-20220930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_0ad07b00-940f-4122-a96a-ca18abb35cfd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:to="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_af57f0ae-09a6-41e2-a7d8-23440aee2af5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:to="loc_srt_ProductsAndServicesDomain_af57f0ae-09a6-41e2-a7d8-23440aee2af5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_714c5ffe-ad13-4931-9775-c25997aaaf29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:to="loc_srt_ProductsAndServicesDomain_714c5ffe-ad13-4931-9775-c25997aaaf29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LecanemabMember_e7f6b0ca-f390-46bd-8f6b-1f6b84622dad" xlink:href="biib-20220930.xsd#biib_LecanemabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_714c5ffe-ad13-4931-9775-c25997aaaf29" xlink:to="loc_biib_LecanemabMember_e7f6b0ca-f390-46bd-8f6b-1f6b84622dad" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended" id="iee207d92ec274eb8a3ec3be8940e0a87_InventoryNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d3027faf-7615-4748-869e-793344ac9f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_us-gaap_InventoryWriteDown_d3027faf-7615-4748-869e-793344ac9f8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_70b7bd00-1c70-492c-bc24-a4bd346571ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_70b7bd00-1c70-492c-bc24-a4bd346571ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_927de500-de4a-4c0a-8156-7ced920639ab" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_927de500-de4a-4c0a-8156-7ced920639ab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_d29e8372-6552-48c9-9bd2-2299f0bed28e" xlink:href="biib-20220930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_d29e8372-6552-48c9-9bd2-2299f0bed28e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_00925fb8-27e0-46a6-8ff9-f0f109cc88ab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:to="loc_srt_ProductsAndServicesDomain_00925fb8-27e0-46a6-8ff9-f0f109cc88ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50bcb596-cd5b-40ae-8222-7d0cfa3c2878" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:to="loc_srt_ProductsAndServicesDomain_50bcb596-cd5b-40ae-8222-7d0cfa3c2878" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_9d5cb914-ac7c-4bca-8624-065ee7a54872" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_50bcb596-cd5b-40ae-8222-7d0cfa3c2878" xlink:to="loc_biib_ADUHELMMember_9d5cb914-ac7c-4bca-8624-065ee7a54872" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80854ad9-98a7-404c-8ff8-2d6834a7d675_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80854ad9-98a7-404c-8ff8-2d6834a7d675_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad7be2b2-494f-4338-9a6c-08bc9c06dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad7be2b2-494f-4338-9a6c-08bc9c06dd57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_bdf06454-f584-420a-92d4-a9dd61c4a9ea" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad7be2b2-494f-4338-9a6c-08bc9c06dd57" xlink:to="loc_biib_EisaiMember_bdf06454-f584-420a-92d4-a9dd61c4a9ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e9afaa-82cd-45b9-851b-decd8924b0e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e9afaa-82cd-45b9-851b-decd8924b0e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_e456afa5-8b41-43e7-82f1-4c54c8265f5d" xlink:href="biib-20220930.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e9afaa-82cd-45b9-851b-decd8924b0e1" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_e456afa5-8b41-43e7-82f1-4c54c8265f5d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended" id="if8e6a9c5c1664b6598805926e12c148f_IntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8467ce94-8f81-4b09-bf35-9b166e93c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8467ce94-8f81-4b09-bf35-9b166e93c3ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6d6e2223-f892-4cd6-8ec9-4ca8b20608f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6d6e2223-f892-4cd6-8ec9-4ca8b20608f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6052f1a-a826-4ab4-aae8-78eee2d23963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6052f1a-a826-4ab4-aae8-78eee2d23963" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_790ba8ec-ff00-4c22-b5f1-6910478f9ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_790ba8ec-ff00-4c22-b5f1-6910478f9ef9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_46e994cc-23fc-4e17-b9b3-be7c1a8e33a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_46e994cc-23fc-4e17-b9b3-be7c1a8e33a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_333c85e5-c15f-48e2-b4b1-a33a75ef9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_333c85e5-c15f-48e2-b4b1-a33a75ef9bf8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_20184838-93dc-495d-9f19-ecd8c7488da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_20184838-93dc-495d-9f19-ecd8c7488da7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_8420b3f4-655a-45a5-9362-3fad52909499" xlink:href="biib-20220930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_8420b3f4-655a-45a5-9362-3fad52909499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b3cf3db3-202e-49b6-abbc-512a2c71845c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_15f86d5c-4d5a-432c-9b1b-4f6ef1a3ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_15f86d5c-4d5a-432c-9b1b-4f6ef1a3ab5e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0d8f8ae9-cc1e-46b2-92d4-c661d186d818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0d8f8ae9-cc1e-46b2-92d4-c661d186d818" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ee3ce095-d108-4fc1-85b6-383f0256ecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ee3ce095-d108-4fc1-85b6-383f0256ecf6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_afa2c5c5-7c1a-4cb7-ab8c-1aa38c21e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_afa2c5c5-7c1a-4cb7-ab8c-1aa38c21e0fa" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_87104b26-f0ca-406e-bcbd-fc40c7a11944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_87104b26-f0ca-406e-bcbd-fc40c7a11944" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_25bb6d19-e783-4bef-8b4e-324f560548fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_25bb6d19-e783-4bef-8b4e-324f560548fe" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6341d175-6583-41c1-9589-3ee0ce5930c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6341d175-6583-41c1-9589-3ee0ce5930c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:href="biib-20220930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_e5833811-bf5a-4b5d-82db-58326f61555d_default" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_e5833811-bf5a-4b5d-82db-58326f61555d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_d817bc67-5219-4404-ae4a-b2f257eb773a" xlink:href="biib-20220930.xsd#biib_BIIB111Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_BIIB111Member_d817bc67-5219-4404-ae4a-b2f257eb773a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_9c28434b-8214-4d0f-9853-a680931c6b8e" xlink:href="biib-20220930.xsd#biib_BIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_BIIB112Member_9c28434b-8214-4d0f-9853-a680931c6b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_530444a9-349e-4717-899a-028857f00d0b" xlink:href="biib-20220930.xsd#biib_VixotrigineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_VixotrigineMember_530444a9-349e-4717-899a-028857f00d0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_8928b9d9-4e50-43ab-8a2a-860d79c02ece" xlink:href="biib-20220930.xsd#biib_TGNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_TGNMember_8928b9d9-4e50-43ab-8a2a-860d79c02ece" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_0fcfbc2f-c2d5-41a4-8ab0-62e083f732dd" xlink:href="biib-20220930.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_BIIB111AndBIIB112Member_0fcfbc2f-c2d5-41a4-8ab0-62e083f732dd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_2fda377c-4b07-477b-9f18-fcddff3d375a" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_81a840ed-e704-487f-8905-19ac63242656_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_81a840ed-e704-487f-8905-19ac63242656_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a03b8f4e-7ad7-4e99-84e5-7bd9ddeb164a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a03b8f4e-7ad7-4e99-84e5-7bd9ddeb164a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_dba2e108-c16d-4c75-9c0a-b8734d258850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_dba2e108-c16d-4c75-9c0a-b8734d258850" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca0e962a-faa0-41aa-a810-c534773eaae1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ca0e962a-faa0-41aa-a810-c534773eaae1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_9ff03beb-8d0d-4377-9292-bddbf73f2e74" xlink:href="biib-20220930.xsd#biib_OutLicensedPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:to="loc_biib_OutLicensedPatentsMember_9ff03beb-8d0d-4377-9292-bddbf73f2e74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_06f7d059-7792-4430-8a84-8e1a2e7d6706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_06f7d059-7792-4430-8a84-8e1a2e7d6706" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e4d1c2d1-926b-4591-87ce-08a0ee7d6158_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:to="loc_srt_RangeMember_e4d1c2d1-926b-4591-87ce-08a0ee7d6158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:to="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_562e3746-b058-471a-a812-aa71b08371ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:to="loc_srt_MinimumMember_562e3746-b058-471a-a812-aa71b08371ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_472b126e-ab41-4aaa-b3d9-12be3cd9a20d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:to="loc_srt_MaximumMember_472b126e-ab41-4aaa-b3d9-12be3cd9a20d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="ieee30330cc3a402984747b8710017280_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c114412-951a-472f-9e43-a5ea90c993f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c114412-951a-472f-9e43-a5ea90c993f2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ab55f85-3f69-4036-ae4e-761237f3f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ab55f85-3f69-4036-ae4e-761237f3f34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6dcdfadb-d5f3-4f9b-97bb-d87e9aac8973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6dcdfadb-d5f3-4f9b-97bb-d87e9aac8973" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_af59bf09-6931-4bc2-9d19-0e1f4fa2b412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_af59bf09-6931-4bc2-9d19-0e1f4fa2b412" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_2a9fc572-dd0a-4c29-9fa7-f8bb4188512d" xlink:href="biib-20220930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_2a9fc572-dd0a-4c29-9fa7-f8bb4188512d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5714fe5b-c71e-4744-9021-1bd2c0f6c571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5714fe5b-c71e-4744-9021-1bd2c0f6c571" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_473ffcfd-f17c-4d3d-9b14-b300da1acf0e" xlink:href="biib-20220930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_473ffcfd-f17c-4d3d-9b14-b300da1acf0e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_8433934c-4ecd-4ace-87e0-96ad964fc63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_8433934c-4ecd-4ace-87e0-96ad964fc63c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aad27809-d07d-4248-80fd-28f1b1d41d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_aad27809-d07d-4248-80fd-28f1b1d41d8f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7e5f4e2d-cc12-416f-a872-dc95e67c6d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7e5f4e2d-cc12-416f-a872-dc95e67c6d3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_24ac6175-a37e-409e-8184-5e4fc97feaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_24ac6175-a37e-409e-8184-5e4fc97feaf5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_82a87c95-c6b8-4434-9b29-cc0d50663f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_82a87c95-c6b8-4434-9b29-cc0d50663f49" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a51c9267-892f-4128-9e2b-c6676cccc469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a51c9267-892f-4128-9e2b-c6676cccc469" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c114412-951a-472f-9e43-a5ea90c993f2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32b7a1f7-2b7e-474f-afdb-86f505552165_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_32b7a1f7-2b7e-474f-afdb-86f505552165_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_21a397b3-5929-407c-baad-91ee6bbaa4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_21a397b3-5929-407c-baad-91ee6bbaa4f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_18f36b92-c559-486d-b920-a0b4191b21e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_18f36b92-c559-486d-b920-a0b4191b21e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d868d52d-5a0c-4adb-b678-d4600a0b1e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d868d52d-5a0c-4adb-b678-d4600a0b1e15" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2e5cb387-3126-4a56-8bb2-e1d41730e616_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2e5cb387-3126-4a56-8bb2-e1d41730e616_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8bf959e6-3960-47c8-b69a-388e79a1663a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8bf959e6-3960-47c8-b69a-388e79a1663a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4e97eed6-6fcb-429e-a45f-e241ed608542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8bf959e6-3960-47c8-b69a-388e79a1663a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4e97eed6-6fcb-429e-a45f-e241ed608542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_32b34b44-3f6d-4ae2-8244-2d34ab312cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_32b34b44-3f6d-4ae2-8244-2d34ab312cbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6ad578e2-c33f-451c-8e72-89dec1e90174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6ad578e2-c33f-451c-8e72-89dec1e90174" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_86135a57-bdf6-4954-b5b1-f1504bfd8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_86135a57-bdf6-4954-b5b1-f1504bfd8c3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_43b84645-30da-4b58-8b92-883213d3b1d6_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_43b84645-30da-4b58-8b92-883213d3b1d6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e09cf14d-358e-4dba-a5c6-59df0be4373b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e09cf14d-358e-4dba-a5c6-59df0be4373b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_12f5ea4f-1985-4777-9c73-ccbb034e8c62" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e09cf14d-358e-4dba-a5c6-59df0be4373b" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_12f5ea4f-1985-4777-9c73-ccbb034e8c62" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended" id="i18de5efb334c441ca1f28f091d416201_FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_30aeecfe-0aed-4335-98d1-0dcbd15b38c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_30aeecfe-0aed-4335-98d1-0dcbd15b38c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beaa4ae4-df15-4936-9eb8-134793fea03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beaa4ae4-df15-4936-9eb8-134793fea03d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:to="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6dcd10e9-7365-435e-bb85-7ce0de9f51b7_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:to="loc_srt_RangeMember_6dcd10e9-7365-435e-bb85-7ce0de9f51b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45cc18f2-4108-4d7b-95fa-c694045b1be2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:to="loc_srt_RangeMember_45cc18f2-4108-4d7b-95fa-c694045b1be2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_deec15bd-8357-41a5-82e9-b9e1f97443ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_45cc18f2-4108-4d7b-95fa-c694045b1be2" xlink:to="loc_srt_WeightedAverageMember_deec15bd-8357-41a5-82e9-b9e1f97443ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f51b79fe-0974-489d-8c87-abcfda1d3cff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f51b79fe-0974-489d-8c87-abcfda1d3cff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_458f4eaa-957c-41d1-b6a0-83baa2dc49a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_458f4eaa-957c-41d1-b6a0-83baa2dc49a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_73d399d6-48ca-4991-a6ff-fd27b1dfd6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_458f4eaa-957c-41d1-b6a0-83baa2dc49a5" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_73d399d6-48ca-4991-a6ff-fd27b1dfd6fe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended" id="i519310437a724508a6371997619e3a21_FairValueMeasurementsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_98b058fd-d67e-4283-989d-49f32441f188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_98b058fd-d67e-4283-989d-49f32441f188" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_70436fc6-0e74-48b8-b03a-a02ac858ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_NotesPayable_70436fc6-0e74-48b8-b03a-a02ac858ca10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e5d50d3e-d8aa-4eb2-89a9-9778c5a07cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e5d50d3e-d8aa-4eb2-89a9-9778c5a07cf1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b0a8ca8-801c-42ae-97a1-936208996607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b0a8ca8-801c-42ae-97a1-936208996607" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:to="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fbda076d-fe24-4893-a465-b9735f242558_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fbda076d-fe24-4893-a465-b9735f242558_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_ab161de5-d0fa-4450-92eb-352c3e4b4303" xlink:href="biib-20220930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_ab161de5-d0fa-4450-92eb-352c3e4b4303" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d852b969-823d-45ca-9611-baea2e17c1ae" xlink:href="biib-20220930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d852b969-823d-45ca-9611-baea2e17c1ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_fd5fe2f6-2758-48cd-b6a9-4289c6c41581" xlink:href="biib-20220930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_fd5fe2f6-2758-48cd-b6a9-4289c6c41581" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c4c62040-543f-42fe-9108-909f8a70869c" xlink:href="biib-20220930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c4c62040-543f-42fe-9108-909f8a70869c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_92c7b4df-cc84-4ac5-a350-f94721a85fac" xlink:href="biib-20220930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_92c7b4df-cc84-4ac5-a350-f94721a85fac" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_b9ce3c69-93e5-4538-b0aa-feac590f66f8" xlink:href="biib-20220930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_b9ce3c69-93e5-4538-b0aa-feac590f66f8" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended" id="i757c70c6edcd40a1aba59ba3e7377a09_FairValueMeasurementsDetails2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f1f8ab4b-c350-4e76-8798-6f3acd9da4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f1f8ab4b-c350-4e76-8798-6f3acd9da4f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_43138d41-c1f6-44c0-9a0a-55e63074cfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_43138d41-c1f6-44c0-9a0a-55e63074cfc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47240eef-9ff9-483d-9231-bae464a802d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_ad98b87e-8208-474b-9f47-5798a01050b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_ad98b87e-8208-474b-9f47-5798a01050b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e956f63f-60d7-4b15-ad0a-575642fc3906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e956f63f-60d7-4b15-ad0a-575642fc3906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9b427b51-de4d-4fe7-9845-a9ca68501b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e956f63f-60d7-4b15-ad0a-575642fc3906" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9b427b51-de4d-4fe7-9845-a9ca68501b3f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended" id="i6e4cb3bdda68421a829b5d7f67b26b59_FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_7a9f278b-dcbc-440e-9f0f-187a8c6f3c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_b6c11659-2406-4012-908a-d1ff38851c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_7a9f278b-dcbc-440e-9f0f-187a8c6f3c89" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_b6c11659-2406-4012-908a-d1ff38851c90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ae035d46-8882-4dcd-8f54-abcbbf609b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_b6c11659-2406-4012-908a-d1ff38851c90" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ae035d46-8882-4dcd-8f54-abcbbf609b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_7a9f278b-dcbc-440e-9f0f-187a8c6f3c89" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:to="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_6c61ebc1-d5c6-4552-9dab-767425549e15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_6c61ebc1-d5c6-4552-9dab-767425549e15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_648222e0-f62c-4b88-bce0-6c367eb4d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_CommercialPaperMember_648222e0-f62c-4b88-bce0-6c367eb4d3b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_d1f6dc55-453c-42a4-80ef-5503a55f8956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_d1f6dc55-453c-42a4-80ef-5503a55f8956" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_85a87dbe-1320-4906-aa72-617a152af6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_85a87dbe-1320-4906-aa72-617a152af6b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_b0dfb513-cefc-4ce7-9e9e-df2eca1fe73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_DebtSecuritiesMember_b0dfb513-cefc-4ce7-9e9e-df2eca1fe73c" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended" id="i8cca8b78a24a42759125ec68c41e5d30_FinancialInstrumentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8e9f2933-ec1b-4a42-bf2b-bdaff3f13797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8e9f2933-ec1b-4a42-bf2b-bdaff3f13797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_87ac79e5-16af-4698-ab1e-8f19707bb680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_87ac79e5-16af-4698-ab1e-8f19707bb680" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_090aecb0-95d7-4d8e-89f8-8e61aa87e738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_090aecb0-95d7-4d8e-89f8-8e61aa87e738" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b794359c-e5cf-464b-a794-2b7192a04293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b794359c-e5cf-464b-a794-2b7192a04293" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_10bd6a3e-114b-43fb-ab44-0dc1e05d667d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_10bd6a3e-114b-43fb-ab44-0dc1e05d667d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_26507c55-0dfe-40f2-b3e3-4797ffb969dc" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_26507c55-0dfe-40f2-b3e3-4797ffb969dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_01677755-6c67-4940-89f9-c4057dee6c31" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_01677755-6c67-4940-89f9-c4057dee6c31" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_264d9a45-c4ad-4569-ae56-db5f16aff474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_264d9a45-c4ad-4569-ae56-db5f16aff474" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:to="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_485036ce-f85f-4949-8232-8ed4e264894f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_485036ce-f85f-4949-8232-8ed4e264894f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_cf8fa886-4fb0-4608-90e5-d76c2465e277" xlink:href="biib-20220930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_cf8fa886-4fb0-4608-90e5-d76c2465e277" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_5f46b2b4-85e5-4300-858d-a55f66207da6" xlink:href="biib-20220930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_5f46b2b4-85e5-4300-858d-a55f66207da6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_1d29ac26-0f9f-4d87-b059-581193c77002" xlink:href="biib-20220930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_1d29ac26-0f9f-4d87-b059-581193c77002" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_48f0f2f4-a221-4603-869d-d6c673f0df25" xlink:href="biib-20220930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_48f0f2f4-a221-4603-869d-d6c673f0df25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_0d9e1a9b-5643-4630-bd6b-548ae5b722d0" xlink:href="biib-20220930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_0d9e1a9b-5643-4630-bd6b-548ae5b722d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_f46ad034-6bf7-4f28-9012-f375a6003121" xlink:href="biib-20220930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_f46ad034-6bf7-4f28-9012-f375a6003121" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_2892e4cc-0eaa-4b9a-aa4d-43d654e14123" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_EquitySecuritiesCurrentMember_2892e4cc-0eaa-4b9a-aa4d-43d654e14123" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_94fe797f-f21f-4cb1-9674-4f2231a76cc6" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_94fe797f-f21f-4cb1-9674-4f2231a76cc6" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended" id="ia758f09ebe684754b48ecd66063c1de0_FinancialInstrumentsFinancialInstrumentsDetailsTextual2">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7c6f7420-840f-4627-83f7-52cab0d0e1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_e6cd04c7-69c0-4b12-adb4-a53d57d7fdca" xlink:href="biib-20220930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7c6f7420-840f-4627-83f7-52cab0d0e1d7" xlink:to="loc_biib_StrategicInvestmentPortfolio_e6cd04c7-69c0-4b12-adb4-a53d57d7fdca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7c6f7420-840f-4627-83f7-52cab0d0e1d7" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d8148f60-87c1-4a27-b254-24919e20744f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d8148f60-87c1-4a27-b254-24919e20744f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_59ab4718-78c5-4e81-a3a7-5f7a73d8b71e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_59ab4718-78c5-4e81-a3a7-5f7a73d8b71e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_efa2fb06-b935-4902-8114-f3eee5825fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_59ab4718-78c5-4e81-a3a7-5f7a73d8b71e" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_efa2fb06-b935-4902-8114-f3eee5825fbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:to="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57fd03ec-b758-4b64-ae17-5ccc35ac81ff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_57fd03ec-b758-4b64-ae17-5ccc35ac81ff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_938768af-a7b8-4ba1-8b5d-20372d68a133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_938768af-a7b8-4ba1-8b5d-20372d68a133" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_37a4b9b3-8aaf-4271-a8a7-b67bd89302f8" xlink:href="biib-20220930.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_938768af-a7b8-4ba1-8b5d-20372d68a133" xlink:to="loc_biib_StrategicInvestmentsMember_37a4b9b3-8aaf-4271-a8a7-b67bd89302f8" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#DerivativeInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended" id="i7fed52824eb64742a2bdebdab51dee4d_DerivativeInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_8d53f861-3aaa-4670-8721-131530f5060a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_8d53f861-3aaa-4670-8721-131530f5060a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_570d98be-ae7d-479e-ae93-2beb93a57c00" xlink:href="biib-20220930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_570d98be-ae7d-479e-ae93-2beb93a57c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9e9e1707-39ae-4243-97e5-44f05d1edadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9e9e1707-39ae-4243-97e5-44f05d1edadd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_da73f969-f2e3-4ce3-b80c-fa2e654ccd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_da73f969-f2e3-4ce3-b80c-fa2e654ccd18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3853c868-f172-4e7e-bb7a-97224052a267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3853c868-f172-4e7e-bb7a-97224052a267" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_96b5c30c-9826-4f78-b429-b9245e77b4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_96b5c30c-9826-4f78-b429-b9245e77b4f7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_a972e4b6-6ca5-46fc-b5b0-f1218a416a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_a972e4b6-6ca5-46fc-b5b0-f1218a416a8f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_d546758f-1026-47ad-a2bd-53a71fa352f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_d546758f-1026-47ad-a2bd-53a71fa352f7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ab810e06-fa5c-4de5-b6cb-832a9010cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ab810e06-fa5c-4de5-b6cb-832a9010cd15" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c33537f8-8ce1-4b66-8a00-a905899ad8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c33537f8-8ce1-4b66-8a00-a905899ad8a9" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_96c3b0b0-2927-4416-afb9-66ec5b715184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_96c3b0b0-2927-4416-afb9-66ec5b715184" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_45a2a406-97c1-4c29-816d-627c110de41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_45a2a406-97c1-4c29-816d-627c110de41a" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_b878348a-1b26-4d55-a085-b4c97a503a40" xlink:href="biib-20220930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_b878348a-1b26-4d55-a085-b4c97a503a40" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_590e5169-a3af-4f87-aba8-34d5d0c92300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_590e5169-a3af-4f87-aba8-34d5d0c92300" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_d8d034b4-949d-40e1-9cce-6168bd922024" xlink:href="biib-20220930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_UnrealizedGainOnDerivatives_d8d034b4-949d-40e1-9cce-6168bd922024" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_d3b84344-8ccf-436e-87fe-5979600e012f" xlink:href="biib-20220930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_UnrealizedLossOnDerivatives_d3b84344-8ccf-436e-87fe-5979600e012f" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_6c39321f-6b0f-49ed-baaf-d6be129a2f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_6c39321f-6b0f-49ed-baaf-d6be129a2f0d" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_b0f6abde-fc2a-42e8-8884-079fb8134c80" xlink:href="biib-20220930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_b0f6abde-fc2a-42e8-8884-079fb8134c80" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_31e7c1f1-3991-4da3-acf6-77250fbf481f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_31e7c1f1-3991-4da3-acf6-77250fbf481f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_ef8c3512-629d-432b-817f-eb82074a59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_ef8c3512-629d-432b-817f-eb82074a59a7" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_823d4de3-d393-4d50-8bef-f4a6d7606289_default" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:to="loc_biib_DerivativeMaturityDomain_823d4de3-d393-4d50-8bef-f4a6d7606289_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_11ff9471-9537-40f6-a590-a2e159934c8f" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:to="loc_biib_DerivativeMaturityDomain_11ff9471-9537-40f6-a590-a2e159934c8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_30c7cc07-3750-4b13-b15c-3c7f46a85027" xlink:href="biib-20220930.xsd#biib_ShorttermderivativeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_DerivativeMaturityDomain_11ff9471-9537-40f6-a590-a2e159934c8f" xlink:to="loc_biib_ShorttermderivativeMember_30c7cc07-3750-4b13-b15c-3c7f46a85027" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_55304bbd-36ef-4558-a38a-7361620945c5_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_55304bbd-36ef-4558-a38a-7361620945c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8a0545e0-159f-43fb-9a03-2c82bae8c70c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8a0545e0-159f-43fb-9a03-2c82bae8c70c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_d4eb538f-a142-49d3-ab1a-052fc6e17c9d" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8a0545e0-159f-43fb-9a03-2c82bae8c70c" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_d4eb538f-a142-49d3-ab1a-052fc6e17c9d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_1736ed88-4e5f-4c08-9982-924a45f811a5_default" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:to="loc_currency_AllCurrenciesDomain_1736ed88-4e5f-4c08-9982-924a45f811a5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:to="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_8a8d939d-16a1-4613-8a30-00e54218e10a" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_EUR_8a8d939d-16a1-4613-8a30-00e54218e10a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_e0255068-9616-4555-bffa-81d551aaa074" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_GBP_e0255068-9616-4555-bffa-81d551aaa074" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_6b4cde1e-221d-4ef6-b287-26a6d08c53ac" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_CHF_6b4cde1e-221d-4ef6-b287-26a6d08c53ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_bfac39b7-4f32-45cb-9cff-0ed70330f880" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_JPY_bfac39b7-4f32-45cb-9cff-0ed70330f880" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_28513af3-3d59-424d-9afa-ee267a2c5d9f" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_CAD_28513af3-3d59-424d-9afa-ee267a2c5d9f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d069bf91-1a6b-43af-9b66-b38b9d41028b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d069bf91-1a6b-43af-9b66-b38b9d41028b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_c28d5938-15c9-4c30-a3b2-3883cdf68233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:to="loc_us-gaap_SalesMember_c28d5938-15c9-4c30-a3b2-3883cdf68233" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_7e38105a-1007-4b72-81f5-2aac22e57565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:to="loc_us-gaap_OperatingExpenseMember_7e38105a-1007-4b72-81f5-2aac22e57565" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3da7a128-4605-4c38-b502-17611a4326c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3da7a128-4605-4c38-b502-17611a4326c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:to="loc_us-gaap_HedgingRelationshipDomain_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_bd7b7bc5-140e-446d-8a1a-b284b5d8c6b6" xlink:href="biib-20220930.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:to="loc_biib_CashflowsrevenueMember_bd7b7bc5-140e-446d-8a1a-b284b5d8c6b6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_e9e5b5c2-89e3-4a68-b475-2353e353a262" xlink:href="biib-20220930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:to="loc_biib_CashflowsoperatingexpensesMember_e9e5b5c2-89e3-4a68-b475-2353e353a262" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8cb5370b-29ae-458a-9b40-ca1ca3eae61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8cb5370b-29ae-458a-9b40-ca1ca3eae61e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_700f9ea9-c56c-42f1-acd9-dd9f83959d24_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_700f9ea9-c56c-42f1-acd9-dd9f83959d24_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a845aee2-e3c8-4444-8a73-9401c46cbdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a845aee2-e3c8-4444-8a73-9401c46cbdb9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_824719b0-7ce6-4fd7-8d3f-4c80ee757771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_824719b0-7ce6-4fd7-8d3f-4c80ee757771" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7fc61950-c443-40d5-8f0c-eb1cd193db44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7fc61950-c443-40d5-8f0c-eb1cd193db44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9cfd3737-7a5d-444d-b7c2-4ecaa4b33e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9cfd3737-7a5d-444d-b7c2-4ecaa4b33e5d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3c35e707-3690-4a42-b913-33b72c5d755b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_3c35e707-3690-4a42-b913-33b72c5d755b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_03dfd03b-e02c-45cf-ab35-728b7d87749b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:to="loc_us-gaap_HedgingDesignationDomain_03dfd03b-e02c-45cf-ab35-728b7d87749b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:to="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7d6d00d8-efdc-43b0-aa88-94f4a9765f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7d6d00d8-efdc-43b0-aa88-94f4a9765f74" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_770bcb89-5c44-41c8-9b23-a0ab54687e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:to="loc_us-gaap_NondesignatedMember_770bcb89-5c44-41c8-9b23-a0ab54687e00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6f82977c-708a-4522-a2a2-4deb150a846d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:to="loc_srt_RangeMember_6f82977c-708a-4522-a2a2-4deb150a846d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:to="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6c2cbbe4-bcce-4735-b92b-b670df7303e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:to="loc_srt_MinimumMember_6c2cbbe4-bcce-4735-b92b-b670df7303e9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d9a52df-defe-4446-9d14-3f0263382860" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:to="loc_srt_MaximumMember_2d9a52df-defe-4446-9d14-3f0263382860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69af6262-0e51-45a7-9421-f5d2ea999b7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_69af6262-0e51-45a7-9421-f5d2ea999b7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df575ac0-bdcb-4dc0-ac01-52ca6c962f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df575ac0-bdcb-4dc0-ac01-52ca6c962f5c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended" id="i2d1af01aa44843a1a17960c1a54abf62_PropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_87d32ea4-d9af-4519-98ab-b27baa1f77b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_87d32ea4-d9af-4519-98ab-b27baa1f77b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_854cd767-f80c-47dd-9322-2c7d4da39c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_Depreciation_854cd767-f80c-47dd-9322-2c7d4da39c69" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_f3d7f849-19ef-4da1-a776-f67f1d1fd624" xlink:href="biib-20220930.xsd#biib_NumberOfSquareFeet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_biib_NumberOfSquareFeet_f3d7f849-19ef-4da1-a776-f67f1d1fd624" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_0083ea3a-4c31-4a37-92c4-9620af0e38b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_ConstructionInProgressGross_0083ea3a-4c31-4a37-92c4-9620af0e38b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_22a606a3-0a0d-4c04-a0f9-88838a5336ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_22a606a3-0a0d-4c04-a0f9-88838a5336ae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_316585ba-1818-414b-9f53-18cb301c9f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_316585ba-1818-414b-9f53-18cb301c9f8e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_63e42676-22e7-489f-8ddc-e32b9f3d6fc6" xlink:href="biib-20220930.xsd#biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_63e42676-22e7-489f-8ddc-e32b9f3d6fc6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71f691fe-b14c-45b8-bf50-b2bdfb53edc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71f691fe-b14c-45b8-bf50-b2bdfb53edc7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_914c58df-8eac-47f6-920c-e430ad72fe37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_914c58df-8eac-47f6-920c-e430ad72fe37" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:href="biib-20220930.xsd#biib_FacilityLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_f0183ac8-ede3-41ed-97c8-33b626b6e540_default" xlink:href="biib-20220930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:to="loc_biib_FacilityLocationDomain_f0183ac8-ede3-41ed-97c8-33b626b6e540_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_e98cc573-5163-4767-a2d0-021924c2943f" xlink:href="biib-20220930.xsd#biib_FacilityLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:to="loc_biib_FacilityLocationDomain_e98cc573-5163-4767-a2d0-021924c2943f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_8cbd48fc-7f76-4c2a-8d7c-7b3ecdb2b30c" xlink:href="biib-20220930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityLocationDomain_e98cc573-5163-4767-a2d0-021924c2943f" xlink:to="loc_biib_SolothurnSwitzerlandMember_8cbd48fc-7f76-4c2a-8d7c-7b3ecdb2b30c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:href="biib-20220930.xsd#biib_FacilityTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_579ffc5b-dfac-4735-822c-60f2319fc92c_default" xlink:href="biib-20220930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:to="loc_biib_FacilityTypeDomain_579ffc5b-dfac-4735-822c-60f2319fc92c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:href="biib-20220930.xsd#biib_FacilityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:to="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_656a861e-811a-4cea-9bdf-463c0223a748" xlink:href="biib-20220930.xsd#biib_BiologicsManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:to="loc_biib_BiologicsManufacturingMember_656a861e-811a-4cea-9bdf-463c0223a748" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_d1ebefbc-4ed4-46e7-9979-ed2a3521bbca" xlink:href="biib-20220930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_d1ebefbc-4ed4-46e7-9979-ed2a3521bbca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_3ba917ad-7f11-4e8a-95b7-49facff48f35" xlink:href="biib-20220930.xsd#biib_AdministrativeSpaceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:to="loc_biib_AdministrativeSpaceMember_3ba917ad-7f11-4e8a-95b7-49facff48f35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_686ecdec-b8c0-4555-9ee9-1b87efee232b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_686ecdec-b8c0-4555-9ee9-1b87efee232b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4d204883-af61-42e5-80c5-6ce73112c392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:to="loc_us-gaap_BuildingMember_4d204883-af61-42e5-80c5-6ce73112c392" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0e1d45e7-28d2-45a1-8fe8-834665547439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:to="loc_us-gaap_LandMember_0e1d45e7-28d2-45a1-8fe8-834665547439" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1d881f57-7413-4e3c-8fbb-fc6de5e7d0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1d881f57-7413-4e3c-8fbb-fc6de5e7d0ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e2efa6a4-1876-4cf0-b39e-29b776020251_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_e2efa6a4-1876-4cf0-b39e-29b776020251_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_579d87d5-2144-4b65-ba73-0e3d5c0f6a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_579d87d5-2144-4b65-ba73-0e3d5c0f6a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A125BroadwayBuildingMember_dfc187c6-d546-4b7b-b003-c0ecb21c8a46" xlink:href="biib-20220930.xsd#biib_A125BroadwayBuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_579d87d5-2144-4b65-ba73-0e3d5c0f6a50" xlink:to="loc_biib_A125BroadwayBuildingMember_dfc187c6-d546-4b7b-b003-c0ecb21c8a46" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#LeasesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended" id="i0e2a46732e534e06872a30ad3cffeb97_LeasesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d95d0c9f-4b24-4283-88f5-f3ada14092b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d95d0c9f-4b24-4283-88f5-f3ada14092b7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10a05a4b-95eb-4596-821d-1293eda7e342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10a05a4b-95eb-4596-821d-1293eda7e342" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2fa1d831-63f9-4dcd-a34a-6238ed359eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_OperatingLeaseLiability_2fa1d831-63f9-4dcd-a34a-6238ed359eb2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_0babd3ec-8062-432d-af91-98cc8752ba5d" xlink:href="biib-20220930.xsd#biib_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_0babd3ec-8062-432d-af91-98cc8752ba5d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseLiabilityDerecognized_367445b0-0c3e-4ff9-85a1-ab726678ac84" xlink:href="biib-20220930.xsd#biib_OperatingLeaseLiabilityDerecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_biib_OperatingLeaseLiabilityDerecognized_367445b0-0c3e-4ff9-85a1-ab726678ac84" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges_99b780f8-6d8d-4917-bbaf-a37f3aff2ab1" xlink:href="biib-20220930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_biib_GainLossOnRestructuringCharges_99b780f8-6d8d-4917-bbaf-a37f3aff2ab1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cc934bd4-e748-420b-9871-9f5f108edfcd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cc934bd4-e748-420b-9871-9f5f108edfcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76a8c0e1-91ca-4fc6-85dd-d47720608120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76a8c0e1-91ca-4fc6-85dd-d47720608120" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_95b69844-3d4a-4a1a-94d5-6c5f0141bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76a8c0e1-91ca-4fc6-85dd-d47720608120" xlink:to="loc_us-gaap_BuildingMember_95b69844-3d4a-4a1a-94d5-6c5f0141bf5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IndebtednessDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended" id="i3c1bbc83c60f4dc68e759ea90dcd176c_IndebtednessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_86ed8dfe-168a-4acc-83a7-14f359b791ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_86ed8dfe-168a-4acc-83a7-14f359b791ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate_077de81a-4c88-46c4-b42c-5936bb3edb81" xlink:href="biib-20220930.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_biib_DebtInstrumentRedemptionRate_077de81a-4c88-46c4-b42c-5936bb3edb81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37cf032b-b5bb-40e0-8a75-76fee59dcdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37cf032b-b5bb-40e0-8a75-76fee59dcdaa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_3f101d42-5f4e-4a59-9954-38442b9cdaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_3f101d42-5f4e-4a59-9954-38442b9cdaab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_99b6a3f6-5b6a-4329-8be8-7a80b245bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_99b6a3f6-5b6a-4329-8be8-7a80b245bea4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_2cc2c3e3-fa58-453f-819a-9ca1b93c5f89" xlink:href="biib-20220930.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_2cc2c3e3-fa58-453f-819a-9ca1b93c5f89" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_6f4bfa96-95f8-40b2-a0ce-91355dac4ace" xlink:href="biib-20220930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_biib_LongTermDebtExchangedAmount_6f4bfa96-95f8-40b2-a0ce-91355dac4ace" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e6ef853-e292-43bc-89f6-079367eabde1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e6ef853-e292-43bc-89f6-079367eabde1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ccfe548e-ff57-4476-b1ea-daa011c86608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_RepaymentsOfDebt_ccfe548e-ff57-4476-b1ea-daa011c86608" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c37a9c60-72ee-45ea-884b-6e65dc86d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_InterestExpense_c37a9c60-72ee-45ea-884b-6e65dc86d64b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:to="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c9f62f91-06b7-45df-922e-57797508b92a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c9f62f91-06b7-45df-922e-57797508b92a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9bf134c8-fad1-4751-bfa9-de9be2067032" xlink:href="biib-20220930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9bf134c8-fad1-4751-bfa9-de9be2067032" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_5bd34928-8294-46d2-9f76-7727dfdb8d81" xlink:href="biib-20220930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_5bd34928-8294-46d2-9f76-7727dfdb8d81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:to="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_c819a1be-da35-4e46-a9fb-fe6a6446edf2_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_c819a1be-da35-4e46-a9fb-fe6a6446edf2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2c8860da-f10f-46fe-ab45-60475fbc348e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2c8860da-f10f-46fe-ab45-60475fbc348e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_40e6a55a-fe02-48f9-bbc5-d1e25cb69a27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2c8860da-f10f-46fe-ab45-60475fbc348e" xlink:to="loc_srt_ScenarioForecastMember_40e6a55a-fe02-48f9-bbc5-d1e25cb69a27" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareRepurchasesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended" id="icfcdc1f5e01c45b0b8dce893bb47a673_ShareRepurchasesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3c143583-bef5-4373-b630-aaa91d066bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3c143583-bef5-4373-b630-aaa91d066bf6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5b2867db-2c62-46c3-96ef-21a2bdd98c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5b2867db-2c62-46c3-96ef-21a2bdd98c94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9a6bfe0b-1c57-4206-a2a0-38a973087db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9a6bfe0b-1c57-4206-a2a0-38a973087db6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_252b2264-d16d-4a00-933c-a8b45d9c6281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_252b2264-d16d-4a00-933c-a8b45d9c6281" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_aba6d2f8-bf49-4a65-b49a-e085685dc3f9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_aba6d2f8-bf49-4a65-b49a-e085685dc3f9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_10f9ec96-dfd1-4cdd-afda-ce7dbf183e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_10f9ec96-dfd1-4cdd-afda-ce7dbf183e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_0e5944c5-11d2-415a-b77c-f8de6fa50daa" xlink:href="biib-20220930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_10f9ec96-dfd1-4cdd-afda-ce7dbf183e89" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_0e5944c5-11d2-415a-b77c-f8de6fa50daa" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="i2bdffd2677f94b8180f0d0fe44c4086c_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ecb5fa4-ed4a-4ad0-8a90-77aa3008de43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ecb5fa4-ed4a-4ad0-8a90-77aa3008de43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b0c29cc8-50f3-42f4-bd11-ec6c0a046164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e9abe322-7cf5-4770-b6b9-309b43dad5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e9abe322-7cf5-4770-b6b9-309b43dad5e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_14093271-cde7-47e4-a3a8-cd2c97ba3ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_14093271-cde7-47e4-a3a8-cd2c97ba3ed1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_65e8c75e-e0bb-44c6-81b6-725ffe8e281e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_65e8c75e-e0bb-44c6-81b6-725ffe8e281e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc0039b4-4a47-4005-b303-243a864d3f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5b3d396f-c854-4f13-a348-ca428476a862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5b3d396f-c854-4f13-a348-ca428476a862" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_887087bd-f913-4f70-a8c7-8f1f30280c41_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:to="loc_us-gaap_EquityComponentDomain_887087bd-f913-4f70-a8c7-8f1f30280c41_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:to="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69f2bd6a-db5f-4f9a-ba04-e3c571a32c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69f2bd6a-db5f-4f9a-ba04-e3c571a32c0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3607758-b4cb-473b-bb8e-b65cf635e1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3607758-b4cb-473b-bb8e-b65cf635e1dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_db59590a-7642-48e3-aaf5-ba7afc78a589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_db59590a-7642-48e3-aaf5-ba7afc78a589" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3a1f3262-7ebd-45c6-b98b-95d0dc73aa41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3a1f3262-7ebd-45c6-b98b-95d0dc73aa41" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe0efffa-8cf9-43cd-8d02-b92276db897c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe0efffa-8cf9-43cd-8d02-b92276db897c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="if71a4ac902ec4b049305d501b5207b07_ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0915f85b-cbf2-4e8c-84d2-986461c75159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0915f85b-cbf2-4e8c-84d2-986461c75159" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_690b600d-16dd-4b22-bb41-a85f8367ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_690b600d-16dd-4b22-bb41-a85f8367ad5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_57f0b1cb-4b34-4091-becd-ec84e0d515dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_Revenues_57f0b1cb-4b34-4091-becd-ec84e0d515dd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_356781da-3c14-4089-9d05-0deae1aa95be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_OperatingExpenses_356781da-3c14-4089-9d05-0deae1aa95be" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49e68748-745b-4be1-8851-ddb1acea0331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_NetIncomeLoss_49e68748-745b-4be1-8851-ddb1acea0331" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c0c044f-7f29-481e-9589-1a27802cb3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c0c044f-7f29-481e-9589-1a27802cb3d2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_68cbc91f-21a9-4071-858e-eef8e65fd38b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:to="loc_us-gaap_EquityComponentDomain_68cbc91f-21a9-4071-858e-eef8e65fd38b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:to="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_34e1b136-b20f-49f6-b2ae-61c4707f76e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_34e1b136-b20f-49f6-b2ae-61c4707f76e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c0e8d0d5-0836-46e4-920e-841e32ba616f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c0e8d0d5-0836-46e4-920e-841e32ba616f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_07826788-d5db-49f3-8097-051734213a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_07826788-d5db-49f3-8097-051734213a8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_055c80de-d463-47c2-abf7-9ac5fb500435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_055c80de-d463-47c2-abf7-9ac5fb500435" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b6216bba-2040-4006-a841-b6ee38a0e490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_b6216bba-2040-4006-a841-b6ee38a0e490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2429282c-0890-4422-b665-c897b2c7623c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2429282c-0890-4422-b665-c897b2c7623c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9af6d4e3-3f5c-4099-83d4-47498a3f6cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2429282c-0890-4422-b665-c897b2c7623c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9af6d4e3-3f5c-4099-83d4-47498a3f6cfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_92b29240-2512-43ba-8d4b-d5f2ae410398_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_92b29240-2512-43ba-8d4b-d5f2ae410398_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_75f52cac-4ec3-469c-bd9d-d06ebf4f9983" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_75f52cac-4ec3-469c-bd9d-d06ebf4f9983" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_672a0571-1aed-4487-96b5-a128b974d214" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_75f52cac-4ec3-469c-bd9d-d06ebf4f9983" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_672a0571-1aed-4487-96b5-a128b974d214" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended" id="iffec5ad02faa48e494d658c4d1b22fc5_EarningsperShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b45f752d-3aac-405e-b311-414e5a3b4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:href="biib-20220930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b45f752d-3aac-405e-b311-414e5a3b4a8e" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_cb2e32b4-a909-4c0c-8f2d-c0b13bfc35f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:to="loc_us-gaap_NetIncomeLossAbstract_cb2e32b4-a909-4c0c-8f2d-c0b13bfc35f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b998390c-85c7-4b12-b699-57671b81bed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cb2e32b4-a909-4c0c-8f2d-c0b13bfc35f2" xlink:to="loc_us-gaap_NetIncomeLoss_b998390c-85c7-4b12-b699-57671b81bed9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_044a8369-f7e2-4349-8f94-50445332191b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_044a8369-f7e2-4349-8f94-50445332191b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8174522c-3c83-4420-9430-1f8246803048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8174522c-3c83-4420-9430-1f8246803048" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ffa65dc3-2845-4b73-813c-a0136528886b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ffa65dc3-2845-4b73-813c-a0136528886b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cae55495-a680-4cb1-a4b4-7dc4d7cee67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cae55495-a680-4cb1-a4b4-7dc4d7cee67e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b45f752d-3aac-405e-b311-414e5a3b4a8e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c38f203d-23c6-40df-9d2c-e7103451a45b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_c38f203d-23c6-40df-9d2c-e7103451a45b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_13182c39-e4ee-4b5f-bca6-899aec223c10" xlink:href="biib-20220930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_13182c39-e4ee-4b5f-bca6-899aec223c10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_e5a65d0f-9b3e-40f9-b409-1db6fb455bc2" xlink:href="biib-20220930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:to="loc_biib_MarketStockUnitsMember_e5a65d0f-9b3e-40f9-b409-1db6fb455bc2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_069d4d82-b96a-46b9-9085-913460a58ff2" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_069d4d82-b96a-46b9-9085-913460a58ff2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareBasedPaymentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended" id="i0f8a7a085d4c44c6b4b026b10d63213a_ShareBasedPaymentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cd44ecf3-ba3b-4f9f-8e88-9c099f5a54ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cd44ecf3-ba3b-4f9f-8e88-9c099f5a54ca" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_efd3aaf6-d2b6-4422-87f4-31d0503d17ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_efd3aaf6-d2b6-4422-87f4-31d0503d17ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ecda07f8-8f12-430f-9bba-a0e16b0cdc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ecda07f8-8f12-430f-9bba-a0e16b0cdc05" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4cbb6b3a-996f-49e6-8030-2eb77a2a6787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4cbb6b3a-996f-49e6-8030-2eb77a2a6787" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_020b99ee-c63a-4773-9470-b99c8a232dfc" xlink:href="biib-20220930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_020b99ee-c63a-4773-9470-b99c8a232dfc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3ab6519f-5551-4879-bf72-0ab9cdb70844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3ab6519f-5551-4879-bf72-0ab9cdb70844" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cd44ecf3-ba3b-4f9f-8e88-9c099f5a54ca" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d576aa3c-ef7a-4965-aefe-d3d673955714_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d576aa3c-ef7a-4965-aefe-d3d673955714_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dddf1db4-a5df-480b-93c8-6734b485d5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dddf1db4-a5df-480b-93c8-6734b485d5c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e8ca54f8-5dce-4134-a4cc-e3a9143fb707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e8ca54f8-5dce-4134-a4cc-e3a9143fb707" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_abf4c88c-a12a-4da2-9fb5-cb48ef74cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:to="loc_us-gaap_ParentMember_abf4c88c-a12a-4da2-9fb5-cb48ef74cf40" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareBasedPaymentsDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended" id="if6f3c9949238427c8bd4193042252699_ShareBasedPaymentsDetails1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a73cc26c-f1ab-4bc7-ad89-d8a0f67f50ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:href="biib-20220930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a73cc26c-f1ab-4bc7-ad89-d8a0f67f50ae" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa04315a-8b31-41b0-98f0-c9328f7f28ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa04315a-8b31-41b0-98f0-c9328f7f28ce" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a843c245-af6b-4cd1-a950-3ab73a37b4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a843c245-af6b-4cd1-a950-3ab73a37b4fb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e9caa74a-6772-4145-8110-f07f8dd36540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e9caa74a-6772-4145-8110-f07f8dd36540" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7b46ca3b-a8cc-455d-889d-da249c0d2f8a" xlink:href="biib-20220930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7b46ca3b-a8cc-455d-889d-da249c0d2f8a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a73cc26c-f1ab-4bc7-ad89-d8a0f67f50ae" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:to="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55bd7083-eb92-4c31-9224-8520b5f29975_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_55bd7083-eb92-4c31-9224-8520b5f29975_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_4bb31993-7e74-4ad3-bfab-26a2b0842feb" xlink:href="biib-20220930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_MarketStockUnitsMember_4bb31993-7e74-4ad3-bfab-26a2b0842feb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ad02a33a-3cae-4a03-bc17-f54499f5d6dc" xlink:href="biib-20220930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_ad02a33a-3cae-4a03-bc17-f54499f5d6dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_0d1c3542-224e-4697-9a30-f10093473ae7" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_0d1c3542-224e-4697-9a30-f10093473ae7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_e318b91c-07cb-4d44-903c-443d483c8775" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_e318b91c-07cb-4d44-903c-443d483c8775" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_cd732622-7adc-49da-a7a2-dc5c2f083b1e" xlink:href="biib-20220930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_cd732622-7adc-49da-a7a2-dc5c2f083b1e" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#IncomeTaxesDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended" id="ie3f99c5179f44025a76c5b605747f3f2_IncomeTaxesDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19ccaa39-dfe3-4ce9-a527-c1fd76ecdf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19ccaa39-dfe3-4ce9-a527-c1fd76ecdf47" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d1022f0f-cae3-4854-95ff-0faa074b8b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_EquityMethodInvestments_d1022f0f-cae3-4854-95ff-0faa074b8b19" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_eaee297b-1ce3-42f8-af34-a0b7d0e41d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_eaee297b-1ce3-42f8-af34-a0b7d0e41d73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_24035fcc-3fad-449a-a00b-c916ed771ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_24035fcc-3fad-449a-a00b-c916ed771ab4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fcc78f27-9b4c-4a1a-b975-85fc191c360d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fcc78f27-9b4c-4a1a-b975-85fc191c360d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ebaaf7fa-5ad2-417a-8d2f-3a69718d8944" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fcc78f27-9b4c-4a1a-b975-85fc191c360d" xlink:to="loc_srt_ScenarioForecastMember_ebaaf7fa-5ad2-417a-8d2f-3a69718d8944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_772951f0-250f-4a4c-95dd-a9dd490a47e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_772951f0-250f-4a4c-95dd-a9dd490a47e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2dce60db-cc40-46d0-9403-2d43d3a3ac95" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_772951f0-250f-4a4c-95dd-a9dd490a47e0" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2dce60db-cc40-46d0-9403-2d43d3a3ac95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_36710593-f201-4853-a088-b777cf1f7d3b_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:to="loc_srt_ProductsAndServicesDomain_36710593-f201-4853-a088-b777cf1f7d3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7e846ce-a1bc-4930-a1cb-d73523ef819a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:to="loc_srt_ProductsAndServicesDomain_d7e846ce-a1bc-4930-a1cb-d73523ef819a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_8c8c50e2-b16d-40a9-b016-259f96540967" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_d7e846ce-a1bc-4930-a1cb-d73523ef819a" xlink:to="loc_biib_ADUHELMMember_8c8c50e2-b16d-40a9-b016-259f96540967" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended" id="i9200aad3fc50409d95395d09f775a836_OtherConsolidatedFinancialStatementDetailDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a85355ea-7695-4825-a869-5f60c77755dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a85355ea-7695-4825-a869-5f60c77755dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7e0cdab0-7036-451f-a99c-3101718bf041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_LitigationSettlementExpense_7e0cdab0-7036-451f-a99c-3101718bf041" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_16fb98c9-059f-40d5-83dd-e6606d23cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_16fb98c9-059f-40d5-83dd-e6606d23cd4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8b5c9545-7b6e-488c-9937-b4e09101f8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_InterestExpense_8b5c9545-7b6e-488c-9937-b4e09101f8b2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_0b494c03-1e99-48db-91d1-2bc4069b494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_0b494c03-1e99-48db-91d1-2bc4069b494a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b01474da-86d1-4a5f-9629-48257e618db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b01474da-86d1-4a5f-9629-48257e618db9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6c143883-099c-43c6-a2df-e7f6ad5197d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6c143883-099c-43c6-a2df-e7f6ad5197d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_40795fb8-d18c-48b3-8169-56b79e3307bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_40795fb8-d18c-48b3-8169-56b79e3307bf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d93582e0-75d1-4a24-ab01-0b9b57a89bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d93582e0-75d1-4a24-ab01-0b9b57a89bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_daf0322c-7ae3-4141-9f5a-31e9d6d073a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_daf0322c-7ae3-4141-9f5a-31e9d6d073a5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5d972fec-8c82-4a47-bd78-4bfbf149e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5d972fec-8c82-4a47-bd78-4bfbf149e29d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_8e5cf2ed-a416-4e66-b617-395edae16556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_8e5cf2ed-a416-4e66-b617-395edae16556" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_028d21b5-bc20-42ce-8336-becda0c1dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_028d21b5-bc20-42ce-8336-becda0c1dbc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2aa7b1b8-4b1c-474f-81fe-d24fdeb7777d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2aa7b1b8-4b1c-474f-81fe-d24fdeb7777d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cf81d5f7-ab9f-4238-9339-bbe905a3a7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cf81d5f7-ab9f-4238-9339-bbe905a3a7e7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_fd16e9cd-e7fd-4e02-8ee1-8d11dc4f68ea" xlink:href="biib-20220930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_biib_Collaborationexpensesaccrual_fd16e9cd-e7fd-4e02-8ee1-8d11dc4f68ea" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_715aad48-4b34-432d-be1d-5021b69ce96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_715aad48-4b34-432d-be1d-5021b69ce96f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d8e570ca-6f35-416c-8cb4-32650a592044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d8e570ca-6f35-416c-8cb4-32650a592044" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d043d80b-c289-4d8e-b423-e226cca6d23e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d043d80b-c289-4d8e-b423-e226cca6d23e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2a96eadb-4c92-426b-a724-a530c584b950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2a96eadb-4c92-426b-a724-a530c584b950" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_bdfe6e9d-6638-4f92-af8e-781bba0b58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2a96eadb-4c92-426b-a724-a530c584b950" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_bdfe6e9d-6638-4f92-af8e-781bba0b58ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:to="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_c835798b-1450-4ece-a3b5-86859ef8f236_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:to="loc_dei_EntityDomain_c835798b-1450-4ece-a3b5-86859ef8f236_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_295b403e-c734-4e59-8791-4e448397edf6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:to="loc_dei_EntityDomain_295b403e-c734-4e59-8791-4e448397edf6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_66c7a5ee-e717-40c5-9f6b-f68b8f6ebc0c" xlink:href="biib-20220930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_295b403e-c734-4e59-8791-4e448397edf6" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_66c7a5ee-e717-40c5-9f6b-f68b8f6ebc0c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended" id="ib4bb61ab7094415997f22ffb00df6a01_OtherConsolidatedFinancialStatementDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4edc0132-cac3-4410-9374-6c27490e6524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4edc0132-cac3-4410-9374-6c27490e6524" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d3fc44cd-3f59-4d07-9184-e788e6f413b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d3fc44cd-3f59-4d07-9184-e788e6f413b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7baf37ca-9728-447f-a2e1-c16884769fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7baf37ca-9728-447f-a2e1-c16884769fa6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_597576f7-cc89-4af0-810a-39e782bb5744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_597576f7-cc89-4af0-810a-39e782bb5744" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:to="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_ad6aa0d6-5921-46fc-be2f-1fde22d63a52_default" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:to="loc_dei_EntityDomain_ad6aa0d6-5921-46fc-be2f-1fde22d63a52_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3b5f5726-0b19-4be4-b45c-17a65e357107" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:to="loc_dei_EntityDomain_3b5f5726-0b19-4be4-b45c-17a65e357107" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_e45c6bc9-2ddd-4bba-8870-9a5fc60a9b97" xlink:href="biib-20220930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3b5f5726-0b19-4be4-b45c-17a65e357107" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_e45c6bc9-2ddd-4bba-8870-9a5fc60a9b97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended" id="ia139145e9b3b420aa5fb99cf1537edbd_CollaborativeandOtherRelationshipsCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_c9cdfadc-cdbb-43c8-b653-9f1d426389c5" xlink:href="biib-20220930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_ExpenseIncurredByCollaboration_c9cdfadc-cdbb-43c8-b653-9f1d426389c5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_f132a608-b2f6-43ea-9ad2-a684411c3ad5" xlink:href="biib-20220930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_Expenseincurredbythecollaboration_f132a608-b2f6-43ea-9ad2-a684411c3ad5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_0e4aa9df-9837-4132-ba78-cac8afbdabe7" xlink:href="biib-20220930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_0e4aa9df-9837-4132-ba78-cac8afbdabe7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9e0640c-59b5-4d98-a428-e17d099a094d" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9e0640c-59b5-4d98-a428-e17d099a094d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_22054e80-8f8c-4874-8c7b-109bfbb02802" xlink:href="biib-20220930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_22054e80-8f8c-4874-8c7b-109bfbb02802" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_07024eba-df66-4ce3-8e73-3ef190868c5b" xlink:href="biib-20220930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_CollaborationAgreementTerm_07024eba-df66-4ce3-8e73-3ef190868c5b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_abadfbac-6065-4bae-8977-16e1b2bcff81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_abadfbac-6065-4bae-8977-16e1b2bcff81" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_525a0749-5a1b-4f70-8413-b207e1a920b6" xlink:href="biib-20220930.xsd#biib_Termofcollaborationagreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_Termofcollaborationagreement_525a0749-5a1b-4f70-8413-b207e1a920b6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_437f21fc-c0c5-4f6d-8239-e50db8266064" xlink:href="biib-20220930.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_437f21fc-c0c5-4f6d-8239-e50db8266064" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_86916098-e171-4fa4-9839-9cc999bf62bb" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_AdditionalMilestonePayment_86916098-e171-4fa4-9839-9cc999bf62bb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5dbf9535-78d8-41bd-9d98-4c48c969d15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5dbf9535-78d8-41bd-9d98-4c48c969d15d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2e95a09a-bce0-4d6e-b17a-a9d68174d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2e95a09a-bce0-4d6e-b17a-a9d68174d9a4" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47dedf28-ae88-4637-a128-62d2be8ad75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47dedf28-ae88-4637-a128-62d2be8ad75f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges_e70e173f-ae87-4b67-9522-e9abf4856781" xlink:href="biib-20220930.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_CostOfGoodsSoldCapacityCharges_e70e173f-ae87-4b67-9522-e9abf4856781" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a3ebce83-2694-41cf-905d-ce18dbbe9c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a3ebce83-2694-41cf-905d-ce18dbbe9c33" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_fcc00aea-131a-4ae0-80a4-e0cd28b8f762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_AdjustmentForAmortization_fcc00aea-131a-4ae0-80a4-e0cd28b8f762" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_2206e30b-b75d-4cf6-9b1a-aa5c7ce6413c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_DueFromRelatedParties_2206e30b-b75d-4cf6-9b1a-aa5c7ce6413c" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a69a344a-2b86-4cea-ad9d-30fd87bdb783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a69a344a-2b86-4cea-ad9d-30fd87bdb783" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_0027b72c-5a9f-41c4-92c9-a8204d81cafa" xlink:href="biib-20220930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_0027b72c-5a9f-41c4-92c9-a8204d81cafa" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_46d18a73-46c0-4d42-a0bd-36f62d0ec815_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_46d18a73-46c0-4d42-a0bd-36f62d0ec815_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df5099b7-77a6-4025-9355-00504388d215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df5099b7-77a6-4025-9355-00504388d215" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bc70d43-2bc6-454c-b345-349d704c1cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bc70d43-2bc6-454c-b345-349d704c1cc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_489c59b1-02ce-48ca-848e-34fd4d26e55f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_489c59b1-02ce-48ca-848e-34fd4d26e55f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ff6b2f91-10e2-4e8e-ac6f-dc85cd16ff31" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_EisaiMember_ff6b2f91-10e2-4e8e-ac6f-dc85cd16ff31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_7ffd5ebd-d0d6-40ed-af66-e87e9fda1601" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_DenaliTherapeuticsIncMember_7ffd5ebd-d0d6-40ed-af66-e87e9fda1601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_1c6486d9-875f-4e79-bec8-b29cfb746ff0" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_61cd3fb9-8359-4493-b5d3-4cfed2d5c28e" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_61cd3fb9-8359-4493-b5d3-4cfed2d5c28e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_7941d9e7-213f-4159-8944-2266f4a33f35" xlink:href="biib-20220930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_SageTherapeuticsIncMember_7941d9e7-213f-4159-8944-2266f4a33f35" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_d79c90c1-e18b-4c98-83d7-6d50f513a04c" xlink:href="biib-20220930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_UCBPharmaS.A.Member_d79c90c1-e18b-4c98-83d7-6d50f513a04c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_67d72722-b514-46c4-9405-d555125e96d2" xlink:href="biib-20220930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_67d72722-b514-46c4-9405-d555125e96d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_fe989a1f-3a90-41b5-b46b-e31fece44a44" xlink:href="biib-20220930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_OtherresearchanddiscoveryMember_fe989a1f-3a90-41b5-b46b-e31fece44a44" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_c9aa788b-e75f-497c-b433-bbda2f6f6929" xlink:href="biib-20220930.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_c9aa788b-e75f-497c-b433-bbda2f6f6929" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_38126372-5953-4fd0-814e-c12ea9d12796_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:to="loc_srt_ProductsAndServicesDomain_38126372-5953-4fd0-814e-c12ea9d12796_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:to="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_b9b0c8f2-bb0d-497b-b514-ff2eb49eab8a" xlink:href="biib-20220930.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:to="loc_biib_E2609andBAN2401Member_b9b0c8f2-bb0d-497b-b514-ff2eb49eab8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_a7c60f41-6347-4938-8549-d6100d5bc5f5" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:to="loc_biib_ADUHELMMember_a7c60f41-6347-4938-8549-d6100d5bc5f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_395785eb-6b53-47db-a7b6-a38097c40fd1_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_395785eb-6b53-47db-a7b6-a38097c40fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_2bc8727d-b5d9-48d3-bb55-bdbdc3fd5e68" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:to="loc_biib_DenaliTherapeuticsIncMember_2bc8727d-b5d9-48d3-bb55-bdbdc3fd5e68" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_10ee207c-8ad4-41d4-98e2-903ef2c06d37" xlink:href="biib-20220930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_10ee207c-8ad4-41d4-98e2-903ef2c06d37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_8abea48b-975c-41ff-892b-852d5ac0cec8" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_8abea48b-975c-41ff-892b-852d5ac0cec8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_b8860260-df70-47f8-a12c-18dc3c2c6807_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:to="loc_srt_RangeMember_b8860260-df70-47f8-a12c-18dc3c2c6807_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34857a41-881a-4e66-9356-7b56b95c98b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:to="loc_srt_RangeMember_34857a41-881a-4e66-9356-7b56b95c98b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e00d7be-9b79-4f6d-b9b5-1af810497ca6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_34857a41-881a-4e66-9356-7b56b95c98b5" xlink:to="loc_srt_MaximumMember_5e00d7be-9b79-4f6d-b9b5-1af810497ca6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_083bf2cd-268c-4939-bbf4-bcf1234873cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_083bf2cd-268c-4939-bbf4-bcf1234873cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e8f03cd3-fc17-4f03-bebe-30d41217fdb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_083bf2cd-268c-4939-bbf4-bcf1234873cc" xlink:to="loc_srt_ScenarioForecastMember_e8f03cd3-fc17-4f03-bebe-30d41217fdb2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended" id="ied3b615ecc954d54b4d9cfce75b262e5_CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5a64a680-84d8-4df8-90cc-fc1d142836e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5a64a680-84d8-4df8-90cc-fc1d142836e1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_d8cda045-9a70-41cf-b719-952d80748dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_d8cda045-9a70-41cf-b719-952d80748dd5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_a594fc89-5e3f-4235-b249-140735b7485d" xlink:href="biib-20220930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_a594fc89-5e3f-4235-b249-140735b7485d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_67203b40-59ac-4bd6-92d8-22cbaefa766c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_67203b40-59ac-4bd6-92d8-22cbaefa766c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d9bac2e3-2b5e-4543-9715-a743526c0101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d9bac2e3-2b5e-4543-9715-a743526c0101" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_235e80c4-2ec5-4453-a0e6-0974adbaf6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_235e80c4-2ec5-4453-a0e6-0974adbaf6ab" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f2c9a5cf-3527-4a47-aa2f-7d63bdc1395f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_EquityMethodInvestments_f2c9a5cf-3527-4a47-aa2f-7d63bdc1395f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_e4d84cbf-6c35-41b6-a91b-fa135d32d222" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_e4d84cbf-6c35-41b6-a91b-fa135d32d222" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_18e09d42-9d02-41a9-90da-1cfedcc76b1c" xlink:href="biib-20220930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_18e09d42-9d02-41a9-90da-1cfedcc76b1c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_4c1fb4c2-22b0-418b-8150-c8b79bec7dad" xlink:href="biib-20220930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_Collaborationprofitlosssharing_4c1fb4c2-22b0-418b-8150-c8b79bec7dad" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_85ebaa11-8386-44a9-b162-adf81841cc05" xlink:href="biib-20220930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_85ebaa11-8386-44a9-b162-adf81841cc05" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6fa2db02-43ce-4dd6-b17f-bf0581ae9eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6fa2db02-43ce-4dd6-b17f-bf0581ae9eac" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1848e63e-152f-4aa5-a56d-8e59df6656d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1848e63e-152f-4aa5-a56d-8e59df6656d4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_ffe03cfb-6033-4349-9b53-fb9f520fa9be" xlink:href="biib-20220930.xsd#biib_AccruedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_AccruedMilestonePayments_ffe03cfb-6033-4349-9b53-fb9f520fa9be" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_05b2de91-062a-42f8-bd47-391f2092408a" xlink:href="biib-20220930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_05b2de91-062a-42f8-bd47-391f2092408a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_d506db44-b3cc-4eda-b09d-6466a597ea67" xlink:href="biib-20220930.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_ContractOptionExerciseFee_d506db44-b3cc-4eda-b09d-6466a597ea67" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2e5f1ddf-407c-4649-9a41-eee3e5c5d6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2e5f1ddf-407c-4649-9a41-eee3e5c5d6e3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7336803e-0b4c-45c1-8323-789b30c5b769_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_7336803e-0b4c-45c1-8323-789b30c5b769_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_d1fe5039-9795-4e42-8a07-fdeecda8a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:to="loc_us-gaap_InventoriesMember_d1fe5039-9795-4e42-8a07-fdeecda8a1db" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0f6be07a-9e95-4326-9282-e12feedb6160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0f6be07a-9e95-4326-9282-e12feedb6160" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b237770-eaf0-4d99-a76d-89cd1cc226c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5b237770-eaf0-4d99-a76d-89cd1cc226c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6ae5a7f0-55d1-450a-9bef-d7394ab4753c" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:to="loc_biib_EisaiMember_6ae5a7f0-55d1-450a-9bef-d7394ab4753c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5c625bc4-3dc6-4d73-afa2-880383224c4e" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5c625bc4-3dc6-4d73-afa2-880383224c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_15420d1e-b90b-4009-a27a-af4cc23eabcd_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_15420d1e-b90b-4009-a27a-af4cc23eabcd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1e58632c-443e-4bcb-9edb-e3a13c2a2906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1e58632c-443e-4bcb-9edb-e3a13c2a2906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_215b44df-df1b-4b20-8c41-980cbe6e8d56" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1e58632c-443e-4bcb-9edb-e3a13c2a2906" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_215b44df-df1b-4b20-8c41-980cbe6e8d56" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_780ec5ec-e4df-4d3a-a02e-689806cd959d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:to="loc_srt_ProductsAndServicesDomain_780ec5ec-e4df-4d3a-a02e-689806cd959d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0cbc52a4-565f-4e73-ba9f-59dc062e5a1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:to="loc_srt_ProductsAndServicesDomain_0cbc52a4-565f-4e73-ba9f-59dc062e5a1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_5c845079-bdd3-473a-a2e9-116b9aa7073f" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_0cbc52a4-565f-4e73-ba9f-59dc062e5a1a" xlink:to="loc_biib_ADUHELMMember_5c845079-bdd3-473a-a2e9-116b9aa7073f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_f34b211f-433a-41a3-bafb-3f07c2548595_default" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_f34b211f-433a-41a3-bafb-3f07c2548595_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_7af8026f-1552-4c2c-b85a-9f3be6365118" xlink:href="biib-20220930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_7af8026f-1552-4c2c-b85a-9f3be6365118" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_179f0b8b-4ffe-47a7-9ade-a591b7168d03" xlink:href="biib-20220930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_179f0b8b-4ffe-47a7-9ade-a591b7168d03" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended" id="if99bcd02870148c797853e85e86d7f07_InvestmentsinVariableInterestEntitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_5f788035-bfb0-40a7-95d0-fc94670d2787" xlink:href="biib-20220930.xsd#biib_CollaborationAgreementTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_CollaborationAgreementTerm_5f788035-bfb0-40a7-95d0-fc94670d2787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_c687f1c3-25ca-4660-bc28-09d8e13d6855" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_c687f1c3-25ca-4660-bc28-09d8e13d6855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a5087012-dc31-4ad7-bbde-69280a05aef0" xlink:href="biib-20220930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a5087012-dc31-4ad7-bbde-69280a05aef0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_635df262-09be-4986-8ec1-de683426feed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_635df262-09be-4986-8ec1-de683426feed" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6d48646d-556c-482d-ad9d-4d954a27bde0" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6d48646d-556c-482d-ad9d-4d954a27bde0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_dcc38312-7490-4892-b3f3-bef440058be0" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_AdditionalMilestonePayment_dcc38312-7490-4892-b3f3-bef440058be0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1f5665d0-2e36-4864-8552-f55ea4d74be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1f5665d0-2e36-4864-8552-f55ea4d74be4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bdef7489-e4a5-4154-9cfd-561e4fcb89bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bdef7489-e4a5-4154-9cfd-561e4fcb89bf" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1d01cb66-ea22-4004-88f9-f2fdf79aad2f" xlink:href="biib-20220930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1d01cb66-ea22-4004-88f9-f2fdf79aad2f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce982606-e516-4dcd-a33d-eaa33f8acc02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce982606-e516-4dcd-a33d-eaa33f8acc02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2130e2b-5bee-4784-bc8f-3eadcf386ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2130e2b-5bee-4784-bc8f-3eadcf386ea3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_07fca8be-966d-42a3-b9d2-d35c7809ff1e" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2130e2b-5bee-4784-bc8f-3eadcf386ea3" xlink:to="loc_biib_EisaiMember_07fca8be-966d-42a3-b9d2-d35c7809ff1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702_default" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_195fcfc1-07c0-4493-872f-1e258bff64e4" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_195fcfc1-07c0-4493-872f-1e258bff64e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_5ae567b8-2855-401e-976b-2b29eee3ceb4" xlink:href="biib-20220930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_195fcfc1-07c0-4493-872f-1e258bff64e4" xlink:to="loc_biib_RegulatoryMilestonesMember_5ae567b8-2855-401e-976b-2b29eee3ceb4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_ab88248b-5422-4b27-8771-8b303d3fc3df_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:to="loc_srt_ConsolidatedEntitiesDomain_ab88248b-5422-4b27-8771-8b303d3fc3df_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d1b525bd-1bc2-4e7e-9699-ee779e04bfb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d1b525bd-1bc2-4e7e-9699-ee779e04bfb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_f90dde90-e222-4616-8156-c63ae498063f" xlink:href="biib-20220930.xsd#biib_NeurimmuneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1b525bd-1bc2-4e7e-9699-ee779e04bfb8" xlink:to="loc_biib_NeurimmuneMember_f90dde90-e222-4616-8156-c63ae498063f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5c9d243d-6295-4562-88fb-d4582b3a64fb_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:to="loc_srt_ProductsAndServicesDomain_5c9d243d-6295-4562-88fb-d4582b3a64fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b763e0d-8540-450c-84f8-f1b707b08b86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:to="loc_srt_ProductsAndServicesDomain_2b763e0d-8540-450c-84f8-f1b707b08b86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_e5014085-cc17-4012-9a38-3b4104d64040" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2b763e0d-8540-450c-84f8-f1b707b08b86" xlink:to="loc_biib_ADUHELMMember_e5014085-cc17-4012-9a38-3b4104d64040" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#DispositionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended" id="ib26d0919f6f24ce79838fa2e6afc64e2_DispositionsDetailsTextual">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_52c43013-da7e-4846-876b-2a18859d939a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_52c43013-da7e-4846-876b-2a18859d939a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_91489ee5-2b93-42b4-8413-ead74704ecb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_91489ee5-2b93-42b4-8413-ead74704ecb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_7ace7654-502a-4dcf-bf9f-87ddc6376fbd" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_7ace7654-502a-4dcf-bf9f-87ddc6376fbd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_3ab54d44-6b5b-4fd8-bae3-83ff0fc52aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_3ab54d44-6b5b-4fd8-bae3-83ff0fc52aee" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_4b2b44b8-546e-452c-a59c-0d72ca1571fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_4b2b44b8-546e-452c-a59c-0d72ca1571fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsMeasurementInput_d077a803-146f-47f1-a388-50aaccf33dbc" xlink:href="biib-20220930.xsd#biib_OtherAssetsMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_OtherAssetsMeasurementInput_d077a803-146f-47f1-a388-50aaccf33dbc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_37ef42c1-1639-4308-a5c7-04f87ac14d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_37ef42c1-1639-4308-a5c7-04f87ac14d5b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_5b65c750-7a2c-40df-82c4-442e98863373" xlink:href="biib-20220930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_5b65c750-7a2c-40df-82c4-442e98863373" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_96d753cb-2a72-4952-9daa-91e1b62a9398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_96d753cb-2a72-4952-9daa-91e1b62a9398" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_879325b9-9959-442d-9cb1-e254943a74b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_879325b9-9959-442d-9cb1-e254943a74b5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_5f41ecd2-d09a-4d76-bab9-b80e25c7b1ed" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_AdditionalMilestonePayment_5f41ecd2-d09a-4d76-bab9-b80e25c7b1ed" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_622cca9a-4240-475d-bd52-b524624aeaeb" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_622cca9a-4240-475d-bd52-b524624aeaeb" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DiscreteIncomeTaxExpenseBenefit_0bd64cb8-e75d-47bb-83ae-80841ab3d3b3" xlink:href="biib-20220930.xsd#biib_DiscreteIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_DiscreteIncomeTaxExpenseBenefit_0bd64cb8-e75d-47bb-83ae-80841ab3d3b3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f3a2a6a-d636-4586-9e28-e70275c16ec8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3f3a2a6a-d636-4586-9e28-e70275c16ec8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28c97f55-365d-4a88-af6e-e59738788da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28c97f55-365d-4a88-af6e-e59738788da1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f337932d-3f67-40f6-8dcf-7a1e2dc8e58c" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28c97f55-365d-4a88-af6e-e59738788da1" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f337932d-3f67-40f6-8dcf-7a1e2dc8e58c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_749745ca-88a1-40f8-98f9-37a478c2ff6d_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_749745ca-88a1-40f8-98f9-37a478c2ff6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c1340629-3140-45d7-a642-63a5fe4b7298" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c1340629-3140-45d7-a642-63a5fe4b7298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_bd9726c0-8e91-422a-99b6-7454c537eba6" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c1340629-3140-45d7-a642-63a5fe4b7298" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_bd9726c0-8e91-422a-99b6-7454c537eba6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e_default" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_c8329f5c-e1aa-4c2f-ac7c-1a6486862f39" xlink:href="biib-20220930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_c8329f5c-e1aa-4c2f-ac7c-1a6486862f39" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_5471f240-06c4-47c3-ae5c-0042df2e3434" xlink:href="biib-20220930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_5471f240-06c4-47c3-ae5c-0042df2e3434" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_6f0319f3-0e55-457a-90cb-f58c3df621e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_6f0319f3-0e55-457a-90cb-f58c3df621e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_de4e92e9-0b38-4d26-b805-c0e1b6164b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_de4e92e9-0b38-4d26-b805-c0e1b6164b47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_85301794-96cf-44da-820d-681b3cc04729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de4e92e9-0b38-4d26-b805-c0e1b6164b47" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_85301794-96cf-44da-820d-681b3cc04729" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e460f1db-650c-4ec5-9e77-4f3a34e67e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e460f1db-650c-4ec5-9e77-4f3a34e67e75" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9d8ac809-cbac-4a18-b872-4a3db959b28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e460f1db-650c-4ec5-9e77-4f3a34e67e75" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9d8ac809-cbac-4a18-b872-4a3db959b28d" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20220930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6f409836-83df-4817-b8b9-7a5ff0648b96,g:f22c5c21-a910-4760-9b39-9695772d8988-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_biib_Expenseincurredbythecollaboration_e86462ab-242f-48e0-b207-16c59d0792a9_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20220930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_0d77d042-20d2-4e30-9564-6379f0be1593_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_3520f4e8-0499-4512-a5fc-14a9ea71fe46_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_b5e30857-ace4-4ad8-ad82-800668ca17ce_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_79078607-0e3a-446d-94e0-b7c33853f6f4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_73ed1f72-718a-4291-90ff-b74b2f261fc1_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20220930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_8e35e20e-f06a-4cc6-956b-f99fc41afaef_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_9d47493d-faf3-47c5-8484-31fd05d516ab_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_c25893c8-a849-41ea-a966-ddbce75f1bfa_terseLabel_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_label_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:label id="lab_biib_TechnologicalAndRegulatorySuccessProbability_documentation_en-US" xlink:label="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technological and Regulatory Success, Probability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:href="biib-20220930.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TechnologicalAndRegulatorySuccessProbability" xlink:to="lab_biib_TechnologicalAndRegulatorySuccessProbability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_0e6bf259-4686-4296-85a9-b008085ce265_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_09fea760-1d0a-4996-bef8-fc19cf3ce7d5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_74f6a209-563a-4cb6-a506-df2266ea4874_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_71d644f1-eab2-4a84-b753-e0323f658c52_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_96bb5560-9430-410d-8be9-f4fd36233d72_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_02f53314-09ea-461d-a4b7-df4e7a9c5c14_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_93d14440-9fc1-4c19-a134-28b439fa2e98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis(1)</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_5d95797b-d893-43b0-b1a7-f1a9292b0903_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8458f3ad-5c6f-40bb-83ce-9d4b1e345a80_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_f84c9b3f-8212-4b30-960d-295ac7c46cf2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZINBRYTAMember_fadb588c-7373-469b-b322-88936d3f53ea_terseLabel_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_label_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:label id="lab_biib_ZINBRYTAMember_documentation_en-US" xlink:label="lab_biib_ZINBRYTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZINBRYTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember" xlink:href="biib-20220930.xsd#biib_ZINBRYTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZINBRYTAMember" xlink:to="lab_biib_ZINBRYTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_8e3f84e4-1706-4390-9936-bf92672244fe_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_e6f59188-cb8e-4189-981e-e9b8ba51a4c0_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_0f2290e2-6f32-4a41-a495-52797277ed5c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_23af52e5-9a3d-4d3c-a25f-912549f0451f_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20220930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2039d199-7d10-4ff2-b032-8075e80d1e31_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_f7864b27-de58-4644-8146-2ea3d6485f20_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_b4182e37-dafd-4f47-877f-2d8fbd8e78e1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_0957f463-058b-4144-9efc-f07cc5a4b407_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of building</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_414f86b7-e8da-4477-9b40-af7c3677389a_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales price</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_792514fa-1789-4922-a2f8-170ed798e214_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_ee092b23-960c-4711-9f26-b4c97c0b48bc_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_5836910e-a0eb-4e36-aa13-603466b1e748_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_8093e1ce-47fe-4308-a3cb-090ecdfca3bb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a485ac79-6741-4e58-9201-b9c172ed3fe6_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_14b0a1e6-cd12-4f1c-838a-23a34d126fb0_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_0ff3c9e6-11d7-4841-91b1-72073c91ebab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_2a9d73fa-03ab-4bbd-b6e9-13869f877a32_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20220930.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_afa000ed-f453-457b-8bdb-67d071ef032a_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_c024ac4d-1361-4bb8-a0a2-c2238645bf6a_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_fd3d013f-ead0-4565-b6d7-ce68e2f3900d_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20220930.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_aabe7dba-f7f3-4c4a-99ab-00a2ab500595_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_fd8ed038-5dd2-47a1-a604-fed97c53fef5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_1a21b94c-562d-4166-8687-4122ee9345bc_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on fair value remeasurement of contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_fe68aeac-1783-41c3-8c10-6c754f196e90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_f9f4b009-4de9-446a-8af2-6f1bdafec966_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration impairment</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_a9f1e8c1-a3c2-4d70-b719-d5811bac34e6_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_f3ee37a9-ead8-4b53-8057-875daaa90215_terseLabel_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_label_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service [Member]</link:label>
    <link:label id="lab_biib_CentersForMedicareAndMedicaidServiceMember_documentation_en-US" xlink:label="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Centers for Medicare and Medicaid Service</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:href="biib-20220930.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CentersForMedicareAndMedicaidServiceMember" xlink:to="lab_biib_CentersForMedicareAndMedicaidServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_039c99ea-f3ae-40e6-b9c1-8dc3c2a4978f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_6df3d048-dd97-4007-b9dc-38ee9b1d1c0b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_39c9e16e-0e43-4a75-b6f1-fd16a19760da_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20220930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e40fd6d5-d893-4bd5-841a-939075885111_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_63e7c38d-bd95-4f5c-a898-056391cc18dc_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_e3d3326b-db15-4558-8257-f95fc5229f02_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_602b169a-f244-4686-9ac4-47a455d8f07e_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_1b62694f-82b0-4137-bf2b-14680ead5f5c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement agreement</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_633086ca-a4ae-4338-b733-bc214deffca0_verboseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation agreement in principle</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3deb9974-699c-4efb-9285-00b8c954e77d_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_c816727d-afaf-466c-9356-378e1d942c37_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_8202ce14-8bbe-4911-ab1e-b4a802bf2f9a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7b0558d0-eaca-4e29-b18c-eaeec4b0fd60_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount remaining under 2019 Share Repurchase Program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_66b10dfd-b23b-4719-9420-69ccf17573b5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_26c5ad92-42e1-4f0a-bbab-9bde89c90c1c_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f76863ab-9bd5-478c-bc67-c8cb1575d267_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_c94f31fb-0fb9-44a1-9741-2aac32b41c53_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_148266cc-c4cc-4b63-bc66-094c17e9f91d_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_d12e13ea-4b17-4f7c-858e-4bf719b67452_terseLabel_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_label_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement [Member]</link:label>
    <link:label id="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember_documentation_en-US" xlink:label="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">InnoCare Pharma Limited (InnoCare) Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:href="biib-20220930.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:to="lab_biib_InnoCarePharmaLimitedInnoCareAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_3a20011f-11d3-4439-a954-0b0c7b0589a0_verboseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_873d7f02-73e5-482f-8341-fe7dff554521_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_61c01c17-c04d-4245-9e43-1946ebcccc92_terseLabel_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_label_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB111AndBIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB111AndBIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 and BIIB112</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member" xlink:href="biib-20220930.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111AndBIIB112Member" xlink:to="lab_biib_BIIB111AndBIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_9a9782c5-6498-49fd-b7bf-64be144b6e0f_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International reorganization</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, International Reorganization</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, International Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:to="lab_biib_EffectiveTaxRateReconciliationInternationalReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5ec73655-c0cb-480c-b146-84b551a66066_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_03daa913-7bff-4f2c-939a-84ac9cbd690e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a96e796b-6198-4654-935d-0c7a179619e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7f7c1a89-bc8e-4dd2-8975-7e6b159c68d4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_519db7c0-7bc2-4313-a96b-a442a34de57f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_a49a8d24-bb5b-457f-9bf6-a6bad42b8433_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20220930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_749828f6-033d-468b-9a93-29d8c58516ac_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_adc3a385-81cb-43da-b96b-21b0ab34f3ed_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfInvestments" xlink:to="lab_us-gaap_GainLossOnSaleOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_4e745a7a-dbfb-41b3-a520-9d3b203456db_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_8dd9c40f-a1f3-4870-afad-6dcb4e0c7d07_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandMember_fae5130c-de24-4eb1-96db-ba72b2406850_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_LandMember_label_en-US" xlink:label="lab_us-gaap_LandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember" xlink:to="lab_us-gaap_LandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_e9a5367e-926d-4579-9d34-ea1be8cdc9dc_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OutLicensedPatentsMember_6cc0ef06-4455-4d3b-8c6f-59987358bd5e_terseLabel_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Completed technology</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_label_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out Licensed Patents [Member]</link:label>
    <link:label id="lab_biib_OutLicensedPatentsMember_documentation_en-US" xlink:label="lab_biib_OutLicensedPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Out-licensed patents.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember" xlink:href="biib-20220930.xsd#biib_OutLicensedPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OutLicensedPatentsMember" xlink:to="lab_biib_OutLicensedPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_232c8d86-c0ac-413d-833e-221b50d35ca4_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20220930.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e1ee3857-352f-4668-8f3b-7ffc8db3a069_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20220930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_e4a6b23d-a02b-4e73-bfb5-5297ba983c60_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:href="biib-20220930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:to="lab_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_bec8a641-5818-44e8-898b-36d6816582fa_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of contractual maturities: available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_078f3d96-a8c4-498d-b0c7-b2574d2a7bd7_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6b160d7c-995d-4a46-8f3b-af22a1ccdbc2_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_42addc8f-a752-46c4-acc3-c43197e7f788_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_6e89b49e-3635-46b8-9a9c-8002b0e6bdba_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_2c53f0b1-2f53-4ee6-9e9e-bd1d30790691_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_9a6f2020-64be-4dac-b532-4b2bbdbe010f_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_3b79ac4c-b0b8-4a4a-b264-b1b750bc4e32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_f6bb03ce-9be8-447a-8fd6-c4e4af4486a2_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_ee298fa8-42e7-41d5-afbe-c8e838b6016d_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20220930.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_ddeef363-02f7-423a-a86e-352147fd11bd_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_20b297da-1299-4960-b57c-0c8b3402562e_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Senior Notes due 2022</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_label_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:href="biib-20220930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:to="lab_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_4842b13b-df5c-4caf-963c-963fbb593b2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_d73389ea-b88f-45fd-950a-b559d7f54d92_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_2fdf5d84-623b-4bfb-a2bd-ed014d7bed56_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments, fair value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFairValue_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFairValue" xlink:to="lab_us-gaap_DebtInstrumentFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_3c9937f8-9641-40fb-ac19-795f3146135b_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:href="biib-20220930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_a213f352-ec73-498e-b677-dac56e2dc4e9_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77949f02-ab98-4e8b-ba00-cec0aa8fd163_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_ac658924-fa8f-496c-96f5-bb5d4e3058cf_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune tax impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:to="lab_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_ce4312cc-6584-43b7-b063-40f77facef11_terseLabel_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_label_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_documentation_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:href="biib-20220930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:to="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_f7d62d4e-d0a5-4d87-84ce-7243fa70a563_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in total costs and expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20220930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_449c05e5-b515-4ec8-981b-845161623e1e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_9a8672b3-ad6e-4fe8-838b-b14e9dbff906_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Samsung Bioepis</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:to="lab_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_ccfa3cab-78e4-4425-b3df-78a68f399ad7_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, All Other Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:to="lab_us-gaap_InvestmentsAllOtherInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_7cb5c0bf-65a3-4a1c-a953-05089dd2e78f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_1ca46076-5094-4c7c-b982-84a05d43618a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_be46aca7-f83a-406e-aaa7-9e52335dcb17_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20220930.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8a55c219-29ca-47de-8f6a-aa305f915d8a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_15d043cb-d256-419a-bafc-6fbe080dcd5b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_8a023273-13af-44d5-9e74-37f90ff69d70_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_127400f9-7925-4e5b-86ab-af87cd3d8ef5_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_c8668213-7289-40db-a785-a217f2e9402f_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20220930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_7ef99294-72ad-46c5-8bb0-9ea72dee852b_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due to Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_4aa810d5-c849-4a26-a515-3baacb9e582e_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income (Expense), Net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNetAbstract_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract" xlink:to="lab_us-gaap_InterestIncomeExpenseNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_3ad80d50-85d9-48da-9a39-f21ee5bd30c6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f1644269-7003-4d17-bf25-44e76892efd3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_9f216463-c5a0-49a2-bcdc-e6d143ed84bd_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_da0c16d5-2ea0-4db8-bc82-9008f21e0fbb_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f113cd67-4fff-4351-bafa-7eb74d761e0f_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Net (gains) losses realized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_3f7b0fa9-07a4-4cbc-9665-204c1aa3a3e0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains (losses) realized during the period on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b2637cb5-80dc-4cfa-b8e9-73d77fd259ca_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_e39a0dff-69d9-4ece-a41a-ecc7b0313718_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_d325d5e2-f0a2-49db-b78b-df7866122290_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_d89676a9-0dd7-48a8-9f4a-9e9b6e2e8a24_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20220930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5f03a927-6061-4e21-9efa-7c86a7a9dbb9_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DiscreteIncomeTaxExpenseBenefit_85f7d7e5-62b9-436e-acd9-2bf8ec494e34_terseLabel_en-US" xlink:label="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete income tax expense (benefit)</link:label>
    <link:label id="lab_biib_DiscreteIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_biib_DiscreteIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DiscreteIncomeTaxExpenseBenefit" xlink:href="biib-20220930.xsd#biib_DiscreteIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DiscreteIncomeTaxExpenseBenefit" xlink:to="lab_biib_DiscreteIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_c8c44239-5ccf-4e45-a429-151a4d336e9f_terseLabel_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_label_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:label id="lab_biib_OtherresearchanddiscoveryMember_documentation_en-US" xlink:label="lab_biib_OtherresearchanddiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other research and discovery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember" xlink:href="biib-20220930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherresearchanddiscoveryMember" xlink:to="lab_biib_OtherresearchanddiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_6bc90206-ea48-4c2b-a9db-78a2afa0821e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_0487c788-d9ec-4d7a-abf3-c9f859a54fda_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_281b4b4f-3c4a-4b0b-9511-f1f11cf3231b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DueFromRelatedParties_3f9927bf-1b77-498d-b14d-20f4d7bddde8_terseLabel_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:label id="lab_us-gaap_DueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_DueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueFromRelatedParties" xlink:to="lab_us-gaap_DueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_b1d45125-99fd-42fd-b5af-b5e665ee2f88_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20220930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_d2c6064a-4ab7-421e-9f43-67c71507b97c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_1e05ef45-b6d6-417d-ae5a-e6ccd1ac57df_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationGILTItax_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, GILTI tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationGILTItax" xlink:to="lab_biib_EffectiveTaxRateReconciliationGILTItax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_10aa804a-05c1-4ec9-a883-0be26df3b46d_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20220930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_824c961d-be1d-47a6-ac68-26bd039d77f2_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_be49e57c-13f3-491a-8929-3d04182368df_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20220930.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_b23c5985-f18b-459f-a9e7-7c6b938c0de6_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_3baf9511-fb6f-4d1d-ac67-dd003f2e7a0c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_5dfec618-51d7-4b31-9214-6325924cab47_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Fair Value, Gross Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_91688b4b-f3e3-481e-b8b9-5ed727c36d0c_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseLiabilityDerecognized_396c0423-c3f1-47fb-94cd-0a403ae4f306_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseLiabilityDerecognized_label_en-US" xlink:label="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseLiabilityDerecognized_documentation_en-US" xlink:label="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseLiabilityDerecognized" xlink:href="biib-20220930.xsd#biib_OperatingLeaseLiabilityDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseLiabilityDerecognized" xlink:to="lab_biib_OperatingLeaseLiabilityDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_34384513-5c81-4016-9848-8a1f69357dde_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20220930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BYOOVIZMember_96b1b546-24e8-4638-84eb-90b63dc8af9b_terseLabel_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ</link:label>
    <link:label id="lab_biib_BYOOVIZMember_label_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ [Member]</link:label>
    <link:label id="lab_biib_BYOOVIZMember_documentation_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BYOOVIZ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember" xlink:href="biib-20220930.xsd#biib_BYOOVIZMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BYOOVIZMember" xlink:to="lab_biib_BYOOVIZMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_6d4bc82a-f57d-4e98-827c-ff1b5c61594e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_afa9a77d-f83e-43cf-85da-1a3c055ed285_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_07e5e7d2-d9c5-4b4c-8ded-2f838a6eecd0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_3d28b9b0-7dca-4249-982b-c4f8b2099afe_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20220930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_8b2d5435-861e-4bf8-bfd4-12ec129aa576_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20220930.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_5198353c-fe40-42aa-bcbc-e2660df2b65b_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_06ab8f4a-2160-449d-bd47-aef5850eeb99_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAccrualAdjustment1_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Accrual Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:to="lab_us-gaap_RestructuringReserveAccrualAdjustment1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7e10abb3-0393-4096-9dd4-10fa69b7d87e_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_54e3070c-4477-4687-8e6f-eeafe990f4e3_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20220930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_c71d6f3d-002f-442a-ba88-887446aee2cb_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_b7cf918b-3c3f-4493-bb6b-41aa37bf3316_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e314bf69-bf93-4543-965f-93e2d71e217c_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_21308bd3-c299-421f-a161-6151f640a712_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_5da0d296-6e37-4f04-b73a-813cd9714a5b_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20220930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_f8112b3d-2593-480b-a2ca-23c076837e2c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_10611e21-d9e5-4d3b-b57e-d1010de254fc_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_708cd951-d71d-464f-bce6-42e89777dd4f_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront and milestone payments made to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20220930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_461dd1cc-99c7-4b6c-94c1-9a3f418a7100_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_7d100dfa-a5f1-4bc5-a4cd-81389f1d187f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_4124d0da-e85d-4846-b20a-40fb9ff6cf88_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_06825079-572f-482d-8e56-f684d6583910_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d5251c37-271e-4356-a10c-b4d04f456b59_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_83b83d63-dc45-445a-b968-3f8bd6b686a0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_ed0e9770-fde4-4e05-9a56-110eeeee1a26_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_bcebf7f4-fa1d-4d99-80e5-593f491e2a05_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_c2f0388a-874b-4220-a984-a1412981edc4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_be4d3b01-f955-4e2b-b1fa-812965073ecb_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent discount on common shares</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_50b86660-8fcd-4d06-b965-497dda746f29_verboseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20220930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_68f7e90c-b453-408b-9efc-6b2402822310_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_f8b5f0d2-966d-42f0-ac98-7b3c2df97e87_terseLabel_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_label_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage [Member]</link:label>
    <link:label id="lab_biib_IonisSangamoDenaliAndSageMember_documentation_en-US" xlink:label="lab_biib_IonisSangamoDenaliAndSageMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ionis, Sangamo, Denali and Sage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember" xlink:href="biib-20220930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisSangamoDenaliAndSageMember" xlink:to="lab_biib_IonisSangamoDenaliAndSageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_7ee479af-2679-4e2c-85b6-2e2cdfb8aaf6_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20220930.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_45679238-7f29-4977-8734-61415c75f536_verboseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_f0dbba7e-2bdb-435a-9576-7a0d25a4dd58_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_c67115ed-f468-440f-8f2f-be45abd41946_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0677ac74-2080-4355-8c29-17d8296a237b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_82c2661c-b11d-475a-aaee-2b30500d1bd1_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_286d00db-4aa8-4f5b-b368-2781fc0a0c46_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable" xlink:to="lab_us-gaap_IncomeTaxContingencyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_35b6181f-196f-41e8-b5e9-239ebb94227a_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_e37d82fd-9d23-4fae-b218-cdf03c8a6b77_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentAssetDomain_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain" xlink:to="lab_biib_ResearchAndDevelopmentAssetDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_702b0d62-61f8-48d4-9025-471a8c6ae54c_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_7a73d0ed-44e8-420e-a088-27a8a59b0209_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_48a3812a-cfb8-4073-b93f-3d1a3a1487e2_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_616ce59a-37fe-4154-960a-821dee56b1ff_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_272ab5dc-0042-4d09-a7c8-d582a812f1a6_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of stake in entity maximum</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_a3f8bacd-711f-46dd-a753-0d22dbd3d5aa_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_b779b997-8360-4ad4-a44a-7ed6453a91c0_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_033f02ff-b749-4241-b84d-e5bb697b8c00_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_87dc1383-0d25-48b6-a39b-31b47da9003b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_7b8c1f58-ceae-473f-87f1-3d106d97b207_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMMember_fd6e8168-3dea-4d89-858f-4c41d76860b3_terseLabel_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM</link:label>
    <link:label id="lab_biib_FUMADERMMember_label_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FUMADERM [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember" xlink:href="biib-20220930.xsd#biib_FUMADERMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMMember" xlink:to="lab_biib_FUMADERMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_0a362100-8c76-481b-bf80-111167e46e2f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_981b746c-7a1e-4eea-ae8a-62c333aa4ff0_terseLabel_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:to="lab_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_bf6de5d0-81d9-448e-9170-9184f19b0eda_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationDomain_b4802fcc-adb6-4d80-a3b6-6ba4b0db5e80_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_label_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Domain]</link:label>
    <link:label id="lab_biib_FacilityLocationDomain_documentation_en-US" xlink:label="lab_biib_FacilityLocationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain" xlink:href="biib-20220930.xsd#biib_FacilityLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationDomain" xlink:to="lab_biib_FacilityLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiologicsManufacturingMember_1042f708-be71-480d-83bf-6ccf8d25f128_terseLabel_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_label_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing [Member]</link:label>
    <link:label id="lab_biib_BiologicsManufacturingMember_documentation_en-US" xlink:label="lab_biib_BiologicsManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biologics Manufacturing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember" xlink:href="biib-20220930.xsd#biib_BiologicsManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiologicsManufacturingMember" xlink:to="lab_biib_BiologicsManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0e489dcf-5f0f-48fd-b854-75061dfa9cc4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_353922b8-4950-45ff-be2e-c5db197237ee_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_eed3d540-32e6-4173-8d1e-d43d207d0038_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_b03ee4e2-2b48-4597-ae4c-e96142a3c4b4_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_315176e6-1e3b-4876-a940-315a7a823f00_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income tax expense and equity in loss of investee, net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_3bdd8797-cc9a-4f9a-8c5b-ef00fbaa1ad8_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_78c4efb6-dec2-458f-b496-3f0a109a4e08_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_eaf140ff-8f94-4fc5-af67-1483ddb3f141_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_8dc951fc-8403-4fc5-9fd6-74ffcd75795d_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_acf969bc-6df6-46e3-acdd-c26aed41fb3b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_584bfb6d-17c7-49e8-bb20-41320432b271_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GainLossOnRestructuringCharges_f2af1cf4-f753-4a81-bb93-5827531097a9_terseLabel_en-US" xlink:label="lab_biib_GainLossOnRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain due to lease termination</link:label>
    <link:label id="lab_biib_GainLossOnRestructuringCharges_label_en-US" xlink:label="lab_biib_GainLossOnRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Restructuring Charges</link:label>
    <link:label id="lab_biib_GainLossOnRestructuringCharges_documentation_en-US" xlink:label="lab_biib_GainLossOnRestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) On Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges" xlink:href="biib-20220930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainLossOnRestructuringCharges" xlink:to="lab_biib_GainLossOnRestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7a540a7a-e043-4175-9948-948fae8bcab6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_cdc50c68-ea34-486e-ac5d-08adbeb4b2e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_57a0cc01-7a2b-4213-bff2-e4703c88054b_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_28d25023-6362-4f8a-8d4e-f5af97f1db31_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_52c867d4-b9d3-451c-b34e-f055284d7abb_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_9ec70854-ac06-42eb-a876-0256a1ab54b0_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20220930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_a935932d-b940-43fd-be88-9ad0fc164da3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_d15c396a-42a5-4cd6-8938-124bace57201_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeDomain_466182ef-2595-406f-88e2-fd23719efc4f_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_label_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Domain]</link:label>
    <link:label id="lab_biib_FacilityTypeDomain_documentation_en-US" xlink:label="lab_biib_FacilityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain" xlink:href="biib-20220930.xsd#biib_FacilityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeDomain" xlink:to="lab_biib_FacilityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35c8e53e-5ae4-45ee-9c06-d1753d18b466_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_d00a1b48-1640-4ed8-a012-4ad0470e6f35_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20220930.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_ce1984d2-c13b-4b67-8e62-3bbdbd46bb23_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_811d21c7-2297-4d66-8cc7-b5e225bdc2ad_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_2b12b39f-a932-4265-853d-117c3df1501f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of basis differences</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_5bb32f30-9430-4bd1-82f8-83bb9c0f24e1_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_454d28c7-f7e6-4645-9184-e0f9b3c4a8f2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_fcf80c28-cc12-4bb0-ba4d-2be0a8014d9c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_f3d9438e-aa56-49a7-a827-7cabdaec6bee_terseLabel_en-US" xlink:label="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant allowance</link:label>
    <link:label id="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_label_en-US" xlink:label="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</link:label>
    <link:label id="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_documentation_en-US" xlink:label="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:href="biib-20220930.xsd#biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:to="lab_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_e364fb32-81c2-4bc5-add2-f5dc4df49741_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_27c2ee7f-160a-479a-b108-87ec520e6eb0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_308c84ff-3690-417d-8f23-5ab91acba656_totalLabel_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventory</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_label_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:label id="lab_biib_Inventorynetcurrentandnoncurrent_documentation_en-US" xlink:label="lab_biib_Inventorynetcurrentandnoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, net current and noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent" xlink:href="biib-20220930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Inventorynetcurrentandnoncurrent" xlink:to="lab_biib_Inventorynetcurrentandnoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_e4f2ae12-73d7-47b5-b787-22f8ede4e9b3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_7455765d-1499-4651-9d9e-39b097f4770b_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_87b909d8-2324-4bd8-93f9-b7f783227329_negatedLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange (gains) losses, net</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_02cbe3d6-1518-4828-b33e-bf9bb339159b_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_2ae8fc6f-9ae5-4f31-be3b-df67c6abd026_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_bd73aa0b-2d0d-4e7d-a209-51d6793e2a55_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20220930.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_10581b74-b102-4775-987f-b38057624c78_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ffd9df19-26c6-481e-a1f9-d7633d705b31_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20220930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_080ba8ed-242f-485f-ab2a-9eb76ca7a5a1_terseLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20220930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f6bcea5c-6190-4959-b774-ba21ea5b6b95_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5e2b5752-f946-43fa-8d71-2f8d8a032000_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_af386f56-d532-4357-9c33-b74e217510fa_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_e7c58ce8-dc5d-4fab-b6a0-fe705c031a9d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_5c4ad3a9-e9ae-4212-b672-f02a2ba52491_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_a0781295-2563-40c2-934a-5623ebffb6b7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3debe481-e779-43ae-8b55-72593f0c7adb_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax beginning balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_d3026fb4-c4da-454f-9cfe-c02c4aa823d5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, January 1, 2018</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_f8ea0998-add5-4ed0-b17b-cac2c8b68f0a_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss), net of tax ending balance</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_24c8bd45-7cec-44c1-8263-8144962187d9_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_72dac566-b4b1-43c3-8938-4882bf839637_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_d68281ed-f62d-4639-bdc1-e37b1c2d7149_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_b38f22f8-0374-4a62-aa05-15ba9c3d5965_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20220930.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_59bae87a-83e6-426c-905f-c19f849cebbc_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables to divestiture of interest in joint venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_6272475d-10f1-4a52-99e3-8f1995583088_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_9d7e9bc6-7326-47b2-9394-3dcc04c61210_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20220930.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_beddd960-2488-47e9-9331-6e1678a20595_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20220930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_1cda1c62-8956-41f1-9468-df660546c3a8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_0f9fa8a8-e6f2-4bf3-acdc-e1e61550761e_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_63c10bf4-4bf7-42bc-9b57-b0fc15f8a0c6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a8dd4808-3a6a-4ff1-b4a1-af7a4c97d08e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_cd5f07d5-5478-47c1-8bf0-ed2e07b9aee2_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_b562ae68-e7ce-48cd-96ae-757133fd9502_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), before reclassifications, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Reclassifications, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_2e5ee748-f127-4922-b2ab-cc384aa68e6a_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_a6a5a0c5-5fe2-4729-a3f2-d35ecfd83cbe_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_3dcbad60-5895-4851-9934-6e08aa0e8b0c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_d555521c-001b-4096-a109-09147e4b207d_terseLabel_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_label_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:label id="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_documentation_en-US" xlink:label="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investment basis difference amortization period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:href="biib-20220930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:to="lab_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_d11ff795-0f35-4f64-bff8-53b67269e962_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_e4d6dc07-e51b-4c8c-a240-5800ef1abb9b_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20220930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdministrativeSpaceMember_4328662b-9592-4768-8b17-029999151832_terseLabel_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_label_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space [Member]</link:label>
    <link:label id="lab_biib_AdministrativeSpaceMember_documentation_en-US" xlink:label="lab_biib_AdministrativeSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Administrative Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember" xlink:href="biib-20220930.xsd#biib_AdministrativeSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdministrativeSpaceMember" xlink:to="lab_biib_AdministrativeSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_4afbd688-9d33-4e0a-865a-0ebec6becb67_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_b8a476ee-4c13-46a4-911f-fe05f74efebd_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_6a1a39b2-7770-4c23-848d-7bdaf21233a0_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_32b7e968-44ee-42ca-8d72-4804117e465e_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityAxis_375c09b5-cd48-441d-8b14-60e0a7f8faa0_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_label_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:label id="lab_biib_DerivativeMaturityAxis_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityAxis" xlink:to="lab_biib_DerivativeMaturityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_573958bb-0c68-4e45-abd9-44feeb6a4bb6_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_f822ec76-690b-4d8b-9ab5-441dc6c71193_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-sale Securities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_28471166-7cf1-4976-9bfa-9ac83155b712_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfSquareFeet_f6e0d3bf-faa2-427e-b2b0-a11c206a69b6_terseLabel_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of square feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_label_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:label id="lab_biib_NumberOfSquareFeet_documentation_en-US" xlink:label="lab_biib_NumberOfSquareFeet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Square Feet</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet" xlink:href="biib-20220930.xsd#biib_NumberOfSquareFeet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfSquareFeet" xlink:to="lab_biib_NumberOfSquareFeet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_99446243-5945-4211-a866-90275fd27aab_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_8374099c-c271-4ddb-8fc8-5621e2274842_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_6e96190d-7c4a-4936-9357-d6ef56909edd_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_bc29ae03-fbca-43df-ad6f-fa53f71b00c0_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0a49aac3-34db-4fb9-a7fc-f961a7795a58_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credits and net operating loss utilization</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_2bb84b5b-5928-461d-92b5-6268945706d7_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20220930.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_e9663ba4-6049-44ec-b086-b485ef442e1f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_d80d73c8-279f-4c88-8766-b3e71f4beec0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_f44fa781-531e-46ad-bf51-687d9d671a3e_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Non-current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:href="biib-20220930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_9742acbf-6290-4a22-ae5a-6681e471956c_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_50fce039-f861-426c-8083-7ef64b664e1b_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_c56cdc4c-d5be-454e-92f8-3b2b5d7898b9_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_4d5c1b21-d336-453a-8d1e-93975c0cb94f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_2573a069-f680-472c-acb8-f985d91498cb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) recognized in net income, excluded component</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_7030007a-6351-4a1f-bbd8-dc3dfb2c1a05_verboseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_8659a243-3b62-4ec9-9477-b022ac8ecd4e_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development costs, percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentCostsPercentage_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Costs, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentCostsPercentage" xlink:to="lab_biib_ResearchAndDevelopmentCostsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShorttermderivativeMember_1c8a6ffc-af1f-4957-9727-5a944e537140_terseLabel_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_label_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:label id="lab_biib_ShorttermderivativeMember_documentation_en-US" xlink:label="lab_biib_ShorttermderivativeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term derivative [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember" xlink:href="biib-20220930.xsd#biib_ShorttermderivativeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShorttermderivativeMember" xlink:to="lab_biib_ShorttermderivativeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_dd08d977-2d0f-492f-9b67-551be97abadd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_68886457-a946-4b37-ac4c-51222318be68_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_843eb81e-3af7-4209-be8a-a8d97221d507_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_9c0e6180-98f0-429b-b332-7f94473b35cf_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d14160b5-aaa0-4bbb-a8b9-45419c46ae72_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_01149cb8-58a0-4f81-8a35-c60b8d3cda3c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsMeasurementInput_b2ec036b-21de-42d2-8046-06ee80e5bf61_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-adjusted discount rates</link:label>
    <link:label id="lab_biib_OtherAssetsMeasurementInput_label_en-US" xlink:label="lab_biib_OtherAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Measurement Input</link:label>
    <link:label id="lab_biib_OtherAssetsMeasurementInput_documentation_en-US" xlink:label="lab_biib_OtherAssetsMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsMeasurementInput" xlink:href="biib-20220930.xsd#biib_OtherAssetsMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsMeasurementInput" xlink:to="lab_biib_OtherAssetsMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_087765d6-8eb0-4c7f-91a9-c7c9502044db_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_a7d1de71-c94c-4e98-b08b-3aa8cb31a01e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_d10e83ac-81b2-4b50-b207-6cad0205e464_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_74361380-4aa8-48e1-8681-e20f6238510e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_06e84119-6018-47d3-a822-c47bad02ef87_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_d4f8f662-0840-480b-8d70-2072def37e4e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_fde91583-93eb-4190-8e50-c92ce675c64e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_6735bd4e-0398-4a4d-8148-299cd9e998c0_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_f60ea7b8-c706-4e65-bb8d-1919f4a980fb_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of borrowings and premiums paid on debt exchange</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfDebt" xlink:to="lab_us-gaap_RepaymentsOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_4997ec55-7f47-4bec-a455-1b7f33aff18f_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20220930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_35ea6082-29e0-4da7-b794-aa405d137ed1_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionAmount_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount" xlink:href="biib-20220930.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionAmount" xlink:to="lab_biib_DebtInstrumentRedemptionAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_e122b0ba-304f-4d59-9928-f4539252a6ac_terseLabel_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent additional milestone payment</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Milestone Payments Made To Collaborative Partner</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20220930.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_ContingentMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_abb9270d-5d9f-4364-b9bb-1a078e5d1c47_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_2d53442b-9dac-4bed-980f-fdbd29a3fd52_verboseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on interest rate swap</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_44fb9725-f57d-4607-b501-c832f50b6772_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_9c44d70d-bb7b-40b2-b692-f4df7abad5ad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e75a65f-5de9-429a-8fc7-8a1ea5ece61a_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_724514db-9c1c-4492-9000-98005024ee22_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_d143a0b8-a475-4768-b0fc-103b322c87df_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e2a660aa-1fa8-422f-b01d-b546a2984739_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_aa93650a-faf6-42c1-b440-2e7e338b7d75_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased and Retired During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_39cdf2a9-1bd0-4734-8d9a-624be59d2708_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_7177a1a5-f190-47bd-af7e-567562bf3e4c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4205da61-8ee1-4fb0-bb44-b5aef4977ad6_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_00e376e9-d366-475c-b0f0-ff4f85954def_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_4fe346fd-940f-4964-8e3c-f0cca6b5d4b5_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20220930.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_cb5179ab-0684-4aa7-bac6-40ed4fa30515_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative translation loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_17492b6a-2595-4234-bc1b-584405930fac_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_565d4f6e-e1ea-4fc6-9b64-b659dfb38206_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a9b69107-e33b-40e7-b79e-7f00a9c3c313_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NeurimmuneMember_876f96a7-8b73-4947-9666-93d27e970df4_terseLabel_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune</link:label>
    <link:label id="lab_biib_NeurimmuneMember_label_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune [Member]</link:label>
    <link:label id="lab_biib_NeurimmuneMember_documentation_en-US" xlink:label="lab_biib_NeurimmuneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neurimmune.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember" xlink:href="biib-20220930.xsd#biib_NeurimmuneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NeurimmuneMember" xlink:to="lab_biib_NeurimmuneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_5f8acc75-6577-4c69-9fca-b567f0a9ff34_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_3c8cbd72-6590-4921-b6ce-481dac434cbf_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_be7b49f4-58f9-4195-a665-740538b67b7f_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_34bdf485-4e49-434f-8c02-3edc48b1fd92_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BAN2401 and Elenbecestat</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20220930.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_5aa5b984-5361-4b2a-ade0-9f5370935764_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_134c9866-09f0-4d49-8adb-71c8521c6838_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_4b86dc1a-f0d4-4f94-affa-de62ce7538b8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_f87491ae-1f69-48f8-8c55-18807e9bdfb3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_cb7126e3-0358-4dc1-b0d9-e9ed860c5449_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20220930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_257242bb-655d-4681-8c1d-d22e5c00b3e7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_2ecf85ba-0236-43b5-811c-e23f503036a2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Biogen Inc. shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_293935e3-8b54-4972-8cd2-27edae1c1585_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_2e95cf3e-5c47-4682-888f-54a7edaf4e2a_verboseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_2ee37ba4-9334-4ee4-8ebf-91df1ef2d7d1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_3f788308-c331-432f-9265-b8538dddc19d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_8e28115d-1ad7-4d99-be7c-425052a4bd8d_terseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_1b840080-77c0-4f39-bdf6-4078ab27924e_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_c6b9d54f-036c-4173-8850-10729007140f_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20220930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_d20da67e-7e83-40ad-bc85-11cfc722d608_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_43cebd01-60ee-489a-8d80-b27e7af0cdbd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_daef0cb2-50cc-4934-93ab-c5aef1a795c0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_b94bf68b-f68e-4ede-9add-92e423f7f84e_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20220930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_bf5f6997-aed9-4957-ad80-cadaf2cec9d9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biogen Idec Inc. shareholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeMaturityDomain_29b6a21c-c718-4432-ba51-18d23d5148db_terseLabel_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_label_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Maturity [Domain]</link:label>
    <link:label id="lab_biib_DerivativeMaturityDomain_documentation_en-US" xlink:label="lab_biib_DerivativeMaturityDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Domain] for Derivative Maturity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeMaturityDomain" xlink:to="lab_biib_DerivativeMaturityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_abc5d34d-ccc9-4ef3-b11c-92028136ad60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_38a732ec-4fb9-4e38-a7d4-27399dfcc969_terseLabel_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital contribution from noncontrolling interest</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_label_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:label id="lab_biib_NoncontrollingInterestCapitalContribution_documentation_en-US" xlink:label="lab_biib_NoncontrollingInterestCapitalContribution" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Capital Contribution</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution" xlink:href="biib-20220930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NoncontrollingInterestCapitalContribution" xlink:to="lab_biib_NoncontrollingInterestCapitalContribution" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_57431591-0e03-464c-9259-a6dc8a162beb_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_f660210e-b0e8-4065-a49b-08ce06db4491_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_89ff9db9-cb0a-445a-b8da-b05319b3a60e_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20220930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LecanemabMember_e1f83770-4cbf-4838-b5c8-9d99aec3ea6f_terseLabel_en-US" xlink:label="lab_biib_LecanemabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lecanemab</link:label>
    <link:label id="lab_biib_LecanemabMember_label_en-US" xlink:label="lab_biib_LecanemabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lecanemab [Member]</link:label>
    <link:label id="lab_biib_LecanemabMember_documentation_en-US" xlink:label="lab_biib_LecanemabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lecanemab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LecanemabMember" xlink:href="biib-20220930.xsd#biib_LecanemabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LecanemabMember" xlink:to="lab_biib_LecanemabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_482cd4aa-7480-4ca8-a2a0-23e3d86ddc01_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_650553ec-2387-4eef-a1a3-75380cf2ddb9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_d6d4ed31-5b8a-4da8-8259-6a97ff8b0959_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_6e982e16-a952-4863-9ef0-3d9559728bb6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_17a904ca-d024-4b1d-b38c-c9e44ef4994d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_861442c3-a3d4-46d6-8b3e-8fca28e99651_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_700c3004-6597-4d08-9651-5c4a5dc575fe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_83d5bc87-31eb-4d47-8a74-7c30fd29ebaa_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_21cb1a8a-1fad-434a-ab87-0476c53ce6c5_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20220930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_61da003a-e26c-462d-bed1-19733d795b8f_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_8f9e07af-45f2-4077-bf01-4322eeb27546_verboseLabel_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from marketable debt securities</link:label>
    <link:label id="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_abef1a38-c499-4bfd-8b92-41d4419f287a_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement agreement</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Agreement</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Litigation Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:to="lab_biib_EffectiveTaxRateReconciliationLitigationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_0a4fc03a-ccbc-4275-84df-2f8d5be8b9b3_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_79a4e641-6e36-48ea-abf5-f331585059c9_negatedTerseLabel_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity in (income) loss of investee, net of tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_label_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:label id="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_documentation_en-US" xlink:label="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:href="biib-20220930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:to="lab_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_1eb0fa7a-99be-4f2e-a084-19d161692703_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_efa458d5-5ccf-4f0c-9f5c-62c153433dc8_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_0ab05860-d282-4ecd-9b0b-07347fbe0ae0_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20220930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_d45ee8fd-0118-46c3-ba0c-8935303c61a2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3c7bc693-cca4-459d-8faf-5a62449818c9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_8714d4c5-d97b-488c-9240-7cf2b267695d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative used in net investment hedge</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_04011fdb-0e5e-4f74-95ca-20e8c56e0fb8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Termofcollaborationagreement_f999a1b2-a2dd-4b5b-b1cf-571c185d7a86_terseLabel_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_label_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:label id="lab_biib_Termofcollaborationagreement_documentation_en-US" xlink:label="lab_biib_Termofcollaborationagreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of collaboration agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement" xlink:href="biib-20220930.xsd#biib_Termofcollaborationagreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Termofcollaborationagreement" xlink:to="lab_biib_Termofcollaborationagreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_594af1b1-bc90-4b98-80e5-bfa0df2253d9_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_406afe56-6fb2-4c96-bfc4-314cd80298d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_2e4d8f11-19f7-4ef7-b1f7-8c107c75033d_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_fdccacd1-cfc6-4284-96ea-15fa8bc9ead5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaS.A.Member_3aca3cc9-b5c4-4469-a50e-510438ebe264_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_label_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaS.A.Member_documentation_en-US" xlink:label="lab_biib_UCBPharmaS.A.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member" xlink:href="biib-20220930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaS.A.Member" xlink:to="lab_biib_UCBPharmaS.A.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_494adb68-023f-40df-85f1-88b04fcf4929_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_046ffa80-bee0-4f58-ab30-c64c51f574c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Asset Class</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_af8f4d95-5f84-4eea-bb3c-62b61480b727_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_1a96a238-acad-40bc-ba38-b213d7bf92d2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_7b4711cc-da01-4d46-a679-c69c418fee61_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid research and development expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_0d1fed75-cad9-4748-b137-768c616aa7b7_terseLabel_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets, receivable</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:label id="lab_biib_OtherAssetsCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current, Fair Value Disclosure,</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:href="biib-20220930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherAssetsCurrentFairValueDisclosure" xlink:to="lab_biib_OtherAssetsCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c54ee80a-6e9e-45a7-b6c6-c762cbed7c7e_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_963ffad5-73c5-4d95-bbe5-090283f215b9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_957fb5b9-6597-4f22-b54a-1db04c280871_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, fair value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_da7fb75d-e73b-46e0-ab73-dd7b8bf455cd_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and Net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_81c29c59-3f9a-4dd5-b0d1-9cbe93f170f7_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_a632d337-70bf-41a2-830f-67af3768f7bf_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3f9439d3-671f-46a8-bec2-952c6882de76_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0d4afacb-baa0-4b29-af0c-1b8dbe74631d_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_e225b292-b3a9-47e0-b54d-3cfc65c593a5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7943dc3d-273f-4049-8732-0bc9d4752be6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_80e8cb12-b847-4ef8-8d21-1ba6c99d0980_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_22bf778f-cb67-4d58-a316-6e17621f4f56_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20220930.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_06fcec07-16d1-4933-bb93-0d9c9c7a01ef_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_98e7067c-68c4-49a1-b004-bbef9204fb76_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_a5be63fe-4966-4da1-955b-1e8dff5319b6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_15a47f0f-5abe-4c4a-be64-f405c52ec420_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_f004ff45-e789-46db-a4db-d181712a9043_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_3729d2fd-1841-498a-8c4c-77b4e4eb7777_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_7c966833-bd4a-4886-adb4-9b92f769fed8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_26668940-cb81-45f1-9a58-5b412b2ebda5_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_82ab3c14-ed66-4883-b749-6fb6e10c0033_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_37985050-88cd-4f52-8783-6fb699083f7d_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_dc8a6200-1b1f-43ac-a6d2-35c69f61d67c_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_8990e86b-26c8-429d-97d5-d75a1f7962ae_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net (distribution) contribution to noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments to) Noncontrolling Interests</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:to="lab_us-gaap_ProceedsFromPaymentsToMinorityShareholders" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_96e28f22-4845-4f2d-abf8-04f781fb88cd_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_3f05eb89-54c7-4907-ab6b-8001dde4995c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c26c9d20-7787-478f-bc23-4d1affcd15b3_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8ee6fe21-5c38-4bd1-a61c-a638774645fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_9e03e565-ec02-4ea1-adc9-c73bcf292b66_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20220930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_fa5f3b63-18a0-4a5a-bd0e-eea6a7528ba8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, receivable</link:label>
    <link:label id="lab_us-gaap_OtherAssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsFairValueDisclosure" xlink:to="lab_us-gaap_OtherAssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_ff48b788-e7a2-4aed-b3fa-1edca73c7c7f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Variable Interest Entities [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:to="lab_us-gaap_ScheduleOfVariableInterestEntitiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_d3e09713-5844-4ed2-9745-b1acf6083254_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c1702019-d03e-4b4b-bc9f-8d643faccc11_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_5016d290-12ce-4367-bd25-808410041897_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_7734baf7-b36b-48d6-a302-d77f40535f74_terseLabel_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_label_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:label id="lab_biib_LongTermDebtExchangedAmount_documentation_en-US" xlink:label="lab_biib_LongTermDebtExchangedAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long Term Debt, Exchanged, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount" xlink:href="biib-20220930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LongTermDebtExchangedAmount" xlink:to="lab_biib_LongTermDebtExchangedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_b04d7962-4539-4518-afed-cbc92be67bc1_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0f964e39-d307-4e0c-83c5-9edddc3603a6_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_6eeadd88-624e-43d9-b3c4-051374e35f39_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_96224a77-2714-442e-b93f-1b1475c2387a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Due from Related Parties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:to="lab_us-gaap_IncreaseDecreaseInDueFromRelatedParties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_d955417f-71b1-41d0-bf95-8ca4ad21ba99_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_b9d9b470-9310-4c4c-be2f-2bf67fa0a3fc_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_8a9d4cda-9f51-44b0-93fb-d301246228df_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_cff93179-9bd8-4973-8cc3-5a419252b89f_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20220930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_9b0fc5a3-026c-411c-a0b3-83e28d9a66df_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20220930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_d98b1006-ccc6-41ae-a602-6271666850ee_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on net investment hedges in AOCI</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_50f3258e-017e-454d-8d2a-69a8c06d9428_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborationAgreementTerm_5f0bdcb8-f945-43c7-a571-8f1bba02917c_terseLabel_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_label_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:label id="lab_biib_CollaborationAgreementTerm_documentation_en-US" xlink:label="lab_biib_CollaborationAgreementTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm" xlink:href="biib-20220930.xsd#biib_CollaborationAgreementTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborationAgreementTerm" xlink:to="lab_biib_CollaborationAgreementTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_73bc8854-6f7e-4e8b-8471-5d03f4d474aa_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation adjustment</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_37008f3b-db27-4d3e-80be-03478592baf6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A125BroadwayBuildingMember_d256601f-ac84-4b47-87dc-357e6f21e65d_terseLabel_en-US" xlink:label="lab_biib_A125BroadwayBuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building</link:label>
    <link:label id="lab_biib_A125BroadwayBuildingMember_label_en-US" xlink:label="lab_biib_A125BroadwayBuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building [Member]</link:label>
    <link:label id="lab_biib_A125BroadwayBuildingMember_documentation_en-US" xlink:label="lab_biib_A125BroadwayBuildingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">125 Broadway Building</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A125BroadwayBuildingMember" xlink:href="biib-20220930.xsd#biib_A125BroadwayBuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A125BroadwayBuildingMember" xlink:to="lab_biib_A125BroadwayBuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_4d5426b1-2996-4edd-bd6d-77c3f13e94b0_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Aducanumab Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:href="biib-20220930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_3664f167-3be6-4251-90e8-f96ad4a1cc3f_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityLineItems_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityLineItems" xlink:to="lab_us-gaap_VariableInterestEntityLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8d9f15e8-03c8-4d4a-ab10-48d01a0c7a49_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_235d5a2d-0d93-49f8-8c60-eeb251904b6d_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20220930.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_ee8ea3a8-629b-4ace-8c38-b6ca9c84c1e1_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.200% Senior Notes due 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20220930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_9674a2e9-efa5-4c62-9165-6d19ae34e15d_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20220930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_b811923f-c375-40a2-8eaf-35ff8aa5f92a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_60186639-01cc-4ead-b21d-95a58d892f73_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_949fae47-2a14-41c8-acb6-fc2c9d5fa2a6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_ea0b1194-0d13-43b7-851e-6a74753a3354_terseLabel_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_label_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:label id="lab_biib_SolothurnSwitzerlandMember_documentation_en-US" xlink:label="lab_biib_SolothurnSwitzerlandMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Solothurn, Switzerland [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember" xlink:href="biib-20220930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SolothurnSwitzerlandMember" xlink:to="lab_biib_SolothurnSwitzerlandMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_7ec6f7a0-97f6-4b2c-8edf-4ac8875ceb26_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Contractual Maturities: Available-for-Sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityTypeAxis_12c24792-77b5-4342-b109-47657f5eb486_terseLabel_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_label_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type [Axis]</link:label>
    <link:label id="lab_biib_FacilityTypeAxis_documentation_en-US" xlink:label="lab_biib_FacilityTypeAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis" xlink:href="biib-20220930.xsd#biib_FacilityTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityTypeAxis" xlink:to="lab_biib_FacilityTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d8ae2c98-41a2-42bd-8eec-5cbffae95d9d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c15c6685-62f6-4dd2-9d00-d162c1c942f1_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ddd7ccfa-f68b-4544-9af4-986bd3e0b752_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_f9b5fdca-bdc8-456a-b7b5-55fcd3a61525_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_JPY_42223873-bbec-44f2-9268-ea1cea7cca30_terseLabel_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:label id="lab_currency_JPY_label_en-US" xlink:label="lab_currency_JPY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan, Yen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_JPY" xlink:to="lab_currency_JPY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_24d938dd-07de-4901-bd36-b21791ea0f4d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_062adbb5-9207-4def-ab29-dd8845408db2_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_c83885ea-e05b-4858-be2b-32286c2ddd13_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement of common stock pursuant to Share Repurchase Progams, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockRetiredCostMethodAmount_label_en-US" xlink:label="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Retired, Cost Method, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:to="lab_us-gaap_TreasuryStockRetiredCostMethodAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_db26b2ec-ce54-4415-8213-949c235880c2_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets, gross</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_80d4a4d3-f56d-421b-a241-2c67878abf28_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ce8f7783-46bf-4eb6-b95c-da55bda5ae6e_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 31, 2021</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WorkforceReductionMember_b4b01db0-3c88-49b2-98d3-7c4c8257bec8_terseLabel_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_label_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction [Member]</link:label>
    <link:label id="lab_biib_WorkforceReductionMember_documentation_en-US" xlink:label="lab_biib_WorkforceReductionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Workforce Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember" xlink:href="biib-20220930.xsd#biib_WorkforceReductionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WorkforceReductionMember" xlink:to="lab_biib_WorkforceReductionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_1dffc9db-a255-48ef-b04f-979d1665b04f_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Expenses and Other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_c7923fbc-fcc7-4c9c-9eb1-60bd04cc7571_verboseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government securities Non-current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non-current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:href="biib-20220930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesNonCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_3f8f06aa-7bd1-44cd-a799-3c99a88e3d9e_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20220930.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_37e62aaa-e185-4bb1-bc6e-04dcd2f194ef_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_95f45ca8-4fd7-43c3-a950-517b4139f759_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b883f9ee-34e9-4c1a-b3e0-f2d8b172d743_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, unrecognized tax benefit</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VixotrigineMember_d653c7a2-5e86-4d6b-9a56-b6af66b31e0c_terseLabel_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:label id="lab_biib_VixotrigineMember_label_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine [Member]</link:label>
    <link:label id="lab_biib_VixotrigineMember_documentation_en-US" xlink:label="lab_biib_VixotrigineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vixotrigine</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember" xlink:href="biib-20220930.xsd#biib_VixotrigineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VixotrigineMember" xlink:to="lab_biib_VixotrigineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_eee6df47-d303-4ba4-aeec-240d66b38916_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_35b6aa18-2ca6-4b18-9829-72cf22897909_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_36900aee-75fd-4399-9af2-536d7f18bdd3_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_ab9a3504-4710-4530-9230-bb3c9e8b41a0_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_0ee8219f-2212-4c39-a9f5-3815646c1ea5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_618f0711-00a0-4300-8834-b878bc0f113f_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20220930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_42b3507a-aa6f-4d6a-b718-78541764c1bc_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_b08dd1c1-f8d9-490c-913e-479969412e4f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_b243ba94-e4fd-474c-be92-2657b650f330_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_c6647c49-dbfa-4514-90e1-dc2b03f1aaf4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_beb6f24c-55dc-46ac-949d-a68f792c3621_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_c4d13ee5-b335-44d9-adb1-fb98faa60546_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_44793086-873f-4bf5-9665-b0a11c26b193_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_ce907214-fd13-423f-ba82-3e0d9a188785_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_32a20532-d810-4991-8f06-db2055e6a53f_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20220930.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_603b86e0-5873-4003-a373-336a401c26d6_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_6c7c37f9-5fb5-4979-946a-479986a2891a_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">VUMERITY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20220930.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_66cff4f0-54f1-47a2-9268-b5c7897da9d2_terseLabel_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative qualifying as net investment hedge, excluded component</link:label>
    <link:label id="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_label_en-US" xlink:label="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:to="lab_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_a2ba6d34-f244-49c5-b031-8befb01c3f1f_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_980b7de1-b3ad-46a1-90ee-2374e05965c2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gains) losses on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_4082b46c-9c57-43ef-92cc-68ed714a5f4a_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_fec24667-4036-4025-ac34-cdcb9e0dd7a6_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_1a1feeaf-0061-4562-8acb-b6874995de9f_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20220930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_9d0acb58-b349-48e1-8937-90e84295a71a_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_5383bd45-5566-4058-bec8-8d91c48bffdf_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_0bac5d43-3ea3-411d-8998-5a41ba3fa196_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_9a69e9d7-c6e8-4de3-8817-25c55025445b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PLEGRIDYMember_b69f0401-074b-4a27-a427-c60977c6fcc4_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_label_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PLEGRIDY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember" xlink:href="biib-20220930.xsd#biib_PLEGRIDYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember" xlink:to="lab_biib_PLEGRIDYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_d57f1579-9ba2-488a-adef-24a33f93543e_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_cdc589f4-003e-4d98-abcd-09eb9f837d6c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_b8b499ff-a8d9-4a68-87a2-5749e52197f9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior notes interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_d1f5d5e4-440c-4da6-911f-485e7a29f58c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OthercorporaterevenuesMember_54482b42-b37b-4177-ad8b-799962e01031_terseLabel_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_label_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:label id="lab_biib_OthercorporaterevenuesMember_documentation_en-US" xlink:label="lab_biib_OthercorporaterevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember" xlink:href="biib-20220930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OthercorporaterevenuesMember" xlink:to="lab_biib_OthercorporaterevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_7d0b2da2-3d4e-4421-9c71-19f0b0d0c155_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_93952dfe-f5e7-4d75-9e0b-25edcb3103e6_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20220930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_43b292ca-3667-42d5-9719-53594e629685_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_1bebeb69-841a-4fca-a5f3-a7308b238ac1_periodStartLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_7da882df-238b-45b5-88f1-f1d95aa6b14f_periodEndLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_9079b131-244f-4a24-ba80-c6da1569621e_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20220930.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_5f6e419d-145d-41bc-bf7b-1cd745cb2275_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_9c1ddc6a-0fb6-46e7-b2de-d273261087fe_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20220930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_3c40e953-e61f-4c7b-8105-c1a3c9d66a7e_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20220930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_e0e82be3-fac6-43f5-a89f-a818cc6881e0_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overnight reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_12e53872-7d15-42c5-8233-3ac84d92be06_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_2a9246c9-3b78-4275-9939-abac80c36435_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_1ed844cf-ec17-4421-b0ea-25a29c2a9313_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_d6ce1de8-ee97-4f86-818b-331ab993fdf7_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_02599917-3113-441a-8fbb-ddb6be4b5618_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_87e3dee6-14f7-4c3d-9bc1-4c0c93b495ce_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_6158828e-bb99-4756-b98c-1f76e97982c3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_60ff5a85-3b97-4865-9570-ae56d0e3a69c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_f204ff91-0473-4533-b59c-1350f9eb5f6d_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0b3b2bdf-e5bf-4a28-8531-47dd90231860_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5b16ad92-bca0-4528-9ff1-47e564ef21ec_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3bc603ce-0719-4428-82bd-8bdb143feb5a_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_f853377b-3f92-40db-b848-18413f89ad2a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_0d5fc328-b8e2-49a6-8b9a-bbac6cc2b062_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20220930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6453e1d7-2089-40f1-b579-2f13a5a70e1e_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_45831c7a-7093-44ba-84e6-1bbfe5989c5a_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_3811f65f-7969-4c3e-add9-815589831ef4_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_02e3b3ee-ddbf-4360-8d7a-ca1791326a70_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember" xlink:to="lab_us-gaap_NetInvestmentHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_9dc7fdcd-edfa-43c9-9b76-16456dfde50c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_279d5317-85db-4bd7-b107-093e5256c049_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_69bf1a44-57fa-4e6f-bb12-edf8d149e932_verboseLabel_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities Non-current</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current [Member]</link:label>
    <link:label id="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage And Other Asset Backed Securities Non Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:href="biib-20220930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:to="lab_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CHF_d1126b3b-22ed-4c93-9737-7b55c274ee95_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_f13125fa-85b1-422e-a27f-d4a97c3cf6bc_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20220930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_cec0325e-9bf4-4e40-a11f-20f2eedb7095_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_4d61eb87-473c-43da-9519-8b2300a75fb7_terseLabel_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_label_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:label id="lab_biib_SangamoTherapeuticsInc.AgreementMember_documentation_en-US" xlink:label="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sangamo Therapeutics, Inc. Agreement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:href="biib-20220930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SangamoTherapeuticsInc.AgreementMember" xlink:to="lab_biib_SangamoTherapeuticsInc.AgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_74e45434-034e-4d1e-8264-d24190ca9050_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_ea0d03d7-db17-4fa3-a861-48112994fcbb_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_66641d17-28fb-467c-a875-9712fe6a879a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_e23749bc-d620-40c8-aed2-924ebeae404d_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_57de29fc-c961-43cb-99a3-97b55ae51aa8_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c13e4293-6007-4d4f-b869-7427115c88e0_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_e0e413d0-bcbb-41fc-b8ee-c89d4a37db30_verboseLabel_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/Loss on fair value of foreign currency forward contracts</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_label_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax</link:label>
    <link:label id="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_documentation_en-US" xlink:label="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:href="biib-20220930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:to="lab_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6230d5b6-ceec-458f-bb01-d7426367adbb_terseLabel_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_label_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:label id="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_documentation_en-US" xlink:label="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of future development costs related to Eisai</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:to="lab_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_f1408c7a-c0dd-426d-825b-00c7fd6b8307_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_ebe7d11f-8228-4722-b315-b2646f3eaf69_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f91af70a-a410-42e1-aee6-8f2ff6e3a994_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_0de39fe9-1a7d-497a-b9ec-82eadf3f5210_terseLabel_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_label_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space [Member]</link:label>
    <link:label id="lab_biib_WarehouseUtilitiesAndSupportSpaceMember_documentation_en-US" xlink:label="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Warehouse, Utilities and Support Space</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:href="biib-20220930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:to="lab_biib_WarehouseUtilitiesAndSupportSpaceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_88539b69-1f68-4cec-be80-d570ec35a32c_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_67910e93-e713-4ce1-aab5-fbcd6019f475_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_fbcf1304-d8e0-4dca-8652-a097db02b4c9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Gain) loss on equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_78924835-61a0-419b-ae93-59c56d8316f6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from equity method investments</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_8ec24e4b-b03e-422d-8c7a-1d9ef58d176d_terseLabel_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_label_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_A3250SeniorNotesDueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.250% Senior Notes, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:href="biib-20220930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3250SeniorNotesDueFebruary152051Member" xlink:to="lab_biib_A3250SeniorNotesDueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_d7d668b6-e223-4e3c-9d39-bd2f923c1f26_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes payable, carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_d1b953ed-622c-452a-b6d0-f04a583fd266_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_b7430724-36d2-4658-a1ee-76ea0c14f80d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_f6eac4fe-1346-4039-a081-43d161dbc230_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_1be0a1b2-dd1c-4aec-a66c-72657a174bc0_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_c44a6fc0-ad09-488a-9ef3-32a89a2f9fe7_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20220930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_125f0ba0-c22b-4066-a59a-69c216f87322_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_a42f2287-df91-4dd1-aebd-e66e6b7817ce_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_399bb125-9b82-4a38-8c46-4a9e33338530_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_5f73fe9d-7684-4484-93c8-c36be4d4293a_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_2e10a0be-9c77-40d7-b29b-9a0416912d29_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense, net of tax</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9d3ed7a0-f2f1-47a1-a711-ee0c4e527154_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_572ba66b-f67f-4b55-a503-847a437bec0c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_0e7d5c61-072d-4ca8-b652-6bbf7e1a0194_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ecd45315-0272-4431-a068-78e1a40dede4_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_2b305303-5cc3-4461-9500-16b48180c41c_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_4c525c25-26f9-412a-a937-66d91f398ab3_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseRightOfUseAssetDerecognized_32a648a9-0b6a-4489-b439-b0c5f6be01a0_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseRightOfUseAssetDerecognized_label_en-US" xlink:label="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Derecognized</link:label>
    <link:label id="lab_biib_OperatingLeaseRightOfUseAssetDerecognized_documentation_en-US" xlink:label="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Derecognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:href="biib-20220930.xsd#biib_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:to="lab_biib_OperatingLeaseRightOfUseAssetDerecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0e35ecd0-39b6-474b-87bc-b6b2f3347df1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_65a061d2-0f80-41af-bb8c-435574def7a0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2019 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_0092cae3-b168-425f-99d4-88a6747c6bec_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_449d84ea-ae54-433c-9aba-fb95bf1b46d5_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_3c2c7357-f09d-454a-9ac2-4c1d1bab4fd1_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, estimated fair value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Fair Value</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:href="biib-20220930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_11f91aa2-98ca-45b2-a57a-5121787f65bd_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_e65c1aff-9084-4b7a-ae92-003c4c29b7e3_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_7e4b89a7-62e2-44bb-91f1-c0c843302b1a_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_f2d44fac-8fc1-47a1-83ab-c7d18fe380e4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_54861f4d-3548-4897-b96d-6c71d07b5132_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fec2572e-9e0c-4853-8915-d3bd025b9686_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_3fd79c7f-3012-4198-9d40-82408adadb43_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_33274692-29b8-4953-8ad9-ea49beb5011b_verboseLabel_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average maturity of marketable securities, months</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average Maturity Of Marketable Securities</link:label>
    <link:label id="lab_biib_AverageMaturityOfMarketableSecurities_documentation_en-US" xlink:label="lab_biib_AverageMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average remaining time to maturity of marketable debt securities, available-for-sale securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities" xlink:href="biib-20220930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AverageMaturityOfMarketableSecurities" xlink:to="lab_biib_AverageMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_9bcad892-80d2-4464-94bc-a13313d0c730_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_09b5db16-4f9b-46d7-92c2-474a53f918e6_verboseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20220930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_20325843-e9d5-426d-93ea-e2b024f21df9_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_5b9c9abc-ff30-4a8d-bb7c-002e1ebc57f8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_fe4f0767-fda9-4c3c-9d94-576bba8b115e_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesCurrentMember" xlink:to="lab_biib_EquitySecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_69e56611-6877-4990-a794-eaf2b1469268_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_42e5340b-42f4-4cc8-8bf0-7ccd99dba97f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fcb92c22-6ae0-4291-8f3e-0fc9c7fa7b50_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on securities available for sale, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_5f257cf1-bd84-4777-8ae9-771c28eafa1c_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_d491153e-ce14-4dd8-8d2f-62a18085c963_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_204068fa-7fd1-40c4-86f2-b45b8615d02e_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20220930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_4a30f584-9226-4746-a670-a9eab9641360_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_3abe3276-99f5-4e2b-8503-4042252103f1_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20220930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_52033c7c-45fa-4c1c-b8aa-5821f907aa03_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_c6f6d85a-4d03-489a-8a72-8b88d581b480_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_0b13dc4f-6c06-416c-af54-2384837a2399_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_bac9e49d-5ec3-409c-bd9c-c48407338ac7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_0390b8ee-b6ff-443a-ab55-3a75aebef114_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_ac6781cb-2109-4a53-a611-a34496cf3e4e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdditionalMilestonePayment_c01db495-6dd7-4a49-9f48-74026b0efe04_terseLabel_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_label_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Milestone Payment</link:label>
    <link:label id="lab_biib_AdditionalMilestonePayment_documentation_en-US" xlink:label="lab_biib_AdditionalMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional milestone payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdditionalMilestonePayment" xlink:to="lab_biib_AdditionalMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_1cc1bffd-b496-41bb-b6f2-99601c37382f_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ADUHELMMember_e58ebfb4-67aa-4943-9450-28ad52251aa1_terseLabel_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:label id="lab_biib_ADUHELMMember_label_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM [Member]</link:label>
    <link:label id="lab_biib_ADUHELMMember_documentation_en-US" xlink:label="lab_biib_ADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ADUHELMMember" xlink:to="lab_biib_ADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_83cdefe4-406e-4943-aebc-7796c1a13670_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_53558a71-a8f6-4444-a9c7-269ce21bb72b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_d637f2fc-21cb-4bb7-b10e-ffd5bd17bd96_verboseLabel_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years, amortized cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_label_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available For Sale Securities Debt Maturities After Five Years Amortized Cost</link:label>
    <link:label id="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_documentation_en-US" xlink:label="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:href="biib-20220930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:to="lab_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_3efdfa68-25e4-47b2-8ea0-07bc029ca661_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TGNMember_50b668a4-dd5c-465c-8a93-649a3cd5a63b_terseLabel_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:label id="lab_biib_TGNMember_label_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN [Member]</link:label>
    <link:label id="lab_biib_TGNMember_documentation_en-US" xlink:label="lab_biib_TGNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TGN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember" xlink:href="biib-20220930.xsd#biib_TGNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TGNMember" xlink:to="lab_biib_TGNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccruedMilestonePayments_f78aa46b-fd47-41fb-b5fc-0ef45984bc71_terseLabel_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued milestone payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_label_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:label id="lab_biib_AccruedMilestonePayments_documentation_en-US" xlink:label="lab_biib_AccruedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments" xlink:href="biib-20220930.xsd#biib_AccruedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccruedMilestonePayments" xlink:to="lab_biib_AccruedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_ffd5937b-c49a-4fc2-8b04-12487cbc6492_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20220930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RegulatoryMilestonesMember_1db3bba7-e244-4c95-84ab-6c7f56a73b8f_terseLabel_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_biib_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_biib_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember" xlink:href="biib-20220930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RegulatoryMilestonesMember" xlink:to="lab_biib_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_98abff15-5d7d-4bd6-8166-1052e7f0f052_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_c1a1f0a6-bf85-4e49-8e41-94e3cb8eee1a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_99824ce8-a78d-4530-9485-befd9488b397_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_fe7f330b-32b0-4377-9951-050bdac4b71d_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock, at cost, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_cfb26daa-da95-4ca9-872f-db602c8c0b5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_932ec253-f987-4b99-a0d7-872395c0b1ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_125cdee5-0a02-4716-a228-ec63cc759883_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of borrowings and premiums paid</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9ecce2a6-e426-4193-802d-105c3e490c86_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ccfabbf8-7dfc-4a80-bb6c-1c83fc99c5a0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_4f97f62d-61e6-43c4-8bae-40dfd4724e65_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_1f0e8783-198e-4c04-b86e-2326f8c56635_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_9ff6b368-ded4-4f99-9538-69a2165e84a1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets placed into service</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_a423ec21-21b3-4d19-b478-3e1a793c64ca_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_769d6fa8-5ba0-4cc1-bb90-576414ce4bdc_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gains recognized on the increase in fair value of equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_579ca2da-6e3f-458b-b8b2-1501a5aa7829_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_dde8a12b-7ffc-4c92-b70b-d374fb28477b_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_56b8e980-fc09-4414-8e04-b023e3e8b83d_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_c960fac1-88ad-4221-a90a-33d3eb3eec0d_netLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_eaa0b1c8-201a-4ece-bcb5-bf346ff8642b_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_91b36e69-231c-41ee-ad9d-d69fd890ce64_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_ab15a6ed-c511-4f3a-8052-a349555d82cb_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_9b8f5ea8-3552-43d0-8fcf-1b3855566fd7_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_c22ca223-3234-40ef-a671-ac549bededd9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of interest in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_fc966a35-af26-496d-9f9c-22231bf1ca11_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_353fb2f4-7b45-43dc-8cb0-e404d3f3f61d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_e3a022eb-23e9-4888-b0cc-2417c828d78f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB111Member_809343c8-bb93-45f6-9ec7-b9046d2cdd16_terseLabel_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111</link:label>
    <link:label id="lab_biib_BIIB111Member_label_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:label id="lab_biib_BIIB111Member_documentation_en-US" xlink:label="lab_biib_BIIB111Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB111 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member" xlink:href="biib-20220930.xsd#biib_BIIB111Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB111Member" xlink:to="lab_biib_BIIB111Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_4edb5033-a17f-45f7-a2bc-788adb7e0eba_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_aa9e2c00-533a-4625-8935-6cd54ff5950f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_f0f96c69-2246-46e7-9931-edcfcaa5a86f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_28dde8dd-20c0-4004-b590-44072c45a25e_verboseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20220930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_8dd0a4a7-3912-4705-aa5f-bbb66101e2fc_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20220930.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_a591b4bc-33b8-4e7c-8bb4-3ca34eb7dd5e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BIIB112Member_9e877edf-7379-4d77-ace4-0482692fac3d_terseLabel_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112</link:label>
    <link:label id="lab_biib_BIIB112Member_label_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:label id="lab_biib_BIIB112Member_documentation_en-US" xlink:label="lab_biib_BIIB112Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BIIB112 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member" xlink:href="biib-20220930.xsd#biib_BIIB112Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BIIB112Member" xlink:to="lab_biib_BIIB112Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_f829a008-d994-473d-9981-0c5f03df3024_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_9da65460-6b52-4b2d-99f6-712252cb0393_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_5112f759-e949-4aa4-9afc-e7df78166404_verboseLabel_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_DuefromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_DuefromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms" xlink:href="biib-20220930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DuefromantiCD20therapeuticprograms" xlink:to="lab_biib_DuefromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_0e4a0839-4050-448e-b381-796442ff2ea8_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_40cb6d75-68b6-4b66-8cd8-9051a811fc0e_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_c699ef8b-a3c3-4cce-8d6d-7eee3d3b0fe5_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_53dbddde-607f-4dc2-ac8c-cab56d621689_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_9bf1877a-6170-474f-8967-c29d7a469bd6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_095fe3c9-5824-4ef3-9a0c-310e7abdf60e_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_bafcebdc-fa53-4284-8d98-95e8544721e9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_e896b9d5-183c-4fe9-b844-3a2e952d18e7_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of building</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_1d16c5b0-1141-401e-bc25-801fb91fddbe_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on sale of building</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_596d7dd4-d66c-4aea-8581-0724349c0b8b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d9dfd0a-4963-419f-8c9c-7786fd6907da_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ded8d720-e1dc-4fe8-a7a2-d686381fc46d_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FacilityLocationAxis_3e7114e7-436a-48c0-903a-25528e04931e_terseLabel_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_label_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facility Location [Axis]</link:label>
    <link:label id="lab_biib_FacilityLocationAxis_documentation_en-US" xlink:label="lab_biib_FacilityLocationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">-- None. No documentation exists for this element. --</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis" xlink:href="biib-20220930.xsd#biib_FacilityLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FacilityLocationAxis" xlink:to="lab_biib_FacilityLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3280e783-71cb-4c72-8df9-1d52abd78a31_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_bd506a33-312a-4af1-9e4f-0e820416bc2e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_c1ed351e-3e9d-4176-81a5-ec0dea5bd074_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_742680bd-d5f8-440e-9fbb-6823447b2c7b_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_635a7909-49a8-4ada-b246-c71f992cb34c_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_d1669415-c031-43b8-8477-e7bbacf62c52_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_69526c79-d890-47d2-bec5-3933a39620fc_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8821bfac-c85d-464a-8e65-fa61ae17ce69_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_ea65a05a-ffa8-4089-a973-1367ce4701b5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_a394e774-8de0-4d1b-a32d-91eb7a8701d1_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_2930d577-0d49-4f0c-b23a-5674ef9b695d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_b505e403-7f42-4ba4-8bbd-ee3bbeb7c67b_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_da2ce0e9-e00f-4e0f-9113-20361daa6cd9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_753e6198-a68e-4d6e-83b9-70d2c645314b_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under award plan, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_b826f3ae-dc94-4f8c-afab-fa7f4933d5dd_terseLabel_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement agreement(1)</link:label>
    <link:label id="lab_us-gaap_SettlementLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlement Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettlementLiabilitiesCurrent" xlink:to="lab_us-gaap_SettlementLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_98d2c75d-b4f5-4d52-8958-1d7771256ca1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a5cf5b68-91df-4993-b2d2-975f93d8d255_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_7bcc4a25-522e-478b-ad5c-9bd0e2613b50_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_e31f71f5-957c-484f-8707-1892af7f73dc_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20220930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_99ddaad5-45e8-4ee7-ad72-7695b108cbd7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_us-gaap_AdjustmentForAmortization_label_en-US" xlink:label="lab_us-gaap_AdjustmentForAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentForAmortization" xlink:to="lab_us-gaap_AdjustmentForAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_7b2fc01e-1c2f-4a9e-9f3a-5f7d0d0b02d6_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_8aecd356-a694-43a5-8ded-ac465c9dae61_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_f6374be1-64d0-4035-be8a-e10e46125b69_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired in-process research and development</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire in Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_7fed936e-eb77-48eb-981d-d3f8ec9f8f34_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20220930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_8e58b22e-4916-4e53-9573-214877148a25_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_13022e57-8e3c-4feb-a3f0-f1d2142097ce_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5bdaf091-700c-4448-b28c-12256d66e306_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_230f6ce1-fe4c-41ba-8d8d-9e52cf5d4ce6_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20220930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_d0cbcc22-be1c-4ff3-b670-7c5d847c20df_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_fe15269e-6602-496c-b4e1-83193a7a43a9_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected future amortization expense, 2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_558b4598-6f37-4022-858e-ec497735e123_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20220930.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_d719887e-0efb-4b76-a263-51452f08a3ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_f946d65d-de9e-4a3c-a7bc-02d1003df101_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire additional investment in equity method investment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_b5802af2-3832-4f30-9aa1-aa259f4a5f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_e5e9e3ca-ee98-4604-8431-17df3735f501_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other restructuring costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_8834381d-bc26-4769-9379-844375ee37e3_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_751a7a44-98c5-462f-bc5d-4678ba5f9b22_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_b01b7a7c-e52d-4c09-b615-4b78a1554d23_terseLabel_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_label_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:label id="lab_biib_ResearchanddevelopmentassetAxis_documentation_en-US" xlink:label="lab_biib_ResearchanddevelopmentassetAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis" xlink:href="biib-20220930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchanddevelopmentassetAxis" xlink:to="lab_biib_ResearchanddevelopmentassetAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_6b651a36-0f9e-49c3-87e2-ef7a588414f1_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d1a48acd-5784-40fe-8152-d5a25d6e3b0e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ad45a4f9-7e09-4717-94c3-d7749a22216c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_85cf1373-c72e-47d6-802f-66660bdf021e_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_cc8e87fc-1ced-4616-bdc3-134f5132a4c4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities, net:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_735787e8-aa9a-4797-aa4b-6ca13bdf0d53_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f4bb6509-9755-4361-923a-67848c2b781f_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_5bb9ddb0-c8ab-40b5-a2d4-ff3c1e204bfd_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_928ad563-16c4-4b9f-9533-3a42aba6a1bb_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_d76091b6-58d7-4cb7-b9df-8f3ce4248b6b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_710bde5b-ed65-49e1-bb1b-2face172bd48_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_e2ee8be1-b0a4-4906-a696-8f4062dc1b3c_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated depreciation expense</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_353df8fc-e6f3-4762-91be-0ae4318f8ceb_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_96a36850-dceb-4844-96c4-6dce313078c8_verboseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_c38c8dd4-15a8-4f70-aa68-22a855522f24_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20220930.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_e2e407a5-f253-4885-bcd4-91e72503c887_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_d7f54c6d-418d-4f99-ad5b-eb932d2e08ce_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_1a80de27-5769-4db1-93a0-ab985ed16ba9_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_69944e99-69d8-4041-8d62-e1f7a13db2d3_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_730a8713-2c47-4b54-bb90-c443cedfc748_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_b2d58f45-bdd9-43a5-8497-2ecd89e105e1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_b0a9fc56-c84e-43e2-9e05-95ffc1e8fa13_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_0f4ed1df-f28c-4f44-bfb9-8413ecf62359_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_ba4e4d0a-acb3-4148-9cc8-8f14391fd009_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_e419a3ef-b901-4469-bb5e-bcecefbdd7e9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_5eb07b89-9f87-4494-924f-a84b57f1b95c_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20220930.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_211d9d45-196b-45cf-8acf-3c0cf2eadd06_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mortgage and other asset backed securities</link:label>
    <link:label id="lab_us-gaap_AssetBackedSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AssetBackedSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset-backed Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetBackedSecuritiesMember" xlink:to="lab_us-gaap_AssetBackedSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0c6f9b63-7754-4072-9c25-9f02084e3d42_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_ebe5738e-4ac3-474b-ac28-75c99ec414f6_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4e6d9522-9f2d-46a5-87d0-d57ebe8b7554_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_78fd4dc7-27a9-403d-ae15-91e2a32645ab_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Fair Value, Gross Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_61bd2a8c-1ad2-4512-a831-e20f5b787e7a_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range of durations of foreign currency forward contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_3ac37c25-bb07-4fbe-bfcb-8b3f0cbbc576_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20220930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_7a4ccdc4-15d3-403c-9fa5-69fe17d6245e_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20220930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_c78ba7ab-c89a-4fe1-8395-570715c84cd2_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_0975bbc5-a5ee-4d69-9815-bed1bcf953ae_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_d0d8ee2c-8326-4220-8a6a-94c4cdc47de0_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_8c39178e-ed62-4096-9aaa-ad0b98593a78_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_d634f9cb-0f71-43fd-b94a-3e1d215a8fac_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_cfe9e330-f23b-4d2e-8d38-5d880e7fce2a_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_d96e88d5-3256-4421-aa8f-75f6f679a53f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_812f8d35-1d02-43d7-affa-08b0910f5329_verboseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_6a3356a2-3417-452e-a0dd-7959884c57e1_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes on foreign earnings</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_a10571c7-3db7-4d99-bdc5-3590e766a9dc_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6fd06382-9e43-469b-bc40-ed594728a65c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_f80e89b7-cfcd-4fc1-b7aa-171ce4f378fc_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_6994d3ee-b57e-4477-8de6-4c7987315b6b_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_10800906-329f-4b5e-920b-99b0bd84932a_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_65cccf9e-face-496e-9c22-e4c87f7d169a_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_9c71a303-f530-4912-9c98-e7930c09391e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f334b93a-a163-4ff0-9e19-7418589599cf_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_d2fc51f2-b8bd-46e0-babe-7c66647abfea_terseLabel_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idle capacity charges</link:label>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_label_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:label id="lab_biib_CostOfGoodsSoldCapacityCharges_documentation_en-US" xlink:label="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods Sold, Capacity Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges" xlink:href="biib-20220930.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CostOfGoodsSoldCapacityCharges" xlink:to="lab_biib_CostOfGoodsSoldCapacityCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_ce651014-75fb-4e67-a1cd-5093bead5905_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_f989cbe5-87d5-4f85-bca3-34429c11c502_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed technology</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_53d38fd1-3503-41eb-87df-47f0b32f6870_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due in one year or less, estimated fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_df6ca991-2b51-417d-ac71-540a151fc345_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_c1f462d7-73f4-44fe-bfca-9ec504032ba8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss recorded on Samsung Bioepis joint venture</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Equity Method Investments, Net of Dividends or Distributions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_5904fd54-97de-4eb8-8a45-4ccf2ab03da9_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Redemption rate</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_label_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Rate</link:label>
    <link:label id="lab_biib_DebtInstrumentRedemptionRate_documentation_en-US" xlink:label="lab_biib_DebtInstrumentRedemptionRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate" xlink:href="biib-20220930.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentRedemptionRate" xlink:to="lab_biib_DebtInstrumentRedemptionRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5b437844-268f-4542-9662-697b4a131e70_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_f534207a-0e4e-46b0-9242-db823e2587fd_terseLabel_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gains (losses) on net investment hedge, excluded component</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_label_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:label id="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_documentation_en-US" xlink:label="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:href="biib-20220930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:to="lab_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_05ce5843-1d71-4b42-9483-b2c0e1ca066f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_cc750b8e-59fd-431e-b6ee-22cbf0cc5ffb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_56972b99-a27b-4543-9328-2e98ee3fa234_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_f858859c-c810-4b11-98c3-9c93732c22ff_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_a3cb2c5b-3a6e-471f-ba51-4c1a950d102c_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20220930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20220930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:6f409836-83df-4817-b8b9-7a5ff0648b96,g:f22c5c21-a910-4760-9b39-9695772d8988-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20220930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_09fd1848-13c6-42fb-988a-8f76e218dec7" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_DocumentType_09fd1848-13c6-42fb-988a-8f76e218dec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_30444460-639e-453b-83a1-442ce83e297f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_DocumentQuarterlyReport_30444460-639e-453b-83a1-442ce83e297f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4e676f16-b1ef-420d-9b1f-fd312043297c" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_DocumentPeriodEndDate_4e676f16-b1ef-420d-9b1f-fd312043297c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_c9247b59-91dd-4b76-94dd-5f4b823d593f" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_DocumentTransitionReport_c9247b59-91dd-4b76-94dd-5f4b823d593f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_324a6ef0-b0e3-41a2-9938-7ede0d484344" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityFileNumber_324a6ef0-b0e3-41a2-9938-7ede0d484344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_da703e47-fe6d-47bc-bc80-f637c090c4d3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityRegistrantName_da703e47-fe6d-47bc-bc80-f637c090c4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_4401f853-b3ff-4a88-81ce-3c8211e41e92" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityCentralIndexKey_4401f853-b3ff-4a88-81ce-3c8211e41e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_164299d4-e8cb-4924-b094-00a0a65dbba1" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_CurrentFiscalYearEndDate_164299d4-e8cb-4924-b094-00a0a65dbba1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_14ee79b3-276f-4f38-bda4-cf549b81179a" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_DocumentFiscalYearFocus_14ee79b3-276f-4f38-bda4-cf549b81179a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6900b77b-346e-4018-b0fd-a7129f5e669d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6900b77b-346e-4018-b0fd-a7129f5e669d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_dc5ad3b3-76f9-461a-869d-f08baa729170" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_AmendmentFlag_dc5ad3b3-76f9-461a-869d-f08baa729170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_0fabfef9-563a-4f5e-9806-df8f1b5c94c9" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityIncorporationStateCountryCode_0fabfef9-563a-4f5e-9806-df8f1b5c94c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_8d1dd33f-6f10-4d74-b330-d39242e80f14" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityTaxIdentificationNumber_8d1dd33f-6f10-4d74-b330-d39242e80f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cb8826c1-9f9d-4bd7-a5b7-9734f475d2dd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityAddressAddressLine1_cb8826c1-9f9d-4bd7-a5b7-9734f475d2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_60a5307f-68af-41e6-8f21-e59f5c926e93" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityAddressCityOrTown_60a5307f-68af-41e6-8f21-e59f5c926e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d5ded18c-6e84-416a-851f-25bb89c9ece4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityAddressStateOrProvince_d5ded18c-6e84-416a-851f-25bb89c9ece4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_28b4bd53-3d5d-494a-a2e5-7c8e78f11f90" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityAddressPostalZipCode_28b4bd53-3d5d-494a-a2e5-7c8e78f11f90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_71f91c7c-3058-4e66-92c8-c33f372473bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_CityAreaCode_71f91c7c-3058-4e66-92c8-c33f372473bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_af15e8a5-b16d-4fdc-9102-28dd11789c77" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_LocalPhoneNumber_af15e8a5-b16d-4fdc-9102-28dd11789c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_65dd20c9-53ac-4214-94c5-5810f56d6d73" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_Security12bTitle_65dd20c9-53ac-4214-94c5-5810f56d6d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_cca63767-a031-478e-8010-0e41ab8590e3" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_TradingSymbol_cca63767-a031-478e-8010-0e41ab8590e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_755e2ddf-513b-4d72-a075-38d462463dbd" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_SecurityExchangeName_755e2ddf-513b-4d72-a075-38d462463dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_34648ca6-26b3-4c52-8f36-eb64094cf0ac" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityCurrentReportingStatus_34648ca6-26b3-4c52-8f36-eb64094cf0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_743b53ac-26cf-4dcb-8307-1529d9d7d4c4" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityInteractiveDataCurrent_743b53ac-26cf-4dcb-8307-1529d9d7d4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_ce064eaa-79a7-4863-a64b-3cd0011dda5d" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityFilerCategory_ce064eaa-79a7-4863-a64b-3cd0011dda5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_2dda018f-d759-48e1-b563-5ef13dbd91bf" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntitySmallBusiness_2dda018f-d759-48e1-b563-5ef13dbd91bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_3fd4a1ea-214d-4402-96e3-19298b8cd799" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityEmergingGrowthCompany_3fd4a1ea-214d-4402-96e3-19298b8cd799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_24c4aa8b-d450-4423-af55-d5a0c72d7862" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityShellCompany_24c4aa8b-d450-4423-af55-d5a0c72d7862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a21303cd-f69e-4ec1-808f-f57fed8801c6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fdbd0d6d-11a8-4cfc-80a1-ccf622c7bb00" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a21303cd-f69e-4ec1-808f-f57fed8801c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_32a9d7a1-2a7d-4aeb-a532-e98adf6793d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_32a9d7a1-2a7d-4aeb-a532-e98adf6793d4" xlink:to="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:to="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5ffbc990-aa1e-460b-8d06-added229c557" xlink:to="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_056d59b5-a3a3-4ff2-ad96-193e7a4dd002" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:to="loc_us-gaap_ProductMember_056d59b5-a3a3-4ff2-ad96-193e7a4dd002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8160d633-2b80-4bff-b151-5eb0f0a2e7dc" xlink:href="biib-20220930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_8160d633-2b80-4bff-b151-5eb0f0a2e7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_bff54b18-7f83-4f3b-89a2-305183ea05ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_edf26323-345b-44bb-a1ab-d57f5da5dcd6" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_bff54b18-7f83-4f3b-89a2-305183ea05ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_488c891f-52aa-4f23-a24e-a167c5b7f2fa" xlink:to="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a207e8ac-47cc-428c-b257-56d47bbfb67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_Revenues_a207e8ac-47cc-428c-b257-56d47bbfb67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ab4a0e45-ca88-4519-a3f6-65f8ff4b57b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ab4a0e45-ca88-4519-a3f6-65f8ff4b57b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b4b14fed-cbe3-4808-92da-13ef4abffc07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_b4b14fed-cbe3-4808-92da-13ef4abffc07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f32837ae-3f0b-4e1c-ba0a-c1818cd315fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_f32837ae-3f0b-4e1c-ba0a-c1818cd315fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9d7fe0dc-0f67-4cf5-8581-698084f3587b" xlink:href="biib-20220930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_9d7fe0dc-0f67-4cf5-8581-698084f3587b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_8729707b-9da3-4ef9-8a0d-fa21c80abc0b" xlink:href="biib-20220930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_biib_Collaborationprofitlosssharing_8729707b-9da3-4ef9-8a0d-fa21c80abc0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_61082ee0-71c4-4420-ba62-3f040c3863aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_61082ee0-71c4-4420-ba62-3f040c3863aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_53cec308-82cd-416f-ae23-03c6b8014df8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_53cec308-82cd-416f-ae23-03c6b8014df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_b68a3402-4e3c-4eac-a506-1bdf046df3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_RestructuringCharges_b68a3402-4e3c-4eac-a506-1bdf046df3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dbaa79be-fbdf-4757-b4a4-37503c80f711" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_dbaa79be-fbdf-4757-b4a4-37503c80f711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_51885926-06e4-4782-83d4-63d8a37bd7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_51885926-06e4-4782-83d4-63d8a37bd7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_15ad937f-9f39-4d56-802c-3e1f09b92320" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_f91f8bf0-4c98-491f-8256-d64e3a0f8a19" xlink:to="loc_us-gaap_CostsAndExpenses_15ad937f-9f39-4d56-802c-3e1f09b92320" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_18cbebb4-304e-435f-9db4-6846cfe9f5cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_18cbebb4-304e-435f-9db4-6846cfe9f5cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_09ce45a0-d032-4012-aa95-73e78ef0ef49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_09ce45a0-d032-4012-aa95-73e78ef0ef49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_f8bbc448-1cf0-45ba-956a-e56fac7ee93a" xlink:href="biib-20220930.xsd#biib_IncomeLossFromEquityMethodInvestmentsNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax_f8bbc448-1cf0-45ba-956a-e56fac7ee93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_bf172330-b3c7-4231-9ef8-8dd6760f33c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_ProfitLoss_bf172330-b3c7-4231-9ef8-8dd6760f33c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a377518-a97b-4ca2-935d-3fcd105cadc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0a377518-a97b-4ca2-935d-3fcd105cadc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_25e617f0-90c6-439d-b8a7-7318b806f553" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_NetIncomeLoss_25e617f0-90c6-439d-b8a7-7318b806f553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_e3e6e40a-2893-449b-ab44-c903168d79aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:to="loc_us-gaap_EarningsPerShareBasic_e3e6e40a-2893-449b-ab44-c903168d79aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_bf8e172a-d3ae-4867-a79e-b6fe71a5e1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c446fdb6-9050-4a87-b2ff-e7087bc204a8" xlink:to="loc_us-gaap_EarningsPerShareDiluted_bf8e172a-d3ae-4867-a79e-b6fe71a5e1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_54102cbf-627a-42fb-8bd0-52c0da8ab845" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c664817-5068-425f-815b-5df8b3561175" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8c664817-5068-425f-815b-5df8b3561175" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0e1db96d-d1e9-447e-bb61-cf5847f9c2e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_ea0ba7ed-d989-4f3d-a61e-9c9a3a34c575" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0e1db96d-d1e9-447e-bb61-cf5847f9c2e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1037ba1b-1d8c-4ce3-83c3-a72cb5a4c012" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e6512392-f0bd-40d2-b998-0f846f5b39e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1037ba1b-1d8c-4ce3-83c3-a72cb5a4c012" xlink:to="loc_us-gaap_NetIncomeLoss_e6512392-f0bd-40d2-b998-0f846f5b39e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1037ba1b-1d8c-4ce3-83c3-a72cb5a4c012" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_81d1d436-3269-490c-b7a2-13f8a0ed113c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_81d1d436-3269-490c-b7a2-13f8a0ed113c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2d34a998-dd12-4de2-9221-953d0c9c1c07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_2d34a998-dd12-4de2-9221-953d0c9c1c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_35db34bd-3aa0-48bb-90ca-cc0f1f0fc509" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_35db34bd-3aa0-48bb-90ca-cc0f1f0fc509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5d1fb276-e8cc-408b-b091-1f1a9d32cf3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_5d1fb276-e8cc-408b-b091-1f1a9d32cf3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1959e851-2357-47dd-9691-5d94bd380607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1959e851-2357-47dd-9691-5d94bd380607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8924d1cc-351e-404b-998b-09fbf61dbba4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8924d1cc-351e-404b-998b-09fbf61dbba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf646556-bbee-4569-9470-3e05f2ddb97a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf646556-bbee-4569-9470-3e05f2ddb97a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7a968408-985d-43cc-bb7c-e08e362ae108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_7a968408-985d-43cc-bb7c-e08e362ae108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1a76b426-4582-4ba2-b05c-0b2a59ca58a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_ef00a9ef-73ed-4add-b3f2-fe084adfb30d" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1a76b426-4582-4ba2-b05c-0b2a59ca58a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_5cc18fd9-078a-4c55-8901-942611473cf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5cc18fd9-078a-4c55-8901-942611473cf5" xlink:to="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7805e289-781d-4fb2-bb46-5a477f38d97e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7805e289-781d-4fb2-bb46-5a477f38d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9ec53d1c-96a3-47d1-bde4-fc908234934e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_9ec53d1c-96a3-47d1-bde4-fc908234934e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9eaa9120-e365-41b3-970c-4a5be9c1f06f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9eaa9120-e365-41b3-970c-4a5be9c1f06f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DuefromantiCD20therapeuticprograms_85811582-bc95-49d8-96cf-22919d755687" xlink:href="biib-20220930.xsd#biib_DuefromantiCD20therapeuticprograms"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_biib_DuefromantiCD20therapeuticprograms_85811582-bc95-49d8-96cf-22919d755687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_1f3d9cf3-0334-4874-8fe3-295963cb29bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_us-gaap_InventoryNet_1f3d9cf3-0334-4874-8fe3-295963cb29bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_81ef598c-8ea5-4116-b571-70154180dd86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_us-gaap_OtherAssetsCurrent_81ef598c-8ea5-4116-b571-70154180dd86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_41b606fd-6ef8-458f-b241-d2416322a78d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_4b4b313a-26f0-4d6d-b6aa-deecdf4bf3c4" xlink:to="loc_us-gaap_AssetsCurrent_41b606fd-6ef8-458f-b241-d2416322a78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_790636dc-387a-4385-8460-ac7fdad7a214" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_790636dc-387a-4385-8460-ac7fdad7a214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c340bb6d-b70c-45fd-8ac8-ab744f9ea933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c340bb6d-b70c-45fd-8ac8-ab744f9ea933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_da1f843b-2322-4568-b118-c7e4a8358481" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_da1f843b-2322-4568-b118-c7e4a8358481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a199d683-815d-490f-8258-d3c7b753f61c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a199d683-815d-490f-8258-d3c7b753f61c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_39133645-6e07-44b6-9e0f-2f4451c80a25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_Goodwill_39133645-6e07-44b6-9e0f-2f4451c80a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2b69844b-a736-43a9-824e-b119d8fae73b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2b69844b-a736-43a9-824e-b119d8fae73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_f521cd0b-72ac-482b-b09e-cd1957289669" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_f521cd0b-72ac-482b-b09e-cd1957289669" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_13ca2802-d172-4660-a285-611b27857a20" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bae04424-36fa-46b6-b8b1-46aef5ea42d3" xlink:to="loc_us-gaap_Assets_13ca2802-d172-4660-a285-611b27857a20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_5cc18fd9-078a-4c55-8901-942611473cf5" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_4c6663e4-f728-41a0-8d0a-81e3bf0e4232" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:to="loc_us-gaap_NotesPayableCurrent_4c6663e4-f728-41a0-8d0a-81e3bf0e4232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_501892bd-297e-42e0-8af2-0c45aff7fb6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:to="loc_us-gaap_TaxesPayableCurrent_501892bd-297e-42e0-8af2-0c45aff7fb6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f9f110e2-23e5-43b4-a7c7-66b7b3b6fc92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:to="loc_us-gaap_AccountsPayableCurrent_f9f110e2-23e5-43b4-a7c7-66b7b3b6fc92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_a60519a1-8cc5-489e-aeb6-ddac991e2e48" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_a60519a1-8cc5-489e-aeb6-ddac991e2e48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8d9c6211-2f80-4450-be1c-80c77addfcc5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0b5f58c4-18c8-4cb3-9c1e-2b046fa2afb9" xlink:to="loc_us-gaap_LiabilitiesCurrent_8d9c6211-2f80-4450-be1c-80c77addfcc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_94403117-7f1c-4ab8-8efa-23d6c5db2b72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_LongTermDebt_94403117-7f1c-4ab8-8efa-23d6c5db2b72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b9b76467-c768-4fd1-80ab-23940a1587cd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_b9b76467-c768-4fd1-80ab-23940a1587cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e3686abb-47d4-4348-92c7-4da44c67a716" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_e3686abb-47d4-4348-92c7-4da44c67a716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_ea0a5e70-8ff5-401f-8a77-9f23f4e21323" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_ea0a5e70-8ff5-401f-8a77-9f23f4e21323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_8c24bd05-37e2-495a-8ae7-e1a4a5d22153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_Liabilities_8c24bd05-37e2-495a-8ae7-e1a4a5d22153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d6199c13-5c49-4de0-a40a-58818dc5cb04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d6199c13-5c49-4de0-a40a-58818dc5cb04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8b0726d9-f977-4c69-9e66-45a33a11bcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8b0726d9-f977-4c69-9e66-45a33a11bcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8b0726d9-f977-4c69-9e66-45a33a11bcf0" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_11ca1d7d-7676-4452-8a04-3f332da8d3e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_PreferredStockValue_11ca1d7d-7676-4452-8a04-3f332da8d3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_3b3fd6a6-a756-4117-ad2b-c102f01079ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_CommonStockValue_3b3fd6a6-a756-4117-ad2b-c102f01079ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bf992be9-f023-492e-bf1f-4bea22981428" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bf992be9-f023-492e-bf1f-4bea22981428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c4aedb5c-2470-4d3a-a49d-c6c937cc7345" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c4aedb5c-2470-4d3a-a49d-c6c937cc7345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b22c68a-e2b4-49fb-b526-f4f086b9a0b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b22c68a-e2b4-49fb-b526-f4f086b9a0b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_63bcc29a-c0ab-4c66-9e8f-38d22bc1708d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_TreasuryStockValue_63bcc29a-c0ab-4c66-9e8f-38d22bc1708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_67188345-6942-4910-bcb7-1a81ddb261d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0e5fcf03-5435-4e61-b48a-1a48dd5101ad" xlink:to="loc_us-gaap_StockholdersEquity_67188345-6942-4910-bcb7-1a81ddb261d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_497dea8b-3bee-4ae8-954a-bc854fd51f94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8b0726d9-f977-4c69-9e66-45a33a11bcf0" xlink:to="loc_us-gaap_MinorityInterest_497dea8b-3bee-4ae8-954a-bc854fd51f94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38809b2b-14a9-40fb-af17-94c43f7d7f51" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_8b0726d9-f977-4c69-9e66-45a33a11bcf0" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_38809b2b-14a9-40fb-af17-94c43f7d7f51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_24e65875-84fe-4ad0-bf4c-00f5407e52cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8f076329-5a73-4b17-91a1-2bd9fbebca01" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_24e65875-84fe-4ad0-bf4c-00f5407e52cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedBalanceSheetsUnauditedParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_492fdda4-061c-4c3a-94c9-d2a6c004f06a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_980ef6f4-30dd-44e8-aff6-8ac00d480f58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_492fdda4-061c-4c3a-94c9-d2a6c004f06a" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_980ef6f4-30dd-44e8-aff6-8ac00d480f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cbbad25a-6ef2-4c80-86d3-834bd51a9770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_492fdda4-061c-4c3a-94c9-d2a6c004f06a" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cbbad25a-6ef2-4c80-86d3-834bd51a9770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3224d667-a00b-4c6b-a455-aaa367cd5acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3224d667-a00b-4c6b-a455-aaa367cd5acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_9d8b3ab3-84c7-4c8c-89e2-01fcedc37088" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3224d667-a00b-4c6b-a455-aaa367cd5acd" xlink:to="loc_us-gaap_ProfitLoss_9d8b3ab3-84c7-4c8c-89e2-01fcedc37088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_3224d667-a00b-4c6b-a455-aaa367cd5acd" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_d25e759e-9cbe-4e15-bb53-f6b8079c96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_d25e759e-9cbe-4e15-bb53-f6b8079c96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_31582291-75e6-485c-8c68-0eba42ecaef7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_31582291-75e6-485c-8c68-0eba42ecaef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_6842e601-052a-46d0-a5d0-c331158da450" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_InventoryWriteDown_6842e601-052a-46d0-a5d0-c331158da450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_2928f1e8-becc-45e2-bcf6-e4ad21ea4241" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_2928f1e8-becc-45e2-bcf6-e4ad21ea4241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a7b0e690-80c9-4151-9503-f5be6660eef4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_ShareBasedCompensation_a7b0e690-80c9-4151-9503-f5be6660eef4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5c00fc46-5921-415d-9d38-e15955b6d4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_5c00fc46-5921-415d-9d38-e15955b6d4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad1620de-6fe6-4685-b599-e756c6803642" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ad1620de-6fe6-4685-b599-e756c6803642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_2108eb54-b092-4099-ac5b-dd56fe31b4e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_2108eb54-b092-4099-ac5b-dd56fe31b4e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_821fc1b6-de8c-414d-a4dc-15e5bf70772c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_821fc1b6-de8c-414d-a4dc-15e5bf70772c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_28a244ad-9285-489c-a70d-b62065673b33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_28a244ad-9285-489c-a70d-b62065673b33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_294a36d4-960f-404e-acf1-de5e7403d9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_294a36d4-960f-404e-acf1-de5e7403d9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_c54e6c58-b189-492b-a811-a93d87e667f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_c54e6c58-b189-492b-a811-a93d87e667f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c7302344-d6ae-4d00-8390-96d779e72991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_c7302344-d6ae-4d00-8390-96d779e72991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_2be049d0-f65f-4e56-a19f-c3c0a2d34731" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDueFromRelatedParties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:to="loc_us-gaap_IncreaseDecreaseInDueFromRelatedParties_2be049d0-f65f-4e56-a19f-c3c0a2d34731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b77c49bc-7ca3-4a83-8717-79ae5025a168" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b77c49bc-7ca3-4a83-8717-79ae5025a168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fead1a76-be48-44fe-8972-f07baa04e327" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_fead1a76-be48-44fe-8972-f07baa04e327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7bdd42e1-e515-402c-b7a9-31af51cbf7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_7bdd42e1-e515-402c-b7a9-31af51cbf7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_57beeab4-dbd5-4df2-9726-926c7e41e581" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_959083a5-21cf-4b51-9597-8a0e6751d245" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_57beeab4-dbd5-4df2-9726-926c7e41e581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9614693-becb-40ba-8e6c-647142764945" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_314d3a2e-ce24-48ef-b4ba-f819a8f505ad" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d9614693-becb-40ba-8e6c-647142764945" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4d7bb24c-9af1-4289-956c-e7ef3771ac1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4d7bb24c-9af1-4289-956c-e7ef3771ac1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e8308b2a-b073-4c10-ae8e-92f08cbd1917" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_e8308b2a-b073-4c10-ae8e-92f08cbd1917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56a48194-803b-45c2-ae30-200f8da45280" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_56a48194-803b-45c2-ae30-200f8da45280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e9988697-0216-4224-9837-d2101a80101d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e9988697-0216-4224-9837-d2101a80101d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e49905f7-f11e-46ae-b614-83157a8b0184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_e49905f7-f11e-46ae-b614-83157a8b0184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_44eacea6-c048-48c7-aff8-86dd9a3ab8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_44eacea6-c048-48c7-aff8-86dd9a3ab8ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_903b9d98-3172-4388-916e-1274f1755b23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment_903b9d98-3172-4388-916e-1274f1755b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2c8a2424-28aa-4d76-8974-846d787092c2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_2c8a2424-28aa-4d76-8974-846d787092c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_3dfb078d-1ef6-4a2f-9033-6e930b4550f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_3dfb078d-1ef6-4a2f-9033-6e930b4550f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c361c166-d3a7-425e-9c40-07d4a422d3de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_c361c166-d3a7-425e-9c40-07d4a422d3de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec302dd2-8e08-4cae-a51b-2576699246cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_4f542188-17fa-4700-8598-310cc9569095" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ec302dd2-8e08-4cae-a51b-2576699246cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dc68a41d-f6f5-48d5-818b-777ec1c85a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_dc68a41d-f6f5-48d5-818b-777ec1c85a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_194e2460-e56b-490e-a50c-a2f03792a2eb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_194e2460-e56b-490e-a50c-a2f03792a2eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_127010e3-8c31-4933-96ee-eaae7b3d6457" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_127010e3-8c31-4933-96ee-eaae7b3d6457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_d4502ba8-f5ef-42ed-b73d-f4b4d19ccaf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsToMinorityShareholders"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:to="loc_us-gaap_ProceedsFromPaymentsToMinorityShareholders_d4502ba8-f5ef-42ed-b73d-f4b4d19ccaf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2d6df2a6-6d31-462e-884e-2ab4f556f1fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_2d6df2a6-6d31-462e-884e-2ab4f556f1fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f5eef56-1cfc-431e-adda-795223fcbd92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_260a4861-0b8c-4ab1-8d13-2f10e4ec0190" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8f5eef56-1cfc-431e-adda-795223fcbd92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_db8b01c7-4ab4-422f-a6ad-f76223d18ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_db8b01c7-4ab4-422f-a6ad-f76223d18ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81ec4ae2-9644-4b9a-a860-631c5614a44d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_81ec4ae2-9644-4b9a-a860-631c5614a44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cce76173-6a8b-4acb-82ad-4e66dca6b781" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cce76173-6a8b-4acb-82ad-4e66dca6b781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_badcdc49-ac07-4bec-8e99-01b82ca44f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8227f62d-4527-48ba-a550-4cbd69219751" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_badcdc49-ac07-4bec-8e99-01b82ca44f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20220930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_70331e15-3672-40bb-956b-a1322db3f8d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_70331e15-3672-40bb-956b-a1322db3f8d4" xlink:to="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_7331b443-5d3f-43de-8923-56ad61648595" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_37635add-66eb-4580-819b-49dff0ee3752" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_7331b443-5d3f-43de-8923-56ad61648595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_4ec13e03-f4df-4b28-952b-1cfbbb7397e2" xlink:href="biib-20220930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_7331b443-5d3f-43de-8923-56ad61648595" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_4ec13e03-f4df-4b28-952b-1cfbbb7397e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_03d26dd6-4c7e-4d75-a6c0-76d8cd31571f" xlink:to="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_b5113d48-ca7e-4712-bff7-7aabe17714c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_PreferredStockMember_b5113d48-ca7e-4712-bff7-7aabe17714c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3eabe72b-6afd-4f88-9d39-ab2f2d999253" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_CommonStockMember_3eabe72b-6afd-4f88-9d39-ab2f2d999253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b246cdcc-caaa-4ccd-869f-cd9d830634ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b246cdcc-caaa-4ccd-869f-cd9d830634ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_941b1f85-bb72-47c2-ad07-0918b6cd59ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_941b1f85-bb72-47c2-ad07-0918b6cd59ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d69d61a8-51e4-482d-a7a9-ac69319e429b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_RetainedEarningsMember_d69d61a8-51e4-482d-a7a9-ac69319e429b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_049f65fc-18d0-4e3a-a4a4-29aad2b972c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_TreasuryStockMember_049f65fc-18d0-4e3a-a4a4-29aad2b972c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_46d04cac-47a8-4b51-b672-4ca47742d16f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_ParentMember_46d04cac-47a8-4b51-b672-4ca47742d16f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_bea418fe-27c0-467f-8ae3-f21b7ee1937d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5ddc3569-e092-4cc0-a093-1a737b947e6f" xlink:to="loc_us-gaap_NoncontrollingInterestMember_bea418fe-27c0-467f-8ae3-f21b7ee1937d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_911c646b-7a3d-45e9-bbc6-8ca2150623a9" xlink:to="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_83ce1887-9278-4bc9-8db7-73129b03ce09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_83ce1887-9278-4bc9-8db7-73129b03ce09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3977d541-d67e-4950-8627-f4641cd31aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_3977d541-d67e-4950-8627-f4641cd31aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_13bad6a6-c529-49d1-a2e2-aa4388fd4da0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_ProfitLoss_13bad6a6-c529-49d1-a2e2-aa4388fd4da0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38b7eda4-2c53-4d12-99a4-04b5445c5d29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_38b7eda4-2c53-4d12-99a4-04b5445c5d29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NoncontrollingInterestCapitalContribution_1b46cc14-d625-425e-aee8-01902aa01dd5" xlink:href="biib-20220930.xsd#biib_NoncontrollingInterestCapitalContribution"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_biib_NoncontrollingInterestCapitalContribution_1b46cc14-d625-425e-aee8-01902aa01dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2c407afc-facf-483e-a3ca-92b9c6a6f8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_2c407afc-facf-483e-a3ca-92b9c6a6f8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_eecab5c4-9d65-4aa5-a086-7ca1d5a02827" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_eecab5c4-9d65-4aa5-a086-7ca1d5a02827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_760ce08b-cafe-4571-97fd-a4db07af0eaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_760ce08b-cafe-4571-97fd-a4db07af0eaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_41b8db8e-2c26-4c5d-859e-debccf972b26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchasedAndRetiredDuringPeriodShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares_41b8db8e-2c26-4c5d-859e-debccf972b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_fb166a5c-60e3-4580-8bbc-b2901518eb35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockRetiredCostMethodAmount"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_TreasuryStockRetiredCostMethodAmount_fb166a5c-60e3-4580-8bbc-b2901518eb35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5d2c41d7-4c96-4c71-8144-c4c4f7d05ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_5d2c41d7-4c96-4c71-8144-c4c4f7d05ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_84a7cddb-9a6b-4b6c-857f-4cc6e16d927d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_84a7cddb-9a6b-4b6c-857f-4cc6e16d927d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75d5841b-4242-49f8-bfc1-9540bd170f44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_75d5841b-4242-49f8-bfc1-9540bd170f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_eba810b5-6a54-4e94-9b35-1c997c129e44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_eba810b5-6a54-4e94-9b35-1c997c129e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_33c20b02-fab3-4d0e-bdb4-a8307d643c08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_33c20b02-fab3-4d0e-bdb4-a8307d643c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_8494caa9-c86f-4c0c-842d-8cac2d3a2765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockholdersEquityOther_8494caa9-c86f-4c0c-842d-8cac2d3a2765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b261a4b1-beba-4d57-ac0d-324ce5640948" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b261a4b1-beba-4d57-ac0d-324ce5640948" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_010cc79f-8d0b-4451-8a65-9a872055852a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5b99ef8e-b705-48e5-b70a-a815434f1590" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_010cc79f-8d0b-4451-8a65-9a872055852a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20220930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5410f69f-0f32-4064-beb5-68ade4226afd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cb0dcb71-eb68-4bec-8221-cb33cc2190a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5410f69f-0f32-4064-beb5-68ade4226afd" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_cb0dcb71-eb68-4bec-8221-cb33cc2190a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20220930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d60ab7b9-161c-4fac-874d-b748c563bdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f8f9f033-171f-4507-b3b6-a7e2ecfc7da6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d60ab7b9-161c-4fac-874d-b748c563bdbc" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f8f9f033-171f-4507-b3b6-a7e2ecfc7da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20220930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5113882d-9f9e-4f82-a42f-a3e9af54c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4ed7e6d4-5e91-42c3-8375-6568d89ac24a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_5113882d-9f9e-4f82-a42f-a3e9af54c16b" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_4ed7e6d4-5e91-42c3-8375-6568d89ac24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20220930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_63c9c6fa-c263-47c2-bf79-b5e0a7d79749" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_677cf6f8-5205-446c-b9f9-41c31cd07f76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_63c9c6fa-c263-47c2-bf79-b5e0a7d79749" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_677cf6f8-5205-446c-b9f9-41c31cd07f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20220930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_828871b8-3ad8-4004-aa1b-da15a713c5d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_744111b9-6c94-4763-b0c7-c75ae58cd456" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_828871b8-3ad8-4004-aa1b-da15a713c5d5" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_744111b9-6c94-4763-b0c7-c75ae58cd456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_6ba7f423-918c-4235-90e1-bcd49df03181" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2dc0451b-d427-4bde-8c74-361ae520f078" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_6ba7f423-918c-4235-90e1-bcd49df03181" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2dc0451b-d427-4bde-8c74-361ae520f078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16dbc8a3-db74-4084-9970-39c7cf8e0deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_27e2b8e4-0db5-480b-8101-9dd489c80be0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_16dbc8a3-db74-4084-9970-39c7cf8e0deb" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_27e2b8e4-0db5-480b-8101-9dd489c80be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20220930.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_aefdaaf2-8ab1-483c-8b08-2604c5c2cfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_9ec29c3a-af5d-4a82-831a-8cc43590788e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_aefdaaf2-8ab1-483c-8b08-2604c5c2cfc0" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_9ec29c3a-af5d-4a82-831a-8cc43590788e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20220930.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_09c56909-1716-49ee-a17d-20e5f4fcc480" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a04d13e8-fc5f-4be4-aa8b-69354fc3739a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_09c56909-1716-49ee-a17d-20e5f4fcc480" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a04d13e8-fc5f-4be4-aa8b-69354fc3739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20220930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_bbc9f051-a729-432c-ae8e-c58a6bbf84df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_87a2acdb-fcf9-4242-b454-5b377aa8605b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_bbc9f051-a729-432c-ae8e-c58a6bbf84df" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_87a2acdb-fcf9-4242-b454-5b377aa8605b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20220930.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5fd84e3e-23c0-4dac-9d54-b2eaa280f383" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_02fce458-29ba-45a5-8d16-a0ebb71ad753" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5fd84e3e-23c0-4dac-9d54-b2eaa280f383" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_02fce458-29ba-45a5-8d16-a0ebb71ad753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20220930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d62f7f1c-1772-4301-90d5-def5539b43ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_61b4944c-4ef8-4d8d-ab01-e2e7575570aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d62f7f1c-1772-4301-90d5-def5539b43ab" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_61b4944c-4ef8-4d8d-ab01-e2e7575570aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20220930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dbfc928e-13ac-4816-8960-06eb408f4c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e3040191-5f83-4ff3-b923-46279e57b56b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dbfc928e-13ac-4816-8960-06eb408f4c7f" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e3040191-5f83-4ff3-b923-46279e57b56b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20220930.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e7fa076-4ff7-4758-a7b2-eea8b2c397bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77174d08-7c7c-40db-968d-746c64c266a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8e7fa076-4ff7-4758-a7b2-eea8b2c397bf" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_77174d08-7c7c-40db-968d-746c64c266a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20220930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0259247f-70eb-49b6-be66-555f3c09673b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_5856d5fb-95fa-4c4a-9f11-88789d9ae689" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0259247f-70eb-49b6-be66-555f3c09673b" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_5856d5fb-95fa-4c4a-9f11-88789d9ae689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_982f4005-c089-492f-a5b1-24f29d78fac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f125871f-132d-47ed-a207-7a9bf5b927ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_982f4005-c089-492f-a5b1-24f29d78fac1" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_f125871f-132d-47ed-a207-7a9bf5b927ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20220930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4c27220-90e7-4ca5-9316-7e9f3718bdfd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ffb0aee5-b79d-467e-831b-96ff367c0d70" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c4c27220-90e7-4ca5-9316-7e9f3718bdfd" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_ffb0aee5-b79d-467e-831b-96ff367c0d70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20220930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_bcefb084-e1cf-4069-89d3-585af816bb17" xlink:href="biib-20220930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_55c2b495-59c0-41ea-aeeb-15f3a860b152" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_bcefb084-e1cf-4069-89d3-585af816bb17" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_55c2b495-59c0-41ea-aeeb-15f3a860b152" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20220930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8e4e03f0-b192-4f12-8639-fdaf13249754" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4e45cd3d-db5d-49b8-ada6-7b084040a6f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_8e4e03f0-b192-4f12-8639-fdaf13249754" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_4e45cd3d-db5d-49b8-ada6-7b084040a6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="simple" xlink:href="biib-20220930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_f0578789-0766-44d3-a527-de68d4a72913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_77e1de01-c4ac-440f-9089-9c0f5ebe9ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_f0578789-0766-44d3-a527-de68d4a72913" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_77e1de01-c4ac-440f-9089-9c0f5ebe9ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Dispositions" xlink:type="simple" xlink:href="biib-20220930.xsd#Dispositions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Dispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_7cb413f9-39df-413a-b172-7bb3cb942212" xlink:href="biib-20220930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d3809383-9b63-48f4-93c6-4dfa306b9fd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_7cb413f9-39df-413a-b172-7bb3cb942212" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_d3809383-9b63-48f4-93c6-4dfa306b9fd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20220930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_75e7650c-6342-4211-a8c3-5e1ebfa3fd02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_977578c3-ad29-4968-a9f7-87aa35d419e9" xlink:href="biib-20220930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75e7650c-6342-4211-a8c3-5e1ebfa3fd02" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_977578c3-ad29-4968-a9f7-87aa35d419e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_057ff2da-080c-40cc-a714-79dd438340be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75e7650c-6342-4211-a8c3-5e1ebfa3fd02" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_057ff2da-080c-40cc-a714-79dd438340be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_989f9b0a-993f-4d17-8ca3-fa9f219c615c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75e7650c-6342-4211-a8c3-5e1ebfa3fd02" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_989f9b0a-993f-4d17-8ca3-fa9f219c615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_16faa705-671f-4150-b983-5dd92a1ebdc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75e7650c-6342-4211-a8c3-5e1ebfa3fd02" xlink:to="loc_us-gaap_UseOfEstimates_16faa705-671f-4150-b983-5dd92a1ebdc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e85be8cb-a8c4-4cc3-b3ac-9f2a0ba99bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_75e7650c-6342-4211-a8c3-5e1ebfa3fd02" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_e85be8cb-a8c4-4cc3-b3ac-9f2a0ba99bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20220930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7a89f904-c942-418a-91ac-f65116054c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6bfda627-6aa3-4621-911b-3d4665c0079a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7a89f904-c942-418a-91ac-f65116054c76" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_6bfda627-6aa3-4621-911b-3d4665c0079a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe0df8ae-e7cb-4a98-a631-2440bd83acc8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_59f8a00e-e7c4-4c78-92be-fbaff909a29c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe0df8ae-e7cb-4a98-a631-2440bd83acc8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_59f8a00e-e7c4-4c78-92be-fbaff909a29c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_744c3b6a-65dd-4c4b-b68c-8e604878716c" xlink:href="biib-20220930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe0df8ae-e7cb-4a98-a631-2440bd83acc8" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_744c3b6a-65dd-4c4b-b68c-8e604878716c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_614d9c1f-2865-481a-8a9b-7e7906309d35" xlink:href="biib-20220930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe0df8ae-e7cb-4a98-a631-2440bd83acc8" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_614d9c1f-2865-481a-8a9b-7e7906309d35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_cae58d78-0659-4d8c-b695-6908691ec73e" xlink:href="biib-20220930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe0df8ae-e7cb-4a98-a631-2440bd83acc8" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_cae58d78-0659-4d8c-b695-6908691ec73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_54c0ac35-1df0-45c6-bc7f-16fd2baa88ba" xlink:href="biib-20220930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_fe0df8ae-e7cb-4a98-a631-2440bd83acc8" xlink:to="loc_biib_OtherrevenuesTableTextBlock_54c0ac35-1df0-45c6-bc7f-16fd2baa88ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20220930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_ceff5c42-dc0f-4e62-8a5f-dbe7a502cf49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f83b30eb-dd07-426c-8918-d1d0bad68c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_ceff5c42-dc0f-4e62-8a5f-dbe7a502cf49" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_f83b30eb-dd07-426c-8918-d1d0bad68c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20220930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1602622a-7c47-443b-afe0-0acd7761a5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_1ea4261c-ff97-46a5-9a12-3f8c84169362" xlink:href="biib-20220930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1602622a-7c47-443b-afe0-0acd7761a5ec" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_1ea4261c-ff97-46a5-9a12-3f8c84169362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8d9313d4-5cb2-4fb5-9b1b-285da614111f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1602622a-7c47-443b-afe0-0acd7761a5ec" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_8d9313d4-5cb2-4fb5-9b1b-285da614111f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_e2b3f2d2-9468-4407-a43c-f4b4f5f1cb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1602622a-7c47-443b-afe0-0acd7761a5ec" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_e2b3f2d2-9468-4407-a43c-f4b4f5f1cb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b1c043a6-cad5-4de6-950e-1e822e794025" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d3f9362f-b312-4301-ad2e-0af08b0109d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1c043a6-cad5-4de6-950e-1e822e794025" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_d3f9362f-b312-4301-ad2e-0af08b0109d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0aea5d08-d8f6-40bc-b38e-46feb4aaa0e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1c043a6-cad5-4de6-950e-1e822e794025" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_0aea5d08-d8f6-40bc-b38e-46feb4aaa0e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_33a86bc2-ca32-4af9-9ea2-4e555d14a16a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b1c043a6-cad5-4de6-950e-1e822e794025" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_33a86bc2-ca32-4af9-9ea2-4e555d14a16a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_944f820c-b995-42ae-b738-9d941d0a0b21" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2fce910f-953b-4a81-b592-2e695eac652a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_944f820c-b995-42ae-b738-9d941d0a0b21" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_2fce910f-953b-4a81-b592-2e695eac652a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ef141871-1afe-4c5f-bf73-b6b75bdbf98e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_944f820c-b995-42ae-b738-9d941d0a0b21" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ef141871-1afe-4c5f-bf73-b6b75bdbf98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_dac206a6-51cf-48e0-b660-7835c5da2b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_944f820c-b995-42ae-b738-9d941d0a0b21" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_dac206a6-51cf-48e0-b660-7835c5da2b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_1d9878cd-dad5-4814-9202-e3886cccb00a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_944f820c-b995-42ae-b738-9d941d0a0b21" xlink:to="loc_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock_1d9878cd-dad5-4814-9202-e3886cccb00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20220930.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b272a2b-618c-4e84-bfd0-5e8eb1ae49f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_246423ec-d55c-4b68-be49-629950036c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b272a2b-618c-4e84-bfd0-5e8eb1ae49f5" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_246423ec-d55c-4b68-be49-629950036c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_fb70c710-a52d-4553-81ff-3cf6b757f672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b272a2b-618c-4e84-bfd0-5e8eb1ae49f5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_fb70c710-a52d-4553-81ff-3cf6b757f672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_56cf85ea-4604-4e7d-bed8-fc8364da217b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b272a2b-618c-4e84-bfd0-5e8eb1ae49f5" xlink:to="loc_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock_56cf85ea-4604-4e7d-bed8-fc8364da217b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6aadfa01-d3f2-4b4e-bcd7-265e5bab5205" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b272a2b-618c-4e84-bfd0-5e8eb1ae49f5" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_6aadfa01-d3f2-4b4e-bcd7-265e5bab5205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_3ac4a9fb-fef5-4e2a-abed-0d17ff6708e2" xlink:href="biib-20220930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_9b272a2b-618c-4e84-bfd0-5e8eb1ae49f5" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_3ac4a9fb-fef5-4e2a-abed-0d17ff6708e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="biib-20220930.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_06729600-9c2a-4e9a-ba7e-a96406b36835" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_47555859-10da-43aa-8a0c-88bd95d530cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_06729600-9c2a-4e9a-ba7e-a96406b36835" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_47555859-10da-43aa-8a0c-88bd95d530cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e418bf08-5ad4-475e-bf43-9b361708b502" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_06729600-9c2a-4e9a-ba7e-a96406b36835" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_e418bf08-5ad4-475e-bf43-9b361708b502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20220930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a428d0dd-db11-4005-a0a1-8c1e9123b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9901680b-4aa7-45b7-9267-5ae7da6bd4f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a428d0dd-db11-4005-a0a1-8c1e9123b6ed" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9901680b-4aa7-45b7-9267-5ae7da6bd4f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2aa14770-0b98-4b59-a50f-c185d8065edf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cea4e832-30fe-4d81-a8dd-7e2816688a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2aa14770-0b98-4b59-a50f-c185d8065edf" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_cea4e832-30fe-4d81-a8dd-7e2816688a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_89f82d1e-ec0d-4435-ba88-5cb1a7317d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2aa14770-0b98-4b59-a50f-c185d8065edf" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_89f82d1e-ec0d-4435-ba88-5cb1a7317d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20220930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0d24341d-542b-4f63-8d5e-90b1a4f7f7fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_885fd00d-fa13-4232-82f7-cf6f7c4ffc83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0d24341d-542b-4f63-8d5e-90b1a4f7f7fb" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_885fd00d-fa13-4232-82f7-cf6f7c4ffc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a926866-43cc-438c-98e7-d8082f212ddb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_636a561f-1450-4bcc-aa87-f50081c61ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a926866-43cc-438c-98e7-d8082f212ddb" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_636a561f-1450-4bcc-aa87-f50081c61ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_cd725d18-4219-478c-a8bc-b1ea5ed2f84a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a926866-43cc-438c-98e7-d8082f212ddb" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_cd725d18-4219-478c-a8bc-b1ea5ed2f84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ceb17d6d-26b7-4ced-b93c-e979513ac921" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1a926866-43cc-438c-98e7-d8082f212ddb" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ceb17d6d-26b7-4ced-b93c-e979513ac921" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20220930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b11ca585-92dd-4a7a-8cd7-b7f8ceb25cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7f3dc066-51cb-4797-9608-edd309808b3b" xlink:href="biib-20220930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b11ca585-92dd-4a7a-8cd7-b7f8ceb25cbe" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_7f3dc066-51cb-4797-9608-edd309808b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_ea0afd93-2aff-455d-94b9-b57651f190cf" xlink:href="biib-20220930.xsd#biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b11ca585-92dd-4a7a-8cd7-b7f8ceb25cbe" xlink:to="loc_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock_ea0afd93-2aff-455d-94b9-b57651f190cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_8b9ac9bf-1584-4ba4-9abc-c46355969069" xlink:href="biib-20220930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b11ca585-92dd-4a7a-8cd7-b7f8ceb25cbe" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_8b9ac9bf-1584-4ba4-9abc-c46355969069" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d7b6f401-7d76-43a4-be2d-291cb6948539" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_ec4261f3-88ca-48ea-90b7-ce07d4a39af2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7b6f401-7d76-43a4-be2d-291cb6948539" xlink:to="loc_us-gaap_NumberOfReportableSegments_ec4261f3-88ca-48ea-90b7-ce07d4a39af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_25a04d12-23dc-4748-acbb-be3400b6316b" xlink:href="biib-20220930.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d7b6f401-7d76-43a4-be2d-291cb6948539" xlink:to="loc_biib_InterestInSubsidiary_25a04d12-23dc-4748-acbb-be3400b6316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_674746a2-4cf0-402a-b58a-4990506cf1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_674746a2-4cf0-402a-b58a-4990506cf1e6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:to="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_9471be22-a881-41de-b5ea-e60fd3a8b2f9" xlink:to="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_303fdf98-1075-441f-8d92-b034cac01fb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:to="loc_srt_MinimumMember_303fdf98-1075-441f-8d92-b034cac01fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bba8ef9a-d6df-4afc-8d4d-621660716579" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_05a852f0-0be0-4347-9ea9-b52efcfc8fbd" xlink:to="loc_srt_MaximumMember_bba8ef9a-d6df-4afc-8d4d-621660716579" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:to="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_8863b9b0-915f-45a4-a8a8-20f039571bcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_a6ed653e-324a-47a3-a1fa-238574d20f3b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_8863b9b0-915f-45a4-a8a8-20f039571bcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_943c1acc-ae42-4d4a-8d22-58f17afab29b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_8863b9b0-915f-45a4-a8a8-20f039571bcd" xlink:to="loc_srt_ScenarioForecastMember_943c1acc-ae42-4d4a-8d22-58f17afab29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_4fa5755b-b363-4a54-a127-ded650659533" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_94d54e81-4dd3-406b-8e21-fafd139646a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_RestructuringCharges_94d54e81-4dd3-406b-8e21-fafd139646a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_74933093-0409-455b-8c87-8ae114fb502a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_SeveranceCosts1_74933093-0409-455b-8c87-8ae114fb502a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges_50c08cb4-9e14-4c02-bfb0-3a8e890ac22c" xlink:href="biib-20220930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_biib_GainLossOnRestructuringCharges_50c08cb4-9e14-4c02-bfb0-3a8e890ac22c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_225a297c-27a6-4eee-b497-141cdfadd55b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_225a297c-27a6-4eee-b497-141cdfadd55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_7c315325-4f94-4d06-b3b7-4711fcc4cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_bee8de0b-fbc5-4fb9-b250-79cf05b1f6ee" xlink:to="loc_us-gaap_OtherRestructuringCosts_7c315325-4f94-4d06-b3b7-4711fcc4cd0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_988b6448-c48d-4777-9941-b115130936af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_988b6448-c48d-4777-9941-b115130936af" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_d163a1ee-8136-4f71-a41b-6ca03fc7dc90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_2525207d-3058-45b0-b7ae-3ad137459afe" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_d163a1ee-8136-4f71-a41b-6ca03fc7dc90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WorkforceReductionMember_69cfe4f0-4097-416f-90ff-5c90f77cd627" xlink:href="biib-20220930.xsd#biib_WorkforceReductionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_d163a1ee-8136-4f71-a41b-6ca03fc7dc90" xlink:to="loc_biib_WorkforceReductionMember_69cfe4f0-4097-416f-90ff-5c90f77cd627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_56043795-2798-4bb2-adb8-d7ddd5543d5e" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_83019400-760e-4439-a1b2-ebe19c130427" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringReserve_83019400-760e-4439-a1b2-ebe19c130427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_a43511ec-c6c0-4c65-b774-df27de73db6b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringCharges_a43511ec-c6c0-4c65-b774-df27de73db6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_15c9f812-f5cc-4ded-8931-635594b68af7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_PaymentsForRestructuring_15c9f812-f5cc-4ded-8931-635594b68af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveAccrualAdjustment1_4ef15b38-a700-45ea-9a6a-d91bf4205032" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserveAccrualAdjustment1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringReserveAccrualAdjustment1_4ef15b38-a700-45ea-9a6a-d91bf4205032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_01b42a0f-58ac-488b-bacb-629d4ffbee15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_a813bfc3-fbb4-4717-a6ba-4ff24c23f0cb" xlink:to="loc_us-gaap_RestructuringReserve_01b42a0f-58ac-488b-bacb-629d4ffbee15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_feff10fd-e2da-4109-b393-7842081538bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_feff10fd-e2da-4109-b393-7842081538bc" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:to="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_337ba005-c220-4bc9-baac-08847beeee59" xlink:to="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:href="biib-20220930.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:href="biib-20220930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:to="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_c0c7b6c2-0fbf-469e-9ed8-4e76472c31a2" xlink:href="biib-20220930.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:to="loc_biib_TECFIDERAMember_c0c7b6c2-0fbf-469e-9ed8-4e76472c31a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_d1d17084-e401-4202-a49e-f201f3f80d78" xlink:href="biib-20220930.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_8b0f4fc0-29d1-4fda-bda8-0b8973c7c448" xlink:to="loc_biib_VUMERITYMember_d1d17084-e401-4202-a49e-f201f3f80d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:href="biib-20220930.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_c885d042-17cd-4c93-9976-57657747a7f8" xlink:to="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_3d844738-767a-4874-a859-5c0a44354ebf" xlink:href="biib-20220930.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:to="loc_biib_AVONEXMember_3d844738-767a-4874-a859-5c0a44354ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_3b386a4d-ca4b-4a92-9a6b-03e182176d5e" xlink:href="biib-20220930.xsd#biib_PLEGRIDYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_7d48bb93-f8e1-4377-91d6-7c8905b6dfc8" xlink:to="loc_biib_PLEGRIDYMember_3b386a4d-ca4b-4a92-9a6b-03e182176d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_b1972fad-501b-4902-9e6b-3933df8da9f4" xlink:href="biib-20220930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_TysabriProductMember_b1972fad-501b-4902-9e6b-3933df8da9f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_20e1fc2b-198a-4f00-83e6-45d5e20812d1" xlink:href="biib-20220930.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_FAMPYRAMember_20e1fc2b-198a-4f00-83e6-45d5e20812d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_bfabdb81-9322-4aec-9057-e1b8f98ea008" xlink:href="biib-20220930.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_SPINRAZAMember_bfabdb81-9322-4aec-9057-e1b8f98ea008" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:href="biib-20220930.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_a75b574c-81de-4b98-9071-4fb81cf6ecd0" xlink:href="biib-20220930.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_BENEPALIMember_a75b574c-81de-4b98-9071-4fb81cf6ecd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_68d0f57a-c871-4850-bdea-99a3d6cfb668" xlink:href="biib-20220930.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_IMRALDIMember_68d0f57a-c871-4850-bdea-99a3d6cfb668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_412afa96-dded-4a1e-b42c-f0b173673f08" xlink:href="biib-20220930.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_FLIXABIMember_412afa96-dded-4a1e-b42c-f0b173673f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_46c31841-f4d1-48db-9ecc-49826d6e983d" xlink:href="biib-20220930.xsd#biib_BYOOVIZMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_6dfe1bb3-d22d-40f3-badd-bd56b7628a66" xlink:to="loc_biib_BYOOVIZMember_46c31841-f4d1-48db-9ecc-49826d6e983d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMMember_4b31f63c-664f-49b0-a468-a618e1091662" xlink:href="biib-20220930.xsd#biib_FUMADERMMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_FUMADERMMember_4b31f63c-664f-49b0-a468-a618e1091662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_f4ea0a66-0f0c-4f21-94cd-60b23b9b4fc7" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_biib_ADUHELMMember_f4ea0a66-0f0c-4f21-94cd-60b23b9b4fc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_56d0f879-2f40-4a4c-9493-6f8ffcc560e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_5df976ee-c2b7-4d1d-bb5d-093b7bd34de5" xlink:to="loc_us-gaap_ProductMember_56d0f879-2f40-4a4c-9493-6f8ffcc560e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:to="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_fa840e52-634e-4705-8163-26f2af9cc54f" xlink:to="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2fb76b6b-e45a-4aff-b495-e513854e2217" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:to="loc_country_US_2fb76b6b-e45a-4aff-b495-e513854e2217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_a79d708d-6ec8-40db-850d-28259213d9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2d6f69ea-bf47-4234-ba23-142273123c42" xlink:to="loc_us-gaap_NonUsMember_a79d708d-6ec8-40db-850d-28259213d9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_9ffd56d3-8dd0-4a1d-94f3-abe5e8638deb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f90087a6-a9b7-4991-9644-9ada690ee94b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_9ffd56d3-8dd0-4a1d-94f3-abe5e8638deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a5f2cd46-cf68-4edb-96f4-a94e0b21427a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_9ffd56d3-8dd0-4a1d-94f3-abe5e8638deb" xlink:to="loc_us-gaap_Revenues_a5f2cd46-cf68-4edb-96f4-a94e0b21427a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_5b569cb3-19fe-4f86-8b69-73a105d4ab46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_5b569cb3-19fe-4f86-8b69-73a105d4ab46" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_66ff0fdc-8895-4c8f-83f0-f447164f0740" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_cf79947c-caf6-4eef-aa36-e919ea947b20" xlink:href="biib-20220930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:to="loc_biib_ReserveforCashDiscountsMember_cf79947c-caf6-4eef-aa36-e919ea947b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_3c66b25c-7b52-408d-9007-f51233821519" xlink:href="biib-20220930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:to="loc_biib_ContractualAdjustmentsMember_3c66b25c-7b52-408d-9007-f51233821519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_acced657-1382-490f-b24c-5841dfe0897d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_470a9504-a9f4-44ab-9715-b3e0b85b8a03" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_acced657-1382-490f-b24c-5841dfe0897d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_1856e7fd-b8cd-43fa-9fc1-273beab7ee67" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_73760b20-085f-4479-bec1-cb3906de258f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_73760b20-085f-4479-bec1-cb3906de258f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_eba93b4c-329b-41a1-8c90-827764d46a42" xlink:href="biib-20220930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_eba93b4c-329b-41a1-8c90-827764d46a42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_97f991f4-0223-47a8-a4b2-fd901c012b46" xlink:href="biib-20220930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_97f991f4-0223-47a8-a4b2-fd901c012b46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_71285022-9c6f-4047-a38b-204eeff4284b" xlink:href="biib-20220930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_71285022-9c6f-4047-a38b-204eeff4284b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_f6915f57-3469-4642-b960-33d5ec7660ee" xlink:href="biib-20220930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_f6915f57-3469-4642-b960-33d5ec7660ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_3f575d4d-abc3-4ae6-896e-b0105c4768a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_741c2b9b-a5d0-4bbd-9fdd-1e8fe3e0eb4d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_3f575d4d-abc3-4ae6-896e-b0105c4768a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_d07d7109-116c-40c6-bc93-d33d6b2ecf8d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_d07d7109-116c-40c6-bc93-d33d6b2ecf8d" xlink:to="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_10dea709-3de8-4006-b7ad-71ddc91ea475" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_57394697-3652-455d-b11a-44fa3f74a0f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:to="loc_us-gaap_AccountsReceivableMember_57394697-3652-455d-b11a-44fa3f74a0f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_58ab37e9-adbe-48fc-9824-7cdf4bfc5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_13b4e97a-e69a-4dfb-b5e7-51b09fc0f5e6" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_58ab37e9-adbe-48fc-9824-7cdf4bfc5b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_fcf88e11-b915-45d7-8572-9d9ebf6e7f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_87cede2e-349f-44fb-beac-ca0bcaec9560" xlink:to="loc_us-gaap_StatementLineItems_fcf88e11-b915-45d7-8572-9d9ebf6e7f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b9b9e0-b3aa-4e3d-ba05-3e710716280a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_fcf88e11-b915-45d7-8572-9d9ebf6e7f2a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_41b9b9e0-b3aa-4e3d-ba05-3e710716280a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6bff5082-b075-4ea3-ad61-cd3345748a68" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6bff5082-b075-4ea3-ad61-cd3345748a68" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:to="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_804d0ee0-6da3-4ab3-a0c1-0790c9cbec5d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_9b29803b-0c0b-403a-9601-eab7bd43730e" xlink:to="loc_srt_ProductsAndServicesDomain_804d0ee0-6da3-4ab3-a0c1-0790c9cbec5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a1ddb780-d59e-460d-b996-b6ce763c7b53" xlink:href="biib-20220930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_804d0ee0-6da3-4ab3-a0c1-0790c9cbec5d" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_a1ddb780-d59e-460d-b996-b6ce763c7b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:to="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_1198c3b5-7531-48e1-bdec-ffa0dcccb0ff" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7612794e-4f50-4109-8534-1c7d41ba3b07" xlink:to="loc_srt_NameOfMajorCustomerDomain_1198c3b5-7531-48e1-bdec-ffa0dcccb0ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_475187b2-462c-47ab-b627-6d8e55309037" xlink:href="biib-20220930.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1198c3b5-7531-48e1-bdec-ffa0dcccb0ff" xlink:to="loc_biib_RocheGroupGenentechMember_475187b2-462c-47ab-b627-6d8e55309037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_68891570-0c7a-414c-91db-55c48f5edc08" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_f41f1452-af11-476d-adef-eac6ea896102" xlink:href="biib-20220930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_biib_ShareOfCoPromotionProfits_f41f1452-af11-476d-adef-eac6ea896102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_910ecae6-a9f7-4fb1-bf14-583122d7e10c" xlink:href="biib-20220930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_910ecae6-a9f7-4fb1-bf14-583122d7e10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_4a7f19dc-a132-4c62-938f-232acd60151b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_faccadb4-e82d-4dd9-b03e-c88c3a1d95f0" xlink:to="loc_us-gaap_Revenues_4a7f19dc-a132-4c62-938f-232acd60151b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_cfd337e9-c484-4edb-bb5a-3dd8e0c652ee" xlink:href="biib-20220930.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_cfd337e9-c484-4edb-bb5a-3dd8e0c652ee" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6901dfe8-b991-4b3f-80ee-63a5f958973e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5675f802-4a77-44a0-b1ce-d68fdbbcfb2e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6901dfe8-b991-4b3f-80ee-63a5f958973e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementMember_55361568-2144-488b-b0bb-86977aa06287" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6901dfe8-b991-4b3f-80ee-63a5f958973e" xlink:to="loc_us-gaap_CollaborativeArrangementMember_55361568-2144-488b-b0bb-86977aa06287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_29e4741f-bfb1-409a-8b07-1b946fa83a6f" xlink:to="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_32fe920a-b574-4970-8b72-e909a3fc7c1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:to="loc_us-gaap_RoyaltyMember_32fe920a-b574-4970-8b72-e909a3fc7c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_61ad31ed-4c02-4d11-bec9-ba7fc00892cf" xlink:href="biib-20220930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:to="loc_biib_OthercorporaterevenuesMember_61ad31ed-4c02-4d11-bec9-ba7fc00892cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_c3a0213a-190d-4711-be6d-85fff0cec49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_73520c3e-35d1-407d-bad4-ca86302ae4e8" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_c3a0213a-190d-4711-be6d-85fff0cec49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_09793fbf-8ae5-4153-84c7-21623347b91b" xlink:to="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_4379c015-dbec-4fd8-9287-a1ede70e6d15" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_4379c015-dbec-4fd8-9287-a1ede70e6d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZINBRYTAMember_d154f913-c412-4070-9e8c-11bc37bb4ab9" xlink:href="biib-20220930.xsd#biib_ZINBRYTAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_b236b532-05ae-4b20-84b5-88fb3266f370" xlink:to="loc_biib_ZINBRYTAMember_d154f913-c412-4070-9e8c-11bc37bb4ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bdc35500-f307-440f-bb03-fd3ee920482f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd946c10-568b-41a2-9610-1846d1fbeac2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bdc35500-f307-440f-bb03-fd3ee920482f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_88befec2-c7f5-4cdf-be27-3b8aa0624770" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bdc35500-f307-440f-bb03-fd3ee920482f" xlink:to="loc_us-gaap_Revenues_88befec2-c7f5-4cdf-be27-3b8aa0624770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52ebcad6-0e28-49d0-b402-1c2a6926d03c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_52ebcad6-0e28-49d0-b402-1c2a6926d03c" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:to="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_c444fdae-1707-4242-9fca-7140da3c5632" xlink:to="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OthercorporaterevenuesMember_c16f682e-df61-4dc6-8592-02b9667eb4a7" xlink:href="biib-20220930.xsd#biib_OthercorporaterevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:to="loc_biib_OthercorporaterevenuesMember_c16f682e-df61-4dc6-8592-02b9667eb4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_856c8ec9-8150-47b3-9a40-87bcbd3be108" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4b1033ea-5410-4695-8e28-61b2591d9f46" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_856c8ec9-8150-47b3-9a40-87bcbd3be108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:to="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_7c7e0106-f1cb-4364-bd86-c12bdb23ae93" xlink:to="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_014015af-78d9-4a3e-89ba-d0924a7c3b13" xlink:href="biib-20220930.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:to="loc_biib_DistributorOneMember_014015af-78d9-4a3e-89ba-d0924a7c3b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_8e051a5f-2e58-4ed1-b313-665086032877" xlink:href="biib-20220930.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_687b13d7-b5c1-44f9-9b77-45bbfd36818e" xlink:to="loc_biib_DistributorTwoMember_8e051a5f-2e58-4ed1-b313-665086032877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_cd47226f-2573-4050-a627-5aeb58193fe5" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_28efe549-4b65-4694-a39b-1302b614bf0c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_us-gaap_Revenues_28efe549-4b65-4694-a39b-1302b614bf0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_3c4de6e8-528e-45a3-a2ce-3bd5e146534f" xlink:href="biib-20220930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_3c4de6e8-528e-45a3-a2ce-3bd5e146534f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_039bda5f-696f-4620-9461-d5077ae58979" xlink:href="biib-20220930.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_bb93a74e-a2ab-4a95-81ca-24f7769d7c76" xlink:to="loc_biib_NumberOfWholesalers_039bda5f-696f-4620-9461-d5077ae58979" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6bd097b6-b99d-45ef-a960-2fb090829c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6bd097b6-b99d-45ef-a960-2fb090829c2c" xlink:to="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:to="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_714c5ffe-ad13-4931-9775-c25997aaaf29" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_af57f0ae-09a6-41e2-a7d8-23440aee2af5" xlink:to="loc_srt_ProductsAndServicesDomain_714c5ffe-ad13-4931-9775-c25997aaaf29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LecanemabMember_e7f6b0ca-f390-46bd-8f6b-1f6b84622dad" xlink:href="biib-20220930.xsd#biib_LecanemabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_714c5ffe-ad13-4931-9775-c25997aaaf29" xlink:to="loc_biib_LecanemabMember_e7f6b0ca-f390-46bd-8f6b-1f6b84622dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_6bbd6d3e-0e80-4ca8-8866-07d1e653330f" xlink:to="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a692a20-ff0b-4eee-bd9f-e00dbb7a0c91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_1a692a20-ff0b-4eee-bd9f-e00dbb7a0c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd2d3552-e3b7-4414-b0a7-061fdb6284f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_dd2d3552-e3b7-4414-b0a7-061fdb6284f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_840e36f4-d052-4f0c-ba52-f9d72090d141" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_840e36f4-d052-4f0c-ba52-f9d72090d141" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Inventorynetcurrentandnoncurrent_0ad07b00-940f-4122-a96a-ca18abb35cfd" xlink:href="biib-20220930.xsd#biib_Inventorynetcurrentandnoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_0e7a53e0-664f-43b3-8333-e41340d4d2ea" xlink:to="loc_biib_Inventorynetcurrentandnoncurrent_0ad07b00-940f-4122-a96a-ca18abb35cfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_477b947d-b7e1-42ed-9409-d5dd275c67e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_477b947d-b7e1-42ed-9409-d5dd275c67e9" xlink:to="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_50bcb596-cd5b-40ae-8222-7d0cfa3c2878" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_00925fb8-27e0-46a6-8ff9-f0f109cc88ab" xlink:to="loc_srt_ProductsAndServicesDomain_50bcb596-cd5b-40ae-8222-7d0cfa3c2878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_9d5cb914-ac7c-4bca-8624-065ee7a54872" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_50bcb596-cd5b-40ae-8222-7d0cfa3c2878" xlink:to="loc_biib_ADUHELMMember_9d5cb914-ac7c-4bca-8624-065ee7a54872" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad7be2b2-494f-4338-9a6c-08bc9c06dd57" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_80854ad9-98a7-404c-8ff8-2d6834a7d675" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad7be2b2-494f-4338-9a6c-08bc9c06dd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_bdf06454-f584-420a-92d4-a9dd61c4a9ea" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad7be2b2-494f-4338-9a6c-08bc9c06dd57" xlink:to="loc_biib_EisaiMember_bdf06454-f584-420a-92d4-a9dd61c4a9ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e9afaa-82cd-45b9-851b-decd8924b0e1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_7c2237b7-e1a1-4e1a-90af-4b8f493eaebb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e9afaa-82cd-45b9-851b-decd8924b0e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CentersForMedicareAndMedicaidServiceMember_e456afa5-8b41-43e7-82f1-4c54c8265f5d" xlink:href="biib-20220930.xsd#biib_CentersForMedicareAndMedicaidServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_58e9afaa-82cd-45b9-851b-decd8924b0e1" xlink:to="loc_biib_CentersForMedicareAndMedicaidServiceMember_e456afa5-8b41-43e7-82f1-4c54c8265f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_75810f1c-d2c9-479c-80b2-1727754f109d" xlink:to="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_d3027faf-7615-4748-869e-793344ac9f8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_us-gaap_InventoryWriteDown_d3027faf-7615-4748-869e-793344ac9f8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_70b7bd00-1c70-492c-bc24-a4bd346571ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_70b7bd00-1c70-492c-bc24-a4bd346571ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_927de500-de4a-4c0a-8156-7ced920639ab" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_927de500-de4a-4c0a-8156-7ced920639ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_d29e8372-6552-48c9-9bd2-2299f0bed28e" xlink:href="biib-20220930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_cd6c8f50-73ff-4080-aa23-fe64a21339c9" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_d29e8372-6552-48c9-9bd2-2299f0bed28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e0c95cf-adc4-4793-b076-9edcf1a04776" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_7e0c95cf-adc4-4793-b076-9edcf1a04776" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:href="biib-20220930.xsd#biib_ResearchanddevelopmentassetAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchanddevelopmentassetAxis_e5833811-bf5a-4b5d-82db-58326f61555d" xlink:to="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111Member_d817bc67-5219-4404-ae4a-b2f257eb773a" xlink:href="biib-20220930.xsd#biib_BIIB111Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_BIIB111Member_d817bc67-5219-4404-ae4a-b2f257eb773a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB112Member_9c28434b-8214-4d0f-9853-a680931c6b8e" xlink:href="biib-20220930.xsd#biib_BIIB112Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_BIIB112Member_9c28434b-8214-4d0f-9853-a680931c6b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VixotrigineMember_530444a9-349e-4717-899a-028857f00d0b" xlink:href="biib-20220930.xsd#biib_VixotrigineMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_VixotrigineMember_530444a9-349e-4717-899a-028857f00d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TGNMember_8928b9d9-4e50-43ab-8a2a-860d79c02ece" xlink:href="biib-20220930.xsd#biib_TGNMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_TGNMember_8928b9d9-4e50-43ab-8a2a-860d79c02ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BIIB111AndBIIB112Member_0fcfbc2f-c2d5-41a4-8ab0-62e083f732dd" xlink:href="biib-20220930.xsd#biib_BIIB111AndBIIB112Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ResearchAndDevelopmentAssetDomain_70a5765f-1fe2-43fa-8bb9-b4fd0eece9c2" xlink:to="loc_biib_BIIB111AndBIIB112Member_0fcfbc2f-c2d5-41a4-8ab0-62e083f732dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentAssetDomain_2fda377c-4b07-477b-9f18-fcddff3d375a" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentAssetDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_81a840ed-e704-487f-8905-19ac63242656" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_a03b8f4e-7ad7-4e99-84e5-7bd9ddeb164a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_a03b8f4e-7ad7-4e99-84e5-7bd9ddeb164a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_dba2e108-c16d-4c75-9c0a-b8734d258850" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_b591d36a-20b3-40c0-b51d-23ed33d1743d" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_dba2e108-c16d-4c75-9c0a-b8734d258850" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ca0e962a-faa0-41aa-a810-c534773eaae1" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OutLicensedPatentsMember_9ff03beb-8d0d-4377-9292-bddbf73f2e74" xlink:href="biib-20220930.xsd#biib_OutLicensedPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:to="loc_biib_OutLicensedPatentsMember_9ff03beb-8d0d-4377-9292-bddbf73f2e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_06f7d059-7792-4430-8a84-8e1a2e7d6706" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_26a0750a-9a2a-4e83-b9a5-a5f167bae233" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_06f7d059-7792-4430-8a84-8e1a2e7d6706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_e4d1c2d1-926b-4591-87ce-08a0ee7d6158" xlink:to="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_562e3746-b058-471a-a812-aa71b08371ef" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:to="loc_srt_MinimumMember_562e3746-b058-471a-a812-aa71b08371ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_472b126e-ab41-4aaa-b3d9-12be3cd9a20d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_860da236-2553-4c3f-bd40-9229854ada48" xlink:to="loc_srt_MaximumMember_472b126e-ab41-4aaa-b3d9-12be3cd9a20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_77371459-0679-4cd4-8062-854255ee4f19" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8467ce94-8f81-4b09-bf35-9b166e93c3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8467ce94-8f81-4b09-bf35-9b166e93c3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6d6e2223-f892-4cd6-8ec9-4ca8b20608f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_6d6e2223-f892-4cd6-8ec9-4ca8b20608f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6052f1a-a826-4ab4-aae8-78eee2d23963" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_c6052f1a-a826-4ab4-aae8-78eee2d23963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_790ba8ec-ff00-4c22-b5f1-6910478f9ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_790ba8ec-ff00-4c22-b5f1-6910478f9ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_46e994cc-23fc-4e17-b9b3-be7c1a8e33a6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_46e994cc-23fc-4e17-b9b3-be7c1a8e33a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_333c85e5-c15f-48e2-b4b1-a33a75ef9bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_333c85e5-c15f-48e2-b4b1-a33a75ef9bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_20184838-93dc-495d-9f19-ecd8c7488da7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_061caaf0-717f-4e90-a8b1-190c449e6e06" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_20184838-93dc-495d-9f19-ecd8c7488da7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_8420b3f4-655a-45a5-9362-3fad52909499" xlink:href="biib-20220930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_8420b3f4-655a-45a5-9362-3fad52909499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b3cf3db3-202e-49b6-abbc-512a2c71845c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_b3cf3db3-202e-49b6-abbc-512a2c71845c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_15f86d5c-4d5a-432c-9b1b-4f6ef1a3ab5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_15f86d5c-4d5a-432c-9b1b-4f6ef1a3ab5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0d8f8ae9-cc1e-46b2-92d4-c661d186d818" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_0d8f8ae9-cc1e-46b2-92d4-c661d186d818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ee3ce095-d108-4fc1-85b6-383f0256ecf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_ee3ce095-d108-4fc1-85b6-383f0256ecf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_afa2c5c5-7c1a-4cb7-ab8c-1aa38c21e0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_afa2c5c5-7c1a-4cb7-ab8c-1aa38c21e0fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_87104b26-f0ca-406e-bcbd-fc40c7a11944" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_87104b26-f0ca-406e-bcbd-fc40c7a11944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_25bb6d19-e783-4bef-8b4e-324f560548fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_25bb6d19-e783-4bef-8b4e-324f560548fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6341d175-6583-41c1-9589-3ee0ce5930c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_8f048695-ec0d-4901-9bf1-9d72190ce8d0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_6341d175-6583-41c1-9589-3ee0ce5930c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#IntangibleAssetsandGoodwillDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8e77b88-6760-4628-954a-9ae74aa87c0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_deb2fdd4-3d52-4be4-9229-d33c5b2571b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8e77b88-6760-4628-954a-9ae74aa87c0b" xlink:to="loc_us-gaap_GoodwillRollForward_deb2fdd4-3d52-4be4-9229-d33c5b2571b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_09d24acd-0541-4e59-b80e-3229ba9f44f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_deb2fdd4-3d52-4be4-9229-d33c5b2571b2" xlink:to="loc_us-gaap_Goodwill_09d24acd-0541-4e59-b80e-3229ba9f44f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_35f57dc0-8a6f-4963-85b1-0c7dc3b332d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_deb2fdd4-3d52-4be4-9229-d33c5b2571b2" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_35f57dc0-8a6f-4963-85b1-0c7dc3b332d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c4b86541-b04a-4bb9-a074-b0ef57af7a98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_deb2fdd4-3d52-4be4-9229-d33c5b2571b2" xlink:to="loc_us-gaap_Goodwill_c4b86541-b04a-4bb9-a074-b0ef57af7a98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7c8f85a3-60a3-4384-bce6-c4e89ecf9d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a8e77b88-6760-4628-954a-9ae74aa87c0b" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_7c8f85a3-60a3-4384-bce6-c4e89ecf9d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d39d7db5-9fb1-4a1f-a949-c1a3f863a1cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d39d7db5-9fb1-4a1f-a949-c1a3f863a1cb" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_32b7a1f7-2b7e-474f-afdb-86f505552165" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_21a397b3-5929-407c-baad-91ee6bbaa4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_21a397b3-5929-407c-baad-91ee6bbaa4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_18f36b92-c559-486d-b920-a0b4191b21e9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_18f36b92-c559-486d-b920-a0b4191b21e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_d868d52d-5a0c-4adb-b678-d4600a0b1e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_75e953cc-b892-453c-93b1-cf06c5bfcdc3" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_d868d52d-5a0c-4adb-b678-d4600a0b1e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_8bf959e6-3960-47c8-b69a-388e79a1663a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2e5cb387-3126-4a56-8bb2-e1d41730e616" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_8bf959e6-3960-47c8-b69a-388e79a1663a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4e97eed6-6fcb-429e-a45f-e241ed608542" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_8bf959e6-3960-47c8-b69a-388e79a1663a" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4e97eed6-6fcb-429e-a45f-e241ed608542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_6506ba4e-358b-40b3-bb1f-0a7625cb6c3c" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_32b34b44-3f6d-4ae2-8244-2d34ab312cbc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_32b34b44-3f6d-4ae2-8244-2d34ab312cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6ad578e2-c33f-451c-8e72-89dec1e90174" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6ad578e2-c33f-451c-8e72-89dec1e90174" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetBackedSecuritiesMember_86135a57-bdf6-4954-b5b1-f1504bfd8c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_5f3ac6fa-7a0a-40aa-be9f-bc784fea6707" xlink:to="loc_us-gaap_AssetBackedSecuritiesMember_86135a57-bdf6-4954-b5b1-f1504bfd8c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_e09cf14d-358e-4dba-a5c6-59df0be4373b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_43b84645-30da-4b58-8b92-883213d3b1d6" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_e09cf14d-358e-4dba-a5c6-59df0be4373b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_12f5ea4f-1985-4777-9c73-ccbb034e8c62" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_e09cf14d-358e-4dba-a5c6-59df0be4373b" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_12f5ea4f-1985-4777-9c73-ccbb034e8c62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c114412-951a-472f-9e43-a5ea90c993f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_9e010740-6c18-4000-a987-67a219d82b25" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c114412-951a-472f-9e43-a5ea90c993f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_1c114412-951a-472f-9e43-a5ea90c993f2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ab55f85-3f69-4036-ae4e-761237f3f34c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_9ab55f85-3f69-4036-ae4e-761237f3f34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6dcdfadb-d5f3-4f9b-97bb-d87e9aac8973" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6dcdfadb-d5f3-4f9b-97bb-d87e9aac8973" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_af59bf09-6931-4bc2-9d19-0e1f4fa2b412" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_af59bf09-6931-4bc2-9d19-0e1f4fa2b412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_2a9fc572-dd0a-4c29-9fa7-f8bb4188512d" xlink:href="biib-20220930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_2a9fc572-dd0a-4c29-9fa7-f8bb4188512d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5714fe5b-c71e-4744-9021-1bd2c0f6c571" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_5714fe5b-c71e-4744-9021-1bd2c0f6c571" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_473ffcfd-f17c-4d3d-9b14-b300da1acf0e" xlink:href="biib-20220930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_473ffcfd-f17c-4d3d-9b14-b300da1acf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_8433934c-4ecd-4ace-87e0-96ad964fc63c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_8433934c-4ecd-4ace-87e0-96ad964fc63c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_aad27809-d07d-4248-80fd-28f1b1d41d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_c84b9626-d774-49fb-aada-849f209c9f88" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_aad27809-d07d-4248-80fd-28f1b1d41d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_c37adb38-d3df-4999-934c-607005aa724f" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7e5f4e2d-cc12-416f-a872-dc95e67c6d3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_7e5f4e2d-cc12-416f-a872-dc95e67c6d3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_24ac6175-a37e-409e-8184-5e4fc97feaf5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_24ac6175-a37e-409e-8184-5e4fc97feaf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_82a87c95-c6b8-4434-9b29-cc0d50663f49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_82a87c95-c6b8-4434-9b29-cc0d50663f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a51c9267-892f-4128-9e2b-c6676cccc469" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_af260f38-8ec5-42ff-8f9f-f6ff4405e79b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_a51c9267-892f-4128-9e2b-c6676cccc469" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_78ffe29d-2cd3-40ec-bd28-5ebdfa47bfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_f5ccd65f-2ceb-4c84-bbf2-85746124f67c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78ffe29d-2cd3-40ec-bd28-5ebdfa47bfb4" xlink:to="loc_us-gaap_AssetImpairmentCharges_f5ccd65f-2ceb-4c84-bbf2-85746124f67c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_942c1605-26c8-4ab8-b369-ea3cc1a72102" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78ffe29d-2cd3-40ec-bd28-5ebdfa47bfb4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_942c1605-26c8-4ab8-b369-ea3cc1a72102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TechnologicalAndRegulatorySuccessProbability_f9203ded-f1c4-491a-9106-1b401250e8ae" xlink:href="biib-20220930.xsd#biib_TechnologicalAndRegulatorySuccessProbability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78ffe29d-2cd3-40ec-bd28-5ebdfa47bfb4" xlink:to="loc_biib_TechnologicalAndRegulatorySuccessProbability_f9203ded-f1c4-491a-9106-1b401250e8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8d6d6dc6-0426-4584-809e-2d46ea9e6c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8d6d6dc6-0426-4584-809e-2d46ea9e6c2f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:to="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_45cc18f2-4108-4d7b-95fa-c694045b1be2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6dcd10e9-7365-435e-bb85-7ce0de9f51b7" xlink:to="loc_srt_RangeMember_45cc18f2-4108-4d7b-95fa-c694045b1be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_deec15bd-8357-41a5-82e9-b9e1f97443ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_45cc18f2-4108-4d7b-95fa-c694045b1be2" xlink:to="loc_srt_WeightedAverageMember_deec15bd-8357-41a5-82e9-b9e1f97443ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_458f4eaa-957c-41d1-b6a0-83baa2dc49a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f51b79fe-0974-489d-8c87-abcfda1d3cff" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_458f4eaa-957c-41d1-b6a0-83baa2dc49a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_73d399d6-48ca-4991-a6ff-fd27b1dfd6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_458f4eaa-957c-41d1-b6a0-83baa2dc49a5" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_73d399d6-48ca-4991-a6ff-fd27b1dfd6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_db029986-9ae6-4fb7-a4ec-3d52172d4fc6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_30aeecfe-0aed-4335-98d1-0dcbd15b38c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_30aeecfe-0aed-4335-98d1-0dcbd15b38c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beaa4ae4-df15-4936-9eb8-134793fea03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_68ca3fd5-864d-4c32-b5a0-f977d2d55930" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_beaa4ae4-df15-4936-9eb8-134793fea03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_28d5b67d-1c7c-4dd1-8b7a-f443189053ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_28d5b67d-1c7c-4dd1-8b7a-f443189053ce" xlink:to="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:to="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fbda076d-fe24-4893-a465-b9735f242558" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_ab161de5-d0fa-4450-92eb-352c3e4b4303" xlink:href="biib-20220930.xsd#biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember_ab161de5-d0fa-4450-92eb-352c3e4b4303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d852b969-823d-45ca-9611-baea2e17c1ae" xlink:href="biib-20220930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_d852b969-823d-45ca-9611-baea2e17c1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_fd5fe2f6-2758-48cd-b6a9-4289c6c41581" xlink:href="biib-20220930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_fd5fe2f6-2758-48cd-b6a9-4289c6c41581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c4c62040-543f-42fe-9108-909f8a70869c" xlink:href="biib-20220930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_c4c62040-543f-42fe-9108-909f8a70869c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_92c7b4df-cc84-4ac5-a350-f94721a85fac" xlink:href="biib-20220930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_92c7b4df-cc84-4ac5-a350-f94721a85fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_b9ce3c69-93e5-4538-b0aa-feac590f66f8" xlink:href="biib-20220930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7b1a7b80-919f-4230-a39b-ace99656bb73" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_b9ce3c69-93e5-4538-b0aa-feac590f66f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_671353b0-e77c-47a8-86c5-21b973fc9a9e" xlink:to="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_98b058fd-d67e-4283-989d-49f32441f188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_98b058fd-d67e-4283-989d-49f32441f188" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_70436fc6-0e74-48b8-b03a-a02ac858ca10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_NotesPayable_70436fc6-0e74-48b8-b03a-a02ac858ca10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFairValue_e5d50d3e-d8aa-4eb2-89a9-9778c5a07cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_DebtInstrumentFairValue_e5d50d3e-d8aa-4eb2-89a9-9778c5a07cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b0a8ca8-801c-42ae-97a1-936208996607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_81d16b1d-1d38-47e6-80e5-c516883cc2a4" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9b0a8ca8-801c-42ae-97a1-936208996607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="simple" xlink:href="biib-20220930.xsd#FairValueMeasurementsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_02f84d5e-7122-4ac7-b3cb-5fce671dd8f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_02f84d5e-7122-4ac7-b3cb-5fce671dd8f1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e956f63f-60d7-4b15-ad0a-575642fc3906" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_ad98b87e-8208-474b-9f47-5798a01050b5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e956f63f-60d7-4b15-ad0a-575642fc3906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9b427b51-de4d-4fe7-9845-a9ca68501b3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e956f63f-60d7-4b15-ad0a-575642fc3906" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9b427b51-de4d-4fe7-9845-a9ca68501b3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_9781d91f-e4fc-4ad9-8536-a91be06cb8a3" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f1f8ab4b-c350-4e76-8798-6f3acd9da4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_f1f8ab4b-c350-4e76-8798-6f3acd9da4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_43138d41-c1f6-44c0-9a0a-55e63074cfc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_43138d41-c1f6-44c0-9a0a-55e63074cfc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47240eef-9ff9-483d-9231-bae464a802d8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_1bbfebb5-34d1-446a-81ec-8a5018055765" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47240eef-9ff9-483d-9231-bae464a802d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27ea729d-e750-4b21-83c7-6c99b7dbb9f0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_27ea729d-e750-4b21-83c7-6c99b7dbb9f0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:to="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_6c61ebc1-d5c6-4552-9dab-767425549e15" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_648222e0-f62c-4b88-bce0-6c367eb4d3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_CommercialPaperMember_648222e0-f62c-4b88-bce0-6c367eb4d3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_d1f6dc55-453c-42a4-80ef-5503a55f8956" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_d1f6dc55-453c-42a4-80ef-5503a55f8956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_85a87dbe-1320-4906-aa72-617a152af6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_85a87dbe-1320-4906-aa72-617a152af6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_b0dfb513-cefc-4ce7-9e9e-df2eca1fe73c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_1cdeb781-37c7-48db-81ce-4c34a4a5e77a" xlink:to="loc_us-gaap_DebtSecuritiesMember_b0dfb513-cefc-4ce7-9e9e-df2eca1fe73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_7a9f278b-dcbc-440e-9f0f-187a8c6f3c89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_5e316f1a-732b-483f-a14f-3d94ba2ef6bb" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_7a9f278b-dcbc-440e-9f0f-187a8c6f3c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_b6c11659-2406-4012-908a-d1ff38851c90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_7a9f278b-dcbc-440e-9f0f-187a8c6f3c89" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_b6c11659-2406-4012-908a-d1ff38851c90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_ae035d46-8882-4dcd-8f54-abcbbf609b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValueAbstract_b6c11659-2406-4012-908a-d1ff38851c90" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_ae035d46-8882-4dcd-8f54-abcbbf609b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a6c4509b-ced3-4f94-b263-cbd4ad956cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_a6c4509b-ced3-4f94-b263-cbd4ad956cea" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:to="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_485036ce-f85f-4949-8232-8ed4e264894f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_cf8fa886-4fb0-4608-90e5-d76c2465e277" xlink:href="biib-20220930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_cf8fa886-4fb0-4608-90e5-d76c2465e277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesNonCurrentMember_5f46b2b4-85e5-4300-858d-a55f66207da6" xlink:href="biib-20220930.xsd#biib_CorporateDebtSecuritiesNonCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_CorporateDebtSecuritiesNonCurrentMember_5f46b2b4-85e5-4300-858d-a55f66207da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_1d29ac26-0f9f-4d87-b059-581193c77002" xlink:href="biib-20220930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_1d29ac26-0f9f-4d87-b059-581193c77002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesNonCurrentMember_48f0f2f4-a221-4603-869d-d6c673f0df25" xlink:href="biib-20220930.xsd#biib_GovernmentSecuritiesNonCurrentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_GovernmentSecuritiesNonCurrentMember_48f0f2f4-a221-4603-869d-d6c673f0df25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_0d9e1a9b-5643-4630-bd6b-548ae5b722d0" xlink:href="biib-20220930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember_0d9e1a9b-5643-4630-bd6b-548ae5b722d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_f46ad034-6bf7-4f28-9012-f375a6003121" xlink:href="biib-20220930.xsd#biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember_f46ad034-6bf7-4f28-9012-f375a6003121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesCurrentMember_2892e4cc-0eaa-4b9a-aa4d-43d654e14123" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesCurrentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_EquitySecuritiesCurrentMember_2892e4cc-0eaa-4b9a-aa4d-43d654e14123" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_94fe797f-f21f-4cb1-9674-4f2231a76cc6" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_98e198d5-d3b4-4a7a-bdde-c3e896651dd5" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_94fe797f-f21f-4cb1-9674-4f2231a76cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_bc6adf5a-dac9-42d9-9724-525cc1684e06" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8e9f2933-ec1b-4a42-bf2b-bdaff3f13797" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8e9f2933-ec1b-4a42-bf2b-bdaff3f13797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_87ac79e5-16af-4698-ab1e-8f19707bb680" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_87ac79e5-16af-4698-ab1e-8f19707bb680" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_090aecb0-95d7-4d8e-89f8-8e61aa87e738" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_090aecb0-95d7-4d8e-89f8-8e61aa87e738" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b794359c-e5cf-464b-a794-2b7192a04293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_783e3460-b93d-40b5-8405-8e7b1652114b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_b794359c-e5cf-464b-a794-2b7192a04293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_fa0905f1-7261-4855-bb25-c1a849e0d9e2" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_10bd6a3e-114b-43fb-ab44-0dc1e05d667d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_10bd6a3e-114b-43fb-ab44-0dc1e05d667d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_26507c55-0dfe-40f2-b3e3-4797ffb969dc" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_26507c55-0dfe-40f2-b3e3-4797ffb969dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_01677755-6c67-4940-89f9-c4057dee6c31" xlink:href="biib-20220930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_01677755-6c67-4940-89f9-c4057dee6c31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_264d9a45-c4ad-4569-ae56-db5f16aff474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_c9ba6832-0f73-45bc-8ff5-b2b8008a84a3" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_264d9a45-c4ad-4569-ae56-db5f16aff474" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d85c4b0d-6279-4c25-a6f0-a52a0de82900" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d85c4b0d-6279-4c25-a6f0-a52a0de82900" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c6c50104-b7c7-4ef4-8c98-624ee855686e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_c6c50104-b7c7-4ef4-8c98-624ee855686e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_252162eb-f29b-47d0-9359-03d9bb008f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_252162eb-f29b-47d0-9359-03d9bb008f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_61af4a98-8948-4004-a7db-807cf5eeb25d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_61af4a98-8948-4004-a7db-807cf5eeb25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e9ef4e33-0575-46b7-8529-494aa58cd3e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_e9ef4e33-0575-46b7-8529-494aa58cd3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e08e3ef8-d50d-49a6-9075-495cc032f1df" xlink:href="biib-20220930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost_e08e3ef8-d50d-49a6-9075-495cc032f1df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_2f61e7e9-eb7c-4a8d-81ad-4b3dc5b66fde" xlink:href="biib-20220930.xsd#biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue_2f61e7e9-eb7c-4a8d-81ad-4b3dc5b66fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea8be482-52ab-48f4-b461-390c556c799e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ea8be482-52ab-48f4-b461-390c556c799e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf1adfe6-948b-4903-a563-448478b3128d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_aa783e67-2ff3-4d07-bbfa-6893f666b390" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_cf1adfe6-948b-4903-a563-448478b3128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetails3"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetails3" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ac7a682-0bad-4385-bbb1-a50e9ae388b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e874d220-ccd7-4662-b434-eb6549995587" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ac7a682-0bad-4385-bbb1-a50e9ae388b8" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_e874d220-ccd7-4662-b434-eb6549995587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9f6f9133-74f6-47fa-861e-fb12d2955eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ac7a682-0bad-4385-bbb1-a50e9ae388b8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_9f6f9133-74f6-47fa-861e-fb12d2955eb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8f1d642c-4710-4421-bd9d-7b90706a174d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1ac7a682-0bad-4385-bbb1-a50e9ae388b8" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_8f1d642c-4710-4421-bd9d-7b90706a174d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0e86f06d-a7e7-41eb-82e3-e52c3ceb484d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AverageMaturityOfMarketableSecurities_511f77d1-7202-4bc8-8072-00f05c2be43e" xlink:href="biib-20220930.xsd#biib_AverageMaturityOfMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0e86f06d-a7e7-41eb-82e3-e52c3ceb484d" xlink:to="loc_biib_AverageMaturityOfMarketableSecurities_511f77d1-7202-4bc8-8072-00f05c2be43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="simple" xlink:href="biib-20220930.xsd#FinancialInstrumentsFinancialInstrumentsDetailsTextual2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_05e1e68b-e73e-4182-b22a-33d1f22da29e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsAllOtherInvestmentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsAllOtherInvestmentsAbstract_05e1e68b-e73e-4182-b22a-33d1f22da29e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_59ab4718-78c5-4e81-a3a7-5f7a73d8b71e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d8148f60-87c1-4a27-b254-24919e20744f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_59ab4718-78c5-4e81-a3a7-5f7a73d8b71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_efa2fb06-b935-4902-8114-f3eee5825fbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_59ab4718-78c5-4e81-a3a7-5f7a73d8b71e" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_efa2fb06-b935-4902-8114-f3eee5825fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:to="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_938768af-a7b8-4ba1-8b5d-20372d68a133" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_57fd03ec-b758-4b64-ae17-5ccc35ac81ff" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_938768af-a7b8-4ba1-8b5d-20372d68a133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_37a4b9b3-8aaf-4271-a8a7-b67bd89302f8" xlink:href="biib-20220930.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_938768af-a7b8-4ba1-8b5d-20372d68a133" xlink:to="loc_biib_StrategicInvestmentsMember_37a4b9b3-8aaf-4271-a8a7-b67bd89302f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7c6f7420-840f-4627-83f7-52cab0d0e1d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e2bbd319-afac-442f-957e-18c69c9f80da" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_7c6f7420-840f-4627-83f7-52cab0d0e1d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_e6cd04c7-69c0-4b12-adb4-a53d57d7fdca" xlink:href="biib-20220930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7c6f7420-840f-4627-83f7-52cab0d0e1d7" xlink:to="loc_biib_StrategicInvestmentPortfolio_e6cd04c7-69c0-4b12-adb4-a53d57d7fdca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#DerivativeInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_80eb2908-ce07-46a1-b4c6-3bc85384a48d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_80eb2908-ce07-46a1-b4c6-3bc85384a48d" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeMaturityDomain_11ff9471-9537-40f6-a590-a2e159934c8f" xlink:href="biib-20220930.xsd#biib_DerivativeMaturityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityAxis_823d4de3-d393-4d50-8bef-f4a6d7606289" xlink:to="loc_biib_DerivativeMaturityDomain_11ff9471-9537-40f6-a590-a2e159934c8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShorttermderivativeMember_30c7cc07-3750-4b13-b15c-3c7f46a85027" xlink:href="biib-20220930.xsd#biib_ShorttermderivativeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DerivativeMaturityDomain_11ff9471-9537-40f6-a590-a2e159934c8f" xlink:to="loc_biib_ShorttermderivativeMember_30c7cc07-3750-4b13-b15c-3c7f46a85027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_8a0545e0-159f-43fb-9a03-2c82bae8c70c" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_55304bbd-36ef-4558-a38a-7361620945c5" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_8a0545e0-159f-43fb-9a03-2c82bae8c70c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_d4eb538f-a142-49d3-ab1a-052fc6e17c9d" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_8a0545e0-159f-43fb-9a03-2c82bae8c70c" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_d4eb538f-a142-49d3-ab1a-052fc6e17c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1736ed88-4e5f-4c08-9982-924a45f811a5" xlink:to="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_8a8d939d-16a1-4613-8a30-00e54218e10a" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_EUR_8a8d939d-16a1-4613-8a30-00e54218e10a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_e0255068-9616-4555-bffa-81d551aaa074" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_GBP_e0255068-9616-4555-bffa-81d551aaa074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_6b4cde1e-221d-4ef6-b287-26a6d08c53ac" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_CHF_6b4cde1e-221d-4ef6-b287-26a6d08c53ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_JPY_bfac39b7-4f32-45cb-9cff-0ed70330f880" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_JPY"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_JPY_bfac39b7-4f32-45cb-9cff-0ed70330f880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_28513af3-3d59-424d-9afa-ee267a2c5d9f" xlink:href="https://xbrl.sec.gov/currency/2021/currency-2021.xsd#currency_CAD"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b05f56da-1d32-4746-83e0-f2d0f1693cd6" xlink:to="loc_currency_CAD_28513af3-3d59-424d-9afa-ee267a2c5d9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d069bf91-1a6b-43af-9b66-b38b9d41028b" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_c28d5938-15c9-4c30-a3b2-3883cdf68233" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:to="loc_us-gaap_SalesMember_c28d5938-15c9-4c30-a3b2-3883cdf68233" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_7e38105a-1007-4b72-81f5-2aac22e57565" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:to="loc_us-gaap_OperatingExpenseMember_7e38105a-1007-4b72-81f5-2aac22e57565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3da7a128-4605-4c38-b502-17611a4326c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e4d843c3-0eb2-4b5a-9ef9-cd371d0a9972" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_3da7a128-4605-4c38-b502-17611a4326c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_5ef12c9a-8d1a-45ce-8ab1-ee0a45d0ef16" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_bd7b7bc5-140e-446d-8a1a-b284b5d8c6b6" xlink:href="biib-20220930.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:to="loc_biib_CashflowsrevenueMember_bd7b7bc5-140e-446d-8a1a-b284b5d8c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_e9e5b5c2-89e3-4a68-b475-2353e353a262" xlink:href="biib-20220930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:to="loc_biib_CashflowsoperatingexpensesMember_e9e5b5c2-89e3-4a68-b475-2353e353a262" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_8cb5370b-29ae-458a-9b40-ca1ca3eae61e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetInvestmentHedgingMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d2cdfaaf-62f1-4cce-99c8-b66a0e88debe" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_8cb5370b-29ae-458a-9b40-ca1ca3eae61e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_700f9ea9-c56c-42f1-acd9-dd9f83959d24" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_a845aee2-e3c8-4444-8a73-9401c46cbdb9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_a845aee2-e3c8-4444-8a73-9401c46cbdb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_824719b0-7ce6-4fd7-8d3f-4c80ee757771" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7c5cfae8-bfae-41f8-a1f3-948f9ac3db0e" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_824719b0-7ce6-4fd7-8d3f-4c80ee757771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bb4af31a-805b-4ae5-bc0a-0a4c899bbbe9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_7fc61950-c443-40d5-8f0c-eb1cd193db44" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_7fc61950-c443-40d5-8f0c-eb1cd193db44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_9cfd3737-7a5d-444d-b7c2-4ecaa4b33e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_9cfd3737-7a5d-444d-b7c2-4ecaa4b33e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_3c35e707-3690-4a42-b913-33b72c5d755b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6a5876b6-2636-419d-b006-604f72f53124" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_3c35e707-3690-4a42-b913-33b72c5d755b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_03dfd03b-e02c-45cf-ab35-728b7d87749b" xlink:to="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7d6d00d8-efdc-43b0-aa88-94f4a9765f74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_7d6d00d8-efdc-43b0-aa88-94f4a9765f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_770bcb89-5c44-41c8-9b23-a0ab54687e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_62f2349b-c2e8-4192-88ed-3d8ab718ab1c" xlink:to="loc_us-gaap_NondesignatedMember_770bcb89-5c44-41c8-9b23-a0ab54687e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6f82977c-708a-4522-a2a2-4deb150a846d" xlink:to="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_6c2cbbe4-bcce-4735-b92b-b670df7303e9" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:to="loc_srt_MinimumMember_6c2cbbe4-bcce-4735-b92b-b670df7303e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2d9a52df-defe-4446-9d14-3f0263382860" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_85b58038-d162-4d6d-91c2-d0de48b93161" xlink:to="loc_srt_MaximumMember_2d9a52df-defe-4446-9d14-3f0263382860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df575ac0-bdcb-4dc0-ac01-52ca6c962f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_69af6262-0e51-45a7-9421-f5d2ea999b7a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df575ac0-bdcb-4dc0-ac01-52ca6c962f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_0e116b55-a1ca-422e-a5db-dd9dce5a3605" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_8d53f861-3aaa-4670-8721-131530f5060a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_8d53f861-3aaa-4670-8721-131530f5060a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_570d98be-ae7d-479e-ae93-2beb93a57c00" xlink:href="biib-20220930.xsd#biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax_570d98be-ae7d-479e-ae93-2beb93a57c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9e9e1707-39ae-4243-97e5-44f05d1edadd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_9e9e1707-39ae-4243-97e5-44f05d1edadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_da73f969-f2e3-4ce3-b80c-fa2e654ccd18" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeNotionalAmount_da73f969-f2e3-4ce3-b80c-fa2e654ccd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3853c868-f172-4e7e-bb7a-97224052a267" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_3853c868-f172-4e7e-bb7a-97224052a267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_96b5c30c-9826-4f78-b429-b9245e77b4f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax_96b5c30c-9826-4f78-b429-b9245e77b4f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_a972e4b6-6ca5-46fc-b5b0-f1218a416a8f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax_a972e4b6-6ca5-46fc-b5b0-f1218a416a8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_d546758f-1026-47ad-a2bd-53a71fa352f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_d546758f-1026-47ad-a2bd-53a71fa352f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ab810e06-fa5c-4de5-b6cb-832a9010cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_ab810e06-fa5c-4de5-b6cb-832a9010cd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c33537f8-8ce1-4b66-8a00-a905899ad8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_c33537f8-8ce1-4b66-8a00-a905899ad8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_96c3b0b0-2927-4416-afb9-66ec5b715184" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_96c3b0b0-2927-4416-afb9-66ec5b715184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_45a2a406-97c1-4c29-816d-627c110de41a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease_45a2a406-97c1-4c29-816d-627c110de41a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_b878348a-1b26-4d55-a085-b4c97a503a40" xlink:href="biib-20220930.xsd#biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease_b878348a-1b26-4d55-a085-b4c97a503a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_590e5169-a3af-4f87-aba8-34d5d0c92300" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet_590e5169-a3af-4f87-aba8-34d5d0c92300" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_d8d034b4-949d-40e1-9cce-6168bd922024" xlink:href="biib-20220930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_UnrealizedGainOnDerivatives_d8d034b4-949d-40e1-9cce-6168bd922024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_d3b84344-8ccf-436e-87fe-5979600e012f" xlink:href="biib-20220930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_UnrealizedLossOnDerivatives_d3b84344-8ccf-436e-87fe-5979600e012f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_6c39321f-6b0f-49ed-baaf-d6be129a2f0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_6c39321f-6b0f-49ed-baaf-d6be129a2f0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_b0f6abde-fc2a-42e8-8884-079fb8134c80" xlink:href="biib-20220930.xsd#biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction_b0f6abde-fc2a-42e8-8884-079fb8134c80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_31e7c1f1-3991-4da3-acf6-77250fbf481f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireEquityMethodInvestments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_PaymentsToAcquireEquityMethodInvestments_31e7c1f1-3991-4da3-acf6-77250fbf481f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_ef8c3512-629d-432b-817f-eb82074a59a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ec56757-38ad-4c7a-85d5-4537f4dad9f6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_ef8c3512-629d-432b-817f-eb82074a59a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5965bf58-fbe4-4cdc-b722-670dc42dec29" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5965bf58-fbe4-4cdc-b722-670dc42dec29" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:href="biib-20220930.xsd#biib_FacilityLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityLocationDomain_e98cc573-5163-4767-a2d0-021924c2943f" xlink:href="biib-20220930.xsd#biib_FacilityLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationAxis_f0183ac8-ede3-41ed-97c8-33b626b6e540" xlink:to="loc_biib_FacilityLocationDomain_e98cc573-5163-4767-a2d0-021924c2943f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SolothurnSwitzerlandMember_8cbd48fc-7f76-4c2a-8d7c-7b3ecdb2b30c" xlink:href="biib-20220930.xsd#biib_SolothurnSwitzerlandMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityLocationDomain_e98cc573-5163-4767-a2d0-021924c2943f" xlink:to="loc_biib_SolothurnSwitzerlandMember_8cbd48fc-7f76-4c2a-8d7c-7b3ecdb2b30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:href="biib-20220930.xsd#biib_FacilityTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:href="biib-20220930.xsd#biib_FacilityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeAxis_579ffc5b-dfac-4735-822c-60f2319fc92c" xlink:to="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiologicsManufacturingMember_656a861e-811a-4cea-9bdf-463c0223a748" xlink:href="biib-20220930.xsd#biib_BiologicsManufacturingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:to="loc_biib_BiologicsManufacturingMember_656a861e-811a-4cea-9bdf-463c0223a748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_d1ebefbc-4ed4-46e7-9979-ed2a3521bbca" xlink:href="biib-20220930.xsd#biib_WarehouseUtilitiesAndSupportSpaceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:to="loc_biib_WarehouseUtilitiesAndSupportSpaceMember_d1ebefbc-4ed4-46e7-9979-ed2a3521bbca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdministrativeSpaceMember_3ba917ad-7f11-4e8a-95b7-49facff48f35" xlink:href="biib-20220930.xsd#biib_AdministrativeSpaceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FacilityTypeDomain_f6524754-968d-4eef-85b7-6e3905605b34" xlink:to="loc_biib_AdministrativeSpaceMember_3ba917ad-7f11-4e8a-95b7-49facff48f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_686ecdec-b8c0-4555-9ee9-1b87efee232b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_4d204883-af61-42e5-80c5-6ce73112c392" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:to="loc_us-gaap_BuildingMember_4d204883-af61-42e5-80c5-6ce73112c392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandMember_0e1d45e7-28d2-45a1-8fe8-834665547439" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:to="loc_us-gaap_LandMember_0e1d45e7-28d2-45a1-8fe8-834665547439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_1d881f57-7413-4e3c-8fbb-fc6de5e7d0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_dc8653bf-efd9-42f6-82cf-4b2377d93844" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_1d881f57-7413-4e3c-8fbb-fc6de5e7d0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_579d87d5-2144-4b65-ba73-0e3d5c0f6a50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_e2efa6a4-1876-4cf0-b39e-29b776020251" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_579d87d5-2144-4b65-ba73-0e3d5c0f6a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A125BroadwayBuildingMember_dfc187c6-d546-4b7b-b003-c0ecb21c8a46" xlink:href="biib-20220930.xsd#biib_A125BroadwayBuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_579d87d5-2144-4b65-ba73-0e3d5c0f6a50" xlink:to="loc_biib_A125BroadwayBuildingMember_dfc187c6-d546-4b7b-b003-c0ecb21c8a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_86179405-188c-41f3-8e16-a9ebb2467c15" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_87d32ea4-d9af-4519-98ab-b27baa1f77b4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_87d32ea4-d9af-4519-98ab-b27baa1f77b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_854cd767-f80c-47dd-9322-2c7d4da39c69" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_Depreciation_854cd767-f80c-47dd-9322-2c7d4da39c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfSquareFeet_f3d7f849-19ef-4da1-a776-f67f1d1fd624" xlink:href="biib-20220930.xsd#biib_NumberOfSquareFeet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_biib_NumberOfSquareFeet_f3d7f849-19ef-4da1-a776-f67f1d1fd624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_0083ea3a-4c31-4a37-92c4-9620af0e38b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_ConstructionInProgressGross_0083ea3a-4c31-4a37-92c4-9620af0e38b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_22a606a3-0a0d-4c04-a0f9-88838a5336ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_22a606a3-0a0d-4c04-a0f9-88838a5336ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_316585ba-1818-414b-9f53-18cb301c9f8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_316585ba-1818-414b-9f53-18cb301c9f8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_63e42676-22e7-489f-8ddc-e32b9f3d6fc6" xlink:href="biib-20220930.xsd#biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance_63e42676-22e7-489f-8ddc-e32b9f3d6fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71f691fe-b14c-45b8-bf50-b2bdfb53edc7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_71f691fe-b14c-45b8-bf50-b2bdfb53edc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_914c58df-8eac-47f6-920c-e430ad72fe37" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a551f43d-d1a8-4398-bf4f-b377034300b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_914c58df-8eac-47f6-920c-e430ad72fe37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#LeasesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_279bcca8-0d3f-4b66-a466-780f33b49dd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_279bcca8-0d3f-4b66-a466-780f33b49dd9" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76a8c0e1-91ca-4fc6-85dd-d47720608120" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_cc934bd4-e748-420b-9871-9f5f108edfcd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76a8c0e1-91ca-4fc6-85dd-d47720608120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_95b69844-3d4a-4a1a-94d5-6c5f0141bf5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_76a8c0e1-91ca-4fc6-85dd-d47720608120" xlink:to="loc_us-gaap_BuildingMember_95b69844-3d4a-4a1a-94d5-6c5f0141bf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_62199f7c-e361-42fe-b933-b7177ab6ec50" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d95d0c9f-4b24-4283-88f5-f3ada14092b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_d95d0c9f-4b24-4283-88f5-f3ada14092b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_10a05a4b-95eb-4596-821d-1293eda7e342" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_10a05a4b-95eb-4596-821d-1293eda7e342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_2fa1d831-63f9-4dcd-a34a-6238ed359eb2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_us-gaap_OperatingLeaseLiability_2fa1d831-63f9-4dcd-a34a-6238ed359eb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_0babd3ec-8062-432d-af91-98cc8752ba5d" xlink:href="biib-20220930.xsd#biib_OperatingLeaseRightOfUseAssetDerecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_biib_OperatingLeaseRightOfUseAssetDerecognized_0babd3ec-8062-432d-af91-98cc8752ba5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseLiabilityDerecognized_367445b0-0c3e-4ff9-85a1-ab726678ac84" xlink:href="biib-20220930.xsd#biib_OperatingLeaseLiabilityDerecognized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_biib_OperatingLeaseLiabilityDerecognized_367445b0-0c3e-4ff9-85a1-ab726678ac84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GainLossOnRestructuringCharges_99b780f8-6d8d-4917-bbaf-a37f3aff2ab1" xlink:href="biib-20220930.xsd#biib_GainLossOnRestructuringCharges"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_0e014cca-a0b6-4694-949d-350a4c48a79b" xlink:to="loc_biib_GainLossOnRestructuringCharges_99b780f8-6d8d-4917-bbaf-a37f3aff2ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IndebtednessDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_e7c4b467-a877-4979-9d1b-4a4e54e89cea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_e7c4b467-a877-4979-9d1b-4a4e54e89cea" xlink:to="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:to="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c9f62f91-06b7-45df-922e-57797508b92a" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9bf134c8-fad1-4751-bfa9-de9be2067032" xlink:href="biib-20220930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_9bf134c8-fad1-4751-bfa9-de9be2067032" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3250SeniorNotesDueFebruary152051Member_5bd34928-8294-46d2-9f76-7727dfdb8d81" xlink:href="biib-20220930.xsd#biib_A3250SeniorNotesDueFebruary152051Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_90f47a04-401d-4c01-86c2-37767020610a" xlink:to="loc_biib_A3250SeniorNotesDueFebruary152051Member_5bd34928-8294-46d2-9f76-7727dfdb8d81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:to="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2c8860da-f10f-46fe-ab45-60475fbc348e" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_c819a1be-da35-4e46-a9fb-fe6a6446edf2" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2c8860da-f10f-46fe-ab45-60475fbc348e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_40e6a55a-fe02-48f9-bbc5-d1e25cb69a27" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_2c8860da-f10f-46fe-ab45-60475fbc348e" xlink:to="loc_srt_ScenarioForecastMember_40e6a55a-fe02-48f9-bbc5-d1e25cb69a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_e4823914-ddbe-4b08-b5fd-45489ff6d8ae" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_86ed8dfe-168a-4acc-83a7-14f359b791ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_86ed8dfe-168a-4acc-83a7-14f359b791ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionRate_077de81a-4c88-46c4-b42c-5936bb3edb81" xlink:href="biib-20220930.xsd#biib_DebtInstrumentRedemptionRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_biib_DebtInstrumentRedemptionRate_077de81a-4c88-46c4-b42c-5936bb3edb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37cf032b-b5bb-40e0-8a75-76fee59dcdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_37cf032b-b5bb-40e0-8a75-76fee59dcdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_3f101d42-5f4e-4a59-9954-38442b9cdaab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_3f101d42-5f4e-4a59-9954-38442b9cdaab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_99b6a3f6-5b6a-4329-8be8-7a80b245bea4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_99b6a3f6-5b6a-4329-8be8-7a80b245bea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentRedemptionAmount_2cc2c3e3-fa58-453f-819a-9ca1b93c5f89" xlink:href="biib-20220930.xsd#biib_DebtInstrumentRedemptionAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_biib_DebtInstrumentRedemptionAmount_2cc2c3e3-fa58-453f-819a-9ca1b93c5f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LongTermDebtExchangedAmount_6f4bfa96-95f8-40b2-a0ce-91355dac4ace" xlink:href="biib-20220930.xsd#biib_LongTermDebtExchangedAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_biib_LongTermDebtExchangedAmount_6f4bfa96-95f8-40b2-a0ce-91355dac4ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e6ef853-e292-43bc-89f6-079367eabde1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_9e6ef853-e292-43bc-89f6-079367eabde1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfDebt_ccfe548e-ff57-4476-b1ea-daa011c86608" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_RepaymentsOfDebt_ccfe548e-ff57-4476-b1ea-daa011c86608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_c37a9c60-72ee-45ea-884b-6e65dc86d64b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d084af9a-296e-4cbf-9719-5211919ee4cb" xlink:to="loc_us-gaap_InterestExpense_c37a9c60-72ee-45ea-884b-6e65dc86d64b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareRepurchasesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareRepurchasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_4ee7a0e5-4ff6-4db5-95ae-0d356d6587e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4ee7a0e5-4ff6-4db5-95ae-0d356d6587e4" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_10f9ec96-dfd1-4cdd-afda-ce7dbf183e89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_aba6d2f8-bf49-4a65-b49a-e085685dc3f9" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_10f9ec96-dfd1-4cdd-afda-ce7dbf183e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_0e5944c5-11d2-415a-b77c-f8de6fa50daa" xlink:href="biib-20220930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_10f9ec96-dfd1-4cdd-afda-ce7dbf183e89" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_0e5944c5-11d2-415a-b77c-f8de6fa50daa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_f5fd7105-e86f-43fa-854f-665bdce9a009" xlink:to="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3c143583-bef5-4373-b630-aaa91d066bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_3c143583-bef5-4373-b630-aaa91d066bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_5b2867db-2c62-46c3-96ef-21a2bdd98c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_5b2867db-2c62-46c3-96ef-21a2bdd98c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9a6bfe0b-1c57-4206-a2a0-38a973087db6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_9a6bfe0b-1c57-4206-a2a0-38a973087db6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_252b2264-d16d-4a00-933c-a8b45d9c6281" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_65fd4ca0-9c90-4f31-9cb9-925e97f7a958" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_252b2264-d16d-4a00-933c-a8b45d9c6281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_76bb9e41-4b04-4396-9e45-8493e9c49eb0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_76bb9e41-4b04-4396-9e45-8493e9c49eb0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_887087bd-f913-4f70-a8c7-8f1f30280c41" xlink:to="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69f2bd6a-db5f-4f9a-ba04-e3c571a32c0a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_69f2bd6a-db5f-4f9a-ba04-e3c571a32c0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3607758-b4cb-473b-bb8e-b65cf635e1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c3607758-b4cb-473b-bb8e-b65cf635e1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_db59590a-7642-48e3-aaf5-ba7afc78a589" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_db59590a-7642-48e3-aaf5-ba7afc78a589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3a1f3262-7ebd-45c6-b98b-95d0dc73aa41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_3a1f3262-7ebd-45c6-b98b-95d0dc73aa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe0efffa-8cf9-43cd-8d02-b92276db897c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6a2142b-b87a-441a-8649-521811a04572" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_fe0efffa-8cf9-43cd-8d02-b92276db897c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e95d0855-37c0-4bbf-b1b3-9a22713d12e6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ecb5fa4-ed4a-4ad0-8a90-77aa3008de43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_8ecb5fa4-ed4a-4ad0-8a90-77aa3008de43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b0c29cc8-50f3-42f4-bd11-ec6c0a046164" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b0c29cc8-50f3-42f4-bd11-ec6c0a046164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e9abe322-7cf5-4770-b6b9-309b43dad5e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax_e9abe322-7cf5-4770-b6b9-309b43dad5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_14093271-cde7-47e4-a3a8-cd2c97ba3ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax_14093271-cde7-47e4-a3a8-cd2c97ba3ed1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_65e8c75e-e0bb-44c6-81b6-725ffe8e281e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_65e8c75e-e0bb-44c6-81b6-725ffe8e281e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc0039b4-4a47-4005-b303-243a864d3f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_dc0039b4-4a47-4005-b303-243a864d3f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5b3d396f-c854-4f13-a348-ca428476a862" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_18934778-8597-4183-bc71-fb269c88241e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_5b3d396f-c854-4f13-a348-ca428476a862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_972ff1d9-012c-4a2d-a8f6-ef66de8a119d" xlink:href="biib-20220930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_972ff1d9-012c-4a2d-a8f6-ef66de8a119d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_68cbc91f-21a9-4071-858e-eef8e65fd38b" xlink:to="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_34e1b136-b20f-49f6-b2ae-61c4707f76e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_34e1b136-b20f-49f6-b2ae-61c4707f76e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c0e8d0d5-0836-46e4-920e-841e32ba616f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_c0e8d0d5-0836-46e4-920e-841e32ba616f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_07826788-d5db-49f3-8097-051734213a8a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember_07826788-d5db-49f3-8097-051734213a8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_055c80de-d463-47c2-abf7-9ac5fb500435" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_663d4eac-4e54-4156-aeab-da9340aeb8bb" xlink:to="loc_us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember_055c80de-d463-47c2-abf7-9ac5fb500435" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2429282c-0890-4422-b665-c897b2c7623c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_b6216bba-2040-4006-a841-b6ee38a0e490" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2429282c-0890-4422-b665-c897b2c7623c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9af6d4e3-3f5c-4099-83d4-47498a3f6cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_2429282c-0890-4422-b665-c897b2c7623c" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_9af6d4e3-3f5c-4099-83d4-47498a3f6cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_75f52cac-4ec3-469c-bd9d-d06ebf4f9983" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_92b29240-2512-43ba-8d4b-d5f2ae410398" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_75f52cac-4ec3-469c-bd9d-d06ebf4f9983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_672a0571-1aed-4487-96b5-a128b974d214" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_75f52cac-4ec3-469c-bd9d-d06ebf4f9983" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_672a0571-1aed-4487-96b5-a128b974d214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_ee69f7f3-f243-463f-b40e-dd949952d7ae" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_0915f85b-cbf2-4e8c-84d2-986461c75159" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_0915f85b-cbf2-4e8c-84d2-986461c75159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_690b600d-16dd-4b22-bb41-a85f8367ad5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_690b600d-16dd-4b22-bb41-a85f8367ad5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_57f0b1cb-4b34-4091-becd-ec84e0d515dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_Revenues_57f0b1cb-4b34-4091-becd-ec84e0d515dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_356781da-3c14-4089-9d05-0deae1aa95be" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_OperatingExpenses_356781da-3c14-4089-9d05-0deae1aa95be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_49e68748-745b-4be1-8851-ddb1acea0331" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_NetIncomeLoss_49e68748-745b-4be1-8851-ddb1acea0331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c0c044f-7f29-481e-9589-1a27802cb3d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_972642d6-9e1e-4355-8c84-9ba1bff30d5b" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_6c0c044f-7f29-481e-9589-1a27802cb3d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_2fa0ee17-c15e-4467-90a0-bc8f55b1808e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_2fa0ee17-c15e-4467-90a0-bc8f55b1808e" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_c38f203d-23c6-40df-9d2c-e7103451a45b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_13182c39-e4ee-4b5f-bca6-899aec223c10" xlink:href="biib-20220930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_13182c39-e4ee-4b5f-bca6-899aec223c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_e5a65d0f-9b3e-40f9-b409-1db6fb455bc2" xlink:href="biib-20220930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:to="loc_biib_MarketStockUnitsMember_e5a65d0f-9b3e-40f9-b409-1db6fb455bc2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_069d4d82-b96a-46b9-9085-913460a58ff2" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4eabf0b2-7a90-4217-8179-b0d05ab3d607" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_069d4d82-b96a-46b9-9085-913460a58ff2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b45f752d-3aac-405e-b311-414e5a3b4a8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_b1314d15-8e62-496d-ac52-23685006549a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b45f752d-3aac-405e-b311-414e5a3b4a8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:href="biib-20220930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b45f752d-3aac-405e-b311-414e5a3b4a8e" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_cb2e32b4-a909-4c0c-8f2d-c0b13bfc35f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:to="loc_us-gaap_NetIncomeLossAbstract_cb2e32b4-a909-4c0c-8f2d-c0b13bfc35f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b998390c-85c7-4b12-b699-57671b81bed9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_cb2e32b4-a909-4c0c-8f2d-c0b13bfc35f2" xlink:to="loc_us-gaap_NetIncomeLoss_b998390c-85c7-4b12-b699-57671b81bed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_58d7bd1d-77cd-409e-b954-90bfc5359686" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_044a8369-f7e2-4349-8f94-50445332191b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_044a8369-f7e2-4349-8f94-50445332191b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8174522c-3c83-4420-9430-1f8246803048" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_8174522c-3c83-4420-9430-1f8246803048" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ffa65dc3-2845-4b73-813c-a0136528886b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_2425be20-eb75-408a-8d61-00ec31703136" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ffa65dc3-2845-4b73-813c-a0136528886b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cae55495-a680-4cb1-a4b4-7dc4d7cee67e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e1bbe99a-6072-4b11-81c4-b1eb7d8acd07" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_cae55495-a680-4cb1-a4b4-7dc4d7cee67e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareBasedPaymentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d57c0a-58f8-4085-b8d5-2e9f949de401" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c7d57c0a-58f8-4085-b8d5-2e9f949de401" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_d576aa3c-ef7a-4965-aefe-d3d673955714" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dddf1db4-a5df-480b-93c8-6734b485d5c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_dddf1db4-a5df-480b-93c8-6734b485d5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e8ca54f8-5dce-4134-a4cc-e3a9143fb707" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_e8ca54f8-5dce-4134-a4cc-e3a9143fb707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_abf4c88c-a12a-4da2-9fb5-cb48ef74cf40" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_a5c8932d-1408-4359-86f4-097d0cbf965b" xlink:to="loc_us-gaap_ParentMember_abf4c88c-a12a-4da2-9fb5-cb48ef74cf40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cd44ecf3-ba3b-4f9f-8e88-9c099f5a54ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_5c2d638f-7093-4606-822c-1b38aafd3486" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cd44ecf3-ba3b-4f9f-8e88-9c099f5a54ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_cd44ecf3-ba3b-4f9f-8e88-9c099f5a54ca" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_efd3aaf6-d2b6-4422-87f4-31d0503d17ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_efd3aaf6-d2b6-4422-87f4-31d0503d17ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ecda07f8-8f12-430f-9bba-a0e16b0cdc05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ecda07f8-8f12-430f-9bba-a0e16b0cdc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4cbb6b3a-996f-49e6-8030-2eb77a2a6787" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_4cbb6b3a-996f-49e6-8030-2eb77a2a6787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_020b99ee-c63a-4773-9470-b99c8a232dfc" xlink:href="biib-20220930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_020b99ee-c63a-4773-9470-b99c8a232dfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3ab6519f-5551-4879-bf72-0ab9cdb70844" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_2b5f8fd7-d60e-4ca4-83c3-922ce877c517" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_3ab6519f-5551-4879-bf72-0ab9cdb70844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="simple" xlink:href="biib-20220930.xsd#ShareBasedPaymentsDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf4b039b-e9b3-4baa-9b3b-d29b72c355f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cf4b039b-e9b3-4baa-9b3b-d29b72c355f5" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:to="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_55bd7083-eb92-4c31-9224-8520b5f29975" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_4bb31993-7e74-4ad3-bfab-26a2b0842feb" xlink:href="biib-20220930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_MarketStockUnitsMember_4bb31993-7e74-4ad3-bfab-26a2b0842feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_ad02a33a-3cae-4a03-bc17-f54499f5d6dc" xlink:href="biib-20220930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_ad02a33a-3cae-4a03-bc17-f54499f5d6dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_0d1c3542-224e-4697-9a30-f10093473ae7" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_0d1c3542-224e-4697-9a30-f10093473ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_e318b91c-07cb-4d44-903c-443d483c8775" xlink:href="biib-20220930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_e318b91c-07cb-4d44-903c-443d483c8775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_cd732622-7adc-49da-a7a2-dc5c2f083b1e" xlink:href="biib-20220930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f34c52ba-a66c-401e-907d-0315ad06cc2c" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_cd732622-7adc-49da-a7a2-dc5c2f083b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a73cc26c-f1ab-4bc7-ad89-d8a0f67f50ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_7e0126c4-de30-42bf-80b5-18415b2d2b6a" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a73cc26c-f1ab-4bc7-ad89-d8a0f67f50ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:href="biib-20220930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a73cc26c-f1ab-4bc7-ad89-d8a0f67f50ae" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa04315a-8b31-41b0-98f0-c9328f7f28ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_aa04315a-8b31-41b0-98f0-c9328f7f28ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a843c245-af6b-4cd1-a950-3ab73a37b4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a843c245-af6b-4cd1-a950-3ab73a37b4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e9caa74a-6772-4145-8110-f07f8dd36540" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_e9caa74a-6772-4145-8110-f07f8dd36540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7b46ca3b-a8cc-455d-889d-da249c0d2f8a" xlink:href="biib-20220930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_770fd07b-0e2b-44a3-8283-07418b2e59bb" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7b46ca3b-a8cc-455d-889d-da249c0d2f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#IncomeTaxesDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_31371547-7edd-4a39-a01a-9aed60592e4d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_31371547-7edd-4a39-a01a-9aed60592e4d" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_fcc78f27-9b4c-4a1a-b975-85fc191c360d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_d3bac8b7-6dd6-4204-8a54-ce1e87edc94b" xlink:to="loc_srt_ScenarioUnspecifiedDomain_fcc78f27-9b4c-4a1a-b975-85fc191c360d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_ebaaf7fa-5ad2-417a-8d2f-3a69718d8944" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_fcc78f27-9b4c-4a1a-b975-85fc191c360d" xlink:to="loc_srt_ScenarioForecastMember_ebaaf7fa-5ad2-417a-8d2f-3a69718d8944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_772951f0-250f-4a4c-95dd-a9dd490a47e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_72ec23d2-126f-4cc3-8a7d-328fdf95bbe0" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_772951f0-250f-4a4c-95dd-a9dd490a47e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_2dce60db-cc40-46d0-9403-2d43d3a3ac95" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_772951f0-250f-4a4c-95dd-a9dd490a47e0" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_2dce60db-cc40-46d0-9403-2d43d3a3ac95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d7e846ce-a1bc-4930-a1cb-d73523ef819a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_36710593-f201-4853-a088-b777cf1f7d3b" xlink:to="loc_srt_ProductsAndServicesDomain_d7e846ce-a1bc-4930-a1cb-d73523ef819a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_8c8c50e2-b16d-40a9-b016-259f96540967" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_d7e846ce-a1bc-4930-a1cb-d73523ef819a" xlink:to="loc_biib_ADUHELMMember_8c8c50e2-b16d-40a9-b016-259f96540967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_636f4648-a17c-47d9-b477-bd3335ec3572" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19ccaa39-dfe3-4ce9-a527-c1fd76ecdf47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19ccaa39-dfe3-4ce9-a527-c1fd76ecdf47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_d1022f0f-cae3-4854-95ff-0faa074b8b19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_EquityMethodInvestments_d1022f0f-cae3-4854-95ff-0faa074b8b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_eaee297b-1ce3-42f8-af34-a0b7d0e41d73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_eaee297b-1ce3-42f8-af34-a0b7d0e41d73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_24035fcc-3fad-449a-a00b-c916ed771ab4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_9748af4e-e1ae-4bb0-8df9-946778d363fd" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_24035fcc-3fad-449a-a00b-c916ed771ab4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#IncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_08af6179-ba01-440d-8ff4-8a0c59026726" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_08af6179-ba01-440d-8ff4-8a0c59026726" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ac0f102c-e7af-4492-90ec-f599cd300cda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ac0f102c-e7af-4492-90ec-f599cd300cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9e4864aa-659e-4341-a9e3-c7d861edf9f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_9e4864aa-659e-4341-a9e3-c7d861edf9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_71bb0698-3e29-4374-a380-7f7c2cbf223c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_71bb0698-3e29-4374-a380-7f7c2cbf223c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_97e5afb3-7f21-4436-a33f-cd6ca4e3f2aa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_97e5afb3-7f21-4436-a33f-cd6ca4e3f2aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_f82f55a4-367d-4ef7-8b69-8cbf68418cd6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_f82f55a4-367d-4ef7-8b69-8cbf68418cd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationGILTItax_4d02e396-672e-43a0-987b-7c58326ff0fd" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationGILTItax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_biib_EffectiveTaxRateReconciliationGILTItax_4d02e396-672e-43a0-987b-7c58326ff0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_5532d6c1-da6c-4410-8bd1-3975e3d4798e" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis_5532d6c1-da6c-4410-8bd1-3975e3d4798e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_e529294e-cedb-4bef-8928-1f86fc2fb389" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationLitigationAgreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_biib_EffectiveTaxRateReconciliationLitigationAgreement_e529294e-cedb-4bef-8928-1f86fc2fb389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_b2b4675e-fa0f-498b-84ff-3ec294daf73d" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts_b2b4675e-fa0f-498b-84ff-3ec294daf73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_f6b61080-8b23-4b96-8d23-c1f08766063d" xlink:href="biib-20220930.xsd#biib_EffectiveTaxRateReconciliationInternationalReorganization"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_biib_EffectiveTaxRateReconciliationInternationalReorganization_f6b61080-8b23-4b96-8d23-c1f08766063d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_97b6686a-8e0c-47a1-91c4-2e7239382acd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_97b6686a-8e0c-47a1-91c4-2e7239382acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dbdec041-6ec5-457f-9975-084fd4c2ca22" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e0c46623-9eb5-4638-88b5-6286918104c8" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_dbdec041-6ec5-457f-9975-084fd4c2ca22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetailDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3139e39c-ddde-41cd-b1da-c8d47ce48cf7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3139e39c-ddde-41cd-b1da-c8d47ce48cf7" xlink:to="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2a96eadb-4c92-426b-a724-a530c584b950" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d043d80b-c289-4d8e-b423-e226cca6d23e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2a96eadb-4c92-426b-a724-a530c584b950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_bdfe6e9d-6638-4f92-af8e-781bba0b58ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2a96eadb-4c92-426b-a724-a530c584b950" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_bdfe6e9d-6638-4f92-af8e-781bba0b58ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:to="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_295b403e-c734-4e59-8791-4e448397edf6" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_c835798b-1450-4ece-a3b5-86859ef8f236" xlink:to="loc_dei_EntityDomain_295b403e-c734-4e59-8791-4e448397edf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_66c7a5ee-e717-40c5-9f6b-f68b8f6ebc0c" xlink:href="biib-20220930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_295b403e-c734-4e59-8791-4e448397edf6" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_66c7a5ee-e717-40c5-9f6b-f68b8f6ebc0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_53422ff2-36cd-4ee2-922d-00c183994c72" xlink:to="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a85355ea-7695-4825-a869-5f60c77755dd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_a85355ea-7695-4825-a869-5f60c77755dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_7e0cdab0-7036-451f-a99c-3101718bf041" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_LitigationSettlementExpense_7e0cdab0-7036-451f-a99c-3101718bf041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_16fb98c9-059f-40d5-83dd-e6606d23cd4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_16fb98c9-059f-40d5-83dd-e6606d23cd4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_8b5c9545-7b6e-488c-9937-b4e09101f8b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_InterestExpense_8b5c9545-7b6e-488c-9937-b4e09101f8b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_0b494c03-1e99-48db-91d1-2bc4069b494a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_0b494c03-1e99-48db-91d1-2bc4069b494a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b01474da-86d1-4a5f-9629-48257e618db9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_b01474da-86d1-4a5f-9629-48257e618db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_6c143883-099c-43c6-a2df-e7f6ad5197d9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_6c143883-099c-43c6-a2df-e7f6ad5197d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_40795fb8-d18c-48b3-8169-56b79e3307bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InterestIncomeExpenseNetAbstract_3340850b-581d-4117-baa2-bb3df541e5c9" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_40795fb8-d18c-48b3-8169-56b79e3307bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d93582e0-75d1-4a24-ab01-0b9b57a89bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_d93582e0-75d1-4a24-ab01-0b9b57a89bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_daf0322c-7ae3-4141-9f5a-31e9d6d073a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_daf0322c-7ae3-4141-9f5a-31e9d6d073a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5d972fec-8c82-4a47-bd78-4bfbf149e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract_4341e95d-5afc-4630-a842-d9caeb029475" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_5d972fec-8c82-4a47-bd78-4bfbf149e29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6fb718d-6543-42dd-b14d-f9d79afffa49" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettlementLiabilitiesCurrent_8e5cf2ed-a416-4e66-b617-395edae16556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SettlementLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_SettlementLiabilitiesCurrent_8e5cf2ed-a416-4e66-b617-395edae16556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_028d21b5-bc20-42ce-8336-becda0c1dbc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_028d21b5-bc20-42ce-8336-becda0c1dbc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2aa7b1b8-4b1c-474f-81fe-d24fdeb7777d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_2aa7b1b8-4b1c-474f-81fe-d24fdeb7777d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_cf81d5f7-ab9f-4238-9339-bbe905a3a7e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_cf81d5f7-ab9f-4238-9339-bbe905a3a7e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_fd16e9cd-e7fd-4e02-8ee1-8d11dc4f68ea" xlink:href="biib-20220930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_biib_Collaborationexpensesaccrual_fd16e9cd-e7fd-4e02-8ee1-8d11dc4f68ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_715aad48-4b34-432d-be1d-5021b69ce96f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_715aad48-4b34-432d-be1d-5021b69ce96f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_d8e570ca-6f35-416c-8cb4-32650a592044" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAbstract_6095053c-cd8d-4ece-b1b4-b35f7fe9a35b" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_d8e570ca-6f35-416c-8cb4-32650a592044" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#OtherConsolidatedFinancialStatementDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73f3ae18-68a2-48e7-8a17-1108d36e2daf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_73f3ae18-68a2-48e7-8a17-1108d36e2daf" xlink:to="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:to="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_3b5f5726-0b19-4be4-b45c-17a65e357107" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_ad6aa0d6-5921-46fc-be2f-1fde22d63a52" xlink:to="loc_dei_EntityDomain_3b5f5726-0b19-4be4-b45c-17a65e357107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisSangamoDenaliAndSageMember_e45c6bc9-2ddd-4bba-8870-9a5fc60a9b97" xlink:href="biib-20220930.xsd#biib_IonisSangamoDenaliAndSageMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3b5f5726-0b19-4be4-b45c-17a65e357107" xlink:to="loc_biib_IonisSangamoDenaliAndSageMember_e45c6bc9-2ddd-4bba-8870-9a5fc60a9b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_4493c120-eedb-40c3-9b79-9551c2c838fe" xlink:to="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4edc0132-cac3-4410-9374-6c27490e6524" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_4edc0132-cac3-4410-9374-6c27490e6524" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d3fc44cd-3f59-4d07-9184-e788e6f413b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_d3fc44cd-3f59-4d07-9184-e788e6f413b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_7baf37ca-9728-447f-a2e1-c16884769fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_7baf37ca-9728-447f-a2e1-c16884769fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_597576f7-cc89-4af0-810a-39e782bb5744" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_1a0a87c2-cfc2-4945-9bcb-c2d0fc5e495c" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_597576f7-cc89-4af0-810a-39e782bb5744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#CollaborativeandOtherRelationshipsCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4bab8c74-e267-4dad-8d73-04f6c83ec466" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4bab8c74-e267-4dad-8d73-04f6c83ec466" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_46d18a73-46c0-4d42-a0bd-36f62d0ec815" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df5099b7-77a6-4025-9355-00504388d215" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_df5099b7-77a6-4025-9355-00504388d215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bc70d43-2bc6-454c-b345-349d704c1cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9356d9f6-36fd-45db-b093-d32dc384ef2b" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0bc70d43-2bc6-454c-b345-349d704c1cc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_489c59b1-02ce-48ca-848e-34fd4d26e55f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ff6b2f91-10e2-4e8e-ac6f-dc85cd16ff31" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_EisaiMember_ff6b2f91-10e2-4e8e-ac6f-dc85cd16ff31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_7ffd5ebd-d0d6-40ed-af66-e87e9fda1601" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_DenaliTherapeuticsIncMember_7ffd5ebd-d0d6-40ed-af66-e87e9fda1601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_1c6486d9-875f-4e79-bec8-b29cfb746ff0" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_61cd3fb9-8359-4493-b5d3-4cfed2d5c28e" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_61cd3fb9-8359-4493-b5d3-4cfed2d5c28e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_7941d9e7-213f-4159-8944-2266f4a33f35" xlink:href="biib-20220930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_SageTherapeuticsIncMember_7941d9e7-213f-4159-8944-2266f4a33f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaS.A.Member_d79c90c1-e18b-4c98-83d7-6d50f513a04c" xlink:href="biib-20220930.xsd#biib_UCBPharmaS.A.Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_UCBPharmaS.A.Member_d79c90c1-e18b-4c98-83d7-6d50f513a04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_67d72722-b514-46c4-9405-d555125e96d2" xlink:href="biib-20220930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_67d72722-b514-46c4-9405-d555125e96d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherresearchanddiscoveryMember_fe989a1f-3a90-41b5-b46b-e31fece44a44" xlink:href="biib-20220930.xsd#biib_OtherresearchanddiscoveryMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_OtherresearchanddiscoveryMember_fe989a1f-3a90-41b5-b46b-e31fece44a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_c9aa788b-e75f-497c-b433-bbda2f6f6929" xlink:href="biib-20220930.xsd#biib_InnoCarePharmaLimitedInnoCareAgreementMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ad70a5d3-fb21-43e3-9d9c-a9aee8359bc9" xlink:to="loc_biib_InnoCarePharmaLimitedInnoCareAgreementMember_c9aa788b-e75f-497c-b433-bbda2f6f6929" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_38126372-5953-4fd0-814e-c12ea9d12796" xlink:to="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_b9b0c8f2-bb0d-497b-b514-ff2eb49eab8a" xlink:href="biib-20220930.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:to="loc_biib_E2609andBAN2401Member_b9b0c8f2-bb0d-497b-b514-ff2eb49eab8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_a7c60f41-6347-4938-8549-d6100d5bc5f5" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_96f301a9-f0e6-42df-81b8-dacdc82f34f6" xlink:to="loc_biib_ADUHELMMember_a7c60f41-6347-4938-8549-d6100d5bc5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_395785eb-6b53-47db-a7b6-a38097c40fd1" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_2bc8727d-b5d9-48d3-bb55-bdbdc3fd5e68" xlink:href="biib-20220930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:to="loc_biib_DenaliTherapeuticsIncMember_2bc8727d-b5d9-48d3-bb55-bdbdc3fd5e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SangamoTherapeuticsInc.AgreementMember_10ee207c-8ad4-41d4-98e2-903ef2c06d37" xlink:href="biib-20220930.xsd#biib_SangamoTherapeuticsInc.AgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:to="loc_biib_SangamoTherapeuticsInc.AgreementMember_10ee207c-8ad4-41d4-98e2-903ef2c06d37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_8abea48b-975c-41ff-892b-852d5ac0cec8" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_abf48784-07a1-41a0-bb35-5e245cad3a5a" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_8abea48b-975c-41ff-892b-852d5ac0cec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_34857a41-881a-4e66-9356-7b56b95c98b5" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_b8860260-df70-47f8-a12c-18dc3c2c6807" xlink:to="loc_srt_RangeMember_34857a41-881a-4e66-9356-7b56b95c98b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5e00d7be-9b79-4f6d-b9b5-1af810497ca6" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_34857a41-881a-4e66-9356-7b56b95c98b5" xlink:to="loc_srt_MaximumMember_5e00d7be-9b79-4f6d-b9b5-1af810497ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_083bf2cd-268c-4939-bbf4-bcf1234873cc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_13ef9a1d-1da6-46f0-bb32-fb8fce33db0d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_083bf2cd-268c-4939-bbf4-bcf1234873cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_e8f03cd3-fc17-4f03-bebe-30d41217fdb2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_083bf2cd-268c-4939-bbf4-bcf1234873cc" xlink:to="loc_srt_ScenarioForecastMember_e8f03cd3-fc17-4f03-bebe-30d41217fdb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9cae189e-cce8-42db-8d9d-ba44a2c941fe" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_c9cdfadc-cdbb-43c8-b653-9f1d426389c5" xlink:href="biib-20220930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_ExpenseIncurredByCollaboration_c9cdfadc-cdbb-43c8-b653-9f1d426389c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_f132a608-b2f6-43ea-9ad2-a684411c3ad5" xlink:href="biib-20220930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_Expenseincurredbythecollaboration_f132a608-b2f6-43ea-9ad2-a684411c3ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_0e4aa9df-9837-4132-ba78-cac8afbdabe7" xlink:href="biib-20220930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_0e4aa9df-9837-4132-ba78-cac8afbdabe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9e0640c-59b5-4d98-a428-e17d099a094d" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_e9e0640c-59b5-4d98-a428-e17d099a094d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_22054e80-8f8c-4874-8c7b-109bfbb02802" xlink:href="biib-20220930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_22054e80-8f8c-4874-8c7b-109bfbb02802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_07024eba-df66-4ce3-8e73-3ef190868c5b" xlink:href="biib-20220930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_CollaborationAgreementTerm_07024eba-df66-4ce3-8e73-3ef190868c5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_abadfbac-6065-4bae-8977-16e1b2bcff81" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_abadfbac-6065-4bae-8977-16e1b2bcff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Termofcollaborationagreement_525a0749-5a1b-4f70-8413-b207e1a920b6" xlink:href="biib-20220930.xsd#biib_Termofcollaborationagreement"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_Termofcollaborationagreement_525a0749-5a1b-4f70-8413-b207e1a920b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_437f21fc-c0c5-4f6d-8239-e50db8266064" xlink:href="biib-20220930.xsd#biib_ContingentMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_ContingentMilestonePaymentsMadeToCollaborativePartner_437f21fc-c0c5-4f6d-8239-e50db8266064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_86916098-e171-4fa4-9839-9cc999bf62bb" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_AdditionalMilestonePayment_86916098-e171-4fa4-9839-9cc999bf62bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5dbf9535-78d8-41bd-9d98-4c48c969d15d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_5dbf9535-78d8-41bd-9d98-4c48c969d15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_2e95a09a-bce0-4d6e-b17a-a9d68174d9a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_2e95a09a-bce0-4d6e-b17a-a9d68174d9a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47dedf28-ae88-4637-a128-62d2be8ad75f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_47dedf28-ae88-4637-a128-62d2be8ad75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CostOfGoodsSoldCapacityCharges_e70e173f-ae87-4b67-9522-e9abf4856781" xlink:href="biib-20220930.xsd#biib_CostOfGoodsSoldCapacityCharges"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_CostOfGoodsSoldCapacityCharges_e70e173f-ae87-4b67-9522-e9abf4856781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a3ebce83-2694-41cf-905d-ce18dbbe9c33" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_a3ebce83-2694-41cf-905d-ce18dbbe9c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentForAmortization_fcc00aea-131a-4ae0-80a4-e0cd28b8f762" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentForAmortization"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_AdjustmentForAmortization_fcc00aea-131a-4ae0-80a4-e0cd28b8f762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueFromRelatedParties_2206e30b-b75d-4cf6-9b1a-aa5c7ce6413c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueFromRelatedParties"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_DueFromRelatedParties_2206e30b-b75d-4cf6-9b1a-aa5c7ce6413c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a69a344a-2b86-4cea-ad9d-30fd87bdb783" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_a69a344a-2b86-4cea-ad9d-30fd87bdb783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_0027b72c-5a9f-41c4-92c9-a8204d81cafa" xlink:href="biib-20220930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f6a089e5-aba4-4540-b8cb-d4a3e93d6777" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_0027b72c-5a9f-41c4-92c9-a8204d81cafa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8715188b-1f76-4b86-ba52-0345f7f307a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8715188b-1f76-4b86-ba52-0345f7f307a5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_7336803e-0b4c-45c1-8323-789b30c5b769" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_d1fe5039-9795-4e42-8a07-fdeecda8a1db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:to="loc_us-gaap_InventoriesMember_d1fe5039-9795-4e42-8a07-fdeecda8a1db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0f6be07a-9e95-4326-9282-e12feedb6160" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_1042c760-ab88-45da-93a9-a4c62b2aebca" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0f6be07a-9e95-4326-9282-e12feedb6160" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5b237770-eaf0-4d99-a76d-89cd1cc226c7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_6ae5a7f0-55d1-450a-9bef-d7394ab4753c" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:to="loc_biib_EisaiMember_6ae5a7f0-55d1-450a-9bef-d7394ab4753c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_5c625bc4-3dc6-4d73-afa2-880383224c4e" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c35c7298-0dbc-4905-89e5-f48ebe134abf" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_5c625bc4-3dc6-4d73-afa2-880383224c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1e58632c-443e-4bcb-9edb-e3a13c2a2906" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15420d1e-b90b-4009-a27a-af4cc23eabcd" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1e58632c-443e-4bcb-9edb-e3a13c2a2906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_215b44df-df1b-4b20-8c41-980cbe6e8d56" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1e58632c-443e-4bcb-9edb-e3a13c2a2906" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_215b44df-df1b-4b20-8c41-980cbe6e8d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0cbc52a4-565f-4e73-ba9f-59dc062e5a1a" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_780ec5ec-e4df-4d3a-a02e-689806cd959d" xlink:to="loc_srt_ProductsAndServicesDomain_0cbc52a4-565f-4e73-ba9f-59dc062e5a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_5c845079-bdd3-473a-a2e9-116b9aa7073f" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_0cbc52a4-565f-4e73-ba9f-59dc062e5a1a" xlink:to="loc_biib_ADUHELMMember_5c845079-bdd3-473a-a2e9-116b9aa7073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_f34b211f-433a-41a3-bafb-3f07c2548595" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_7af8026f-1552-4c2c-b85a-9f3be6365118" xlink:href="biib-20220930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_7af8026f-1552-4c2c-b85a-9f3be6365118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_179f0b8b-4ffe-47a7-9ade-a591b7168d03" xlink:href="biib-20220930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_c27e2afc-0569-44b3-88c0-8e150d837c34" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_179f0b8b-4ffe-47a7-9ade-a591b7168d03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_cb8fd020-33eb-417c-8a47-cc9dbfb1a732" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5a64a680-84d8-4df8-90cc-fc1d142836e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5a64a680-84d8-4df8-90cc-fc1d142836e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_d8cda045-9a70-41cf-b719-952d80748dd5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_d8cda045-9a70-41cf-b719-952d80748dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_a594fc89-5e3f-4235-b249-140735b7485d" xlink:href="biib-20220930.xsd#biib_Equitymethodinvestmentbasisdifferenceamortizationperiod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod_a594fc89-5e3f-4235-b249-140735b7485d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_67203b40-59ac-4bd6-92d8-22cbaefa766c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions_67203b40-59ac-4bd6-92d8-22cbaefa766c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d9bac2e3-2b5e-4543-9715-a743526c0101" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_d9bac2e3-2b5e-4543-9715-a743526c0101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_235e80c4-2ec5-4453-a0e6-0974adbaf6ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_235e80c4-2ec5-4453-a0e6-0974adbaf6ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_f2c9a5cf-3527-4a47-aa2f-7d63bdc1395f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_EquityMethodInvestments_f2c9a5cf-3527-4a47-aa2f-7d63bdc1395f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_e4d84cbf-6c35-41b6-a91b-fa135d32d222" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_e4d84cbf-6c35-41b6-a91b-fa135d32d222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_18e09d42-9d02-41a9-90da-1cfedcc76b1c" xlink:href="biib-20220930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_18e09d42-9d02-41a9-90da-1cfedcc76b1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_4c1fb4c2-22b0-418b-8150-c8b79bec7dad" xlink:href="biib-20220930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_Collaborationprofitlosssharing_4c1fb4c2-22b0-418b-8150-c8b79bec7dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_85ebaa11-8386-44a9-b162-adf81841cc05" xlink:href="biib-20220930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_85ebaa11-8386-44a9-b162-adf81841cc05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6fa2db02-43ce-4dd6-b17f-bf0581ae9eac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6fa2db02-43ce-4dd6-b17f-bf0581ae9eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssets_1848e63e-152f-4aa5-a56d-8e59df6656d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssets_1848e63e-152f-4aa5-a56d-8e59df6656d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccruedMilestonePayments_ffe03cfb-6033-4349-9b53-fb9f520fa9be" xlink:href="biib-20220930.xsd#biib_AccruedMilestonePayments"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_AccruedMilestonePayments_ffe03cfb-6033-4349-9b53-fb9f520fa9be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_05b2de91-062a-42f8-bd47-391f2092408a" xlink:href="biib-20220930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_05b2de91-062a-42f8-bd47-391f2092408a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_d506db44-b3cc-4eda-b09d-6466a597ea67" xlink:href="biib-20220930.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_biib_ContractOptionExerciseFee_d506db44-b3cc-4eda-b09d-6466a597ea67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2e5f1ddf-407c-4649-9a41-eee3e5c5d6e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DueToRelatedPartiesCurrentAndNoncurrent"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_cfa49356-f9dc-44e1-9895-c3f905c9166a" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent_2e5f1ddf-407c-4649-9a41-eee3e5c5d6e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_08d85fcd-f29f-4e06-ad54-e0334344e484" xlink:href="biib-20220930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfVariableInterestEntitiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_08d85fcd-f29f-4e06-ad54-e0334344e484" xlink:to="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2130e2b-5bee-4784-bc8f-3eadcf386ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ce982606-e516-4dcd-a33d-eaa33f8acc02" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2130e2b-5bee-4784-bc8f-3eadcf386ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_07fca8be-966d-42a3-b9d2-d35c7809ff1e" xlink:href="biib-20220930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f2130e2b-5bee-4784-bc8f-3eadcf386ea3" xlink:to="loc_biib_EisaiMember_07fca8be-966d-42a3-b9d2-d35c7809ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_195fcfc1-07c0-4493-872f-1e258bff64e4" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_4f6de3bb-63ca-4ddb-a791-2ae87d5d9702" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_195fcfc1-07c0-4493-872f-1e258bff64e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RegulatoryMilestonesMember_5ae567b8-2855-401e-976b-2b29eee3ceb4" xlink:href="biib-20220930.xsd#biib_RegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_195fcfc1-07c0-4493-872f-1e258bff64e4" xlink:to="loc_biib_RegulatoryMilestonesMember_5ae567b8-2855-401e-976b-2b29eee3ceb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_d1b525bd-1bc2-4e7e-9699-ee779e04bfb8" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_ab88248b-5422-4b27-8771-8b303d3fc3df" xlink:to="loc_srt_ConsolidatedEntitiesDomain_d1b525bd-1bc2-4e7e-9699-ee779e04bfb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NeurimmuneMember_f90dde90-e222-4616-8156-c63ae498063f" xlink:href="biib-20220930.xsd#biib_NeurimmuneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_d1b525bd-1bc2-4e7e-9699-ee779e04bfb8" xlink:to="loc_biib_NeurimmuneMember_f90dde90-e222-4616-8156-c63ae498063f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2b763e0d-8540-450c-84f8-f1b707b08b86" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5c9d243d-6295-4562-88fb-d4582b3a64fb" xlink:to="loc_srt_ProductsAndServicesDomain_2b763e0d-8540-450c-84f8-f1b707b08b86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ADUHELMMember_e5014085-cc17-4012-9a38-3b4104d64040" xlink:href="biib-20220930.xsd#biib_ADUHELMMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2b763e0d-8540-450c-84f8-f1b707b08b86" xlink:to="loc_biib_ADUHELMMember_e5014085-cc17-4012-9a38-3b4104d64040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableInterestEntityLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfVariableInterestEntitiesTable_76cf8959-e81c-4500-8093-695b667719ba" xlink:to="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborationAgreementTerm_5f788035-bfb0-40a7-95d0-fc94670d2787" xlink:href="biib-20220930.xsd#biib_CollaborationAgreementTerm"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_CollaborationAgreementTerm_5f788035-bfb0-40a7-95d0-fc94670d2787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentCostsPercentage_c687f1c3-25ca-4660-bc28-09d8e13d6855" xlink:href="biib-20220930.xsd#biib_ResearchAndDevelopmentCostsPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_ResearchAndDevelopmentCostsPercentage_c687f1c3-25ca-4660-bc28-09d8e13d6855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a5087012-dc31-4ad7-bbde-69280a05aef0" xlink:href="biib-20220930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_a5087012-dc31-4ad7-bbde-69280a05aef0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_635df262-09be-4986-8ec1-de683426feed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_635df262-09be-4986-8ec1-de683426feed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6d48646d-556c-482d-ad9d-4d954a27bde0" xlink:href="biib-20220930.xsd#biib_PercentageoffuturedevelopmentcostsrelatedtoEisai"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai_6d48646d-556c-482d-ad9d-4d954a27bde0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_dcc38312-7490-4892-b3f3-bef440058be0" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_AdditionalMilestonePayment_dcc38312-7490-4892-b3f3-bef440058be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1f5665d0-2e36-4864-8552-f55ea4d74be4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_1f5665d0-2e36-4864-8552-f55ea4d74be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bdef7489-e4a5-4154-9cfd-561e4fcb89bf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_bdef7489-e4a5-4154-9cfd-561e4fcb89bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1d01cb66-ea22-4004-88f9-f2fdf79aad2f" xlink:href="biib-20220930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableInterestEntityLineItems_b674d70a-a01a-4295-8555-65020cd4023f" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_1d01cb66-ea22-4004-88f9-f2fdf79aad2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20220930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_0349b8da-e828-440a-a108-98748b132409" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_f3b4134f-e9e7-48c8-8fd1-b3f2cb0ea76e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_0349b8da-e828-440a-a108-98748b132409" xlink:to="loc_us-gaap_LitigationSettlementExpense_f3b4134f-e9e7-48c8-8fd1-b3f2cb0ea76e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_3a44eb1d-a6a6-485c-8e94-9c00b9d13854" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_0349b8da-e828-440a-a108-98748b132409" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_3a44eb1d-a6a6-485c-8e94-9c00b9d13854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20220930.xsd#DispositionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_c71f1a98-49b8-4639-9084-5ab04b2c0ebb" xlink:href="biib-20220930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_c71f1a98-49b8-4639-9084-5ab04b2c0ebb" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28c97f55-365d-4a88-af6e-e59738788da1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3f3a2a6a-d636-4586-9e28-e70275c16ec8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28c97f55-365d-4a88-af6e-e59738788da1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_f337932d-3f67-40f6-8dcf-7a1e2dc8e58c" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_28c97f55-365d-4a88-af6e-e59738788da1" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_f337932d-3f67-40f6-8dcf-7a1e2dc8e58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_c1340629-3140-45d7-a642-63a5fe4b7298" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_749745ca-88a1-40f8-98f9-37a478c2ff6d" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_c1340629-3140-45d7-a642-63a5fe4b7298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_bd9726c0-8e91-422a-99b6-7454c537eba6" xlink:href="biib-20220930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_c1340629-3140-45d7-a642-63a5fe4b7298" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_bd9726c0-8e91-422a-99b6-7454c537eba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:href="biib-20220930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_716fbbb4-3d02-49d6-9de9-ac7c5aad0b6e" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_c8329f5c-e1aa-4c2f-ac7c-1a6486862f39" xlink:href="biib-20220930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_c8329f5c-e1aa-4c2f-ac7c-1a6486862f39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_5471f240-06c4-47c3-ae5c-0042df2e3434" xlink:href="biib-20220930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_29654544-dfe9-41ac-8971-3242f4e7373d" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_5471f240-06c4-47c3-ae5c-0042df2e3434" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_de4e92e9-0b38-4d26-b805-c0e1b6164b47" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_6f0319f3-0e55-457a-90cb-f58c3df621e8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_de4e92e9-0b38-4d26-b805-c0e1b6164b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_85301794-96cf-44da-820d-681b3cc04729" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_de4e92e9-0b38-4d26-b805-c0e1b6164b47" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_85301794-96cf-44da-820d-681b3cc04729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_e460f1db-650c-4ec5-9e77-4f3a34e67e75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_1b27eb7b-f37f-4dbe-96fd-0d04b49eee3c" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_e460f1db-650c-4ec5-9e77-4f3a34e67e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9d8ac809-cbac-4a18-b872-4a3db959b28d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_e460f1db-650c-4ec5-9e77-4f3a34e67e75" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9d8ac809-cbac-4a18-b872-4a3db959b28d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_35d4af4a-cbb5-42a0-9d85-84d02d2e6836" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_52c43013-da7e-4846-876b-2a18859d939a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_52c43013-da7e-4846-876b-2a18859d939a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_91489ee5-2b93-42b4-8413-ead74704ecb6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_91489ee5-2b93-42b4-8413-ead74704ecb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_7ace7654-502a-4dcf-bf9f-87ddc6376fbd" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_7ace7654-502a-4dcf-bf9f-87ddc6376fbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfInvestments_3ab54d44-6b5b-4fd8-bae3-83ff0fc52aee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_GainLossOnSaleOfInvestments_3ab54d44-6b5b-4fd8-bae3-83ff0fc52aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_4b2b44b8-546e-452c-a59c-0d72ca1571fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_4b2b44b8-546e-452c-a59c-0d72ca1571fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsMeasurementInput_d077a803-146f-47f1-a388-50aaccf33dbc" xlink:href="biib-20220930.xsd#biib_OtherAssetsMeasurementInput"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_OtherAssetsMeasurementInput_d077a803-146f-47f1-a388-50aaccf33dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_37ef42c1-1639-4308-a5c7-04f87ac14d5b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_37ef42c1-1639-4308-a5c7-04f87ac14d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherAssetsCurrentFairValueDisclosure_5b65c750-7a2c-40df-82c4-442e98863373" xlink:href="biib-20220930.xsd#biib_OtherAssetsCurrentFairValueDisclosure"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_OtherAssetsCurrentFairValueDisclosure_5b65c750-7a2c-40df-82c4-442e98863373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsFairValueDisclosure_96d753cb-2a72-4952-9daa-91e1b62a9398" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_OtherAssetsFairValueDisclosure_96d753cb-2a72-4952-9daa-91e1b62a9398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_879325b9-9959-442d-9cb1-e254943a74b5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_879325b9-9959-442d-9cb1-e254943a74b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdditionalMilestonePayment_5f41ecd2-d09a-4d76-bab9-b80e25c7b1ed" xlink:href="biib-20220930.xsd#biib_AdditionalMilestonePayment"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_AdditionalMilestonePayment_5f41ecd2-d09a-4d76-bab9-b80e25c7b1ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_622cca9a-4240-475d-bd52-b524624aeaeb" xlink:href="biib-20220930.xsd#biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent_622cca9a-4240-475d-bd52-b524624aeaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DiscreteIncomeTaxExpenseBenefit_0bd64cb8-e75d-47bb-83ae-80841ab3d3b3" xlink:href="biib-20220930.xsd#biib_DiscreteIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_2ddf6780-4ce8-4948-a135-142e79540d53" xlink:to="loc_biib_DiscreteIncomeTaxExpenseBenefit_0bd64cb8-e75d-47bb-83ae-80841ab3d3b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biib-20220930_g1.jpg
<TEXT>
begin 644 biib-20220930_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH _+_ ,0V3>&_'&L:>PVM8WT]N1C&TI(R
M]/PK7TC4]H7FM/\ :_\ #A\%?M+^)H=NV*^G6_C./O\ G*'8_P#?9<?A7&Z;
MJ6%ZU^N4VJU"%1=4G]Z/RVHG2K2IOHVON.\MM9PGWJ;=ZU\GWJYB+5L+UIES
MJ^5ZUE[#4T]MH6M8U7<#S7)ZU?[MU6M1U/.>:YS5;[.:[Z%*QQUJAFZM<Y)K
MGK^7)K1U&YR36-=RY->M2B>;4D59WYK$\:^+[;P1H$U]<'.T;8HP?FE?LH_S
MP,T[Q?XQLO"%EYUU)\[#]W$OWY3[#^O2O#O&?B2\\=ZQ]JNOEC3(AA!^6%?0
M>I/<]_R ,17Y%9;BHT7-W>QSM]<W'B#6+B^NFWW%U(9'/N?3V'3Z"M+3;'&.
M*DM=,P>E:]AIO/2O*C!WNST92Z$NEVG2NDTJVZ53TVQZ?+70:9:=*[:<3EJ2
M.Z^ 6@MJ_P 3M(4)N6&;[0W^R$&[/Y@?B:^K*\S_ &<OA<W@_1&U2]C,=_J"
M (C##0Q=0#[MP3]!7IE?QOXQ<24,USSV>%?-"C'DNMG*[<FO*^GG:ZT9]]P_
M@Y4,->>\G?Y=/\QR#FK4"5! N:NVR5^5P1[T2Y:1UJV472J5G'6M8Q?=XKMI
MQ-8FA80]*]&^ MCY_P 1K!L?+"LCG_OA@/U(K@M/ASBO6_V;M)\S7[V[(^6W
M@$?T+-_@IKZGAVA[3,*,5_,G]VOZ&_2Y[)1117[D2>8_M=?M,6/[(OP,U/QU
MJ6EWFKVFFS00M:VTBQR/YLJQ@@MQP6R?I7Q[_P 1#G@W_HG?B;_P.@_PKV+_
M (+6?\H]O%7_ %^Z?_Z5Q5^(-?K7 W">6YEE\L1BX-R4VMVM$HOH_,_+.-.*
M,PR['QH86:47%/9/5MKJO(_5S_B(<\&_]$[\3?\ @=!_A1_Q$.>#?^B=^)O_
M  .@_P *_*.BOLO^(=Y'_P ^W_X%+_,^1_U^SK_GXO\ P&/^1^KG_$0YX-_Z
M)WXF_P# Z#_"C_B(<\&_]$[\3?\ @=!_A7Y1T4?\0[R/_GV__ I?YA_K]G7_
M #\7_@,?\C]7/^(ASP;_ -$[\3?^!T'^%'_$0YX-_P"B=^)O_ Z#_"ORCHH_
MXAWD?_/M_P#@4O\ ,/\ 7[.O^?B_\!C_ )'ZN?\ $0YX-_Z)WXF_\#H/\*U-
M-_X.$OAE*8OMG@OQW!NQYODK:2[/IF9=WXXK\CZ*4O#K)'M3:_[>?^8X^(&<
MK>:?_;J_R/VD\(_\%T?@1XD=5O+GQ9X?#8R;_2#(%^OV=Y>GMFO</A5^W-\(
M/C9/%#X:^(GA>^N[@[8K26[%K=2'T6&;9(?P6OYZZ*\S%>%V6S7[BI.+^37W
M63_$]+#>)680?[Z$9+YI_?=K\#^FRBOP1_95_P""E?Q5_9/U&UCTK7KC7/#L
M) DT+5I&N+,IW$>3NA/)(,9 SC(8<']?/V)_V]O!?[;O@R2ZT&9M-\0:>BMJ
MFB7+#[39D\;U/22(G@.H[@$*>*_-^(N"\=E2]K+WZ?\ ,NG^)=/Q7G<_0LAX
MPP6:/V4?<J?ROKZ/K^#\CW*BBBOCSZP*X/\ ::^.]G^S+\"_$'CJ^L+G4[/P
M]#'+):P.$DE#2I'@%N!@N#SZ5WE?._\ P5A_Y1Z_$O\ Z\K?_P!*X*[\JP\*
M^-HT:GPRG%/T;29PYI7G1P=6M3^*,9->J3:/G?\ XB'/!O\ T3OQ-_X'0?X4
M?\1#G@W_ *)WXF_\#H/\*_*.BOWW_B'>1_\ /M_^!2_S/PS_ %^SK_GXO_ 8
M_P"1^KG_ !$.>#?^B=^)O_ Z#_"OM3]F7X[V?[37P+\/^.K&PN=,L_$,,DL=
MK.X>2(+*\>"5X.2A/'K7\Y]?O)_P2>_Y1Z_#3_KRN/\ TKGKXGCSA;+LLP4*
MV#@U)S2=VWI9OJ_(^RX)XFS#,<9.CBY)Q46UHEK=+HO,^B****_*3]/"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X[_ ."H7@-K35O#?BN)
M/W<T;:7<,.S*3)%^8,O_ 'R/P^6[2_P.M?I)^U1\*6^,OP,UW1X8]]^L7VJQ
MXR?/C^90/][!3Z.:_,&&]:-MK95AP0>U?IG"^)5?!^S>\';Y/5?JOD?GO$F'
M='%^T6TE?Y[/_/YG4)J>T=:CGU3*GFL-=1XZTR74>.M?0^QU/!]H7;[4<CK6
M+?WF<TV[O\*>?S-<UKWC&&S#+&&GD]ONC\?\*Z:=.QSSJ%S4+M45F9E55Y))
MQBN \8_%*.U5X=-433=#*P_=K]/7^7UJOXCU*\UUCYTA\O/$:\*/\?QK"FTG
MVK24FE9$1BKZG,:G'<:O>-<74CS3/U9SD_Y]JACT?GI73G2?:E32*YO9ZW-_
M::6,.VTK!Z5IV6F;>U:<&D\]*],^!'[+7BKX]:H(]$T]ELD<+/J%P#':P>N6
MQ\Q_V5!;V[UEB*]##4G6Q$E&*W;=D53C.K)0IJ[?1'G>C:-)=W$<,,3RS2L$
M1$7<SL3@  =23VKZN^$'[".N^%O#=OXH\262^<O[V/3/O2VR]1)*O3/?;G*\
M9YR!]%?LY?L9^%_V>;>.\5!K'B+;A]1G0?NB1@B%.0@Z\\L<\G' ]8EEK\+X
MV\1I8RC/+\I;A"2LY[2?^'LGWW?D?;93PRJ=JV+UET71>O=_AZGRO0!DUZ_\
M1_@S#K,DEYI2QV]TQ+/#]V.4^W]T_I].M>476GS:9>/#<120S1G#(XPPK^9L
M5@ZE"5I;='T/HY4W'<6 5?M8ZJP)6E:1U%-#B7+**MBPBZ50LHNE;-A%TKT*
M43:)I:?#TKW_ .!&@?V1X*6X9<27\AE_X"/E7^1/XUXOX+\.R>)-<M;*'[UP
MX4G'W1U)_ 9/X5],65G'I]G#;PKMBA01HOH ,"OTC@? .566*EM%67J]_N7Y
MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
MR,\/_P!?(?\ I2/Z4SO_ )%V(_P3_P#26?@W1117]7'\OA7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\&Z_>3_@D]_P H]?AI_P!>5Q_Z5SU^9>*?_(MI?]?%_P"D
MR/T;PS_Y&-3_  /_ -*B?1%?SR_MP>&&\'?MC_%'3V4JL7BC4'C!SGRWN'=/
M_'66OZ&J_$W_ (+=?#!_A_\ MWZMJ2Q[;;Q?IEIJT6!\N0GV9Q]=UN6/^^/4
M5\IX78I0S&I1?VH:>J:_1L^H\2L.YY?3K+[,OP:?ZI'R+1117[P?B)],_P#!
M'KQ*OAK_ (*&^ 3)M$5\;VS8GJ"]E.$QR.2X4=^"?:OW3K^<?]G#XG'X+_'_
M ,%^+-S+'X>UJTOIL?QQ)*ID7_@2;A^-?T:6]Q'>01S0R)+%*H='1MRNIY!!
M'4&OPWQ4PSCCJ.(Z2A;YQ;?_ +<C]I\,L0I8*K0ZQE?Y227_ +:R2BBBORT_
M2PHHHH *_'O_ (. /$":C^U[X=T^,JW]F^%8/,]0[W5RV#_P'8?^!5^PE?@W
M_P %6_B@OQ5_;U^(%U#)OM=)NTT:$9SM^RQK#(!_VU64_C7Z)X9X=U,V=7I"
M#?WM+]6? >(V(4,K5/K*27W7?^1\[T445_0!^%%K0M&F\1:Y9Z?;C=/?3I;Q
M#&<L[!1^I%?TN65G'IUE#;PKMAMT6.-<D[5 P!GKTK\ ?^"=OPU;XL?MO?#/
M2%C,D::W#J$RXX,5KFY<'V*Q$?C7] E?B?BMB%*OA\.OLJ3^]I+_ -)9^Q>&
M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
M<!2563 X!D(   %?I/!?'%7,JWU+&17/9M26E[;IKO;733R1^><8<&4LNH_7
M,))\E[-/6U]FGVZ:Z^9\C4445^F'YR?I%_P;Q?$J:W\9_$7P=)*6M[NRMM9@
MC)XC>)S#(1_O"6+/^X.G?]2J_'__ (-];21OVP/%$X7]U'X.N(V;T9KVR('X
M[6_*OV K^<_$2E&&=U''JHM^MK?H?T!P#4E/)H*71R2]+W_4*\R_:;_9$\!_
MM<^#_P"Q_&NBQWOD@_9+^$B*^T\GJT4N,KT&5.5; RIQ7IM%?&X?$5:%15J,
MG&2V:=FCZZOAZ=:FZ5:*E%[IJZ9^//[3?_!"CXC?#.ZN+[X?W=MX]T499+<L
MMIJ<(]"C'RY,#NCAC@_(.E?&OC[X7^)/A5K#:?XG\/ZUX?OE)'D:C926LAQW
M <#(]QQ7]*%4]<\/6'B?3GL]2L;/4+23[T%S"LT;?56!%?I&5^)^.HQ4,9!5
M%W7NOYZ-/[D?GN9>&^#K2<\)-T_+XE\M4U][/YGZ*_H,\2?L!?!+Q9,TEY\+
M? _F.VYGM])BMF<\G),87).><]:YZ+_@EE^S_#?M<K\,M#\QB209;AH^>OR&
M3;^G%?30\5, U[U&=_+E?ZH^=EX98Z_NU86^:_1GX*5O?#_X4^*/BQJOV'PO
MX=USQ%>9QY.FV,ETX^H13@>YXK]\O"W[!?P5\'.K6/PM\#+(O*O/H\-RZGU#
M2*Q'X&O4M)T:ST"Q2UL;6VLK6/A(;>)8XU^BJ,"N+%>*U)+_ &;#MO\ O22_
M!)_FCLPWAA4;_P!HKI+^ZK_BVOR/R%_9D_X(3_$;XEW=O??$&\M? >BMAWM@
MR7>IS+Z!$)CCR.[N64GE#R*_33]F']CWP#^R%X2.E>"]%CM))U47FH3GSK[4
M".AEEQDCJ0J@("3A1DUZA17YYG?%F8YI[N(G:'\L=(_/J_FV?>9-POE^6>]0
MC>?\SU?^2^204445\V?1!1110!^(_P#P4_\ @#X\\6_MX?$34M*\$^+M4T^Z
MO(&ANK31[B:&8"UA!*NJ$'D$<'J#7@O_  R]\3/^B=^.O_!#=?\ QNOZ,J*_
M3L#XF5\-AZ>'5!/DBHWYGK9)=O(_-\9X<T,1B)UW6:YI-VLM+N_<_G-_X9>^
M)G_1._'7_@ANO_C=?:7_  0J^#7C#X>?M<>(KWQ!X5\2:'9R^$+F!)]0TR>U
MB:0WEDP0,Z@%B%8XZX4^AK]8**QS;Q&KX[!U,)*BDIJU[O3\#;*_#^C@L7#%
M1K-N#O:RU_$****_-S]""BBB@ K\6?\ @K1\!O'7C3_@H'\0-2T?P7XLU;3;
MC^SO)N[/2+B>"7;IMJK;75"IPRD'!X(([5^TU%?0\-<03R?%2Q,(*3<7&S=M
MVG?\#P>(LAAFV&CAIS<4I*5TK[)JWXG\YO\ PR]\3/\ HG?CK_P0W7_QNC_A
ME[XF?]$[\=?^"&Z_^-U_1E17V_\ Q%;$?] Z_P# G_D?%_\ $,*'_/\ ?_@*
M_P S\>_^"+_P0\:> _VWK'4-<\(>*-%L%TB]0W-]I4]O"&*+@;W4#)],\U^P
ME%%?"\19]/-L7]:G!1=DK)WVO_F?;</Y)'*L+]6A)R5V[M6WM_D>;_MAZ5=:
MY^R/\4K*QM[B\O+SPAJT$$$$9DEGD:RF5451DLQ)   R2:^.K7X4:]>_\$P_
MV>-!N/#>L27UEXWTR74-/DT^0S6\ OKHNTL97<J!6!)8  $9ZU^AM%9Y?G4\
M)25*,;VFIWOVBXV_&YICLGCBJKJRE:\'#;HY)W_ _'3QA^P=XV\)_#+]H"RN
MM'\0:MI_P^%MH/@FV6TEF:Y@N=;@NGFMU"DN1"N7(SCSF'.TD%?L717V&"\2
ML50C)2I*5W?=K[*3Z=6G)^;9\EC/#K#5W%QJN-E;9/[3:^Y-17DD%%%%?FI^
MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20220930_g10.jpg
<TEXT>
begin 644 biib-20220930_g10.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
MO VD_##]C#QC\--!O;ZYL?#O[0?C_3+*XU2\:XN98H->N8D>:5_FED*H"SGE
MF))Y-?:MTFJ:?H,D>BQQWM[!:$6B:A=&);B4+\HDD5'*!F W.$8C)(4]*^??
M^";'[+'QM_9#^&WC+X>_&/6?"NJ-XB^)OB#Q?97_ (9N+G$9U:_EO9+5XYXE
M_P!4\A59 YW@\HA7+ 'T;1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >;Z/^R3\!- _:%U#]JO2O"-['X_U735T[4?$+
M>)-0=KBR5RZ6K1-.8C CLS)%LV(S%E )S7I%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/QE^)
MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
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ME'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\
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M_P CT?\ #RBV_P"B0?\ EP'_ .1Z/[/K_P T/_!E/_Y(/[6PO\M3_P %5?\
MY ^H:*^7O^'E%M_T2#_RX#_\CT?\/*+;_HD'_EP'_P"1Z/[/K_S0_P#!E/\
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M?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%%
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M_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7YY?\%J/#/_!/G]K_ .''Q?\ V5OVE/#?A^7XF_##X(W7
MC_X=WUWJ:VFK0M);ZCLFL'!61UCGTU/.B!>-M\/F)RM?H;7G/[0O[(_[-G[5
M/@?6_ 'Q[^"WAOQ)9:_I3V%]/J>BP37"QE)$5HYG0O')'YKM&ZD-&S%E(/-
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M,E>73;?QCX7M-32T=P [1+<QN(RP !*X) &>E9_P@_9%_90_9[UZY\4_ /\
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M K]"?V3_ /DW;PK_ -@]O_1KU^>U?H3^R?\ \F[>%?\ L'M_Z->@#T.BBB@
MHHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q
M[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHK%^)'_).]?_ .P+=?\ HEJ -JBORSHH _4R
MBORSHH _4RBORSHH _4RBORSHH _4RBORSHH _4RBORSHH _4RBORSHH _4R
MBHK'_CRA_P"N2_RJ6@ K\V/C+_R6#Q7_ -C+??\ I0]?I/7YL?&7_DL'BO\
M[&6^_P#2AZ .:HHHH **** "BBB@ HHHH **** "BBB@ K]"?V3_ /DW;PK_
M -@]O_1KU^>U?H3^R?\ \F[>%?\ L'M_Z->@#T.BBB@ HHHH **** "BBB@
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MW)8Y8_0W[.OPBL_@'\"O"?P;L[QKG_A'="M[.>[9B3<SJ@\Z8D\Y>0N__ J
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MH_L[3_\ GQA_[]"@"G_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\
MOT*/[.T__GQA_P"_0H I_P#"8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\
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M<@U^DG]G:?\ \^,/_?H5^;OQC54^+WBI$4 #Q)?  #I_I#T <W1110 4444
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%^)'_).]?_ .P+=?\
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M* "BBB@ HHHH **** "BBB@ K%^)'_).]?\ ^P+=?^B6K:K%^)'_ "3O7_\
ML"W7_HEJ /S-HHHH **** "BBB@ HHHH **** "BBB@ HHHH _4>Q_X\H?\
MKDO\JEJ*Q_X\H?\ KDO\JEH *_-CXR_\E@\5_P#8RWW_ *4/7Z3U^;'QE_Y+
M!XK_ .QEOO\ TH>@#FJ*** "BBB@ HHHH **** "BBB@ HHHH *_0G]D_P#Y
M-V\*_P#8/;_T:]?GM7Z$_LG_ /)NWA7_ +![?^C7H ]#HHHH **** "BBB@
MHHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-:
M .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *Q?B1_R3O7_^P+=?^B6K:K%^)'_).]?_ .P+=?\ HEJ /S-H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH _4>Q_P"/*'_KDO\ *I:BL?\
MCRA_ZY+_ "J6@ K\V/C+_P E@\5_]C+??^E#U^D]?FQ\9?\ DL'BO_L9;[_T
MH>@#FJ*** "BBB@ HHHH **** "BBB@ HHHH *_0G]D__DW;PK_V#V_]&O7Y
M[5^A/[)__)NWA7_L'M_Z->@#T.BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y
M-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/
M_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%^)'_
M "3O7_\ L"W7_HEJVJQ?B1_R3O7_ /L"W7_HEJ /S-HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH _4>Q_X\H?^N2_RJ6HK'_CRA_ZY+_*I: "OS8^,O\
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M0?2/^?F]_P# MJ -BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M^_\ 2AZ_0_\ X0?2/^?F]_\  MJ_.WXO0I;?%CQ1;QDE8_$5ZJECDX$[CDT
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MX]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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MQ&L2J0@ !]>T444 ?J/8_P#'E#_UR7^52UA67@C239PG[3>?ZI?^7MO2I?\
MA!](_P"?F]_\"VH V*_-CXR_\E@\5_\ 8RWW_I0]?H?_ ,(/I'_/S>_^!;5^
M=OQ>A2V^+'BBWC)*Q^(KU5+')P)W')H YVBBB@ HHHH **** "BBB@ HHHH
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M]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFR_M]*_:*_:D^'/@&ZNXO-M+;QKXWL-*DF3)&Y%NID++D$9'&0:L?L_?M0?
M+]JO0M:\6_LY_%?0O&NAZ%KQT>ZU_P ,ZM!?6$UVMK;W+K#<0.\<H5+J,,5/
M#AE/*F@#OJ\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
M[KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^ Q_QH^Q>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\:
M-BBL?[%XW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8HK'^Q>-_^@W9?^ Q_QH^Q
M>-_^@W9?^ Q_QH V**Q_L7C?_H-V7_@,?\:/L7C?_H-V7_@,?\: -BBL?[%X
MW_Z#=E_X#'_&C[%XW_Z#=E_X#'_&@#8K%^)'_).]?_[ MU_Z):G?8O&__0;L
MO_ 8_P"-8WQ#L_&8\ :X9M9LR@T>YW@6Q!(\ILT ?G)1110 4444 %%%% !1
M110 4444 %%%% !1110!^H]C_P >4/\ UR7^52UA65EXV^QPXUNS_P!4O_+L
M?3ZU+]B\;_\ 0;LO_ 8_XT ;%?FQ\9?^2P>*_P#L9;[_ -*'K]#_ +%XW_Z#
M=E_X#'_&OSM^+RS+\6/%"W+AI!XBO1(RC +>>^2* .=HHHH **** "BBB@ H
MHHH **** "BBB@ K]"?V3_\ DW;PK_V#V_\ 1KU^>U?>O[+EKXL?X >&'L-5
MM8X38ML1X"2!YC]30!ZO1679VGBU+I'OM6M7B#?O$2W()'L:U* "BBB@ HHH
MH **** "BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#
MNOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *Q?B1_R3O7_ /L"W7_HEJVJQ?B1_P D[U__ + MU_Z):@#\
MS:*** "BBB@ HHHH **** "BBB@ HHHH **** /U'L?^/*'_ *Y+_*I:BL?^
M/*'_ *Y+_*I: "OS8^,O_)8/%?\ V,M]_P"E#U^D]?FQ\9?^2P>*_P#L9;[_
M -*'H YJBBB@ HHHH **** "BBB@ HHHH **** "OT)_9/\ ^3=O"O\ V#V_
M]&O7Y[5^A/[)_P#R;MX5_P"P>W_HUZ /0Z*** "BBB@ HHHH **** "BBB@
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MHH **** "BBB@ HHHH _4>Q_X\H?^N2_RJ6HK'_CRA_ZY+_*I: "OS8^,O\
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M761W9G4\.3ELF@#XT_9E_;7_ &]-:_X(._%']HWQ3'I_Q"^*/@*P\6Z;X/\
M%MEI"O:^-+73998+?6TMU79<1LJ2.%5=LX@S@^8:Y_7/V</V=_V);']CKXX_
ML2?$'4O&'B;7/B#H_AG0;?4_$L^KV7B#P[K"EM:NM/L)9'MM'6*W#WOF:;';
M1PI"86!B<QG]/=+TK3-#TRWT71-.@L[.S@2&TM+6%8XH(E 5415 "J    ,
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M)P,4 =?1110 4444 %8OQ(_Y)WK_ /V!;K_T2U;58OQ(_P"2=Z__ -@6Z_\
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M**_+.O>/^">/_)<KW_L6I_\ T=!0!]J4444 %%>4?MLR/'^S;KSH<$2V?/\
MV]15\'_;;G_GK_XZ*Z:,<)*/[V<D_**?XN4?R./$3S",[4*<9+O*;B[^BA+[
M[_(_4>BORX^VW/\ SU_\=%'VVY_YZ_\ CHK7V>6_\_)_^ +_ .6&'M<Y_P"?
M-/\ \&2_^5'ZCT5^7'VVY_YZ_P#CHH^VW/\ SU_\=%'L\M_Y^3_\ 7_RP/:Y
MS_SYI_\ @R7_ ,J/U'HK\N/MMS_SU_\ '11]MN?^>O\ XZ*/9Y;_ ,_)_P#@
M"_\ E@>USG_GS3_\&2_^5'ZCT5^7'VVY_P">O_CHH^VW/_/7_P =%'L\M_Y^
M3_\  %_\L#VN<_\ /FG_ .#)?_*C]1Z*_+C[;<_\]?\ QT4?;;G_ )Z_^.BC
MV>6_\_)_^ +_ .6![7.?^?-/_P &2_\ E1^H]%?EQ]MN?^>O_CHH^VW/_/7_
M ,=%'L\M_P"?D_\ P!?_ "P/:YS_ ,^:?_@R7_RH_4>BOSP_9IN[A_CYX35I
M.#K46>!ZU^A]<]:-",E[*3:\TE^4I'7AY8J47[>,8O\ NR<OQ<8_D%8OQ(_Y
M)WK_ /V!;K_T2U;58OQ(_P"2=Z__ -@6Z_\ 1+5B=!^9M%%% !1110 4444
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MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH \__ &W?^3:]>_ZZV?\
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MU^A_V+QO_P!!NR_\!C_C7YV_%Y9E^+'BA;EPT@\17HD91@%O/?)% '.T444
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MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2O!O\ @I)_R*WA;_L(7/\
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M/'_DN5[_ -BU/_Z.@H ^U**** /)_P!MW_DVO7O^NMG_ .E45?!=?>G[;O\
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MO7_^P+=?^B6K:K%^)'_).]?_ .P+=?\ HEJ /S-HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _4>Q_P"/*'_KDO\ *I:BL?\ CRA_ZY+_ "J6@ KX"^*_
MP1^)^I_%+Q+J5CX8WPW&OWDL+_;8!N5IW(."^1P>]??M>!^*_P#D:=2_["$W
M_H9KPL]S/$993A*DD[M[W_1H#Y?_ .%"?%G_ *%3_P GH/\ XY1_PH3XL_\
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MJXWY(7TKQ[\(M(^(/C+PGXUU'Q3X@L9_"&I2WMG::1J[V]M>M)$8BEU&O$Z
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MXTO;&X^(.NV]W=(^EZK)<2_:+BSFMRN"7B_=><#YRN%VN%41C[*^"GP!\$_
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M_#*/_4^_^4O_ .VU[!11_K#G'_/W_P EC_D!X_\ \,H_]3[_ .4O_P"VT?\
M#*/_ %/O_E+_ /MM>P44?ZPYQ_S]_P#)8_Y >/\ _#*/_4^_^4O_ .VT?\,H
M_P#4^_\ E+_^VU[!11_K#G'_ #]_\EC_ ) >/_\ #*/_ %/O_E+_ /MM'_#*
M/_4^_P#E+_\ MM>P44?ZPYQ_S]_\EC_D!X__ ,,H_P#4^_\ E+_^VT?\,H_]
M3[_Y2_\ [;7L%%'^L.<?\_?_ "6/^0'T3:IY=M''G.V,#/X4^FP_ZI?]T4ZO
MTU; %>!^*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-?(\7?P*7J_R
MSZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO\ UP_]F->'U[A\
M-O\ D1M-_P"N'_LQKZGA/_?I_P"']4!N4445]^ 4444 %%%% !1110 4444
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M/_H"4 ?)-%%% !1110 4444 %%%% !1110 4444 %>\?\$\?^2Y7O_8M3_\
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MQ'8:A ?4,Q2==Q7'W2R(8_0/V*/^"@/Q*\??#[XW:+^TW^S2WAGXN_ MA/\
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M!_PRC_U/O_E+_P#MM'_#*/\ U/O_ )2__MM'^L.3_P#/W_R67^0'C]%>P?\
M#*/_ %/O_E+_ /MM'_#*/_4^_P#E+_\ MM'^L.3_ //W_P EE_D!X_17L'_#
M*/\ U/O_ )2__MM'_#*/_4^_^4O_ .VT?ZPY/_S]_P#)9?Y >/T5[!_PRC_U
M/O\ Y2__ +;1_P ,H_\ 4^_^4O\ ^VT?ZPY/_P _?_)9?Y >/T5[!_PRC_U/
MO_E+_P#MM'_#*/\ U/O_ )2__MM'^L.3_P#/W_R67^0'C]>\?\$\?^2Y7O\
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MAV!=H+*UW,6D=B\DLDCEGFE=V9WED9G=F+,Q))KS_P :_L4^#?$'CWQ3\0O
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MIXM\06XTS3/ TUVVLPC3=2CL[NPN;7*6TSJ+:8K*T#1,K,ZB.,M7U#_P2_\
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MW3+5M-\&Z)JU[I^F6O\ 8EG);V\;S6D4N1%(I<R11EY&=PH5A7;?M=>/]:^
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M>$_">I3W]O:6L]Y%=W5U/>3V]LT\TDD$"JBP(L21GF0N2OM_V_4?^A'\6_\
MA&:E_P#&*/M^H_\ 0C^+?_",U+_XQ4K"9JH<OL9;6^%WL]6M@/GOQ'^S7^T=
M\+OBK\3?&W[)GB3PE;67Q>^SWNL)XJN+F)O#6N1VB63ZM:QP0R+?"2WBMRUK
M(UOF6V#>=B1@O4Z+^SQX[_9Q_8FL/V;/V,-?T73_ !#X5\*0:7X0U;QI;27%
MHUQ'MWW%VL.&9I#YCL5_CDSM(^6O6_M^H_\ 0C^+?_",U+_XQ1]OU'_H1_%O
M_A&:E_\ &*;PN:R23HRTM]EZVT5].BT \8_:7_9I^(WQ>O?A7\8_!7BC1;7X
MC?";Q"VL::NH0RKI6JFXL)K&_LY-N^2W26*>39,!(T3*AV2#*F#X8_LZ_%G7
M/VN[C]LSX^S^'=-U6R\ /X/\+^$_">HSW]M9VDUY'>75U/>3V]NT\TDD$"JB
MP1K$D1YD+DCV[[?J/_0C^+?_  C-2_\ C%'V_4?^A'\6_P#A&:E_\8H6%S50
MY?8RVM\+V>K6P%FBJWV_4?\ H1_%O_A&:E_\8H^WZC_T(_BW_P (S4O_ (Q6
M']FYC_SYG_X"_P#(#HOA]_R.NF?]?:U[G7S-=>.?%/@>W?Q=X?\ @SXSU^]T
M]3-:Z-;>%[V"2\<=(UDEA"(3ZL0*S/\ AX)^T]_TBZ^*?_@=:5]KPQ0KX?"S
M56#B^;JFNB[@?5E5==_Y =Y_UZ2?^@FOEW_AX)^T]_TBZ^*?_@=:4Z']O']I
M/6I5T;4/^"9_Q0L(+MA#/?27-O(MNC?*9"J99@H). "3C YKZ*JFZ4DNS WJ
M*K?;]1_Z$?Q;_P"$9J7_ ,8H^WZC_P!"/XM_\(S4O_C%?E']FYC_ ,^9_P#@
M+_R LT56^WZC_P!"/XM_\(S4O_C%'V_4?^A'\6_^$9J7_P 8H_LW,?\ GS/_
M ,!?^0%FBJWV_4?^A'\6_P#A&:E_\8H^WZC_ -"/XM_\(S4O_C%']FYC_P ^
M9_\ @+_R LT56^WZC_T(_BW_ ,(S4O\ XQ1]OU'_ *$?Q;_X1FI?_&*/[-S'
M_GS/_P !?^0%FBJWV_4?^A'\6_\ A&:E_P#&*/M^H_\ 0C^+?_",U+_XQ1_9
MN8_\^9_^ O\ R LT56^WZC_T(_BW_P (S4O_ (Q1]OU'_H1_%O\ X1FI?_&*
M/[-S'_GS/_P%_P"0%FBJWV_4?^A'\6_^$9J7_P 8H^WZC_T(_BW_ ,(S4O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\
M>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M
M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_
M -@%_P#T-:]7J*^L+'5+233]3LHKBWE7;+!/&'1QZ%3P10!C_"[_ ))GX=_[
M 5I_Z)2MVO$-1_8$^"VI:A/J,GB?QK&UQ,TC1P>+KA$4L2<*H.% SP!T%1?\
M.]_@G_T-OCO_ ,+*Y_QH ]THKPO_ (=[_!/_ *&WQW_X65S_ (T?\.]_@G_T
M-OCO_P +*Y_QH ]THKPO_AWO\$_^AM\=_P#A97/^-'_#O?X)_P#0V^.__"RN
M?\: /=**\+_X=[_!/_H;?'?_ (65S_C1_P .]_@G_P!#;X[_ /"RN?\ &@#W
M2BOC?PG^R'\.-4_:[\7?"JZ\5>,/[+TKPK87MJ4\4W F\V5V#;I,Y9>.!VKU
M3_AWO\$_^AM\=_\ A97/^- 'NE%>%_\ #O?X)_\ 0V^._P#PLKG_ !H_X=[_
M  3_ .AM\=_^%E<_XT >Z45X7_P[W^"?_0V^._\ PLKG_&C_ (=[_!/_ *&W
MQW_X65S_ (T >Z45X7_P[W^"?_0V^.__  LKG_&C_AWO\$_^AM\=_P#A97/^
M- 'NE%>%_P##O?X)_P#0V^.__"RN?\:/^'>_P3_Z&WQW_P"%E<_XT >Z45X7
M_P .]_@G_P!#;X[_ /"RN?\ &C_AWO\ !/\ Z&WQW_X65S_C0![I17A?_#O?
MX)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\ C0![I17A?_#O?X)_]#;X
M[_\ "RN?\:/^'>_P3_Z&WQW_ .%E<_XT >Z45X7_ ,.]_@G_ -#;X[_\+*Y_
MQKROX_\ [(?PX\#?$[X7^'-#\5>,#;^)/%4EEJ1N/%-Q(XB$!<;"3\C9'44
M?9%%>%_\.]_@G_T-OCO_ ,+*Y_QH_P"'>_P3_P"AM\=_^%E<_P"- 'NE%>%_
M\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\ X65S_C0![I17A?\ P[W^"?\
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MKG_&@#W2BO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !H
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MWCOP5\-?!>I_$?XA>+-.T30-%L)+[5]:U2\2"UL[:-2[S22.0J(J@DL3@ 4
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M^SK\6M!\9^'9YGA75?#^H)<1I,F-\,FTYBE7(W1N%=<C(% %+]FOX,ZG\#/
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MTIXU_L[3KJR\)BSUCQ)JDRI'8Z3:O/=/EW^6&/,CO(1@,(XRV?+3'75\@?\
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M6T"?PW#:)';16!A\I8HD Q&$4+L*@;"BE<%17Q?_ ,$"_C1\0_&O_!(+P/\
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MDL-AH7P<36IKZYN JI!#(VI(J1P -+*[J3,\J1Y.&DR >3?\'(OP/UWXA?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*M(\,+K&G>(? MXEIXU\'Z[H\MOJVC2R0^=")+<!O-26+YXI83)%,,^6[%6
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MCE6VN%=A<1O=B&-X5"K^\W;9#-&(3*6(%5/^"LO[(.I?#6;XX^$=4\2Z_P"
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *XOXC?L]?!_XLZW%XC^('A#^T+V"
MU6VBF_M"XBVQ!F8+B.10>78YQGGZ5VE<=\0?C[\)?A7K47A[QYXL^P7DUJMQ
M'#]@GES$690V8XV'5&&,YX^E:4J-:O/EIQ<GV2N_P,:^(P^%I\]::C'NVDOO
M9SO_  Q5^S-_T33_ ,K-[_\ 'J/^&*OV9O\ HFG_ )6;W_X]4O\ PV1^S?\
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M KW27$6C7=KJEW;74%O-& DML+B*;R70!3$4PJ_= !] T444 %%%% !1110
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)%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20220930_g11.jpg
<TEXT>
begin 644 biib-20220930_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/FGNY8(![RB@#QO_ ()B:U^U]KU[\8/^&G/VJH?BOH_AWXAMX8\%Z_#X#LM
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MQG_@FU:77CGX4>(OVP-=M9$U'XZ^+;CQ?9B="'BT(QQV>A18/*C^RK6SF9.
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M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJO./VA?V>/V1?VJ? ^M^ /C
MW\,/"OB2RU_2GL+Z?4]'@FN%C*2(K1S.A>.2/S7:-U(:-F+*0>:]3_L[3_\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
M%/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_
M 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#S
MXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H4 5K;Q1X?O)UM;758GD<X1%/)-7ZB2QLHV#QV<2L.A6, BI: "BB
MB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\
M8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "L?XA_\ (@:Y_P!@>Y_]%-6Q6/\ $/\ Y$#7/^P/
M<_\ HIJUH_QH^J,<1_N\_1_D?F_1117[.?S:%%5-=UW1O#&C7/B'Q%J<%E8V
M4+37=W<R!(X8U&2S$\  =ZMT75QV=KA1110(**** "BBB@ HHHH **** /TT
MLO\ CSB_ZY+_ "J2H[+_ (\XO^N2_P JDK\4>Y_2T?A04444B@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?
M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M?$7X(>)-5\%7G@V,Z+XCT[PZ=0LS</"_GVT\<0:4*I$3B4QM&"[AG4H!4?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@@O+=6F1EEC)C<HRAN#C]$?$6AV?B;P_?>&]0>1;?4+.6VG:)@&"2(48@D$
MX)QP:XG]G3]F[P=^RW^S-X5_99^%/B'68M$\&^%X=#T+5+Z6":_CABC\N.5F
M,0B>4<-DQ;"1RA'% 'P#^V9XV_:_^,>I_LM?\$OOB%\!-/T[Q=J_Q'\/:[\0
M_$>D>)[:]L9M"\-7$%[>:E91)BX@@EEA@4/=QP%9)D@03,Q9?U KS;X+_LI_
M"?X(^,M?^*ND0ZCK?C?Q6D4?B;QUXFOC=ZIJ$41)BM]^%2VMD+,4M;=(H$9F
M98PS,39\:_L[>'/''[0?@C]HR^\>>,+/4O NGZG:6&@:9XCE@T?45OHTC=[V
MS'R7+QA 8V.-C'/)"[0#XN^$O[/FK_M;_P#!8K]J;XQ^-OC=XT\.-\,=*\,?
M#[P-9>$M8%C/8VEQI,&KW%PS[&+J]U=!UC/[ES'^]27:@3Z&_P""77[17Q1_
M:/\ V8[O4?C7JMOJOBOP5\0O$O@G6_$=G9I;PZ])H^JW%BNHI$@"1F:.)'=4
M 02&3:%7"CH_B3^Q-X0\7_&'5_C[\-_BYXW^&GB[Q+HEOI'B_5_ =Y8K_;UI
M;[_LPN8;ZTNHO.A$LBQW,21W"HY02[0H';_ #X"?"W]F'X0:+\"_@OX<_LKP
MYH$#QV-J]S)/([R2/+--++(S/--++))+)(Y+.\C,Q))H [&BBB@ HHHH ***
M* "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]
M@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH
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M_*19_P#QFC_5+,OYX?>__D0_XB!DW_/NI]T?_DS[JHKX5_X;(_:0_P"BC?\
ME(L__C-'_#9'[2'_ $4;_P I%G_\9H_U2S+^>'WO_P"1#_B(&3?\^ZGW1_\
MDS[JHKX5_P"&R/VD/^BC?^4BS_\ C-'_  V1^TA_T4;_ ,I%G_\ &:/]4LR_
MGA][_P#D0_XB!DW_ #[J?='_ .3/NJBOA7_ALC]I#_HHW_E(L_\ XS1_PV1^
MTA_T4;_RD6?_ ,9H_P!4LR_GA][_ /D0_P"(@9-_S[J?='_Y,^ZJ*^%?^&R/
MVD/^BC?^4BS_ /C-?7?P#\4:[XU^#^A>*?$U]]IO[VT+W,_E*F]M[#.U %'
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M_/C]<"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
MY-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K
M=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "L?XA_\ (@:Y_P!@>Y_]%-6Q6/\ $/\
MY$#7/^P/<_\ HIJUH_QH^J,<1_N\_1_D?F_1117[.?S:%%%% !1110 4444
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M\N-5; 9VD.&8!J]?^!'P\^%5Q^VI^TOJGQM\-:-<:_?W6DRQOX@MXI$?PO\
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M %X'_P!&/7RG%W^XP_Q?HS[SP^_Y&E7_  ?^W1._HHHK\^/UP**** "BBB@
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M 2LD2,CEU^<*LC@'IU>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[
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MQ/\ )'.4445]X?E84444 %%%% !1110 4444 %%%% !7WS^RU_R;_P"&/^O
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M** "BBB@ HHHH *^^?V6O^3?_#'_ %X'_P!&/7P-7WS^RU_R;_X8_P"O _\
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MF R85K;_ .$'TC_GYO?_  +:HOA=_P DS\._]@*T_P#1*5NT 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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M #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\
MX%M6Q10!C_\ "#Z1_P _-[_X%M5;6/!FE0Z1=3)<WA*6SD W3$<*:Z&JNN_\
M@.\_Z])/_036=;^%+T8'S[1117XV 4444 %%%% !1110 4444 %%%% !1110
M![E%X(TDQJ?M-Y]T?\O;4[_A!](_Y^;W_P "VK6A_P!4O^Z*=7[.M@,?_A!]
M(_Y^;W_P+:OS_P#BQ"EM\4_$MO&25C\07BJ6.3@3N.37Z,5^=7Q@_P"2M>*?
M^QCOO_1[U]CPA_O%7T7YGYWXA_[I0_Q/\D<Y1117WA^5A1110 4444 %%%%
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MGR@[C0!^87_"E/\ @G;_ -*I_P 7_P#PW?A[_P"6]?8__!'_ $'X7>&OA/\
M$O2/@]^Q5X@^ &AQ_%>0P_#KQ+816MS YT/1R]QY4$LL2+*?F CD8'DG#%@/
M(OVSO&_Q@^"'Q_\ %4OQ;_X.,_"_P(T?5M62[\#?#O4_!?@V>[LM+:V@SO-]
M;_:9!]I^TA7;</+$>7+;L>Q?\$BO&T7Q!^%WQ,\30?MU6O[1:2?%>1%^)MEH
M]E8PW.W0]''V98K%5ML1?=S$ "<Y^;=0!]95Y1^W/_R:/X]_[ +_ /H:UZO7
ME'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\
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M** "BBB@ HHHH **** "OOG]EK_DW_PQ_P!>!_\ 1CU\#5]\_LM?\F_^&/\
MKP/_ *,>OE.+O]QA_B_1GWGA]_R-*O\ @_\ ;HG?T445^?'ZX%%%% !1110
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M;C2IM+&EZ=Y<L4]U%%-,3,;@,SQJ0RL@&U!0![77E'[<_P#R:/X]_P"P"_\
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M .4W_P"V5ZM11_Q$3C'_ *"O_)*?_P @'^IW#G_/C_R:?_R1Y3_PS'_U._\
MY3?_ +91_P ,Q_\ 4[_^4W_[97JU%'_$1.,?^@K_ ,DI_P#R ?ZG<.?\^/\
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M* "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
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M_P#A5^TM\4)86U_QKX6CU74A;PK'&CRNY"*J #"KM4''.W)Y)H ]T_L[3_\
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M0LVI7<LSI%96,;,JM/*PW,PCB660B,_$/_!,7]N/X+?%W_@L%^T?X?\ A_\
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MP_L>>\5*_-;=M6MROL?IQ17YCT5ZG^IW_3__ ,E_^V/#_P"(B_\ 4+_Y/_\
M:'Z<45^8]%'^IW_3_P#\E_\ M@_XB+_U"_\ D_\ ]H?IQ17YCT4?ZG?]/_\
MR7_[8/\ B(O_ %"_^3__ &A^G%%?F/11_J=_T_\ _)?_ +8/^(B_]0O_ )/_
M /:'Z<45^8]%'^IW_3__ ,E_^V#_ (B+_P!0O_D__P!H?IQ17YCT4?ZG?]/_
M /R7_P"V#_B(O_4+_P"3_P#VA^G%%?G[^S?_ ,EV\*_]AB+^=?H%7@9OE?\
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M1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\
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M_P",T?\ #9'[2'_11O\ RD6?_P 9KS&BC^S,M_Y\P_\  5_D']M9S_T$U/\
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MW13J;#_JE_W13J_9UL 5X'XK_P"1IU+_ +"$W_H9KWRO _%?_(TZE_V$)O\
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M^&O OB+PI\+_ !!XE@U+X>^"-8M)OMME'':8O9TM/FEA6>?/EP,!+LA0%!D
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M **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
M7_\ 0UH [KX7?\DS\._]@*T_]$I7A_\ P43_ .18\,_]?]Q_Z M>X?"[_DF?
MAW_L!6G_ *)2O-OVQ_AQ_P +%T+1+7^V?L?V6[F;=]G\S=E5&/O+CI79E^88
M3*\9#%8J7+3CN[-VNK;)-[OL>+Q%A,1CLFJT*$;SDE972^TGN[(^+:*]6_X9
MC_ZG?_RF_P#VRC_AF/\ ZG?_ ,IO_P!LKZO_ (B)P=_T%?\ DE3_ .0/R?\
MU.XC_P"?'_DT/_DCYG\8_LG_ +-?C[Q-HOB_Q=\#?"M]J&@7#3:;/<>'[9RA
M,;I@Y0[E&\L > P5AR :]!5510B*  ,  =*]7_X9C_ZG?_RF_P#VRC_AF/\
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M_P F/);2TM;"UBL;&VCA@AC6.&&) J1H!@*H'   P *DKU;_ (9C_P"IW_\
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MX4C\4/\ H6/_ "=@_P#BZ^@:*/\ B+/$?_/JE_X#/_Y8'_$/\F_Y^5/OC_\
M('S]_P *1^*'_0L?^3L'_P 71_PI'XH?]"Q_Y.P?_%U] T4?\19XC_Y]4O\
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M#W_]#2O2R;_D:4?\2 ]9HHHK]6 YKXN_\B!>_P"]%_Z,6O&*]G^+O_(@7O\
MO1?^C%KQBOSWBO\ Y&4?\*_.0!1117S(!1110 4444 %%%% !1110 4444 ;
M/P^_Y'73/^OM:]SKPSX??\CKIG_7VM>YU][PE_N=3_%^B *JZ[_R [S_ *])
M/_035JJNN_\ (#O/^O23_P!!-?3UOX4O1@?/M%%%?C8!1110 4444 %%%% !
M1110 4444 %%%% 'T5#_ *I?]T4ZFP_ZI?\ =%.K]G6P!7@?BO\ Y&G4O^PA
M-_Z&:]\KP/Q7_P C3J7_ &$)O_0S7R/%W\"EZO\ (#/HHHKX8 HHHH ****
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M@.:^+O\ R(%[_O1?^C%KQBO9_B[_ ,B!>_[T7_HQ:\8K\]XK_P"1E'_"OSD
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M>C#*K@?M6?$ $JV<'^U"?ZBN>G&#PM1M:IK7[P/JZBBBN4#9^'W_ ".NF?\
M7VM>YUX9\/O^1UTS_K[6O<Z^]X2_W.I_B_1 %5==_P"0'>?]>DG_ *":M55U
MW_D!WG_7I)_Z":^GK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HHHH *
M*** /HJ'_5+_ +HIU-A_U2_[HIU?LZV *\#\5_\ (TZE_P!A";_T,U[Y7@?B
MO_D:=2_["$W_ *&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%
M% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\ #^J
MW****^_ **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY
M_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E<[\>_\ D&Z=_P!=W_\
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M->^5X'XK_P"1IU+_ +"$W_H9KY'B[^!2]7^0&?1117PP!1110 4444 %%%%
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M/^G_ /Y+_P#; >I_#[_D==,_Z^UKW.OCG_AR%^R;_P!%&^*?_A;'_P"-4?\
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M[CFN+F[\I0TKQV]NDDKI&&4O($V)N7<1N&0#UNBN9^#?QG^%'[0OPSTCXR_
M_P"(.E>*?"NO6WVC2-=T6[6>WN4W%3M9>ZLK*RG#*RLK $$"?Q1\4/ 7@OQ=
MX9\!^)_$L-IK'C&^N+/PU8.C,]]-!:RW<RKM!"A((9'+-A> ,[F4$ WZ***
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M=O82W&FQPR7&HI)*MU=I'"0ICM8;J=TM1&$^Y7H'_!/+P[X'\'_L%_!CP?\
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MX* _LRZ[^S5\4[^^TV#4G@O-&\0:0X2]T/4[>02VM_;MVDBD4''&Y2R$X8T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M.[FL8I[#[/<02,&9(GWON<(I7YL@ _1NBO(O@G^V=\&/B=^S=X)_:%\:^-M
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MGH3T/I5KQM\3?AO\-(+6Z^(_Q!T/P_%?7 @LI-;U:&T6XE/2-#*R[V_V1DT
M;E%>-_MG_MU?L^_L*^ ]%\:?'#QOIUC-XF\2Z?H?AK29]1BAN-3N;J[@MR8E
M<_-'"LXFE?[L<:$DCC/K6B:YHOB72+;Q!X<U>UU"PO(5FL[VRN%EAGC895T=
M2592.00<&@"U1110 4444 %%%% !1110!YWK?[5_P!\.:U>>'M9\>^3>6%U)
M;W</]E73;)48JRY6(@X((R"157_ALC]F_P#Z*-_Y2+S_ .,U\>?&S_DLWB[_
M +&>_P#_ $HDKF*^_H\*Y=4HQFY3NTGNO_D3\FQ''F;T<1."A3LFUM+H_P#$
M?>FB?M7_  !\1ZU:>'M&\>^=>7]U';VD/]E72[Y78*JY:( 9) R2!7HE?G=\
M$_\ DLWA'_L9[#_THCK]$:^>SW*\/E=6$:3;NKZV_1(^OX6SS%YYAZDZ\8IQ
M:2Y4UT\VPHHHKP3ZH***^9_^"P'Q:^-W[//_  3M^*'[1G[/'Q5N/"GBOP%X
M:EUK3;E-(LKV"Z,14M!/%=0R HR[AE"C D') *D ^F**_.3XF?$3_@IE\ _^
M"9L/_!1_2_V^]&\5ZCHGPMM/'&N>!_'7PPTRWTO4XC91W<UC%/8?9[B"1@S)
M$^]]SA%*_-D?9'P:_:R^&7Q$_9K^&?[17C[7]*\$Q?$SPAI.M:;I?B/68;=X
MY+ZSAN1:!I2GF2)YH4@#)(Z4 >IT5E>+_'/@GX?:,?$?CWQCI6AZ<)%C-_J^
MH1VT(=ONKOD8+DXX&>:Q+C]H;X VGAVW\7W?QQ\'Q:3=W#P6FJ2>)K5;::5
M"\:2&3:S*""5!R,\T =A16+X%^)/PZ^*.E2Z[\,_'VB^(K&&Y:WFO-"U6&[B
MCF7&Z-GB9@&&1E2<C(KYL\8_M1_%WX<_\%:K+X!^//BIX>L/A'/^SEK?C6YM
M;K2XK0Z?>66KZ;;&YN;Z65LQK%<3GCRHU#?,&*AJ /JVBO#?V4_^"B'[+/[7
M7P-N_P!H?X=?%?0(/#-KX@U/3FOK[7+>,"*VU.ZL(;M]S Q1W7V4S0[]I9'7
MOFO0F_:&^ *>&E\9M\<?!XT=[LVJ:L?$UK]F:<+N,0E\S87V\[<YQSB@#L**
MIZ!XAT#Q7HUOXC\+:Y9ZEI]W'YEI?Z?<I-#,G]Y'0E6'N#5R@ HHHH ****
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MG:?;)#!:PHH5(HXT 5$50 %     H N4444 %%%% !1110 4444 ?G=\;/\
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M;V-$CN)Y+N[O[F1HALQ-#&"_DAB ?0L,,5O$L$$2HB*%1$7 4#@  =!3J**
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
H@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20220930_g12.jpg
<TEXT>
begin 644 biib-20220930_g12.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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M&9%M9[]K&YLTEN$*$R>5'=S/& RA9-CG)1<=G0 4444 %%%% !1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
M'=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 445G^*_%7AOP+X6U+QOXRURVTS1]&T^:^U74KV81PV
MEM"ADEFD8\*BHK,2>  30!H4444 %%%% !1110 4444 %%%% !1110 4444
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M:'[6T7[&7PWTCXJZI\$/&GC72+OQ1:Z9KS^"M.2ZDT"RE61I-4ND9U(M81&
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M"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%%
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M^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\
MX%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U
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M577?^0'>?]>DG_H)JU577?\ D!WG_7I)_P"@FLZW\*7HP/GVBBBOQL HHHH
M**** "BBB@ HHHH **** "BBB@#Z*A_U2_[HIU-A_P!4O^Z*=7[.M@"O _%?
M_(TZE_V$)O\ T,U[Y7@?BO\ Y&G4O^PA-_Z&:^1XN_@4O5_D!GT445\, 444
M4 %%%% !1110 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_]</\
MV8U]3PG_ +]/_#^J W****^_ **** "BBB@ HHHH ^,O$?P__;%_;*^,_P 0
MM,\)_P#!277/@UI_@WQ1)I%I\._ W@S1I]0AMDCC:'4+VYU&&>5_M2L9XQ$L
M40BDC7YW5V/JO[!WP0^(/P"T7XB^"OBA^U1JWQ>UF?XB?;+CQ-K]M;P7UNKZ
M+I2I:3QVT<<*,JH'41J 8YD)^8M7RO\ '+]B#_@@A\2?^"EFH?!?XZ_#>S\6
M_'WXKZB^KW&E07VL$Z:B:5YYCFDLY4M[(2Q6$]RL<K+)(\KLH*L,?6'[!?[*
MW[*'[)/PS\1^"?V-M'CTSPCK'C6ZU*XT>*]N)QI^HK;VUC=0$W+O,C![++(Y
MRKLPP!@4 >X5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
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M0 4444 %%%% !1110 4444 %%%% !1110 55UW_D!WG_ %Z2?^@FK55==_Y
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MC3J7_80F_P#0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH
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MQ%\':CX'UZ^U>VL]3MF@N+C0=>N]+O(U/>&[LY8IX']'C=6'K0!:T7Q%X?\
M$D5Q-X=UVSOTM+R6TNGLKI)1#<1,4EA<J3MD1@593RI&" :K^%O&OA3QM#?3
M>%->M[X:9J<^G:BL+_-:W<+;9(9%/*..#@@95E895E)_)GQ-^SE^S1^R)XZ\
M2_ .Y_:V_P""@WQ<\6V7B2]U;Q):_ SQMXLU%?#]O?3-=6L6I/9R^2+LV\D;
M,=QGF&)3&!(N?O+_ ()B>!?V2O"/[-#Z_P#L=^-/$_B30O%?B>^UCQ#KWCC6
M;^]UR\UHE+:Z_M%M0Q<QW4?V:.%XI51D\D KGD@'T17E'[<__)H_CW_L O\
M^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R
M3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHKA% /0;&62XLH9Y1\SQ*S8'<C->6_MS_P#)H_CW_L O_P"AK7J]>4?MS_\
M)H_CW_L O_Z&M '2?#6S\9-\.= :#6+14.B6NQ6MR2!Y*X'6MO[%XW_Z#=E_
MX#'_ !J+X7?\DS\._P#8"M/_ $2E;M &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
M0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[
M+_P&/^-;%% &/]B\;_\ 0;LO_ 8_XT?8O&__ $&[+_P&/^-;%% &/]B\;_\
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M':^+)/"%@]AJMK'"8?D1X"2!D]37D=>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\
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MY_UZ2?\ H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH
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M?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M ,+:^(/_ $,'_DI%_P#$4?\ "VOB#_T,'_DI%_\ $5SE%']I9C_S^G_X$_\
M,#H_^%M?$'_H8/\ R4B_^(H_X6U\0?\ H8/_ "4B_P#B*YRBC^TLQ_Y_3_\
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M:)I4L%K;6UR[R0 &61RA8C=(2N%8 ?G-_P *%_X(Q_\ 2O/^U_\ ^&L\1?\
MRTK[<_X(R^'?V?/"OP;^)>B?LR?LL^/?@YX6B^+<QB\#_$C2[JRU2"=M#T9I
M9F@NIII4CD)WKER"#N  (  /L*O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#D
MT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E9OQ<\4:[X8L;*;0[[R&EE=9
M#Y2MD #'W@:C^&MGXR;X<Z T&L6BH=$M=BM;DD#R5P.M8WQF@UZ&PL3K%_!,
MIF?8(8MN#@=:\K.ZE2EE=2<&TU;5:/= 87_"VOB#_P!#!_Y*1?\ Q%'_  MK
MX@_]#!_Y*1?_ !%<Y17YS_:68_\ /Z?_ ($_\P.C_P"%M?$'_H8/_)2+_P"(
MH_X6U\0?^A@_\E(O_B*YRBC^TLQ_Y_3_ / G_F!T?_"VOB#_ -#!_P"2D7_Q
M%'_"VOB#_P!#!_Y*1?\ Q%<%\0_B'X/^%7@^\\?>/M7^P:38>7]KN_L\DOE[
MY%C7Y8U9CEW4< ]<GC)KS'_AX7^Q_P#]%>_\H&H?_(]?093DG'>?89XC+,-B
M:]-/E<J<*LXJ22;BW%-)I-.V]FGU/%S'B3AW)ZZHX_&4J,VKJ,ZD(-J[5TI-
M.UTU?:Z?8^B_^%M?$'_H8/\ R4B_^(H_X6U\0?\ H8/_ "4B_P#B*^=/^'A?
M['__ $5[_P H&H?_ "/1_P /"_V/_P#HKW_E U#_ .1Z]3_4GQ5_Z%N-_P#!
M-?\ ^1//_P!>N"?^AIA__!]/_P"2/HO_ (6U\0?^A@_\E(O_ (BC_A;7Q!_Z
M&#_R4B_^(K@OAY\0_!_Q5\'V?C[P#J_V_2;_ ,S[)=_9Y(O,V2-&WRR*K##H
MPY Z9'&#6U7R.)Q.=8+$SP^(G4A4@W&49.2E&2=G&2=FFFK-/5/1GTM"O0Q5
M"-:C)2A))QDFFFFKIIK1IK5-:-'1_P#"VOB#_P!#!_Y*1?\ Q%'_  MKX@_]
M#!_Y*1?_ !%<Y16/]I9C_P _I_\ @3_S-3H_^%M?$'_H8/\ R4B_^(KIOA3X
MY\4^)?$DEAK6J>="MFSA/(1?F#*,Y50>YKS:NJ^$,6J2^*)5TFZBBE^Q.2TJ
M;AMW)QC\J]#*L?CJF94HSJR:;V<G;\P/8J*Q_L7C?_H-V7_@,?\ &C[%XW_Z
M#=E_X#'_ !K]+ I?%W_D0+W_ 'HO_1BUXQ7JOQ-M?%$?@N[?4M4MI(0T>](X
M"I/[Q<<_6O*J_/>*_P#D91_PK\Y %%%%?,@%%)))'"AEED55499F. *P-8^+
M7PJ\.[O^$@^)GAZQV_>^V:U!%CZ[G%=.&P>+QD^6A3E-]HIM_@85\3AL-'FK
M345YM+\S\?Z***_V7/\ +H*^T/\ @D-_S4+_ +A/_M[7Q?7U]_P2D\9>$/"L
M_CJU\3^*]-TV6\_LO[)'?WT<+3[?M>[8'(W8W+G'3</6OQSZ0%&MB/"/,J=*
M+E)^QT2N]*])O1=EJ?I_@S5I4?$K 3J245^]U;LM:-1?F?<5%0V.H6&IP"ZT
MV^AN(CTD@E#J?Q%35_F'*,H2<9*S/[\C*,E=.Z"BBBD,V?A]_P CKIG_ %]K
M7N=>#^"5NG\66"64JI*;E?+=UR ?<5[!]B\;_P#0;LO_  &/^-?>\)?[G4_Q
M?H@-BJNN_P#(#O/^O23_ -!-4?L7C?\ Z#=E_P" Q_QJMK%GXS&D71FUFS*"
MV?>!;$$C:<U]/6_A2]&!XI1117XV 4444 %%%% !1110 4444 %%%% !1110
M!]%0_P"J7_=%.K%BLO&WEKC6[/&T?\NQ_P :=]B\;_\ 0;LO_ 8_XU^SK8#8
MKP/Q7_R-.I?]A";_ -#->R?8O&__ $&[+_P&/^->,>(UF7Q#?K<N&D%[*)&4
M8!;><D5\CQ=_ I>K_("E1117PP!1110 45YC\0_VR/V;_A5XPO/ /C[XC?8-
M6L/+^UVG]D7DOE[XUD7YHX64Y1U/!/7!YR*Q?^'A?['_ /T5[_R@:A_\CU];
MAN ..\;AH8C#Y5B9TYI2C*-"JXRBU=2BU!IIIW36C6J/FZ_&7"&%KRHULQH1
MG%M2BZU---.S33E=-/1IZIGM%%>+_P##PO\ 8_\ ^BO?^4#4/_D>MKX>?MD?
MLW_%7QA9^ ? /Q&^WZM?^9]DM/[(O(O,V1M(WS20JHPB,>2.F!S@48G@#CO!
M8:>(Q&58F%."<I2E0JJ,8I7<I-P2225VWHEJPH<9<(8JO&C1S&A*<FE&*K4V
MVV[))*5VV]$EJV>G4445\D?2!1110 5[A\-O^1&TW_KA_P"S&O#Z]<\!VOBR
M3PA8/8:K:QPF'Y$> D@9/4U]3PG_ +]/_#^J ["BLNSM/%J72/?:M:O$&_>(
MEN02/8UJ5]^ 4444 %%%% !7GG[0_@C]H#QM;^#3^SY\6=%\(W.D^/=.U'Q5
M-K7AI=3_ +3T./S%O+"$,Z_9IIE=0MP,E & 'S9'H=% 'P9^U9J/[;?PW^-G
MBG4_%?\ P7"^#'P(\(W^L"3P#X8\<?#/1KJZ;3C;0%G>XN]3M&8BY-S$!L;Y
M8E8L2Y5?3_\ @E;XH\6^+O /Q.U7QI^VMX1^/]X/BH\8^(O@?2+2QTZ=!H6C
MXMDAM)YXE:+)5MLKDG))!RJ_.?Q!^+/[!?PD_;-^+/P[^/G_  3U\1?'SQM>
M^)QJE_\ $#P1\")/&[VEO/;1-;:->RK!(]G/:P!%6V3='Y'DS$K)-(B_3G_!
M,SQ_^SU\1? GQ%U;]FW]ES6_A%HMM\3)+6_\*^(/ S>&KE[U='THO<G36C1K
M8,C1*,J"_E^9_'0!]*5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
M^AK0!W7PN_Y)GX=_[ 5I_P"B4KG?CW_R#=._Z[O_ .@BNB^%W_),_#O_ & K
M3_T2E<[\>_\ D&Z=_P!=W_\ 017CY_\ \BBK\OS0'F5%%%?EX!1110!XO_P4
M+_Y,_P#%_P#W#_\ TX6U?F/7Z<?\%"_^3/\ Q?\ ]P__ -.%M7YCU_H)]%'_
M )-WBO\ L*G_ .F:!_%_TB_^2VP__8/#_P!.U@HHHK^G#\#/TX_X)Z?\F?\
MA#_N(?\ IPN:]HKY)_8W^$'QV\9_LW^'-4\/_M07WA[0Y?MGV/1-/\-6S/!B
M\G5\W#'>VYPS<CC=@=*]._X8_P!6U3YO%O[5'Q1O<_?BM/$2VL3^Q1(^GXU_
MF#Q_D7#DN/,UJXG-J<7+$UVX0I5YRBW5DW%\U.$.9;/EG*-UI)K4_O[@W-\\
M7!^74Z&6S:5"BE*52C&,K4XKF5ISE9[J\5*VZ3T/:"0!DG '4FL76/B3\.O#
MN[_A(/'VBV.W[WVS588L?7<PKS$?L$?L]7I!\56GB#7CW.L>)[M\_78ZUM:/
M^QE^RWH>T67P3T5]O3[9$UQ^?FLV:^1^I>'U#X\;B:C[1P]."_\  I8F3_\
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MN-J'!_">&ES4L!13[^SA?[[7_$_%^BOM#_AT-_U<)_Y:?_W71_PZ&_ZN$_\
M+3_^ZZ_T,_XF%\'_ /H9_P#E'$?_ "H_BG_B"OB;_P! '_E6C_\ +#XOKZN_
MX)C_  D^&7Q6@\=6_P 1_ VFZRMI_9GV0W]L':#?]KW[&ZKG:N<'G:/2NB_X
M=#?]7"?^6G_]UU[1^R%^R%_PRI_PD/\ Q<+^WO[>^R?\PG[+Y'D>=_TUDW;O
M.]L;>^>/SKQ9\<. L[\/\9@LAS*3Q<_9\G+"O3E[M6G*5ING%+W5+[2NM.MC
M[?PX\)N,<IXSPN*SC KZM'GY^:=&:UIS4;Q4Y-^\UT=M^ER6^_8(_9<N)S>:
M9\/I]+N.UQI6M7<+#Z 2[1^50_\ #&-II?S>"_VC/BAH^/N01>*C+ /K&Z'/
MYU[317\?Q\1...7EJ9A5J+M4E[5?=4YD?TU+@GA.]Z>"IP?>G'V;^^'*SQ?_
M (4-^U%HO/A7]LN]D1>EOK?A&TN=WUDR&'X"C^ROV^]!_P"/+Q5\,]>C7K_:
M-C>6LK#V\HE0?KQ7M%%/_7K,JO\ O6&PU7UPM"+^<J4*<G\W<G_5' T_]WKX
MBGZ8BK)?=4G.*^X\I\'?%K]MSPQXHL;B\_9/T;Q%)'<*0FA>-X;;>?87"FO5
MO^&ZOBEX>'_%Q?V!/BY9X_UC>'M-@U95]\Q.N1[UL_#[_D==,_Z^UKW.OMN&
M.(<EQ6%FZN4T8^]O3G7@WHNDJTXKY12\@_L'.:7\'-*OI.%":_"E&7WR/G,?
M\%1OV8=*./B'9>-O"!'WQXE\$7L6SZ^4DE;UG_P4'_8K\8Z/<Q:-^T?X:1I;
M9PBZC=-9DDJ<#_2%3%>W$ C!%<?X_P#@O\'?%^CWLOBWX3^&M4;[-(=VHZ%;
MSG.T\_.AKZ*KBN#JU*7/A:U/1_#6A)?^ RHI_P#DX?5>,Z/PXJA47:5&<7_X
M%&LU_P"2'A&A_$OX<>)L?\(W\0-$U#=]W[#JL,N?^^6-;=>9:Y^QG^RYXAW?
M;_@GHD>[K]AA:U_+R67%8G_#!WP0T[_D2]3\6>&\?<_L/Q5<Q[/IYC/7Y/\
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MGX=_[ 5I_P"B4KG?CW_R#=._Z[O_ .@BNB^%W_),_#O_ & K3_T2E<[\>_\
MD&Z=_P!=W_\ 017CY_\ \BBK\OS0'F5%%%?EX!1110!XO_P4+_Y,_P#%_P#W
M#_\ TX6U?F/7[#?$/X>>#_BKX/O/ /C[2/M^DW_E_:[3[1)%YFR19%^:-E88
M=%/!'3!XR*\Q_P"'>G['_P#T2'_ROZA_\D5_4?@EXV\*^&W"E;+,SHUYU)UY
M5$Z<:;CRNG3BDW*I!WO!]+6MKV_GWQ7\*.(N.N(J6/P%6E&$:48-3E-.ZG.5
MURPDK6DNM[WT/S'HK]./^'>G['__ $2'_P K^H?_ "11_P .]/V/_P#HD/\
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M1UTS_K[6O<Z\,^'W_(ZZ9_U]K7N=?>\)?[G4_P 7Z( JKKO_ " [S_KTD_\
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MU+_L(3?^AFO?*\#\5_\ (TZE_P!A";_T,U\CQ=_ I>K_ " SZ***^& ****
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MS*K897O)[GRV57C6-U#5] 44 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4KG?CW_P @W3O^N[_^@BNB^%W_
M "3/P[_V K3_ -$I7._'O_D&Z=_UW?\ ]!%>/G__ "**OR_- >94445^7@8O
MQ&D^(D/@/5Y/A)9:+<>)QI\O]@Q>([J:&P-UM/EFX>%'D$8;!;8I8@8&,Y'Q
M[\"/@?\ \%EOAM<RV7B7Q%^S>T_B;7(KOQYXZMI==NM;NE9E22:&.6%+??%
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M(QY:I%'M^9G)]2HK>6(<J*I\JTZVU ^=_P!H_P#9]_:#^)/[9_P1^/\ \/\
M3O!K^'/A9-KTFIP:SXCN[>]O_P"TM/%GB)([&6-/*Y?YG._I\G6O4?C%IW[0
MM_JW@U_@3XD\+:?96_BVWE\>1^)+&>:2[T0(_G0V9B8".Y+&/:SY48)/3:W;
MT4G6DU%-+W59?>W^;8'@_P 2OV=OBUX?_:ZC_;*^ ,WAS4]3U'P%'X1\4^$O
M%FI3V%O=VT%W+=VEU!>06]RT$L;SSHR- ZRI(O,93+:7[)7[-?BSX,Z_\1_B
M_P#%3Q%IVH>-?BMXMCUSQ%'HB2"PTZ."S@LK2RMS( \RQ06Z;IF5&E=F;8@P
MH]FHIO$5'3Y?*WG9;(#S5O@=?^-?BWKOQ)^+=W:WMJFE2Z)X+TFSD<IIMA/$
MGVRX<LJ_Z7</\A89$<,$2H07F+^/_"+]BOXZZ-I_P/\ @_\ %3Q/X7F\$?L^
M7D=SX:U71[FX;4_$KVFF7.EZ=]JMW@2*Q$5M=.\OES7'G2HI'E*2M?55%$<3
M5C&R_P"&T:T^]_??< HHHK  KW#X;?\ (C:;_P!</_9C7A]>X?#;_D1M-_ZX
M?^S&OJ>$_P#?I_X?U0&Y1117WX!1110 4444 %%%% !1110 5Y1^W/\ \FC^
M/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2N=
M^/?_ "#=._Z[O_Z"*Z+X7?\ ),_#O_8"M/\ T2E<[\>_^0;IW_7=_P#T$5X^
M?_\ (HJ_+\T!YE1117Y> 4444 %%%% !1110 4444 %%%% !79_ W_D<)O\
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M7WE11_J]D_\ SZ_\FE_F!\&_\-"_M/?](Y_BG^5I_P#'*/\ AH7]I[_I'/\
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M-_J]D_\ SZ_\FE_F!\&_\-"_M/?](Y_BG^5I_P#'*/\ AH7]I[_I'/\ %/\
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M(;KQ!JEW;-;V*$']Y(%Y*C';UKZ,HHKT "BBB@ HHHH **** "BBB@ HHHH
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M*.>(!_P5)^#/[!?P]^''C;3M*U^3Q-<^-/%?B/P%?:=IFI?V?I<SQ6.GW5[
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MH(@A).5VXH _.;_@A=X@T&?]@']JO58=:M'M8/VC/B3+-<+<*4CC,<+AV;.
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2U#]I'QI\9_#5EX"TNQ>\O/%K:Q"]@L2G&5F5BKDM\BJI+,Q"J"Q JA^R/\
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MXJ_$']GWP1KOBC3,?V;XDUGPG9W5_:8&!Y5Q+&TD? Q\K"@#YL_8WDL/!/\
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M>(Q^)4T_P/I\(U9"X<K<A(1YX+JK8?<-R@]10!^:?_!-WQWJ_P >->_8&O\
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MSGPT_9@_9I^"_B.]\8_!W]GCP-X3U?4HV34=5\,^$K.PN;I68.RR2P1*S@L
MQ#$Y(SUH _-[_@J9K?QET;]L;]JZ_P#V=KO44\86_P"P5HK6+Z&Q^WPP#Q'K
M'VM[?;\PF6U:9D*_,&V%><5ZG^U#X8_9P\#WG[$NI_L#:3X=M-9N_BUHEIX%
MF\&QQK+?>!7LIWUL,8OFFL?L0661GRHG6W8GS"I/VAI_[,O[-VD_%.;XYZ7^
MSYX'MO&UP6-QXQM_"=FFJREN6W78C\YL]\MS4GP]_9Q_9Y^$GBC4O&_PI^ W
M@SPQK6L!O[7U?P]X7M+*ZOMS[SYTL,:O+ER6.XG).>M 'P?^UQ\,_P!DZX_X
M.*OV=]9^-/@_PRNK:W\'?$;:#-J5C /[5UV"YM1:"4L,3RQVWVHP[\E61"F&
M5<<A^T#X*^'^JZ9_P4P\"^!_"FCWOPGTOX,QZC+IXLHI-*T_QXOA_4Y=0DM$
MP8HKI8DTN:<H Z3E'.)"QKZ#^/\ ^S)XY^-/_!6?P7\3?B!^R ?&7PAL/@GK
M/A77M8UR30[O3C?WFJZ=>0EK&YN_M$D:)9ON80$AF7:&Y(^F;K]FG]G*]^%<
M?P+O/@!X)F\$1?ZKP=+X4LVTI.2>+0Q^2.6;^'N?6@#\U?VEOV;_ (/>"?\
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M?Q*^%'PM^,WAAO!/Q@^&N@>*]&>9)7TCQ+HT%]:M(OW7,4ZLA8=CC(JKX?\
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M_K5DRK=6-PL;NF]-Z-E&8%74\'*@ ]GHHHH **** "BBB@ HHKQ'XL_ME/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&;EK6P@$44E[>27,\F.KRS2LTDLC'+-([%F8EF)))H _&7]NS_@I5\:O&_[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>%O'OP_T?P]XTT._\/RSZG')IEQ>2P2V-P)EBC$BWC(_FQR%=F5!+ K]*T4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
I10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20220930_g13.jpg
<TEXT>
begin 644 biib-20220930_g13.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
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M110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
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M'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\
ML!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?FQ\9?\ DL'B
MO_L9;[_TH>OTGK\V/C+_ ,E@\5_]C+??^E#T <U1110 4444 %%%% !1110
M4444 %%%% !7Z$_LG_\ )NWA7_L'M_Z->OSVK]"?V3_^3=O"O_8/;_T:] 'H
M=%%% !1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R
M:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVN,^&OB+58OASH$2>%+MPN
MB6H#JRX8>2O-;?\ PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L5^;'QE_P"2P>*_^QEOO_2AZ_0__A)=7_Z%"]_[Z6OSM^+T
MCS?%CQ1-)$8V;Q%>ED;JI,[\&@#G:*** "BBB@ HHHH **** "BBB@ HHHH
M*_0G]D__ )-V\*_]@]O_ $:]?GM7WK^RYKVI6OP \,6\/AFZF5;%@)49<-^\
M?IF@#U>BLNSU[4KFZ2";PS=0JS8:5V7"^YK4H **** "BBB@ HHHH **** "
MO*/VY_\ DT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V
M K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD:(,I49! /KFBBB@ K]"?V3_ /DW;PK_ -@]O_1KU^>U?H3^R?\ \F[>%?\
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M#[7/! \9Z%J.FZ7I_BZR^S7UJ</'#<7%NI)A'FJ) F23'M)P6VCAO$"_$_\
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MLHH **** "OT)_9/_P"3=O"O_8/;_P!&O7Y[5^A/[)__ ";MX5_[![?^C7H
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M *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5B_$C_DG>O_\ 8%NO_1+5M5B_$C_DG>O_ /8%NO\ T2U
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M:*]B_P"&3?\ J?O_ "E?_;:/^&3?^I^_\I7_ -MH \=HKV+_ (9-_P"I^_\
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M_;:/^&3?^I^_\I7_ -MKV*B@#QW_ (9-_P"I^_\ *5_]MH_X9-_ZG[_RE?\
MVVO8J* /'?\ ADW_ *G[_P I7_VVC_ADW_J?O_*5_P#;:]BHH \=_P"&3?\
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M&\5?\C/J7_7_ #?^AFO>:\&\5?\ (SZE_P!?\W_H9H H4444 %%%% !1110
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M9^$M-L;I+N&XNBT;94/<L1^(K4HHH **** "BBB@ HHHH **** "O*/VY_\
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M'T[_ *X'_P!"->)5[;\-_P#D1]._ZX'_ -"- &W1110 4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M1110 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
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MY)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *JZ[_ ,@.\_Z])/\
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MQUT%?B ?@_JWA;PU?P"70)?%$RP:I?1G!6=[%58VL3J=RB619L$!X8SQ7H%
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M'K]E/XJ?LI^./BGJGBC3/&_PQLM$U:W\8/H2-J4-Q:VZ2)?6QCM]S2X59%9
M#D$]C7SI\>?AE^SS\*OVI_V5_%'[$/P^\+^&O%OB;QE+'>P>!M(@L(M4\#-I
M5S-?R74=NJ++;1R?87B:0$),Z;,,]?:/A7P1X,\":.WA[P1X1TO1M/>XEG:Q
MTJPCMX3+*Y>60I&H7<[LS,V,L6).2:Q_A[\!?@9\(]4O]<^%'P8\)^&+W5,?
MVG>>'O#EK92W?S%OWKPHIDY)/S$\DF@#K**** "O;?AO_P B/IW_ %P/_H1K
MQ*O;?AO_ ,B/IW_7 _\ H1H VZ*** "BBB@ HHHH **** "BBB@ KRC]N?\
MY-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T
M2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JNN_\
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M,^I?]?\ -_Z&:]YKP;Q5_P C/J7_ %_S?^AF@"A1110 4444 %%%% !1110
M4444 %%%% !7MOPW_P"1'T[_ *X'_P!"->)5[;\-_P#D1]._ZX'_ -"- &W1
M110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %5==_Y =Y_UZ2?^@FK55==_Y =Y_P!>DG_H)H \
M!HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^AH?\ 5+_NBG4V'_5+_NBG
M4 %>#>*O^1GU+_K_ )O_ $,U[S7@WBK_ )&?4O\ K_F_]#- %"BBB@ HHHH
M**** "BBB@ HHHH **** "O;?AO_ ,B/IW_7 _\ H1KQ*O;?AO\ \B/IW_7
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MW_Y$?3O^N!_]"- &W1110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@
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M+?\ ^-UQM%'^MG%/_0?6_P#!L_\ Y(/K.)_G?WL[+_AH#XN?]#;_ .2%O_\
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MHNH+'PSJ-[=2;8H;&9Y&P3A0A).![4I2C&+;=D@V/!:*XW_AH#X1_P#0V_\
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M_!L/_D@^LX;^=?>CLJ*XW_AH#X1_]#;_ .2%Q_\ &Z/^&@/A'_T-O_DA<?\
MQNC_ %LX6_Z#Z/\ X-A_\D'UG#?SK[T?7$/^J7_=%.IENP>!'4\% 1^5/KZ#
M<W"OS4^,_P#R6'Q9_P!C+?\ _I0]?I77YJ?&?_DL/BS_ +&6_P#_ $H>OP[Q
MO_Y%N#_QR_)'CYO\$/5G-4445_.AX84444 %%%% !1110 4444 %%%% !7Z&
M?LF_\FZ^%?\ L'M_Z->OSSK]#/V3?^3=?"O_ &#V_P#1KU^R>"G_ "4.(_Z]
M/_TN!ZF4_P >7I^J/1****_I@^@"BBB@ HHHH *\9^//P#^.7[1FKR^&)_VD
MO$/PU\#1 (UI\-I8[;7M8;'S--J4L;M8PYX6.T5)CM#FY7>84]FHH ^/F_X(
M7_L 27']N7%M\6Y=?^]_PE,G[0OC ZAYG'[S?_:FW=D9SMQ[5ZM\"?V=_C?^
MS9K4/A_1?VF/$WQ'\#3'8^E?%"Z2]UG2#VDMM41$DNHA_%#>"64[MRW"[/*D
M^9O&'_!0W]KSXH:G\,?V4OV9/'/PIN_C3\4K^^UK6;JWT&YN[+X9^$;,GS9]
M4M1?-))J!E:&U$3- AN&ECQB+>?KS]DGXK>)/C1\!M*\<>,=7T/4M634=4TK
M4M6\,1NFG:E/I^HW-@]Y;([R-'#,UL9D0R2;%D"^9)C>P!Z17E'[<_\ R:/X
M]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"
M^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8OQ(_Y)WK_
M /V!;K_T2U;58OQ(_P"2=Z__ -@6Z_\ 1+5RXW_<ZG^&7Y,F?P,_,FBBBOX-
M/C0HHHH **** "BBB@ HHHH **** "BBB@#]2['_ (\H?^N2_P JEJ*Q_P"/
M*'_KDO\ *I:_OJ'P(^S6P5^:GQG_ .2P^+/^QEO_ /TH>OTKK\U/C/\ \EA\
M6?\ 8RW_ /Z4/7XAXW_\BW!_XY?DCR,W^"'JSFJ***_G0\,**** "BBB@ HH
MHH **** "BBB@ K]#/V3?^3=?"O_ &#V_P#1KU^>=?H9^R;_ ,FZ^%?^P>W_
M *->OV3P4_Y*'$?]>G_Z7 ]3*?X\O3]4>B4445_3!] %%%% !1110 4444 ?
MG]HOP:_X*"?M5Q^(_P!H'X ^(?V9OA?X9^(MQ<Q7.DZA\%I=>UG6+&*>6!%U
MNZ-W;I-<84^9!Y96%BT19RC,WTQ_P3V^$_Q)^!O[*&A_"GXN:IX8O=?T?6M>
MCO+GP7I,-AI3(VM7TD(MK6$E+6,1/&/(R3$048EE-?)FH?\ !+#]BGX(_$W6
M=*\>_P#!6OXY>"?&'C_Q9J.MMHFG_M/W&@RW[7=Y+) B6IF$D[)$T</F'<SF
M+=U.!]H_LA_LXVW[)GP#TSX#V?Q!\0>*H=)U35KF+7_%>IO>ZG>+>:G=7H-S
M</\ -/*!<;6D;ERI8\F@#TNO*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'
M\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUQGPU\&Z5/\.= G>YNP7T2U8A;
MI@,F%:V_^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+
M:@#8HK'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ M
MJ/\ A!](_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -
MBBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/
M^$'TC_GYO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_
M .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](
M_P"?F]_\"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BBL?_A!]
M(_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\ X0?2/^?F]_\  MJ/^$'TC_GY
MO?\ P+:@#8HK'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:@#8HK'_ .$'TC_G
MYO?_  +:C_A!](_Y^;W_ ,"VH V**Q_^$'TC_GYO?_ MJ/\ A!](_P"?F]_\
M"VH V**Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P# MJ -BL7XD?\ ).]?_P"P
M+=?^B6IW_"#Z1_S\WO\ X%M6-\0_!FE0^ -<F2YO"4T>Y(!NF(XB:N7&_P"Y
MU/\ #+\F3/X&?G!1117\&GQH4444 %%%% !1110 4444 %%%% !1110!^I=C
M_P >4/\ UR7^52UA67@C239PG[3>?ZI?^7MO2I?^$'TC_GYO?_ MJ_OJ'P(^
MS6QL5^:GQG_Y+#XL_P"QEO\ _P!*'K]$_P#A!](_Y^;W_P "VK\Z?B_"EM\6
MO%%O&25C\17JJ6.3@3N.37XAXW_\BW!_XY?DCR,W^"'JSG:**\)_;E_:3U?X
M 67@'P_IOBW3_"L7CSQK%H5[XWU>T6:VT*(P2R^9M<B/S7:-8T,A\M=S.P(0
M@_S_ ('!5\PQ4</1^)W_  3;VNWHGHDV]DF]#Q80<Y<J/=J*^<?V/9/VG+3Q
M)IUMXT^*,7B_P)>Z?XG<:C=:,L5_;ZE!KD<,"RW$;>7)&\+7#(JHFW8P^950
M+O?'CPM^W#XXU76M2^ 7QC\/^!K+0X@N@Z=J?A>/46\13B)9':YF>0?9("Y,
M*B-"XV-(6(*H.VIE,:>.>'EB()*_O/FY='RV:Y7*]^G+HM;VU+=-*?+S(]PH
MKPGX1_MHV7BS_@GY9_MP>/O#/]G+'X)N=;U72K=R TMNL@>.(MDA9'B/EYR<
M.N2>M947Q8_:"^#+_"WQY\;?&%KJVG_$C7+31/$NA0Z5%!'X;U"^B9[,6<B@
M220K,JVT@G:1W,JR*4P8R+(\<JE2G*RE"4H6;UE*";E&-DTVK=TG=):L/8SN
MT]UI]Q]%T5X)^V3\2OB=I'CKX>?!WX4_'72_AS=^)YM4O=4\3ZKH]M?)#964
M$8*"*X=$R\]S;+G<",\9Z'TGX&^$_B;X0\#I9?%CXW'Q]JL\[3#74T&VTV+R
MF V)'#;Y&T#G<68DDG(& .>KE[HX"GB9U(^_=J/O<UDW&]^7DW3TYK^1+A:"
MDWO_ %Z'9445\V>)OVGOBEJW[:?PO\!^![RT@^'/B'4O$.E7DSVBO-K5W8:?
M)-)+'(>8X(IU6)2N#(\<V<H$+3@LOKX]S5.RY(RDV]%:,7)KU:B[+\DFT0@Y
MWMT/I.BBBN$@*_0S]DW_ )-U\*_]@]O_ $:]?GG7WQ^RUX3TV_\ V?\ PQ=S
M7%T&DL"2$N64?ZQ^@%?LG@I_R4.(_P"O3_\ 2X'J93_'EZ?JCUBBLNS\):;8
MW27<-Q=%HVRH>Y8C\16I7],'T 4444 %%%% !117S!^VE^U'^S9^SY^TE\+M
M8^.G_!2G0_@[!H-OJ>H:M\.=9U*QMX?&MK<PFV@>=KC]XB6\T;NAB/+;@>@(
M /E/2_B#_P $>/@DOBGX3?\ !27]F*RN/C?K/B'47\:S>-O@C?\ B+4?&EQ)
M<2F*[TV\CL;@75I+&4^S0PR#[,FR(I$T9 ^XO^">?ACQ;X._8]\'^'?%WAO6
M]$\@7[:%H'B:Y,NI:/HCZA<OI.GW;,SM]HM].:S@D5F9E>)E9F()/Y[+\=?V
M5M9U'5-9U_\ X.L=7TYKS7=0GL=.T'Q?X7%M9V+W<K6D"^=8LY9+8PH[%CEU
M<C@BON[_ ():7_AW5/V)O#NH^$OVA+SXKZ9/XC\3O9?$;4)$>;Q!&?$.I8NF
M:,*C9Z;D"H0 5 4@  ^A*\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_
M & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ K%^)'_ "3O7_\ L"W7_HEJVJQ?B1_R3O7_ /L"
MW7_HEJY<;_N=3_#+\F3/X&?F31117\&GQH4444 %%%% !1110 4444 %%%%
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M4'3-6^)+S-KUW'_PD>I?O+XSJLIG)SN,H$G]\!LB@#Z1KRC]N?\ Y-'\>_\
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M?^P>W_HUZ_9/!3_DH<1_UZ?_ *7 ]3*?X\O3]4>B4445_3!] %%%% !1110
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MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
ML!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%^)'_).]?_ .P+=?\ HEJV
MJQ?B1_R3O7_^P+=?^B6KEQO^YU/\,OR9,_@9^9-%%%?P:?&GB?Q^_8NT7XP7
MOBKQAX6^*?BKPMXD\4Z!%I-]=:7J2FSFMXE<11RVLL;Q. 9)#OV^8-[!74'%
M==\)_P!G?P?\'-&\00>&-=UJYUOQ5=-=^(O%^JW:7&J7USY0BCF=VC\L>7&J
MK'&L8B0* $P3GOJ*]">:8^IA5AY3;@K::;*UDWNTN563T5EH6ZDW'EOH?,>B
M_P#!,30/#UA=:5HO[:/[0-K:WUW/<WT%K\08HA<33.7FD8I:AB[LQ);.[GK7
MN/Q)^"_@+XI?#^+X;^(M/EAL;26VGTF?3YS#<:9<VSJ]M<6\@YCDB=%*GD<8
M(*D@]7158G.,RQ=6-2K4;E%W3T5GWT2UT'*K4D[MG%_"WX'^'OAAK>M>,G\0
MZMXA\2>(C -:\2Z_)"UW<Q0*RP0!;>**&**,.Y5(XT7=([$%G9C%\0?@@/'\
M.I::GQ6\6Z)INM1&/5M,T2]MTCN%9=C[9)8))K;>@P3!)%SEQAR7/<T5S_7<
M3[?VW-[VG1=+6LK65K*UEI96L3SRO<XCQ1\ / >O? >3]G/09=3\,>'?[&BT
MNR/A74&L[FPMHPH18)1DH0% R<Y&0<Y-;6M>!8]5\-V6@6?BC6-/FTX1_8=6
ML[L-=1LB%-S&9728E20PE1U).XC< 1NT5+Q6(:2<F]7+775VNW?>]E>^X<TC
MB?AO\"/"WP[\8ZU\2YM:U77_ !3XAA@M]4\1Z]-$UPUK!N,-M&L,<4,,*%W;
M9'&NYG9FW,<UVU%%16KU<1/GJ.[T7R2LDNR2T26B0FW)W84445D(_4NQ_P"/
M*'_KDO\ *I:BL?\ CRA_ZY+_ "J6O[ZA\"/LUL%?FI\9_P#DL/BS_L9;_P#]
M*'K]*Z_-3XS_ /)8?%G_ &,M_P#^E#U^(>-__(MP?^.7Y(\C-_@AZLYJBBBO
MYT/#"BBB@ HHHH **** "BBB@ HHHH *_0S]DW_DW7PK_P!@]O\ T:]?GG7Z
M&?LF_P#)NOA7_L'M_P"C7K]D\%/^2AQ'_7I_^EP/4RG^/+T_5'HE%%%?TP?0
M!1110 4444 %%%01ZIIDVIS:+%J,#7EO!'//:+,IECBD9UC=ESD*QBD"DC!,
M; ?=. #YA^,G_!:;_@FE\!_B%JOPK\>_M&33ZYH5\]EK5KX6\#ZYKR6-TAQ)
M;RS:997$22HP*M&6#(P*L 017K_[)_[3OPY_;'^!.E?M$_"0WC>&]<O]2ATF
M:_LI;::>*TU"YLO-:&9$DBWFW+[)%5U# , 0:^-?V4/VF?\ @J/\'? NI_!W
MPY_P1KU37?"GA7Q9K.F>$_$L7QD\/Z;/JEI#J5S'YL]M<.K^875\W!Q]I_UX
M11)BOK3]AOXB_$/XL?LXV/C[XL?!1/AUXCOO$OB(:QX+6_ANSI<T>N7T11YX
M"8IY&V!WEC)1W=F4D$4 >N5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L
M O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %8OQ(_Y)WK_P#V!;K_ -$M6U6+\2/^2=Z__P!@
M6Z_]$M7+C?\ <ZG^&7Y,F?P,_,FBBBOX-/C0HHHH **** "BBB@ HHHH ***
M* "BBB@#]2['_CRA_P"N2_RJ6HK'_CRA_P"N2_RJ6O[ZA\"/LUL%?FI\9_\
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M_P!/T+4-!^"GCA]#U*[D-[?7(GOOE8O;[95$)V[68S8;Y2*^WZ\P_:1_8\^
MG[5EC8_\+8\+WB:OHX<^'O%WAO6KK2-<T9GQN-IJ%E)%<0 E5+(K['*+O5@
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MUX'_ -&/7RG%W^XP_P 7Z,^\\/O^1I5_P?\ MT3OZ***_/C]<"BBB@ HHHH
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M+_QX5I44?\2T<"?]!.)_\#I?_*0_UJS#^6'W/_Y(S?L%W_SR_P#'A1]@N_\
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M6++@?NFYK6C_ !H^J,<1_N\_1_D?GM1117[.?S:%%%% !1110 4444 %%%%
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MQ5=MX)^%6K:[:>(]8\]S96TDMG"\:PV;0"[>-CNDG:T(PL$BR<5_P0,_:L\
M?&Z^_:/\(>%_"'C6PN;K]I'QEXHCF\1>#+W3H%M+R^C\J!I9XU5;M<?O+8GS
M8_XE%?HI7G'[-_[+OP[_ &7+7QM9_#K4-6N%\>_$C6/&VM'5KF.4QZCJ4JRW
M"0[(TVPAE&Q6W,!U9J /1Z*** "BBB@ K'^(?_(@:Y_V![G_ -%-6Q6/\0_^
M1 US_L#W/_HIJUH_QH^J,<1_N\_1_D?F_1117[.?S:?&W[;/[3OCF[^,GC3]
MEGPS\98OAXVB_"P>(M.FCLXFU#Q//(\ZO#;2396..%806\M3,Q=BK((V)^@_
MV?7_ &@+"V\8Z/\ M!:U8:Q<:7XK,'AK5=)T4V*7^E_V?92)(8B[YD\][E'(
M;:71@H4 */!?^"C'AK]DC]ICPWX\^#7Q8TW34\?_  _\+)KGA:^^WK;ZG!',
MCLL]JP(9D62%@\?SID(6&2M;/_!-?QC\;K?6/BO\!/BE\77^(V@_#3Q/::;X
M3^(UQM:;4HI;43S6LTJDB::V+1I(Y);>[ G@ >12J3CF+C)W3>C3TTYM&NEK
M;KMKJ]?HJU&G/)U*$5%Q2NFE=WY/>C+=WNKI]W:Z6F)^T7\4?V^OV8?"VG_M
M;^+?B1X9U7PROB#38/%'PDM_"ZHVG6-[=Q6J+;ZB)6EN+J-IHPQ*K&[;B$"@
M*?JWQOXQTOX?^%;SQAK5AJMU;6,8>6WT/1+K4KN3+!0([:UCDFE.2.$0X&2<
M $CYM\9?M*?LL?M%_$"TN?&'[0_@6P^'?P_UT:B8]1\5V<3>(=8M&)CDV/("
M+*UD!D5B/W\Z(R_NH@T_U#IU_:ZKI\&J63,8;F%982\3(Q5@",JP#*<'H0".
MXKHPMG.?).ZTM=WUUN_1Z::+1VT9Q8Z\:=)5:?+)7O9<NFEH[6NM;O5ZI/5'
MBO[!W[2GBK]JCX?^+_B-XH\.ZAHJV?Q'U72-+T35]/\ LMYI]I;&*-(;B,@,
MDV=[.K9968KG"BL4?$SXX?&CXO?&#POX,^+,/@6Q^%D]II^DVYTBVN/[0NI-
M/CO6N[\W",PM#YJHJ0&%R(Y&\W) 5O\ P3CEBET+XRF*16Q^T7XQ!VG.#]M%
M<#I?P:^%7[5GQ>_:#UC]IS7K_1+_ $'5#X9%AI?B*;1UM?#,=G%<6U[="!XQ
M>I,\UQ(&NQ-"H0QJH57!Y_:5I86EK>3O?6U]'U6W?_@'7[+#0QM=\MHQ2MHI
M6O*/1[Z76O?O8^B/V3_C1J7[1?[-7@?XYZQX=_LF[\4^&[74+K3USLADD0%M
MA;DQDY*D\E2IK"_:C^,GCGP5XH^'/P5^%EU:V7B'XF>*9=-AUF^M?/CTNSMK
M.>]N[A8R0LDWE0;(U;Y=\@9@P4HV-^R#\?7A_8)\(?'?]HS6M-\.V]MX?WZC
MJUU;)I]J;..=X+6Z\L!4A6>%8)0B@*/. 4 8%==^T#\+_ /QA\%Z+X[U#X@K
MX<G\(:C'XD\,^-;6XAV:;(D3J96:7,<EM)!+(DBL0K1N>5(5EZE.=7!QY9>\
MU%]G;2_HVK^C.)TZ=#,9*<?=4I)=4GK;U2=FUU734YSX?_%#XD>!?VM)_P!E
M7XA^+W\4V.J>!&\4>&?$5[8P6]]'Y%W':W5I<BV2.&09G@DCD2.,X+JP8J&/
MMM?*'[%G@OXG?%_]I_QG^W%\1O%<NIZ-<>'8O"7PUG.AG38[S3%G%S=7T-LS
MR/'!+.J>4\CL\JH7X1HU'U?58.<YTG)WLV[7WM_6J\K&>8TZ=*NH1M=)<UM%
MS6UTTM;9Z+6X4445UG ?II9?\><7_7)?Y5)4=E_QYQ?]<E_E4E?BCW/Z6C\*
M"OSJ^,'_ "5KQ3_V,=]_Z/>OT5K\ZOC!_P E:\4_]C'??^CWKZ_A#_>*OHOS
M/SWQ#_W2A_B?Y(YRN#^-7[/?A'XY7GA[5?$'B/Q#I.H>%K^6]T+4O#>KM9SV
MUQ)$T)?<H.\>6[J4<-&P<AE85WE%?=3A&I'EDKH_+J=2I2GS0=F>)?L\?L5>
M&_@UXDM_B+XU^(.O^-_%&GC4X=%U3Q!<1>7I5M>WCW$RVT$$444<DN8_-EVE
MV*X!5,(,OXC_ /!/O2OB+\8=8^-J_M8_&CP_J^LP16\L/ACQ;;6=O;VT9)CM
MHD%H2L2EF;:6)+,S$EB37T#16'U/#^S4.71:]=]K_<=7]H8Q574YM6K;+:][
M6M9*^NAP?P]_9Y\%^"/@S=?!#7M8UKQCIFIPW<6O7_C74?M][JZW)82BYE*K
MY@V-Y0  "QHB@845@>%OV// ^A:KX6N/$7C_ ,6^)].\"SB?P5H/B348)K31
MYEB:*.8&.!);F2.)F2-[J29D#$@AOFKUNBK]A1TTVV,EB\0G)\WQ;_/?TTTT
MZ:;&!XT\"W/BN6WO](\=:WX=OK=&C6^T62 EXVP2CQ7,4T+\@$,8RR\[64,X
M;/\ @[\$?!?P3TO5+7PN][=WVO:O+JOB+6]5N!->:I>R*JM/,X"J"$1$5$5(
MT5%5%4#%=?15^SAS\UM3/VM3V?)?0XOX6? WPY\*OAS=_#&R\4^)=9L;V\O;
MB:[\0Z]-=7@^TR/(Z+/D.BJ7(3:05 !SGYJS4_9L\/ZGX_T'XB?$3Q[XD\6W
M7A6>6X\,6>O2VJVNFW,D;1&Y6.UMX?-F$;NBR3&0H'8KM9B3Z-12]C2Y5&VB
M_3;[BOK-?FE+FU=[OUW^_K;<****T,0K[Y_9:_Y-_P##'_7@?_1CU\#5]\_L
MM?\ )O\ X8_Z\#_Z,>OE.+O]QA_B_1GWGA]_R-*O^#_VZ)W]%%%?GQ^N!111
M0 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\
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M-_\ #'_7@?\ T8]? U??/[+7_)O_ (8_Z\#_ .C'KY3B[_<8?XOT9]YX??\
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M5+FY6WL=-MYU@0N027FF<%8(E56+.03P%57=E1N2^"O[0EU\2/'GB?X.^._
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M@?\ T8]? U??/[+7_)O_ (8_Z\#_ .C'KY3B[_<8?XOT9]YX??\ (TJ_X/\
MVZ)W]%%%?GQ^N!1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7
ME'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\
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M7R7TEC-'IEQ%#<M$PMY9X3(B/CY69 RE@#@E0RDCC(ZU\X_LY6_B'P-^V_\
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MH'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\
MDG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^
MH'_RK_\ <P_XAU_U%?\ DG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\
MDG_VY\IT5]644?\ $8/^H'_RK_\ <P_XAU_U%?\ DG_VY]$67_'G%_UR7^52
M4V'_ %2_[HIU3>^I^EI65@KX0^*?P=^(^H_$[Q'J%GX=WPSZ]>21/]LA&Y6F
M<@X+Y'!K[OKP/Q7_ ,C3J7_80F_]#-<F+XHQ_#$54PL8R<]'S)O;72THGC9S
MD>$SRG"%>4DHMM<K2W]4SYN_X4C\4/\ H6/_ "=@_P#BZ/\ A2/Q0_Z%C_R=
M@_\ BZ^@:*X?^(L\1_\ /JE_X#/_ .6'@?\ $/\ )O\ GY4^^/\ \@?/W_"D
M?BA_T+'_ ).P?_%T?\*1^*'_ $+'_D[!_P#%U] T4?\ $6>(_P#GU2_\!G_\
ML#_B'^3?\_*GWQ_^0/G[_A2/Q0_Z%C_R=@_^+H_X4C\4/^A8_P#)V#_XNOH&
MBC_B+/$?_/JE_P" S_\ E@?\0_R;_GY4^^/_ ,@?/W_"D?BA_P!"Q_Y.P?\
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M=_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHHH **** "O</AM_R(VF_]</\
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MY@_X(]?L[GQE_P $X/ GB;3O&D:M/<:]Y,7V'>I9-;OT'S"3H2OIQF@#O/\
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M@#2JKKO_ " [S_KTD_\ 035?_A,?#'_0:@_[ZJKK/BWPW+H]W%'K$)9K:0*
M>I*FLZW\*7HP/#Z***_&P"BBB@ HHHH **** "BBB@ HHHH **** /HJ'_5+
M_NBG5EQ>,/# B4'6H?NCO3O^$Q\,?]!J#_OJOV=; :5>!^*_^1IU+_L(3?\
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M69O@QHGA[P]J%GH&K:O/?0>&_$-VL[SV5I)<.[JCVRPW#QECM\Z(\!AGUO\
M;8_:V^)7[//P6TCQ'\*?V;/B%XP\4^*7C@LM-\,^"KC6#H"LJ-+=7T=L=O[E
M7X@\Q3/(NQ75=\L?+?L ?'31]?O9?@UX(_9#^./A.%;>ZUWQ9X]^,/@W^QVU
MK4Y98Q)*SEB;FZF9RVU52.**'8NQ$BCH ^IJ*** -;P&B2>,=.21 RFZ7((R
M#7MG]G:?_P ^,/\ WZ%>*^ /^1TTW_K[6O<* (?[.T__ )\8?^_0JKKEA8+H
MMXRV4((M9,$1C^Z:T*JZ[_R [S_KTD_]!-9UOX4O1@?/M%%%?C8!1110 444
M4 %%%% !1110 4444 %%%% 'T)%IVG^4O^@P_='_ "R%._L[3_\ GQA_[]"I
M(?\ 5+_NBG5^SK8"'^SM/_Y\8?\ OT*\(\4JJ>)]11%  OY@ !T^<U[[7@?B
MO_D:=2_["$W_ *&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%
M% !7M?PYLK*3P1ISR6D3,8.2T8)/S&O%*]P^&W_(C:;_ -</_9C7U/"?^_3_
M ,/ZH#72QLHV#QV<2L.A6, BI:**^_ **** "BBB@ HHHH **** "O*/VY_^
M31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$
MI7/_ !X_Y!VG?]=W_D*Z#X7?\DS\._\ 8"M/_1*5S_QX_P"0=IW_ %W?^0H
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M$$.ERZC-IUOHE_ 4M8WC1Y2T\"(%#RQKUZN!WKW6BI2JT9<M2+3\U8 HHHJ
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M2+0V5[<6JR&UFO(I)) (G=@0$C=]@Y7D40H<]*51R22[WU]+)_C8#Z]HHHK
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M(KJXD5 AW,M>WUD>+? '@3Q_9C3_ !WX*TC6[<1O&(-7TV*Y38X ==LBD88
M CO@9KXJE)0J*3OIVT?E]P'YC_\ !-#1/BU^QK^VIX(_94^"?QZO?&WP=\>6
M'C6[U#X>ZI=B]F^'4>E:G-!:7,4V2\5M<MY42JV%=VE8AF :O7OCOHW_  5+
M\%ZE\</'ND_ +X0:_I/B.SU*VT_Q%JGQ#OK>^M?#=O#.MG;);+8LD96-Y9W3
MS#NN+B8[@I54^M?@)^S#\ ?V7_#UUX8^ GPET#PM:7U[-=7PT728;9KB22:2
M7]XT:*7"F1E0'(1,*N  *[>_L+'5;&?2]4LH;FVN86BN+>XC#QRQL"&1E/#*
M02"#P0:[ZV/C/$>T4$^]]WK>[LUKLOEKJ!^=OP9^%G[1W[2W_!NA+\'?$G@?
M1[36]2^!5M;?#VS\.:G+=OJ]A%I%M+9-,'C3RKJ9T:-HEW*N5P[9./1/VK?B
MAX6_;!^%O[+GA[X3:E#J%Y\0OBSX6\606MHX:2TTK27&IZA.X',0A,*6S[L%
M9ITC(W';7V-X;\->'/!OAZQ\)>$- LM*TK3+2.UTW3--M4@M[2"-0J111H L
M:*H "J    !6/X4^#/P?\!^+-6\>^!_A3X:T;7=???KNM:3H5O;W>I-NW9GF
MC0/,<\Y<GGFH>-BZCGR_:<EZOO\ <G^'70/F;]KSPWI'QX_X*)_"#]F_XT7E
MWH_@BV\':QXL\,W^E:C+IE]J_B:WG@MA9P:C;M'<VYAL[B>=H[>6-Y58[RT<
M;+5K_@FS96?PT^,_[07[,WPSG;4OAMX&\<6,WAC6YY/M-Q_:>H6?VO5K">].
M7OI;>=HV,LS23K]I$<CL8QCZ8^(7PQ^&OQ;\/'PC\5OA[H?B?2C,LQTSQ#I,
M-[;F1?NOY<RLNX9.#C(S5GP;X)\&?#KPW:^#?A]X1TS0M'L4*66E:-81VMM;
MJ220D4:JJ#))P .36;Q2>&]E;I:W2][\WKT^>_0#SGQY\>?V5/BG^RIXX^*>
MJ>*=,\;?#*RT35K?Q@^A*VI0SVMNDB7UL8[?<TN%6160 Y!/8U\Z?'CX9?L]
M?"K]J?\ 98\4_L1?#[POX:\6^)O&,L=[!X&TB"PBU3P,VE7,M_)=1VZHLMM'
M)]A>)I 0DSILPSU]H>%?!/@SP+H[>'O!'A'2]&T][B6=['2K".WA:65R\LA2
M-0I9W9F9L98L2<DUC_#WX#? WX1ZI?ZY\*?@QX3\,7NJ?\A.\\/>';:REN_F
M+?O7A13)R2?F)Y)-*E7A1ORWMKI?1W5M?3\=M .LHHHKD *]P^&W_(C:;_UP
M_P#9C7A]>X?#;_D1M-_ZX?\ LQKZGA/_ 'Z?^']4!N4445]^ 4444 %%%% !
M1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=
M?"[_ ))GX=_[ 5I_Z)2N?^/'_(.T[_KN_P#(5T'PN_Y)GX=_[ 5I_P"B4KG_
M (\?\@[3O^N[_P A0!YI1110 4444 %%%% !1110 4444 %%%% !78_!#_D;
MYO\ KP?_ -#2N.KL?@A_R-\W_7@__H:4 >KT444 >3?MO_\ )M.O_P#76S_]
M*HJ^"*^]_P!M_P#Y-IU__KK9_P#I5%7P17\O^-'_ "55+_KS'_TNH?/9K_O*
M]/U84445^1GF'S3JW[<OQ'\2^+M.O_@;^S_=>)_!P\5ZKHD^I1ZW;17VLS6%
MO<M<"QMY"%VK+;LJO++'YAC(50&5Z]!UK]I/6O\ AF/PW\?? 7P?U3Q!K'B[
M2])N= \$0WD<%U/-?)%((&F<;(_*C=Y)';"JL+DX KY3^,G[/?QG_9E^,&@_
MM'?\$^?%L?BK1O%7BO4]9F^$>O2-]A>_:PNVNYK&4%6@D>-9U$1P!(5SN"JB
M_7?[)'QU\(_M+?LW>$?C=X%\-OHVEZYI0:WTAU4?86B=H'@&T %4>)U4@ %5
M!P,X'VF<8'+<+A*&+PM*,Z5TGK)2O>?N58MW3?+\4;)\LN5K1+KJPA&*E%77
M]:,\\\*_M<_M/2?&'PA\*_BM^PW<>$X?%U_<6]OJS_$?3[\0)!;O/+*T5NK.
M554"Y.!ND1<@L*[WQM^T!J]M\8C\ ?A)X!B\2>)K70DUG6VO]8^P6&EVDDCQ
MP"6=89G,TK1R[(EB;B-F9D&TMF?#T?\ "T?VK_&'Q+?]YIO@/38_"&A,>5-Y
M,(K[4Y5]1C^SH<CHUM*,]0,OQCX(\>? []I+Q/\ M1^$?#D&O^'O%/@ZRLO%
MVG?VK!9W6GSZ<UR\%XCW+I"T!BN)%E#2(R>6KC?D@<52GEU7$J/L8PFJ::BI
M3493DTTFY3;5J;VYE[ZMUUAJFY;6=O.U_F^WXG>? ;XXZ%\>/"E_K>FZ->:3
MJ.AZ[=:)XDT/4"AGTS4;9@)8&:,E'&&1T=20\<B-QG [6>>"U@>YN9DCCC0M
M))(P"JH&223T %?-O_!,%/&OBOX1>,/VAO'6@C2YOBO\1]1\4:7IZLQ\G3GC
M@M;7EE4L&CM1('*KO5U; R!5[_@J/?>)6_8XUOP5X5UM]+N/&6MZ/X9FU1,_
MZ);ZAJ-O:SN?8Q2.A_WZYZ^4TI<1_P!G4Y<J<U!O=1;:4M>JB[KNTB94U[?D
M7>QZ'\'?C_!\>YW\1?#+P?=3^#$FDBMO&&H3B"+560E3)8P[6>>#>-OG/Y2M
M]Z/S%Y/H=?.-[;>(?V1/C3\'/ACX,\>ZWK'A+QG<77AG4-"UVX2X:UDM].EN
M;:\MB$4P!1;-')$N(=DBE40KS]'5QYIAJ-&I"=!?NYJ\=[V4I1]Z_P!J\7>U
MEU26Q-2*336SV"BBBO,,SNOV9?\ DO\ X2_[#47\Z_1:OSI_9E_Y+_X2_P"P
MU%_.OT6K^E/!/_D18G_KY_[;$][*?X,O4*JZ[_R [S_KTD_]!-6JJZ[_ ,@.
M\_Z])/\ T$U^R5OX4O1GK'S[1117XV 4444 %%%% !1110 4444 %%%% !11
M10!]%0_ZI?\ =%.IL/\ JE_W13J_9UL 5X'XK_Y&G4O^PA-_Z&:]\KP/Q7_R
M-.I?]A";_P!#-?(\7?P*7J_R SZ***^& **** "BBB@ HHHH **** "BBB@
MKW#X;?\ (C:;_P!</_9C7A]>X?#;_D1M-_ZX?^S&OJ>$_P#?I_X?U0&Y1117
MWX!1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)
MH_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2O!/^"E'_(J^%O^PA<?^@)7O?PN
M_P"29^'?^P%:?^B4KP3_ (*4?\BKX6_["%Q_Z E?#>)7_)$8STC_ .EQ./,/
M]SE\OS1\CT445_'A\N%%%5;?7-'N]8NO#]MJ<,E]90Q2W=HL@,D*2EQ&S#J
MQC?![[#Z4TFTVN@%JBBBD 4444 %%%% !1110 5[S_P3M_Y+G??]BU<?^CX*
M\&KWG_@G;_R7.^_[%JX_]'P5];P'_P EC@O^OB.G!_[U#U/M>BBBO[//JSR;
M]M__ )-IU_\ ZZV?_I5%7P17WO\ MO\ _)M.O_\ 76S_ /2J*O@BOY?\:/\
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M .V_9O\ ^2[>%?\ L,1?SK] J_/W]F__ )+MX5_[#$7\Z_0*O@.+_P#?*?\
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M.._^@G#?^!U?_E)^<_ZU9?\ RS^Y?_)&;3%MK=)WND@02R*JR2!1N8#. 3W
MR<?4UJ_8+3_GE_X\:/L%I_SR_P#'C1_Q+3QW_P!!.&_\#J__ "D?^M67_P L
M_N7_ ,D9M%:7V"T_YY?^/&C[!:?\\O\ QXT?\2T<=_\ 03AO_ ZO_P I%_K5
ME_\ +/[E_P#)&;16E]@M/^>7_CQH^P6G_/+_ ,>-'_$M''?_ $$X;_P.K_\
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MR$6VOZE:+:B"TN%! FBCCFGG\ELHYC!96$?$/[,NHVW@7]M#XP_LW^!;X_\
M"'Z%H?A[6;'1$F+0>'[Z]6Z6>U@4D^3%(D$,XA7"(7<JH#D5'UK]]R6TORW\
M^7FV[6_X:Q?U'_9O:<VO+S6MI;FY-[[W\K>=]#Z.HHHKK. *]Q_8!_Y+7>_]
MBY/_ .CH*\.KW']@'_DM=[_V+D__ *.@KS,Z_P"156_PGM\-_P#(]P_^)'V/
M1117Y,?OIY;^V?\ \FZ:[_UUM/\ TJBKX9K[\_:6\+?\)I\&M5\.?;_LWGO;
MGSO*W[=L\;=,C/3'6OEG_AF/_J=__*;_ /;*^CRCBO(,CPSP^.K<DV^9+EF]
M&DKWC%K=,_-^+\@S;-,SC5PM/FBH)7O%:WD^K7='E-%>K?\ #,?_ %.__E-_
M^V4?\,Q_]3O_ .4W_P"V5ZG_ !$3@[_H*_\ )*G_ ,@?*_ZG<1_\^/\ R:'_
M ,D>326UM-+'--;H[PL6B=D!*$@@D'L<$CZ$T^O5O^&8_P#J=_\ RF__ &RC
M_AF/_J=__*;_ /;*/^(B<'?]!/\ Y)4_^0#_ %/XC_Y\?^30_P#DCRFBO5O^
M&8_^IW_\IO\ ]LH_X9C_ .IW_P#*;_\ ;*/^(B<'?]!7_DE3_P"0#_4[B/\
MY\?^30_^2/*:*]6_X9C_ .IW_P#*;_\ ;*/^&8_^IW_\IO\ ]LH_XB)P=_T%
M?^25/_D _P!3N(_^?'_DT/\ Y(\IHKU;_AF/_J=__*;_ /;*/^&8_P#J=_\
MRF__ &RC_B(G!W_05_Y)4_\ D _U.XC_ .?'_DT/_DCRFBO5O^&8_P#J=_\
MRF__ &RC_AF/_J=__*;_ /;*/^(B<'?]!7_DE3_Y /\ 4[B/_GQ_Y-#_ .2.
M?_9O_P"2[>%?^PQ%_.OT"KY$^"_[/W_"-_%;0=>_X2WSOLFHI)Y7V#;NQVSY
MAQ^5?7=?/YQGF5Y[6C5P-3GC%6;M):[_ &DC]#X.RO'Y5@JE/%0Y6Y76J>EE
MV;"JNN_\@.\_Z])/_035JJNN_P#(#O/^O23_ -!->)6_A2]&?7GS[1117XV
M4444 %%%% !1110 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZOV=; %>
M!^*_^1IU+_L(3?\ H9KWRO _%?\ R-.I?]A";_T,U\CQ=_ I>K_(#/HHHKX8
M HHHH **** "BBB@ HHHH **** "O</AM_R(VF_]</\ V8UX?7N'PV_Y$;3?
M^N'_ +,:^IX3_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\
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MZD#)QZ9-<6+P:Q:Y92]WM;UU79Z[^1Z6 S%X!\T(^]T=WY:-=5IMUN^AX/\
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M_P"@W9?^ Q_QKQCQ&LR^(;];EPT@O91(RC +;SDBO?Z\#\5_\C3J7_80F_\
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M !1110 4444 %%%% !1110 5V?P-_P"1PF_[![_^AI7&5V?P-_Y'";_L'O\
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M<F&!VV3PR12))#&RMM(WJP:A4:KI\Z6G]?,#UVBO"OB3^V1XCTKXC>-/A_\
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MA/5_BWXK\;W<LO@>\N?$/C.YMI;Z9YM.O7*?Z+!!"D:9V)''$BHB@ <5ZO\
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MUE'X4%?SK_M>_P#)V7Q0_P"RB:W_ .E\U?T45_.O^U[_ ,G9?%#_ +*)K?\
MZ7S5^J^%/^_8G_#'\S\P\3_]SP_^*7Y(\[HHHK]M/QP**** "BBB@ HHHH *
M*** "BBB@ K][O\ @EM_R8!\,?\ L!/_ .E,U?@C7[W?\$MO^3 /AC_V G_]
M*9J_,?%/_D2T?^OG_MLC]'\,O^1Q6_Z]O_TJ)[]1117X2?MH4444 %%%% !1
M110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T
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M@.:^+O\ R(%[_O1?^C%KQBO9_B[_ ,B!>_[T7_HQ:\8K\]XK_P"1E'_"OSD
M4445\R 4444 %%%% !1110 4444 %%%% &S\/O\ D==,_P"OM:]SKPSX??\
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M@2"JE<'UX>"/!/Q/^"/P!7XO?&+3_A@^E)>65E!JD,[MJ>FMJ4LZZI;"W1Q
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M8_\ T$59JMHO_(&M/^O6/_T$59K^/9?$S^LH_"@K^=?]KW_D[+XH?]E$UO\
M]+YJ_HHK^=?]KW_D[+XH?]E$UO\ ]+YJ_5?"G_?L3_AC^9^8>)_^YX?_ !2_
M)'G=%%%?MI^.!1110 4444 %%%% !1110 4444 %?O=_P2V_Y, ^&/\ V G_
M /2F:OP1K][O^"6W_)@'PQ_[ 3_^E,U?F/BG_P B6C_U\_\ ;9'Z/X9?\CBM
M_P!>W_Z5$]^HHHK\)/VT**** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_
M /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E<[\>_\
MD&Z=_P!=W_\ 0171?"[_ ))GX=_[ 5I_Z)2N=^/?_(-T[_KN_P#Z"*\?/_\
MD45?E^: \RHHHK\O **** "BBB@ HHHH **** "BBB@ KL_@;_R.$W_8/?\
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MOYU_VO?^3LOBA_V436__ $OFK^BBOYU_VO?^3LOBA_V436__ $OFK]5\*?\
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MHY;B%X\!9)H5WR,RY*JL8^53MKP+]G+]G[XAVVB6O[2]_P#!C7_$NDV%\?\
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M7S_-8*C3Y:\:L/>C!VOT::Z=_P CP2BBBO5/,"OWN_X);?\ )@'PQ_[ 3_\
MI3-7X(U^]W_!+;_DP#X8_P#8"?\ ]*9J_,?%/_D2T?\ KY_[;(_1_#+_ )'%
M;_KV_P#TJ)[]1117X2?MH4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O
M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2O)_VY?VC/
M@U^SOX>\/ZE\8O&/]CP:G>S16+_V?<7'F.B*6&((W(P".N*]8^%W_),_#O\
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M_P J#_B)>>_\^Z7W2_\ DS]:/^'FG[$/_1;/_+;U+_Y&H_X>:?L0_P#1;/\
MRV]2_P#D:OR7HH_X@#P=_P _\1_X%3_^5!_Q$O/?^?=+[I?_ "9^M'_#S3]B
M'_HMG_EMZE_\C5Z]^Q7^V+^SC\??BS=>"OA+\1?[6U.'0IKN2V_LB\@Q"LL*
MLVZ:%%X9U&,YYZ<&OPYK[?\ ^" __)ZNL_\ 9.[[_P!++&O/S3P8X7R'+ZF8
M8>M6<Z2YDI2@U==[4T[>C1ZF2<?9QF6;4<+5ITU&<DG92O\ *\G^1^QM%%%?
MG9^NGG7[5OQ2\"?!GX%ZQ\1/B5KO]FZ-8R6RW5Y]EEFV&2XCC3Y(E9SEF4<
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M]B'_ *+9_P"6WJ7_ ,C4?\/-/V(?^BV?^6WJ7_R-7Y+T4?\ $ >#O^?^(_\
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M_"3]M"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
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MN<)1M*#L];K5*2L[+HUT6MQ8G#JBH2B[QFKK2SW:U5WU7?:P4445U'*>U?\
M!.3_ )/J^%G_ &.-K_Z%7] 5?S^_\$Y/^3ZOA9_V.-K_ .A5_0%7X9XJ?\C:
MA_@_]N9^T^&7_(KK_P"/_P!M05Q_[0__ "0#QS_V)VI_^DDE=A7'_M#_ /)
M/'/_ &)VI_\ I))7YMA?]ZI_XE^9^B8K_=I^C_(_G#HHHK^O#^4@HHHH ***
M* "BBB@ HHHH **** "BBB@#^F/1?^0-:?\ 7K'_ .@BK-5M%_Y UI_UZQ_^
M@BK-?Q[+XF?UE'X4%?SK_M>_\G9?%#_LHFM_^E\U?T45_.O^U[_R=E\4/^RB
M:W_Z7S5^J^%/^_8G_#'\S\P\3_\ <\/_ (I?DCSNBBBOVT_' HHHH **** "
MBBB@ HHHH **** "OWN_X);?\F ?#'_L!/\ ^E,U?@C7[W?\$MO^3 /AC_V
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MAOJ_/)N\IN[>VME';IHE^9CB,1[?EBE:,59+?JWOZMA11174<Q[5_P $Y/\
MD^KX6?\ 8XVO_H5?T!5_/[_P3D_Y/J^%G_8XVO\ Z%7] 5?AGBI_R-J'^#_V
MYG[3X9?\BNO_ (__ &U!7'_M#_\ ) /'/_8G:G_Z225V%<?^T/\ \D \<_\
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M5]S_ ,12X@_Y]4O_  &?_P F?%?\0TR+_GY5^^/_ ,@?SM?\(_/_ -!C1?\
MPH+/_P".T?\ "/S_ /08T7_PH+/_ ..U_1+_ ,,O_LT_]&\>!?\ PDK/_P"-
M4?\ #+_[-/\ T;QX%_\ "2L__C5'_$4N(/\ GU2_\!G_ /)A_P 0TR+_ )^5
M?OC_ /('\[7_  C\_P#T&-%_\*"S_P#CM'_"/S_]!C1?_"@L_P#X[7]$O_#+
M_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5'_ !%+B#_GU2_\
M!G_\F'_$-,B_Y^5?OC_\@?SLC0YC(8QJ^CY R3_;UIC\_-Q2_P#"/S_]!C1?
M_"@L_P#X[7[=^!_V?_@-<?MU^.?#EQ\$O",FGVW@K3);>P?PW:F&*1G;<ZH8
M]JL>Y R:]J_X9?\ V:?^C>/ O_A)6?\ \:H_XBEQ!_SZI?\ @,__ ),/^(:9
M%_S\J_?'_P"0/YVO^$?G_P"@QHO_ (4%G_\ ':/^$?G_ .@QHO\ X4%G_P#'
M:_HE_P"&7_V:?^C>/ O_ (25G_\ &J/^&7_V:?\ HWCP+_X25G_\:H_XBEQ!
M_P ^J7_@,_\ Y,/^(:9%_P _*OWQ_P#D#^=K_A'Y_P#H,:+_ .%!9_\ QVC_
M (1^?_H,:+_X4%G_ /':_HE_X9?_ &:?^C>/ O\ X25G_P#&J/\ AE_]FG_H
MWCP+_P"$E9__ !JC_B*7$'_/JE_X#/\ ^3#_ (AID7_/RK]\?_D#^=K_ (1^
M?_H,:+_X4%G_ /':^J/^"0OQO^#_ .R[^U!J7Q$^.OQ*T70]&N/!EU80WGV]
M+G=</<VKJFRW,CC*QN<D8^7KR,_K[_PR_P#LT_\ 1O'@7_PDK/\ ^-4?\,O_
M +-/_1O'@7_PDK/_ .-5PYEXAYUFF!J82K3IJ,U9V4K_ "O-K\#LR_@')\MQ
MM/%4JE1R@[J[C;YVBOS/+/\ A[=_P3H_Z.DT7_P O/\ XS1_P]N_X)T?]'2:
M+_X 7G_QFO4_^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\
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MS5C^=K_A'Y_^@QHO_A06?_QVC_A'Y_\ H,:+_P"%!9__ !VOZ)?^&7_V:?\
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M_A06?_QVOZ)?^&7_ -FG_HWCP+_X25G_ /&J/^&7_P!FG_HWCP+_ .$E9_\
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MXGT6[TK6O&>J7^F77]MVT?G6\UW+)&^UY RY5@<, 1G! -?OE_PR_P#LT_\
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M_D#^=K_A'Y_^@QHO_A06?_QVC_A'Y_\ H,:+_P"%!9__ !VOZ)?^&7_V:?\
MHWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\ \:H_XBEQ!_SZI?\ @,__ ),/
M^(:9%_S\J_?'_P"0/YV8]#FE7<NKZ..<?-KUH/YRTO\ PC\__08T7_PH+/\
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MVO?$'[;&N?L#V'[ WAG_ (3GP_X M_&%]+)\;"+ Z=-<BV0)+_8^XR^8>5*
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MXF^+WPROH)O ?B/XO>'M)UK2[2!/-S:SZ?IUMIOG+F9G2;S5N(9522.4$,'
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M^;OV7/A5>?'#]L;Q7_P4W\3Z+<:99ZOX#M/ GPFL+NW:&YE\-17CW\^J7$;
M-&U[=NCQ1, R6UM SA7F>./NOVY?V*/#7[>7PDM_@KXW^-WQ#\&:+'J\&H7W
M_"N]9MK&;46A;?%#<//;3[X5D"R>6 H9D4MNV@5RG[-7_!-G2_V=OBY:_&#7
M/VU?V@OBC<Z?87%OI>C?%?XBIJFFV4LP5&NXX([:$?:!&)(ED8MM2>4 ?-D
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M,RJK)&KAP_FY+9<[FR >%_\ !*;_ )2R_P#!0K_LH7@W_P!,TU0^$[FTU_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM+?3M;N[J,1W<^Z6UEN;-KA0/.%I/ LI+,ZLSN6U?!/_  3>_9P\'?L)P?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M2TDECLV;386G?=#.4)G@0BX0.C>5N< ^_**** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME,GCG0=2T:QUFSF\):M<0S6UO.XAF8%/G8HL\1*I*$^5:^J?@Y^WI\/OC?\
M'?XC_LT^%?A1X[L_&?PKLK.Y\7:5K6E6MJ(Q>)*]FL$K7/EW(G6&39)&S1#;
M\[IQ7C7[?6MZUKW[;_['GCSPO\)_B'K&B^%?'.MZSXGU/1_AMK%U#I%G=^';
MZR@>Y,5JWDLT]Q&IB;$B9)=5 )KB_P#@K-\/OVA?A+^UM\+?VD/V/D2'Q/\
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MS]H[]O[XE?"#_@HU\'_V,]"_9\\4WVA>-M&UW5-2\36EM:2)?BRM[?$%JK7
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M 'R7\&OV%OVW? 'PWT[]G7Q]_P %$M,U[X:Z9H$>A0VFE?!FWTO7WTR.$0)
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MQ]4?I-1117]V'V(4444 ?,__  6 ^+7QN_9Y_P""=OQ0_:,_9X^*MQX4\5^
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MDK7+-]GA'F%]OR95$W$'T7]GOXW?$+0_V<].\??MU_$GX0:/XE;6KZQU+4_
MOB*1?#V]+V>*WABFOG#F<1HJR(3D2K( !C ^/O\ @F98_LB6G_!7K]O;X0?!
ML^%&T;5G\#1ZEX7LS;M9W-]_9VJ?VK%%;_=D432/YZJ"%EDE# $D5XY^P)\-
M?BM=_LN_ S7OV'_BEX#TSXF>!_$'QD/AWX5^.[)SH/BO0)/%[0WL >W/F64\
M'^@B&:-6"K.ZLIC=Z /V T?6M'\0Z;%K.@:M;7UG."8;JSG66.0 D':RD@X(
M(X[BLS3/B=\-=:\97GPZT;XAZ'=^(-.C$FH:%;:M#)>6J'&&D@5BZ#D<L!UK
MY5_9Z^,OBGXO_P#!&/7?B?\ LA? F]^''BT?#WQ?;^#/ ,5PES_8_B&TDU&W
M2VM9(P$F@%_"?(= %:,QX5?NC,_8W^"'["WC?]@W]E_QGH5]:V+Z3/X>USPK
MKNBW0BU74/$I@Q>QW$J*9IYII9+M;Z-N6'V@S85'*@'U[XI^)WPV\#:IINA^
M-OB%H>CWNLS^3I%GJNK0V\M])Q\D*2,#*W(X4$\T_P :_$7X??#;3H]8^(OC
MK1M M)I?*BNM:U.*UC>3!.P-*R@M@$X'/%?#W[+7ACX >//BM^VQ>?MWZ+X:
MO]=L_B9=V?B7_A-XHF6S^'JZ3:/I(4R\1:>T1NY=RX4SFY8G>"1V'_!.#X1Z
MI^UA_P $5/ /P5_;,T?4-<M_&GPYN-,U*+Q+&7O;G1Y99TTZ:4R@L+C[#]DE
M$C?.) 'SN&: /IK4?VAO@#I&C6/B/5OCCX/M=/U0.=,O[CQ-:I#=A#M?RG:0
M+)M/!VDX/6KO@[XP?"7XB:K>:%\/_BCX<UV]T]0U_9Z-K<%U+; ]#(D;L4!R
M,9 ZU^&'[3NN_M)?M*_\$NM5_85T+PI=3^._V&- OE^(%WI^D'<][ITIT?1+
MFSX!+/H4FIZFKH0Z2VMN0>0:^W+#]A'4?&_@;]G/XA_"G]LOX#>$-!\%>)-%
MU+X4Z_\ #/X%WEA?:O8F/$FDQ7#^))O.MKVV9UN$,;Y ,KC,98 'WUXK^)OP
MV\"&9?''Q!T/1C;:<^H7 U75H;?RK1'2-[AO,8;8E>2-"Y^4,Z@G)%97AG]H
MG]G[QK?C2_!OQT\':O=&!YQ;:9XGM+B0Q(I9WVI(3M5023T &37Q3\4?V:/V
M?OB9_P '%7AG5/'/PP\/ZC/#^RCJ6LW-K=:9"Z7]['XBM+6&XN4*XN&CBED"
M&0-M(4C!1<<]^VI9_!G_ ((S?MH^!/V_/A9\#=,TCX=^-_A]J'PR\:^'/!?A
M^*V5=4MH7U'PZ8(;>,8DGDMI].S@+^]MP<[5P ?H/X(^+OPG^)LUQ;_#?XG^
M'?$,EHJM=)H>M079A!R 7$3MM!P<9]*Z&O&?V _V9(_V4OV8="^'FL:5ID/B
MO5)+CQ!\1+S2[5(X[_Q'J$K7>HSC;]Y?M$KI'DG;%'$@.$ KV:@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYL\=?\ !/7_ (37
MQOK/C+_A;WV;^UM5N+W[-_8&_P KS96?9N^T#=C=C.!G'05])T5X>><.9+Q'
M2A3S&E[2,'=>]*-F]/LM?B8UJ%*NDJBO8^5_^'9W_5:__+;_ /NFM7P+_P $
M]?\ A"O&^C>,O^%O?:?[)U6WO?LW]@;/-\J57V;OM!VYVXS@XST-?2=%>!1\
M,^"*%6-2&$M*+37[RKNM5]LQ67X2+NH_B_\ ,****^[.P**** .6^+'P.^"G
MQZ\/IX3^.?P?\+>--*CE$L>F>+/#]MJ-ND@QAQ'<(ZAN!SC/%91_92_9</PK
M_P"%%']FSP"?!'G^=_PAQ\'6/]E>9C&_[)Y7D[L=]N:[ZB@#R=OV"_V&7\+6
MW@9_V,/A.=$L[EKBST<_#K3/LL$S<-(D7D;%<YY8#)KKO$WP+^"7C7P)9?"W
MQE\'?"NK^&--\K^SO#FI^'K:XL+7RT*1^7;NAC3:I*KM48!(& :ZJB@#(\#_
M  ^\!?#'0%\*?#;P1I'A[2TE>5--T/38K2W5W;<[B.)54,Q)).,D\FN;^(/[
M+G[,OQ:\7VGQ!^*O[.G@3Q-K]@$%CKGB#PC97MY;A#N3RYIHF=-IY&",'D5W
M=% '+_$WX(?!;XUQZ9#\9/A#X7\6IHM^M]HR>)O#]M?BPNEX6>$3HWE2#LZX
M8>M2>&/@Y\(O!,GB";P9\*_#>D/XMOY+[Q4VEZ';VYUFZD7;)/=F-!]HD8<,
M\FYB.":Z2B@#C/A7^SE^SU\"KG4+SX(_ CP9X-FU:4RZK+X5\+VFG->.3DM*
M;>-#(2><MDT[X<_L[_L__![7M3\5?"/X&>#O"VJ:T2=9U+PYX8M+&XOR6+DS
M20QJTOS$M\Q/))ZUV-% 'GVB?LE?LJ>&O$6L>,/#G[,OP^T_5O$,+PZ_JEEX
M,L8KG4XV!#)<2+$&F4@D$.2"":U/A)\ ?@1\ -+N=$^!'P4\(^";*]E$MY:>
M$?#=KIL4[C.&=+>- Q&YN2">3ZUUM% ')>)/@#\"/&/Q"M?BWXN^"GA+5?%=
MCITFGV7B?4O#=K/J%O:2!@]NER\9D2)@[@H&"G>V1R:9;_L]? *S^$J_ *T^
M!W@^+P(D#0)X*C\,VJZ0L1<N4%F(_)"ER6(V8R2>IKL** /,;[]B;]C/4_ %
MI\*-2_9'^&-QX6L+I[FP\-3^ M.?3[:=@H:6.W,/EHY"("P4$[%YX%:/C']E
M;]F#XAC15\?_ +.'@+71X;B$7AT:QX/LKK^RHP0P2V\R(^0H*@@)@9 ]*[VB
M@#%\!?#;X=?"K0?^$5^%_@'1?#>E_:))_P"S= TJ&SM_-D;<\GEPJJ[F8DEL
M9)Y-1?$GX5?"_P",OA=_!'Q?^&^@>*]%DF2632/$NCP7UJTB'*.8IU9"RGD'
M&1VK?HH X?PE^S)^S;X LK_3O G[/?@?1+?5=.33]4@TCPG9VR7EHB[4MY5C
MC DB5> C94#@"N>TW]@G]A?1K2"PT?\ 8O\ A-:06TKR6T-M\.=,C2)WQO90
ML "EL#)')P,UZS10!5T/0M$\,:-:^'/#6CVNG:=86Z06-A8VZPPV\2 *L:(@
M"HH  "@  #BN8\-_L[_L_P#@WXC7_P 8O"'P+\':5XNU4.-4\4Z;X8M(-2O
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MXN\-_&2/XB6=]X+TR2+QY&NW_A(#]FC#7Q7 V-*P9V0@%68J0""* /0:***
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M]/\ .>4Q01+@;G<EG<\LSL268DDY-==10 4444 %%%% !1110 4444 %%%%
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M\(:3X/\ BMXET?0+ZQ\,ZQ<S:CX(OM6(33_M;S1K%?1-.\5O,\8@\EY5*B9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20220930_g14.jpg
<TEXT>
begin 644 biib-20220930_g14.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
MO VD_##]C#QC\--!O;ZYL?#O[0?C_3+*XU2\:XN98H->N8D>:5_FED*H"SGE
MF))Y-?:MTFJ:?H,D>BQQWM[!:$6B:A=&);B4+\HDD5'*!F W.$8C)(4]*^??
M^";'[+'QM_9#^&WC+X>_&/6?"NJ-XB^)OB#Q?97_ (9N+G$9U:_EO9+5XYXE
M_P!4\A59 YW@\HA7+ 'T;1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >;Z/^R3\!- _:%U#]JO2O"-['X_U735T[4?$+
M>)-0=KBR5RZ6K1-.8C CLS)%LV(S%E )S7I%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/QE^)
MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
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M /\ :Z\YHH_UASC_ )^_^2Q_R ]&_P"%_P#_ %*7_D__ /:Z/^%__P#4I?\
MD_\ _:Z\YHH_UASC_G[_ .2Q_P @/1O^%_\ _4I?^3__ -KH_P"%_P#_ %*7
M_D__ /:Z\YHH_P!8<X_Y^_\ DL?\@/1O^%__ /4I?^3_ /\ :Z/^%_\ _4I?
M^3__ -KKSFBC_6'./^?O_DL?\@/1O^%__P#4I?\ D_\ _:Z/^%__ /4I?^3_
M /\ :Z\YHH_UASC_ )^_^2Q_R ]&_P"%_P#_ %*7_D__ /:Z/^%__P#4I?\
MD_\ _:Z\YHH_UASC_G[_ .2Q_P @/HM&WH&QU&:6FP_ZI?\ =%.K]-6P!7 Z
MM\<?[+U2YTW_ (1??]GN'BW_ &W&[:Q&<;..E=]7@?BO_D:=2_["$W_H9KYW
MB+'XO 4J<J$K-MWT3_-,#MO^%_\ _4I?^3__ -KH_P"%_P#_ %*7_D__ /:Z
M\YHKY3_6'./^?O\ Y+'_ " ]&_X7_P#]2E_Y/_\ VNC_ (7_ /\ 4I?^3_\
M]KKSFBC_ %ASC_G[_P"2Q_R ]&_X7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y/_\
MVNO.:*/]8<X_Y^_^2Q_R ]&_X7__ -2E_P"3_P#]KH_X7_\ ]2E_Y/\ _P!K
MKSFBC_6'./\ G[_Y+'_(#T;_ (7_ /\ 4I?^3_\ ]KH_X7__ -2E_P"3_P#]
MKKSFBC_6'./^?O\ Y+'_ " ]&_X7_P#]2E_Y/_\ VNC_ (7_ /\ 4I?^3_\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKKO_(#O/^O23_T$U:JKKO\
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M!6G_ *)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'I,VHRK)</;6END$32LJJK.4C!8A5!.< =*ZFBHYI<O+?0 KW#X;?\B-IO\
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M!](_Y^;W_P "VH_X0?2/^?F]_P# MJV** ,?_A!](_Y^;W_P+:C_ (0?2/\
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\
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M* "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8JKKO_(#O/\ KTD_]!-4?^$EU?\ Z%"]_P"^
MEJMK'B+59-(NHW\)WB!K9P6++@?*>:SK?PI>C \4HHHK\; **** "BBB@ HH
MHH **** "BBB@ HHHH ^BH?]4O\ NBG5BQ>)=6$:C_A$+S[H_B6G?\)+J_\
MT*%[_P!]+7[.M@-BO _%?_(TZE_V$)O_ $,U[)_PDNK_ /0H7O\ WTM>,>(Y
M'F\0W\LD1C9KV4LC=5)<\&OD>+OX%+U?Y 4J***^& **** "BBB@ HHHH **
M** "BBB@ KW#X;?\B-IO_7#_ -F->'UZYX#U[4K7PA86\/AFZF58<"5&7#<G
MIFOJ>$_]^G_A_5 =A1679Z]J5S=)!-X9NH59L-*[+A?<UJ5]^ 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 55UW_ ) =Y_UZ2?\ H)JU577?^0'>?]>D
MG_H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?\
M5+_NBG4V'_5+_NBG5^SK8 KP/Q7_ ,C3J7_80F_]#->^5X'XK_Y&G4O^PA-_
MZ&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%% !7N'PV_Y$;3
M?^N'_LQKP^O</AM_R(VF_P#7#_V8U]3PG_OT_P##^J W****^_ **** "BBB
M@ HHHH ^%O ?P5_;:_;9TR_^+UM_P5<\5_#8MKM];7'PT^'?@?01'X4DBN9(
M_P"S[J6\MI[F:[157S7D95=RS1HB,HKZ+_86^&WB/X0_LWV'PY\8?'"X^)&J
MZ9XF\1KJ'C6]5%N-2F?7;^1C,L:JBS(7,3JBA%>-@H"@5^6'AKQW_P &S_QC
M\9>+/%'_  4+^*V@:U\=8O$]_:?$C7/&'BO7HS=74-S)&@M&AE2W6R6)8T@@
MB"F&-5CD19$<5^EW_!+V#]E&V_8D\*P?L.733?"A=6U__A"Y-\SH;;^W+_=Y
M;3DR-%YOF"-G)8Q[">30![_7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC
M^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%<U\7?^1 O?]Z+_ -&+
M7C%?/9KGW]F8E4O9\UU>][=6NS[ ?1E%?.=%>9_K?_TX_P#)O_M0/HRBOG.B
MC_6__IQ_Y-_]J!]&45\YT4?ZW_\ 3C_R;_[4#Z,HKYSHH_UO_P"G'_DW_P!J
M!]&45\YT4?ZW_P#3C_R;_P"U ^C**^<Z*/\ 6_\ Z<?^3?\ VH'T917AGP^_
MY'73/^OM:]SKWLIS3^U*,JG)RV=M[_H@"JNN_P#(#O/^O23_ -!-6JJZ[_R
M[S_KTD_]!->E6_A2]&!\^T445^-@%%%% !1110 4444 %%%% !1110 4444
M?14/^J7_ '13J;#_ *I?]T4ZOV=; %>!^*_^1IU+_L(3?^AFO?*\#\5_\C3J
M7_80F_\ 0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P
M^&W_ "(VF_\ 7#_V8UX?7N'PV_Y$;3?^N'_LQKZGA/\ WZ?^']4!N4445]^
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MER7$T<\4<PE)+&1=S%B3GU"BMYXK$3M>6VOS[^OF!Y5\//V3/"OA#XP+\?\
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M2 ]9HHHK]6 YKXN_\B!>_P"]%_Z,6O&*]G^+O_(@7O\ O1?^C%KQBOSWBO\
MY&4?\*_.0!1117S(!1110 4444 %%%% !1110 4444 ;/P^_Y'73/^OM:]SK
MPSX??\CKIG_7VM>YU][PE_N=3_%^B *JZ[_R [S_ *])/_035JJNN_\ (#O/
M^O23_P!!-?3UOX4O1@?/M%%%?C8!1110 4444 %%%% !1110 4444 %%%% '
MT5#_ *I?]T4ZFP_ZI?\ =%.K]G6P!7@?BO\ Y&G4O^PA-_Z&:]\KP/Q7_P C
M3J7_ &$)O_0S7R/%W\"EZO\ (#/HHHKX8 HHHH **** "BBB@ HHHH ****
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M7PN_Y)GX=_[ 5I_Z)2N=^/?_ "#=._Z[O_Z"*\?/_P#D45?E^: \RHHHK\O
M**** "BBB@ HHHH **** "BBB@ KL_@;_P CA-_V#W_]#2N,KL_@;_R.$W_8
M/?\ ]#2O2R;_ )&E'_$@/6:***_5@.:^+O\ R(%[_O1?^C%KQBO9_B[_ ,B!
M>_[T7_HQ:\8K\]XK_P"1E'_"OSD 4445\R 4444 %%%% !1110 4444 %%%%
M &S\/O\ D==,_P"OM:]SKPSX??\ (ZZ9_P!?:U[G7WO"7^YU/\7Z( JKKO\
MR [S_KTD_P#035JJNN_\@.\_Z])/_037T];^%+T8'S[1117XV 4444 %%%%
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M\>_^0;IW_7=__017CY__ ,BBK\OS0'F5%%%?EX!1110 4444 %%%% !1110
M4444 %=G\#?^1PF_[![_ /H:5QE=G\#?^1PF_P"P>_\ Z&E>EDW_ "-*/^)
M>LT445^K <U\7?\ D0+W_>B_]&+7C%>S_%W_ )$"]_WHO_1BUXQ7Y[Q7_P C
M*/\ A7YR ****^9 **** "BBB@ HHHH **** "BBB@#9^'W_ ".NF?\ 7VM>
MYUX9\/O^1UTS_K[6O<Z^]X2_W.I_B_1 %5==_P"0'>?]>DG_ *":M55UW_D!
MWG_7I)_Z":^GK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HHHH ****
M/HJ'_5+_ +HIU-A_U2_[HIU?LZV *\#\5_\ (TZE_P!A";_T,U[Y7@?BO_D:
M=2_["$W_ *&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%% !7
MN'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\ #^J W***
M*^_ **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#D
MT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E<[\>_\ D&Z=_P!=W_\ 0171
M?"[_ ))GX=_[ 5I_Z)2N=^/?_(-T[_KN_P#Z"*\?/_\ D45?E^: \RHHHK\O
M **** "BBB@ HHHH **** "BBB@ KL_@;_R.$W_8/?\ ]#2N,KL_@;_R.$W_
M &#W_P#0TKTLF_Y&E'_$@/6:***_5@.:^+O_ "(%[_O1?^C%KQBO9_B[_P B
M!>_[T7_HQ:\8K\]XK_Y&4?\ "OSD 4445\R 4444 %%%% !1110 4444 %%%
M% &S\/O^1UTS_K[6O<Z\,^'W_(ZZ9_U]K7N=?>\)?[G4_P 7Z( JKKO_ " [
MS_KTD_\ 035JJNN_\@.\_P"O23_T$U]/6_A2]&!\^T445^-@%%%% !1110 4
M444 %%%% !1110 4444 ?14/^J7_ '13J;#_ *I?]T4ZOV=; %>!^*_^1IU+
M_L(3?^AFO?*\#\5_\C3J7_80F_\ 0S7R/%W\"EZO\@,^BBBOA@"BBB@ HHHH
M **** "BBB@ HHHH *]P^&W_ "(VF_\ 7#_V8UX?7N'PV_Y$;3?^N'_LQKZG
MA/\ WZ?^']4!N4445]^ 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +
M_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4KG?CW_P @
MW3O^N[_^@BNB^%W_ "3/P[_V K3_ -$I7._'O_D&Z=_UW?\ ]!%>/G__ "**
MOR_- >94445^7@%%%% !1110 4444 %%%% !1110 5V?P-_Y'";_ +![_P#H
M:5QE=G\#?^1PF_[![_\ H:5Z63?\C2C_ (D!ZS1117ZL!S7Q=_Y$"]_WHO\
MT8M>,5[/\7?^1 O?]Z+_ -&+7C%?GO%?_(RC_A7YR ****^9 **** "BBB@
MHHHH **** "BBB@#9^'W_(ZZ9_U]K7N=>&?#[_D==,_Z^UKW.OO>$O\ <ZG^
M+]$ 55UW_D!WG_7I)_Z":M55UW_D!WG_ %Z2?^@FOIZW\*7HP/GVBBBOQL H
MHHH **** "BBB@ HHHH **** "BBB@#Z*A_U2_[HIU-A_P!4O^Z*=7[.M@"O
M _%?_(TZE_V$)O\ T,U[Y7@?BO\ Y&G4O^PA-_Z&:^1XN_@4O5_D!GT445\,
M 4444 %%%% !1110 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_]
M</\ V8U]3PG_ +]/_#^J W****^_ **** "BBB@ HHHH **** "O*/VY_P#D
MT?Q[_P!@%_\ T-:]7KSC]KOPIXC\<_LT^,?"/A'2);_4K_1VBL[.  O*^Y3M
M&>_% '5?"[_DF?AW_L!6G_HE*YWX]_\ (-T[_KN__H(KR'PC_P %3?V /"7A
M33/"OB']I?1[;4-,TZ&TOK=K.[8Q31QJCIE82#A@1D$CBL#XN?\ !47]@7Q/
M8V4.A_M*Z+.T4KM(/LMTN 0,?>B%>5G=.I5RNI"";;MHM7N@.PHKQ;_AXI^Q
M1_T<)HO_ '[G_P#C='_#Q3]BC_HX31?^_<__ ,;K\Y_LW,?^?,__  %_Y >T
MT5XM_P /%/V*/^CA-%_[]S__ !NC_AXI^Q1_T<)HO_?N?_XW1_9N8_\ /F?_
M ("_\@/::*\6_P"'BG[%'_1PFB_]^Y__ (W1_P /%/V*/^CA-%_[]S__ !NC
M^S<Q_P"?,_\ P%_Y >TT5XH/^"C'[$YD,8_:#T?(&2?)N,?GY>*=_P /%/V*
M/^CA-%_[]S__ !NC^S<Q_P"?,_\ P%_Y >TT5XM_P\4_8H_Z.$T7_OW/_P#&
MZ/\ AXI^Q1_T<)HO_?N?_P"-T?V;F/\ SYG_ . O_(#VFBO%O^'BG[%'_1PF
MB_\ ?N?_ .-T?\/%/V*/^CA-%_[]S_\ QNC^S<Q_Y\S_ / 7_D![379_ W_D
M<)O^P>__ *&E?,?_  \4_8H_Z.$T7_OW/_\ &ZZ7X4_\%-/V$?#7B22_UK]H
M_1886LV0/]GN6^8LIQA8B>QKT,JP&.IYE2E.E))/=Q=OR ^T**^<_P#A[=_P
M3H_Z.DT7_P  +S_XS1_P]N_X)T?]'2:+_P" %Y_\9K]+ ]G^+O\ R(%[_O1?
M^C%KQBL/XC?\%5O^"?.O>$+K2]*_:;T66>1H]D?V.[7.'4GDP@= :\R_X>*?
ML4?]'":+_P!^Y_\ XW7PO$N$Q=?'QE2IRDN5:I-]7V ]IHKQ;_AXI^Q1_P!'
M":+_ -^Y_P#XW1_P\4_8H_Z.$T7_ +]S_P#QNOGO[-S'_GS/_P !?^0'M-%>
M+?\ #Q3]BC_HX31?^_<__P ;H_X>*?L4?]'":+_W[G_^-T?V;F/_ #YG_P"
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M_P"'BG[%'_1PFB_]^Y__ (W1_P /%/V*/^CA-%_[]S__ !NC^S<Q_P"?,_\
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M $;QX%_\)*S_ /C5=S10!PW_  R_^S3_ -&\>!?_  DK/_XU1_PR_P#LT_\
M1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX%_\ "2L__C5'_#+_ .S3_P!&
M\>!?_"2L_P#XU7<T4 ?+G@?]G_X#7'[=?CGPY<?!+PC)I]MX*TR6WL'\-VIA
MBD9VW.J&/:K'N0,FO:O^&7_V:?\ HWCP+_X25G_\:K5TSX4^$=(^*.J?&"SA
MG&M:OIL%C>NTY,9AB)* )V.3U[UTE '#?\,O_LT_]&\>!?\ PDK/_P"-4?\
M#+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5'_  R_
M^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT
M_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\
MT;QX%_\ "2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5'_  R_^S3_ -&\
M>!?_  DK/_XU7<T4 <-_PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT_P#1O'@7
M_P )*S_^-5W-% '#?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\
M"2L__C5=S10!PW_#+_[-/_1O'@7_ ,)*S_\ C5>*_M/_ +/_ ,!M'^,/P:L=
M)^"7A&U@O_&LL5]#;>&[5$N(_L['9(%C =<\X.17U'7-^-_A3X1^(/B+PYXH
M\1PSM=^%M2:^TDPSE%68H4)8?Q#!Z4 97_#+_P"S3_T;QX%_\)*S_P#C5'_#
M+_[-/_1O'@7_ ,)*S_\ C5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-
M/_1O'@7_ ,)*S_\ C5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O
M'@7_ ,)*S_\ C5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_
M ,)*S_\ C5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*
MS_\ C5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\
MC5=S10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S
M10!PW_#+_P"S3_T;QX%_\)*S_P#C5'_#+_[-/_1O'@7_ ,)*S_\ C5=S10!\
M[?MH?L[_ +/^@?LL>-]9T+X&>#K*\M]$=[>ZM/#%I')$VY>598P5/N*[7X;?
MLS_LX7?P[T"ZNOV?O!$LLNBVKR22>%+-F=C"I)),>22>]=S\2/A]X<^*O@74
M_AWXNBE?3=6MC!>+!*4<H2#PPZ'BM+1M*M-!T>TT/3U8065M'! ';)"(H5<G
MN< 4 <?_ ,,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5=
MS10!PW_#+_[-/_1O'@7_ ,)*S_\ C5'_  R_^S3_ -&\>!?_  DK/_XU7<T4
M <-_PR_^S3_T;QX%_P#"2L__ (U1_P ,O_LT_P#1O'@7_P )*S_^-5W-% '#
M?\,O_LT_]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5=S10!PW_#
M+_[-/_1O'@7_ ,)*S_\ C5'_  R_^S3_ -&\>!?_  DK/_XU7<T4 <-_PR_^
MS3_T;QX%_P#"2L__ (U1_P ,O_LT_P#1O'@7_P )*S_^-5W-% '#?\,O_LT_
M]&\>!?\ PDK/_P"-4?\ #+_[-/\ T;QX%_\ "2L__C5=S10!PW_#+_[-/_1O
M'@7_ ,)*S_\ C5'_  R_^S3_ -&\>!?_  DK/_XU7<T4 ?+G["/[/_P&\1_!
M[5+[Q#\$O"-_.GC75XDFO?#=K*ZQK<$*@+1DA0. .@KVK_AE_P#9I_Z-X\"_
M^$E9_P#QJM7X6_"GPC\'O#L_A?P7#.EI<:E<7T@N)S(WG3/O<Y/;/0=JZ2@#
MAO\ AE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\
MAE_]FG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#AO\ AE_]
MFG_HWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J[FB@#D-$_9\^ ?AG5
MK?7_  Y\$/"&GWUI()+6]L?#5K%-"XZ,CK&"I]P:Z^BB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \/_;)_;K^'W[(-UX-\ GP;K7C;XC?$K5Y-+^'
M'PW\+B+^T-;N(T\R>4O,Z16UK A$DUS(P2)#GDD*>$U[_@H_X\_9[^)/@SP5
M^WK^RY)\,-%^(6MQ:'X8\?:+XSAU_1(=7E!,&GW\H@MY;&67!$;F)X68$&5<
M$UXW\6;BT\)?\'.'PP\0_%>18=$\0?LF:QI?PUN+P[8?[?@UDW-^L1;CS1IQ
MRQ'.QESQ7,?\%\?VO/V._P!I?_@CQ\:/!7P<^-?A?QWKPU7P]H^C:1X8U:*[
MO1K=QJMK)8B%(R7+.L4LB.O$D<4NTL U 'U_^TI^U3\?/@J?$OB7X<_L;:MX
MU\*^"---]XGU8>)[?3;NZC6$7$R:3:S1L-0>.$@G?);QLX,2.[JZKZE\&_BU
MX%^/GPC\+_''X8:O]O\ #GC#P_9ZUH-Z8RAFL[J%)HG*GE24=<J>0<@\BO'?
MVOO@U^V?\8/V++CX3_ GXS^'_#'B_4?!3V'B2ZU;0GNKC497M426&UNQ<+'I
MTDA\Y/M3V]V$,BN(LISJ?\$R?B7\'/B]_P $]_@WX_\ V?/!5SX:\%W?P\TR
M'P[X=O9_-ETNW@@6 6K2?\M3&8BGF_\ +3;O_BH L?M@_ME6G[)'B3X/^'KS
MX4ZQXE'Q<^+>G>!(+G2IXT32);N&XE%W-OY>-%MW)48.U6.<@!JO[5W[5_QH
M^$'B*V^&7[+_ .Q[KWQF\9MI/]K:II-AXFL=$LM*L&D>**2>]O6">;/)%,D,
M,:NS>1*S>6J;C[%XA\&^$_%MSI=YXH\.6>H2Z)J:ZCI#WENLAL[M8Y(EGCR/
MED"2R*&'(#GUKG?CO\:?!G[/G@.X^(GB:QN+V[GEBL-$T32H5DU#7M0D+"VT
M^U0D>9-(Y8*"0J#?([)&CNH!PW[ _P"W1\//V^O@-/\ &;PCX3UKPMJ&B>(K
M_P .>-_!_B>%8[_PWK=DP6[L;C:2I9-R,&!Y2120IRJ^&?$3_@LAXL^#/B#P
MW\2_C-^P7XZ\.? #Q=XDM-&T7XW76O6$@C-W((K.^N])1C=65E,[*4EE(<*Z
M%HE9UC/L_P#P3T_92UO]E[X*Z\OQ):QE\<_$WQ[K'C[XD+IKE[.+6=5F$DMK
M 2 7AMXE@M5<@&06^\A2^T<9^W5X"T_]O;7=+_X)\^'8$N?"UAXGT77_ (W:
MK& 8-.TZPNH-2L]&5AUO;R>"V8QCF&T$DK[3+;"8 ^K:*** "BBB@ HHHH *
M*** "N#_ &G/VEO@U^Q[\"?$G[2/[0'B^+0_"?A:Q^TZI?NA=CE@D<4:+\TD
MLDC)&B+RSNH'6N\K\]/^#C@)IG[.GP'\=^+XRWP]\+_M9>!M5^*Y<?N(_#Z7
M$Z2O/V\GSI+<'/&YDH ]-\3?\%&_VIOAY\&)/VJ_B9_P3.\6Z7\,K6P&JZJ+
M;QI8W/BO2]*V[VO;G150(OEQ_O)(([N2:-0V4W*RCUW6/VI=7\?_  P\&?$G
M]C3X:P_%6T\>:7_:NA:L->&E:/%I^R-O/N;QH96B9O-14@6%Y682915BD9+7
MC3]M/]C3PU\0M2^!'CS]HOP1:^)+;1KF]U/PUJ&MP"<6D5M]IN-T;'YMML?.
M>/EA$=Y78<U\B?\ !NIX9^,47_!$WP;;>!M6M/#=QJ>L^(+SX>3>*]#FU&"Q
MTF76KF2W,MK'<VTDJ,AD90)DXD1@2O! /K7]CO\ :VT7]K3P?XDO&\":EX2\
M4>!?&-WX4\>^$=6GBFETC5K9(I'19HB8[B%XIX9HIEP'CE4D*VY%W?VL/CU!
M^RQ^S%\0?VE;OP;>^(8/ /@[4?$%QHFG2JDUY':6[SO&K-D+E4/S8.!DX.,'
MYT_X)%+<> ]:_:"_9Z^)SG4?BWX5^,DFI?%;Q?"P^R^*+K5=.M+VRU"WB"@6
M<7V!K: 6>7\C[-@R2EC(WU]XE\-Z!XR\.:AX0\5Z/;ZAI>JV4MGJ5A=Q!XKF
MWE0I)$ZGAE96*D'J": /(=>_;&N+#]D_P1^T5X9^!7B;7O$/Q%T?2IO"/PTT
MZ2W74KJ_OK/[6MD\TSI! (8EF>:>1UCCCMY6YP%;B?V-?^"CVN_M!?M#^+OV
M-?VC/V7M>^#7Q=\)>'X/$7_"*:KKMKJUKJ^A33>0NHV5]:XCF19L1R*54H[!
M>2'"?2&HS>$O!?AMM5U>;3M*TC0K)IGN;ED@M]/MXHSN<LV%B1(PV3P%4'H*
M^;OV7/A5>?'#]L;Q7_P4W\3Z+<:99ZOX#M/ GPFL+NW:&YE\-17CW\^J7$;
M-&U[=NCQ1, R6UM SA7F>., ]!_;Q_;2^%O[ 7[,/B3]I;XJW=N\&CVZQZ/H
M\M^MO+K.HRL$MK&%B&.^20@$A6V('<J50U[#7P5_P<4? #X$>-O^":?Q(^-O
MC+X*>$=7\9^&-,TN+PWXNU/PW:W&J:2C:S9AEMKIXS+ "'?(1E!WMZFOO6@
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M\4:DJ_;/$.L73>;>:C<%>/,EE)(4?+&@2- J1HH /DKX+_\ !7O]K?\ :$^
M'Q)_:(^$7_!-NPUC3/A=XIUOP_KVD1?&:-=1N[S2@INA:QMI8248;*9=6?&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20220930_g15.jpg
<TEXT>
begin 644 biib-20220930_g15.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
M8XY9!).ICC9]N #V&BODC_@G)\>?B'XR_:+_ &C_ -F[Q7+XK;0_ACXL\/OX
M-B\=7BW.KVECJFAV]XUO/.))'E03^=+'YSM.B3B.0@IL7A?#FE_M&_&7_@L-
M\:_V>_$_[7?CV'X7>'/ACX8UZR\,:/>6VGS6M]?7&H(D4-S:P1RI;J+=V;YC
M-(RPAY6C5HW /O&O$;C]LI[3_@H1I_[!5Y\'M4MVU'X77_C.S\:7&IV_V:YC
MM;ZSM'MXH$+2YW7@)>3R\&/ 5PP8?'GPU_;D_:C^*WASX5_L:77Q>OM.\3^(
MOVH?'GPP\5_%6"QM5U"?1?"_]I7)>(>5Y$-_=V]K;6YF$>%)FD1%<J4Z7P/\
M)O%7P?\ ^#ACP[H%W\;/$7BOP_=_LFZ]=:#I_BN^6\O=&8^(M)2>(71433PN
M4C=?/:1U;S0&V;54 ^_?%%SXGL_#]W<^#-'L=0U5(2;&RU/47M()I.RO,D,S
M1C_:$;_2OEW_ ()M?\%9?A;_ ,%!/%OQ(^!VJ>!Y?A]\6?A-XIOM&\;?#K4=
M:BOI8Q;73VK7EM<1JBW5OYT;Q,ZJ-CJ W#QL_P!8U^47BW_@GE\4/C)\$[C]
MOG]A#5+?P[^TO\(OV@/BS-X4O6PEOXNTP>/_ ! T_A^_Y420S*7$9<@([L-R
M"0N@!]7?M3_\%'?BO^RS^T8OP@NOV*O$7CK0#X9M]=&L_#K5I-3U9K675+?3
M65=*%HK-)')<I*_[[RQ"KMYFX",_5]?B-^T[_P %4]5_:U\ W_[8/[+GQ+\2
M_"WXA^"?A%9Z-\0?!T,=NNHZ!JK^-]$LK[2[L7$#2(FR>0QRQ^2[#:25(DB'
MVA\5$_:/^(G_  6SM?V9;;]J_P :Z1\+;S]G*;Q9K'A;1YK6T87:ZVEDD5M<
MP0)/"&!5VE+M, C(DB)(PH ^Z:*_*_XP_P#!1G]KSX+_  !\<_L_^ _%&L>(
MO'-G^VC8?!/PAXS:UTZ?5K?2-2M;;48;C%VT%E<7\4$TMI$]R4C>00/,S$N6
M]U^$%S_P4%\#?M?> +7P3\"/C7_PI_6K*_LOBLGQI\:^%-2?2KA8/,LM5L);
M+5[F[WM,IAFM@I@V2J\<:%#D ^T]5DU2'3+B70[.WN+U8&-I;W=RT,4DF#M5
MY%1RBDX!8(Q YVGI7R]^P5_P4_T+]LG]H/XT_LE^,OA;'X&^(_P1\0QV&NZ'
M'XE75(-1M9 P2^MIA! S1[U(96C#)OBW8+[1]4U^+G[1-E>_L&_M@3?\%J?!
MMI*FC>%_VDM?^'OQ_CM8R?M'A'4I+18+R0+][[)=LK@=6>2!?NK0!^B7_!5+
M_@I1\-/^"6'[*L_[2?Q!\+3>([NYUVST;PUX5M-02UFUB^N'/[I975A&$A2:
M9F*GB(CJ17OG@F^\8ZGX3L-0^(/ANPT?6IH VH:7IFK-?06TA_@2=H83+@8R
MWEKSG&0,G\<_^#A^]LOVK_V2?C)^TG:W<5]X+^$GB#P[X&^'=Q#()(+W6)]<
MTV?7M2C(X<)LL].1QRCVVH*#B0U]*?#+XA?M+_M6_L'?$_\ X*+Z?^U'XG\'
M>*K/4_&5W\-O#FGRP+HGAVQT*_OK.WLKZS>,I?&?[ 7N99R9!]H80M!L3 !^
MAM%?GO\ \%!?VIOVF?B%_P $O/@-^UQ^S=\6]5^&'BKXC>(_AU/-865I;36S
M+KMU8![6Y$T32F*,W!!6*2(N-RN6!Q7H>J:S\2?V:_\ @HG\*_V6'^.7C7Q5
MX0^-WPT\72:FGB?5UGN]/UC2#IL@O[6=$1K;S8;^9&ABVPJR1-%''M(8 ^F[
MSXL:)?\ A[Q1J7PULW\7:CX4O9+#4-$T6Z@68WZ0Q3&UWSO'$KA)HR=S@+NP
M?F!6N._82_:MTS]N/]D7P)^UIHO@R?P]:>.M&_M&VT6ZO%N)+5#*Z!6D55#'
M"9.!@9QSC)^9/^"&/PATCX;^#_VA_P"RO&/BK4(K#]J+Q]H\$&O>)[J_5HK?
M4@JS/Y[L9+E@!OG8F1^K$DU\P?L::_\ 'C]D/_@W1^&7[?7ASX_^)7\0>"='
MTK4;#PI%<1KH,FA?VZEM-IDMF4(E:6TDE=KEC]H2=P8Y$C18P ?LK17YX?M5
M?M2>/?@/^U3XMT+]L#QA\2?AOX*UGQEHB_!CXV^$KN6X\'Z?:>58K/HFMPP$
MI:7$]ZEVAN;N(YCNQY<T(B6OT/H ^8/^"FW_  4'\<?\$[O"'@CQ[I/[/-IX
M[TOQIX]TWP?'CQI_9D]GJ-^TBV[LC6<RM!F/#.'WJ6'R$9(L>._VI?V]_A;X
M4O/B'XV_8 \.7&AZ.@N==/AKXS?;;Z"Q5@;B>&VDTJ$7#11;Y/*$BL^S:N6(
M!\!_X.6XM>G_ &1O@[!X5OK.UU1_VI/!2Z;<ZA://;PW!FN/+>6))(VD0-@L
MBNA8 @,I.1[UI_@;_@IIIWQA\'>(_CE^TQ\*[[X?:?+JC^*X_A]\/;WP]=6^
M[3+E;>YEEU#5]0BG@CE()CV* YB=MZH=H!]-(Z2()(W#*PRK Y!'K2U^6W[/
MNM?ME>//V%/VH_VF/%_[<WC^_P#%?PF^(GQ'M?A7=QS6<-O##H4]P;=KZVBM
MU@OO->#RWC=!"L( BCB<M(WK_P (/VD_BI_P4(_:B\,?"FX^(.N> _!5C^S7
MX6^(VMZ9X0OC8WVN:KK[S^5']K ,T=G:QVK_ "PLADEF'F,RIL8 ]\_9/_;*
M?]I_XG_&+X7WGP>U3PC>?"'QM;^';Q-6U.WN)+]IK"WO4G MR\<:F.X3"B1S
MZD'('MU?D5\./VB/C#_P3@^!G_!23X_'QE+\1O%_P_\ BE:?V)K6N6T(>Z>3
M1=+MK![Q;9(DD:".: 3%53S#!(QVEB1[-IDW_!4GP"_PM\8_"+X.?'[Q/XCC
M\1Z;'\81\3?&'@9M!\1Z1-A=0N+:"TUJ1M-GBW>=;"SC5"(_+D27=F@#]"=1
MNI[+3Y[VVTZ:\DAA9X[2W9!).P!(13(RH&)X&YE7)Y('->._L*_M@)^VQ\(]
M9^*0^%]]X/ET7Q]KOA:ZT74=1BNIDGTR]DLY79X1Y8+/&QVJ7 [,W6O(_ >N
M_%3]MS]LK]H'X>ZW\=?&'@CPE\&M8TGPMX4T7P1J,>GW,M_<:3;ZC<:O=2&-
MWN#F[BB@A?-ML@9GBD+_ "\]_P &^MEXLT[]B3Q9I_CWQ='X@UV#X_>/8]:U
MZ&VCA34KM==N1-<K'& B"1PSA5 4;L 8% 'W+1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %>#?\%#?^"?GPW_X*4_ 2X_9G^-7Q2\;:#X/U&Z@GUK3?!EW8V[:D
M8)DGA662YM)W"I+&C@1E,E1NW 8KWFB@#@]>_9Y\%_$3]GN__9J^.^HW_P 1
M= UK0I=(\0S^+!;BYU:VD4JWG&SA@0/M/#QHC J&!##=7"^ ?V!_ OAKXC^#
M_B;\1OC+\0?B/>_#JWGC^'EMX]U6TG@\//+";=[B,6MK ]U<_9V:$7-XUQ,J
M.^'#22,WNU% 'B=W^Q%X<NOVW+?]O _&_P =)XGMO!;^$X]!1]+_ +)_LA[Q
M+Q[8QFQ,V6GC1O,\[S %VAP,BO;**^>_&?\ P5$_8Z\#>(?$.DZKXJ\57>F^
M$+Z>Q\7^,="^&NNZEX>T.[@P)X+K5;2SDLX7B/$N9<0D%9"A&* ,GP!_P2U^
M$OPL^ GQ _9I^'OQR^*&F>$/'[ZPG]F#7[2=/#UKJDT\]]::<D]HZ11R2W,S
M[Y5EF4M\LBCBH_'/_!+?X?\ C_\ 95^'7['^K_M(_%"'PO\ #"^T2Z\.7=I<
M:*M](VD- VFK/(VF%9%@:WC8812Y!\PR5]"?#?X@^$_BU\/-!^*O@+5/MVA>
M)M%M=6T6]\ID^T6EQ"LT,FU@&7<CJ<$ C/(%;5 '@K_L"^&-!^)WB'XQ_!OX
M_?$+X>>(O&L-H?'UYX3DTAX?$MW;PK E_<6M]I]S;PW9C4*\UK' 7 7=G:N/
M9?!'@_2O 'A6R\(:+<7LUO91E1<:E?27-Q.Q8L\LLLA+R2,S,S,Q))8FM6B@
M"GX@TR]UG1+K2M.\17FDSSPE(M2T](6GMF/\:">.2,L/]M&'J#7RO^SW_P $
MB/AG^S/\ OB7^S?\.?VI/B])X=^*VHZIJ/B=]6OM$N+I+W48UCO;F"4Z6/+>
M5%P00R*26558[J^M** /E[QI_P $L/AUXY_9#\ ?L4ZG^TA\48/"/PWN-%E\
M/W-I<:*M^ZZ0UN^FQS2MIA5U@:UB8816<@^8T@P!UO@?]A71O!?[8%_^VO<?
MM#?$/6?%>J^#;7PMJ5AJIT8:=<:;;SRW$,9BM].B=66:>9]Z2*Q,A!)7"CW2
M@D 9- 'S_P"$_P#@GGX)^%E[KFF_ ;X\_$CX?>$O$FOW.LZSX \)ZG8)I;7=
MS(9+MK9[BREO-.69RSLEG<P*KNSQB-F+5TWQX_8R^$GQXOO!'BFYO=:\+^*O
MAI<RS?#[QIX3O4@U+0_.@$$\49FCEAF@EB"I)!/%+%(%4LA*J1J_L]_M7? O
M]J9_&"?!#Q9<:K_P@GBR7PUXG^T:/=61M-3C@AGD@"W,4;/B.XB.]04.[@G%
M>BT <7\(O@Y<_# W^I>(?BWXL\<:SJ7EK=:[XNN+3S1%'N\N&."QM[:U@4%F
M),4",Y.79RJXY_\ ;!_9#^''[:?PKL_A=\1O$/B+1#I'B?3?$?AWQ%X2U%+7
M4M'U6PG$]K=V\DD<D8=''1XW4AC\N<$>J44 >$_ C]@+X<_L_?M%>+/VG/#/
MQ:^(FJ^(/'>F:?!XQM=?\2)/9:M>6<)@AU&2)84*W A8Q>6C+;*H79 A1"LG
MA#]AC0_!/[6GC;]L?2/V@/B WB3QYH%KHVLZ9<-I#:=%:6@N/L:PQC3A(I@:
MYE=6:1BS-^\\Q?EKU'XI_%/P+\%O U[\1OB/K+V6E6)C61X+*:ZFFEDD6**"
M&"!'EN)I)'2..&)'DD=U5%9F /(_ #]L'X%_M)Z]K_@SX=ZQK%IXD\*BW;Q'
MX2\6>%[_ $35M/CG#&":2SOX89C#*$?9,JF-BC ,2K  'DO@O_@DC\"_"/@+
M6_ UY\8/B-K,NI_%>[^)>E>(-1U+3HM2\/>*KF9YI]2L)K2QA"%VEE#0RK+"
MR2R1M&4=E.CX$_X)=_"KPK^V7:?M\>*_CS\5?%_Q+MO"S^'9-4U_Q+;06T^F
MF9)UMFM-/M;:!8TD0.(XT1'9F:19&8M7HOQT_;+^ G[._B:#P5\0M<UBXUJ7
M19M:N-'\,>%=0UJZLM*B?9)J%S%803/;VP;*B60*'965-S*P'H/@[QCX4^(?
MA+3/'O@3Q'9:QHFM:?#?:1JVFW*S6]Y;2H'BFBD4E71D8,&!P00: +6KV5SJ
M6E7.G66L7.GS3P/'%?V:QM+;,00)$$J.A93R Z,N1RI'%>6_LB_LEZ=^R#X/
MUGP/H/QM\<>,;'6?$^IZ_(?&T^G2R6]]J%[-?7KQM9V=L=LMS<32E6W!2Y"!
M1Q7K5>4_M6_MJ_L[?L6^&=.\2?'OQ?>VCZU<20:'HVB:!>:MJ>IO&H>7R+.R
MBEGD5%*EY FR,,N]EW+D \1_:?\ ^"(7['O[3OQ2\?\ Q@GU[QEX'UGXIZ)I
MFF_$&3P'>6%NFM"POX+^WN)%N;.?9.)K:WW21E-ZP@,#EBWI6B?L&:7I7[7U
MK^VQJ'[2OQ(U3QA;>!/^$/>VOAHBV$^DF\%X8GAATR,AS. _F*RO@;<[>*[7
M]EG]K3]GC]M;X06?QW_9A^)UEXK\+WEQ+;+?6L4L,D%Q&0)+>>"9$EMYERI,
M<B*P#*<88$\_XH_;\_99\'?$VZ^%FO>/KN.YTW7[30=:UR'P[?2Z+I6KW7E_
M9M.N]32$V=M<R>;$!%)*I#30JVUIHE< \]L/^"1_[/EUI'Q4\._$CXE>/O&6
MG_%WQA%XL\0VVNZA86[Z?KT(MA;ZGI\^GV=M/9W$(M+<1E)-H\OE222?7/A=
M^SOK7@3Q+!XI\<?M)?$+X@W%A;-#I$/B^?3(H+'<NUY!%IEC:)/*R_+YDXE=
M06"%=[[M[XX_'3X3_LV_##4_C)\;O&=OH/AS25C^V:A/%)*2\DBQQ11Q1*TD
MTLDCI&D4:L[NZJJL2!7GW['_ /P44_9'_;IN?$6C?LZ_$JXOM:\(3Q1>*/#&
MN:!>Z1JNEF4$Q--9WT,4P1P,K(%*GIG(( ![3>P2W5G+:P7LML\D3*EQ"%+Q
M$C =0ZLI(ZC<",CD$<5\ZZ#_ ,$S?A5#\&_B_P# +XD_&#Q[X]\+?&R^U6]\
M7Z;XNGTMO(NM014GFM'M;"!H"-B-&N62-D#*H/-6OVM_^"IW[$/[#WBA/!O[
M1/Q5OM/U!+"._P!4AT7PEJ>KC1[*1V1+N^:QMYELHF9&"M,5+[6*A@K$>W^!
M/'?@SXH>"M)^(_PZ\46.MZ!KNG0W^C:QIERLUO>VTJ!XYHW4D,C*001V- 'R
MW\:?^",/[,GQF_8,\)?\$W!\1OB!X6^%OA.VLXQIOA34M/AN=5DMY?/2>[GG
MLI6:5KC-PYC\L/*Q8C& -6V_X)0_"B'P3XF^$\W[0?Q4D\%>/=2N=0^(W@V/
M5]-MK'Q/=73;KV29K>PCGM!=?\MX[&6UCFRY9"TLK/\ 4M% 'B7[6O["OP]_
M:Y^&?A?X0:U\1O%?@OP_X1\0Z7K6E6'@7^SK=?M.FS1SV(;[59W&V.&2)&6-
M-BG;A@PP*@^(?["VB_$S]IWX;_M8>(?VA/B$GB/X6Z5J%AX<L[4Z.EC+'?PV
M\5^9XSIQ9VG%M"S%74(R_NA&.*]THH \$^%/_!/KP%\#/&/Q/\9?"+XU_$?0
MV^*/B._\07^EPZW:SV&BZK?/&][>6-O/:NBR3-$I/GB<)N?RA'O;/"S?\$?O
M@U-_P3NA_P""8A_:#^*2_#2"VCLXY$O='&I_8TN5N4M?M']FX\L2J#NV>9CY
M2Y'%>W^!/VK_ (%_$K]H#Q=^R_X-\67%UXU\":;9W_BC2I=&NH%M(+IY4@=9
MI8EBF#-!*/W3.!MYQ77?$#X@>"?A3X&U?XF?$GQ39:)X?T'3I;_6=7U*<106
M=M$I>25V/ 4*": /!_$7_!-+P%X]\.>+_A_\5?VA/B7XM\)?$#6K?5/&OA#7
M+K2?L.JSQ?9P5/D:='-;Q2?98?,CMY(E8AC@&1RWTA7SY^RQ_P %2?V)/VRO
MBAJOP2^!_P 5;U_&&D:<-2F\,>)O"FI:'?3Z>6"B]@AU&WA>> D@;XPVW<N[
M;N&?0OCC^T]\(OV>[S1-#\?:CJESK7B:2X3P[X:\->'KS5]4U$0()+B2*TLH
MI96BB1E,DNT(F] 6#2(K 'GG[??_  3I^'W_  41T#POX3^*_P ;/B%X;TKP
MCXHL_$>E6'@F\TVW5M5M#(;>ZD>YL9Y'*>8V$W",D E"0#6!XS_X)G^)_B/X
M7O/ WQ _X*4?M&:MHFIQ>3JNDS:MX;BBOH"07@E,.B(YB< HZ!@'1F4Y#$'W
M_P"$7Q>^&WQY^'&E?%OX0^+;;7/#NM0&73M2M0RA]KLCHR. \<B.KQO&ZJ\;
MHR.JLI \(\,?\%B/^"=_B_\ :(TW]F'1_C[CQ)KFJRZ7X;O+SPWJ-OH^MW\;
ME'M++5);=;.[E##:!%*P=B%0LW% #OA]_P $PO OPW_9T^)W[,FB?M)?%";0
M?BQK&MZGXGO;R?16O8KC6&E;4C;R+IBK&)FF<X*-L)_=[*L>%/\ @F=\.?A_
MH_@&?X=_'CXC:%XL^&_@B/P;X?\ B#I]SI)U6;P[&L8CTR[CDT][*\A1HD=&
MEMFE1]SJZEW+?2-<O\+?C'\._C19:UJ/PW\0+J4'A_Q/?^']5ECC95BU&RF,
M-S""0-VR160D<94C/% 'A/[/O_!)/]E7X :=\7=%.H^,_&VG_'.XGG^)&F^/
M_%#ZA;ZG+<0+%<R&-5C4/-@LSX+*7*QF- J+VGPA_8NA^$</A[PVG[37Q2\0
M^$_":0IX<\&>(M7L)+2T6# MQ)<P645]>"(!=JW5S,"54N'95(]JHH \5^(W
M[$/A#Q9\7]=^._PV^+_CGX:>*?%ND6VF>--1\!7UD@\06]LKK;&XCOK2YC6>
M))'1+J%8KA4(7S=JH%A_8,_X)_\ P/\ ^"=/PKU'X-_ +7/%UWH>H^(+O5S#
MXK\22:@UM+<2O*Z1%@ JY<_-@R/@&1Y&&ZO<** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ K\IM,\=_MO_ /!!5?%'A;XE_ 2Z^/'[(%_XFU;7
M]-\9>"(UE\1^!;74;N6\NHM1LW(%[;+)-,YF4A<,SM(NY8%_5FOD3P9^R]_P
M4P^%?P0D_9T\*?M._"7Q#HT]G=6>G^(?%GP]OS?Z':3L^VW\F*_\G4E@CD\N
M(O\ 9]R1H'#?,2 2_%K_ (* ?LT_L7_\$HO#_P"UW^SO:+XS\"V7A/0M+^%>
MF6UV;?\ M8W#06&G6[R2)F !F02ETWQK%)E"R[#R7AO_ (*6_%/P/\<_A5\/
M?B-XU^&WQ/T;XF:^GA[5KCX3>&=3LKKP=J4T3/;33+<W5T+ZP>13;O<8M3$S
MQN4(<HO<:O\ \$E_@C/_ ,$P-%_X)A^'/&6M:7HOAG1[!/#7C"-8WU"QU:SN
MDOH-4"D!&?[8GFM&,*RL\8*@Y'JGPNT+]M)]9TJ#XW^/_A\--TR+_B93^#]$
MNUN->F"E0Q6ZD=+"(GYVC4SN3A1*@!+ 'A'B?]K3]O\ \5?\%4O$'[ ?PIT#
MX4Z%X3TGX56/C7_A.->TK4M6NK>*>_N+-+9[6*[M%EEE>!F $B+$J.2TIVJ?
M _\ @IQ^V%^U%\4/^"9'[3GPWA\9:#X!^(GP4\2VGACXG#1M$FN[?Q'I.H+8
MRVT]@TERK:?'=V=^ID23[0\>V:(,<K/7H/BWPQ^T-??\'!GBWQC^S]XW\.VD
MVE?LK^'8=:\.^*["=[/6+>;7M7VD3P.'M9HGB5E?9*K*\B%!N#IVWQ/_ ."3
MOB'XM_L9_M!?!WQC\;[27XG?M#ZRNN>*/&\&A-'865Y;I:1Z=9P6IE9Q9VT-
MC;PC?(TCYDD)!<(H!?\ VMO^"@WQ!_9@^+WPG_8YN_&G@$_$/Q_I^J:QXB\?
M:UX?O+;0= TBR90;@::EZ\]Q-+)+%!'"+Q06621I$4!#K_L<_MZ>/_CI\<_B
M-^S#XJL?#7B'6/">@VNN>$OB'X/L+VR\/^)+2X+QF&2.=[A[&ZMYU5)(O.GW
M1RI*N 2@G^('[%'[1/CKXE?"K]L8_&/PA8_''X=:?J>F:HUEX9N4\-Z_I&H"
M/S]+>%KEKF%4>&&:*Y\UV6578Q,CB)/:OAW8_M'VNF:UX@^*VL^%+W59X0-!
M\-:!'/;:?:% Y EO)5DFE>1F&Z01*J*JA868,\@!\3?"/_@I%_P45\?_ +$'
MQ=_;G\0^ OA+I^F_!;Q#XN@U#PC;:5J<TWBRQT"YG^U26UX;U1I[F&"2-"\%
MSYDT;,4B1@H]-N?V]/VC/!?A_P"!?[2/Q'\.>$8_AM\>?'.A^']/\)6^D746
MO^&8]<B=M*N+F^-W);W<AD^SI/ EO$(S<L$FE$.Z7&^%_P#P3V_:N\"_\$X?
MC+^P]JOB;X>W6K_%"\\8M8^);>^OH[:PB\1RWLMQO@-N6=K=KO" .!*/O&+;
M\^E\;OV%_P!J[XJ?LK?L^? ;2=:^'MCJWP8\<>#O$>J:I<:E?26^K-X>>)XH
M8HQ;!H1<&(%F9F\D94"7.X 'D_[#=Y^V_=?M5_MNV/[-?_"N;'1]*^/\U[;/
MXUTB^O)->U1]#TP-8*]M=P#3XUCAA)N62Y.;L$0XB(?L_'/_  6L\.ZW\#/V
M;_%7PC\/:1H'B?\ :1DO_L4GCN6633?!\&EQ;M8FNQ;E)+QK>;%O'"CP^?)(
MI\R(9KM_ /[&_P"VS\!OB=\:O$_P"^,?PZM=-^-WBA?%,C^(M!O;J\\(:S+I
M]K97#0^7)''JD"K:QO&D@M3NR&)!IES_ ,$G/#WPT^%_[/.F_LO_ !-?0?&G
M[-+W?_"%^(?$NGF_@UJ&_MS#J]MJ,4;Q,1>[C*TD;*T4H1U5@NP@%O\ 92_;
M_P#''Q._:QU_]D7QO<>%O&1B\$KXG\)_$WP!HU[IVCWRK<"WN-+NX+F:Z-G>
M1,T<BE9Y5FA<N%0H4/'_ +(/[67_  4[_;!\:?%&STG1_@EX3T;X2?'V_P#!
M&H2W^C:O?R^(;&SDMC<FW9+R$6DR02EEF=)DEDD$9AA$322?4_PSL/VE?M&H
M^(?C+KOA(O\ 9?*T;PUX7@G6V1^IEN+RX!ED9B JA(HUC4ON$Q*E/+?^">O[
M+7QU_99O?B\OQ=U7PEJ%O\2_C#K7CVRD\.7=T7T]M1, -@ZS0J)1&(<^>&7>
M6QY2XS0!]%7UM;SQ"6:P2X>!O-@1E4D. <%2W ;DC/'6OB;]G77O$_CO_@LS
MX]\<?M">!I_AUXPM?@79:+\.O!DE[#?#Q#X;35GN+O66N[=C$98[R:&W^R??
M@5@Y+"X!'V)X_P!.\>:CH'_%M?$MCIFK03I+ VJ:>;FUN%&0T,J*Z.%8$X='
M5D8*V'4-&_CGP\_92^(NM_MD_P##;_[0OBO19-<TCP'/X1\%>$_"\4K66D6=
MS=175[=2W,^V2ZN9WM[=01'$D4<6T*[.ST >>_L)W,_B?_@I)^VCXK\1<ZGI
MWC+PAX=LHY.6M]*M_#=M=P(N>0C3W]Y+CH6E8T?\$0KJXM?V,M:\ 6Q+:)X+
M^-?CWP[X4?\ A_LJU\2WZVR*?[B*3$H' 6-5' KN/B)^RE\;O"/[27BW]IW]
MD3XC>&-#U?XD>%['2/'.E>,='GN[-KNP$R6&L0>1*C>?%%.\,D#$)<1I /,A
M,6Y]#P7^S>O[&O\ P3_G_9X^ GQ?A\.:GX>\(WZ:5\0O%.GI>!-9N3-/+JUU
M!E4F>2]GDN'C'RLTA4#&!0![Q7/>(M*^&WA'5K[XY>+5T[3[C2O#\L%]XCU*
M<1I8Z;&QN)@9'.V&+*B21A@-Y2%R1&FWEOV.]7^/&O?LP>"=7_:=\AO'D^A1
M-XCFM]+:Q%Q+DA9VM6.;622,)(\!_P!4[LF!MP/'/^"BG[-G_!0']I#Q7X2T
MO]F7XM?"?1_ NB2)J'B+PO\ $;PYJ.H)X@U&.1F@6Y6TN(0]K"1%*L);;)*,
MR*ZHJT 5/^"3WP*U#P7:_&K]J&X\-7'A[3_C[\8;_P 9^&O#=Q:M;R6NDM!#
M;6MU- P!AN+P0->NA 91<QJX#JP'SY^SIH.B_%'_ (-FOB=XJ^(:K)J/C/X?
M_$WQ/XKOYS^].L27^L74EP['GS(9D3:3ROD(/X:^T/V0O!7[>?A^?Q#K?[<_
MQI^'_B6[NQ:P^&]+^&WA>YTRPL(D\TS2R?:IIII9I6>,<OL585VJ"SD^1>*_
M^"9OQ,N_A=X]_8R\$_&72-+^ _Q+\6W^KZYIITJ;^W-)L-2NFN]7T2QE640"
MVNIY+C;,Z;[>.\F0)(1&Z 'M_P"S+&OQT_9;^"WQ3^+VC)?^(4\'Z)XC\V[!
M+6^JS:2$EFQG!<"ZG'.<%\CD CQ3X%?"RP^-?_!7KXA?M\^![-(/"OA;X2P_
M"B+5X5Q'XFUB/5FO]0F0C_6QV1C@LO-Y!F^U1 _N"*]-_;M^#7[6_P 4OV>$
M^#?[#/Q3\(_#W4KJ:&UU+6-?L+R00:4JX>VM/L<D4D$D@"Q^<CJ\<98Q,DFR
M1.._8X^!?_!2[X9>,-!\/?M%_&/X(6_PS\+Z'):Z3X/^#_P_OM+>241K#;Q2
M/>74ZI;1(7<+$$8NL>25# @'J'[1OB?X-_LT_!?Q]\4]?\ PZH_B5O\ 3O#U
MO;^?<^+]5FMHK"TTY(VSYTUP([:U2/&W&,X4,:Y;_@E9^R=XJ_8;_P"">7PH
M_97\=ZNE[KOA+PNL6MRPS&2*.\FEDN9X8W/WHXI)GB1NZ1J<#I7E7[1/[,'_
M  5I\<_M>R?'[X.?';X!Q>&M"MC;?#KPWXZ\&:Q?OH9="EQ?9M[R&-[V96:,
MS%28X28HM@EG,WTI^S#X6_:,\*?"6VM/VK_B9H7BOQU<7MS<:OJ'A71WL-+A
M5I"(;>U@D9Y%C2(1@F1W=G,C;L$  %+]J3QY\=? ?AW0+GX(Z9X5MX;OQ"L?
MC+QAXUNE&F^%-&2WGFFU"2#[3;O=$O'# L:2IAKD2,=D; \A_P $\/VP=0_;
M%^&?C/5]=ET.ZU3P#\4=:\%ZEK/AA)$TW6&LGC:&^MHY)96BCFMYX'\LRR[6
M+ 2.N&,?[>?[*WQF_:1N_A7XL^"?Q,T'2-1^&GQ%A\33^'_&&ES7FC:^BVT\
M BN8X9$<20M,+B!_F"31(VW(5ES_ -@W]CWXY_LE^/?C%>^/_C!X9\3^'_B5
M\2;SQO9QZ5X9GL;NWU&^M[5+N-R]S*BVZ-;?ND&Y]LAWR$J,@'F_P2_:S_X*
M._M(?M0_M#_L]>$]&^#WA.U^"OB6PT_2M<U/1M4U9-9:\TN&^BM&5+RU,;()
M 9+G! $B*L#_ #,$^%7_  5-\>?M:>$OV=_#/[-/@;1-%\;_ !Q\&ZIXHUV?
MQ9'-?Z?X.T_2WBMK\M#!);R7\C7TR6T*"6 $;Y'9=H1NX_9=_9B_:F^ GQ\_
M:!^.6OIX U+_ (7)XEL=?TC2K/7;Z/\ LF>UTVVTY+::5K,^<C1VZR&540JP
M*B,ALIY/^RA_P2G_ &BOV9OA3\$[W2OBIX+3XF? RW\0:58ZM#:W<ND^+="U
MF\:[NK"\A(2:S=)5MWBFC>;:\!8QLLC1@ C_ &(+[X]S?\%N/VD-(_:(M?#<
MFL:7\'/!-MI^L^%+6>UL]8L3=ZM+%="VGEFDM7W221-$9I0&@+!R& 'W5XR\
M$^%/B#HJ^'/&FAPZC8K?VEZ+6X!*&>UN8[F!R >=DT,;@'@E!D$9%?+G[+_[
M#G[67PT_X*$_$G]NGXV_M$^#M9M?B1X3TK1KGP7H?A"ZB&DQV!N/L\5M=R7?
MW%\XN[R1,9GED(6 ;5KW#]K7PQ^TWXT^ >O>$?V0/B)X<\(^/=2MQ;Z1XG\4
M:=)>6VEACB2=88_]9*JY\L-E ^"P8 J0#P/XB?"RP_:@_P""POPN^,'@6T1;
M#]FGPGXB@\9^)8%&V\U;7+6WAM=#WC'F-!;":]E7)$7VBUX!F-2?#>ZN/%/_
M  70^*<OB/A_!_[-_A:R\+Q/T6WU#6-5FO94![O+9VJ,1U^SQ@_=%9_[(G[+
MW_!5KX+ZQX/^'GQ+^/\ \";3X9:)?O=>(+'X?^!=6CUO5V/F3/YEYJ-]<!Y+
MBZ827$[JTTN^5MX=]U>M?'']E[XB7W[3&@_ME_LX^*]#TSQOI_@^X\)>(=+\
M46DTFG:_HTEP+J!'>!A)!/;7(>6*10X*W%Q&R_O%DC /+O\ @F1;1R_%#]L/
MX0(LC^&=._:4U,Z<L,S1B)]1T72[Z^AC9""G^E7,\I*D$/.QSDU4_P""GOP(
M\(_M(:'\&?\ @GG\*O#5G;:E%\0O#WBC.FVRHG@OPUHERLLM^NT8MRXC73[=
M1@N]RP4%(IBGM7[,'[+GB']E7X#^)/#?AOQ?8>(OB%XLUW6/%?B7Q1JMB]M9
MZKXDOV,C2M!&[-#:(1# D2NS);P1KO9@6/S%\+/V/_\ @N9\-[CQ%>0?M=_L
MY/J_C/56N_%/C63X9ZO/K,H)*Q+$9;[[.J6T1\NW@\KR4 R49GD9P#[D^*?P
M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
MO VD_##]C#QC\--!O;ZYL?#O[0?C_3+*XU2\:XN98H->N8D>:5_FED*H"SGE
MF))Y-?:MTFJ:?H,D>BQQWM[!:$6B:A=&);B4+\HDD5'*!F W.$8C)(4]*^??
M^";'[+'QM_9#^&WC+X>_&/6?"NJ-XB^)OB#Q?97_ (9N+G$9U:_EO9+5XYXE
M_P!4\A59 YW@\HA7+ 'T;1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 >;Z/^R3\!- _:%U#]JO2O"-['X_U735T[4?$+
M>)-0=KBR5RZ6K1-.8C CLS)%LV(S%E )S7I%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S/QE^)
MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
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MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
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M"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %%%%
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M^IX3_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[
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M16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16/_P@^D?\_-[_ .!;4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\C3J7_80F_P#0S7OE
M>!^*_P#D:=2_["$W_H9KY#B[^!2]7^0&?1117PP!1110 4444 %%%% !1110
M 4444 %>X?#;_D1M-_ZX?^S&O#Z]P^&W_(C:;_UP_P#9C7U/"?\ OT_\/ZH#
M<HHHK[\ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/V
MY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_H
ME*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ KP/Q7_P C3J7_ &$)O_0S7OE>!^*_^1IU+_L(3?\
MH9KY#B[^!2]7^0&?1117PP!1110 4444 %%%% !1110 4444 %>X?#;_ )$;
M3?\ KA_[,:\/KW#X;?\ (C:;_P!</_9C7U/"?^_3_P /ZH#<HHHK[\ HHHH
M**** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7
M_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\ (TZE_P!A";_T,U[Y7@?B
MO_D:=2_["$W_ *&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%
M% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\ #^J
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M@%__ $-: .U^&%A8M\-?#S-91$G0[0DF,<_N4K<_L[3_ /GQA_[]"LCX7?\
M),_#O_8"M/\ T2E;M $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H5X1XI54\3ZBB* !?S  #I\YKW
MVO _%?\ R-.I?]A";_T,U\AQ=_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHH
MH **** "O:_AS964G@C3GDM(F8P<EHP2?F->*5[A\-O^1&TW_KA_[,:^IX3_
M -^G_A_5 :Z6-E&P>.SB5AT*Q@$5+117WX!1110 4444 %>??M!?#?XW?$FT
M\(P_!#]H9_AW+HOCK3M6\33)X7MM4_M_1H2_VK1R)R/LHN RC[2F9(]GR@[C
M7H-% 'YU_MG>-_C!\$/C_P"*I?BW_P '&?A?X$:/JVK)=^!OAWJ?@OP;/=V6
MEM;09WF^M_M,@^T_:0KMN'EB/+EMV/8O^"17C:+X@_"[XF>)H/VZK7]HM)/B
MO(B_$VRT>RL8;G;H>CC[,L5BJVV(ONYB !.<_-NKQG7/VD_@W^SC^UE\7? =
MU_P3;^(_Q\O;[Q>VJ:Q\3?A;\)H]<-O<SP0L-%U"YN_)0SVD(AC18)9E2 P*
MXBD#I7TA_P $Z?B_X*^-GA+XB>,/!'[)7BGX-0Q_$AK:\\+>-/#*:/J5S.NC
M:4?MDUK&[I'O1HT4JQ#)$K'#,PH ^B*\H_;G_P"31_'O_8!?_P!#6O5Z\H_;
MG_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B
M4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O _%?_(TZE_V$)O\ T,U[Y7@?BO\ Y&G4O^PA-_Z&
M:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%% !7N'PV_Y$;3?^
MN'_LQKP^O</AM_R(VF_]</\ V8U]3PG_ +]/_#^J W****^_ **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%>!^*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-?(<7?P*7J_R SZ**
M*^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO\ UP_]F->'U[A\-O\
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M=_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHHH **** "O</AM_R(VF_]</\
MV8UX?7N'PV_Y$;3?^N'_ +,:^IX3_P!^G_A_5 ;E%%%??@%%%% !1110 444
M4 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN
M_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !7@?BO_ )&G4O\ L(3?^AFO
M?*\#\5_\C3J7_80F_P#0S7R'%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BB
MB@ HHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\
MA_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\ ^AK7J]>4
M?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@
M*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %>!^*_P#D:=2_["$W_H9KWRO _%?_ "-.I?\
M80F_]#-?(<7?P*7J_P @,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P^&
MW_(C:;_UP_\ 9C7A]>X?#;_D1M-_ZX?^S&OJ>$_]^G_A_5 ;E%%%??@%%%%
M!1110 4444 %%%% !7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z
M&M '2?#6S\9-\.= :#6+14.B6NQ6MR2!Y*X'6MO[%XW_ .@W9?\ @,?\:B^%
MW_),_#O_ & K3_T2E;M &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C6Q1
M0!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL44 8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-;%% &/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C6Q10!C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UL
M57U:>6VTJYN8&VO';NR-C."%)%3*2C%M] ,_[%XW_P"@W9?^ Q_QH^Q>-_\
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MQK7C):-6)Y*C-+7TZU Q_L7C?_H-V7_@,?\ &O&/$:S+XAOUN7#2"]E$C*,
MMO.2*]_KP/Q7_P C3J7_ &$)O_0S7R'%W\"EZO\ (#/HHHKX8 HHHH ****
M"BBB@ HHHH **** "O7/ =KXLD\(6#V&JVL<)A^1'@)(&3U->1U[A\-O^1&T
MW_KA_P"S&OJ>$_\ ?I_X?U0%BSM/%J72/?:M:O$&_>(EN02/8UJ445]^ 444
M4 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
MO_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110
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M%% !1110 4444 %%%% !1110 55UW_D!WG_7I)_Z":M55UW_ ) =Y_UZ2?\
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M-?4\)_[]/_#^J W****^_ **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V
M7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^
M29^'?^P%:?\ HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKKO_(#O/^O23_T$
MU:JKKO\ R [S_KTD_P#036=;^%+T8'S[1117XV 4444 %%%% !1110 4444
M%%%% !1110!]%0_ZI?\ =%.IL/\ JE_W13J_9UL 5X'XK_Y&G4O^PA-_Z&:]
M\KP/Q7_R-.I?]A";_P!#-?(\7?P*7J_R SZ***^& **** "BBB@ HHHH ***
M* "BBB@ KW#X;?\ (C:;_P!</_9C7A]>X?#;_D1M-_ZX?^S&OJ>$_P#?I_X?
MU0&Y1117WX!1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>
M4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_
M]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-?%W_D0+W_
M 'HO_1BUXQ7L_P 7?^1 O?\ >B_]&+7C%?GO%?\ R,H_X5^<@"BBJ7B3Q)H'
M@_0+SQ3XIUBWT_3=/MVGO;Z[E"101J,L[,>  .]?,I-NR NT444 %%%% !11
M10 4444 %%%% &S\/O\ D==,_P"OM:]SKPSX??\ (ZZ9_P!?:U[G7WO"7^YU
M/\7Z( JKKO\ R [S_KTD_P#035JJNN_\@.\_Z])/_037T];^%+T8'S[1117X
MV 4444 %%%% !1110 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZOV=;
M%>!^*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-?(\7?P*7J_R SZ**
M*^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO\ UP_]F->'U[A\-O\
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MQ:_B;6]&\%:C>V6F"]T<6]KYL\$#1C?+\O!.WJVT<UHE&.-FK\WNRU>_P/\
M%/1[Z@?3/Q%O?B+I_@N_O/A+X;T75_$21#^R].\1:W-IUE,Y8 ^;<0VUS)&
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M^3__ -KH_P"%_P#_ %*7_D__ /:Z\YHKX/\ UASC_G[_ .2Q_P @/1O^%_\
M_4I?^3__ -KH_P"%_P#_ %*7_D__ /:Z\YJE:^)- OM?O/"UGK%O+J6GV\$]
M]8I*#+!',9!$[KU4.8I,$]=C>E'^L.<O_EY_Y+'_ " ]3_X7_P#]2E_Y/_\
MVNC_ (7_ /\ 4I?^3_\ ]KKSFBC_ %ASC_G[_P"2Q_R ]&_X7_\ ]2E_Y/\
M_P!KH_X7_P#]2E_Y/_\ VNO.:*/]8<X_Y^_^2Q_R ]&_X7__ -2E_P"3_P#]
MKH_X7_\ ]2E_Y/\ _P!KKSFBC_6'./\ G[_Y+'_(#T;_ (7_ /\ 4I?^3_\
M]KH_X7__ -2E_P"3_P#]KKSFBC_6'./^?O\ Y+'_ " ]&_X7_P#]2E_Y/_\
MVNMGP-\4?^$TUA])_L+[-LMVE\S[5OS@J,8VCU_2O(*[/X&_\CA-_P!@]_\
MT-*[LMSO-,1CZ=.I4O%O72/^0'K-%%%?H '-?%W_ )$"]_WHO_1BUXQ7L_Q=
M_P"1 O?]Z+_T8M>,5^>\5_\ (RC_ (5^<@"H[NTM+^VDLKZVCFAE4K+%*@97
M4]00>"*DHKYD HHHH **** "BBB@ HHHH **** -GX??\CKIG_7VM>YUX9\/
MO^1UTS_K[6O<Z^]X2_W.I_B_1 %5==_Y =Y_UZ2?^@FK55==_P"0'>?]>DG_
M *":^GK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@ HHHH **** /HJ'_5
M+_NBG4V'_5+_ +HIU?LZV *\#\5_\C3J7_80F_\ 0S7OE>!^*_\ D:=2_P"P
MA-_Z&:^1XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%% !7N'PV_Y
M$;3?^N'_ +,:\/KW#X;?\B-IO_7#_P!F-?4\)_[]/_#^J W****^_ **** "
MBBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-
M: .Z^%W_ "3/P[_V K3_ -$I7._'O_D&Z=_UW?\ ]!%=%\+O^29^'?\ L!6G
M_HE*YWX]_P#(-T[_ *[O_P"@BO'S_P#Y%%7Y?F@/,J***_+P/+OVVK7X]WO[
M(?Q)M/V7)WC^(<G@V_7P@\+JLHOC"WE^4S?*LO\ <)X#[2>,U^=?[ %C^Q9^
MV)\7I[;X(W6N_"SXH^#[KP'J.O\ A'Q%XCOK#7+N^TO5)KG6K:^ADEWZLDD<
M:!I)5D 9X6;RF!"_I5^TWXM^*G@3X#^)?&/P0\&S^(O%FFV(GT+0+95+ZE.L
MB8MP7^5=XRI<X"ABQ(QD?FY^V]\([;]OS]I/4-2^!_[,GQ(\+_'729O USX2
M\::MX3GTK_A#Q#?WKW\]]?9%O-"+8,$6*2;S9(T$6[8V/9RUWHR@WRI_:3VV
M^)=8_EKOL!],?\%8=+\,?$7Q-\$O@K\3/A#X[\:>"+_QCJ>N>,M&\ :3J-S=
M7%M9:3<P6\<C6!62*,WE_:N6+HI,0&>Q]%_X)TZ!^Q%H'PCU>R_8A\*SZ)IL
M'B*:V\5Z/JZ:@FK:=JL2H)+6^CU)FNH9$4KB-SM"N&3*ON/<_&SXS^.?@]XT
M\*31?"+5=>\%:F+Z+Q7KWAZQNM1OM$G5(VLR-/M(99[F*5O.1WC4F)A&2-K%
ME\R_8C^'GC^\_:)^/7[67B?P/J7A;1?BAX@T6+PGH6MVIMKZ:STO3A:'4KBW
M;#V[7#LVV*4+*(H(MZJ3@<W/*6!Y6VDEIKHWS=5WM^"\T!X<_P"VGX9_:0_:
M#^)_Q%^-5EX[@_9\^"WB:?PR!H.CW#:+J.HVN!J&JZQ) ?,N[2%R8TMT66WC
M1'GN%&Z,I]]Z!+H4^A64WA>2T?3'M(VTYK J8# 5'EF/9\NS;C;MXQC'%?#G
MPLTCXG?LJ_L??%']B74_V=/&'B;Q;<ZYXN7P-/HWAF>YTOQ9;ZS>W=U:7$^H
M(AM;':+P13K=21,@@8J)%*%O=O!C>.OV$OV'/AE\/G^&7B?XFZUX0\.>&_"V
MHV7@RW2>YE=(H+2:\ E9/W$95I"2<A!DX&6%XNG3E:-/O9*^ZMO\WOZVZ >8
M?\%8-*\+_$;Q7\$O@M\3OA#X[\:^![[Q=JNN^,=%\ :1J-S=7$%EI-Q!;QR-
M8%9(H_M>H6SEBZ*3$!GL?1_^"=6@_L1Z!\(-5L_V(?"TVBZ7!XBGMO%6D:LF
MH)JNGZK$J"2UOH]29KJ&5%*XC<[0K!DRK[CW'QK^-'CGX/>-O"LD?PBU;7O!
M6II?1>*M?\/6-UJ-]HEPB1M9XT^TAEGN(ICYZ.\:GRF6,L-K%E\S_8B^'7C^
MZ_:$^/7[6'BCP/J7A;1OBCXCT9/"F@ZU:FVOI;/2]-6S.HW%NV'MWN7+;8I
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M+]DW_HHWQ3_\+8__ !JC_AR%^R;_ -%&^*?_ (6Q_P#C5'^J'_3_ /\ )?\
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M?Q/J-A&MAXO:-#%#,40D&,_-@<G/->G?\.0OV3?^BC?%/_PMC_\ &J/]4/\
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MO]HOX(? C6_!_ASXO_$G3M OO'WB:+P]X.M;YV#:KJ<JLT=M'@'YF"G!.!G
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MSM?_ !-\):+=\VUWXFFU@Z6+EHS\LDD%O^\B)RT3!F7:3D['_!R)X5TS3_\
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MPD*8[6&ZG=+41A/N5Z!_P3R\.^!_!_[!?P8\'_#3XJQ>.?#^D?"_0K'1_&,
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M_9S\+?"KPSHDL-AH7P<36IKZYN JI!#(VI(J1P -+*[J3,\J1Y.&DR >3?\
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MOQAXQU:,)=>(=:O)/,NKZ502$+':JKEBJ1H"SD%F]UH ^2/^"H/PH^$6@_\
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MQ[X2\%7-J;=_#>AZE=!M/LF@('V=OLT<<S08'E-<,A 92*\U_:0^!^N^"O\
M@NM^RI\7=<_:$\>>*5\2V7Q#@L/"OB"XT]=(\.PQ:/'($L(;2S@<%C-M>6XD
MGE=8HP7.ROJC]D6P_;GC\/:WJO[=VN?#)]=N-21-!TGX40WQTVTL4B7,DDM^
MHGDN))6DW# C5(XMHW&0GS[]IW]FC]ICXH_M^? /]IKX<Z7X%;PI\(4\2KJU
MOK?BF]MM0U'^U["*U_<QQ:?+&GDF,O\ -(?,!Q^[ZT ?3U%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
,% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20220930_g16.jpg
<TEXT>
begin 644 biib-20220930_g16.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
M\FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2
ME;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:
M/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P F
MC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !116!=_%#P+8W4ME=:YMEAD9)%^S2G# X(R%]:QK8C#X=)
MU9J-^[2_,#?HKG/^%M?#[_H8/_)27_XBC_A;7P^_Z&#_ ,E)?_B*P_M++O\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -B
MBL?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QH V**Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&@#8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
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M45]^ 4444 %%%% !1110 4444 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
M)H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;
MM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-?(<7?P*7J_R SZ***^&
M**** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO\ UP_]F->'U[A\-O\ D1M-
M_P"N'_LQKZGA/_?I_P"']4!N4445]^ 4444 %%%% !1110 4444 %>4?MS_\
MFC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^
MB4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X'XK_ .1IU+_L(3?^
MAFO?*\#\5_\ (TZE_P!A";_T,U\AQ=_ I>K_ " SZ***^& **** "BBB@ HH
MHH **** "BBB@ KW#X;?\B-IO_7#_P!F->'U[A\-O^1&TW_KA_[,:^IX3_WZ
M?^']4!N4445]^ 4444 %%%% !7DW[1O[97PK_9ON[;PKJ&@>*O&7C#4+;[1I
M?@#X=^')M8UFZAW%?/:&+"6L&Y67[1<O#!N4KYF[BO6:I:7X<T#1+R^U'2=&
MMK>YU.X$^I7,4($EU*%"!Y&ZN0BJ@))PJJHP   #Y+;_ (*#_M_O<?VQ;_\
M!$7XMG0/O_:I/B7X/34/+XY^P_VGNW8_@WYKV/\ 9S_;3^%_[16J3>"O^$4\
M7^!/&EI:FYO? 'Q)\-R:1JZ0 A6GB1RT5[ &95:>UEFB5F52X8@5=\>?MN_L
M=_#+X7ZI\:_'7[47@+3_  EHFJC3-6\0R>*K5K6UOB<"T=T<@3Y_Y9??X/'!
MKL/#^J?"_P"-'A;P_P#$KPMJ6C>)M'N4AU;PQKVGS1W4$BO&?+N;:9"00T;D
M!T/S([#)#$$ Z&O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E9OQ<\4:[X8L;*;0[[R&EE=9#Y2MD #'W@:T
MOA=_R3/P[_V K3_T2E<[\>_^0;IW_7=__017E9W4J4LKJ3@VFK:K1[H#E?\
MA;7Q!_Z&#_R4B_\ B*/^%M?$'_H8/_)2+_XBN<HK\Y_M+,?^?T__  )_Y@='
M_P +:^(/_0P?^2D7_P 11_PMKX@_]#!_Y*1?_$5SE%']I9C_ ,_I_P#@3_S
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M_P"^EH_X275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH
MV**Q_P#A)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_
M (275_\ H4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK
M'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X
M275_^A0O?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A
M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BO _%?\ R-.I?]A";_T,U[)_PDNK
M_P#0H7O_ 'TM>,>(Y'F\0W\LD1C9KV4LC=5)<\&OD.+OX%+U?Y 4J***^& *
M*** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO_7#_P!F->'UZYX#U[4K7PA8
M6\/AFZF58<"5&7#<GIFOJ>$_]^G_ (?U0'845EV>O:E<W203>&;J%6;#2NRX
M7W-:E??@%%%% !1110 445Y_\2OVE?AQ\*?C7\._@'XIM=<?7OB?/J<7AF33
M]!N+FT1K"V%S/]IN(U,=J"C#9YA&\Y ^Z< 'SRO[0?\ P5=^.T]U\6?V/O@/
M\#;#X9B_N%\,P?$WQ7JL6M>*K6*5T^W)]AMG@TZ*XVEX1)YSE&5Y%C+%!]$_
MLR_&6'X^_!72?B>W@:Y\,7UU<7MGKWAJ\FCEETG5;2\GL]0M&DC^2;RKR"XC
M\U?EDV[QPU?EOXP_:[M?!GCWQ)X0_9$_;8_:N\!_#\^*M4BO_!VF_LBR^)H=
M'O1>3)?V^DZE/9,UM"MRLP6)O/2!@5C"*H0?H=_P31\6?"[QK^Q9X2U[X,^'
MO%.F^'1=ZQ:VB>.5E&M7<L&K7D%Q>Z@)E607=S/'+<S!U#"2=\@'B@#W>O*/
MVY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3
M_P!$I7._'O\ Y!NG?]=W_P#0171?"[_DF?AW_L!6G_HE*YWX]_\ (-T[_KN_
M_H(KQ\__ .115^7YH#S*BBBOR\"MJ^C:/X@T^32->TJVOK27;YMK>0++&^"&
M&58$'! (]P#7GW@O]CO]EWX=?&'4OCYX'^ OA/2O%VJVT4-SKEAX>MHIU">;
M\R.D89&<2L'8'+A4#9VBO2J*J,YQ32=K@%9GA[P7X.\)76IWWA7PGIFF3ZWJ
M!O\ 69M/L(X7O[LHD9N)B@!EE*1QJ7;+;449P!6G14W8')W_ , _@7JOQ&A^
M,.I_!;PE<^+K<J;?Q3/X<M7U*(JNU2MR8_-7"\##<#BMGQ9X+\'>/=*70O'/
MA/3-:L5N8KA;/5K".YB$T3B2*0)("-Z.JLK8RK $8(K3HJN>3:UV R/&W@#P
M'\2]#;PQ\1O!.D>(--:59&T[6]-BNX"Z_=8QRJRY&3@XR*E\(>#/!_P^\.VW
MA#P%X4TW1-)LU*VFEZ18QVUO "22$CC 5022>!U)K2HI<TK6OH 4444@"NS^
M!O\ R.$W_8/?_P!#2N,KL_@;_P CA-_V#W_]#2O2R;_D:4?\2 ]9HHHK]6 *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KP/Q7_ ,C3J7_80F_]#->^5X'XK_Y&
MG4O^PA-_Z&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 4444 %%%% !7N
M'PV_Y$;3?^N'_LQKP^O</AM_R(VF_P#7#_V8U]3PG_OT_P##^J W****^_ *
M*** "BBB@ KYL_;&L?\ @I-J/Q>T*P_8X^.WPB\&^$I/#<\FNS?$3PI<:E<C
M44N$$:QB&]@/ER12.<X8*ULV3\ZBOI.OC_\ ;T_8T_8;_:7_ &P/A!%^U/\
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M5?E^: \RHHHK\O **** "BBB@ HHHH **** "BBB@ KL_@;_ ,CA-_V#W_\
M0TKC*[/X&_\ (X3?]@]__0TKTLF_Y&E'_$@/6:***_5@"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *\#\5_P#(TZE_V$)O_0S7OE>!^*_^1IU+_L(3?^AFOD.+
MOX%+U?Y 9]%%%?# %%%% !1110 4444 %%%% !1110 5[A\-O^1&TW_KA_[,
M:\/KW#X;?\B-IO\ UP_]F-?4\)_[]/\ P_J@-RBBBOOP"BBB@ HHHH ****
M/A;P'\%?VVOVV=,O_B];?\%7/%?PV+:[?6UQ\-/AWX'T$1^%)(KF2/\ L^ZE
MO+:>YFNT55\UY&57<LT:(C**^B_V%OAMXC^$/[-]A\.?&'QPN/B1JNF>)O$:
MZAXUO51;C4IGUV_D8S+&JHLR%S$ZHH17C8* H%?EAX:\=_\ !L_\8_&7BSQ1
M_P %"_BMH&M?'6+Q/?VGQ(USQAXKUZ,W5U#<R1H+1H94MULEB6-(((@IAC58
MY$61'%?I=_P2]@_91MOV)/"L'[#ETTWPH75M?_X0N3?,Z&V_MR_W>6TY,C1>
M;Y@C9R6,>PGDT >_UY1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O
M_P"AK0!W7PN_Y)GX=_[ 5I_Z)2N=^/?_ "#=._Z[O_Z"*Z+X7?\ ),_#O_8"
MM/\ T2E<[\>_^0;IW_7=_P#T$5X^?_\ (HJ_+\T!YE1117Y> 4444 %%%% !
M1110 4444 %%%% !79_ W_D<)O\ L'O_ .AI7&5V?P-_Y'";_L'O_P"AI7I9
M-_R-*/\ B0'K-%%%?JP%;5]8T[0=/?5-5N/*@C(WR;"V,D < $]2*Q?^%M?#
M[_H8/_)27_XBF_%W_D0+W_>B_P#1BUXQ7RV=YYB\MQ:I4HQ:<4]4^[[-=@/:
M?^%M?#[_ *&#_P E)?\ XBC_ (6U\/O^A@_\E)?_ (BO%J*\?_6S,?Y(?<__
M )(#VG_A;7P^_P"A@_\ )27_ .(H_P"%M?#[_H8/_)27_P"(KQ:BC_6S,?Y(
M?<__ )(#VG_A;7P^_P"A@_\ )27_ .(H_P"%M?#[_H8/_)27_P"(KQ:BC_6S
M,?Y(?<__ )(#VG_A;7P^_P"A@_\ )27_ .(H_P"%M?#[_H8/_)27_P"(KQ:B
MC_6S,?Y(?<__ )(#VG_A;7P^_P"A@_\ )27_ .(H_P"%M?#[_H8/_)27_P"(
MKQ:BC_6S,?Y(?<__ )(#VG_A;7P^_P"A@_\ )27_ .(H_P"%M?#[_H8/_)27
M_P"(KQ:BC_6S,?Y(?<__ )(#V_3_ (E>"M5O8M.L-:\R:9PL:?9I!D_4KBMV
MO#/A]_R.NF?]?:U[G7TV1YE7S.A*=5)-.VE^WFV 4445[8!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %>!^*_^1IU+_L(3?^AFO?*\#\5_\C3J
M7_80F_\ 0S7R'%W\"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P
M^&W_ "(VF_\ 7#_V8UX?7N'PV_Y$;3?^N'_LQKZGA/\ WZ?^']4!N4445]^
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MB_\ 1BUXQ7L_Q=_Y$"]_WHO_ $8M>,5^>\5_\C*/^%?G( HHHKYD#P7XL?\
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M7R=XH^%VG?&C_@KQX/\ C-\/;"."/X-?#O5],^(/B&V0 :A>:I]G-AHSN/\
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MSOX ^"?BO\.OV8O#/PR\41^'[7Q7X>\'VNDI-IU[/>Z>UQ;VJ0I-EXH)"A9
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ME*YWX]_\@W3O^N[_ /H(KHOA=_R3/P[_ -@*T_\ 1*5SOQ[_ .0;IW_7=_\
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M=J*E.G5@X32:?1ZH#S#_ (9?T[_HKGBW_OG3?_D.C_AE_3O^BN>+?^^=-_\
MD.O3Z*Y?[-R[_GS#_P !7^0'F'_#+^G?]%<\6_\ ?.F__(='_#+^G?\ 17/%
MO_?.F_\ R'7I]%']FY=_SYA_X"O\@/,/^&7]._Z*YXM_[YTW_P"0Z/\ AE_3
MO^BN>+?^^=-_^0Z]/HH_LW+O^?,/_ 5_D!YA_P ,OZ=_T5SQ;_WSIO\ \AT?
M\,OZ=_T5SQ;_ -\Z;_\ (=>GT4?V;EW_ #YA_P" K_(#S#_AE_3O^BN>+?\
MOG3?_D.C_AE_3O\ HKGBW_OG3?\ Y#KT^BC^S<N_Y\P_\!7^0'F'_#+^G?\
M17/%O_?.F_\ R'1_PR_IW_17/%O_ 'SIO_R'7I]%']FY=_SYA_X"O\@/,/\
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M/_DVC_AAK]G'_H">)_\ PXVN?_)M>N44?VEF/_/Z?_@3_P P/(_^&&OV<?\
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M HHHH **** "BBB@ HHHH ^BH?\ 5+_NBG4V'_5+_NBG5^SK8 HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%
M:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M577?^0'>?]>DG_H)JU577?\ D!WG_7I)_P"@FLZW\*7HP/GVBBBOQL HHHH
M**** "BBB@ HHHH **** "BBB@#Z*A_U2_[HIU-A_P!4O^Z*=7[.M@"BBBF
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_
MY)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444
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MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
M,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^A0O?^^EH_P"$
MEU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH Q_^
M$EU?_H4+W_OI:K:QXBU632+J-_"=X@:V<%BRX'RGFNAJKKO_ " [S_KTD_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX;G_ &1_^B]:#_W^?_XF@#U>BO*/^&Y_V1_^B]:#_P!_G_\ B:/^&Y_V1_\
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M_/\ _$T?\-S_ +(__1>M!_[_ #__ !- 'J]%>4?\-S_LC_\ 1>M!_P"_S_\
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M_P#$T >KT5Y1_P -S_LC_P#1>M!_[_/_ /$T?\-S_LC_ /1>M!_[_/\ _$T
M>KT5Y1_PW/\ LC_]%ZT'_O\ /_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q- 'J]%>
M4?\ #<_[(_\ T7K0?^_S_P#Q-'_#<_[(_P#T7K0?^_S_ /Q- 'J]%>4?\-S_
M +(__1>M!_[_ #__ !-'_#<_[(__ $7K0?\ O\__ ,30!ZO17E'_  W/^R/_
M -%ZT'_O\_\ \31_PW/^R/\ ]%ZT'_O\_P#\30!ZO17DEO\ MW_LAW2&2+X\
M:* &(Q(9$.1[,@./>I/^&Y_V1_\ HO6@_P#?Y_\ XF@#U>BO*/\ AN?]D?\
MZ+UH/_?Y_P#XFC_AN?\ 9'_Z+UH/_?Y__B: /5Z*\H_X;G_9'_Z+UH/_ '^?
M_P")H_X;G_9'_P"B]:#_ -_G_P#B: /5Z*\H_P"&Y_V1_P#HO6@_]_G_ /B:
M/^&Y_P!D?_HO6@_]_G_^)H ]7HKSCPI^UW^S3XY\1VGA'PC\8]'O]2OY?*L[
M."5B\KXSM&5Z\5Z/0 4444 %%%% !1110 4444 %%%% &)+\-/AQ/*T\_P /
M]$=W8L[OI4)+$]23MY--_P"%7?#/_HG>A?\ @HA_^)K=HH PO^%7?#/_ *)W
MH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")K=HH PO^%7?#/_HG>A?^"B'_ .)H
M_P"%7?#/_HG>A?\ @HA_^)K=HH PO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#H
MG>A?^"B'_P")K=HH ^=? O@/P-+^WIX[TF7P9I+6D7@C2WBM6TZ(QHQD;+!=
MN 3ZU[;_ ,*N^&?_ $3O0O\ P40__$U!IGPI\(Z1\4=4^,%G#.-:U?38+&]=
MIR8S#$24 3L<GKWKI* ,+_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA
M_P#B:W:* ,+_ (5=\,_^B=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B:W:* ,
M+_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA_P#B:W:* ,+_ (5=\,_^
MB=Z%_P""B'_XFC_A5WPS_P"B=Z%_X*(?_B:W:* ,+_A5WPS_ .B=Z%_X*(?_
M (FC_A5WPS_Z)WH7_@HA_P#B:W:* ,+_ (5=\,_^B=Z%_P""B'_XFC_A5WPS
M_P"B=Z%_X*(?_B:W:* ,+_A5WPS_ .B=Z%_X*(?_ (FC_A5WPS_Z)WH7_@HA
M_P#B:W:* ,+_ (5=\,_^B=Z%_P""B'_XFO$OVI? ?@:P^,OP6MK'P9I,,=UX
MWE2YCATZ)5E7[,QVL OS#/8U]%5S?C?X4^$?B#XB\.>*/$<,[7?A;4FOM),,
MY15F*%"6'\0P>E $_P#PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\
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MX*(?_B:/^%7?#/\ Z)WH7_@HA_\ B:W:* ,+_A5WPS_Z)WH7_@HA_P#B:/\
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MK8#5=5%MXTL;GQ7I>E;=[7MSHJH$7RX_WDD$=W)-&H;*;E91Z[K'[4NK^/\
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M\%Q+!*8K&>SMXYI 89"L2W&Y\ *"S 5YO_P0R_Y,/_:F_P"SDOB5_**O3/\
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M]-TG2+V>QCM;= 2$^T3V\U]<.,>;/<D8"0PHE'X7?\K._P 4?^S1]'_]/:T
M:_[+_P#P5C_;&_:L^*OQ;^"G@K_@FE9:3XE^"NO6VD>,]+\0_&>&!VGG65X3
M;,FFO',CI"75RR JZ'.#Q[G^Q9_P4%\!?M?^)/&OP@U3X=>(OAW\4OAG?0VO
MC_X:>+UA^W:;YRE[>ZAE@=X;NTF4%HYXF(88)"[EW?.O_!*;_E++_P %"O\
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MH^J^*+_6[BWB"2ZKJ<=NEQ<G^^XMXHH@?]R-1QTJ_10 4444 %%%% !1110
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20220930_g17.jpg
<TEXT>
begin 644 biib-20220930_g17.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=KC/AK9^,F^'.@-!K%H
MJ'1+78K6Y) \E<#K6W]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?
M8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L
M45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_
M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_
M\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P
M&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B\;_]
M!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&
M[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8_P!B
M\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+Q
MO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T ;%%8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-
M'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (T
M;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8
M_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_
M (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;L
MO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]!NR_
M\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&_
M_0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B\;_]
M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
M8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\ C1]B
M\;_]!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q1
M6/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\ C0!L45C_ &+QO_T&[+_P&/\
MC1]B\;_]!NR_\!C_ (T ;%%9=G:>+4ND>^U:U>(-^\1+<@D>QK4H **** "B
MBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__
M $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#N
MOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NO
MA=_R3/P[_P!@*T_]$I6[7R)X6_X)-?LW>+?#&G>*M2\=_$R.YU.PAN[B.V\?
M74<:O(@=@BCA5R3@#H.*I^-?^"87[-'PYMX+J#5_'^J&Z<H4U3XBZGB/ SE?
M(FC.3GN37-C,53P6&E6FFTNV^]O(#['HKX7_ .&&OV<?^@)XG_\ #C:Y_P#)
MM'_##7[./_0$\3_^'&US_P"3:\'_ %LR[^2?W+_Y(#[HHKX7_P"&&OV<?^@)
MXG_\.-KG_P FT?\ ##7[./\ T!/$_P#X<;7/_DVC_6S+OY)_<O\ Y(#[HHKX
M7_X8:_9Q_P"@)XG_ /#C:Y_\FT?\,-?LX_\ 0$\3_P#AQM<_^3:/];,N_DG]
MR_\ D@/NBBOA?_AAK]G'_H">)_\ PXVN?_)M'_##7[./_0$\3_\ AQM<_P#D
MVC_6S+OY)_<O_D@/NBBOA?\ X8:_9Q_Z GB?_P .-KG_ ,FT?\,-?LX_] 3Q
M/_X<;7/_ )-H_P!;,N_DG]R_^2 ^Z**^%_\ AAK]G'_H">)__#C:Y_\ )M'_
M  PU^SC_ - 3Q/\ ^'&US_Y-H_ULR[^2?W+_ .2 ^Z**^%_^&&OV<?\ H">)
M_P#PXVN?_)M:O@[_ ()P?LU_$'57T2>;QOI@2 S?:--^(NK>8<$#:?.N)%Q\
MV>F>!SUSOAN),#BL1&C",KR=M4K?F!]IT5\I_P##GK]F'_HH/Q3_ /#B7='_
M  YZ_9A_Z*#\4_\ PXEW7T 'U917R'XH_P""4O[,O@K1)O$D7BCXCW[0%0+6
M_P#B)?\ E/N8+SY3HW&<C##D#.1Q7)_\,-?LX_\ 0$\3_P#AQM<_^3:\;,,\
MPF6UU2JQDVU?1+S[M=@/NBBOA?\ X8:_9Q_Z GB?_P .-KG_ ,FT?\,-?LX_
M] 3Q/_X<;7/_ )-KA_ULR[^2?W+_ .2 ^Z**^%_^&&OV<?\ H">)_P#PXVN?
M_)M'_##7[./_ $!/$_\ X<;7/_DVC_6S+OY)_<O_ )(#[HHKX7_X8:_9Q_Z
MGB?_ ,.-KG_R;1_PPU^SC_T!/$__ (<;7/\ Y-H_ULR[^2?W+_Y(#[HHKX7_
M .&&OV<?^@)XG_\ #C:Y_P#)M'_##7[./_0$\3_^'&US_P"3:/\ 6S+OY)_<
MO_D@/NBBOA?_ (8:_9Q_Z GB?_PXVN?_ ";1_P ,-?LX_P#0$\3_ /AQM<_^
M3:/];,N_DG]R_P#D@/NBBOA?_AAK]G'_ * GB?\ \.-KG_R;1_PPU^SC_P!
M3Q/_ .'&US_Y-H_ULR[^2?W+_P"2 ^Z**^(=#_X)_?LW>)=7M]!DL_%UHMW(
M(S<VOQ%UGS(\]UWW3+GZJ1[5V7_#GK]F'_HH/Q3_ /#B7=>OEV94,SIN=)-)
M.VMOT; ^K**^4_\ ASU^S#_T4'XI_P#AQ+NH[S_@D-^S%IUG+J"^.?BA*8(V
MD$4OQ$O-K[1G!VD'!QV(/N*[I248MOH!]845\+_\,-?LX_\ 0$\3_P#AQM<_
M^3:/^&&OV<?^@)XG_P##C:Y_\FU\U_K9EW\D_N7_ ,D!]T45\+_\,-?LX_\
M0$\3_P#AQM<_^3:/^&&OV<?^@)XG_P##C:Y_\FT?ZV9=_)/[E_\ ) ?=%%?"
M_P#PPU^SC_T!/$__ (<;7/\ Y-H_X8:_9Q_Z GB?_P .-KG_ ,FT?ZV9=_)/
M[E_\D!]T45\+_P###7[./_0$\3_^'&US_P"3:/\ AAK]G'_H">)__#C:Y_\
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M:_9Q_P"@)XG_ /#C:Y_\FT?\,-?LX_\ 0$\3_P#AQM<_^3:/];,N_DG]R_\
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M^(EQ?Z-=BYM8=4\<7-Q;NX!&)(VX=>>AKZ,KV "BBB@ HHHH **** "BBB@
MKRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P
M[_V K3_T2E<[\>_^0;IW_7=__0171?"[_DF?AW_L!6G_ *)2MVN/,,)]>PDJ
M'-;FMK:_5/R ^<Z*^C**^7_U0_Z?_P#DO_VP'SG179_MW_M&ZW^R%^QE\3_V
MH/#7@IO$6H> _!6H:U9:-E@MS+!"SJ)"OS"($!G(Y"*Q'2OBS]F[XJ?MX?%C
MXA6WQX_9[_;P\/?%[0-:7X87GB[3X?!,'V Z/J.L74.JC2A;2AK"2V@6<O\
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M:*Z<'PQ]4Q4*WM;\KO;EM_[< 4445]6!S7Q=_P"1 O?]Z+_T8M>,5[/\7?\
MD0+W_>B_]&+7C%?GO%?_ ",H_P"%?G( HHHKYD HHHH **** "BBB@ HHHH
M**** -GX??\ (ZZ9_P!?:U[G7AGP^_Y'73/^OM:]SK[WA+_<ZG^+]$ 55UW_
M ) =Y_UZ2?\ H)JU577?^0'>?]>DG_H)KZ>M_"EZ,#Y]HHHK\; **** "BBB
M@ HHHH **** "BBB@ HHHH ^BH?]4O\ NBG4V'_5+_NBG5^SK8 KP/Q7_P C
M3J7_ &$)O_0S7OE>!^*_^1IU+_L(3?\ H9KY'B[^!2]7^0&?1117PP!1110
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M[EQMPVYLYR:VO#?AKPYX-\/6/A+PAH%EI6E:9:1VNFZ9IMJD%O:01J%2**-
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MW/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[
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M[#45SPCPWSP0L1@-#>2%]QBBV^V5E*#C!2Z/] "BBBH ^BH?]4O^Z*=38?\
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MJGCC_@GWX3^,&NWLB:_\39]5\7Z]J,>UI3=ZE?W%P"-P*_NHWBB0$%0D*+C
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M$S?O--\.2Q?#OP>Y^Z4LF^T:M.G^_?S"U?WTA>!W]H\(>#/!_P /?#EMX/\
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M;_UP_P#9C7U/"?\ OT_\/ZH#<HHHK[\ HHHH **** "BBO+_ (^M^U7XI=/
M'[,MUX:\+--%NU3X@^+K!]1CL >D=GIT4L1NY\<EYIHH8]R8%P=\: 'J%%?'
M]U_P2_\ VA?$]S_PD/CS_@LG^TU)K+$LS^&;KPUI.GANVVRCT=U"C^Z6/'4]
MZ[WX/_#S]O']GG6;?2_B#^T!8_'3P;*XCGN]9\-6VB^*-+7H)1)9[;+4D'&Z
M,PVLH4,RR3/MB8 ^@Z\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
M7_\ 0UH ZGX9^+/#</PX\/PRZQ"K)HEHK*3T(A3BMS_A,?#'_0:@_P"^JS_A
MA86+?#7P\S641)T.T))C'/[E*W/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"
M8^&/^@U!_P!]5<_L[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\
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M'_OT* *?_"8^&/\ H-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\
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MK7_/*#_P,B_^*KW7^SM/_P"?&'_OT*/[.T__ )\8?^_0H_U3R[^>?WK_ .1
M\*_X1;6O^>4'_@9%_P#%4?\ "+:U_P \H/\ P,B_^*KW7^SM/_Y\8?\ OT*/
M[.T__GQA_P"_0H_U3R[^>?WK_P"1 \*_X1;6O^>4'_@9%_\ %4?\(MK7_/*#
M_P #(O\ XJO=?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"C_5/+OYY_>O_D0/"O\
MA%M:_P">4'_@9%_\51_PBVM?\\H/_ R+_P"*KW7^SM/_ .?&'_OT*/[.T_\
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M_P"A?_\ )N7_ .+KHZ*YZN$PE>7-5IQD^[2?Y@<Y_P *E^'W_0O_ /DW+_\
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M&:]\KP/Q7_R-.I?]A";_ -#-?(<7?P*7J_R SZ***^& **** "BBB@ HHHH
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@
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MHT:*58ADB5CAF84 ?1%>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
MO_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110
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M_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\
MT2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?_(TZE_V$)O\
MT,U[Y7@?BO\ Y&G4O^PA-_Z&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110
M 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_]</\ V8U]3PG_ +]/
M_#^J W****^_ **** "BBB@ HHKY,_X*'?L\?MU_M$?&#X<3?L%_MG6?P6U#
MPOI>NKXR\2R^%[37B\%T=.^S6AL+K,;&1H))!(V-@@;!R<$ ^>'_ &@/V9/A
M[^V/\=? 7QF_X)(?%GXMZ];?$%YKKXKZ%^SZ/$D5Y'+9VLL&GR7+JS)]FMY(
M$BCC+1F PR'8\CH/JO\ X)L?$CX+_$_P5\1=<^!O[*?B'X.Z;;?$M[6_\*^*
M/!?_  CUY-=KHVE,UVUA@>0'1HE4X_>+&)/XZ^>X?^"=W_!?:VDFFM_^#@?2
MXWN)!).Z?LJ^&P9'"JH9B#R=JJN3V4#L*]^_X)S_  5_:S_9E^&_Q&L/V\?V
ME;7XE^)=1^),VJV_Q!;28-)AOM-;2=,@B/V2'$5IY;P2Q%%^7*%LG?F@#Z5K
MRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#I/AK9^,F^'
M.@-!K%HJ'1+78K6Y) \E<#K6W]B\;_\ 0;LO_ 8_XU%\+O\ DF?AW_L!6G_H
ME*W: ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E
M_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W
M9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7
MC?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[
M%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK
M8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_
M (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E
M_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-
M_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7
MC?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MB
MB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\
M@,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_
M (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_
M .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P" Q_QH^Q>-
M_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\:V**
M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
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M%_P5TT^X-AX7_P""Q.B3Z=G$<WB;]FW3+K4%7L6EM;^UA=NG(@49YP>E>A_
M_P#8B\0>%?$UG\3?VHOVH_&GQJ\6:?*LVF3>)HK33M%TJ9?NS6FD:?%%;+*O
M\,\XGG3G9*NYL^^44 %>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L
MO_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5X'XK_Y&G4O^PA-_Z&:]\KP/Q7_R-.I?]A";_P!#-?(<7?P*7J_R
M SZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\ (C:;_P!</_9C7A]>
MX?#;_D1M-_ZX?^S&OJ>$_P#?I_X?U0&Y1117WX!1110 4444 %%%% !1110
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX
M=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5_\ (TZE_P!A";_T,U\AQ=_ I>K_ " SZ***^& **** "BBB@ HHHH ****
M"BBB@ KW#X;?\B-IO_7#_P!F->'U[A\-O^1&TW_KA_[,:^IX3_WZ?^']4!N4
M445]^ 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:
M/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7@?BO_D:=2_["$W_ *&:]\KP/Q7_ ,C3J7_80F_]#-?(
M<7?P*7J_R SZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO_7#_
M -F->'U[A\-O^1&TW_KA_P"S&OJ>$_\ ?I_X?U0&Y1117WX!1110 4444 %%
M%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\
M+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M@?BO_D:=2_["$W_H9KWRO _%?_(TZE_V$)O_ $,U\AQ=_ I>K_(#/HHHKX8
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M &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U;%% &/_P@^D?\_-[_ .!;4?\
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MLM/T^W4$+M2")R53C$0"!AD;TZUV%%1/%5ZL%"<FTG?7SM_D!Y)^S'^RO;?
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M_P#BZ/\ A4OP^_Z%_P#\FY?_ (NNCHH_LW+O^?,/_ 5_D!SG_"I?A]_T+_\
MY-R__%UN:;IMEH]C'ING0^7!"NV--Q.!]22:GHK6CA,+AY<U*G&+\DE^0!11
M170 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
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M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
M-*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH
M TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
M-*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3
M'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#
M'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH
M TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q
M\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_
M $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J
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MJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\
MGQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0
MH_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__
M )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ*
M (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQ
MA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y\8?^_0H_
ML[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (?[.T_P#Y
M\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_[]"IJ* (
M?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (?[.T__ )\8?^_0H_L[3_\ GQA_
M[]"IJ* (?[.T_P#Y\8?^_0H_L[3_ /GQA_[]"IJ* (DL;*-@\=G$K#H5C (J
M6BB@ HHHH **** "BBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5ZBOK"QU2T
MDT_4[**XMY5VRP3QAT<>A4\$4 8_PN_Y)GX=_P"P%:?^B4K=KQ#4?V!/@MJ6
MH3ZC)XG\:QM<3-(T<'BZX1%+$G"J#A0,\ =!47_#O?X)_P#0V^.__"RN?\:
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M#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\ C0![I17A?_#O?X)_]#;X[_\
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MGC@37>E6\TOE^,+E5W-$K' SP,GI0!]$T5X7_P .]_@G_P!#;X[_ /"RN?\
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M,!<0>*M2LHQ9^*;B)/*AG*)D \MCJ>]>J?\ #O?X)_\ 0V^._P#PLKG_ !H
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M^('BSX6?L\_$^YU_Q!X$G6#QGIC^%M3LGT2=GD18;DW5M$(92T,P$;$.?*?
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M:\,?LL_M$Z)XLU;P]&LNL:1!'/;7EO"Q 6;R+F..1H22H$JJ4RR_-\PS[;0
M4444 %%%% !1110 445XCK__  46_9 \*_M1Z5^Q7XC^)FH6?Q1UW>VB>$)_
M!FKK/J$2+*SSP/\ 9?+F@589F,Z.8@L3DMA20 >W45YI^TQ^U_\ L^?L?:)H
MGB/]H;QK=:%9>(]:31]$GM_#M_J'VN_D5FCM5%G!*1*X5RB$ OL;;G:<>8P?
M\%?_ -@*Z\=W'PNMOBEXFD\36FG+J%UX=C^$_B8W\-HS;%N'MQIWF+$6^4.5
MVD\9S0!],T5\K>!/^"U__!-3XHOJZ?#7X^ZGX@_X1^X$&OG1?AQXANAI<A+#
M9<F.P(@.4?A]OW&]#7NOP$_:,^!'[4GP\@^*_P"SK\6M!\9^'9YGA75?#^H)
M<1I,F-\,FTYBE7(W1N%=<C(% %+]FOX,ZG\#/ 5[X0U76H+^2Z\0WVHK-;QL
MJJL\I<)@]P#@UZ#7%?%O]HOX(? C6_!_ASXO_$G3M OO'WB:+P]X.M;YV#:K
MJ<JLT=M'@'YF"G!.!G SE@#S/[67[=_[(O[#.@Z;XB_:L^.6D^#X-8DE32H;
MN.:XN;ORE#2O';VZ22ND892\@38FY=Q&X9 /6Z*YGX-_&?X4?M"_#/2/C+\#
M_B#I7BGPKKUM]HTC7=%NUGM[E-Q4[67NK*RLIPRLK*P!! G\4?%#P%X+\7>&
M? ?B?Q+#::QXQOKBS\-6#HS/?306LMW,J[00H2"&1RS87@#.YE! -^BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\OC]#'^T'_P<
M<?"']G_XJG[1X0^%'[.U_P#$WPEHMWS;7?B:;6#I8N6C/RR206_[R(G+1,&9
M=I.3L?\ !R)X5TS3_P#@E_XF_:<T74QHOCOX*Z]HWB[X<>*H<+<:5JD>I6T.
M$?KMECF>)DSM8LF0=HKUS]N;]@CQ)^T#\5_AY^UU^SI\2;3P3\9_A4]W%X<U
MK4[&2XTW6M+NTV7>CZC%$Z2-;R#E)4;S(')D0$G%?&7[17_!*C]N7QKX@\/:
MQX_\$IXA^#4'BW2=6^*O[/?@7XYZIXBNO&TUD\LD5]'=^*(;6. B8P-/9K-&
MMTD63*)8XV8 ^Q/VX?BI\2?"_P"P3XI\9_"G]CS4O&^N^/O 5S/X@L-)%E';
MV$MQIL<,EQJ*22K=7:1PD*8[6&ZG=+41A/N5Z!_P3R\.^!_!_P"P7\&/!_PT
M^*L7CGP_I'POT*QT?QC &":S;PV$,:72JWS('"[@C?,F=IY!JIKWB+]NSQ=X
M%N[OX9?#+P9X=O=?LG;24\?^(72_\*NZE%%S;:=#=VVHNA FVQW4*G?Y/F'9
MY[[W[%G[+GA7]BC]E'P#^REX+URZU33O OAN#2X]4O4"RWLB#,L[*"0F^1G?
M8"0N[:"<9H F_:$_99^%W[3&M?#G6_B5:2RR_##XB6GC/PZ(2H_XF-M;7,$6
M\D'Y!]I9\#&61.>*V_$_ASX1^ O$>M_M*>-?[.TZZLO"8L]8\2:I,J1V.DVK
MSW3Y=_EACS([R$8#".,MGRTQUU?('_!0?X(?\%.OCG\5_#%G^S,OP(N?AAH(
MCU#4_#'Q/U;6E?7M620/ UU'8VQ5K6W95D2#S"LDH5Y 1&B  3_@C)^SIJ?P
M2_9I\>>)Y/"UUX5T;XN?&?Q-X^\&^$)K8VTOAW0]1F06%L8"!]E9H(4N3!@>
M4UR4(#*0.6_X*N?LN?#;XJ?LQ?"S_@F_\#_!MG8^)=8\?>'Y_ )L81YOA'3=
M(O[:[U+7 WWHUBM%DMS*2#)/J$,>2\PS] ?LP6O_  4%MO!7BC7/VS+_ .$]
MUXJEE">$- ^&LFHQ:1##'#E7N;F]B:X\V6=V5RJ,D<<49168ON^7?AY\"?\
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M[J=K&$A\3>)8]2:]NI05XG-A EM9M,<D222P9S;NJ^N?\% ?"'[=/Q"^!3^
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MOB/X]\1^+/#][IOC?58[2UN-62,&VN ^D[]D3*S"1,EP0NQ/OUE?L0_L??\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
6444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20220930_g18.jpg
<TEXT>
begin 644 biib-20220930_g18.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
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M /\ :Z\YHH_UASC_ )^_^2Q_R ]&_P"%_P#_ %*7_D__ /:Z/^%__P#4I?\
MD_\ _:Z\YHH_UASC_G[_ .2Q_P @/1O^%_\ _4I?^3__ -KH_P"%_P#_ %*7
M_D__ /:Z\YHH_P!8<X_Y^_\ DL?\@/1O^%__ /4I?^3_ /\ :Z/^%_\ _4I?
M^3__ -KKSFBC_6'./^?O_DL?\@/1O^%__P#4I?\ D_\ _:Z/^%__ /4I?^3_
M /\ :Z\YHH_UASC_ )^_^2Q_R ]&_P"%_P#_ %*7_D__ /:Z/^%__P#4I?\
MD_\ _:Z\YHH_UASC_G[_ .2Q_P @/HM&WH&QU&:6FP_ZI?\ =%.K]-6P!111
M3 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
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M3P_^VEX3T7P3XL^-WQ#\'Z?HNL1ZH(_ &M6]BU[<Q,KV[3M+;S%Q#(HD105
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "JNN_\ (#O/^O23_P!!-6JJZ[_R [S_ *])/_03
M6=;^%+T8'S[1117XV 4444 %%%% !1110 4444 %%%% !1110!]%0_ZI?]T4
MZFP_ZI?]T4ZOV=; %%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>
M_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH *JZ[_R [S_ *])/_035JJNN_\ (#O/^O23
M_P!!-9UOX4O1@?/M%%%?C8!1110 4444 %%%% !1110 4444 %%%% 'T5#_J
ME_W13J;#_JE_W13J_9UL 4444P"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC
M]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_
MZ)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *JZ[_P @.\_Z])/_ $$U:JKKO_(#
MO/\ KTD_]!-9UOX4O1@?/M%%%?C8!1110 4444 %%%% !1110 4444 %%%%
M'T5#_JE_W13J;#_JE_W13J_9UL 4444P"BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7K
MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
ML!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKKO_(#O/\ KTD_]!-6JJZ[
M_P @.\_Z])/_ $$UG6_A2]&!\^T445^-@%%%% !1110 4444 %%%% !1110
M4444 ?14/^J7_=%.IL/^J7_=%.K]G6P!1113 **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7
M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKKO_ " [S_KTD_\
M035JJNN_\@.\_P"O23_T$UG6_A2]&!\^T445^-@%%%% !1110 4444 %%%%
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\
MH4+W_OI:V** ,?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6MBB@#'_X275_^
MA0O?^^EH_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O
M?^^EK8HH Q_^$EU?_H4+W_OI:K:QXBU632+J-_"=X@:V<%BRX'RGFNAJKKO_
M " [S_KTD_\ 036=;^%+T8'S[1117XV 4444 %%%% !1110 4444 %%%% !1
M110![E%XEU81J/\ A$+S[H_B6G?\)+J__0H7O_?2UK0_ZI?]T4ZOV=; 8_\
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M0ZMX8U[3YH[J"17C/EW-M,A((:-R Z'YD=ADAB" =#7E'[<__)H_CW_L O\
M^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R
M3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC6KN6#5KR"XO=0$RK(+NYGCEN9@ZAA).^0#Q0![O7E'[<_\ R:/X]_[ +_\
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M [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@
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M0 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZOV=; %%%%, HHHH ****
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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M):L0MTP&3"M;?_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M@^D?\_-[_P"!;4P-BBL?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJ -BBL?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\
ML O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7
M?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5==_P"0'>?]>DG_
M *":M55UW_D!WG_7I)_Z":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@
M HHHH **** /HJ'_ %2_[HIU-A_U2_[HIU?LZV ****8!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__ ":/
MX]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2MVL+
MX7?\DS\._P#8"M/_ $2E;M !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 55UW_D!WG_7
MI)_Z":M55UW_ ) =Y_UZ2?\ H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH
M**** "BBB@ HHHH ^BH?]4O^Z*=38?\ 5+_NBG5^SK8 HHHI@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_
M /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?
M^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !577?\
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M45*E.E!SFTDNKT0&A17.?\+:^'W_ $,'_DI+_P#$4?\ "VOA]_T,'_DI+_\
M$5R_VEEW_/Z'_@2_S Z.BN<_X6U\/O\ H8/_ "4E_P#B*/\ A;7P^_Z&#_R4
ME_\ B*/[2R[_ )_0_P# E_F!T=%<Y_PMKX??]#!_Y*2__$4?\+:^'W_0P?\
MDI+_ /$4?VEEW_/Z'_@2_P P.CHKG/\ A;7P^_Z&#_R4E_\ B*/^%M?#[_H8
M/_)27_XBC^TLN_Y_0_\  E_F!T=%<Y_PMKX??]#!_P"2DO\ \11_PMKX??\
M0P?^2DO_ ,11_:67?\_H?^!+_,#HZ*YS_A;7P^_Z&#_R4E_^(H_X6U\/O^A@
M_P#)27_XBC^TLN_Y_0_\"7^8'1T5SG_"VOA]_P!#!_Y*2_\ Q%7="\<^%O$M
MX;#1=4\Z98RY3R'7Y00,Y90.XJH8_ U)J,*L6WT4E?\ ,#6HHHKK **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ JKKO_(#O/^O23_T$U:JKKO\
MR [S_KTD_P#036=;^%+T8'S[1117XV 4444 %%%% !1110 4444 %%%% !11
M10!]%0_ZI?\ =%.IL/\ JE_W13J_9UL 4444P"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_
M /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E<[\>_\
MD&Z=_P!=W_\ 0171?"[_ ))GX=_[ 5I_Z)2N=^/?_(-T[_KN_P#Z"*\?/_\
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M_H ^BBN,^#?[0WP6_:#C\1S?!?XA6/B*/PEXFN/#WB&;3]Y2TU.!8WEM]S*
MY594)9"R_-P3@XA1DTVEH@.SHHHI %=G\#?^1PF_[![_ /H:5QE=G\#?^1PF
M_P"P>_\ Z&E>EDW_ "-*/^) >LT445^K %%%% !1110 4444 %%%% !1110
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M'XE6?AO6/%-BUYXDUR358[6;0] #F.6:)V8%;JX<-;VY'*MYTXW?961O(/\
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MI)_Z":M55UW_ ) =Y_UZ2?\ H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH
M**** "BBB@ HHHH ^BH?]4O^Z*=38?\ 5+_NBG5^SK8 HHHI@%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_
M /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29^'?^P%:?
M^B4KG?CW_P @W3O^N[_^@BNB^%W_ "3/P[_V K3_ -$I7._'O_D&Z=_UW?\
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M ,9H ^C**^<_^'MW_!.C_HZ31?\ P O/_C-'_#V[_@G1_P!'2:+_ . %Y_\
M&: /HRBOG/\ X>W?\$Z/^CI-%_\  "\_^,T?\/;O^"='_1TFB_\ @!>?_&:
M/HRJNN_\@.\_Z])/_037S[_P]N_X)T?]'2:+_P" %Y_\9JOJW_!6?_@G;<Z5
M<VT'[4.BL\ENZHOV&\&25('_ "QK.JFZ4DNS L45XM_P\4_8H_Z.$T7_ +]S
M_P#QNC_AXI^Q1_T<)HO_ '[G_P#C=?E']FYC_P ^9_\ @+_R ]IHKQ;_ (>*
M?L4?]'":+_W[G_\ C='_  \4_8H_Z.$T7_OW/_\ &Z/[-S'_ )\S_P# 7_D!
M[317BW_#Q3]BC_HX31?^_<__ ,;H_P"'BG[%'_1PFB_]^Y__ (W1_9N8_P#/
MF?\ X"_\@/::*\4?_@HO^Q/&A=OV@]'P/[L,Y/Y".E'_  45_8H(!'[0FC<^
ML4__ ,;H_LW,?^?,_P#P%_Y >U45XM_P\4_8H_Z.$T7_ +]S_P#QNC_AXI^Q
M1_T<)HO_ '[G_P#C=']FYC_SYG_X"_\ (#VFBO%O^'BG[%'_ $<)HO\ W[G_
M /C='_#Q3]BC_HX31?\ OW/_ /&Z/[-S'_GS/_P%_P"0'M-%>+?\/%/V*/\
MHX31?^_<_P#\;H_X>*?L4?\ 1PFB_P#?N?\ ^-T?V;F/_/F?_@+_ ,@/O.'_
M %2_[HIU?.,?_!6S_@G2L:J?VH]%R%&?]!O/_C-._P"'MW_!.C_HZ31?_ "\
M_P#C-?K2V ^C**^<_P#A[=_P3H_Z.DT7_P  +S_XS1_P]N_X)T?]'2:+_P"
M%Y_\9I@?1E%?.?\ P]N_X)T?]'2:+_X 7G_QFC_A[=_P3H_Z.DT7_P  +S_X
MS0!]&55UO0M$\2Z9+HOB/1K74+.;;YUI>VZRQ2;6#+N1@0<, 1D<$ ]J^??^
M'MW_  3H_P"CI-%_\ +S_P",T?\ #V[_ ()T?]'2:+_X 7G_ ,9H [;P'^PW
M^R'\+_CCJO[2'P^_9Q\%Z/XUUBUA@N_$&G>&;2&Y41^=EHY$C#1NXF82,"#(
M%0-G8,>K5\Y_\/;O^"='_1TFB_\ @!>?_&:/^'MW_!.C_HZ31?\ P O/_C-
M'T917SC'_P %<O\ @G-*NY?VH]''./FTZ]'\X*=_P]N_X)T?]'2:+_X 7G_Q
MF@#Z,HKYS_X>W?\ !.C_ *.DT7_P O/_ (S1_P /;O\ @G1_T=)HO_@!>?\
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MO",FGVW@K3);>P?PW:F&*1G;<ZH8]JL>Y R:]J_X9?\ V:?^C>/ O_A)6?\
M\:K5TSX4^$=(^*.J?&"SAG&M:OIL%C>NTY,9AB)* )V.3U[UTE '#?\ #+_[
M-/\ T;QX%_\ "2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT
M_P#1O'@7_P )*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5=S10!PW_  R_^S3_
M -&\>!?_  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\
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ME'*$@\,.AXK2T;2K30='M-#T]6$%E;1P0!VR0B*%7)[G % ''_\ #+_[-/\
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M  DK/_XU1_PR_P#LT_\ 1O'@7_PDK/\ ^-5W-% '#?\ #+_[-/\ T;QX%_\
M"2L__C5'_#+_ .S3_P!&\>!?_"2L_P#XU7<T4 <-_P ,O_LT_P#1O'@7_P )
M*S_^-4?\,O\ [-/_ $;QX%_\)*S_ /C5=S10!\N?L(_L_P#P&\1_![5+[Q#\
M$O"-_.GC75XDFO?#=K*ZQK<$*@+1DA0. .@KVK_AE_\ 9I_Z-X\"_P#A)6?_
M ,:K5^%OPI\(_![P[/X7\%PSI:7&I7%](+B<R-YTS[W.3VST':NDH X;_AE_
M]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\
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MSX:?!3PCX=\2>,3\2)_%WB#0O#=K:7VMRKHL#+)>3Q1K)<L#(Y#2,Q!=CW-
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M\<ZSXJE#7'C;XE>*X]8U>R1(?*AAMI'@6*.*)FEE2,Q,OF32,P8-BO /#/\
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M^MW%O$$EU74X[=+BY/\ ?<6\440/^Y&HXZ5?HH **** "BBB@ HHHH ****
M/"?^"A7[ ?PY_P""DO[/]Y^S%\9_BEXUT'P=JMS!-KNG>#+NQMWU/R)X[B%)
M9+FTG<*DT4;@1E,E1NW#BO3O"WP[UWPQ\++;X;O\8/$VHWMK8"UC\7ZE'I[:
MFQ PLK!+1;9I ,<F#!QD@G)KJ** /E+]F?\ X)-^ OV3?@K\0O@1\(_VKOC
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M):EX[\%:CX1TCQ]K/A>XU"V,*:]X>%M]MM,]7B^U0S1!L9&6C;&<C!P1M44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
1HHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20220930_g19.jpg
<TEXT>
begin 644 biib-20220930_g19.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
M\FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2
ME;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:
M/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\ 1*5N
MT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P F
MC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)
MH_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9)GVQ, ?0=>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T
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MP%:?^B4KG?CW_P @W3O^N[_^@BO'S_\ Y%%7Y?F@/,J***_+P"BBB@ HHHH
M**** "BBB@ HHHH *[/X&_\ (X3?]@]__0TKC*[/X&_\CA-_V#W_ /0TKTLF
M_P"1I1_Q(#UFBBBOU8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "JNN_\ (#O/^O23_P!!-6JJZ[_R [S_ *])/_036=;^%+T8'S[1117XV 44
M44 %%%% !1110 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZOV=; %%%%
M, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP>__ *&E<979_ W_ )'";_L'O_Z&E>EDW_(TH_XD!ZS1117ZL 4444 %%%%
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M7N/*@EEB193\P$<C \DX8L  ?6]>4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\
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M_P#D&Z=_UW?_ -!%=%\+O^29^'?^P%:?^B4KG?CW_P @W3O^N[_^@BO'S_\
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M4O\ NBG4V'_5+_NBG5^SK8 HHHI@%%%% !1110 4444 %%%% !1110 4444
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M_P!=W_\ 017CY_\ \BBK\OS0'F5%%%?EX!1110 4444 %%%% !1110 4444
M%=G\#?\ D<)O^P>__H:5QE=G\#?^1PF_[![_ /H:5Z63?\C2C_B0'K-%%%?J
MP!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5==_P"0'>?]>DG_
M *":M55UW_D!WG_7I)_Z":SK?PI>C ^?:***_&P"BBB@ HHHH **** "BBB@
M HHHH **** /HJ'_ %2_[HIU-A_U2_[HIU?LZV ****8!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__ ":/
MX]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2N=^/
M?_(-T[_KN_\ Z"*Z+X7?\DS\._\ 8"M/_1*5SOQ[_P"0;IW_ %W?_P!!%>/G
M_P#R**OR_- >94445^7@%%%% !1110 4444 %%%% !1110 5V?P-_P"1PF_[
M![_^AI7&5V?P-_Y'";_L'O\ ^AI7I9-_R-*/^) >LT445^K %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 55UW_ ) =Y_UZ2?\ H)JU577?^0'>
M?]>DG_H)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^B
MH?\ 5+_NBG4V'_5+_NBG5^SK8 HHHI@%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KU
MY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*YWX]_\@W3O^N[_P#H
M(JY\-?$6JQ?#G0(D\*7;A=$M0'5EPP\E>:I_$RQ\3^,K2U@T_P *W2&"1F;>
MR\Y 'K7E9W3J5<KJ0@FV[:+5[H#S*BMW_A6?CK_H7)O^^E_QH_X5GXZ_Z%R;
M_OI?\:_.?[-S'_GS/_P%_P"0&%16[_PK/QU_T+DW_?2_XT?\*S\=?]"Y-_WT
MO^-']FYC_P ^9_\ @+_R PJ*W?\ A6?CK_H7)O\ OI?\:/\ A6?CK_H7)O\
MOI?\:/[-S'_GS/\ \!?^0&%16[_PK/QU_P!"Y-_WTO\ C1_PK/QU_P!"Y-_W
MTO\ C1_9N8_\^9_^ O\ R PJ*W?^%9^.O^A<F_[Z7_&C_A6?CK_H7)O^^E_Q
MH_LW,?\ GS/_ ,!?^0&%16[_ ,*S\=?]"Y-_WTO^-'_"L_'7_0N3?]]+_C1_
M9N8_\^9_^ O_ " PJ[/X&_\ (X3?]@]__0TK)_X5GXZ_Z%R;_OI?\:W_ (<^
M'/%OA'7I-3OO#%PZ-:M& C+G)93Z^U>AE6 QU/,J4ITI))[N+M^0'J%%8_\
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M_@+_ ,@,*BMW_A6?CK_H7)O^^E_QH_X5GXZ_Z%R;_OI?\:/[-S'_ )\S_P#
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M"EQXZ\%ZEX-M_$=[I']J6K6LVHZ9)LN8(G^60PO_ ,LY-A8+)R48A@"1BI/
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX
M=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P"AM\=_^%E<_P"- 'NE%>%_\.]_@G_T-OCO_P +*Y_QH_X=[_!/_H;?'?\
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M+^"'P$U3PCHOQB^).G>'[KQ[XJM_#?@^"_=@VJ:K.&,-K'@'YVV'&<#.!G+
M'F_VL/VZ?V2OV&_#NG>*/VJ_C?I7@^VU>66/2HKN.:>YO#$H:5HK>W22:1(U
M92[JA5 R[B-PR >LT5R_P6^-GPD_:,^&.D?&CX%?$32O%?A77K<SZ3KNBW:S
M6]R@8JV&'1E965E.&5E96 ((KR73O^"JW_!._5?VE5_9!L/VL_"DGQ#DU232
MX-!\^0)-?H=KV4=R4%O)<JWR&!9#('^0KNXH ^@J*** "BBB@ HHHH ****
M"BBH=1U'3](T^?5M6OH;6UM86FN;FXE"1PQJ"S.S-@*H ))/  H FHKYSTW_
M (*U_P#!.S5;^TAM?VGM)33M0U(:?I_BNYTV]A\/W=T7*+%#K$D"V$K%P5&R
M<[CP,FO5OC9^T5\'OV=]%L=<^+'BN2R75+HVVDV.GZ5=:C>W\H4NRV]I9Q2S
MSE4!9O+C;:HRV!S0!VU>??&/X,ZG\3?'O@#Q?8ZU!:Q^#O$+ZC<PS1L6N%,1
M38I'0Y.>:UO@M\<?A'^T5\/+/XK?!#Q_IWB7P_?/)'!J6FS;E$L;F.6%U(#1
M2QNK(\3A71E*LH((JY\5?BG\/?@?\-==^,/Q8\56NA^&?#.E3:EKNL7A/E6=
MK"A>21MH)("@\ $GH 2<4 ;]%<)XG_:=_9]\%?L^I^U7XN^+NB:;\.I-"MM9
MB\7WMX([.2QN$1[>96/WO-$D810"SF154%F KGOV3OV\?V0_VYM&U?6_V4_C
MKI'C!/#]VMMKMK:++!=Z=(V[8)[:X2.:(-M?:S( VQMI.TX /7**P/BG\4/
M7P3^'&N?%SXI>)8='\.>'-,FU#6M3N$9EMK>)2SOM0%F.!PJ@LQP "2!6_0
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M+I5;YD#A=P1OF3.T\@U4U[Q%^W9XN\"W=W\,OAEX,\.WNOV3MI*>/_$+I?\
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M%[NWB?\ NI,\,+2#W,:'VH OT444 %%%% !1110 4444 ?F-_P %8=,\1?\
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MM301O-<7;K)<7,A:5PTI!#N'7[,H **** "BBB@ HHHH *^.O^"R/["/C_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20220930_g2.jpg
<TEXT>
begin 644 biib-20220930_g2.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK 'W117Y5_"GXL?\%9/C#^PSX-_:U^"_PR^-_B+XU^*M'TWQ;I\UWXD\$P>
MM6M;LQW/]DC3GUH2V]B;63RDN/*2_#A9)'W;HZ_4G0KW4=2T.SU'5]&DTZ[N
M+2.2ZT^69)&M9&4%HBZ$JQ4DJ64D'&02* /E#]IW_@HK^T?\ OAQ\6?V@O#O
M[$5GKOPT^%/]HM/XCU+XFKIM[K4>GQ?Z;+;60L)L(EPEQ IDD7S# 6 "LIKD
M;W_@K+^TKX4\$? GXR?$+_@G]:6G@3X[^+/">B:1XAT?XMPWDVC'7Y8%M);J
MU?3X6.$FR5C+C<FTLNX-7I7_  6K_P"42'[1O_9'M=_]))*^4_VN;#QAJO\
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M.?,H ^Q_C7\1;[X1?"3Q'\4=.\#W_B2;P_I$]^-#TNX@BGNQ$A=E5[B2.->
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M@'PC\3-7\.VI^&7Q"37=7TV8?VE+8(NB%HH9Y WE22R")6F \P(TA0I(5D0
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MD,9%OEXBD494[@#](**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)OB?X,W43V'B;PM';7=UIL[@_:M-NO,^RW\)XWPNT,\1X!2:VF3D!'< \O\
M^">O_!.[X<?\$V_A9??!;X-_&#Q]XB\-WFLW.JQV'CB^L+IK6[N&#SR1RV]G
M!)\[ L5=F4%F( )-9MY_P32\%7G[?\7_  4??]I#XGKX[@\+'PQ%IR76C_V2
MNA&Y:Y_LWR#IN\Q><QDWF3SMW/F5])44 ?(.D?\ !(3P_P"%OVC?B)^U9X&_
M;N^/>@^-/BI)IY\;ZAI>I^'52^2Q@,%G&(WT5EB2*(E%"!21RQ8\UZ!^S?\
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MT!;_ +5GQ?L?$?Q U[0=8UF?3M0T6*."ZT:)H=/,"C2_D1(W9'C8LDRDB42
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MU"$W4RQWL]O&$\I(6WL?/W<9G_!+'X2?ML>*OV9_CEX9^#'QY\'Z1X=\;_M
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MQGX O?A;XLNL?+IUVU]'J6BSN>T<DXOK/)X\Z]MD',@KZ3\2?\)%_P ([?\
M_"(_8O[6^Q2_V7_:6_[/]HV'R_-V?-Y>_;NV\XSCF@#XX_X*C? 'P9^T1\./
MA-_P3<^$OABSM=2O/'/A[6[5=-MPJ^"O#6B7<,]QJ2[>(,QQKI\ X,DEYM7Y
M4E9/K_5_!/A37O$ND>,-:T2&YU'03.VC7,V6-F\T?ER2("=H<Q[DWXW!'D4$
M"1PWP?\ #/\ 9"_X+H_#F_\ $VM6?[6_[-TFN>--2-SXC\97/PRUFXU4H"RP
M11;[_P A(K6-BD$'E^4OS,RL\LKR>Z_\%#_@!^VQ\?O@[HOP=_9&^,W@KPW:
MSW(7QY=^/--OKF36K! @%B#8RP/''/\ O!.R,CLGR*5#O0!Q?[#GPKL/B-_P
M4"_: _X**>#[-+3P?XYL-"\(>$[N!-B>)QI"3+=ZUQQ+"TTHM8)?^6D=FTBD
MQR1LUK]KC6[OX:?\%5OV3/%^@N87\=6_C;P/XB$9_P"/NR_LE=8MPX_B\JYT
ML%3_  ^?)_>-=9^Q]\+/^"D'@[QL9_VP/C3\(;WPAI?ATV'ASPE\)/ UWI42
M3[X@DLS7=Q,0D4,;1QQ1%$_>DL#M3&;\1_ 6H?M"_P#!4KX:^(K"W8^'?V>?
M"6M:IJVH 923Q%KEO%96EDIZ>9%IRWL\@Y*K>VA( E4D ]D_:4\4_''P?\(K
M[5_V<_ VDZ_XM:]LK>R@U^_6WL;.&6ZBCN;^X)DC,D5M;M+<-"CJ\HA\M"&<
M$>5?L._MJ:I^T=\9?C)\ O$/BOP?XHO?A5JFB_9O&7@.VD@TW6+'4['[3$5A
MDN;K9+%+%<PN5GD5MBL-A+(N_P#\%$_V6_B'^V%^S)>?!KX7?$NQ\,ZQ_P )
M!I&K0R:SI[W>F:FEC?0W3Z=?P1NC36=P(C%*@;E6Y##*GC_V8_V-_P!I;X-?
MMM?$G]J?QY\8?!&IZ5\6/#GA]/$^@Z)X4NK62RU#2K>XM88[222ZD MC%.&9
MI SN\?"QJVT '-ZI^UK^W7XQ_P""G_C']@CX;Z!\,-"\.:%\,--\96?CC6=+
MU#59H([B]N;06TUK'=V@FEE: LH62-8E1R7E.U3AZ+_P52^)OB;X4^'? >A?
M#?P]+\;=?_:$UGX.FQ::<:';ZEI3W4E[K)&?/:S6QM?M2V^\2%IHX?,',P])
M\)?LO_M&^&_^"E'CC]M:XF\$S^'/%/PVT[PA9: FK7B7L":?=WEU!=O(;8QD
MRO=LCQ ?NQ@AY"F'\@^'O_!*G]H+3[/Q%XE\2?$_P=H_C6V_:8U7XS_#?Q)H
ML%U>P:;>7Z&"XT:^MI5A:YM9+62>%YHY8G/F*ZHIC&X RTG_ &G++_@OO\*/
M"O[0]UX.U>VM/V>/%MQX=\4>#M&NM+CO5EU'25GMYK*YNKMHI(6B0[UG=9%G
M7Y4*D'[Z\9>$/#?Q!\(ZKX"\9:3'?Z1K>G3V&JV,I(2YMIHVCEC8J0<,C,#@
M@X-?)NF_L/?MI^+?^"E7@[_@H%\4OVA/ -GIWACP'J'A7_A7FB>$[RYB6TN;
MB">62.\ENHF^T2/$"96BV(L42"%SND/U)\5X/BC=?#77+7X)ZCHEGXNETV5/
M#MWXDMY9;""[*XCDGCA*O)&IY*JREL8R,Y !\L?M\_"32OVM?VM_V<?V?O 6
MG1?VE\(OB?8?%+QAKMK&!_PCND6,%U%:V188VOJ%TT<:0Y^:&SN9""(A4_[0
M5U/XD_X+3_LX^#M>XTO0?A)X]\1:,C?=EU4RZ18%QZO':W-P >H6X?LQKA_V
M=_V/O^"TGPBBA\)Z]^UG\ FTW6_$D>I?$+Q;I?P[U5_$NLEY(Q=7(GN+U[<7
M+0((HLP^3 B11QQ)%$D:_2'[5/[+OB#XP^.OAS\?_A-XLL=#^(GPJU>\N?#=
MWJ]H\]CJ%C?6_P!FU#3+I(V5Q%/&L3B1"6BFMH)-KA&C< \G_9FNKCP__P %
MD_VHO!FA\Z5JWP]^'WB+5(T^Y#JKQZK8LY X#R6ME:@D\D6Z>E)_P5>^$O@W
MQ;^P-K?_  3^^%'@?3[GQ+\9VD\.^"_#[1>8L=U<7(N;S6I\Y81V>Z6_FN&R
MQD5!EIIHP_K7[*7[+NN_!?Q=\1/CG\5O%MEKWQ%^*VNVU_XIU#2K-[>QLK6S
MMEM;#3+1'9G\FWA#$R.=TLL\\I"!Q&GS;9?LJ?\ !;_0OC=XO^.FA_M)?LT7
M.K^)I#;6%SK_ ,/M=NIM$TE6W0Z9:LE_&D<*M^\<A-TTIWR%ML80 ^T]%^&J
M:%\'[+X0Z?XMU:!;'P[#I,.N6TZK?((X!"+A796 E^7=D@C=S@U\9?\ !'?X
M0Z-\"?VI/VS_ (8:#XH\0:U;V/QMTN8ZKXJUB34-0NI;CPYIUS*\UQ)\TA,D
MSXST7"C@"OM3X5Z%XV\,?#30/#WQ+\9+XB\1V>CV\6OZ\EHMNNH7HC43SK$@
M"Q(\FYE0<*I"]J\)_8S_ &7/V@/@5^TM\=OC1\4K[P=<:9\9?%MEX@MK+0-0
MNY)]&DMM-MM/6W8S6Z+<J\=LKF4>65;(V,&!4 ^E:^*_^"6_AO0_VI/V3/C9
MX\^*%JU['\;?C1X^B\11NW[QM.BOI] M[4L<\1V&GP1+V 7IS7VI7R__ ,$[
M_ .H?LT>.?C1^R3KMNT,%I\4-4\;^!7(Q'>:!KT[7V(R>IM]0?4+9UY*!(&;
MB9"0#VKP/^SS\*/ /PO\!?!_2O#*3Z)\-;+3[;PC;WC;_LGV*T-I;2$#"NZ1
M$X)& V' #*I'SC\-/A98_'C_ (+&>)?VVO ]HD7AKX;_  BD^&-SKT"[5\1:
MY+JBWMW"CC_70V"PQPNW07-Q+$#NMI /7?V\/AO^U_\ %WX WGPX_8K^+OAG
MP+XHU:Z2&_\ $WB2RNIC;:>0WG+;?971XIW^5!*&#1JSLA60(Z^:_L<?L_\
M_!3;X4>+O#'A;X\_&?X&VGPM\*Z9+!:^$/A+X U#3Y[EA"8K>*26]NYPL"%C
M*=@61GC3+%2X(!YY_P ''GP&TKXL?\$I_B[XPUOXB>+]/A\*>#Y=1@T'1-=:
MTT_49XY8WC-Y$BYN45@"(V;9D*2I*@C[G\-_\B[8?]>47_H KQ'_ (*;?LQ?
M$_\ ;3_8D\>?LG?"O6M!TF]\?:.VE7.M^()9O*T^!F5GE6*&-C,^%VA2R ;M
MQ8[=K>O^ !XMT[P#IL?Q)M]*M-6M;%4U,:3>R36@9!@NCRQQMM( ;#*-N2,M
MC<0#YA_X)Z:W=>%?VT/VP_V;[1R=$\-_%K2?$VC1D\6[:_H-G?7D:CH%-ZMS
M-CNUP[?Q5]=5\P_\$WOAYJNHZW\9_P!M#Q%9203?';XEG6?#J2H5<^&M/L;;
M2M(E*GIY]O9F\7OLO4! 8,*^GJ "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "H=1L(-4T^?3+
MF298[F%HI&MKEX9 K @E9(RKHV#PRD,#R"",U-10!Y[^SS^RQ\"OV4] U+PK
M\!/!L^@Z;JVJS:GJ%B=;O;N*6\F<O-<!;F:0+)([%G9<%V.6R>:]"HHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *VLZ-I/B'2
MY]$UW38+RSN8REQ;7,8=)%]"#P:L@8&*** "BBB@ JKI>BZ1HB31Z1IL-L+F
MYDN+CR8POFS.<O(V.K$]2>:M44 %%%% !1110 4444 %%%% !1110 4444 %
M5;G1=(N]5MM<N=-A>]LHY$M+MHQYD22;?,16ZA6V(2O0E%)Y48M44 %%%% !
M5;6-'TKQ#I5SH6NZ=#>65Y"T-W:7$8>.>)AAHW4\,K D%3P02""#5FB@  "@
M*H  ' %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %<S\9?B98_!OX7:W\4-3TR
M:]M]%LC<RVL#A7D (& 3P#S735Y1^W/_ ,FC^/?^P"__ *&M 'I7AS68O$?A
MZP\0P0M&E_917"1N<E Z!@#[C-7:POA=_P DS\._]@*T_P#1*5NT %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O
M_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[
MZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC
M_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$
MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[
MZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC
M_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJ@#2HK-_P"$
MQ\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
MOJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH TJ*S?^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJ@#2HK-_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZH QOC1\<?A)
M^SM\/[KXI?&WQ]I_AO0;.6**74-1E(#S2N$BAC4 O++([*B1(&=V(55).*\O
M_98_X*6?LB?M>^(Y?A_\*_B6D?BZ*ZU@-X+UFSFLM7%IIVHR6,EZUI.B2QP.
MZ*59U4CS C!9%=%\[_X*U_ 3X[?M'_";P%\0/V,_B!X<M_B;\'/B98^.O"FA
M^*RW]E:_+;6]S;O87!&/++QW+[),C:PQNCW>:GSW_P $AO\ @H;^S-^T1\9K
M?X._M&?#C5OA7^TQX+UWXA3KX5UZ!6M[RUU;Q+=7VHP:=?*"M]%!-$D;8*$M
M:2,JNBLP /TF^*/Q,\"?!;X:^(/C!\4?$<.C^&O"VBW6K:_JMPK,EG9V\32S
M2D("S!41CA06., $X%;D<B2QK+&<JP!4^HK\\?\ @Y$^&Z_%G_@EI\5?%6G_
M +37C?P]8>&O"AO9_!OABYT^'3_$$J7$91;YY+.2[>,9YBBN(D; W*V*^]]/
M\8^&!80#^VH/]2O\7L* .4_:>_:O_9Z_8R^%DGQJ_:;^)MIX3\,1ZA!8G5+N
MWFF#7,S%8HEC@1Y'9B#PJG@$G !->5?LZ?\ !8C_ ()O?M9_%[3?@-^SS^TQ
M:^)?%NKPW$NGZ/!X<U2%I4@B:65B\]JD:A44G+,.< 9) /MOB?3_ (2>--7T
M+7?%=M87]UX9U1M2T"6YRWV*\-O-;>>@Z"00W$R!B,@2MC&:\,^&7BKP[\=/
M^"A_COXOW.K0R:%\'?#</@+PN['*-K%^+?5-;F3L=L*Z);AARKQ729^\* .D
M_:R_X*>_L)?L,^,M,^'W[5/[05CX2UK6=,.HZ;I\VDWUU)-:B1H_-_T:"0*N
M]64;L9*G'2O6?A-\5/ _QP^&^C?%SX::G<7OA_Q#8I>Z/>W.F7%FUS;ORDHB
MN(XY%5A\REE&Y2&&003\E?$OPQ^WEX*_;K^)G[6/[/O@OX2>)M$U3P#X<\.:
M!I7C/QK?:??W4&FOJ-[/% ;>RFBMS-<:DZ"29CS;J2@7#5!^TK_P42T3XX?\
M$/?B=^VM\!6U#0M4U#X-^()K'3[QMM]H>IPPW-I<1,4./-M;F.9=PX)AR.#0
M!]%?#7]M?]EWXP?$,?"WX=?%NTU'6)_MG]E@65S%:ZQ]DD\N[_L^ZEC6WU'R
M'^67[+)+Y1X?;7J=?GK^W/8_#[]G_P#8)_9@U+X1W-K!=?"GXL_#*'PDEF-K
M&WENK;2+B!2,';-8WES&X'WE<YK[X_X3'PQ_T&H/^^J .%^,7[8/[/'P(\51
M> _B)XZG&O/I+:K+H6AZ#?:O>VNG*Y0WUQ!80326UJ&#+]HE5(LJPWY4X[;P
M+X[\%?%#P;IGQ%^&_BW3M>T#6K*.\TC6=(O$N+6]MY%#)+%(A*NC @@@D5\4
M_#3XR_#3]C;_ (*+_M-^/?VIO%*>']*^)K>%]:^'_C+4;:5K/4M.L='6SFTJ
M*9%91=6]U'<2"TSYL@O1)&C[FQ8_X((?$?0?%G[ <OQ'TXR:7X5\7?%GQMKO
MP^TB\C,;6&@W7B"]EM(1&?\ 5K@NP7@8?(X(H ^Y**S?^$Q\,?\ 0:@_[ZH_
MX3'PQ_T&H/\ OJ@#2HJA;>*/#]Y.MK:ZK$\CG"(IY)J_0 4444 %%%% !111
M0 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =K\,+"
MQ;X:^'F:RB).AVA),8Y_<I6Y_9VG_P#/C#_WZ%9'PN_Y)GX=_P"P%:?^B4K=
MH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?
M&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C
M^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\
MGQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH
MA_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'
M_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^S
MM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQ
MA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_
ML[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/_P"?&'_O
MT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_[]"C^SM/
M_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[3_\ GQA_
M[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*FHH A_L[
M3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\ ^?&'_OT*
MFHH A_L[3_\ GQA_[]"C^SM/_P"?&'_OT*FHH A_L[3_ /GQA_[]"C^SM/\
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M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 1)8V4;!X[.)6'0K& 14M%% !1110
M4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O
M_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
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MB--L:1C]DO#_ (>T#PGHEIX9\+:'9Z9IMA;K!8Z?I]LD,%O$HPL<<: *B@<
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M,711_K__ -0W_D__ -H'_$I7_4Y_\MO_ +N?TZ45_,711_K_ /\ 4-_Y/_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "L+XI:=9ZO\,O$>DZC#YEO=:#>0SQ[B-R-
M"ZL,C!&03TYK=K(^('_(AZW_ -@BY_\ 135%76G+T9TX)N.,IM;\R_-'Y,?\
M,6_LS_\ 1-?_ "LWO_QZC_ABW]F?_HFO_E9O?_CU>I45^1_5L-_(ON1_<?\
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ME&#?M9WYI)-65]5JM;]]-#YM_P"&+?V9_P#HFO\ Y6;W_P"/4?\ #%O[,_\
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M@BY_]%-45/X;]#IP?^]T_P#$OS/SJHHHK\J/[+"BBB@ HHHH **** "BBB@
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M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\
M),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D?$#_D0];_[!%S_
M .BFK7K(^('_ "(>M_\ 8(N?_135%3^&_0Z<'_O=/_$OS/SJHHHK\J/[+"BB
MB@ HHHH **** "BBB@ HHHH **** /THLO\ CSB_ZY+_ "J2H[+_ (\XO^N2
M_P JDK]76Q_%LOB85^>GQ<_Y*MXG_P"QAO?_ $>]?H77YZ?%S_DJWB?_ +&&
M]_\ 1[U\QQ/_  :?JS]=\(O]_P 5_AC^;.>HHHKX\_=0HHHH **** "BBB@
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M>!_]&/7T?#7^^3_P_JC\K\6O^1'0_P"OB_\ 29'>4445]J?S^%%%% !1110
M4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M
M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[WVTMT^\US.M7P\(5*<FES13T5K.23<KZ[;<NSU>FWGE%%%<YZ@5]X?LP_\
M)!/#/_7@?_1CU\'U]X?LP_\ )!/#/_7@?_1CU]'PU_OD_P##^J/ROQ:_Y$=#
M_KXO_29'>4445]J?S^%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\
MH:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/
MP[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %9'Q _Y$/6_^P1<_P#H
MIJUZR/B!_P B'K?_ &"+G_T4U14_AOT.G!_[W3_Q+\S\ZJ***_*C^RPHHHH
M**** "BBB@ HHHH **** "BBB@#]*++_ (\XO^N2_P JDJ.R_P"/.+_KDO\
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M1'0_Z^+_ -)D>H45EV=IXM2Z1[[5K5X@W[Q$MR"1[&M2OM3^?PHHHH ****
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M_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %9'Q _Y$/6_^P1<_^BFK7K(^('_(AZW_ -@BY_\
M135%3^&_0Z<'_O=/_$OS/SJHHHK\J/[+);*RN]1NX[&PMWFFE<+%%&N69CT
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MBLSJ/THLO^/.+_KDO\JDJ.R_X\XO^N2_RJ2OU=;'\6R^)A7YZ?%S_DJWB?\
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MK-K'A'6],NM)UO3HR=H>?3KZ*&YC3=\HD,>PD8#&@#U^O*/VY_\ DT?Q[_V
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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M,_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH
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MB4K=K"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%%
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MBBB@ HHHH *^\/V8?^2">&?^O _^C'KX/K[P_9A_Y()X9_Z\#_Z,>OH^&O\
M?)_X?U1^5^+7_(CH?]?%_P"DR.\HHHK[4_G\**** "BBB@ HHHH _-7QC\&O
MV9_VC?VT?BUXK^-?_!4?QW\&_B%IOB$:0_@+X8_%NQ\(H=&MXD%C>7"HGFZI
M+*A9FN97?RCFU41_9BM?3G_!-OX5_"GX0>"_B)X7^$?[6/B7XR64GQ*>XO\
MQ5XO\8C7]0@NFT;2E:SEO@ )MB)&R@?<654ZJ:U/$O\ P2Y_X)U>//B5XJ^,
M'Q/_ &)?A9XO\2^,M734M;UCQAX"T[5)WF6U@M@$>YA=HT*0*Q4'!=Y'/+FN
MZ_9Y_9:^ /[*&A:YX2_9R^%>B>#-#U_Q VM77A_PWI<-E807;6MM;.T-O BI
M$&2UC8A1RY=OXJ /0*\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V
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M?S9SU%%%?'G[J%%%% !1110 4444 %%%% !1110 5]X?LP_\D$\,_P#7@?\
MT8]?!]?>'[,/_)!/#/\ UX'_ -&/7T?#7^^3_P /ZH_*_%K_ )$=#_KXO_29
M'>4445]J?S^%%%% !1110 445\Y?MY_\%3/V1O\ @FEKO@I?VQ?&]QX6\/\
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M3=#&<+T/WV /M&O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *R/B!_P B'K?_ &"+G_T4U:]9'Q _Y$/6_P#L$7/_ **:
MHJ?PWZ'3@_\ >Z?^)?F?G51117Y4?V6%%%% !1110 4444 %%%% !1110 44
M44 ?I19?\><7_7)?Y5)4=E_QYQ?]<E_E4E?JZV/XME\3"OST^+G_ "5;Q/\
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M_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %9'Q _Y$/6_^P1<_P#HIJUZR/B!_P B'K?_ &"+G_T4U14_AOT.
MG!_[W3_Q+\S\ZJ***_*C^RPHHHH **** "BBB@ HHHH **** "BBB@#]*++_
M (\XO^N2_P JDJ.R_P"/.+_KDO\ *I*_5UL?Q;+XF%?EW\;_ /DM/B__ +&C
M4/\ TIDK]1*_+OXW_P#):?%__8T:A_Z4R5^@\ ?[W7_PK\SX3CC_ ':CZO\
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M +H'_$S7_4I_\K__ '$] HKS^BC_ (@M_P!1_P#Y2_\ N@?\3-?]2G_RO_\
M<3T"BO/Z*/\ B"W_ %'_ /E+_P"Z!_Q,U_U*?_*__P!Q/0**\_HH_P"(+?\
M4?\ ^4O_ +H'_$S7_4I_\K__ '$_6BR_X\XO^N2_RJ2HK#_CQ@_ZXK_(5+7A
MVMH?*WYM0K\N_C?_ ,EI\7_]C1J'_I3)7ZB5^7?QO_Y+3XO_ .QHU#_TIDK]
M X _WNO_ (5^9\-QQ_NU'U?Y'+T445^H'YP%%%% !1110 4444 %%%% !111
M0 5^D7['W_)M/A'_ +!S?^C7K\W:_2+]C[_DVGPC_P!@YO\ T:]?#<>_\BRE
M_C_]M9]GP3_R,:G^#]4>E4445^4'Z:%%%% !1110 4444 %%%% !7E'[<_\
MR:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4
MK=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110
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M>Y^_K8*_+OXW_P#):?%__8T:A_Z4R5^HE?EW\;_^2T^+_P#L:-0_]*9*^_X
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M!^SI_P!%$_\ *1=__&J/K^!_Y^Q_\"7^8?ZM<1_] =7_ ,%S_P CTNBO-/\
MAL#]G3_HHG_E(N__ (U1_P -@?LZ?]%$_P#*1=__ !JCZ_@?^?L?_ E_F'^K
M7$?_ $!U?_!<_P#(]+HKS3_AL#]G3_HHG_E(N_\ XU1_PV!^SI_T43_RD7?_
M ,:H^OX'_G['_P "7^8?ZM<1_P#0'5_\%S_R/2Z*\T_X; _9T_Z*)_Y2+O\
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M>OAN/?\ D64O\?\ [:S[/@G_ )&-3_!^J/2J***_*#]-"BBB@ HHHH ****
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M_MC_ /)O.N?]=;3_ -*8J^(J^'XD_P!_C_A7YL_H;PG_ .2<J?\ 7V7_ *3
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M_![4?A/_ ,)MH,FG^*;%]?FTN2X5;?5+FT9@EO;-"Z2O&DLTT4;&0H2C1C]
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M*,DTM]&VN^BN[IV/-****XCW@HHHH [3]G7_ )+EX7_["\7\Z^^*^!_V=?\
MDN7A?_L+Q?SK[XK[3AG_ '2?^+]$?@?BW_R.,/\ ]>__ &YA6'\3_P#DFGB+
M_L!7?_HEZW*P_B?_ ,DT\1?]@*[_ /1+U]5A_P"/#U7YGY%7_@2]'^1^5]%%
M%?T4?@@4444 %%%% !1110 4444 %%%% !1110!^L]A_QXP?]<5_D*EJ*P_X
M\8/^N*_R%2U_.#W/W];!7Y=_&_\ Y+3XO_[&C4/_ $IDK]1*_+OXW_\ ):?%
M_P#V-&H?^E,E??\  '^]U_\ "OS/A^./]VH^K_(Y>BBBOU _. HHHH ****
M"BBB@ HHHH **** "OTB_8^_Y-I\(_\ 8.;_ -&O7YNU^D7['W_)M/A'_L'-
M_P"C7KX;CW_D64O\?_MK/L^"?^1C4_P?JCTJBBBOR@_30HHHH **** "BBB@
M HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
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M2:3!/#;&W18PR$K<2;]SODA<;<$'4\9_ SP=X]^,7@KXU>([N_DU#P#%J?\
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M3?$:9+CQ_I_@+4[&*VUN[6!+?[85O+.X>SNF@CCB:XLVMY'$:,S%T5P 9/\
MP20\:_"'QY_P3<^$.K_ CX>7GA+PQ9>%$TFR\-W]\+J;3IK"62QN87N %%P1
M<6\W[_:OF_?VKNP/HRN7^"GP7^&/[.OPF\/_  -^#'A&WT+PMX7TR.PT32;9
MF9;>!!@ LY+.Q.69W)9V9F8EB2>HH **** "BBB@#S#]L?\ Y-YUS_KK:?\
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M\-@?\%NO^BB?^4CPU_\ &J/^&P/^"W7_ $43_P I'AK_ .-4?ZY8'_GS5_\
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M_MC_ /)O.N?]=;3_ -*8J^(J^'XD_P!_C_A7YL_H;PG_ .2<J?\ 7V7_ *3
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MP7_R6>\_[%Z?_P!'05WY5_R,:7J?,\9?\DMB_P# S[ HHHK])/Y1/,/VQ_\
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M^B7KZK#_ ,>'JOS/R*O_  )>C_(_*^BBBOZ*/P0**** "BBB@ HHHH ****
M"BBB@ HHHH _6>P_X\8/^N*_R%2U%8?\>,'_ %Q7^0J6OYP>Y^_K8*_G7_:]
M_P"3LOBA_P!E$UO_ -+YJ_HHK^=?]KW_ ).R^*'_ &436_\ TOFK]6\*?]^Q
M/^&/YGY?XG_[GA_\4OR1YW1117[:?C@4444 %%%% !1110 4444 %%%% !7[
MW?\ !+;_ ), ^&/_ & G_P#2F:OP1K][O^"6W_)@'PQ_[ 3_ /I3-7YCXI_\
MB6C_ -?/_;9'Z/X9?\CBM_U[?_I43WZBBBOPD_;0HHHH **** "BBB@ HHHH
M *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS
M\._]@*T_]$I7BO\ P4(_Y%GPW_U_S_\ H"U[5\+O^29^'?\ L!6G_HE*\5_X
M*$?\BSX;_P"O^?\ ] 6O+SK_ )%E3Y?FC[#@'_DKL+ZR_P#2)'RU1117YV?U
M(%=-\-K+Q[!/>^,OAU=W<5_H4*7#FR4F01,P1C@?>49&00003G@&N9JQI^K:
MII,GG:5J5Q;/D'=;S,AR.AR#VJZ4E":;O\MSGQ5*=;#RA&VO\RNFKZIKS5T>
MU_&FYT#XB_#?4_'7B7PM%IOB'2Y=-CAU:"/RUU<SPJTB,O1G0;F)'( 4<#BN
M-^&\X\?V>G^$/%V@1W&DZ [S-K#W;6ZZ?;.^^197 (="V2J##EF(5N<5R?BK
MQMXK\;W<=[XJU^ZOGBC5(OM,[.$ 4+P"3C.T$^IY-49-3U*6PCTN74)VM8F+
M16S2L8T8]2%S@&NRKC(U,1[2W37;WM;Z_A]W<\/!9'5PV6+#<UG>\;.3]G[J
MBU!W3_F:6B7,U;E5GT_Q.\1S?%_XL7>H^%-'E9+ZXCM=(L8H_G\I%6*)0HZ$
MJH..Q)JAX2U_7_ 'B:YLUT;SY)XI=-U/2;F-OWZ.=KPL%PP;< 1CD,H/:L2T
MN[NPNH[ZPNI()H7#Q30N59&!R"".01ZU+;ZSJ]I>R:E::K<Q7$N[S9XYV5WW
M?>RP.3GOZUSNLY5/:-^\W<]2.!A2PBPL4G2C%12=[Z:*[]+:[WUN>B_$G4_#
M_@GX66OPKTG1?L6J:AJ(U'7H'O//EME5"L,$C!5 ?YF8H "G /)->8T$DG).
M2>I-%*M6=:=[625DO+^M7YE9?@HX&BX<SE*3<I-WU;]6W9*R6KLDM7N%%%%8
MG<%>V?L%_P#)9[S_ +%Z?_T=!7B=>V?L%_\ )9[S_L7I_P#T=!7?E7_(QI>I
M\SQE_P DMB_\#/L"BBBOTD_E$\P_;'_Y-YUS_KK:?^E,5?$5?;O[8_\ R;SK
MG_76T_\ 2F*OB*OA^)/]_C_A7YL_H;PG_P"2<J?]?9?^DP"BBBOGS]."BBB@
M HHHH **** "BBB@ HHHH [3]G7_ )+EX7_["\7\Z^^*^!_V=?\ DN7A?_L+
MQ?SK[XK[3AG_ '2?^+]$?@?BW_R.,/\ ]>__ &YA6'\3_P#DFGB+_L!7?_HE
MZW*P_B?_ ,DT\1?]@*[_ /1+U]5A_P"/#U7YGY%7_@2]'^1^5]%%%?T4?@@4
M444 %%%% !1110 4444 %%%% !1110!^L]A_QXP?]<5_D*EJ*P_X\8/^N*_R
M%2U_.#W/W];!7\Z_[7O_ "=E\4/^RB:W_P"E\U?T45_.O^U[_P G9?%#_LHF
MM_\ I?-7ZMX4_P"_8G_#'\S\O\3_ /<\/_BE^2/.Z***_;3\<"BBB@ HHHH
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M)",20,^N#["J-3).+LS:$U4@I*]GKJFG\T[->CU"O;/V"_\ DL]Y_P!B]/\
M^CH*\3KVS]@O_DL]Y_V+T_\ Z.@KNRK_ )&-+U/F^,O^26Q?^!GV!1117Z2?
MRB>8?MC_ /)O.N?]=;3_ -*8J^(J^W?VQ_\ DWG7/^NMI_Z4Q5\15\/Q)_O\
M?\*_-G]#>$__ "3E3_K[+_TF 4445\^?IP4444 %%%% !1110 4444 %%%%
M':?LZ_\ )<O"_P#V%XOYU]\5\#_LZ_\ )<O"_P#V%XOYU]\5]IPS_ND_\7Z(
M_ _%O_D<8?\ Z]_^W,*P_B?_ ,DT\1?]@*[_ /1+UN5A_$__ ))IXB_[ 5W_
M .B7KZK#_P >'JOS/R*O_ EZ/\C\KZ***_HH_! HHHH **** "BBB@ HHHH
M**** "BBB@#]9[#_ (\8/^N*_P A4M16'_'C!_UQ7^0J6OYP>Y^_K8*_G7_:
M]_Y.R^*'_91-;_\ 2^:OZ**_G7_:]_Y.R^*'_91-;_\ 2^:OU;PI_P!^Q/\
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M2P6Z.0(=KL""[+O8XY4(!U8'*\2?&BZ\1:3=Z9%\.?"FFR7J[9K_ $S23'<
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MZTKS22;WU]7J_5ZO=A7MG[!?_)9[S_L7I_\ T=!7B=>V?L%_\EGO/^Q>G_\
M1T%=>5?\C&EZGA\9?\DMB_\  S[ HHHK])/Y1/,/VQ_^3>=<_P"NMI_Z4Q5\
M15]N_MC_ /)O.N?]=;3_ -*8J^(J^'XD_P!_C_A7YL_H;PG_ .2<J?\ 7V7_
M *3 ****^?/TX**** "BBB@ HHHH **** "BBB@#M/V=?^2Y>%_^PO%_.OOB
MO@?]G7_DN7A?_L+Q?SK[XK[3AG_=)_XOT1^!^+?_ ".,/_U[_P#;F%8?Q/\
M^2:>(O\ L!7?_HEZW*X_]H?_ )(!XY_[$[4__222OJ\,KXB"\U^9^0XAVP\W
MY/\ (_,.BOS_ **_J/\ L?\ O_A_P3^:_P"V/[GX_P# /T HK\_Z*/['_O\
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M$_\ Z#__ "E0_P#E9T'_  G7_4+_ /(__P!C1_PG7_4+_P#(_P#]C7/T4?\
M$->"?^@7_P GJ?\ R8?\1M\3_P#H/_\ *5#_ .5GK/[,_C'[;\?O"5I_9VWS
M-:B7=YV<<_2OT3K\TOV6?^3B?!W_ &'8?YU^EM?&\2Y!E/#^*A1P%/DC)7:O
M)ZW:^TV]CV<MXMXAXOI2Q&;UO:S@^5/EA&RWM:$8K=]=0KC_ -H?_D@'CG_L
M3M3_ /222NPKC_VA_P#D@'CG_L3M3_\ 222O#PO^]4_\2_,Z\5_NT_1_D?SA
MT445_7A_*04444 %%%% !1110 4444 %%%% !1110!_3'HO_ "!K3_KUC_\
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M4%RMVOS:[7;MRM:6?VD%.CAYT)2<WS)7MRZ;V6O-?KV9Y111178<AW_[+/\
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M)O\ "C_A*=!_Y_O_ "$W^%<?11_Q![AG_G]6_P# H?\ RL/^)CN./^@?#?\
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MHKY #Q_]O+_DUWQ#_P!=K+_TKAK\\Z_0S]O+_DUWQ#_UVLO_ $KAK\\Z_6^
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M_P!))*^+PO\ O5/_ !+\SZ[%?[M/T?Y'\X=%%%?UX?RD%%%% !1110 4444
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M110 4444 %?O=_P2V_Y, ^&/_8"?_P!*9J_!&OWN_P""6W_)@'PQ_P"P$_\
MZ4S5^8^*?_(EH_\ 7S_VV1^C^&7_ ".*W_7M_P#I43WZBBBOPD_;0HHHH **
M** "BBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH
M [KX7?\ ),_#O_8"M/\ T2E?._\ P5!_Y%+PE_V$;G_T6E?1'PN_Y)GX=_[
M5I_Z)2OG?_@J#_R*7A+_ +"-S_Z+2OH>%?\ D?T/5_\ I+/"XF_Y$=;T7_I2
M/CBBBBOV\_'#Z)\%?$;P1\4O!NH?#/\ :,T=M)O=)TBULD\8Z>H^T+;BXA$*
M3K@B158QG>/X<]"2Q\?^+'@OQ%\(OBMJOA'4];:XU'2K\,-2AD8-(2%D24'.
M58AE;KD'N<9K?L_VC+U[>]E\1?#OPWJ5]-8V]K;7<^GLN%A>,H)51U68*L8
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MT?\ 5+O_ "M__:*/^&Z/^J7?^5O_ .T5^]?V=C/Y?Q7^9^)?VC@_YOP?^1]
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M^4@HHHH **** "BBB@ HHHH **** "BBB@#^F/1?^0-:?]>L?_H(JS5;1?\
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M\6_"BZ\5>+_[+TKPK87MJR>)IA,9978-N?JR\<#M7J?_  [J^!__ $-WCO\
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MCO\ \*^>O>J* /!?^'=7P/\ ^AN\=_\ A7ST?\.ZO@?_ -#=X[_\*^>O>J*
M/!?^'=7P/_Z&[QW_ .%?/1_P[J^!_P#T-WCO_P *^>O>J* /!?\ AW5\#_\
MH;O'?_A7ST?\.ZO@?_T-WCO_ ,*^>O>J* /!?^'=7P/_ .AN\=_^%?/1_P .
MZO@?_P!#=X[_ /"OGKWJB@#XR_9$_8X^&?Q9^&>H>)/%7BKQ>MS!XJU*RC%E
MXFFB3RH9RB9 ZMCJ>]>I_P##NKX'_P#0W>.__"OGKN?V:_@SJ?P,\!7OA#5=
M:@OY+KQ#?:BLUO&RJJSREPF#W .#7H- '@O_  [J^!__ $-WCO\ \*^>C_AW
M5\#_ /H;O'?_ (5\]>]44 >"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\
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M\36D8 U34=6:V?3]#D<8\U[:!)KUUR?*%Y;9 ,PQ]G4 %%%% !1110 4444
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MB6R^(<%AX5\07&GKI'AV&+1XY EA#:6<#@L9MKRW$D\KK%&"YV4 ?H+1110
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MX86D'N8T/M5^B@ HHHH **** "BBB@ HHHH ^2?^"UW[%_[1?_!1']@KQ/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML([A9+5%L2$W.Q!60R87 SGDT=<\;_\ !3'PK_P61T#_ ()ZZO\ \%&M3N?
MOBGX.W?C33=9MOAKX>CU:UG@NOLS6TI:R:&1"REPZHIPP7 V[FZ#_@K5JNEV
M/_!5S_@GK;WNHP0R2?$KQ7L2695+9TJ!!@$\Y=T4>[ =2*XG]M[X=_#+XO\
M_!QQ\*? _P 2_B1XA\.6,7[+>J7$M[X3^(FH>&KU'_MB4(IN].N;><(WS?N]
M^U]O(.W@ ]7_ &W/VC_VB_\ @E9X$'[3?CO]JS6/C5HMF1I5]\+-2\-Z)I^H
MW^H:@LL6D26LUA:Q2+NO8/)=660&)YY%!:WV-WNA_!?_ (*XZS\)A\3=?_;7
M\':/\3;C33>1?#J#X:VT_@^SNF3<NG2S&3^TID5OW;727*$G+B(C"'X^_P""
MLO[&/@+X6?!6+Q%^R-\2_%OQ2\>/\5O"?CS1OAYKWQ!OO%>KZM_PC$6H7-['
M#<7US/<F#[',S"(LRB9$C0%[B-*_1[X,_MO_ +*'QZ^ NG_M+?#WX\>&9/!U
M]IZW4NJWNM06ZZ?E07ANA(X^S31D[9(Y,,C @@$4 ?&W[9W[1?\ P4!^&GCS
M]BCP1HW[1^I^"-4^.>H6OA_XJZ4O@_1[EK&_&EP7$\UM]IM7:&03F961BZ<C
M:J;3NW/^"H,/_!0S]CG]BCQ]^T7\$/\ @IUJ=[XI\$^')_$$.@^+OAWX;>'4
M;&V>(72J(+&.16595PXW*'9%8#>&'&_\%PK'P+\8OVK?V"/#&K>*M7TW3?%/
MQINC#=:/KUYH>I"&2PC"M#<6\D-U;2;I(URC(X+A>"<5;_X*Q_L"?"K]G+]@
M7]H/]HCPK\6_B3J4Y_9[U_PU/8_$3XI:SXECQ=7%E/&\#ZM=W#6S;[;85C($
MGF+D909 .?\ 'W[37_!0+2_'_P"P5X T;]N/6K<?M,^&KR?XA7I\"^'G>VNH
MM%MM262R4V&(5+SO&4?S/D5.=VXMZ[\??VG?VS/^"8WQQ^&.J_M'_&#3/BW\
M#?B=XXL_!FI>(KSPM;Z3X@\&ZM>;A97,C66RVO+%V5ED/DQ/'\I#-D*WSM\4
MO%'AFS^.O_!(/4;OQ%8Q6_\ PB.IS>?)=HJ>6?".G*'W$XVY(&>F2*]*_P""
MYOQ7\ _M;:C\%O\ @F-^SYXJL?%GQ(\;?&7P_KFLZ;H%TMTWAOP[I\YN+O5;
MQHBWV:-0$"[\&3+[<E<$ V_A;\2OVZ?C1_P5G_:$_8HC_;Q\1Z'X.^&7AOPW
MK/AF6R\"^'9;PG4[?S98)I);!ED5&!"$*K;2 Q8@L<7_ (*M?$+_ (*3_L$?
MLB?$_P#:<^$7_!06\\4VO@KPY:R[-8\#>&_-TW5VU/3HA;SI#9KYD4]E?22
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M\;-8M?#WCM_VD?$'Q!\/:;JEPL#:YX:UA8'M+^TWD?:$'D.LACW")B%;!XH
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M.O%]GHC^++CPAI-S/K>HHG]N3?$*6YA&K"65_P!^U\UV;Z.X5B7\H3!OD4X
M/VNLI'FLX9I#EGB4L?<BOAGX0?M1?'K]N7]KKX\?!'X<_MD6'PCU3X+>-SX?
MTCX<0>#;#4;[5+*.U@D&N7WVW,LMK<3S2)&EJ;?8D*[I2T@-?;'@OQ)X>\7^
M%-/\2>%-=L]3TZ[M5>UO]/N4FAF7&,JZ$JPR".#VKX%_:8_9'_X)S_\ !5OQ
MKXM^)^@_%E_A'^T'\'?%&HZ!<?$OP+XG33_$6@364KQP2W85D^T6LD(CE7S
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MGK7PXTNZN)<=-TDL#,WXFOG/_@C5^U+^U%\6/&_[0G[,?[<GQE;Q-\5/@O\
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M,\@UW_@OXI_#'XD37UO\._B-H.O2:9-Y.I)HNKPW1M).?DE$3-Y;<'AL'@T
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M'X@\&^)M/U>PE)$5]IEZEQ"^/1T)4_G0!=@@@M8$MK:%(XXT"QQQJ JJ!@
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MS=%VHT4<J,L95> 5 P.!6OX1\&^$/A_X>M_"/@/PKINB:39AA::7I%C';6\
M9BS!(XP%7+$DX'))/>@#2HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#Y$_;[_Y+%IO_8LP_P#I1<5X=7N/[??_ "6+3?\ L68?_2BX
MKPZOS?-O^1C5]3^K>"_^25PG^!?FPK]!_@O_ ,D=\)_]BS8?^DZ5^?%?H/\
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M_!5S_@GK;WNHP0R2?$KQ7L2695+9TJ!!@$\Y=T4>[ =2*XG]M[X=_#+XO_\
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MG]I3_A#=8D\,PRVVF?\ "'7^H^;;&XN0LWF6ZE5RZR+M/S#9GH17AG_#0?\
MP3=_Z/M_\QAK'_QNO*O^#@[_ )/-\,_]DPLO_3CJ-?"=?DV=YS+#YM6I^Q@[
M/=\]_P )I?@?WMX:>%V"SG@/+\;/,,1!U*:?+'ZORK5Z+FP\I6]9-^9^H/\
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M &BOC9I?P^\>^&;7PYIVH6L"37UW:7%[9M>V\DL;%K)WC#NZ[)DR&*EF[_\
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M\'&W[1OA+Q?\1O'&AW6E? [PM):S_#OXFZKX<O8V8(K[WTRYA>55$D3;)=Z
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>biib-20220930_g20.jpg
<TEXT>
begin 644 biib-20220930_g20.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MK8HH Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\
MOI:/^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V**
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MNM-%AX?MX9=+9(-.ALK.WV)_I!5Y)C--((H=\C%,G[I^ 'P&^%G[,'P9\.?
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MX275_P#H4+W_ +Z6KNA:'H_AC0[/PUX=TR&RT_3K2.VL;.VC"1P0QJ$2-5'
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M_P#_ *E+_P G_P#[71_K#D__ #]_\EE_D!Z-17G/_"__ /J4O_)__P"UT?\
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M[^!2]7^0&?1117PP!1110 4444 %%%% !1110 4444 %>X?#;_D1M-_ZX?\
MLQKP^O</AM_R(VF_]</_ &8U]3PG_OT_\/ZH#<HHHK[\ HHHH **** "BBB@
M HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
M),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?
M_(TZE_V$)O\ T,U[Y7@?BO\ Y&G4O^PA-_Z&:^0XN_@4O5_D!GT445\, 444
M4 %%%% !1110 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_]</\
MV8U]3PG_ +]/_#^J W****^_ **** "BBB@ HHHH **** "O*/VY_P#DT?Q[
M_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA
M?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\ (TZE_P!A";_T,U[Y
M7@?BO_D:=2_["$W_ *&:^0XN_@4O5_D!GT445\, 4444 %%%% !1110 4444
M %%%% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\ 7#_V8U]3PG_OT_\
M#^J W****^_ **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O
M*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[
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M#7AB*ZCN#!D<+>7QM_LT$758VGN" L*A_JBWMX+2W2UM85CBB0)'&@P%4#
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@?BO_ )&G4O\
ML(3?^AFO?*\#\5_\C3J7_80F_P#0S7R'%W\"EZO\@,^BBBOA@"BBB@ HHHH
M**** "BBB@ HHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^I
MX3_WZ?\ A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\
M^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R
M3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_#O_ & K3_T2E;M &/\ \(/I'_/S>_\ @6U'_"#Z1_S\WO\ X%M6Q10!C_\
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M?_ MJ/\ A!](_P"?F]_\"VK8HH Q_P#A!](_Y^;W_P "VH_X0?2/^?F]_P#
MMJV** ,?_A!](_Y^;W_P+:C_ (0?2/\ GYO?_ MJV** ,?\ X0?2/^?F]_\
M MJ/^$'TC_GYO?\ P+:MBB@#'_X0?2/^?F]_\"VH_P"$'TC_ )^;W_P+:MBB
M@#'_ .$'TC_GYO?_  +:C_A!](_Y^;W_ ,"VK8HH Q_^$'TC_GYO?_ MJ\8\
M1PI;>(;^WC)*QWLJJ6.3@.1R:]_KP/Q7_P C3J7_ &$)O_0S7R'%W\"EZO\
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M10 4444 %%%% !1110 4444 %%%% '-?%W_D0+W_ 'HO_1BUXQ7L_P 7?^1
MO?\ >B_]&+7C%?GO%?\ R,H_X5^<@"BBBOF0"BBB@ HHHH **** "BBB@ HH
MHH V?A]_R.NF?]?:U[G7AGP^_P"1UTS_ *^UKW.OO>$O]SJ?XOT0!1117U8!
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>!^*_^1IU+_L(3?\
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M6&X<L9(;6([Y!B1@#Z3KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\
M8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#FOB[_R(%[_ +T7_HQ:\8KV
M?XN_\B!>_P"]%_Z,6O&*_/>*_P#D91_PK\Y %%%%?,@%%%% !1110 4444 %
M%%% !1110!L_#[_D==,_Z^UKW.O#/A]_R.NF?]?:U[G7WO"7^YU/\7Z( HHH
MKZL HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O _%?_(TZE_V$
M)O\ T,U[Y7@?BO\ Y&G4O^PA-_Z&:^0XN_@4O5_D!GT445\, 4444 %%%% !
M1110 4444 %%%% !7N'PV_Y$;3?^N'_LQKP^O</AM_R(VF_]</\ V8U]3PG_
M +]/_#^J W****^_ **** "BBB@ KS#]IZ_^-UG9>#?^%&_%_P #^$9D\=:?
M<>+I/&]HTR:CX>C+?;K6T"R)LNF#1;)#E5P0<;@1Z?7Q?_P6 \*_LR>*6^$E
MK^T=_P $Y_'/[1+#Q-J0\-:+X,T:PO5L[DZ=(9$NDO+F >7)$KRKM)^>R4DC
M: P!PW[47[._[9'[3_QF\2:IJ7[3_P"RD_@G2M?!^'.G_$7X,V?B6]M[)K:W
MD:1II+]!&ZW#3Q8"@D0*_P#& /?O^"<*?'JP\&_$+PS^T1\?/"'Q$UG1OB(+
M.QU;P+I T_3+.R&AZ0\5G%:B646^PR.Q3>V3(6XW8'P9_P *4_X)V_\ 2J?\
M7_\ PW?A[_Y;U]C_ /!'_0?A=X:^$_Q+TCX/?L5>(/@!H<?Q7D,/PZ\2V$5K
M<P.=#T<O<>5!++$BRGY@(Y&!Y)PQ8  ^MZ\H_;G_ .31_'O_ & 7_P#0UKU>
MO*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!
M6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXN_P#(
M@7O^]%_Z,6O&*]G^+O\ R(%[_O1?^C%KQBOSWBO_ )&4?\*_.0!1117S(!11
M10 4444 %%%% !1110 4444 ;/P^_P"1UTS_ *^UKW.O#/A]_P CKIG_ %]K
M7N=?>\)?[G4_Q?H@"BBBOJP"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH *\#\5_\C3J7_80F_\ 0S7OE>!^*_\ D:=2_P"PA-_Z&:^0XN_@4O5_
MD!GT445\, 4444 %%%% !1110 4444 %%%% !7N'PV_Y$;3?^N'_ +,:\/KW
M#X;?\B-IO_7#_P!F-?4\)_[]/_#^J W****^_ **** "BBB@ KS[]H+X;_&[
MXDVGA&'X(?M#/\.Y=%\=:=JWB:9/"]MJG]OZ-"7^U:.1.1]E%P&4?:4S)'L^
M4'<:]!HH _.O]L[QO\8/@A\?_%4OQ;_X.,_"_P "-'U;5DN_ WP[U/P7X-GN
M[+2VMH,[S?6_VF0?:?M(5VW#RQ'ERV['L7_!(KQM%\0?A=\3/$T'[=5K^T6D
MGQ7D1?B;9:/96,-SMT/1Q]F6*Q5;;$7W<Q  G.?FW5XSKG[2?P;_ &<?VLOB
M[X#NO^";?Q'^/E[?>+VU36/B;\+?A-'KAM[F>"%AHNH7-WY*&>TA$,:+!+,J
M0&!7$4@=*^D/^"=/Q?\ !7QL\)?$3QAX(_9*\4_!J&/XD-;7GA;QIX931]2N
M9UT;2C]LFM8W=(]Z-&BE6(9(E8X9F% 'T17E'[<__)H_CW_L O\ ^AK7J]>4
M?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@
M*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '-?%W_D0
M+W_>B_\ 1BUXQ7L_Q=_Y$"]_WHO_ $8M>,5^>\5_\C*/^%?G( HHHKYD HHH
MH **** "BBB@ HHHH **** -GX??\CKIG_7VM>YUX9\/O^1UTS_K[6O<Z^]X
M2_W.I_B_1 %%%%?5@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWZC_ -"/XM_\(S4O_C%']FYC_P ^9_\ @+_R LT56^WZC_T(_BW_ ,(S4O\
MXQ1]OU'_ *$?Q;_X1FI?_&*/[-S'_GS/_P !?^0%FBJWV_4?^A'\6_\ A&:E
M_P#&*/M^H_\ 0C^+?_",U+_XQ1_9N8_\^9_^ O\ R LT56^WZC_T(_BW_P (
MS4O_ (Q1]OU'_H1_%O\ X1FI?_&*/[-S'_GS/_P%_P"0'1?#[_D==,_Z^UKW
M.OF:Z\<^*? ]N_B[P_\ !GQGK][IZF:UT:V\+WL$EXXZ1K)+"$0GU8@5F?\
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M7?\ AO7]H[_I'EXG_P##@Z'_ /)%'_#>O[1W_2/+Q/\ ^'!T/_Y(H_M++O\
MG]#_ ,"7^8'U%17R[_PWK^T=_P!(\O$__AP=#_\ DBC_ (;U_:._Z1Y>)_\
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M^31_S \YHKT;_A0'_4V_^2'_ -LH_P"% ?\ 4V_^2'_VRC_5[./^?7_DT?\
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M% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\
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M[1=I-\/-(_9@\0>#=%T72O%EF/'EIXGTZXG>X\.1Q.LMM8&)@([K/E;&DRH
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MOAOP[IH07FJZI.(XU9W$<<:]WD=V5$C4%W9E5020*\;_ %>R?_GU_P"32_S
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MBD?'0^"7_!=[3_VA_$_[05E;?LDZI?ZEYEAX3'B/6_$\[>&M%+*PL+?RK2-
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M^(W[+WP0_P"$:BUOQ]X;N-$%_P"*M6N+2UL8IT*M/FWMKAY&7M'M4'/WQCD
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M6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^
MW/\ \FC^/?\ L O_ .AK7J]17UA8ZI:2:?J=E%<6\J[98)XPZ./0J>"* ,?X
M7?\ ),_#O_8"M/\ T2E;M>%:A_P3W^"6HW\^H2>*/&T;3S-(T</BR9$4L2<*
MHX YX':HO^'=7P/_ .AN\=_^%?/0![U17@O_  [J^!__ $-WCO\ \*^>C_AW
M5\#_ /H;O'?_ (5\] 'O5%>"_P##NKX'_P#0W>.__"OGH_X=U? __H;O'?\
MX5\] 'O5%>"_\.ZO@?\ ]#=X[_\ "OGH_P"'=7P/_P"AN\=_^%?/0![U17QE
MX3_8X^&>J_M<>+?A1=>*O%_]EZ5X5L+VU9/$TPF,LKL&W/U9>.!VKU/_ (=U
M? __ *&[QW_X5\] 'O5%>"_\.ZO@?_T-WCO_ ,*^>C_AW5\#_P#H;O'?_A7S
MT >]45X+_P .ZO@?_P!#=X[_ /"OGH_X=U? _P#Z&[QW_P"%?/0![U17@O\
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M,4JY&Z-PKKD9 H I?LU_!G4_@9X"O?"&JZU!?R77B&^U%9K>-E55GE+A,'N
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M53]H\(?"C]G:_P#B;X2T6[YMKOQ--K!TL7+1GY9)(+?]Y$3EHF#,NTG)V/\
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M_P"'WQ U"SN&A9-!O9IY+J/S%(**_P!G1&Y *%U/#$'[^KQW]O+]BKX8?\%
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ML#>%/V%?AOJ?[.]C<^%M*NK&P^)%QXBUO49K<W%W/<&X736TV".21//(56N
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MM];\4WMMJ&H_VO816O[F.+3Y8T\DQE_FD/F X_=]: /IZBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
,@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>biib-20220930_g21.jpg
<TEXT>
begin 644 biib-20220930_g21.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
M\FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2
ME;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6T$'FV=Q%?+M6569)82%?:Q4?9% !1110 4444 %%%% !1110 4444 %%%%
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+6Q10!C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2UL44 8__  DNK_\ 0H7O_?2T?\)+J_\
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M3_\  G_F!T?_  MKX@_]#!_Y*1?_ !%'_"VOB#_T,'_DI%_\17.44?VEF/\
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M@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MKKO_ " [S_KTD_\ 035JJNN_\@.\_P"O23_T$UG6_A2]&!\^T445^-@%%%%
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M** "JNN_\@.\_P"O23_T$U:JKKO_ " [S_KTD_\ 036=;^%+T8'S[1117XV
M4444 %%%% !1110 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZOV=; %%
M%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#N
MOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH
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M@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH
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M@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J
MKKO_ " [S_KTD_\ 035JJNN_\@.\_P"O23_T$UG6_A2]&!\^T445^-@%%%%
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M'F_>&Z6\>X642?.)%<-\P- 'IE>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !577?\ D!WG_7I)_P"@FK55==_Y =Y_UZ2?
M^@FLZW\*7HP/GVBBBOQL HHHH **** "BBB@ HHHH **** "BBB@#Z*A_P!4
MO^Z*=38?]4O^Z*=7[.M@"BBBF 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% 'Y;?"KX@_P#!2KP/\7O#\G[(O[(7@CXT>!/
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M_D!WG_7I)_Z":M55UW_D!WG_ %Z2?^@FLZW\*7HP/GVBBBOQL HHHH ****
M"BBB@ HHHH **** "BBB@#Z*A_U2_P"Z*=38?]4O^Z*=7[.M@"BBBF 4444
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M-$TV&T.@6]GJUY:10/% 3$LA2!7?RR4+NQ4D$&OF7X'?";_@X ^$.C:QX*\
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M^B6K$+=,!DPK6-\9M!LM'L+&2UEG8O,X/G3%NPZ9KK_A=_R3/P[_ -@*T_\
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MWO\ X%M1_P (/I'_ #\WO_@6U;%% &/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
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M*XRNS^!O_(X3?]@]_P#T-*]+)O\ D:4?\2 ]9HHHK]6 **** "BBB@ HHHH
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M_"_^W>B.QHHHKP#U@HHHH ^BH?\ 5+_NBG4V'_5+_NBG5^SK8 HHHI@%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^,_P $
M_CA_P4!N_AG<0?L)_ [Q)\2_A]X7D>$_%CXQ?#BRN=6\$WPOF348O#-M'<PS
M^(K6U)G,,)56B-N(EFNOD@'Z"_\ !(O6].\2_L!^$/$6E_'W5/BE%?:WXEN#
M\0M:T&72[K77?Q#J+/<26<H#VQ+EAY1"[0H 50 !F?LU_MV2?%+]I2X_9>^$
MW[)FLZ)\-M)\(:W+X'^).J:I!:V7B.XT6^T_3[FVL+(!IOLBO?H%O9"J2>63
M&LBG>/;OV=O$WPV\9?"N#Q1\*O#TND:;>ZSJTE]I5S"(YK+5?[2N1J<,RAF4
M3)?B[63:S)Y@?:S+@D [BO*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%
M_P#T-: .Z^%W_),_#O\ V K3_P!$I7._'O\ Y!NG?]=W_P#0171?"[_DF?AW
M_L!6G_HE*YWX]_\ (-T[_KN__H(KQ\__ .115^7YH#S*BBBOR\ HHHH ****
M "BBB@ HHHH YCQ5X-OTU+_A,O!$J6VK(N)HFXBO4_N./7T;_P"L1?\ "'C*
MP\66TBI$]M>VS;+VPFXD@?T([CT/_P"JMBN>\8>"9-6N4\2>&[L6.LVR_N;D
M#Y9E_P"><@_B4_I7O8?&8?,:$<)CI6<5:%3^7M&?5P[/>'2Z]T\JMAZV#JNO
MA5=/64._]Z/:7?I+K9ZG0UV?P-_Y'";_ +![_P#H:5Y=X.\;1^(6DTC5;0V.
MKV@Q>6$AY_WT_O(?7W^A/J/P-_Y'";_L'O\ ^AI4X+!XC YW3HUHVDFO--/9
MIK1IK5-:-;'=A\11Q5)5*3NG_336Z:ZIZH]9HHHK],-PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "JNN_\@.\_Z])/_035JJFO$#0[TDX M),G
M_@)K.K_"EZ,#Y^) &2:XO4]3U#XFZA+X:\-73P:- ^S5-4C/,Y[PQ'^;?T^\
M:GJ>H?$W4)?#7AJZ>#1H'V:IJD9YG/>&(_S;^GWNLTO2]/T73XM+TNU2&"%-
ML<:#@#^I]^]?GT(0R""JU5?$O6,7M3724E_/UC%_#\4M;(\:4I9M)P@[4%HV
MOM_W8_W?YI==EI=AI>EZ?HNGQ:7I=JD,$*;8XT' ']3[]ZL445\].<ZLW.;N
MWJV]V^[/7C&,(J,59+9!1114E!1110 5E^,?#-OXN\/SZ-,^QV&ZWF'6*4<J
MX^A_3-:E%;8;$5L)B(5J3M*+33[-&=:C3Q%*5.HKQDK->3,+X?>)KCQ%HIAU
M5/+U*PD-OJ,1ZB1>-WT;KZ=?2MVN.\8J_@CQ3!\0[5"+.YVVNN(HZ*3A)OJI
MP#[8'<UV".DBAT8,K#((.017IYOAZ/-#&8=6I5;M+^62^.'_ &ZW=?W7%G#E
MU:IRRPU9WG3TO_-'[,OFM_[R8M%%%>,>D?14/^J7_=%.IL/^J7_=%.K]G6P!
M1113 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#\\];_9=_X+(?L_?'[1E_9/N/@-XP\!>&=!\0Z%\/M4^(-_JEAJ&@Z;JU
M]IMY]GOH+2-UOA:?V='!"\3QM+&1YF'!8_9?[+/P5U?]GWX%Z-\,?$_C9O$N
MN1S7NI>)O$1LUMEU/5K^\GO[^Y2%21#')=W,[I$"0BLJY.W-=_++%!$T\\BH
MB*6=W; 4#J2>PKB?@E^TU^SM^TIIU[JW[/GQQ\*>-K73I1'?3^%]>@ODA)9U
M4L8F;"L8Y K?=;8V"<&@#N*\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_
M]@%__0UH [KX7?\ ),_#O_8"M/\ T2E<[\>_^0;IW_7=_P#T$5T7PN_Y)GX=
M_P"P%:?^B4KG?CW_ ,@W3O\ KN__ *"*\?/_ /D45?E^: \RHHHK\O ****
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MR3/P[_V K3_T2E<[\>_^0;IW_7=__017CY__ ,BBK\OS0'F5%%%?EX!1110
M4444 %%%% !1110 4444 %=G\#?^1PF_[![_ /H:5QE=G\#?^1PF_P"P>_\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /R:_9O\
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M !MT3PXU]<SMI^EZA<R-=-9B5EMYY4$0\EY8@DODG+1B0(^'#* #ZD) &2<
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M]_)?_B* /?Z*\ _X>G_\$]O^CJ_#'_?R7_XBC_AZ?_P3V_Z.K\,?]_)?_B*
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M$O\ PG+7_P"-T?\ "@_@7_T1;PE_X3EK_P#&ZZRB@#D_^%!_ O\ Z(MX2_\
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M-WUY<1;I[N\T.WEED.2,LS(23@#J:\RKW#X;?\B-IO\ UP_]F-?4\)_[]/\
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MM/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH **** "BBB@
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M'OV5/V:/"MO=VVA_ 3PC$M_JU[J=ZTF@02/-=W=S)=7$K,ZEB7FED;K@;L#
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MO_7#_P!F->'U[A\-O^1&TW_KA_[,:^IX3_WZ?^']4!N4445]^ 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH *\#\5_\C3J7_80F_\ 0S7OE>!^*_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
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M[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:
M-BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$
MEU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z%"]_[Z6C_A)=7_Z%
M"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI: -BBL?_A)=7_Z
M%"]_[Z6C_A)=7_Z%"]_[Z6@#8HK'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M!6G_ *)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
M.Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M\#\5_P#(TZE_V$)O_0S7OE>!^*_^1IU+_L(3?^AFOD.+OX%+U?Y 9]%%%?#
M%%%% !1110 4444 %%%% !1110 5[A\-O^1&TW_KA_[,:\/KW#X;?\B-IO\
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MVY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\
MHE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[S1PS,N<A'>VG53T)A<=C7D_ZIY=_//[U_\ (@>??\*E^(/_ $+_ /Y-Q?\
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M_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV%K<,!PBO?I:P_[UTBCK7T5\4?C=HGPJU V/C/X?^+[W3;BQ\RWU#PSX-O\
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M  4$_P"B_P#@3_PE)/\ XJC_ (0'_@H)_P!%_P# G_A*2?\ Q5 'NE%>%_\
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MJ/\ A ?^"@G_ $7_ ,"?^$I)_P#%4 >Z45X7_P (#_P4$_Z+_P"!/_"4D_\
MBJ/^$!_X*"?]%_\  G_A*2?_ !5 'NE%>%_\(#_P4$_Z+_X$_P#"4D_^*H_X
M0'_@H)_T7_P)_P"$I)_\50![I17A?_" _P#!03_HO_@3_P )23_XJC_A ?\
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M ,"?^$I)_P#%4 >Z45X7_P (#_P4$_Z+_P"!/_"4D_\ BJ/^$!_X*"?]%_\
M G_A*2?_ !5 'H_Q/^#WAGXOWOAZ/QPSW6E>']<@UI-&*CR;R_MV$EG)-_?6
M"8"=$QCSHH9,YB /6UX7_P (#_P4$_Z+_P"!/_"4D_\ BJ/^$!_X*"?]%_\
M G_A*2?_ !5 'NE%>%_\(#_P4$_Z+_X$_P#"4D_^*H_X0'_@H)_T7_P)_P"$
MI)_\50![I17D'@7P;^VG8>+K"\^('QG\'ZAHL<X.HV5AX<>*:6/!^5'+?*<X
MYKU^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#R#P;X%
M\76'[:?C3X@7F@SQZ+J'@_3K6RU%@/+EFC=BZ#GJ :]?HHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "O(/VC_  +XN\6?%CX2:WX<T&>[M-#\8276
MK3P@%;6$P,H=N>F>*]?HH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#SC]KOPIXC\<_LT^,?"/A'2);_4K_1VBL[.  O*^Y3M&>_%=?\/K&[TO
MP#H>F:A;M%/;Z/;13Q/U1UB4,I]P016Q10 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'D'[%/@7Q=\/OA/J6B>--!GTZ[F\8:I=1P7  9H9)RR
M/P>A'(KU^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** /@G]N/Q[\0_VLO^"I_P -/^"3OA_QYK/AKP#!\,;OXH?&:7PW
MJDMC?>(-,2^_LZRT=;J!EE@@>Z^:X$;*\D3!0RC.>3_X*F?L^^&O^"5_[.1_
MX*1_\$]-#;P)K'PHU?3KOQKX+T;4)H]&\;Z!-=Q6UW9WMH7,+3*LPECNMOG(
M4;#$L,>C?MV_LY_'WX4?M_?#7_@JW^S%\.KOQQ<>'O!-[X!^+/@326C&IZCX
M:GN#=P75@LCHD\UK=DRM;E@TR85"&%?'W_!1G]H/]L+]J7X:Q?L6?'W5[CP[
M\"?BGXIT.W^(OQ]\9_!76_A_;^![6.Z-U<:8\>IM*)UN'MH(H+QF2&-I3%-(
MWFI( #Z^_P""F.C?\$]K/]GGQ%^U)^TKX[EA\1>*?"+2?"B]N/$DL&MV5Y]D
MC^QP>'(8766.Z:XDBE)@#2/)/^\8QA43Z7_8Y7XZ)^R3\,5_:>;/Q''@#2!X
M\.5).K_8XOM>[9\N[SM^[;\N[.WC%>>_$#]I'X >)?V?-6\(:%\#/$OQ-\(:
MMX:EL?"^E^#O!]UKFD>,+ PF%(8;RWCDM(HG8-#ON9(D 7S=QA9)6W/^";'P
M:^-/[/'[ _PD^!_[17B'^T_&WA?P-8:?XBN?M?VC9/'&!Y'FY/F^4NV'?DAO
M+W9.<T 4/VXOV3/&_P"U#XM^!6O>"_B'>:!'\,?C=IGC#7DMM2E@74M/M;6[
M5[1ECXEWRR0 JWR[/,!X)J7]JS_@G]\'OVX?%,%O^U%>:WK_ ((TS1UBTCP-
MI_B2_P!+M!J+R2F?4+@V4\37,@B\B.$.2L.)F4;I<K[Q7QC_ ,%,OVTOB=\-
M?&&D_LP_#_\ 9;_:"U_1/$%@UQX]^(/PA^&EYJ;Z?8,2O]GV-PFQ$O9QE6N%
M?-K&2R9F9#& 1_\ !#F+XMZ1^REX[\!^*_B)K'B[PKX0^.'BWP[\&?$_B6]:
MZNM1\*6-V+>T:2X;YKA4GCNXEDZ&.)=N%"@>&_\ !2;_ ()\Z7^RK\,?!W[9
M'[./Q0\<3_M3M\5?"]AI_B^;QCJ$K>.;Z_U2""\TZXL7G:U2Q-M)<RBVCC2.
M&&UVC"*^?L7]B+]HCPY\0_@IJ)\$_L8_$SX/^"/A_9P:5X>\/>.O!#Z5J%S#
M;VP=EL],C\R5H(XS#'&PRTLGF(J9CR_R;H7_  4G\4>-OCK/^T5\<?\ @E;^
MU]?ZAX8FO+/X3>$K#X&W#6FCP2*T3ZC)+-,BMJ-U'\AD8!+6"0P1D[[F6< _
M3&BJVC7&IW>D6MUK>G1V=Y+;(]W:17'G+!*5!=!)M7>%.0&P,XS@=*LT %%%
M% !1110 4444 %?'O_!:_P#:O^-'[,W[+OA;P1^S5KD6C_$?XV_%?0?ACX*\
M0S0B4:+=ZK)(K7P0\,T<44NS/ D9&.<8/V%7RU_P5Y_8F^(W[;O[+.G:1\"-
M=L=.^)OPU\>:1\0/A=<ZHQ6U;7-+D9X89B.522.2:+=T5G5CPIH PO&7_!%_
M]F0_ VY\,_"35O%/AOXJ6^F%]$^.B>+;Y_%(UA4)2_NKXR^9=!I?FE@?,+JS
M($5=H7A_V&/CQ\(_^"F?_!,7P%^U/_P4<N]&M(_"?]IZ7\2--\0:M%8^')]8
ML[S["U]>1LR0R9\H21QN?)1[Q\(66)DX?]I/_@IG_P %./!7A"^^*?P5_9!\
M<7FOVFD3QZQ\$=<^!6KH-'=;%R]]%XH@FFT_4/)ND+B*%#]I@(C1(Y<,WH/_
M  1X\1?LS_LB?\$^_ 7P.^$GQA7XQP:38S7WCSQS\+["X\11Q:]J$TE[-#/!
M8QRW,;%I9%0-$&1(%\]86DC#@'7_ /!&'6M8\1? WXAZUX6U_5=3^$,_QAUG
M_A0%[K-[-<22>$U2W5/)DG)E:R%ZM\+;S"6\@1X_=^77NG[:OP6\3?M'_L?_
M !0^ 7@GQ'+I&M^,O .K:/HNJ0W;P&UO+BTDC@D+I\RJ)&0MC^'([UY'_P $
MV/A-\1/"/Q%_:!^,E_\ #_4?!'@/XF_%2/6_AUX(U:T-K<VT":9:6U[J<EJ<
M-9M?WD,USY$BI*,AI$1W(KZJH \,U3]CF\\8?LB_#_\ 9$\9_%77QHFA:)I.
MD^.KW2=:N;6_\265G8^2]L;V)TN(1/.D+2R(RR21"6/</-)'S=^PU^SM;?L8
M?\%>OB9^S)^RGK>NQ? Q_@AI7B3Q'X.U#7KK4K+PSXMN=4FAMTM7NI)'@^T6
M-O<3/%NYVHQ^7RPOTE_P4!_:P\?_ +(OP*?QQ\)/V;O'7Q0\5:E>II^A:!X(
M\(W>K?9Y'SNO+Q;892VB7+D;E:0A8T(+%T\?_P""</[2EGKWB^3X/>&_V)OV
MBM#UGQ!)=^)?B5\5OC/\-CX>@U:_\N.,RF1I'$DS-]GA@LXP$AM8-JD);JK
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M[V*W23[&RIM:X)W" [T!E<*' /F7X0?LE^&?V#_^"RW@7X3?L-:AXATKX?\
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M% !3(+:WM5*6T"1AG+,$4 %B<D\=R:?10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?FPI<,"H>=XQYBVL'FW)3#>5AE)J?%K_ (*4?LC_  C_ &+D_P""@-YX[O\
M7_A;/IT=[:>(/"6@7>H^;$[^6I9(HR;?$G[MC/Y2QN"DA1ABOE#X3?LG:%^S
M#^U'^T0O[4G@_P#:!N=.^)'Q:N_'7@3QK\'_ !1XW:PU*ROK:W5]/N;3PQ<@
M6]U:RPO'YEQ$GF1-%MD94PNE_P %#_V5_"?PH_X(3_$K]ES]DC]EOX@6<WC'
M3YY?#_P[T^'5O$VJ_;+S4X[J8S.)+MXF?+S/OEV(S.-Q/4 ^K?AU^WE\$OB-
M\3/#7PPBTSQ1HMQX[L;J]^'.I^(O#TEI9^++>VB6:9[*1LG(A83".98I'B#2
M(CHK,)/AQ^W#\+OBGXC\)Z?X2\(^*Y=#\>WU[:^"?&ITJ-M(UE[6"XFE9)4E
M:2%2EK,8S/'%YP7=%O7+#P+]OOQ->>)?VA/V//'/PS^#GQ)O]*\+?%:?6M=N
M='^%>MN-$TB70]3T_-RB6FZWS+-$AA8"0*=Q79AJ\W_8[^$7Q@^%'[0OPG\8
M_L8^%?BUX%\!^,]6O[OXZ_ #XD^%[Y/#G@QI;*XGDOM&N[Z%?LLAOV2,6]I+
M)',MT6\N)8Y-H!]O?'_]K/X2?LZ:[X6\#>+9-4U7Q;XYO)[;P7X+\-::][JF
MLO!&)+AHHEPL<,,9#23RM'#&&7<X+*"[]GW]K#X1?M(ZGXH\)^"KG4M.\4>!
MM0AL?&O@WQ'ICV6JZ'--'YL'G0OPT<L?SQ3QL\,J@E';:V/EO]OW]E37]1_X
M*1?"G]M7Q1X0^(_B/X<V'PVU?P7XIC^%?B/6['6/#5S/=P7EMJ:Q:)/%?7EO
M)Y<EO+%#YA7,3M&P4,GKO[%_[.W[,_AKXJ>+OVD_@Q\(OBCIFL>(-)LM%U#Q
MA\5?$OB:?4-;MK=Y)$B%IX@N9+F&.!GPLDD418R.$RG+ 'TC1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6!>?
M##P-J%Y+?W>A[Y9Y&DE?[3*-S$Y)P&P.36_16-;#T,0DJL%*W=)_F!SG_"I?
MA]_T+_\ Y-R__%U)9_##P-I]Y%?VFA[)8)%DB?[3*=K Y!P6P>16_16*R[+X
MNZHQ_P# 5_D 4445V %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 </^TM\+/$_QR^ 'C+X,>$/&=CX>O?%GAJ^T<:UJ.BOJ$=HES;O"TGV
M=+B R%0Y('F*,CFLW]COX&>)_P!F']EOP!^SAXJ\?6/B>;P%X0TWP[;:[8:"
M^FK>6]E:Q6T4C0/<W&V0K$"V),$DX '%>E44 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117._$34O
MB9IME;/\,_#6G:E.TI%U'J-X851,<$$#DYJZ<'4FHII7[NR^]F=6HJ--S:;M
MV3;^Y:G145YC_P )3^U=_P!$J\,?^#QO\*/^$I_:N_Z)5X8_\'C?X5U_4*G\
M\/\ P./^9P?VK2_Y]U/_  7+_(].KY\_;"^)7QW^$.O6&N^"/&;6^AZE%Y?D
MG3;:007"=5W/&6PRX89/4-V%=K_PE/[5W_1*O#'_ (/&_P *YOXL^&_VD?B[
MX'NO!6O_  L\.)',5DAGAULEX9%.5=<C&>H]PQ'>N[+:$,-C(SK.G*&S3E%Z
M/KJ^FYY6=8JIC<NG3PRJPJ;Q:C-:KI=+9[?CT/!_^&R/VD/^BC?^4BS_ /C-
M=9\$?CY^TW\6_B5IO@R'XBL()9?,U"5='L_W5NG+MGR>"1\H_P!IA7A5]97>
MFWLVG7]NT,]O*T<\3C#(ZG!4CU!!%?1?[*G@3XX> _#DGCOP?\.=(O?[>A4P
M7.IZF8I%@4G 50. Q^;)Z@*:^RS/#Y=A<'*4:5-2>D;J*5WZ]MS\YR3&9SCL
MRA"=>JX)WE:4V[+I9.^KT^9]445YC_PE/[5W_1*O#'_@\;_"C_A*?VKO^B5>
M&/\ P>-_A7Y_]0J?SP_\#C_F?K?]JTO^?=3_ ,%R_P CTZBO,?\ A*?VKO\
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M?#&N_$?]GD>'/"=MX6_;[T"#Q3J_B/6GN/$6L>([?7;&SU2>,22#^S[)+<O
MBDRB2T# 1P1$;OTH_:L?]ECQI^R5XTNOVI]2\/7?PDU#PG<3>*[[59T>P?3&
MCW&82#()QM:-T^;?L*?-MH W[#]H?X :KJUCH.E_'+P=<WVIE!IME;^)K1Y;
MLN<)Y2"3,FX\#:#D]*Z77_$?A[PII;ZWXHUVRTVRC9%DO-0NDAB5F8*H+N0
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M8#TS0+;6+KXO^&[7X=W/A*.);F_\&26\C:Z':(;I;,Z=OEG9\KYRPNW[S8:
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MT[PQX7M+""]X8?O8X(U63AF'S \,?4UV=% '$_"K]FC]G'X%:E?:Q\$/V?\
MP3X-N]314U*Z\*^%+/3I+M0<A96MXT,@!Y ;/-2^+_V=_P!G_P"(7CS3?BGX
M^^!?@[7/$^BE#H_B/6/#%I<W]B4;<GDW$D9DBVM\PVL,'D5V-% '.?$WX/\
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MX\MOBGX4_9;^'.F>)[*%(K/Q'I_@BPAOX(T4*J)<)$)%4*   P   %;'Q;^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
B**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>biib-20220930_g22.jpg
<TEXT>
begin 644 biib-20220930_g22.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
MHE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_
M ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_H
ME*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\
M\FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z
M)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__)H_
MCW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*
MW:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@^#FD7,&G)?W6H:A>ZE?27=]JNH74S3W5]=W$A+W%Q-*[.\C'J< !0JCOZ*
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MAK]G'_H">)__  XVN?\ R;7W111_868_]!L_Q_\ DP/A?_AAK]G'_H">)_\
MPXVN?_)M'_##7[./_0$\3_\ AQM<_P#DVONBBC^PLQ_Z#9_C_P#)@?$.A_\
M!/[]F[Q+J]OH,EGXNM%NY!&;FU^(NL^9'GNN^Z9<_52/:NR_X<]?LP_]%!^*
M?_AQ+NOJRBO7R[!U\%3<:M5U&W>[OIY:M@?*?_#GK]F'_HH/Q3_\.)=U'>?\
M$AOV8M.LY=07QS\4)3!&T@BE^(EYM?:,X.T@X..Q!]Q7UA577?\ D!WG_7I)
M_P"@FNRJVJ4FNS ^(?\ AAK]G'_H">)__#C:Y_\ )M'_  PU^SC_ - 3Q/\
M^'&US_Y-KURBORC^TLQ_Y_3_ / G_F!Y'_PPU^SC_P! 3Q/_ .'&US_Y-H_X
M8:_9Q_Z GB?_ ,.-KG_R;7KE%']I9C_S^G_X$_\ ,#R/_AAK]G'_ * GB?\
M\.-KG_R;1_PPU^SC_P! 3Q/_ .'&US_Y-KURBC^TLQ_Y_3_\"?\ F!Y'_P ,
M-?LX_P#0$\3_ /AQM<_^3:/^&&OV<?\ H">)_P#PXVN?_)M>N44?VEF/_/Z?
M_@3_ ,P/(_\ AAK]G'_H">)__#C:Y_\ )M'_  PU^SC_ - 3Q/\ ^'&US_Y-
MKURBC^TLQ_Y_3_\  G_F!Y'_ ,,-?LX_] 3Q/_X<;7/_ )-H_P"&&OV<?^@)
MXG_\.-KG_P FUZY11_:68_\ /Z?_ ($_\P/(_P#AAK]G'_H">)__  XVN?\
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M'5/'%S<6[N 1B2-N'7GH:^C***^W **** "BBB@ HHHH ^2/VFO^"E7C_P"
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M/#7C"*2/4K+X*^&8KJ&8$/"1IEOB-@>A484CL5H ^@J*** "BBB@ ID\$5S
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M[RC^S<N_Y\P_\!7^0'.?\*E^'W_0O_\ DW+_ /%T?\*E^'W_ $+_ /Y-R_\
MQ=='11_9N7?\^8?^ K_(  "@*!P!Q1117: 5X'XK_P"1IU+_ +"$W_H9KWRO
M _%?_(TZE_V$)O\ T,U\AQ=_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHHH
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M [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@
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M & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_LJ+X'_9UU"+P[X_\*^,]%\8^"[C7(Q)IUUJ>E7B7<%M>(,[H79!G@@,$)!
M(H Z7]GC_@J1^QC^TO\ $=_@[X$^*0L_%LNNWFG:-X7\0:;<Z=J6K+;6QN9;
MJ"UN8TE:W$:N3(5 4@ X+H&]=^)GQ;\+?"^70M+U=WN-6\4ZVFD>&M(ML&>_
MNFC>5PH/1(H(IIY'_@BA=L$@*?S)_P""=G_!13X??%3]K6W_ &9/^"@/[/6J
M?"O]I71/BIKGB+PMI<@272=4NYM):PO+;3M0^<3*89))##N&2L.'E9"*^E-(
M\>Z]\4?^"V&M:/JGAV[ET_X1?L]61T?3W92(=0U_5IS<W0'3<;?2+:(-U :4
M='.0#ZL^(_Q0\ _"+0+;Q1\1_$L.E6%YKNF:-:W$R,PEOM0O8;&S@ 0$[I;F
MXAC!Q@%\L0H)&7^T)^T-\&/V4_@_K'Q\_:#\>VOAGPAH"PMJ^MWD4CQV_FSQ
MP1#;$K.Q:66- %4DEQ7PS_P6K^%OC#7O&O[.GQPO_B]\1H--T;]JGX=0V?PY
MBNM-B\/RS2:U AN)52S%W/-C[HDN6C0DE4!-?='C'0]"^(2:;#XV^%LFIQ:1
MJ\&J:?#=[6CBO(23#-LSM9HV.]-P.UU1QAD5@ >$?!?_ (+8_P#!,#]H?XK:
M%\#_ (,_M46FN>*O$UZ;30]'@\,ZM&]W,$:0J&EM%1<(CL2S !5)) %?5%?+
MESX@U/X]_P#!2:V4>%KN;0O@#X-:9XPRE3XHUU"B$^DEMI4,O']S7!U[?1?_
M  DNK_\ 0H7O_?2T >+?'3_@JE_P3R_9G^-%O^SW\=_VL/"OAGQ=/+;Q2:9J
M$\FRR>==T*74Z(8;-G4AU$[QDJ0P^4@UZ_\ %/XE:-\)?AYJ7Q1U^TN;C1]%
MMC>:O+81&62WLEYFN0B\R+%'NE94RY1&V*[;4;Y9_P""E_@OX9Z%_P $]/BM
M\ -%^ RZMK'QD35=)\,^'9(XY9]=\6:P9FMY<MEBT4S"Y,O_ "[6]F9,I';Y
M7W7]FKP/XF^"'[,_@#X#>)M/O==NO"'@72M U#5)R&_M"2TLHK>29MW)\PQE
MCG^]S0!Z9I>J:9KFF6^M:+J,%Y9WD"3VEW:RB2*>)U#*Z,I(92"""."#FIZ^
M-_\ @C5\0_$</[)6L_ V[T.]O(O@Y\6_&'P\TRX:0$_V=I6LW,%C%R>D5H;>
M$>T(KZP_X275_P#H4+W_ +Z6@#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH
M V**R[/7M2N;I()O#-U"K-AI79<+[FM2@ HHHH **** "BBB@ HHHH *\H_;
MG_Y-'\>_]@%__0UKU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_
M $2E;M87PN_Y)GX=_P"P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR3]L#X4_M!
M_%+PGX6E_9D^)6A>%?%/AKQM::VFH^)-/FN[.>VBAN(YK22&%T=UG28PL0Z%
M%D9P2R*K>MT4 ?GW\/O^"?G[6'[1O[2OAKXJ_MD>'/A_X2\/_"SXYZCX_P##
M]MX0U*[U+4==U)[*.W@ GN+>W%I8!OWK(!)),\**VP(&;U_Q5X(O_@M_P5NT
M'X_SP,OAOXQ_"4^![V[0?);Z_I-Y/J5@DA[?:+.ZU)5;INLE3K(N?J6J/B+P
MUH/BW2SHOB32H;RV,T4RQ3+G9+%(LL4JGJCI(B.C@AE958$$ T ?.W_!2_\
M9D_:'_:G\*_#/PY\!;7P6&\%_&7PSXXU.;Q?XAN[(31Z1?)=BUB6WLKC+2E
MF]BH3.=K=*^D=-DU&73K>75[6&"[:%#=06UP98XY,#<J.R(74'(#%5)'.T=*
MFHH \I_9&^ _BCX'^#_$U_\ $G5;#4/&'CGQ]J_BCQ5?Z6[M TMS/Y=I!&TB
MJ[);:?!8V@9E!(M0<#-:UAI?[3:_M/7^L:EXJ\'M\(&\%PQ:9HL.G7 UU-?%
MRQEFDF+>2;4V^%"@;]_H 2WH%% 'P9XM^"7_  7#F_:J\0_M#>&K;]E/5+9#
M-I_P[LO%NM>)99/#6D,1O2,06B1_:;@HCW$^"S[4C4K'&JU]9^"?$WCOX/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_R:/X]_
M[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL
M+X7?\DS\._\ 8"M/_1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_P FC^/?
M^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W
M_),_#O\ V K3_P!$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[
M+_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_
M "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KU%?6%CJEI)I^IV45Q;RKME@GC#HX]"IX(H Q_A=_P DS\._]@*T
M_P#1*5NUX5J'_!/?X):C?SZA)XH\;1M/,TC1P^+)D12Q)PJC@#G@=JB_X=U?
M _\ Z&[QW_X5\] 'O5%>"_\ #NKX'_\ 0W>._P#PKYZ/^'=7P/\ ^AN\=_\
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M*RC%EXFFB3RH9RB9 ZMCJ>]>I_\ #NKX'_\ 0W>._P#PKYZ />J*\%_X=U?
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MB7PSK-IJ.FZA:QW-AJ%A<+-!<PNH9)(Y$)5T92"&!((((KE;#]HOX(:I\?\
M4/V6-.^).G3?$+2O#,7B'4/"B.WVJ#3))O)2Y88V[3)A<9R-RD@!E) .UHKY
M^^-__!53_@GC^S=\;+?]G;XY?M8^%?#?B^>:WADTO4)Y-EG).NZ%+JX5#!9L
MZD.JSO&2I# ;2#7M?C;QWX*^&O@O4_B/\0O%FG:)H&BV$E]J^M:I>)!:V=M&
MI=YI)'(5$5026)P * -:BO$OV4?^"CO[$/[<&MZUX8_99_:)T3Q9JWAZ-9=8
MTB".>VO+>%B LWD7,<<C0DE0)54IEE^;YAGVV@ HHHH **** "BBB@ HHKQ'
M7_\ @HM^R!X5_:CTK]BOQ'\3-0L_BCKN]M$\(3^#-76?4(D65GG@?[+Y<T"K
M#,QG1S$%B<EL*2 #VZBO-/VF/VO_ -GS]C[1-$\1_M#>-;K0K+Q'K2:/HD]O
MX=O]0^UW\BLT=JHLX)2)7"N40@%]C;<[3CS&#_@K_P#L!77CNX^%UM\4O$TG
MB:TTY=0NO#L?PG\3&_AM&;8MP]N-.\Q8BWRARNTGC.: /IFBOE;P)_P6O_X)
MJ?%%]73X:_'W4_$'_"/W @U\Z+\./$-T-+D)8;+DQV!$!RC\/M^XWH:]U^ G
M[1GP(_:D^'D'Q7_9U^+6@^,_#L\SPKJOA_4$N(TF3&^&3:<Q2KD;HW"NN1D"
M@"E^S7\&=3^!G@*]\(:KK4%_)=>(;[45FMXV556>4N$P>X!P:]!KBOBW^T7\
M$/@1K?@_PY\7_B3IV@7WC[Q-%X>\'6M\[!M5U.56:.VCP#\S!3@G S@9RP!Y
MG]K+]N_]D7]AG0=-\1?M6?'+2?!\&L22II4-W'-<7-WY2AI7CM[=))72,,I>
M0)L3<NXC<,@'K=%<S\&_C/\ "C]H7X9Z1\9?@?\ $'2O%/A77K;[1I&NZ+=K
M/;W*;BIVLO=65E93AE965@""!/XH^*'@+P7XN\,^ _$_B6&TUCQC?7%GX:L'
M1F>^F@M9;N95V@A0D$,CEFPO &=S*" ;]%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% 'YY?'Z&/]H/_@XX^$/[/_Q5/VCPA\*/V=K_
M .)OA+1;OFVN_$TVL'2Q<M&?EDD@M_WD1.6B8,R[2<G8_P"#D3PKIFG_ /!+
M_P 3?M.:+J8T7QW\%=>T;Q=\./%4.%N-*U2/4K:'"/UVRQS/$R9VL63(.T5Z
MY^W-^P1XD_:!^*_P\_:Z_9T^)-IX)^,_PJ>[B\.:UJ=C)<:;K6EW:;+O1]1B
MB=)&MY!RDJ-YD#DR("3BOC+]HK_@E1^W+XU\0>'M8\?^"4\0_!J#Q;I.K?%7
M]GOP+\<]4\177C::R>62*^CN_%$-K' 1,8&GLUFC6Z2+)E$L<;, ?8G[</Q4
M^)/A?]@GQ3XS^%/['FI>-]=\?> KF?Q!8:2+*.WL);C38X9+C44DE6ZNTCA(
M4QVL-U.Z6HC"?<KT#_@GEX=\#^#_ -@OX,>#_AI\58O'/A_2/A?H5CH_C& ,
M$UFWAL(8TNE5OF0.%W!&^9,[3R#537O$7[=GB[P+=W?PR^&7@SP[>Z_9.VDI
MX_\ $+I?^%7=2BBYMM.AN[;470@3;8[J%3O\GS#L\]][]BS]ESPK^Q1^RCX!
M_92\%ZY=:IIW@7PW!I<>J7J!9;V1!F6=E!(3?(SOL!(7=M!.,T 3?M"?LL_"
M[]IC6OASK?Q*M)99?AA\1+3QGX=$)4?\3&VMKF"+>2#\@^TL^!C+(G/%;?B?
MPY\(_ 7B/6_VE/&O]G:==67A,6>L>)-4F5(['2;5Y[I\N_RPQYD=Y",!A'&6
MSY:8ZZOD#_@H/\$/^"G7QS^*_ABS_9F7X$7/PPT$1ZAJ?ACXGZMK2OKVK)('
M@:ZCL;8JUK;LJR)!YA624*\@(C1  )_P1D_9TU/X)?LT^//$\GA:Z\*Z-\7/
MC/XF\?>#?"$UL;:7P[H>HS(+"V,! ^RLT$*7)@P/*:Y*$!E('+?\%7/V7/AM
M\5/V8OA9_P $W_@?X-L['Q+K'C[P_/X!-C"/-\(Z;I%_;7>I:X&^]&L5HLEN
M9209)]0ACR7F&?H#]F"U_P""@MMX*\4:Y^V9?_">Z\52RA/"&@?#6348M(AA
MCARKW-S>Q-<>;+.[*Y5&2..*,HK,7W?+OP\^!/\ P7_\!^+_ !7\27O_ -C_
M %/Q;XPN2+WQ3J]YXIGFLK)&<VEA;Q+!&B6ML)&*0KMWNTDLC-)+)(0#]"Z*
MK:-:7VGZ1:V&IZK)?W,%LD=Q?2Q(C7#A0&D*H JEB"2%  SP *LT %%%% !1
M110 4444 %? /_!Q+XAU^_\ V8?A#^S=!KUWI7AKXY?M+>#_ (??$#4+.X:%
MDT&]FGDNH_,4@HK_ &=$;D H74\,0?OZO'?V\OV*OAA_P4!_9EUW]FKXIW]]
MIL&I/!>:-X@TAPE[H>IV\@EM;^W;M)%(H..-RED)PQH ZSXB?LY_!;XH_L_:
MI^RUXM^'NF2> ]6\,MH$_AN&T2.VBL##Y2Q1(!B,(H785 V%%*X*BOB__@@7
M\:/B'XU_X)!>!_B5XL\'ZI\2O$_@*77?"7AZ^TU[(:IK.EVFJM;PK#/?3P0J
MOE6]NK;YD5A9H2695SR?[2?_  3L_P""OGQ6\(7U[X%^/?@?0?B?%I$]C)\7
M]#^)_B6W/B&U-B]LUI+X:FMYM-L//&QS)%*XMYR;B)0V0?H']A+P%\:OV?/V
M5?!GP'^ /[&<WPXT'P!HD>D+X.^*WC*P6?4KAB99[^*_T4Z@I!F,C,9(4-P]
MPSA+<1@2@&+_ ,$;)6UGP[\>?B#XEA70/&/B[]H/6M9\:_#)PPG\#W;VME#%
M83DJ$FFDMX(+M[B'=!*UV3$\BC>WT[^T!\%_"7[1WP)\9_L^^/1)_8GCCPKJ
M&@ZLT&/,6WN[=X)&3((#A9"5/8@&O-OV-_V5?&?P2\<?%C]H#XQ>)M,U#Q[\
M9O%]MK7B*UT 2?V=I-M9V$&GV-A;O*JO<>5;VZ[[ADC,LCLWEQC"CW>@#A],
M_9U^$VF^!O 7PZ;PQ'<:3\-6LG\)VES\R6TEI9O:6SLN-KM''(2N1\KJCC#(
MI'S3\!OA#I?Q*_X+._%;]MOX9:='9^%= ^$EE\,]=U.UC"0^)O$L>I->W4H*
M\3FP@2VLVF.2)))8,YMW5?7/^"@/A#]NGXA? I_ ?[ WBGP+X?\ %&JWJ0ZO
MX@\;ZI?6WV+3N?.%F;.WE=;F0?()3M\H,SKEPI7A?V)OAA_P4]^&WB30? '[
M0NG_ +.?A;X5>&=$EAL-"^#B:U-?7-P%5((9&U)%2. !I97=29GE2/)PTF0#
MR;_@Y%^!^N_$+_@FWXW^(Z?M">/-"TSPK'I5S-X'T"XT^'2=<F_M:U16OR]F
M]W*J^9D1)<QQ%HXV*$KD_H+7SA_P5?\ V8/CE^VE^P]XP_9;^ C^$[;5_%RV
M<3ZIXOUBYM;:RC@OK>Z+ 6UK.TK,(2FWY -P.3C%?0'ABX\37>@6MQXRTBPL
M-4>(&]L],U%[NWB?^ZDSPPM(/<QH?:@"_1110 4444 %%%% !1110!^8W_!6
M'3/$7_!)K]JW2O\ @N9\$?#EQ?>#M1BL_"G[47@S3'1&U?3994@T_68E<JAN
MX)FAAR2"P:),HK3/7V-^Q9^SYXM\"6>N_M&_'T6US\7?BB;:]\:S6MR9K?1[
M6(/]AT*S8\?9;*.5TW@#SYI+BX8 S87SS_@M=^Q?^T7_ ,%$?V"O$_[&'[/5
MUX*TZ?QI<Z<=5U[QGK=Y;)816>H6U\OE16UG.9F=K8(=S1A0Q/S'@?1GA"Z^
M,D/PFM)_%WA+PS'XSBTY1<:5IOB.XDTQKE1C"W;V:RB,XSDVY*YQAL9(!^>?
M_!$33=/UC_@G_P#M7:1J]A#=6EU^T7\3(;JVN(@\<T;)&K(RG(92"00>"#7H
MW_!NMX<\/^,/^"$WP2\)^+-#L]3TO4_#&KVNHZ;J%LLT%U!)JU^KQ21N"KHR
MD@J0002#5;_@GI^PI^W[^QM^RS\;/@OXPTSX/ZUKWQ'\>^(_%GA^]TWQOJL=
MI:W&K)&#;7 ?2=^R)E9A(F2X(78GWZROV(?V/O\ @L3^Q1^P-X4_85^&^I_L
M[V-SX6TJZL;#XD7'B+6]1FMS<7<]P;A=-;38(Y)$\\A5:X"%D4L""5H L?\
M!NU>WWA?X&?'W]F;3]2N+KPG\%OVK/&G@KX?^=.T@M=%MYH)H;968DD(\\IZ
MXPX X%?7NE_LL_"_2?VN-9_;1MK27_A,=:^'UAX/N9,J(EL+6]NKP$#&2[27
M(#$G[L,8[5R?_!.?]A/P7_P3N_9CL/V?O"_C#4/$^I3:K>:WXP\8ZM&$NO$.
MM7DGF75]*H)"%CM55RQ5(T!9R"S>ZT ?)'_!4'X4?"+0?^"='Q5_9X\-_"ZR
MUO7?C*-4T?PGX:,2R3ZYXNUAI7@GRV3NAG;[6TIXMH+)I,HD V^S?#3]F/P[
MH_[+/P]_9K^+DZ^+(/!?A[P_:7MQ>Y:/5+O2X[<Q7$JM]\?:+=)MK=65<YZ5
M\M^)_@E_P7'?]J;Q%^T-X>MOV4M4A)ET_P"'UGXKUKQ++)X9T=BNZ*(06B)]
MHG*(]Q/@LY5(P1'&B#WKXN>&O^"CES^Q)#X2^#?COX9#X]ZAI<46J^*-92[M
MM TRZERUS-91);SRRK"6,=NLR\A4>8N0R. >6>(OA%I?QV_X+;>$_C[\,M.B
MM[?X'_"O5]$^)/B:TC &J:CJS6SZ?H<CC'FO;0)->NN3Y0O+;(!F&/LZOC/]
MC#X*_P#!6KX0:[X5^&GQ:'[-N@_#+3+N>Z\33_#^Y\07_B'5I7665G:;4T$;
MS7%VZR7%S(6E<-*00[AU^S* "BBB@ HHHH **** "OCK_@LC^PCX_P#VJ?@O
MH7Q\_9;O5TC]H#X':L?%7PAUN, -<W$8#7&DRDX#P7<:>648A2XCW'87!^Q:
MQ/B-<?$.V\$:E-\*-$T;4?$0MF&E6?B'59;*RDE/ \V:&"=T4=?EC8G&.,Y
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>biib-20220930_g23.jpg
<TEXT>
begin 644 biib-20220930_g23.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M^-/"TB"1=9B 8 C=D'\01D4[_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
M\^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_]^A1_9VG
M_P#/C#_WZ% %:V\4>'[R=;6UU6)Y'.$13R35^HDL;*-@\=G$K#H5C (J6@ H
MHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_
M & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%% !1110 4444 %%%% !1110 4444 %>!^*_^1IU+_L(3?\ H9KWRO _%?\
MR-.I?]A";_T,U\AQ=_ I>K_(#/HHHKX8 HHHH **** "BBB@ HHHH **** "
MO</AM_R(VF_]</\ V8UX?7N'PV_Y$;3?^N'_ +,:^IX3_P!^G_A_5 ;E%%%?
M?@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/
MX]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %>!^*_^1IU+_L(3?^AFO?*\#\5_\C3J7_80F_\ 0S7R'%W\
M"EZO\@,^BBBOA@"BBB@ HHHH **** "BBB@ HHHH *]P^&W_ "(VF_\ 7#_V
M8UX?7N'PV_Y$;3?^N'_LQKZGA/\ WZ?^']4!N4445]^ 4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@?BO_
M )&G4O\ L(3?^AFO?*\#\5_\C3J7_80F_P#0S7R'%W\"EZO\@,^BBBOA@"BB
MB@ HHHH **** "BBB@ HHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\
MKA_[,:^IX3_WZ?\ A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<__)H_
MCW_L O\ ^AK7J]>4?MS_ /)H_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*
MW:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>!^*_P#D:=2_["$W_H9K
MWRO _%?_ "-.I?\ 80F_]#-?(<7?P*7J_P @,^BBBOA@"BBB@ HHHH ****
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M#Z1_S\WO_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\
M/S>_^!;4 ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\
MWO\ X%M1_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\
M@6U &Q16/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO
M_@6U'_"#Z1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4
M ;%%8_\ P@^D?\_-[_X%M1_P@^D?\_-[_P"!;4 ;%%8__"#Z1_S\WO\ X%M1
M_P (/I'_ #\WO_@6U &Q16/_ ,(/I'_/S>_^!;4?\(/I'_/S>_\ @6U &Q16
M/_P@^D?\_-[_ .!;4?\ "#Z1_P _-[_X%M0!L45C_P#"#Z1_S\WO_@6U'_"#
MZ1_S\WO_ (%M0!L45C_\(/I'_/S>_P#@6U'_  @^D?\ /S>_^!;4 ;%%8_\
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M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\
M),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5X'XK_Y&G4O^PA-_Z&:]\KP/Q7_R
M-.I?]A";_P!#-?(<7?P*7J_R SZ***^& **** "BBB@ HHHH **** "BBB@
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MM/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH **** "BBB@
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M)\$:K^R_\2?#WAGQ)X1\>0ZY-/XHT^>ZLK^S6POK::RDBA=&(E%TJ[MP\O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&@B_^3J\;_6')_\ G[_Y++_(#[%HKXZ^U_\ !0G_ */1\,?^&@B_^3J/M?\
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M#PMI?A'XZ7GA7PEX:\6: VF:II^G6NC:1)_I4$B++'++<3W-QME&]%N%0\(
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M#Z*A_P!4O^Z*=38?]4O^Z*=7[.M@"BBBF 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:U
MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
MV K3_P!$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 5^6G_!2;X&?L _\%&_&<7C;PQ\0+;X9?M _##XTVO@W4/B/X2U]++Q'X=C2
M9A%<R[7C,T#1-%*C2#Y-SQI(I#FOU+KR;XV_L*?L>?M&2:9/\:OV:O!/B*32
M=<75K275/"]I.WVGS6E<L7C)99'9FD4\.22V: /@WP7\7OVN_P!K;_@W!_:
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MWRS&P)!3;M()!'-:-AH.AZ5H</AC2]&M+;3;:T6UM]/M[=4@B@50BQ+&!M5
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M@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\
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M#XC_ !-T_2O%OQ(O+FU\$:!-O:XU:2WB\Z?8J*=JHG)=]J\@9R0#J_&;XO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M*;@3>;*[!MTF<LO' [5ZI_P[W^"?_0V^._\ PLKG_&@#W2BO"_\ AWO\$_\
MH;?'?_A97/\ C1_P[W^"?_0V^.__  LKG_&@#W2BO"_^'>_P3_Z&WQW_ .%E
M<_XT?\.]_@G_ -#;X[_\+*Y_QH ]THKPO_AWO\$_^AM\=_\ A97/^-'_  [W
M^"?_ $-OCO\ \+*Y_P : /=**\+_ .'>_P $_P#H;?'?_A97/^-'_#O?X)_]
M#;X[_P#"RN?\: /=**\+_P"'>_P3_P"AM\=_^%E<_P"-'_#O?X)_]#;X[_\
M"RN?\: /=**\+_X=[_!/_H;?'?\ X65S_C1_P[W^"?\ T-OCO_PLKG_&@#W2
MBO"_^'>_P3_Z&WQW_P"%E<_XT?\ #O?X)_\ 0V^._P#PLKG_ !H ]THKPO\
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M#.43(!Y;'4]Z]4_X=[_!/_H;?'?_ (65S_C0![I17A?_  [W^"?_ $-OCO\
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MHH **** "BBH=1U'3](T^?5M6OH;6UM86FN;FXE"1PQJ"S.S-@*H ))/  H
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M_P#$+I?^%7=2BBYMM.AN[;470@3;8[J%3O\ )\P[//?>_8L_9<\*_L4?LH^
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MXRC5-'\)^&C$LD^N>+M8:5X)\MD[H9V^UM*>+:"R:3*) -OLWPT_9C\.Z/\
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)** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>biib-20220930_g3.jpg
<TEXT>
begin 644 biib-20220930_g3.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OFK_@JM^W_P"(?^"9/[)^I_M?)\#(
M?'7A[P]>VD'B&QC\5?V;=VZW5S%:PR1!K699AYLR!@60J#D;N<?2M?GK_P '
M3_\ R@U^,7_7YX:_]2'3J />?&'[1'_!2+PEX5U'Q1;_ /!.KPGK3Z=927"Z
M1HGQT#WEYL4MY4"RZ1&C2-C"JSJ"2!D5] >$/%.C^./">E^-?#TS2:?K&G07
MUC(Z%6:&6-9$)4\@E6'!Z5^?'_!3[XJ?\%D_V0/V79OVDM._:(^".LV7AK7K
M%-4T_P -?"K5=%GVWDG]GP3R37.N7R2P0W=W;7$D/EH9$A8&0#*MZ3\;=0^,
MW[ GQ;_9[UG3?VC_ !GX^TOXF_%*T^'WQ#T;QI=0W(U&>]T^\GAU>T"1*+"6
M&>S!:"W"6[0RR#RPR(X /L^BOA#XY6G[3'Q/_P""T>E_LMZ)^V%XZ\,_#/5?
MV<[WQ3K?A[P^]E;2QW,6M6UFJVEPMMYL+,71FE9GE"K(B/&)#CZZ\.?!E])^
M ]M\"O$'Q8\9ZZ8M!_LNZ\8W^M^1KMV-FPW+7=HD.RX(Y\V-4(/(P>: ,3XQ
M?M1^%_AY^S-XT_:9^'GA^X\>V'@NRUJ6[T[P]>V\<DTVE2W$%]")+AT0-%-:
MSQMR3NB8*&. =O\ 9L^,</[1/[.O@']H&W\/MI,?CKP5I7B&/2GN1,UFM[:1
M7(A,@5?,*>;MW;5SC.!G%?GI_P $SOAUI_@C_@W?^(&I6'B77[T7_@[XGP_9
MM7UR:[AMEM]7\0Q*85E8^6SCYI&',C_,Q)YH^$?B#X\?L;_\$U?V/?VHK?X_
M^)=6O];N_AGX?\6^&;JXC.BS>']82TL!90V>S;#+;1W,#I<H1-));DR.Z2,E
M 'Z@45^;'@#]I+]K/]LW]H']H:>#P#\>Y?"_PU^*NH?#WP#;_!CQ)X5TNWTN
MXTZ&'[1J-W_:NJ6T]]<S2S"18IHI+18?* 5V:0C[ _X)^>)OVP_%/[*/AF[_
M &]/AU%X:^*5K]IL_$=O!<V,B7PBGD2"^Q8SSP1-/ (I7B20A)'=0 H H =\
M;_C_ /M">%_C!9?![]G7]F&T\=SIX<_MCQ%K&M>-UT.RTM))VAM80WV2Y>XE
MF,-TV%4"-;?+']X@/S#\*/\ @L=^U1\:_P!G7XE_M-_#C_@G#8:EH/PH\4:Y
MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
M9:OBU_Z2B@#]'?V7_C9!^TM^S1\._P!HVU\.OH\7Q \"Z1XDCTF2Z$[62WUG
M%=" R!5$A02[=VU=VW.!G%=U7Y:_!37_ (\?L;_\$JOV0_VL;/X_^)=4O[Y?
MAAHOB7PQ<7$9T6?PWJPL=/6QCL]FV&:W@N876Y0B9YH"7=T<QUZAXXT']IKX
MT?\ !9+QU^RQ+^VI\1?#_P +X?V?M*\5-HOA>>QLKNSU&YU:_M$CM;E+7?'"
M%MS*S-OF9TC4R^5OC8 ^^J*_(C]BKXV_\%*OVN/^">D'[37@?3OVD-<^(VM6
MFH-\,/$FG^(O \?AZU2RN)K2SM[ZRNM4MFOC*UL/ML]Q:K,999_($2K%CVK]
MIG]L?]M[7?CM^S3^R'=_!KQGX:U_QW\-K_QG\:O#OPQUG0QK"RV<5M$^D6-_
MJ-]%:Q0K=W#-+-#,UP8DC$3+N=P ?H;17RA^PSJG[>&C_M%^/? 7QI^$'C^Q
M^#,NBV>I?#K7?BCXA\/7NMZ;J.]H[S29'TK4+N2[MR-D\,\_[Q?WL;N^(Z].
M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
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MGB_P_I_PYE^%6CW7P'A\=7NS1=D)N_[?EM5)V#5EF:RPZC[4(3#Y)QNKT_\
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MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,
M?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,
M?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\
MA,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'
M_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M /+/VN?CA\:?@1J/P[\1_"[X%>)_'VB7WC"6S\?Z?X1L(KB]L-*.FWCK>HDC
MIO"726H*(WF,KL$5VPA_.[]@?]EC3OB5_P %/O!?[<'[)7P'\:_#W3]+\6_%
MB/X]^)]<\,W>@6'BNVNM?U--&TU;6Z6-[JZ@D9'E98@L/V18Y'\V-8U_63_A
M,?#'_0:@_P"^JBM/$G@RPB,%C?VD"-*\C)"H4%W8N[8 ZLS,Q/4DDGDT ?+W
M_!=7P_XR\>_\$JOC%\*?AM\._$_BKQ+XK\+G3= T+PGX9O-4N;FX>:(@;+6)
MRB@ DN^U1CKT%?0.M?%Y]'_9ZU+XV^%/AKXKU^33?"]SJEEX1M]"FL]9U*2"
M%W%G':W:Q.EQ(R;$20+EF7L0:Z7_ (3'PQ_T&H/^^JIZ_JW@WQ)HMUH-_P"(
MI8H+N%HI9+#4)K695/!V30LLD;>C(RL.H(/- '._LO?M!:/^U#\ ?#GQ[T?P
M7KOAR/7K21[GP[XELA#J&EW,,TD%Q:SQJ6 DCFBD0X)!VY'6OG'_ ()@R^)+
M;]I_]K&]\1?"WQSH%IXO^-*Z_P"%[_Q1X#U32[;5-.71=,LC-#+=V\:-^_MY
M0$SO(7<%V\U]5^$YOAGX%\,V'@SP<+#3=*TJTCM=.T^S39%;PHH5$50.   *
MT?\ A,?#'_0:@_[ZH ^/]!T[7?V7/^"A_P ?_C?^T!\&O&7BG0_B?I/AY?AU
MXM\)^!K[Q)]FTVST_P BZ\/R0V$,\UE_I?G70WHEO-]L+&3>C*,/X ?L>_M9
M:9_P1P^*'[-GASSOA]XU\;6_CB?X7>&9]10/X+T_5+N\FTG26GA9EA,,,T:$
MQL1 7*J3Y0K[<_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZH _/[XA>#M9^/_ ,"O
MV:_V;/V<?V1_&_P\\9_#3X@>$]3O+O6O UUI5C\/+'370ZH(]1DC6UO_ #K=
M9[-8[*6<7 NLOB/<P^T_&OQM\1^$OV@_!'P0L?@1XPUC3?%VGZG<W_CS3+2)
MM'\/-:1HZ0WLA<.CSEBD8"G<P] Q7KO^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J
M /C'XW_\$I?C+J&K_%3XE_"K_@II\<_#0\=ZEJ6NWOA#08-%EMI+F6W$:6RM
M-823NBQ10VZ!G++'$B @*,=-_P $-/V=?B_^S-_P31^&7@3XW>-O&=_KMQX8
ML+J;P[XVL8K:?PF#9PQG2(HDAC=(HFC8@3;I SMECP!]4?\ "8^&/^@U!_WU
M1_PF/AC_ *#4'_?5 &E16;_PF/AC_H-0?]]4?\)CX8_Z#4'_ 'U0!I450MO%
M'A^\G6UM=5B>1SA$4\DU?H **** "BBB@ HHHH **** "O*/VY_^31_'O_8!
M?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .U^&%A8M\-?#S-91$G0[0DF,<_N4K
M<_L[3_\ GQA_[]"LCX7?\DS\._\ 8"M/_1*5NT 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%?.?C#
M_@JM_P $[? 7BW5/ OBSXX0VFJZ+J,]AJ=K_ ,(AJDGDW$,C1R)N2T*MAE(R
MI(.,@D5])5_.A^V!_P G:?%'_LHNM_\ I?-7S'$V=8K):-.=",6Y-I\R;V7D
MT?M_@EX:9%XDYEC,/F=2I"-&$91]FXIMMM._-">GI8_8S_A\%_P3-_Z+_#_X
M1>K_ /R'1_P^"_X)F_\ 1?X?_"+U?_Y#K\+J*^._U[S?^2G]TO\ Y(_HO_B5
MCP^_Z"L5_P"!TO\ Y0?NC_P^"_X)F_\ 1?X?_"+U?_Y#H_X?!?\ !,W_ *+_
M  _^$7J__P AU^%U%'^O>;_R4_NE_P#)!_Q*QX??]!6*_P# Z7_R@_='_A\%
M_P $S?\ HO\ #_X1>K__ "'1_P /@O\ @F;_ -%_A_\ "+U?_P"0Z_"ZBC_7
MO-_Y*?W2_P#D@_XE8\/O^@K%?^!TO_E!^Z/_  ^"_P""9O\ T7^'_P (O5__
M )#H_P"'P7_!,W_HO\/_ (1>K_\ R'7X744?Z]YO_)3^Z7_R0?\ $K'A]_T%
M8K_P.E_\H/W1_P"'P7_!,W_HO\/_ (1>K_\ R'1_P^"_X)F_]%_A_P#"+U?_
M .0Z_"ZBC_7O-_Y*?W2_^2#_ (E8\/O^@K%?^!TO_E!^Z/\ P^"_X)F_]%_A
M_P#"+U?_ .0Z/^'P7_!,W_HO\/\ X1>K_P#R'7X744?Z]YO_ "4_NE_\D'_$
MK'A]_P!!6*_\#I?_ "@_='_A\%_P3-_Z+_#_ .$7J_\ \AU[[\+/B#\-/C7\
M/M+^*?PROX=3T'68#-IM_P#89(?.0,5SLE177E2,,H/%?S8U^^O_  2R_P"4
M?OPP_P"P"_\ Z4S5]'PUQ'CLYQDZ5:,4E&^B?=+JWW/QOQJ\&N&/#CA[#X_+
M*U:<ZE50:J2@U;DG+3EIP=[Q75JU]#WI+&RC8/'9Q*PZ%8P"*EHHK[4_FD**
M** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!
M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MJO\ DBL%_P!A"_\ 3=0]_HHHK]5/X."BBB@ HHHH **** "BBB@ KRC]N?\
MY-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T
M2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
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M_"[XF^ M=_9RU[]F+XBZ[)H0NO%=IXD\.>(!9R7%O%>1V\MM+!<I$&D$;Q2
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
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M?_T-: .Z^%W_ "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "BBB@
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M?3_&N#P)=J_AY-0FN;0Z#)LB/E#561=1,K ><81^^.?+K]!J "BBB@ HHHH
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M_P"@C_R2I_\ (GRW17U)_P .UO\ JM'_ );G_P!T4?\ #M;_ *K1_P"6Y_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:G_Z22U%63A3E)=$SJP5"&)QM*C+:4HIVWLVD>)_\/DO^";O_1QO_EH:Q_\
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M *.-_P#+0UC_ .1*_"BBC_7O-_Y*?W2_^2#_ (E8\/O^@K%?^!TO_E!^Z_\
MP^2_X)N_]'&_^6AK'_R)1_P^2_X)N_\ 1QO_ ):&L?\ R)7X444?Z]YO_)3^
MZ7_R0?\ $K'A]_T%8K_P.E_\H/W7_P"'R7_!-W_HXW_RT-8_^1*/^'R7_!-W
M_HXW_P M#6/_ )$K\***/]>\W_DI_=+_ .2#_B5CP^_Z"L5_X'2_^4'[K_\
M#Y+_ ()N_P#1QO\ Y:&L?_(E'_#Y+_@F[_T<;_Y:&L?_ ")7X444?Z]YO_)3
M^Z7_ ,D'_$K'A]_T%8K_ ,#I?_*#^G*":.XA2XA;<DBAD.,9!&13JK:+_P @
M:T_Z]8__ $$59K]73NKG\#S2C)H*_/3XN?\ )5O$_P#V,-[_ .CWK]"Z_/3X
MN?\ )5O$_P#V,-[_ .CWKYCB?^#3]6?KOA%_O^*_PQ_-G/4445\>?NH4444
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MK;[ZM_JSU\'E=3!XC%UH5-:\U4V^%JG3IVWU5J:;V=V[-:6]P^+?B7P[X?\
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M/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\
M1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7'?M$?\ )O\ XZ_[$[4__226NQKC
MOVB/^3?_ !U_V)VI_P#I)+6.(_@3]'^1Z&4_\C2A_CC_ .E(_F\HHHK^>3_8
M **** "BBB@ HHHH **** "BBB@ HHHH _IKT7_D#6G_ %ZQ_P#H(JS5;1?^
M0-:?]>L?_H(JS7]%1^%'^.53^(_4*_/3XN?\E6\3_P#8PWO_ */>OT+K\]/B
MY_R5;Q/_ -C#>_\ H]Z^9XG_ (-/U9^N>$7^_P"*_P ,?S9SU=-\-K+Q[!/>
M^,OAU=W<5_H4*7#FR4F01,P1C@?>49&00003G@&N9JQI^K:II,GG:5J5Q;/D
M'=;S,AR.AR#VKY*E)0FF[_+<_;<52G6P\H1MK_,KIJ^J:\U='M?QIN= ^(OP
MWU/QUXE\+1:;XATN738X=6@C\M=7,\*M(C+T9T&YB1R %' XK@OAU\/_ !#'
M8Q?$J?P;?ZE:03_\2RSM[*207MPO(W;0<0J<%C_%C8.2Q7GO%7C;Q7XWNX[W
MQ5K]U?/%&J1?:9V<( H7@$G&=H)]3R:FL/B9\1]*LH].TOX@:W;6\*!88+?5
M9D1%'8*&P!["NVKB:-;$>TDG^%V[[O\ K6VO4\'"91C\#E?U6C):O9N5HQLD
MXQ>Z3:;Z6YFHI:6V?#OA[4-=^-6EZ=\7)+JRDU?58I=3>[)BFQ*^[+9P8RV1
M@G& P(XQ766WBKQ1\09/'7AWX@Z9%8V=OID]W<O#:+!):W4!Q;I+(H#S[FQ'
MB4N6+;A\PS7D^IZKJFMW\FJ:SJ5Q=W,I!EN;J9I)'(  RS$D\ #\*L:EXM\5
MZS8QZ7K'B;4+NVAQY5O<WLDD:8&!A6) XK.GB8TTTK[M^MU:S_KJ_4Z,3E-7
M$RA*3BFHQ2LO@:DI-P];):_RKI=/M/"VK:G:?LY^(+/PQ=21W+>([5M8%NQ#
M_8O*D"$XYV>;@'W(]:K_ !6:6?P!X(O=>9CK<NFW/VIYO]<]H)L6K/GD_+O"
MD_PA>V*XS2=9UC0;P:AH>JW-E<!2HGM)VC< ]1N4@TS4-1U#5KR34=5OIKFX
ME.99[B4N[GU+'DU+Q-Z/)Y6\M[W]>GWFL,K<,=[9-6YW.]O>=X<G*_+K?RBK
M:7-)(_&/PP\5V>H3V5QIFIV3Q7=LMQ$58='1L'J#^O2O1(?$/A_P7\/M?\97
M/@V/2=<\763V6F6@NV?%O*?W\Z1,,PPD?*NXL6)^4[0<^67&LZQ=WR:I=:M<
MRW,001W$D[-(FT +AB<C  QZ8J*[O+N_N7O+ZZDFFD.9)97+,Q]23R:5/$>Q
MOR>=KVTOI?UMVM^!6*RSZ_[/VS2:MS<MUS6=^7?X;][Z72M>Y'1117,>N%?>
M'[,/_)!/#/\ UX'_ -&/7P?7WA^S#_R03PS_ ->!_P#1CU]'PU_OD_\ #^J/
MROQ:_P"1'0_Z^+_TF1WE%%%?:G\_A1110 4444 %%%% !1110 5Y1^W/_P F
MC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K
M"^%W_),_#O\ V K3_P!$I6[0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<W\9-'_X2
M'X0^*M ^T>3]N\-WUOYNS=LWV[KNQD9QG.,BNDK(^('_ "(>M_\ 8(N?_135
MG52=*2?9G5@92AC:4H[J4?S1^(W_  [6_P"JT?\ EN?_ '11_P .UO\ JM'_
M );G_P!T5]245^/?V=@_Y?Q?^9_?/^OG%?\ T$?^24__ )$^6_\ AVM_U6C_
M ,MS_P"Z*/\ AVM_U6C_ ,MS_P"Z*^I**/[.P?\ +^+_ ,P_U\XK_P"@C_R2
MG_\ (GRW_P .UO\ JM'_ );G_P!T4?\ #M;_ *K1_P"6Y_\ =%?4E%']G8/^
M7\7_ )A_KYQ7_P!!'_DE/_Y$^6_^':W_ %6C_P MS_[HH_X=K?\ 5:/_ "W/
M_NBOJ2BC^SL'_+^+_P P_P!?.*_^@C_R2G_\B?+?_#M;_JM'_EN?_=%'_#M;
M_JM'_EN?_=%?4E%']G8/^7\7_F'^OG%?_01_Y)3_ /D3Y;_X=K?]5H_\MS_[
MHH_X=K?]5H_\MS_[HKZDHH_L[!_R_B_\P_U\XK_Z"/\ R2G_ /(GRW_P[6_Z
MK1_Y;G_W11_P[6_ZK1_Y;G_W17U)11_9V#_E_%_YA_KYQ7_T$?\ DE/_ .1/
MTETR+R=-MX=V=D"+G'7"BIZCLO\ CSB_ZY+_ "J2OV2.R/\ /Z;O-A7YZ?%S
M_DJWB?\ [&&]_P#1[U^A=?GI\7/^2K>)_P#L8;W_ -'O7S'$_P#!I^K/UWPB
M_P!_Q7^&/YLYZBBBOCS]U"BBB@ HHHH **** "BBB@ HHHH *^\/V8?^2">&
M?^O _P#HQZ^#Z^\/V8?^2">&?^O _P#HQZ^CX:_WR?\ A_5'Y7XM?\B.A_U\
M7_I,CO****^U/Y_"BBB@ HHHH **** "BBB@ KRC]N?_ )-'\>_]@%__ $-:
M]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L
M!6G_ *)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5D?$#_ )$/6_\
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M -C#>_\ H]Z^8XG_ (-/U9^N^$7^_P"*_P ,?S9SU%%%?'G[J%%%% !1110
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M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
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M$_\ @^K_ /)&A_PE.O?\_P!_Y"7_  H_X2G7O^?[_P A+_A6?11_JOPS_P!
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MOE.2MLD]$>GZIXC_ &:-2L;+21%XYALK%/W=G!'9JLDA WR,2Q)=\#+<X
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M]C[_ )-I\(_]@YO_ $:]?F[7Z1?L??\ )M/A'_L'-_Z->OAN/?\ D64O\?\
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M,U?FWB=A:%#)Z+@K/VGG_+(_0O#C%5Z^;58S=UR>7\T3WZBBBOQ$_90HHHH
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M_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/
M_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0
M!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP
M_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN?V=I_P#SXP_]^A1_
M9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_OJKG]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@_P"^JN?V=I__ #XP
M_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZJY_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H4 4_\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^JN
M?V=I_P#SXP_]^A1_9VG_ //C#_WZ% %/_A,?#'_0:@_[ZH_X3'PQ_P!!J#_O
MJKG]G:?_ ,^,/_?H4?V=I_\ SXP_]^A0!3_X3'PQ_P!!J#_OJC_A,?#'_0:@
M_P"^JN?V=I__ #XP_P#?H4?V=I__ #XP_P#?H4 4_P#A,?#'_0:@_P"^J/\
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M/^(:\$_] O\ Y/4_^3#_ (C;XG_]!_\ Y2H?_*SH/^$Z_P"H7_Y'_P#L:/\
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MN/VK/B=/"X9'^(6M,C#N#?38-?T2?V=I_P#SXP_]^A7\[G[7:JG[6'Q/1%
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MXA_&7PE<_&*Y33_'OQ.:0ZI>,FB:,LD?[RWMW\J-P43=#&<+T/WV?<?\%O\
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M 4444 %%%% !1110 4444 %8?Q/_ .2:>(O^P%=_^B7K<K#^)_\ R33Q%_V
MKO\ ]$O6V'_CP]5^9E7_ ($O1_D?E?1117]%'X(%%36%A>ZI>Q:=IUJ\\\[A
M(88URSL>@ [FH:5U>P6=KA1113 **** "BBB@ HHHH **** /UGL/^/&#_KB
MO\A4M16'_'C!_P!<5_D*EK^<'N?OZV"OYU_VO?\ D[+XH?\ 91-;_P#2^:OZ
M**_G7_:]_P"3LOBA_P!E$UO_ -+YJ_5O"G_?L3_AC^9^7^)_^YX?_%+\D>=T
M445^VGXX%%%% !1110 4444 %%%% !1110 5^]W_  2V_P"3 /AC_P!@)_\
MTIFK\$:_>[_@EM_R8!\,?^P$_P#Z4S5^8^*?_(EH_P#7S_VV1^C^&7_(XK?]
M>W_Z5$]^HHHK\)/VT**** "BBB@ HHHH :T4;NLCQJ60_(Q'*]N/2G444 %>
M4?MS_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[
M 5I_Z)2MVL+X7?\ ),_#O_8"M/\ T2E;M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_"3]M"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
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M .-5\?T4?V3AN[_#_(/[6Q/9?C_F?8'_  U)\"?^AZ_\IEU_\:H_X:D^!/\
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MXI_\B6C_ -?/_;9'Z/X9?\CBM_U[?_I43WZBBBOPD_;0HHHH **** "BBB@
MHHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7
M?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KC_VA_P#D@'CG_L3M3_\ 222NPKC_ -H?_D@'CG_L3M3_ /222NC"
M_P"]4_\ $OS,,5_NT_1_D?SAT445_7A_*04444 %%%% !1110 4444 %%%%
M!1110!_3'HO_ "!K3_KUC_\ 015FJVB_\@:T_P"O6/\ ]!%6:_CV7Q,_K*/P
MH*_G7_:]_P"3LOBA_P!E$UO_ -+YJ_HHK^=?]KW_ ).R^*'_ &436_\ TOFK
M]5\*?]^Q/^&/YGYAXG_[GA_\4OR1YW1117[:?C@4444 %%%% !1110 4444
M%%%% !7[W?\ !+;_ ), ^&/_ & G_P#2F:OP1K][O^"6W_)@'PQ_[ 3_ /I3
M-7YCXI_\B6C_ -?/_;9'Z/X9?\CBM_U[?_I43WZBBBOPD_;0HHHH **** "B
MBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH
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M'[]CC2O%/[(6IZ?XB^%7BNXUB[M;26R40J;Z_N;B]L9;9T7RE2:XFB\AT^5
M%^88)\1_:R\4:W\0/^"I'[,W@_XD_#?5/ASX9\&^+-=U'PIX_P!;FM9(_&>L
M/H]U:QZ'8M9S3&U62WEGNF%[]G>9;01QQNP8J ?5OQI_:)^#G[/=EI5S\5_&
M'V&?7M0-CX?TFRT^XO\ 4=7N@C2&"TLK2.6XNI BLY6*-RJJ6. ":M_!KXX_
M"?\ :"\'-X\^#OC6UUO38K^>QNWA5XYK*\A;;-:W$,JK+;7$;</#*J2(<;E&
M:^4/V]O$&J_#G_@I?^S=\6/AAX/O_B1XQLO#?BW2I_A/HDL*:B-%NUL&N->M
MYKJ2*TMOL\UO;P/]IFA$RW>R-RZ[&L_\$G[J?QI\4OVH/BAXXT^;PCXV\6?&
M.*;Q7\))Y-MWX.C@T>RL[-IWC_=337MM EX;BV>2!_.58Y9#$QH M^(O^"__
M /P2!\*ZYJ/AW6_VTM)CNM*O9[2_$7AS5I8XYH7:.11)':,C ,K#<I*G'!(K
MZP\!^./#'Q-\#:-\2/!&I&\T7Q!I5OJ6D7C6\D1GM9XEEBDV2*KIN1E.UE##
M." >*^=?VZ?!_AG1/V;?!?\ P3\^#NC0Z':?%G7;'P!8Z9I0\M=/\-K"]QK+
M(%Y0+I%I>Q*^1B:>')RP!^F[*RL]-LX=.TZTC@M[>)8X((4"I&BC"JH'
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M<!F5E!0D@'N%%%% !1110 5Q_P"T/_R0#QS_ -B=J?\ Z225V%<?^T/_ ,D
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M:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[0 4444 %%%%
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M7YCXI_\ (EH_]?/_ &V1^C^&7_(XK?\ 7M_^E1/?J***_"3]M"BBB@ HHHH
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M[)?@#]J/0M$?2X_&?AR&^NM)EDWMI]V,QW5J6P-QBG26+=@9V9P.E>IU\O\
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M_P"]]'_$1S_U9O\ ^9#_ /O?7YBT5\S_ *V\0?\ /[_R6'_R)^W?\2_^$?\
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MIK1IGZ=?\1'/_5F__F0__O?1_P 1'/\ U9O_ .9#_P#O?7YBT5G_ *V\0?\
M/[_R6'_R)V?\2_\ A'_T+?\ RMB/_EI^N'[-_P#P77_X:"^._A7X*?\ #+7]
MD?\ "3:S%8?VG_PF_P!H^S;SC?Y?V)-^/3<OUK]!*_GW_P""<'_)]OPK_P"Q
MQM?_ $(U_017WO"69XW,\'4GB9\S4K+1+2R[)'\G_2!X*X9X(XBPF%R6A[&$
MZ7-)<TYWESR5[SE)K1+1.P5Q_P"T/_R0#QS_ -B=J?\ Z225V%<?^T/_ ,D
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MOH9[B\?1;P1A?]H_,H]20.]8.E_L>_M.:3J=MJL/PNAE>VG258KG4[&2-RK
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M8J^__A=_R3/P[_V K3_T2E? '_!Q3_R3+X9?]A[4/_1,5?/\4_\ (@K^B_\
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M '2?^+]$?@?BW_R.,/\ ]>__ &YA7'_M#_\ ) /'/_8G:G_Z225V%<?^T/\
M\D \<_\ 8G:G_P"DDE?687_>J?\ B7YGY!BO]VGZ/\C^<.BBBOZ\/Y2"BBB@
M HHHH **** "BBB@ HHHH **** /Z8]%_P"0-:?]>L?_ *"*LU6T7_D#6G_7
MK'_Z"*LU_'LOB9_64?A05_.O^U[_ ,G9?%#_ +*)K?\ Z7S5_117\Z_[7O\
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MGKV^9"HUGRVB_>VTW].YD45TGC[X2?$#X90V%[XOT-([/54=M+U2QOH;RRO
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M^/9?$S^LH_"@K^=?]KW_ ).R^*'_ &436_\ TOFK^BBOYU_VO?\ D[+XH?\
M91-;_P#2^:OU7PI_W[$_X8_F?F'B?_N>'_Q2_)'G=%%%?MI^.!1110 4444
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M^0F_PH_X2G0?^?[_ ,A-_A5VW^"MC;ZEH_A3Q+XYATW7M>MH)K&Q>R9X8!.
M8%N9@P,3."IPJ.%#@L5YQQ>LZ1J/A_5[K0=8M6@N[*Y>"ZA?K'(C%64_0@BI
MI>$_"=:5H5ZSZ[PV[K]WJO-%5/I#\>T5>>&PW_@-3?L_WVC\F=/_ ,)3H/\
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MI\BJMKS5_P!0KY]+$3YG22]'_P  _0"BOS_HK?\ L?\ O_A_P3'^V/[GX_\
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M_>J?^)?F?HF*_P!VGZ/\C^<.BBBOZ\/Y2"BBB@ HHHH **** "BBB@ HHHH
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M>=T445^VGXX%%%% !1110 4444 %%%% !1110 5^]W_!+;_DP#X8_P#8"?\
M]*9J_!&OWN_X);?\F ?#'_L!/_Z4S5^8^*?_ "):/_7S_P!MD?H_AE_R.*W_
M %[?_I43WZBBBOPD_;0HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\
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MVDC@+O*,3M8@$H4)&22?,*K#5Z>*H1JPVDKBQ%">&KRI3WB[!7V__P $!_\
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MN?E( D-M-#+@$AOED7E1G(R#[S_P4L\3?\)I\2OAYXO'A_3=)_M3X+^&KO\
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M_P#0J_H"K^?W_@G)_P GU?"S_L<;7_T*OZ J_#/%3_D;4/\ !_[<S]I\,O\
MD5U_\?\ [:@KC_VA_P#D@'CG_L3M3_\ 222NPKC_ -H?_D@'CG_L3M3_ /22
M2OS;"_[U3_Q+\S]$Q7^[3]'^1_.'1117]>'\I!1110 4444 %%%% !1110 4
M444 %%%% '],>B_\@:T_Z]8__015FJVB_P#(&M/^O6/_ -!%6:_CV7Q,_K*/
MPH*_G7_:]_Y.R^*'_91-;_\ 2^:OZ**_G7_:]_Y.R^*'_91-;_\ 2^:OU7PI
M_P!^Q/\ AC^9^8>)_P#N>'_Q2_)'G=%%%?MI^.!1110 4444 %%%% !1110
M4444 %?O=_P2V_Y, ^&/_8"?_P!*9J_!&OWN_P""6W_)@'PQ_P"P$_\ Z4S5
M^8^*?_(EH_\ 7S_VV1^C^&7_ ".*W_7M_P#I43WZBBBOPD_;0HHHH **** "
MBBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX
M7?\ ),_#O_8"M/\ T2E? ?\ P<1?\DS^&?\ V'=0_P#1,5??GPN_Y)GX=_[
M5I_Z)2O@/_@XB_Y)G\,_^P[J'_HF*OK.!O\ DJ\-ZR_])D?+<:_\DQB?2/\
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M<JE-3NVVW>]VFNC7=[WW?<U;/X;>)_%<'B3Q%\./#6K:MH/AI?M&HZDEB?\
M1+1I=D4L^W(CW<<9(SGG )KV[P7XPU[X%_L+:?X]^$EM9:A>>+/'MS9^-Y]7
MTJ#4[73/L<4$FGP?9+I)(%>7SKB03-'YF(RBL '!^?-,\2^(]%L+[2M'U^]M
M+74X5AU*VMKIXX[N-6#JDJJ0)%# , V0" :N^"OB3\1?AK=S:A\.?'VM:!/<
M1B.XGT359K5Y4!R%9HF4L,\X-=&+P=7%049-.,9)V>TDEM+_ +>]Y65KI:/4
MPPN*I8:3E&Z;BU=;Q;>\?E[KN^KU/6_V_P"RBG^*'AKQ]JT<MKXH\8^ M,US
MQMI4LSL;#4YA(I0+(2T*O"D$PA)Q&)@JA5"J/"JGU/5-3UO49]7UG49[N[N9
M3)<W5U,TDDKDY+,S$EB3U)YJ"M\%AWA,)"BW?E5O^ O);+R,,976*Q4ZJ5N9
MW_X/J]WYA7V__P $!_\ D]76?^R=WW_I98U\05]O_P#! ?\ Y/5UG_LG=]_Z
M66->-Q?_ ,DSBO\  SU^%?\ DH\+_C1^QM%%%?R\?TH?+?\ P6<_Y1U^.?\
MKZTG_P!.=M7X;U^Y'_!9S_E'7XY_Z^M)_P#3G;5^&]?OGA=_R3U3_K[+_P!)
M@?AOB5_R/J?_ %[C_P"E3"BBBOT@_/0HHHH **** "BBB@ HHHH **** /:O
M^"<G_)]7PL_['&U_]"K^@*OY_?\ @G)_R?5\+/\ L<;7_P!"K^@*OPSQ4_Y&
MU#_!_P"W,_:?#+_D5U_\?_MJ"N/_ &A_^2 >.?\ L3M3_P#222NPKC_VA_\
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MM_\ I?-7ZKX4_P"_8G_#'\S\P\3_ /<\/_BE^2/.Z***_;3\<"BBB@ HHHH
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M_$OS/T3%?[M/T?Y'\X=%%%?UX?RD%%%% !1110 4444 %%%% !1110 4444
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M !JC_AR%^R;_ -%&^*?_ (6Q_P#C5?8U% 'QS_PY"_9-_P"BC?%/_P +8_\
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M&I>+C+;O(AR!(GEC>OJ,\U]2444 %%%% !1110 4444 %%%% !1110 4444
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M\4_BAX"^"?PXUSXN?%+Q+#H_ASPYIDVH:UJ=PC,MM;Q*6=]J LQP.%4%F.
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MTCP[#%H\<@2PAM+.!P6,VUY;B2>5UBC!<[* /T%HHHH **** "BBB@ HHHH
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M7T!X8N/$UWH%K<>,M(L+#5'B!O;/3-1>[MXG_NI,\,+2#W,:'VJ_10 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MAWKS6NG>/?@A>Z=IMH+[_A!-4BC:RD,=S#)%)-#^Y\XRQLPDO&CX\L;?;?\
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MOQ%XX\ VTWB#X,>"=07P[X+OP;-;Z*XU>(QHSL&NYTMO*5IA%"7B2',2*BT
M?1Y_X*"?LRS?MKC]@_3_ (F:+<>-X/"4NMZM;)K, ^P/]KM[>WL77=DW4WG2
M2"$?.J0ABN)$)]0U[XJ?##PKXHT_P/XH^(^@Z;K6K8_LO1[_ %B"&ZO,G \J
M)V#R<\?*#S7QIXIO?A1X*_X."K?4_&]QX?TIK_\ 9,C;3[C4S#";F]'BO8/+
M+XWS?.BC;E_F4#J*^>OV$OV9_B_^U-^S]^T;H_QW^+GP5M?%&O\ Q8\5Z?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% '&_M%^%M*\<_L^>._!.N^(_['L=8\&ZI8WFK_8VN/L,4
MMI+&\_E*09=BL6V @MMP",U^4'_#K;]E?_I(O_YB*^_^2:_63X_?\D(\;?\
M8HZE_P"DLE?F!7Z=P%+&+"5O8UY4US+2*@[Z?WH2_"Q^<\;QP<L51]M1C4?*
M]W-6U_NRC^)S7_#K;]E?_I(O_P"8BOO_ ))KZ6_X)7_L9?!;]G7]H/6/&WPY
M_:O_ .$ZOKKP;<6,ND?\(+<Z7Y,37=I(9_-EF<-AHE79C)\S.?E.?#J^B?\
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M#=!'6W3<R3AE+L0#@+0!^E6FZ;IVCZ=!I&D6$-K:6L*PVMK;1!(X8U 5455
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MT+,2SNV6Y8@"@#VEOV;_ -G=YO%ER_P$\%F3QZH7QS(?"UIN\1*%*@7Y\O\
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M:W^MQ0:S P@NIYYXQIP4-EKI%@:22,?-&KIN W5ZEH_Q-^&_B+Q=J'P_\/\
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M/AMX^T7Q#9#&;S0]5ANXN>GSQ,PYP>] &U1110 4444 %%%% !1110 4444
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M%^RQ^VO\5YDTOX97OA?Q%\/];\7W3;++0M4O$\ZP%W*?EA2X?,2NQ"AE;<5
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M2_@%\"?C/X=L_!_QA^"OA+Q9I.GL&L-+\2^&[6_MK8A=H,<<\;*A"\< <<4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"H&D=CM4!1G  % 'J-%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MMUJ"^(IK9) 4^T>>NGI,RCS!"8 WR,,\=^P5X-\"_$+]A;]I;P%JOA72=?\
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MQM8C&":[#PQX6\,>"?#]GX2\&>'+#2-*T^ 0V&F:79I;V]M&.B1QQ@*BCL
M* +]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>biib-20220930_g4.jpg
<TEXT>
begin 644 biib-20220930_g4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MF@)Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\9/A]\(] T;Q7XO^'VOP^*?$.G:;'%=ZK':^)+Z*W6>11ND$<8"J#]T# KZ
M_;&_8G^ _P"Q?HG[*7[3GP0\+_V;\5YOVDO FC>+/B<DS_VUXIM-7N!:ZI%J
M-QG=<QW"R,?+;Y(\*L2QHH6@#]/=3UG2-%BCFUC5;:T2658HGN9UC#NW1 6(
MRQ[#J:LU^1NA>#?&G[<__!1;]J#Q;\<_^">_AS]H2P^'/CF#P-X)T'QYXUL[
M:P\):;'80RM):Z?=P2H)KQYC.UWC><*J,H3%?9/_  2%^%G[2/P/_9N\1?"+
M]H>RMK*TT'XEZS#\-=(C\9+KT^C^%V:.6STVXO!\TDEJ\D]N WS+'#$.@  !
M7_X*%_M\_M:?L0Z;XE^)G@C_ ()TWOQ'^&OA#PC)KWB'QU;?%72M*^RQPI))
M<QBRG5KB0QQQALHIW[L*"17$6'_!6/\ :K\-_LB^-?VV?CW_ ,$R=1\$^!?#
MGPO'C'0+\_%W2M2?7@_D/#:B*VC,MLSPS-)YDB87R]I&2*]5_P""R/\ RB<_
M:0_[(GXD_P#3=/7A'[=__*LQXB_[->TO_P!-EK0!]Z>$_&&E>*])L+Z"XABN
M;W2X+YM/^T*TL4<J!@2.N,G&[ !Q6A?ZCI^E6_VS5+^&VB#*IEGE"+N8@*,G
MC)) 'J37Y:_M>_L3_ ;]C;X7_LM?M5?!?PO_ &?\7%_: \ 6'B;XH+,_]M^)
MH-5N8[74X=0N<[KB&XCE8&%OW<:A4B6-%"CH/A7^QA\&?VN?^"WW[6&O_M$:
M,_B70OAW?_#S4_#7A&[N)%TX:S-X?4+J<T2,!/-#';A(=^Y8_/F8#<P( /TG
MN]9TBPO;?3;[5;:&XNR1:6\LZJ\Q R0BDY; ZXJ>66."-III%1$4L[L<!0.I
M)[5^+7[$OP3\7_\ !0_X-_$#]J7]HO\ X)C:%\:_%WQ$^('B.U?QYXE^)]G9
MZGX7MK349[.UTS2TF@>71Q:+"-AA9'9CYA)W#&Q\<9/VXO&.A?L(_P#!/O\
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MX??#_6+?4_ OPA\;^.([WPWHL]LVZS"Q+;)<W4=L0/)BNKB=$VJ-I %?8M%
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M%N?^".WPC\8>+_ WQ&^._P"U%\:OB=XD^&WC+2_$7@G6_'/BFQE?2Y;*=9A
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M?"/X4_L]?'RYT3XK_!+Q?<>,/"GQ3UK15NQJFNWC3OJIO[574O:WIN9D>-)
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M*GQ7\%_VM\.OA!^W/K][\.]$CO9H;*Q-I/::E#9>7&RI-;PW5Q-FWD#1'?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S/QE^)EC\&_A=K?Q0U/3)KVWT6R
M-S+:P.%>0 @8!/ /-=-7E'[<_P#R:/X]_P"P"_\ Z&M 'I7AS68O$?AZP\0P
M0M&E_917"1N<E Z!@#[C-7:POA=_R3/P[_V K3_T2E;M !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !16+\.OB+X#^+G@;2_B9\,/%UAKWA[6[-;K2-9T
MJY6:WO(&^[)&Z\,I[$5M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M15;6M:T?PWH]WXA\1:M;6&GV%L]Q?7U[.L4-O"BEGDD=B%1%4$EB0  2:^9O
MV9?^"QO_  3[_:T_:(\5_LT?!W]HSPM?^(?#^IP6>B[?$%J8_%0>SBN9)=,(
MDS=)$9'B?;D[H9" 4 8@'U%17,?&;XS_  J_9X^%VM_&KXW^/-.\,^%?#EBU
MWK6N:K/Y<-M$.,D]68DA5106=F55!8@'1\!^./"OQ.\#:-\2? FL)J.A^(=)
MMM3T;4(T95N;2>)9890' 8!D=6P0#SR!0!K45R/QX^/'PE_9C^$FM?'7XZ^,
MX?#WA/P] DVLZQ<02RI;(\J1*2D2L[9>1% 52<L*\(^'/_!:C_@F=\6OB!H?
MPL^'O[2AU'7O$>K6^F:-8#P9K47VBZGD6**/?)9JB9=E&YF"C.20 30!]2T5
MX)^U!_P4\_88_8R^(]G\(OVD_CO#X;\27^B1ZQ:Z2-!U&\D>Q>:6%)R;6WE5
M5,D$JC)!RAXZ5T7[*W[<G[+?[;.G:SJW[,?Q//B:W\/SPPZO+_8=]9"!Y0[1
MC_2X(B^0C?=SC'.,C(!ZS17S+JG_  60_P"":.B_%B7X-:G^U7I,6J6^O#1+
MG4SI-^=%@U+=L^QR:P+?^STF#_*8VN P;*D C%?35 !15?5=5TO0=+N=<US4
MH+.RLK=Y[R[NIECB@B12SR.S$!550223@ $FO/\ ]EG]KO\ 9Q_;8^&3_&3]
MEOXI6?B_PS'JL^FOJ]C;3Q1BZA"F2/$R(Q(#KSC!SP30!Z11110 4444 %%%
M% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^
MP"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %?#/_!9WQCK_ (1UGX+/\6-3^(VG?LXW'B35
M5^/>J_#!]1CO8$%D#I:W<NE_Z=%IK3^<)V@(Y$2L<-@_<U>!_MB_$O\ ;C^"
M_C'P?\3?V:/@78?%/P/;I>6WQ&\!Z=?067B([Q&UM?Z=/=S1VTWE%)5DMG9&
M<2@JQ(PH!\<_\&W/A+]GJZ_9J\ ^/OV9OVUM0U>2'X9067Q5^"S^,VU:TT[6
MFD5H]16VN9GFTF3"RQM'$$@F# [0T8)@_P""EW@K]M>U_:F_9K^-W[0/QTL[
M#PY/^VWX=\.> /AAX&:6/3TT1QJ<J:CJLTF'O-1F2V@_=C;!;*TB(':1GKB?
M^"&'[.7Q8^+^M?LR?M>Z3^RTOPK\*?#3X%:CH.N>-KR\L5U'XH37PMUMXS;V
MCO)]BM3 \Z2W15VD=0D8 8UZ'_P50_:G\4_'CQS\!-$^&'[#'[2>I_\ "H_V
MJ=!\7>*KV'X':L;:32M/@U*">:UD$96XRT\90+]]6R#B@#]/*_-K_@MOJ/[/
M.M?MI?LN_"S]IKX9>+O'OAK5-(\>7D?@#P-:W]QJ6O:A#!I$=I#%%921.2#/
M+)N>1(D6)V=U4$U]"_&[_@IE;_"[]@7QY^W=X?\ V2?BQ>1> YHUN? ?BCPE
M<Z!K-Y#Y]JDUU'#<QEOL\45P\S2[2NVVF&1M)$_[3_[4W[27P!\9?#SXO:9^
MQ9KOQ!^&6IZ#.OC1? VE-J/C#PIJ4HB>"2.QW*UU:E?,BF2%3,K -@@;& /&
MO^"84/\ P3,^'O[3^N?#?X(?L;_$;X!_&27PA)*_A/XL_;([[5]"-Q$9+BR9
MM0O;2YB6>*(.89#(A7! &ZN#_P""U/Q*\8?MD_!W]H']GSX/^*[_ $WX=_ #
MX4:WXD^+'B31KMX6U7Q3%I4UWI'AV*5"/EMV$6H7>TG!6SA;'F2"N_T.W^,_
M_!1?_@I-\)/VJ?#/[._Q!^%7PY^ _A?Q5%!XE^)OAAM%U;Q+JVM6D5DMO;:;
M<_OTM;>./SS+.B*\@150A=Q\V_:$_P""/7[5O[/G_!-;XU?!G]G[_@HW\5?%
M5CJG@;Q7J$_@'_A6_AF\N_%^I7UM<S7$$UTNFM?SSW<LAC,BRF;YU5&7:@ !
M] 77[/OQS_:V_P""7/P)^#/PI^/-YX#M-;\+>#7^(^N:;<S0ZK>^'%T^%[ZS
MLKF/YK:YG^1/.[(9!_%FOGO]K_\ 8Y_9M_X)I_M%_LQZM_P36\/7O@/XH^.O
MCAI6@:OX2T#Q%>SP^,/"I61M:EU*UGFD$Z6\ 68W;@R1.4.XDKCT&U^*G[<G
M_!,7_@D]X%N]!^&/Q._:0^)VJZ7HVG>'_"X\!PQ-X-5])A'D7T.DVL<QLK1H
M) S,CW,DDBQ-(-P=.*_8'^+7A'X<_&A/C?\ '_\ 9*_:W^(/QY\>/;Z1K_Q8
M\8?L_7UCIVBVDLRXL-/B+&/2-*B9M[!<L^&DF=SC: ?IY7X>_ O0O^">_P 9
M;OXO_%3XR_\ !-WX]_'KQ6WQ[\>S^*_$OPUT[4IK+1;<>(KT6MH2=3M([B1+
M40R>39I/(J2)N ) K]:;']I/QM=_MJ7G[*$G[,_C2'P_:^ 1XBC^+4EDW]@3
MW)N4A_LI9=N#=;7,NW=G8A.*\ \*?\%)_P!H+X&VFM_"W]JG_@F?\7Y/'>F:
MW?+IMQ\#_AU<:[X:\3VS3NUK=VU\CF.T>2,IYJ7KPLC[B< X4 ]W_8$\3_LG
M>,/V1/!6N_L/7L$WPOET^0>&$AGN7:!1/)YT,GVIFG25)O-1TE.]'5E.,8KV
M&OEG_@D'^S+\9/V9_P!EO67_ &@/#]IH'B_XC_$[Q'X^UGPAI]XES;^&FU:]
M:X33$E3Y)/*CV!BGR;V<*6 #'ZFH **** "BBB@#PG_@IE^RMXT_;9_85^(O
M[,'PZ\5V.BZYXITF%-*O-61VLY)H+J&Y6WN1'EOL\WD^1+M!/ES/\K?=/YP_
M!7]J3P1X*_;#^,/@O_@J?_P3LN_"6G7/QL\!O;^*_#4UOK?A;P'XBM_#VC6^
ME,][ 8IK&.8I;212B((@NE@E(P]?J7^UM^SO-^U-\"-7^#NG_%SQ1X#U&[FM
MKO1?&'@_4&M[[2KZVG2XMYE&=LR"6-=\,@*2(64XR&'P!\-_^"6?_!0+]H;]
MH#XV> ?VYOVE="G^%WB#XE^$M;\4R>%OAL=-G^)8TO2-*,"I+)>S+IUJ);*!
M+A8D9WE@E"/&C@  ]G_X+5?L3?"_XS_LK?&[]ISXM>(/$&O_ /"#_LY>*_\
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M9;&*;KYZ5@?\$&M/L-)^$'[0>EZ790VUK;?MA?$6*VMK>,)'%&NI*%15'"J
M  !P *]=^,/_  20_P"":'[0/Q*U;XQ?&K]BCP!XF\4Z[.LVL:[JVB++<7<B
MHL:L[$\D(BK]%%><?\$H?^"0/PA_X)QZQ\1?'T?PO\"V_BWQ/\0_$=QX;U_P
MO;2":Q\)WM[%<66D.\D:%1$(8P8U#("B[6;&: /M&BBB@ HHHH **** "BBB
M@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .
MZ^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHJ#5-2LM&TRXUC4IO+MK2!YKB3:3L15+,< $G !X'--)MV
M0FTE=D]%>2?\-T_LK_\ 14O_ "B7W_QBC_ANG]E?_HJ7_E$OO_C%>C_8V<?]
M ]3_ , E_D<']K95_P!!$/\ P./^9ZCHFA:)X9TBWT#PWH]KI]A:1".ULK&W
M6*&%!T5$4!5'L!BK5>2?\-T_LK_]%2_\HE]_\8H_X;I_97_Z*E_Y1+[_ .,4
M?V-G'_0/4_\  )?Y!_:V5?\ 01#_ ,#C_F>A>/?A]X,^*'AP^$?'_A^'5-,:
M^M+Q[&Y)\MYK:XCN82P!&X+-%&VTY5MN&!!(.S7DG_#=/[*__14O_*)??_&*
M/^&Z?V5_^BI?^42^_P#C%']C9Q_T#U/_  "7^0?VME7_ $$0_P# X_YGK=%>
M2?\ #=/[*_\ T5+_ ,HE]_\ &*/^&Z?V5_\ HJ7_ )1+[_XQ1_8V<?\ 0/4_
M\ E_D']K95_T$0_\#C_F>MT5Y)_PW3^RO_T5+_RB7W_QBC_ANG]E?_HJ7_E$
MOO\ XQ1_8V<?] ]3_P  E_D']K95_P!!$/\ P./^9ZW17DG_  W3^RO_ -%2
M_P#*)??_ !BC_ANG]E?_ **E_P"42^_^,4?V-G'_ $#U/_ )?Y!_:V5?]!$/
M_ X_YGK=%>2?\-T_LK_]%2_\HE]_\8H_X;I_97_Z*E_Y1+[_ .,4?V-G'_0/
M4_\  )?Y!_:V5?\ 01#_ ,#C_F>MT4D<B2QK+&<JP!4^HI:\T] ***^7?''_
M  4F_P"$-\::QX0_X4Q]I_LK5+BS^T?\)%L\WRI&3?M^SG;G;G&3C/4UZ&7Y
M5C\TG*.%AS..KU2_-HX<=F6"RV*EB9\J>VC?Y)GU%17R3_P]*_ZH7_Y<_P#]
MS4?\/2O^J%_^7/\ _<U>I_JCQ#_SY_\ )H?_ "1YO^M.0_\ /[_R67_R)];4
M5\D_\/2O^J%_^7/_ /<U'_#TK_JA?_ES_P#W-1_JCQ#_ ,^?_)H?_)!_K3D/
M_/[_ ,EE_P#(GUM17R3_ ,/2O^J%_P#ES_\ W-1_P]*_ZH7_ .7/_P#<U'^J
M/$/_ #Y_\FA_\D'^M.0_\_O_ "67_P B?6U%?)/_  ]*_P"J%_\ ES__ '-1
M_P /2O\ JA?_ )<__P!S4?ZH\0_\^?\ R:'_ ,D'^M.0_P#/[_R67_R)];45
M\D_\/2O^J%_^7/\ _<U'_#TK_JA?_ES_ /W-1_JCQ#_SY_\ )H?_ "0?ZTY#
M_P _O_)9?_(GUM17R3_P]*_ZH7_Y<_\ ]S4?\/2O^J%_^7/_ /<U'^J/$/\
MSY_\FA_\D'^M.0_\_O\ R67_ ,B?6U%?)/\ P]*_ZH7_ .7/_P#<U?2/P>^(
M?_"V/AII'Q$_L?[!_:ML9?L?VCS?*P[+C?M7=]W/0=:X<?D>:97253$T^5-V
M6L7KOT;.W YSEN8U'3P\^9I7V:T^:1TM%%%>2>F%%%% !1110 4444 %%%%
M!7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L
M!6G_ *)2MVN,^&O@W2I_ASH$[W-V"^B6K$+=,!DPK6W_ ,(/I'_/S>_^!;4
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M^]U_\*_,^'XX_P!VH^K_ ".:HHHK]0/S@**** "BBB@ HHHH **** "BBB@
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M_'C!_P!<5_D*EK^<'N?OZV"OR[^-_P#R6GQ?_P!C1J'_ *4R5^HE?EW\;_\
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M!^L]A_QXP?\ 7%?Y"I:BL/\ CQ@_ZXK_ "%2U_.#W/W];!7Y=_&__DM/B_\
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MOZV"OR[^-_\ R6GQ?_V-&H?^E,E?J)7Y=_&__DM/B_\ [&C4/_2F2OO^ /\
M>Z_^%?F?#\<?[M1]7^1R]%%%?J!^<!15F_T;5M,MK2]U'3YH8K^ S64DB$">
M,.R%U/<;D9<^JFJU)-25T-IK<****8@HHHH **** "BBB@ K](OV/O\ DVGP
MC_V#F_\ 1KU^;M?I%^Q]_P FT^$?^P<W_HUZ^&X]_P"192_Q_P#MK/L^"?\
MD8U/\'ZH]*HHHK\H/TT**** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-
M:]7KRC]N?_DT?Q[_ -@%_P#T-: .D^&OB+58OASH$2>%+MPNB6H#JRX8>2O-
M;?\ PDNK_P#0H7O_ 'TM1?"[_DF?AW_L!6G_ *)2MV@#'_X275_^A0O?^^EH
M_P"$EU?_ *%"]_[Z6MBB@#'_ .$EU?\ Z%"]_P"^EH_X275_^A0O?^^EK8HH
M Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EK8HH Q_P#A)=7_ .A0O?\ OI:/
M^$EU?_H4+W_OI:V** ,?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI:V** ,?\
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M-#XSR/-\8?%DLD1C9O$M^61NJDW#\&OU'K\N_C?_ ,EI\7_]C1J'_I3)7W_
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M/A'_ +!S?^C7KX;CW_D64O\ '_[:S[/@G_D8U/\ !^J/2J***_*#]-"BBB@
MHHHH *JZW<ZC9Z-=WFD6(NKN*UD>UMBVT2R!253/;)P,^]6JAU"_L]*L)]4U
M"=8K>VA:6>5NB(H)8GZ $T ?BM\,_B1IO_!0CX7_ +(_[!?B/]K?Q)X^U3XP
M^(=:^(_[6-E:^,Y8[_28+&Q:6?0KM;:19=*L/[0>*SCMAY>/LX*X(W5]S?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%8?Q/_Y)IXB_[ 5W_P"B7K<K#^)__)-/$7_8"N__ $2];8?^/#U7YF5?^!+T
M?Y'Y7T445_11^"!1110 4444 %%%% !1110 4444 %%%% 'ZSV'_ !XP?]<5
M_D*EJ*P_X\8/^N*_R%2U_.#W/W];!7Y=_&__ )+3XO\ ^QHU#_TIDK]1*_+O
MXW_\EI\7_P#8T:A_Z4R5]_P!_O=?_"OS/A^./]VH^K_(Y>BBBOU _. HHHH
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MW\;_ /DM/B__ +&C4/\ TIDK]1*_+OXW_P#):?%__8T:A_Z4R5]_P!_O=?\
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M ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\ Z#=E_P"
MQ_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\
M@,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH Q_L7C?\
MZ#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'_&C[%XW_
M .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK8HH
MQ_L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&MBB@#'^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:V** ,?[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P"
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M%% !1110 4444 %%%% !1110 5Q_[0__ "0#QS_V)VI_^DDE=A7'_M#_ /)
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MS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVI?LC_!^'4H]*_L\QQ"(.-29IOM'F>=NP=FTQXYW4 >K5Y1^W/\ \FC^/?\
ML O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7
M?\DS\._]@*T_]$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<?^T/\ \D \<_\
M8G:G_P"DDE=A7'_M#_\ ) /'/_8G:G_Z225T87_>J?\ B7YF&*_W:?H_R/YP
MZ***_KP_E(**** "BBB@ HHHH **** "BBB@ HHHH _ICT7_ ) UI_UZQ_\
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M\-6&F6OV(QQHL$:V#O%,!(DK^;N)/F;>BBO7O^$Q\,?]!J#_ +ZH TJ*S?\
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M5\*?]^Q/^&/YGYAXG_[GA_\ %+\D>>T445^VGXX%%%% !1110 4444 %%%%
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M%?I]X4\)>%? ?ANR\&^!_#.GZ-H^F6ZV^G:5I5DEO;6L*C"QQQ1@+&H'15
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M_ED/[HJS_9VG_P#/C#_WZ%,T7_D#6G_7K'_Z"*LU_'LOB9_64?A1#_9VG_\
M/C#_ -^A7\[G[7:JG[6'Q/1%  ^(>M  #I_I\U?T4U_.O^U[_P G9?%#_LHF
MM_\ I?-7ZKX4_P"_8G_#'\S\P\3_ /<\/_BE^2/.Z***_;3\<"BBB@ HHHH
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M7Y)T4?\ $/O^HG_R3_[</]>O^H?_ ,G_ /M3];**_).OH/\ X)K_ /)?;_\
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M ":?_P D'^M.??\ /[_R6/\ \B?6W_#TK_JA?_ES_P#W-1_P]*_ZH7_Y<_\
M]S5\DT4?ZH\/?\^?_)I__)!_K3GW_/[_ ,EC_P#(GUM_P]*_ZH7_ .7/_P#<
MU'_#TK_JA?\ Y<__ -S5\DT4?ZH\/?\ /G_R:?\ \D'^M.??\_O_ "6/_P B
M?6W_  ]*_P"J%_\ ES__ '-1_P /2O\ JA?_ )<__P!S5\DT4?ZH\/?\^?\
MR:?_ ,D'^M.??\_O_)8__(GUM_P]*_ZH7_Y<_P#]S4?\/2O^J%_^7/\ _<U?
M)-%'^J/#W_/G_P FG_\ )!_K3GW_ #^_\EC_ /(GVK\+/^"B/_"R_B+H_@'_
M (4_]B_M:^2V^U_\)!YGE;OXMOV==WTR*^EZ_-+]EG_DXGP=_P!AV'^=?I;7
MP'%V68'*\93IX6'*G&[U;UN^[9]QPMF.,S+"5)XB7,U*RT2TLNR05Q_[0_\
MR0#QS_V)VI_^DDE=A7'_ +0__) /'/\ V)VI_P#I))7S6%_WJG_B7YGT.*_W
M:?H_R/YPZ***_KP_E(**** "BBB@ HHHH **** "BBB@ HHHH _ICT7_ ) U
MI_UZQ_\ H(JS5;1?^0-:?]>L?_H(JS7\>R^)G]91^%!7\Z_[7O\ R=E\4/\
MLHFM_P#I?-7]%%?SK_M>_P#)V7Q0_P"RB:W_ .E\U?JOA3_OV)_PQ_,_,/$_
M_<\/_BE^2/.Z***_;3\<"BBB@ HHHH **** "BBB@ HHHH *_>[_ ();?\F
M?#'_ + 3_P#I3-7X(U^]W_!+;_DP#X8_]@)__2F:OS'Q3_Y$M'_KY_[;(_1_
M#+_D<5O^O;_]*B>_4445^$G[:%%%% !1110 4444 %%%% !7E'[<_P#R:/X]
M_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*^=_
M^"H/_(I>$O\ L(W/_HM*^B/A=_R3/P[_ -@*T_\ 1*5\[_\ !4'_ )%+PE_V
M$;G_ -%I7T/"O_(_H>K_ /26>%Q-_P B.MZ+_P!*1\<4445^WGXX%%6=)T;5
MM=NFLM&T^:ZE2"29XX4+$1QH7=\#LJJS$]@#5:E=7MU'9VN%%%%,04444 %%
M%% !1110 5]!_P#!-?\ Y+[?_P#8KW'_ */MZ^?*^@_^":__ "7V_P#^Q7N/
M_1]O7B\1?\B/$?X6>OD/_(YH?XD?=-%%%?A)^TGC_P"WE_R:[XA_Z[67_I7#
M7YYU^AG[>7_)KOB'_KM9?^E<-?GG7ZWP'_R)Y_XW_P"DQ/R[C7_D;0_P+\Y!
M116KX.\$>+/B!K:>'O!OA^[U&[<;C#:0-(47/+M@?*HSR3Q7V<YPIQ<I.R74
M^2C"4Y*,5=LRJ*ZGXK_![QS\&_$LWAWQEHL\*K/)':7Q@=8+Q4;&^)F W#H?
M49&0*O>&OV</C7XNT.W\1:%X%FDM;Q"]D9[N&&2Z4=XHY'5Y1[H#FL'C<&J,
M:KJ149;-M),V6#Q;JNDJ;<ENK-M'$45-J&G7^D7\VEZK92VUS;RM'<6\\91X
MW!P593R"#V-:\GPT\=0^ H_B?-X;G309;O[-%J3E0CR\_* 3N/*L,@8R",Y%
M;2JTH).4DKZ+7=O9+N91IU)-\J;MJ_)>9A45J>#?!7BKX@^((/"O@O0Y]1U"
MXSY5M;KR0!DDDX  '4D@5FRQO#(T,JX9&(8>A%-3@YN*>JZ===OR$X245*VC
MZ_UZC:*V_ ?PZ\9_$W6G\/>!=#>_O([=IWA25$Q&"H+9=@.K*.O>NEUS]EGX
M]^&]%O/$6M?#V:"RL+9Y[N<WMNPCC499B!(2>/3FL*F,P=&I[.I4BI=FTGKY
M&U/"8JK3YX4Y./=)M?>>?T445TG.=_\ LL_\G$^#O^P[#_.OTMK\TOV6?^3B
M?!W_ &'8?YU^EM?E?'W_ ",*7^#]6?I?!'^XU?\ %^B"N/\ VA_^2 >.?^Q.
MU/\ ]))*["N/_:'_ .2 >.?^Q.U/_P!))*^+PO\ O5/_ !+\SZ[%?[M/T?Y'
M\X=%%%?UX?RD='\*_A%\2_C;XNA\#?"KP3J6O:G*N\VNF6;S-'&" TC[0=B#
M(RQP!GK71?M*?LM_&+]E7Q_=^!?BKX3O+5([R>'3-8-G(EGJJ1OM,UO(Z@2*
M>#Z@,,@9KM?V.OBO\(]'\$>.?@#\7/%6K^%[7QY-I+VGBW1]/-W]EDLYY'^S
MW$"LKR6\OF_-L.0T:':PZ>D_\%*/A3\7_#WB'Q_XJ\,_&'2_%7PYOOB[?7&I
MZ+H]\TDGA[6I'FVQ74$B!H9"GF('0E'V]<[<_.U<TQ5//(X6=HP=[73][X=5
M+X;W;7+OIO[R/?IY;AJF2RQ,+RFK7LU[OQ:..]K)/FVU\F>+^"?V%?VJOB!X
M6T_QGX=^%3)8:O&)-';5-9LK"744/1K>&ZFCDG![&-6#=LUYGXH\+>)/!'B*
M]\(^,-"N]+U33KAH+_3[Z!HIK>53AD=& *D>]?>WQ\^ '[.W[17C[P1XN_:<
M_:5M_@WXZO?#6G6/B7X?:K%'=FV6"W5(GCE201Z:)4"L(KG:R%RQ!Z-Y9^T!
M\%/'_P"T#^WWXCT_XM>&)O NAZ-I5K?^)-4N;Q+S[%X>LK2&%;XW"?+<RS11
M)L*YWS2JG8XYLOXAE7J/V[27)*3M&2M9I)1;;55.[]Z"MHOYDCHQ^0JC!>Q3
M;YE%>\G>Z;O)))TFM/=F[ZO^5L^?9_@#\8K7X,0_M#77@.\B\&7&I_V?;Z](
MR+%+<?,-BJ6WL,HXW!=N589R"*V/@[^R/^T/\>]!N/%7PO\ AQ)>:3:W(MI=
M6OM1MK"T,^,^2LUW+'&\F,'8K%N1QR*]\^)_QF7XV_L"_$77M'T;^R?#VF?$
M_P /Z7X1T%6RNEZ7!97:P0Y_B<@EY&_CDDD;^*LWQC\+?&'[7G[+WPCLOV;]
M4TK45\"^'[K2_%/@J37K6RN=.OVNY9I-0,=Q)&)(YT>,^:I."F&Q@XT_MC&J
MDW54:;]HXN4KN,%R<RYO>5W=\M^91OMT3C^R<'[5*GS5%[-225E*3YN5\ONN
MR^U:S=OFU\U_$OX7?$/X-^,;KX?_ !1\(7VAZS9;?M%A?P[' 895AV96'(92
M5(Y!-8-?6'[=O@O3?#?[(GP .H^-K'Q#XCTJ#7]"U36-/NA<0R16]S#+';13
MC(GCMC<M '4E-P<(2H!/B/[-'P-_X7K\13I.M:N=(\,:+92:MXS\0%<KIFEP
MX,TH_O2-D1QIU:21!W->C@LTIU\M>*JZ*+DG9/7EDXW2W]ZUTM7JEJSS\9EL
MZ.8K#4M6U%J]M.:*E9O;2]F]%I?1&;<_ #XQ6?P8@_:&N_ =W%X,NM3_ +/M
MM>D9%BFN/F&Q5+;V&4<;@NW*,,Y!%<?7V'\4OC-_PN[]@+XA>(=*T8:3X?TW
MXIZ!IGA+04;*:7I<%C=K! #W;&7=OXY))&/WJ^/*K*\9B<7"HZ\5%QDU9=%:
M+2?FKV;6G8G,L)A\+.G[&3DI13N^KNT[>3M=7U[A1117J'FG],>B_P#(&M/^
MO6/_ -!%6:K:+_R!K3_KUC_]!%6:_CV7Q,_K*/PH*_G7_:]_Y.R^*'_91-;_
M /2^:OZ**_G7_:]_Y.R^*'_91-;_ /2^:OU7PI_W[$_X8_F?F'B?_N>'_P 4
MOR1YW5C2M*U37=3M]%T33;B\O+N98;6TM86DEFD8X5$502S$D  #))JO7IO[
M'?QI\-?L]_M%^'OBMXQTN]NM,L/M4%[_ &8RB[@2XM9K8W$!;"^=%YOF)DCY
MD'(ZC]FQ-2K2PTYTH\TDFTN[2T7SV/R+#4Z57$0A4ERQ;2;[)O5_(U/C7^PG
M^TS\ _AYHGQ.^(7POU>VTK5=.^TWTW]FRXT=S<2PK!=DKB&1A&K@'C$J#.[(
M'._"#]EWX[_'?2KWQ#\,? ,EYI>G2B*^UB]O[>QLH92,B-KFZDCBWX(.W=NP
M0<<U]8?%_P"#'B?5/@CX0\0_L@?M0VFO"W^#NJQ:IH%]'+IVK^(=$;5]2FNI
M1:RATG"%Y5=-Y?,#.N=RUSGPJ\"?#KXQ?\$\_#_@W]I7XB_\*GTO0O%E_>^!
M/%MW$+JW\2&8JMS&;&-A<2M"ZA1<(I102A.00?EJ6?8GZC[24HN7M.5^Y.Z5
MY6_=74V]-D[VNW\+/IJF1X?ZYR1C)1]GS+WHV;M&_P"\LXI:[M6O9?:1\Q_$
M_P" /QB^#7BNR\%?$OP)=Z7J&I1I)IBNZ217L;MM5X9HV:.92W&Y&(SQFO1Y
M_P#@F=^V[:SO;7/P0>.2-BLD<GB'3@RD<$$&XX->I_M0^#O#WP6T3X">!?#6
MN)XB^%.@^(9[VU^*D5W'<0:G/<W5M)>1K%"7-HL*PC]PQ+DESR0<8WQ$T[_@
MGI\<?VG?$>CR?$[XBMJGC7QG>S6WCJUM+-=&M[F\NW>/-G(OVB2W5I ID\U&
M(!8(!Q6L<YQ]>A3J4TK-3;:IRE\,K+13BXNVKBVY)Z6NF9RRC T:TZ=1NZ<4
MDZD8_%&[U<'S*^BDDHM:WLT?*=]9W.G7LVGWD82:"5HY5# X93@C(X/(ZBNL
M^(7P ^,?PI\&>&OB%\1? =WI.C^,+9[CPW>73(/MT2K&Q=5#%E&V6-AN R'!
M&17IWPO_ &7K?X9?%/QQXE_:3TY'\)_![4W@\1VT4A":[J2R,EKID#$987#I
MN9@,K LC'!Q75?MD_$OQ9\8OV*?@Q\3O'%ZL^J:SXO\ &5Q=,B[43-Q9A8XU
M_@C10J(HX554#@5WU,UE+'4*5"TH2=I2\W"4TH^=DF[[)KOIP0RN,<%6JUKQ
MG%7C'R4XP;EY7;2MU3[:_*ZJSL$1223@ #K7LTG_  3R_;-C\+GQ6WP(U+RE
ML/MK:<+RV.I+;XSYAL!+]J"XYYBKS#X?>-M6^&WCK1_B%H-M:37VAZG!?V4=
M_;B:%I8G#IO0\.NY1D'K7O7['5K\5/BK^U0O[9/C[QC/H^@^$_$R>(_'OCF\
ME=(8E642M:(V<R2SC]RD"[F(DQM*@UMFF)QN%I.K2<5&*;]Y-N3Z1235F]D_
M>;;246999A\)BJJI5%)RD[>ZTDEUDVT[VWMHK)MR1\VD$'!&".HHKI?C+XST
MGXC?&#Q7\0M T?\ L^QU[Q+?:C96  'V:&>X>5(L#@;58+QQQ7-5Z=.4ITU*
M2LVM5V\CSJD8QJ.,7=)[]_,*_>[_ ();?\F ?#'_ + 3_P#I3-7X(U^]W_!+
M;_DP#X8_]@)__2F:OS3Q3_Y$M'_KY_[;(_1/#+_D<5O^O;_]*B>_4445^$G[
M:%%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC
M^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*^=_^"H/_(I>$O\ L(W/_HM*^B/A
M=_R3/P[_ -@*T_\ 1*5\[_\ !4'_ )%+PE_V$;G_ -%I7T/"O_(_H>K_ /26
M>%Q-_P B.MZ+_P!*1\<4445^WGXX?3O[,6F:@? 6F7_P>L-&N=0.C:X/%6Z"
MWEU%;OR)A9H%F!;R3^ZP$&UF+!\C(KR?5O%6B6'QET[7?BY\&ET_^SD3^WM!
MM+7[(+Z=58K(T+ +&')0LJ@*P!Q]ZNL_9Q\.?"S6;N#6/#_CXZ-KT'A;6(-7
MT[5DD*R,UE< 74$L2$!%5@60X8!"1N[Y_CB\\'_&?QSX-^''_"UK5H=(T<V6
MJ^.=;#0QSD/),<>;AF5%/EIOVECZ YKY2DHT\RK<R;33YG:2E%>^]UI)=(VU
MM:VS/IJCE4R^ERM)IJRO%Q;]U;/6+ZROI>]]T;OP*^,/Q!^-?Q(;P5\2C9:A
MX.GLKF76M.DT^*.TTNT2)CYL1508-A"A6!SG&22<UP_P:\9^.],,_@?X(>$T
ME\2ZE>-)!K44"27HMD0DPQ!P1$."[,N&.,9P!7>>./!]O'X<E^&/PA^)_P /
M]'\-NRF^GG\8P&^UAUZ/<N!@*#RL*_(N?XCS7F_A/X:^!_&WA)HM.^(VG:7X
MGM+Z1;FSU^_2VL[NVP-CP3$!0X.X%789!!'3!UH+!3IU)J*C"7*N6S:5KVE-
M*RU;U79*[[95GC(5*<')RFN9\UTF[VO&+=WIT?=NR[]M^T7'K5M\-_"\?QTL
M$7QZ^I3O=20Q1K<OI>%V"X9!M:3?G;G)"]>IS4LOVD/B+J_CZQ\'?!+18+'P
M_)<Q6FE^$?[.ADBN8^%*W *DRL_)9R21DD$=:3QM=Z-X>^!&G?!+5_B-I&OZ
MW/XI6\M9K&_^TVFC6QC\LJ;@#;\['<40E0 2>>O4+X&T'X6^'CH7P3^,'@)M
M7O;;9J_C"^\4P1W ##YH+1,GR$QP9,^8W^R,"L8O#0PJA5@I.\^6Z:A9N_,D
M_A2V2U>_*VFV;-8B>)<Z<W%6CS6:<[I?#?JWN]EMS:I(\G_:*T?P=X?^.'B;
M1? (C72;;5'2V2$Y2,X&]%_V5?>H]@*[_P" :^.-+^ >L:]X$\5Z3H$S>+K>
M*^UK67B6&&W6UE)0F1')+.\>%12QQTQFO/-!^%>GZGX\OO!6M_$_P[8)9V;S
M_P!L'4%EL[A@JL(XY 0&8[L?52.U3>!? 7A'QYX,N+2W^)%GI'B*"^WC3]>O
M%MK*[M]F T<S#:LJMD%7(!4\'J*]'$QHSP$*$IW4>2[<7*Z[OIK;5ZI;O0X,
M/*K#&RK1A9RY[)24;/LNNE]-K]#:^/B_&:^T/2M<\<^.-+\3:'+/(FFZQH9B
M:V$^!OB8K'&ZO@ [74<<CO7E]>I^-+KPW\-_@4WP>@\8:;KNL:IXCCU2^;1K
MCS[2PBCA:-4$H&UY&+$G9D +@GI7EE=>6_[NTDE%-I67*FN]NGY/=:,Y<P_W
MB[;;:5[OFL^U_P"K;/5!7T'_ ,$U_P#DOM__ -BO<?\ H^WKY\KZ#_X)K_\
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M $IFK\$:_>[_ ();?\F ?#'_ + 3_P#I3-7YEXI_\B6C_P!?/_;9'Z-X9?\
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MTMTQ\-7 ,<1&0/.@YY_SS7B\1?\ (CQ'^%GKY#_R.:'^)'WE16/_ ,)+J_\
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MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
M.Z^%W_),_#O_ & K3_T2E? ?_!Q%_P DS^&?_8=U#_T3%7WY\+O^29^'?^P%
M:?\ HE*^ _\ @XB_Y)G\,_\ L.ZA_P"B8J^LX&_Y*O#>LO\ TF1\MQK_ ,DQ
MB?2/_I43\K****_I@_G0**T/#?A7Q)XPU"32O"NAW.H7,5G<7<D%I"798((F
MFFD('\*1H[L>P4GM6?2YHN5KZCY9)7MH%%%%,04444 %%%% !1110 5]O_\
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M6Q_^-5^F?\19_P"H/_RI_P#<S\Z_XA;_ -1?_E/_ .W/Q9HK]IO^'(7[)O\
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MJ?\ W,/^(6_]1?\ Y3_^W/Q9HK]IO^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\
MHHWQ3_\ "V/_ ,:H_P"(L_\ 4'_Y4_\ N8?\0M_ZB_\ RG_]N?BS17[3?\.0
MOV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U1_P 19_Z@_P#RI_\
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M9J\W_P"'(7[)O_11OBG_ .%L?_C5'_#D+]DW_HHWQ3_\+8__ !JOF.*N-?\
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M[6'[.?['G@&/XF_M+?%K2O"6CSWJ65E-J#.\U]=/G9;VT$2M-<S$ D1Q([D
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M<AMHALK^ZMH[2\<MPJPRN6) 7)(KZ@H **** "BBB@ HHHH ***X/X,?M-_
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M6_P8M=7/PX^'_P ))=0O8)+_ %*V^RSWU_?W\,#R%( 52&.!5#-N+<$-]H4
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M#/A&RTO0[[X=:_JMW>7,]O''"&G2\M(41#&A;*,3NP,8YH ^A:*** "BBB@
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M;X7?M%?\$L_A=\$?C3X+L?$/A?Q+\#_#]CK&DZC 'CGB?2;<'K]UAPRN,,K
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M"N=7O='L+1B@GGG%U:^9]I5?-\H>7)%NV%P1D4 >,_\ !;Z[\ _M!_ G3/\
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M-?B?QUI=]XWN?$<NHV:ZK=^:D<D5K#'$Q1%CRH?&[<-Y&#7T;_P3Q_82U?\
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M9:F;R_%G_96J2P:9;' 2TL(-^V.WB55X#/O?YJ^L_P!C_P .?\%)/ WB#3O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU+;LPF2'15M3?G9MRQ,(55=&8A74FIX$_P""H_[(?Q&^'7C?X@^&=9\9-/\
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MYL/"6H/!IK:;'?QE[V2:W6*U)N+"=8XYRIF$89%9'1FM_!3_ (*-_#KX;_\
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MX7T6T\-^&=&M-.TZPMT@L;"PMUAAMXE&%CC1 %10  %   % %NBBB@ HHHH
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M5XKKX.^-?!G@[7K)K9OM/_"-1:0VG^*!%#_$IUC7[J4=S_9J,0N,C]UZY4?
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F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>biib-20220930_g5.jpg
<TEXT>
begin 644 biib-20220930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OFK_@JM^W_P"(?^"9/[)^I_M?)\#(
M?'7A[P]>VD'B&QC\5?V;=VZW5S%:PR1!K699AYLR!@60J#D;N<?2M?GK_P '
M3_\ R@U^,7_7YX:_]2'3J />?&'[1'_!2+PEX5U'Q1;_ /!.KPGK3Z=927"Z
M1HGQT#WEYL4MY4"RZ1&C2-C"JSJ"2!D5] >$/%.C^./">E^-?#TS2:?K&G07
MUC(Z%6:&6-9$)4\@E6'!Z5^?'_!3[XJ?\%D_V0/V79OVDM._:(^".LV7AK7K
M%-4T_P -?"K5=%GVWDG]GP3R37.N7R2P0W=W;7$D/EH9$A8&0#*MZ3\;=0^,
MW[ GQ;_9[UG3?VC_ !GX^TOXF_%*T^'WQ#T;QI=0W(U&>]T^\GAU>T"1*+"6
M&>S!:"W"6[0RR#RPR(X /L^BOA#XY6G[3'Q/_P""T>E_LMZ)^V%XZ\,_#/5?
MV<[WQ3K?A[P^]E;2QW,6M6UFJVEPMMYL+,71FE9GE"K(B/&)#CZZ\.?!E])^
M ]M\"O$'Q8\9ZZ8M!_LNZ\8W^M^1KMV-FPW+7=HD.RX(Y\V-4(/(P>: ,3XQ
M?M1^%_AY^S-XT_:9^'GA^X\>V'@NRUJ6[T[P]>V\<DTVE2W$%]")+AT0-%-:
MSQMR3NB8*&. =O\ 9L^,</[1/[.O@']H&W\/MI,?CKP5I7B&/2GN1,UFM[:1
M7(A,@5?,*>;MW;5SC.!G%?GI_P $SOAUI_@C_@W?^(&I6'B77[T7_@[XGP_9
MM7UR:[AMEM]7\0Q*85E8^6SCYI&',C_,Q)YH^$?B#X\?L;_\$U?V/?VHK?X_
M^)=6O];N_AGX?\6^&;JXC.BS>']82TL!90V>S;#+;1W,#I<H1-));DR.Z2,E
M 'Z@45^;'@#]I+]K/]LW]H']H:>#P#\>Y?"_PU^*NH?#WP#;_!CQ)X5TNWTN
MXTZ&'[1J-W_:NJ6T]]<S2S"18IHI+18?* 5V:0C[ _X)^>)OVP_%/[*/AF[_
M &]/AU%X:^*5K]IL_$=O!<V,B7PBGD2"^Q8SSP1-/ (I7B20A)'=0 H H =\
M;_C_ /M">%_C!9?![]G7]F&T\=SIX<_MCQ%K&M>-UT.RTM))VAM80WV2Y>XE
MF,-TV%4"-;?+']X@/S#\*/\ @L=^U1\:_P!G7XE_M-_#C_@G#8:EH/PH\4:Y
MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_DF?AW_L!6G_ *)2MVN,^&MGXR;X<Z T&L6BH=$M=BM;DD#R5P.M;?V+QO\
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MWA*\:QU#5M2FO- TS45@<037$SQV\DEJL@1G.Q&V[@.F3U/V+QO_ -!NR_\
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M-/\ RL__ &FO":*/]<^)?^?_ /Y+#_Y$/[>S7_GY^$?\CW;_ (;6_P"J:?\
ME9_^TT?\-K?]4T_\K/\ ]IKPFBC_ %SXE_Y__P#DL/\ Y$/[>S7_ )^?A'_(
M]V_X;6_ZII_Y6?\ [31_PVM_U33_ ,K/_P!IKPFBC_7/B7_G_P#^2P_^1#^W
MLU_Y^?A'_(]V_P"&UO\ JFG_ )6?_M-'_#:W_5-/_*S_ /::\)HH_P!<^)?^
M?_\ Y+#_ .1#^WLU_P"?GX1_R/=O^&UO^J:?^5G_ .TT?\-K?]4T_P#*S_\
M::\)HH_USXE_Y_\ _DL/_D0_M[-?^?GX1_R/=O\ AM;_ *II_P"5G_[37KW@
M#Q9_PG/@ZP\6?8/LOVV$O]G\W?L^8C&[ ST]!7Q77UY\ O\ DCV@_P#7H?\
MT-J^PX,S_-LVS"I3Q=3FBHW6D5K=+HEW/;R+,L;C<3*%:=TE?9+JNR1V%%%%
M?I!]4%%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_
M ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P '_MT3Z3AC_?)_X?U1V%%%%?L!]P%%%% !1110 4444 %%%% !7E'[<_\
MR:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4
MK=KD?AGXL\-P_#CP_#+K$*LFB6BLI/0B%.*W/^$Q\,?]!J#_ +ZH TJ*S?\
MA,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_
M +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
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M_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344 0_V=I_\
MSXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_ 'Z%344
M0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9VG_\^,/_
M 'Z%344 0_V=I_\ SXP_]^A1_9VG_P#/C#_WZ%344 0_V=I__/C#_P!^A1_9
MVG_\^,/_ 'Z%344 0_V=I_\ SXP_]^A6;XRL+!?"&JLME""--GP1&/\ GFU;
M%9OC/_D3]6_[!D__ *+:L<1_N\_1_D9U?X4O1GQ+1117\RGY.%%%% !1110
M4444 %%%% !1110 4444 ?<=KIVG_9H_]!A^X/\ ED/2G_V=I_\ SXP_]^A3
M[7_CVC_ZYC^5/K^GH_"C];6Q#_9VG_\ /C#_ -^A7QE\1E5/B%KR(H &LW0
M Z?OFK[3KXM^)'_)1-?_ .PU=?\ HYJ_.?$;_=,/_B?Y(^7XH_@4_5_D8M%%
M%?DY\8%%%% !1110 4444 %%%% !1110 5];_ 6RLI/A!H3R6D3,;0Y+1@D_
M.U?)%?7GP"_Y(]H/_7H?_0VK] \._P#D:U?\'_MT3Z3AC_?)_P"']4=6EC91
ML'CLXE8="L8!%2T45^P'W 4444 %%%% !1110 4444 %>4?MS_\ )H_CW_L
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M_P#7,?RI]?T]'X4?K:V"OBWXD?\ )1-?_P"PU=?^CFK[2KXM^)'_ "437_\
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M7XJ:7X6U34--N6@NH-+9)[R^\F5"&B>2WM)(1(IW+Y^Y2" 1B^&]/T;]EO\
MX* >&_@C\-=.CTCP/\4?AWJE[%X9LAML[+6M)N+3=<P1?=A,UM>XE" "1X(W
M(+;F)\>AXA_:S_9P^%G[47P;\!ZLVL>#O&VD>.++PAJ,:6^H3Q0^;;W^GD,V
MQ;C[-<72J"VUI40;L$-6AX,T+7_VA_VW=*_:6/@S7M'\'?#_ , WVB^'9/$^
MAW.EW>I:KJ5Q;R7<J6MTB3K##!:11[Y$42/,VS<J;CUTN6GA.26B2J*2_O\
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MI';>+6:QND;S)([9!(;-BH7R2NTOA]V17VM75G#A+&*49J5X0U6BOR179?\
M VWT-L=RNNFFG[L=O\*"BBBO+.,^T+;P1I)MXS]IO/N#_E[;TJ3_ (0?2/\
MGYO?_ MJU;7_ (]H_P#KF/Y4^OZ>C\*/UM;&/_P@^D?\_-[_ .!;5\A?$&%+
M;Q[K=O&25CU>Y52QR<"5AR:^U:^+?B1_R437_P#L-77_ *.:OSGQ&_W3#_XG
M^2/E^*/X%/U?Y&+4=M:VUG%Y%I;QQ)N9MD:!1EB6)P.Y))/J2:DHK\G/C JI
MKFC6GB'2+C1+^:Z2&YC*2M9WLMO*%/7;+$RNA]U8'WJW133:=T&Q5T+0]&\,
M:)9^&_#FEV]CI^GVL=M8V5K$$BMX44*D:*.%55   X %6J**&VW=AN%%%%(
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M F&TMKJ-+=63#32Q76<Q+$T@!]A_8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
MC6)\>_C1I'P'^&]SXXOM(N-6OY+B*Q\.^'K!U%UK>ISN([6QAW<!Y)" 7;"1
MH'D<K'&[#PK_ ()._M!_M(_M _#3XKG]J?Q3H^K>)_!'Q\\3^$5GT#3!:V<5
MM8R0JD,2XW,BL[A7D)D9<%B30!](?8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^-?'G_!6W]NOX]?L^_#ZY@_9)U'3[74/!_BCPG_PL;Q#?Z>EW%96VJZY8
MV$.E1*X*?;)XKM[AB0Q@@B0E0;J!Q]MT 8_V+QO_ -!NR_\  8_XT?8O&_\
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M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M/@U\(/@9X9'@KX)_"GPUX.T83-*-(\+:%;Z?:^8W5_*@1$W'N<9- '24444
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MZ]#_ .AM7Z!X=_\ (UJ_X/\ VZ)])PQ_OD_\/ZH["BBBOV ^X"BBB@ HHHH
M**** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6
M@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4KC/VG/B+XQ^'FDZ3<
M^#]8^QO<W$JSM]GCDW *I ^=3CKVKAS''T<LP4\553<8[VWU:75KOW.?%8F&
M$P\JTT[+MOV/4**^3O\ AI?XV_\ 0Z_^4VV_^-T?\-+_ !M_Z'7_ ,IMM_\
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M 5ZK^Q__ ,E1NO\ L"R_^C8J\JKU7]C_ /Y*C=?]@67_ -&Q5[G#/_(_P_\
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M'4_!/_DK/A__ +"<?\Z^PZ^//@G_ ,E9\/\ _83C_G7V'7Z]X=?\BVM_C_\
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MJ'_I-)74URWQR_Y(IXP_[%;4/_2:2OM:W\*7HSWI_ S\&****_'SXDYSQ_\
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M-*AAFER<G<Z*&;)Y.3UK;HJN>>NNX^9]PHHHJ1!7[2_\$Y_^3)OA[_V!G_\
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M9U5J<%34H+3\>NC18\%?&7POX^^)GBOX;>&Y8[A_"$=BNI7D,X=?M%P)F,&
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ML1:SX6\(Z;JT6IZ=8:VD3W6FRP)++/<WLD7DNP D(R VTG:W!P:/B'/8W_\
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MD4\8?]BMJ'_I-)7TU;^%+T9ZL_@9^#%%%%?CY\2%%%% !1110 4444 %%%%
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M?"S7!TFVL6M1 #/%Y4N\20.S[DXY;CJ,'FOU^_X<A?LF_P#11OBG_P"%L?\
MXU1_PY"_9-_Z*-\4_P#PMC_\:I_ZL5>=S]OJ]/A\K?S=M/0?]DSYN;VFOI_P
M3\IO$.A?V_9I;QZO>6$T4HDM[RPD421/@C.'5D<8)&UU9><XR 1C^#/A5H7@
M_P 2:GXVEU._U;7=7BBAO=9U62-IC!%N,<"+$B1Q1J68[41<LQ9MQYK]<?\
MAR%^R;_T4;XI_P#A;'_XU7F/QV_X)-?LY?#WXD?#3PMH?CWXC/;>*O$[V&I-
M=>+V=TB$)<&,B,;6R.I!J5PK-1<57T?]W_[82RB25O:?A_P3\W->^$_AGQ;X
MIL_%'C&>\U8:9<K<Z3IEY,/L=G.HP)EB15$D@ZJ\N\H22A6KWQ#\$V/Q'\%:
MCX'U+5]2L(-2M_*EO-'O3;W,0R#F.0<J>/Q&0>#7ZQ_\.0OV3?\ HHWQ3_\
M"V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5'^JU1-/V^VWN[?\ DP?V1*Z_>;>7
M_!/R.\;?";PQX]T+3-(UBYOH[C1+J*ZT;5[:Z(O+.XC4HLRR,"&8JS*P<,KA
MF#*0:C\'?"/1?"OBN\\?ZAKNIZ[X@O;)+*76=9DB,L=JC%U@C2&..*)-Y+':
M@+-@L6P,?KK_ ,.0OV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U3
M_P!5ZBAR^WT_P_\ VP?V1*UO:?A_P3\M:*_4K_AR%^R;_P!%&^*?_A;'_P"-
M4?\ #D+]DW_HHWQ3_P#"V/\ \:K/_5+_ *??^2__ &Q/]C?]//P_X)\(?L&_
M\GD?#C_L:;;^=?MK7QS_ ,.0OV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^
M%L?_ (U7NY3EG]ET90Y^:[OM;]6>A@\+]4@XWO=^A]C5RWQR_P"2*>,/^Q6U
M#_TFDKYB_P"'(7[)O_11OBG_ .%L?_C5'_#D+]DW_HHWQ3_\+8__ !JO3G'G
M@X]SK:NK'Y:T5^I7_#D+]DW_ **-\4__  MC_P#&J/\ AR%^R;_T4;XI_P#A
M;'_XU7Q_^J7_ $^_\E_^V/$_L;_IY^'_  3\M:*_4K_AR%^R;_T4;XI_^%L?
M_C5'_#D+]DW_ **-\4__  MC_P#&J/\ 5+_I]_Y+_P#;!_8W_3S\/^"?EK17
MZE?\.0OV3?\ HHWQ3_\ "V/_ ,:H_P"'(7[)O_11OBG_ .%L?_C5'^J7_3[_
M ,E_^V#^QO\ IY^'_!/RUHK]$/VFO^"0G[-/PH^ GBGXB^&O'_Q)DO\ 2-+:
M>U2]\8L\3,& ^91&"1SZBNG\$_\ !%C]E;7O!FD:Y>_$3XH+->Z9;SRK%XT(
M4,\:L<#RN!DT?ZI?]/O_ "7_ .V#^QO^GGX?\$_,BBOU*_X<A?LF_P#11OBG
M_P"%L?\ XU1_PY"_9-_Z*-\4_P#PMC_\:H_U2_Z??^2__;!_8W_3S\/^"?EK
M17ZE?\.0OV3?^BC?%/\ \+8__&J/^'(7[)O_ $4;XI_^%L?_ (U1_JE_T^_\
ME_\ M@_L;_IY^'_!/RUHK]2O^'(7[)O_ $4;XI_^%L?_ (U1_P .0OV3?^BC
M?%/_ ,+8_P#QJC_5+_I]_P"2_P#VP?V-_P!//P_X)]?:3_R"K;_KW3_T$58K
MXY_X<A?LF_\ 11OBG_X6Q_\ C5'_  Y"_9-_Z*-\4_\ PMC_ /&J^Q6B/</L
M:OPI_:A_Y.8^(G_8]:O_ .ELM?HA_P .0OV3?^BC?%/_ ,+8_P#QJC_AR%^R
M;_T4;XI_^%L?_C5>5FV5_P!J4XQY^7E=]K_JCBQF$^MQ2YK6\KGY:T5^I7_#
MD+]DW_HHWQ3_ /"V/_QJC_AR%^R;_P!%&^*?_A;'_P"-5X?^J7_3[_R7_P"V
M.#^QO^GGX?\ !/RUHK]2O^'(7[)O_11OBG_X6Q_^-4?\.0OV3?\ HHWQ3_\
M"V/_ ,:H_P!4O^GW_DO_ -L']C?]//P_X)^6M%?J5_PY"_9-_P"BC?%/_P +
M8_\ QJC_ (<A?LF_]%&^*?\ X6Q_^-4?ZI?]/O\ R7_[8/[&_P"GGX?\$_+6
MBOOS]D__ ()-?LY?&/X;W_BGQ5X]^(T5S;^)]1L(UL/%[1H8H9BB$@QGYL#D
MYYKT[_AR%^R;_P!%&^*?_A;'_P"-4?ZI?]/O_)?_ +8/[&_Z>?A_P3\M:*_4
MK_AR%^R;_P!%&^*?_A;'_P"-4?\ #D+]DW_HHWQ3_P#"V/\ \:H_U2_Z??\
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ML2(UPX4!I"J *I8@DA0 ,\ "K- !1110 4444 %%%% !7P#_ ,'$OB'7[_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MOPG?^ OB/X/TOQ!H6JVY@U31=;T^.[M+R(]8Y8959)%/]U@10!\4_M0?%?\
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M'X5_\**/[-G@$^"//\[_ (0X^#K'^RO,QC?]D\KR=V.^W-8K?L%_L,OX6MO
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>biib-20220930_g6.jpg
<TEXT>
begin 644 biib-20220930_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P
M[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** /R=_;L_88^.OP3_ &E=-_X*"?\ !(OXVVUWK7CCXSRM
MXM^!_BV1F\,^(?%%I;ZC;W-TDF]&LKDFUNH7((#RN&\U$&#[S\-?^"L<GQ'_
M ."45S^V_P##?]F?Q#H7BP:]=>']9\!:5X:N-7FT'Q"VIFTO;B2WLXQ+=P0S
M227<FQ5DD4,IVR,2.N^)G_!)C0]:\9KXN^"_[6/Q8\ ?VI\4;OQKXIL='\16
M]Q;SWMRET)I;2*\M9TL9?]("!H0@**2P>0B4?0?[./[.GPE_91^#ND_ OX)>
M'7TWP_HXE:))[N2XGN9YI7FGN9YI2SSSRS222R2.269R?:@#\J-3_;Z_9;\,
M?\% ?V.M-^'GPJ^.QM/"H\>IKU_XI^#6LVVIZYJ6JV5J)=09)+96N9)+DRSW
M$D:[(A)N(1-H'['UYQ\2?V7?AW\4_P!HGX9_M->(]0U:/Q#\*8=;C\-P6ES&
MMK,-5MHK>Y^T(T99R$A4IM9,$DG=T$^M_L[>'-=_:6T+]J"?QYXPAU30/"UW
MH5OX<M?$<L>B7,-Q*DK3SV0^26X4H LA/ /(.U2H!X;\3/\ @G5XI\1?&GXL
M?M*? W]OGXD> _''C*:RECL]"ETJ31-+NK'3(+:T2ZM+BSE>YCPGFR1R2 $7
M#E!&6#5Z#_P35_:C\2?MJ?L&_"S]J/QGH-OINL^,?"<%WK-I9@B 7:EHIGA!
M)(B>2-G0$DA'7D]34^)7_!/;X<^._%7COQ%X5^+OC[P+:_%3RC\3=%\%:G9V
M]OXD>.U2S\V22>UFN+25K6..!Y;*:V=E126W@/7L7PW^'/@?X0?#[1/A3\,O
M#%KHOAWPWI5OIFA:18IMAL[2"-8XHD']U44#G)XYS0!M4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T
M=U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *Y;XY?\D4\8?]BMJ'_I-)74URWQR_Y(IXP_[%;4/_2:2LZW\*7H
MR9_ S\&****_'SXD**** "BBB@ HHHH **** "BBB@ HHHH _H(TG_D%6W_7
MNG_H(JQ5?2?^05;?]>Z?^@BK%?L:V/MUL%%%%,84444 %%%% !1110 4444
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M 4444 %%%% !1110 4444 %%%% ']!&D_P#(*MO^O=/_ $$58JOI/_(*MO\
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MKUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR3/P[_V K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RWQR_P"2*>,/^Q6U
M#_TFDKJ:Y;XY?\D4\8?]BMJ'_I-)6=;^%+T9,_@9^#%%%%?CY\2%%%% !111
M0 4444 %%%% !1110 4444 ?T$:3_P @JV_Z]T_]!%6*KZ3_ ,@JV_Z]T_\
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M*$\=LFD0?#^ZN;C2IM+&EZ=Y<L4]U%%-,3,;@,SQJ0RL@&U!0![77E'[<_\
MR:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:?^B4
MK=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1110
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MEK]UJ_"G]J'_ ).8^(G_ &/6K_\ I;+7R?%G\"EZO\CQ\Y_AP]3A:***^(/
M"BBB@ HHHH **** "BBB@ HHHH *_:7_ ()S_P#)DWP]_P"P,_\ Z/EK\6J_
M:7_@G/\ \F3?#W_L#/\ ^CY:^GX5_P!^G_A_5'K9/_O$O3]4>UT445]Z?1!1
M110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW
M_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2OBW_@NC_R3[X?_ /89O?\ T5'7VE\+
MO^29^'?^P%:?^B4KXM_X+H_\D^^'_P#V&;W_ -%1UY&??\BFK\OS1Q9C_N<_
ME^:/S>HHHK\R/E HHHH **** "BBB@ HHHH **** "OK[_@BC_R=KJO_ &(M
MY_Z56=?(-?7W_!%'_D[75?\ L1;S_P!*K.O2R?\ Y&=+U.K!?[W#U/U2HHHK
M]2/K@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N6^.7_)%/&'_
M &*VH?\ I-)74URWQR_Y(IXP_P"Q6U#_ -)I*SK?PI>C)G\#/P8HHHK\?/B0
MHHHH **** "BBB@ HHHH **** "BBB@#^@C2?^05;?\ 7NG_ *"*L57TG_D%
M6W_7NG_H(JQ7[&MC[=;!7X4_M0_\G,?$3_L>M7_]+9:_=:OPI_:A_P"3F/B)
M_P!CUJ__ *6RU\GQ9_ I>K_(\?.?X</4X6BBBOB#P HHHH **** "BBB@ HH
MHH **** "OVE_P""<_\ R9-\/?\ L#/_ .CY:_%JOVE_X)S_ /)DWP]_[ S_
M /H^6OI^%?\ ?I_X?U1ZV3_[Q+T_5'M=%%%?>GT04444 %%%% !1110 4444
M %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+O^29
M^'?^P%:?^B4KXM_X+H_\D^^'_P#V&;W_ -%1U]I?"[_DF?AW_L!6G_HE*^+?
M^"Z/_)/OA_\ ]AF]_P#14=>1GW_(IJ_+\T<68_[G/Y?FC\WJ***_,CY0****
M "BBB@ HHHH **** "BBB@ KZ^_X(H_\G:ZK_P!B+>?^E5G7R#7U]_P11_Y.
MUU7_ +$6\_\ 2JSKTLG_ .1G2]3JP7^]P]3]4J***_4CZX**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KEOCE_R13QA_P!BMJ'_ *325U-<M\<O
M^2*>,/\ L5M0_P#2:2LZW\*7HR9_ S\&****_'SXD**** "BBB@ HHHH ***
M* "BBB@ HHHH _H(TG_D%6W_ %[I_P"@BK%5])_Y!5M_U[I_Z"*L5^QK8^W6
MP5^%/[4/_)S'Q$_['K5__2V6OW6K\*?VH?\ DYCXB?\ 8]:O_P"ELM?)\6?P
M*7J_R/'SG^'#U.%HHHKX@\ **** "BBB@ HHHH **** "BBB@ K]I?\ @G/_
M ,F3?#W_ + S_P#H^6OQ:K]I?^"<_P#R9-\/?^P,_P#Z/EKZ?A7_ 'Z?^']4
M>MD_^\2]/U1[71117WI]$%%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P
M"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*^+?^"Z/
M_)/OA_\ ]AF]_P#14=?:7PN_Y)GX=_[ 5I_Z)2OBW_@NC_R3[X?_ /89O?\
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MZ]T_]!%6*KZ3_P @JV_Z]T_]!%6*_8UL?;K8*_"G]J'_ ).8^(G_ &/6K_\
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MZ99"Z2A7,>QE_9U_9H^)>F?M)>-_VT/VCKG0!XX\6>']-\,:+H/A>_GO-/\
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M_3S\/^"?EK7U]_P11_Y.UU7_ +$6\_\ 2JSKZ,_X<A?LF_\ 11OBG_X6Q_\
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M_P :H_U2_P"GW_DO_P!L']C?]//P_P""?EK17ZE?\.0OV3?^BC?%/_PMC_\
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M:KX__5+_ *??^2__ &QXG]C?]//P_P""?EK17ZE?\.0OV3?^BC?%/_PMC_\
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M_"V/_P :H_U2_P"GW_DO_P!L']C?]//P_P""?EK7[2_\$Y_^3)OA[_V!G_\
M1\M>2?\ #D+]DW_HHWQ3_P#"V/\ \:H_X<A?LF_]%&^*?_A;'_XU7J95DG]F
M5Y5/:<UU;:W5/N^QUX/ ?5*CES7NK;6_4^QJ*^6_A+_P2._9K^#7Q+T3XJ>%
M_'7Q%N-1T'4$O+.#4O%QEMWD0Y D3RQO7U&>:^I*]X]$**** "BBB@ HHHH
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M^(+#2191V]A+<:;'#)<:BDDJW5VD<)"F.UANIW2U$83[E>@?\$\O#O@?P?\
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M[OK0!]/4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y[^UO_P FI?$[_LGNM?\
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M'UA'I7CKP?I6M6L,K20VVK:?'<QH[1/$S!9%(!,<LB$CDK(Z]&((!^87P?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
)44 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>biib-20220930_g7.jpg
<TEXT>
begin 644 biib-20220930_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
MH:T >E>'-9B\1^'K#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_ "3/P[_V K3_
M -$I6[0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1
M^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T
M2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\
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M^PIJ1U)(=GR!5*I\@6HOVE9X%_X+<_LMP-,@<_";XD80L,G+:%CC_@)_(^E
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M 49(&2,D5^?W[1GQG_X*N_L(^-/AA^TE\:OC]X$\?^!O'?Q1T7PCXX^$.A>
MA8GPVNK7 MX9=+U+SFN+]X)713YZJ)AE@D6["?;_ (!^/_P0^*;>*T^'7Q7T
M#63X%UVXT7QE_9^IQR#1=0MU#SVUR0?W4D:L"P;&.<]#CXYU?]M_]@O]KSXR
MZ)\<?B9^U]\,M/\ A7\(-=FU7P/HU[XVL1=^*?$4*20+K#6WFF7[+;!YDLXM
MF^XGD-PJ[8[5I #[UHI(W$B+(H(# $!E(/X@\BEH **** "BBB@ HHHH ***
M* "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\ DT?Q[_V 7_\
M0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W: "BBB@ HHHH
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M)X4NW"Z):@.K+AAY*\UM_P#"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T
M;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &Q16/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM &
MQ16/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2T ;%%8_P#PDNK_ /0H7O\
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M8SF*_M=*TRTTU[N)AP\;W$%PJL.&\K()!!KZ5JOI.DZ5H&EVVAZ%IEO965G
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M  3\7Z#\:_$":[XE^%_Q=\3> -0\51V<=M_PD"Z5?-##?M%$JQQRR0F,2K&
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M%'_Y6?SC]>S3_H*K?^#JO_R9PW]K?\%-?^DDO_F'=%_PH_M;_@IK_P!))?\
MS#NB_P"%=S11_LG_ $#4/_!%'_Y6'U[-/^@JM_X.J_\ R9^3_P 7?B-_P4K_
M ."5GQ,T'PY\7/C7<ZW\#I?B#XA\2:7\0/#GP\TS5;RSO=5MKY]0_M"PF7>Z
MD75R[LSO&(]Q3)"QI]T?LS:E^V3+^S+X'TK]F/\ X*?PR> +3P=8V'@B[T[X
M0Z-(L6FPVZ06P4RJ3N2-%4B0;@RD,,@BO,=>^!7_  40\-2>"?!&G?\ "K_&
M=CI?B36IK/6M;FOK<:99W=E?QQ6]Y;K%(+R.)+E8E9&A,FV-&50S2#WC]C/]
MF30/V-OV8/!W[-'AK7I]4MO"FF&!]2N(A&UU/)*\\TNP$[%:660JF3M4A<G&
M3XF6T(4:LZ?U:FZ;N_?HTG)-VT4G!MK?TMOJ>_FF98BKAX3CBJBJ*R]RK449
M)<VKBI>Z]O6^VA\S?L4>%?V\OAU^WS^U#I?AO_@HIK=UX@NYO"%YXH\5:_X"
MTR^GU9Y;"Z>%!$X$=K'"I:-(X55-I VC:!7U=_:W_!37_I)+_P"8=T7_  KS
MSX#? GX[^ /VR?C!\>O&NG^$5\._$F+0DTZ'2_$%U->V7]FVDL&9(Y+..-_-
M,N[Y9!LQCY^M>E6FG_'E?CY>:G?>(?#3?#1O"T4=AI<=E,-736//)DE>4MY1
MMS#@!0-V[T ^;KP,,-A\.H/"TG[TMZ-*3LY2:NY0;M:UM=%9=+'%F&/S"OB>
M>.+J+W(;5:B5U"*DDHRM>][Z*[NSYI_;E^'7[6>B?L8_$+X*:G^UI8^*HOBI
M=W]G;^"C\(M'2;Q/K^J2.Z_ON9$<2'SC.#FUAMO,4HENNWVKX+^$O^"E'PA^
M#OA/X3Z=_P %)&%OX7\,V&D0!OA3I5P=EM;I"N99<R2\(/G<EFZGDFO'O$?P
MJ_X*Q2_M"ZU\:="@_9XU"!3)9>"K7Q'JNNR/H6FL1N1!#;HGGS;5::7!9MJH
M"$0+7T]\)[+XFV'PXT>W^,^M:5?^*S9*_B"XT*W:*Q%TV6>.V5_G\E"=B%_G
M*(I?+$TZ$L-5Q4IO"4EI97H4;63WMR6N^]KV6X8G%9C1PD(1QE23;N[5JC=V
MMK\VR]=6_F8_]K?\%-?^DDO_ )AW1?\ "C^UO^"FO_227_S#NB_X5W-%=_\
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M[_3/%T@U.\T)(M1MM5MO$$4%NLUS$WE2120-=/&B1Q[=CCYE5 OH7[87B/\
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MOL7AWPKH\\,$EY-L:1FDGG98K:!$1F>9S@?*H#.Z(W!_LG?ML7/[07Q"\8?
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M44Q'VS:_\>T?_7,?RI],M?\ CVC_ .N8_E3Z_!'N?TVM@KX[^(?_ "/^N?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOV2_X)Y_\F8> /\ L#O_ .CY:^>XD_W2'^+]&?4<*?[[/_#^J/9J***^,/O
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M0_F7WH/JN)_D?W,]'HKSC_AK;]GS_HH'_E*N_P#XU1_PUM^SY_T4#_RE7?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*YCXW?\ )&/%_P#V*^H?^DTE=/7,?&[_ )(QXO\ ^Q7U#_TFDK2E_%CZHSJ_
MPI>C/PNHHHK]0/Q\**** "BBB@ HHHH **** "BBB@ HHHH _?'2O^07;?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH
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M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H
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M /8KZA_Z325T]<Q\;O\ DC'B_P#[%?4/_2:2M*7\6/JC.K_"EZ,_"ZBBBOU
M_'PHHHH **** "BBB@ HHHH **** "BBB@#]\=*_Y!=M_P!>Z?\ H(J>H-*_
MY!=M_P!>Z?\ H(J>ORQ[G[&M@K\/_P!IK_DY'X@_]CQJW_I9+7[@5^'_ .TU
M_P G(_$'_L>-6_\ 2R6OI>&OXU3T1\GQ9_ I>K_(X>NP^$?PCN_BC+K.HW6N
MPZ1HGAO2SJ.OZO/ \HMX/,2)0D:<R2/(ZJJ\#DDE0"1Q]>D_LU_&SQA\!-?U
M3QGI/A&Q\0:#=6 T[Q7H>J1A[:]M)F_U;]=I++\KX.#P002#]37=14G[/?\
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M\5OV@?#WC^>^TIO#%YX>\,V-UI<MO/\ :M20Q)%*S_NWECB+LRQ-(-H+EE&
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MCY:^>XD_W2'^+]&?4<*?[[/_  _JCV:BBBOC#[P**** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
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M>KUY1^W/_P FC^/?^P"__H:T =)\-?!NE3_#G0)WN;L%]$M6(6Z8#)A6MO\
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M[_X%M6Q10!C_ /"#Z1_S\WO_ (%M1_P@^D?\_-[_ .!;5L44 8__  @^D?\
M/S>_^!;4?\(/I'_/S>_^!;5L44 8_P#P@^D?\_-[_P"!;4?\(/I'_/S>_P#@
M6U;%% &/_P (/I'_ #\WO_@6U'_"#Z1_S\WO_@6U;%% &/\ \(/I'_/S>_\
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MD9)B(*,2RF@#VFO*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\
MT-: .Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH ****
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MX#V?Q!\0>*H=)U35KF+7_%>IO>ZG>+>:G=7H-S</\T\H%QM:1N7*ECR:_/\
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *XG]I?\
MY-P^('_8D:K_ .D<M=M7$_M+_P#)N'Q _P"Q(U7_ -(Y:J'QHBI\#]#^76BB
MBOLCX8**** "BBB@ HHHH **** "BBB@ HHHH _JUT#_ ) 5E_UZ1_\ H(JW
M530/^0%9?]>D?_H(JW7QCW/NUL%?S&?MK?\ )Y/Q;_[*;KW_ *<9Z_ISK^8S
M]M;_ )/)^+?_ &4W7O\ TXSUZV4?Q)>AXN=?PX>K/,J***]T^>"BBB@ HHHH
M **** "BBB@ HHHH *_HR_X)%_\ *-[X3?\ 8NO_ .E,U?SFU_1E_P $B_\
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M7_Y-P^('_8D:K_Z1RU4/C1%3X'Z'\NM%%%?9'PP4444 %%%% !1110 4444
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M;F8@'- 'OM>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T
M=U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444
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MY)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MRLV_@1]?T/7R;_>9>GZH^CJ***\ ^E"BBB@ HHHH **** "BBB@ KRC]N?\
MY-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T
M2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH
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M )1O?";_ +%U_P#TIFKRLV_@1]?T/7R;_>9>GZH^CJ***\ ^E"BBB@ HHHH
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M@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\
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M.6JA\:(J? _0_EUHHHK[(^&"BBB@ HHHH **** "BBB@ HHHH **** /ZM=
M_P"0%9?]>D?_ *"*MU4T#_D!67_7I'_Z"*MU\8]S[M;!7\QG[:W_ ">3\6_^
MRFZ]_P"G&>OZ<Z_F,_;6_P"3R?BW_P!E-U[_ -.,]>ME'\27H>+G7\.'JSS*
MBBBO=/G@HHHH **** "BBB@ HHHH **** "OZ,O^"1?_ "C>^$W_ &+K_P#I
M3-7\YM?T9?\ !(O_ )1O?";_ +%U_P#TIFKRLV_@1]?T/7R;_>9>GZH^CJ**
M*\ ^E"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
MY-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K
M=H ***P?BG'X^E^&/B.+X4S6L?BEM!O!X:DO0#"NH>0_V<R9XV"79G/;- %\
M^*O#8\4CP0=<MO[7.GF^&F^</.^S!_+\[;UV;R%STSQ5^OPA_8GT?]EK]M+Q
M3>_LF?%>]\7_  <_:VL?@Y/H_C2^\;^+;_2_$&M>,ENE>2[%SYV[4[.Z&]VM
M5WH+:1T6+8J.?V_^*%_\4-,\!:E??!?PKH&M^*(X5_LC2_%&OSZ783R%U!\Z
MZ@M;J2)0I9AM@D+%0ORABR@&_17Q7_P0^\9?'GQU\&/C/K'[3NL:1>^/+;]I
MCQCIWB23P[+*^G1SVDT%MY-H9E60VT:Q!(RZARB*6&XFO&?VA/B7^R%X+_:\
M_:<L_P#@K#XWLM/G@T?3+WX$1:WJ#QO#X:_LM$>;PX =R:I_:@NQ(]MBZ\SR
M,'RQ'0!^G5%?*OP-_9Y^.'[5O_!)WX>?L_\ [=7B?6M/\7^)/ NAQ?%&:UNF
MBU&Z1'@FNK66:-E:*:>&,P3R(=RF64J0V&'AEW_P23_8!^%'_!1+X'^"?V:?
M@A>:'K'AB6^^(?B[4F\<:U?"*PL5%KI]JT=W>2Q SZC=13J=A)72IP",F@#]
M':**_.GXY_MK7W[1_P"WO\0_V?[S1_BB_P #?V>+&S;XER?##1[J1_$>MW$'
MVEX+NYMG2X:PLX-OF65IOGN9782(\*;' /T6HKF/@KXD^$GC'X1^&_%WP$O=
M&N?!>J:-;W?A>Y\/(BV4MC(@>)H50!0A5@0 !C/05T] !1110 4444 %%%%
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M1HR 'Z)?$+X:_#KXN>$[GP%\5_ .B>)]"O=OVS1?$.E0WMI/M8,N^&961L,
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MX8>%;3P+\-/!>D^'=$T]"EAHVA:;%:6MLI))6.*)51!DDX ')-:U% !1110
M4444 %<3^TO_ ,FX?$#_ +$C5?\ TCEKMJXG]I?_ )-P^('_ &)&J_\ I'+5
M0^-$5/@?H?RZT445]D?#!1110 4444 %%%% !1110 4444 %%%% ']6N@?\
M("LO^O2/_P!!%6ZJ:!_R K+_ *](_P#T$5;KXQ[GW:V"OYC/VUO^3R?BW_V4
MW7O_ $XSU_3G7\QG[:W_ ">3\6_^RFZ]_P"G&>O6RC^)+T/%SK^'#U9YE111
M7NGSP4444 %%%% !1110 4444 %%%% !7]&7_!(O_E&]\)O^Q=?_ -*9J_G-
MK^C+_@D7_P HWOA-_P!BZ_\ Z4S5Y6;?P(^OZ'KY-_O,O3]4?1U%%%> ?2A1
M110 4444 %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW
M_L O_P"AK0!TGPUL_&3?#G0&@UBT5#HEKL5K<D@>2N!UK;^Q>-_^@W9?^ Q_
MQJ+X7?\ ),_#O_8"M/\ T2E;M &/]B\;_P#0;LO_  &/^-<Q\:[GXT:#\&O%
MNN_#K4(;CQ!9>&;^?0H+;3#/))>);R-"J1X/F,9 H"X.XG&#FN_HH _%O_@I
MMX(UG_@IGJ,/P^\<?L%?$ZP^/@^#\2^!K0^#IK:3PMXC_M*-TNAKD3_8EL8W
M+%YOM!5DR @EVJ/UG^'6@_%[P)\(="TGXC>.X-;UG1O#=K#KVJV^G2S27]U#
M;JL\RHH+NSNK,%"EB6P!DXKN/L5G]L_M'[)%]H\KR_/\L;]F<[=W7&><=,U+
M0!\1?\$?M.^*NDZ)\>=.\3^!?%7A:;6_VE_&GB724\8> M2TH:AIE]?"6UNX
M6NX8PZ2)R%!WKCYE6L+X8Z)XY_94^-W[3,?[3/P$\6>.+CXK>.7UKPWXA\-_
M#:\\2P>)_#SZ9;6UMH4CVT4B67V5XKB'R;TP0$3^:KE7D9?OJB@#YI_X);_
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M+4ND>^U:U>(-^\1+<@D>QK4HHKP#Z4**** "BBB@ HHHH **** "O*/VY_\
MDT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_ -$I
M7(?M)_MA?LY_LAZ5I>M?M$?$3_A'K76KB2#3)?[(O+OSI(U#.,6T,A7 8<L
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M_P LW6O_ )#KBJ*W_P!4.$_Y*_\ X-I__*#G_P!?N*/^G/\ X+G_ /+CM?\
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M -A*/^=?6U?F_&O^_4O\/ZL_6_#S_D6UO\?Z(*XG]I?_ )-P^('_ &)&J_\
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MX)%_\HWOA-_V+K_^E,U>5FW\"/K^AZ^3?[S+T_5'T=1117@'TH4444 %%%%
M!1110 4444 %>4?MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U
M\+O^29^'?^P%:?\ HE*\X_;"_P"0+HG_ %]3?^@K7H_PN_Y)GX=_[ 5I_P"B
M4KSC]L+_ ) NB?\ 7U-_Z"M>YPW_ ,CNCZO_ -)9\WQ=_P D[7]%_P"E(\'H
MHHK]@/P<\U_;'M_CA=_LJ?$*U_9JF>/Q[)X1OE\*/$ZK(+PPML\LMP)?[A/
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ME-I7]EKP'XK\3_M'?%?]KWQ7X5U+1+/QE'H^@^#--UNS>UO?[)TV*8FZF@D
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MU&48ZJ2ZO_,_4*BBBOS(_7CYZ_X*G_\ )CWB[_KXTW_TOMZ_(ROUS_X*G_\
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M1117NGSP4444 %%%% !1110 4444 %%%% !7]&7_  2+_P"4;WPF_P"Q=?\
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MQH^FJ? _0_EUHHHK[(^&"BBB@ HHHH **** "BBB@ HHHH **** /ZM= _Y
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MN4_E^:/Q]HHHKZ@^1"BBB@ HHHH **** "BBB@ HHHH *^_?^#</_D_+7/\
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M_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*_-[_ (.;/^23_"G_ +&+4O\
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MN?\ Y-'\>_\ 8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I7YO?\ !S9_R2?X4_\
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M3_T2E?F]_P '-G_))_A3_P!C%J7_ *(AK](?A=_R3/P[_P!@*T_]$I7YO?\
M!S9_R2?X4_\ 8Q:E_P"B(:[,!_O</ZZ'#F7^Y3^7YH_'VBBBOJ#Y$^Y/&W[.
MGP(_91^%MQIGQ*_9SU/Q5I&M?#'0/$$OQ#BUZ2"34GO+RQ,\>F.$:W@$'G;/
MG221M@+D)*%KY*^+WA[P*OQ\\4>%/@W?Q2^&1XPO;3PI=7FH1JCV/VITMG>>
M1@@!CV$R,P7&6) YK[:_9E^)_P"TW^S!X5\3_LN?M _""^^*_P -)M TC4/#
M_@;6M(>>*_M[Z]LPLFG2%697$=RS*J,RI,IX5P37RI^WO\)OA9\"_P!L3Q_\
M)?@KJQO/#.AZZT&F.USYQA_=HTEN7R2_DR,\.223Y7))R:XZ$G[1Q;OY]'M]
MS.W$1C[-2BK=+=5O]Z.@_:L_9+T']FS]G;X1>+CXMT#7?$/CB37;K6[[PQXA
MAU.R@2WDLXH;19[>1X'>/=*7:,GYY67<P137._L5?LP/^U9\=M!^&][X[\,^
M']+N-:L[?5;OQ!XFM+&62*67;Y5K#-(LMW.^"B1PJYWN@;:&!KK_ -H^*5/^
M">_[-<C1L%>Y\:[6(X.-2MNE</\ L,JS_ML?!Y44DGXI>'\ #_J)05I%S]@W
M?777T;,Y1IK$15M/=T]4C ^*?P^BLOVA_$?PK\!:6WEP^-+S2=%LA(SM@7;P
MPQ[F))/W1DDD]Z][NOV:/@)XB_:&\5_L'^"_#DY\5^&],U*UT;QX-3F:35O$
M.G6TD]U;RVY;R4M)7@N((0B+*A\IFDDRR5Y7X\\80?#7]N[6O'VH6K21Z!\6
M[G4)X-O++!JC2,N#W(4BOHGP+X>G^%/_  5S\;_'K5I/,\(>%[[Q#X_;71DV
M]SI%U;W-QI\J/T<7#W5M"F,[GEVC)R*FI*2COTO\]"J4(N6J^TD_):_U\CX;
MKUWX$^*_V1OAQX>BUWX\_!S5_B-JNHWSH=%LO%,FD6VE62[1YIDBC9Y[B1B^
MU,JB*BD[S)A//_"OPP^(GCCP]KOBSP?X+U+4],\,6:77B&^LK1I(M/A=]BR2
ML!A%+< GT/8&O2/V9/V6/&GQ0TN[^-6L?"OQ/KW@GP]=K'=6GAW2IY[C6[S&
MY-.@,2,4W#F6<C;#&<_-(T4<FU1PY7=F-)3YE9?@._;T^ 'P^_9S_:!E\)?"
M77KV_P#"VL:!INO^'O[4V_:[:TOK9+B."?;QYB!\9[C:>IKQBO2/VJ&^/VN?
M%>Z^)/[1O@G4?#^N>*5^W6VG:EIKV31VBDP0K%;R /';QK#Y,>1C;#@$[37F
M].G?V:N[L56WM'9605]^_P#!N'_R?EKG_9,M0_\ 2VPKX"K[]_X-P_\ D_+7
M/^R9:A_Z6V%8XW_=9^AM@?\ >X>I^X=%%%?*'V1\B?\ !=3_ )1C?$#_ *^]
M&_\ 3K:5_/U7] O_  74_P"48WQ _P"OO1O_ $ZVE?S]5]#E7^[/U_1'S.<_
M[TO1?FPK[ _X)T>)?VM_V:/$?@3XR_"?4M3D\ ^/_%+Z)XIL/L#7&F3R0NBM
M!<J055VCF4I)\CX+A3@-GX_KL_A+^T+\:_@9XCL/$_PK^)VMZ-<:;)OMH[+5
M)HXL;MQ1D5@K(3DE3P<\UWU8.I!Q_,\ZC-4ZBD[_ "/<_P#@I5X1^"$NC?"G
MX_?#'X2)\.-=^)/A>[U+Q;\.X,I#ILL5T8(KJ&)@###<A9'1  NQ%('))Q/V
M9HI7_8%_::D6-BJ6W@_<P' SK)QFO!/%/BWQ5XYUZX\5>-O$VH:QJEVVZ[U+
M5;U[B>9L8R\DA+,< #D]JUO#/QK^,G@OPQ=>"?!WQ:\3:3HM]G[;I&F:]<06
MMQ_OQ(X1_P 0:CV4E24+[-?@[_\  *]K%U7.VZ:^]6O^IH? +]G[XE_M(>/%
M\!?#/0+B[EBMWN]4NXK266/3[./F2XE$2L^U1T559W8JB*SLJGT']JGPW\9[
M7P7H6@-\%/%_A7X9> P=,\-S^*="EL6OKRY9I9[N7S0 UU<M&SF)"WE10QQY
M98BY\M^'7QF^,'P?ENYOA+\5O$OA=[]46^?P[KMQ8FY";M@D,+KO"[FQG.-Q
MQUJ?XA_'SXZ?%S3[?2?BO\:?%OB>UM9C-:VWB'Q'=7L<,A&TNBS2,%;!(R.<
M&J<9NHGI8E2IJFUK=GM?[2?A3Q+^T1X"_9S\3?"S19]5?4? -MX$%K9QEVBU
MJQO[E3;-C[K/#<6TP!ZK+N['&?\ MQI??M-?\%"?%OA[X"Z9<>*KB[U2VT71
M(M&B,S:DUA90V;21!?OJWV9W##@J=V<<UXMX2^*7Q-\ :;J.C^!/B-KVB6>K
MP^5JUKI&KS6T=['@C9,L; 2+AF&&R,,?6L[P[XD\1>$-;MO$WA/7KW2]2LI1
M)9ZAIUT\$\#C^))$(93[@@THTW%W72]OGJ5*K&2LUO:_R5CZ%_8&L-2\!77Q
M9^+&@:?/-\0_A[X#GNO"GAR97_>2O=0VE]-+!_R\+;VLL\C6[AHV /F(RJPJ
MW\<?%&L_&_\ X)]^%/C'\6;2ST[Q!H/Q#G\.^#H]*TR'3+/4](>U:ZNWCL;9
M([=6@N?)5IXHU+_: DA<HI'SCHOBGQ/X:\00^+?#GB._T_5;>?SK?4[*\>*X
MBD_OK(I#*W)Y!SS5OQS\2/B)\3]637OB5X]UKQ#?1Q")+W7-4FNY50'(0/*S
M$+R>,XYH=)NIS?UZ JR5/D_KU,6BBBMC ]Y_X)>?\I"OA#_V.]I_Z$:_I'K^
M;C_@EY_RD*^$/_8[VG_H1K^D>O!S;^-'T/H\E_@2]?T"N)_:7_Y-P^('_8D:
MK_Z1RUVU<3^TO_R;A\0/^Q(U7_TCEKRX?&CUJGP/T/Y=:***^R/A@HHHH **
M** "BBB@ HHHH **** "BBB@#^K70/\ D!67_7I'_P"@BK=5- _Y 5E_UZ1_
M^@BK=?&/<^[6P5_,9^VM_P GD_%O_LINO?\ IQGK^G.OYC/VUO\ D\GXM_\
M93=>_P#3C/7K91_$EZ'BYU_#AZL\RHHHKW3YX**** "BBB@ HHHH **** "B
MBB@ K^C+_@D7_P HWOA-_P!BZ_\ Z4S5_.;7]&7_  2+_P"4;WPF_P"Q=?\
M]*9J\K-OX$?7]#U\F_WF7I^J/HZBBBO /I0HHHH **** "BBB@ HHHH *\H_
M;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\
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M_/U7T.5?[L_7]$?,YS_O2]%^;"BBBO3/)"BBB@ HHHH **** "BBB@ HHHH
M]Y_X)>?\I"OA#_V.]I_Z$:_I'K^;C_@EY_RD*^$/_8[VG_H1K^D>O!S;^-'T
M/H\E_@2]?T"N)_:7_P"3</B!_P!B1JO_ *1RUVU<3^TO_P FX?$#_L2-5_\
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MI0HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_'O\
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M?\@*R_Z](_\ T$5;JIH'_("LO^O2/_T$5;KXQ[GW:V"OYC/VUO\ D\GXM_\
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MDD\*6;,[&%2228\DD]Z/[6Q/9?C_ )A_8V%[R_#_ "/YMO\ A5/B[_GKHO\
MX4UA_P#'J/\ A5/B[_GKHO\ X4UA_P#'J_ID_P"&7_V:?^C>/ O_ (25G_\
M&J/^&7_V:?\ HWCP+_X25G_\:H_M;$]E^/\ F']C87O+\/\ (_F;_P"%4^+O
M^>NB_P#A36'_ ,>H_P"%4^+O^>NB_P#A36'_ ,>K^F3_ (9?_9I_Z-X\"_\
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M6\TC7?'6KZAI5W_PD-G'Y]M->RR1/L>567<C*<, 1G! /%?T5?\ #+_[-/\
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M^>NB_P#A36'_ ,>H_P"%4^+O^>NB_P#A36'_ ,>K^F3_ (9?_9I_Z-X\"_\
MA)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJC^UL3V7X_P"8?V-A>\OP_P C^9O_
M (53XN_YZZ+_ .%-8?\ QZC_ (53XN_YZZ+_ .%-8?\ QZOZ9/\ AE_]FG_H
MWCP+_P"$E9__ !JC_AE_]FG_ *-X\"_^$E9__&J/[6Q/9?C_ )A_8V%[R_#_
M "/YF_\ A5/B[_GKHO\ X4UA_P#'J_:;_@G1_P %$OV*O@1^Q-\/?A%\5OV@
M]%TKQ#H>C-!JFG^7//Y$AGE<+YD,;HWRL#E6(YKZ^_X9?_9I_P"C>/ O_A)6
M?_QJC_AE_P#9I_Z-X\"_^$E9_P#QJN?$8VKB8J,DM.W_  YTX7 4<)-R@WKI
MK;_(X/P!_P %,/V%OBEXUTSX=^ ?VB=)U+6M9NTM=,L(K2Z5IYF.%0%X@H)/
MJ17NM<AHG[/GP#\,ZM;Z_P"'/@AX0T^^M)!):WMCX:M8IH7'1D=8P5/N#77U
MQG<%%%% !1110 4444 %%%% !1110 4444 %%%% !17A_P"V3^W7\/OV0;KP
M;X!/@W6O&WQ&^)6KR:7\./AOX7$7]H:W<1IYD\I>9TBMK6!"))KF1@D2'/)(
M4\)KW_!1_P >?L]_$GP9X*_;U_9<D^&&B_$+6XM#\,>/M%\9PZ_HD.KR@F#3
M[^406\MC++@B-S$\+,"#*N": /JNBO"/VE/VJ?CY\%3XE\2_#G]C;5O&OA7P
M1IIOO$^K#Q/;Z;=W4:PBXF32;6:-AJ#QPD$[Y+>-G!B1W=75?4O@W\6O OQ\
M^$?A?XX_##5_M_ASQAX?L]:T&],90S6=U"DT3E3RI*.N5/(.0>10 NF?"GPC
MI'Q1U3XP6<,XUK5]-@L;UVG)C,,1)0!.QR>O>NDKQ3]L']LJT_9(\2?!_P /
M7GPIUCQ*/BY\6].\"07.E3QHFD2W<-Q*+N;?R\:+;N2HP=JL<Y #5?VKOVK_
M (T?"#Q%;?#+]E_]CW7OC-XS;2?[6U32;#Q-8Z)9:58-(\44D][>L$\V>2*9
M(88U=F\B5F\M4W$ ]UHKQ']@?]NCX>?M]? :?XS>$?">M>%M0T3Q%?\ ASQO
MX/\ $\*QW_AO6[)@MW8W&TE2R;D8,#RDBDA3E5\,^(G_  60\6?!GQ!X;^)?
MQF_8+\=>'/@!XN\26FC:+\;KK7K"01F[D$5G?7>DHQNK*RF=E*2RD.%="T2L
MZQD ^X:*** "BBB@ HHHH **** "BBN#_:<_:6^#7['OP)\2?M(_M >+XM#\
M)^%K'[3JE^Z%V.6"1Q1HOS22R2,D:(O+.Z@=: .\HKY!\3?\%&_VIOAY\&)/
MVJ_B9_P3.\6Z7\,K6P&JZJ+;QI8W/BO2]*V[VO;G150(OEQ_O)(([N2:-0V4
MW*RCUW6/VI=7\?\ PP\&?$G]C3X:P_%6T\>:7_:NA:L->&E:/%I^R-O/N;QH
M96B9O-14@6%Y682915BD9 #V&N;\;_"GPC\0?$7ASQ1XCAG:[\+:DU]I)AG*
M*LQ0H2P_B&#TKAOV._VMM%_:T\'^)+QO FI>$O%'@7QC=^%/'OA'5IXII=(U
M:V2*1T6:(F.XA>*>&:*9<!XY5)"MN1=W]K#X]0?LL?LQ?$']I6[\&WOB&#P#
MX.U'Q!<:)ITJI->1VEN\[QJS9"Y5#\V#@9.#C! /0**\4U[]L:XL/V3_  1^
MT5X9^!7B;7O$/Q%T?2IO"/PTTZ2W74KJ_OK/[6MD\TSI! (8EF>:>1UCCCMY
M6YP%;B?V-?\ @H]KO[07[0_B[]C7]HS]E[7O@U\7?"7A^#Q%_P (IJNNVNK6
MNKZ%--Y"ZC97UKB.9%FQ'(I52CL%Y(<( ?4-%>/?MX_MI?"W]@+]F'Q)^TM\
M5;NW>#1[=8]'T>6_6WEUG496"6UC"Q#'?)(0"0K;$#N5*H:]AH **** "BBB
M@ HHHH ***@U.34HM-N)=&M(+B\6!S:075PT,4DH!VJ\BHY12< L%8@'.UL8
M(!/17R3^QW_P4T\9_M$?MO\ Q5_8,^-'[-EM\,O&7PNTZUU'R;GQO_:+>(["
MX=E2_P!/46<(EM0/*WR,RLC7$:% V\)N^-_VVOVA;_\ :\\5?LJ_LT?LHZ'X
M^C\%>'M.U'Q3XLO/B=_95KI=U>^8T.FS(=/F879BC\_8A<"&6)W*&5%(!],T
M5\!_!?\ X*]_M;_M"? #XD_M$?"+_@FW8:QIGPN\4ZWX?U[2(OC-&NHW=YI0
M4W0M8VTL)*,-E,NK/C 7. =7]G/_ (*M?M:?M+_L?:!^W1\-?^"9]UKO@?7M
M/N+^#2?#/Q5MKKQ"UO!<2P2F*QGL[>.:0&&0K$MQN? "@LP% 'V9\2/A]X<^
M*O@74_AWXNBE?3=6MC!>+!*4<H2#PPZ'BM+1M*M-!T>TT/3U8065M'! ';)"
M(H5<GN< 5Y_^R1^UC\$OVWO@!H'[2O[/GB5]3\,^(87,!N+<PW-I/&[1S6MQ
M$W,4T4BLCH<\KD%E(8\[H7[95KK?_!0;7_V!C\*-8@N="^%=EXV/C&6>/[%<
MQ7-_+9K:J@^</NBD(8G!\N08&T%@#VNBOC3]K'_@JQ\5/V:5\4?%;PY_P3U\
M>^-_@Q\/]0GM/'OQ1TCQ!IUN]I]ED,5_/9Z7,_VF^M[61726;]TNZ*4KN2,R
M5]">.?VG? 7AC]G*U_:7\(Z=J?C#2-9TJPO/">G>&;42WGB!K\Q+8PVR2%%#
M3-/$ TC(B!B\C(BLP /1Z*^3?V;?^"F/CKQU^UHO[$?[7?[&_B'X)?$#6/#4
M_B#P/%?^*+'7-.\26$#A;A8;RS.Q+F+<&> @D+EMV-N[ZRH **** "BBB@ H
MHHH ***^0OVC_P#@IQ\1?V6?V\OA3^R!\6/V8=/L?"WQCUB;3?!_Q:?Q^5TX
M74:,PLKB$V&^&\DQ$D<.XI(\Z!92!(4 /KVBO!OVS?VP/'W[.'B_X:_"WX,_
M VS^)/C/XF>(;C3M+\+MXO&DS6]K;VS7%SJ3NUM,OV2!5597)4JT\"*)'E5:
M\=T/_@IS^U[X@_;8US]@>P_8&\,_\)SX?\ 6_C"^ED^-A%@=.FN1;($E_L?<
M9?,/*E ,<[NU 'VW17P;^R__ ,%8_P!L;]JSXJ_%OX*>"O\ @FE9:3XE^"NO
M6VD>,]+\0_&>&!VGG65X3;,FFO',CI"75RR JZ'.#Q[G^Q9_P4%\!?M?^)/&
MOP@U3X=>(OAW\4OAG?0VOC_X:>+UA^W:;YRE[>ZAE@=X;NTF4%HYXF(88)"[
MEW 'K?PM^%/A'X/>'9_"_@N&=+2XU*XOI!<3F1O.F?>YR>V>@[5TE>*?M=?M
ME6O[)WC/X.>#[SX4:QXD_P"%O_%2S\$V]YI<\:1Z1+/;SSBZFW<NBI;R,57!
MVHYS\H5J7[5W[67QK^$'B:W^&/[+O['&O?&?Q@-(&L:OI=AXGL=#LM*L&DDB
MA>:]OF"---)#,L4$:NS>1(SF-5#, >\45XK^P/\ MP_#S]O_ . ?_"Z_ OA7
M6O#=[INOWWA[Q?X0\26XBU#P[K5E(([JPN I*[T)5@0>5=20I)46?BK^VE\+
M?A?^UK\+/V,I+NWO_&?Q/&K74.GPWZB73-.L+&:Y>\EC )*O(B0H#LW%I&!/
ME,I /8:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MSP^+-Q:>$O\ @YP^&'B'XKR+#HGB#]DS6-+^&MQ>';#_ &_!K)N;]8BW'FC3
MCEB.=C+GBN8_X+X_M>?L=_M+_P#!'CXT>"O@Y\:_"_CO7AJOA[1]&TCPQJT5
MW>C6[C5;62Q$*1DN6=8I9$=>)(XI=I8!J^X_VK?V-O@5^V7X1TKPS\9=#O1>
M>'-8CU?PEXFT'4I;#5_#VHQ_<N[*[A(>&0=".4<<.K#BOG'XN?\ !%NP\=_&
M+P1^UA9_M9^+/$WQ>^&5]!-X#\1_%[P]I.M:7:0)YN;6?3].MM-\Y<S,Z3>:
MMQ#*J21R@A@X!ZU^U]\&OVS_ (P?L67'PG^!/QG\/^&/%^H^"GL/$EUJVA/=
M7&HRO:HDL-K=BX6/3I)#YR?:GM[L(9%<193G4_X)D_$OX.?%[_@GO\&_'_[/
MG@JY\->"[OX>:9#X=\.WL_FRZ7;P0+ +5I/^6IC,13S?^6FW?_%4^N_LF^/_
M (B>!KOPU\1_VKO&=C<^(K)XO&L7@"&TTNPU)I 4E^S)=17EUIJ-%MBQ;72.
M-OF;_.9Y6]-^%GPO^'_P2^&V@_!_X4^%;70_#7AC28-,T+1[)2(K2UA01QQK
MDDG"J.222>22230!<\0^#?"?BVYTN\\4>'+/4)=$U-=1TA[RW60V=VL<D2SQ
MY'RR!)9%##D!SZUSOQW^-/@S]GSP'<?$3Q-8W%[=SRQ6&B:)I4*R:AKVH2%A
M;:?:H2/,FD<L%!(5!OD=DC1W7M:^8_VNO^"8GA[]K[XY:'\?-8_;)^._@35?
M#.D2Z?X?L?AKXSM-,M+!9O\ 7S1JUE(_G2@*KR%R2BA!A>* .B_X)Z?LI:W^
MR]\%=>7XDM8R^.?B;X]UCQ]\2%TUR]G%K.JS"26U@) +PV\2P6JN0#(+?>0I
M?:.,_;J\!:?^WMKNE_\ !/GP[ ESX6L/$^BZ_P#&[58P#!IVG6%U!J5GHRL.
MM[>3P6S&,<PV@DE?:9;83>B?LP?L6Z?^R]X*\4>'+#]I/XL>.=9\52AKCQM\
M2O%<>L:O9(D/E0PVTCP+%'%$S2RI&8F7S)I&8,&Q7@'AG_@A3X0\':3?>'_#
M'_!3?]L"PL-5U"ZOM5M+#XPV]NMY<W,C27$TC16"L9)'9BS@AR3G(XH ^Z**
MK:-H^F>'M(M= T2RCMK.QMDM[2VB&%BB10J(!Z   ?2K- !1110 4444 %%%
M% !7YZ?\'' 33/V=/@/X[\7QEOA[X7_:R\#:K\5RX_<1^'TN)TE>?MY/G26X
M.>-S)7Z%U@?%/X6?#GXW_#G6OA%\7/!EAXA\,^(M/DL=;T75(!+!=V[C#(RG
M\P1@@@$$$ T </XT_;3_ &-/#7Q"U+X$>//VB_!%KXDMM&N;W4_#6H:W )Q:
M16WVFXW1L?FVVQ\YX^6$1WE=AS7R)_P;J>&?C%%_P1-\&VW@;5K3PW<:GK/B
M"\^'DWBO0YM1@L=)EUJYDMS+:QW-M)*C(9&4"9.)$8$KP>S^-?\ P0G^ _QY
M^ 9_97\>_M2_&N^^&UFN[PWX)U'Q'IUY:Z)-'$\5L\5S/8-?RB!7PD<UU(A1
M0C!D)4^R?![]EK]H/PWX TSPK\3/VH[*SU#PYIT&D^&;_P"$/@&W\.VUOIL4
M83RIK&^EU*UE=MD1!6.-81'MA6)7D\P \O\ ^"12W'@/6OV@OV>OB<YU'XM^
M%?C))J7Q6\7PL/LOBBZU73K2]LM0MX@H%G%]@:V@%GE_(^S8,DI8R-]?>)?#
M>@>,O#FH>$/%>CV^H:7JME+9ZE87<0>*YMY4*21.IX965BI!Z@FN'_9S_9@^
M&O[,ND:];^"9M3U+5_%WB&77?&7BGQ!>"XU+7=2D1(VN+B151!B...-(HDCB
MBCC5(XT48KT6@#.U&;PEX+\-MJNKS:=I6D:%9-,]S<LD%OI]O%&=SEFPL2)&
M&R> J@]!7S=^RY\*KSXX?MC>*_\ @IOXGT6XTRSU?P':>!/A-87=NT-S+X:B
MO'OY]4N(V :-KV[='BB8!DMK:!G"O,\<?=?MR_L4>&OV\OA);_!7QO\ &[XA
M^#-%CU>#4+[_ (5WK-M8S:BT+;XH;AY[:??"L@63RP%#,BEMVT"N4_9J_P""
M;.E_L[?%RU^,&N?MJ_M!?%&YT^PN+?2]&^*_Q%35--LI9@J-=QP1VT(^T",2
M1+(Q;:D\H ^;( /'?^#BCX ? CQM_P $T_B1\;?&7P4\(ZOXS\,:9I<7AOQ=
MJ?ANUN-4TE&UFS#+;73QF6 $.^0C*#O;U-?>M>1?MO\ ['/@W]O']GW5_P!F
MCXE?$;Q9X>\-Z^T']LGPA/90W-TD4\4Z1F2ZM9]BB2)#E K'!!."17IWAC2-
M0T'0+71]5\47^MW%O$$EU74X[=+BY/\ ?<6\440/^Y&HXZ4 7Z*** "BBB@
MHHHH **** /S5_X.-O VN?LW_!CP[_P69_9YUNWT'XN_L\:I90P7<UL9(/$6
MAZE?0V$^DWB*RF2'S+L2+\V4!FV[6D#K]Q_LH_L^^'OV:O@OI_P_TG6;K6=2
MNII=5\5^*-25?MGB'6+IO-O-1N"O'F2RDD*/EC0)&@5(T4<A_P %"OV _AS_
M ,%)?V?[S]F+XS_%+QKH/@[5;F";7=.\&7=C;OJ?D3QW$*2R7-I.X5)HHW C
M*9*C=N'%>G>%OAWKOACX66WPW?XP>)M1O;6P%K'XOU*/3VU-B!A96"6BVS2
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MV=MXK^(S6&N6NC0SJEJMFBW27050) A@&[(.#FN3_:/UGXA?%?\ X-H/B/\
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M5\!^&;/2M/B\$Z6XMK* (K2-:1,\C8Y>1F)9G;+,Q))))- 'I]%%% !1110
M4444 %8'Q7\<_P#"L/A;XE^)?]E_;O\ A'?#]YJ?V+S_ "OM'D0/+Y>_:VS=
MLQNP<9S@]*WZX#]J_P#Y-:^)7_8@:S_Z0S5I1BI58Q>S:,JTG"C*2W29\A?\
M/R?^K7__ "]O_N*C_A^3_P!6O_\ E[?_ '%7P'17W?\ 8F6?\^_QE_F?G/\
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M>Y\8^+M$W:IJ0::^LCI*74,;)")/LB*+<B2*WC&'SS^?7_!/]?VS?@%^V/\
MLTV'[0O[&'[0%]X-_9E@^(7A*Q\>V_P8UNX&L:%>(4T:=(8[8R@X)BV%!LCC
MB)ZMC]_Z* /RZ_X+??MB^/OVIO\ @G!X]_9@_95_85_:)\4>*?'L%OIH%Y\"
M/$%C!I]NLZ7$D[O/:IO)$(C55R=TH8_*IK[[_8Z\1'Q+^RWX NIO#&OZ-<VW
MA#3;6^TKQ/X>NM+O;2XCM8DDBD@NHXY%*L"N<%20=I(YKTJB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M='_)DOQB_P"R5^(?_3;<5ZG7EG[='_)DOQB_[)7XA_\ 3;<5Z.3_ /(VP_\
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MW*PPPR7L$*R7$EP]NJ0H& B2=CMV+D ^@J*** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
(0 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>biib-20220930_g8.jpg
<TEXT>
begin 644 biib-20220930_g8.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
MM )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "OFK_@JM^W_P"(?^"9/[)^I_M?)\#(
M?'7A[P]>VD'B&QC\5?V;=VZW5S%:PR1!K699AYLR!@60J#D;N<?2M?GK_P '
M3_\ R@U^,7_7YX:_]2'3J />?&'[1'_!2+PEX5U'Q1;_ /!.KPGK3Z=927"Z
M1HGQT#WEYL4MY4"RZ1&C2-C"JSJ"2!D5] >$/%.C^./">E^-?#TS2:?K&G07
MUC(Z%6:&6-9$)4\@E6'!Z5^?'_!3[XJ?\%D_V0/V79OVDM._:(^".LV7AK7K
M%-4T_P -?"K5=%GVWDG]GP3R37.N7R2P0W=W;7$D/EH9$A8&0#*MZ3\;=0^,
MW[ GQ;_9[UG3?VC_ !GX^TOXF_%*T^'WQ#T;QI=0W(U&>]T^\GAU>T"1*+"6
M&>S!:"W"6[0RR#RPR(X /L^BOA#XY6G[3'Q/_P""T>E_LMZ)^V%XZ\,_#/5?
MV<[WQ3K?A[P^]E;2QW,6M6UFJVEPMMYL+,71FE9GE"K(B/&)#CZZ\.?!E])^
M ]M\"O$'Q8\9ZZ8M!_LNZ\8W^M^1KMV-FPW+7=HD.RX(Y\V-4(/(P>: ,3XQ
M?M1^%_AY^S-XT_:9^'GA^X\>V'@NRUJ6[T[P]>V\<DTVE2W$%]")+AT0-%-:
MSQMR3NB8*&. =O\ 9L^,</[1/[.O@']H&W\/MI,?CKP5I7B&/2GN1,UFM[:1
M7(A,@5?,*>;MW;5SC.!G%?GI_P $SOAUI_@C_@W?^(&I6'B77[T7_@[XGP_9
MM7UR:[AMEM]7\0Q*85E8^6SCYI&',C_,Q)YH^$?B#X\?L;_\$U?V/?VHK?X_
M^)=6O];N_AGX?\6^&;JXC.BS>']82TL!90V>S;#+;1W,#I<H1-));DR.Z2,E
M 'Z@45^;'@#]I+]K/]LW]H']H:>#P#\>Y?"_PU^*NH?#WP#;_!CQ)X5TNWTN
MXTZ&'[1J-W_:NJ6T]]<S2S"18IHI+18?* 5V:0C[ _X)^>)OVP_%/[*/AF[_
M &]/AU%X:^*5K]IL_$=O!<V,B7PBGD2"^Q8SSP1-/ (I7B20A)'=0 H H =\
M;_C_ /M">%_C!9?![]G7]F&T\=SIX<_MCQ%K&M>-UT.RTM))VAM80WV2Y>XE
MF,-TV%4"-;?+']X@/S#\*/\ @L=^U1\:_P!G7XE_M-_#C_@G#8:EH/PH\4:Y
MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
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M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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M'A>7PYX;^,WQR\0>/? WA26U-L=+T.\\B*S)MR!]F:XCMA=^3@>6MRB%596
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MAUH?Q0TV]^//A;P'<2QZMJ/A!(KC[2D?DNDDD*S?9GFB5EWQH5=EB,I'F/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_M2?"_X8^&?$'[(NK^"3XF?QUI\-[X=\96MQ,_B/3VWK-I]B+=@R7;L8F$K
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MM=3T?4)K'4;;_A#]5?R9XG,<B;DMBK892,J2#C@D5]-5_/O^UE_R=/\ $O\
M[*!K/_I=-7W? G"^7\48JM3Q4I14(IKE:6[MK>,C\J\5>.LWX&P.&K8"$).I
M*2?.I-623TY91_4_5[_A[3^Q1_T<]9?^$5J__P BT?\ #VG]BC_HYZR_\(K5
M_P#Y%K\8:*_2_P#B$O#G_/VK_P"!0_\ E9^)_P#$P?&?_0/A_P#P"I_\M/V>
M_P"'M/[%'_1SUE_X16K_ /R+1_P]I_8H_P"CGK+_ ,(K5_\ Y%K\8:*/^(2\
M.?\ /VK_ .!0_P#E8?\ $P?&?_0/A_\ P"I_\M/V>_X>T_L4?]'/67_A%:O_
M /(M'_#VG]BC_HYZR_\ "*U?_P"1:_&&BC_B$O#G_/VK_P"!0_\ E8?\3!\9
M_P#0/A__  "I_P#+3]GO^'M/[%'_ $<]9?\ A%:O_P#(M'_#VG]BC_HYZR_\
M(K5__D6OQAHH_P"(2\.?\_:O_@4/_E8?\3!\9_\ 0/A__ *G_P M/V>_X>T_
ML4?]'/67_A%:O_\ (M'_  ]I_8H_Z.>LO_"*U?\ ^1:_&&BC_B$O#G_/VK_X
M%#_Y6'_$P?&?_0/A_P#P"I_\M/V>_P"'M/[%'_1SUE_X16K_ /R+1_P]I_8H
M_P"CGK+_ ,(K5_\ Y%K\8:*/^(2\.?\ /VK_ .!0_P#E8?\ $P?&?_0/A_\
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MY]/Z\"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\
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M% !1110 5^Z7_!,G_DP_X;?]@-__ $HEK\+:_=+_ ()D_P#)A_PV_P"P&_\
MZ42U^4^+G_(CH?\ 7S_VV1^^?1Z_Y*G%?]>7_P"EP/=J***_GT_KP**** "B
MBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__
M $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V**Q_P#A)=7_ .A0O?\
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M_HTG-=.#_P![I_XE^9QYC_R+ZW^&7Y,_G[HHHK^SS_-,**** "BBB@ HHHH
M**** "BBB@ HHHH _H_T;_D#VG_7M'_Z"*LUSVC^)=6&D6H_X1"\_P"/9/XE
M_NBK/_"2ZO\ ]"A>_P#?2U_%,OB9_IK3^!>AL5_/O^UE_P G3_$O_LH&L_\
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MN?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V
MK3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2
M^/W_ "0CQM_V*.I?^DLE=;7)?'[_ )(1XV_[%'4O_262NG!_[W3_ ,2_,X\Q
M_P"1?6_PR_)G\\E%%%?V>?YIA1110 4444 %%%% !1110 4444 %%%% ']'^
MC?\ ('M/^O:/_P!!%6:K:-_R![3_ *]H_P#T$59K^*9?$S_36G\"] K^??\
M:R_Y.G^)?_90-9_]+IJ_H(K^??\ :R_Y.G^)?_90-9_]+IJ_7O"#_D88K_#'
M\V?SO](G_D4X#_'/_P!)1Y_1117[P?RD%%%% !1110 4444 %%%% !1110 5
M^Z7_  3)_P"3#_AM_P!@-_\ THEK\+:_=+_@F3_R8?\ #;_L!O\ ^E$M?E/B
MY_R(Z'_7S_VV1^^?1Z_Y*G%?]>7_ .EP/=J***_GT_KP**** "BBB@ HHHH
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MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+X_?\
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MOB+58OASH$2>%+MPNB6H#JRX8>2O-;?_  DNK_\ 0H7O_?2U%\+O^29^'?\
ML!6G_HE*W: ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"
M]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MB
MB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C
M_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,
M?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_
M .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_
M *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[
MZ6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_
M[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A)=7_ .A0O?\ OI:V
M** ,?_A)=7_Z%"]_[Z6C_A)=7_Z%"]_[Z6MBB@#'_P"$EU?_ *%"]_[Z6C_A
M)=7_ .A0O?\ OI:V** ,?_A)=7_Z%"]_[Z6N3^//B+59/@;XSC?PG>(&\)ZB
M"Q9<#_1I.:]$KDOC]_R0CQM_V*.I?^DLE=.#_P![I_XE^9QYC_R+ZW^&7Y,_
MGDHHHK^SS_-,**** "BBB@ HHHH **** "BBB@ HHHH _HGT?Q+JPTBU'_"(
M7G_'LG\2_P!T59_X275_^A0O?^^EJ_HW_('M/^O:/_T$59K^*9?$S_36G\"]
M#'_X275_^A0O?^^EK\#/VJI'F_:@^)$TD1C9O'NL%D;JI-[-P:_H+K^??]K+
M_DZ?XE_]E UG_P!+IJ_7O"#_ )&&*_PQ_-G\[_2)_P"13@/\<_\ TE'G]%%%
M?O!_*04444 %%%% !1110 4444 %%%% !7[??\$UM>U*U_89^'-O#X9NIE71
M7 E1EPW^D2],U^(-?NE_P3)_Y,/^&W_8#?\ ]*):_*?%S_D1T/\ KY_[;(_?
M/H]?\E3BO^O+_P#2X'L5GKVI7-TD$WAFZA5FPTKLN%]S6I117\^G]>!1110
M4444 %>?_$K]I7X<?"GXU_#OX!^*;77'U[XGSZG%X9DT_0;BYM$:PMA<S_:;
MB-3':@HPV>81O.0/NG'H%?-G[8UC_P %)M1^+VA6'[''QV^$7@WPE)X;GDUV
M;XB>%+C4KD:BEP@C6,0WL!\N2*1SG#!6MFR?G44 ?!OC#]KNU\&>/?$GA#]D
M3]MC]J[P'\/SXJU2*_\ !VF_LBR^)H='O1>3)?V^DZE/9,UM"MRLP6)O/2!@
M5C"*H0?H=_P31\6?"[QK^Q9X2U[X,^'O%.F^'1=ZQ:VB>.5E&M7<L&K7D%Q>
MZ@)E607=S/'+<S!U#"2=\@'BO$;#X=_\%L=*@:UTO]NW]EFVB>>69H[?X0:@
MBF21VDD<@:M]YG9G8]2S$G))KWK_ ()[CXII^R[81_&[QYX?\3^+$\7>*4U[
M7O"ML8=.N[@>(=1!:",EC&@ "["S%2I!9B"Q /:Z\H_;G_Y-'\>_]@%__0UK
MU>O*/VY_^31_'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=
M_P"P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2^/W_)"/&W_ &*.I?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %<E\?O^2$>-O^Q1U+_TEDKK:Y+X_?\ )"/&W_8H
MZE_Z2R5TX/\ WNG_ (E^9QYC_P B^M_AE^3/YY****_L\_S3"BBB@ HHHH *
M*** "BBB@ HHHH **** /Z/]&_Y ]I_U[1_^@BK-5M&_Y ]I_P!>T?\ Z"*L
MU_%,OB9_IK3^!>@5_/O^UE_R=/\ $O\ [*!K/_I=-7]!%?S[_M9?\G3_ !+_
M .R@:S_Z735^O>$'_(PQ7^&/YL_G?Z1/_(IP'^.?_I*//Z***_>#^4@HHHH
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MX7\":0V@>#]$@T^R>_N[UK:W7">?<W$ES.^.Q>:61SVRYQ@<4 :=>4?MS_\
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MU[1_^@BK-5M&_P"0/:?]>T?_ *"*LU_%,OB9_IK3^!>@5_/O^UE_R=/\2_\
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MU_ '_0?_ /)67_XFC_A:_@#_ *#_ /Y*R_\ Q-']I9=_S^A_X$O\P_L#/?\
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M "3/P[_V K3_ -$I7-?M _M5? 7]EK3=-U?X[^//["M]7GDAT^3^R[JZ\UT
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ME'_#W;_@GC_T<'_Y:>K?_(E?B311_P 0EX<_Y^U?_ H?_*P_XF#XS_Z!\/\
M^ 5/_EI^VW_#W;_@GC_T<'_Y:>K?_(E'_#W;_@GC_P!'!_\ EIZM_P#(E?B3
M11_Q"7AS_G[5_P# H?\ RL/^)@^,_P#H'P__ (!4_P#EI^VW_#W;_@GC_P!'
M!_\ EIZM_P#(E'_#W;_@GC_T<'_Y:>K?_(E?B311_P 0EX<_Y^U?_ H?_*P_
MXF#XS_Z!\/\ ^ 5/_EI^VW_#W;_@GC_T<'_Y:>K?_(E'_#W;_@GC_P!'!_\
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M_FWHH_X@[_U'?^4O_N@?\3&_]2O_ ,K_ /W$_I(HK^;>BC_B#O\ U'?^4O\
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M_P#MSZ(HKYWHH_UO_P"G'_DW_P!J'_$+_P#J+_\ *?\ ]N?1%%?.]%'^M_\
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MG_)[OPQ_[&ZU_F:_>.OP<_X)Z?\ )[OPQ_[&ZU_F:_>.OP'Q=_Y'&'_Z]_\
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MXP_W"G_B_1GVW O_ ",JG^#_ -N1])4445^=GZD%%%% !1110 4444 %%%%
M!7E'[<__ ":/X]_[ +_^AK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L
M!6G_ *)2OA3_ (. O^2;_#C_ +#E_P#^B8J^Z_A=_P DS\._]@*T_P#1*5\*
M?\' 7_)-_AQ_V'+_ /\ 1,5?8\ ?\E?A?67_ *1(_./%O_DW>/\ \,/_ $Y
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M% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\
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M7_D95/\ !_[<CZ2HHHK\[/U(**** "BBB@ HHHH **** "O*/VY_^31_'O\
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M_$T?ZV9=_)/[E_\ )!_Q#7/?^?E/[Y?_ "![-17C/_"U_'__ $'_ /R5B_\
MB:/^%K^/_P#H/_\ DK%_\31_K9EW\D_N7_R0?\0USW_GY3^^7_R![-17C/\
MPM?Q_P#]!_\ \E8O_B:/^%K^/_\ H/\ _DK%_P#$T?ZV9=_)/[E_\D'_ !#7
M/?\ GY3^^7_R![-17C/_  M?Q_\ ]!__ ,E8O_B:/^%K^/\ _H/_ /DK%_\
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MW/\ ^2/S7_B&N1?\_*GWQ_\ D#V;_A:_@#_H/_\ DK+_ /$T?\+7\ ?]!_\
M\E9?_B:\9HH_ULS'^2'W/_Y(/^(:Y%_S\J??'_Y ]F_X6OX _P"@_P#^2LO_
M ,31_P +7\ ?]!__ ,E9?_B:\9HH_P!;,Q_DA]S_ /D@_P"(:Y%_S\J??'_Y
M ]F_X6OX _Z#_P#Y*R__ !-'_"U_ '_0?_\ )67_ .)KQFBC_6S,?Y(?<_\
MY(/^(:Y%_P _*GWQ_P#D#V;_ (6OX _Z#_\ Y*R__$T?\+7\ ?\ 0?\ _)67
M_P")KQFBC_6S,?Y(?<__ )(/^(:Y%_S\J??'_P"0/9O^%K^ /^@__P"2LO\
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MJG^#_P!N1])4445^=GZD%%%% !1110 4444 %%%% !7E'[<__)H_CW_L O\
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M7Y&?N!\@?\%W_P#E%]\0O^OO1?\ T[6E?SW5_0C_ ,%W_P#E%]\0O^OO1?\
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MQ0!U7PN_Y)GX=_[ 5I_Z)2OS6_X.>O\ DDWPG_[&+4O_ $1#7U3X1_X*F_L
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MG;_M"ZE::9XFU^+69=4NU\66 OK;4+F0LTCW$;$"3<SLQY!W8(((%4O^%/\
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M2_\ "G_&W][1?_"HL/\ X_1_:>6_\_X?^!1_S#^Q\V_Z!Y_^ 2_R.8HKI_\
MA3_C;^]HO_A46'_Q^C_A3_C;^]HO_A46'_Q^C^T\M_Y_P_\  H_YA_8^;?\
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M-VEKIEA%:72M/,QPJ O$%!)]2*]UKX0_2 HHHH **** "BBB@ HHHH ****
M.)N/V:/V<;RXDN[O]G_P1++*Y>663PI9LSL3DDDQY))[TS_AE_\ 9I_Z-X\"
M_P#A)6?_ ,:KN:* .&_X9?\ V:?^C>/ O_A)6?\ \:H_X9?_ &:?^C>/ O\
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M25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\
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M"_\ A)6?_P :H_X9?_9I_P"C>/ O_A)6?_QJNYHH X;_ (9?_9I_Z-X\"_\
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M^&7_ -FG_HWCP+_X25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\
MV:?^C>/ O_A)6?\ \:KN:* .&_X9?_9I_P"C>/ O_A)6?_QJC_AE_P#9I_Z-
MX\"_^$E9_P#QJNYHH X;_AE_]FG_ *-X\"_^$E9__&J/^&7_ -FG_HWCP+_X
M25G_ /&J[FB@#AO^&7_V:?\ HWCP+_X25G_\:H_X9?\ V:?^C>/ O_A)6?\
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M_P#C5=S10!PW_#+_ .S3_P!&\>!?_"2L_P#XU1_PR_\ LT_]&\>!?_"2L_\
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MA=-<O9Q:SJLPDEM8"0"\-O$L%JKD R"WWD*7VCC/VZO 6G_M[:[I?_!/GP[
MESX6L/$^BZ_\;M5C ,&G:=874&I6>C*PZWMY/!;,8QS#:"25]IEMA, ?5M%%
M% !1110 4444 %%%% !7!_M.?M+?!K]CWX$^)/VD?V@/%\6A^$_"UC]IU2_=
M"['+!(XHT7YI)9)&2-$7EG=0.M=Y7YZ?\'' 33/V=/@/X[\7QEOA[X7_ &LO
M VJ_%<N/W$?A]+B=)7G[>3YTEN#GC<R4 >F^)O\ @HW^U-\//@Q)^U7\3/\
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MAEXR^%VG6NH^3<^-_P"T6\1V%P[*E_IZBSA$MJ!Y6^1F5D:XC0H&WA-WQO\
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M>&[6TOM;E718&62\GBC62Y8&1R&D9B"['N: /O6BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MZ;XN\+:_-J>C7;S3313:<TL]K;21W4!B1R C+)',C@H<QCUBOBO7=/\ &GQ
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MZ?)I5E'=W NG;P\K@,DH5#&CY8'.T<U-\-_^"E7[;>H_\%2+?_@F5\9OV,/
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M"$ H^.X_X*":C9OKOP"\(13!]3U?]H/0VTZQ0YDG6UM[V\N'5>I6.""61FZ
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M7O'OAW0/A+XGTOPAX(\+^"/&]_H#6ADT>UU";6)VL)8GNY9I+P+$LYD@2.V
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MI8;73](TCXUZS-J&LW\S;8+&TB;PVHEF<Y(&0 JN[$*C$> ?!CXF?%[]A/\
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M?M?^'=#T;XX>&+NZOO"VJ+J?A/Q/H^K7&F:QH5^HP+JSO;1XYK=S@;@C!7P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK\V_^(A'_ *M%_P#+^_\
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MS+";2YI3Q$EQ$[*'. '6,,RJ68?R[XB_\EEBO^W/_3<#^ZO!O_DV^!_[B_\
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MOZY:2-#=Z<MIHU]:Z/:+-&0Z"YU"1[G;G:ZZ+(K#D5[/^V;^SOXF_P""KO\
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MA66A^!K>'Q/X;\66<L4CQ0YNFG&KI>I-'+B(RRL\P*D2'/L?[?GPN^#GC/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
4B@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>biib-20220930_g9.jpg
<TEXT>
begin 644 biib-20220930_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH?BJPC^,\*7[SZ0H:]>VCETU(Y4"DLF9%9\8"YP#^@=?E1_P2A_Y13_MJ_\
M9:OBU_Z2B@#]'?V7_C9!^TM^S1\._P!HVU\.OH\7Q \"Z1XDCTF2Z$[62WUG
M%=" R!5$A02[=VU=VW.!G%=U7Y:_!37_ (\?L;_\$JOV0_VL;/X_^)=4O[Y?
MAAHOB7PQ<7$9T6?PWJPL=/6QCL]FV&:W@N876Y0B9YH"7=T<QUZAXXT']IKX
MT?\ !9+QU^RQ+^VI\1?#_P +X?V?M*\5-HOA>>QLKNSU&YU:_M$CM;E+7?'"
M%MS*S-OF9TC4R^5OC8 ^^J*_(C]BKXV_\%*OVN/^">D'[37@?3OVD-<^(VM6
MFH-\,/$FG^(O \?AZU2RN)K2SM[ZRNM4MFOC*UL/ML]Q:K,999_($2K%CVK]
MIG]L?]M[7?CM^S3^R'=_!KQGX:U_QW\-K_QG\:O#OPQUG0QK"RV<5M$^D6-_
MJ-]%:Q0K=W#-+-#,UP8DC$3+N=P ?H;17RA^PSJG[>&C_M%^/? 7QI^$'C^Q
M^#,NBV>I?#K7?BCXA\/7NMZ;J.]H[S29'TK4+N2[MR-D\,\_[Q?WL;N^(Z].
M_;I\1W_A?X R7]I^T6GPO@E\2Z/;ZEXEBTIKR^GM)-0@2;3M/B0,YOKM"UK
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M_;XH^ ]0\"#QQXA\.#4(PC:QX5U$6E_ NX$^5-M8QD@;=P&X G!!P1\@?\$
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MEC\&_A=K?Q0U/3)KVWT6R-S+:P.%>0 @8!/ /-=-7E'[<_\ R:/X]_[ +_\
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MS_\ )H_CW_L O_Z&M>KUY1^W/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\
MHE*W:POA=_R3/P[_ -@*T_\ 1*5NT %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_
M ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_H
ME*W:POA=_P DS\._]@*T_P#1*5NT %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/\
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M1_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4K=H
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M<VRPR,DB_9I3A@<$9"^M;]>!^*_^1IU+_L(3?^AFO"SW,\1EE.$J23NWO?\
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M^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\
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MK5I-;F+[&Q@(>'Y]DHF&[8T*?NY 2M>M45\3";IRYD!\5?LJ?L/?'GQ'\?O
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MZKH&MV$=YHNJ6>3!>6LBAHIHB0-\;J0R./E965E)!!(!\9?!SP]_P4L^&/\
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M/BG6+?3]-T^W:>]OKN4)%!&HRSLQX  [U=HL[7 **** "BBB@ HHHH ****
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M^B4K=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "JNN_P#(#O/^O23_ -!-6JJZ[_R
M[S_KTD_]!-9UOX4O1@?/M%%%?C8'Y9_\%FOB;H_PP_:-UZ+]M;X>:[JOPB\2
M_"=--^$OB"&.:;0M!\4^;.;C[=%&=J7,JF 1SR*WEI&-F 9F3[A_8I^#?@7X
M3>"O%^L_!3XI_P#"6>#/&_BX^(O!5V_BF;68;2R?2]/M1;17,KR%H%FM)FC1
M794215!&,#R#_@HC\=/&FA_#_P"-_P '?BM^SIXNUOX>W_@&(^'O%>D^%3J=
MB;J2"07-I<10AIE52L,@F,;1 R.&="@!H_\ !*7]F[4/V6;_ .//CCPC\-_%
M7@KX-^*/%UOJWPM^'>NV,_\ :.GQ16.-0N4L?GF@6XN,B&W8";9!&"@)4'VJ
MKY\N5W9JVE[J7P_=+J_1[ <!^W[^P]IO[-GP\\*_M6_ 3XB^,9OVD&^)7AVR
ML?%,OBJ^D;QC>7NHPPW5A/9O,UNMF;=[B401QJD,5OM&$#9^Z/CA\6[/X->!
M'\2)HTNK:M>74>G^&?#]M*$FUC4IB5@M4)R%W$%GD(VQ1))*^$C8CXGT;]O[
MQ%XN^,LWQW^,/_!-O]J2]OO#LMW:_#+PQ9?!V8VVE0N&B>^DDEE16O[E/E,A
M 2VA<PH3OGEF^COVG_V//&/[4FO>!OB)I?[2_CCX5:[X1L;U4C\$RV-PC2WB
M0+*6-Y;2AG01-&DJJC;)I1P)&!RKJ=Z<,2]KZ[]O=TULOPN[: >3?\$\O"GC
M?P/_ ,%"?VI?#OQ%\>W/B+6Y-+\ W^LW\DK_ &<WMQ9:E),MM$Y/D6Z';'%'
MU6**,,68,QO?M_\ [ ?P+^)WPJ^)O[2_[07Q'\4P>)]"\/ZCJOA/Q7IOB^_T
M^/P5#:6S26YLH(9EB5E,8EE=U9Y9)'Y""-$Y+]A;]BC]HCX,?\%*_C3\1_B%
M^TE\4_$6@1Z1X82TU3Q1I]E':>,V:PO4999(K6-9#9,RA1"5VF7$F[(JQ^U#
M^V1JGC']H2\^#_Q#_88_:)\0?#+P7J<4KCPI\([N\M/&6J02[T,DCM&&TZWD
M1'50&%U*JL2(8PMQJU5>.4J,KVC%MK3[*T5[;]OOZ@?2?["VM?&CQ)^QE\+/
M$/[12S#QS?> M+G\4_:8MDQO'MD9S*N!ME).77 PY88'2O-?^"B.LZUJWQ._
M9]^ ^L:S>Z9X"^(GQ4ET[QW=65V]O]NC@TF]O+/2I)$(8175U!&CH"/,5#&<
MJ[*?1&_:<\8?\,G7?[3L/[+?Q!?44L9KRQ^&)TY%\1SQB<QQ(UL6Q',\864Q
M;F9%;;\S#%:?Q\3X:^-?@@+?XP_ [6?%>GZHEO,GA"W\/M?7HNP!-"N(R4MI
MHY%&VX:2-(I%5O-3AJX8-PQ/.X[MJRMH_+TO==- /#_A>OA[X ?\%7[C]EWX
M))!I'@SQ)\!Y?%FM>"--/EZ?I.I6VKP6<%Y;6X^2T^T13RI(D059#;(Y!8,Q
M^N:^5_\ @GQ^PYJ/P0^(_P 0?VM?BQX:72O'GQ,DMK=-!/B"?5W\.Z+;#%M9
M2W\\DDEY=.?WMQ+O9-X2./\ =Q*6^J*G&2A*JE%WLDF^[Z_Y>=@"BBBN4#Z*
MA_U2_P"Z*=38?]4O^Z*=7[.M@"O _%?_ "-.I?\ 80F_]#->^5X'XK_Y&G4O
M^PA-_P"AFOD>+OX%+U?Y 9]%%%?# %%%% !1110 4444 %%%% !1110 5[A\
M-O\ D1M-_P"N'_LQKP^O</AM_P B-IO_ %P_]F-?4\)_[]/_  _J@-RBBBOO
MP"BBB@ HHHH *\9^//P#^.7[1FKR^&)_VDO$/PU\#1 (UI\-I8[;7M8;'S--
MJ4L;M8PYX6.T5)CM#FY7>84]FHH ^/F_X(7_ + $EQ_;EQ;?%N77_O?\)3)^
MT+XP.H>9Q^\W_P!J;=V1G.W'M7JWP)_9W^-_[-FM0^']%_:8\3?$?P-,=CZ5
M\4+I+W6=(/:2VU1$22ZB'\4-X)93NW+<+L\J3YF\8?\ !0W]KSXH:G\,?V4O
MV9/'/PIN_C3\4K^^UK6;JWT&YN[+X9^$;,GS9]4M1?-))J!E:&U$3- AN&EC
MQB+>?KS]DGXK>)/C1\!M*\<>,=7T/4M634=4TK4M6\,1NFG:E/I^HW-@]Y;(
M[R-'#,UL9D0R2;%D"^9)C>P!Z17E'[<__)H_CW_L O\ ^AK7J]>4?MS_ /)H
M_CW_ + +_P#H:T =U\+O^29^'?\ L!6G_HE*W:POA=_R3/P[_P!@*T_]$I6[
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %5==_Y =Y_P!>DG_H)JU577?^0'>?]>DG
M_H)K.M_"EZ,#Y]HHHK\; CN[2TO[:2ROK:.:&52LL4J!E=3U!!X(J2BB@ HH
MHH **** "BBB@ HHHH **** /HJ'_5+_ +HIU-A_U2_[HIU?LZV *\#\5_\
M(TZE_P!A";_T,U[Y7@?BO_D:=2_["$W_ *&:^1XN_@4O5_D!GT445\, 4444
M %%%% !1110 4444 %%%% !7N'PV_P"1&TW_ *X?^S&O#Z]P^&W_ "(VF_\
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M1110 55UW_D!WG_7I)_Z":M55UW_ ) =Y_UZ2?\ H)K.M_"EZ,#Y]HHHK\;
M**** "BBB@ HHHH **** "BBB@ HHHH ^BH?]4O^Z*=38?\ 5+_NBG5^SK8
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M%% !1110 4444 %%%% !1110 55UW_D!WG_7I)_Z":M55UW_ ) =Y_UZ2?\
MH)K.M_"EZ,#Y]HHHK\; **** "BBB@ HHHH **** "BBB@ HHHH ^BH?]4O^
MZ*=38?\ 5+_NBG5^SK8 KP/Q7_R-.I?]A";_ -#->^5X'XK_ .1IU+_L(3?^
MAFOD>+OX%+U?Y 9]%%%?# %%%% !1110 4444 %%%% !1110 5[A\-O^1&TW
M_KA_[,:\/KW#X;?\B-IO_7#_ -F-?4\)_P"_3_P_J@-RBBBOOP"BBB@ HHHH
M *^2OVZ+G]I^T_:,\*S_ +/W_!,SP#\9R/!5^K^,?&?CU-(&E9O+8S6&V2PN
M58OMMY4)()V3!0 KEOK6O/\ XE?L_P 'Q)^-?P[^-4GQ@\=Z(_P[GU.1/"_A
MWQ";71O$7VVV$!75+;8?M8AQYD(W+Y<A+<YQ0!\@_P!O?\%0/^D&'[/_ /X>
M^S_^4E?1W_!.E?'J_LHZ8?BC\(-$\ ^(&\5^*&U7P=X<O([FQTJ4^(=1)BAE
MC55E7!#;PJ[BQ.U<[1^>?Q7/_!/WX=_$WQ5X3\5_\%4?V\_%6N6?B[5DU:+X
M4^-O&VHZ5H[F^F9--6:RMYK?=;(5MF5968- VX*V5'W7_P $D[KP%>_L'>%[
MKX7^*/&^MZ!)XB\4'3-6^)+S-KUW'_PD>I?O+XSJLIG)SN,H$G]\!LB@#Z1K
MRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#J?AGXL\-P_
M#CP_#+K$*LFB6BLI/0B%.*W/^$Q\,?\ 0:@_[ZK/^&%A8M\-?#S-91$G0[0D
MF,<_N4K<_L[3_P#GQA_[]"@"G_PF/AC_ *#4'_?5'_"8^&/^@U!_WU5S^SM/
M_P"?&'_OT*/[.T__ )\8?^_0H I_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]5<_L
M[3_^?&'_ +]"C^SM/_Y\8?\ OT* *?\ PF/AC_H-0?\ ?5'_  F/AC_H-0?]
M]5<_L[3_ /GQA_[]"C^SM/\ ^?&'_OT* *?_  F/AC_H-0?]]4?\)CX8_P"@
MU!_WU5S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0H I_\)CX8_P"@U!_WU1_PF/AC
M_H-0?]]5<_L[3_\ GQA_[]"C^SM/_P"?&'_OT* *?_"8^&/^@U!_WU1_PF/A
MC_H-0?\ ?57/[.T__GQA_P"_0H_L[3_^?&'_ +]"@"G_ ,)CX8_Z#4'_ 'U1
M_P )CX8_Z#4'_?57/[.T_P#Y\8?^_0H_L[3_ /GQA_[]"@"G_P )CX8_Z#4'
M_?5'_"8^&/\ H-0?]]5<_L[3_P#GQA_[]"C^SM/_ .?&'_OT* *?_"8^&/\
MH-0?]]4?\)CX8_Z#4'_?57/[.T__ )\8?^_0H_L[3_\ GQA_[]"@"G_PF/AC
M_H-0?]]4?\)CX8_Z#4'_ 'U5S^SM/_Y\8?\ OT*/[.T__GQA_P"_0H I_P#"
M8^&/^@U!_P!]4?\ "8^&/^@U!_WU5S^SM/\ ^?&'_OT*/[.T_P#Y\8?^_0H
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M!I6WBCP_>3K:VNJQ/(YPB*>2:OU$EC91L'CLXE8="L8!%2U]^ 4444 %%%%
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MHHH *]P^&W_(C:;_ -</_9C7A]>X?#;_ )$;3?\ KA_[,:^IX3_WZ?\ A_5
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M%2E6&E:_:W3"^1755$H:5S*7(#%I&W98,3XO\"/@#\"/V=_^"]7BOPK^S_\
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M"+61N_[,NY(9;BREBO[:YMIH6EMH) )(69'C!1DRV[0_9J_9B^%_[*G@>_\
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M"C.*]:_;L\*_ OX2?L6?&"SU?X8VVOS_ !)LKZTD\.?9EN+SQAK^HQ?9+*R
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M .@BO-S?$5L+EU2K2=I*UG\UW @_X7__ -2E_P"3_P#]KH_X7_\ ]2E_Y/\
M_P!KKSFBO@_]8<X_Y^_^2Q_R ]&_X7__ -2E_P"3_P#]KH_X7_\ ]2E_Y/\
M_P!KKSFBC_6'./\ G[_Y+'_(#T;_ (7_ /\ 4I?^3_\ ]KH_X7__ -2E_P"3
M_P#]KKSFBC_6'./^?O\ Y+'_ " ]&_X7_P#]2E_Y/_\ VNC_ (7_ /\ 4I?^
M3_\ ]KKSFBC_ %ASC_G[_P"2Q_R ]&_X7_\ ]2E_Y/\ _P!KH_X7_P#]2E_Y
M/_\ VNO.:*/]8<X_Y^_^2Q_R ]&_X7__ -2E_P"3_P#]KH_X7_\ ]2E_Y/\
M_P!KKSFBC_6'./\ G[_Y+'_(#T;_ (7_ /\ 4I?^3_\ ]KK9\#?%'_A--8?2
M?["^S;+=I?,^U;\X*C&-H]?TKR"NS^!O_(X3?]@]_P#T-*[LMSO-,1CZ=.I4
MO%O72/\ D!ZS1117Z !S7Q=_Y$"]_P!Z+_T8M>,5[/\ %W_D0+W_ 'HO_1BU
MXQ7Y[Q7_ ,C*/^%?G( K@/CC^RS^SS^TAX3U/P;\:?@]X=U^TU:+9=R:CH\$
MLV=NQ761T+*ZK@*X.5P,&N_HKYN,Y0E>+LP,OP9X(\%_#CPU:^"_AYX0TO0=
M'L4*6.DZ+I\=K;6ZDDD)%$JH@R2< #DUA^+_ -GKX!?$'QC9?$3Q[\#O!^N>
M(-.Q_9^NZOX9M;F\M<=/+FDC+IT_A(KL**%.:=T]0"LS3?!?@[1?$NJ>,]'\
M)Z9::QK:0)K.K6UA''<WZP*RP">50'E$:NX0,3M#$#&36G12NT!RWC3X&_!/
MXCZ[:^*/B'\'O"VO:G8A!9:CK7A^VNI[?8V]-DDJ,R;6)88(P3D<UL^*O"?A
M7QUX=N_"'C?PSI^LZ3J$)BO]+U6R2XM[F,]4DCD!5U]B"*T**?-+378#-\0^
M#/!_BWPO<>!_%?A33=3T6[M_L]UH^H6,<UK-#Q^[>)P49>!\I&.*H_#GX3?"
MOX.Z(_AKX1_#/P_X6TZ2<S2:?X<T:"Q@>0@ N8X452Q '.,\5T%%+FE:U] "
MBBBD!L_#[_D==,_Z^UKW.O#/A]_R.NF?]?:U[G7WO"7^YU/\7Z( JKKO_(#O
M/^O23_T$U:JKKO\ R [S_KTD_P#037T];^%+T8'S[1117XV 4444 %%%% !1
M110 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZOV=; %>!^*_^1IU+_L(
M3?\ H9KWRO _%?\ R-.I?]A";_T,U\CQ=_ I>K_(#/HHHKX8 HHHH **** "
MBBB@ HHHH **** "O</AM_R(VF_]</\ V8UX?7N'PV_Y$;3?^N'_ +,:^IX3
M_P!^G_A_5 ;E%%%??@%%%% !1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\
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MJF@6GPM_:E^*_A3P_8>(]4U?5M$T[Q-%('FOX+M;A[26>WDDL&DDNG+"!HT
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M#W_]#2O2R;_D:4?\2 ]9HHHK]6 YKXN_\B!>_P"]%_Z,6O&*]G^+O_(@7O\
MO1?^C%KQBOSWBO\ Y&4?\*_.0!1117S(!1110 4444 %%%% !1110 4444 ;
M/P^_Y'73/^OM:]SKPSX??\CKIG_7VM>YU][PE_N=3_%^B *JZ[_R [S_ *])
M/_035JJNN_\ (#O/^O23_P!!-?3UOX4O1@?/M%%%?C8!1110 4444 %%%% !
M1110 4444 %%%% 'T5#_ *I?]T4ZFP_ZI?\ =%.K]G6P!7@?BO\ Y&G4O^PA
M-_Z&:]\KP/Q7_P C3J7_ &$)O_0S7R/%W\"EZO\ (#/HHHKX8 HHHH ****
M"BBB@ HHHH **** "O</AM_R(VF_]</_ &8UX?7N'PV_Y$;3?^N'_LQKZGA/
M_?I_X?U0&Y1117WX!1110 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:U
MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4KG?CW_R#=._Z[O_
M .@BNB^%W_),_#O_ & K3_T2E<[\>_\ D&Z=_P!=W_\ 017CY_\ \BBK\OS0
M'F5%%%?EX!1110 4444 %%%% !1110 4444 %=G\#?\ D<)O^P>__H:5QE=G
M\#?^1PF_[![_ /H:5Z63?\C2C_B0'K-%%%?JP'-?%W_D0+W_ 'HO_1BUXQ7L
M_P 7?^1 O?\ >B_]&+7C%?GO%?\ R,H_X5^<@"BBBOF0"BBB@ HHHH ****
M"BBB@ HHHH V?A]_R.NF?]?:U[G7AGP^_P"1UTS_ *^UKW.OO>$O]SJ?XOT0
M!577?^0'>?\ 7I)_Z":M55UW_D!WG_7I)_Z":^GK?PI>C ^?:***_&P"BBB@
M HHHH **** "BBB@ HHHH **** /HJ'_ %2_[HIU-A_U2_[HIU?LZV *\#\5
M_P#(TZE_V$)O_0S7OE>!^*_^1IU+_L(3?^AFOD>+OX%+U?Y 9]%%%?# %%%%
M !1110 4444 %%%% !1110 5[A\-O^1&TW_KA_[,:\/KW#X;?\B-IO\ UP_]
MF-?4\)_[]/\ P_J@-RBBBOOP"BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V
M 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5SOQ[_
M .0;IW_7=_\ T$5T7PN_Y)GX=_[ 5I_Z)2N=^/?_ "#=._Z[O_Z"*\?/_P#D
M45?E^: \RHHHK\O **** "BBB@ HHHH **** "BBB@ KL_@;_P CA-_V#W_]
M#2N,KL_@;_R.$W_8/?\ ]#2O2R;_ )&E'_$@/6:***_5@.:^+O\ R(%[_O1?
M^C%KQBO9_B[_ ,B!>_[T7_HQ:\8K\]XK_P"1E'_"OSD 4445\R 4444 %%%%
M !1110 4444 %%%% &S\/O\ D==,_P"OM:]SKPSX??\ (ZZ9_P!?:U[G7WO"
M7^YU/\7Z( JKKO\ R [S_KTD_P#035JJNN_\@.\_Z])/_037T];^%+T8'S[1
M117XV 4444 %%%% !1110 4444 %%%% !1110!]%0_ZI?]T4ZFP_ZI?]T4ZO
MV=; %>!^*_\ D:=2_P"PA-_Z&:]\KP/Q7_R-.I?]A";_ -#-?(\7?P*7J_R
MSZ***^& **** "BBB@ HHHH **** "BBB@ KW#X;?\B-IO\ UP_]F->'U[A\
M-O\ D1M-_P"N'_LQKZGA/_?I_P"']4!N4445]^ 4444 %%%% !1110 4444
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M_P"AFOD>+OX%+U?Y 9]%%%?# %%%% !1110 4444 %%%% !1110 5[A\-O\
MD1M-_P"N'_LQKP^O</AM_P B-IO_ %P_]F-?4\)_[]/_  _J@-RBBBOOP"BB
MB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\
M8!?_ -#6@#NOA=_R3/P[_P!@*T_]$I7._'O_ )!NG?\ 7=__ $$5T7PN_P"2
M9^'?^P%:?^B4KG?CW_R#=._Z[O\ ^@BO'S__ )%%7Y?F@/,J***_+P"BBB@
MHHHH **** "BBB@ HHHH *[/X&_\CA-_V#W_ /0TKC*[/X&_\CA-_P!@]_\
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M] O_ )/4_P#DP_UQXC_Y_P#_ )+#_P"1/5O^&G/^I(_\J7_VNC_AIS_J2/\
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M/#__ ()H/_B*^@_UMS+^2'W/_P"2/D_^(?Y-_P _*GWQ_P#D#\V_^$F\*?\
M0Y:)_P"#FW_^+KQG]L_X$_!3]J_PEHOP[UWXW1>%/%&G:K_;'@3Q3H6NPI>:
M7J%NG^MC(<!AM?YHRREAR""H9?V*_P"%3?"O_HFGA_\ \$T'_P 17EW[2?\
MP3V_9V_:<N?"VJ>);'5/#>I>#-3FU'P[JO@B\33+BVNI(6@,C,B$3*(WD7RI
M \3!V#HXQC.IQ3CJU-PG"#3\I?\ R1K1X&RO#U54IU:BDMG>/_R!^(O[ 7[4
M?QA^%WQ:T#]D;]JW2O#.JMKI\2R?#_XJ:->PI_:1MK^:2_ANXRV+=W=/-^4J
MA'D@*W#CM(3X_P#B5^UW\:O$?[*?QI\*> C9Z=IN@>*=3\2VT6J1:WK4=D)H
M+JVA^T0?9_L]O<1PM*6E24X!A_=;G_43]C__ ()'?!']G#Q5%\5OB?XIU;XH
M>-+'^V+;0M7\80V9M]%L[_4)+N9+2TMK:"".64&(2SE&D8H55DB(C'6^/_\
M@FM\$/$GQ6U[XS_#/Q5XA^&^N^+=/M[3Q?)X)MM*,&LK AC@ED@U"QNHX9TC
M/EBXMUAF*!59V")MYX\0X^-*--V:B[IZWVM:Z:?Z]W8[)\(Y5+$3K)R3DK-+
MEMNG?E<6M6MK6ZI)V9^9W_!.;QQ\*&_9+\->$_"OV703X;EOM'U73M1U^*X<
M:A;7LT-W+]H(03B6X6682!5W"4':OW1G_P#!1CQ%X2UOX9^#OA[H6NZ:_BWQ
M'\2](MO >KPZY L>A:O"TEW'J4Q^<-%#';REHRO[W=Y65\S>OW3\._V /V:]
M'^(7Q&_8@\#^&KWPWX,D^$]KIEM=:)J+IJEFUT\IGO8KR3?(+QWD>5IV+,TC
M%FW9(KVWXA?\$[OV8/BA\!?#WP"\7^$KB>W\)C3)?#OBE+D+KEE?6"J+;41>
M[=[W0*Y=W#++OD61721U.KXFQ[P_L>6-K6V?^=OP,%P5E2QGUGGGS7YMU:][
M_P M_O?J?D9\/[_6/AY_P4(LW_:(^)OAGQ7KOB[X:7-IX)\2^'Q'IUEIEK97
M-O+?64EHUQ.4DFDF@F$[3MO$/EA$V?-]0?\ "3>%/^ART3_P<V__ ,77V7\)
MO^"=_P #/AU\6;KX]>-+_4_B%XTFT3^QK/Q!XTL=,']G:<9!*]O;6NGV=K:0
M[Y%1GE$/FR;$#2%451ZS_P *F^%?_1-/#_\ X)H/_B*JEQ1F%&+48QU=]5)_
MCS7^\BOP/E.(DI2G/1):.*6GERV7RLC\V_\ A)O"G_0Y:)_X.;?_ .+H_P"$
MF\*?]#EHG_@YM_\ XNOTD_X5-\*_^B:>'_\ P30?_$4?\*F^%?\ T33P_P#^
M":#_ .(K7_6W,OY(?<__ )(P_P"(?Y-_S\J??'_Y _-O_A)O"G_0Y:)_X.;?
M_P"+KU3]D#XW?"#X6_%"Z\1>._B7HEC9R:++ DW]HQRYD,L3!<1ECT5N<8XK
M[0_X5-\*_P#HFGA__P $T'_Q%'_"IOA7_P!$T\/_ /@F@_\ B*Y\5Q+CL7AY
M49QC:2MHG?\ ,ZL%P7E> Q<,13G-RB[J[C;Y^ZCA?^&[OV0_^B\:)_WU)_\
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M<H2W3<;7[JT4T_-/U/"M1\;>!M)T^?5=2\=Z%!;6T+2W$TFM6X6-%!+,?GZ
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MNI>(D\2^,M1\1W$_C2[74Y;.:\=7:UMGD3,-I'M CA'" GDEB3H?#?\ 8_\
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MX;N_9#_Z+QHG_?4G_P 17=?\*F^%?_1-/#__ ()H/_B*/^%3?"O_ *)IX?\
M_!-!_P#$5X^8YG7S.I&=5)-*VE_U;/H<GR7"Y)1E2H2DU)W]YI]+=$CA?^&[
MOV0_^B\:)_WU)_\ $5F^,OVWOV3]5\(:KI=A\<]$DGN=-GB@CWN-SM&P R5P
M.2.M>F?\*F^%?_1-/#__ ()H/_B*/^%3?"O_ *)IX?\ _!-!_P#$5P1DX24E
MT/6G!5(.+ZZ'YM_\)-X4_P"ART3_ ,'-O_\ %T?\)-X4_P"ART3_ ,'-O_\
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MS2NF]8ZM72O[O2[^\_-O_A)O"G_0Y:)_X.;?_P"+H_X2;PI_T.6B?^#FW_\
MBZ_23_A4WPK_ .B:>'__  30?_$4?\*F^%?_ $33P_\ ^":#_P"(K7_6W,OY
M(?<__DC'_B'^3?\ /RI]\?\ Y _-O_A)O"G_ $.6B?\ @YM__BZ^NO@'^V+^
MS#X*^#^A>%O$WQJT2VO[*T*7,'G,^QM['&Y 5/!'0FO:O^%3?"O_ *)IX?\
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M&];LF"W=C<;25+)N1@P/*2*2%.57PSXB?\%D/%GP9\0>&_B7\9OV"_'7ASX
M>+O$EIHVB_&ZZUZPD$9NY!%9WUWI*,;JRLIG92DLI#A70M$K.L9 /N&BBB@
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M!B\C(BLP /1Z*^3?V;?^"F/CKQU^UHO[$?[7?[&_B'X)?$#6/#4_B#P/%?\
MBBQUS3O$EA X6X6&\LSL2YBW!G@()"Y;=C;N^LJ "BBB@ HHHH **** "BBO
MD+]H_P#X*<?$7]EG]O+X4_L@?%C]F'3['PM\8]8FTWP?\6G\?E=.%U&C,+*X
MA-AOAO),1)'#N*2/.@64@2% #Z]HKP;]LW]L#Q]^SAXO^&OPM^#/P-L_B3XS
M^)GB&XT[2_"[>+QI,UO:V]LUQ<ZD[M;3+]D@5565R5*M/ BB1Y56O'=#_P""
MG/[7OB#]MC7/V![#]@;PS_PG/A_P!;^,+Z63XV$6!TZ:Y%L@27^Q]QE\P\J4
M QSN[4 ?;=%?!O[+_P#P5C_;&_:L^*OQ;^"G@K_@FE9:3XE^"NO6VD>,]+\0
M_&>&!VGG65X3;,FFO',CI"75RR JZ'.#Q[G^Q9_P4%\!?M?^)/&OP@U3X=>(
MOAW\4OAG?0VOC_X:>+UA^W:;YRE[>ZAE@=X;NTF4%HYXF(88)"[EW 'K?PM^
M%/A'X/>'9_"_@N&=+2XU*XOI!<3F1O.F?>YR>V>@[5TE>*?M=?ME6O[)WC/X
M.>#[SX4:QXD_X6_\5+/P3;WFESQI'I$L]O/.+J;=RZ*EO(Q5<':CG/RA6I?M
M7?M9?&OX0>)K?X8_LN_L<:]\9_& T@:QJ^EV'B>QT.RTJP:22*%YKV^8(TTT
MD,RQ01J[-Y$C.8U4,P![Q17BO[ _[</P\_;_ /@'_P +K\"^%=:\-WNFZ_?>
M'O%_A#Q);B+4/#NM64@CNK"X"DKO0E6!!Y5U)"DE19^*O[:7PM^%_P"UK\+/
MV,I+NWO_ !G\3QJUU#I\-^HETS3K"QFN7O)8P"2KR(D* [-Q:1@3Y3*0#V&B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\\/BS<6G
MA+_@YP^&'B'XKR+#HGB#]DS6-+^&MQ>';#_;\&LFYOUB+<>:-..6(YV,N>*Y
MC_@OC^UY^QW^TO\ \$>/C1X*^#GQK\+^.]>&J^'M'T;2/#&K17=Z-;N-5M9+
M$0I&2Y9UBED1UXDCBEVE@&K[C_:M_8V^!7[9?A'2O#/QET.]%YX<UB/5_"7B
M;0=2EL-7\/:C']R[LKN$AX9!T(Y1QPZL.*^<?B[_ ,$6[#QW\8?!'[6%E^UG
MXL\3?%[X97T$W@/Q'\7O#VDZUIEK GFYM9]/TZVTWSES,SI-YJW$,JI)'*"&
M#@'K7[7WP:_;/^,'[%EQ\)_@3\9_#_ACQ?J/@I[#Q)=:MH3W5QJ,KVJ)+#:W
M8N%CTZ20^<GVI[>["&17$64YU/\ @F3\2_@Y\7O^">_P;\?_ +/G@JY\->"[
MOX>:9#X=\.WL_FRZ7;P0+ +5I/\ EJ8S$4\W_EIMW_Q5/KO[)OC_ .(G@:[\
M-?$?]J[QG8W/B*R>+QK%X AM-+L-2:0%)?LR745Y=::C1;8L6UTCC;YF_P Y
MGE;TWX6?"_X?_!+X;:#\'_A3X5M=#\->&-)@TS0M'LE(BM+6%!''&N22<*HY
M)))Y)))- %SQ#X-\)^+;G2[SQ1X<L]0ET34UU'2'O+=9#9W:QR1+/'D?+($E
MD4,.0'/K7._'?XT^#/V?/ =Q\1/$UC<7MW/+%8:)HFE0K)J&O:A(6%MI]JA(
M\R:1RP4$A4&^1V2-'=>UKYC_ &NO^"8GA[]K[XY:'\?-8_;)^._@35?#.D2Z
M?X?L?AKXSM-,M+!9O]?-&K64C^=* JO(7)**$&%XH Z+_@GI^REK?[+WP5UY
M?B2UC+XY^)OCW6/'WQ(737+V<6LZK,));6 D O#;Q+!:JY ,@M]Y"E]HXS]N
MKP%I_P"WMKNE_P#!/GP[ ESX6L/$^BZ_\;M5C ,&G:=874&I6>C*PZWMY/!;
M,8QS#:"25]IEMA-Z)^S!^Q;I_P"R]X*\4>'+#]I/XL>.=9\52AKCQM\2O%<>
ML:O9(D/E0PVTCP+%'%$S2RI&8F7S)I&8,&Q7@'AG_@A3X0\':3?>'_#'_!3?
M]L"PL-5U"ZOM5M+#XPV]NMY<W,C27$TC16"L9)'9BS@AR3G(XH ^Z**K:-H^
MF>'M(M= T2RCMK.QMDM[2VB&%BB10J(!Z   ?2K- !1110 4444 %%%% !7Y
MZ?\ !QP$TS]G3X#^._%\9;X>^%_VLO VJ_%<N/W$?A]+B=)7G[>3YTEN#GC<
MR5^A=8'Q3^%GPY^-_P .=:^$7Q<\&6'B'PSXBT^2QUO1=4@$L%W;N,,C*?S!
M&"" 000#0!P_C3]M/]C3PU\0M2^!'CS]HOP1:^)+;1KF]U/PUJ&MP"<6D5M]
MIN-T;'YMML?.>/EA$=Y78<U\B?\ !NIX9^,47_!$WP;;>!M6M/#=QJ>L^(+S
MX>3>*]#FU&"QTF76KF2W,MK'<VTDJ,AD90)DXD1@2O![/XU_\$)_@/\ 'GX!
MG]E?Q[^U+\:[[X;6:AO#7@G4?$>G7EKHDT<3Q6SQ7,]@U_*(%?"1S74B%5",
M&0E3[)\'OV6OV@_#?@#3/"OQ,_:CLK/4/#FG0:3X9O\ X0^ ;?P[;6^FQ1A/
M*FL;Z74K65VV1$%8XUA$>V%8E>3S #R__@D4MQX#UK]H+]GKXG.=1^+?A7XR
M2:E\5O%\+#[+XHNM5TZTO;+4+>(*!9Q?8&MH!9Y?R/LV#)*6,C?7WB7PWH'C
M+PYJ'A#Q7H]OJ&EZK92V>I6%W$'BN;>5"DD3J>&5E8J0>H)KA_V<_P!F#X:_
MLRZ1KUOX)FU/4M7\7>(9==\9>*?$%X+C4M=U*1$C:XN)%5$&(XXXTBB2.**.
M-4CC11BO1: ,[49O"7@OPVVJZO-IVE:1H5DTSW-RR06^GV\49W.6;"Q(D8;)
MX"J#T%?-W[+GPJO/CA^V-XK_ ."F_B?1;C3+/5_ =IX$^$UA=V[0W,OAJ*\>
M_GU2XC8!HVO;MT>*)@&2VMH&<*\SQQ]U^W+^Q1X:_;R^$EO\%?&_QN^(?@S1
M8]7@U"^_X5WK-M8S:BT+;XH;AY[:??"L@63RP%#,BEMVT"N4_9J_X)LZ7^SM
M\7+7XP:Y^VK^T%\4;G3["XM]+T;XK_$5-4TVREF"HUW'!';0C[0(Q)$LC%MJ
M3R@#YL@ \=_X.*/@!\"/&W_!-/XD?&WQE\%/".K^,_#&F:7%X;\7:GX;M;C5
M-)1M9LPRVUT\9E@!#OD(R@[V]37WK7D7[;_['/@W]O']GW5_V:/B5\1O%GA[
MPWK[0?VR?"$]E#<W213Q3I&9+JUGV*)(D.4"L<$$X)%>G>&-(U#0= M='U7Q
M1?ZW<6\0275=3CMTN+D_WW%O%%$#_N1J..E %^BBB@ HHHH **** "BBB@#\
MU?\ @XV\#:Y^SA\&/#O_  69_9YUNWT'XN_L\:I90P7<UL9(/$6AZE?0V$^D
MWB*RF2'S+L2+\V4!FV[6D#K]Q_LH_L^^'OV:O@OI_P /])UFZUG4KJ:75?%?
MBC4E7[9XAUBZ;S;S4;@KQYDLI)"CY8T"1H%2-%'(?\%"OV _AS_P4E_9_O/V
M8OC/\4O&N@^#M5N8)M=T[P9=V-N^I^1/'<0I+)<VD[A4FBC<",IDJ-VX<5Z=
MX6^'>N^&/A9;?#=_C!XFU&]M; 6L?B_4H]/;4V(&%E8):+;-(!CDP8.,D$Y-
M 'Y\?\$,O^3#_P!J;_LY+XE?RBKTS_@VT('_  1&^ I)_P"8'J?_ *>+ZNV_
M9G_X)-^ OV3?@K\0O@1\(_VKOC FD?$O6-1U?7KK4K_1+B[@U&_5$N[JWE.E
M#RWD5!D$,BDEE56.ZN7^&?\ P1'^&GPI_9TLOV0O"O[<?[1,/PNLK&:R3P7;
M^+]*LX7M)97EFMVN;33(;L1R-))N"S@E79<X.* .&_X-U[BUUGX9_M/^,_!S
MJW@C7_VR_'5_X EAY@FTMGM0LD!''DEE<+CC*M7WW#X-\)V_C&Y^(4'ARS37
M;S3(-.NM76W7[1+:0R2RQ0%\9,:O/,P7H#(Q[UA_ 3X"?![]E_X0:#\!/@%X
M!L?#'A#PS9"UT71-.5O+MX]Q9B68EG=G9G>1RSN[,S$LQ)Z^@#YO_P""A=QJ
M_P 8_A1K'_!/OX+20_\ "9?%SPY=:3JMRD0:+PMX<NP]MJ&LW('"_NGFCMHS
M\UQ=,JCY(YY(O;_AI\,_!7P=^%_AOX3^#=.6VT+P?H=II6B0SL&-O:VL"P1#
M<>ZQH!GZU\G:W_P1<T+4_BGXO^,.D?\ !2?]JW0=8\<:P=2\0'PY\3;*RBED
M"A(HU2/3@%BBC CCCZ(B@#OGUCXL?\$_O _Q8_8G@_85G^.GQ.T/PX=,BL-9
M\3Z)XEA_M_7(1DW'VR]N+>7S6NG9I+A@BF4NX)".R$ X_P"&7@*T_;&_;JTC
M]O@P ^ _A?X2U/PS\(+PCGQ!=ZC+"=4UN,][/R[6"UMGZ3C[3,N8G@DD^JJ^
M5?@'_P $I] ^!GQ0\.?$C5/VZOVD/']KX7E:73/!WQ#^)<=[H;2^0\,3R6D5
MI$)#%OWQ@G:DB(X&47'U50 4444 %%%% !1110 5X1_P4C_84^'G_!17]D?Q
M+^S5X[NVTZ[NXUO_  EXD@!^T:!K5OE[._A8$,K(_#!2"T;R)D;R:]WK%^(G
MA+4O'?@K4?".D>/M9\+W&H6QA37O#PMOMMIGJ\7VJ&:(-C(RT;8SD8." #X>
M_P"#?+Q?X^_:[_8O\._\%*?VD/%/_"2?$_XB:2^@3ZF]J(H]-TG2+V>QCM;=
M 2$^T3V\U]<.,>;/<D8"0PHE'X7?\K._Q1_[-'T?_P!/:U](_P#!//\ X)__
M  X_X)K_  "M?V9?@M\4O&VO>#M-NIY]$T[QG=V-PVF&>:2>98I+:T@<J\LK
MN1(7P6.W:#BL+P]_P3-\&^&OV[=:_P""AUA^TQ\4F\=:_P"&H_#NI6<USHS:
M6VDQR)+'9K;_ -F955DC5PX?S<ELN=S9 /"_^"4W_*67_@H5_P!E"\&_^F::
MH?"=S::__P '1_BRZ^'SJ]KH7[&MG8>/WM^4CU27Q$L]I%-CI,;1HW7//ECC
MBO3?!G_!'OP[\-?C)\1OCQ\-OV\_C_H'B/XKZQ#J?CJYTW5O#P34)H4:.$!7
MT9O)6.-V11'MPN.I ->M_L=?L%?L[_L.Z7XC'P:TC5KO7O&FJC4_'/C;Q5K4
MVIZWXCO &"S7EW,2S[0S!44+&FYBJ@LQ(!ZIX@\&^$_%EYI.H>)O#EG?SZ%J
M?]HZ-+=VZR&RN_)E@$\>1\DGE3S)N'.)&'>N;^//QK\'_L]^ Y_'VO:9<ZA?
MW4\=AH'A_28E?4/$&I2;OL^GVJ$C?*YW8+$)&@DDD9(XY'7MZ^8?VM?^"8'A
M[]KGX[Z/^T'JW[9GQY\"ZMX>T:33=!L?AMXTM-,L]/CE(-Q)&K64CB6;:HDD
M+DLJ*O"@+0!T_P#P3Q_94UO]E/X'ZK:?$"YLI_'7Q#\=:QX]^(\NEN6M%US5
M;@W$\%N2 6A@3RK9'(!=;<.0I8J/ ?VEO@!\"/A?_P %K/V3/B9\-/@IX1\.
M^)/&)^)$_B[Q!H7ANUM+[6Y5T6!EDO)XHUDN6!D<AI&8@NQ[FOIC]D7]D#1O
MV1_#VMZ7#\=_B;\2-3U_4DNK[Q/\5_%?]KZDL<<2QQ6D<HBB6.WC_>.L:H/G
MGE8DE^*'QI_8B\.?&[]I_P"'/[5NK?&_QUH^N?"Q=2'A32=$?2QIZ#4+=+>\
M\Y)[&667S(HU',GR$938>: /;**** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MOQ]^T\_A31-=^$WQ6UWP%XL\3:+<&VT/5I=,:$?VG;FX=O*@D6=.&=AN5L$
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M(/P4^'MK(O[8?@2'3/"=I:Z<#$_Q1T^;[+8K/L7$<-U!J(EE8YRUG/(<DL:
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MC\!_ 'P5HFH>&M'DTGPY?Z1X5L[:;2K!W+O:6SQQAH(&=BQB0A"221DUVM%
M'.>)O@]\(_&OC70_B5XR^%GAS5O$?AAI&\-:_J>AV]Q>Z29 !(;:=T,D&X !
MMA7..:Q_'W[+?[,OQ6\8VOQ$^*/[.G@3Q+X@L?+^Q:[K_A&RO+RWV'<FR::)
MG3:>1@C!Z5W=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
5110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303679020672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Oct. 24, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,001,404<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303674814448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">469.5<span></span>
</td>
<td class="nump">511.8<span></span>
</td>
<td class="nump">1,707.4<span></span>
</td>
<td class="nump">1,449.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">549.2<span></span>
</td>
<td class="nump">702.4<span></span>
</td>
<td class="nump">1,629.5<span></span>
</td>
<td class="nump">1,801.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">563.3<span></span>
</td>
<td class="nump">654.1<span></span>
</td>
<td class="nump">1,770.8<span></span>
</td>
<td class="nump">1,886.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">56.5<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="nump">190.9<span></span>
</td>
<td class="nump">813.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="nump">45.3<span></span>
</td>
<td class="nump">21.2<span></span>
</td>
<td class="num">(42.6)<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">(Gain) loss on fair value remeasurement of contingent consideration</a></td>
<td class="num">(2.1)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(13.7)<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">15.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">124.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="num">(503.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(503.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="num">(56.0)<span></span>
</td>
<td class="nump">502.9<span></span>
</td>
<td class="num">(221.3)<span></span>
</td>
<td class="nump">913.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,137.4<span></span>
</td>
<td class="nump">2,487.8<span></span>
</td>
<td class="nump">4,641.4<span></span>
</td>
<td class="nump">6,907.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income tax expense and equity in loss of investee, net of tax</a></td>
<td class="nump">1,371.1<span></span>
</td>
<td class="nump">291.1<span></span>
</td>
<td class="nump">2,988.0<span></span>
</td>
<td class="nump">1,340.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">236.2<span></span>
</td>
<td class="num">(25.9)<span></span>
</td>
<td class="nump">578.5<span></span>
</td>
<td class="num">(390.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax', window );">Equity in (income) loss of investee, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(17.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,134.9<span></span>
</td>
<td class="nump">318.1<span></span>
</td>
<td class="nump">2,412.1<span></span>
</td>
<td class="nump">1,748.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net&#160;income (loss) attributable to noncontrolling interests, net&#160;of&#160;tax</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="num">(84.4)<span></span>
</td>
<td class="nump">560.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">$ 329.2<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
<td class="nump">$ 1,187.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.86<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 17.12<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">$ 7.84<span></span>
</td>
<td class="nump">$ 2.22<span></span>
</td>
<td class="nump">$ 17.07<span></span>
</td>
<td class="nump">$ 7.90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">144,400<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="nump">145,800<span></span>
</td>
<td class="nump">149,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc.</a></td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">148,600<span></span>
</td>
<td class="nump">146,200<span></span>
</td>
<td class="nump">150,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,962.1<span></span>
</td>
<td class="nump">$ 2,205.7<span></span>
</td>
<td class="nump">$ 6,083.3<span></span>
</td>
<td class="nump">$ 6,653.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">416.9<span></span>
</td>
<td class="nump">415.4<span></span>
</td>
<td class="nump">1,252.6<span></span>
</td>
<td class="nump">1,244.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 129.5<span></span>
</td>
<td class="nump">$ 157.8<span></span>
</td>
<td class="nump">$ 293.5<span></span>
</td>
<td class="nump">$ 350.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IncomeLossFromEquityMethodInvestmentsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) from Equity Method Investments, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IncomeLossFromEquityMethodInvestmentsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303678843072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">$ 329.2<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
<td class="nump">$ 1,187.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gains (losses) on securities available for sale, net of tax</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustment</a></td>
<td class="num">(59.6)<span></span>
</td>
<td class="num">(47.7)<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
<td class="num">(80.3)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">1,081.5<span></span>
</td>
<td class="nump">364.4<span></span>
</td>
<td class="nump">2,439.6<span></span>
</td>
<td class="nump">1,350.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="num">(84.4)<span></span>
</td>
<td class="nump">560.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income (loss) attributable to noncontrolling interests, net of tax</a></td>
<td class="nump">$ 1,081.7<span></span>
</td>
<td class="nump">$ 353.3<span></span>
</td>
<td class="nump">$ 2,355.2<span></span>
</td>
<td class="nump">$ 1,911.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4613674-111683<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303677333648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,675.6<span></span>
</td>
<td class="nump">$ 2,261.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">1,235.5<span></span>
</td>
<td class="nump">1,541.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">1,568.8<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DuefromantiCD20therapeuticprograms', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="nump">415.4<span></span>
</td>
<td class="nump">412.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">1,375.0<span></span>
</td>
<td class="nump">1,351.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">1,495.5<span></span>
</td>
<td class="nump">740.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">9,765.8<span></span>
</td>
<td class="nump">7,856.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Marketable securities</a></td>
<td class="nump">860.3<span></span>
</td>
<td class="nump">892.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,266.4<span></span>
</td>
<td class="nump">3,416.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">424.5<span></span>
</td>
<td class="nump">375.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,008.9<span></span>
</td>
<td class="nump">2,221.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,741.2<span></span>
</td>
<td class="nump">5,761.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">1,174.5<span></span>
</td>
<td class="nump">1,415.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">1,612.6<span></span>
</td>
<td class="nump">1,939.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">24,854.2<span></span>
</td>
<td class="nump">23,877.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">999.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">237.3<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">383.2<span></span>
</td>
<td class="nump">589.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">3,305.9<span></span>
</td>
<td class="nump">2,535.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,926.4<span></span>
</td>
<td class="nump">4,298.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">6,279.2<span></span>
</td>
<td class="nump">6,274.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">328.9<span></span>
</td>
<td class="nump">694.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">354.8<span></span>
</td>
<td class="nump">330.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,198.1<span></span>
</td>
<td class="nump">1,320.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">12,087.4<span></span>
</td>
<td class="nump">12,917.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Idec Inc. shareholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(163.6)<span></span>
</td>
<td class="num">(106.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">15,916.1<span></span>
</td>
<td class="nump">13,911.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Biogen Inc. shareholders&#8217; equity</a></td>
<td class="nump">12,775.5<span></span>
</td>
<td class="nump">10,896.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interests</a></td>
<td class="num">(8.7)<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">12,766.8<span></span>
</td>
<td class="nump">10,959.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 24,854.2<span></span>
</td>
<td class="nump">$ 23,877.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DuefromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DuefromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303677376880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 2,412.1<span></span>
</td>
<td class="nump">$ 1,748.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">398.6<span></span>
</td>
<td class="nump">353.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">629.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">321.6<span></span>
</td>
<td class="nump">36.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">186.9<span></span>
</td>
<td class="nump">179.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration</a></td>
<td class="num">(13.7)<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(139.8)<span></span>
</td>
<td class="num">(750.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">160.3<span></span>
</td>
<td class="nump">710.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(17.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="num">(1,505.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="num">(503.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">147.8<span></span>
</td>
<td class="nump">164.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(109.5)<span></span>
</td>
<td class="nump">157.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties', window );">Due from anti-CD20 therapeutic programs</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">13.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(338.3)<span></span>
</td>
<td class="num">(322.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="nump">632.3<span></span>
</td>
<td class="num">(243.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(100.2)<span></span>
</td>
<td class="nump">260.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="num">(87.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">1,559.3<span></span>
</td>
<td class="nump">2,801.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(153.9)<span></span>
</td>
<td class="num">(206.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sales and maturities of marketable securities</a></td>
<td class="nump">3,104.7<span></span>
</td>
<td class="nump">2,028.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(2,805.9)<span></span>
</td>
<td class="num">(2,372.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity interest in Samsung Bioepis</a></td>
<td class="num">(990.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of building</a></td>
<td class="nump">582.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of Hiller&#248;d, Denmark manufacturing operations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">28.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment', window );">Acquired in-process research and development</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(18.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="nump">1,717.7<span></span>
</td>
<td class="num">(451.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(750.0)<span></span>
</td>
<td class="num">(1,800.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(5.8)<span></span>
</td>
<td class="num">(8.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of borrowings and premiums paid</a></td>
<td class="num">(1,002.2)<span></span>
</td>
<td class="num">(170.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders', window );">Net (distribution) contribution to noncontrolling interest</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="num">(94.8)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="num">(22.9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="num">(1,739.9)<span></span>
</td>
<td class="num">(2,096.0)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,537.1<span></span>
</td>
<td class="nump">254.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(122.9)<span></span>
</td>
<td class="num">(44.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,261.4<span></span>
</td>
<td class="nump">1,331.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">$ 3,675.6<span></span>
</td>
<td class="nump">$ 1,541.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123583714&amp;loc=SL75117360-209713<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3444-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsToMinorityShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsToMinorityShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668224144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
<th class="th"><div>Noncontrolling interest</div></th>
<th class="th"><div>2020 Share Repurchase Program</div></th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Common stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Additional paid-in capital</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Retained earnings</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Treasury stock</div>
</th>
<th class="th">
<div>2020 Share Repurchase Program </div>
<div>Parent</div>
</th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 10,686.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
<td class="nump">$ 13,976.3<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 10,700.3<span></span>
</td>
<td class="num">$ (14.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,748.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,187.9<span></span>
</td>
<td class="nump">560.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">163.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Distribution to noncontrolling interest</a></td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(100.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800.0)<span></span>
</td>
<td class="num">$ (1,800.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (231.9)<span></span>
</td>
<td class="num">$ (1,568.1)<span></span>
</td>
<td class="nump">$ 1,800.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(52.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">186.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">10,881.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
<td class="nump">13,543.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,429.9<span></span>
</td>
<td class="nump">451.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">172.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2021</a></td>
<td class="nump">11,214.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(171.8)<span></span>
</td>
<td class="nump">13,900.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,751.9<span></span>
</td>
<td class="nump">462.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">318.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
<td class="num">(11.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="num">(750.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(68.6)<span></span>
</td>
<td class="num">(681.4)<span></span>
</td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">10,881.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
<td class="nump">13,543.5<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,429.9<span></span>
</td>
<td class="nump">451.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">10,959.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">68.2<span></span>
</td>
<td class="num">(106.7)<span></span>
</td>
<td class="nump">13,911.7<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">10,896.2<span></span>
</td>
<td class="nump">63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">2,412.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,496.5<span></span>
</td>
<td class="num">(84.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="num">(750.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (750.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(257.9)<span></span>
</td>
<td class="num">(492.1)<span></span>
</td>
<td class="nump">$ 750.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(43.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(43.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">194.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">194.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">12,766.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
<td class="nump">15,916.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">12,775.5<span></span>
</td>
<td class="num">(8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">167.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2022</a></td>
<td class="nump">11,863.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(110.4)<span></span>
</td>
<td class="nump">14,959.9<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">11,872.5<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,134.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,134.7<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(53.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NoncontrollingInterestCapitalContribution', window );">Capital contribution from noncontrolling interest</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock, at cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares', window );">Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockRetiredCostMethodAmount', window );">Retirement of common stock pursuant to Share Repurchase Progams, at cost</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (250.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (71.5)<span></span>
</td>
<td class="num">$ (178.5)<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock under award plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation related to share-based payments</a></td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">$ 12,766.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (163.6)<span></span>
</td>
<td class="nump">$ 15,916.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 12,775.5<span></span>
</td>
<td class="num">$ (8.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">167.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NoncontrollingInterestCapitalContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Noncontrolling Interest, Capital Contribution</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NoncontrollingInterestCapitalContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedAndRetiredDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased and retired during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedAndRetiredDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockRetiredCostMethodAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockRetiredCostMethodAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676191360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). </span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div>In June 2022 the FASB issued Accounting Standards Update (ASU) No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676085520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text">RESTRUCTURING <div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2022 Cost Saving Initiatives</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized approximately $15.4 million and $124.1 million, respectively, of net pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $21.6&#160;million and $110.2&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets. In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge, MA (300 Binney Street), as well as to reduce the lease term for the majority of the remaining space.  This resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. For additional information on our 300 Binney Street lease modification, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 11, Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the nine months ended September 30, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized other restructuring costs of approximately $8.8&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303758993856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">833.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the United States (U.S.) in June 2022 and became commercially available during the third quarter of 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,161.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,157.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,568.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,850.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,802.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2022, and 26.8% and 10.7% of gross product revenue for the nine months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 26.9% and 10.8% of gross product revenue for the three months ended September 30, 2021, and 29.1% and 10.0% of gross product revenue for the nine months ended September 30, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,993.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,501.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,442.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,821.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(463.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,244.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Revenue</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675781392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work in process inventory as of September 30, 2022, includes approximately $118.0&#160;million related to lecanemab.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#8217;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. We have recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fourth quarter of 2021 we wrote-off approximately $120.0&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income for the year ended December 31, 2021. We have recognized approximately $59.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2022, the carrying value of our ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0&#160;million of ADUHELM inventory. For additional information please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675758368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,579.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,835.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,588.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,579.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,609.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, amortization and impairment of acquired intangible assets totaled $56.5 million and $190.9 million, respectively, compared to $111.0 million and $813.2 million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2022, we had no impairment charges.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.</span></div><div style="margin-top:5pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). </span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In-process research and development (IPR&amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;D assets as of September 30, 2022, relates to the IPR&amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Vixotrigine</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rst quarter of 2021. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, the carrying value associated with the remaining vixotrigine IPR&amp;D intangible asset for DPN </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $109.3&#160;million a</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial, or sooner if there is a reevaluation event, and may record an impairment charge related to this asset.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">BIIB111 and BIIB112</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recognized impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111, and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112, reducing the remaining book values of these IPR&amp;D intangible assets to zero.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1&#160;million during the third quarter of 2021 related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,761.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,741.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">no</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ac</span>cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675956000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,605.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,515.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,193.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">866.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,228.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. As of September 30, 2022, we elected to early adopt ASU 2022-03 on a prospective basis, which resulted in removing the impact of contractual sale restrictions from the fair value measurement of our remaining Sage common stock subject to certain holding period restrictions. As of September 30, 2022, our entire investment in the common stock of Sage was classified as a Level 1 measurement. Prior to the adoption of this standard, the fair value of Level 2 instruments classified as marketable equity securities represented a portion of our investment in the common stock of Sage and was valued using an option pricing valuation model. The initial holding period restriction for a portion of our investment in the common stock of Sage expired during the second quarter of 2022 with the remaining holding period restriction set to expire in the fourth quarter of 2022. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Denali Therapeutics Inc. (Denali) had holding period restrictions that expired during 2022. As of September 30, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as Level 2 measurements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Sangamo, Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of September 30, 2022 and December 31, 2021. There have been no significant changes to our valuation techniques as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 to 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 10.9% to certain probability as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2022 and December 31, 2021.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, approximately</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$195.4&#160;million and $209.1 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">component of accrued expense and other. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, the changes in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2021, the changes in the fair value of our contingent consideration obligations were primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,697.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,744.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,895.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,183.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,457.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,296.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,279.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,004.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 3.625% Senior Notes due September 15, 2022, were redeemed in full in July 2022. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2022, compared to December 31, 2021, are related to increases in U.S. treasury yields and wider credit spreads used to value our Senior Notes since December 31, 2021. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675758368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,070.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities (gains) losses are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">833.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,122.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,095.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,235.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,245.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,095.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,122.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2022 and December 31, 2021, was approximately 9 months and 10 months, respectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Proceeds from Marketable Debt Securities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,643.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,104.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized losses for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022, our strategic investment portfolio was comprised of investments totaling $948.5 million which are included in investments and other assets in our condensed consolidated balance sheets. As of  December 31, 2021, our strategic investment portfolio totaled $1,110.3 million and was included in other current assets and investments and other assets in our condensed consolidated balance sheets. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2022, was primarily due to a decrease in the fair value of our investments in Denali and Sangamo common stock.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali, Sage and Sangamo common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680391488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2022 and December 31, 2021, had durations of 1 to 15 months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the net unrealized gains of approximately $144.3&#160;million to be settled over the next 15 months, of which approximately $142.6 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Investment Hedges - Hedging Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0&#160;million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale of our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49.9% </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">equity interest in Samsung Bioepis, we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $10.6 million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $3.6 million as of December 31, 2021.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,285.4 million and $1,268.0 million as of September 30, 2022 and December 31, 2021, respectively. Net losses of $36.5 million and $85.8&#160;million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2022, respectively, compared to net losses of $13.5&#160;million and $26.1&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI http://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123477628&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675951216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,098.0 million and $2,006.6 million as of September 30, 2022 and December 31, 2021, respectively. For the three and nine months ended September 30, 2022, depreciation expense totaled $64.2 million and $207.7&#160;million, respectively, compared to $65.1 million and $168.7&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Solothurn, Switzerland Manufacturing Facility</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2022 and December 31, 2021, we had approximately $701.0 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite at the Solothurn facility will be operational during the second half of 2023.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">125 Broadway Building Sale</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we completed the sale of our building and land parcel located at 125 Broadway, Cambridge, MA (125 Broadway) for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. This transaction included approximately $79.2&#160;million of property, plant and equipment, net, which comprised of approximately $72.6&#160;million for buildings, approximately $1.6&#160;million for land and approximately $5.0&#160;million for machinery and equipment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675836656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES <div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">125 Broadway Building Sale and Leaseback Transaction</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in connection with the sale of our building at 125 Broadway, we simultaneously leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2&#160;million in new lease liabilities and right-of-use assets recorded within our condensed consolidated balance sheets as of September 30, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our building, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Property, Plant and Equipment</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">300 Binney Street Lease Modification</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge MA, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of right of use assets of approximately $47.4&#160;million and lease liabilities of approximately $52.7&#160;million, which resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675856288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.625% Senior Notes due September 15, 2022</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.0&#160;billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $2.4&#160;million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges were recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Exchange Offer</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2021.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675951216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2&#160;million and 3.6 million shares of our common stock at a cost of approximately $250.0&#160;million and $750.0 million during the three and nine months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2021, we repurchased and retired approximately 2.2&#160;million and 6.0&#160;million shares of our common stock at a cost of approximately $750.0&#160;million and $1.8&#160;billion, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676053696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,134.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,496.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680391488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675796512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:7pt"><span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the increases in our effective tax rates include the tax impacts on the sale of one of our buildings and the favorable prior year tax effects of changes in the value of our equity investments, where we recorded unrealized losses, and the BIIB111 and BIIIB112 impairment charges. The tax effects of this change in value of our equity investments were recorded discretely as changes in value of equity investments cannot be forecasted.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in our effective tax rate also reflects the net effects of the Neurimmune SubOne AG (Neurimmune) matters, as discussed below, and the litigation settlement agreement.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our collaboration arrangement with Neurimmune, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 19, Investments in Variable Interest Entities</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $500.0&#160;million, including approximately $455.0&#160;million related to the unrecognized</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tax benefits related to Neurimmune's tax basis in ADUHELM, in the next 12 months as a result of various audit</span></div>closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as w<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675956000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">913.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2022.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis Pharmaceuticals, Inc. (Ionis), Sangamo and Denali common stock of approximately $112.5&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,305.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other long-term liabilities were $1,198.1 million and $1,320.5 million as of September 30, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $559.7 million and $664.5 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676053696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Lecanemab Collaboration</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits or losses equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years for the manufacture of lecanemab drug substance and drug product.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022 Eisai completed the submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date of January 6, 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Lecanemab Collaboration, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the nine months ended September 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022, we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of September 30, 2022, Eisai's portion of these expenses was approximately $300.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#8217;s economics beyond these royalties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">C</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">o-promotion Profits and Losses</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022, we recognized a net reduction to our operating expense of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$3.4&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$214.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, compared to $50.6&#160;million and $90.7&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM. F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we have also recorded approximately $76.0&#160;million of aggregate gross idle capacity charges related to ADUHELM.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have recognized approximately $177.0&#160;million related to Eisai's 45.0% share of inventory and idle capacity charges in collaboration profit (loss) sharing within our condensed consolidated statements of income</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> months ended September 30, 2022.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.6&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $285.4&#160;million as of September 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively. Amounts payable to Eisai related to the agreements discussed above were </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$81.7&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and $46.5&#160;million as of September 30, 2022 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021, respectively</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the ADUHELM Collaboration Agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, we and UCB will co-promote dapirolizumab pegol and share profits equally.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sage Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sage sales and marketing expense incurred by the collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#8217;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2022 we and Denali announced the initiation of the Phase 3 LIGHTHOUSE study for BIIB122 (DNL151), a small molecule inhibitor of LRRK2 for the potential treatment of Parkinson's disease.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sangamo Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#8217;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#8217;s proprietary zinc finger </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Sangamo collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">InnoCare Pharma Limited</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#8217;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">that was recorded as research and development expense in our condensed consolidated statements of income. </span><span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Research and Discovery Arrangements</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recorded $14.0&#160;million and $51.5&#160;million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$7.7&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $84.9&#160;million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Samsung Bioepis Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Joint Venture Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of this transaction.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $675.0 million and related to inventory, developed technology, IPR&amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;D for marketed products were being amortized, net of tax, over their estimated useful lives of 15 years.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2022, we recognized net income on our investment of $2.6 million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $17.0&#160;million, offset by amortization of basis differences totaling $14.4&#160;million. This amount reflects our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2021, we recognized net income on our investment of $1.1 million and $17.2 million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax to</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">taling $8.9&#160;million and $39.5&#160;million, respectively, offset by amortization of basis differences totaling $7.8&#160;million and $22.3&#160;million, respectively.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 713.3 billion South Korean won ($599.9 million), which is classified as a component of investments and other assets in our condensed consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to zero.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $37.0 million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the third quarter of 2021 we accrued $15.0&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the United Kingdom (U.K.), that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also acquired an option to extend the term of our 2013 c</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2022, we recognized net profit-sharing expense of $48.7&#160;million and $171.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $71.8 million and $210.2 million, respectively, in the prior year comparative periods. </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Services</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.8&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and $4.1&#160;million as of September 30, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed abo</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ve were $53.8&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$148.7&#160;million as of September 30, 2022 and December 31, 2021, respectively.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span> to our consolidated financial statements included in our 2021 Form 10-K.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675869808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Neurimmune SubOne AG</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#8217;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45.0%</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million related to this deferred tax asset. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $25.3 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Neurimmune and other variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675951216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2021 Form 10-K.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Loss Contingencies </span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ADUHELM Securities Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are named as defendants in actions filed by shareholders in November 2020 (the November 2020 Securities Action) and February 2022 (the February 2022 Securities Action) and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief. In September 2022, the court dismissed the November 2020 Securities Action, and the plaintiff has appealed to the U.S. Court of Appeals for the First Circuit. Our motion to dismiss the February 2022 Securities Action is pending. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Derivative Action</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders on February 9 and July 21, 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. &#167;78n(a) and 17 C.F.R. &#167;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. The court has stayed both cases. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris and proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent). In June 2022 Fresenius Kabi amended both actions to assert claims under European Patent 3 145 488 (the EP &#8216;488 Patent), which expires in May 2035. No hearing has been set in either action.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020 Fresenius Kabi commenced preliminary injunction proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a corresponding Danish utility model, DK 2020 00038 Y3. In September 2021 the Court refused Fresenius Kabi's request for a preliminary injunction, finding that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark, and a hearing is scheduled for January 2023.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP '510 Patent, which resolves all pending infringement claims under the EP '510 Patent. The EPO has scheduled a hearing on the validity of the EP '488 Patent for October 26, 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#252;sseldorf Regional Court, alleging infringement of the German counterpart of European Patent No. 3 212 667 (EP '667 Patent), which expires in October 2035. The case has been stayed pending proceedings in the EPO to invalidate the EP '667 Patent.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the Opposition Division of the EPO revoked the EP '667 Patent. Gedeon Richter Nyrt have appealed that decision to the TBA of the EPO. No hearing has been set in that appeal.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 Gedeon Richter Nyrt commenced proceedings against Biogen GmbH in the D&#252;sseldorf Regional Court alleging infringement of a German utility model corresponding to EP '667. The proceeding has been stayed pending the outcome of proceedings that Biogen has filed in the German Patent and Trademark Office to cancel the utility model. No hearing has been set in the cancellation proceedings.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Qui Tam Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In September 2022, without admitting any liability, we agreed to pay $900.0 million to settle previously disclosed litigation unsealed in July 2015 and filed by Michael Bawduniak on behalf of the U.S. and certain states in the U.S. District Court for the District of Massachusetts alleging violations of the federal False Claims Act and state law counterparts. In October 2022 the court dismissed the case with prejudice.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Dispute with Former Convergence Shareholders</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ERISA Class Action Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan, alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts, alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. The Company also received a civil investigative demand from the Federal Trade Commission (FTC) and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#8217;s approval and ADUHELM&#8217;s marketing. In July 2022 the FTC informed us that it had closed its investigation.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TECFIDERA Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022 the U.S. Supreme Court denied our petition for writ of certiorari for review of the previously disclosed decision of the U.S. Court of Appeals for the Federal Circuit holding that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid. Thereafter, we moved to dismiss our appeals from the judgments in the previously disclosed Delaware Actions, and we and Mylan Pharmaceuticals, Inc. (Mylan) agreed that the judgment in our favor in the previously reported </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review filed by Mylan in 2018 should be vacated.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">TYSABRI Patent Matters</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc. and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement, following our receipt of Sandoz inc.'s notice of intent to commercially market a biosimilar version of TYSABRI (natalizumab). No trial date has been set.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent), which covers administration of natalizumab to treat MS and expires in February 2023. A hearing has been set for November 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 Polpharma Biologics S.A. brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has not been scheduled.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021 the EPO revoked the EP &#8216;967 Patent. A hearing on our appeal to the TBA of the EPO is set for December 2022.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#8216;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#8217;s proposed natalizumab biosimilar. A hearing has been set for February 2023.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annulment Proceedings in the General Court of the European Union relating to TECFIDERA</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.</span></div><div style="margin-top:9pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675956000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTS<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675769232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Dispositions</a></td>
<td class="text">DISPOSITIONS <div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics). Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of this transaction. </span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to the sale, the carrying value</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of our investment in Samsung Bioepis totaled $581.6&#160;million. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022, we recognized a pre-tax gain of approximately $1.5&#160;billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accumulated other comprehensive income (loss)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to net income of approximately $58.9&#160;million in cumulative translation losses, partially offset by approximately $57.0&#160;million in gains resulting from the termination of our net investment hedge.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our condensed consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of September 30, 2022, the estimated fair values of the first and second payments using risk-adjusted discount rates of 4.9% and 5.3%, respectively, were approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$790.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$402.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, respectively. These payments have been classified as level 3 measurements and are reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">months ended September 30, 2022, we recognized a gain of approximately $2.7&#160;million and a loss of approximately $4.0&#160;million to reflect the changes in fair value related to our first and second payments, respectively. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any payments due to us remain outstanding after the second anniversary of the closing of this transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for the nine months ended September 30, 2022, we recorded a discrete tax expense of approximately $258.3&#160;million related to this transaction, which is reflected in income tax (benefit) expense in our condensed consolidated statements of income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=2122178<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303674773872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Overview</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18, Collaborative and Other Relationships,</span> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements</span></div>In June 2022 the FASB issued Accounting Standards Update (ASU) No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676114032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2022:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:82.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.545%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303678842096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">92.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">339.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">256.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">299.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">319.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">619.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">301.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">86.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">336.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">273.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">505.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">281.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">241.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,340.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">833.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">722.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,556.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">139.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">444.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">120.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">850.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,111.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,962.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">973.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,232.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,205.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the United States (U.S.) in June 2022 and became commercially available during the third quarter of 2022.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis (MS):</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">330.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,146.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">520.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,465.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">713.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">836.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,549.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">805.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">945.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,750.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">743.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">636.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">286.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">923.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">252.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">608.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">995.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">751.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,188.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">693.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,542.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">696.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,550.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: MS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,170.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,990.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,161.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,410.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,157.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,568.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">891.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,334.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">437.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,464.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">340.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">576.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">610.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FUMADERM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ADUHELM</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,619.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,463.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,083.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,850.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,802.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,653.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.7&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">759.6&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">499.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,993.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,501.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(379.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,442.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,821.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(124.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(463.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">829.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:5pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">983.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">498.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OCREVUS and other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">269.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">838.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">745.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">416.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">415.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,252.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,244.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.286%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from collaborative and other relationships:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other royalty and corporate revenue:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other corporate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">114.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">314.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">350.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675856288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">394.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">349.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">771.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">814.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,375.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,351.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Work in process inventory as of September 30, 2022, includes approximately $118.0&#160;million related to lecanemab.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675839344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.257%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.383%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.396%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.659%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.669%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4-28 years</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,415.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,579.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,835.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,413.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,024.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,588.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,579.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,008.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,609.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,388.5)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,221.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,761.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,741.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675774976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,219.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">702.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">790.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Receivable from Samsung BioLogics</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">402.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,605.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,515.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,193.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">218.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant&#160;Other<br/>Observable&#160;Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,108.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">866.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,228.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,046.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">219.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%">December 31, 2021</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" rowspan="2" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">4.50&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">2023 to 2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.625% Senior Notes due September 15, 2022</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,020.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">999.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,697.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,744.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,895.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,742.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,183.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,492.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">997.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,100.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,463.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,099.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">965.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,457.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,473.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">452.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,296.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,279.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,004.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,273.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Our 3.625% Senior Notes due September 15, 2022, were redeemed in full in July 2022. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair value of contingent consideration obligations</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:41.757%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.412%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">226.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">209.1&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">195.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">210.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680330448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Overnight reverse repurchase agreements</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,070.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">901.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">283.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,191.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,632.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">833.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">826.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">400.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">412.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">408.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">177.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,122.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(27.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,095.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(237.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">896.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">723.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">817.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">816.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">377.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">376.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mortgage and other asset backed securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,004.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,167.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">160.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(279.4)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,048.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Summary of contractual maturities: available-for-sale securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:41.924%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.413%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,235.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,245.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,541.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">848.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">864.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">868.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">870.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due after five years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,095.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,122.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,433.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,435.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock', window );">Proceeds from marketable debt securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.245%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Proceeds from maturities and sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,643.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">575.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,104.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,028.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized gains</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Realized losses</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized gains and losses on investments reported in the statement of income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676201088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,089.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,828.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Japanese yen</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,208.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,126.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.980%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.195%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.202%"/><td style="width:0.1%"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Effective Portion) (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) <br/>(in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Recognized in Net Income <br/>(Amounts Excluded from Effectiveness Testing) (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Net Investment Hedging Instruments:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676003392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.2)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">53.8&#160;</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.0)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(106.7)</span></td><td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">204.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(154.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(125.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(38.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(97.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(95.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(234.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(163.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.696%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.002%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.466%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.859%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gains (Losses) on Net Investment Hedges, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized gains (losses) on pension benefit obligation, Net of Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(66.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(46.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(299.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">205.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(62.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.6)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.964%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.730%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on securities available for sale</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(68.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax benefit (expense)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on net investment hedges</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(58.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(63.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675837888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,134.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">329.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,496.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,187.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">144.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670094448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development </span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">157.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">201.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675863648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.671%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sale of Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune tax impacts</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(36.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">International reorganization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303676035616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of equity interest in Samsung Bioepis</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,505.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(23.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">191.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">187.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(101.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">707.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(56.0)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">502.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(221.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">913.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Dispositions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div>(<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">705.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(109.3)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">426.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">715.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis Pharmaceuticals, Inc. (Ionis), Sangamo and Denali common stock of approximately $112.5&#160;million.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Litigation settlement agreement</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">900.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">854.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">802.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">260.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">324.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">208.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">313.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">769.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">828.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,305.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,535.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation settlement agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675198576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">264.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">236.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Lecanemab Collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock', window );">Summary of Activity Related to Aducanumab Collaboration</a></td>
<td class="text">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">116.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">63.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">73.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">83.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">211.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total ADUHELM collaboration third party milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to this collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:56.794%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.701%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303678878432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303674728528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 124.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_GainLossOnRestructuringCharges', window );">Gain due to lease termination</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Accelerated depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Other restructuring costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainLossOnRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Restructuring Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainLossOnRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303672044320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 15.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 124.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveAccrualAdjustment1', window );">Foreign currency and other adjustments</a></td>
<td class="num">(1.3)<span></span>
</td>
<td class="num">$ (0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember', window );">Workforce Reduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">52.2<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">21.6<span></span>
</td>
<td class="nump">60.9<span></span>
</td>
<td class="nump">27.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(32.3)<span></span>
</td>
<td class="num">(29.7)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 52.2<span></span>
</td>
<td class="nump">$ 21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAccrualAdjustment1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAccrualAdjustment1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=biib_WorkforceReductionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669295584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,340.3<span></span>
</td>
<td class="nump">1,556.0<span></span>
</td>
<td class="nump">4,161.4<span></span>
</td>
<td class="nump">4,568.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">707.9<span></span>
</td>
<td class="nump">833.4<span></span>
</td>
<td class="nump">2,170.7<span></span>
</td>
<td class="nump">2,410.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">632.4<span></span>
</td>
<td class="nump">722.6<span></span>
</td>
<td class="nump">1,990.7<span></span>
</td>
<td class="nump">2,157.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">476.8<span></span>
</td>
<td class="nump">619.5<span></span>
</td>
<td class="nump">1,549.4<span></span>
</td>
<td class="nump">1,750.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">220.4<span></span>
</td>
<td class="nump">299.9<span></span>
</td>
<td class="nump">713.3<span></span>
</td>
<td class="nump">805.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">256.4<span></span>
</td>
<td class="nump">319.6<span></span>
</td>
<td class="nump">836.1<span></span>
</td>
<td class="nump">945.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">339.0<span></span>
</td>
<td class="nump">498.6<span></span>
</td>
<td class="nump">1,146.8<span></span>
</td>
<td class="nump">1,465.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">92.5<span></span>
</td>
<td class="nump">179.2<span></span>
</td>
<td class="nump">330.3<span></span>
</td>
<td class="nump">520.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">246.5<span></span>
</td>
<td class="nump">319.4<span></span>
</td>
<td class="nump">816.5<span></span>
</td>
<td class="nump">945.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">137.8<span></span>
</td>
<td class="nump">120.9<span></span>
</td>
<td class="nump">402.6<span></span>
</td>
<td class="nump">285.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">127.9<span></span>
</td>
<td class="nump">120.7<span></span>
</td>
<td class="nump">383.0<span></span>
</td>
<td class="nump">285.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">9.9<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">19.6<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">336.0<span></span>
</td>
<td class="nump">387.5<span></span>
</td>
<td class="nump">995.8<span></span>
</td>
<td class="nump">1,188.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">214.5<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
<td class="nump">608.0<span></span>
</td>
<td class="nump">751.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">121.5<span></span>
</td>
<td class="nump">135.1<span></span>
</td>
<td class="nump">387.8<span></span>
</td>
<td class="nump">436.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">255.1<span></span>
</td>
<td class="nump">301.3<span></span>
</td>
<td class="nump">743.4<span></span>
</td>
<td class="nump">923.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">174.8<span></span>
</td>
<td class="nump">213.2<span></span>
</td>
<td class="nump">493.8<span></span>
</td>
<td class="nump">636.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">80.3<span></span>
</td>
<td class="nump">88.1<span></span>
</td>
<td class="nump">249.6<span></span>
</td>
<td class="nump">286.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">80.9<span></span>
</td>
<td class="nump">86.2<span></span>
</td>
<td class="nump">252.4<span></span>
</td>
<td class="nump">265.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">39.7<span></span>
</td>
<td class="nump">39.2<span></span>
</td>
<td class="nump">114.2<span></span>
</td>
<td class="nump">115.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">41.2<span></span>
</td>
<td class="nump">47.0<span></span>
</td>
<td class="nump">138.2<span></span>
</td>
<td class="nump">149.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">505.5<span></span>
</td>
<td class="nump">522.8<span></span>
</td>
<td class="nump">1,542.5<span></span>
</td>
<td class="nump">1,550.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">273.0<span></span>
</td>
<td class="nump">281.1<span></span>
</td>
<td class="nump">849.4<span></span>
</td>
<td class="nump">854.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">232.5<span></span>
</td>
<td class="nump">241.7<span></span>
</td>
<td class="nump">693.1<span></span>
</td>
<td class="nump">696.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
<td class="nump">78.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">26.2<span></span>
</td>
<td class="nump">73.7<span></span>
</td>
<td class="nump">78.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">431.1<span></span>
</td>
<td class="nump">444.1<span></span>
</td>
<td class="nump">1,334.7<span></span>
</td>
<td class="nump">1,464.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">140.2<span></span>
</td>
<td class="nump">139.8<span></span>
</td>
<td class="nump">443.3<span></span>
</td>
<td class="nump">437.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">290.9<span></span>
</td>
<td class="nump">304.3<span></span>
</td>
<td class="nump">891.4<span></span>
</td>
<td class="nump">1,026.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">187.6<span></span>
</td>
<td class="nump">202.8<span></span>
</td>
<td class="nump">576.3<span></span>
</td>
<td class="nump">610.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">186.9<span></span>
</td>
<td class="nump">202.8<span></span>
</td>
<td class="nump">575.1<span></span>
</td>
<td class="nump">610.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">110.2<span></span>
</td>
<td class="nump">120.8<span></span>
</td>
<td class="nump">340.7<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">110.2<span></span>
</td>
<td class="nump">120.8<span></span>
</td>
<td class="nump">340.7<span></span>
</td>
<td class="nump">363.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">172.4<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">57.7<span></span>
</td>
<td class="nump">57.4<span></span>
</td>
<td class="nump">172.4<span></span>
</td>
<td class="nump">170.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">19.0<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMMember', window );">FUMADERM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">1,962.1<span></span>
</td>
<td class="nump">2,205.7<span></span>
</td>
<td class="nump">6,083.3<span></span>
</td>
<td class="nump">6,653.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">850.4<span></span>
</td>
<td class="nump">973.5<span></span>
</td>
<td class="nump">2,619.7<span></span>
</td>
<td class="nump">2,850.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">$ 1,111.7<span></span>
</td>
<td class="nump">$ 1,232.2<span></span>
</td>
<td class="nump">$ 3,463.6<span></span>
</td>
<td class="nump">$ 3,802.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BYOOVIZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670427440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,501.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(28.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,821.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(602.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">983.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">137.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">499.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(379.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(124.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">130.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">759.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">1,993.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(18.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,442.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(463.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">829.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">38.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">8.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(14.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 24.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680055200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 983.9<span></span>
</td>
<td class="nump">$ 935.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">129.4<span></span>
</td>
<td class="nump">133.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 854.5<span></span>
</td>
<td class="nump">$ 802.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303678943504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">131.1<span></span>
</td>
<td class="nump">145.8<span></span>
</td>
<td class="nump">414.2<span></span>
</td>
<td class="nump">498.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">285.8<span></span>
</td>
<td class="nump">269.6<span></span>
</td>
<td class="nump">838.4<span></span>
</td>
<td class="nump">745.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 416.9<span></span>
</td>
<td class="nump">$ 415.4<span></span>
</td>
<td class="nump">$ 1,252.6<span></span>
</td>
<td class="nump">$ 1,244.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670188128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="nump">29.7<span></span>
</td>
<td class="nump">20.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">114.2<span></span>
</td>
<td class="nump">143.8<span></span>
</td>
<td class="nump">242.9<span></span>
</td>
<td class="nump">314.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">129.5<span></span>
</td>
<td class="nump">157.8<span></span>
</td>
<td class="nump">293.5<span></span>
</td>
<td class="nump">350.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative arrangement | ZINBRYTA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 6.5<span></span>
</td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_ZINBRYTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_ZINBRYTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670392976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 2,508.5<span></span>
</td>
<td class="nump">$ 2,778.9<span></span>
</td>
<td class="nump">$ 7,629.4<span></span>
</td>
<td class="nump">$ 8,247.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.90%<span></span>
</td>
<td class="nump">26.80%<span></span>
</td>
<td class="nump">29.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember', window );">Other corporate revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 114.2<span></span>
</td>
<td class="nump">$ 143.8<span></span>
</td>
<td class="nump">$ 242.9<span></span>
</td>
<td class="nump">$ 314.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Other Revenues</a></td>
<td class="nump">$ 129.5<span></span>
</td>
<td class="nump">$ 157.8<span></span>
</td>
<td class="nump">$ 293.5<span></span>
</td>
<td class="nump">$ 350.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OthercorporaterevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669150848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 394.2<span></span>
</td>
<td class="nump">$ 349.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">771.0<span></span>
</td>
<td class="nump">814.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">209.8<span></span>
</td>
<td class="nump">187.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Inventorynetcurrentandnoncurrent', window );">Total inventory</a></td>
<td class="nump">1,375.0<span></span>
</td>
<td class="nump">$ 1,351.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LecanemabMember', window );">Lecanemab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">$ 118.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Inventorynetcurrentandnoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, net current and noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Inventorynetcurrentandnoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LecanemabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LecanemabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669940896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 321.6<span></span>
</td>
<td class="nump">$ 36.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
<td class="nump">$ 214.0<span></span>
</td>
<td class="nump">$ 90.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="nump">$ 120.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 223.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">177.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Eisai | Centers for Medicare and Medicaid Service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 136.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_CentersForMedicareAndMedicaidServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669514064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Total intangible assets, gross</a></td>
<td class="nump">$ 7,588.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,588.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,609.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,579.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,579.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,388.5)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">2,008.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,008.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,221.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">56.5<span></span>
</td>
<td class="nump">$ 111.0<span></span>
</td>
<td class="nump">190.9<span></span>
</td>
<td class="nump">$ 813.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">Expected future amortization expense, 2019 (remaining three months)</a></td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">Expected future amortization expense, 2020</a></td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">215.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">Expected future amortization expense, 2021</a></td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">Expected future amortization expense, 2022</a></td>
<td class="nump">190.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">Expected future amortization expense, 2023</a></td>
<td class="nump">175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">Expected future amortization expense, 2024</a></td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">7,415.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,415.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,413.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">1,835.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,835.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,024.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(5,579.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,579.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,388.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember', window );">Completed technology | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and Trade Names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member', window );">BIIB111</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">365.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member', window );">BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember', window );">Vixotrigine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember', window );">TGN | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and Net</a></td>
<td class="nump">109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite-lived Intangible Assets (Excluding Goodwill)</a></td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member', window );">BIIB111 and BIIB112</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OutLicensedPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_VixotrigineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_TGNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_TGNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchanddevelopmentassetAxis=biib_BIIB111AndBIIB112Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303677225456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Details 1)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 5,761,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(19,900,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">5,741,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668566560">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 2,095.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,433.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 3,191.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">896.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">195.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">7,605.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,228.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">195.4<span></span>
</td>
<td class="nump">$ 197.5<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="nump">$ 210.7<span></span>
</td>
<td class="nump">$ 226.3<span></span>
</td>
<td class="nump">$ 259.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">218.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">219.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">790.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">402.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,219.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">702.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">174.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">896.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">896.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">181.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,191.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,632.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">195.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">32.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">5,515.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,046.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">22.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">1,219.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,108.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">702.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,192.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">174.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,193.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">195.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">195.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="nump">790.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="nump">402.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Mortgage and other asset backed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303677330480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 195,400,000<span></span>
</td>
<td class="nump">$ 195,400,000<span></span>
</td>
<td class="nump">$ 209,100,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_TechnologicalAndRegulatorySuccessProbability', window );">Technological and Regulatory Success, Probability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_TechnologicalAndRegulatorySuccessProbability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Technological and Regulatory Success, Probability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_TechnologicalAndRegulatorySuccessProbability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680417344">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details) - Discount rate<br></strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.0450<span></span>
</td>
<td class="nump">0.0130<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669963008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 6,279.2<span></span>
</td>
<td class="nump">$ 7,273.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFairValue', window );">Debt instruments, fair value</a></td>
<td class="nump">$ 5,296.4<span></span>
</td>
<td class="nump">8,004.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember', window );">3.625% Senior Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">1,020.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">999.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,697.8<span></span>
</td>
<td class="nump">1,895.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,744.3<span></span>
</td>
<td class="nump">1,742.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 997.2<span></span>
</td>
<td class="nump">1,475.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,100.2<span></span>
</td>
<td class="nump">1,492.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 1,183.0<span></span>
</td>
<td class="nump">1,463.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,492.7<span></span>
</td>
<td class="nump">1,099.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 965.6<span></span>
</td>
<td class="nump">1,457.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 1,473.6<span></span>
</td>
<td class="nump">1,473.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Notes payable, fair value</a></td>
<td class="nump">$ 452.8<span></span>
</td>
<td class="nump">692.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Notes payable, carrying value</a></td>
<td class="nump">$ 468.4<span></span>
</td>
<td class="nump">$ 466.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20,22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668058368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Contingent consideration impairment</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 15.6<span></span>
</td>
<td class="nump">$ 13.7<span></span>
</td>
<td class="nump">$ 49.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, beginning of period</a></td>
<td class="nump">197.5<span></span>
</td>
<td class="nump">226.3<span></span>
</td>
<td class="nump">209.1<span></span>
</td>
<td class="nump">259.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value, end of period</a></td>
<td class="nump">$ 195.4<span></span>
</td>
<td class="nump">$ 210.7<span></span>
</td>
<td class="nump">$ 195.4<span></span>
</td>
<td class="nump">$ 210.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303674477776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 3,191.8<span></span>
</td>
<td class="nump">$ 1,632.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">247.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember', window );">Overnight reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">115.5<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">3,070.6<span></span>
</td>
<td class="nump">901.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValueAbstract', window );"><strong>Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="nump">$ 283.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303674886864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,122.7<span></span>
</td>
<td class="nump">$ 2,435.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(27.0)<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">2,095.8<span></span>
</td>
<td class="nump">2,433.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,133.8<span></span>
</td>
<td class="nump">1,167.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">160.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(237.8)<span></span>
</td>
<td class="num">(279.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">896.0<span></span>
</td>
<td class="nump">1,048.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate debt securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">833.6<span></span>
</td>
<td class="nump">723.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(6.9)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">826.7<span></span>
</td>
<td class="nump">723.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember', window );">Corporate debt securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">400.5<span></span>
</td>
<td class="nump">385.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">392.4<span></span>
</td>
<td class="nump">384.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">412.1<span></span>
</td>
<td class="nump">817.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">408.7<span></span>
</td>
<td class="nump">816.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember', window );">Government securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">298.8<span></span>
</td>
<td class="nump">377.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(5.5)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">293.3<span></span>
</td>
<td class="nump">376.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember', window );">Mortgage and other asset backed securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember', window );">Mortgage and other asset backed securities Non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Marketable debt securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">177.6<span></span>
</td>
<td class="nump">131.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized losses</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value</a></td>
<td class="nump">174.6<span></span>
</td>
<td class="nump">131.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember', window );">Equity Securities, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Marketable equity securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">1,133.8<span></span>
</td>
<td class="nump">1,133.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">151.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(237.8)<span></span>
</td>
<td class="num">(279.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 896.0<span></span>
</td>
<td class="nump">$ 1,004.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670403728">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Summary of Contractual Maturities: Available-for-Sale Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less, amortized cost</a></td>
<td class="nump">$ 1,235.5<span></span>
</td>
<td class="nump">$ 1,541.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less, estimated fair value</a></td>
<td class="nump">1,245.8<span></span>
</td>
<td class="nump">1,541.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years, amortized cost</a></td>
<td class="nump">848.3<span></span>
</td>
<td class="nump">868.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years, estimated fair value</a></td>
<td class="nump">864.0<span></span>
</td>
<td class="nump">870.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost', window );">Due after five years, amortized cost</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue', window );">Due after five years, estimated fair value</a></td>
<td class="nump">12.9<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">2,095.8<span></span>
</td>
<td class="nump">2,433.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 2,122.7<span></span>
</td>
<td class="nump">$ 2,435.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680358960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details 3) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Proceeds from maturities and sales</a></td>
<td class="nump">$ 1,643.2<span></span>
</td>
<td class="nump">$ 575.4<span></span>
</td>
<td class="nump">$ 3,104.7<span></span>
</td>
<td class="nump">$ 2,028.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Realized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Realized losses</a></td>
<td class="nump">$ 7.9<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 9.3<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670189488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AverageMaturityOfMarketableSecurities', window );">Average maturity of marketable securities, months</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AverageMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Average remaining time to maturity of marketable debt securities, available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AverageMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303675799024">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments Financial Instruments (Details Textual 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 948.5<span></span>
</td>
<td class="nump">$ 1,110.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303667476240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Details)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2018 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>May 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (13.5)<span></span>
</td>
<td class="nump">$ 85.8<span></span>
</td>
<td class="num">$ (26.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="num">$ (25.5)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,268.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,208.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,126.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember', window );">Foreign Exchange Forward</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized Gain on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146.5<span></span>
</td>
<td class="nump">60.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized Loss on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized Gain (Loss) on Derivatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144.3<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax', window );">Unrealized gain (loss) on net investment hedges in AOCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax', window );">Derivative qualifying as net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease', window );">Gains (losses) on net investment hedges, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="nump">46.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease', window );">Gains (losses) on net investment hedge, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember', window );">Net Investment Hedging | Foreign exchange contract | Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
<td class="num">(68.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Revenue | Cash flows, revenue | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember', window );">Operating expense | Cash flows, operating expenses | Foreign exchange contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Gain on interest rate swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other income (expense) | Net Investment Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet', window );">Gain (loss) recognized in net income, excluded component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,828.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_JPY', window );">Japan, Yen | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar | Foreign exchange contract | Designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, Notional Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction', window );">Percentage of stake in entity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireEquityMethodInvestments', window );">Payments to acquire additional investment in equity method investment</a></td>
<td class="nump">$ 676.6<span></span>
</td>
<td class="nump">&#8361; 759.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember', window );">Short-term derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Range of durations of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax', window );">Gain/Loss on fair value of foreign currency forward contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80784-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1),(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121577467&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_JPY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_JPY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeMaturityAxis=biib_ShorttermderivativeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668528608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,098.0<span></span>
</td>
<td class="nump">$ 2,098.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,098.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,006.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64.2<span></span>
</td>
<td class="nump">$ 65.1<span></span>
</td>
<td class="nump">207.7<span></span>
</td>
<td class="nump">$ 168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">582.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">503.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,266.4<span></span>
</td>
<td class="nump">3,266.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,266.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,416.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingMember', window );">125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Sales price</a></td>
<td class="nump">603.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance', window );">Tenant allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of building</a></td>
<td class="nump">503.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">79.2<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Building | 125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">72.6<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land | 125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and Equipment | 125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember', window );">Biologics Manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">393,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember', window );">Warehouse, Utilities and Support Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember', window );">Administrative Space</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfSquareFeet', window );">Number of square feet | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember', window );">Solothurn, Switzerland</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">701.0<span></span>
</td>
<td class="nump">701.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 701.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 677.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Fixed assets placed into service</a></td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfSquareFeet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Square Feet</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfSquareFeet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=biib_A125BroadwayBuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_BiologicsManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_BiologicsManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_WarehouseUtilitiesAndSupportSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityTypeAxis=biib_AdministrativeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityTypeAxis=biib_AdministrativeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FacilityLocationAxis=biib_SolothurnSwitzerlandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303680183040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 424.5<span></span>
</td>
<td class="nump">$ 375.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseRightOfUseAssetDerecognized', window );">Right-of-use assets derecognized</a></td>
<td class="nump">47.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseLiabilityDerecognized', window );">Lease liabilities derecognized</a></td>
<td class="nump">52.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_GainLossOnRestructuringCharges', window );">Gain due to lease termination</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">125 Broadway Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">$ 168.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 168.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_GainLossOnRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Restructuring Charges</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_GainLossOnRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseLiabilityDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, Derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseLiabilityDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseRightOfUseAssetDerecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Derecognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseRightOfUseAssetDerecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670235904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2022</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 15, 2022</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionRate', window );">Redemption rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.92%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Extinguishment of Debt, Amount</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 151.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.9<span></span>
</td>
<td class="nump">$ 66.3<span></span>
</td>
<td class="nump">$ 191.8<span></span>
</td>
<td class="nump">$ 187.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Repayments of Senior Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DebtInstrumentRedemptionAmount', window );">Debt Instrument, Redemption, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">624.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Gain (Loss) on Extinguishment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Repayments of borrowings and premiums paid on debt exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member', window );">3.250% Senior Notes, Due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Senior notes interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_LongTermDebtExchangedAmount', window );">Long Term Debt, Exchanged, Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentRedemptionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Redemption Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentRedemptionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LongTermDebtExchangedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long Term Debt, Exchanged, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LongTermDebtExchangedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467658&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3250SeniorNotesDueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303679873568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share Repurchases (Details) - USD ($)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 750,000,000.0<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock Repurchase Program, Authorized Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost, shares</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 750,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669413328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (106.7)<span></span>
</td>
<td class="num">$ (299.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">$ (163.6)<span></span>
</td>
<td class="num">$ (136.6)<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.4<span></span>
</td>
<td class="nump">99.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97.3)<span></span>
</td>
<td class="nump">63.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="nump">163.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(163.6)<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
<td class="num">(163.6)<span></span>
</td>
<td class="num">(136.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(53.2)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
<td class="num">(56.9)<span></span>
</td>
<td class="nump">162.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.2)<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(26.4)<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19.0)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="num">(179.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">204.5<span></span>
</td>
<td class="nump">143.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(125.5)<span></span>
</td>
<td class="nump">62.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.0<span></span>
</td>
<td class="nump">205.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
<td class="nump">26.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.5<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(38.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(25.5)<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">26.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(44.8)<span></span>
</td>
<td class="num">(66.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(62.4)<span></span>
</td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(62.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(62.4)<span></span>
</td>
<td class="num">(40.6)<span></span>
</td>
<td class="num">(62.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(139.0)<span></span>
</td>
<td class="num">(46.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Balance, January 1, 2018</a></td>
<td class="num">(234.6)<span></span>
</td>
<td class="num">(126.9)<span></span>
</td>
<td class="num">(234.6)<span></span>
</td>
<td class="num">(126.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax', window );">Other comprehensive income (loss), before reclassifications, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(154.5)<span></span>
</td>
<td class="num">(80.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax', window );">Amounts reclassified from accumulated other comprehensive income, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(95.6)<span></span>
</td>
<td class="num">(80.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss), net of tax ending balance</a></td>
<td class="num">$ (234.6)<span></span>
</td>
<td class="num">$ (126.9)<span></span>
</td>
<td class="num">$ (234.6)<span></span>
</td>
<td class="num">$ (126.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668527792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="num">$ (502.9)<span></span>
</td>
<td class="nump">$ 221.3<span></span>
</td>
<td class="num">$ (913.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">236.2<span></span>
</td>
<td class="num">(25.9)<span></span>
</td>
<td class="nump">578.5<span></span>
</td>
<td class="num">(390.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">2,508.5<span></span>
</td>
<td class="nump">2,778.9<span></span>
</td>
<td class="nump">7,629.4<span></span>
</td>
<td class="nump">8,247.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">329.2<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
<td class="nump">1,187.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 62.8<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="nump">$ 97.3<span></span>
</td>
<td class="num">(63.0)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gains (losses) on securities available for sale | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(8.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Unrealized gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="num">(14.0)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Product revenues</a></td>
<td class="nump">77.7<span></span>
</td>
<td class="num">(14.9)<span></span>
</td>
<td class="nump">143.2<span></span>
</td>
<td class="num">(68.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(3.5)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Gains (losses) on net investment hedge | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">38.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember', window );">Currency Translation Adjustments | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (58.9)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669159680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 1,134.7<span></span>
</td>
<td class="nump">$ 329.2<span></span>
</td>
<td class="nump">$ 2,496.5<span></span>
</td>
<td class="nump">$ 1,187.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">144,400<span></span>
</td>
<td class="nump">148,000<span></span>
</td>
<td class="nump">145,800<span></span>
</td>
<td class="nump">149,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">144,800<span></span>
</td>
<td class="nump">148,600<span></span>
</td>
<td class="nump">146,200<span></span>
</td>
<td class="nump">150,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669177728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (65.7)<span></span>
</td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="num">$ (194.1)<span></span>
</td>
<td class="num">$ (186.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">194.8<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(13.0)<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="num">(36.0)<span></span>
</td>
<td class="num">(35.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="nump">72.6<span></span>
</td>
<td class="nump">72.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">46.5<span></span>
</td>
<td class="nump">42.6<span></span>
</td>
<td class="nump">129.3<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Total share-based compensation expense, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 56.0<span></span>
</td>
<td class="nump">$ 49.3<span></span>
</td>
<td class="nump">$ 158.8<span></span>
</td>
<td class="nump">$ 157.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669211776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Details 1) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="num">$ (65.7)<span></span>
</td>
<td class="num">$ (57.6)<span></span>
</td>
<td class="num">$ (194.1)<span></span>
</td>
<td class="num">$ (186.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">201.9<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(6.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total costs and expenses</a></td>
<td class="nump">69.0<span></span>
</td>
<td class="nump">60.2<span></span>
</td>
<td class="nump">194.8<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">4.0<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="nump">35.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">48.7<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
<td class="nump">150.4<span></span>
</td>
<td class="nump">121.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">10.5<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">22.1<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">13.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 10.1<span></span>
</td>
<td class="nump">$ 14.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303667422160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes (Details Textual)<br> $ in Millions, &#8361; in Billions</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 390.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 713.3<span></span>
</td>
<td class="nump">$ 599.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 455.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669166880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">1.90%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings</a></td>
<td class="num">(3.40%)<span></span>
</td>
<td class="num">(20.20%)<span></span>
</td>
<td class="num">(4.40%)<span></span>
</td>
<td class="num">(11.50%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Credits and net operating loss utilization</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(7.10%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="num">(4.10%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased intangible assets</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(6.20%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationGILTItax', window );">GILTI</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis', window );">Sale of Samsung Bioepis</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationLitigationAgreement', window );">Litigation settlement agreement</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts', window );">Neurimmune tax impacts</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.005)<span></span>
</td>
<td class="nump">0.028<span></span>
</td>
<td class="num">(0.364)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationInternationalReorganization', window );">International reorganization</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">17.20%<span></span>
</td>
<td class="num">(8.90%)<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
<td class="num">(29.20%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationGILTItax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, GILTI tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationGILTItax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationInternationalReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, International Reorganization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationInternationalReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationLitigationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Litigation Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationLitigationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, NuerImmune Tax Impacts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669842144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNetAbstract', window );"><strong>Other Income (Expense), Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Gain on sale of equity interest in Samsung Bioepis(1)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (1,505.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement agreement</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(23.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="num">(39.4)<span></span>
</td>
<td class="num">(8.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.3<span></span>
</td>
<td class="nump">191.8<span></span>
</td>
<td class="nump">187.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">(Gains) losses on investments, net</a></td>
<td class="num">(101.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.5<span></span>
</td>
<td class="nump">167.5<span></span>
</td>
<td class="nump">707.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange (gains) losses, net</a></td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.7<span></span>
</td>
<td class="nump">39.0<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">25.2<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense</a></td>
<td class="num">(56.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">502.9<span></span>
</td>
<td class="num">(221.3)<span></span>
</td>
<td class="nump">913.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains) losses recognized on equity securities</a></td>
<td class="num">(109.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424.2<span></span>
</td>
<td class="nump">158.1<span></span>
</td>
<td class="nump">705.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains) losses realized on equity securities</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="num">(109.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 426.9<span></span>
</td>
<td class="nump">158.1<span></span>
</td>
<td class="nump">$ 715.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SettlementLiabilitiesCurrent', window );">Litigation settlement agreement(1)</a></td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">983.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">983.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">935.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Collaboration expense</a></td>
<td class="nump">313.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">208.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">234.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">260.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">260.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">324.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">769.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">769.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">828.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">3,305.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,305.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,535.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract', window );"><strong>Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">198.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Expenses and Other</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 854.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 854.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 802.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=120253306&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04.3(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SettlementLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SettlementLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668203104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="num">$ (109.3)<span></span>
</td>
<td class="nump">$ 426.9<span></span>
</td>
<td class="nump">$ 158.1<span></span>
</td>
<td class="nump">$ 715.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Net gains (losses) realized during the period on equity securities</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="num">$ (2.7)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">$ (9.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">1,198.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,198.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,320.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">559.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">559.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember', window );">Ionis, Sangamo, Denali and Sage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net gains recognized on the increase in fair value of equity securities</a></td>
<td class="nump">$ 112.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 198.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123583765&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_IonisSangamoDenaliAndSageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670582800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Collaborations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 702.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,629.5<span></span>
</td>
<td class="nump">$ 1,801.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">469.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">511.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,707.4<span></span>
</td>
<td class="nump">1,449.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentForAmortization', window );">Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 275.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM | Maximum | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214.0<span></span>
</td>
<td class="nump">90.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 285.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Expense Incurred By Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">118.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264.9<span></span>
</td>
<td class="nump">236.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132.5<span></span>
</td>
<td class="nump">118.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueFromRelatedParties', window );">Due from Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContingentCommercializedRightsNumberOfProducts', window );">Contingent Commercialized Rights, Number Of Products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember', window );">Sangamo Therapeutics, Inc. Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Termofcollaborationagreement', window );">Term of collaboration agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember', window );">Other research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and Development Expense (Excluding Acquired in Process Cost)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51.5<span></span>
</td>
<td class="nump">84.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember', window );">InnoCare Pharma Limited (InnoCare) Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner', window );">Contingent additional milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">116.0<span></span>
</td>
<td class="nump">132.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63.8<span></span>
</td>
<td class="nump">73.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.0<span></span>
</td>
<td class="nump">27.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.5<span></span>
</td>
<td class="nump">16.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16.4<span></span>
</td>
<td class="nump">16.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.4<span></span>
</td>
<td class="nump">134.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">65.2<span></span>
</td>
<td class="nump">67.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | UCB Pharma S.A. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.5<span></span>
</td>
<td class="nump">49.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.7<span></span>
</td>
<td class="nump">24.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | BAN2401 and Elenbecestat</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.3<span></span>
</td>
<td class="nump">15.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.2<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">154.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
<td class="nump">391.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.1<span></span>
</td>
<td class="nump">211.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Sage Therapeutics Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69.9<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.9<span></span>
</td>
<td class="nump">$ 11.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentCommercializedRightsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Commercialized Rights, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentCommercializedRightsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Milestone Payments Made To Collaborative Partner</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Termofcollaborationagreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Termofcollaborationagreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentForAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentForAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsInc.AgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_OtherresearchanddiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_InnoCarePharmaLimitedInnoCareAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaS.A.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668901616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Equity Method Investments (Details)<br> &#8361; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>KRW (&#8361;)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 07, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42.6)<span></span>
</td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ADUHELMMember', window );">ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Percentage of stake in entity maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Amortization of basis differences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 675.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions', window );">Loss recorded on Samsung Bioepis joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="nump">39.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 599.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 713,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit (loss) sharing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">171.4<span></span>
</td>
<td class="nump">210.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214.0<span></span>
</td>
<td class="nump">$ 90.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Income (loss) from equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 177.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Investment in Samsung Bioepis | &#8361;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8361; 581.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Equity Method Investments, Expected Profit Share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone payments made to collaborative partner</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssets', window );">Prepaid research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccruedMilestonePayments', window );">Accrued milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 180.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Contract Option Exercise Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent', window );">Due to Related Parties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember', window );">Inventory | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed technology | Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod', window );">Equity method investment basis difference amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccruedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccruedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Equitymethodinvestmentbasisdifferenceamortizationperiod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity method investment basis difference amortization period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Equitymethodinvestmentbasisdifferenceamortizationperiod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(3),(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303670473824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="nump">$ 17.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Deferred tax assets, unrecognized tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">390.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember', window );">Neurimmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborationAgreementTerm', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchAndDevelopmentCostsPercentage', window );">Research and development costs, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
<td class="nump">$ 214.0<span></span>
</td>
<td class="nump">90.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai', window );">Percentage of future development costs related to Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">(Gain) loss on equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59.0<span></span>
</td>
<td class="nump">45.0<span></span>
</td>
<td class="nump">$ 45.0<span></span>
</td>
<td class="nump">177.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai | Regulatory Milestones | Neurimmune | ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityLineItems', window );"><strong>Variable Interest Entity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborationAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborationAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageoffuturedevelopmentcostsrelatedtoEisai">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of future development costs related to Eisai</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageoffuturedevelopmentcostsrelatedtoEisai</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentCostsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Costs, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentCostsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=biib_NeurimmuneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303669946896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation agreement in principle</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 900.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss Contingency, Estimate of Possible Loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2.2</span><table class="report" border="0" cellspacing="2" id="idm140303668876064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions (Details Textual)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,505.4)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsCurrentFairValueDisclosure', window );">Other current assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 790.8<span></span>
</td>
<td class="nump">$ 790.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsFairValueDisclosure', window );">Other assets, receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 402.8<span></span>
</td>
<td class="nump">$ 402.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary | Discount rate | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsMeasurementInput', window );">Risk-adjusted discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.049<span></span>
</td>
<td class="nump">0.049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary | Discount rate | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherAssetsMeasurementInput', window );">Risk-adjusted discount rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.053<span></span>
</td>
<td class="nump">0.053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfInvestments', window );">Gain on sale of equity interest in Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Cumulative translation loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Gain on derivative used in net investment hedge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdditionalMilestonePayment', window );">Additional milestone payment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent', window );">Contingent discount on common shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DiscreteIncomeTaxExpenseBenefit', window );">Discrete income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 258.3<span></span>
</td>
<td class="nump">$ 258.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdditionalMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional milestone payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdditionalMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DiscreteIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Discrete Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DiscreteIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Current, Fair Value Disclosure,</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherAssetsMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Assets, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherAssetsMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of other assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>biib-20220930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20220930"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:currency="http://xbrl.sec.gov/currency/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20220930.xsd" xlink:type="simple"/>
    <context id="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8b9473308ccd44839cb2a3b16f056f1e_I20221024">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-10-24</instant>
        </period>
    </context>
    <context id="if8b5bc83e8644cd983699f6fb8858208_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if551793810f14521aa422baeecc3bfbf_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i64c2a0bb31734409bb0e29d39fc13bae_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2765e6631dd6439f847c09bcca089302_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id677ff3bfec54adbaa112244fd4799d4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i31f777fcba294e1981f4bbec61fe6842_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie1bc6e1753ff4db990730bfcea938673_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i07dd344004654602b840c7084123794f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i599788f95f5d42d1afd8d372967a5f5d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c6c0f5fe10b475babd385cc9a5f1933_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i01501338195d4d64b3297f4c712b4a35_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i76bd2bb0d53b471685923452d6735342_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i79e041e2494c45019e324230082e286e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id7caa4287cd44462b9d9cd33c1545d15_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6cac6a36cb7544188ce0dee2256caca4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia953e5a0fc224c8c9f234d2c963d4105_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i957729f8711844ff89317163bd3b28ee_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if1aee04605d242bfb83b7fe9c6cb1edc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i835d8ccc4e79473b96d3739d3fc0f451_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id36ae3eeb09d4b00b8023ee15c29a104_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i385b6988b4664d52a88f8aaf055e4153_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i3df7f5528d01483d85bf88ee051bf26a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie99add0e88f54844bcc4c75b8cdd5670_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibedabc034ea240c0b3ac08428570bb02_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i2a2bd09b86954ad5a4bee8091dd95fdf_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idd70f96bb3774f148eea2bb8f9432dc4_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i239d15fce1e540cea5ec4ef251ea8908_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib92b65c6517c4a3480678a0a31182921_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i66f984c3b15d4a31acd93e52732606cb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic367eb9333f6492b83e15ec443ce582f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i702681f6e9854a2c9237a3f37fa30d3a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i759633f59042448b81434c16a76b3557_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47eb6434b4184bf1862e2d8683e198b4_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icfdf3c77bb8d4707b6431886367684a2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i52b178fd120d412a861501afee397e6e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i47664e2a665d414a81f45b227301ee8b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaef22786954a47d5be08054078b6dbc6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib5068c3b18e94e8eaaf2091ea3cf9695_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7e0fa57a6c3f4fa4942ba9c62ac16a53_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5b3d30bc29ae41cb9335a4b23f385945_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3caac96ac07546cc86bfb686908d7b3e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie2a2cbbf2a9947cc889f57763f6fb24a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7ac4673c093c48e281f08d7e26c19005_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id54e452525014575861abb8575bfa40f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6150f5ddab6c45c9aa1fbef55937177e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i06a5ef7f9cda42e78d300b36e9338315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7cee2e97b0274d3aa6084ff72dceb5e3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibfaaee5621ff405286fd6056576cd59b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if66f99b3393445feb052472c42d6ea59_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2e74df0a4fa34fa7b4d9f15ccfa2ccce_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3990a5fbd8c6491e91e119ed2fdea887_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i823c7f9f43d342ba884251bf9f5bd146_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic891f4015650489eb42c53e2bfc38c39_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4e12504ff04743d888a4e88d3bff71b4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia0e15bd993a74d7398c821d849b6ea3c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia7258ddc589f4c9088e286caf7f6e0b7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4495699cfde945d2a01834b568e58db0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i016bab72022342ff94ff7761ad5e759f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i40f04ec35e4e4acb994f1e07cc20f981_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6ecf9467f994f5599b5246c048da7f0_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="if30d21aaea274bffaf4cb30ef1f8e3dc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5fb9684f2f3649a1bffccb6af71ea857_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i49fb8433ee7144e590c0de93a2924ac6_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ie8eac1696a0f401e8764ac4f1f27de37_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib4194d914ec04ff093919ddd1c085893_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ib55ef7924a674515889fe70f6b17eb7f_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i71feb4d0055c4b68bbe964b0257e980a_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5de6cf32968c4297a40eb09bdeb942bc_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i21588e5af69246eb8bf060b182d4cef9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e1be32983094b30a756db2fdf7ba492_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i830fd3fe92594ddca8ffd711b4e954ed_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i142a8abed9f24909ac2458987495c92a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ied6c3cb168af4d3f93e74f6073e0a218_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4d3c54dd7e9843cea195c454def9d2ee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5351af1a8e574e448a3647a4f7afd7b0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i940fb720af7649c3b174e6131bd6809b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iacd07c7062014cc6810ba0fe03987501_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic3a55df4cbc94d0f84173632a99327a0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i654c8bf1e47f4749b94d94eb9db91cad_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i986fcf8b728f45a5aade17658c08c927_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie7fcd64658864191b6d0041174b23749_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7543833405d140a9b03a3c2c4959f28c_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i97905b3b54ce40cb912f87e63e0db92d_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i2e04c673b4ba4bfeb809934ced292e5b_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="id028a6bff3b24d2f9b0854cfb01e2f33_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iddcd0ac5de004c8584ccf204981e3c5a_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="if91d142efb024f1784dcfc0a7ba633de_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i1ae20d5729dc44e2bbeb4f64c73911df_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i85003cc1f8c04f36b4ffbbf6882c9e1e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie9e6a8dcb7c44e968654b2542e3eba4c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ida229f85edf14616bba475cf65eab0e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ide8a35ebfa6c49c4940e18829274b634_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i672dd8e6f6974a0681e2532e151fe07d_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7764d2904f084d0487b1c7d0a1c60a98_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i9d65d2e85cb14209a4f5a5f72eaf1a06_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id80ceaef197d43efbe8a7cb665f36bd3_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5a8c604e337a41529c5ebe37e6e83167_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib7dcf494036c4e47bb9cb906a08568a5_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i66de57d0942e46cfb25b1d0f1fd008d1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idbd356e38fd146938c9d48f464ee5866_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i07d6d89e16864773a22d6d824c32ffd4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iac062867190e40d291330b2582dde77d_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i316ee61fce71448090e9e99d3e03605f_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i607186b7dfc843688ebf32e0578fc19b_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="ie8da0e6904f247e0a072f97c4201c43b_I20220131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-31</instant>
        </period>
    </context>
    <context id="i30e4e1687d1446f2a418d8e2edce385e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic1f7ed163c5b4dc1a6bbd9abf449fa0f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0f5bb12cf4d14733835facacabb3cc9b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iba57778587524c7389b5d85413395030_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i50d36a66d9ab43cdb58d18874e1a3785_D20230101-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i61ca34953d844cb0860dc038de00e235_D20230101-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic1f37877cc204468be6364c936821118_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d680499749847fbb5726594897a6967_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iea6f6f793edc47d08a4cb4fbe2bea78d_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i1f41754e9d7e480eb6a52dc448c1e2bc_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibe53d000d3d24ab085f9e7a60f3038fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i50e9ef276762476587698a382951d243_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i75d90b3006f344218e928d1ad4dfdd95_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">biib:WorkforceReductionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ieae68b14dd844654b97d8e0821a7d63d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia678bb0bdba34f6d8468b6ea458c7c67_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idee5f0f1a0fc412eac579e1d0b56f5c0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i524a5a89350540a3bc0f4b10a71bb6aa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i94cd8b6ab6a24b2d8c28a1fef87c6153_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia14b4c4bce6a4909a76b690dbb1dda86_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i052a675de8aa4e5d9832465ff8570284_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibada012125344986aaa29e2b44e3995b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iecc52be6137340a5b547b2482e77071b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30f15676d39144d6be62e0983a2c677d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17d433d159ae4a1ab0cd0e666f0067b5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i86dce0a14ccd4ac7b68ee2512c78b229_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if5d02c3121d046fa80f33ce0ea159f1b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id90d2fa8645d41c59b47948a99c4c9a8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifeb6cdfb945042ec929ed76602fc0d41_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic82f6ca075b24e908f242a5f756da00b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0112f1abc12545e994f30a836d2cb12f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6a4811b664994d1a81bade00a2863057_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2775701ccced4d349950476cf4ac935f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib9e8c8756b2146eca09944df5c248397_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie5abd26923c541018c31b313875f2f0a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i54d1f43c44b042958f27d4875e2c518e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8c9d7081eeb3425aaab5ae1f08229ad0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9e3fe4bcdeb74d82a40d4194dfecf8e0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i22a55754206442b9ad7d2a15bb0c2ed8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1539f85dca834b21b083a5841069d1f9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i413272e3f9254d67a44927e69cdc2477_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if1260db1e62944da8c762971630a803f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8a6c9354a1594ed984122907bfaf64d9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icd1a7dde2606420ab2beaa988524cc5e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i67dbc5422bc347699fed7d1ba9192ef3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib54b6aedfcba481d9b05a81e2c49254c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4a3f69c1b08b48a7ad41ca04403e0c5c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9c8b237efb1e4c6bb345fa501d512b04_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i35666f9afdf94c86b0dadb5d20099aa4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2eff75aba234462e895ad96c0ec0c13c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ieca6a0988c1143f78d17d64f36bd59d0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7f4ebfef6a604efa9a0c65992472c0d7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib4b9ad0869ff4c3fb817b4710e10a630_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i15a90a6d21554cd3b7fbe3e029fbaac9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9fe0b10bf3a4a2fbaac7c18a2d43b48_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe746589d79e42be854dd4cb784c05e9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id00b404c1c0143a69096eacb3dc9e10c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifebf0d8ca7134f8a863034f1a0b81573_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5a04530193ba4b518e49e6435d62ee0e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied70d0ff45d4458aa25726112c8513dd_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i41cbc8191ce24bd3873905bcb5a73840_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d3ea9011ece4aec9bbf5dd07e371b5f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e67a47e02e64b21801d078a6891829d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3cb20e8bd6614d08aae2157a736ee0bc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id05eb883732b498a834f089684813866_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iabd90fb1abfc4a8fb6a417188bd3b333_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d6326e426354c5cab099ca0de375d35_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8812745790a446cbad04fb159242ad1f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e033d68ed2c41b3ad7632aa89aec9a8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2af6c017ace04a208fed42ce9a986242_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6a5b99981159460c97cd042e3a67f70d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i25429e48c15549dd9fd5d52789bdf66e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i152fc65157fa4362b32c7674d4f3af52_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0c5c8cd61c24cfabd4664c10261b0e5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i757c59aeb42e4b328db5739cfaf1d0cc_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib31ea0e171e14113bef79d2f5da80f7b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9438c78c688a4bfeadfaaa6784905992_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i12c8a988b4e0420e89ff703030bbadfa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib3d0a194344841dba3b5f8ff6d1c4f81_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1908a95691ba4679b174a8dfdd916a93_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibcc0686d78a742bd8fdd73944fe180e7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5ad6d7a35eac421397e8362b9656f4b8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i95b05c62014347fab4835789f107cfe0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4b466566e8754a25a7bfeab1a81a2cea_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idec7cc8cd0034b3eb2562e8018818d3c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2e4f384abac34bae9d5bf87acf30d4ee_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if8c9122746944d3f9095dbb7cc11377a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2516de1ac60a4e90831421c900ff396e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9ac6ccbe24af4deaa5a62b863311b57c_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib50af91715af4a78bba950701876534e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i657478733d8d43ed87decbb8c4f5d541_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i51f276f171e54d29894f040aa5ab5443_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2a905ec064574da2bf8cee1f4d8bd703_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia6a59839d59b407ea4068c5b93d2ba34_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib0e0989aaba247af8dc5f027f0f887ef_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i613b7926acf54b98ac70428273633e52_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6cfc69fc6c34480b827a3877c93ab58_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1f6e2e5b23e04f37a8291ce446990fd4_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i26ce3d87d7074b3db7e594727ab76ac8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icad85b2a32a540c2be8bee5055609f06_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i308866a912504314ad0566776705f1fa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia643249264394743951818a9aa78ae5d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0c11e3688c394fb189088fdb0469db74_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i08acc85b03b14f00a2f9ca0f2979648e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i50c2970d6269468d9f534821befd3de2_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i30db570b4e794739ac24a66ec8692dae_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia02964d914cc47388a24d99a47433421_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ife378d865970465ba0ce74157101a61f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie3319dce269e41ad92a3ddcfe5bf5189_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib1c72b384af94d18b63dff491dca9a24_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9d798d15c7984659815575140f16c70b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb65596c915c406cbc7bf9acd98622e5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5dfead640e914b38b2696de5407f84ba_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6470a08268ef4de99f119d927d1a4d2f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b19835c69324505bc3bbe38750f529b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1ecbaf37433b4d40b16bc5671b74f060_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0f24d1c8c3584b7c8926aeeea29cd96b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6345900a23346efb313425848fb28e9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i093cbce56499494f8d57067e66f44ff9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i652da0112b604ae891ebdd50c297d7b5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2f5a9325fee04e2cba98e5d937adfc74_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia413a1e58ac1484aa3e51cdfe63a6c21_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5164cd322f6648be8b5b9b79fc0d4cf2_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic152d3b856314bd5bbd4d922f5b1f015_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29dd87c31a2a4a4eae9d3aae32da4d82_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8300e4d26c6147549e8368f3079a0031_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1a97f7fa27df49c584d3adb23745a423_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i502d3aeb3a4d41ef97ee7cc08116a94c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic67b3715c36b42269427fe5c63da86f8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i66c8c948a5be433c868d626d7809cd82_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i755ecabb947b4b71a2c01fa25760d3d7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45d4b0e30bae4689bf949adfac85bab6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i659ebe25d6134f28930cc20ef43b65ef_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8a9d2d82af3f46eab21badf9ac3a6981_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i27be45bcbe624d5980096e1785112fdc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib82aa5e2bd524a66bc66939217047a6d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac5d67fc3dd24634b8a4e9c26b4458f1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6770d7e189d34ca88257ea5c55b40ebf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i937b847996cd4321b4854f84342ab7a3_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ide726508c8b14430a7064d271b9e7f5d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6bca8925482a46e2bc9ec6966695df2a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i68aced51bea449ccb43e7ba29ae949ae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i59833a1a99db458b86c073d840320416_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i61ca7ff7f1294b878f3affcec832bf63_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1357d813e6fc4d059c8f9d8460edabad_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86b062cf2b8e4fcba6125d3f43aba52c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0f6299f5a6b94d23a99157b0a82cf59d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1053bcff8b284ac390b5229c577c0a2f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1bc39363344843769eab66bc91bcd94b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ifbb1af036ea24e969a66a5344c047fac_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i56fe58d06e354206ac06d6c22f264c16_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if01198d0ed2345ce9da3494a19010f80_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i17c1f93f7995494ba74ed1cbfe9a5453_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0324cb7d71b14d358a44ddaf249e9c3b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i8592dfe9d1b04943b8d47d4fe572c054_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib9c613ef03654592a30cd87dad818832_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3f69bddf17d545ee8a128bacba69d2ff_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i06c6cf6db10348b4bf28c5a5845cf749_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib41052befcfa4e75b65cfb241f1f0da7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7782237c1c694b6a815faeed508e0178_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icab523ef9fd74083a6a33e39224832dd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3e3216e6a74f4785916f831d67d9d956_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5e3d7bbc24a94e268d3446995f65a4cd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i78ef0131528e441a8a6df4550ce7e43c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iea2d09427bd04c80941fbfc24a9f7d03_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if0b3afb1cd4f478a818eb6239991e0c1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic7441a70014540ecb01931d60471c8db_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie32ae0d4377945619a0b004bca44e643_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0ee7d380900c45aabe38933fa9737ca5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i023eec0df3f048a9b3e4824e8ed3ab2a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia7abe78fd6cf4342a3cc9da64b09d5b4_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia3d5d9ecb0104bb3a06537378655c966_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i969d874254604c79af7ddf89bcd68f38_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10e1787100a84bd8bffa4619e4984d73_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a0a6d1a5b414021b5171c6b7d9fb15d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieec166a2d8374cc7abab4547af3faf08_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic7cdc5646c6548bd8cc644b73018859b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9531b1a6d294f8ea6c46caa9162ea5c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3c012248699d44a19bf1b3ad593025f7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if879beacfc67428891a4ad60e8881285_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic18416d266bc4669a44779b7ea401676_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9d74fbbf09504685acefcb2a4557aa87_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i730101ba7e3344f3a767d6b2aad9f3cc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5506665c921446e28905adb32f532db9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7afa8b191c2a4834a01ef669ef46770c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iea3cff758de541ed88b25aac322f9445_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i53a426a19b4043ba8a16122036b18ddd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i60eeb012b13c4da095da075b0f10d9cc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibab47af987094aeab2253c68b0b4781a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id8fc23920c4547298b885029056b0d73_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i078e0ac095bc447c9134a911525da50b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia01a554c2ebb48d39f052bebdba83ffd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic6b844bf5cc94564a2ea1dc24656006a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i72d549b89a0d4280b7cbec3d16492a8d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8b356d5dccac4dc0a67e6486ae9004c6_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9f59cd8393d427894d27c27f376c119_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d01410013b84b008e63a03d34b48335_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3823cd2bfc3c42808394d87cf2b96174_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic9d72c66352d4e0ab7a43307ebcfaab7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idd11875ea0ab4093a2da88d3dbb08434_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i37bc23335780472587bf9311eee7023d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i61a94521878b432cb2e9c5db2c9a03d9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d932603e9c9416bb175281368f58803_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i1305265f23d04121a22583b545fe9bef_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a9573b057d440c3a41440888f9bc519_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8008ca07420f4639a1bee2e6a25b83b1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3b600d7fd8d42519eb7d5e81b59a62c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6d991b8372b64a33973a4e1e72f10d14_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a74210ccbe44871b085a79bdcf8b0ab_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie61b19d0952c468285e72114e0c815fa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6aeb83f9ea074f7ca098ec2277b76dcf_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibfbcb20de8de4987b63b10487fe1503f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i455d14ea6c564470b68cf17c79c8b1ec_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3c1038b4167343c2894ae361d7838cf6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b33b1754e9a4fd8861a165f689594b7_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if31045dd949540548e6be6125e1e8384_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7037c9ec74674577a86a47384437b333_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6998a8488a944245ac8b554c781cd12e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1722b2d0cc7645f1a42a9c8bb59390c0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie0c5dd5e3cf24dbc93e12d0785e49cc2_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45a195ea9682417d82da6447b85f8eb4_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6d77cc63bd804d2195547eeb78d38213_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d2601de96ae48c0893072540afa20be_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaf5eb57f75b949ddb446686c65bd2b5d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if382ab28a2c14f67953b81e1f8e224a6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0599c4c9cd214ece84111681c4bd49cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4508c31bb9b042d2bf4dcb1d266392a0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie2e3e533c0e2443196830784733320d3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i382decd071794d58a8eb96ab53eaa0fb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0a124abe85aa4a19a264079c46a16e9f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1ada2bf116084c4fa8e8e98e14a03495_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2424282c7e6f49e1a4c067b8194f126f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic979c424773c4abda7b0f080e9803dfa_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i354359e6eb63451598deb6430cb7b015_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if28aa7d47b4e4774b232d953458d1d70_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i95ce0946ae03453e9adefffc884e3e56_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i04d9b2bdab044462bcfd071d9cae87fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8f1f736cf0c848ceb0338e6ef724d11d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2aa9db267e8b405ebe94ed94f54a1041_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie9e630e38d8e4abc913f03bb50be1f22_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i85e08dba5a5d46c48d1d0ba4950b19c1_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4789aad763454e5aa2bf7c06207aaf14_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i809babb0c0c0499093a3c1b393fd910b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ide348a94f52a4b6fbe470e76039c8fd9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if13532228d6b4faa9945313be54cbe8a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia83d6b8be2f94d1ca6fdeb88a1fd79be_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie57145cefb184ed0a3414659db9ff24a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idc4ea9a082274af0bbf9b1541950118d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia21ebca31e894acc847e9662f2798865_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i83428f933f704288a217da35a25533ab_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic58515149d05482e8c241be729c7cebb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icf1edb54ce2347b69f028201a0598732_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:ZINBRYTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d47538d8dcd446ca3b4284f191efc96_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaefd6081d97b42989d5b2062fea0e2c0_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7cee8c4809cc43778d9d5dd7095222d0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4883b5a7fdb64564a053bc40e6173d46_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib12491491b0e466ebdc29adb36c32405_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i16bb558d82d1463380f6b8863e69e26a_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i17597137521d4e01a99df9202a256434_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i294799e924cb4e7fb31a94d1eb9af81b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OthercorporaterevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i45f788f2e9604cf7abd1e93ae4f8f733_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LecanemabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ibf9a5892d99e44d8b1534f84205aaefe_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2837cc88485b432d98238003fed8b676_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CentersForMedicareAndMedicaidServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ib904f98f905e4ad3953b630e2bca4280_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i47ad44653f43466cbe8c8233fd37d1a4_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ia350432a960f43db838c5d34090e798f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if99a29e320c44befaad6c64343facc66_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i085d08ca766f453bb0b1ed59eda80c1d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaeafe70f44754eb2a753ad330c4edea3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5a922c6b9d0648949c052b847de903cf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4df75de89f2a48e1ac98377bbeff106a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idf245f7c03b94d219b053513a7037afe_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if13c845f22a44a8bbbd7ebeccf43f5e8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9f3a6e8db3344edcb5ed43acaf59842c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia7d41aebda1d4947b30b143badbf9555_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7948b4b0b9c44243a39e812b8fbbcdae_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0fd374623fbf4e19a6f32d3cc68790b9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:VixotrigineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2cfeace678454dfeafaf48a68a2f8986_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:TGNMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8c5d0bb749664bab88044a8c3f5fed55_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:ResearchanddevelopmentassetAxis">biib:BIIB111AndBIIB112Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5fe5cd2bc5bd45a7a679664aecb0fb65_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d5087bb8d414f3a9c0ece6a6b58e9c7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OutLicensedPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7c435e88eff34c74b9a309271c43e352_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic329b49057fa46bba58db3d0c2daed85_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id00f8990c87c4edab48f9433250dcf28_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4bd688a827a34b67a0e784b5fb549597_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iaad538ee04e34626a6eea7c18b5170f0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0ab6e798443f48349a275b2f127d63aa_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i320468fceb194a22b349781516794d96_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4229dbf5c29146898a310730f9f2a556_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i21935cd1c743479b8b352f61a8406ef3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4ed4059cc532499cb0d947b46e8c2790_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i508e95abdda94a41920a1c67a004ec92_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff6e063c1a884b0e80c8af000019a9b2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8b7cf9a8189c4e4badbd47fc34b589a4_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i13cda5e55cec4e3aba7217644a62e136_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id1977ca3896f4eba933be81acfc29491_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ice735e68404d4fb58b4cc4f43fa85a6a_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i349975b3917d48bb8801949ca1421861_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i79b9cb96a23b4137a822345574780176_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iebbfb14f37df42ada487358aa320ac59_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if1a82f9151b54f9ebfe04551807803e2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4631e2214cef421b815632fdba8b8cf5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i126cacdb6c3e45eb94667935f595ce8a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22a9faf176f64839888f1c73d5604d08_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id599ac01e6414ccd9716756cd0c865de_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia4a5207e2c6849eda81b356e237635cb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bfd0daf2c604315aee2e5514037add9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4f9583d6da0848eaadca5e7997e92ab7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idf3747bdadb44befa911a3d96310ff13_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib5fbb5c6be6b4e50a17ab9ebfa5c3d3d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i58730b06ccbb4aa3b96956a5848ff476_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ieb48448825914249a3d6d269e0343fed_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icbe4b913116b4794b2827d45ad900e88_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id29abbf0715a4be1a4a2755996712479_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic7487b639fa246688caae909a985fa49_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic2ccf4f8b82f4fda959e8343a1d3dde5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6033459c5bd84004a95df092bb16d49d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0b72d88f82114d2580cad7720faae9d6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i67936f8313184aba9a6a811874849e9e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i56a9350f33f340dfac40b834b36fbee2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i8f224e8cb20d4247baed59ca9186ca70_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie8d22419e65e4acdb11df2fd6d50ab7e_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5b184b88aa274ec19c0f59ff28afb452_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="idb58e5595fd8416d9ad9613922e40315_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i1f54baa0a0034028959f4f1dd23cf711_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i286147027fd848569c362d90f20b6f37_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i93f9683196184871a6a8088e9b6526da_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i314cc95227f74e429b94104786b26357_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i56a4148355e345a48fcfef9143a41e51_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id8657f446214427d9d8b9bd45a3d47e5_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9ddc68c90fa6433c864fb720db1a4975_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8278526fab9042518d7f4accd2d4a217_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i205e68692a474c17b451db6c94fec530_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i981abb5814734c34b5ba0e1cfe305f9d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib07f093c1bcb4f10bfd6b343935a270d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6606034d42124a12b44cdb4c5fba6c23_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i64a78bdbf8e24900b4b8c65ca0447bcf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7f61cc110f204304ba8ab5bbe034f465_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3600b20cbb584539b04e82e09e3dc634_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3d3e200523fc4be9bb17d504c77c4dee_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8f54474067a24bd5b888172e5b16c777_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id0679777b7204048a91c984d68574247_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iecab3d1c123b45d38c30c5bec136d009_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i62fe1e7bda30406db87fea2368ed0582_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i169651b95d8845368e7d477cb953ff71_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iaa04c9b7320b461cba254a374d51bda4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i200d118e7ed64bf5af0105a017c0fece_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib1d995ddecf64fadbaf96fe1384500ac_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:MortgageAndOtherAssetBackedSecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib271e1f2e84443bca4859f128d33db6b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2c07337e773d46e6ad996880dd86a2fe_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0caa15f7fec549d5b6d3e7a3c8450b9e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iff043d96d6794a88b3666b1deedfcd35_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i83d8b0ff4a59482aa6bdc802c56365fc_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i22a07047b8e84600ba3373e7735d13ac_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i9ac3efa6755547028b1585766ed0d6a8_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id1e84a127d4d438c93f97cacfe5c9ceb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia1b944b88e544c5aacd839481cf31357_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="iafa20a7bcf2748dcbeac35d8a0e0ca7a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic5e498c8f45242b3a2d9e70d2c42a503_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7bd633e40e1e41b1b9c1ae520b9468ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id52d6723b04d4723a146148f91d54d4d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i61daafc34b6c4be389482539c0515d29_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc378ef82c4040a2a4ab36fe9ca4766b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i8335794299174638814a89b8c49ff4e9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:JPY</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie5e6a6220363429f80e31efa34a52864_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if95bf11f05e341b19847e153ea08fdc7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i120d294420ac4cc5a5287c7acc20fa00_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8996f46ad23e477a8251393d59e34875_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i5fa5a40f0ac14aa19a149832f0cf7187_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:DerivativeMaturityAxis">biib:ShorttermderivativeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i32243243b47a43fb8c6ba0eb85b30fd8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7855fb3a8a984c0abaab370eeac02ee2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie45b0d8165e24b5a9fbc05c247e52911_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic258686cd3a6456ebc2c9b09e2ff27be_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="idea016b088d845d98937c3a05df5d947_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97bd4991354c4a15ac876c71524967c5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie96b8241173c4299901100e5efed591a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6b8795f0fecd44bc833219a58dfaee62_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iec630ea085d14b79a6702770f05c54fc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1b690018155f45cdb7f208616597334e_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c24c29444b548aca4187e271cfa886b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i3d5d2ca68e014dc3922d00d93a88be43_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id5e7ec03b8354dbab75b233556df07d5_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i88cbc69efa06413895dfc1180ad985c9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib29380d2bf674aeb8ea8724965b1f6b8_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1d977c21aa234f7f99392c7a1a2c212c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i52fa7dd299c7425bbc3bba8fd21f9067_I20180531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="i89423fcf9d5d4c26a6860a1d370bc9f4_D20181101-20181130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-11-01</startDate>
            <endDate>2018-11-30</endDate>
        </period>
    </context>
    <context id="if414410918334d9bb8c6e78f27e2bd55_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic2f87e0409bf4de6bbfb65f1f00e2861_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i22be7e941fc4472097793c58bfe13c85_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icd0cd6a0501e4513abdff115c36b8a4c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iff7a68233a6346a3b41b5ba48c00eb25_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9172dc7ebd564a448d1ab478d505ac9e_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i507cb74104cc4af691f7ec53fa51daf0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id6f4b8580bdd4045984ea773c64855bd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4e7d3a50e8e24a18a4f3bebf9a25ee71_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idecbeb6a787b45e999586e7f179ad321_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib88cc97bd13d40ac90880007f88756da_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if41dae46b1004553a798193cc1c16ae9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i4c0575de61ec44b4950ffd44163cfc4e_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i53ce27e2d1834006bccaafc6efdf9bff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="iac791a4319614586b5fa4b20e746145d_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ia15c5a492bc341798bf62fd3955ff770_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id6a5fda462c643bdb69ff40ab7f9019c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ib019b33e0733407486645ee0e3dba238_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5aa0d743936f4ed9aafcdf381a12a281_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ic2ec860c976745568331c92c49c8ddbb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i27638e932c864367ae3db51bb6a4e81f_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i31b779d2d9c44b8e902c134c0f3a5def_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i3c6767b12f4843b4be545567280f6604_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i034507e9f9464a29a0c701e02ba11b39_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i15cf3398e090470b836590f86a9494e7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:BiologicsManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iff59169dbc0c45b4897fff451d70d7df_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:WarehouseUtilitiesAndSupportSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ieaa1ea81bcf844509d4e9629d0129c76_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityTypeAxis">biib:AdministrativeSpaceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i92a75cf0ee8a497393ba39d608afef91_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i3a57d1b2e861499fab173d2ef85a3b1e_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="biib:FacilityLocationAxis">biib:SolothurnSwitzerlandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia758334f8b3d4c2bb05db550ef70a7a0_D20220901-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-09-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i24f4a773df0340cc9dcea4430ac7f361_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i41b979e0fcbd45a49408dd1c5807f36c_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i52ed0ad90e1a409da68a677b1a180bed_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie0993033b50e4a51badc996a38d9d905_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i0974435913f44b15b34152a1fee687d0_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">biib:A125BroadwayBuildingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i7037a7c948b64786be2cf157e66fc0cb_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i737aacf58c3f4d9b8d3e88a3953abda7_I20150915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="iec0813dbc2c649b99fb2b393fca060b6_I20220915">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2022-09-15</instant>
        </period>
    </context>
    <context id="i9a76584efadd4ffb99238713fd21af42_D20220701-20220731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-07-31</endDate>
        </period>
    </context>
    <context id="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i43b8001bd67d4407bc0ad37c6a818891_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3250SeniorNotesDueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i97bfc367938746ae877a3fe76a5d66e2_D20210201-20210228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i6619831da50241829e986aa29f5743ad_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iaec7e30533b342c590bb4d7ffe633982_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="i0abcd53e74c94a7c833bb12a8fd01cfe_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i2f65dc8cba414b409a0f8978d6ed6d6a_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i59ae9f957d5c456c9db2d0b8de63c577_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="idc7da9d0cf1d468abb521a902e87c1d0_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1cdd7aef8328422d92318a8fb44162a7_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i566fa85dece64a33ba2afa4c152f1217_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ica81c533dc694911997333f2bdba6785_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="if562d93e14c149bf85526ac1ea39f925_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4a801c0708314316ba9f6b3812a045ba_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="ie0d5210f96b74598bfeb245483674c64_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i6e94d3bedc394a18ac6119d2d5a633ef_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i4f0d8ba0521942b4b77b6c16befe6648_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i225e191ffa7842e98d83316aa99374a1_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i8ffee1d6cf8a41c9a6241f4cc1056e1b_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4ea7c38a0a34d079a17eefda9d0a994_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i62ec65b1ad2d4bc99e0fe80385ecaee2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i29b15de8609a499c99c1288814cbddff_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i0a62332cc2dd41a7b9a9be9081dd2307_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i80f60ecb887d4be79a4bb68b4285b869_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i5733cabf96334e7ab886168311c47ed0_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i7f2f649fd1a74126a144c38bb92e1623_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="ie69a59bf2fb143128c5de3ed05732a32_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i849dd4a8f4c64ed988e7ed27a7acc5aa_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if71a1afa58f84476abfee908e733759f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i27ac905d40cc4c0b8cfce80524bd7f9f_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ied4f63161aa64b41b8e31012f313c41d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie529a3e858834552a0a5634398d18674_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic83040f816404800a727b532e6017bb0_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i23f5a5169ebd42aba57956e30523887b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia9cf20ed80544d3aa60312bf7249ea5b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if299c0d105f14cf986a61dc16c3cb70c_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9019b680c6754477845629fe912cca42_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iee1e133f85df4fcda4b5fbf47287ab83_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i9a8c74397f6e462ca3d0a16f7d7d1724_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21633472081e499f84d2d8a16c51f6c1_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie8e3376c311a4ab1ba9f36f3d6388b0b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i69bc310b2d7d4bdda29eb1089e137559_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i93992c5f9dc945f6b4d933f8893cab02_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0310cfc482e54baf860e1cc61e2cb08b_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i7af590a969ea4209b99c133a0dbaa97d_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9385ae1537df4bc4b697a93604cec286_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6ec20c3acd4e4e87afaf283b335fcd61_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i87a19de3dc2c48cc83fa43e9c9f68324_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ibe4a1ed6e5af4242b0dd4a5d99cdd5d3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i86189fb69f0b4545b7c8c310762bef0d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2b2c0753f0cd4a10bc3da9507bfdac2d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i423847116cc5490a9bdce5eb39edf6cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5726a88b7bb7444385b56260f3916f3a_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i19e2ef680f084dee982a474253928b22_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia84ab3f48f3942d2a12b2e1aa732dcf0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7e38e0479cb74c8fa5f98e9890ca19cc_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if0ab96fe04b24b54881a9fb26fd5d9e9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i020a6d175274414c85d5892faf01ae3b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2916810b28d34baab3e072744e15d7f9_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie280a8f5fb6f4a64a937ed98bf711fcd_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="icc5c47cebcd646a29a4d500a8101cb83_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id1200447817a47ce88c12b9b2d542734_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0d2d23ef6a94bc2ab3418e068cdf65a_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i643e3738705a431185c23ad01faf0241_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5ea82c65b64d4a08b32f42941f129ccd_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ia985ab3c9c6947ce9bbddd4486e39ab2_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if43e265e90d84abea2ec20efefd5e160_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1a056e0535b44f73a14fb5b5866c995f_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ic363356bb33f48c5be8d5bb4b72a7bf6_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6f4a133d037248e49ca85fc0d7750a92_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48833179911f4b4da985ff177df33255_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9bd91ba74efe415d96d36566a8533af0_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4971fa532f65444a849a4efe193ef3b9_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i5fdb74af71e2435d84ec8c2691f9906f_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia28cefc2251e4aaabc62eda2e1948a43_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="if71aa78fc18748d9bfdd023c98e48b21_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i28eda3a32b1a4782908d9192bc909c52_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i29a060d008f4427d9936c693dd36d7d5_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5d36468b37944b318ad8e33e0eb69a3d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21f7cf90b35a4e9cadd33e5ac5864d7a_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5f2b501618744c89aa413dcc343decd8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i815aa12c57884893ade8be8bae2934ae_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i10042e38a8a542d693db8947e7136f70_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7db73a71288148e78f2f4ecd84931f93_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ie29a14310e7041918de391cbb7abc267_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4441454a34d345f9842e1c241d644d60_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i893566fba033473daa38c35e9da2c3eb_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i0c02e6a550e94385bd647008ae2d2a57_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i54de034401784154b4ba0d3eb7e3d450_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i12b0509f87024db39c961704c8e7c7e0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6c37ed99d794477582d69045529410a5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i70546cdb486b478dbb121a7e30415292_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:IonisSangamoDenaliAndSageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i514b2ba420f64268a1d2daffdaab5268_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i78a6bb2bc10a4e3c91f961981fa702e8_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i3443044069b84a6e88b9b3cc9b330446_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idb735cebf0af4abd9050e30bb5f39f33_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i4c76958e4cf140f8ad08dea4b3f1ab5f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="idcac94427f544cbbae306a72b2a5e7ad_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6031c646c1504c3086d61ab2593a7c25_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="iddb4c4c4dd53404e8de0fcbf8e7d9a10_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id6f9bec593be4e5d91def662f86f3734_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ide22393d682f495894e1b5ec178709c1_D20230101-20230630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="i1f8e21b88c804c23b9bfcb582dae16ce_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i348dea4c284f4a53bb11bb12aec530fa_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i141e695e78b143d688d46ac172f1b598_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i179603334c294ba3b273f1bedccca3c9_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="id03c149483b744869649d8b1d34aa36b_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i591976370b814e62bd8c8b9ed758f611_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i02b6a4d48c4a4334acaae1eb260e0b13_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i505f65ad62c3405996f7fb81bba9d4cb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19a6d0acc3304bb9aa01590e1e7460fb_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i6511e416082b49b9a364fc869d30a213_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i21152c4b7a304de9aeb9f9105783865d_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i2dd4b5749a9a44fab753be0fde81fae7_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic0b2780de2c442749c94a8cf029cc0bc_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="id4b772a8ed2c4a2aac06ce78bbdaec90_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if842e4daa2c44c5aaad2b10260a4d9ba_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5edddd85627f4628a01d57ff448a161b_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="id9708e37fa77451aadd22d8e388458e8_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i68bdd3eb1eb14260abcb70364529e312_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic3154c9870f64f398d5ee5795b0ed8a9_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ib0000607651b4c2da18c5e8d251aa79d_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i97091bfe16ce48fa8f91049acef10017_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaS.A.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i19c19ba4f7294ef3b3f1a8cc3f9e7a51_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9bddd0739a28443f9a5addc1d0165587_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i6280e0f3e31e4892b76bcf7697d7da8c_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i9dca4a205fd04aff8770a8d6c0648246_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i637a39c4b67547449f9bb69b9022b010_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie6be2070a42f4a50adbcea4041c3995b_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="ia6514e9099d749e2a24676b1e0964505_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie96ed8937b44437397b52545c683f8ca_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i63077c7ccbc64b09ba57ccfcb24dc699_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i67337d92701149d7a5ac303a93defa2c_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac8df81074864fdca6b0580aa1c815e0_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4853d9b210a44032a2de85b0f2c6b1bb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if6a86bf51ac541cab63587970a524ba7_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SangamoTherapeuticsInc.AgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i94f98a47df764e30ba42983d8f26f8ff_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i2b59abb400d4439985bc8aede1323697_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i442b682326924c119499dfef30296ddd_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i06a34504b754441cb3200ef36b1270d9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64fbcbfb69f64e4bad4eaf9e2feb10e6_D20210801-20210831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:InnoCarePharmaLimitedInnoCareAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="i2688c6f795fe495b87c7088b9af08f05_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="icb2ae5cb50394082889ddf96ebccf655_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i43982e8c28374e20a8abf7ff9c154d4d_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i5c00ebed6f7d4754af195586caa15662_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:OtherresearchanddiscoveryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iecc1e7ba25054542bf09508f1c307e7e_I20181107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-11-07</instant>
        </period>
    </context>
    <context id="i54f716cdfda745bd9304e51b2b5d7a59_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic158a58579df49b6bfc1555e6b8983da_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="if1c25ceefcea49b9827a310222a5b592_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i534cd99ae2f945f4b8b88984e7158822_D20191201-20191231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="ib960c5c895e446e0acbf3a757df2ab49_D20200101-20200331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="i92a4535230f44352ba473e29091c1ed5_I20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-31</instant>
        </period>
    </context>
    <context id="ie2a1da015b744d1bad39bd303d279f1e_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ifbc42c348d684b9cbcdd1bfb3d7628c9_I20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="i9c991d99f95e47928b97d145d5eb1271_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7a682c52ea24aa381955c02cfe12e06_D20220101-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i476cf962e66248c3a8819cbb993cf272_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">biib:NeurimmuneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1b8287024d7d445698e5003d95aef21d_D20211001-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="krw">
        <measure>iso4217:KRW</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY18xLTEtMS0xLTEzNDY5Mw_f4a006ba-2eff-4377-bab3-7718401026bf">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY18yLTEtMS0xLTEzNDY5Mw_6069d453-f9ab-4996-aa33-bfcfb0b7eb91">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY18zLTEtMS0xLTEzNDY5Mw_a73b190d-cbb4-4b46-8e48-38f517be2e43">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY180LTEtMS0xLTEzNDY5Mw_0b9f2483-031b-4320-9553-b589943ad514">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY181LTEtMS0xLTEzNDY5Mw_2cb0a1a1-6680-4077-87b9-667e4a0ebf78">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8b9473308ccd44839cb2a3b16f056f1e_I20221024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80L2ZyYWc6ZTMxZDhjYjgzODk3NDM0MGIyMzM1ZGJmOWQ0MWY2ODIvdGFibGU6YjJmNTc0N2JhNGJhNDZiMWFjMzZlZDE3YjMzOTY5MWMvdGFibGVyYW5nZTpiMmY1NzQ3YmE0YmE0NmIxYWMzNmVkMTdiMzM5NjkxY182LTItMS0xLTEzNDY5Mw_90f9a363-3604-4181-8b62-0b2cb3b32abd"
      unitRef="shares">144001404</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i5fe5cd2bc5bd45a7a679664aecb0fb65_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81OC9mcmFnOjgxZTA4OGY5MTZmNjRiNTNhOTg3ODBiMDdiYjcyMWJmL3RhYmxlOjM2MWFkNGRmNjQ0MTQ1NDJiNWRhYTdhZjBiNGQyNjJhL3RhYmxlcmFuZ2U6MzYxYWQ0ZGY2NDQxNDU0MmI1ZGFhN2FmMGI0ZDI2MmFfMS0xLTEtMS0xMzQ2OTM_9b000636-ef02-4f72-bf1a-3ccdaec35b98">P4Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4d5087bb8d414f3a9c0ece6a6b58e9c7_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81OC9mcmFnOjgxZTA4OGY5MTZmNjRiNTNhOTg3ODBiMDdiYjcyMWJmL3RhYmxlOjM2MWFkNGRmNjQ0MTQ1NDJiNWRhYTdhZjBiNGQyNjJhL3RhYmxlcmFuZ2U6MzYxYWQ0ZGY2NDQxNDU0MmI1ZGFhN2FmMGI0ZDI2MmFfMi0xLTEtMS0xMzQ2OTM_3cfb99bc-9ad4-4423-bdf5-83d2051a6b07">P28Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5b184b88aa274ec19c0f59ff28afb452_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfNS0xLTEtMS0xMzQ2OTM_ce9bc511-0464-4b71-a185-e17efa3c2ab2"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfNi0xLTEtMS0xMzQ2OTM_bc4f4706-227a-4633-9197-789ec8cf7a7e"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i286147027fd848569c362d90f20b6f37_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfNy0xLTEtMS0xMzQ2OTM_0ea18eb9-905f-4d47-9587-c1ddb62424f3"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i314cc95227f74e429b94104786b26357_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfOC0xLTEtMS0xMzQ2OTM_1b6235de-5180-4ef3-b2b4-ebe76a3ad1b2"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id8657f446214427d9d8b9bd45a3d47e5_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfOS0xLTEtMS0xMzQ2OTM_160112df-ffb6-4fd9-bc12-8e76b9edc175"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8278526fab9042518d7f4accd2d4a217_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RhYmxlOmZiYTE3OTkxNmIyNTRlYjM4M2EwZWZiY2YxYmFkZDg1L3RhYmxlcmFuZ2U6ZmJhMTc5OTE2YjI1NGViMzgzYTBlZmJjZjFiYWRkODVfMTAtMS0xLTEtMTM0Njkz_78f9bc5c-b1cb-4569-8c1e-56e67755044f"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82NC9mcmFnOjkzZjAxMTE5MWEzMzQwZDJhZTIxNzQ2M2U0YjVhMzUwL3RleHRyZWdpb246OTNmMDExMTkxYTMzNDBkMmFlMjE3NDYzZTRiNWEzNTBfOQ_6b83c6c3-2715-455a-8840-ab5fe53fd934"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDYvZnJhZzpmYWYyYzEzODQyNjU0ZWE0OTA3OGQ2MzExOThhOTA5Ny90ZXh0cmVnaW9uOmZhZjJjMTM4NDI2NTRlYTQ5MDc4ZDYzMTE5OGE5MDk3XzEy_7b0e9c35-c94f-42d1-bff6-e329c3eb5f2b">SUBSEQUENT EVENTS</us-gaap:SubsequentEventsTextBlock>
    <dei:DocumentType
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA4_33d64726-8450-4fd4-9806-931674c83ea6">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6OTI3NWU4ZTY4MGY4NDI2Njk1ZGVjNDk5M2QwNjAzYzMvdGFibGVyYW5nZTo5Mjc1ZThlNjgwZjg0MjY2OTVkZWM0OTkzZDA2MDNjM18wLTAtMS0xLTEzNDY5Mw_7d846037-6c51-4c27-a32a-c687d8fff1bb">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8xMjM_98b79c02-fcba-412b-a91b-f021a3dcc5ac">2022-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6ODhlYWFjOWVmY2FlNDgzZGI2OWU0NTI1YjJkNmU0NDkvdGFibGVyYW5nZTo4OGVhYWM5ZWZjYWU0ODNkYjY5ZTQ1MjViMmQ2ZTQ0OV8wLTAtMS0xLTEzNDY5Mw_76395e99-1c19-4e80-9ee4-ffe038dc63eb">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA5_87387673-053c-489f-a047-0eec4fe96f1c">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEw_c0cc26b6-437a-41b7-a2c0-2b9016d8b6d5">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6MmVkNDFmN2MyYmIyNDg0YjkyODFlZTBiMGM4NjMxY2IvdGFibGVyYW5nZToyZWQ0MWY3YzJiYjI0ODRiOTI4MWVlMGIwYzg2MzFjYl8wLTAtMS0xLTEzNDY5Mw_7e79dbd0-7666-44c1-99c5-5ea79872aaf7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6MmVkNDFmN2MyYmIyNDg0YjkyODFlZTBiMGM4NjMxY2IvdGFibGVyYW5nZToyZWQ0MWY3YzJiYjI0ODRiOTI4MWVlMGIwYzg2MzFjYl8wLTItMS0xLTEzNDY5Mw_d60f258e-e033-46b9-9bc8-ff9ccdcfb997">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEx_4b376543-6040-4be3-b7c7-cea0671447c5">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEz_9b589aae-3c30-4d0d-bb85-062d6aa471de">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE0_bf2fbf33-0b93-40b3-a861-f259d9371e28">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE1_eb9626e0-5272-456d-84cc-3c1dbca4b788">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDEy_0c0fed8a-f82b-438d-9b84-23cdff709487">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE2_bb0e7f3b-b105-4073-98a1-133dc1aac404">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NzUyMDZlN2RiZjczNDdiYmE4N2ZhNzc2NDc0ZDZkNzUvdGFibGVyYW5nZTo3NTIwNmU3ZGJmNzM0N2JiYTg3ZmE3NzY0NzRkNmQ3NV8xLTAtMS0xLTEzNDY5Mw_5744d0ec-0d3c-4191-841e-0efc1f808c65">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NzUyMDZlN2RiZjczNDdiYmE4N2ZhNzc2NDc0ZDZkNzUvdGFibGVyYW5nZTo3NTIwNmU3ZGJmNzM0N2JiYTg3ZmE3NzY0NzRkNmQ3NV8xLTItMS0xLTEzNDY5Mw_8725c0dc-9d81-4d09-a379-68e03818ca9b">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NzUyMDZlN2RiZjczNDdiYmE4N2ZhNzc2NDc0ZDZkNzUvdGFibGVyYW5nZTo3NTIwNmU3ZGJmNzM0N2JiYTg3ZmE3NzY0NzRkNmQ3NV8xLTQtMS0xLTEzNDY5Mw_1944e02e-4878-4400-95f6-d7070f449f8a">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA2_925b06dd-4361-43cd-b3d1-4e4b06b52105">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDA3_f03dbb77-4fd6-4ac1-a084-06b974e7261b">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NDNkNGFlZTI0MTI5NDJlZmEyMGYyNGMzYmE2ZDRmNmIvdGFibGVyYW5nZTo0M2Q0YWVlMjQxMjk0MmVmYTIwZjI0YzNiYTZkNGY2Yl8wLTAtMS0xLTEzNDY5Mw_7bdba093-d46b-4083-a78d-c41cbbd9b697">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NDNkNGFlZTI0MTI5NDJlZmEyMGYyNGMzYmE2ZDRmNmIvdGFibGVyYW5nZTo0M2Q0YWVlMjQxMjk0MmVmYTIwZjI0YzNiYTZkNGY2Yl8xLTQtMS0xLTEzNDY5Mw_1763f61f-d545-46ac-aa62-080221f449b3">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGFibGU6NDNkNGFlZTI0MTI5NDJlZmEyMGYyNGMzYmE2ZDRmNmIvdGFibGVyYW5nZTo0M2Q0YWVlMjQxMjk0MmVmYTIwZjI0YzNiYTZkNGY2Yl8yLTQtMS0xLTEzNDY5Mw_2de5aa3e-cfaa-4e6e-8f4c-d0b607e24dca">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8yMDE3_ec19768b-de55-47fd-93a8-3c2b1ef175e7">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i8b9473308ccd44839cb2a3b16f056f1e_I20221024"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xL2ZyYWc6NGYzMzNiZjM3MGI0NDY2YjkwMGNlY2VhN2FjMWE3ZTkvdGV4dHJlZ2lvbjo0ZjMzM2JmMzcwYjQ0NjZiOTAwY2VjZWE3YWMxYTdlOV8xOTk1_90f9a363-3604-4181-8b62-0b2cb3b32abd"
      unitRef="shares">144001404</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues
      contextRef="if8b5bc83e8644cd983699f6fb8858208_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy0xLTEtMS0xMzQ2OTM_7a8f9712-82c2-4468-afca-7fc1e3284956"
      unitRef="usd">1962100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if551793810f14521aa422baeecc3bfbf_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy0zLTEtMS0xMzQ2OTM_d1d1d8cd-6c54-4525-8b1d-484110dcb038"
      unitRef="usd">2205700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64c2a0bb31734409bb0e29d39fc13bae_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy01LTEtMS0xMzQ2OTM_09f0586c-6faf-4923-b7fc-3b5ccf00be15"
      unitRef="usd">6083300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2765e6631dd6439f847c09bcca089302_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMy03LTEtMS0xMzQ2OTM_5d5b7238-224d-4e59-ad02-8dfc63ceea61"
      unitRef="usd">6653400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id677ff3bfec54adbaa112244fd4799d4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC0xLTEtMS0xMzQ2OTM_896d1a2e-746f-4200-8993-adbb088c5153"
      unitRef="usd">416900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31f777fcba294e1981f4bbec61fe6842_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC0zLTEtMS0xMzQ2OTM_3e06e4bc-6e9f-4ac5-b062-6fb0edbadc28"
      unitRef="usd">415400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1bc6e1753ff4db990730bfcea938673_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC01LTEtMS0xMzQ2OTM_7700f9a2-7180-4c09-8458-8509bce45c31"
      unitRef="usd">1252600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07dd344004654602b840c7084123794f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNC03LTEtMS0xMzQ2OTM_2941d478-a712-402a-bde2-e4483e2a41c8"
      unitRef="usd">1244400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i599788f95f5d42d1afd8d372967a5f5d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS0xLTEtMS0xMzQ2OTM_43fccec4-8ddf-491c-ad9b-2cbe8b737ecb"
      unitRef="usd">129500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c6c0f5fe10b475babd385cc9a5f1933_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS0zLTEtMS0xMzQ2OTM_0d739d5f-b3b6-4ef3-8983-89fce613c406"
      unitRef="usd">157800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01501338195d4d64b3297f4c712b4a35_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS01LTEtMS0xMzQ2OTM_f936bf42-74db-442e-a966-4e78c5d3a5e9"
      unitRef="usd">293500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76bd2bb0d53b471685923452d6735342_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNS03LTEtMS0xMzQ2OTM_929d2ac8-a5a7-4075-b9db-eda41ae0232c"
      unitRef="usd">350100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi0xLTEtMS0xMzQ2OTM_2835aed2-ab3b-4cb6-80d7-ecb793512d8f"
      unitRef="usd">2508500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi0zLTEtMS0xMzQ2OTM_969a7569-0cef-49c1-916c-aec2e139b9ac"
      unitRef="usd">2778900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi01LTEtMS0xMzQ2OTM_10d45364-1707-4684-a6dd-8806203fab85"
      unitRef="usd">7629400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfNi03LTEtMS0xMzQ2OTM_0118ba70-d560-4a46-866c-1f2c31491460"
      unitRef="usd">8247900000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC0xLTEtMS0xMzQ2OTM_9d580152-6754-4c6b-bf33-db0acb09be7b"
      unitRef="usd">469500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC0zLTEtMS0xMzQ2OTM_b337444a-9554-455d-b77b-9e3768dfaaab"
      unitRef="usd">511800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC01LTEtMS0xMzQ2OTM_c4a2815d-38eb-4a06-bf71-13ab9864c030"
      unitRef="usd">1707400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOC03LTEtMS0xMzQ2OTM_09e80e2a-b849-4e4a-8e46-2cb05aaec672"
      unitRef="usd">1449600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS0xLTEtMS0xMzQ2OTM_d6398ae3-36cb-4ac3-ae77-8f711d0942fb"
      unitRef="usd">549200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS0zLTEtMS0xMzQ2OTM_d76b35a6-0979-4456-9c9d-aa2a6c2a85b1"
      unitRef="usd">702400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS01LTEtMS0xMzQ2OTM_38662257-c59f-48e9-9971-450b891dacdd"
      unitRef="usd">1629500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfOS03LTEtMS0xMzQ2OTM_97e338f7-53cf-42c9-ac55-507c75f02a64"
      unitRef="usd">1801700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtMS0xLTEtMTM0Njkz_b0dd5fcd-7ec4-41a1-8fe3-82e2ca2a7e0b"
      unitRef="usd">563300000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtMy0xLTEtMTM0Njkz_7247576e-b42e-47c3-82d1-37f2603a982f"
      unitRef="usd">654100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtNS0xLTEtMTM0Njkz_348f78f2-fc77-4795-a03d-be4e84f41410"
      unitRef="usd">1770800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTAtNy0xLTEtMTM0Njkz_9a3fd9fe-35c2-4bae-a70a-e4dcf64ccba8"
      unitRef="usd">1886400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtMS0xLTEtMTM0Njkz_e5ba969c-3df7-42b0-8a25-957f4d379a25"
      unitRef="usd">56500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtMy0xLTEtMTM0Njkz_51878a2c-b45c-4a8d-a324-ff802eba20af"
      unitRef="usd">111000000.0</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtNS0xLTEtMTM0Njkz_2d74b9c6-2d45-44e0-958f-bb849c979d23"
      unitRef="usd">190900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTEtNy0xLTEtMTM0Njkz_0c91072a-4963-459b-a2b0-a7a8b18336c4"
      unitRef="usd">813200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItMS0xLTEtMTM0Njkz_6938e702-c608-455d-be77-588258f45084"
      unitRef="usd">45300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItMy0xLTEtMTM0Njkz_5f7567ea-f026-45e4-a242-8906aff1ee81"
      unitRef="usd">21200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItNS0xLTEtMTM0Njkz_f4abe252-1994-4472-95ea-467a54412e7c"
      unitRef="usd">-42600000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTItNy0xLTEtMTM0Njkz_41d2d8b8-bf78-4455-9d6f-acb31e780373"
      unitRef="usd">74500000</biib:Collaborationprofitlosssharing>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtMS0xLTEtMTM0Njkz_10d2c144-f019-4bcf-961d-39622ed682e0"
      unitRef="usd">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtMy0xLTEtMTM0Njkz_998a309b-2cc8-485b-a40d-802cb44ccc11"
      unitRef="usd">15600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtNS0xLTEtMTM0Njkz_7dc5ca20-b0b0-440f-90e7-2e75f0f7a598"
      unitRef="usd">13700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTMtNy0xLTEtMTM0Njkz_765826da-8da9-469a-8da4-90f74cf4603e"
      unitRef="usd">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtMS0xLTEtMTM0Njkz_1166dfed-acc9-41f3-a3c5-baa77dadfb29"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtMy0xLTEtMTM0Njkz_d50970b2-6ae6-4f3d-a3c4-ce3d6923cd0f"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtNS0xLTEtMTM0Njkz_b116edba-6f09-4563-a240-9ae75fb00e11"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTQtNy0xLTEtMTM0Njkz_2b39fe1a-02c3-4e47-86c1-2618d50be74d"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:RestructuringCharges
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtMS0xLTEtMTM0Njkz_f5a7aa6b-b3a8-443b-852a-3452784325ea"
      unitRef="usd">15400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtMy0xLTEtMTM0Njkz_cce5ddf4-3e24-4677-b2e7-f125b5d1a6e7"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtNS0xLTEtMTM0Njkz_aea80e3e-4dc5-4806-abd1-3e26089ac6ac"
      unitRef="usd">124100000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTUtNy0xLTEtMTM0Njkz_0d533e17-4f3e-4fe2-a4c7-1792f8147ac2"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMS0xLTEtMTQzNDI4_1cbfa3a3-3b23-4da7-b1c8-8dcc6bc8a290"
      unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMy0xLTEtMTQzNDI4_e7465133-c1e3-4588-993d-d96c0e7cdd0a"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNS0xLTEtMTQzNDI4_2e3a7de9-9c31-4efb-8594-7ab783e83cba"
      unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNy0xLTEtMTQzNDI4_7172091c-611a-4b7c-8159-1efbff9ee607"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMS0xLTEtMTM0Njkz_4809d55f-1ece-47d4-b5c6-f4717a81993e"
      unitRef="usd">56000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtMy0xLTEtMTM0Njkz_9648949e-5129-4ccd-ae80-7202b5ddd583"
      unitRef="usd">-502900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNS0xLTEtMTM0Njkz_efaf69dd-e59d-4dfd-bb25-85fac390b6e0"
      unitRef="usd">221300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTYtNy0xLTEtMTM0Njkz_590de148-93ff-4bdd-beea-7118bf33073a"
      unitRef="usd">-913400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctMS0xLTEtMTM0Njkz_cb0c6410-b72f-4a2b-a5a2-1a85f1bd22d1"
      unitRef="usd">1137400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctMy0xLTEtMTM0Njkz_996906fb-8354-4d16-974a-0be4e9ccc685"
      unitRef="usd">2487800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctNS0xLTEtMTM0Njkz_883eae6d-089a-4e02-8b78-a10d7d90d29f"
      unitRef="usd">4641400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTctNy0xLTEtMTM0Njkz_393553ca-f608-41a0-ab37-83077c800980"
      unitRef="usd">6907700000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtMS0xLTEtMTM0Njkz_a37967a1-4c72-469b-ad05-4d14f1c7a837"
      unitRef="usd">1371100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtMy0xLTEtMTM0Njkz_42faed2b-952c-4481-9b20-8334eac13cd6"
      unitRef="usd">291100000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtNS0xLTEtMTM0Njkz_fc7b9a91-0536-4820-b5d4-87cad8736eb2"
      unitRef="usd">2988000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTgtNy0xLTEtMTM0Njkz_a19fe433-d0c4-4a9b-9d75-2c11ee0b66ea"
      unitRef="usd">1340200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktMS0xLTEtMTM0Njkz_1ccd4d0e-6d13-4e76-a42c-078b7099dbdb"
      unitRef="usd">236200000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktMy0xLTEtMTM0Njkz_cb48ef51-faca-44e9-b125-893054b581c9"
      unitRef="usd">-25900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktNS0xLTEtMTM0Njkz_a750c141-aaf4-4815-9ec6-39c2356bb7a9"
      unitRef="usd">578500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMTktNy0xLTEtMTM0Njkz_06cfe8c2-b000-4585-bed4-363b2c6cc837"
      unitRef="usd">-390700000</us-gaap:IncomeTaxExpenseBenefit>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtMS0xLTEtMTM0Njkz_07a30522-571f-4269-86e3-b4c0fa09c638"
      unitRef="usd">0</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtMy0xLTEtMTM0Njkz_d548aea7-7813-45aa-ab2f-9cdf4af1cd38"
      unitRef="usd">1100000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtNS0xLTEtMTM0Njkz_7ba9af7d-b285-4da2-ae21-588e52f65e3e"
      unitRef="usd">2600000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <biib:IncomeLossFromEquityMethodInvestmentsNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjAtNy0xLTEtMTM0Njkz_7936eb59-cb28-4f49-bd67-7988e0636f63"
      unitRef="usd">17200000</biib:IncomeLossFromEquityMethodInvestmentsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtMS0xLTEtMTM0Njkz_8fd8d9be-6ad2-4780-8369-948a753042bf"
      unitRef="usd">1134900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtMy0xLTEtMTM0Njkz_80caf3c8-bf75-4fa5-bdbf-1274d5f042a3"
      unitRef="usd">318100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtNS0xLTEtMTM0Njkz_5e90d360-1a87-440c-b93e-a704864d3e77"
      unitRef="usd">2412100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjEtNy0xLTEtMTM0Njkz_75631a91-6b0d-4228-be35-0dae561a452b"
      unitRef="usd">1748100000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItMS0xLTEtMTM0Njkz_8218b95d-916c-4055-8470-1282e87f01c6"
      unitRef="usd">200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItMy0xLTEtMTM0Njkz_66468bac-2766-483d-a833-d8dd8bdb4168"
      unitRef="usd">-11100000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItNS0xLTEtMTM0Njkz_72c0cd04-a470-47d2-8ba3-5a20e9a680f5"
      unitRef="usd">-84400000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjItNy0xLTEtMTM0Njkz_8498941d-e20e-4f06-801b-f724aa80d934"
      unitRef="usd">560200000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtMS0xLTEtMTM0Njkz_88c50014-8324-4d3a-aa83-47cddb07997d"
      unitRef="usd">1134700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtMy0xLTEtMTM0Njkz_12f3a7f3-0154-4c5a-b687-8d1674fdde27"
      unitRef="usd">329200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtNS0xLTEtMTM0Njkz_6f5b464c-1a54-4223-bd59-9ec16a977632"
      unitRef="usd">2496500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjMtNy0xLTEtMTM0Njkz_f61f3b11-0239-4ba7-90c1-1c2ab4c804e9"
      unitRef="usd">1187900000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtMS0xLTEtMTM0Njkz_524c8197-9bae-461a-8cc3-dd2ad9f788a0"
      unitRef="usdPerShare">7.86</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtMy0xLTEtMTM0Njkz_53853d3c-1029-4e5c-8035-65ad204fcf15"
      unitRef="usdPerShare">2.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtNS0xLTEtMTM0Njkz_ca552457-2705-48e5-b347-4fd22989b316"
      unitRef="usdPerShare">17.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjYtNy0xLTEtMTM0Njkz_a58264f0-8807-4e95-9f4b-b3b8c14a147f"
      unitRef="usdPerShare">7.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctMS0xLTEtMTM0Njkz_ea38b6ff-c6e4-4892-948f-9d1eafe94ac0"
      unitRef="usdPerShare">7.84</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctMy0xLTEtMTM0Njkz_229ae766-10f0-423e-a017-67b29306f82d"
      unitRef="usdPerShare">2.22</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctNS0xLTEtMTM0Njkz_b258822d-3ed0-4e0d-b671-8d9efe2049e7"
      unitRef="usdPerShare">17.07</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMjctNy0xLTEtMTM0Njkz_75937a43-1ebb-4e05-9321-965d63f109a8"
      unitRef="usdPerShare">7.90</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtMS0xLTEtMTM0Njkz_c5a78c91-cbe6-4364-8124-deb3564e88da"
      unitRef="shares">144400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtMy0xLTEtMTM0Njkz_e2972d91-c8ba-44a9-b9b6-6dcbed242dbf"
      unitRef="shares">148000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtNS0xLTEtMTM0Njkz_d4494750-2b7d-42de-9848-5af3211a1e3a"
      unitRef="shares">145800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzAtNy0xLTEtMTM0Njkz_c34116dd-d6cf-4568-bba3-c6e2142d9f7a"
      unitRef="shares">149900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtMS0xLTEtMTM0Njkz_9a853797-afdf-4160-b2ab-07de8009c686"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtMy0xLTEtMTM0Njkz_4a5cb506-44c9-4df4-a209-ffaa0429920e"
      unitRef="shares">148600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtNS0xLTEtMTM0Njkz_57258ac9-cd31-48a1-8ccb-80b4d6298d6e"
      unitRef="shares">146200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xOS9mcmFnOmMwYzlhOGQ3OWRlYTRiNWQ5NmUxMDMzZjNmODIxYjZjL3RhYmxlOjVmZWQyMDg0YTFhZDRhNGY5NGU0YWIyYzUxNWI2NDY2L3RhYmxlcmFuZ2U6NWZlZDIwODRhMWFkNGE0Zjk0ZTRhYjJjNTE1YjY0NjZfMzEtNy0xLTEtMTM0Njkz_5d7cf22f-276a-436c-9f0f-70142470799d"
      unitRef="shares">150300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi0xLTEtMS0xMzQ2OTM_48167aca-252e-4de3-a8e3-31e56dc7f205"
      unitRef="usd">1134700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi0zLTEtMS0xMzQ2OTM_cf580c98-4cd3-44f6-afeb-0bb21e85885a"
      unitRef="usd">329200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi01LTEtMS0xMzQ2OTM_58d09195-b381-431e-b06d-59e4fd7a3487"
      unitRef="usd">2496500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMi03LTEtMS0xMzQ2OTM_195dbac8-b3a4-49ac-a10f-af43e62cf04a"
      unitRef="usd">1187900000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC0xLTEtMS0xMzQ2OTM_23f5947c-30d0-4cd2-9814-45a2f08c0022"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC0zLTEtMS0xMzQ2OTM_d95d6d5f-37d8-415d-8661-23bc0a9a2d4d"
      unitRef="usd">100000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC01LTEtMS0xMzQ2OTM_1de46930-17bd-4e02-a293-3fde497b8011"
      unitRef="usd">-19000000.0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNC03LTEtMS0xMzQ2OTM_feead1f0-e261-4c04-94e7-6cbc56c62b19"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS0xLTEtMS0xMzQ2OTM_253ea4e1-d792-42c7-8d99-3596f02ea48c"
      unitRef="usd">5900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS0zLTEtMS0xMzQ2OTM_611a3d55-f185-49a5-a9f0-0d237c518178"
      unitRef="usd">66200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS01LTEtMS0xMzQ2OTM_77c5d34d-f583-4e75-994e-6e0b253f0978"
      unitRef="usd">79000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNS03LTEtMS0xMzQ2OTM_1edd3c59-4f05-4fc1-92aa-34d38e666248"
      unitRef="usd">205000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi0xLTEtMS0xMzQ2OTM_80d0e3e8-2131-4530-a2e4-6f65c8542834"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi0zLTEtMS0xMzQ2OTM_70c5a620-378e-478d-818e-8131e919922e"
      unitRef="usd">15100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi01LTEtMS0xMzQ2OTM_8f788ef9-fcb6-408e-a890-d4e7ba6fee37"
      unitRef="usd">-25500000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNi03LTEtMS0xMzQ2OTM_e7ed165d-dbc3-4888-b909-4f13701ea3c3"
      unitRef="usd">35200000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy0xLTEtMS0xMzQ2OTM_713bfb80-e9f6-4c59-b55c-d9ff36d926fd"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy0zLTEtMS0xMzQ2OTM_d8a4036b-a186-4708-9bf6-c0558ab2a91d"
      unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy01LTEtMS0xMzQ2OTM_155c897b-a670-4623-b706-4c2c4de55ddd"
      unitRef="usd">-4200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfNy03LTEtMS0xMzQ2OTM_62783f4e-3a22-4daa-bee6-f2e6d44addec"
      unitRef="usd">-3900000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC0xLTEtMS0xMzQ2OTM_5e9dce82-a0aa-4a3a-8d5b-ab6e31b77363"
      unitRef="usd">-59600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC0zLTEtMS0xMzQ2OTM_0842b85d-8fc8-4e44-b4eb-d368717b92f8"
      unitRef="usd">-47700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC01LTEtMS0xMzQ2OTM_8533b29b-9131-4e8f-8626-4f3a3a8f4d48"
      unitRef="usd">-95600000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOC03LTEtMS0xMzQ2OTM_f1688502-c8b0-4e82-a20d-f59ad877dcbb"
      unitRef="usd">-80300000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS0xLTEtMS0xMzQ2OTM_2b0b7b6e-441a-4f1b-b051-8945707d8af0"
      unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS0zLTEtMS0xMzQ2OTM_f40bc51f-0629-42ad-8810-4443ef30eac7"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS01LTEtMS0xMzQ2OTM_facd7ab9-4301-4ccc-ac9b-2f186704d3ff"
      unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfOS03LTEtMS0xMzQ2OTM_a1292bd9-5969-42e9-8bb2-c499bf2a5ee5"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtMS0xLTEtMTM0Njkz_f2e70150-85e5-4eeb-a5de-4694afb3c7c2"
      unitRef="usd">1081500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtMy0xLTEtMTM0Njkz_9d7629fc-0477-4727-9fd2-86a7396f42b0"
      unitRef="usd">364400000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtNS0xLTEtMTM0Njkz_20e289d6-bbe5-4afb-bfe4-c5eb1335c5d8"
      unitRef="usd">2439600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTAtNy0xLTEtMTM0Njkz_a2b0599d-accc-4c7a-968c-f8de1bdde1dd"
      unitRef="usd">1350300000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtMS0xLTEtMTM0Njkz_5ac3da47-ec48-413e-8039-eefedc0dc120"
      unitRef="usd">200000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtMy0xLTEtMTM0Njkz_caa6bb4f-3aae-4dd0-881d-63f0e0866d82"
      unitRef="usd">-11100000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtNS0xLTEtMTM0Njkz_2202ebcc-ccf1-4a88-82c0-3831bec375f8"
      unitRef="usd">-84400000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTEtNy0xLTEtMTM0Njkz_041f9f69-eef7-4033-af28-cc38fca3ca80"
      unitRef="usd">560800000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItMS0xLTEtMTM0Njkz_f38fd29b-31d8-4941-bb9b-543b7a8350e3"
      unitRef="usd">1081700000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItMy0xLTEtMTM0Njkz_2862f09b-c70f-4057-b437-c128c11cb37b"
      unitRef="usd">353300000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItNS0xLTEtMTM0Njkz_c5c4d869-1aca-4dce-b7e5-8046df648710"
      unitRef="usd">2355200000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yMi9mcmFnOjc0MWUwMTY4NjY5YzQwY2Y4Y2QyNzFiMzBmNWNiNDc2L3RhYmxlOmQ1MmM1MGI3YTM1MDRkM2NhMGNhZTJkZWJlMmEwMzBkL3RhYmxlcmFuZ2U6ZDUyYzUwYjdhMzUwNGQzY2EwY2FlMmRlYmUyYTAzMGRfMTItNy0xLTEtMTM0Njkz_c7efe3a4-2ac7-4684-988e-b3e721ed7a58"
      unitRef="usd">1911100000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMy0xLTEtMS0xMzQ2OTM_14c26c12-0673-454c-8943-849e8f6f5203"
      unitRef="usd">3675600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMy0zLTEtMS0xMzQ2OTM_2f537028-1a70-454c-9ccd-c515479e006a"
      unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNC0xLTEtMS0xMzQ2OTM_d3266221-5a74-435e-adfb-a1449f743987"
      unitRef="usd">1235500000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNC0zLTEtMS0xMzQ2OTM_16a508ca-d5bb-42a7-82c2-12f19ac295f9"
      unitRef="usd">1541100000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNS0xLTEtMS0xMzQ2OTM_5935179f-efc9-49f9-a643-0374dcbab9a7"
      unitRef="usd">1568800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNS0zLTEtMS0xMzQ2OTM_728e12c0-07aa-4755-9aec-bed5b148d50e"
      unitRef="usd">1549400000</us-gaap:AccountsReceivableNetCurrent>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNi0xLTEtMS0xMzQ2OTM_abf2b209-e603-4b5c-a529-7f60e68fed76"
      unitRef="usd">415400000</biib:DuefromantiCD20therapeuticprograms>
    <biib:DuefromantiCD20therapeuticprograms
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNi0zLTEtMS0xMzQ2OTM_ab6107e3-6a14-4ced-b5e8-722f2d67fffc"
      unitRef="usd">412300000</biib:DuefromantiCD20therapeuticprograms>
    <us-gaap:InventoryNet
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNy0xLTEtMS0xMzQ2OTM_e1d4b5a3-1e61-47f4-a99b-d86c6454d060"
      unitRef="usd">1375000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNy0zLTEtMS0xMzQ2OTM_4039e541-aceb-480a-a7a8-e609b26214c7"
      unitRef="usd">1351500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOC0xLTEtMS0xMzQ2OTM_e67fd6f9-f493-4cb6-b5ca-1c00c33e6d2d"
      unitRef="usd">1495500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOC0zLTEtMS0xMzQ2OTM_f0195a09-1bb4-41c4-bb5d-fcf5f94e3b28"
      unitRef="usd">740800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOS0xLTEtMS0xMzQ2OTM_447acece-bfa5-4076-8ad9-3756509082dc"
      unitRef="usd">9765800000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfOS0zLTEtMS0xMzQ2OTM_3f8bb207-0894-4d34-abf8-ebda683d0aaa"
      unitRef="usd">7856500000</us-gaap:AssetsCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTAtMS0xLTEtMTM0Njkz_aefe1342-5353-4f1d-b208-2e617a325d90"
      unitRef="usd">860300000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTAtMy0xLTEtMTM0Njkz_6cd9a13e-97c8-4843-b946-ec9ff0c63474"
      unitRef="usd">892000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTEtMS0xLTEtMTM0Njkz_e2f099af-86bf-47df-a8de-24ecbabf2dc2"
      unitRef="usd">3266400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTEtMy0xLTEtMTM0Njkz_54fc54a5-38c6-40e2-a390-b15340c90d7a"
      unitRef="usd">3416400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTItMS0xLTEtMTM0Njkz_e3221085-c6da-43dc-a5b7-3d82233a7c78"
      unitRef="usd">424500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTItMy0xLTEtMTM0Njkz_dd7b688a-2654-4ea7-aadd-d2e14df53fcc"
      unitRef="usd">375400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTMtMS0xLTEtMTM0Njkz_cda00772-0bfa-458f-bbaf-4970f6e47bd7"
      unitRef="usd">2008900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTMtMy0xLTEtMTM0Njkz_7c971a40-29ac-4772-a383-39f243964e96"
      unitRef="usd">2221300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTQtMS0xLTEtMTM0Njkz_c5c77256-abdd-43d5-b872-296db7b2e7ae"
      unitRef="usd">5741200000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTQtMy0xLTEtMTM0Njkz_b2ae8372-c72b-4407-b308-798a5a96852d"
      unitRef="usd">5761100000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTUtMS0xLTEtMTM0Njkz_d6175e91-760f-488f-8ac1-3c147cae158a"
      unitRef="usd">1174500000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTUtMy0xLTEtMTM0Njkz_7cf79015-9c28-4509-a8ef-c3f4f2eaf71c"
      unitRef="usd">1415100000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTYtMS0xLTEtMTM0Njkz_2fc31f80-7ec6-457e-878d-81b9d81a376c"
      unitRef="usd">1612600000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTYtMy0xLTEtMTM0Njkz_6af4e389-6735-4a40-aace-451ad2cd8129"
      unitRef="usd">1939500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTctMS0xLTEtMTM0Njkz_b0dc9b0f-1b3f-4a6f-b419-e6a7f87c9e05"
      unitRef="usd">24854200000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMTctMy0xLTEtMTM0Njkz_b79dd895-3f84-48fb-a16d-af03e704cc58"
      unitRef="usd">23877300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjAtMS0xLTEtMTM0Njkz_02561168-a402-4bd7-8d65-035510fb96be"
      unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjAtMy0xLTEtMTM0Njkz_2340b03b-8388-450f-b4d4-ec5a3fd367c9"
      unitRef="usd">999100000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjEtMS0xLTEtMTM0Njkz_50e36a84-d13f-448b-a08e-2390b09f609c"
      unitRef="usd">237300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjEtMy0xLTEtMTM0Njkz_31993e4b-9b32-4839-bd26-5e5a02b7a98c"
      unitRef="usd">174700000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjItMS0xLTEtMTM0Njkz_ff3ad1d1-52f3-49dd-a9d3-4860e4323d12"
      unitRef="usd">383200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjItMy0xLTEtMTM0Njkz_3bf8b24c-ab93-4e11-a61f-c358ee7444df"
      unitRef="usd">589200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjMtMS0xLTEtMTM0Njkz_cf5878a9-845b-4943-aa87-8825d971681e"
      unitRef="usd">3305900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjMtMy0xLTEtMTM0Njkz_79a1135a-0b10-4f87-a470-73066ac36b10"
      unitRef="usd">2535200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjQtMS0xLTEtMTM0Njkz_ca709c37-d21f-4c64-8f15-4d4031f8ab26"
      unitRef="usd">3926400000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjQtMy0xLTEtMTM0Njkz_e5d0f1ff-0917-4439-a6ba-399066b4654e"
      unitRef="usd">4298200000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjUtMS0xLTEtMTM0Njkz_277c52ef-8419-460e-9f86-ba72b758c0c5"
      unitRef="usd">6279200000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjUtMy0xLTEtMTM0Njkz_ac3fa771-36a5-4848-9b6a-8fb92d8c66f9"
      unitRef="usd">6274000000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjYtMS0xLTEtMTM0Njkz_6e3a73eb-94fa-4081-a938-f0019196b7ea"
      unitRef="usd">328900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjYtMy0xLTEtMTM0Njkz_76a55d38-4a5c-4d22-8cc9-9abe385b04ce"
      unitRef="usd">694500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjctMS0xLTEtMTM0Njkz_d4889af5-9f4f-42f0-9ccf-ad3c930bfd69"
      unitRef="usd">354800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjctMy0xLTEtMTM0Njkz_1f2af86c-6b43-4be3-aedb-2c955d9f84ab"
      unitRef="usd">330400000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjgtMS0xLTEtMTM0Njkz_caa622a0-64e6-4f0a-89ff-632b41453167"
      unitRef="usd">1198100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjgtMy0xLTEtMTM0Njkz_53d78308-8b66-487c-bde4-907a3cb6e11b"
      unitRef="usd">1320500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjktMS0xLTEtMTM0Njkz_caf1988d-8c45-4550-b9cc-1d04260cb0cf"
      unitRef="usd">12087400000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMjktMy0xLTEtMTM0Njkz_a179907e-f777-4150-9356-c51becb94b2c"
      unitRef="usd">12917600000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzAtMS0xLTEtMTM0Njkz_ac7928ee-075d-4509-ae40-8e3536dc736e"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzAtMy0xLTEtMTM0Njkz_be24c4aa-92d2-4590-b947-152dd4c8e591"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzMtMS0xLTEtMTM0Njkz_c08e0e97-0722-480f-842a-e6bb98433a62"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzMtMy0xLTEtMTM0Njkz_b5f0982e-9bb7-4541-a51f-7143cbf68c38"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzQtMS0xLTEtMTM0Njkz_4626de38-403b-45cd-a492-8e9d6a17fbb4"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzQtMy0xLTEtMTM0Njkz_f377be43-e6c0-41f9-bb0e-7deff2f76742"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzUtMS0xLTEtMTM0Njkz_d36a0c2b-a7d6-4c4b-b355-c560d426fd87"
      unitRef="usd">0</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzUtMy0xLTEtMTM0Njkz_a521925f-d7c7-450a-a6d1-dd4bff809e5c"
      unitRef="usd">68200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzYtMS0xLTEtMTM0Njkz_001ed8ea-25d3-4d96-8bab-383fba2bf1ef"
      unitRef="usd">-163600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzYtMy0xLTEtMTM0Njkz_2fa412ab-05c2-4604-90c1-6f0fae8d678e"
      unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzctMS0xLTEtMTM0Njkz_53ddca5d-4770-4317-9d91-6d2aeb3fdb5c"
      unitRef="usd">15916100000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzctMy0xLTEtMTM0Njkz_bac97810-f889-476d-a96f-fae83b373fa7"
      unitRef="usd">13911700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzgtMS0xLTEtMTM0Njkz_a3bcd732-0a13-4f7d-b83d-cf4a0d058c80"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzgtMy0xLTEtMTM0Njkz_710d4362-ca83-46da-9e71-a697b3b16857"
      unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquity
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzktMS0xLTEtMTM0Njkz_1e6bff31-aaac-48f5-a172-1e3921fa6b62"
      unitRef="usd">12775500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfMzktMy0xLTEtMTM0Njkz_95ac500b-59e1-4a59-88c9-22fb4d1e42a7"
      unitRef="usd">10896200000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDAtMS0xLTEtMTM0Njkz_8f78c770-9530-47c8-b54f-d045dd47ce92"
      unitRef="usd">-8700000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDAtMy0xLTEtMTM0Njkz_88532913-6a63-4ef0-9168-54ff9782432c"
      unitRef="usd">63500000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDEtMS0xLTEtMTM0Njkz_5077589a-9954-4c8c-be83-c1bdd226d4e1"
      unitRef="usd">12766800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDEtMy0xLTEtMTM0Njkz_d9f85c3a-514a-4778-b96f-ccd492d5db2d"
      unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDItMS0xLTEtMTM0Njkz_740dc726-9ca8-4e9b-8f2c-80c38630d26c"
      unitRef="usd">24854200000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yNS9mcmFnOjYyM2JlZmNlM2VjNDQ2NDY5OGM1OWVmYzYzYjk2MGFhL3RhYmxlOjcwMmM5OTQ0NDc4NDQwYWZiYTJmODVjNGRhMmNmYTQ5L3RhYmxlcmFuZ2U6NzAyYzk5NDQ0Nzg0NDBhZmJhMmY4NWM0ZGEyY2ZhNDlfNDItMy0xLTEtMTM0Njkz_66871b1c-bb8a-40b0-9fd1-b3a388894fb3"
      unitRef="usd">23877300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMy0xLTEtMS0xMzQ2OTM_e1bf3e03-a01d-4657-ac2f-ebbb87f53a94"
      unitRef="usd">2412100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMy0zLTEtMS0xMzQ2OTM_ad853939-bced-447a-8137-748a7816917a"
      unitRef="usd">1748100000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNS0xLTEtMS0xMzQ2OTM_70080dd9-aa24-4f13-93b4-6902ed3fec93"
      unitRef="usd">398600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNS0zLTEtMS0xMzQ2OTM_a6337bb7-502f-47dc-abab-2c703105dd83"
      unitRef="usd">353000000.0</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNi0xLTEtMS0xMzQ2OTM_1e135023-b39c-44c2-a8cf-57456b73153c"
      unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNi0zLTEtMS0xMzQ2OTM_d25105ca-d1cd-45be-a83a-b1e9c0fcc454"
      unitRef="usd">629300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNy0xLTEtMS0xMzQ2OTM_d3bbad86-c278-4646-a44e-3b47d6e59be0"
      unitRef="usd">321600000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNy0zLTEtMS0xMzQ2OTM_aeea4c7b-3369-44a4-879f-0cdc02c7c714"
      unitRef="usd">36500000</us-gaap:InventoryWriteDown>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOC0xLTEtMS0xMzQ2OTM_4857c29b-ec35-4a7e-9282-6eaa100f7121"
      unitRef="usd">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOC0zLTEtMS0xMzQ2OTM_323f4c36-6cf4-4f73-8b26-51251881b3c8"
      unitRef="usd">18000000.0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ShareBasedCompensation
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOS0xLTEtMS0xMzQ2OTM_18eca0d5-c766-4a95-866f-45ac17c22900"
      unitRef="usd">186900000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfOS0zLTEtMS0xMzQ2OTM_fc692072-09a2-4466-9ab6-de5b33f8c4e2"
      unitRef="usd">179800000</us-gaap:ShareBasedCompensation>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTAtMS0xLTEtMTM0Njkz_d61c1fa0-b78a-42ad-b221-dfa5fc3a5282"
      unitRef="usd">13700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTAtMy0xLTEtMTM0Njkz_03cef0d6-a0e2-4c84-b6de-943589f30c7e"
      unitRef="usd">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTEtMS0xLTEtMTM0Njkz_f744018d-d873-4127-963d-751ee72819d7"
      unitRef="usd">-139800000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTEtMy0xLTEtMTM0Njkz_86605106-6814-4f9e-98d5-9252bff79ed5"
      unitRef="usd">-750100000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTItMS0xLTEtMTM0Njkz_1e35380c-3236-4e73-8f73-95ec845eec54"
      unitRef="usd">-160300000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTItMy0xLTEtMTM0Njkz_1cfcea87-7f09-4d73-b50d-188bb699fca4"
      unitRef="usd">-710500000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTMtMS0xLTEtMTM0Njkz_584b0062-0c10-4e16-9cfe-8bc4c1f4fc0a"
      unitRef="usd">2600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTMtMy0xLTEtMTM0Njkz_d2ca92e0-c7a3-4b19-b98c-6d0554e29f3f"
      unitRef="usd">17200000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTQtMS0xLTEtMTM0Njkz_7e129a48-c38c-40db-a134-67a2332888e9"
      unitRef="usd">1505400000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTQtMy0xLTEtMTM0Njkz_3b57b893-e76a-4fd3-89aa-17533b2a502e"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMS0xLTEtMTQwMjU5_de6fa2d2-e762-4d54-a9b7-8b55f94f3066"
      unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMy0xLTEtMTQwMjU5_15f496aa-a949-487e-919a-9f2b6eee39de"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMS0xLTEtMTM0Njkz_ae912c20-90a2-4866-bd6b-d8ab1af66872"
      unitRef="usd">-147800000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTUtMy0xLTEtMTM0Njkz_0299335b-012b-492b-b088-d0c46381b228"
      unitRef="usd">-164500000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTctMS0xLTEtMTM0Njkz_14cc37e4-c94e-4490-b807-7b5c134b0b52"
      unitRef="usd">109500000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTctMy0xLTEtMTM0Njkz_3944c16d-01cc-4e37-a775-8c3297bd87e2"
      unitRef="usd">-157800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTgtMS0xLTEtMTM0Njkz_2a020938-bd0c-4d0f-b87d-72590c36782b"
      unitRef="usd">3000000.0</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInDueFromRelatedParties
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTgtMy0xLTEtMTM0Njkz_dfa342f0-8124-4579-8240-14b1ca23461d"
      unitRef="usd">-13500000</us-gaap:IncreaseDecreaseInDueFromRelatedParties>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTktMS0xLTEtMTM0Njkz_7714ab06-8bc4-4dda-8bd1-cad83fd0b55b"
      unitRef="usd">338300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMTktMy0xLTEtMTM0Njkz_0ef4293d-79a2-4465-8b3c-c52ad4acb0c1"
      unitRef="usd">322600000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjAtMS0xLTEtMTM0Njkz_8686af22-c1e6-494e-a770-f69da89a0657"
      unitRef="usd">632300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjAtMy0xLTEtMTM0Njkz_281e3fe1-ab6f-43d7-9d54-8d6f22eb9846"
      unitRef="usd">-243300000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjEtMS0xLTEtMTM0Njkz_81e8a614-d108-4bc5-8e9b-b2db77940b07"
      unitRef="usd">-100200000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjEtMy0xLTEtMTM0Njkz_82aa8e1d-f97b-4e33-aa14-7e6db098f215"
      unitRef="usd">260500000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjItMS0xLTEtMTM0Njkz_62aaca8a-a8d4-4900-abd1-69039f6eabd3"
      unitRef="usd">-15900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjItMy0xLTEtMTM0Njkz_0ec2c985-3787-445a-806f-ecccbed4b852"
      unitRef="usd">87600000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjMtMS0xLTEtMTM0Njkz_1e692244-31e7-4b8b-ab27-ee8cb444b0d1"
      unitRef="usd">1559300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjMtMy0xLTEtMTM0Njkz_a8bdf586-9884-4e39-87e0-d53fc88e89b5"
      unitRef="usd">2801600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjUtMS0xLTEtMTM0Njkz_d3258cd8-147f-4ccd-b0dc-56089bb661e3"
      unitRef="usd">153900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjUtMy0xLTEtMTM0Njkz_d82e6f8d-3418-43e2-afb3-67072d48ff4f"
      unitRef="usd">206500000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjYtMS0xLTEtMTM0Njkz_0604243c-44c0-47c4-bc84-dacfa93d5d8c"
      unitRef="usd">3104700000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjYtMy0xLTEtMTM0Njkz_b7bc709b-559f-4b37-9c4d-838b27c0c5b5"
      unitRef="usd">2028100000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjctMS0xLTEtMTM0Njkz_9ff31b76-8987-4a79-b5b3-e8cd744e5693"
      unitRef="usd">2805900000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjctMy0xLTEtMTM0Njkz_ea8ac102-1b03-4aa3-9599-499640c57654"
      unitRef="usd">2372600000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjgtMS0xLTEtMTM0Njkz_bff6ebc0-a9ad-4e94-82cd-b5ef9539b5d9"
      unitRef="usd">990300000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjgtMy0xLTEtMTM0Njkz_50436ed2-5c7a-4a14-9144-2f388fb1ee37"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMS0xLTEtMTQwMjg1_8e85be88-9892-47b1-b55d-469f0e449ea4"
      unitRef="usd">582600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMy0xLTEtMTQwMjg1_eba9a21f-3f3b-4ca3-86a3-8d63504f7958"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjktMS0xLTEtMTM0Njkz_1721cce2-0224-4b37-83e5-b2fa05277b11"
      unitRef="usd">0</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMjktMy0xLTEtMTM0Njkz_6746700e-647d-49ad-9d21-10561a0e31d2"
      unitRef="usd">28100000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMS0xLTEtMTM0Njkz_40e2f5d0-b53a-429e-99ed-f545d8920375"
      unitRef="usd">0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzAtMy0xLTEtMTM0Njkz_c82ebae4-36e2-4ac7-b68a-7b6a1ea42075"
      unitRef="usd">18000000.0</us-gaap:PaymentsToAcquireInProcessResearchAndDevelopment>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzEtMS0xLTEtMTM0Njkz_99e0994a-b8cd-46a3-a408-b38dee6a556d"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzEtMy0xLTEtMTM0Njkz_65191059-44e3-4c80-a6a5-40e73bfe90ec"
      unitRef="usd">1900000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzItMS0xLTEtMTM0Njkz_29a9d420-da38-4470-8801-b873156e7faf"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzItMy0xLTEtMTM0Njkz_0eb133ef-bf93-4c49-9a1a-c621241909c7"
      unitRef="usd">91200000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzMtMS0xLTEtMTM0Njkz_a4bacbc8-5943-4443-99e3-39efd03f0c64"
      unitRef="usd">-1800000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzMtMy0xLTEtMTM0Njkz_0b972873-cc98-40ce-adb3-4e0b2c1b4048"
      unitRef="usd">-600000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzQtMS0xLTEtMTM0Njkz_07dba1ff-916d-4412-a9eb-937d294b94bb"
      unitRef="usd">1717700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzQtMy0xLTEtMTM0Njkz_d7c0d8f3-0797-43ca-8ce5-9d2abcf4452a"
      unitRef="usd">-451000000.0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzYtMS0xLTEtMTM0Njkz_6f4f489b-7c00-45d0-a2ff-5b541c853df9"
      unitRef="usd">750000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzYtMy0xLTEtMTM0Njkz_16eee98c-17ee-4020-b1e4-7a5c3416fa40"
      unitRef="usd">1800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzctMS0xLTEtMTM0Njkz_6a8c1c11-18fa-48f7-8a88-fded6f8ded72"
      unitRef="usd">5800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzctMy0xLTEtMTM0Njkz_c7c0a737-5e49-46b2-9334-b299ba03c0ad"
      unitRef="usd">8300000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzgtMS0xLTEtMTM0Njkz_167ccc7f-9d53-420f-a94f-bd9ed6bbc2d8"
      unitRef="usd">1002200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfMzgtMy0xLTEtMTM0Njkz_280c4221-9ee4-43ac-917f-e6263d114229"
      unitRef="usd">170000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDEtMS0xLTEtMTM0Njkz_46796b44-2ea4-499f-9834-9749e00ba4c1"
      unitRef="usd">12200000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsToMinorityShareholders
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDEtMy0xLTEtMTM0Njkz_08a1eab1-07c6-4e44-abb2-9e2abe3d1950"
      unitRef="usd">-94800000</us-gaap:ProceedsFromPaymentsToMinorityShareholders>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDItMS0xLTEtMTM0Njkz_c9a278b0-adc1-4acf-8206-89ed901e051f"
      unitRef="usd">5900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDItMy0xLTEtMTM0Njkz_574d7bfa-99cd-4bb2-9f11-1f07edfb1ce4"
      unitRef="usd">-22900000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDMtMS0xLTEtMTM0Njkz_d5bc6295-90ed-4b34-afef-eb213d8dd90c"
      unitRef="usd">-1739900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDMtMy0xLTEtMTM0Njkz_71280bbf-fe60-4082-8ff5-06b029e12224"
      unitRef="usd">-2096000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDQtMS0xLTEtMTM0Njkz_48d317ef-2467-48d0-9956-c317877f8277"
      unitRef="usd">1537100000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDQtMy0xLTEtMTM0Njkz_047eb0d0-6339-4b3b-af30-1f0d6495e700"
      unitRef="usd">254600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDUtMS0xLTEtMTM0Njkz_b4e92392-cfa3-42ed-8aee-f9311c3d3094"
      unitRef="usd">-122900000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDUtMy0xLTEtMTM0Njkz_6d56e111-f79c-4945-931f-4090490a5286"
      unitRef="usd">-44000000.0</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDYtMS0xLTEtMTM0Njkz_8b595b62-9a45-4045-8b51-1e9be19a5594"
      unitRef="usd">2261400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDYtMy0xLTEtMTM0Njkz_8cb9462f-a49c-453a-98cc-95d848e1ef55"
      unitRef="usd">1331200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDctMS0xLTEtMTM0Njkz_347f3155-88f4-49cd-a580-80082ef52787"
      unitRef="usd">3675600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i957729f8711844ff89317163bd3b28ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8yOC9mcmFnOmU0Y2NkYTVkN2Y4MzQyYzhiYTlkMmY0NzI5MWRmZDE4L3RhYmxlOjVhZWZmNjQyZTg0NjQzZmJhMjU2NDJkNjI1YjZjNjU3L3RhYmxlcmFuZ2U6NWFlZmY2NDJlODQ2NDNmYmEyNTY0MmQ2MjViNmM2NTdfNDctMy0xLTEtMTM0Njkz_e06f4a7c-4232-4558-a63a-23cc5bf89634"
      unitRef="usd">1541800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if1aee04605d242bfb83b7fe9c6cb1edc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xLTEtMS0xMzQ2OTM_dc0369ea-c870-4763-94e3-375ccb7ea4b7"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if1aee04605d242bfb83b7fe9c6cb1edc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0zLTEtMS0xMzQ2OTM_da0db8db-6c7a-4fbb-8f09-f6c55ff8e8ca"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i835d8ccc4e79473b96d3739d3fc0f451_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi01LTEtMS0xMzQ2OTM_7d42588f-3cc7-40b0-9f99-1f7ca99b55ab"
      unitRef="shares">169000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i835d8ccc4e79473b96d3739d3fc0f451_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi03LTEtMS0xMzQ2OTM_96371406-f757-47e6-a117-96872e9134d3"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id36ae3eeb09d4b00b8023ee15c29a104_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi05LTEtMS0xMzQ2OTM_f1f67500-2e38-47e9-81b3-02c9a1b965c1"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i385b6988b4664d52a88f8aaf055e4153_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xMS0xLTEtMTM0Njkz_4e906cdd-e479-4b1d-a3f0-859ada4d917d"
      unitRef="usd">-110400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3df7f5528d01483d85bf88ee051bf26a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xMy0xLTEtMTM0Njkz_768c8ec1-17eb-4dba-9a27-413b5c14a7e9"
      unitRef="usd">14959900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ie99add0e88f54844bcc4c75b8cdd5670_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xNS0xLTEtMTM0Njkz_b3b89059-d73f-43bc-aa8d-27af526722d5"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie99add0e88f54844bcc4c75b8cdd5670_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xNy0xLTEtMTM0Njkz_7b98d6db-fbc6-4e09-942b-67500ee0a1d6"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibedabc034ea240c0b3ac08428570bb02_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0xOS0xLTEtMTM0Njkz_d528d69c-394e-48ee-961f-63d8a7f4de97"
      unitRef="usd">11872500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2a2bd09b86954ad5a4bee8091dd95fdf_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0yMS0xLTEtMTM0Njkz_48c59b77-8ee1-4615-ac9a-553905c40fe1"
      unitRef="usd">-9100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="idd70f96bb3774f148eea2bb8f9432dc4_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMi0yMy0xLTEtMTM0Njkz_96e5ebdb-a24b-4655-aacf-307949182f9a"
      unitRef="usd">11863400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i239d15fce1e540cea5ec4ef251ea8908_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0xMy0xLTEtMTM0Njkz_a6352eee-2af4-4c53-809f-2238efb11cb4"
      unitRef="usd">1134700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0xOS0xLTEtMTM0Njkz_f5c193fb-1a97-4368-b591-447800462c6e"
      unitRef="usd">1134700000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ib92b65c6517c4a3480678a0a31182921_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0yMS0xLTEtMTM0Njkz_9c38e793-f309-451d-8acb-01f5e96ce6b5"
      unitRef="usd">200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMy0yMy0xLTEtMTM0Njkz_40173ff8-cf56-4f06-a5a9-749302c16b2f"
      unitRef="usd">1134900000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i66f984c3b15d4a31acd93e52732606cb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNC0xMS0xLTEtMTM0Njkz_4c9766b1-b431-4ca3-a8bd-482157cdf969"
      unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNC0xOS0xLTEtMTM0Njkz_efa048cb-5c64-406e-9030-950e9397abea"
      unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNC0yMy0xLTEtMTM0Njkz_a43abb8c-5baf-44e3-aa28-a5e474413147"
      unitRef="usd">-53200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ib92b65c6517c4a3480678a0a31182921_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNi0yMS0xLTEtMTM0Njkz_ac26a8d1-60cc-4dee-bc04-fd8738eff133"
      unitRef="usd">200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNi0yMy0xLTEtMTM0Njkz_6b0ebd29-b312-4945-827f-24e75694fb4c"
      unitRef="usd">200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0xNS0xLTEtMTM0Njkz_cb33d586-d70f-44e6-900e-9fcf31788e14"
      unitRef="shares">1200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0xNy0xLTEtMTM0Njkz_70fcff13-c663-4fa2-9277-bb965167fd39"
      unitRef="usd">250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic367eb9333f6492b83e15ec443ce582f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0xOS0xLTEtMTM0Njkz_e5f25a87-1bfb-4d0b-966d-69661ba8bbd9"
      unitRef="usd">250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfNy0yMy0xLTEtMTM0Njkz_6d464d13-0a99-4ef2-aded-057c54cc3786"
      unitRef="usd">250000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i702681f6e9854a2c9237a3f37fa30d3a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC01LTEtMS0xMzQ2OTM_5c5dd55b-9945-498b-90e1-ef7dc323c0e1"
      unitRef="shares">1200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i759633f59042448b81434c16a76b3557_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC05LTEtMS0xMzQ2OTM_b1ae31df-efc0-4e0f-8689-1dc406ffbc8b"
      unitRef="usd">71500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i47eb6434b4184bf1862e2d8683e198b4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0xMy0xLTEtMTM0Njkz_dd991cbb-1012-4bd1-a613-5b418faff1f1"
      unitRef="usd">178500000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0xNS0xLTEtMTM0Njkz_17edee35-b107-4536-8d03-68a15a32dd84"
      unitRef="shares">1200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="if1ebcc2ff4a24906ac43ac0616637174_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0xNy0xLTEtMTM0Njkz_c1895a35-4205-40e3-a5f7-a7de4831dd7d"
      unitRef="usd">-250000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOC0yMy0xLTEtMTM0Njkz_0527283e-9bba-475c-b51a-b2764e02e086"
      unitRef="usd">0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="icfdf3c77bb8d4707b6431886367684a2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS01LTEtMS0xMzQ2OTM_74dfd0ce-3478-4ea3-ae11-ca93e01eeca0"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS05LTEtMS0xMzQ2OTM_2c1bd277-3a8b-4cc4-aaab-87b62778a416"
      unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS0xOS0xLTEtMTM0Njkz_8164ff14-8b69-4ba5-ab85-86ac62624fa0"
      unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfOS0yMy0xLTEtMTM0Njkz_5687cdef-99ba-4856-9d0b-0f0abd9f18a3"
      unitRef="usd">8600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="icfdf3c77bb8d4707b6431886367684a2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtNS0xLTEtMTM0Njkz_30253854-a761-4be4-9b48-b01664b0a4f4"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtOS0xLTEtMTM0Njkz_d93944d8-14cf-4bd6-95a6-117c140eb45a"
      unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtMTktMS0xLTEzNDY5Mw_fb36c7f4-27f8-4d3b-86db-8f3608cabd02"
      unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTAtMjMtMS0xLTEzNDY5Mw_869a6654-b148-4f9d-b51a-73e2aabfb5e3"
      unitRef="usd">-2800000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTEtOS0xLTEtMTM0Njkz_a6ae6a7f-d8a6-4bb5-97eb-0b2622b2c82b"
      unitRef="usd">-65700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTEtMTktMS0xLTEzNDY5Mw_f095c8a7-e45c-43b1-943b-1680045fbd25"
      unitRef="usd">-65700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTEtMjMtMS0xLTEzNDY5Mw_96284f5c-79d4-425a-b881-23b662723d7d"
      unitRef="usd">-65700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i52b178fd120d412a861501afee397e6e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTItOS0xLTEtMTM0Njkz_d6724bfa-dfdf-41dc-8539-63d106117f13"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i9f6bf1ae721a4ca285fd0f96d0409ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTItMTktMS0xLTEzNDY5Mw_584245fe-e37f-423e-91aa-7b46c5c8aa63"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTItMjMtMS0xLTEzNDY5Mw_e3144e0e-565e-4551-9cdd-5fa8543b1831"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMS0xLTEtMTM0Njkz_dd33648a-661c-4adf-ba81-aeda4ffb9b3f"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMy0xLTEtMTM0Njkz_12e9d805-657c-4302-9105-9f377a8eddc3"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtNS0xLTEtMTM0Njkz_5613e90d-e003-47b5-a8a9-bedd34c8a75a"
      unitRef="shares">167800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtNy0xLTEtMTM0Njkz_1f0c8c63-61be-4ad1-8790-cb184e3e9cd9"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5068c3b18e94e8eaaf2091ea3cf9695_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtOS0xLTEtMTM0Njkz_b4c8c9ea-ad52-4447-b402-ebe831adeb48"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0fa57a6c3f4fa4942ba9c62ac16a53_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTEtMS0xLTEzNDY5Mw_76ab45e1-72b7-4ec4-bf83-968db0f2742a"
      unitRef="usd">-163600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b3d30bc29ae41cb9335a4b23f385945_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTMtMS0xLTEzNDY5Mw_c99ae88f-4ea7-4d6f-990a-777b09fcb231"
      unitRef="usd">15916100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTUtMS0xLTEzNDY5Mw_e2747741-0944-4d9b-8cd7-e999762d5574"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTctMS0xLTEzNDY5Mw_bfa18b41-4ddb-46a3-8c66-60366c5b6676"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2a2cbbf2a9947cc889f57763f6fb24a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMTktMS0xLTEzNDY5Mw_2f425ccf-a938-4d86-b7f1-3eec8748af9d"
      unitRef="usd">12775500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ac4673c093c48e281f08d7e26c19005_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMjEtMS0xLTEzNDY5Mw_76368d41-dd27-4bbd-8090-5156e4a54c76"
      unitRef="usd">-8700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmQzYTU1YWMxNTEyODRlM2RiZWU5ZjVkZTFmNWZmMjRkL3RhYmxlcmFuZ2U6ZDNhNTVhYzE1MTI4NGUzZGJlZTlmNWRlMWY1ZmYyNGRfMTMtMjMtMS0xLTEzNDY5Mw_6e38e77b-e993-42d3-af11-dc11e3e6ba68"
      unitRef="usd">12766800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="id54e452525014575861abb8575bfa40f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xLTEtMS0xMzQ2OTM_8252b7be-adad-485d-b062-33f67dc5da99"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id54e452525014575861abb8575bfa40f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0zLTEtMS0xMzQ2OTM_41f277cc-f207-4be3-ac67-9a093eb60974"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i6150f5ddab6c45c9aa1fbef55937177e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi01LTEtMS0xMzQ2OTM_f3a56749-9fb0-4a3d-b17f-d38c7ebfcb2c"
      unitRef="shares">170800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6150f5ddab6c45c9aa1fbef55937177e_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi03LTEtMS0xMzQ2OTM_53d0b5f3-de8c-4e68-8fa0-22a2af5c88bc"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i06a5ef7f9cda42e78d300b36e9338315_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi05LTEtMS0xMzQ2OTM_6e5f08e5-9982-4e42-ab25-8de073a01562"
      unitRef="usd">68200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7cee2e97b0274d3aa6084ff72dceb5e3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xMS0xLTEtMTM0Njkz_6bf4d663-dfa8-446f-8af1-4e8586710b72"
      unitRef="usd">-106700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibfaaee5621ff405286fd6056576cd59b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xMy0xLTEtMTM0Njkz_f4d5e2c1-e3ae-4a96-93d7-05a2874bea94"
      unitRef="usd">13911700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if66f99b3393445feb052472c42d6ea59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xNS0xLTEtMTM0Njkz_11d29300-137b-4e10-882c-cd4f6b3bd8b7"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if66f99b3393445feb052472c42d6ea59_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xNy0xLTEtMTM0Njkz_7b29d961-4087-4ffc-91f2-4af652b0e3b1"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e74df0a4fa34fa7b4d9f15ccfa2ccce_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0xOS0xLTEtMTM0Njkz_b712a86e-3dd9-44e0-b0c3-f0f7779e1332"
      unitRef="usd">10896200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3990a5fbd8c6491e91e119ed2fdea887_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0yMS0xLTEtMTM0Njkz_9348c71a-6067-46e6-8d6e-bf2cfebc269b"
      unitRef="usd">63500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMi0yMy0xLTEtMTM0Njkz_94536c04-4745-46ed-a9e9-e71c62a5d5e6"
      unitRef="usd">10959700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i823c7f9f43d342ba884251bf9f5bd146_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0xMy0xLTEtMTM0Njkz_2e7d7f12-a1c0-422c-83c8-8d40d40fef52"
      unitRef="usd">2496500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0xOS0xLTEtMTM0Njkz_31080d92-4412-4206-90e3-86856b3f8ea0"
      unitRef="usd">2496500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ic891f4015650489eb42c53e2bfc38c39_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0yMS0xLTEtMTM0Njkz_7fd1a309-044f-4ab1-af25-e096a7893542"
      unitRef="usd">-84400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMy0yMy0xLTEtMTM0Njkz_e534237c-aa22-41ff-9720-7a525a4e8683"
      unitRef="usd">2412100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e12504ff04743d888a4e88d3bff71b4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNC0xMS0xLTEtMTM0Njkz_42e4466b-cc49-43c0-8490-e99fa7f0472a"
      unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNC0xOS0xLTEtMTM0Njkz_8cc35c85-6a95-4977-811b-db640fc59eed"
      unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNC0yMy0xLTEtMTM0Njkz_0443836c-4dad-4423-9afc-2793174c1049"
      unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ic891f4015650489eb42c53e2bfc38c39_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNi0yMS0xLTEtMTM0Njkz_536ebe55-ea23-4cf9-a421-9fff5ae76e34"
      unitRef="usd">12200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNi0yMy0xLTEtMTM0Njkz_de9d9be8-c46b-4d5a-b630-40120d9cf621"
      unitRef="usd">12200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0xNS0xLTEtMTM0Njkz_d479f211-79f9-4138-87c2-7d27ea00c1a0"
      unitRef="shares">3600000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0xNy0xLTEtMTM0Njkz_77e55f0e-c134-4723-9366-9f6339b7397c"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ia0e15bd993a74d7398c821d849b6ea3c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0xOS0xLTEtMTM0Njkz_592440a3-3ea0-4b2c-847d-67b9be20d251"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfNy0yMy0xLTEtMTM0Njkz_65f81ae8-acf3-40ef-a699-339c9d1752b4"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ia7258ddc589f4c9088e286caf7f6e0b7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC01LTEtMS0xMzQ2OTM_71135029-edf3-4f0b-a51a-045979b50d5d"
      unitRef="shares">3600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i4495699cfde945d2a01834b568e58db0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC05LTEtMS0xMzQ2OTM_874d64fc-6ba9-46b3-8d68-d9299a68966c"
      unitRef="usd">257900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i016bab72022342ff94ff7761ad5e759f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC0xMy0xLTEtMTM0Njkz_9e2cc628-b472-4032-93e5-17e06ddc1d17"
      unitRef="usd">492100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC0xNS0xLTEtMTM0Njkz_f4b7530a-fe04-48e6-8ec9-dd4ba0d002d7"
      unitRef="shares">3600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i76331b1a436c4090b5a229c6d64a734f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOC0xNy0xLTEtMTM0Njkz_1049199c-cf20-4133-9115-23c3db8a1c78"
      unitRef="usd">-750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i40f04ec35e4e4acb994f1e07cc20f981_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS01LTEtMS0xMzQ2OTM_512c5783-4c78-42ed-a57f-148f85e17aee"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS05LTEtMS0xMzQ2OTM_8ebb0583-26d3-4289-8904-df7ae7aa620d"
      unitRef="usd">37500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS0xOS0xLTEtMTM0Njkz_e21b41b8-0e16-48fa-ae42-1d668caf9a88"
      unitRef="usd">37500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfOS0yMy0xLTEtMTM0Njkz_ea2cb4ec-019a-4df0-844a-b28654c963b6"
      unitRef="usd">37500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i40f04ec35e4e4acb994f1e07cc20f981_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtNS0xLTEtMTM0Njkz_c3b23c27-f36e-41d6-87a9-65a7ff35012c"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtOS0xLTEtMTM0Njkz_20d0a6a9-ef6c-4347-b636-e3de1a1760d3"
      unitRef="usd">-43200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtMTktMS0xLTEzNDY5Mw_4a065699-f9b2-4240-8971-cefb22f45ac3"
      unitRef="usd">-43200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTAtMjMtMS0xLTEzNDY5Mw_4ff269e8-c453-4950-bf27-a1cc5c7172e2"
      unitRef="usd">-43200000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTEtOS0xLTEtMTM0Njkz_b701e2cf-0f0b-4e88-a133-6ca8e79ab276"
      unitRef="usd">-194100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTEtMTktMS0xLTEzNDY5Mw_e062eaf8-80d8-4d77-a476-3094b252ddb9"
      unitRef="usd">-194100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTEtMjMtMS0xLTEzNDY5Mw_b6f61b33-92c8-41f4-9b8e-5549b48a8e34"
      unitRef="usd">-194100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="ie9529afbf9a14b74aea64f2f3f4b2b99_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTItOS0xLTEtMTM0Njkz_7594154a-3079-4689-9762-581f32cea37f"
      unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i555c6b2b8fc6475bbf02f934dfa861dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTItMTktMS0xLTEzNDY5Mw_9e876f53-6266-435f-960a-0230f08f966b"
      unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTItMjMtMS0xLTEzNDY5Mw_be2b3afc-b8d7-4101-9bfe-2fd0d42b678f"
      unitRef="usd">-1300000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMS0xLTEtMTM0Njkz_d258d0e5-f948-4456-b55f-05bd02606b3a"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i47664e2a665d414a81f45b227301ee8b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMy0xLTEtMTM0Njkz_b96f9fed-b0a5-44ba-bab5-ee4d27f1fdfd"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtNS0xLTEtMTM0Njkz_9a5e022d-eeb0-45e2-ad4e-73bdd381627b"
      unitRef="shares">167800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaef22786954a47d5be08054078b6dbc6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtNy0xLTEtMTM0Njkz_76e2915f-b251-4d02-bdf7-24d487095ff0"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5068c3b18e94e8eaaf2091ea3cf9695_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtOS0xLTEtMTM0Njkz_bd142849-6190-4f4f-8d65-d929e830f444"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7e0fa57a6c3f4fa4942ba9c62ac16a53_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTEtMS0xLTEzNDY5Mw_63386bcd-7a3b-4e6d-bd46-a29a9df37135"
      unitRef="usd">-163600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b3d30bc29ae41cb9335a4b23f385945_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTMtMS0xLTEzNDY5Mw_122bf409-ae23-4be7-a539-e3580dc8effb"
      unitRef="usd">15916100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTUtMS0xLTEzNDY5Mw_7ff89596-2930-4d0d-b9b4-07ebd0bdeda4"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3caac96ac07546cc86bfb686908d7b3e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTctMS0xLTEzNDY5Mw_99a5d0c8-842c-40cb-af2d-bf6ea3f1a8a8"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie2a2cbbf2a9947cc889f57763f6fb24a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMTktMS0xLTEzNDY5Mw_cedde628-84cc-470a-a6a0-206ffa736ff3"
      unitRef="usd">12775500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7ac4673c093c48e281f08d7e26c19005_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMjEtMS0xLTEzNDY5Mw_dab81fa2-9d0e-4faf-b14d-417e68cc1994"
      unitRef="usd">-8700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOmZkOGE0MDIxOTA4YjQ1NmI5ZmZmYzUwNGQ4ZDc5NTBjL3RhYmxlcmFuZ2U6ZmQ4YTQwMjE5MDhiNDU2YjlmZmZjNTA0ZDhkNzk1MGNfMTMtMjMtMS0xLTEzNDY5Mw_c0c269b2-122d-4e95-950f-02e7bc7c529d"
      unitRef="usd">12766800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia6ecf9467f994f5599b5246c048da7f0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xLTEtMS0xMzQ2OTM_b59a38fb-7c47-40fc-865b-07907ec6be31"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia6ecf9467f994f5599b5246c048da7f0_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0zLTEtMS0xMzQ2OTM_7df46929-ba91-4bcf-845a-5a3b4ec71eec"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if30d21aaea274bffaf4cb30ef1f8e3dc_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi01LTEtMS0xMzQ2OTM_46dd246c-eb6a-416c-a5f1-d9c4f75cf012"
      unitRef="shares">172900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if30d21aaea274bffaf4cb30ef1f8e3dc_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi03LTEtMS0xMzQ2OTM_2a81111d-9ec9-495f-a1fb-25052de64e30"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5fb9684f2f3649a1bffccb6af71ea857_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi05LTEtMS0xMzQ2OTM_4bbae366-45a5-4310-b6c1-5991e94654ee"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i49fb8433ee7144e590c0de93a2924ac6_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xMS0xLTEtMTM0Njkz_3bb30992-075d-49f4-9077-e9b8631e5f30"
      unitRef="usd">-171800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie8eac1696a0f401e8764ac4f1f27de37_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xMy0xLTEtMTM0Njkz_a2e3ffbf-19fc-4137-beb3-24334e91dd17"
      unitRef="usd">13900700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib4194d914ec04ff093919ddd1c085893_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xNS0xLTEtMTM0Njkz_5698ada5-520a-4494-bbf9-6a5c9aa3b4c7"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib4194d914ec04ff093919ddd1c085893_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xNy0xLTEtMTM0Njkz_fd8afcdc-efc4-40e0-9f03-d37776328eb0"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib55ef7924a674515889fe70f6b17eb7f_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0xOS0xLTEtMTM0Njkz_dd1321f1-2318-4751-a637-113d29668a8d"
      unitRef="usd">10751900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i71feb4d0055c4b68bbe964b0257e980a_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0yMS0xLTEtMTM0Njkz_4f4fab2b-6f2a-44ea-9ea3-eab413a0528e"
      unitRef="usd">462900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5de6cf32968c4297a40eb09bdeb942bc_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMi0yMy0xLTEtMTM0Njkz_3c384ca8-2d58-455c-bb73-ecde9749bc07"
      unitRef="usd">11214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i21588e5af69246eb8bf060b182d4cef9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0xMy0xLTEtMTM0Njkz_1c5ee336-204e-4e04-a81e-af9031440a1e"
      unitRef="usd">329200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0xOS0xLTEtMTM0Njkz_dcd2d547-6ce7-44e8-8c86-5bd54d091429"
      unitRef="usd">329200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i4e1be32983094b30a756db2fdf7ba492_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0yMS0xLTEtMTM0Njkz_e608146a-7528-4126-90a9-c441f7b122e1"
      unitRef="usd">-11100000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMy0yMy0xLTEtMTM0Njkz_4caa5633-aad2-49d0-bfed-fcc0b1616ecd"
      unitRef="usd">318100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i830fd3fe92594ddca8ffd711b4e954ed_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0xMS0xLTEtMTM0Njkz_bba3845e-797e-4579-aa2a-c7e579e345ce"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0xOS0xLTEtMTM0Njkz_130eb89d-c0ec-4eb6-b8df-ef5a657488be"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4e1be32983094b30a756db2fdf7ba492_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0yMS0xLTEtMTM0Njkz_8e546ced-95d7-49df-b27b-df6e452e86b9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNC0yMy0xLTEtMTM0Njkz_cbf57e7d-12f4-4bad-b940-4fed83f4ce20"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0xNS0xLTEtMTM0Njkz_569ef62a-562c-4806-9573-963673da75dd"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0xNy0xLTEtMTM0Njkz_66234a46-d525-4872-b5ac-8425e41d4547"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ied6c3cb168af4d3f93e74f6073e0a218_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0xOS0xLTEtMTM0Njkz_a171a753-1ece-42d4-8bf1-c9b12445f639"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfNy0yMy0xLTEtMTM0Njkz_54413991-2afc-4dc5-bd56-2a04f6962e8c"
      unitRef="usd">750000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i4d3c54dd7e9843cea195c454def9d2ee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC01LTEtMS0xMzQ2OTM_320ef945-bd99-434c-bcb1-990a2671dbb4"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i5351af1a8e574e448a3647a4f7afd7b0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC05LTEtMS0xMzQ2OTM_9dfbd1f8-d40c-4b70-99b0-6dd0393b070f"
      unitRef="usd">68600000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i940fb720af7649c3b174e6131bd6809b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC0xMy0xLTEtMTM0Njkz_76e35260-e558-4259-8ed2-afc8408f8310"
      unitRef="usd">681400000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC0xNS0xLTEtMTM0Njkz_2d550f02-08fd-4e84-82b5-b7fea9f11ace"
      unitRef="shares">2200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i142a8abed9f24909ac2458987495c92a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOC0xNy0xLTEtMTM0Njkz_08c5d949-cedc-41c7-88e7-1f68d0b4078f"
      unitRef="usd">-750000000.0</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="iacd07c7062014cc6810ba0fe03987501_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS01LTEtMS0xMzQ2OTM_545a0747-163d-4df9-8ead-23118df5c359"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ic3a55df4cbc94d0f84173632a99327a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS05LTEtMS0xMzQ2OTM_962f0926-4251-42ec-bb4a-5d6dcca866a5"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS0xOS0xLTEtMTM0Njkz_4a7edf9e-a2b2-4df1-ab17-ce28903c10b9"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfOS0yMy0xLTEtMTM0Njkz_10a0e76c-557b-43bb-8f09-90dc90203024"
      unitRef="usd">11000000.0</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="iacd07c7062014cc6810ba0fe03987501_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtNS0xLTEtMTM0Njkz_029a22f9-7a4c-47ec-96ba-f4485c929998"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i21588e5af69246eb8bf060b182d4cef9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtMTMtMS0xLTEzNDY5Mw_6356457d-adcf-49bb-ab69-1427fbf9026b"
      unitRef="usd">-5000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtMTktMS0xLTEzNDY5Mw_0a61b24e-887b-4915-a366-e5da10ea2a49"
      unitRef="usd">-5000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTAtMjMtMS0xLTEzNDY5Mw_b50ace79-c759-4079-87dd-0126c4bd5092"
      unitRef="usd">-5000000.0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic3a55df4cbc94d0f84173632a99327a0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTEtOS0xLTEtMTM0Njkz_fdd27bd2-6d6b-4675-956c-cdf47eca7cd1"
      unitRef="usd">-57600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5e941a0a25b144c0b35160f30adbf7be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTEtMTktMS0xLTEzNDY5Mw_64bb3de4-6c6c-46fa-bc0b-94431e9335ca"
      unitRef="usd">-57600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTEtMjMtMS0xLTEzNDY5Mw_c4bb591a-d222-4cf7-b930-4db53ad1f937"
      unitRef="usd">-57600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMS0xLTEtMTM0Njkz_691ce58a-2deb-4898-b7e4-72b30520451f"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMy0xLTEtMTM0Njkz_5db7fea1-6d3d-4233-9b7c-8adcf50cee33"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtNS0xLTEtMTM0Njkz_b82e98af-dfa9-401a-9e3a-eaa732623bfe"
      unitRef="shares">170700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtNy0xLTEtMTM0Njkz_2a127830-935f-47cd-be2d-22621351cfdc"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7fcd64658864191b6d0041174b23749_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtOS0xLTEtMTM0Njkz_18813ea4-a0c1-41ee-8bf4-90b30fed9715"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7543833405d140a9b03a3c2c4959f28c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTEtMS0xLTEzNDY5Mw_217924a2-f085-44d1-9996-28c935337f64"
      unitRef="usd">-136600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97905b3b54ce40cb912f87e63e0db92d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTMtMS0xLTEzNDY5Mw_c4118969-a54b-427a-a06b-c4f1734a8d14"
      unitRef="usd">13543500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTUtMS0xLTEzNDY5Mw_32456f19-6793-446f-a2ad-2ecf342fe962"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTctMS0xLTEzNDY5Mw_a4f68d6f-5654-4b1b-b411-1e531140f7ba"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id028a6bff3b24d2f9b0854cfb01e2f33_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMTktMS0xLTEzNDY5Mw_ba6cae48-d1ea-4171-a423-993b0a54a0d3"
      unitRef="usd">10429900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddcd0ac5de004c8584ccf204981e3c5a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMjEtMS0xLTEzNDY5Mw_98353f05-1977-4d14-85db-68535656b161"
      unitRef="usd">451800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i957729f8711844ff89317163bd3b28ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjRhNzQ0YWRhZDNjNDQzMTA4Y2Y4ZDFlMWZkNjQ4YzMzL3RhYmxlcmFuZ2U6NGE3NDRhZGFkM2M0NDMxMDhjZjhkMWUxZmQ2NDhjMzNfMTMtMjMtMS0xLTEzNDY5Mw_3d792f45-cffd-48f6-a26b-85a760bfc2c7"
      unitRef="usd">10881700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if91d142efb024f1784dcfc0a7ba633de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xLTEtMS0xMzQ2OTM_4ca1c897-4427-4a08-9865-65ab17a596cd"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if91d142efb024f1784dcfc0a7ba633de_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0zLTEtMS0xMzQ2OTM_e78890bc-a40a-4226-8f7e-a2cb86db086f"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i1ae20d5729dc44e2bbeb4f64c73911df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi01LTEtMS0xMzQ2OTM_a4a6a1ed-8729-4137-8ea5-59681e59f07c"
      unitRef="shares">176200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i1ae20d5729dc44e2bbeb4f64c73911df_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi03LTEtMS0xMzQ2OTM_2c2f9ac8-e98a-4e19-858d-ba676c1ef08c"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i85003cc1f8c04f36b4ffbbf6882c9e1e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi05LTEtMS0xMzQ2OTM_75b1abe9-9af7-4da5-a6d9-df418b4bab76"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9e6a8dcb7c44e968654b2542e3eba4c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xMS0xLTEtMTM0Njkz_760c716b-6b4e-453d-a3fb-cd8c88dd6669"
      unitRef="usd">-299000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ida229f85edf14616bba475cf65eab0e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xMy0xLTEtMTM0Njkz_4f0dcded-fada-43e0-9a5c-7ffe6d5a7b07"
      unitRef="usd">13976300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ide8a35ebfa6c49c4940e18829274b634_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xNS0xLTEtMTM0Njkz_3755262f-fcf5-43e1-86e3-4a258144b259"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ide8a35ebfa6c49c4940e18829274b634_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xNy0xLTEtMTM0Njkz_9c767e48-bbe8-4f7b-a4ed-fb590760b26f"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i672dd8e6f6974a0681e2532e151fe07d_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0xOS0xLTEtMTM0Njkz_e5bfa0d8-8b89-4e97-8fb6-1d02a5870d20"
      unitRef="usd">10700300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7764d2904f084d0487b1c7d0a1c60a98_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0yMS0xLTEtMTM0Njkz_93654d06-e616-482a-91dc-13ad721e61c1"
      unitRef="usd">-14200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMi0yMy0xLTEtMTM0Njkz_06d8efff-9d8a-4320-b972-567dc0a1d2d0"
      unitRef="usd">10686100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="i9d65d2e85cb14209a4f5a5f72eaf1a06_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0xMy0xLTEtMTM0Njkz_6178df7f-d9e7-4256-8dba-f6ea35b2aefc"
      unitRef="usd">1187900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0xOS0xLTEtMTM0Njkz_1a7849d2-dfe5-4099-aa48-8f0dc4e82b32"
      unitRef="usd">1187900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0yMS0xLTEtMTM0Njkz_c1d75c88-6551-419a-9e46-e4cfa8658f27"
      unitRef="usd">560200000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMy0yMy0xLTEtMTM0Njkz_6543431b-07e3-4fe9-8077-ad9694b0ee04"
      unitRef="usd">1748100000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="id80ceaef197d43efbe8a7cb665f36bd3_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0xMS0xLTEtMTM0Njkz_b49fa3cd-6ce3-40d1-a230-96dba3c5cb52"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0xOS0xLTEtMTM0Njkz_3ba3b3f7-8144-41b0-beda-d232f5a5f542"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0yMS0xLTEtMTM0Njkz_d71164a5-aa4d-4ce8-99be-51d6acb28b1e"
      unitRef="usd">600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNC0yMy0xLTEtMTM0Njkz_29b835cc-0876-47f6-a83e-b505b5b397cd"
      unitRef="usd">163000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNS0yMS0xLTEtMTM0Njkz_40c61a8c-00c3-4d2a-839d-fbe11b51b815"
      unitRef="usd">100000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNS0yMy0xLTEtMTM0Njkz_190d0de2-a3db-4279-ae40-e02064733332"
      unitRef="usd">100000000.0</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="ia9de77c507a740a1ae2c9371d9a6ba40_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNi0yMS0xLTEtMTM0Njkz_8c325ba3-1300-4844-9845-fcc46f708a7d"
      unitRef="usd">5200000</biib:NoncontrollingInterestCapitalContribution>
    <biib:NoncontrollingInterestCapitalContribution
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNi0yMy0xLTEtMTM0Njkz_e2a6d02c-6796-40f6-b196-f548234c1fbf"
      unitRef="usd">5200000</biib:NoncontrollingInterestCapitalContribution>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0xNS0xLTEtMTM0Njkz_4f7da10b-0a91-4658-9363-dcd156b626a8"
      unitRef="shares">6000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0xNy0xLTEtMTM0Njkz_fcde60e4-27c6-4145-933b-edaa8857806c"
      unitRef="usd">1800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i5a8c604e337a41529c5ebe37e6e83167_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0xOS0xLTEtMTM0Njkz_54ff4269-5331-4a17-97c1-e14aa52f5e2f"
      unitRef="usd">1800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfNy0yMy0xLTEtMTM0Njkz_a9d83a6b-eb18-4ca3-a97e-ad37712c82a1"
      unitRef="usd">1800000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ib7dcf494036c4e47bb9cb906a08568a5_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC01LTEtMS0xMzQ2OTM_57e13171-96b4-41f2-b751-dac3bbc601af"
      unitRef="shares">6000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i66de57d0942e46cfb25b1d0f1fd008d1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC05LTEtMS0xMzQ2OTM_b14a921d-da23-438e-b529-4cd8f0c905af"
      unitRef="usd">231900000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="idbd356e38fd146938c9d48f464ee5866_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC0xMy0xLTEtMTM0Njkz_cdfc34ad-07d8-410c-a827-259aeaa149c3"
      unitRef="usd">1568100000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC0xNS0xLTEtMTM0Njkz_c45e453f-58bf-4d9d-acfb-3de4fada30c8"
      unitRef="shares">6000000.0</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="ic4b1b65c33a941a48695b536b06bcccd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOC0xNy0xLTEtMTM0Njkz_06d3d72c-1cac-4923-87ed-e64b77aef2a0"
      unitRef="usd">-1800000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued
      contextRef="i07d6d89e16864773a22d6d824c32ffd4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS01LTEtMS0xMzQ2OTM_d7564d3a-6917-4b70-839e-95e24aae0c60"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS05LTEtMS0xMzQ2OTM_681534a7-6fb2-4c15-b6d7-eb38ada839df"
      unitRef="usd">44300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS0xOS0xLTEtMTM0Njkz_b2b8871e-5a8a-4a65-a685-a189df05233f"
      unitRef="usd">44300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfOS0yMy0xLTEtMTM0Njkz_9daf1d87-1197-47cd-8edd-9231cfb3d8fa"
      unitRef="usd">44300000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i07d6d89e16864773a22d6d824c32ffd4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtNS0xLTEtMTM0Njkz_bf9898fd-7177-4408-b017-357383513c71"
      unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i9d65d2e85cb14209a4f5a5f72eaf1a06_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtMTMtMS0xLTEzNDY5Mw_4d1602cf-ccd4-4343-a174-f811fa0307d6"
      unitRef="usd">-52600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtMTktMS0xLTEzNDY5Mw_36bbc237-f6dd-4ccc-b21c-5132d82f9103"
      unitRef="usd">-52600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTAtMjMtMS0xLTEzNDY5Mw_fe51e5ff-06a9-4744-a0de-72b546f5a607"
      unitRef="usd">-52600000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTEtOS0xLTEtMTM0Njkz_bc56b8e7-6244-400d-ab5c-76ae970708e3"
      unitRef="usd">-186100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTEtMTktMS0xLTEzNDY5Mw_05bde443-94da-4f1d-87f6-0b8c5176c75d"
      unitRef="usd">-186100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTEtMjMtMS0xLTEzNDY5Mw_15a966d2-ad35-4a77-99b9-d12196bda391"
      unitRef="usd">-186100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:StockholdersEquityOther
      contextRef="i61622a812d794151bdacefd0e6e1401f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTItOS0xLTEtMTM0Njkz_81df3628-5223-4e54-8b09-4f7fce401f87"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="ibf22bc1f1549412cbf6feb80868fa61e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTItMTktMS0xLTEzNDY5Mw_c378bfed-e201-4e44-82ff-a0498b92e96b"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTItMjMtMS0xLTEzNDY5Mw_22913fda-c522-48e7-bf38-15272fb91f7c"
      unitRef="usd">-1500000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMS0xLTEtMTM0Njkz_bd537360-b8f9-482c-8698-f2bcc1d8fc87"
      unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i654c8bf1e47f4749b94d94eb9db91cad_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMy0xLTEtMTM0Njkz_48027d77-4d99-4626-8234-79487bd62cf5"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtNS0xLTEtMTM0Njkz_2c35bbc4-cd14-42ad-8aa4-a7e03c469808"
      unitRef="shares">170700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i986fcf8b728f45a5aade17658c08c927_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtNy0xLTEtMTM0Njkz_2dbe8b97-fc4d-4911-9a79-a1625f1cce1d"
      unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie7fcd64658864191b6d0041174b23749_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtOS0xLTEtMTM0Njkz_a5932d76-ce62-45b3-8cfc-6ba8c8490799"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i7543833405d140a9b03a3c2c4959f28c_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTEtMS0xLTEzNDY5Mw_f376177b-7969-4005-a4db-fef57ab71f57"
      unitRef="usd">-136600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i97905b3b54ce40cb912f87e63e0db92d_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTMtMS0xLTEzNDY5Mw_6b30bbc9-6c50-4789-bee7-4d09336bbb1e"
      unitRef="usd">13543500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTUtMS0xLTEzNDY5Mw_126e9e9a-75e2-4e5a-bcdd-d61d1fb09df8"
      unitRef="shares">23800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i2e04c673b4ba4bfeb809934ced292e5b_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTctMS0xLTEzNDY5Mw_fcc93f4d-2747-445f-a2ee-395e3bf11ffd"
      unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id028a6bff3b24d2f9b0854cfb01e2f33_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMTktMS0xLTEzNDY5Mw_8f2a55d3-1c5e-498c-a9c5-ddf17349b9d6"
      unitRef="usd">10429900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iddcd0ac5de004c8584ccf204981e3c5a_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMjEtMS0xLTEzNDY5Mw_e6afb7b8-0653-4073-a77d-8c984b965975"
      unitRef="usd">451800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i957729f8711844ff89317163bd3b28ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zMS9mcmFnOjlkNGQ3MDI4M2Q1ZDRmZTBiZmE0OWI4NTQyMDBjNTNhL3RhYmxlOjNlZTQ2MzNlNGNiOTQ4NWY5YzY0NmM0MWUyZjg4YzIxL3RhYmxlcmFuZ2U6M2VlNDYzM2U0Y2I5NDg1ZjljNjQ2YzQxZTJmODhjMjFfMTMtMjMtMS0xLTEzNDY5Mw_acf13bf2-22c1-4037-9457-f1f747b732af"
      unitRef="usd">10881700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUyMA_aa407ce3-0285-49d5-a2d1-4a9d781a80c1">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;In June 2022 the FASB issued Accounting Standards Update (ASU) No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUwNw_00e936f1-c86f-4da6-a1d2-cfd28db56b0a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. We have a leading portfolio of medicines to treat multiple sclerosis (MS), have introduced the first approved treatment for spinal muscular atrophy (SMA) and developed the first and only approved treatment to address a defining pathology of Alzheimer's disease. We also commercialize biosimilars of advanced biologics and focus on advancing our pipeline in neuroscience and specialized immunology. Lastly, we are focused on accelerating our efforts in digital health to support our commercial and pipeline programs while also creating opportunities for potential digital therapeutics. We support our drug discovery and development efforts through the commitment of significant resources to discovery, research and development programs and business development opportunities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS); and other potential anti-CD20 therapies, including mosunetuzumab, pursuant to our collaboration arrangements with Genentech, Inc. (Genentech), a wholly-owned member of the Roche Group. For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our audited consolidated financial statements included in our Annual Report on Form&#160;10-K for the year ended December 31, 2021 (2021 Form&#160;10-K).&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our innovative drug development and commercialization activities are complemented by our biosimilar business that expands access to medicines and reduces the cost burden for healthcare systems. Through our collaboration with Samsung Bioepis Co., Ltd. (Samsung Bioepis) we market and sell BENEPALI, an etanercept biosimilar referencing ENBREL, IMRALDI, an adalimumab biosimilar referencing HUMIRA, and FLIXABI, an infliximab biosimilar referencing REMICADE, in certain countries in Europe, as well as BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUyOA_472664b1-1a9c-4807-98e9-76f169741563">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with accounting principles generally accepted in the United States (U.S.&#160;GAAP). The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2021 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2021 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine months ended September 30, 2022, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfNDExMA_7fd3f8e8-d545-4e07-a3ed-9fdd0a44f2a9"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUzNg_1b2ab6c3-207d-4177-b5ab-58f5fa588750">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and those of certain variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfNDYyMA_50e57475-eccc-4fdc-83d9-fa3abfc6bbd4"
      unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUzMw_62c1246b-0610-495b-872a-2b0d90ec73de">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The length of time and full extent to which the COVID-19 pandemic directly or indirectly impacts our business, results of operations and financial condition, including sales, expense, reserves and allowances, the supply chain, manufacturing, clinical trials, research and development costs and employee-related costs, depends on future developments that are highly uncertain, subject to change and are difficult to predict, including as a result of new information that may emerge concerning COVID-19 and the actions taken to contain or treat COVID-19 as well as the economic impact on local, regional, national and international customers and markets. Additionally, the ongoing geopolitical tensions related to the conflict in Ukraine, and the related sanctions and other penalties imposed, are creating substantial uncertainty in the global economy. The extent and duration of the conflict, sanctions and resulting market disruptions are highly unpredictable. We have made estimates of the impact of the COVID-19 pandemic and the ongoing geopolitical conflict within our condensed consolidated financial statements and there may be changes to those estimates in future periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8zNy9mcmFnOmUwNGU0ZWU2Yjc1ZjRhNTY4NTU2NThjNjUzYzk4YWEyL3RleHRyZWdpb246ZTA0ZTRlZTZiNzVmNGE1Njg1NTY1OGM2NTNjOThhYTJfODUyMg_054964a2-6c2f-41b4-967b-fcb402aef3aa">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had or may have a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;In June 2022 the FASB issued Accounting Standards Update (ASU) No. 2022-03, Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions. This standard clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. This standard becomes effective for us on January 1, 2024. We elected to early adopt this standard on a prospective basis during the third quarter of 2022.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjgzMg_bd1a19f3-bee3-4be0-85af-36841002142b">DISPOSITIONS &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sale of Joint Venture Equity Interest in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics Co., Ltd (Samsung BioLogics). Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of this transaction. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale, the carrying value&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of our investment in Samsung Bioepis totaled $581.6&#160;million. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, we recognized a pre-tax gain of approximately $1.5&#160;billion related to this transaction, which was recorded in other (income) expense, net in our condensed consolidated statements of income. This pre-tax gain included reclassifications from &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to net income of approximately $58.9&#160;million in cumulative translation losses, partially offset by approximately $57.0&#160;million in gains resulting from the termination of our net investment hedge.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have concluded that the divestment of Samsung Bioepis does not meet the criteria to be reported as discontinued operations in our condensed consolidated financial statements, as our decision to divest this business does not represent a strategic shift that will have a major effect on our operations and financial results.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We elected the fair value option and measured the payments due to us from Samsung BioLogics at fair value. As of September 30, 2022, the estimated fair values of the first and second payments using risk-adjusted discount rates of 4.9% and 5.3%, respectively, were approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$790.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$402.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, respectively. These payments have been classified as level 3 measurements and are reflected in other current assets and investments and other assets, respectively, in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; three &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;months ended September 30, 2022, we recognized a gain of approximately $2.7&#160;million and a loss of approximately $4.0&#160;million to reflect the changes in fair value related to our first and second payments, respectively. These changes were recorded in other (income) expense, net in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:27pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If any payments due to us remain outstanding after the second anniversary of the closing of this transaction, we may elect to receive shares of Samsung BioLogics common stock at a 5.0% discount in lieu of a cash payment for the remaining amount due. Currently, we believe that the likelihood of Samsung BioLogics failing to make timely payments to us for the amounts due is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, for the nine months ended September 30, 2022, we recorded a discrete tax expense of approximately $258.3&#160;million related to this transaction, which is reflected in income tax (benefit) expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTEz_87489fb2-69a4-4e3a-922d-19880424e2d7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture
      contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjY1_192d59ff-ed91-4d07-9503-7ea9bcb0fdf6"
      unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i316ee61fce71448090e9e99d3e03605f_I20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMzIz_0fcfce3c-0a3a-4d42-8efc-11d188235b8c"
      unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i607186b7dfc843688ebf32e0578fc19b_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMzg0_f667ce64-0313-4cfb-9416-315c9efa1b7f"
      unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="ie8da0e6904f247e0a072f97c4201c43b_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNDM0_a92fa58f-a17f-4dc0-bb3c-41f9b74f1baa"
      unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <us-gaap:EquityMethodInvestments
      contextRef="i30e4e1687d1446f2a418d8e2edce385e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNTg2_fa54f23b-700e-42c9-ae65-a3c09436456f"
      unitRef="krw">581600000</us-gaap:EquityMethodInvestments>
    <us-gaap:GainLossOnSaleOfInvestments
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNjcx_ea2f9c94-9f2f-4d5b-af1e-9707bfddc082"
      unitRef="usd">-1500000000</us-gaap:GainLossOnSaleOfInvestments>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfOTMx_ce8967d6-690b-49f9-b468-9818a46427b3"
      unitRef="usd">-58900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTAwMg_879562a8-55d4-4f73-8dbc-91be6cf85ccb"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <biib:OtherAssetsMeasurementInput
      contextRef="ic1f7ed163c5b4dc1a6bbd9abf449fa0f_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNTQ5NzU1ODE4NTYz_e3f8e5d8-6f69-45dd-8bfb-6c9566550125"
      unitRef="number">0.049</biib:OtherAssetsMeasurementInput>
    <biib:OtherAssetsMeasurementInput
      contextRef="i0f5bb12cf4d14733835facacabb3cc9b_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfNTQ5NzU1ODE4NTcx_673d48bc-2550-4bac-808a-526ba49307bb"
      unitRef="number">0.053</biib:OtherAssetsMeasurementInput>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTcwMw_0b7ee53a-ccdc-4672-b67c-3c0a7052eb6e"
      unitRef="usd">790800000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTcxMA_2e1d8a79-b1b6-4f87-8013-e2abfb52c0cc"
      unitRef="usd">402800000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="iba57778587524c7389b5d85413395030_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjE5OTAyMzI1OTIwMg_2b7df0c5-7463-434b-ac1c-eb48f3aef2df"
      unitRef="usd">2700000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjE5OTAyMzI1OTIzOQ_bd89af3d-cde4-481d-bf04-e2d8184ec7eb"
      unitRef="usd">-4000000</us-gaap:GainLossOnDispositionOfAssets1>
    <biib:AdditionalMilestonePayment
      contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMTk4NQ_96136127-4524-4f39-b718-e6b4699c4026"
      unitRef="usd">50000000</biib:AdditionalMilestonePayment>
    <biib:PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent
      contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjM5Nw_90a0f5d6-350b-48f9-878b-a09900461392"
      unitRef="number">0.050</biib:PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent>
    <biib:DiscreteIncomeTaxExpenseBenefit
      contextRef="iba57778587524c7389b5d85413395030_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjY5OA_7a4e25a4-fae7-4178-beb1-2a3efb7b0fe1"
      unitRef="usd">258300000</biib:DiscreteIncomeTaxExpenseBenefit>
    <biib:DiscreteIncomeTaxExpenseBenefit
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80My9mcmFnOjQ1M2I0NjY5NTBmZTQ0NGE5Yzg5MDM0MWNhYTY0ODM5L3RleHRyZWdpb246NDUzYjQ2Njk1MGZlNDQ0YTljODkwMzQxY2FhNjQ4MzlfMjY5OA_ea0ab306-cfe3-4f95-b1e1-cb381a806ed3"
      unitRef="usd">258300000</biib:DiscreteIncomeTaxExpenseBenefit>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjQyMw_29faf7d6-6c18-457e-ad11-0fbbf4553c3b">RESTRUCTURING &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2022 Cost Saving Initiatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021 and May 2022 we announced our plans to implement a series of cost-reduction measures during 2022. These savings are being achieved through a number of initiatives, including reductions to our workforce, the substantial elimination of our commercial ADUHELM infrastructure, the consolidation of certain real estate locations and operating efficiencies across our selling, general and administrative and research and development functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under these initiatives, we expect to incur restructuring charges ranging from approximately $130.0&#160;million to $150.0&#160;million. These amounts are primarily related to severance and are expected to be substantially incurred and paid by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, we recognized approximately $15.4 million and $124.1 million, respectively, of net pre-tax restructuring charges related to our 2022 cost saving initiatives, of which approximately $21.6&#160;million and $110.2&#160;million, respectively, consisted of employee severance costs. These costs were recorded in restructuring charges in our condensed consolidated statements of income. Our restructuring reserve is included in accrued expense and other in our condensed consolidated balance sheets. In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge, MA (300 Binney Street), as well as to reduce the lease term for the majority of the remaining space.  This resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. For additional information on our 300 Binney Street lease modification, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 11, Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following an evaluation of our current capacity needs, in March 2022 we ceased using a patient services office space in Durham, North Carolina. Our decision to cease use of the facility resulted in the immediate expense of certain leasehold improvements and other assets at this facility. As a result, for the nine months ended September 30, 2022, we recognized approximately $10.4&#160;million of accelerated depreciation expense, which was recorded in restructuring charges in our condensed consolidated statements of income. In May 2022 we entered into a lease assignment agreement whereby we assigned our remaining lease obligations to an external third party. As a result of the lease assignment, we derecognized the related operating lease obligation and right-of-use asset during the second quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, we recognized other restructuring costs of approximately $8.8&#160;million, which were recorded in restructuring charges in our condensed consolidated statements of income. Other restructuring costs include items such as facility closure costs, employee non-severance expense, asset write-offs and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i50d36a66d9ab43cdb58d18874e1a3785_D20230101-20230630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNTk0_1f24a0d7-63cf-447b-9bec-cba1f44abbd1"
      unitRef="usd">130000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i61ca34953d844cb0860dc038de00e235_D20230101-20230630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNjAw_a3a9a711-ca43-4fc3-876e-5b9fba4e3a80"
      unitRef="usd">150000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNzkx_f5a7aa6b-b3a8-443b-852a-3452784325ea"
      unitRef="usd">15400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfNzk4_aea80e3e-4dc5-4806-abd1-3e26089ac6ac"
      unitRef="usd">124100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfOTE3_18cef8ef-1a65-4cc5-9b41-fa546f107d2e"
      unitRef="usd">21600000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfOTI0_8c9f148d-5894-4ea7-bf8b-6e1a6d5c8618"
      unitRef="usd">110200000</us-gaap:SeveranceCosts1>
    <biib:GainLossOnRestructuringCharges
      contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjc0ODc3OTA3MzgzMQ_0e597dce-283b-4818-902c-285225afb820"
      unitRef="usd">5300000</biib:GainLossOnRestructuringCharges>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMTU1NQ_4d4cfa08-7506-468b-ba3e-d7df631decd9"
      unitRef="usd">10400000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:OtherRestructuringCosts
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjA0Mw_6a81fee7-5228-4d9c-8dc3-ea9187f5f2d6"
      unitRef="usd">8800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RleHRyZWdpb246NzkzMThiOGZjODEwNDg4NjkxYTIxNDRjMzU1Y2MzY2ZfMjQzMw_11edc2d5-3b89-40bd-8e21-adc3887cddfb">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the charges and spending related to our 2022 workforce reductions for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:82.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.545%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="ic1f37877cc204468be6364c936821118_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMS0yLTEtMS0xMzQ2OTM_4e4ccf0c-1c6a-4eb6-b8bb-a39783d24480"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i3d680499749847fbb5726594897a6967_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMi0yLTEtMS0xMzQ2OTM_b1daa9e3-6a2b-4a4a-a555-f0b085145902"
      unitRef="usd">27700000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i3d680499749847fbb5726594897a6967_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMy0yLTEtMS0xMzQ2OTM_c16a5c86-ca15-411a-9fb7-83cde36ac890"
      unitRef="usd">6200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserve
      contextRef="iea6f6f793edc47d08a4cb4fbe2bea78d_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfNS0yLTEtMS0xMzQ2OTM_da952152-08ec-46a4-b94c-46b1a38708fa"
      unitRef="usd">21500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i1f41754e9d7e480eb6a52dc448c1e2bc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfNi0yLTEtMS0xMzQ2OTM_be2d9295-6fc3-468d-8de6-79eab03552ab"
      unitRef="usd">60900000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i1f41754e9d7e480eb6a52dc448c1e2bc_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfNy0yLTEtMS0xMzQ2OTM_4b2e4620-b765-4bf6-93d8-d34af60c54c9"
      unitRef="usd">29700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfOC0yLTEtMS0xMzQ2OTM_5ad27e26-290c-494f-b383-be240ea18012"
      unitRef="usd">-500000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve
      contextRef="ibe53d000d3d24ab085f9e7a60f3038fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfOS0yLTEtMS0xMzQ2OTM_7b435f89-61ee-48fc-84d5-f13ca9dff087"
      unitRef="usd">52200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i50e9ef276762476587698a382951d243_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTAtMi0xLTEtMTM3MDQz_e8c4e125-b0a7-4f41-841e-c3114539f9c3"
      unitRef="usd">21600000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring
      contextRef="i50e9ef276762476587698a382951d243_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTEtMi0xLTEtMTM3MDQz_0a3ab7d2-d52a-4fd6-bdb1-8c503105a8a4"
      unitRef="usd">32300000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveAccrualAdjustment1
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTItMi0xLTEtMTQ4OTAx_3171f6d2-633b-4dc7-8e58-bf56fe07272d"
      unitRef="usd">-1300000</us-gaap:RestructuringReserveAccrualAdjustment1>
    <us-gaap:RestructuringReserve
      contextRef="i75d90b3006f344218e928d1ad4dfdd95_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80Ni9mcmFnOjc5MzE4YjhmYzgxMDQ4ODY5MWEyMTQ0YzM1NWNjM2NmL3RhYmxlOmNlNzliM2IyMTg1ZjRmYThhYjFmYmJmZGY4NGY0ZjUwL3RhYmxlcmFuZ2U6Y2U3OWIzYjIxODVmNGZhOGFiMWZiYmZkZjg0ZjRmNTBfMTItMi0xLTEtMTM3MDQz_e9d29ccb-f250-416b-b9b6-cc939e72104d"
      unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYwNw_0ccad4ec-57e4-414f-b2c1-d866cea9208f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;619.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;833.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,556.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,111.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,962.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the United States (U.S.) in June 2022 and became commercially available during the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,465.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;713.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;805.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;923.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;696.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,990.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,157.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,464.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,619.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,463.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,083.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,850.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,653.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.9% and 10.5% of gross product revenue for the three months ended September 30, 2022, and 26.8% and 10.7% of gross product revenue for the nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 26.9% and 10.8% of gross product revenue for the three months ended September 30, 2021, and 29.1% and 10.0% of gross product revenue for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,993.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,501.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,442.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,821.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(124.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(463.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(602.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OCREVUS and other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2472b9;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive royalties from net sales on products related to patents that we have out-licensed and we record other corporate revenue primarily from amounts earned under contract manufacturing agreements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYyMQ_c3c15d9b-f532-47e2-9a50-380c28589e34">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;92.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;339.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;256.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;299.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;319.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;619.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;213.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;301.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;86.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;336.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;273.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;505.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;281.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;241.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;632.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,340.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;833.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;722.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,556.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;140.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;139.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;304.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;444.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;110.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;120.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;850.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,111.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,962.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;973.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,232.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,205.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the European Union (E.U.) during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the United States (U.S.) in June 2022 and became commercially available during the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.550%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis (MS):&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;330.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;520.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,465.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;383.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;713.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;836.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,549.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;805.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;945.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,750.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;743.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;636.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;286.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;923.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;138.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;252.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;608.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;995.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;751.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,188.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;849.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;693.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;696.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,550.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: MS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,170.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,990.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,161.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,410.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,157.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,568.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Spinal Muscular Atrophy:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;891.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,334.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;437.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,464.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;340.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;172.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;576.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;610.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FUMADERM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ADUHELM&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,619.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,463.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,083.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,850.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,802.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,653.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;VUMERITY became commercially available in the E.U. during the fourth quarter of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;BYOOVIZ launched in the U.S. in June 2022 and became commercially available during the third quarter of 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues
      contextRef="ieae68b14dd844654b97d8e0821a7d63d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC0yLTEtMS0xMzQ2OTM_b9d0744d-159d-402a-8459-d5c56c9ade13"
      unitRef="usd">92500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia678bb0bdba34f6d8468b6ea458c7c67_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC00LTEtMS0xMzQ2OTM_0a8b2ff9-aba0-408c-b16b-d321056abb10"
      unitRef="usd">246500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idee5f0f1a0fc412eac579e1d0b56f5c0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC02LTEtMS0xMzQ2OTM_f2a17845-582e-46ed-bb5f-e381bd7770e8"
      unitRef="usd">339000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i524a5a89350540a3bc0f4b10a71bb6aa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC04LTEtMS0xMzQ2OTM_a9eb5344-359f-4f74-8677-494fb09ee471"
      unitRef="usd">179200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i94cd8b6ab6a24b2d8c28a1fef87c6153_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC0xMC0xLTEtMTM0Njkz_b8c1f727-4ef7-453c-8fd8-586533fcbb21"
      unitRef="usd">319400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia14b4c4bce6a4909a76b690dbb1dda86_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNC0xMi0xLTEtMTM0Njkz_fc660a28-8b48-46aa-bbb4-0619fd4e5de2"
      unitRef="usd">498600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i052a675de8aa4e5d9832465ff8570284_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS0yLTEtMS0xMzQ2OTM_f2a9ee85-f935-4a44-b89f-2649d7ac60f2"
      unitRef="usd">127900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibada012125344986aaa29e2b44e3995b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS00LTEtMS0xMzQ2OTM_a5ae98b3-c669-4901-8308-6cc6848905be"
      unitRef="usd">9900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iecc52be6137340a5b547b2482e77071b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS02LTEtMS0xMzQ2OTM_0f56269d-f6da-4f34-949b-6bbbf662c06e"
      unitRef="usd">137800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30f15676d39144d6be62e0983a2c677d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS04LTEtMS0xMzQ2OTM_8e3aad25-b29a-4aad-881d-c37e7edb24de"
      unitRef="usd">120700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17d433d159ae4a1ab0cd0e666f0067b5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS0xMC0xLTEtMTM0Njkz_5bb3ce1f-ac6b-4519-a929-d7a3402a1c29"
      unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86dce0a14ccd4ac7b68ee2512c78b229_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNS0xMi0xLTEtMTM0Njkz_96542bbb-48c3-4cf4-83da-2ce7549bc461"
      unitRef="usd">120900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if5d02c3121d046fa80f33ce0ea159f1b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi0yLTEtMS0xMzQ2OTM_10bdc958-8861-4425-bffa-76aa4387d1a5"
      unitRef="usd">220400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id90d2fa8645d41c59b47948a99c4c9a8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi00LTEtMS0xMzQ2OTM_82833f0d-8191-4f9d-b030-ad26ac005f9f"
      unitRef="usd">256400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifeb6cdfb945042ec929ed76602fc0d41_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi02LTEtMS0xMzQ2OTM_f5c6cbe1-7a20-4039-a88d-53a73be650ca"
      unitRef="usd">476800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic82f6ca075b24e908f242a5f756da00b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi04LTEtMS0xMzQ2OTM_14f50696-deae-43d9-97ce-3bfff6c5d445"
      unitRef="usd">299900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0112f1abc12545e994f30a836d2cb12f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi0xMC0xLTEtMTM0Njkz_301f7ba2-0057-42b0-9d97-447941b97e00"
      unitRef="usd">319600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a4811b664994d1a81bade00a2863057_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNi0xMi0xLTEtMTM0Njkz_5b3df34e-f762-4b57-b150-1fd2cad8a743"
      unitRef="usd">619500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2775701ccced4d349950476cf4ac935f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy0yLTEtMS0xMzQ2OTM_19cf4c31-4bad-4f4a-9b50-984a4637ed40"
      unitRef="usd">174800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9e8c8756b2146eca09944df5c248397_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy00LTEtMS0xMzQ2OTM_ec60fdaa-6c43-46d5-afbc-946f1382c61a"
      unitRef="usd">80300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie5abd26923c541018c31b313875f2f0a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy02LTEtMS0xMzQ2OTM_b5bdd1f3-9397-425a-b323-d17b7aee4e7e"
      unitRef="usd">255100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i54d1f43c44b042958f27d4875e2c518e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy04LTEtMS0xMzQ2OTM_e00ef1ca-94d6-4115-9e6f-813b699dc513"
      unitRef="usd">213200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8c9d7081eeb3425aaab5ae1f08229ad0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy0xMC0xLTEtMTM0Njkz_b00fc718-979b-4324-84fb-9e1ed28045ab"
      unitRef="usd">88100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9e3fe4bcdeb74d82a40d4194dfecf8e0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfNy0xMi0xLTEtMTM0Njkz_058d8f49-dec6-46cb-a324-895b9187e837"
      unitRef="usd">301300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i22a55754206442b9ad7d2a15bb0c2ed8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC0yLTEtMS0xMzQ2OTM_b71bc96e-475e-4245-afa0-9393a69c9781"
      unitRef="usd">39700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1539f85dca834b21b083a5841069d1f9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC00LTEtMS0xMzQ2OTM_f0a67707-1e47-44d1-9556-a412b39d995f"
      unitRef="usd">41200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i413272e3f9254d67a44927e69cdc2477_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC02LTEtMS0xMzQ2OTM_546779fc-bd11-4e5a-b9d4-d5bd09d5273d"
      unitRef="usd">80900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if1260db1e62944da8c762971630a803f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC04LTEtMS0xMzQ2OTM_c30b7d44-ad3a-4f08-a9b1-126254c3167d"
      unitRef="usd">39200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a6c9354a1594ed984122907bfaf64d9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC0xMC0xLTEtMTM0Njkz_d1d81940-d6c5-4243-865c-5ef486fffe67"
      unitRef="usd">47000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icd1a7dde2606420ab2beaa988524cc5e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOC0xMi0xLTEtMTM0Njkz_3ffacbad-ad9e-4d71-b8b8-a4e1f26d2682"
      unitRef="usd">86200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i67dbc5422bc347699fed7d1ba9192ef3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS0yLTEtMS0xMzQ2OTM_40c16178-0b3f-4cb6-8d72-943bdc0e47cf"
      unitRef="usd">214500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib54b6aedfcba481d9b05a81e2c49254c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS00LTEtMS0xMzQ2OTM_5c1a6002-0cff-442e-8d2e-834126e29cc3"
      unitRef="usd">121500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4a3f69c1b08b48a7ad41ca04403e0c5c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS02LTEtMS0xMzQ2OTM_2e8ead92-a868-4009-8461-3ee26160fa8c"
      unitRef="usd">336000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9c8b237efb1e4c6bb345fa501d512b04_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS04LTEtMS0xMzQ2OTM_ba0c2ef8-2244-49e0-985d-935bd513eab1"
      unitRef="usd">252400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i35666f9afdf94c86b0dadb5d20099aa4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS0xMC0xLTEtMTM0Njkz_df020e1c-f079-408a-b0a7-89dc5562911d"
      unitRef="usd">135100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2eff75aba234462e895ad96c0ec0c13c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfOS0xMi0xLTEtMTM0Njkz_401d30e2-da18-40d3-86f5-23db840ada99"
      unitRef="usd">387500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieca6a0988c1143f78d17d64f36bd59d0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtMi0xLTEtMTM0Njkz_088db5b5-59a0-49d3-a627-baa5c352d983"
      unitRef="usd">273000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7f4ebfef6a604efa9a0c65992472c0d7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtNC0xLTEtMTM0Njkz_cb84f924-cb89-4ca9-841b-fe18e7606688"
      unitRef="usd">232500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib4b9ad0869ff4c3fb817b4710e10a630_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtNi0xLTEtMTM0Njkz_ad5a9f1c-e53c-4143-a7e1-2eca07812ab9"
      unitRef="usd">505500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i15a90a6d21554cd3b7fbe3e029fbaac9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtOC0xLTEtMTM0Njkz_8212042f-7569-44af-a06d-d6fc4c57c9d1"
      unitRef="usd">281100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia9fe0b10bf3a4a2fbaac7c18a2d43b48_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtMTAtMS0xLTEzNDY5Mw_3b0bf920-2fa3-4fa8-8c2d-394dca9b91b2"
      unitRef="usd">241700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibe746589d79e42be854dd4cb784c05e9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTAtMTItMS0xLTEzNDY5Mw_53fdb895-a0fb-4a56-a231-711a58afc75e"
      unitRef="usd">522800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id00b404c1c0143a69096eacb3dc9e10c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtMi0xLTEtMTM0Njkz_ad065d86-c6cd-46a4-b74b-d2dfa701aa6a"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifebf0d8ca7134f8a863034f1a0b81573_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtNC0xLTEtMTM0Njkz_11b1099b-a7e0-4e97-b896-31c94c68f1f6"
      unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5a04530193ba4b518e49e6435d62ee0e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtNi0xLTEtMTM0Njkz_abd2e8ed-6a26-4a1a-877d-d608ce9b136f"
      unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ied70d0ff45d4458aa25726112c8513dd_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtOC0xLTEtMTM0Njkz_246c93a8-70b7-4e7c-a9c4-72c5ce4c53bc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i41cbc8191ce24bd3873905bcb5a73840_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtMTAtMS0xLTEzNDY5Mw_67cd9a9f-f6e7-421a-aeb5-6b2c5b9855a1"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d3ea9011ece4aec9bbf5dd07e371b5f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTEtMTItMS0xLTEzNDY5Mw_46954681-c839-4699-abaf-b8b2a327e0d1"
      unitRef="usd">26200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e67a47e02e64b21801d078a6891829d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItMi0xLTEtMTM0Njkz_184fcc33-ca97-49c1-838b-eb355c246b7c"
      unitRef="usd">707900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3cb20e8bd6614d08aae2157a736ee0bc_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItNC0xLTEtMTM0Njkz_4b742bfb-9092-4dbd-83e4-79f55ddfb19e"
      unitRef="usd">632400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id05eb883732b498a834f089684813866_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItNi0xLTEtMTM0Njkz_46d9e19d-0beb-48a2-9f38-4bf988dc61fe"
      unitRef="usd">1340300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iabd90fb1abfc4a8fb6a417188bd3b333_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItOC0xLTEtMTM0Njkz_5fb8dc3b-ca54-4e4d-9435-7cf5e81769ed"
      unitRef="usd">833400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d6326e426354c5cab099ca0de375d35_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItMTAtMS0xLTEzNDY5Mw_8fbb0460-dee4-4317-84fb-10177339849b"
      unitRef="usd">722600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8812745790a446cbad04fb159242ad1f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTItMTItMS0xLTEzNDY5Mw_c4ba032a-a0d8-4883-8c00-451f3b6e3043"
      unitRef="usd">1556000000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4e033d68ed2c41b3ad7632aa89aec9a8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtMi0xLTEtMTM0Njkz_fbca9a80-f3c2-4eeb-ae63-1c739928725a"
      unitRef="usd">140200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2af6c017ace04a208fed42ce9a986242_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtNC0xLTEtMTM0Njkz_384fc30e-93c3-4ec5-aa0c-60e1741934d1"
      unitRef="usd">290900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6a5b99981159460c97cd042e3a67f70d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtNi0xLTEtMTM0Njkz_70d5d90f-452e-4c15-93d2-0fdbe261baeb"
      unitRef="usd">431100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i25429e48c15549dd9fd5d52789bdf66e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtOC0xLTEtMTM0Njkz_38bb225e-2680-4fe2-a241-209b893cceff"
      unitRef="usd">139800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i152fc65157fa4362b32c7674d4f3af52_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtMTAtMS0xLTEzNDY5Mw_2b0a8234-0698-4315-8797-fc31bfcbea25"
      unitRef="usd">304300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0c5c8cd61c24cfabd4664c10261b0e5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTUtMTItMS0xLTEzNDY5Mw_157c183a-e7ac-4702-bac5-0bb0fc518ab7"
      unitRef="usd">444100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i757c59aeb42e4b328db5739cfaf1d0cc_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtMi0xLTEtMTM0Njkz_84bab073-bf65-4339-9229-00f1f31a7449"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib31ea0e171e14113bef79d2f5da80f7b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtNC0xLTEtMTM0Njkz_2e7cc5f8-daaf-488e-8ea2-4ea7e10b97ed"
      unitRef="usd">110200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9438c78c688a4bfeadfaaa6784905992_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtNi0xLTEtMTM0Njkz_dde6f406-a64b-42e1-8625-aec432a4a8f2"
      unitRef="usd">110200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i12c8a988b4e0420e89ff703030bbadfa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtOC0xLTEtMTM0Njkz_1bee3f8f-e128-4c34-929a-c03fc0912374"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib3d0a194344841dba3b5f8ff6d1c4f81_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtMTAtMS0xLTEzNDY5Mw_ac69ec18-1507-4d30-9319-550aac19cc63"
      unitRef="usd">120800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1908a95691ba4679b174a8dfdd916a93_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTgtMTItMS0xLTEzNDY5Mw_95030db3-24d1-4962-9fc2-8a21e27f7ba7"
      unitRef="usd">120800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibcc0686d78a742bd8fdd73944fe180e7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktMi0xLTEtMTM0Njkz_7124d24a-277f-45dd-8561-fded033e81ad"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5ad6d7a35eac421397e8362b9656f4b8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktNC0xLTEtMTM0Njkz_3d35be2d-ba52-4f28-8340-0c86e955bd70"
      unitRef="usd">57700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i95b05c62014347fab4835789f107cfe0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktNi0xLTEtMTM0Njkz_40c6609e-f0c9-4b38-a2f1-5b67cc5f78a0"
      unitRef="usd">57700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4b466566e8754a25a7bfeab1a81a2cea_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktOC0xLTEtMTM0Njkz_2a965771-7aa6-4f0d-8345-6bb59c0db3d1"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idec7cc8cd0034b3eb2562e8018818d3c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktMTAtMS0xLTEzNDY5Mw_510093f5-bdd2-41fc-b8c5-bf7dcc1dd244"
      unitRef="usd">57400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2e4f384abac34bae9d5bf87acf30d4ee_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMTktMTItMS0xLTEzNDY5Mw_21228dc5-a389-41ca-9e94-54866a126623"
      unitRef="usd">57400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8c9122746944d3f9095dbb7cc11377a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtMi0xLTEtMTM0Njkz_91ba91fc-c2f8-4e3a-bb83-c33e9af556d0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2516de1ac60a4e90831421c900ff396e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtNC0xLTEtMTM0Njkz_12d4ed11-06e8-498c-ad87-de2943f2692f"
      unitRef="usd">19000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9ac6ccbe24af4deaa5a62b863311b57c_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtNi0xLTEtMTM0Njkz_367ef11c-74c0-4963-b160-98d6a0adf774"
      unitRef="usd">19000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib50af91715af4a78bba950701876534e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtOC0xLTEtMTM0Njkz_1312e581-d16b-4183-a31b-ee5026745390"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i657478733d8d43ed87decbb8c4f5d541_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtMTAtMS0xLTEzNDY5Mw_7efac3a7-695b-43a4-ae87-10f3b62a1d4e"
      unitRef="usd">24600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i51f276f171e54d29894f040aa5ab5443_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjAtMTItMS0xLTEzNDY5Mw_c23d468c-10c6-4fb7-8a2d-9e894c73d7b5"
      unitRef="usd">24600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2a905ec064574da2bf8cee1f4d8bd703_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtMi0xLTEtMTM0Njkz_83ddbe94-d670-4d9b-bec7-19105dc35ce6"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6a59839d59b407ea4068c5b93d2ba34_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtNC0xLTEtMTM0Njkz_6c7b970f-6116-4e18-b694-e60ded2b04cd"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib0e0989aaba247af8dc5f027f0f887ef_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtNi0xLTEtMTM0Njkz_5d955713-f0fd-409e-8fd1-d1c8169c5aed"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i613b7926acf54b98ac70428273633e52_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtOC0xLTEtMTM0Njkz_18205cee-451e-4f5d-b6db-02726dc00df5"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia6cfc69fc6c34480b827a3877c93ab58_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtMTAtMS0xLTEzNDY5Mw_166cee1e-5cf2-44d4-b405-f0ae390dbb6c"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1f6e2e5b23e04f37a8291ce446990fd4_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjEtMTItMS0xLTEzNDY5Mw_b8a9e2ee-4060-46e6-8ce8-55960bb25594"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i26ce3d87d7074b3db7e594727ab76ac8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItMi0xLTEtMTM0Njkz_bb0ce573-2ad6-4d1b-b5ca-f8220c064b12"
      unitRef="usd">700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icad85b2a32a540c2be8bee5055609f06_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItNC0xLTEtMTM0Njkz_35ce3df4-5cfd-4843-a8e5-fd4400f0bbae"
      unitRef="usd">186900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i308866a912504314ad0566776705f1fa_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItNi0xLTEtMTM0Njkz_ae9425f5-df9c-4f52-9ec7-aa66422169c3"
      unitRef="usd">187600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia643249264394743951818a9aa78ae5d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItOC0xLTEtMTM0Njkz_1dbabdd8-ec37-4938-820d-67322e1b0367"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0c11e3688c394fb189088fdb0469db74_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItMTAtMS0xLTEzNDY5Mw_6505f83c-556a-4212-8e11-ca2f62e8f467"
      unitRef="usd">202800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i08acc85b03b14f00a2f9ca0f2979648e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjItMTItMS0xLTEzNDY5Mw_cb3a765b-c1ad-4cb3-9f9a-6bdaa4a49142"
      unitRef="usd">202800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i50c2970d6269468d9f534821befd3de2_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtMi0xLTEtMTM0Njkz_c60aaf92-d482-4216-87cf-60be6faf87c9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i30db570b4e794739ac24a66ec8692dae_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtNC0xLTEtMTM0Njkz_cd19a715-9d2c-4546-8f79-279fe4f9f314"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia02964d914cc47388a24d99a47433421_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtNi0xLTEtMTM0Njkz_2171b387-1626-4bc4-90c9-42216e7d4c80"
      unitRef="usd">1500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ife378d865970465ba0ce74157101a61f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtOC0xLTEtMTM0Njkz_bbd5af98-836c-4fbd-8906-535834457987"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie3319dce269e41ad92a3ddcfe5bf5189_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtMTAtMS0xLTEzNDY5Mw_d09401da-44e7-4952-a930-571426f354e0"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib1c72b384af94d18b63dff491dca9a24_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjUtMTItMS0xLTEzNDY5Mw_05540bd5-f64c-4c67-9afc-e992812c9631"
      unitRef="usd">2500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d798d15c7984659815575140f16c70b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtMi0xLTEtMTM0Njkz_9f28d9a3-a79d-47e4-a3e1-f1fdc1a1d97d"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icb65596c915c406cbc7bf9acd98622e5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtNC0xLTEtMTM0Njkz_b196ee65-3947-4739-8c60-92b7a00894b3"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5dfead640e914b38b2696de5407f84ba_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtNi0xLTEtMTM0Njkz_ff939415-da74-4705-a735-d614d3f5c8bc"
      unitRef="usd">1600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6470a08268ef4de99f119d927d1a4d2f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtOC0xLTEtMTM0Njkz_bc53a88b-17a3-4469-bebe-4563416af073"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b19835c69324505bc3bbe38750f529b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtMTAtMS0xLTEzNDY5Mw_7f7fec5c-9af3-4877-baab-dde7b2d54dfc"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1ecbaf37433b4d40b16bc5671b74f060_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjYtMTItMS0xLTEzNDY5Mw_dc0698ba-b698-4582-984a-d7a97912ba24"
      unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f24d1c8c3584b7c8926aeeea29cd96b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctMi0xLTEtMTM0Njkz_28b2636f-7f74-4fab-861a-d28ac3ad56df"
      unitRef="usd">850400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id6345900a23346efb313425848fb28e9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctNC0xLTEtMTM0Njkz_d4bf6d65-66f9-4f5e-a0ea-0a5ffe7f7633"
      unitRef="usd">1111700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if8b5bc83e8644cd983699f6fb8858208_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctNi0xLTEtMTM0Njkz_afb42f76-e1b7-47e8-bd5a-7573b0fec55b"
      unitRef="usd">1962100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i093cbce56499494f8d57067e66f44ff9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctOC0xLTEtMTM0Njkz_6ff8999c-71dc-47ea-a7ab-9b2c6d1d08a0"
      unitRef="usd">973500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i652da0112b604ae891ebdd50c297d7b5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctMTAtMS0xLTEzNDY5Mw_a28dcb93-8b65-483b-9e91-8c6a43e765b7"
      unitRef="usd">1232200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if551793810f14521aa422baeecc3bfbf_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjliYzY5YjZmMDAwZDQwMTI5ZGQ3MDE3ZDYxYmY5M2Y0L3RhYmxlcmFuZ2U6OWJjNjliNmYwMDBkNDAxMjlkZDcwMTdkNjFiZjkzZjRfMjctMTItMS0xLTEzNDY5Mw_7171bf11-f854-4cee-9bfc-37bc5cbd5fcb"
      unitRef="usd">2205700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2f5a9325fee04e2cba98e5d937adfc74_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC0yLTEtMS0xMzQ2OTM_11f2bc79-947c-46fb-84bf-3a4114c8185d"
      unitRef="usd">330300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia413a1e58ac1484aa3e51cdfe63a6c21_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC00LTEtMS0xMzQ2OTM_042ce583-b321-4d2d-bb00-bdb0a29b445e"
      unitRef="usd">816500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5164cd322f6648be8b5b9b79fc0d4cf2_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC02LTEtMS0xMzQ2OTM_3411fe0a-bce8-4e17-86ac-9219f5b74997"
      unitRef="usd">1146800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic152d3b856314bd5bbd4d922f5b1f015_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC04LTEtMS0xMzQ2OTM_b8506bda-1182-4cd3-8d6f-a0a8c0ecb931"
      unitRef="usd">520100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i29dd87c31a2a4a4eae9d3aae32da4d82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC0xMC0xLTEtMTM0Njkz_9199108b-9210-4211-8c76-4f78f8f49624"
      unitRef="usd">945300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8300e4d26c6147549e8368f3079a0031_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNC0xMi0xLTEtMTM0Njkz_bfe99a9c-130c-4f5f-bffb-a23cf84aa87a"
      unitRef="usd">1465400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1a97f7fa27df49c584d3adb23745a423_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS0yLTEtMS0xMzQ2OTM_a8dad4e8-f4a7-45c7-8de2-3ddedfc6a6a7"
      unitRef="usd">383000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i502d3aeb3a4d41ef97ee7cc08116a94c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS00LTEtMS0xMzQ2OTM_f7a363b4-daef-478b-a5a3-14f6ed90a554"
      unitRef="usd">19600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic67b3715c36b42269427fe5c63da86f8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS02LTEtMS0xMzQ2OTM_47ccb513-6260-4bc9-b610-d1080ac11f42"
      unitRef="usd">402600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i66c8c948a5be433c868d626d7809cd82_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS04LTEtMS0xMzQ2OTM_ef44294c-a8ae-41df-93e2-ff69fcc5cef1"
      unitRef="usd">285000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i755ecabb947b4b71a2c01fa25760d3d7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS0xMC0xLTEtMTM0Njkz_e00bec2b-8760-4afe-acd2-550db8b9a45c"
      unitRef="usd">500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45d4b0e30bae4689bf949adfac85bab6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNS0xMi0xLTEtMTM0Njkz_11fc89f1-144e-4b60-a8d5-5432b4b1e8f4"
      unitRef="usd">285500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i659ebe25d6134f28930cc20ef43b65ef_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi0yLTEtMS0xMzQ2OTM_52a1ca5f-bfcb-4044-b8cc-8c72fe54e564"
      unitRef="usd">713300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8a9d2d82af3f46eab21badf9ac3a6981_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi00LTEtMS0xMzQ2OTM_9ae36f20-46ce-4725-9b3c-5e899f4ab5b5"
      unitRef="usd">836100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i27be45bcbe624d5980096e1785112fdc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi02LTEtMS0xMzQ2OTM_21a75889-3343-450f-8f85-c9a3477e9185"
      unitRef="usd">1549400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib82aa5e2bd524a66bc66939217047a6d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi04LTEtMS0xMzQ2OTM_fa43ad5e-87d5-4d34-8053-b49198364980"
      unitRef="usd">805100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iac5d67fc3dd24634b8a4e9c26b4458f1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi0xMC0xLTEtMTM0Njkz_74ddc967-150f-49f0-a600-1f825233e9ac"
      unitRef="usd">945800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6770d7e189d34ca88257ea5c55b40ebf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNi0xMi0xLTEtMTM0Njkz_46279d75-45f3-4221-b249-8e9f3c06b41e"
      unitRef="usd">1750900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i937b847996cd4321b4854f84342ab7a3_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy0yLTEtMS0xMzQ2OTM_020a2551-3900-48ac-b4da-355dc2009fbf"
      unitRef="usd">493800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ide726508c8b14430a7064d271b9e7f5d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy00LTEtMS0xMzQ2OTM_97e8fb3f-793d-49fe-b219-b8e646a3ea17"
      unitRef="usd">249600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6bca8925482a46e2bc9ec6966695df2a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy02LTEtMS0xMzQ2OTM_38fb52f6-82a0-4c86-9cc9-73d28c9e05d4"
      unitRef="usd">743400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i68aced51bea449ccb43e7ba29ae949ae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy04LTEtMS0xMzQ2OTM_fd5d1ec0-702d-436d-ae10-9ff0cbe867b0"
      unitRef="usd">636400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i59833a1a99db458b86c073d840320416_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy0xMC0xLTEtMTM0Njkz_a6a2f360-fae3-463a-b42f-734d1cc22bea"
      unitRef="usd">286900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61ca7ff7f1294b878f3affcec832bf63_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfNy0xMi0xLTEtMTM0Njkz_7f75e8be-1e85-473a-82b2-6fc23a1f4bef"
      unitRef="usd">923300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1357d813e6fc4d059c8f9d8460edabad_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC0yLTEtMS0xMzQ2OTM_19569cfa-0b3f-4ff2-9e6a-154ea2e29fb9"
      unitRef="usd">114200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i86b062cf2b8e4fcba6125d3f43aba52c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC00LTEtMS0xMzQ2OTM_b526704b-3081-4f0b-af6f-71a5ffd62f18"
      unitRef="usd">138200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0f6299f5a6b94d23a99157b0a82cf59d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC02LTEtMS0xMzQ2OTM_94813097-47cc-4ed3-bf52-714c7e182e7e"
      unitRef="usd">252400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1053bcff8b284ac390b5229c577c0a2f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC04LTEtMS0xMzQ2OTM_82062324-de19-410b-b2b8-fbd1308cb241"
      unitRef="usd">115200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1bc39363344843769eab66bc91bcd94b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC0xMC0xLTEtMTM0Njkz_1cd05935-45f0-4ea6-bf06-801f4508cea8"
      unitRef="usd">149900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ifbb1af036ea24e969a66a5344c047fac_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOC0xMi0xLTEtMTM0Njkz_9b747ab8-8d7b-465f-afba-81400cbfda15"
      unitRef="usd">265100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i56fe58d06e354206ac06d6c22f264c16_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS0yLTEtMS0xMzQ2OTM_8356ff96-d45e-4870-abc9-4db370ed91df"
      unitRef="usd">608000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if01198d0ed2345ce9da3494a19010f80_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS00LTEtMS0xMzQ2OTM_76048b4e-9ebb-499e-9741-286b03310013"
      unitRef="usd">387800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17c1f93f7995494ba74ed1cbfe9a5453_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS02LTEtMS0xMzQ2OTM_0904a12a-2d5c-4b4e-b14c-331c1676faba"
      unitRef="usd">995800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0324cb7d71b14d358a44ddaf249e9c3b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS04LTEtMS0xMzQ2OTM_836e93ba-fd57-44fd-bfa7-26a71d2dba4f"
      unitRef="usd">751600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8592dfe9d1b04943b8d47d4fe572c054_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS0xMC0xLTEtMTM0Njkz_a67c1839-54f4-428f-863d-ea9f19922c13"
      unitRef="usd">436800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib9c613ef03654592a30cd87dad818832_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfOS0xMi0xLTEtMTM0Njkz_2395baca-4cca-4321-973c-9dd92bd68a0e"
      unitRef="usd">1188400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3f69bddf17d545ee8a128bacba69d2ff_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtMi0xLTEtMTM0Njkz_3febb137-c559-4912-b64a-8eb9b252f524"
      unitRef="usd">849400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i06c6cf6db10348b4bf28c5a5845cf749_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtNC0xLTEtMTM0Njkz_d41a92ac-d8b1-46d1-a1e9-fe012badd5e3"
      unitRef="usd">693100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib41052befcfa4e75b65cfb241f1f0da7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtNi0xLTEtMTM0Njkz_21b8b898-43c9-4c46-9051-83aef5196f5e"
      unitRef="usd">1542500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7782237c1c694b6a815faeed508e0178_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtOC0xLTEtMTM0Njkz_1f1d19cf-a92d-4364-9a6f-d31088dbf92e"
      unitRef="usd">854200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icab523ef9fd74083a6a33e39224832dd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtMTAtMS0xLTEzNDY5Mw_87a12b19-5a6f-4345-a9d3-25fbe8014357"
      unitRef="usd">696200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3e3216e6a74f4785916f831d67d9d956_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTAtMTItMS0xLTEzNDY5Mw_a4f32083-3520-4dbf-9352-be9d36429297"
      unitRef="usd">1550400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5e3d7bbc24a94e268d3446995f65a4cd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtMi0xLTEtMTM0Njkz_2a2d1a0e-cf99-4a86-8f49-d85a317104f2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i78ef0131528e441a8a6df4550ce7e43c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtNC0xLTEtMTM0Njkz_67b3ada0-ac91-44f3-bbba-da31465fb47e"
      unitRef="usd">73700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea2d09427bd04c80941fbfc24a9f7d03_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtNi0xLTEtMTM0Njkz_7356ca85-88d9-41be-ab03-b252f399a511"
      unitRef="usd">73700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if0b3afb1cd4f478a818eb6239991e0c1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtOC0xLTEtMTM0Njkz_5a212928-cb6c-46f5-8cd7-a8faf7d39cd2"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7441a70014540ecb01931d60471c8db_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtMTAtMS0xLTEzNDY5Mw_3854bff5-5631-4ca5-baa3-93b2004cbc29"
      unitRef="usd">78800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie32ae0d4377945619a0b004bca44e643_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTEtMTItMS0xLTEzNDY5Mw_bc672254-a000-4bdd-ac17-2bce22ef451e"
      unitRef="usd">78800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0ee7d380900c45aabe38933fa9737ca5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItMi0xLTEtMTM0Njkz_2b92a61a-79f4-46f5-a4e6-76bf42455cb8"
      unitRef="usd">2170700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i023eec0df3f048a9b3e4824e8ed3ab2a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItNC0xLTEtMTM0Njkz_72745010-62e4-4911-8404-86715c47feb2"
      unitRef="usd">1990700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7abe78fd6cf4342a3cc9da64b09d5b4_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItNi0xLTEtMTM0Njkz_20f56ccb-81ea-45ea-a7c0-c3244bbf85ff"
      unitRef="usd">4161400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia3d5d9ecb0104bb3a06537378655c966_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItOC0xLTEtMTM0Njkz_7fea7672-94f0-4834-841b-57df1bb94477"
      unitRef="usd">2410900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i969d874254604c79af7ddf89bcd68f38_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItMTAtMS0xLTEzNDY5Mw_fcf5773f-5688-4368-a251-8d93ad0743ec"
      unitRef="usd">2157600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i10e1787100a84bd8bffa4619e4984d73_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTItMTItMS0xLTEzNDY5Mw_1189f480-9fa4-45bc-b5cc-d6fc5e1e9503"
      unitRef="usd">4568500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0a0a6d1a5b414021b5171c6b7d9fb15d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtMi0xLTEtMTM0Njkz_e9ee6cfd-e24c-452e-bbfe-7647e6e2fe1e"
      unitRef="usd">443300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ieec166a2d8374cc7abab4547af3faf08_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtNC0xLTEtMTM0Njkz_3db0194b-1f51-48ea-b7e1-54798fb55bc0"
      unitRef="usd">891400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic7cdc5646c6548bd8cc644b73018859b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtNi0xLTEtMTM0Njkz_0ad15d26-b868-43cc-8513-75bda8758c9c"
      unitRef="usd">1334700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9531b1a6d294f8ea6c46caa9162ea5c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtOC0xLTEtMTM0Njkz_aee5ca7e-45ab-4b31-b2c6-759a07970538"
      unitRef="usd">437800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c012248699d44a19bf1b3ad593025f7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtMTAtMS0xLTEzNDY5Mw_275bc203-35c3-482c-8aee-90ecf50d880a"
      unitRef="usd">1026600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if879beacfc67428891a4ad60e8881285_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTUtMTItMS0xLTEzNDY5Mw_d986d80a-dae2-4f74-a253-16a7fc58afe5"
      unitRef="usd">1464400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic18416d266bc4669a44779b7ea401676_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtMi0xLTEtMTM0Njkz_2a8aa883-958a-42cf-9b6c-5a14297b248b"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9d74fbbf09504685acefcb2a4557aa87_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtNC0xLTEtMTM0Njkz_262bca43-f538-44c3-9b08-743d7f044cbc"
      unitRef="usd">340700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i730101ba7e3344f3a767d6b2aad9f3cc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtNi0xLTEtMTM0Njkz_2e61a270-ae8d-4507-a5d2-0fcb63702179"
      unitRef="usd">340700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5506665c921446e28905adb32f532db9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtOC0xLTEtMTM0Njkz_1b88794c-3d07-4dbe-bb05-cac992cab5a6"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7afa8b191c2a4834a01ef669ef46770c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtMTAtMS0xLTEzNDY5Mw_742234a1-8d9c-4695-86a8-6260fdb24635"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iea3cff758de541ed88b25aac322f9445_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTgtMTItMS0xLTEzNDY5Mw_1e052d35-3897-4611-990d-0870caa74667"
      unitRef="usd">363900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i53a426a19b4043ba8a16122036b18ddd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktMi0xLTEtMTM0Njkz_4cb029aa-3e42-4b86-a2d5-a61a5f3f87fb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i60eeb012b13c4da095da075b0f10d9cc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktNC0xLTEtMTM0Njkz_92253704-be72-4997-adca-53be69db1e4a"
      unitRef="usd">172400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibab47af987094aeab2253c68b0b4781a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktNi0xLTEtMTM0Njkz_45ee53f3-2997-4e46-9020-b517fdb73d06"
      unitRef="usd">172400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id8fc23920c4547298b885029056b0d73_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktOC0xLTEtMTM0Njkz_1588b6b9-ab85-4cde-81f6-d8f6b20f66fb"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i078e0ac095bc447c9134a911525da50b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktMTAtMS0xLTEzNDY5Mw_f5fd622f-6213-4ec0-933e-6b818c360a93"
      unitRef="usd">170900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia01a554c2ebb48d39f052bebdba83ffd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMTktMTItMS0xLTEzNDY5Mw_ea857cd8-1353-4747-9370-d4b4c1a5f5fe"
      unitRef="usd">170900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic6b844bf5cc94564a2ea1dc24656006a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtMi0xLTEtMTM0Njkz_71115405-f897-4940-889d-f43928d80d18"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i72d549b89a0d4280b7cbec3d16492a8d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtNC0xLTEtMTM0Njkz_48127b07-576d-4c31-a69a-b9f541d33625"
      unitRef="usd">62000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8b356d5dccac4dc0a67e6486ae9004c6_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtNi0xLTEtMTM0Njkz_24d29e41-f95e-4e46-b582-69f8a2c4dbd0"
      unitRef="usd">62000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie9f59cd8393d427894d27c27f376c119_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtOC0xLTEtMTM0Njkz_2006ba2b-7c51-469a-aaea-129364cc2e46"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d01410013b84b008e63a03d34b48335_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtMTAtMS0xLTEzNDY5Mw_28752cda-a28a-45c0-8e6d-8890c74ed29f"
      unitRef="usd">75400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3823cd2bfc3c42808394d87cf2b96174_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjAtMTItMS0xLTEzNDY5Mw_77cf0bc9-7753-456e-aca5-96a21239de5a"
      unitRef="usd">75400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic9d72c66352d4e0ab7a43307ebcfaab7_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtMi0xLTEtMTM0Njkz_3a427931-1101-4027-8198-5e6bb195653c"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="idd11875ea0ab4093a2da88d3dbb08434_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtNC0xLTEtMTM0Njkz_e97eeee3-4153-43eb-acb4-91902d3ecc7d"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i37bc23335780472587bf9311eee7023d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtNi0xLTEtMTM0Njkz_f42bf99d-a407-46c6-ade7-f43795a91fd3"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i61a94521878b432cb2e9c5db2c9a03d9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtOC0xLTEtMTM0Njkz_e69792a6-c19b-4633-90cb-0d2c41a65842"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5d932603e9c9416bb175281368f58803_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtMTAtMS0xLTEzNDY5Mw_d58deeb3-4a6d-439b-a7ff-6863ac5901a9"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1305265f23d04121a22583b545fe9bef_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjEtMTItMS0xLTEzNDY5Mw_46c928ad-a3ca-4d4b-ac00-21998910c6c0"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a9573b057d440c3a41440888f9bc519_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItMi0xLTEtMTM0Njkz_f4f7b7c0-efe5-4ed6-9f7e-46725bce232b"
      unitRef="usd">1200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i8008ca07420f4639a1bee2e6a25b83b1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItNC0xLTEtMTM0Njkz_fd6ad83a-63ee-476d-ad12-47ba31439e22"
      unitRef="usd">575100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic3b600d7fd8d42519eb7d5e81b59a62c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItNi0xLTEtMTM0Njkz_b89b97a1-4500-4bf7-a032-4d1691456528"
      unitRef="usd">576300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d991b8372b64a33973a4e1e72f10d14_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItOC0xLTEtMTM0Njkz_ac889482-c35b-4c4e-bd70-f4a491f7bd64"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i9a74210ccbe44871b085a79bdcf8b0ab_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItMTAtMS0xLTEzNDY5Mw_a3749a06-c2ed-4419-8302-cd73f38c5e5e"
      unitRef="usd">610200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie61b19d0952c468285e72114e0c815fa_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjItMTItMS0xLTEzNDY5Mw_4b9889c1-cf18-43ca-be1a-28bd35afef25"
      unitRef="usd">610200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6aeb83f9ea074f7ca098ec2277b76dcf_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtMi0xLTEtMTM0Njkz_5e3f6085-c908-401a-92cc-af52709f6032"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ibfbcb20de8de4987b63b10487fe1503f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtNC0xLTEtMTM0Njkz_ddf02da2-2a0b-44c2-aadd-83fd97deba7a"
      unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i455d14ea6c564470b68cf17c79c8b1ec_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtNi0xLTEtMTM0Njkz_fc051439-8669-4986-b94c-c2403a4d4446"
      unitRef="usd">6400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i3c1038b4167343c2894ae361d7838cf6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtOC0xLTEtMTM0Njkz_5a25fdb5-52ca-48ff-8b72-43641f299844"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2b33b1754e9a4fd8861a165f689594b7_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtMTAtMS0xLTEzNDY5Mw_fc78f9e0-91ee-441d-8b80-c95dfe1520b9"
      unitRef="usd">8300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if31045dd949540548e6be6125e1e8384_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjUtMTItMS0xLTEzNDY5Mw_da6718e5-389c-4ee3-a46a-9ed6e71679a5"
      unitRef="usd">8300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7037c9ec74674577a86a47384437b333_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtMi0xLTEtMTM0Njkz_9ea0d34e-f8e2-4a56-b416-bebd16277ba3"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6998a8488a944245ac8b554c781cd12e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtNC0xLTEtMTM0Njkz_ac3d22cf-1224-46cb-ac54-ccd2388e1122"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i1722b2d0cc7645f1a42a9c8bb59390c0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtNi0xLTEtMTM0Njkz_34158212-6fa7-4d81-a7fa-71edf1121446"
      unitRef="usd">4500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie0c5dd5e3cf24dbc93e12d0785e49cc2_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtOC0xLTEtMTM0Njkz_01b0a1ef-2467-473c-9d1b-da7bf844cc85"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i45a195ea9682417d82da6447b85f8eb4_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtMTAtMS0xLTEzNDY5Mw_51156ea3-3fe4-4b74-8779-0d074414c7a7"
      unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i6d77cc63bd804d2195547eeb78d38213_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjYtMTItMS0xLTEzNDY5Mw_eae4e3c2-dad5-4b0c-81f5-4963df6a4497"
      unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d2601de96ae48c0893072540afa20be_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctMi0xLTEtMTM0Njkz_ec0a9233-ec4c-419b-9d1c-097d10a1701a"
      unitRef="usd">2619700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaf5eb57f75b949ddb446686c65bd2b5d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctNC0xLTEtMTM0Njkz_b966ce12-ae94-4250-a3e1-14ff7b6ec2f6"
      unitRef="usd">3463600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i64c2a0bb31734409bb0e29d39fc13bae_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctNi0xLTEtMTM0Njkz_d4cb5883-ff4d-4d7e-8f63-1f7ec0c1e848"
      unitRef="usd">6083300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="if382ab28a2c14f67953b81e1f8e224a6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctOC0xLTEtMTM0Njkz_dea63954-23f1-4f00-b994-da0ef4289698"
      unitRef="usd">2850700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i0599c4c9cd214ece84111681c4bd49cc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctMTAtMS0xLTEzNDY5Mw_d39dd150-8d7a-4173-aa59-e7ba95c26a76"
      unitRef="usd">3802700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i2765e6631dd6439f847c09bcca089302_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmMxODIwNGRmOGVlZTRmOWNhNGJmZTI2MDg4ZmViMzM1L3RhYmxlcmFuZ2U6YzE4MjA0ZGY4ZWVlNGY5Y2E0YmZlMjYwODhmZWIzMzVfMjctMTItMS0xLTEzNDY5Mw_b74792b0-b162-4dea-8ab2-45da29956f36"
      unitRef="usd">6653400000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzU3_4cb837a2-0ca0-4a24-a398-93a59107fe1a"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzU3_dbab42d1-cb95-4790-a2bb-7c5590f399c7"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i4508c31bb9b042d2bf4dcb1d266392a0_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzg3_0f8c4b85-c2a6-489c-aea3-63aa9e6635b6"
      unitRef="number">0.269</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ie2e3e533c0e2443196830784733320d3_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMzk0_41d8f787-8331-4454-a2e7-065ee43d8d62"
      unitRef="number">0.105</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i382decd071794d58a8eb96ab53eaa0fb_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNDU0_34b4b80d-f673-41f9-9a9f-bad2aab2f7e3"
      unitRef="number">0.268</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i0a124abe85aa4a19a264079c46a16e9f_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNDYx_2506403c-dd1d-4a3c-834e-7e04d11e63d9"
      unitRef="number">0.107</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTQ0_4cb837a2-0ca0-4a24-a398-93a59107fe1a"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTQ0_dbab42d1-cb95-4790-a2bb-7c5590f399c7"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i1ada2bf116084c4fa8e8e98e14a03495_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTc0_b2b0c753-6bb9-485c-ae7d-4ad8bed82394"
      unitRef="number">0.269</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i2424282c7e6f49e1a4c067b8194f126f_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNTgx_28165f8e-3ed0-4ec9-9536-23a8e5b49d87"
      unitRef="number">0.108</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="ic979c424773c4abda7b0f080e9803dfa_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNjQx_b7a79f86-de88-4cf7-8c92-b6d0fe6e944a"
      unitRef="number">0.291</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="i354359e6eb63451598deb6430cb7b015_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfNjQ4_c6d79efb-f36e-408e-9d1a-235fce9626ea"
      unitRef="number">0.100</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTY0OQ_408d15f4-c797-4cba-876c-73ac049d367f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.155%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.109%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;137.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;759.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;499.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,993.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,501.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(379.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,442.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,821.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(124.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(463.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(602.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;829.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="if28aa7d47b4e4774b232d953458d1d70_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS0yLTEtMS0xMzQ2OTM_2fc4d7bd-b604-401c-aa6f-0bdc092281c8"
      unitRef="usd">137700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i95ce0946ae03453e9adefffc884e3e56_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS00LTEtMS0xMzQ2OTM_badfee55-c423-43a2-8057-c0cb48b0a71c"
      unitRef="usd">759600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i04d9b2bdab044462bcfd071d9cae87fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS02LTEtMS0xMzQ2OTM_000c93fc-40fb-4e0c-a6bf-c89866171998"
      unitRef="usd">38000000.0</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMS04LTEtMS0xMzQ2OTM_2ff01fcb-f438-40cd-bb43-aa2b0c7da56f"
      unitRef="usd">935300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi0yLTEtMS0xMzQ2OTM_c4be572a-be56-4652-8bf3-ed779b080387"
      unitRef="usd">499300000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi00LTEtMS0xMzQ2OTM_bcc9c69c-72df-4fda-a0d9-8c4ce038d5c0"
      unitRef="usd">1993600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi02LTEtMS0xMzQ2OTM_3c8ea97b-d904-4d7d-bfbd-fcb3a4e327bd"
      unitRef="usd">8500000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMi04LTEtMS0xMzQ2OTM_cc9d4f9c-37ef-41fb-9d5c-0f9d5e95aa81"
      unitRef="usd">2501400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy0yLTEtMS0xMzQ2OTM_55d83d9b-56dd-4d25-8fef-02cae6c0686b"
      unitRef="usd">2500000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy00LTEtMS0xMzQ2OTM_c9c662a2-2da9-414e-b39a-d944913fe3f1"
      unitRef="usd">18400000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy02LTEtMS0xMzQ2OTM_935c8ec7-34ec-4831-8909-628403be743b"
      unitRef="usd">7700000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfMy04LTEtMS0xMzQ2OTM_2d4c2f83-4c05-45cf-94d9-56977aed8861"
      unitRef="usd">28600000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC0yLTEtMS0xMzQ2OTM_40d23121-f4ec-4d49-aa92-170ce7420e34"
      unitRef="usd">379600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC00LTEtMS0xMzQ2OTM_fa87315d-6e4b-4dbe-a71f-ed4edd162b08"
      unitRef="usd">1442000000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC02LTEtMS0xMzQ2OTM_3152709e-8f32-4752-8b75-0744537b9f14"
      unitRef="usd">0</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNC04LTEtMS0xMzQ2OTM_2067a586-21df-43ee-a599-728de2ba8bd4"
      unitRef="usd">1821600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="ibd1d9a8cd6b841aba47a161d45e7cd91_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS0yLTEtMS0xMzQ2OTM_9fce3bf2-53ee-44ef-aa74-3066fb1d43af"
      unitRef="usd">124500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i2d15b4736f184bca87982eb18d15abf1_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS00LTEtMS0xMzQ2OTM_32628624-c93a-4e89-8af6-eb2f47613be4"
      unitRef="usd">463700000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i1f6b4965296847d7b19bb07dda2deb5d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS02LTEtMS0xMzQ2OTM_199ebf1c-332c-4269-ad27-452b294cfa3c"
      unitRef="usd">14400000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNS04LTEtMS0xMzQ2OTM_5d58d095-0f12-4ff9-9577-51fd73f755c8"
      unitRef="usd">602600000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i8f1f736cf0c848ceb0338e6ef724d11d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi0yLTEtMS0xMzQ2OTM_553aed40-40e5-41ce-82dc-62beb47fba9f"
      unitRef="usd">130400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i2aa9db267e8b405ebe94ed94f54a1041_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi00LTEtMS0xMzQ2OTM_7a65f7fb-836b-4249-b117-6a0482f2802f"
      unitRef="usd">829100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie9e630e38d8e4abc913f03bb50be1f22_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi02LTEtMS0xMzQ2OTM_cfa7b651-26a7-4d80-a407-ff5d05e89b56"
      unitRef="usd">24400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOmJmNWJlYzRjMDcwYTQyYTU5OGVmYzMwOGY5NjgwZTEzL3RhYmxlcmFuZ2U6YmY1YmVjNGMwNzBhNDJhNTk4ZWZjMzA4Zjk2ODBlMTNfNi04LTEtMS0xMzQ2OTM_1322724a-2d97-4fc5-9a1c-e796aa20e4ec"
      unitRef="usd">983900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYxNQ_a1b2f7a6-2f32-4b44-b7cb-db26e40e9a28">&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.543%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.546%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;983.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i85e08dba5a5d46c48d1d0ba4950b19c1_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMS0yLTEtMS0xMzQ2OTM_c17f63b6-8198-4ee8-b924-9d403c2a72c3"
      unitRef="usd">129400000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i4789aad763454e5aa2bf7c06207aaf14_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMS00LTEtMS0xMzQ2OTM_9adbcf05-0142-4903-aef0-b971599b4038"
      unitRef="usd">133200000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i809babb0c0c0499093a3c1b393fd910b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMi0yLTEtMS0xMzQ2OTM_4dbc6e9e-8707-4051-aed4-60c0276ab844"
      unitRef="usd">854500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ide348a94f52a4b6fbe470e76039c8fd9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMi00LTEtMS0xMzQ2OTM_fc252cb6-1b93-4224-ae2b-e3edcec729f3"
      unitRef="usd">802100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMy0yLTEtMS0xMzQ2OTM_ac488276-c8cb-496d-915e-2c779578fadb"
      unitRef="usd">983900000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjc5NzBmYzY4MzI0ODRlZDNiY2M4NWQwMDZkMTg1NmU5L3RhYmxlcmFuZ2U6Nzk3MGZjNjgzMjQ4NGVkM2JjYzg1ZDAwNmQxODU2ZTlfMy00LTEtMS0xMzQ2OTM_5a9b5cf3-886b-41b1-b39e-41c6d933f417"
      unitRef="usd">935300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYxOA_760caae5-5e91-4053-a118-0e218aaaa9d3">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN and GAZYVA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;498.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OCREVUS and other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;269.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;838.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;745.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;416.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;415.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,252.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,244.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <biib:ShareOfCoPromotionProfits
      contextRef="if13532228d6b4faa9945313be54cbe8a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi0yLTEtMS0xMzQ2OTM_f8c5a1f7-4d77-4a25-88ac-f8a46bc16cba"
      unitRef="usd">131100000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="ia83d6b8be2f94d1ca6fdeb88a1fd79be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi00LTEtMS0xMzQ2OTM_447ce461-bcbb-4808-bb72-bd7686d62eda"
      unitRef="usd">145800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="ie57145cefb184ed0a3414659db9ff24a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi02LTEtMS0xMzQ2OTM_8fb99ea7-7bfd-4f32-9f97-c45a71d26d43"
      unitRef="usd">414200000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits
      contextRef="idc4ea9a082274af0bbf9b1541950118d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMi04LTEtMS0xMzQ2OTM_df87946e-9bc6-4b70-bf32-2f9926e86f69"
      unitRef="usd">498700000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="if13532228d6b4faa9945313be54cbe8a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy0yLTEtMS0xMzQ2OTM_38c61db2-c546-4f20-8272-4724dcf32c89"
      unitRef="usd">285800000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="ia83d6b8be2f94d1ca6fdeb88a1fd79be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy00LTEtMS0xMzQ2OTM_83eb9b81-ee7f-47ba-baab-ffed54d3e9a0"
      unitRef="usd">269600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="ie57145cefb184ed0a3414659db9ff24a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy02LTEtMS0xMzQ2OTM_8e02f824-68b6-4937-ad89-a7c71332368f"
      unitRef="usd">838400000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms
      contextRef="idc4ea9a082274af0bbf9b1541950118d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfMy04LTEtMS0xMzQ2OTM_e2bd37d0-ba78-4764-b5f8-a0ee8fa7cb4d"
      unitRef="usd">745700000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues
      contextRef="id677ff3bfec54adbaa112244fd4799d4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC0yLTEtMS0xMzQ2OTM_482264c3-363a-4bc5-9c2d-139ef6d255b7"
      unitRef="usd">416900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i31f777fcba294e1981f4bbec61fe6842_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC00LTEtMS0xMzQ2OTM_2f9c4612-b23b-4a76-8049-e733bd39dafd"
      unitRef="usd">415400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie1bc6e1753ff4db990730bfcea938673_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC02LTEtMS0xMzQ2OTM_04f95b60-3724-408a-a01e-d16d651f207e"
      unitRef="usd">1252600000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i07dd344004654602b840c7084123794f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjdkNjFkN2E1NGI1YzQzYTQ4M2FjMTliMDRlZjJmZjBmL3RhYmxlcmFuZ2U6N2Q2MWQ3YTU0YjVjNDNhNDgzYWMxOWIwNGVmMmZmMGZfNC04LTEtMS0xMzQ2OTM_23b2c57d-8fca-4455-9172-1e10cd1ad1a8"
      unitRef="usd">1244400000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RleHRyZWdpb246NTYxNDFjM2M3OWJiNDUzMWEwMjVlY2M2OGYxNDIxNWZfMTYzOA_a46d3710-0f3f-43df-a20d-526b3cfeb897">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.870%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.286%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue from collaborative and other relationships:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue earned under our technical development agreement, manufacturing services agreements and royalty revenue on biosimilar products with Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other royalty and corporate revenue:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;114.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;314.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;350.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues
      contextRef="ia21ebca31e894acc847e9662f2798865_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy0yLTEtMS0xMzQ2OTM_f09dd5e9-8d40-492b-a7d1-f069575e312e"
      unitRef="usd">6500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i83428f933f704288a217da35a25533ab_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy00LTEtMS0xMzQ2OTM_a074d7e4-05fa-4a2a-9506-c410a6a727c1"
      unitRef="usd">6300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic58515149d05482e8c241be729c7cebb_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy02LTEtMS0xMzQ2OTM_1144525b-d78a-4e1b-a88d-224f2a2ff7d2"
      unitRef="usd">20900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="icf1edb54ce2347b69f028201a0598732_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfMy04LTEtMS0xMzQ2OTM_87b43007-beab-4d61-bebc-19482059ccac"
      unitRef="usd">15700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7d47538d8dcd446ca3b4284f191efc96_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi0yLTEtMS0xMzQ2OTM_77ca20a2-ff88-4e31-ac6d-dafb67df30af"
      unitRef="usd">8800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iaefd6081d97b42989d5b2062fea0e2c0_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi00LTEtMS0xMzQ2OTM_1c36ac37-af5e-4dc1-8053-c322ff62259a"
      unitRef="usd">7700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7cee8c4809cc43778d9d5dd7095222d0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi02LTEtMS0xMzQ2OTM_5001c522-5a5a-4334-b92a-bc1bcfc24a97"
      unitRef="usd">29700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i4883b5a7fdb64564a053bc40e6173d46_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNi04LTEtMS0xMzQ2OTM_1b4dc579-e5cb-4480-b791-cb0c89285dfa"
      unitRef="usd">20300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib12491491b0e466ebdc29adb36c32405_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy0yLTEtMS0xMzQ2OTM_aa808aab-7b80-4ed7-b5a3-a567fffaa115"
      unitRef="usd">114200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i16bb558d82d1463380f6b8863e69e26a_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy00LTEtMS0xMzQ2OTM_ff638f8d-1fa2-4e46-8142-859865d872f9"
      unitRef="usd">143800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i17597137521d4e01a99df9202a256434_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy02LTEtMS0xMzQ2OTM_1ba321bd-589b-429a-92eb-f8d7166dea86"
      unitRef="usd">242900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i294799e924cb4e7fb31a94d1eb9af81b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfNy04LTEtMS0xMzQ2OTM_0449860b-028c-4e11-be89-ddd40e07c72e"
      unitRef="usd">314100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i599788f95f5d42d1afd8d372967a5f5d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC0yLTEtMS0xMzQ2OTM_4baf1912-a14a-4c1b-a541-d4fb4ae6b5ba"
      unitRef="usd">129500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i7c6c0f5fe10b475babd385cc9a5f1933_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC00LTEtMS0xMzQ2OTM_c5da674a-db93-4d5c-b0e2-b7e7eca36036"
      unitRef="usd">157800000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i01501338195d4d64b3297f4c712b4a35_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC02LTEtMS0xMzQ2OTM_5ca904c7-ef7b-44d0-ba10-2e1d9182f22c"
      unitRef="usd">293500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i76bd2bb0d53b471685923452d6735342_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl80OS9mcmFnOjU2MTQxYzNjNzliYjQ1MzFhMDI1ZWNjNjhmMTQyMTVmL3RhYmxlOjUyMmRjZjRkMTNkZjRlNzhiMzM5YjJjNGI5M2YzM2NmL3RhYmxlcmFuZ2U6NTIyZGNmNGQxM2RmNGU3OGIzMzliMmM0YjkzZjMzY2ZfOC04LTEtMS0xMzQ2OTM_a9206ee0-18c2-4ccf-b7d0-4a55c47bb7b2"
      unitRef="usd">350100000</us-gaap:Revenues>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTUyNA_4c412007-72ff-49a6-9001-81663df3c205">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;771.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,351.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Work in process inventory as of September 30, 2022, includes approximately $118.0&#160;million related to lecanemab.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2022 the Centers for Medicare and Medicaid Services (CMS) released the final National Coverage Decision (NCD) for the class of anti-amyloid treatments in Alzheimer&#x2019;s disease, including ADUHELM. The final NCD  confirmed coverage with evidence development, in which patients with Medicare can only access treatment if they are part of an approved clinical trial. We expect that this decision will reduce future demand for ADUHELM to a minimal level. During the first quarter of 2022 we wrote-off approximately $275.0&#160;million of inventory related to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ADUHELM, as a result of this CMS decision, which was recognized in cost of sales within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;. We have recognized approximately $136.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the fourth quarter of 2021 we wrote-off approximately $120.0&#160;million of inventory in excess of forecasted demand related to ADUHELM, which was recognized in cost of sales within our condensed consolidated statements of income for the year ended December 31, 2021. We have recognized approximately $59.0&#160;million related to Eisai's 45.0% share of these charges in collaboration profit (loss) sharing within our condensed consolidated statements of income for the year ended December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;As of September 30, 2022, the carrying value of our ADUHELM inventory was de minimis. As of December 31, 2021, we had approximately $223.0&#160;million of ADUHELM inventory. For additional information please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTUyMQ_947e97e9-ed39-4ad1-82d7-d0d84c5c2c95">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;394.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;349.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;771.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;814.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,375.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,351.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Work in process inventory as of September 30, 2022, includes approximately $118.0&#160;million related to lecanemab.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMS0yLTEtMS0xMzQ2OTM_5f4b8d16-b205-43f0-abea-8eb9b960a66e"
      unitRef="usd">394200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMS00LTEtMS0xMzQ2OTM_8004b425-8e5b-4fe1-b2a0-d7a4b790cc39"
      unitRef="usd">349600000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMi0yLTEtMS0xMzQ2OTM_c19a4d23-6d3b-4f89-ada6-9e4b78ed6167"
      unitRef="usd">771000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMi00LTEtMS0xMzQ2OTM_38fc377d-90df-4584-9fa3-3e9d3b8ce93d"
      unitRef="usd">814000000.0</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMy0yLTEtMS0xMzQ2OTM_2e805e9f-9ff9-4f76-9c44-6109f397ebb9"
      unitRef="usd">209800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfMy00LTEtMS0xMzQ2OTM_35dd1f86-0a54-4de2-b29a-b0d70edb5052"
      unitRef="usd">187900000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfNC0yLTEtMS0xMzQ2OTM_869203ec-c7e3-4c22-a577-93130def1303"
      unitRef="usd">1375000000</biib:Inventorynetcurrentandnoncurrent>
    <biib:Inventorynetcurrentandnoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RhYmxlOjQzYjkzYTI5YTE4MzQ4MGQ4Y2I5NTI5OWI5Nzc5N2QzL3RhYmxlcmFuZ2U6NDNiOTNhMjlhMTgzNDgwZDhjYjk1Mjk5Yjk3Nzk3ZDNfNC00LTEtMS0xMzQ2OTM_e4800b63-a3cc-4a50-9aed-73f65994e364"
      unitRef="usd">1351500000</biib:Inventorynetcurrentandnoncurrent>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i45f788f2e9604cf7abd1e93ae4f8f733_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTM1_a9f245e3-68e5-404f-876a-b48611b1c035"
      unitRef="usd">118000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWriteDown
      contextRef="ibf9a5892d99e44d8b1534f84205aaefe_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfNjc3_5da037ce-728e-416d-a13f-29911fbaac92"
      unitRef="usd">275000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2837cc88485b432d98238003fed8b676_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfODcx_ce676874-9255-4d5c-b03e-3822eced0af2"
      unitRef="usd">136000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfODc3_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:InventoryWriteDown
      contextRef="ib904f98f905e4ad3953b630e2bca4280_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfOTcy_d3744cb7-4d6f-4f41-abdf-5654b1f14d01"
      unitRef="usd">120000000</us-gaap:InventoryWriteDown>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i47ad44653f43466cbe8c8233fd37d1a4_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTE2Ng_6c723216-2f6c-4819-8605-9c5994f5f98a"
      unitRef="usd">59000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTE3Mg_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:InventoryNetCurrentAndNoncurrent
      contextRef="ia350432a960f43db838c5d34090e798f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81Mi9mcmFnOjIxNDM3YmEwODY1ZjRlMzdhZTcyZDAyMGM3MDAyYzBiL3RleHRyZWdpb246MjE0MzdiYTA4NjVmNGUzN2FlNzJkMDIwYzcwMDJjMGJfMTQwMA_10ab7435-dde2-4b80-899f-ff30f2ddba36"
      unitRef="usd">223000000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDkwNA_ade22aca-a03f-4017-9076-a8ae30745be0">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,415.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,579.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,835.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,588.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,579.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,609.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, amortization and impairment of acquired intangible assets totaled $56.5 million and $190.9 million, respectively, compared to $111.0 million and $813.2 million, respectively, in the prior year comparative periods. For the three and nine months ended September 30, 2022, we had no impairment charges.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021, amortization and impairment of acquired intangible assets reflects impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111 (timrepigene emparvovec) for the potential treatment of choroideremia and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112 (cotoretigene toliparvovec) for the potential treatment of X-linked retinitis pigmentosa.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, amortization and impairment of acquired intangible assets also reflects a $44.3&#160;million impairment charge related to vixotrigine (BIIB074) for the potential treatment of trigeminal neuralgia (TGN). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our acquisition of all remaining rights to TYSABRI as well as other amounts related to our other marketed products and programs acquired through business combinations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In-process research and development (IPR&amp;amp;D) represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations. We review amounts capitalized as acquired IPR&amp;amp;D for impairment annually, as of October 31, and whenever events or changes in circumstances indicate to us that the carrying value of the assets might not be recoverable. The carrying value associated with our IPR&amp;amp;D assets as of September 30, 2022, relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of Convergence Pharmaceuticals Holdings Ltd. (Convergence). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Vixotrigine&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the periods since we acquired vixotrigine, there have been numerous delays in the initiation of Phase 3 studies for the potential treatment of TGN and for the potential treatment of diabetic painful neuropathy (DPN), another form of neuropathic pain. We have engaged with the U.S. Food and Drug Administration (FDA) regarding the design of the Phase 3 studies of vixotrigine for the potential treatment of TGN and DPN and are now performing an additional clinical trial of vixotrigine, which is expected to be completed by the end of 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The performance of this additional clinical trial has delayed the initiation of the Phase 3 studies of vixotrigine for the potential treatment of TGN, and, as a result, we recognized an impairment charge of $44.3&#160;million related to vixotrigine for the potential treatment of TGN during the fi&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rst quarter of 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, the carrying value associated with the remaining vixotrigine IPR&amp;amp;D intangible asset for DPN &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was $109.3&#160;million a&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd the fair value of this asset was not significantly in excess of its carrying value. We will reassess the carrying value of this program upon conclusion of the ongoing clinical trial, or sooner if there is a reevaluation event, and may record an impairment charge related to this asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;BIIB111 and BIIB112&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we announced that our Phase 3 STAR study of BIIB111 and our Phase 2/3 XIRIUS study of BIIB112 did not meet their primary endpoints. In the third quarter of 2021 we suspended further development on these programs based on the decision by management as part of its strategic review process. For the three and nine months ended September 30, 2021, we recognized impairment charges of $15.0&#160;million and $365.0&#160;million, respectively, related to BIIB111, and impairment charges of $28.4&#160;million and $220.0&#160;million, respectively, related to BIIB112, reducing the remaining book values of these IPR&amp;amp;D intangible assets to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, as a result of our decision to suspend further development of BIIB111 and BIIB112, we recorded charges of approximately $39.1&#160;million during the third quarter of 2021 related to our manufacturing arrangements and other costs that we expect to incur as a result of suspending these programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;no&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ac&lt;/span&gt;cumulated impairment losses related to goodwill. Other includes adjustments related to foreign currency exchange rate fluctuations.</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDkwNQ_754d5f2d-eb48-4bc8-8cce-a6fdd30c116d">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.257%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.383%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.396%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.972%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.529%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.669%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4-28 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,415.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,579.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,835.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,413.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,024.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,588.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,579.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,008.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,609.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5,388.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,221.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="if99a29e320c44befaad6c64343facc66_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi00LTEtMS0xMzQ2OTM_d62a0126-4446-494c-93d4-fc4624c954bd"
      unitRef="usd">7415000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="if99a29e320c44befaad6c64343facc66_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi02LTEtMS0xMzQ2OTM_8e9b5c0c-b524-4f1a-a5f2-cd73b32f064e"
      unitRef="usd">5579400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="if99a29e320c44befaad6c64343facc66_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi04LTEtMS0xMzQ2OTM_612735d2-220d-4cdd-81b6-3e3354768a22"
      unitRef="usd">1835600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i085d08ca766f453bb0b1ed59eda80c1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi0xMC0xLTEtMTM0Njkz_d1dfd2f3-1f14-47dc-bf69-d34e295618ee"
      unitRef="usd">7413100000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i085d08ca766f453bb0b1ed59eda80c1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi0xMi0xLTEtMTM0Njkz_ee34e788-e818-461e-b8b8-87decc45d729"
      unitRef="usd">5388500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i085d08ca766f453bb0b1ed59eda80c1d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMi0xNC0xLTEtMTM0Njkz_85b1e92f-4d62-4f14-bb4f-a0bfb7e7592c"
      unitRef="usd">2024600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaeafe70f44754eb2a753ad330c4edea3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy00LTEtMS0xMzQ2OTM_3b9b7313-e404-4d35-80a4-e07b96570d6e"
      unitRef="usd">109300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaeafe70f44754eb2a753ad330c4edea3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy02LTEtMS0xMzQ2OTM_d716aad5-0590-4287-b0dc-ba864244eb37"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="iaeafe70f44754eb2a753ad330c4edea3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy04LTEtMS0xMzQ2OTM_a8731991-3197-4337-a949-41859a8e91f0"
      unitRef="usd">109300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5a922c6b9d0648949c052b847de903cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy0xMC0xLTEtMTM0Njkz_55c618f5-5fee-4507-b4c1-6ae862eec051"
      unitRef="usd">132700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i5a922c6b9d0648949c052b847de903cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy0xMi0xLTEtMTM0Njkz_6205a2be-7d18-4417-bfce-2fe244fafce3"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5a922c6b9d0648949c052b847de903cf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfMy0xNC0xLTEtMTM0Njkz_15d88cb6-8dac-42cf-80cc-e6fdf1c56092"
      unitRef="usd">132700000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4df75de89f2a48e1ac98377bbeff106a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC00LTEtMS0xMzQ2OTM_33ec4150-6a30-4d44-8490-2a14058f9eea"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i4df75de89f2a48e1ac98377bbeff106a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC02LTEtMS0xMzQ2OTM_f1d1e5aa-122e-43ec-a3c2-acf90722bd94"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4df75de89f2a48e1ac98377bbeff106a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC04LTEtMS0xMzQ2OTM_d05182a9-f0c4-43d8-ba28-8f3b2fb9422c"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="idf245f7c03b94d219b053513a7037afe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC0xMC0xLTEtMTM0Njkz_c2aef57f-240f-4659-b293-6f400d08dcb9"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="idf245f7c03b94d219b053513a7037afe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC0xMi0xLTEtMTM0Njkz_84aa87c9-7bed-4f20-95ae-6f584aaf8bed"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="idf245f7c03b94d219b053513a7037afe_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNC0xNC0xLTEtMTM0Njkz_f43f3453-9883-4bec-b73b-6da15d7e8f17"
      unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS00LTEtMS0xMzQ2OTM_98859968-d983-4436-a2ad-6dd1bdc976de"
      unitRef="usd">7588300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS02LTEtMS0xMzQ2OTM_db8f0ec6-a0a0-4b77-b9c3-29f44b143153"
      unitRef="usd">5579400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS04LTEtMS0xMzQ2OTM_8d825465-6c70-4124-aed6-b5879ccc31ec"
      unitRef="usd">2008900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS0xMC0xLTEtMTM0Njkz_7b0d8b1f-1362-4b62-87df-d2e158b60832"
      unitRef="usd">7609800000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS0xMi0xLTEtMTM0Njkz_1215bf5c-e0eb-4cf1-b2e1-2002775d7182"
      unitRef="usd">5388500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOjQ5MmNjZTU5ZGZhMDRiZTNiNjM2YWIzNzFiOTFkZjcxL3RhYmxlcmFuZ2U6NDkyY2NlNTlkZmEwNGJlM2I2MzZhYjM3MWI5MWRmNzFfNS0xNC0xLTEtMTM0Njkz_7c971a40-29ac-4772-a383-39f243964e96"
      unitRef="usd">2221300000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjc3_e5ba969c-3df7-42b0-8a25-957f4d379a25"
      unitRef="usd">56500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjg0_2d74b9c6-2d45-44e0-958f-bb849c979d23"
      unitRef="usd">190900000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMzE0_51878a2c-b45c-4a8d-a324-ff802eba20af"
      unitRef="usd">111000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMzIx_0c91072a-4963-459b-a2b0-a7a8b18336c4"
      unitRef="usd">813200000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="if13c845f22a44a8bbbd7ebeccf43f5e8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNTQ4_5295b8fe-e921-4fee-a5b7-2f2313f89729"
      unitRef="usd">15000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i9f3a6e8db3344edcb5ed43acaf59842c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMjc1OA_710a2a5e-3bc3-4c8f-933d-e4e93859f0bf"
      unitRef="usd">365000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ia7d41aebda1d4947b30b143badbf9555_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNjY0_54a1120f-c177-42ee-abeb-804908f8832b"
      unitRef="usd">28400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7948b4b0b9c44243a39e812b8fbbcdae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMjg4OQ_6a47bb18-cc83-4cf3-bc82-fcb988844df1"
      unitRef="usd">220000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i0fd374623fbf4e19a6f32d3cc68790b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfODk2_b0544a52-b0dd-46ac-b3c0-4f5bb075c0fb"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i0fd374623fbf4e19a6f32d3cc68790b9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjc1OA_b0544a52-b0dd-46ac-b3c0-4f5bb075c0fb"
      unitRef="usd">44300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i2cfeace678454dfeafaf48a68a2f8986_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMjk0OA_7ab22d06-2f27-4725-b04c-9fda80a6234e"
      unitRef="usd">109300000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="if13c845f22a44a8bbbd7ebeccf43f5e8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMzUxNg_5295b8fe-e921-4fee-a5b7-2f2313f89729"
      unitRef="usd">15000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i9f3a6e8db3344edcb5ed43acaf59842c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMzMzMQ_710a2a5e-3bc3-4c8f-933d-e4e93859f0bf"
      unitRef="usd">365000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="ia7d41aebda1d4947b30b143badbf9555_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMzM5OA_54a1120f-c177-42ee-abeb-804908f8832b"
      unitRef="usd">28400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i7948b4b0b9c44243a39e812b8fbbcdae_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzMzQwNg_6a47bb18-cc83-4cf3-bc82-fcb988844df1"
      unitRef="usd">220000000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets
      contextRef="i8c5d0bb749664bab88044a8c3f5fed55_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfMTA5OTUxMTYzNjA1MQ_94dcb7fd-04c5-44f3-8ece-f30b894813e8"
      unitRef="usd">39100000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDkwMQ_35edab7e-14ce-4411-b064-8b1e2790d2f7">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2022 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfMS0yLTEtMS0xMzQ2OTM_89a5c169-2bb2-45cc-8850-701ab17a3639"
      unitRef="usd">55000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfMi0yLTEtMS0xMzQ2OTM_3d049be2-60c4-42ae-b835-086500a8e0a3"
      unitRef="usd">215000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfMy0yLTEtMS0xMzQ2OTM_882cf862-4637-4762-a0c3-16534264bf58"
      unitRef="usd">195000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfNC0yLTEtMS0xMzQ2OTM_2f70faa8-9d94-4698-a7be-4ba4712dd17e"
      unitRef="usd">190000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfNS0yLTEtMS0xMzQ2OTM_2984ca9b-c0ce-4676-ba32-a5d14427d7bd"
      unitRef="usd">175000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmJhMTc3YjU4YjkzYTQxNzM5ZjA2YTcxNGMzNjdmZTU1L3RhYmxlcmFuZ2U6YmExNzdiNThiOTNhNDE3MzlmMDZhNzE0YzM2N2ZlNTVfNi0yLTEtMS0xMzQ2OTM_99ea6788-6adf-485e-91b0-aca8889ca3d8"
      unitRef="usd">165000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDg2NQ_0efd6fbc-a495-400b-8233-268a285a9375">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:78.724%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.346%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,761.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,741.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmUzYTUyNzAyNTU3OTQwZDQ5YmRlMTFkZDhiODk4OTNjL3RhYmxlcmFuZ2U6ZTNhNTI3MDI1NTc5NDBkNDliZGUxMWRkOGI4OTg5M2NfMS0yLTEtMS0xMzQ2OTM_b2ae8372-c72b-4407-b308-798a5a96852d"
      unitRef="usd">5761100000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmUzYTUyNzAyNTU3OTQwZDQ5YmRlMTFkZDhiODk4OTNjL3RhYmxlcmFuZ2U6ZTNhNTI3MDI1NTc5NDBkNDliZGUxMWRkOGI4OTg5M2NfMy0yLTEtMS0xMzQ2OTM_7ec9894c-19cd-4b1c-8d33-5c4f14b97c48"
      unitRef="usd">-19900000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RhYmxlOmUzYTUyNzAyNTU3OTQwZDQ5YmRlMTFkZDhiODk4OTNjL3RhYmxlcmFuZ2U6ZTNhNTI3MDI1NTc5NDBkNDliZGUxMWRkOGI4OTg5M2NfNC0yLTEtMS0xMzQ2OTM_edb39dd1-d6af-4d9f-be56-836e4a28c4a1"
      unitRef="usd">5741200000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl81NS9mcmFnOmQ4ZmFlYWEyZmJkNTQ0ZWVhNDM5NTAwMTY2YmI0MTk5L3RleHRyZWdpb246ZDhmYWVhYTJmYmQ1NDRlZWE0Mzk1MDAxNjZiYjQxOTlfNDcxMw_e5e77e42-cd7c-462b-a85e-e0f8bd18f407"
      unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk0Mw_b8a74a42-21e9-4927-b7de-b485f94a8cb4">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,605.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,515.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,193.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;866.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of Level 2 instruments classified as cash equivalents and marketable debt securities was determined through third-party pricing services. As of September 30, 2022, we elected to early adopt ASU 2022-03 on a prospective basis, which resulted in removing the impact of contractual sale restrictions from the fair value measurement of our remaining Sage common stock subject to certain holding period restrictions. As of September 30, 2022, our entire investment in the common stock of Sage was classified as a Level 1 measurement. Prior to the adoption of this standard, the fair value of Level 2 instruments classified as marketable equity securities represented a portion of our investment in the common stock of Sage and was valued using an option pricing valuation model. The initial holding period restriction for a portion of our investment in the common stock of Sage expired during the second quarter of 2022 with the remaining holding period restriction set to expire in the fourth quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our investments in the common stock of Sangamo Therapeutics, Inc. (Sangamo) and Denali Therapeutics Inc. (Denali) had holding period restrictions that expired during 2022. As of September 30, 2022, the fair values of our investments in Sangamo and Denali common stock were classified as Level 1 measurements. Prior to the expiration of these holding period restrictions the investments were classified as Level 2 measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Sangamo, Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of September 30, 2022 and December 31, 2021. There have been no significant changes to our valuation techniques as of September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Level 3 Assets and Liabilities Held at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023 to 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rates were calculated based on the relative fair value of our contingent consideration obligations. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of our contingent consideration obligations, which ranged from 10.9% to certain probability as of September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers of assets or liabilities into or out of Level 3 as of September 30, 2022 and December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December 31, 2021, approximately&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$195.4&#160;million and $209.1 million, respectively, of the fair value of our total contingent consideration obligations was reflected as a component of other long-term liabilities in our condensed consolidated balance sheets with any remaining balances reflected as a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;component of accrued expense and other. Changes in the fair values of our contingent consideration obligations are recorded in (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, the changes in the fair value of our contingent consideration obligations were primarily due to increases in the discount rates used to revalue these obligations and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2021, the changes in the fair value of our contingent consideration obligations were primarily due to reductions in the probability of technical and regulatory success and delays in the expected timing of the achievement of certain remaining developmental milestones related to our vixotrigine programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0f7f40;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,697.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,744.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,183.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,457.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,296.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,279.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our 3.625% Senior Notes due September 15, 2022, were redeemed in full in July 2022. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2022, compared to December 31, 2021, are related to increases in U.S. treasury yields and wider credit spreads used to value our Senior Notes since December 31, 2021. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk2MQ_9e783143-c2d0-4a41-a8ae-79d7e5f46514">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,219.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;702.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;790.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Receivable from Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;402.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,605.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,515.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,193.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;218.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents the fair value of the current and non-current payments due from Samsung BioLogics as a result of the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics during the second quarter of 2022, for which we elected the fair value option. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.420%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&#160;Other&lt;br/&gt;Observable&#160;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,108.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;866.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,228.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;181.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,046.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;219.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC0yLTEtMS0xMzQ2OTM_6f8dd9c3-f839-492a-93c7-488236bff6b0"
      unitRef="usd">3191800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC00LTEtMS0xMzQ2OTM_2adbe613-ba73-4a30-b5ac-b6920da6d82f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC02LTEtMS0xMzQ2OTM_86ae6c9e-3926-4e11-bff5-413eb7ec848f"
      unitRef="usd">3191800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNC04LTEtMS0xMzQ2OTM_a50b1519-66fa-498e-b3ee-1acd3aae6af6"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaad538ee04e34626a6eea7c18b5170f0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi0yLTEtMS0xMzQ2OTM_57ca058e-0eb9-474a-a2f2-574215d5d279"
      unitRef="usd">1219100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0ab6e798443f48349a275b2f127d63aa_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi00LTEtMS0xMzQ2OTM_c824ca95-a190-44cd-9ad5-6095ee1f7d03"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i320468fceb194a22b349781516794d96_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi02LTEtMS0xMzQ2OTM_009c49cb-7013-4ae6-92c9-fb622effef1c"
      unitRef="usd">1219100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4229dbf5c29146898a310730f9f2a556_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNi04LTEtMS0xMzQ2OTM_b862e677-e609-44af-bab1-a2840ddc9a9c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i21935cd1c743479b8b352f61a8406ef3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy0yLTEtMS0xMzQ2OTM_4dc3a411-57bf-43ab-87b2-f07bf98097b0"
      unitRef="usd">702000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4ed4059cc532499cb0d947b46e8c2790_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy00LTEtMS0xMzQ2OTM_73081339-7cba-4b3e-bd92-f0f1b1367512"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i508e95abdda94a41920a1c67a004ec92_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy02LTEtMS0xMzQ2OTM_5aa57105-9e4d-4a88-a829-e85d65544117"
      unitRef="usd">702000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iff6e063c1a884b0e80c8af000019a9b2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfNy04LTEtMS0xMzQ2OTM_87e1a757-56ea-4eda-8582-50ca574637d3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8b7cf9a8189c4e4badbd47fc34b589a4_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC0yLTEtMS0xMzQ2OTM_289905e8-c859-4bf1-90c6-e9cee883bf8e"
      unitRef="usd">174700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i13cda5e55cec4e3aba7217644a62e136_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC00LTEtMS0xMzQ2OTM_f56dba93-a7a8-46f7-8ebe-1f7cfa5b1829"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id1977ca3896f4eba933be81acfc29491_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC02LTEtMS0xMzQ2OTM_b6ad824e-6e40-43bf-aefa-bda99494534a"
      unitRef="usd">174700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ice735e68404d4fb58b4cc4f43fa85a6a_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOC04LTEtMS0xMzQ2OTM_136a806a-fc8b-4674-8f28-607de5653044"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS0yLTEtMS0xMzQ2OTM_78a0d714-d73f-43cf-bcd9-ab295612620c"
      unitRef="usd">896000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS00LTEtMS0xMzQ2OTM_cb23fba4-c34c-4059-a63a-d0ac0e45cc61"
      unitRef="usd">896000000.0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS02LTEtMS0xMzQ2OTM_ccc3d8a6-bde2-4df7-a730-902efbaf9324"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfOS04LTEtMS0xMzQ2OTM_2d77362a-bf51-4abd-afc6-dc88432a8776"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtMi0xLTEtMTM0Njkz_0b7ee53a-ccdc-4672-b67c-3c0a7052eb6e"
      unitRef="usd">790800000</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i349975b3917d48bb8801949ca1421861_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtNC0xLTEtMTM0Njkz_d285a2bd-85b2-442a-a8cf-b8210977352f"
      unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="i79b9cb96a23b4137a822345574780176_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtNi0xLTEtMTM0Njkz_216064c3-7f7b-4185-b20d-86465cb81e34"
      unitRef="usd">0</biib:OtherAssetsCurrentFairValueDisclosure>
    <biib:OtherAssetsCurrentFairValueDisclosure
      contextRef="iebbfb14f37df42ada487358aa320ac59_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTEtOC0xLTEtMTM0Njkz_c85647a3-5fc1-4745-87e8-6d5be942b0a0"
      unitRef="usd">790800000</biib:OtherAssetsCurrentFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtMi0xLTEtMTM0Njkz_f345fe43-61ab-403d-9395-99b879864a83"
      unitRef="usd">195900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtNC0xLTEtMTM0Njkz_b51bc230-c170-470b-b40e-93dbd216de58"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtNi0xLTEtMTM0Njkz_546d1b3e-dba3-40c1-a4e4-eb3c36b3c810"
      unitRef="usd">195900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTMtOC0xLTEtMTM0Njkz_482bce55-1e0f-4296-ac5b-7d1f9e126cbf"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtMi0xLTEtMTM0Njkz_ffdd6c63-46f8-46f9-9b00-c40ab3f803bc"
      unitRef="usd">32200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtNC0xLTEtMTM0Njkz_3adec600-e6cd-451e-8d0b-17cc0266fd6e"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtNi0xLTEtMTM0Njkz_c76c487c-b6ca-4422-88fd-4c660aea107a"
      unitRef="usd">32200000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTQtOC0xLTEtMTM0Njkz_af45267a-dd8e-4626-8e54-122235608474"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i528f6cd6abb44aeb922d2c691bbba4e6_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtMi0xLTEtMTM0Njkz_2e1d8a79-b1b6-4f87-8013-e2abfb52c0cc"
      unitRef="usd">402800000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i349975b3917d48bb8801949ca1421861_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtNC0xLTEtMTM0Njkz_432b338a-ea67-4dba-b902-beafe4476d23"
      unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="i79b9cb96a23b4137a822345574780176_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtNi0xLTEtMTM0Njkz_567d46ef-ed2d-4cb2-9eae-c489f54dcece"
      unitRef="usd">0</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:OtherAssetsFairValueDisclosure
      contextRef="iebbfb14f37df42ada487358aa320ac59_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTUtOC0xLTEtMTM0Njkz_6239395e-b105-48a5-8f81-6f300f4f4d8c"
      unitRef="usd">402800000</us-gaap:OtherAssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtMi0xLTEtMTM0Njkz_e4bdf468-9f4e-4d8b-b329-30f611b9aab2"
      unitRef="usd">7605300000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtNC0xLTEtMTM0Njkz_be0d5730-615e-4de3-8765-e216429628a1"
      unitRef="usd">896000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtNi0xLTEtMTM0Njkz_9cef61ae-cc2c-4788-b002-afa99a166ebb"
      unitRef="usd">5515700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTYtOC0xLTEtMTM0Njkz_d6392618-7e39-406f-b2b9-51e8f62c2700"
      unitRef="usd">1193600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtMi0xLTEtMTM0Njkz_4fbd57f6-f39e-4724-8709-c0c0e67db297"
      unitRef="usd">22800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtNC0xLTEtMTM0Njkz_8e9dba36-11af-4e29-9f06-05912c67c6b2"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtNi0xLTEtMTM0Njkz_d5f029f8-e283-4ecf-83e9-aa957fae34d9"
      unitRef="usd">22800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTgtOC0xLTEtMTM0Njkz_442bedb7-d5c2-42bc-b5d3-b806d22dbd59"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktMi0xLTEtMTM0Njkz_58b34ba3-ac58-4e97-85d6-fc37d28363a0"
      unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktNC0xLTEtMTM0Njkz_fef50f06-5bdb-41ce-a722-4b1973901156"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktNi0xLTEtMTM0Njkz_f11127f9-2995-45ba-90d3-4a052bb8c4f8"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMTktOC0xLTEtMTM0Njkz_16e59426-8386-41ce-8580-c7bbcfb0f4ab"
      unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtMi0xLTEtMTM0Njkz_4aac545b-d523-4926-a7cb-c8ad3ad81eca"
      unitRef="usd">218200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ic329b49057fa46bba58db3d0c2daed85_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtNC0xLTEtMTM0Njkz_1317eb86-8cec-4fac-bd8e-7908a0222ebf"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="id00f8990c87c4edab48f9433250dcf28_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtNi0xLTEtMTM0Njkz_be5ca0c3-a3ff-4cd0-9845-2188391b7bfe"
      unitRef="usd">22800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4bd688a827a34b67a0e784b5fb549597_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjc3MWIyM2VlNjg4ZDQyNTk5MDRlOGRiMzA1MDBlNGJkL3RhYmxlcmFuZ2U6NzcxYjIzZWU2ODhkNDI1OTkwNGU4ZGIzMDUwMGU0YmRfMjAtOC0xLTEtMTM0Njkz_f619a7b9-edcd-48d6-b859-23f43c422b64"
      unitRef="usd">195400000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzk0_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC0yLTEtMS0xMzQ2OTM_888f2028-b352-432d-8674-5e8ff3d8e189"
      unitRef="usd">1632200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC00LTEtMS0xMzQ2OTM_b91df0a7-6f36-4c7f-abc5-7b9264a71d1f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC02LTEtMS0xMzQ2OTM_9cbfbb02-6807-4edb-a695-6d0ee66f5c34"
      unitRef="usd">1632200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNC04LTEtMS0xMzQ2OTM_a0380635-90b6-439c-9cb4-4d74cd9b3a7f"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i22a9faf176f64839888f1c73d5604d08_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi0yLTEtMS0xMzQ2OTM_c14f9edf-6806-42cf-b2dc-0d9457c2159c"
      unitRef="usd">1108200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id599ac01e6414ccd9716756cd0c865de_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi00LTEtMS0xMzQ2OTM_3578c9d9-5b99-49b4-ae1f-c3cf05dba578"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ia4a5207e2c6849eda81b356e237635cb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi02LTEtMS0xMzQ2OTM_5e0fc747-913b-4b3c-a8d7-e45896f9dc35"
      unitRef="usd">1108200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bfd0daf2c604315aee2e5514037add9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNi04LTEtMS0xMzQ2OTM_df6363c0-8b3b-494b-9dc3-d705f981a2f5"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4f9583d6da0848eaadca5e7997e92ab7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy0yLTEtMS0xMzQ2OTM_5a837945-205a-43a7-a0ae-568c2e43e2f3"
      unitRef="usd">1192700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="idf3747bdadb44befa911a3d96310ff13_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy00LTEtMS0xMzQ2OTM_06dbafb2-81f1-4753-85b6-d140b9da5de7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib5fbb5c6be6b4e50a17ab9ebfa5c3d3d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy02LTEtMS0xMzQ2OTM_40e3de6a-0423-4d88-825f-35ce962df20e"
      unitRef="usd">1192700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i58730b06ccbb4aa3b96956a5848ff476_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfNy04LTEtMS0xMzQ2OTM_ad3414aa-4d97-4ba7-940f-bf6dd6874203"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ieb48448825914249a3d6d269e0343fed_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC0yLTEtMS0xMzQ2OTM_febc2733-de3d-4c4e-9da6-fd339d2cdde9"
      unitRef="usd">132200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icbe4b913116b4794b2827d45ad900e88_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC00LTEtMS0xMzQ2OTM_16445e3b-726b-470a-99a1-d291371123dd"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id29abbf0715a4be1a4a2755996712479_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC02LTEtMS0xMzQ2OTM_0a89e670-de04-417e-8799-efcbdb0d0a74"
      unitRef="usd">132200000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic7487b639fa246688caae909a985fa49_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOC04LTEtMS0xMzQ2OTM_2cfa1889-acae-4a70-a714-16ab219d4c9f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS0yLTEtMS0xMzQ2OTM_f0153cbb-6bbf-404a-a679-326eff3c0427"
      unitRef="usd">1048500000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS00LTEtMS0xMzQ2OTM_92cb8822-68e8-4325-871d-41092a768933"
      unitRef="usd">181700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS02LTEtMS0xMzQ2OTM_46330dbc-fab8-4861-b1f7-e2146c246e5f"
      unitRef="usd">866800000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfOS04LTEtMS0xMzQ2OTM_d810df73-9325-4db9-90c9-201ee28b7ab5"
      unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtMi0xLTEtMTM0Njkz_ab95725d-5d00-4ebe-bcdb-122d96c47b72"
      unitRef="usd">80900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtNC0xLTEtMTM0Njkz_cea6bf4a-de81-4da5-94cb-89be801d6f71"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtNi0xLTEtMTM0Njkz_b51325b4-12b8-4b8b-8bf6-e0a040178fd4"
      unitRef="usd">80900000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTAtOC0xLTEtMTM0Njkz_d7f6feff-6f5a-4a6a-aaf2-6936f995f2e5"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtMi0xLTEtMTM0Njkz_6102e575-1e25-402f-a5c3-d8487a57519a"
      unitRef="usd">33400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtNC0xLTEtMTM0Njkz_ce02ae55-1a35-4a9d-8578-a40bb9e1068a"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtNi0xLTEtMTM0Njkz_f879db67-06b1-4cf0-9df3-c8c83049a678"
      unitRef="usd">33400000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTEtOC0xLTEtMTM0Njkz_52e7a894-eb91-4361-9521-a61f5d7d3662"
      unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItMi0xLTEtMTM0Njkz_cdc6d599-2a78-4338-9dc7-df71d834ee87"
      unitRef="usd">5228100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItNC0xLTEtMTM0Njkz_6833e7ab-d708-45a6-ba62-6ea5bd6cc69e"
      unitRef="usd">181700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItNi0xLTEtMTM0Njkz_c482cad4-65a8-4c43-904f-9d5858e1f6b8"
      unitRef="usd">5046400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTItOC0xLTEtMTM0Njkz_df1a36a2-7731-4962-a9ea-7a1eca245357"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtMi0xLTEtMTM0Njkz_8d6445e2-fa10-4cd6-b0c4-ccf5ce776d7e"
      unitRef="usd">10800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtNC0xLTEtMTM0Njkz_e56903ab-a568-4361-83b6-1c62e2ed5d36"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtNi0xLTEtMTM0Njkz_3ba5cf70-9691-43a0-a25b-87f887b36113"
      unitRef="usd">10800000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTQtOC0xLTEtMTM0Njkz_50fe3a80-2a43-4a5a-a9d2-dfd27d3f84a9"
      unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtMi0xLTEtMTM0Njkz_cf734bbd-80bb-4fb1-aeb5-6d2c9ff01009"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtNC0xLTEtMTM0Njkz_724ba349-b2ac-48fd-bde5-e0b64a0beeea"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtNi0xLTEtMTM0Njkz_83faf02f-9017-4120-b77c-ec8f95883015"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTUtOC0xLTEtMTM0Njkz_591aeb41-b63f-4648-8ff3-683c5c1d5989"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtMi0xLTEtMTM0Njkz_02907934-81c3-4db4-8108-d7fcc0ae84fc"
      unitRef="usd">219900000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i4631e2214cef421b815632fdba8b8cf5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtNC0xLTEtMTM0Njkz_d983e9c7-b2b7-4738-bb5c-dd21003663f3"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i6bc501bbf2dc4a4da17e593cf51fd223_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtNi0xLTEtMTM0Njkz_c1af3c33-2a83-4137-be32-f7635670fc6e"
      unitRef="usd">10800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i126cacdb6c3e45eb94667935f595ce8a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjBjZDA4NmZjNDg1YTQ0MjFhZDE3OTkwNDI5YzQ2NTI1L3RhYmxlcmFuZ2U6MGNkMDg2ZmM0ODVhNDQyMWFkMTc5OTA0MjljNDY1MjVfMTYtOC0xLTEtMTM0Njkz_405f3e4f-f556-4fe4-a7cc-171a3dd69ad6"
      unitRef="usd">209100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTQ5NzU1ODI0MDg4_4f0b3282-a3ec-486c-b0c3-bd280319ec04"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTQ5NzU1ODI0MDg4_89ee227a-f3f6-4126-b9e3-b12b4ec7513b"
      unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk1Ng_fdceced8-3d94-42b9-96a2-bed5ed2bfbdb">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.110%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.788%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.689%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.040%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.256%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-style:italic;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" rowspan="2" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.50%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;4.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;2023 to 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.091%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.369%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,020.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;999.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,697.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,744.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,895.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,742.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,183.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,492.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;997.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,100.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,463.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,099.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;965.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,457.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,473.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,296.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,279.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,273.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Our 3.625% Senior Notes due September 15, 2022, were redeemed in full in July 2022. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 12, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0yLTEtMS0xMzQ2OTM_58b34ba3-ac58-4e97-85d6-fc37d28363a0"
      unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC00LTEtMS0xMzQ2OTM_cf734bbd-80bb-4fb1-aeb5-6d2c9ff01009"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ic2ccf4f8b82f4fda959e8343a1d3dde5_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0xMC0xLTEtMTM0Njkz_e9649c05-5547-4b09-ab03-3cd0d31099c9"
      unitRef="number">0.0450</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i6033459c5bd84004a95df092bb16d49d_I20220930"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0xMi0xLTEtMTM0Njkz_0c3c42ab-2faf-443d-aa87-864bf9329900"
      unitRef="number">0.0450</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i0b72d88f82114d2580cad7720faae9d6_I20211231"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjAwNTQ5MDJkOGFiMTQzMjNhNTZlY2FjZjg2ZTNiZWIzL3RhYmxlcmFuZ2U6MDA1NDkwMmQ4YWIxNDMyM2E1NmVjYWNmODZlM2JlYjNfOC0xNC0xLTEtMTM0Njkz_5f7aa5b0-1706-4c0f-a30e-235fb1bb5c75"
      unitRef="number">0.0130</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <biib:TechnologicalAndRegulatorySuccessProbability
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzMxOA_3ea3ac87-769b-4d64-8fab-dddbc6e956cf"
      unitRef="number">0.109</biib:TechnologicalAndRegulatorySuccessProbability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfNTk2Nw_bff7a3a1-05dc-4692-ab51-eb9c016ed26c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisitions of Convergence and Biogen International Neuroscience GmbH, we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair values of our contingent consideration obligations, which are classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.757%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.412%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;197.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;226.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;209.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;195.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;210.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i67936f8313184aba9a6a811874849e9e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi0yLTEtMS0xMzQ2OTM_66eaf166-f3ca-4746-950d-5f7e6fc98b3d"
      unitRef="usd">197500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i56a9350f33f340dfac40b834b36fbee2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi00LTEtMS0xMzQ2OTM_156591a5-557e-475e-8f01-23f714493b32"
      unitRef="usd">226300000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="if1a82f9151b54f9ebfe04551807803e2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi02LTEtMS0xMzQ2OTM_f87dd8bc-cf3d-41b6-ab66-4362347ce4ab"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i8f224e8cb20d4247baed59ca9186ca70_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMi04LTEtMS0xMzQ2OTM_325e8dc0-aa91-407b-836d-f6bb3be19c37"
      unitRef="usd">259800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy0yLTEtMS0xMzQ2OTM_10d2c144-f019-4bcf-961d-39622ed682e0"
      unitRef="usd">2100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy00LTEtMS0xMzQ2OTM_998a309b-2cc8-485b-a40d-802cb44ccc11"
      unitRef="usd">15600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy02LTEtMS0xMzQ2OTM_7dc5ca20-b0b0-440f-90e7-2e75f0f7a598"
      unitRef="usd">13700000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfMy04LTEtMS0xMzQ2OTM_765826da-8da9-469a-8da4-90f74cf4603e"
      unitRef="usd">49100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS0yLTEtMS0xMzQ2OTM_bd461e5f-1fa6-460d-8306-efa5e12cd5ab"
      unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie8d22419e65e4acdb11df2fd6d50ab7e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS00LTEtMS0xMzQ2OTM_b3111101-007c-444d-8b89-effb6b0c0d0b"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7c435e88eff34c74b9a309271c43e352_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS02LTEtMS0xMzQ2OTM_58c55fa0-0be9-4719-a3d1-b81fa9480a99"
      unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ie8d22419e65e4acdb11df2fd6d50ab7e_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOmMwOTljOWI1Yjc1MzRlNDFiYzdiOGRjNzA4MDNiZDIxL3RhYmxlcmFuZ2U6YzA5OWM5YjViNzUzNGU0MWJjN2I4ZGM3MDgwM2JkMjFfNS04LTEtMS0xMzQ2OTM_c48b69d2-1951-4ceb-a9cb-c608b212de5f"
      unitRef="usd">210700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzg2Mw_4d619c8d-1918-481e-8627-704fe8795ebe"
      unitRef="usd">195400000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RleHRyZWdpb246MTE5YzM2MjIwNDRjNDlkMmE2NjY2OTU5MmNhNTIwN2FfMzg3MA_0303cbb6-c77a-4e02-84ad-3677a066c1f6"
      unitRef="usd">209100000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i5b184b88aa274ec19c0f59ff28afb452_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy0yLTEtMS0xMzQ2OTM_845a15c6-cdfd-462c-827d-f377a9745a34"
      unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i5b184b88aa274ec19c0f59ff28afb452_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy00LTEtMS0xMzQ2OTM_87d8265b-bd22-4a22-b1af-857c3f349c6b"
      unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="idb58e5595fd8416d9ad9613922e40315_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy02LTEtMS0xMzQ2OTM_467e9df6-3a4e-44a6-b6e8-65c22dfc4b44"
      unitRef="usd">1020000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="idb58e5595fd8416d9ad9613922e40315_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfMy04LTEtMS0xMzQ2OTM_e468f961-7a9e-4807-8bcf-fe9cb98ec57f"
      unitRef="usd">999100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC0yLTEtMS0xMzQ2OTM_c3ca0fcf-3ee4-4462-9e74-ce471282dbeb"
      unitRef="usd">1697800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i7bd8e5b6e7f24386a888f74bb76f51e3_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC00LTEtMS0xMzQ2OTM_ddc8bfbc-0aec-4702-904f-8b84e05eab73"
      unitRef="usd">1744300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i1f54baa0a0034028959f4f1dd23cf711_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC02LTEtMS0xMzQ2OTM_f2a4a152-10c3-4957-8108-18c62553b8af"
      unitRef="usd">1895200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i1f54baa0a0034028959f4f1dd23cf711_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNC04LTEtMS0xMzQ2OTM_94809878-9bda-4944-8801-566bb24b8e31"
      unitRef="usd">1742900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i286147027fd848569c362d90f20b6f37_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS0yLTEtMS0xMzQ2OTM_c95e932e-90d6-44a3-b222-eb9f9ad94a56"
      unitRef="usd">1183000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i286147027fd848569c362d90f20b6f37_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS00LTEtMS0xMzQ2OTM_b2f78851-1911-4118-a796-c65ff9e7df9f"
      unitRef="usd">1492700000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i93f9683196184871a6a8088e9b6526da_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS02LTEtMS0xMzQ2OTM_d90665aa-fd85-4a6e-8bd6-0e714a1fb7f9"
      unitRef="usd">1475900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i93f9683196184871a6a8088e9b6526da_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNS04LTEtMS0xMzQ2OTM_8f50b24b-02ba-4269-9b67-9485df8e21c8"
      unitRef="usd">1492000000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i314cc95227f74e429b94104786b26357_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi0yLTEtMS0xMzQ2OTM_c854d3ef-7b95-466c-a2a1-26deaf34360c"
      unitRef="usd">997200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i314cc95227f74e429b94104786b26357_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi00LTEtMS0xMzQ2OTM_97f31017-f4d5-44e0-af11-ddc4ed8f167a"
      unitRef="usd">1100200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i56a4148355e345a48fcfef9143a41e51_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi02LTEtMS0xMzQ2OTM_82e1d218-ad78-418f-a070-848f6f569388"
      unitRef="usd">1463000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i56a4148355e345a48fcfef9143a41e51_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNi04LTEtMS0xMzQ2OTM_c9a4217c-acea-4146-9b4e-40c168d2ef62"
      unitRef="usd">1099900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="id8657f446214427d9d8b9bd45a3d47e5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy0yLTEtMS0xMzQ2OTM_dc573971-ba7e-42c3-b527-01aea414949f"
      unitRef="usd">965600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="id8657f446214427d9d8b9bd45a3d47e5_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy00LTEtMS0xMzQ2OTM_610516b0-a5b9-4d4e-8831-a706117d76cb"
      unitRef="usd">1473600000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i9ddc68c90fa6433c864fb720db1a4975_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy02LTEtMS0xMzQ2OTM_82510187-62e9-4305-97a1-dedd7cbc1922"
      unitRef="usd">1457700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i9ddc68c90fa6433c864fb720db1a4975_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfNy04LTEtMS0xMzQ2OTM_5fb0a050-1365-4371-87d5-bdfe2027a095"
      unitRef="usd">1473200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i8278526fab9042518d7f4accd2d4a217_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC0yLTEtMS0xMzQ2OTM_06e36f3b-9ceb-43cd-9d3c-13707c239e85"
      unitRef="usd">452800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i8278526fab9042518d7f4accd2d4a217_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC00LTEtMS0xMzQ2OTM_fc67f157-3161-4128-a67f-869d2eddda2a"
      unitRef="usd">468400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure
      contextRef="i205e68692a474c17b451db6c94fec530_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC02LTEtMS0xMzQ2OTM_61909fe7-6c45-487f-96f7-f4d386eeb39f"
      unitRef="usd">692900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable
      contextRef="i205e68692a474c17b451db6c94fec530_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOC04LTEtMS0xMzQ2OTM_f34944ba-60f8-4964-92e4-94be19069021"
      unitRef="usd">466000000.0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS0yLTEtMS0xMzQ2OTM_a710b6a5-ae1c-40a0-b83a-27697eb3014a"
      unitRef="usd">5296400000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS00LTEtMS0xMzQ2OTM_6f0c5f20-4fe9-4537-af68-4a9e0a97b561"
      unitRef="usd">6279200000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFairValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS02LTEtMS0xMzQ2OTM_283d4252-a8db-43aa-b934-f55aec5ad7de"
      unitRef="usd">8004700000</us-gaap:DebtInstrumentFairValue>
    <us-gaap:NotesPayable
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82MS9mcmFnOjExOWMzNjIyMDQ0YzQ5ZDJhNjY2Njk1OTJjYTUyMDdhL3RhYmxlOjFjMDYxODkyYjZjYzQ5NWE5NjlmZWU5NjA4ODE3NDEwL3RhYmxlcmFuZ2U6MWMwNjE4OTJiNmNjNDk1YTk2OWZlZTk2MDg4MTc0MTBfOS04LTEtMS0xMzQ2OTM_bba5dd13-8785-453c-80ba-dc744f626cfc"
      unitRef="usd">7273100000</us-gaap:NotesPayable>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjQ5MQ_7e12d4db-7f22-4c5b-8e86-b2782a968aec">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,070.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our commercial paper, including accrued interest, overnight reverse repurchase agreements, money market funds and short-term debt securities approximate fair value due to their short-term maturities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities (gains) losses are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;833.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;408.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,095.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(237.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(237.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;817.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,235.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,245.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;864.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,095.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2022 and December 31, 2021, was approximately 9 months and 10 months, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Proceeds from Marketable Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,643.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,028.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized losses for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2022 and 2021, primarily relate to sales of corporate bonds, agency mortgage-backed securities and other asset-backed securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022, our strategic investment portfolio was comprised of investments totaling $948.5 million which are included in investments and other assets in our condensed consolidated balance sheets. As of  December 31, 2021, our strategic investment portfolio totaled $1,110.3 million and was included in other current assets and investments and other assets in our condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 7, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio as of September 30, 2022, was primarily due to a decrease in the fair value of our investments in Denali and Sangamo common stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali, Sage and Sangamo common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjUwNg_cf09169a-c169-462b-8932-474504bef87b">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Overnight reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,070.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;901.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;283.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,632.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i981abb5814734c34b5ba0e1cfe305f9d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMS0yLTEtMS0xMzQ2OTM_0b36c8f8-e483-4adb-8961-c258c61cad8f"
      unitRef="usd">3200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="ib07f093c1bcb4f10bfd6b343935a270d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMS00LTEtMS0xMzQ2OTM_f0c548e7-59d9-4889-94f9-9e60cacba0e4"
      unitRef="usd">247600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6606034d42124a12b44cdb4c5fba6c23_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMi0yLTEtMS0xMzQ2OTM_7fbbdcb8-8a5a-44f6-bbe4-39a155ef1bd2"
      unitRef="usd">115500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i64a78bdbf8e24900b4b8c65ca0447bcf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMi00LTEtMS0xMzQ2OTM_9e97c94b-5d70-414b-bf3e-39c376e37be3"
      unitRef="usd">200000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i7f61cc110f204304ba8ab5bbe034f465_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMy0yLTEtMS0xMzQ2OTM_55271916-a8a6-48f6-b703-5e7dbd7a56a6"
      unitRef="usd">3070600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i3600b20cbb584539b04e82e09e3dc634_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfMy00LTEtMS0xMzQ2OTM_a24f6c42-d1ae-4858-9155-65fdf29dfe75"
      unitRef="usd">901600000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i3d3e200523fc4be9bb17d504c77c4dee_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNC0yLTEtMS0xMzQ2OTM_e193ee0b-1959-40ae-a4d8-aa3589ae496c"
      unitRef="usd">2500000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i8f54474067a24bd5b888172e5b16c777_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNC00LTEtMS0xMzQ2OTM_ff9ba06e-6138-498f-bd16-a75f654183c5"
      unitRef="usd">283000000.0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNS0yLTEtMS0xMzQ2OTM_7954e6fe-3bc4-4e0e-9303-2278c783b518"
      unitRef="usd">3191800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmUyMjA5ZDViZTBkNzQ2ZTdhZmMzMTE5YzExODcyZTU5L3RhYmxlcmFuZ2U6ZTIyMDlkNWJlMGQ3NDZlN2FmYzMxMTljMTE4NzJlNTlfNS00LTEtMS0xMzQ2OTM_ebbafcc6-f84e-46df-b435-5490eb25de03"
      unitRef="usd">1632200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjQ4Mw_ca0f4a8e-9c22-41e7-9fa6-655b38f101cc">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;833.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;826.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;400.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;392.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;412.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;408.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;293.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;177.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(27.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,095.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(237.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(237.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;896.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.252%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;723.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;817.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;816.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;377.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;376.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Mortgage and other asset backed securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,004.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,167.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;160.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(279.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,048.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id0679777b7204048a91c984d68574247_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC0yLTEtMS0xMzQ2OTM_fd1dab9c-6a3e-483b-9ed3-fcabb03ec4db"
      unitRef="usd">833600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id0679777b7204048a91c984d68574247_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC00LTEtMS0xMzQ2OTM_28e76790-de1f-4841-8c44-c06009ad8779"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id0679777b7204048a91c984d68574247_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC02LTEtMS0xMzQ2OTM_780e3a4f-a172-4bd5-b969-bde9557e1db1"
      unitRef="usd">6900000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id0679777b7204048a91c984d68574247_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNC04LTEtMS0xMzQ2OTM_132fcecc-8ffa-42eb-bb6e-d6d9b1dfeb2c"
      unitRef="usd">826700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS0yLTEtMS0xMzQ2OTM_ea33487b-8f27-462f-a1cc-2265013fb762"
      unitRef="usd">400500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS00LTEtMS0xMzQ2OTM_e890876f-62f5-4772-8961-f486125d253a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS02LTEtMS0xMzQ2OTM_69c9e28b-ef0b-457d-b74d-c3f760a58864"
      unitRef="usd">8100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iecab3d1c123b45d38c30c5bec136d009_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNS04LTEtMS0xMzQ2OTM_43ef640b-ee6d-42c7-90bf-d05e097a68c0"
      unitRef="usd">392400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy0yLTEtMS0xMzQ2OTM_97710078-8274-4e40-8a8d-665fa0f2c83e"
      unitRef="usd">412100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy00LTEtMS0xMzQ2OTM_48c93b6d-bec2-49c8-9844-a3c9e4c36bd0"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy02LTEtMS0xMzQ2OTM_90ac96ee-34b2-403b-a692-4fcd29d695c5"
      unitRef="usd">3500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i62fe1e7bda30406db87fea2368ed0582_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfNy04LTEtMS0xMzQ2OTM_5eaf192f-b257-4c8d-8c33-29c0f8a2aa58"
      unitRef="usd">408700000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i169651b95d8845368e7d477cb953ff71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC0yLTEtMS0xMzQ2OTM_3137d971-40b7-4d03-ad38-7114d3641795"
      unitRef="usd">298800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i169651b95d8845368e7d477cb953ff71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC00LTEtMS0xMzQ2OTM_56d79581-061c-4d14-8dd2-2bddf856ab82"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i169651b95d8845368e7d477cb953ff71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC02LTEtMS0xMzQ2OTM_7e8c4937-e710-4ca9-af01-29d46570da4a"
      unitRef="usd">5500000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i169651b95d8845368e7d477cb953ff71_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfOC04LTEtMS0xMzQ2OTM_ed30cf88-80eb-4fa7-9c17-6ace12d493e3"
      unitRef="usd">293300000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtMi0xLTEtMTM0Njkz_eea8db12-6926-4b67-8684-5c28b812bc4d"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtNC0xLTEtMTM0Njkz_6360fe46-5648-4c7c-9086-88af935aa6dd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtNi0xLTEtMTM0Njkz_a17ff3ac-9d5c-42a6-bc96-9b691a232a19"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0475262fc8644e3c8c1e81f1428ff7d2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTAtOC0xLTEtMTM0Njkz_11f0bffa-52ee-455d-8154-20183223626d"
      unitRef="usd">100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtMi0xLTEtMTM0Njkz_7d81e498-3414-4fd9-82a1-e5b7a646e14d"
      unitRef="usd">177600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtNC0xLTEtMTM0Njkz_f24a00c8-1af7-4d1b-9602-f829bdb619b6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtNi0xLTEtMTM0Njkz_990a7223-6cd4-4f84-9606-36546e431ce4"
      unitRef="usd">3000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib2e4f0ef7bb7426cb9a0b89d219d8de7_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTEtOC0xLTEtMTM0Njkz_5864864e-cbbf-45a2-89f7-f42878719e1d"
      unitRef="usd">174600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItMi0xLTEtMTM0Njkz_551f6efb-d0f9-4eb2-919c-f2704109d9c7"
      unitRef="usd">2122700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItNC0xLTEtMTM0Njkz_0aa8b4d9-af20-4215-81de-2a2b6c496aa7"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItNi0xLTEtMTM0Njkz_7dd431fe-4e06-4d2a-b6ea-a666e94b59de"
      unitRef="usd">27000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTItOC0xLTEtMTM0Njkz_27246b43-5b2b-4fa7-90f1-51d2f72de88e"
      unitRef="usd">2095800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtMi0xLTEtMTM0Njkz_06f5c84f-6415-4fdb-9934-48a340d2a163"
      unitRef="usd">1133800000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtNC0xLTEtMTM0Njkz_c140f274-65c3-47ac-8704-afcbb547c46d"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtNi0xLTEtMTM0Njkz_020a3da0-62a8-43d0-9d35-ce5a556acf51"
      unitRef="usd">237800000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ic2651e59aca44bbeb34ea7ef96f1bec2_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTYtOC0xLTEtMTM0Njkz_a7f27771-e708-4744-a729-74d7ce5fd48e"
      unitRef="usd">896000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctMi0xLTEtMTM0Njkz_196b8358-00a9-45a2-a220-37ee53c467e1"
      unitRef="usd">1133800000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctNC0xLTEtMTM0Njkz_959f8cef-3adc-450c-8f2b-b772da6d9656"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctNi0xLTEtMTM0Njkz_7f869d19-bc0f-491d-8e5d-693f63026a5c"
      unitRef="usd">237800000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjIwZTllMjAzNWMxMDRjMWNiYzkwZmY4ZWRkYjg1NjBjL3RhYmxlcmFuZ2U6MjBlOWUyMDM1YzEwNGMxY2JjOTBmZjhlZGRiODU2MGNfMTctOC0xLTEtMTM0Njkz_ab591357-d38b-45d7-82b7-055c20dfe671"
      unitRef="usd">896000000.0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC0yLTEtMS0xMzQ2OTM_68cb7933-5c65-4f94-b155-5ac6a2d6e3e9"
      unitRef="usd">723600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC00LTEtMS0xMzQ2OTM_a9f56bc8-24ae-468a-b3a2-367c296df072"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC02LTEtMS0xMzQ2OTM_f197f351-25e5-416d-a7c3-f515313795be"
      unitRef="usd">300000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id15a229f23ef4eeaa0b2ee71a4cb0da8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNC04LTEtMS0xMzQ2OTM_2a782928-aebc-4864-afeb-7c6ba4175993"
      unitRef="usd">723400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS0yLTEtMS0xMzQ2OTM_20092e10-a48f-4eac-a6b3-39e9f0d71111"
      unitRef="usd">385400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS00LTEtMS0xMzQ2OTM_0fbfa6dc-77ec-4ebc-a61d-b3052ad10bc4"
      unitRef="usd">200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS02LTEtMS0xMzQ2OTM_955ad030-f14e-4bae-87c6-c7132386c933"
      unitRef="usd">800000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaa04c9b7320b461cba254a374d51bda4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNS04LTEtMS0xMzQ2OTM_9a4f02d4-68c8-4d94-b042-cd07bc7e2012"
      unitRef="usd">384800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy0yLTEtMS0xMzQ2OTM_9dc94139-f78a-460c-9b8c-9ac7248f20af"
      unitRef="usd">817000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy00LTEtMS0xMzQ2OTM_9e85bce4-ade1-4748-bed7-a95ec0845255"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy02LTEtMS0xMzQ2OTM_e184546b-88e0-46ed-8fc1-9cc91b085f2f"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c5dbe1cd36a4633afc2162ef05f7c39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfNy04LTEtMS0xMzQ2OTM_0c984b9d-7663-489e-bf12-e8440b5e150e"
      unitRef="usd">816600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC0yLTEtMS0xMzQ2OTM_7e51429b-edfe-4ae5-9518-acf47f85b492"
      unitRef="usd">377000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC00LTEtMS0xMzQ2OTM_fccdc4e9-a567-40cb-a555-ede65b668141"
      unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC02LTEtMS0xMzQ2OTM_60571d99-21fc-437f-a83f-b791f8be8c7c"
      unitRef="usd">1000000.0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i200d118e7ed64bf5af0105a017c0fece_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfOC04LTEtMS0xMzQ2OTM_45713e2b-bbc9-44e1-9743-a141a36c1ed6"
      unitRef="usd">376100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtMi0xLTEtMTM0Njkz_dcd3b5cf-c63e-40dd-bb5e-4cef14d9d6ff"
      unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtNC0xLTEtMTM0Njkz_aefbcadc-d054-429a-a9b5-9929dfdff3c8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtNi0xLTEtMTM0Njkz_f3cd14b6-c67d-4399-9198-19caf7e35ac6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1d995ddecf64fadbaf96fe1384500ac_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTAtOC0xLTEtMTM0Njkz_b1e75002-d5ec-4586-b8f8-6dbbfbc37706"
      unitRef="usd">1100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtMi0xLTEtMTM0Njkz_f60246ce-fb18-4975-bc5e-cbc997ccdd0c"
      unitRef="usd">131800000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtNC0xLTEtMTM0Njkz_05b8ce68-3e2d-4139-97e7-854e40ea58cf"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtNi0xLTEtMTM0Njkz_ca382f6e-14dd-4d82-a1b2-1d4388be981e"
      unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i98aefaa4fb3840e3bd6f25d03fcea633_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTEtOC0xLTEtMTM0Njkz_f34c518a-adb0-4ad4-a2d1-cc3a06233c6c"
      unitRef="usd">131100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItMi0xLTEtMTM0Njkz_0cb0724f-5ea4-4904-bc47-295b268b4a5a"
      unitRef="usd">2435900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItNC0xLTEtMTM0Njkz_22e83e5f-08d0-4ed1-9d57-b9f207728ed8"
      unitRef="usd">400000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItNi0xLTEtMTM0Njkz_b8232b21-1a88-4c85-8b72-e5a891c83f1a"
      unitRef="usd">3200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTItOC0xLTEtMTM0Njkz_ca043627-01ce-4723-bed8-be3c931cdc4a"
      unitRef="usd">2433100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtMi0xLTEtMTM0Njkz_475e3d74-48ee-4966-b9fd-390d9c4b5513"
      unitRef="usd">33900000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtNC0xLTEtMTM0Njkz_4463b92d-3b5a-4e14-9f2d-3997097f18b8"
      unitRef="usd">9900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtNi0xLTEtMTM0Njkz_057c179e-d71f-4821-9e78-5d96e0ad67a5"
      unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ib271e1f2e84443bca4859f128d33db6b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTUtOC0xLTEtMTM0Njkz_750323b5-6467-43a6-8748-6a9097c54e90"
      unitRef="usd">43800000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtMi0xLTEtMTM0Njkz_6e50ea45-3e57-4eec-b981-704f17c3b276"
      unitRef="usd">1133100000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtNC0xLTEtMTM0Njkz_c78092c9-2104-45a8-a3dc-468f60c33d21"
      unitRef="usd">151000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtNi0xLTEtMTM0Njkz_9f6e3586-482f-4569-9fbd-46c2fc650b4f"
      unitRef="usd">279400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i345b9752e8bf4d7997cbfa7dbd6829b7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTYtOC0xLTEtMTM0Njkz_388f8ade-f73c-4977-b78c-7493afa8488d"
      unitRef="usd">1004700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctMi0xLTEtMTM0Njkz_f94503c1-ad01-47c3-abc7-613f11d8daac"
      unitRef="usd">1167000000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctNC0xLTEtMTM0Njkz_28aedbaa-3198-4fb9-be3b-83bdab8d12da"
      unitRef="usd">160900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctNi0xLTEtMTM0Njkz_87242655-d8fa-48e7-9f8d-93afae50d87b"
      unitRef="usd">279400000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOmM3NzQyZmQ1NDI0YzQxOWI4YTg5MGJlNjI1YmE3ZDhkL3RhYmxlcmFuZ2U6Yzc3NDJmZDU0MjRjNDE5YjhhODkwYmU2MjViYTdkOGRfMTctOC0xLTEtMTM0Njkz_120c3483-0bb5-4758-bdda-9d3ee0742c0b"
      unitRef="usd">1048500000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjUyMQ_657180cf-9727-4b96-82e2-102e287ae90e">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.924%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.413%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,235.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,245.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,541.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;848.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;864.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;868.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;870.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due after five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,095.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,433.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,435.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi0yLTEtMS0xMzQ2OTM_65e79962-cda7-4d10-85eb-9a9434f65806"
      unitRef="usd">1235500000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi00LTEtMS0xMzQ2OTM_73159623-905f-44c6-a4ec-b3c682207fd3"
      unitRef="usd">1245800000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi02LTEtMS0xMzQ2OTM_0f37a28b-410e-4525-9c61-e914da938b85"
      unitRef="usd">1541100000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMi04LTEtMS0xMzQ2OTM_74c5c97d-5b6b-48ee-8c51-c5c344f0d7bb"
      unitRef="usd">1541700000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy0yLTEtMS0xMzQ2OTM_ea79b3a5-e88c-4a92-bd78-90bb4b65d457"
      unitRef="usd">848300000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy00LTEtMS0xMzQ2OTM_4d83573e-30b9-4286-b4ad-3f58187712e9"
      unitRef="usd">864000000.0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy02LTEtMS0xMzQ2OTM_c94e74f5-ace3-4c55-92b8-15871262d033"
      unitRef="usd">868200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfMy04LTEtMS0xMzQ2OTM_12d4e830-ad77-4612-b0bf-1d7a1dc238f6"
      unitRef="usd">870200000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC0yLTEtMS0xMzQ2OTM_dba50666-10d4-48f8-9f5d-53feeaa2cc9b"
      unitRef="usd">12000000.0</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC00LTEtMS0xMzQ2OTM_67813f6d-d729-4822-b0b3-787a81c4b60f"
      unitRef="usd">12900000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC02LTEtMS0xMzQ2OTM_e8e2bbec-ff52-44b5-8483-49cb157d38b7"
      unitRef="usd">23800000</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost>
    <biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNC04LTEtMS0xMzQ2OTM_a32c1d3b-6043-4941-8b3b-74c94708932c"
      unitRef="usd">24000000.0</biib:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS0yLTEtMS0xMzQ2OTM_01f0474e-713d-4add-91ab-2846cc0880a5"
      unitRef="usd">2095800000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS00LTEtMS0xMzQ2OTM_66d8384d-073b-4d97-84fb-a37c587a06cb"
      unitRef="usd">2122700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS02LTEtMS0xMzQ2OTM_7821b441-4e0c-4875-98c6-74216fa4fd75"
      unitRef="usd">2433100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjk0NzY2NjJmMjk1YTQzMWI5NmRiYWJlMDlkZDJkOTI4L3RhYmxlcmFuZ2U6OTQ3NjY2MmYyOTVhNDMxYjk2ZGJhYmUwOWRkMmQ5MjhfNS04LTEtMS0xMzQ2OTM_de053e22-4dee-4c46-8389-e45452c81c60"
      unitRef="usd">2435900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTA1MQ_e73ec821-ffbc-4bf0-a7f5-4595fb4b0456">P9M</biib:AverageMaturityOfMarketableSecurities>
    <biib:AverageMaturityOfMarketableSecurities
      contextRef="i2c07337e773d46e6ad996880dd86a2fe_D20220101-20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTA1OA_7ef1128c-edf4-481b-a6d1-0d822304d6e1">P10M</biib:AverageMaturityOfMarketableSecurities>
    <us-gaap:RealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMjQ4Ng_d5e7b914-5cc4-45bb-906a-be65ba418536">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The proceeds from maturities and sales of marketable debt securities and resulting realized gains and losses are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.245%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Proceeds from maturities and sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,643.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;575.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,104.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,028.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Realized losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi0yLTEtMS0xMzQ2OTM_fa9d405e-8d95-443c-8ce0-d3dcb658ac15"
      unitRef="usd">1643200000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi00LTEtMS0xMzQ2OTM_6a61941b-31a1-4e6d-b4ae-2ddec683f8da"
      unitRef="usd">575400000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi02LTEtMS0xMzQ2OTM_68d34573-24f4-4e66-aebe-d4116001a057"
      unitRef="usd">3104700000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMi04LTEtMS0xMzQ2OTM_5a8d4bf9-18cb-4cee-bd1f-099d0dc22e57"
      unitRef="usd">2028100000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy0yLTEtMS0xMzQ2OTM_c04d59d3-8091-4757-a40a-656d33d76526"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy00LTEtMS0xMzQ2OTM_35fc20dd-062e-4a8e-89fd-93f53137d885"
      unitRef="usd">100000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy02LTEtMS0xMzQ2OTM_94178896-8d91-48cf-8183-d13fb2fd74b4"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfMy04LTEtMS0xMzQ2OTM_4e707904-862e-4343-9757-c302701ca5c8"
      unitRef="usd">400000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC0yLTEtMS0xMzQ2OTM_afba7124-f405-41b3-82a3-373813dfe662"
      unitRef="usd">-7900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC00LTEtMS0xMzQ2OTM_0485030c-a053-4798-b8a6-8c86c35fa5c4"
      unitRef="usd">-500000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC02LTEtMS0xMzQ2OTM_9055a0aa-49eb-466a-9a4b-b1e46ea4c9ef"
      unitRef="usd">-9300000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RhYmxlOjM0MzMzOGZhMGUyYzQ5ODI5ZWY2ZTIwMDdiYjNiM2ZkL3RhYmxlcmFuZ2U6MzQzMzM4ZmEwZTJjNDk4MjllZjZlMjAwN2JiM2IzZmRfNC04LTEtMS0xMzQ2OTM_21ea13ef-f5ed-472f-b829-6f13e4cbc563"
      unitRef="usd">-1700000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <biib:StrategicInvestmentPortfolio
      contextRef="i0caa15f7fec549d5b6d3e7a3c8450b9e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTU0MA_77c9f0a9-a1e0-4055-b64e-4b6f2c301a3e"
      unitRef="usd">948500000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio
      contextRef="iff043d96d6794a88b3666b1deedfcd35_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl82Ny9mcmFnOjE5YTY3ZGQzYjNhNzRjZmY5NDgwNjg5NjhkZWIzODgzL3RleHRyZWdpb246MTlhNjdkZDNiM2E3NGNmZjk0ODA2ODk2OGRlYjM4ODNfMTU0Nw_0354103f-ba22-4870-a567-83f407d321fa"
      unitRef="usd">1110300000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcwNg_7c0a8248-8f9f-4248-8b97-c4edcc36a97c">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts and foreign currency options in effect as of September 30, 2022 and December 31, 2021, had durations of 1 to 15 months. These contracts have been designated as cash flow hedges and unrealized gains or losses on the portion of these foreign currency forward contracts that are included in the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;effectiveness test are reported in accumulated other comprehensive income (loss) (referred to as AOCI in the tables below). Realized gains and losses of such contracts are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from accumulated other comprehensive income (loss) and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,208.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect the net unrealized gains of approximately $144.3&#160;million to be settled over the next 15 months, of which approximately $142.6 million of these net unrealized gains are expected to be settled over the next 12 months, with any amounts in accumulated other comprehensive income (loss) to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2022 and December 31, 2021, credit risk did not materially change the fair value of our foreign currency forward contracts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Net Investment Hedges - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products. In June 2018 we exercised our option under our joint venture agreement to increase our ownership percentage in Samsung Bioepis from approximately 5.0% to approximately 49.9%. The share purchase transaction was completed in November 2018 and, upon closing, &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;we paid 759.5 billion South Korean won ($676.6 million) to Samsung BioLogics. Our investment in the equity of Samsung Bioepis related to this transaction was exposed to the currency fluctuations in the South Korean won. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to mitigate the currency fluctuations between the U.S. dollar and South Korean won, we entered into foreign currency forward contracts. These contracts were designated as net investment hedges. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and closed these foreign currency forward contracts. Upon completing this sale, the cumulative gains on our net investment hedges of $57.0&#160;million were reclassified from accumulated other comprehensive income (loss) and reflected within the total pre-tax gain recognized from the sale, which was recorded in other (income) expense, net in our condensed consolidated statements of income. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to the sale of our &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;49.9% &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;equity interest in Samsung Bioepis, we recognized changes in the spot exchange rate of these foreign currency forward contracts in accumulated other comprehensive income (loss). The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity reflected net gains of $10.6 million as of December 31, 2021. We excluded fair value changes related to the forward rate from our hedging relationship and amortized the forward points in other (income) expense, net in our condensed consolidated statements of income over the term of the contract. The pre-tax portion of the fair value of the forward points that were included in accumulated other comprehensive income (loss) in total equity reflected net losses of $3.6 million as of December 31, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,285.4 million and $1,268.0 million as of September 30, 2022 and December 31, 2021, respectively. Net losses of $36.5 million and $85.8&#160;million related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2022, respectively, compared to net losses of $13.5&#160;million and $26.1&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i83d8b0ff4a59482aa6bdc802c56365fc_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNzE0_36f687bb-0261-4e26-99cc-3992e2445a0c">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i22a07047b8e84600ba3373e7735d13ac_D20210101-20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNzIw_f522ebf5-2439-4bfb-bbba-a1155be9be6e">P15M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjczMQ_6b49306c-ac57-4258-a44a-d604edebdfaf">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,089.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,828.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;166.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;37.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Japanese yen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,208.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,126.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i9ac3efa6755547028b1585766ed0d6a8_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMi0yLTEtMS0xMzQ2OTM_51cdd283-682c-4f51-b28f-e668d51eae47"
      unitRef="usd">1089200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id1e84a127d4d438c93f97cacfe5c9ceb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMi00LTEtMS0xMzQ2OTM_699e8ddf-187f-42e5-96e2-5750874b4c95"
      unitRef="usd">1828000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia1b944b88e544c5aacd839481cf31357_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMy0yLTEtMS0xMzQ2OTM_3d4c12e4-cc89-43df-b583-8debc9028b60"
      unitRef="usd">43500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iafa20a7bcf2748dcbeac35d8a0e0ca7a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfMy00LTEtMS0xMzQ2OTM_97edf1d5-0faf-4212-a2c5-9ab3ca713651"
      unitRef="usd">166200000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic5e498c8f45242b3a2d9e70d2c42a503_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNC0yLTEtMS0xMzQ2OTM_117e8d22-d7ba-479c-ae68-317b8c964f1d"
      unitRef="usd">37800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i7bd633e40e1e41b1b9c1ae520b9468ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNC00LTEtMS0xMzQ2OTM_7d628865-c291-4098-a335-df5a07b9af54"
      unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="id52d6723b04d4723a146148f91d54d4d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNS0yLTEtMS0xMzQ2OTM_5e93d58b-26bc-4804-bbe5-7a2d1a5edd66"
      unitRef="usd">23500000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i61daafc34b6c4be389482539c0515d29_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNS00LTEtMS0xMzQ2OTM_7dc07837-b1b8-4fc4-a91a-1d08ce7cc78d"
      unitRef="usd">72700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="idc378ef82c4040a2a4ab36fe9ca4766b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNi0yLTEtMS0xMzQ2OTM_9cb1cedb-0042-414f-939e-37f4d6d0882a"
      unitRef="usd">14700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i8335794299174638814a89b8c49ff4e9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNi00LTEtMS0xMzQ2OTM_69856b9d-4c3c-41db-9e97-f921d3c5b84a"
      unitRef="usd">59900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie5e6a6220363429f80e31efa34a52864_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNy0yLTEtMS0xMzQ2OTM_c0a471f8-5f4f-4f3b-ba32-d498683d5a44"
      unitRef="usd">1208700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if95bf11f05e341b19847e153ea08fdc7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOmFjMjViYjAzMDZiODQxMjE4MTVmYTgxMzllODQyOWJiL3RhYmxlcmFuZ2U6YWMyNWJiMDMwNmI4NDEyMTgxNWZhODEzOWU4NDI5YmJfNy00LTEtMS0xMzQ2OTM_4c624297-2457-4d34-a17d-6b7a3734d6de"
      unitRef="usd">2126800000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcyNA_b03c6290-6bad-4ceb-9edd-7d09e484027d">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts that were included in accumulated other comprehensive income (loss) in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.783%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives
      contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMi0yLTEtMS0xMzQ2OTM_7548d7f2-b096-469f-8325-ff227e92c762"
      unitRef="usd">146500000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives
      contextRef="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMi00LTEtMS0xMzQ2OTM_1947e05c-4bd5-4cfe-a70f-6d2dece01b3f"
      unitRef="usd">60800000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives
      contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMy0yLTEtMS0xMzQ2OTM_9ae6cb28-6b20-4b90-aa92-56e276f50d28"
      unitRef="usd">2200000</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives
      contextRef="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfMy00LTEtMS0xMzQ2OTM_e9b76a87-d8af-4f04-8189-298b7d63ec81"
      unitRef="usd">7000000.0</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfNC0yLTEtMS0xMzQ2OTM_b63cd0c9-ebf4-405b-ba64-5d28b258cbf0"
      unitRef="usd">144300000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="ie0f135baed114c2abf14530ad97d3acb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjIxMDYzNDUxNDZlMTQyYWI5MDM3ZDRmNjliYmU2YzhkL3RhYmxlcmFuZ2U6MjEwNjM0NTE0NmUxNDJhYjkwMzdkNGY2OWJiZTZjOGRfNC00LTEtMS0xMzQ2OTM_e0acbe3f-0ec2-4ed7-9fda-f18b7f074736"
      unitRef="usd">53800000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="i0df5ee45dae64856988254a8fd28f919_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMTkxMA_b63cd0c9-ebf4-405b-ba64-5d28b258cbf0"
      unitRef="usd">144300000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i120d294420ac4cc5a5287c7acc20fa00_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMTk0MQ_3f9206b1-3126-412e-9d08-00e99c241ea0">P15M</us-gaap:DerivativeRemainingMaturity1>
    <biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="i8996f46ad23e477a8251393d59e34875_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMTk2OA_bd93d137-755c-44e6-b5bf-721483a2fb72"
      unitRef="usd">142600000</biib:UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:DerivativeRemainingMaturity1
      contextRef="i5fa5a40f0ac14aa19a149832f0cf7187_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMjA0Mg_2fb0fce7-a9ec-4093-84f2-9bac1c3aa611">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcxMQ_e1a0cfe1-11e7-43a1-801a-c99dbfe98f13">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.765%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.198%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.345%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.154%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.641%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i32243243b47a43fb8c6ba0eb85b30fd8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy0yLTEtMS0xMzQ2OTM_3163f4d3-a686-4df0-943b-7a97d426de7a"
      unitRef="usd">77700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7855fb3a8a984c0abaab370eeac02ee2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy00LTEtMS0xMzQ2OTM_e3760ae6-bf44-4688-be65-0908e0496dc2"
      unitRef="usd">-14900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ie45b0d8165e24b5a9fbc05c247e52911_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy04LTEtMS0xMzQ2OTM_9a5bbd7a-63a7-41c8-ae3b-315696ca7fe6"
      unitRef="usd">6600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ic258686cd3a6456ebc2c9b09e2ff27be_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMy0xMC0xLTEtMTM0Njkz_cd13d4b8-2a03-4f0a-94cb-bc8c21a4a577"
      unitRef="usd">-700000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="idea016b088d845d98937c3a05df5d947_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC0yLTEtMS0xMzQ2OTM_bcb5aa40-d101-4fcd-8021-a11c4032db05"
      unitRef="usd">-800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i97bd4991354c4a15ac876c71524967c5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC00LTEtMS0xMzQ2OTM_7d686793-26db-4254-bb27-9994219d6888"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ie96b8241173c4299901100e5efed591a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC04LTEtMS0xMzQ2OTM_946d9583-4bee-46fb-8d2b-db9afb616b92"
      unitRef="usd">-100000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i6b8795f0fecd44bc833219a58dfaee62_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfNC0xMC0xLTEtMTM0Njkz_cb6889ac-accb-49cc-9040-031b30651952"
      unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="iec630ea085d14b79a6702770f05c54fc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS0yLTEtMS0xMzQ2OTM_4b3bf447-7468-48cf-bba5-5b20ae09e0f8"
      unitRef="usd">143200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i1b690018155f45cdb7f208616597334e_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS00LTEtMS0xMzQ2OTM_7709393b-fb51-4735-84d6-ca62ae6151a4"
      unitRef="usd">-68700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i5c24c29444b548aca4187e271cfa886b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS04LTEtMS0xMzQ2OTM_b8635668-77af-4edc-ab2b-3a2d46540ef4"
      unitRef="usd">-800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i3d5d2ca68e014dc3922d00d93a88be43_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfOS0xMC0xLTEtMTM0Njkz_f457ee94-563d-4dd5-ba07-a068079182c5"
      unitRef="usd">-4500000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="id5e7ec03b8354dbab75b233556df07d5_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtMi0xLTEtMTM0Njkz_c0a886e2-ac81-4d31-8797-eeb7859fff0f"
      unitRef="usd">-3500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i88cbc69efa06413895dfc1180ad985c9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtNC0xLTEtMTM0Njkz_24b4ad4b-e5eb-4f5a-819b-bc80f583ff78"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="ib29380d2bf674aeb8ea8724965b1f6b8_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtOC0xLTEtMTM0Njkz_23a06140-b5ae-4504-942a-7e5c99e25be3"
      unitRef="usd">-400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="i1d977c21aa234f7f99392c7a1a2c212c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjMwYTIwMWNmOTJhZjRjOTY5MDc0YzUyZmQ0MDc0YWZiL3RhYmxlcmFuZ2U6MzBhMjAxY2Y5MmFmNGM5NjkwNzRjNTJmZDQwNzRhZmJfMTAtMTAtMS0xLTEzNDY5Mw_d9ee66f3-a803-4e44-8e82-fc149b9b6a73"
      unitRef="usd">-400000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction
      contextRef="i52fa7dd299c7425bbc3bba8fd21f9067_I20180531"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzAwNA_75a37485-7efa-42e1-8c8d-5b957d1d7006"
      unitRef="number">0.050</biib:EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzAyNA_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i89423fcf9d5d4c26a6860a1d370bc9f4_D20181101-20181130"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzExNw_3000ef82-0296-4ff9-845b-8cdfc4ea059e"
      unitRef="krw">759500000000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:PaymentsToAcquireEquityMethodInvestments
      contextRef="i89423fcf9d5d4c26a6860a1d370bc9f4_D20181101-20181130"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzEzOA_76d06682-4fc2-49f7-8f10-b9db8aab9d40"
      unitRef="usd">676600000</us-gaap:PaymentsToAcquireEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzUxMw_87489fb2-69a4-4e3a-922d-19880424e2d7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfMzY1Mg_d473323a-ca4f-414a-8561-f8cef95181a0"
      unitRef="usd">57000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTQ5NzU1ODIwNjk4_87489fb2-69a4-4e3a-922d-19880424e2d7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax
      contextRef="if414410918334d9bb8c6e78f27e2bd55_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNDQzOQ_88228e69-efe2-4ec4-abac-238ac4d3d8fb"
      unitRef="usd">10600000</us-gaap:UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax>
    <us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax
      contextRef="ic2f87e0409bf4de6bbfb65f1f00e2861_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNDg1NQ_6ab6a5d3-91cf-41a7-9551-7ae586f1a836"
      unitRef="usd">3600000</us-gaap:AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax>
    <us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcyOQ_80c345c5-f24c-4391-b798-2c3737d7936a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of our net investment hedges in our condensed consolidated financial statements:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.980%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.195%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.202%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="51" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Effective Portion) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Other Comprehensive Income (Amounts Excluded from Effectiveness Testing) &lt;br/&gt;(in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Recognized in Net Income &lt;br/&gt;(Amounts Excluded from Effectiveness Testing) (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i22be7e941fc4472097793c58bfe13c85_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0yLTEtMS0xMzQ2OTM_2cb088c2-f927-4781-93a3-25b8fa542190"
      unitRef="usd">0</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="icd0cd6a0501e4513abdff115c36b8a4c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy00LTEtMS0xMzQ2OTM_d0fd4d21-c930-47dd-8881-fac1925f237c"
      unitRef="usd">24900000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i22be7e941fc4472097793c58bfe13c85_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy04LTEtMS0xMzQ2OTM_7fcaba36-66ea-45e1-ab7d-1fa102709153"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="icd0cd6a0501e4513abdff115c36b8a4c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0xMC0xLTEtMTM0Njkz_e10dbbd3-1cc0-47b1-8614-a76a5a6c8527"
      unitRef="usd">0</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="iff7a68233a6346a3b41b5ba48c00eb25_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0xNC0xLTEtMTM0Njkz_fbb92690-0f98-4c23-b448-f4113acdbb69"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i9172dc7ebd564a448d1ab478d505ac9e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfMy0xNi0xLTEtMTM0Njkz_fd672ec1-1b15-4512-9492-29fe601c6ab9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="i507cb74104cc4af691f7ec53fa51daf0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0yLTEtMS0xMzQ2OTM_eaf78794-2a9f-4347-9995-23f7e2b583b0"
      unitRef="usd">20400000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease
      contextRef="id6f4b8580bdd4045984ea773c64855bd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC00LTEtMS0xMzQ2OTM_113366ff-9dce-4fa6-b692-075e5395b285"
      unitRef="usd">46100000</us-gaap:TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="i507cb74104cc4af691f7ec53fa51daf0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC04LTEtMS0xMzQ2OTM_22692ab3-95e0-4136-a2aa-ba5fe68a296f"
      unitRef="usd">-3200000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease
      contextRef="id6f4b8580bdd4045984ea773c64855bd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0xMC0xLTEtMTM0Njkz_cb8a3e30-d8bb-48f6-9ef0-f4a98b2c8a44"
      unitRef="usd">-1100000</biib:Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="i4e7d3a50e8e24a18a4f3bebf9a25ee71_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0xNC0xLTEtMTM0Njkz_ffeacdb3-3864-4421-bc7c-05d4df67f09b"
      unitRef="usd">-4600000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet
      contextRef="idecbeb6a787b45e999586e7f179ad321_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjkwOTA1NTJhMWM4YjQ0ZWZiMTNmOWZmODhhN2ViOTY5L3RhYmxlcmFuZ2U6OTA5MDU1MmExYzhiNDRlZmIxM2Y5ZmY4OGE3ZWI5NjlfOC0xNi0xLTEtMTM0Njkz_57967d39-ecf0-45a8-8302-723604303f4f"
      unitRef="usd">100000</us-gaap:DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTEyMA_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ib88cc97bd13d40ac90880007f88756da_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTc0MQ_e0d0d6b7-3dc8-423e-b22f-6b44789b3547"
      unitRef="usd">1285400000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="if41dae46b1004553a798193cc1c16ae9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTc0OA_74d5c3f2-5862-4e6b-a18b-16739f731f79"
      unitRef="usd">1268000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTc5Ng_481e5928-6a52-4f2a-8a81-5625517823c8"
      unitRef="usd">36500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTgwMw_fa75af62-a2c7-410b-851d-8fb7db8cdf84"
      unitRef="usd">85800000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTk2Nw_7831dbd8-8108-46ca-a24a-d6a755698a83"
      unitRef="usd">-13500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNTk4OA_039aea07-f959-436e-88fe-6e7fba1a3fdb"
      unitRef="usd">-26100000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjcwNA_52ac17ff-91bc-4257-8318-1b812962b114">&lt;div style="margin-bottom:3pt;margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.372%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Net Investment Hedging Instruments:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-style:italic;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. Amount represents unsettled balance of our closed net investment hedges. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i4c0575de61ec44b4950ffd44163cfc4e_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMi00LTEtMS0xMzQ2OTM_a578b8b4-cd2a-4fb0-bc3c-251632ccbd99"
      unitRef="usd">158200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i53ce27e2d1834006bccaafc6efdf9bff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMi02LTEtMS0xMzQ2OTM_a6629ff5-b065-4023-bf27-fac53a61475f"
      unitRef="usd">66200000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iac791a4319614586b5fa4b20e746145d_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMy00LTEtMS0xMzQ2OTM_f19cc1c1-27e5-4cde-a3b2-c2f88d7f2e65"
      unitRef="usd">5000000.0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ia15c5a492bc341798bf62fd3955ff770_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMy02LTEtMS0xMzQ2OTM_afcb4e91-9230-4331-bc5a-470ce3dc2c63"
      unitRef="usd">5500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="id6a5fda462c643bdb69ff40ab7f9019c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfNC00LTEtMS0xMzQ2OTM_366c01a4-6a4e-4375-b736-d7b691fd5389"
      unitRef="usd">2600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ib019b33e0733407486645ee0e3dba238_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfNC02LTEtMS0xMzQ2OTM_3098f8ef-a8de-4a7a-99db-73d75785d2f1"
      unitRef="usd">6600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5aa0d743936f4ed9aafcdf381a12a281_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfOC00LTEtMS0xMzQ2OTM_8b4ed538-b0ac-402d-8640-06877d4ca388"
      unitRef="usd">21400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic2ec860c976745568331c92c49c8ddbb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfOC02LTEtMS0xMzQ2OTM_74d80106-e125-4253-ba3c-58d7d5992eed"
      unitRef="usd">4100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i27638e932c864367ae3db51bb6a4e81f_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTYtNC0xLTEtMTM0Njkz_793ff9f1-2b45-43a1-9633-c20c50b427ea"
      unitRef="usd">11300000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i31b779d2d9c44b8e902c134c0f3a5def_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTYtNi0xLTEtMTM0Njkz_f7cd2501-9211-4237-b611-84e070ee168e"
      unitRef="usd">5100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i3c6767b12f4843b4be545567280f6604_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTctNC0xLTEtMTM0Njkz_d4fff806-0eb4-4bbf-8906-6b7d2354e53d"
      unitRef="usd">20200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i034507e9f9464a29a0c701e02ba11b39_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RhYmxlOjM0NTc1YzlmOWNkMDQ5Y2ZiMGE1NGY0MDJkOWZiYmQyL3RhYmxlcmFuZ2U6MzQ1NzVjOWY5Y2QwNDljZmIwYTU0ZjQwMmQ5ZmJiZDJfMTctNi0xLTEtMTM0Njkz_56efb6f9-bb05-40c5-b131-5570c2e05cbd"
      unitRef="usd">4200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83MC9mcmFnOmI2ZjU5NWYwYjQ3MzQxODY4ODJkM2E1NzI2MjllOWEyL3RleHRyZWdpb246YjZmNTk1ZjBiNDczNDE4Njg4MmQzYTU3MjYyOWU5YTJfNjYxNg_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTIxMw_d5ec51bb-99c0-4f52-9da4-f56153aa92ad">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,098.0 million and $2,006.6 million as of September 30, 2022 and December 31, 2021, respectively. For the three and nine months ended September 30, 2022, depreciation expense totaled $64.2 million and $207.7&#160;million, respectively, compared to $65.1 million and $168.7&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Solothurn, Switzerland Manufacturing Facility&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In order to support our future growth and drug development pipeline, we are building a large-scale biologics manufacturing facility in Solothurn, Switzerland. Upon completion, this facility will include 393,000 square feet related to a large-scale biologics manufacturing facility, 290,000 square feet of warehouse, utilities and support space and 51,000 square feet of administrative space. As of September 30, 2022 and December 31, 2021, we had approximately $701.0 million and $677.0 million, respectively, capitalized as construction in progress related to this facility. In the second quarter of 2021, a portion of the facility received a Good Manufacturing Practice multi-product license from the Swiss Agency for Therapeutic Products, resulting in approximately $1.2&#160;billion of fixed assets being placed in service during the second quarter of 2021. In April 2022 the FDA approved the Prior Approval Supplement for the Solothurn facility for ADUHELM. We estimate the second manufacturing suite at the Solothurn facility will be operational during the second half of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;125 Broadway Building Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we completed the sale of our building and land parcel located at 125 Broadway, Cambridge, MA (125 Broadway) for an aggregate sales price of approximately $603.0&#160;million, which is inclusive of a $10.8&#160;million tenant allowance. This sale resulted in a pre-tax gain on sale of approximately $503.7&#160;million, net of transaction costs, which is reflected within gain on sale of building in our condensed consolidated statements of income for the three and nine months ended September 30, 2022. This transaction included approximately $79.2&#160;million of property, plant and equipment, net, which comprised of approximately $72.6&#160;million for buildings, approximately $1.6&#160;million for land and approximately $5.0&#160;million for machinery and equipment.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTcx_5f6e0a22-6abf-4e6d-b9cc-ec789b19dce3"
      unitRef="usd">2098000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTc4_521e100e-bbbd-4118-b0a3-0a4041f8f7a0"
      unitRef="usd">2006600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc2_9afbf7fb-6a57-438b-8d59-4244c2bebb40"
      unitRef="usd">64200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjgz_fbb782a7-5d12-4eaf-baee-1170f99f62a2"
      unitRef="usd">207700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMzEz_4180efb0-4e75-4950-aa9e-b1755d5c6a96"
      unitRef="usd">65100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMzIw_2e90787f-aba5-4eac-8cd4-d4ff765ddca7"
      unitRef="usd">168700000</us-gaap:Depreciation>
    <biib:NumberOfSquareFeet
      contextRef="i15cf3398e090470b836590f86a9494e7_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNjI2_dbe34b08-5c69-4bd2-af6f-6108d44d72c2"
      unitRef="sqft">393000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="iff59169dbc0c45b4897fff451d70d7df_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNzAw_923a58a6-fba8-443d-a62b-b806dcd33c31"
      unitRef="sqft">290000</biib:NumberOfSquareFeet>
    <biib:NumberOfSquareFeet
      contextRef="ieaa1ea81bcf844509d4e9629d0129c76_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNzYx_777707ac-68d3-492c-b592-5c7bf4f3aae3"
      unitRef="sqft">51000</biib:NumberOfSquareFeet>
    <us-gaap:ConstructionInProgressGross
      contextRef="i92a75cf0ee8a497393ba39d608afef91_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfODM5_306cecb5-44b5-461f-acf8-96d9580ef9f0"
      unitRef="usd">701000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross
      contextRef="i3a57d1b2e861499fab173d2ef85a3b1e_I20211231"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfODQ2_d60c507d-923a-45f7-9529-831a1ee54d79"
      unitRef="usd">677000000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i92a75cf0ee8a497393ba39d608afef91_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTEyMw_ee984e2b-35c8-407b-b8aa-794a1a86e163"
      unitRef="usd">1200000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="ia758334f8b3d4c2bb05db550ef70a7a0_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc3OA_d9f25a8e-024e-4f6b-8f81-6e2eaf5df490"
      unitRef="usd">603000000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <biib:GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance
      contextRef="i24f4a773df0340cc9dcea4430ac7f361_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc4Ng_2b4b7d1e-2240-413d-b51a-3de79a44a8da"
      unitRef="usd">10800000</biib:GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="ia758334f8b3d4c2bb05db550ef70a7a0_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMjc4Mg_0131dd63-4ce9-4de8-9764-10ebae20a435"
      unitRef="usd">503700000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i41b979e0fcbd45a49408dd1c5807f36c_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNTQ5NzU1ODE1NzI4_e82113aa-4d54-423a-acb6-641c863e8a34"
      unitRef="usd">79200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i52ed0ad90e1a409da68a677b1a180bed_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfNTQ5NzU1ODE1NzQ3_3a87d891-924b-4711-872f-331984f27fba"
      unitRef="usd">72600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ie0993033b50e4a51badc996a38d9d905_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTA5OTUxMTYzMTAxMw_6b5b42aa-7602-4b98-9118-8dcd41fd5f63"
      unitRef="usd">1600000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i0974435913f44b15b34152a1fee687d0_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83My9mcmFnOjg2ZmJkYjQwZDNkMjRlYTBhMTUxNDJkMjY2OThhYzI0L3RleHRyZWdpb246ODZmYmRiNDBkM2QyNGVhMGExNTE0MmQyNjY5OGFjMjRfMTA5OTUxMTYzMDk5OQ_93ccc35e-88f7-44b1-9ae9-942b7bef63bb"
      unitRef="usd">5000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfMzI5ODUzNDg5NjExOA_ee510e60-7148-46a5-a4aa-018222e3c87c">LEASES &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;125 Broadway Building Sale and Leaseback Transaction&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in connection with the sale of our building at 125 Broadway, we simultaneously leased back the building for a term of approximately 5.5 years, which resulted in the recognition of approximately $168.2&#160;million in new lease liabilities and right-of-use assets recorded within our condensed consolidated balance sheets as of September 30, 2022. The sale and immediate leaseback of this building qualified for sale and leaseback treatment and is classified as an operating lease. For additional information on the sale of our building, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10, Property, Plant and Equipment&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;300 Binney Street Lease Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we entered into an agreement to partially terminate a portion of our lease located at 300 Binney Street, Cambridge MA, as well as to reduce the lease term for the majority of the remaining space. The agreement was driven by our 2022 efforts to reduce costs by consolidating real estate locations. The transaction was treated as a lease modification as of the effective date and resulted in the derecognition of right of use assets of approximately $47.4&#160;million and lease liabilities of approximately $52.7&#160;million, which resulted in a gain of approximately $5.3&#160;million, which was recorded within restructuring charges in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i7037a7c948b64786be2cf157e66fc0cb_I20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIwODY1_a54d1ca8-4763-43da-9454-075123168828">P5Y6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i7037a7c948b64786be2cf157e66fc0cb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIwNTgw_47f408d6-9f4c-4357-bdda-a122ad54a4ad"
      unitRef="usd">168200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i7037a7c948b64786be2cf157e66fc0cb_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIwNTgw_7029747c-9e43-40f4-ae9b-74ec89c1a8c6"
      unitRef="usd">168200000</us-gaap:OperatingLeaseLiability>
    <biib:OperatingLeaseRightOfUseAssetDerecognized
      contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIyMTAz_2d289e6a-4609-4a9c-a622-3f42e1d0eede"
      unitRef="usd">47400000</biib:OperatingLeaseRightOfUseAssetDerecognized>
    <biib:OperatingLeaseLiabilityDerecognized
      contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIyMDg3_f67a9869-f5ca-4e21-8a1e-0e4d623242b1"
      unitRef="usd">52700000</biib:OperatingLeaseLiabilityDerecognized>
    <biib:GainLossOnRestructuringCharges
      contextRef="icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83OS9mcmFnOjZmZmMwMWI0NGQxZDQyZDliNzU5ZWIyNjQ0YTJkODJjL3RleHRyZWdpb246NmZmYzAxYjQ0ZDFkNDJkOWI3NTllYjI2NDRhMmQ4MmNfNTQ5NzU1ODIyMTE5_0e597dce-283b-4818-902c-285225afb820"
      unitRef="usd">5300000</biib:GainLossOnRestructuringCharges>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjUwNg_cb8793e3-9c0e-4249-9323-d61c81d78aec">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;3.625% Senior Notes due September 15, 2022&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.0&#160;billion aggregate principal amount of our 3.625% Senior Notes due September 15, 2022, at 99.920% of par. Our 3.625% Senior Notes were senior unsecured obligations. In July 2022 we redeemed our 3.625% Senior Notes prior to their maturity and recognized a net pre-tax charge of approximately $2.4&#160;million upon the extinguishment of these Senior Notes, which primarily reflects the payment of an early call premium as well as the write-off of remaining unamortized original debt issuance costs and discount balances. These charges were recognized as interest expense in other (income) expense, net in our condensed consolidated statements of income for the three and nine months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Exchange Offer&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021 we completed our Exchange Offer of our tendered 2045 Senior Notes for our 2051 Senior Notes and cash, and an offer to purchase our tendered 2045 Senior Notes for cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An aggregate principal amount of approximately $624.6&#160;million of our 2045 Senior Notes was exchanged for an aggregate principal amount of approximately $700.7&#160;million of our 2051 Senior Notes and aggregate cash payments of approximately $151.8&#160;million. Our Exchange Offer has been accounted for as a debt modification; as such, the cash component has been reflected as additional debt discount and is amortized as an adjustment to interest expense over the term of our 2051 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we redeemed an aggregate principal amount of approximately $8.9&#160;million of our 2045 Senior Notes for aggregate cash payments of approximately $12.1&#160;million, excluding accrued and unpaid interest. The redemption has been accounted for as a debt extinguishment; as such, we recognized a pre-tax charge of $3.2&#160;million upon the extinguishment of such 2045 Senior Notes. This charge, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2021, reflects the payment of an early call premium and the write-off of the remaining unamortized original debt issuance costs and discount balances associated with such 2045 Senior Notes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon settlement, we also made aggregate cash payments of approximately $13.8&#160;million to settle all accrued and unpaid interest from the last interest payment date on our 2045 Senior Notes that were exchanged or redeemed. We incurred approximately $6.1&#160;million of costs associated with our Exchange Offer, which was recognized in interest expense in other (income) expense, net in our condensed consolidated statements of income for the nine months ended September 30, 2021.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i737aacf58c3f4d9b8d3e88a3953abda7_I20150915"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfODk_4d8e912b-bb44-4812-a4c2-efdf3f6fd28c"
      unitRef="usd">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTI2_0fdddac2-a010-456c-a958-02225367e494"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTI2_e7da9044-1357-4730-9c18-bcdb767b56d2"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:DebtInstrumentRedemptionRate
      contextRef="iec0813dbc2c649b99fb2b393fca060b6_I20220915"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTY5_98a85924-b8b0-4c3a-a715-d10dc040fdd2"
      unitRef="number">0.99920</biib:DebtInstrumentRedemptionRate>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTg0_0fdddac2-a010-456c-a958-02225367e494"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTg0_e7da9044-1357-4730-9c18-bcdb767b56d2"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjY0_0fdddac2-a010-456c-a958-02225367e494"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjY0_e7da9044-1357-4730-9c18-bcdb767b56d2"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="i9a76584efadd4ffb99238713fd21af42_D20220701-20220731"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMzYx_977b0fb2-205f-40d8-9a48-a028088ea7ee"
      unitRef="usd">2400000</us-gaap:ExtinguishmentOfDebtAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfOTg1_54f9ff41-75ae-41e4-a9de-5a803761f165"
      unitRef="usd">624600000</biib:LongTermDebtExchangedAmount>
    <biib:LongTermDebtExchangedAmount
      contextRef="i43b8001bd67d4407bc0ad37c6a818891_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTA3OA_21cd800e-a685-4ad2-8615-7c65560ff3ad"
      unitRef="usd">700700000</biib:LongTermDebtExchangedAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i97bfc367938746ae877a3fe76a5d66e2_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTE1MQ_a3719f9d-85a3-4842-9dbc-82f5b897766e"
      unitRef="usd">151800000</us-gaap:RepaymentsOfSeniorDebt>
    <biib:DebtInstrumentRedemptionAmount
      contextRef="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTQ2Mg_3907a91b-4a39-48fc-9a02-f62a83b98441"
      unitRef="usd">8900000</biib:DebtInstrumentRedemptionAmount>
    <us-gaap:RepaymentsOfSeniorDebt
      contextRef="i9dbd576d661c4766a7402d67c5d91861_D20210201-20210228"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTUzNQ_ab2eaf35-f0e4-40f1-8def-42b0412c4179"
      unitRef="usd">12100000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="i6619831da50241829e986aa29f5743ad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMTY4NQ_d10c57d8-8258-49f9-bae7-807790cb9786"
      unitRef="usd">3200000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="i6619831da50241829e986aa29f5743ad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjE1MQ_d78a0354-0eed-4253-8777-5be95a35b5c8"
      unitRef="usd">13800000</us-gaap:RepaymentsOfDebt>
    <us-gaap:InterestExpense
      contextRef="i6619831da50241829e986aa29f5743ad_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl83Ni9mcmFnOjg1NDdjMjdjY2Y4NjRmYmQ5YjgwZDViODExNzBhYTdlL3RleHRyZWdpb246ODU0N2MyN2NjZjg2NGZiZDliODBkNWI4MTE3MGFhN2VfMjMxNg_54a5c053-22ff-4a0c-bfa6-1897b7f92976"
      unitRef="usd">6100000</us-gaap:InterestExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA3Ng_dfd38f97-a109-4cc6-b1d6-ac3cd7c78846">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized a program to repurchase up to $5.0 billion of our common stock (2020 Share Repurchase Program). Our 2020 Share Repurchase Program does not have an expiration date. All share repurchases under our 2020 Share Repurchase Program will be retired. Under our 2020 Share Repurchase Program, we repurchased and retired approximately 1.2&#160;million and 3.6 million shares of our common stock at a cost of approximately $250.0&#160;million and $750.0 million during the three and nine months ended September 30, 2022, respectively. During the three and nine months ended September 30, 2021, we repurchased and retired approximately 2.2&#160;million and 6.0&#160;million shares of our common stock at a cost of approximately $750.0&#160;million and $1.8&#160;billion, respectively. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="iaec7e30533b342c590bb4d7ffe633982_I20201031"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTEx_ee93976c-30c9-4722-a61d-8a1dc7d45096"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMzk2_265ee65b-a64e-4d5a-bcb2-4be67a1906a7"
      unitRef="shares">1200000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:StockRepurchasedAndRetiredDuringPeriodShares
      contextRef="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5OTUxMTYyODg4Mg_aa1516ab-54b4-4fd4-9602-a34b181599da"
      unitRef="shares">3600000</us-gaap:StockRepurchasedAndRetiredDuringPeriodShares>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i9857c6192bd646b2833d3dc4f06f2985_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNDUz_858c4041-bbed-4417-ae95-24d9540bddee"
      unitRef="usd">250000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockRetiredCostMethodAmount
      contextRef="i28ee00caa417464f85b5db64351ebec0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5OTUxMTYyODg5NA_1f29ae66-858b-432a-8695-cd95268ce926"
      unitRef="usd">750000000</us-gaap:TreasuryStockRetiredCostMethodAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNTcz_e56a9e8d-de7a-48ca-905c-73b052096a0b"
      unitRef="shares">2200000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNTgw_da62eba4-1c12-4670-bc95-dbdf2e2df9a2"
      unitRef="shares">6000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i41b9130553304fd2bdf15dba7605ac67_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNjM3_227eaf19-0d15-4e35-a70f-93f4452108f7"
      unitRef="usd">750000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i2c90f3ad010f4e13affd01da08d29b77_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNjQ0_72b6df88-022f-4673-a1cb-e6a326fff1bc"
      unitRef="usd">1800000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="i0abcd53e74c94a7c833bb12a8fd01cfe_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfNTQ5NzU1ODE1NDA2_b0a276c3-3317-4fef-8433-068a0ef1b2bc"
      unitRef="usd">2100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5Mw_462c89e3-a167-48a1-a175-e4aed52608bc">&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in accumulated other comprehensive income (loss), net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;53.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(44.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(139.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"/&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(106.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(26.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;204.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(154.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(125.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(38.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(97.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(19.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(95.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(21.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(40.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(234.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(163.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.002%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.466%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Securities Available for Sale, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gains (Losses) on Net Investment Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized gains (losses) on pension benefit obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(179.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(66.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(46.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(299.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;205.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(80.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(62.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2f65dc8cba414b409a0f8978d6ed6d6a_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS0yLTEtMS0xMzQ2OTM_75d85915-5c9b-41cb-986f-ebcad68bed00"
      unitRef="usd">-2200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i59ae9f957d5c456c9db2d0b8de63c577_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS00LTEtMS0xMzQ2OTM_fe867dfe-cd40-4d0d-81ae-d26518a7912d"
      unitRef="usd">53800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="idc7da9d0cf1d468abb521a902e87c1d0_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS02LTEtMS0xMzQ2OTM_8d9d7949-e3a4-4534-9f83-9f6acde3e5dd"
      unitRef="usd">25500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i1cdd7aef8328422d92318a8fb44162a7_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS04LTEtMS0xMzQ2OTM_dee971fe-629b-4167-a0f4-19711c056139"
      unitRef="usd">-44800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i566fa85dece64a33ba2afa4c152f1217_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS0xMC0xLTEtMTM0Njkz_f194c7ba-e132-4a08-8d9f-e1ce6d27c0cb"
      unitRef="usd">-139000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMS0xMi0xLTEtMTM0Njkz_2fa412ab-05c2-4604-90c1-6f0fae8d678e"
      unitRef="usd">-106700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi0yLTEtMS0xMzQ2OTM_5e77ffa7-a549-48a7-af8e-823431357fe6"
      unitRef="usd">-26400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi00LTEtMS0xMzQ2OTM_58464a77-686a-4d2e-9752-45d336a64907"
      unitRef="usd">204500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi02LTEtMS0xMzQ2OTM_51d8fc72-a9a8-4291-95b2-9fd825e1995f"
      unitRef="usd">12600000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi04LTEtMS0xMzQ2OTM_57ea4def-58a9-491b-a3f9-873f80894dce"
      unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi0xMC0xLTEtMTM0Njkz_8e60cc80-a79b-4de6-9801-78e8c3dd17d8"
      unitRef="usd">-154500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMi0xMi0xLTEtMTM0Njkz_fdbf0e6e-bb8a-4676-af44-e9c15ee4d5a3"
      unitRef="usd">40400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy0yLTEtMS0xMzQ2OTM_5b9fb7a7-decc-4ba9-8205-9116ac94574e"
      unitRef="usd">7400000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy00LTEtMS0xMzQ2OTM_2cf938ee-1108-4a21-a9b2-46627e72f787"
      unitRef="usd">-125500000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy02LTEtMS0xMzQ2OTM_832f82b0-6800-475a-b135-06ce5827f694"
      unitRef="usd">-38100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy04LTEtMS0xMzQ2OTM_5f120540-5c40-4fcd-acc8-6df51b16ec81"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy0xMC0xLTEtMTM0Njkz_ac5a2a46-348e-4716-a2b9-15b39455948b"
      unitRef="usd">58900000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfMy0xMi0xLTEtMTM0Njkz_228c6a4e-b4c9-4e72-b203-a68c01380d97"
      unitRef="usd">-97300000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7c449d58d6d6449ea43397744f601f61_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC0yLTEtMS0xMzQ2OTM_6a4c1f9f-021b-4528-a89b-86ebfb42e73d"
      unitRef="usd">-19000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i860b78dd5d744c4a868ae20cb2f5d53e_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC00LTEtMS0xMzQ2OTM_b05e7607-d3bc-4375-8c25-8f9aeef07f04"
      unitRef="usd">79000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9a39f650f16f4ad3b3ad0597891dd91c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC02LTEtMS0xMzQ2OTM_2b4bfa7e-4dff-44d7-8374-9832eaa582cd"
      unitRef="usd">-25500000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4d1efddd209647af9e0422e2ead625dc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC04LTEtMS0xMzQ2OTM_dc510cde-1ab6-491d-a50b-228034ca1a71"
      unitRef="usd">4200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie1f0f80b38934e8785eebf9286044d20_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC0xMC0xLTEtMTM0Njkz_192f7cee-9176-427f-bbfe-23e3e27303ed"
      unitRef="usd">-95600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNC0xMi0xLTEtMTM0Njkz_646894dc-a31a-4b76-bbd4-378898001a7b"
      unitRef="usd">-56900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ica81c533dc694911997333f2bdba6785_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS0yLTEtMS0xMzQ2OTM_c3b232a1-f2ef-487b-b77c-ecd8288acf1a"
      unitRef="usd">-21200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="if562d93e14c149bf85526ac1ea39f925_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS00LTEtMS0xMzQ2OTM_c3a5e180-023b-4d81-bc9e-38a2c8f2e6b0"
      unitRef="usd">132800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4a801c0708314316ba9f6b3812a045ba_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS02LTEtMS0xMzQ2OTM_0c2ef2fe-16be-4d51-bbe5-b9aa685f97f7"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie0d5210f96b74598bfeb245483674c64_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS04LTEtMS0xMzQ2OTM_b3f9e24b-a797-4a72-8e67-76070bf4525f"
      unitRef="usd">-40600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i6e94d3bedc394a18ac6119d2d5a633ef_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS0xMC0xLTEtMTM0Njkz_d66b2505-9889-4f92-986a-ba19f286b882"
      unitRef="usd">-234600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmEwOTdiMjM4M2E5NDRmM2M4NzdjODk0NWViZDIyYzQxL3RhYmxlcmFuZ2U6YTA5N2IyMzgzYTk0NGYzYzg3N2M4OTQ1ZWJkMjJjNDFfNS0xMi0xLTEtMTM0Njkz_981225dc-8f21-4c05-92c3-51846885f3f4"
      unitRef="usd">-163600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfOTIz_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i4f0d8ba0521942b4b77b6c16befe6648_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS0yLTEtMS0xMzQ2OTM_4e739b17-befe-4a7b-9d7a-d2a9589fefa8"
      unitRef="usd">1400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i225e191ffa7842e98d83316aa99374a1_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS00LTEtMS0xMzQ2OTM_280687e6-e565-4f67-bce5-88c1c67f4c6a"
      unitRef="usd">-179000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i8ffee1d6cf8a41c9a6241f4cc1056e1b_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS02LTEtMS0xMzQ2OTM_0fff098e-bf53-479c-bfeb-f4dbc5ea3edb"
      unitRef="usd">-8500000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ic4ea7c38a0a34d079a17eefda9d0a994_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS04LTEtMS0xMzQ2OTM_62d7c57e-c507-44b0-ba1f-6ae12ed09034"
      unitRef="usd">-66300000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i62ec65b1ad2d4bc99e0fe80385ecaee2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS0xMC0xLTEtMTM0Njkz_0bf48957-ec1c-49f8-a604-1f2d02c28aeb"
      unitRef="usd">-46600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMS0xMi0xLTEtMTM0Njkz_5bf5bac5-0b5f-4aec-bbb8-16d9849796fc"
      unitRef="usd">-299000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi0yLTEtMS0xMzQ2OTM_1b4859e6-b01a-4b18-a5cf-074e61c21ad5"
      unitRef="usd">-2500000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi00LTEtMS0xMzQ2OTM_c3d86312-f89c-4038-b382-bee77583039a"
      unitRef="usd">143000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi02LTEtMS0xMzQ2OTM_9e6c5258-0da2-4f7a-bffe-c05f6ffa9099"
      unitRef="usd">35300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i29b15de8609a499c99c1288814cbddff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi04LTEtMS0xMzQ2OTM_d599edb5-b56a-4a7f-9953-517d2311c23c"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi0xMC0xLTEtMTM0Njkz_7f6d6610-625f-437f-a95f-bbd48f4e7b77"
      unitRef="usd">-80300000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMi0xMi0xLTEtMTM0Njkz_30ec659e-1396-4b9c-be7b-531330a8a357"
      unitRef="usd">99400000</us-gaap:OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy0yLTEtMS0xMzQ2OTM_adda5353-3195-4432-8d0b-c5277c52c766"
      unitRef="usd">1100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy00LTEtMS0xMzQ2OTM_3d722675-96ae-4174-9dd1-a59406788f7d"
      unitRef="usd">62000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy02LTEtMS0xMzQ2OTM_1a30473c-1fba-4d30-b714-f9190ff74967"
      unitRef="usd">-100000</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i29b15de8609a499c99c1288814cbddff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy04LTEtMS0xMzQ2OTM_be913447-605d-47b1-95c7-7d2a053ba378"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy0xMC0xLTEtMTM0Njkz_42a52ee8-c4ff-47c5-bcdd-ae85df9daedb"
      unitRef="usd">0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfMy0xMi0xLTEtMTM0Njkz_f6d1c418-e65e-4aa1-935b-5b807f4d84a6"
      unitRef="usd">63000000.0</us-gaap:ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ib9051e23fa004bb69618c6f7aee5f524_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC0yLTEtMS0xMzQ2OTM_178e2150-1899-4ad1-bb4f-910747f2f68a"
      unitRef="usd">-1400000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i3532b048bcd44bdcbf080727e6f4e4cf_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC00LTEtMS0xMzQ2OTM_61d9ccd2-b11f-407f-8d91-4ee2a5ef2408"
      unitRef="usd">205000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i2faaba9cbe7841a7b9e6e62b573b3192_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC02LTEtMS0xMzQ2OTM_81666358-923b-4ab4-8e4f-4e278c776daa"
      unitRef="usd">35200000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i29b15de8609a499c99c1288814cbddff_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC04LTEtMS0xMzQ2OTM_3299e4a3-8997-4a91-99d4-5cfc5c3b0880"
      unitRef="usd">3900000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d04c905a8764fbdbf38c0c09e307610_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC0xMC0xLTEtMTM0Njkz_1cfe7bf7-b240-4f94-be9f-8d4dcf3429d1"
      unitRef="usd">-80300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNC0xMi0xLTEtMTM0Njkz_e405f56b-dbaa-4c48-986c-220e31c62d18"
      unitRef="usd">162400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i0a62332cc2dd41a7b9a9be9081dd2307_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS0yLTEtMS0xMzQ2OTM_5ebe48ba-4491-4a98-a8b9-89c975c2a982"
      unitRef="usd">0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i80f60ecb887d4be79a4bb68b4285b869_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS00LTEtMS0xMzQ2OTM_4ebd5bfa-2d72-402c-921b-ce6b7d673111"
      unitRef="usd">26000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5733cabf96334e7ab886168311c47ed0_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS02LTEtMS0xMzQ2OTM_ba40da7c-553c-4816-861b-d110841fad58"
      unitRef="usd">26700000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7f2f649fd1a74126a144c38bb92e1623_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS04LTEtMS0xMzQ2OTM_132d4852-d96c-4019-bad8-eba01dc64f4f"
      unitRef="usd">-62400000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ie69a59bf2fb143128c5de3ed05732a32_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS0xMC0xLTEtMTM0Njkz_da06a6d0-d8bf-4e51-a38f-96c906c15477"
      unitRef="usd">-126900000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i957729f8711844ff89317163bd3b28ee_I20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOjA1ZmQzZjA4NzJlYzQyYjk4ZTlkMGQ4YzJjNTIxODM4L3RhYmxlcmFuZ2U6MDVmZDNmMDg3MmVjNDJiOThlOWQwZDhjMmM1MjE4MzhfNS0xMi0xLTEtMTM0Njkz_94150102-7479-4fdf-b703-54870e5f026a"
      unitRef="usd">-136600000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA5MQ_9db3caa4-b3db-4dc6-9a49-db044da8ed16">&lt;div style="margin-top:9pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from accumulated other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.964%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.730%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on securities available for sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(68.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax benefit (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on net investment hedges&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(58.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(63.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Beginning in the second quarter of 2022 we no longer hold net investment hedges as they were closed with the sale of our 49.9% equity interest in Samsung Bioepis in April 2022. For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i849dd4a8f4c64ed988e7ed27a7acc5aa_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy0zLTEtMS0xMzQ2OTM_9d9eab81-c552-4cc2-9996-e5ed9988dae9"
      unitRef="usd">-8000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if71a1afa58f84476abfee908e733759f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy01LTEtMS0xMzQ2OTM_1dc6d1f4-7b23-415c-96e5-4fc24b61ea0b"
      unitRef="usd">-400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i27ac905d40cc4c0b8cfce80524bd7f9f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy03LTEtMS0xMzQ2OTM_288fd501-92b2-407f-b72c-6013dae81e7b"
      unitRef="usd">-9400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ied4f63161aa64b41b8e31012f313c41d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMy05LTEtMS0xMzQ2OTM_59248eae-7645-4c08-808e-c1b271c4389b"
      unitRef="usd">-1300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i849dd4a8f4c64ed988e7ed27a7acc5aa_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC0zLTEtMS0xMzQ2OTM_7c3d27a4-cdec-4973-97d1-94e3b2d9eb54"
      unitRef="usd">1700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if71a1afa58f84476abfee908e733759f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC01LTEtMS0xMzQ2OTM_ccba09e3-fcbd-4f3f-9e24-db8dd89c0f18"
      unitRef="usd">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i27ac905d40cc4c0b8cfce80524bd7f9f_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC03LTEtMS0xMzQ2OTM_2eccb747-7d8b-457f-bf05-4aabc650f5e9"
      unitRef="usd">2000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ied4f63161aa64b41b8e31012f313c41d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNC05LTEtMS0xMzQ2OTM_6372fded-72c0-4d21-96b5-9b29024c9b2c"
      unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:Revenues
      contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi0zLTEtMS0xMzQ2OTM_b78802bd-b4d8-4ed8-aac2-b4fca80776a0"
      unitRef="usd">77700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi01LTEtMS0xMzQ2OTM_dfa323ca-fbbe-43c7-a797-448d6b5dd078"
      unitRef="usd">-14900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi03LTEtMS0xMzQ2OTM_d000b733-2635-4d51-8ce7-554fa9ce0cb7"
      unitRef="usd">143200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNi05LTEtMS0xMzQ2OTM_d5a58598-ecb2-457b-b968-7abade2d4197"
      unitRef="usd">-68700000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses
      contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy0zLTEtMS0xMzQ2OTM_6bc865ab-46bb-4517-93f1-76f39189dc19"
      unitRef="usd">800000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy01LTEtMS0xMzQ2OTM_7751508c-39f4-4c03-87bd-b5e531da9a06"
      unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy03LTEtMS0xMzQ2OTM_3bbd8065-5012-4238-b8a8-3f4b77fe6cf7"
      unitRef="usd">3500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfNy05LTEtMS0xMzQ2OTM_7f753467-cda8-4c3f-b38e-dc86a07e1482"
      unitRef="usd">300000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC0zLTEtMS0xMzQ2OTM_5a048733-6c3b-4fdf-a692-94b1e56ccf5f"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC01LTEtMS0xMzQ2OTM_4d1f454e-85ea-4499-ac09-f7a54de21003"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC03LTEtMS0xMzQ2OTM_585f2c38-52e9-4ed5-b2b9-3b47691b34bf"
      unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOC05LTEtMS0xMzQ2OTM_d042824d-7510-46a2-8501-8c3e10956672"
      unitRef="usd">100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="if413daedc0274389ad35e990a1c6b2f5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS0zLTEtMS0xMzQ2OTM_496b5f1f-7b0f-42e0-a53e-947a27b760b1"
      unitRef="usd">-7800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie529a3e858834552a0a5634398d18674_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS01LTEtMS0xMzQ2OTM_07b202fa-04e2-4cb4-8481-235898931692"
      unitRef="usd">1500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i475a88db5c394601ae63d053e55d0d2a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS03LTEtMS0xMzQ2OTM_fa9b0e33-e998-45e8-a411-3053d748c70e"
      unitRef="usd">-14000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="iba42788b00f54ecdb483e50556232ee6_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfOS05LTEtMS0xMzQ2OTM_9e5f338c-3ce5-47dd-a977-2fea2ff316f3"
      unitRef="usd">6800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ic83040f816404800a727b532e6017bb0_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtMy0xLTEtMTM0Njkz_bce8d3fe-c542-4cf2-9a83-e439a0b69f33"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i23f5a5169ebd42aba57956e30523887b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtNS0xLTEtMTM0Njkz_fcdec070-ffb3-461b-a4f0-ca233e3f194d"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="ia9cf20ed80544d3aa60312bf7249ea5b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtNy0xLTEtMTM0Njkz_4b175e1a-dbf3-469b-94b0-50fe536a994d"
      unitRef="usd">38100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="if299c0d105f14cf986a61dc16c3cb70c_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTEtOS0xLTEtMTM0Njkz_e28274bd-1c76-4356-857e-53e5c2c32ff1"
      unitRef="usd">100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9019b680c6754477845629fe912cca42_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtMy0xLTEtMTM0Njkz_e96a708d-dff7-43de-9ce0-f493b8614f09"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="iee1e133f85df4fcda4b5fbf47287ab83_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtNS0xLTEtMTM0Njkz_dde421b6-25fb-4f94-98a4-c65d81f428ac"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i9a8c74397f6e462ca3d0a16f7d7d1724_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtNy0xLTEtMTM0Njkz_98e84979-be25-4bcb-a17c-82162680f357"
      unitRef="usd">-58900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i21633472081e499f84d2d8a16c51f6c1_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTQtOS0xLTEtMTM0Njkz_4ec3e64f-dd9e-4005-87ef-d17a00ea5590"
      unitRef="usd">0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:NetIncomeLoss
      contextRef="ie8e3376c311a4ab1ba9f36f3d6388b0b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtMy0xLTEtMTM0Njkz_9d1d79f8-ad8b-4539-93b1-4c5ccc15a4fa"
      unitRef="usd">62800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i69bc310b2d7d4bdda29eb1089e137559_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtNS0xLTEtMTM0Njkz_3b11df72-164f-4b4a-a1c9-5697522b4f99"
      unitRef="usd">-14000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i93992c5f9dc945f6b4d933f8893cab02_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtNy0xLTEtMTM0Njkz_f38e4c05-6f8e-4732-90fe-b4f3c84f6b9c"
      unitRef="usd">97300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i0310cfc482e54baf860e1cc61e2cb08b_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RhYmxlOmNiYTNmNmY2OWY0YzQ5MDliMDhiZmJkYzZiNGU1YTI1L3RhYmxlcmFuZ2U6Y2JhM2Y2ZjY5ZjRjNDkwOWIwOGJmYmRjNmI0ZTVhMjVfMTUtOS0xLTEtMTM0Njkz_61fb981f-e44c-4a1d-8b5a-378b13786cf3"
      unitRef="usd">-63000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84Mi9mcmFnOjM0M2QxZjg2ZjM0ODQ2MjM4OWM1MmMyYzYzODQyN2I2L3RleHRyZWdpb246MzQzZDFmODZmMzQ4NDYyMzg5YzUyYzJjNjM4NDI3YjZfMTA2MA_fa26a1eb-d01a-4de2-8c94-a522d87ba4fb"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RleHRyZWdpb246YWRhOGJjNzdhODVhNDg4Njk5NjIxNWJlODAwODJjMjhfMjY3_aa2260b8-797a-4c93-be3d-e7225fa9ab55">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,496.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RleHRyZWdpb246YWRhOGJjNzdhODVhNDg4Njk5NjIxNWJlODAwODJjMjhfMjU4_ffa13da3-c098-4f35-87da-44936f07b07f">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,134.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;329.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,496.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,187.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;144.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy0yLTEtMS0xMzQ2OTM_88c50014-8324-4d3a-aa83-47cddb07997d"
      unitRef="usd">1134700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy00LTEtMS0xMzQ2OTM_12f3a7f3-0154-4c5a-b687-8d1674fdde27"
      unitRef="usd">329200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy02LTEtMS0xMzQ2OTM_6f5b464c-1a54-4223-bd59-9ec16a977632"
      unitRef="usd">2496500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMy04LTEtMS0xMzQ2OTM_f61f3b11-0239-4ba7-90c1-1c2ab4c804e9"
      unitRef="usd">1187900000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS0yLTEtMS0xMzQ2OTM_ee88fb6e-d1e7-41ee-940c-ada8ec830541"
      unitRef="shares">144400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS00LTEtMS0xMzQ2OTM_f5cd5dfd-e5b7-474f-aee7-f6e2ec03ba3d"
      unitRef="shares">148000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS02LTEtMS0xMzQ2OTM_9f2c6120-d671-4f1d-a350-9308770f79f6"
      unitRef="shares">145800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfNS04LTEtMS0xMzQ2OTM_7ab33c1c-d06b-45fa-baa5-c446125a5dcc"
      unitRef="shares">149900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7af590a969ea4209b99c133a0dbaa97d_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC0yLTEtMS0xMzQ2OTM_0a722133-8289-4a88-81ac-bf3deee72a4a"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i9385ae1537df4bc4b697a93604cec286_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC00LTEtMS0xMzQ2OTM_76f65194-2689-425e-9b88-ba6f9c9cee5f"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i6ec20c3acd4e4e87afaf283b335fcd61_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC02LTEtMS0xMzQ2OTM_d7b8221b-fe19-4220-aa17-058d5ba6eb06"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i87a19de3dc2c48cc83fa43e9c9f68324_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOC04LTEtMS0xMzQ2OTM_ccdd780a-3c4e-4ac8-a763-bd2881c7fb98"
      unitRef="shares">200000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ibe4a1ed6e5af4242b0dd4a5d99cdd5d3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS0yLTEtMS0xMzQ2OTM_22bc323c-86e6-4009-ba11-a52c88ad9fa5"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i86189fb69f0b4545b7c8c310762bef0d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS00LTEtMS0xMzQ2OTM_9ed55095-c5d9-4b8c-b91c-64c68ec81f9a"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i2b2c0753f0cd4a10bc3da9507bfdac2d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS02LTEtMS0xMzQ2OTM_a4d06435-7dc4-49f1-9bed-cb4bb03282cc"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i423847116cc5490a9bdce5eb39edf6cc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfOS04LTEtMS0xMzQ2OTM_caba9970-34fd-4377-bacb-ab00f45548b4"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i5726a88b7bb7444385b56260f3916f3a_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtMi0xLTEtMTM0Njkz_584a3444-be2f-4345-acea-d0d33d45d0da"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i19e2ef680f084dee982a474253928b22_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtNC0xLTEtMTM0Njkz_a3282c05-f48b-4714-9665-6603d1c1572e"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia84ab3f48f3942d2a12b2e1aa732dcf0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtNi0xLTEtMTM0Njkz_a7304b3e-76b1-4670-8f88-1e4f5f8d0a36"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="i7e38e0479cb74c8fa5f98e9890ca19cc_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTAtOC0xLTEtMTM0Njkz_3550fc55-b29f-4fdf-a94a-69b8c2649a99"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtMi0xLTEtMTM0Njkz_5f6d5e89-0685-4aca-bed0-e518226af25b"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtNC0xLTEtMTM0Njkz_a0419be8-036b-4f1e-9a39-61752ad1c4a4"
      unitRef="shares">600000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtNi0xLTEtMTM0Njkz_6c9d234d-afa5-4937-b897-ed0ee3f96fb7"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTEtOC0xLTEtMTM0Njkz_a2c6c43b-2de1-4fb7-ac8f-d4d2c773f5fb"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItMi0xLTEtMTM0Njkz_ff6e5ace-29ac-4ca0-8eb4-58c29b3d685e"
      unitRef="shares">144800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItNC0xLTEtMTM0Njkz_b79df29c-8738-4758-a291-14238f99b82d"
      unitRef="shares">148600000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItNi0xLTEtMTM0Njkz_fc2339ae-9f63-4675-941a-36d7a525296a"
      unitRef="shares">146200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84NS9mcmFnOmFkYThiYzc3YTg1YTQ4ODY5OTYyMTViZTgwMDgyYzI4L3RhYmxlOjQxY2U5MGU5OWM5ODQxMGI5ODgwNTgxYzgzZjU4NWQzL3RhYmxlcmFuZ2U6NDFjZTkwZTk5Yzk4NDEwYjk4ODA1ODFjODNmNTg1ZDNfMTItOC0xLTEtMTM0Njkz_0b2fbae0-14a8-404a-aff3-52f91d76fafd"
      unitRef="shares">150300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RleHRyZWdpb246NTYyZjg4OTIxNWJjNDA2ZmE3MDZmMTBkNTI4ZTQ5MzJfNjQy_3a166681-eead-4a6d-bee9-86e605eb3ca2">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate the fair value of our obligations associated with our performance stock units settled in cash at the end of each reporting period through expected settlement.&#160;Cumulative adjustments to these obligations are recognized each quarter to reflect changes in the stock price and estimated outcome of the performance-related conditions.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RleHRyZWdpb246NTYyZjg4OTIxNWJjNDA2ZmE3MDZmMTBkNTI4ZTQ5MzJfNjY3_c9c10dd0-ccdb-4068-882b-cf9ded625270">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;72.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;46.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(13.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;157.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if0ab96fe04b24b54881a9fb26fd5d9e9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi0yLTEtMS0xMzQ2OTM_f2c4932f-7759-44c4-8448-a457d60d13d0"
      unitRef="usd">24500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i020a6d175274414c85d5892faf01ae3b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi00LTEtMS0xMzQ2OTM_62afcd6d-b76d-48a2-9d18-d9fc683c79c3"
      unitRef="usd">19500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2916810b28d34baab3e072744e15d7f9_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi02LTEtMS0xMzQ2OTM_b89d5b5d-0690-4634-9bfb-dfc7cc156f3b"
      unitRef="usd">72600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie280a8f5fb6f4a64a937ed98bf711fcd_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMi04LTEtMS0xMzQ2OTM_1c43df84-0201-4abf-b2de-db7d86863896"
      unitRef="usd">72200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="icc5c47cebcd646a29a4d500a8101cb83_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy0yLTEtMS0xMzQ2OTM_31028dcf-db2f-442b-92de-b8b9ed756832"
      unitRef="usd">46500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id1200447817a47ce88c12b9b2d542734_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy00LTEtMS0xMzQ2OTM_f2ac8901-d21f-4651-824a-b8bd0d178b73"
      unitRef="usd">42600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib0d2d23ef6a94bc2ab3418e068cdf65a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy02LTEtMS0xMzQ2OTM_d69715f3-6ecc-4346-8ae8-c3faa96e0010"
      unitRef="usd">129300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i643e3738705a431185c23ad01faf0241_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfMy04LTEtMS0xMzQ2OTM_f0dced47-c5e8-4287-854a-c5abb3d86e55"
      unitRef="usd">127800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS0yLTEtMS0xMzQ2OTM_e3c93f6f-b742-41e3-814c-fc34f6eed055"
      unitRef="usd">71000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS00LTEtMS0xMzQ2OTM_c58660c4-1901-49ae-9afc-81851bc47ad0"
      unitRef="usd">62100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS02LTEtMS0xMzQ2OTM_c96aade7-7c71-4001-bbeb-85a7029bed3c"
      unitRef="usd">201900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNS04LTEtMS0xMzQ2OTM_77b1794d-e2a6-443e-9731-c78de1296a2c"
      unitRef="usd">200000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi0yLTEtMS0xMzQ2OTM_76a066b5-cd8c-47cc-9122-089b1ba4d0c2"
      unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi00LTEtMS0xMzQ2OTM_6bfd2a10-bd5f-4366-82a4-1c502a974761"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi02LTEtMS0xMzQ2OTM_6250adef-4afc-4588-b212-9b22001e42dd"
      unitRef="usd">7100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNi04LTEtMS0xMzQ2OTM_f246eb0a-7fb5-4be2-a10b-c58b611272ac"
      unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy0yLTEtMS0xMzQ2OTM_63c2cf7b-5aec-4150-82cd-34acb6b6eaf8"
      unitRef="usd">69000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy00LTEtMS0xMzQ2OTM_61ee3738-8e18-45b1-a9a4-ed183f60a20f"
      unitRef="usd">60200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy02LTEtMS0xMzQ2OTM_e75b17c7-def6-4fde-80a1-186c33301e71"
      unitRef="usd">194800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfNy04LTEtMS0xMzQ2OTM_023fccb3-7792-4fa7-ad1e-2ba56bfdc3b0"
      unitRef="usd">193700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC0yLTEtMS0xMzQ2OTM_9c3c4722-1cad-4b89-969c-efe9f8020d75"
      unitRef="usd">13000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC00LTEtMS0xMzQ2OTM_10d7a62c-3b91-4e71-a5ad-c7a1f5115933"
      unitRef="usd">10900000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC02LTEtMS0xMzQ2OTM_f42720fe-1d21-4d27-9228-22fc94a849ff"
      unitRef="usd">36000000.0</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOC04LTEtMS0xMzQ2OTM_7800e131-f7d1-4756-aa96-66478a742e33"
      unitRef="usd">35800000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5ea82c65b64d4a08b32f42941f129ccd_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS0yLTEtMS0xMzQ2OTM_7bfa8114-aab0-4034-997b-321131ec8c3c"
      unitRef="usd">56000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia985ab3c9c6947ce9bbddd4486e39ab2_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS00LTEtMS0xMzQ2OTM_53b2651a-55ec-4df6-b7bb-1b8e558e4bc6"
      unitRef="usd">49300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if43e265e90d84abea2ec20efefd5e160_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS02LTEtMS0xMzQ2OTM_22c6b07f-a2e0-4814-9349-92d55b00514c"
      unitRef="usd">158800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1a056e0535b44f73a14fb5b5866c995f_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmM3OTMzZjZiNzA3MTQxNGY4NTEwYmQ0NTI5MTIyMzk5L3RhYmxlcmFuZ2U6Yzc5MzNmNmI3MDcxNDE0Zjg1MTBiZDQ1MjkxMjIzOTlfOS04LTEtMS0xMzQ2OTM_058ba0f4-c6b9-467c-b639-541917d7f83f"
      unitRef="usd">157900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RleHRyZWdpb246NTYyZjg4OTIxNWJjNDA2ZmE3MDZmMTBkNTI4ZTQ5MzJfNjQ5_3e224d1a-af3f-4c56-a507-c045af51ca21">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;201.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic363356bb33f48c5be8d5bb4b72a7bf6_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi0yLTEtMS0xMzQ2OTM_d6741a15-9f98-4025-af7f-70155f71a033"
      unitRef="usd">4000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6f4a133d037248e49ca85fc0d7750a92_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi00LTEtMS0xMzQ2OTM_2fefea61-9fd9-4f67-b6c0-2cafa4472385"
      unitRef="usd">9700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i48833179911f4b4da985ff177df33255_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi02LTEtMS0xMzQ2OTM_1e7c0356-20dd-4355-90d7-42a2c4cbf3b6"
      unitRef="usd">11400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9bd91ba74efe415d96d36566a8533af0_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMi04LTEtMS0xMzQ2OTM_4ce9e56f-cd62-4d42-9bdf-4e51cfd2ed1a"
      unitRef="usd">35500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4971fa532f65444a849a4efe193ef3b9_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy0yLTEtMS0xMzQ2OTM_906dfe64-fe3c-4e98-88f9-660dcbe64b2e"
      unitRef="usd">48700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5fdb74af71e2435d84ec8c2691f9906f_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy00LTEtMS0xMzQ2OTM_aba9bc81-ba5e-4186-b49d-d8e7ae0ea3f8"
      unitRef="usd">38800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia28cefc2251e4aaabc62eda2e1948a43_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy02LTEtMS0xMzQ2OTM_49f33081-4477-4893-afb7-c76831b1aad3"
      unitRef="usd">150400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="if71aa78fc18748d9bfdd023c98e48b21_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMy04LTEtMS0xMzQ2OTM_adecadf6-645f-4732-8089-bbdb87109766"
      unitRef="usd">121900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i28eda3a32b1a4782908d9192bc909c52_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi0yLTEtMS0xMzQ2OTM_fedfa53e-2b13-4d6f-9f8c-5c468f4d2778"
      unitRef="usd">10500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i29a060d008f4427d9936c693dd36d7d5_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi00LTEtMS0xMzQ2OTM_8f85d89f-7956-4a21-8496-0bcc3d182d30"
      unitRef="usd">4900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d36468b37944b318ad8e33e0eb69a3d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi02LTEtMS0xMzQ2OTM_c0bc1cb7-d3b7-472b-b985-dece1172aa83"
      unitRef="usd">22100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i21f7cf90b35a4e9cadd33e5ac5864d7a_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNi04LTEtMS0xMzQ2OTM_d6b302de-c638-43d8-b331-3b6e9f6a0b56"
      unitRef="usd">14200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5f2b501618744c89aa413dcc343decd8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy0yLTEtMS0xMzQ2OTM_a3899c11-b3cb-4ecb-9588-e0c264010819"
      unitRef="usd">5400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i815aa12c57884893ade8be8bae2934ae_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy00LTEtMS0xMzQ2OTM_d420fb7f-ee63-4e80-854e-37db2d1719c5"
      unitRef="usd">4400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i10042e38a8a542d693db8947e7136f70_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy02LTEtMS0xMzQ2OTM_c8e5828f-f0c6-4e30-965c-6ae17c6afc0a"
      unitRef="usd">7900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7db73a71288148e78f2f4ecd84931f93_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfNy04LTEtMS0xMzQ2OTM_efb48100-4757-4a27-9a09-a8079bedd990"
      unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie29a14310e7041918de391cbb7abc267_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC0yLTEtMS0xMzQ2OTM_a796686a-3036-42e5-818d-962b9dcdd82a"
      unitRef="usd">2400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4441454a34d345f9842e1c241d644d60_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC00LTEtMS0xMzQ2OTM_9e6f24a1-d469-42fd-9958-d009b192880b"
      unitRef="usd">4300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i893566fba033473daa38c35e9da2c3eb_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC02LTEtMS0xMzQ2OTM_1962aead-6d09-48b7-a56c-cb3ebf9d8fb1"
      unitRef="usd">10100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0c02e6a550e94385bd647008ae2d2a57_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfOC04LTEtMS0xMzQ2OTM_b064e46f-7f74-4ce6-84a1-90742a4c0d16"
      unitRef="usd">14500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtMi0xLTEtMTM0Njkz_8592e00b-81bb-478f-88f8-52c62c737c29"
      unitRef="usd">71000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtNC0xLTEtMTM0Njkz_0abea6ea-fcda-4386-86bf-44f5fc8af5e4"
      unitRef="usd">62100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtNi0xLTEtMTM0Njkz_5da8a4df-2957-4fa2-b506-433712f8f603"
      unitRef="usd">201900000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTAtOC0xLTEtMTM0Njkz_47af49a4-c893-408f-a9b2-46f4ff215aaa"
      unitRef="usd">200000000.0</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtMi0xLTEtMTM0Njkz_3d8684f4-2400-429d-af0b-462e690c6c11"
      unitRef="usd">2000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtNC0xLTEtMTM0Njkz_ecd6b5cc-b1b9-4e2e-942c-450af366142d"
      unitRef="usd">1900000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtNi0xLTEtMTM0Njkz_6887523f-012e-4a56-9027-2174535a0a55"
      unitRef="usd">7100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTEtOC0xLTEtMTM0Njkz_ba81a876-6d26-4588-8979-746f27b80df8"
      unitRef="usd">6300000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItMi0xLTEtMTM0Njkz_f44a2383-9672-4185-ba79-e3e8a65ddfad"
      unitRef="usd">69000000.0</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItNC0xLTEtMTM0Njkz_a8a9bffb-0c39-4bbe-b1e5-ace8507de21e"
      unitRef="usd">60200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItNi0xLTEtMTM0Njkz_8c5322ec-6423-4d59-84b4-ef313e917ec0"
      unitRef="usd">194800000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl84OC9mcmFnOjU2MmY4ODkyMTViYzQwNmZhNzA2ZjEwZDUyOGU0OTMyL3RhYmxlOmFkYmY5ZDkxMTYyMTQ1OWM5ODU0NWRkNzNmNGM5YWY3L3RhYmxlcmFuZ2U6YWRiZjlkOTExNjIxNDU5Yzk4NTQ1ZGQ3M2Y0YzlhZjdfMTItOC0xLTEtMTM0Njkz_6ec580d1-5ad9-46e2-ad4f-ec85ff055f69"
      unitRef="usd">193700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzkyMw_ff68ac6b-6173-4b33-94bf-36de32a6fc86">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sale of Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#00823b;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2022, compared to the same periods in 2021, the increases in our effective tax rates include the tax impacts on the sale of one of our buildings and the favorable prior year tax effects of changes in the value of our equity investments, where we recorded unrealized losses, and the BIIB111 and BIIIB112 impairment charges. The tax effects of this change in value of our equity investments were recorded discretely as changes in value of equity investments cannot be forecasted.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2022, compared to the same period in 2021, the increase in our effective tax rate also reflects the net effects of the Neurimmune SubOne AG (Neurimmune) matters, as discussed below, and the litigation settlement agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For additional information on the litigation settlement agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 20, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For additional information on our collaboration arrangement with Neurimmune, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 19, Investments in Variable Interest Entities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2017 or state, local or non-U.S. income tax examinations for years before 2012.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease by up to approximately $500.0&#160;million, including approximately $455.0&#160;million related to the unrecognized&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;tax benefits related to Neurimmune's tax basis in ADUHELM, in the next 12 months as a result of various audit&lt;/span&gt;&lt;/div&gt;closures, settlements and expiration of the statute of limitations. Any changes to our gross unrecognized tax benefits related to Neurimmune's tax basis in ADUHELM would result in a zero net impact to net income attributable to Biogen, Inc., as w</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzkzNw_b38900f0-156c-4560-a15a-bdd6e247151a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:57.671%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.384%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.700%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Sale of Samsung Bioepis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Neurimmune tax impacts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(36.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;International reorganization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi0xLTEtMS0xMzQ2OTM_2f367f5d-fbb3-4994-b95f-1d319fdfb3fd"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi0zLTEtMS0xMzQ2OTM_0df5c547-51be-4850-b5d9-6f983fcf1391"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi01LTEtMS0xMzQ2OTM_d1fe6e61-3717-4f2f-a836-825b4f21fb2b"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMi03LTEtMS0xMzQ2OTM_ab56a7b6-2dc7-4d56-ae9f-109b61350017"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy0xLTEtMS0xMzQ2OTM_c8255fe2-67c4-42ed-90b2-ced6293ea4f4"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy0zLTEtMS0xMzQ2OTM_4ff63802-89f7-4360-be18-0cf9fe476a25"
      unitRef="number">0.003</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy01LTEtMS0xMzQ2OTM_0807f31b-7402-43f9-ad7c-b5c75890809b"
      unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMy03LTEtMS0xMzQ2OTM_4e9f0ad9-70c3-4592-8d22-c701e7410e06"
      unitRef="number">0.009</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC0xLTEtMS0xMzQ2OTM_ebb4c58d-bac5-447c-b93c-bffd8bd656a3"
      unitRef="number">-0.034</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC0zLTEtMS0xMzQ2OTM_42bbbe9c-e3b5-4a5f-91e0-fc7476091281"
      unitRef="number">-0.202</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC01LTEtMS0xMzQ2OTM_e3c4bbd7-2e19-4023-987a-1e55f7f6f595"
      unitRef="number">-0.044</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNC03LTEtMS0xMzQ2OTM_1445b755-467e-4aaa-9574-86d4857ba3e0"
      unitRef="number">-0.115</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS0xLTEtMS0xMzQ2OTM_f9d00fb2-ed65-4c23-8985-aac9e72137dd"
      unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS0zLTEtMS0xMzQ2OTM_20994cfe-d1c9-4ac7-ba98-e8b45ed4f3e0"
      unitRef="number">0.071</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS01LTEtMS0xMzQ2OTM_0e5afb94-bf41-4114-82a1-b17cb166ce67"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNS03LTEtMS0xMzQ2OTM_b032934a-63ca-4312-9320-0d4b1980d925"
      unitRef="number">0.041</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi0xLTEtMS0xMzQ2OTM_032d98b5-094a-46ed-8232-e4fa9c12e67c"
      unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi0zLTEtMS0xMzQ2OTM_aff0fe2e-9fcd-45da-a733-4db009a47ef9"
      unitRef="number">-0.062</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi01LTEtMS0xMzQ2OTM_fe1fe5a3-edb5-46be-ade4-b0234f54d11f"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfNi03LTEtMS0xMzQ2OTM_fb3e1330-8ce2-4dcd-b9c2-2a83f5409b08"
      unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtMS0xLTEtMTM0Njkz_dd1b6249-f970-4c39-9a62-cd9aa4470e57"
      unitRef="number">0.008</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtMy0xLTEtMTM0Njkz_ec232e05-895d-48f2-a7da-466b418efaf7"
      unitRef="number">0.026</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtNS0xLTEtMTM0Njkz_7b6287d6-85af-483b-971c-99c988d3bccd"
      unitRef="number">0.005</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationGILTItax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTAtNy0xLTEtMTM0Njkz_a315b215-18b9-4946-94ed-4e6142f3d81f"
      unitRef="number">0.016</biib:EffectiveTaxRateReconciliationGILTItax>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtMS0xLTEtMTM0Njkz_bb7dc61c-f793-49d8-ab3e-d88fd75df5c3"
      unitRef="number">-0.008</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtMy0xLTEtMTM0Njkz_13613c91-abe8-4d26-87fc-d50e77c646bc"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtNS0xLTEtMTM0Njkz_cdbf5aeb-e7ae-482a-b370-44616fe3f656"
      unitRef="number">-0.019</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTQtNy0xLTEtMTM0Njkz_0ef27f46-cb4e-4011-bc5e-c028288161ba"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationSaleOfSamsungBioepis>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtMS0xLTEtMTM0Njkz_0bad6bd6-2202-4522-89ab-ac4de6a6d962"
      unitRef="number">-0.012</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtMy0xLTEtMTM0Njkz_0cca9a5e-9b87-4364-b12a-c0e06f53751b"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtNS0xLTEtMTM0Njkz_d17b076d-ab99-4dd8-b233-ef899d1d93cd"
      unitRef="number">0.031</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationLitigationAgreement
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTUtNy0xLTEtMTM0Njkz_1269547c-10e6-43d3-8fe8-696acce4b581"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationLitigationAgreement>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtMS0xLTEtMTM0Njkz_368b4067-5b3c-4de8-b7c4-0120b16f925d"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtMy0xLTEtMTM0Njkz_a9484bb3-5309-451a-8d81-02dcc018120f"
      unitRef="number">-0.005</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtNS0xLTEtMTM0Njkz_8c6ba6de-cc1f-4313-b8c8-5e6903c043a0"
      unitRef="number">0.028</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTYtNy0xLTEtMTM0Njkz_46a92880-e0c6-42a2-9e19-171f0c8f3dcc"
      unitRef="number">-0.364</biib:EffectiveTaxRateReconciliationNuerImmuneTaxImpacts>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctMS0xLTEtMTM0Njkz_51ca3314-018e-4c32-8db5-18186d48574a"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctMy0xLTEtMTM0Njkz_2e77ba7c-e246-421a-81d5-efde8433c882"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctNS0xLTEtMTM0Njkz_807fad74-0c1c-47d3-86cb-102aafe38276"
      unitRef="number">-0.017</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <biib:EffectiveTaxRateReconciliationInternationalReorganization
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTctNy0xLTEtMTM0Njkz_87c4f90d-2076-40d9-bf5d-998e9a196302"
      unitRef="number">0</biib:EffectiveTaxRateReconciliationInternationalReorganization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtMS0xLTEtMTM0Njkz_ec807687-9e94-400f-84d5-d25c9870453c"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtMy0xLTEtMTM0Njkz_fcc94e17-3299-4140-92aa-ab5fef29a4b1"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtNS0xLTEtMTM0Njkz_cf967dc3-8dfa-4fa9-bc99-f83bdf024e61"
      unitRef="number">0.002</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTgtNy0xLTEtMTM0Njkz_141370fb-f356-447a-86fc-35d4af244772"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktMS0xLTEtMTM0Njkz_0f967e28-ad15-4c27-9747-f9aaccf275e9"
      unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktMy0xLTEtMTM0Njkz_e2839e95-2c45-4f62-91c6-d3bf26c8ff14"
      unitRef="number">-0.089</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktNS0xLTEtMTM0Njkz_1a724f0a-7716-4cdf-8321-362ec2b7496a"
      unitRef="number">0.194</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RhYmxlOjljMmRmODJmNWIxOTQxMDg5OTY5MmQ1YmRmZWM3MTIxL3RhYmxlcmFuZ2U6OWMyZGY4MmY1YjE5NDEwODk5NjkyZDViZGZlYzcxMjFfMTktNy0xLTEtMTM0Njkz_ae4133b9-c4e6-403c-a923-fce9747ed31e"
      unitRef="number">-0.292</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTE5MA_2818e4df-91bd-4daf-8322-5d5d7a14f603"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTE5MA_8cf5f050-5d42-4eff-9f2f-d405a5389dd1"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTQ0Nw_7a30d501-5942-4bf9-a8f9-51eee8593f9b"
      unitRef="usd">390000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMTU5OQ_bbf0a272-4e14-40b5-bd14-57bf5c11721a"
      unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i54de034401784154b4ba0d3eb7e3d450_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzQxNA_a2b82ef8-2ce9-4cee-93d0-77465ab77829"
      unitRef="usd">500000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="i12b0509f87024db39c961704c8e7c7e0_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85MS9mcmFnOjcwZTQzODU5YTI2OTRmMzE5ZDY1YjUwMjQ3Njc4YWI0L3RleHRyZWdpb246NzBlNDM4NTlhMjY5NGYzMTlkNjViNTAyNDc2NzhhYjRfMzQ0Mg_e0153141-7146-42b9-99ec-9d67d85bd096"
      unitRef="usd">455000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEzNg_f062740f-19a7-438e-b9d1-63303580583f">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other (Income) Expense, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity interest in Samsung Bioepis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;502.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(221.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;913.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Gains) losses on investments, net, as reflected in the table above, relate to debt securities, equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. This charge is included within other (income) expense, net in our condensed consolidated statements of income for the nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; For additional information on the litigation settlement agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Note 20, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;705.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis Pharmaceuticals, Inc. (Ionis), Sangamo and Denali common stock of approximately $112.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;769.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation settlement agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Other long-term liabilities were $1,198.1 million and $1,320.5 million as of September 30, 2022 and December 31, 2021, respectively, and included accrued income taxes totaling $559.7 million and $664.5 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjE1Ng_38c4a728-3e71-40b1-9465-d428a4dcc51c">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gain on sale of equity interest in Samsung Bioepis&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,505.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(23.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;191.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;187.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(101.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;707.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(56.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;502.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(221.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;913.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Reflects the pre-tax gain, net of transaction costs, recognized from the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in April 2022. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;(</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi0yLTEtMS0xMzQ2OTM_a858eca6-4fdf-459c-8a68-8c05578884cf"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi00LTEtMS0xMzQ2OTM_237c08fb-38d1-455f-8815-bd95e3e8aba0"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi02LTEtMS0xMzQ2OTM_d967ba19-7996-4a5e-8d19-cc9657de7009"
      unitRef="usd">1505400000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMi04LTEtMS0xMzQ2OTM_5b508020-97e2-46ef-a5b6-5e1b0da22a14"
      unitRef="usd">0</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:LitigationSettlementExpense
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy0yLTEtMS0xMzQ2OTM_986aef38-4be5-41c4-abb2-d468fa5f29ab"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy00LTEtMS0xMzQ2OTM_bf2a9657-fe96-49d4-8cde-886981d19cc1"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy02LTEtMS0xMzQ2OTM_d2b51264-f7c8-419c-99a5-c9baf9c6b399"
      unitRef="usd">900000000.0</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfMy04LTEtMS0xMzQ2OTM_25984229-ad05-4c96-8519-178778f5fc92"
      unitRef="usd">0</us-gaap:LitigationSettlementExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC0yLTEtMS0xMzQ2OTM_7d051cbd-9043-4d16-87c7-8cedc012449c"
      unitRef="usd">23900000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC00LTEtMS0xMzQ2OTM_7cded189-5673-4e13-9306-5d1612e5f8ad"
      unitRef="usd">2600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC02LTEtMS0xMzQ2OTM_727f65f3-4490-4233-b9dc-7eb600e5c79a"
      unitRef="usd">39400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNC04LTEtMS0xMzQ2OTM_e2079e33-e26e-405d-a66f-2e6cf16c4097"
      unitRef="usd">8200000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS0yLTEtMS0xMzQ2OTM_f19aee7b-1520-46b9-9ff5-b6a164741197"
      unitRef="usd">59900000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS00LTEtMS0xMzQ2OTM_186fc4db-a0f0-4bbd-94e9-e64df37dedd2"
      unitRef="usd">66300000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS02LTEtMS0xMzQ2OTM_d2262101-9dfa-491e-9736-c32e0eaabd69"
      unitRef="usd">191800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNS04LTEtMS0xMzQ2OTM_837737dc-5a88-44d6-825b-a712c5ff23d4"
      unitRef="usd">187300000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi0yLTEtMS0xMzQ2OTM_ccdd9ab0-19dc-4c72-817c-721d03005a20"
      unitRef="usd">101800000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi00LTEtMS0xMzQ2OTM_d9ae792c-b4cc-419a-9324-515dc1e42ad3"
      unitRef="usd">-424500000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi02LTEtMS0xMzQ2OTM_3e6826e7-c68d-4215-968a-dce240ea31f2"
      unitRef="usd">-167500000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNi04LTEtMS0xMzQ2OTM_9ef0d08a-bf3b-4f2d-98de-5dba87890e9c"
      unitRef="usd">-707200000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy0yLTEtMS0xMzQ2OTM_a4d2e92c-8d1e-4f55-ac17-b457ebf9338c"
      unitRef="usd">-11500000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy00LTEtMS0xMzQ2OTM_db0ea26d-3d80-4bb7-a59b-d97898c002e6"
      unitRef="usd">-13700000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy02LTEtMS0xMzQ2OTM_13f70789-4099-4e71-bc1d-c9476958c36d"
      unitRef="usd">-39000000.0</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfNy04LTEtMS0xMzQ2OTM_11fe9ce7-6406-4333-a90c-bb6f8c8f25ff"
      unitRef="usd">-23100000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC0yLTEtMS0xMzQ2OTM_4161e3af-ff07-4ed6-812c-1f862813e7d0"
      unitRef="usd">1700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC00LTEtMS0xMzQ2OTM_0ad63534-c030-4801-9f6d-c3ed96bffea7"
      unitRef="usd">-1000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC02LTEtMS0xMzQ2OTM_1a78b72f-6bc4-4782-a4bc-7c4afa038c14"
      unitRef="usd">-25200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOC04LTEtMS0xMzQ2OTM_3ca8a998-af21-49cb-a4e4-afdbbbfa0ee2"
      unitRef="usd">-4000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS0yLTEtMS0xMzQ2OTM_4040abda-725b-4f65-bb27-f24f896021eb"
      unitRef="usd">56000000.0</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS00LTEtMS0xMzQ2OTM_7db4cfb1-13e1-412d-b5a6-c036fe6e9b25"
      unitRef="usd">-502900000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS02LTEtMS0xMzQ2OTM_0ed282fc-4467-42e7-a348-1d0f93244e53"
      unitRef="usd">221300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjE4OTFmNGYxZTM2NDQ2ZTY5MDhhZmZkNzQwYWNiYWU2L3RhYmxlcmFuZ2U6MTg5MWY0ZjFlMzY0NDZlNjkwOGFmZmQ3NDBhY2JhZTZfOS04LTEtMS0xMzQ2OTM_88b46d2b-78d2-4f57-828f-9a4d9705c698"
      unitRef="usd">-913400000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjA0_87489fb2-69a4-4e3a-922d-19880424e2d7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfNjA0_d5d84396-b933-4f48-8a55-b611efd76617"
      unitRef="usd">900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnInvestmentsTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEyOQ_87985f6a-73e6-4f66-8a04-faf670bc7455">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;424.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;705.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(109.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;426.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;715.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2022, primarily reflect an increase in the aggregate fair value of our investments in Sage, Ionis Pharmaceuticals, Inc. (Ionis), Sangamo and Denali common stock of approximately $112.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2022, primarily reflect a decrease in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $198.0&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi0yLTEtMS0xMzQ2OTM_e191d6a0-a1b1-422d-82d3-d8558c956c80"
      unitRef="usd">-109800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi00LTEtMS0xMzQ2OTM_953f24f1-b242-4ce9-b154-8cf76444170c"
      unitRef="usd">424200000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi02LTEtMS0xMzQ2OTM_a0c9d852-8744-4d5a-97ab-cefea1daf447"
      unitRef="usd">158100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMi04LTEtMS0xMzQ2OTM_3369fa62-c139-4cc4-98c2-d238d27165e2"
      unitRef="usd">705900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy0yLTEtMS0xMzQ2OTM_e3342d2a-bd37-4990-9ca4-cac4f223bc75"
      unitRef="usd">-500000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy00LTEtMS0xMzQ2OTM_422e2648-e631-48c3-95c5-84d2616b60bb"
      unitRef="usd">-2700000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy02LTEtMS0xMzQ2OTM_8dd7da3b-0c10-43d4-b2be-ef0926e76be1"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfMy04LTEtMS0xMzQ2OTM_eb383203-e63a-4fdc-8568-3c70af756774"
      unitRef="usd">-9300000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC0yLTEtMS0xMzQ2OTM_55cfa1f3-b243-4940-ab34-ca80551fd868"
      unitRef="usd">-109300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i79e041e2494c45019e324230082e286e_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC00LTEtMS0xMzQ2OTM_9b19b78f-5ff0-4297-b42a-549f83e4509d"
      unitRef="usd">426900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC02LTEtMS0xMzQ2OTM_1571007a-5d14-4f3c-93f5-39fd45c960c3"
      unitRef="usd">158100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i86ccb055fe0441a1900d49cdc5addaad_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjI2N2VmM2MxZGExNjQwMWM4ZWIzODQyMWUyMmZlMGQ2L3RhYmxlcmFuZ2U6MjY3ZWYzYzFkYTE2NDAxYzhlYjM4NDIxZTIyZmUwZDZfNC04LTEtMS0xMzQ2OTM_f8fa043d-62fd-41b7-a9ba-fc44656cf1c7"
      unitRef="usd">715200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i6c37ed99d794477582d69045529410a5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMTM3MA_943969d7-000d-4531-864a-2644636f2a28"
      unitRef="usd">112500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="i70546cdb486b478dbb121a7e30415292_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMTU3Ng_55e968dc-92d3-4169-ab2f-3c5d9c86f438"
      unitRef="usd">198000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEzNA_0bf2201a-d7e1-4583-9ba6-36403b028305">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.347%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Litigation settlement agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;900.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;854.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;802.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;260.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;324.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;208.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;313.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;769.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;828.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,305.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,535.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.017%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.105%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.578%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2022 we recorded a pre-tax charge of $900.0&#160;million, plus estimated fees and expenses, related to a litigation settlement agreement to resolve a qui tam litigation relating to conduct prior to 2015. For additional information on the litigation settlement agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Litigation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMS0yLTEtMS0xMzQ2OTM_25bcf630-c9b9-41fe-ac30-270ecda8fc39"
      unitRef="usd">900000000.0</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:SettlementLiabilitiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMS00LTEtMS0xMzQ2OTM_2a0f6ec6-4778-4b6b-95fd-4ffac07e2e35"
      unitRef="usd">0</us-gaap:SettlementLiabilitiesCurrent>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i809babb0c0c0499093a3c1b393fd910b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMi0yLTEtMS0xMzQ2OTM_74807629-e79d-41a6-b2fd-f75f605928a9"
      unitRef="usd">854500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ide348a94f52a4b6fbe470e76039c8fd9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMi00LTEtMS0xMzQ2OTM_1e33985d-158a-4828-a825-f60dbed88e50"
      unitRef="usd">802100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:Collaborationexpensesaccrual
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMy0yLTEtMS0xMzQ2OTM_9fcb1ab4-6f7a-451a-8e73-67141b437e3e"
      unitRef="usd">260100000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfMy00LTEtMS0xMzQ2OTM_07922185-817a-4c5b-b07c-d913241021b6"
      unitRef="usd">324700000</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNC0yLTEtMS0xMzQ2OTM_652c1f80-df0f-4d9c-bf1a-e94742717d5c"
      unitRef="usd">208600000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNC00LTEtMS0xMzQ2OTM_77e0686c-f46d-4a79-9b31-13278842ed0e"
      unitRef="usd">234700000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNS0yLTEtMS0xMzQ2OTM_b3051390-1be6-4123-9d5a-80c9d745fc0d"
      unitRef="usd">313500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfNS00LTEtMS0xMzQ2OTM_b631bcb8-2589-4d78-a56a-78ddef763856"
      unitRef="usd">345100000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOC0yLTEtMS0xMzQ2OTM_8f7b7f3b-b097-4d93-a3cd-03349128a353"
      unitRef="usd">769200000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOC00LTEtMS0xMzQ2OTM_9e8ee3ec-4474-4115-ada6-de1d02991625"
      unitRef="usd">828600000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOS0yLTEtMS0xMzQ2OTM_43ba9d90-c8cd-43bf-93cd-3aa05acc7a3e"
      unitRef="usd">3305900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RhYmxlOjUyMDY2N2RjNmY2NTRmZTc5MzNjNjE4Y2MwZTFjMzI3L3RhYmxlcmFuZ2U6NTIwNjY3ZGM2ZjY1NGZlNzkzM2M2MThjYzBlMWMzMjdfOS00LTEtMS0xMzQ2OTM_fc007af8-3e8f-4c3e-8f90-7ae19794dc0a"
      unitRef="usd">2535200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LitigationSettlementExpense
      contextRef="ie21d724e1d804ebf9cecb4254958e096_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMTY3Mg_f83b00ce-0eb3-439b-84b6-04d08a28f032"
      unitRef="usd">900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjAxNA_caa622a0-64e6-4f0a-89ff-632b41453167"
      unitRef="usd">1198100000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjAyMQ_53d78308-8b66-487c-bde4-907a3cb6e11b"
      unitRef="usd">1320500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjA5OA_a7aaccb4-8e79-42ad-bb19-35063d3e7de4"
      unitRef="usd">559700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85NC9mcmFnOjgzMmYzNTk4MjI2ZTRhNjViMDg0M2MwZTc0NWZlNWM3L3RleHRyZWdpb246ODMyZjM1OTgyMjZlNGE2NWIwODQzYzBlNzQ1ZmU1YzdfMjEwNQ_8effc5fb-6bdb-466c-abbf-365702fa0eb9"
      unitRef="usd">664500000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NDI_51d60405-94bd-4b5c-9700-995968c89a93">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Lecanemab Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai Co., Ltd. (Eisai) to jointly develop and commercialize lecanemab (BAN2401), an anti-amyloid antibody, and elenbecestat, the oral BACE (base amyloid cleaving enzyme) inhibitor, two Eisai product candidates for the potential treatment of Alzheimer's disease (the Lecanemab Collaboration). In September 2019 we and Eisai discontinued the global Phase 3 studies of elenbecestat in early Alzheimer's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Eisai serves as the lead of lecanemab development and regulatory submissions globally with both companies co-commercializing and co-promoting the product, and Eisai having final decision-making authority. All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. If lecanemab receives marketing approval, we and Eisai will co-promote lecanemab and share profits or losses equally. In March 2022 we extended our supply agreement related to lecanemab from five years to ten years for the manufacture of lecanemab drug substance and drug product.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022 Eisai completed the submission of a Biologics License Application (BLA) to the FDA for the accelerated approval of lecanemab. In July 2022 the FDA accepted the BLA and granted Priority Review with a Prescription Drug User Fee Act action date of January 6, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Lecanemab Collaboration also provided Eisai with an option to jointly develop and commercialize ADUHELM (aducanumab) (ADUHELM Option). In October 2017 Eisai exercised its ADUHELM Option and we entered into a new collaboration agreement for the joint development and commercialization of ADUHELM (the ADUHELM Collaboration Agreement).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the Lecanemab Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our Lecanemab Collaboration, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under our initial ADUHELM Collaboration Agreement, we would lead the ongoing development of ADUHELM, and we and Eisai would co-promote ADUHELM with a region-based profit split. Beginning January 1, 2019, Eisai was reimbursing us for&#160;45.0%&#160;of development costs incurred by the collaboration for the advancement of ADUHELM (ADUHELM development expense). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA for the treatment of Alzheimer's disease and had its first commercial sale. As a result of the launch of ADUHELM in the U.S., we made a $100.0&#160;million milestone payment to Neurimmune. For the nine months ended September 30, 2021, we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's 45.0% share of the $100.0&#160;million milestone payment, which was recorded in collaboration profit (loss) sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2022 we amended our ADUHELM Collaboration Agreement with Eisai. Effective March 2022, we have sole decision making and commercialization rights worldwide on ADUHELM and beginning January 1, 2023, Eisai will receive a tiered royalty based on net sales of ADUHELM, rather than sharing global profits and losses. Eisai's share of development, commercialization and manufacturing expense is limited to $335.0&#160;million for the period from January 1, 2022 to December 31, 2022. As of September 30, 2022, Eisai's portion of these expenses was approximately $300.0&#160;million. Once this limit is achieved, we will be responsible for all ADUHELM related development costs. After the tiered royalty model commences on January 1, 2023, Eisai will not participate in ADUHELM&#x2019;s economics beyond these royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;C&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;o-promotion Profits and Losses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S. we recognize revenue on sales to third parties as a component of product revenue, net in our condensed consolidated statements of income. We also record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income as these costs are incurred. Payments made to and received from Eisai for its 45.0% share of the co-promotion profits or losses in the U.S. are recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2022, we recognized a net reduction to our operating expense of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$3.4&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$214.0&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively, to reflect Eisai's 45.0% share of net collaboration losses in the U.S.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, compared to $50.6&#160;million and $90.7&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we and Eisai co-promote AVONEX, TYSABRI and TECFIDERA in Japan in certain settings and Eisai distributes AVONEX, TYSABRI, TECFIDERA and PLEGRIDY in India and other Asia-Pacific markets, excluding China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2022 we recorded approximately $275.0&#160;million of gross charges associated with inventory and purchase commitments in excess of forecasted demand related to ADUHELM. F&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2022,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; we have also recorded approximately $76.0&#160;million of aggregate gross idle capacity charges related to ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have recognized approximately $177.0&#160;million related to Eisai's 45.0% share of inventory and idle capacity charges in collaboration profit (loss) sharing within our condensed consolidated statements of income&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; months ended September 30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$110.6&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $285.4&#160;million as of September 30, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively. Amounts payable to Eisai related to the agreements discussed above were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$81.7&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and $46.5&#160;million as of September 30, 2022 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021, respectively&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the ADUHELM Collaboration Agreement, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of systemic lupus erythematosus and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, we and UCB will co-promote dapirolizumab pegol and share profits equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of UCB development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sage Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize BIIB125 (zuranolone) for the potential treatment of major depressive disorder and postpartum depression and BIIB124 (SAGE-324) for the potential treatment of essential tremor with potential in other neurological conditions such as epilepsy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Sage potential tiered royalties in the high teens to low twenties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sage sales and marketing expense incurred by the collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sage sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize Denali's small molecule inhibitors of leucine-rich repeat kinase 2 (LRRK2) for Parkinson's disease. Under this collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition to the LRRK2 program, we also have an exclusive option to license two preclinical programs from Denali&#x2019;s Transport Vehicle platform, including its Antibody Transport Vehicle (ATV): ATV enabled anti-amyloid beta program and a second program utilizing its Transport Vehicle technology. Further, we have the right of first negotiation on two additional ATV-enabled therapeutics for indications within specific neurodegenerative diseases, should Denali decide to seek a collaboration for such programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In October 2022 we and Denali announced the initiation of the Phase 3 LIGHTHOUSE study for BIIB122 (DNL151), a small molecule inhibitor of LRRK2 for the potential treatment of Parkinson's disease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Sangamo Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2020 we entered into a collaboration and license agreement with Sangamo to develop and commercialize ST-501 for tauopathies, including Alzheimer's disease; ST-502 for synucleinopathies, including Parkinson&#x2019;s disease; a third neuromuscular disease target; and up to nine additional neurological disease targets to be identified and selected within a five-year period. The companies are leveraging Sangamo&#x2019;s proprietary zinc finger &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;protein technology delivered via adeno-associated virus to modulate the expression of key genes involved in neurological diseases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, we may pay Sangamo tiered royalties on potential net sales of any products developed under this collaboration in the high single digit to sub-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Sangamo collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Sangamo development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;InnoCare Pharma Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In July 2021 we entered into a collaboration and license agreement with InnoCare Pharma Limited (InnoCare) for orelabrutinib, an oral small molecule Bruton&#x2019;s tyrosine kinase inhibitor for the potential treatment of MS. Orelabrutinib is currently being studied in a multi-country, placebo-controlled Phase 2 trial in relapsing-remitting MS. Under the terms of the collaboration, we have exclusive rights to orelabrutinib in the field of MS worldwide and certain autoimmune diseases outside of China (including Hong Kong, Macau and Taiwan), while InnoCare retains ex&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;clusive worldwide rights to orelabrutinib in the field of oncology and certain autoimmune diseases in China (including Hong Kong, Macau and Taiwan). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In connection with the closing of this transaction in August 2021 we made an upfront payment of $125.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;that was recorded as research and development expense in our condensed consolidated statements of income. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0a0a0a;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We may also pay InnoCare up to approximately $812.5&#160;million in potential development milestones and potential commercial payments should this collaboration achieve certain development, commercial milestones and sales thresholds. In addition, we may pay InnoCare tiered royalties on potential net sales of any products developed under this collaboration in the low to high teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2022, we recorded $14.0&#160;million and $51.5&#160;million, respectively, as research and development expense in our condensed consolidated statements of income related to other research and discovery related arrangements, compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$7.7&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $84.9&#160;million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Joint Venture Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2012 we entered into a joint venture agreement with Samsung BioLogics establishing an entity, Samsung Bioepis, to develop, manufacture and market biosimilar products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing and expect to receive approximately $1.3&#160;billion in cash to be deferred over two payments of approximately $812.5&#160;million due at the first anniversary and approximately $437.5&#160;million due at the second anniversary of the closing of this transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the transaction, we are also eligible to receive up to an additional $50.0&#160;million upon the achievement of certain commercial milestones. Our policy for contingent payments of this nature is to recognize them in the period that they become realizable, which is generally the same period in which they are earned.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to this sale, we recognized our share of the results of operations related to our investment in Samsung Bioepis under the equity method of accounting one quarter in arrears when the results of the entity became available, which was reflected as equity in (income) loss of investee, net of tax in our condensed consolidated statements of income. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon investment, the equity method of accounting required us to identify and allocate differences between the fair value of our investment and the carrying value of our interest in the underlying net assets of the investee. These basis differences were being amortized over their economic life until the completion of the sale in April 2022, as discussed above. The total basis difference was approximately $675.0 million and related to inventory, developed technology, IPR&amp;amp;D and deferred tax balances. The basis differences related to inventory were amortized, net of tax, over their estimated useful lives of 1.5 years, and the basis differences related to developed technology and IPR&amp;amp;D for marketed products were being amortized, net of tax, over their estimated useful lives of 15 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the nine months ended September 30, 2022, we recognized net income on our investment of $2.6 million, reflecting our share of Samsung Bioepis' operating profits, net of tax totaling $17.0&#160;million, offset by amortization of basis differences totaling $14.4&#160;million. This amount reflects our share of results prior to the sale of Samsung Bioepis as the results are recognized one quarter in arrears. Following the sale of Samsung Bioepis we no longer recognize gains or losses associated with Samsung Bioepis' results of operations and amortization related to basis differences.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2021, we recognized net income on our investment of $1.1 million and $17.2 million, respectively, reflecting our share of Samsung Bioepis' operating profits, net of tax to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;taling $8.9&#160;million and $39.5&#160;million, respectively, offset by amortization of basis differences totaling $7.8&#160;million and $22.3&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December 31, 2021, the carrying value of our investment in Samsung Bioepis totaled 713.3 billion South Korean won ($599.9 million), which is classified as a component of investments and other assets in our condensed consolidated balance sheets. In connection with the sale of Samsung Bioepis, the carrying value of our investment was reduced to zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Dispositions, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ (ranibizumab-nuna), a ranibizumab biosimilar referencing LUCENTIS, and SB15, a proposed aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with this transaction, we made an upfront payment of $100.0 million to Samsung Bioepis in January 2020, of which $63.0 million was recorded as research and development expense in our condensed consolidated statements of income in 2019 and $37.0 million was recorded as intangible assets, net in our condensed consolidated balance sheets in 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the third quarter of 2021 we accrued $15.0&#160;million in milestone payments related to the approval of BYOOVIZ in the U.S., the E.U. and the United Kingdom (U.K.), that were capitalized within intangible assets, net in our condensed consolidated balance sheets. We may also pay Samsung Bioepis up to approximately $180.0 million in additional development, regulatory and sales-based milestones.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also acquired an option to extend the term of our 2013 c&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ommercial agreement for BENEPALI, IMRALDI and FLIXABI by an additional five years, subject to payment of an option exercise fee of $60.0 million, and obtained an option to acquire exclusive rights to commercialize these products in China.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our commercial agreement with Samsung Bioepis, which is recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income. For the three and nine months ended September 30, 2022, we recognized net profit-sharing expense of $48.7&#160;million and $171.4 million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to a net profit-sharing expense of $71.8 million and $210.2 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a technical development services agreement, a manufacturing agreement and a license agreement with Samsung Bioepis. Revenue related to these services is reflected in revenue from collaborative and other relationships as a component of other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.8&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and $4.1&#160;million as of September 30, 2022 and December 31, 2021, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed abo&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ve were $53.8&#160;million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$148.7&#160;million as of September 30, 2022 and December 31, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt; to our consolidated financial statements included in our 2021 Form 10-K.</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NjQ_2ca0cd47-3b05-4a69-b32b-50fa0c403b74">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of lecanemab and elenbecestat&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;264.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;236.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Lecanemab Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of lecanemab and elenbecestat sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i514b2ba420f64268a1d2daffdaab5268_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi0yLTEtMS0xMzQ2OTM_847bcd78-5cb1-4bb7-b07b-c0bb0af97388"
      unitRef="usd">109300000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i78a6bb2bc10a4e3c91f961981fa702e8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi00LTEtMS0xMzQ2OTM_eb6ed0ef-e1cd-4bc6-b068-a0a4f69cd9d5"
      unitRef="usd">118400000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="i3443044069b84a6e88b9b3cc9b330446_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi02LTEtMS0xMzQ2OTM_cc21c31d-f3e5-420e-9b75-a5b7ba9174ae"
      unitRef="usd">264900000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration
      contextRef="idb735cebf0af4abd9050e30bb5f39f33_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMi04LTEtMS0xMzQ2OTM_51070550-58d8-4974-a6c7-2d176da53db3"
      unitRef="usd">236100000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i514b2ba420f64268a1d2daffdaab5268_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy0yLTEtMS0xMzQ2OTM_cf7726d5-97c2-4081-94e5-65237f490e8a"
      unitRef="usd">54700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i78a6bb2bc10a4e3c91f961981fa702e8_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy00LTEtMS0xMzQ2OTM_c182bd93-4533-46fb-9dd4-3b3fead83785"
      unitRef="usd">59200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3443044069b84a6e88b9b3cc9b330446_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy02LTEtMS0xMzQ2OTM_a11d5992-cea2-4e6c-8f59-f708dd3e6520"
      unitRef="usd">132500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="idb735cebf0af4abd9050e30bb5f39f33_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfMy04LTEtMS0xMzQ2OTM_cd7995e4-419b-424c-90a9-28554828f0c1"
      unitRef="usd">118000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i4c76958e4cf140f8ad08dea4b3f1ab5f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC0yLTEtMS0xMzQ2OTM_86a44b37-d1b3-4b36-9304-1e11e91e4884"
      unitRef="usd">29000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="idcac94427f544cbbae306a72b2a5e7ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC00LTEtMS0xMzQ2OTM_1a22bedc-0f85-40cf-ba2b-7b2e307ad729"
      unitRef="usd">5600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6031c646c1504c3086d61ab2593a7c25_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC02LTEtMS0xMzQ2OTM_fef18e0d-f4bd-4146-b787-e9b180b84f28"
      unitRef="usd">68300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="iddb4c4c4dd53404e8de0fcbf8e7d9a10_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNC04LTEtMS0xMzQ2OTM_2dfe5d3d-51db-48f4-8d97-bd54227f037f"
      unitRef="usd">15600000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i4c76958e4cf140f8ad08dea4b3f1ab5f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS0yLTEtMS0xMzQ2OTM_cb2510d8-1730-4146-9263-2a8383da9c5a"
      unitRef="usd">14500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="idcac94427f544cbbae306a72b2a5e7ad_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS00LTEtMS0xMzQ2OTM_3045dfde-426d-42c7-8a37-f9c25d7f509c"
      unitRef="usd">2800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6031c646c1504c3086d61ab2593a7c25_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS02LTEtMS0xMzQ2OTM_3b23bb27-7382-4799-ae21-dd0787da979f"
      unitRef="usd">34200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="iddb4c4c4dd53404e8de0fcbf8e7d9a10_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmJmMjg3MGM5NmI5OTQyZjQ5OTg3MjFlNDMyZGY4ODU4L3RhYmxlcmFuZ2U6YmYyODcwYzk2Yjk5NDJmNDk5ODcyMWU0MzJkZjg4NThfNS04LTEtMS0xMzQ2OTM_38c78130-3a01-4871-a25f-7fe910bf440a"
      unitRef="usd">7800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjI0Ng_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="id6f9bec593be4e5d91def662f86f3734_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjU2NA_f11c2a40-3c9c-4d7f-9b0e-2514fe3bcf8b"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjY3OA_d6cb4bf9-72ce-472b-9cac-3dd6c62351a3"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjcwMA_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:AdditionalMilestonePayment
      contextRef="id6f9bec593be4e5d91def662f86f3734_D20210601-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjcxNg_f11c2a40-3c9c-4d7f-9b0e-2514fe3bcf8b"
      unitRef="usd">100000000</biib:AdditionalMilestonePayment>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ide22393d682f495894e1b5ec178709c1_D20230101-20230630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMzI1NA_83befbc3-b4a6-467d-8c5d-12a39f236b24"
      unitRef="usd">335000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i1722b2d0cc7645f1a42a9c8bb59390c0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMzM3Nw_73efc2cf-9d06-44cd-ae1e-4593a46ce50a"
      unitRef="usd">300000000</us-gaap:ResearchAndDevelopmentExpense>
    <biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NTA_49940b90-c6f9-4a43-89dc-27b72031cb3d">A summary of development expense, sales and marketing expense and milestone payments related to the ADUHELM Collaboration Agreement is as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;116.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;63.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;73.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM sales and marketing expense incurred by the ADUHELM Collaboration Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of ADUHELM sales and marketing expense reflected in selling, general and administrative expense and collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;83.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;211.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total ADUHELM collaboration third party milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of reimbursement from Eisai of ADUHELM milestone payments reflected in collaboration profit (loss) sharing in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</biib:SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i1f8e21b88c804c23b9bfcb582dae16ce_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi0yLTEtMS0xMzQ2OTM_ace33cdc-eaad-4d67-b6f0-6aa7b3ad386a"
      unitRef="usd">34600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i348dea4c284f4a53bb11bb12aec530fa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi00LTEtMS0xMzQ2OTM_a43a8dd8-e6a9-4e39-bb6e-609d3e3df20c"
      unitRef="usd">43700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i141e695e78b143d688d46ac172f1b598_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi02LTEtMS0xMzQ2OTM_5148364d-e11a-4599-84c9-5e919ee0c97e"
      unitRef="usd">116000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i179603334c294ba3b273f1bedccca3c9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMi04LTEtMS0xMzQ2OTM_0fa017d8-de7a-4481-9128-e98c205bf5b3"
      unitRef="usd">132800000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i1f8e21b88c804c23b9bfcb582dae16ce_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy0yLTEtMS0xMzQ2OTM_24ffea17-4999-495e-95f8-23e8d1fc6035"
      unitRef="usd">19000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i348dea4c284f4a53bb11bb12aec530fa_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy00LTEtMS0xMzQ2OTM_aea79f3f-c78a-4411-b0a3-1a2a9336aae7"
      unitRef="usd">24000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i141e695e78b143d688d46ac172f1b598_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy02LTEtMS0xMzQ2OTM_29049ae9-5e61-4d59-9cde-2b17b49eb751"
      unitRef="usd">63800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i179603334c294ba3b273f1bedccca3c9_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfMy04LTEtMS0xMzQ2OTM_57d43fa3-0e50-449b-84db-183a281bf103"
      unitRef="usd">73000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="id03c149483b744869649d8b1d34aa36b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC0yLTEtMS0xMzQ2OTM_fe2fc959-e3b2-45b6-a956-bf0721ce4955"
      unitRef="usd">-8000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i591976370b814e62bd8c8b9ed758f611_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC00LTEtMS0xMzQ2OTM_2ddd01fd-4a77-4373-a3ee-95513f4b63bf"
      unitRef="usd">154300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i02b6a4d48c4a4334acaae1eb260e0b13_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC02LTEtMS0xMzQ2OTM_596afe37-a350-4503-876d-5f69751106cd"
      unitRef="usd">127800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i505f65ad62c3405996f7fb81bba9d4cb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNC04LTEtMS0xMzQ2OTM_649803bd-a722-4240-a4fd-1d1879edb6fe"
      unitRef="usd">391700000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="id03c149483b744869649d8b1d34aa36b_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS0yLTEtMS0xMzQ2OTM_1ec1fd5a-cee9-4a91-897e-65c40ced432e"
      unitRef="usd">-3900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i591976370b814e62bd8c8b9ed758f611_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS00LTEtMS0xMzQ2OTM_07ade190-a60e-4ac3-8602-25363dc2ae8a"
      unitRef="usd">83300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i02b6a4d48c4a4334acaae1eb260e0b13_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS02LTEtMS0xMzQ2OTM_23e4e826-c67a-4649-bbf6-20ba8d064a84"
      unitRef="usd">68100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i505f65ad62c3405996f7fb81bba9d4cb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNS04LTEtMS0xMzQ2OTM_9224687b-4ea6-43cf-8344-7342d3abdbe5"
      unitRef="usd">211200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AdditionalMilestonePayment
      contextRef="i19a6d0acc3304bb9aa01590e1e7460fb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi0yLTEtMS0xMzQ2OTM_b4cb3ab6-4a8c-444f-aa5a-c7fd608991cd"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi00LTEtMS0xMzQ2OTM_6a5b8376-9d0b-4601-a871-e1c48818bac7"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i6511e416082b49b9a364fc869d30a213_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi02LTEtMS0xMzQ2OTM_e4a49f52-efb0-45ae-a34a-24732dc03bd7"
      unitRef="usd">0</biib:AdditionalMilestonePayment>
    <biib:AdditionalMilestonePayment
      contextRef="i21152c4b7a304de9aeb9f9105783865d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNi04LTEtMS0xMzQ2OTM_a5b34c2c-c9f0-48a4-a4c7-a340ccc288bf"
      unitRef="usd">100000000.0</biib:AdditionalMilestonePayment>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i19a6d0acc3304bb9aa01590e1e7460fb_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy0yLTEtMS0xMzQ2OTM_6e8f00d2-14d8-4c66-9d25-d43d3ecd3a68"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i3978c63033dc4414a4b78eeadccd7a62_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy00LTEtMS0xMzQ2OTM_8575ee36-76b2-4a0a-afcf-6d1b34df304c"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6511e416082b49b9a364fc869d30a213_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy02LTEtMS0xMzQ2OTM_cc8e2fcb-66eb-4cf1-80e8-fe608e452db1"
      unitRef="usd">0</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i21152c4b7a304de9aeb9f9105783865d_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOmE3YmEzNjA3ODhkYjQ5ZGY4ZDJjZjBjYjk3Y2I1NDUzL3RhYmxlcmFuZ2U6YTdiYTM2MDc4OGRiNDlkZjhkMmNmMGNiOTdjYjU0NTNfNy04LTEtMS0xMzQ2OTM_0d4cbae8-85b8-4b34-abec-3d097fd86458"
      unitRef="usd">45000000.0</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDE0Ng_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i2dd4b5749a9a44fab753be0fde81fae7_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDQwNA_d482ee32-b02b-4c93-8a4f-3ff31a14e969"
      unitRef="usd">3400000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic0b2780de2c442749c94a8cf029cc0bc_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDQxMQ_e7bf9551-a1df-4e68-a037-559a6170c405"
      unitRef="usd">214000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="id4b772a8ed2c4a2aac06ce78bbdaec90_D20210701-20210930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDQ0OA_6be04980-eeef-4284-8ba1-1dc6e2a8df55"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="id4b772a8ed2c4a2aac06ce78bbdaec90_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDUxMA_cb9a5bf8-4b31-4cb9-8b3b-b744339f5029"
      unitRef="usd">50600000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="if842e4daa2c44c5aaad2b10260a4d9ba_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA5OTUxMTY0NTI4Mw_1fd35a78-cb70-4d8e-89b1-5631c63ccec4"
      unitRef="usd">90700000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ib904f98f905e4ad3953b630e2bca4280_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNDgzNQ_3ae7b598-ad06-4400-9541-21e1a81f1204"
      unitRef="usd">275000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i6511e416082b49b9a364fc869d30a213_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMjc0ODc3OTA5MjQ4OQ_66c53d9a-e9f1-49e3-9996-e4f347ff63c5"
      unitRef="usd">177000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTE5NA_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <us-gaap:DueFromRelatedParties
      contextRef="i5edddd85627f4628a01d57ff448a161b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTQxOQ_4b8b7987-24ba-4dee-9920-5ca629e6db2e"
      unitRef="usd">110600000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="id9708e37fa77451aadd22d8e388458e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTQyNg_5196ae57-ea3a-49a1-aac5-35813075cfb3"
      unitRef="usd">285400000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i5edddd85627f4628a01d57ff448a161b_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTUzMg_e9c7dd89-1000-4d40-8b08-87b024cf263a"
      unitRef="usd">81700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="id9708e37fa77451aadd22d8e388458e8_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfNTUzOQ_07628d30-9a84-4be1-9f5c-3b2b2fbd77f0"
      unitRef="usd">46500000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <biib:Expenseincurredbythecollaboration
      contextRef="i68bdd3eb1eb14260abcb70364529e312_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi0yLTEtMS0xMzQ2OTM_2c99f72b-21db-403e-a2b5-90569d5e4138"
      unitRef="usd">18300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ic3154c9870f64f398d5ee5795b0ed8a9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi00LTEtMS0xMzQ2OTM_c9cd4ecc-065c-4dd8-a336-daa4b77821bf"
      unitRef="usd">16500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ib0000607651b4c2da18c5e8d251aa79d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi02LTEtMS0xMzQ2OTM_44ab4112-103c-4990-a5e2-3e0c07ff35ab"
      unitRef="usd">51500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i97091bfe16ce48fa8f91049acef10017_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMi04LTEtMS0xMzQ2OTM_44e15115-2995-41f1-8ef9-f1c3c9ef1f07"
      unitRef="usd">49500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i68bdd3eb1eb14260abcb70364529e312_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy0yLTEtMS0xMzQ2OTM_9f12948b-1b5a-4ba6-8d6a-c5fa027528c6"
      unitRef="usd">9100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ic3154c9870f64f398d5ee5795b0ed8a9_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy00LTEtMS0xMzQ2OTM_8d62c734-dfef-4207-8142-ef35798ba1a5"
      unitRef="usd">8200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ib0000607651b4c2da18c5e8d251aa79d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy02LTEtMS0xMzQ2OTM_b7d67d52-08fa-4d5f-a83e-252a69bdd9e9"
      unitRef="usd">25700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i97091bfe16ce48fa8f91049acef10017_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjhjMjQ0M2UyYzk2YTRjNzNhMDU3YTQwNDYyMjY0NTlmL3RhYmxlcmFuZ2U6OGMyNDQzZTJjOTZhNGM3M2EwNTdhNDA0NjIyNjQ1OWZfMy04LTEtMS0xMzQ2OTM_3042be36-b0aa-420f-b5a2-be48c4c70ab6"
      unitRef="usd">24800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i19c19ba4f7294ef3b3f1a8cc3f9e7a51_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi0yLTEtMS0xMzQ2OTM_217d28ab-25ab-4afb-b0aa-d31bbab2a4e9"
      unitRef="usd">40900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i9bddd0739a28443f9a5addc1d0165587_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi00LTEtMS0xMzQ2OTM_288fd6fb-59a3-4996-a304-d812995038c4"
      unitRef="usd">40800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i6280e0f3e31e4892b76bcf7697d7da8c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi02LTEtMS0xMzQ2OTM_d1f38176-d050-4ca7-b75a-d298cde791c6"
      unitRef="usd">130400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i9dca4a205fd04aff8770a8d6c0648246_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMi04LTEtMS0xMzQ2OTM_30624e1b-0ef6-4195-b345-cf3a7da86e4b"
      unitRef="usd">134900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i19c19ba4f7294ef3b3f1a8cc3f9e7a51_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy0yLTEtMS0xMzQ2OTM_5ec6ab43-26a7-4e47-be2f-6276af4d01f4"
      unitRef="usd">20500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i9bddd0739a28443f9a5addc1d0165587_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy00LTEtMS0xMzQ2OTM_3abafc13-134d-42cc-8790-579547eb3a0e"
      unitRef="usd">20400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i6280e0f3e31e4892b76bcf7697d7da8c_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy02LTEtMS0xMzQ2OTM_e89139d7-d4bc-402c-9380-9fc3e0b81529"
      unitRef="usd">65200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i9dca4a205fd04aff8770a8d6c0648246_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfMy04LTEtMS0xMzQ2OTM_35df9a27-ca67-4912-bc54-18af95e81fe9"
      unitRef="usd">67300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration
      contextRef="i637a39c4b67547449f9bb69b9022b010_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC0yLTEtMS0xMzQ2OTM_282d2cdc-96f0-404a-898c-f3e05a4931b0"
      unitRef="usd">28500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ie6be2070a42f4a50adbcea4041c3995b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC00LTEtMS0xMzQ2OTM_b7488148-e161-4f2d-948f-cc73b749b6d8"
      unitRef="usd">7400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ia6514e9099d749e2a24676b1e0964505_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC02LTEtMS0xMzQ2OTM_21f33f70-532a-4bfd-acbd-4621abedc142"
      unitRef="usd">69900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="ie96ed8937b44437397b52545c683f8ca_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNC04LTEtMS0xMzQ2OTM_31f41353-6f49-4f5c-b21a-5bcea2c0f8b4"
      unitRef="usd">23200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i637a39c4b67547449f9bb69b9022b010_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS0yLTEtMS0xMzQ2OTM_03b8daf9-b396-4fe2-b7fd-c4630d92dfcb"
      unitRef="usd">14200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ie6be2070a42f4a50adbcea4041c3995b_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS00LTEtMS0xMzQ2OTM_7815e107-f778-4a83-8360-a22d50bc991b"
      unitRef="usd">3700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ia6514e9099d749e2a24676b1e0964505_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS02LTEtMS0xMzQ2OTM_8e963649-3002-45d4-ae61-eaa8e244f343"
      unitRef="usd">34900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="ie96ed8937b44437397b52545c683f8ca_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjQ2NjMwZWNkM2I4YTRhNjFiNmVlYzhlN2Q0MGQwMjFmL3RhYmxlcmFuZ2U6NDY2MzBlY2QzYjhhNGE2MWI2ZWVjOGU3ZDQwZDAyMWZfNS04LTEtMS0xMzQ2OTM_dff28dce-f13b-4a70-b7fa-c2f1ababda93"
      unitRef="usd">11600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NjY_7020b927-7c28-4a04-9ab6-1c0f5d42412a">&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to this collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.794%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.701%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of Denali development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration
      contextRef="i63077c7ccbc64b09ba57ccfcb24dc699_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi0yLTEtMS0xMzQ2OTM_b254b3ae-d62b-481f-b068-18ad27bb82ff"
      unitRef="usd">19900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i67337d92701149d7a5ac303a93defa2c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi00LTEtMS0xMzQ2OTM_a8fbc311-511f-4f61-8fd2-edb36551b6b4"
      unitRef="usd">8500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="iac8df81074864fdca6b0580aa1c815e0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi02LTEtMS0xMzQ2OTM_b56bf162-a54c-40b4-9bdf-c56f97594d1e"
      unitRef="usd">58000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i4853d9b210a44032a2de85b0f2c6b1bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMi04LTEtMS0xMzQ2OTM_2f6e98da-b643-4514-9400-bb2fcadc4a1b"
      unitRef="usd">27200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i63077c7ccbc64b09ba57ccfcb24dc699_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy0yLTEtMS0xMzQ2OTM_3d17c593-e727-44b6-a043-0b5752890e72"
      unitRef="usd">11400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i67337d92701149d7a5ac303a93defa2c_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy00LTEtMS0xMzQ2OTM_f9396929-3aaa-4fcf-99c0-72c84b7323d2"
      unitRef="usd">5100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="iac8df81074864fdca6b0580aa1c815e0_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy02LTEtMS0xMzQ2OTM_e5326077-ff17-4424-8270-5019be5f51ce"
      unitRef="usd">33500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i4853d9b210a44032a2de85b0f2c6b1bb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjNmNjg0OWYyNzk2NDRlYWJiYThmZDdkYjIxOGFkYzUyL3RhYmxlcmFuZ2U6M2Y2ODQ5ZjI3OTY0NGVhYmJhOGZkN2RiMjE4YWRjNTJfMy04LTEtMS0xMzQ2OTM_16fcb8af-e602-4baf-a5f4-c53c9c36ce32"
      unitRef="usd">16300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Termofcollaborationagreement
      contextRef="if6a86bf51ac541cab63587970a524ba7_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0NTM_c76616cf-d5d9-4075-95e6-a1a7bc513dd2">P5Y</biib:Termofcollaborationagreement>
    <biib:Expenseincurredbythecollaboration
      contextRef="i94f98a47df764e30ba42983d8f26f8ff_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi0yLTEtMS0xMzQ2OTM_218f8a88-4487-4ef9-a148-37d84988a26c"
      unitRef="usd">5500000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i2b59abb400d4439985bc8aede1323697_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi00LTEtMS0xMzQ2OTM_15e7ab5d-25b5-4e28-a9d5-076fd2627bc0"
      unitRef="usd">6200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i442b682326924c119499dfef30296ddd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi02LTEtMS0xMzQ2OTM_ac813efe-9ccc-4d60-8341-0e6d1580035d"
      unitRef="usd">16400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration
      contextRef="i06a34504b754441cb3200ef36b1270d9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMi04LTEtMS0xMzQ2OTM_4bd2b0cd-d9a6-4337-8d3a-d6330bd041be"
      unitRef="usd">16400000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i94f98a47df764e30ba42983d8f26f8ff_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy0yLTEtMS0xMzQ2OTM_c8ef007d-6f74-4028-8713-c6030300ffcf"
      unitRef="usd">3100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i2b59abb400d4439985bc8aede1323697_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy00LTEtMS0xMzQ2OTM_8af95f25-f7bd-4550-93c5-1f4fa3515ea0"
      unitRef="usd">1900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i442b682326924c119499dfef30296ddd_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy02LTEtMS0xMzQ2OTM_d4f4f570-afaa-461d-9e02-7a4e270cc34d"
      unitRef="usd">10200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome
      contextRef="i06a34504b754441cb3200ef36b1270d9_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RhYmxlOjRjZTA2N2U5YjNiYzRjMzc4NzZlYTZlOTFhZTY1OWQ5L3RhYmxlcmFuZ2U6NGNlMDY3ZTliM2JjNGMzNzg3NmVhNmU5MWFlNjU5ZDlfMy04LTEtMS0xMzQ2OTM_f85ecb6e-e531-4f1a-aeec-bcd281ee5bab"
      unitRef="usd">9500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="i64fbcbfb69f64e4bad4eaf9e2feb10e6_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA0NDI_e06be5b2-dd57-43ae-8993-b0a4f20da5e8"
      unitRef="usd">125000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:ContingentMilestonePaymentsMadeToCollaborativePartner
      contextRef="i64fbcbfb69f64e4bad4eaf9e2feb10e6_D20210801-20210831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA1OTY_f6f1e124-1e42-415a-be51-5e1fdaa89dd6"
      unitRef="usd">812500000</biib:ContingentMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i2688c6f795fe495b87c7088b9af08f05_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTEyMTE_bb416fdc-3809-4c67-90e1-0a1ed5bdb698"
      unitRef="usd">14000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="icb2ae5cb50394082889ddf96ebccf655_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTEyMTg_c41cee66-f3ea-48ef-b2d3-2d408ade1a54"
      unitRef="usd">51500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i43982e8c28374e20a8abf7ff9c154d4d_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTEzOTc_4fdfc887-57e5-4d05-9c4f-85ed5a6571d7"
      unitRef="usd">7700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i5c00ebed6f7d4754af195586caa15662_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTA5OTUxMTY0NTM0Nw_68c4cefa-2aa6-46a1-b100-e396a8df7536"
      unitRef="usd">84900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE2Nzk_87489fb2-69a4-4e3a-922d-19880424e2d7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture
      contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE2ODk_192d59ff-ed91-4d07-9503-7ea9bcb0fdf6"
      unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i316ee61fce71448090e9e99d3e03605f_I20220131"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE2OTU_0fcfce3c-0a3a-4d42-8efc-11d188235b8c"
      unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="i607186b7dfc843688ebf32e0578fc19b_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE3MDE_f667ce64-0313-4cfb-9416-315c9efa1b7f"
      unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture
      contextRef="ie8da0e6904f247e0a072f97c4201c43b_I20220131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE3MDc_a92fa58f-a17f-4dc0-bb3c-41f9b74f1baa"
      unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:AdditionalMilestonePayment
      contextRef="iac062867190e40d291330b2582dde77d_D20220401-20220430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTE3NDc_96136127-4524-4f39-b718-e6b4699c4026"
      unitRef="usd">50000000</biib:AdditionalMilestonePayment>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="iecc1e7ba25054542bf09508f1c307e7e_I20181107"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI1MTU_35f6a334-0a96-4a33-9d82-d141f551f15c"
      unitRef="usd">675000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="i54f716cdfda745bd9304e51b2b5d7a59_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI3MDc_83052180-f3e9-4aac-8f54-359c877df399">P1Y6M</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <biib:Equitymethodinvestmentbasisdifferenceamortizationperiod
      contextRef="ic158a58579df49b6bfc1555e6b8983da_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI4Nzg_940242c7-6ea4-41c1-93ff-7a58e59bba8a">P15Y</biib:Equitymethodinvestmentbasisdifferenceamortizationperiod>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTI5NzY_cd357630-1c8c-4f3f-88ad-73a98bb36690"
      unitRef="usd">2600000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTMwODE_ae2fee6f-b092-4ee3-a780-272ed6446d13"
      unitRef="usd">17000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTMxNTk_9d144360-bb12-4bab-bb13-11f29439ed0b"
      unitRef="usd">14400000</us-gaap:AdjustmentForAmortization>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM1NzE_59329f45-430b-4ba1-8511-374e4e1c1590"
      unitRef="usd">1100000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions
      contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM1Nzg_ade37fd0-e4e6-4c93-9880-32218901b49b"
      unitRef="usd">17200000</us-gaap:IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM2NzU_cce3ea6e-5ab5-47ea-bfde-754c310257b6"
      unitRef="usd">8900000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM2ODI_6629f95e-72d0-43d2-bf36-f2436f2494e5"
      unitRef="usd">39500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:AdjustmentForAmortization
      contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM3NDc_468b5af1-02d6-4c27-be8a-b03d581c21db"
      unitRef="usd">7800000</us-gaap:AdjustmentForAmortization>
    <us-gaap:AdjustmentForAmortization
      contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM3NTQ_0640ea20-a189-45e7-aaf6-c53b3c14b641"
      unitRef="usd">22300000</us-gaap:AdjustmentForAmortization>
    <us-gaap:EquityMethodInvestments
      contextRef="if1c25ceefcea49b9827a310222a5b592_I20211231"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM4NDY_cffb97e6-ba2f-4051-ab57-8882f9861577"
      unitRef="krw">713300000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="if1c25ceefcea49b9827a310222a5b592_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTM4Njc_cb39c2e4-ca73-4013-a858-3b9e79727397"
      unitRef="usd">599900000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTc0MTg_decd90de-6961-4c55-97ad-75aa5ad71e35"
      unitRef="krw">0</us-gaap:EquityMethodInvestments>
    <biib:ContingentCommercializedRightsNumberOfProducts
      contextRef="i534cd99ae2f945f4b8b88984e7158822_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQyNjU_1d5403e9-4732-42f3-b3e3-4892549e6ad5"
      unitRef="product">2</biib:ContingentCommercializedRightsNumberOfProducts>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="i534cd99ae2f945f4b8b88984e7158822_D20191201-20191231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ2NzM_94ce2111-524d-4a5a-ad75-58e6df71e925"
      unitRef="number">0.450</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner
      contextRef="ib960c5c895e446e0acbf3a757df2ab49_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ3NDQ_28245301-1c32-4d1b-a361-2e394658089d"
      unitRef="usd">100000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib960c5c895e446e0acbf3a757df2ab49_D20200101-20200331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ3OTI_71c170c9-588d-4bc6-81f5-f0966fc72ae8"
      unitRef="usd">63000000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:PrepaidExpenseAndOtherAssets
      contextRef="i92a4535230f44352ba473e29091c1ed5_I20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTQ5MDc_5c131347-f2fb-447c-9ef8-ef1ad78fb8aa"
      unitRef="usd">37000000</us-gaap:PrepaidExpenseAndOtherAssets>
    <biib:AccruedMilestonePayments
      contextRef="iba57778587524c7389b5d85413395030_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTUwNDg_c510ba21-48d8-4470-91ad-1ceaf77d823a"
      unitRef="usd">15000000</biib:AccruedMilestonePayments>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTUzMTE_74507743-6abb-465e-a0d5-592a3fb7d8f9"
      unitRef="usd">180000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborationAgreementTerm
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTU1MTA_730626d1-f281-4cd6-9bac-d1c2d1fa887f">P5Y</biib:CollaborationAgreementTerm>
    <biib:ContractOptionExerciseFee
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTU1NjI_9ccd19ec-2ccc-456a-b8ff-a9089665c175"
      unitRef="usd">60000000</biib:ContractOptionExerciseFee>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYwMzI_332c330b-9609-427a-a94e-c5b7c653ed8e"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing
      contextRef="ie2a1da015b744d1bad39bd303d279f1e_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYzMDU_227f5020-3069-4a6d-8b69-9720263361e5"
      unitRef="usd">48700000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="ie8134924215b4f3491ae530dd0e9db0b_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYzMTI_76da47e0-3e3a-4516-ab57-5c089a587742"
      unitRef="usd">171400000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTYzNTg_332c330b-9609-427a-a94e-c5b7c653ed8e"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing
      contextRef="ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY0NDc_2e7886f4-e036-4a6f-992a-4b657fc11476"
      unitRef="usd">71800000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing
      contextRef="i48988f0124d6475db3021fcd0fb1eabb_D20210101-20210930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY0NTQ_07472e58-4690-492c-8e36-db0a763b7c99"
      unitRef="usd">210200000</biib:Collaborationprofitlosssharing>
    <us-gaap:DueFromRelatedParties
      contextRef="ifbc42c348d684b9cbcdd1bfb3d7628c9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY5ODg_ea4a5c52-ca65-446c-8c8f-e26b95a2e41e"
      unitRef="usd">1800000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueFromRelatedParties
      contextRef="i9c991d99f95e47928b97d145d5eb1271_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTY5OTU_b6756e10-dba6-4d32-9395-2f11ef6a7e3e"
      unitRef="usd">4100000</us-gaap:DueFromRelatedParties>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="ifbc42c348d684b9cbcdd1bfb3d7628c9_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTcxMTE_f69c2645-0828-464c-8c30-0abf5c88a7e2"
      unitRef="usd">53800000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:DueToRelatedPartiesCurrentAndNoncurrent
      contextRef="i9c991d99f95e47928b97d145d5eb1271_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl85Ny9mcmFnOjIwNzM4MWU0Y2M4MTRmNTg4ZGE4ZjY1OTc3ZDI2ZDhlL3RleHRyZWdpb246MjA3MzgxZTRjYzgxNGY1ODhkYThmNjU5NzdkMjZkOGVfMTcxMTg_3ad41ec9-d125-4496-8314-b30822157321"
      unitRef="usd">148700000</us-gaap:DueToRelatedPartiesCurrentAndNoncurrent>
    <us-gaap:VariableInterestEntityDisclosureTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzM3MjI_7fc998a6-c0b6-499c-ae0f-c5f0531c9cd0">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements include the financial results of variable interest entities in which we are the primary beneficiary. The following are our significant variable interest entities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Neurimmune SubOne AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration and license agreement with Neurimmune for the development and commercialization of antibodies for the potential treatment of Alzheimer's disease, including ADUHELM (as amended, the Neurimmune Agreement). We are responsible for the development, manufacturing and commercialization of all collaboration products. The Neurimmune Agreement is effective for the longer of the duration of certain patents relating to a licensed product or 12 years from the first commercial sale of a licensed product.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We consolidate the results of Neurimmune as we determined that we are the primary beneficiary of Neurimmune because we have the power through the collaboration to direct the activities that most significantly impact the entity&#x2019;s economic performance and we are required to fund 100.0% of the research and development costs incurred in support of the collaboration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 ADUHELM was granted accelerated approval by the FDA. Under the terms of the Neurimmune Agreement, we were required to pay Neurimmune a milestone payment of $100.0&#160;million related to the launch of ADUHELM in the U.S. During the second quarter of 2021 we made this $100.0&#160;million payment, which was recognized as a charge to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income. In addition, during the second quarter of 2021 we recognized net profit-sharing income of $45.0&#160;million to reflect Eisai's &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;45.0%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; share of the $100.0&#160;million milestone payment, which was recognized in collaboration profit (loss) sharing in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021 we recorded a net deferred tax asset in Switzerland of approximately $490.0&#160;million on Neurimmune's tax basis in ADUHELM, the realization of which is dependent on future sales of ADUHELM. During the fourth quarter of 2021, due to reduced future expected revenue associated with ADUHELM, we recorded a valuation allowance of approximately $390.0&#160;million related to this deferred tax asset. During the first quarter of 2022, upon issuance of the final NCD related to ADUHELM, we recorded an additional valuation allowance of approximately $85.0&#160;million to reduce the net value of this deferred tax asset to zero. These adjustments to our deferred tax assets and their valuation allowances are each recorded with an equal and offsetting amount assigned to net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income, resulting in a zero net impact to net income attributable to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Excluding the impact of the Neurimmune deferred tax asset, the assets and liabilities of Neurimmune are not significant to our condensed consolidated financial position or results of operations as it is a research and development organization. We have provided no financing to Neurimmune other than contractually required amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2022 and December 31, 2021, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $25.3 million and $24.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Neurimmune and other variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:CollaborationAgreementTerm
      contextRef="if7a682c52ea24aa381955c02cfe12e06_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzc0Mg_04065fa3-798d-4871-9adc-cb3fe79b8956">P12Y</biib:CollaborationAgreementTerm>
    <biib:ResearchAndDevelopmentCostsPercentage
      contextRef="if7a682c52ea24aa381955c02cfe12e06_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzEwODU_3c56855a-2d47-4518-80be-1844b6029653"
      unitRef="number">1.000</biib:ResearchAndDevelopmentCostsPercentage>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i476cf962e66248c3a8819cbb993cf272_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzEzMzg_f21d2bfd-7de5-4ff2-bff9-65275baec0bc"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i476cf962e66248c3a8819cbb993cf272_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE0MzM_f21d2bfd-7de5-4ff2-bff9-65275baec0bc"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="i1b8287024d7d445698e5003d95aef21d_D20211001-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE2OTQ_9cb5c657-0a9e-45a8-898f-082101186eec"
      unitRef="usd">45000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <biib:PercentageoffuturedevelopmentcostsrelatedtoEisai
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE3MTY_05d7c961-0c8a-4566-93f4-4aca444902ea"
      unitRef="number">0.450</biib:PercentageoffuturedevelopmentcostsrelatedtoEisai>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately
      contextRef="i476cf962e66248c3a8819cbb993cf272_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE3MzI_f21d2bfd-7de5-4ff2-bff9-65275baec0bc"
      unitRef="usd">100000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE4Njk_2818e4df-91bd-4daf-8322-5d5d7a14f603"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE4Njk_8cf5f050-5d42-4eff-9f2f-d405a5389dd1"
      unitRef="usd">490000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE4OTQ_7a30d501-5942-4bf9-a8f9-51eee8593f9b"
      unitRef="usd">390000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzE5MDE_bbf0a272-4e14-40b5-bd14-57bf5c11721a"
      unitRef="usd">85000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="id7caa4287cd44462b9d9cd33c1545d15_I20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzI5MDU_b973788f-af3d-4fc1-82a3-5925f3529a8c"
      unitRef="usd">25300000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities
      contextRef="i6cac6a36cb7544188ce0dee2256caca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDAvZnJhZzoyZTBmOGNlMmRjNmY0MjU2OTA1YWJjMzBiOTczMGZjMi90ZXh0cmVnaW9uOjJlMGY4Y2UyZGM2ZjQyNTY5MDVhYmMzMGI5NzMwZmMyXzI5MTI_7ed69936-b362-40cb-993b-440c433faa5f"
      unitRef="usd">24600000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDMvZnJhZzpiNTI5OWUwODAwNDY0NDYyYTU3NGFjOGE3Y2U3ZGYyYy90ZXh0cmVnaW9uOmI1Mjk5ZTA4MDA0NjQ0NjJhNTc0YWM4YTdjZTdkZjJjXzEyOTU0_44cbc55a-7e2f-485b-b6e8-277e032e235d">&lt;div style="margin-top:6pt;padding-left:4.5pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2021 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Loss Contingencies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ADUHELM Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are named as defendants in actions filed by shareholders in November 2020 (the November 2020 Securities Action) and February 2022 (the February 2022 Securities Action) and pending in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief. In September 2022, the court dismissed the November 2020 Securities Action, and the plaintiff has appealed to the U.S. Court of Appeals for the First Circuit. Our motion to dismiss the February 2022 Securities Action is pending. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Derivative Action&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;We and members of the Board of Directors are named as defendants in derivative actions filed by shareholders on February 9 and July 21, 2022, in the U.S. District Court for the District of Massachusetts. The actions allege violations of federal securities laws under 15 U.S.C. &#xa7;78n(a) and 17 C.F.R. &#xa7;240 14.a-9, breaches of fiduciary duties and waste of corporate assets, and seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#x2019; fees and costs payable to the plaintiffs. The court has stayed both cases. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2018 Fresenius Kabi Deutschland GmbH (Fresenius Kabi) commenced proceedings for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris and proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court, alleging that IMRALDI, the adalimumab biosimilar product of Samsung Bioepis that Biogen commercializes in Europe, infringes national counterparts of European Patent No. 3 148 510 (the EP '510 Patent). In June 2022 Fresenius Kabi amended both actions to assert claims under European Patent 3 145 488 (the EP &#x2018;488 Patent), which expires in May 2035. No hearing has been set in either action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020 Fresenius Kabi commenced preliminary injunction proceedings in Denmark's Maritime and Commercial High Court alleging that IMRALDI infringes the Danish counterpart of the EP '488 Patent and a corresponding Danish utility model, DK 2020 00038 Y3. In September 2021 the Court refused Fresenius Kabi's request for a preliminary injunction, finding that the patent and utility model are invalid and not infringed. Fresenius Kabi has appealed to the High Court of Eastern Denmark, and a hearing is scheduled for January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022 the Technical Boards of Appeal (TBA) of the European Patent Office (EPO) affirmed the revocation of the EP '510 Patent, which resolves all pending infringement claims under the EP '510 Patent. The EPO has scheduled a hearing on the validity of the EP '488 Patent for October 26, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019 Gedeon Richter Nyrt commenced proceedings for damages and injunctive relief against Biogen GmbH in the D&#xfc;sseldorf Regional Court, alleging infringement of the German counterpart of European Patent No. 3 212 667 (EP '667 Patent), which expires in October 2035. The case has been stayed pending proceedings in the EPO to invalidate the EP '667 Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021 the Opposition Division of the EPO revoked the EP '667 Patent. Gedeon Richter Nyrt have appealed that decision to the TBA of the EPO. No hearing has been set in that appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 Gedeon Richter Nyrt commenced proceedings against Biogen GmbH in the D&#xfc;sseldorf Regional Court alleging infringement of a German utility model corresponding to EP '667. The proceeding has been stayed pending the outcome of proceedings that Biogen has filed in the German Patent and Trademark Office to cancel the utility model. No hearing has been set in the cancellation proceedings.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An estimate of the possible loss or range of loss in the IMRALDI patent litigation described above cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Qui Tam Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In September 2022, without admitting any liability, we agreed to pay $900.0 million to settle previously disclosed litigation unsealed in July 2015 and filed by Michael Bawduniak on behalf of the U.S. and certain states in the U.S. District Court for the District of Massachusetts alleging violations of the federal False Claims Act and state law counterparts. In October 2022 the court dismissed the case with prejudice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Dispute with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November and December 2019 Shareholder Representative Services LLC, on behalf of the former shareholders of Convergence, sent us correspondence asserting claims of $200.0 million for alleged breach of the contract under which we acquired Convergence. We dispute the claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ERISA Class Action Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020 the U.S. District Court for the District of Massachusetts consolidated two cases filed against us in July and August 2020 by participants in the Biogen 401(k) Savings Plan, alleging breach of fiduciary duty under ERISA. Plaintiffs seek a declaration of the action as a class action and monetary and other relief. An estimate of the possible loss or range of loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Humana Inc. (Humana) filed suit against us in the U.S. District Court for the District of Massachusetts, alleging damages related to our providing MS patients with free medications and making charitable contributions to non-profit organizations that assist MS patients. Humana alleges violation of the federal RICO Act and state laws and seeks statutory treble damages, attorneys' fees and costs. We filed a motion to dismiss, which is pending. An estimate of the possible loss cannot be made at this time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. House of Representatives Committees on Oversight and Reform and Energy and Commerce and the Office of Inspector General of the U.S. Department of Health and Human Services have announced investigations relating to ADUHELM. The Company also received a civil investigative demand from the Federal Trade Commission (FTC) and a subpoena from the Securities and Exchange Commission seeking information relating to ADUHELM, including healthcare sites, ADUHELM&#x2019;s approval and ADUHELM&#x2019;s marketing. In July 2022 the FTC informed us that it had closed its investigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TECFIDERA Patent Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022 the U.S. Supreme Court denied our petition for writ of certiorari for review of the previously disclosed decision of the U.S. Court of Appeals for the Federal Circuit holding that the asserted claims of our U.S. Patent No. 8,399,514 (the '514 Patent) are invalid. Thereafter, we moved to dismiss our appeals from the judgments in the previously disclosed Delaware Actions, and we and Mylan Pharmaceuticals, Inc. (Mylan) agreed that the judgment in our favor in the previously reported &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;inter partes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; review filed by Mylan in 2018 should be vacated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;TYSABRI Patent Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc. and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#xa7;262, seeking a declaratory judgment of patent infringement, following our receipt of Sandoz inc.'s notice of intent to commercially market a biosimilar version of TYSABRI (natalizumab). No trial date has been set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017 Swiss Pharma International AG, affiliated with the Polpharma Group, filed an action in the Commercial Court of Rome to invalidate the Italian counterpart of the European Patent No. 1 485 127 (the EP '127 Patent), which covers administration of natalizumab to treat MS and expires in February 2023. A hearing has been set for November 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 Polpharma Biologics S.A. brought an action in the Polish Patent Office to revoke our Polish Patent No. 215263, which corresponds to the EP '127 Patent and expires in February 2023. The action was suspended by the Polish Patent Office in April 2021 pending examination of our amended patent claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2021 Polpharma Biologics S.A., Sandoz B.V. and Sandoz AG filed an action in the District Court of the Hague, Netherlands to invalidate the Dutch counterpart of our European Patent 2 676 967 (the EP '967 Patent), which expires in 2027 and covers methods of treatment using natalizumab (TYSABRI) and pre-treatment testing of patients. A hearing has not been scheduled.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021 the EPO revoked the EP &#x2018;967 Patent. A hearing on our appeal to the TBA of the EPO is set for December 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021 Polpharma Biologics S.A., Sandoz AG, Sandoz Limited and Sandoz GmbH filed an action in the English High Court to revoke the U.K. counterpart of the EP &#x2018;967 Patent and seeking a declaration that the patent would not be infringed by the marketing of Polpharma&#x2019;s proposed natalizumab biosimilar. A hearing has been set for February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Annulment Proceedings in the General Court of the European Union relating to TECFIDERA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical Works Polpharma SA (Polpharma) and Mylan Ireland Ltd. (Mylan Ireland) each filed actions in the General Court of the European Union (Polpharma in October 2018 and Mylan Ireland in November 2020) to annul the European Medicines Agency's (EMA) decision not to validate their applications to market generic versions of TECFIDERA on the grounds that TECFIDERA benefits from regulatory data protection. On May 5, 2021, the European General Court annulled the EMA's non-validation decision with respect to Polpharma. We have appealed the decision to the European Court of Justice and the appeal is pending. The case brought by Mylan Ireland has been stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings generally incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ia953e5a0fc224c8c9f234d2c963d4105_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xMDMvZnJhZzpiNTI5OWUwODAwNDY0NDYyYTU3NGFjOGE3Y2U3ZGYyYy90ZXh0cmVnaW9uOmI1Mjk5ZTA4MDA0NjQ0NjJhNTc0YWM4YTdjZTdkZjJjXzYyNDI_d4915250-960c-4891-84dc-137cb152a607"
      unitRef="usd">200000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="i1aab1ff5785845ea8ddcf294ef8c1eee_I20220930"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xODEvZnJhZzo1ZDExZjhkMzA1ZjA0MjEyYTFlODJkZTU4ZjUzNWJmNi90ZXh0cmVnaW9uOjVkMTFmOGQzMDVmMDQyMTJhMWU4MmRlNThmNTM1YmY2XzU0OTc1NTgxNjM5OA_87489fb2-69a4-4e3a-922d-19880424e2d7"
      unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xODEvZnJhZzo1ZDExZjhkMzA1ZjA0MjEyYTFlODJkZTU4ZjUzNWJmNi90ZXh0cmVnaW9uOjVkMTFmOGQzMDVmMDQyMTJhMWU4MmRlNThmNTM1YmY2XzE1MzQ_bff6ebc0-a9ad-4e94-82cd-b5ef9539b5d9"
      unitRef="usd">990300000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmYxYzVlZjE3NDkxZjRjMmNiYjk4YzhmNjdiMjAzZjM2L3NlYzpmMWM1ZWYxNzQ5MWY0YzJjYmI5OGM4ZjY3YjIwM2YzNl8xODEvZnJhZzo1ZDExZjhkMzA1ZjA0MjEyYTFlODJkZTU4ZjUzNWJmNi90ZXh0cmVnaW9uOjVkMTFmOGQzMDVmMDQyMTJhMWU4MmRlNThmNTM1YmY2XzU0OTc1NTgxNzcyOA_8e85be88-9892-47b1-b55d-469f0e449ea4"
      unitRef="usd">582600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>118
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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ML@4Y)N41/E9"- (DCSG KP+\;D#8$Q!4 <%K,X150/C:#%$54'3=*?M>"+>
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M]5T\_,DW$PJTOU043?<O>NAM(W^&TK91HMP,!@5E7O7_L\=-($8#\-0 LAE
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M+/NWJOV%$G7W8O)&*"7*[N.:,\AE;0"_WPK8?6PN]+O.[;OMY7]02P,$%
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MB64KA7[K\UJGE?FUF@W^5N]X+BXGL(.U:.[%9/W+3WB1_.HS^864'3F '1S
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M!.#SC5+M]QOS#PYOQ:W_!U!+ P04    " !E@5E5\>S+=PT5  !"-@$ &
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M*;.J]']9Q1./CY+#WF&6^6:6'B:S;FO,(++E +G8C-F8"DT=&7C@Y>-K" ]
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M#P'3C8P%3+L9(QEL^Q T0TH@83>+1.1MINF"IML%[$[_9:!).X*(/"% .MZ
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MO9=% GSS]T%+W>KI?$O_/^%MU\_SR*VH3;_3TMIS.EK::_< Q L<6>-@9;1
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ME1&R+HM#T:>(QXTOJ:$KGHG45YNIK!F(##F8E4!V=#"]NCGTCCE$) O6N5#
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M[1X*7K 5W\[D\6X9'._>+6^%9>)W2T.4YS>RA>]Q  RYI!3#!;<U+"G97)O
M?;^!<^'H !H-(?)6OC._ .Q#%B 2&/R0!O%>&L1)_SD:('-^&YB/:>0$&;$^
MYX:=NUCR2SAPQYEIZO%$TO]+ZX].__>=WP_QN7.N6XLL,^;.Y[!B<AD0^"PV
M.G+?7M^EC->:(FSTW"'9]?0IV),J)LG@(7&>1(@(UTYB62::XT&H^@X>RA9.
M$?+7</H(;N+@[.+\:"N[JD^A/X'(T+5ODC_C"U%9ZOIF-5W975M_(J@4TKM5
MY6C7!:>W=>_$D;,(MVL+9TOEZBMH.]M>X"?UO?5^>7W[OP(_A++0YARF_>CD
MJ$.FOE'7 Z>K<(N=:X<[<7@M@)X;OP#?<XTR- ,?H/U;,_X)4$L#!!0    (
M &6!654:,:WHH@D  +X:   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM
M;+59;7/;-A+^*QC5DY%G%%JD)+\DCF?LN&DUTZ8>VVE[<W,?(!*2<"$!!0 M
M*[_^G@5(BI(EQTVO'RR3 ':QK\\NP/.E-I_M7 C''HM<V7>=N7.+-T='-IV+
M@MM(+X3"S%2;@CN\FMF171C!,T]4Y$=)OW]\5'"I.A?G?NS&7)SKTN52B1O#
M;%D4W*RN1*Z7[SIQIQZXE;.YHX&CB_,%GXD[X3XM;@S>CAHNF2R$LE(K9L3T
M7><R?G,UI/5^P>]2+&WKF9$F$ZT_T\LX>]?IDT B%ZDC#AS_'L1[D>?$"&)\
MJ7AVFBV)L/U<<__@=8<N$V[%>YW_(3,W?]<Y[;!,3'F9NUN]_%E4^HR(7ZIS
MZW_9,JP=#3HL+:W3144,"0JIPG_^6-FA17#:WT.05 2)ESMLY*6\YHY?G!N]
M9(96@QL]>%4]-823BIQRYPQF)>C<Q5@YKF9RD@MV::UPEG&5L9^TSI8RS\^/
M'/:@E4=IQ>\J\$OV\#MCOVKEYI;]J#*1;=(?0;9&P*06\"IYEN&=6$1LT.^Q
MI)\DS_ ;- H//+_!'GZU:E[/I]I?2YOFVI9&L']?3JPS")O_[#)#V&6X>Q=*
MI3=VP5/QKH-<L<(\B,[%JQ_BX_[;9W08-CH,G^/^'4[[J_Q:(]R/])@"0N@I
MTB@MBS+G3F2,%]HX^953?O68+!9<&B2L8^F<FYD(8O'LOPAC&L8[S!K27WXE
M>LNF.@<NV#?8F+C#VTX4$V$:EU<3UR*MQF,_'K/N6"$A\AQ[VT/VHW6R\$+]
M(J>"O=?6L<N6J!\A_9[!8I$+>G,BG2N=Z]F*#5\GIVPEN+'L@)WTAO$HZN.I
M.^J-3LZBX2&>X][I8!0=5_.#* [S@]/3:$3S2:^?##$_5J\71J?"6D:!P$TZ
M]V;)Q ,0<>'--4:N3*623K!2.9FS5!>%,*GD>65=%O?/H@%[]<-I$B=OJ[=X
MD$0GZS'_=F]X!M@&I/M='+TRQ0MAV[L<#Z%/3>A?GH[<:\=S)K<#P2L\@I:#
M+8- X?YI=.;GCR'?Z1.#)$D,JLM6T(0D;.+&,B M<W.!/R.$GU6(558$3!&$
M*3MBI+<1B9ZL%8P^:+^4TH#VJ3J.U,3,P>@X&M4!Y5D<Q&=]Z%,-]<A]"^&+
M2+[JD8L6G%@ZC95Q#(MM$)\B)I)]Q%)Y+1=&0E^*LXH=IP5L(3">V>B[K;$4
M;,ZQ6._(R>_D&O\=&Z/04A6VNR "E <^O3:L-SAN#6U;SXB0OK#\U7A\!>.S
M+K+?B(6<"6@BR)0/^D&DA\"7H.Q".^R*A$)*".YJH=.Y-EIFPHA"\FVEVB(F
MI]%P4\0DZ?\%$1/63;731K@@H].Y?+&4?[X&8G\&.R)' DO+H"K-:LO7#GV)
M&]G?\2//K5X[D[.#X1 )75OEB>7:5GB0C]H9.2,1NV22_LGPFWH3 1RC,*Y$
M:7@^@Y.Z]S]]/(Q:N'V_QNV=8(XLHX*3KRIY*.>9+DW0U$IO!U(<30'B (VL
M5#-FJ)WS2^__=7=Y=3NF:K44U#@@(B"T(4.6RH=WHR:Q#9.$P5X2H']6IE6-
MQLO,\,*NK8PLU.5LSB:EA6U0)8 $$ZA,4B%9QS>WKWBQ>'O-;ELA5:]]WUK[
MHDK3;?@=8I%O34@#\L$4SF,//"^]N^5,A;WVLJKQ<\X= 4ZC$,R#P ZAM%,K
MSRG@DP/X.6S!<=9H^4RF\/A4<"LG,I=NQ; %B9C! $V(!L?!0BK-R\S':\M:
M$YYSE8K0<K1;D):S$'UHVA7:;&.$2E=,/")P%04N;33-X;:R=L0?%,X/=,RH
MW9[RA714H8/2C0'60E!XM[*"*U4BR  /W(/*;ZG3=4M#-EG.@0P/&, /;0#J
M((\EW5)IT+E8%]22*H.5' $)*RLOD(E2;LR*XC=XDI)HWN1O03'MS3XA;5*
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M1IUPO*Y?G%[X+Q03[9PN_.-<\$P86H#YJ49C4KW0!LTGJXO_ 5!+ P04
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M,>SNM@S'T12*.+"2FT9ROU<-6ME=M&@PHK,'&&6IRXMVO)8;Y^UI?52Q$G_
M,XL0WI*S<$[Z34@XFH6S!ZV19B5P1EE"39^26@,[ $/[Q-.:T86)*N@I%9]J
M:4"$R!.R!&PN=ZL,L 50XTR%,&U'S#7I,Q1(0H1,TXQ&4)Z/W;K<8_W+3 =B
MG0,4"<]E*GX!G@EPA-"XUI87P0S(!<*6K2.%*;-1EU;G62J)U456RC+)P(ZM
M<(/U'7X+[+Z$#SC4C1AUH[\2=:-@P@[HV]W^O6]%W6@P]9Q[=WP8=<DY8Q\P
M=\9?@[P];.F/3B)O% Q&TW LHFF$E:>3B0<W!W%B.O! L#>X)R(./7SH#5IX
M& =Q/$7(.F^8HCN#T00SM]MT'SR+!CMXMG/C7G@6#_SHV5[=W2V> 3$.K=1,
MVP.PGSD;BN&>2$)KYR9)#M7!C"F7PFC7?LD$BJ.V*>[P3I<2$9@872]7N&8F
MO5@#?S9(_[*$') 25O*D\&CN$_1P20O%:9],@4GB^<VO/.=B,'2>O3;:KA57
M650H$<(X;', JR@1Q.]"W[:PF!5(GAEYV]VJ"4H(Q@BTP*93/:/W#BP66V1I
M,0\C5*%$_(9\!<96@#&44,E'Y(;S_X W$B)1IL(\L=)Y2I/7,!J=]E8\I1%&
M5]@+,N&LO,5+A4NE73#RUR0"Q AM27]39;/QD2]&2, &;W&@Z[3,1DB!"4@)
MB"U3:=+@0"#\LAT5IWS?M$&6Y@I 6[LP"7M/*<DN25+F*16U)=T"!QHI6J/;
MIO2%3E4>LE-@URJ*(L>WA''D6UE3G]<9P<\7(S+7)?Q\:TLG>"($)J]@\BT'
M"S &(CN40_&VQZ\]SG"YE(4FM1BY5JAT$CC2ZS()Q</FV2/6]4N%-"#KS6NF
MN2>/Q IQ_821NXIN1S>.U^/6WS<]N[\1UJ4:3@B/SYZ<=TA*=NSS@$/8'8]@
M5N76)R@Q.2V?ZC%V=-5X9]73J=9Q>8-66))[#X,.)%S1-$#PR7,4W\:%+7K3
M)3/O5>XBSRI;6\&Y&*W\Q?P+_"1YG3JXI3<XG:(6%H+1Q3_8X:"'E2285JI$
MT@QP@*D2&4+DS#3IVL)O!]RGUC]603LSV,GP#C)BO0PN64&KRK:"'^P%?.V2
MO+.(CS8QV=I'$E GG3JDTHE*N3ED: ]<Z%N[I!,/;S-2[GQS,J:Z3 V$3\/?
M(9L(Q(WKD+)H?DJ;)+KF3$6\@PDDA-P7Q[+M/]%@G),,FY2:)?.R+O&3RMD2
M/$8XT8%=ZSO&6XXZ71D'9(00E;-WS[>"9C?);8E;VS6.$/)<>^IH3XAX\FVG
M+O6<MH)7SLIUC75KZT3L$VGV/V]DW"KH2!MLZP<]V^<,R'2U#><_CU&P>**^
MWNNVM8H]5C!Y]W_G]C*6?8[Z@9"E7Q\=\(#]DNJW3N@/K>9Z]O6>_.U^I'I9
M][W2Y[:F;W-AZL&2-5-50"GN@AJ3[4W!M=4H' \>\'_Q0$3AD"X_?%XWV6A6
MD**Q?3)995!DFPFFI%2]YB$4!)C6I:+T/1Z22^"ZWT8A>[UK-2P;#:<^,VWT
MD'E2.TR@LX"T+;T9*&B3^VE9XW]?U$X(X^@B#B?=<KU&IGTK$=5J1IWYU@3)
M1V@#=4Z-!C+5,FVZLI4&;-@Z 0+9-FSN0 [?AU:RHFW)'HCG]V&Z2^_);%*7
MI*/<F3WPD^PMYYMOC ^L=X0&U >E11W)1!KG!)K[OIF5A'G W+K:)L7#KU[7
ML^?KGO!O/7O&AD$S97.XQ'DC1\L$R773/Z%500#F!%J)B^TO,HT!WD; +663
M8/RB:M1.P'.:]6,Q_\F9P-(H%WL*^5'Y"4G7VG(V6*\;*]SQA'8/.B\0>,@)
MSF%\YLC&'3$\HH3[#M5&B\A_T$CDD=1KV$N]'G. IN4^K"!\[TAI9P/;B;]0
MY__$O#Y.\K8S@FU_O>HD"Y"'++.R;("ER2D)N:[",3<G)]Q==0B&ZWB&ZOZZ
MR5.@:<_['\9A]$@\C,;AA"[#\ J7T8QN^@NJ,MU9J@%)>-+5WOCH&<5!2PX(
M18S^S)X.-#EWQ!IM\#OG3I3F5D#Y<U/"YYM@?^O;G:^XWW&?_>>2T*A%TT/@
MVI>Z0+#&IG#G9#?7Y?*"FA8[_MS:V:'FXUSFDAR&#S^M<T%9;KS2K9EQF@&9
M)(8*5E07M,BVQ1;Z._L'7* Y-$NT:7*LATOP]P@R6^Z)>NHE-^BU-8[2/ZT:
M+[D#$>1WNE!AYS(5^Q;WR\EY"N<\ZH#S;&N^Y)@JODH3C.5(A9'=9C!(ZLP#
MWL"?H22XH[X3>3EQPSRCW(JN\NMI&+(@M,E-1T+MYPDG$')K,E[V  OW\@>O
M%.!Z(?NL46DN28'PL:61A?U&#4=_O8:1K]9-4=R0]^-RFT^<RB7^;S3<Y>>O
MO587"B=QO:U)O;S9U=*'WWKIE,/MH)4VE0,@1&4XH,_[MB;PVFO-IF'135O7
M*0]GO@JZJ+?5'6.Y(H_4T1X+!MLC+"HG+JY?Q@-:O>W[=.H)&C3M'Y$&6YI(
M'#C6TVX>Q;U>V+">(88(,?.JI\*NH]UV!;;*Z#"2.]0]S6U3@K;_XJ%^P _<
M1T)\QB]MDZL@/3@: .]WC,2&<=VRV1\-PTD\?@#:);6<J!1W1X?;Q:)Q^T4
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M@MC*T 0\7VC(WPQH@>Z#TV?_ U!+ P04    " !E@5E5&4U\9%D(  #F%P
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MU+L]CW\0-4+.:O# ZP6Z('OY /AJ(]-'SV9HGF4%7;G"FD7M[HT)X+(^SG$
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M>#5-XFKM7[RIP[5@;3PN&>&QQ!X@+$W ]XW!9M"]4(#^GKCX#U!+ P04
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M4-S3Y]@=S.[]5*VX<L^ABVK1\H<Q?%"XDTNO":^0#]O$QO$-<G3-,ZP2)S"
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MLAM18#NBX 6N";O;4-.CGPLD3$UO-#T2MFLU6:T9+7^;F3\'M7W;;6VI($>
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M.P'A(#Z*KKOP!X:MYJ!@Z2XJ3//-1(R(Z:9QL8GKL&C@C+M^S!AV?F<J"8<
M_C4M*"FHZ2>G]FW[@]U%^IUJLSS]VO<&9P@# A8TAR@.@H<]Y=,O:.DANDI^
MM9JY&%TIMTNT"O*\ -_G#CVC>> -VI\QS_\'4$L#!!0    ( &6!656%PGN@
M0 <  ',4   9    >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;.586V_;.!;^
M*X3',T@ 5Y;D>R8)D#2=W0*=;I!T9AX6^T!+M$V4(E62BI/Y]?L=2K*5UKF@
M^[ #S(LMD8>'Y_*=[U \W1K[V6V$\.R^4-J=]3;>ER?#H<LVHN N,J70F%D9
M6W"/5[L>NM(*GH=%A1JF<3P=%ESJWOEI&+NVYZ>F\DIJ<6V9JXJ"VX=+H<SV
MK)?TVH$;N=YX&AB>GY9\+6Z%_ZV\MG@;[K3DLA#:2:.9%:NSWD5R<CDF^2#P
MNQ1;UWEFY,G2F,_T\CX_Z\5DD% B\Z2!X^].O!5*D2*8\:71V=MM20N[SZWV
M7X+O\&7)G7AKU!\R]YNSWKS'<K'BE?(W9OM/T?@S(7V942[\LFTC&_=85CEO
MBF8Q+"BDKO_Y?1.'URQ(FP5IL+O>*%AYQ3T_/[5FRRQ)0QL]!%?#:A@G-27E
MUEO,2JSSY__R&V'96Z.=43+G7N3L%ZFYSB17[-9C !GP[$IX+M7IT&-+6CC,
M&O67M?KT"?4+]JO1?N/8.YV+_/'Z(4S=V9NV]EZFSRJ\%67$1O& I7&:/J-O
MM/-_%/2-GO+?KKF6?W*"R* 3AX 8G;-K*QP"4 ^8U:'@./;OBZ7S%@#[SZ$(
MU0:,#QM 17?B2IZ)LUY)>]D[T3O_Z8=D&O_\C'OCG7OCY[3_[^E]C?JC]SHS
MA3AF[^[!%4X,V$>PR5M3E$:'^"!NII:4C:1H);7P \:M:%A!_@D+N6,KHT 7
M[H2A]!B6LD\;*\0C,#%  >8OH9;PT I^A(G/R<%8U)%2R*<[#BBBGZ3S] ]0
M&4.V'5>"3!=?*ND?F-1>($$>#^R6%Z[2:W8IC2BE8T?),>NSGWZ8ITGZ\Z.G
MHV0PB2?1N#O_07JYKA'EA/>JS@%?P\/PU,JU_XLXCN+=V_N]'11+=I2.HL4Q
M_J(I?D<+VNMH'J7'>\DFVFRRB!9L.HU&+%DDT9PE\QF>C\AAQ$(9YX0CSZ6^
MP[* [9 A>!%#_IB-TW$T8<ETAM]9/(M2"CN(3V.+;,/U&N:LN]KJY4E"JT;1
MC,&\F,'@A 7HM-JCV3%+:&8"E6,\?#(> 'T&-!3:R32**:Z3.(5?&$C3)!K1
MR *;C4-6;L2*&H +V$"!O?'\GI&)M1:D%X6K':][1&8<N6Q%9M8Z8'%E31'6
MMF@PE65CQ/''U^#"F^[0![.6F2.YB])*%2 7!>#R/)=D 'R6NNZT@6_T-UN_
MO.F E4J@3S'JT>RC\8*E W8E76E<V 02L N*(9,9E ABFM/3GB-6.XYP.Y:+
M7@&4 =6NK4,.-;*VW_,E'.!+<R<HM@H:R8)<+#T*(*LLS"*H-+[MA\CI3%A/
M!;F4\"3;:*/,^@'6%B5XFU;=8?<*!)+Q4A)H5I7.'=L".2+LCE=AU8-$A#KF
M!LZ!VN_9,S0&;?0;$-9G47OWC9Z(7>$)FX8,"@HT^U)QB[S1%H%NMB) S1)+
M\1TZ44AV'1+>KRN_H2M*;.48/)!%G271V-(4AFNCFU-X.5,O\ R$@"&C[I <
MV":1J**[*"@++I@ E"KS,%(2T1HXD$PBT#)0WA@L"=J9JLB;K?0;8M%G"IBF
M >@G$+C''06BH;I5P_&:.+ZH.5X<X/C7%M8+ 3I42=#>H>_OK:1/&]&TN!#>
M@*!= W0A+H]Y]" K^PWWG7KJT$,'SANA<I;OH;C?MA3(9?[_Z;%T0/C*PP[I
MFD-U2;TT7E 7ZH<^E.(_F<S12OKH11-T@ _"P9N#JKEZ6O%1'$U"_T03:IOL
MT8(:":FJ]&[U]QD\J@V>AA:U,SBA3D<PT(_W"%MT57=2YT-^7L#]@$J4@*0>
M6B8&1U %V8#EAI/Y&BA?$W)67%IVQU6UZS%=F@S]98V2?6\T"OP:I5[@L%IY
MF7$%'.+HA\80)H\'$-5K7IA 2E<"52>)-0NJ+V^RS[0!+TMK[@.#P<)^DJ0X
M&S1@B0Y%Y-MH=T+R&B8X&!%TG^\.2.,9.=DZ_)*7B_F>QR-VD66V@JW->3EH
MJH_2[8SHS-0D2JPB74V'C^KXY*MRNP@BWX:AF;@263.>#.I:?.DX6A]NZU:T
M/\3>"#3>2KQI.T[S[>("2>?29:8*;18.<+(4+(C)^80.D',<V!)\("B%0X&M
MMVX]3J<QYD8H\!F[,0]<^;;C*IG190 R'QI?&L^C*<Z2)/BN*)5Y$"+T: CM
MO]^60HN5A"$C' DG;#2>M&=/-ILN4(/SE-34YTW^9/3[;#08!9+IXS0U&5'U
M4ES^#CW^+]Q'ZT1^,'K]!C$OH)(OI:KIMYY3NSG5F=O2X;"?#*@NDS;V(<P8
M'*7QGI+H0'NXG&J.^ZJ8*#NN%.&J23T,@M#N4-3"JSG-  >"/A& /$I ?X+/
ML]EC8Z;3\=Z4Q[JC0[<#P\Y%4"& ,+KNP@&-:K&^$]J-[F[4+NJ+I+UX?1WW
M*P!*K4B)%9;&T6S28[:^XJI?O"G#M=+2>&^*\+A!?H4E <RO#!+=O- &NWO&
M\_\"4$L#!!0    ( &6!654QUMH3)1H  %Q=   9    >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;-U<:7,;.9+]*PB->T:*H&CQT-6'(W1Y6MWR$9;=/;T;
M^P$L@B3&=; +59+I7S\O$T 5JEBD9+N]W;L1#E.B"D BD7CY,I&H[^^S_+U9
M*%6(#TF<FA]V%D6Q_/;I4Q,M5")-/UNJ%'^997DB"_R:SY^:9:[DE!LE\=/A
MP<'1TT3J=.?9]_S=Z_S9]UE9Q#I5KW-ARB21^>I<Q=G]#SN#'?_%&SU?%/3%
MTV??+^5<W:KBW?)UCM^>5KU,=:)2H[-4Y&KVP\[9X-OS,3W/#_RBU;T)?A8T
MDTF6O:=?KJ<_[!R00"I644$]2'S<J0L5Q]01Q/C=];E3#4D-PY]][\]Y[IC+
M1!IUD<6_ZFFQ^&'G9$=,U4R6<?$FN_]1N?D<4G]1%AO^7]R[9P]V1%2:(DM<
M8TB0Z-1^R@].#X]I,'0-ABRW'8BEO)2%?/9]GMV+G)Y&;_0#3Y5;0SB=TJ+<
M%CG^JM&N>(;9Q'*2Y9*4(V0Z%:^*A<K%&Q5+4IM9Z*7Y_FF!H:C!T\AU>VZ[
M'6[H]E2\R-)B8<15.E739ONG$+&2<^CE/!]N[?!6+?MB=- 3PX/A<$M_HVK>
M(^YOM*&_5_E<IOHCS[$G+C#1+-93:2T%6GB=*Z/2PGZ1S<1SG<HTTC(6M_A2
MP2P+(_[[;&**'(;U/UT:L@*,NP6@S?:M6<I(_;"SI+'R.[7S[.]_&QP=?+=E
M>N-J>N-MO7_^LF[O]DH;J:&M?D_<%-.^N%&13($2$Q$,"(7]JL1"TL B:GPO
MY[EBW<'*BX5H=[?+7^R)(A/_SG1:Q"MLL#L QY*G$&5)HG):!/U1B;@:>_?\
M[.5P?##8Z^$Q_"OTODQ6<::G_,LDFZYZW &P()VH2!DL84] (0*"Q>+\[.)*
M[-+>%KY=%"MYI].Y4.G'5:+VA$X7>J*++$>[^\Q)OLRS:1D5 H),R7B4$8!)
M[GB9%9@FV4L!K"QXSC"CL_CC0@'4\G\8,=5&T9B[]/P&3>[UQ74J8/PPN0G6
M;W@P.!7W=D6M#.@EPE;3::FF//(\SB88]O6"^AX)4Y13#<$P>#A]3$@HF4/#
M'2+U7=]LE49(PQU#)5/JIE:\6QR>'$F4JWD)^\KR%4!^DFA#T&V<1!B*%WV2
MX3\LY1+[#YU'V7ZXKJ1SN];[T&Z2%?0%*]3JNA=,?6&7:(:M&4.62--P^XE\
MSYV4Q2++=;'J8X8Q^C.%Z6'640Q]X.^TYV0>+7KA+'K"R)AFC#'@H]XK'EY]
M@ LT"D/G2I@%_H<I_5[RE":JN%<J%:6I!<.:A5K*H7)->JQ[E$M,YT[&O>9:
MWFN6U,T\-'%ZAD<F/<PTL =V%F?&H%LG"EO*"YH28R3UK#[ "(&_(BO)#R^7
M$+C>@CEA 1E-%@PTP]#0*/;N"NHQ]$?TX7[QQIW(M)P!]DK(TS2(O)S3TL/"
MTLC.C+]RB^=$7%D![9S)$F)5...MS88ZEN)<9W$VUY$1-SJB11!GF(6.+)SL
MGM^<,5I0T^>79Y6 ,HI@[#E/S^NZ(2E+\E,9.U%\>VJW]+*@<Y[!/ >**'()
MF@T*('K'=(.L6;*GB'*]9(DN:;;OL&_$<P59@0W2L@]"!Y+@)Z@.Y$<<L2<;
M]<7;S9M?R-ADI+L[38OH;81&A7KL@(^"RK/+=S]>W;P0NQ*K  $PTI[8]=^^
M6M9(\RHJ,H<SQVY ]8$Z,A" S*[9B,<B0X.":%= D PJ2:&=3<#OEXBE7D.0
M4.[*]U;B4SO_2U-39[Y_3./,,TQJVQY@R_X.-\062!::$7&&[[)[\ZUX[B;T
M=@$1&K0GP&UB+O[!EW"JVY[;Q3HD0 +"SCUKG_AO$/ST-BL8\>JI^2D W\J<
M5F*RXK&:J]":H)S>T3;UOJF)-@UG\40,#D[[(_H<G/3'^!P>C?NG]#DZZ@]H
MF\Y5"@=B,6I[9UUR@XH33V<3JJ#9XD?G+!G1X/>F]#N9C>=O^,74! V"0"-9
MHL3AN'\L#D_[0S$8#?N'/(\#I\AM-M%6Z":C&)ZBN\/^D3@Z@9X&]-,G*66[
M70;*04 #5C;O"?2MB+U0&SE%:*")BS+?^P(]#<90SK!_(D9CZ.H8/Y#9RNE4
MTS0QG$YM),A[T_:_02<] 6"7+#^(PTMR:(.3GG@4-14],E(G?"WRK&+A@?#6
MIUOM4 O>(A2RP6CW?^X_A!CB';23<TOHD"G; RW8:]]G93RUG(B)9#K/:,U"
M<ZVAJ^>!,O#UW#YP]GY0YU; I8C-$"N=.J<O#%P?G.@Y_I2F-)KW)H,>,\.>
M[QOXE(/33<K<T&.E==WCP_[!-VU09&+T &Y4;K4)&!4N^Q\Z]NJ>\[2 /%Z7
M:I80T3O63F_M! F]^H-,FK2[D-91S71NBL"?\ Z#,1C6K4'03KTPKY5E"K )
M)@1#HC^\Z]_V>:T3.:58YLG@X "[W&$S?6+O9IC94JY8+)CL2U7F.DDPWWX%
M^"D!?F(!7W4 /BF&QP%3S.:(2O%$J@JWZOL$'[2*;H="SB>TDI4<&-4AA%U^
M*,2N=(4[),1#PD. A88:K.U$6>YV5-,2G"'N$O7<$[5DGXHS'615)C57?6C+
MUM$C0I793'%J)^B/M<D1*,1056P@?&S0R31R2N 8RB+%TWLP+H(W+PBUF'1O
MN^&H%])WQ_9A+H5F3I1G*QF#-=J=C#YI:2W<AP"!.1(*%@MP.Z]7%\IYRD]"
M6,[?KU:Z6N-&%+,^.>M9/&UO>#@C8IUHQPN>C$:A;57AK +YG=KHH#G[(;6Z
MQ*2M.;LO>:-!JC5#'_8JT9=9[AD>AC"5VS)L@PP$'S0\C0*W?3(*K;<O7E%X
M42R\[,S)HH6&#J86G6DI)K2CS!*VJ">P IH+ J5J33T;6D-#"#\KE,.<YB(F
MV53%5KV0P-!R;C.&-,,NEIAFI)<4 .C*HO[^MY/AX/@[  +V2I90A#-1*VP@
MIPL[H*:EWLAGJ[AT&WG@;]N;W;2IX$,;[J_">;=X&I!1<)8C?(Q'X'I$58]@
M,D^8\)UTL+%M?7UU/CH@OC@<X[^C$:0['E5LU(OU*:STH>7;!=G= RL=$S<=
M$JL;G0Z@I,U*^2I\U.+NU_ G8G?4/]T3)R-,$ P<AC,8@+\V-=H<&NB13WEW
MKNH-8@1OS.%W:Y_6?:XKS/,L%]T20%H ")39N?\"'7XEG6R:"K.'"U%EV##F
MZ\#%W-BTTG5-@AK<!#_=J;1D]VBMA#'$*U/;A*'DQ ZF;-F:SY2ZMCUV@I]#
M&WY5-BMB*0I+Z*&,L-NNB)7OH7#_,S1J,Z%&.=9,)N"W8E^\]FO+=)$2(9P2
M93HP#2V#'!$INX.E1>&BK*?Z F+*@P>$\2M2-0_B!:,]S>H1C';89K22UQR:
M*B.?N2))LB4Q_W!=B.".^N.*@]" 3X:#<4!+>NS8+>V+5[U'4& :NZF?#I7V
M;%XZ=U3H\ #NI"'%Z0% TWW3EL%UM*0L(>=+76<6 BV!,LQ[?33=ROZ&L> O
MKUY>_:LGWOYV>W;^YIH?>GMU\?SZ\NK-&8WTDUR")]*:J[R0#,,%*3'(0E-4
M5.1Z4M*Q1*O#7M ;GW;=7/WSS?7E;]3C=3K5DK_-F)&>&2WW7\M(SW3D=I'I
M8;%\(OUB@:"\+RXMJR05V-#K=[ B8E%0OJ?X55S1(G?#XY!SHL$\Q^*("(LW
M9S@Q&;@L&2@3?YUB@_,I TFY+.&:)>_)!%30YP1(0F78CK'?5"2-Y7J)W945
M^W$8#2L7CP_7@@ C0*/UB1T?-><EYW#)<V*"=H9Z"EX:82TCRBO[^79)YT_4
MP@W5'&MP?!P,%O2Q84<TM=@MR2-!A5;E,]!T]@D*!PU.LM)Z3D)4R8R^QM1V
M:M-3'TX.1*4AB3 -:/ >A![:&JQM[N')88@Z&^(7?K8=[PQ:B%1+"X?/HOIU
M^&1!3P8UY%@YQT?]P\\4LRFEZ#^0W'L$M?R2)-\?F.-[=W'^V$-G>O11IR93
MN=0YQ/I(YR4 \'D6UP?,%Y?C@QOZ<F67\[F<]!XZ_#4K8!!"/1&7RQ*FGJ\*
M*K$I,N-.#RW@SDH^6&.Q:<)3=]S%43\_<4\'USR11*YH3RXSH]JIQP[Q27N-
MU0ZZOK8$Q%.X:<;!*PO!7&9*A^E!$R9YZ;J4WK"C9BJX(3+46-CC/LK.!'Z?
M=X0]X*--P^2\1PAORN;\R..5B,BL&VH(L&OV>G2.^&]B \S"Z*QL7[L$CQ\F
MS=)][I@ S$8!DJ-^J!./X%^$N 9]QK9RJ'F27$=@G%586ZJO?](,5?*BK1\J
M4[">38@5N&2(>WSM>+G+0M8/FJOCY8?R$&UHHR$W[<2_2CYA7<;NS,+@Q)Y^
M$?0^$8<#_AB?XF,](J0^_Y2<PBGBWA-$O<-#N(SA&%'^K9R34L&PEZHL= 2[
MO$XC)J$OX6)<2<GPH.,,U^4>6PM(&4AW$-^"51[J4;AZ?GU]/A@>BMV/92[3
M+$:0N/<0=";RWWA@JJA4RI!+@;,DQI5;"H@M25NX3*I'G+!VK+'8O3W[Y]7^
M:#A^<"0TKK].\"S/KGZ8UH5!.%5E;HL36$VIA55C<0G&K9:(^I<&&\<>,'&V
MLH6*K5H8WJ#6CGC7U>E+'1,ML[HD^)FQ-H*C;316:(S/]6PQ/[V>$@XCGU=E
M83CE/6N>?-@@LYE#??#,/HP..%!!N"'UO;1+<IN5F/3/X.2R9Y7K. E93VT2
M#AE7Q*"L<04+%B9E=1W$+0#PH@!(<DX"T"( F>D#6=1/J@IH+^%?!LA80X]!
MLO$!G]OCXX1SHP=\G#\8T7'^.I9QMW\*F T/Z"":I#LZ!*8='0. @ZE^2G:T
MJ9;A"3H^IGY/,>7A")UOF/=?Z$Q^*"BGS8LT&"!PN50@<+H![16RGY7S$O'W
M!EQ_-*"[(= (E*&)YOM-0+=/DOH2.E])0.JB,E9US:2QQ0]E!&/?S^F4,5=+
M8*YX#ZZ/D8=B]^;-FY^'%IQ?0]D:.DG#@L1'8ZA=PJW Z5Q;:*C5X1PAD9YI
M.G/'!*D"V&8@O@Q>Z6&7)_%(N_ZW37B[Z3#/0J-;ILW@V$@Y5;5-I&Z:RSR7
MB45ZRF/8^"FU^,U^MBXS\V9"Y:_PL14[=IT8&XU;<:K3K;> <T,'?>(7M= 1
M<7J@*069(4/FPC)7J=O19/?L[2][WPK\#V.FP&#:+/(%,Y9>#+OUL"-I@U5?
M8H.XVE(::GV$0D4+<CMS>.OG94[^O<[P<([9APXVMY6"*T/959Q\GX5Q%03=
M]X(6X0[EQ&\=)/B\B;.YR%**J;(H4CB:0_8/WF867##BEIM.M&V2V2CU?FU;
MTT#,0_SBM(K[W(E[6O4GTS0KT\A5/MHZF.!PMJHFOKG^YX]O?WSU[O:*"XM7
M/)(E6=C$ER]O!H=<AKT1"JA#:WP/\+!.%/BT$.0OZZR=TA\5>)RRNSZQ<<<)
M'V@.CSM]5F4:?\9QY@ .]1#QQVA$Q75'<-:W,IW+)-L0?CQ7DYR/S;_43?EA
MT&ISR''[=O_P8&!-3I;94L(X5"-([R@G^LXVLY9J5FD)I-!I5^/*5BO<J[J0
M[FB,MW92&NP&F5<%2P6E68OO6.)R27/@7&B )8THH]F,2>X$RS6E_<,^B[FL
M<DOMT$5R.?<^GTC84PA;=%R[3+*?&+K+Y9QFXS1:S87R2[D&QF*U@*$19>CF
M-E%2*/)R%7AB!6*,1<MX1V<($"S;#[+W=SHO6>HDF])% 8NM,#L?LL&@WJL5
MTR@B]7=9?&=MMDL-9ALKX*HM'SPX"VE'#93/KL"G494CTY4_LC3>K-"TW#!<
M(_Z@BCNJ.=)SS2&-*2?[%).$A.+_#9)YW3X&R@X9PXZ 79Q(&?N/+O9M>_U3
MH&P$%!L0SSZ I)3AN89OO"#)X 3S1(H;5RT5W" 8? F";>I_U__!TN*,+ *@
MB3!$3S@1S9>76H[V' \$.%2L\LS06CNF7?OA!]SO"TH*A".2R7%8Q=F=B2*D
ML'>+>"6D2$KL*D0&95KDE+2-9:0F%"K@=Z@"CUD2,<1 +I%"_2]IO^SG"G/F
M (L&]MN:B%F>F/IPO+W%F9_59-55\-&I0E/TU)U+JGAJ)Q=4^;&W<*>H$LJS
MU9L5R,!^JM2(I>F[-?#_F.&_GS,*_5[(2);VH)9S'7M<4(D5J98W5S2&@;S"
M"UQ+\5C1,Q@I0^U#8N/K3Q*7O3(6*W779=DT6>MQQD7$O @P@H+8L[O5HL-H
M<U"7RJ;P9@@'TJ(JC:5#_<&P4;:Z0 #8J#;EG__P#<UGI^0+[&T:_%"MB'6Y
MK7/4D\$P.%_3H8\(!0I*AFP*TC\4E!Q7U3Z.O'< N:M:K)9R0QEG>SA7> .X
M1]=Q5UV!]W[59+^^^^.$6U9GX9H>SQ\ !@M\27<7P1=6XBR'5<W=TKWE$AL9
M?D6S<6> +=0B'',G9AUE5E5<;V^%L:Z]/7J5U^<\#=[86&U_C$O2 NM<.2R=
MZ3%OBNT%.3_)+RR8X<WPI%'PP@>_?.RPH?KDZ^R=D(78K'=SD&K]_'/AHK6J
M:8[;Y]@GE,WZLF*:6X2V); )%$(M89;U5>*?^'K9+Y"#+*.NA&R&'H-AA^.V
M-]/N7-.U<*,:\<9>3*3[.Y-8FX6M+*?>-)U:MF3K!1%*KW&#LDXPBHD&UD(E
M,J_VGTWI01%Q%;>WKDS*F)T3+>T8T>(W='9 22_-TS)\6-I6%&19F\D&O]N$
M?&^DMJBM78("BYW4P!E)LZ"37N]!^-+3!Y_JKPKEVWV,UOJP<<Y4S12G=7D3
M<AK*;W/"K&TH/J5RP"(H3I)I2H&*D:[\I=5Z/#KN;NWR2F%S3TXVNTDNAJ?S
M*?]L6Y\$S^R=$#[-M2L7\?IQ3JIQ<D^E:34XE,L' *[+C5 F$E:&[1^M7)J1
M;I'/5>VT:P-()5NJ-9RZ$I3*%ZJM:B&1O3I^)XKH$(3SEIB4OV&"7ER>/%XY
M"TZJ]NC-/L5]\$F8S%,NKV0L\.$067V[PI!O.8?5E/:>#T_#E1E2UBW$-+[T
M=0>5^*J"]D8IJRWA=E6BBH6%?ADQV>5%![K[>C?B8S!3NB]]OU!I6Q#NBB&"
M-$0SEW<2.SY0D"5%/LR1IM[03.8R>A\!I9Y]%9>!L[45M=2__/!9).G=DC><
MUT7OP3GG]$?:CC:D=UD(MYT0ET84WT_U#)O6WI7P!0R\"Z7.Q9V,RPJZ@F60
M]A8$]GZ>KVBHUH,UK-%3O$(Q/T<JD,:H6M->/7U'*L 'M&E(Q556-IQ!R)D7
MUI+N[*)#2'\_ ]';C 8K ,3%H@+A($?*0*Q#L&:WW"KKLLF7@J/GMC1=%U^.
M&K61K>+%JH:O%]"T.A_3$]>OW_Q=)LOO+ATI< A*1C*1,5WF,U:@=<5T#6.U
M5>DI-+I>0VFFX F0<:A9&8N87X" )XG",%?J5<N\=>BN:7'+>F8$7M9_JFE-
M6[O6]7/D/?34[A-N\ZW5/MMJ=WM]+VV;.X5&P[H8L>?W/@-+"&DM;/I'4#OM
M3J4:*, V1G]\,@@J0S'OV<P0UUAYQ529_O65"/H8U\619#*4@>(:1R^N:0KK
M(6]9PW;-5=HHZ]XPXMNT2MN[T956A-)?ONIX4]_W5.L%O.2<9>V[YAR+UZ7U
M[2+C-65W.Q-&NU"-@>VNJ?,S2^D[+X=N-:=!?]#DV@,Z,MC M?\P<Q/>5DYJ
M8F^''YUNCEP^SQSI#E.S>G<(XM@YA+^+V%$-N\W+;&,%+ <6XG@P"NAJ4-D"
M%D/O)WER>'I:ZV(O8$!1#(-S2?NUVS+UX&%=J/-LVYV[0W7!;P0S&Y,Z&S;+
M(S5B"0IPUMKY1Y5GCRDE#B.5AV.4CLIBX.JE-DL0;5=D:6&%:_\[M=%52]RW
M+U&Z;)4 7:R=LC>"QLIX_!N8ZB!,-E)B7>#ASF6B,G<Q6U?*LGEBQ>%-E>3(
ME@L0ZSBQ[J\C2NR)\]]>O?KE^K_$+F31$UO3N9^6J>3CV.#+L'FN[-:BQ;YY
M=W'U\NWUK77,M^>#0VKHBHLQRUFL)Y3/61:;>KCZ[>;JC&-W6Z[G+HO46<[P
MS*PN,[N0J9S*GK@J,1:>L7=;2(BSDLIG8BW7(_U-%WS;E5VVI,Z^^H@K12J"
M )53*6W!DU3[=>&'O9H!X><Z78\L^1;%AGW5$2IOS8<V;N0W0W*>I*YO%],Q
M*6&E0Y G1Z.@Z?]"%I6:L.E;/#_>,CKVM$QM&&LAZS&W_9JXY4=K7"NR!ZG-
M:T6<<T90DI><,@NILNYXR<':O>?PY5!^!S7>_D _7?7?]2NV^B[EPYF?(=4T
M2\3NN_[/_;V>RV83YXSD4A>\B:LCV#] (^M9[+5(M2N9/3@Y:*HD0.A&JCEX
M=5N57W8O'PES!O[ZI8Q<\-=X$Y5]WUB50/)8CY4<B4C468CFVZ#.KUY>O3Z[
MN4:T\N+-V<VEO>[V_.;Z7V?GU\P+&F+7+R=KE/D'&ZN6R;^[2LR4O5=X=! R
M8?:MKE*^.1,WO\< -?N?"E7\L4O?SKKV*H$[^;4ZQ5R_2TMVN%4?:Y=M=?I'
MW:[U%U;_A(NU=COJ/"!N@EX^*;#9DCJ1LN'F[:_NLH2@M-@W/AYW=]4<Q6^G
M?:(N<^QRW@%I^[]TW;;C!3+A!=OQ23L=/S@>U!'>E@NV:V&!5;H?Q%^O6;MO
M6\4,X:F ?$A."-4F^GPP_V7G!O:8YE;E=YK"BEM-A]<R55EI:HX<\-<.HNQ+
M)EN'!YREL%4J@=\U?B19WYN3K?>QU%9H2Q@WUCLU!.G3VPAY5S8]FU'UH+KU
MN@&_C[E@,U@D=U//'_2$K^-:CU'\4[:KS['S31<ZVX[MDZ]VMBUF'$;#7W!?
MLO-6YV=**RIQ#T=M>0?-S?E%$C_\]K;6>71XZKHQEN&+^VP 1@-O9C#XM+W?
MFT>!7W!+M.MUR$^#-UX#QN?\7F\ZEL;RV)=?5]\*_^KP,_O&[/IQ^][Q%TST
MC8C5#$T/^L>'.];9^U^*;,GOST;X4&0)_[C -%1.#^#OLPSS<;_0 -4+U9_]
M!U!+ P04    " !E@5E5W@HM)2T(  "4%P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970R-"YX;6S%6&USVS82_BL8->VU,ZHDRW;JI+9G_)*VN;N\3'QI/]S<
M!XB$1%Q(@ % R\JOOV<7!$W)DNQ,/MQ,)A9)8%^>W7UV@=.E=9]\H500=U5I
M_-F@"*%^.1[[K%"5]"-;*X,O<^LJ&?#H%F-?.R5SWE25X^ED\GQ<26T&YZ?\
M[KT[/[5-*+51[YWP355)M[I4I5V>#0X&Z<4'O2@"O1B?G]9RH6Y4^%B_=W@:
M=U)R72GCM37"J?G9X.+@Y>41K><%?VJU]+W?@CR96?N)'E[G9X,)&:1*E062
M(/'G5EVILB1!,.-S*W/0J:2-_=])^F_L.WR92:^N;/F7SD-Q-C@9B%S-95.&
M#W;YAVK].29YF2T]_R^6<>WQX4!DC0^V:C?#@DJ;^%?>M3CT-IQ,=FR8MANF
M;'=4Q%9>RR#/3YU="D>K(8U^L*N\&\9I0T&Y"0Y?-?:%\]?F5OD E(,7VH@_
MI=-R5BKQV@3E\$6\,D$'K?SI.$ =;1IGK>C+*'JZ0_0+\<::4'B(R%6^OG\,
M,SM;I\G6R^E>@3>J'HG#R5!,)]/I'GF'G>^'+._P6WT7_[Z8^>"00?_9!D/4
M<K1="U752U_+3)T-4#9>N5LU./_ANX/GDU_W^'#4^7"T3_JWQ6^_Z"MKO"UU
M+H/*]X'SKG$BLXBQ\5B8]7?-M9$FT[(4/N!%,C,KFUR)4*C> LA$(7EAY^(V
MZ=))ETJZX.*RT%DAEDI(%V743A.?B)DR:JXAS*U&XE\DW);@'&T6O-3"3*\7
M1F.--&&/EI%XJQH(K1JCQ$TS>X<_%[^+OY0HY"WTPL>RE#/K9"06DXM29^2^
MD NGV$V4<2CZ<L"?;&VN;L&$-:^AG9FM*N4( OTER@,"L$_/;$X>IWVU#60?
MD H@7XXXK;PHOQ0*+.G^YD6NO0)!#5N$R?&+ZX]_O/KG&_&C]$)B#PIQR.)Z
MEETDFW\:D8^$%>"H$4=-\&PQ? @&,LT<]0 A!.]./\IR ZS:V;S)T$<X0MNL
M$-H+-9\KINM.>VG-0CF2R;8TKM.1*1?0?$0M Z>74R6^P:I@$:HV,'E2+"#O
M8"I62CI@ZVS5IJ%#_.]=$%["<W+@@0#&J)?DO+^7O#V7@/F2<$-Z@;DA(A0R
M/)*Y&R)F*I,-\FK9YE[,A*4B4)QM%@6_68<8?N?: 3_^QFTO%@^KKRP\[=5!
MN1*Z CW%U5P"JQ^^.YD>_/(KX@!';:4S42O' X#)%$=[F?+D<P-5.>F<-WA_
M,)F,)M^G,!'=28=JI2W]Q,]@!!-!XV@WHN>;NK8NI)UK'HU .N+O! >(_Z#+
MZ27P73BX  DRR]#H'9..K!&J6P1QMF)9OUU?C,1'I'[,)(J&3WJV)>"0O /$
MZ^[5<K466S3C$J1A\1N?4CD^8P#H6QFGEI)-PGY.8MD8H$%EV_H S^G#Q]'-
M2%S'8J)G3\#GXG,C78A9SY[#KDHR<Z)&-E2U1@P3/TJJA,PBSE\($T^T54BW
M4&2,P;0']&VEQ(^E]?XG(4-P>M8$9D1:8?'9!(<XD%&)(_V0]Q)Z\HZLM[O)
MOT?Y6!_5<2AEGFN*ZY#J^'&7>VZ0;@1WKL//'LY$R]@-PO[HN(<'?,!\1\.?
M>*6]U.!'^OZ]H(TJQ7\#Q <QW0$G''] :S J@7EOV]?C\Z0L(%-<3G%E2#"%
M*BXD"HKTGJ,K;M""OBA74O$1E5%9W(%P@D+-/SMZT7<<_^Z3&U"1( R[FCMN
MFZS#MJ;7&#["@W6YJJF]4!D8< $Z@V(6];UT7_-N#FC0(C>\HYQ0,7A@6QHA
MHBAU5R.4>':@$=,0N7H+QJ17W&H[(]?A 0\T;9NF88 )["$8AR]V5BV[M@GO
MNB/</-;]F Y%@PX*8'R3=*9YIQ1OKZ[[2K:;?E\GV/$T-TX>% !AR(HI34A(
M:\E6KV@+$L9R;Z9A)O]ODV9+?*)4?KC),[E#A7;;K/3<)Y1$DG2N<;S@']@5
MKL7TG$,4=VU9V89&(T\]*N+S?V.K8=O8VUJ6C$XTIVV9:\9M6G6I[4(9,%XV
M$J_NTDA&T6BW/VQ"#_&-5=>#NL34JLO8T3?F#2!M[%IW3W%[=#ZOK=>QIEU_
MFL'A/S*<IQ:B>3B3N_NZ=0MI6G88=0,SM6--@3<V:8SC6<]V"R^I/TMB5L-G
M+20'DKKKP3$Q,#CB--XO#6WBU41+8]';M?G<84A8M+'EW..&,!1U2>,R,5HN
MWF*\%@<G0W%UO_<VSCKOV+0//%8"B$+7R*O8T;WZFI,/32'9$P]5"3O75QNM
MIX.+;?R^8U(:-'/+"=$?5^-06LKL4W^8W#LR[IX6TWCH&\Q?/DU57O6.4I%*
MUMU()T"]?GA-D_Q,(QA986QI%RN:RFLDE8K9WZ7>1HS3\ :-%VS'C:H!^PS.
MI1L#WG^MLO;MP;!M.#QO(DE6E)4=1U(>?:5]3O$!WS!?W)_7FO6@[PN;#>B8
MN7@V/1X==D1.9C^;'HV>IS=,2W4\()4XZ](!O))H TU%?=)Z:I@(*7'EQ@B*
M4.P[77NP2Z5[$^NCN-Q7N2R])5$J3O3<?AZ)5<SG!.L>PY8%C>.[#AU)P-K1
MNLOAE(+;O[+$-A]YKMO);32!T!'_Z]L(U1S 7"5=?.AY CT^&J\>:2+S;ID5
MOIT]-[*^WV"H5;/.W49MH]470_'D>ZIAKV4][2(I3R'AZ9CN:G$,_?D?HVVW
M:^/>32G.^@N^#R;0 $Z\-.W>=E?.%_&F]7YYO*]^@\.41E\LU1Q;)Z-?C@?"
MQ3O@^!!LS?>N,QN"K?AG 4R4HP7X/K< IWT@!=U%_/G_ %!+ P04    " !E
M@5E590:SK^X1  "\,@  &0   'AL+W=O<FMS:&5E=',O<VAE970R-2YX;6S-
M6VES&S<2_2LH92N2JFB*I.[XJ*(N6XEE:25G4UM;^P&< 4G$<S ##&GEU^_K
M!C"#H2CE_+!?;'(X !K=KU\?@-ZLRNJ+F2MEQ=<\*\S;K;FUB^_V]DPR5[DT
M_7*A"OPR+:M<6GRM9GMF42F9\J \VQL-!D=[N=3%UKLW_.RN>O>FK&VF"W57
M"5/GN:P>SU16KMYN#;?"@WL]FUMZL/?NS4+.U(.R/R[N*GS;:V9)=:X*H\M"
M5&KZ=FL\_.[L@-[G%_ZEU<I$GP7M9%*67^C+=?IV:T "J4PEEF:0^&^ISE66
MT400XQ<_YU:S) V,/X?9KWCOV,M$&G5>9C_IU,[?;IULB51-99W9^W+U0?G]
M'-)\29D9_E>LW+M'1ULBJ8TM<S\8$N2Z</_+KUX/T8"3P3,#1G[ B.5V"[&4
M%]+*=V^J<B4J>ANST0?>*H^&<+H@HSS8"K]JC+/O/FJK9Y(4]&;/8CYZNI?X
ML6=N[.B9L:?BIBSLW(C+(E5I=_P>Y&B$&05ASD8O3OB@%GVQ/^B)T6 T>F&^
M_69S^SS?_G.;*XT1YY!1%S-5)(\]<5TX'#,@)@"I:!4@;J2UJC+B/^.)L17P
M\M]-.G%+'FQ>DGSH.[.0B7J[!2<QJEJJK7???C,\&KQ^84,'S88.7IK]-ZSU
M\MB?E)"5 J:J2A4V>Q2Z6);94J7X():RTF5M1)))G1LABU1D:B8SL:C*1*D4
M"C0]O)AD-7T6=JZ 0J>N5)FDTA-,-"$?[PNX"UZ-%&V$+4595_#!I*S9'&)1
M9CK1RL"S,\E/\,[O7;XV2I13H8S56$.Y$4EC:$S;$XM,P5L%,97X5%HEACWQ
MX*B'QC[H6:&G.I&%%>-6K#LO5B^(C%D-GJ58)A5374A,#\&,Q0.0DS5>+*='
M&@'P#DD'N1@.7OW0%S]I.X<89@$BHEE-F2N1$337))9%LR.2D'2\P&MZDOGW
MH==*XGWZU4T@BZ*TT#N,D2I!>\CPL0"=DFQB#M5/ZPHS=2P2J;(G\%2HKS*'
MOGIB1^^*U5PG<V\*O#F%7/"<E<ZPZ[I:@D1%J@TDTT2H(B_9R MR&)VHUY@#
MD\3VQYXA83FQB!%0DYU793V;TR1)N535(P]9&^,PPRJ0E85ZMD4J<^RK@U%3
M+Q9EQ8932YU"D;S^<C<>^>TW)Z/A\6N/*/Q05GCZFB?8Z;ZZ+8RR-G/*<SN$
M^?OB,UYY"9MD>J>VE?.RQK=D9LJ $)',99:I@C;A-P<-+*#VI03"M'TD"RO2
M0J+D1&?\Q ,!H""PQ=Y"8(,0:9U8PKM>*/)YFH-%,R8XQE]?=JXRN#<>$Y2<
M0HQJ]^54@]_M7%=IT":^24L:@6$KPCE-J:LP:5^,8><4""!OKFU"?@%% FY^
M>3R/E0PGA13P)$1<=C:WV;RL&G^9EADHB/1#&Y]+X%,24:F*G%;G8&:+<:RZ
M26V@+N=6'2]W*QB:$VJJ&)!.DZW_!W!\QR[CO'/J=T9"6Y=U--X0]$HDQUY?
M*_H,JP#3M)E$5>0?+DW1MD4HN\9"/C(FL8:)B,N[1$]4Y:/,K.,]5;B/-'P/
M>P.A(8F";E0 0&2COE@+DC1P?/'CA\N/-^)!(5JP+'&8I$!"J/("^X#B] /_
M!=644\A'H8%<H9 Y^0'%B:DJ4NDHD_=):IWJ3#&TS!QOS\LLI8%XX1.X(9\H
MYM.!V"'K=A]%THUYLEV6X4I-JII(GI((-Z[[Z)EQT!O'%BQ-8W[L/_3%A48B
MH &9<P#&,E72;\UCF.-&&B.3>4W$X9DB;(V\#L9=ZC+S&,+[4X4-4@!II<CD
MRH"[\5P,#WGA<T$IP_'KXY.?=R9.O/# [DCW8'@LSOM7_?N^_VET,.@/!Y-7
MAXX9E?H"C<,SJW9M&PO'1 K3-P\P*H=+65(4:$:K:1_Y$M2UL(W61SV>)&%U
M@,!S#99)Q>\P3H\78$X!6P!MTRF')[E8*$D0\-3$>G?JAL1C_M4TFK_2E8$U
M=)74VO;%;5V%^(/A7A[Q.TPNM D&9QKZ:W$7+ >GPL(H5P :D,U2<FSTBWF/
MR5D_C27.2@D_Q)<+78$MRI?])6UG?=EUL%ZS^5->]_L:V=YHV/,&_+\ >+\!
M=/$"H,7PH"]?G?;$!&D<ZE&W@$;$T[2]M X\)U;2..LE9864@$P)N94UO:?N
M4&(H/=3%SW7!5:''>V_= 8AW)<$ Z#K3)?C138?,MZP*]=CD%LRM+@DUL%<T
MK(/XD$JPL@G]2",?R8:(JP"54>9O1^/US?WXX\6UN'.A*>+Q-=\>GH@KJE@*
MC3K@!\0K +FV)IEGM*_W^>2#V.F^L(N-Y#DE76DG3A.*0K*V4<]"SJ 0.++3
M*=9%5%7B8?P0P/D9!46-. :;B??X%?]=8P"_AL]W*%?<W/&Z:[.RR'Z^BV^_
M&1V.7@,165I64W&O9E !YF?<]QR276$#]7F=.:Z3*;*DO,[E1$PTHGZN :*0
M=W$E(7-38RB650OMLQXO RNHHHQ!_ZK8CR_KBG.OD!,9.+QULG 1HBJ*S QT
M]RJJ F^[3R6J8[C$B3@<^HAX>2>VZ8M[8Y<)^_L:>1'3WIH]02Q4J#NT!1\&
M1,E1@$>?Q3D_75^;UCT4!R<GS;H,_:/7],BOWO,YL/JZ */Q;F\D,?#^81_"
M(XF4M&4&_D1!._!/>DEI+E"<1)TM#-:W$ ,.4,J16%6/#<"X#.DDY1>J0,'W
M9=M $B*CW#'Q>6,6\4&C%''LMQ$$D:$82++09AZ;*C@IF:)5AJ,)8B.J_$J7
M6OC!8"W.!?,R55E/7/S@MCH8#/9/Q+_WGT;=(2_@A*S4M*:0VU7,-E4&O]0@
M#O8^^8QZ>I3!ILT6VPR?Q>W(%<H8*A'X5Z*8H(NTOVZ83:$\4BVAF1BZ:DSB
MB;0!!1R'.HYI31/0'KZ710C@^VNX9H90R;Q %IRY.&K:;$'L?#X;[S9F60/R
M+>>F8N?R[A9A!U^JW"<PE5J6B:/&R*2M=P5X8^-4VW'XB[)&IQG.TCN>]'0B
M%P0@@ L!S:Y;992.M=KZ;"/$2$NW2!P8)4<NO'M-4< ?#$_%>P1C3'8/N:%\
M\>F1_/SO(>T_1:\=-?E=O5<H^HMUE]I,?J/A2!P='9/YQ#9]>)YZ&LTP_7#8
MI7Y02SXN] 8#KA&']1:R97 "BL?!".W*L;Z]G]XN0G&(/&JI30=0MPRS+QYR
MZW-M,I<K8AO7(K]%(N.F]8X&O$<KO,BU/-[-QJ)WL_;?#Y<_#8;GL2 #$KH\
MU*50[-@KS=FTE>E9RY),H;U -7JTBSA4<Z^,,VJ_#R]-Q.>?*^171%Z!1:B:
MIYR$VTI=N7_#"LH/=(ES+-2?R0#]E"%D>4[/VERO[='*"2S^<LKXSUJ+SS)_
M(5>D,F*%J$T-=)GFVEK7<GG$FK[3T>-6V*Q2+AX@(Q;_.!T,^@.!!"KSX'7=
M-@I62VH_PXNH*8@M85 D?5T8AW[=<MNA;\CX$N@&D)6PPYE<I76AY1?BT(F:
MRVP:=,@%3]RYX!ZN^4OU4(OF;A'$O2A?"%VA@$7T=C$!%:$K2&AM*HPZ61^[
M9$M</M1MJK:9R\@$I+R?ZQ1H9.D7M?7/KUPOYKPLEJJBS@X2[+A.C)V?)+I0
M25,*G,:OPH'Y**.PKOQ\4-42RQGQ\>-Y[ZF:?0^H6Y-.8SEZ@B83=-S0^#;+
MYQ)1TJ:/H!CWCU$'-)S=<-F9^J(PK$MM->I!^[#;MF.37VK$A#26H$\E>>JU
M99OF;E]<WE\_C,E6IND4O. %@[\ G$['T:Y*5_YY0 =VK4T#>3+1N)[5>,HK
M _/<PDOT(K0(N*G@R.Q@,-SYLHO29,D\=X<:+HK"K>(ZM?1CR/U)"7T:Y*M6
M5S[+N)_4;2=1NT)V^DG==A)]X=9QTUCZFZO<#S6=>A!7:X+6&#/Y:O$%\PW#
ML.LBZ8L=]V77F\#4VJ[9X4\;.U)]2+&XC^^HT;?QEYJCU<T#T;?FKCO[\104
M*I"CZB1J1.?R"[O)G*H:;C4P_%$T-U5=41:O,.T4VRBK&2J/7_UXEP*PAN+5
M&B4Z]S(MHZT3VOWU^>U3(C--HX7;&K;F/HNM%$G7-*J;SLGV6L^$7=*C_VE/
M+^1W?ZAM]R)B;AF.X<CW/1U$%9R)7(,E3,",X22#C?ZA]*>.73HT7$PB M)N
M(/,MG6?050#>VKTB.N2/EP7(YS$N/U73$O7I!":_+OB<$(AZKPK6=AR]+A3Y
M?$B8/B H4B6/2=AT+3.[G!&[KSEQT]TMQ6=(OM7ODBG(M: @SH=6%>*!YB,L
MD2"-S>)9Z @0B1 %X*K,?</5@8-S)*<3PSGJSM7G\UU?[)EZLB@5,-8,BSJS
MK*2O@#1Y?30!0<KGB\WQX(8MQ.?#<]9,0B4L,G'"G7_)]^NX5H7+05[FU;4?
M*<53ED$69?<N&&,W7A*HIO;>I"E-!Y!=YJ*9CB.50[N7YU?7%Y?WXY!.!N!M
MBO=LZH<:*,M#U8_XJ#$S4P4DLR$4KBK-4*"41I<5V( ?4SZE5HU7;$JOFAHB
MQM?S?7=O7=]Y%Q38.VT$%[I5&D5N$I9GC2JXD][^Z6GO<'C@VDC;],F7<''#
M@>&((#6%CCB1S,NE(\O0X^?;!$'( ";D0;-P)O_\SB^ G14MY@*\[Q"OG#?>
M/&:4\X-7<YDHL&F"%7H^0O"/NTU6&_8>E@T7 *9RR3<@UD6H%!U6LS]2=46N
MS)& ;=5FLBP!1G-+ULSYT'-"S8"$(@94\^^'\=G]]08D=5-TVI(GU'#<]D>C
M6*.J$ @?H*/R5Z<.4M==F2U85Y1X9.5,)T8\])$\M+V/]H>[BDB.2"9 F*:X
M!DTMG5?#(#UQ,.J>$(R.1KV& V2GB=\HOCUZC8O*7G0<3'9A1EOXGBWO XS1
MWS;4VO+T2Y8IK#NE#2U"6,X1 E:/.L#,\\Y_@D5V"FFITTO-XETN "V?.W/O
M(*X!UTOOX;%X6!&L'?#P*[7*0E]X_+['G2K45H0>S@I(LZWRWU=EO>@]9^VH
MV]DX^#U5PT^;&]<D_]-FS*9&&KGS4!R<'(KAZ+CM1M.7M:8,W_(P7"@6!*XF
MJ8C4Q:T,>#RG) 2+J),3G^7M(^YO+JL)OW$WP[7"XI3Y6;!.^$**?:HYN@UD
MYFNM0UOZ'@Z#JOL**64T/!P=[;>;#R5.<_NBJZ;?V&U[WD9G7(B@9N&[^(_/
MBXAIQHL*,9NSW- (H5L^NFBTSQ3JCP2\]X0R*.JV#I]56R]XT5G_7XX-_/?Q
M^^>0N$8Y'ED?Y*Q&4?A)44I&ITUF S(O:IL\Z;O3%M9Q.1)'QT?B]"C"Y.F+
MC4)L\MCGH8S3''*4KJ',B,Q=L4H:C &[X[W>WQZHU*OV;4NQGUAG&J777=RZ
MS)2P&_J_&UJ)&_J%_MCE-.H:CN.^<1L8-W<'N='NW24J^;V[K-5'OVEZHB;_
M\2-XT:HT!@)W!9^!PF4Q8^!&AP2M8[D8]4/_F7.6)SIH2H]NC. :8NV@8\7Q
MU-<%S7E&\*8F\Z/5FMTWB2%RQ@7G$#$0VICP(C>MLUA1U!F#Y>YIYSGD_ATW
M:8#^8[&> D?I92=S$3_1Y>[(C ]CL=-\VXTRGFN:#M\^VC0D.N'9KN!N@;>C
M/S;\ X*V"W;;\LANGJZ_?O%GEP\H25?=J6^H(*;K6V+,5WL1Q7<N;\:[;5Y+
M)L;8F$0TNT;65-+XV4?V&>U#)R&HL_.W2O7',3.$"28G@E3[ZP1CIY3S<QY:
MJ5F=N?0$R\KH+AAJ3G<@>LA'-<->=T==5?*6L^#V-V/.4HI7?C>NI>LWNEJ[
M7]JHFTOJ]>,#]>3TH)&@,>+W")DZ*D\]G\3%=W.>$F)GD[D&2ZZUX_N$<SXR
M_QA:Q#R_J\,_\HW*V!/\=65_?[*]J1P.WIM&<WPQT_68GE[/G#G=\J7GA.Z)
M6D>/1)8%%959>QNPO8 '_<UUIM8/$)Z_G]CT&V2"JA:@PX((#$ JB)'KF+3T
MU)-IM70SUYGO8?"Y8AVB<V<5]56[@!+N7#L66[_?&"Y3JNE4;;[GV%Y@3.A
MA6&YZ5[Z7O07!3DU3>GO)HRC8_?'!<W3YD\SQNXO$MK7W=]UW,AJAMH!5IEB
MZ*!_?+@E*O>W$NZ++1?\]PF3TMHRYX\@490/] )^GY;P(/^%%FC^8.7=_P!0
M2P,$%     @ 98%952W?=PH# @  G00  !D   !X;"]W;W)K<VAE971S+W-H
M965T,C8N>&ULC91=;YLP%(;_BN5)NYIB0M*N30$IZ3)M%YVRLG07TRX<. E6
M_4%M$[I_/]L0EDIIUAOCC_,^?@^<0](J_6@J (N>!9<FQ96U]8P04U0@J!FI
M&J0[V2HMJ'5+O2.FUD#+(!*<Q%%T201E$F=)V%OI+%&-Y4S"2B/3"$'UGP5P
MU:9XC \;]VQ76;]!LJ2F.\C!KNN5=BLR4$HF0!JF)-*P3?%\/%M,?7P(>&#0
MFJ,Y\IELE'KTBZ]EBB-O"#@4UA.H>^SA%CCW(&?CJ6?BX4HO/)X?Z)]#[BZ7
M#35PJ_A/5MHJQ5<8E;"E#;?WJOT"?3X7GE<H;L*(VBXVOL:H:(Q5HA<[!X+)
M[DF?^_=P)!A?O2*(>T$<?'<7!9>?J*59HE6+M(]V-#\)J0:U,\>D_RBYU>Z4
M.9W-\F9CX*D!:=%R[T:3$.NP_I 4/6+1(>)7$-?H3DE;&;24)90O]<39&3S%
M!T^+^"PPAWJ$)M$'%$=Q?(8W&7*<!-[DK3FB7_.-L=I5Q.]3Z7:TZ6F:[Y*9
MJ6D!*79M8$#O 6?OWXTOHYLS7J>#U^DY^MN^QW\0ZT6^_+Y>?ON!E@]NS$_9
M(D<E(T#O0F,85*A&VJYZAMVA]^9=R?T+[QKWCNH=DP9QV#II-/IX@9'NFJ%;
M6%6' MPHZ\HY3"OW_P#M ]SY5BE[6/@+AC]2]A=02P,$%     @ 98%952[4
MS]/1!@  C1$  !D   !X;"]W;W)K<VAE971S+W-H965T,C<N>&ULM5CO;]LV
M$/U7""\=6B"5'=MIDBX)D'0MEJ%=@Z8_/@S[0$LGBPTEJB05Q_WK]XZ49+5Q
MTJ' OB26S'N\>W?W>/3QRMAK5Q!Y<5OJRIV,"N_KY^.Q2PLJI4M,316^R8TM
MI<>C78Y=;4EFP:C4X^ED\FQ<2E6-3H_#NTM[>FP:KU5%EU:XIBRE79^3-JN3
MT=ZH>_%.+0O/+\:GQ[5<TA7Y#_6EQ=.X1\E42953IA*6\I/1V=[S\SFO#PL^
M*EJYP6?!D2R,N>:'B^QD-&&'2%/J&4'BWPV](*T9"&Y\:3%'_99L./S<H;\*
ML2.6A73TPNA/*O/%R>AP)#+*9:/].[/Z@]IX]ADO-=J%OV(5UT[G(Y$VSINR
M-88'I:KB?WG;\C P.)S<8S!M#:;![[A1\/)WZ>7IL34K87DUT/A#"#58PSE5
M<5*NO,6W"G;^]'?E:N,4,^2.QQZ(_'Z<MM;GT7IZC_61>&,J7SCQLLHH^]9^
M#$]Z=Z:=.^?3!P&OJ$[$;+(KII/I] &\61_>+.#-[@WOAIQ7OK'DQ-]G"^<M
MZN"?;9%&H/EV(.Z-YZZ6*9V,4/R.[ V-3G_]9>_9Y+<'W)SW;LX?0O]A%GY@
M?7%U^?;JXOW%V[^NQ)74)$PN_C2J\N(C51R[>/FE47XM+BI/\-X+56%AZ9IJ
M*<Z5H5HY?"?.:JMTH%ZL2*2FK#5YRH0O2+@6US16S(^2HT>"(J9Z -.;X:O7
M9JE2)UZ89%>\]IEX?.>[)XGX@$JR84? EHZW] 5#65DY&5IYE[VSE!*2FPE9
MU];<*C0HZ;78V4LF8J&TYI:'1ZETA9!>I!K\8BM998)N:V@".]>"W,68W<'
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M3#UJS+X&6[326>52,!XR,/:.A/;T*P\O 1+>U>#\?1PY=%, ;(54!&]2)5C
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MCF0 J4#ULO(0A]D%"X.C\0.YU)C##8B[3)!?&NS:XOZ>T_%\O1UJAN9V&SU
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M,Q9,%0 Y_C-3*$Y'#^#^W(*RUU]H@_9W3>?_ 5!+ P04    " !E@5E5LI=
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M<N!1VJ8P;5)@_TGA'#XJ:7,#-S+#[$__B.ATG-B.TY0=!)QC%4(O/@46,W8
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M$(!N1G6SL:KRXW&I+ U;O\SI=4/M#.C[2BF[V[@ W7LY^0U02P,$%     @
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M ??G._9K[YV\+)G!2R6>>&'+63 *H, 5VPA[K[9?L/4S<'RY$L9_8=OD]M(
M\HVQJFK!I*#BLAG9:_L?]@"C^!U V@)2K[LYR*N\8I9E4ZVVH%TVL;F)M^K1
M)(Y+=RD/5M,N)YS-;N0+2JOT&YP^LJ5 <S:-+/&ZW2AO.18-1_H.QQANE;2E
M@<^RP.)O?$1Z.E'I3M0B/4KX@'4(O?@<TCA-C_#U.I,]S]?[K\DK;G*AS$8C
M?)\OC=7T*GX<<MP0]@\3NDJ9F)KE. NH% SJ%PRRCQ^2B_C3$;G]3F[_&'MV
MJ:I:25)L0*V [\0?DGF<Z+%$R ^3 :-?T%0B_X4%, ,K):A$S01.;R0]-2&H
M:LP9S#V0KL1BM43=W4N[<85Y&T]\/(%[MJ47:E%S)@R<0&_<#U,W]L?A!3Q1
MD9(,J+7*T1@X3<Y@.$S"&$9)G[[77')ZS@6LE2H,,8[#$22C83B&1V69V+-P
M LEY;S@@D)\-DG#@Z?X]8L_T.U[.*2<7FP(-L)I@K]P9$'1$DHR(O_T;U(4$
MQ0NP"JBM,$D-<AD>NO%HKR(KU&O?=PQ=QD;:ICB[:-?:YDU%_TEO^N(MTVLN
M#1VX(F@<#@<!Z*;7- NK:E_?2V6I6_AI2>T9M4N@_952=K=P!W0-/_L-4$L#
M!!0    ( &6!654Q?0\@,@0  'X*   9    >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;(U6;7/B-A#^*SM<YR:9(<8V8" 'S.3EVF:FUV8N:?NATP_"7K!Z
MLN231$CNUW<E&X<<QNT7T*ZTN\^^>N<[I;^8'-'"<R&D6?1R:\O+P<"D.1;,
M!*I$23=KI0MFB=2;@2DULLP+%6(0AV$R*!B7O>7<\^[U<JZV5G")]QK,MBB8
M?KE&H7:+7M3;,S[S36X=8["<EVR##VA_+^\U48-&2\8+E(8K"1K7B]Y5='F=
MN/?^P1\<=^;@#,Z3E5)?''&7+7JA X0"4^LT,/I[PAL4PBDB&%]KG;W&I!,\
M/.^U_^A])U]6S."-$G_RS.:+WK0'&:[95MC/:O<SUOZ,G;Y4">-_85>]3<AB
MNC56%;4PT067U3][KN-P(# -3PC$M4#L<5>&/,I;9MERKM4.M'M-VMS!N^JE
M"1R7+BD/5M,M)SF[O).6R0U?"80K8] :8#*#GY3*=EP(.'MD=&7.YP-+QIS(
M(*T57U>*XQ.*9_!)29L;^"@SS-[*#PAD@S3>([V..Q4^8!G ,.Q#',9QA[YA
MX_G0ZQN>T-?XZ!P^#L,M-ZE09JL1_KI:&:NI?OYN"T-E9=1NQ?74I2E9BHL>
M-8U!_82]Y?MW41)^Z/!AU/@PZM)^F#WF8;<![%31#O!(;Q\D#0BUIBY*M\56
M,(L9L$)IR[\QUUY]X$7)N*9^M9#F3&^P*B66_4-5[-A$4S"K[N??G+R!M1(T
M%LPE1=UIIQQ;+%:HFT37%[>8UOS(\R,XNY/4#T*0;7,.'XWEA0?U"U\CW"AC
MX>H ZJ^$_@2S* 4ZRF*:2R74Y@5&%_$47I!I S_ I#^*QD%(I[-Q?SR9!:-S
M.D?]Z7 <)/7],(BJ^^%T&HS=?=P/XQ'=W\F+4JL4C0$77:;3W(<EPR<:B*4/
MUQUUR)I+;A&VTG(!J2H*U"EGHHXN1.$L&,+[=],XBC_45#2,@\DKSU./FF4T
MM6FB>RO6D2!90<DXL)*,R)^]H">..8_*,@'\^T+P#H_)R^%W 2&'PVDP\_<)
MX9L>!22.(Y+JJ/IQ4_7CSJI_3?9Z:UV#'A8BE92F*OVZY9H>'.%O:Y!.:^T-
M\I@C8"<,*MHJVA>"/CLM2#Q02WHD/EMZ^X1UR7$#^%S25\L5I8(5OFF4MW5_
MLFW\SYE&]UWF<D.&-"(4?B2[=(Q=2=.C(<11?1Q!-*N/8SJ&U3&!:%)S)Q E
M[MB1PJ1)8=*9PH=J!W#@-7GF8K%C.G.T"PD-$.D&")>PJ<=T6^(Z;9Q.7!5+
M'Q7W=0-JT">>N7GU7V#45C> :!D03*;XOU.R_^#T6Z89):0_22(:([^120UG
MT2R8G1^(M.CS,J,HB%L3,CC8"6B8;/SF8VBTT(BIUH.&VRQ75]5.\?J\VLP^
MT33GTH# -8F&P80:1E?;3D585?H-8Z4L[2O^F-."B-H]H/NU4G9/. /-RKG\
M%U!+ P04    " !E@5E5?"+$*GH(  !H&   &0   'AL+W=O<FMS:&5E=',O
M<VAE970S,RYX;6RU66UOVS@2_BN$-UVT@$^69,LOV21 FFYW>VC:7I/K?CC<
M!UJB;:(2Z9)2TMROOV=(298=V_45.""P1(H<S@QGGGG(7#QJ\]6NA"C9]R)7
M]K*W*LOU^6!@TY4HN WT6BA\66A3\!)-LQS8M1$\<Y.*?!"'X7A0<*EZ5Q>N
M[Y.YNM!5F4LE/AEFJZ+@YNFUR/7C92_J-1V?Y7)54L?@ZF+-E^).E/]<?S)H
M#5HIF2R$LE(K9L3BLG<=G;\>TW@WX(L4C[;SSLB2N=9?J?$NN^R%I)#(15J2
M!(['@[@1>4Z"H,:W6F:O79(F=M\;Z6^=[;!ESJVXT?E?,BM7E[UICV5BP:N\
M_*P?_Q2U/0G)2W5NW2][]&.328^EE2UU44^&!H54_LF_UW[H3)B&!R;$]838
MZ>T7<EJ^X26_NC#ZD1D:#6GTXDQULZ&<5+0I=Z7!5XEYY=5;+@W[PO-*L%O!
M;64$/%Y:]O*>SW-A7UT,2JQ"8P=I+?&UEQ@?D#ACMUJ5*\M^5YG(MN</H%VK
M8MRH^#H^*O!.K ,V#/LL#N/XB+QA:_+0R1O^V.0WTJ:Y)JLM^]?UW)8&4?+O
M?39[D:/](BESSNV:I^*RA]2PPCR(WM6OOT3C\+<C"H]:A4?'I%_=^81A>L&X
MM0*[PU7&<LGG,I>EA.Y&I-K VXR7;$'F/9!Y^^PXNM)^.^Y7@I4N&MB<DIBY
M3ZID4GE0<-DU1\8S79E#*I8KZ,:-@*[+*N<F?V*%#[C,C4VY,7+7 O=%JDRF
MO(024"07#X)RI%Q)Y3HZ@U=2&&[2E?,4?:-NKUXITI62WRHH\BA854*K_V"Q
M4B.#2V&06 *XE*XZXL[9H=P@<]EGD5;06"W9:VZE9=>65D6LEJ*8"],&+'OY
M3B%Q\QQJV%?L7I<\9_^H=(GE/QF90J,[N51R 1OATX_0VVSU7#M_GK,;;E=,
M?*LDM'-JG+%A/YI%P11OO_XRC:/XM[U]M]Q\%6X#8>R\9)8T=YL"H=JLM2'G
M[GQB43^.9D'42MEM_Z$?A%'DD.ZL21@'83MFNW6K3;D$T+M-U<Y.%RM U?0K
MO-%=?#(*)INEMUH=<\@;Y5-WXG0VQHK^MYG0/+UK:==(:5Z[%?LHX%(2MS"Z
M8'>\L!7MJM3O]5*F@,+H%9O,0OAT5Z+O_;@Q!?+>" -Q5&I8"APD0($]LR28
M;>S9:GW*N6J2!OE$)448RHI4%RB]U@?P, [B=LI6XS0#1MB*YP;X7A^39VS2
M'X=),,2;=^ 92_I)E,#W9]C^:#8,QNS])J4/V'K&XG@G)G<Z;C 6B4.[@&E6
M9DA;9Z2>YW+I7KW+1L\4]KV-PG$TA2/VK.2'D=V?18U6=A<M:HQHXP%!J;3Z
M6]->\R>?[5EUT+$<?\ S"P;0B+-(3GHG)!S-@MF+)DBE LX(2ZC9E236P [
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M:(SQKZ#0:T&AMX_"P-O%O>M$?3OG'8?",!@Y$^NOD/R%DZ!?SP>D]*^#< M
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ML<SB3(ED9$_AW<:P:6Y8\THAR*3$1MN"J25+,?\<3^?<E$E8=%SRJ&@/?'L
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M#BR*-40$AM.+Y_K'B]T,X-:/1'2_D5$8#V>">3 6;T!>0IQE"!5F),6C_&%
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M*X2'#BDP^$5)TZ9+ C3;;@NPEZ+I[CX<[H-BT[8P6_))<M/MUX^2'3?#LNR
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M4E$[ SK/E;)[Q048'NGE=U!+ P04    " !E@5E5_'?1;W\&   >$0  &0
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M\;A/A^$:+@I+"_!]:>!K^T(*NK]$SOX!4$L#!!0    ( &6!656>CX;CMP0
M )(/   9    >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;,U7VV[;.!#]%<(-
MN@D0R+I9L5/;@',I6J!I@R3=?5CL VV-+2(2J27I.-FOWQG*5NU&4;8-@NZ+
M>9_+X9QC<;A2^M9D );=%[DTHTYF;7G<[9I9!@4WGBI!XLI<Z8);'.I%UY0:
M>.H.%7DW]/VD6W A.^.AF[O4XZ%:VEQ(N-3,+(N"ZX<3R-5JU DZFXDKL<@L
M373'PY(OX!KLU_)2XZA;6TE% =(()9F&^:@S"8Y/$MKO-OPN8&6V^HPRF2IU
M2X./Z:CC4T"0P\R2!8[-'9Q"GI,A#./OM<U.[9(.;O<WUM^[W#&7*3=PJO(_
M1&JS4:??82G,^3*W5VKU =;Y],C>3.7&_;+5>J_?8;.EL:I8'\8("B&KEM^O
M<?@O!\+U@=#%73ER49YQR\=#K59,TVZT1AV7JCN-P0E)EW)M-:X*/&?'F$W.
MITIS H=QF;(O-@/-KB#G!)O)1&G8_@V?YF .AEV+/NED=[:V?U+9#Y^P/V 7
M2MK,L'.90KI[OHNQU@&'FX!/PE:#UU!Z+/(/6>B'88N]J 8@<O:B)^Q]T0LN
MQ3\NV4-VBAFK7*2\*AF$XU*# 6FK"35G[X7D<B9XSJYQ$K ^K6%_3J;&:JRP
MOYH0J@*(FP,@UAV;DL]@U"G)E[Z#SOCMFR#QW[6D%]?IQ6W6Q]<5V2CR"1%
MV(?J;B%E5K&3R><P]@.7Z7D.<@HS,)@7VZH+)9N2:G7;G!32B&%QL9M, ^S4
M!<-;12RG6'ATM9N-G]%JV[[]CQ(YD>=4IP>N(.@GV.K=*(LWE<(=JD])=\7@
M'O7, !-RMM0:34X?G*_9=L(H-S5$M,C3.[QT=]F$)$H*ERB.4X<;;..VQP)_
MX$74!GTOQC9,8F] ;91X 3L1:@'R-\-,QC4\8ZPI;A0M4C2,35"8!KB>9>YH
M<Y9,+34FA^CA.*7>NL!Q8+Y5, :"B*@"6"_VCEAOX(4LB$*OY_+PUT :CBK@
MG&%1W8(5<O$DH)_JO'9JB84#--?S$I;T$:> >C\$2EL,.^"@]&-9+@X9V@:-
MT=,9GJ*("B*K$[P7X!3$"$[H]5D4(U9'V&FA:Z^F:^\E=)VD2\1E^0C4)H*V
M.FHFZ&3SWTS^&\KIL!5\-RMPW2JD;<D?*L2^H]+D[.N'\T\7WQ7%9(&2X%P)
M-&_8'%?5RARS7Z89FSB;6+5'=YY@$T?(%:)Z@C6]YPC3;ZCF-ENOSN> ^!;&
M^)-$&-U15+-Y$]:/L/JYZ]M'L3A 5L?$[9!8$0T"!.EI4%Z%S[2TJ^BE5G.!
M\>7*X+U3%.3H)_#<C[S! >M'F" J&!9.$"#_=Q'==6TSH5,DA$8RUP0Q[.V;
M?AB$[QZU@>_C%3T&3(,HIDMM*J#G6A7L7!@NML%LY-\6AJ^$R5.IQ#W,I$46
MDUH6DY?(XAE(G@O4""R+$I96S,SS^MCJ\>?T<5?K4,EVX?Z_2-L:KMW@FG4.
MQ8.^7?KX5[?'>GVG<LCJL*$\UU9_C<8%^*G50S)&$7VQ),C-IJKK;KV3"M +
M]QJD6UI*6SV9ZMGZP3FIWEG?ME>OU0NN%T(:_%"9XU'?.\*_6UV] *N!5:5[
M=4V5Q3><ZV;X: 9-&W!]KI3=#,A!_0P?_PM02P,$%     @ 98%956.0I417
M @  3@4  !D   !X;"]W;W)K<VAE971S+W-H965T-#(N>&UL?51=C],P$/PK
M5I#0(:$F3=L#2AJIO0-Q#X>JJX 'Q(.3;!+K'#O8V_;X]ZSM-A2I[4OBCYW9
M67O'V5Z;9]L"('OII+*+J$7LYW%LRQ8Z;D>Z!T4[M38=1YJ:)K:] 5YY4"?C
M-$ENXXX+%>697UN;/--;E$+!VC"[[3IN_JQ ZOTB&D?'A2?1M.@6XCSK>0,;
MP&_]VM L'E@JT8&R0BMFH%Y$R_%\-7/Q/N"[@+T]&3-72:'ULYL\5(LH<8)
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M!77]GC'Y?*(;:+?9E_\!4$L#!!0    ( &6!655[C63$/@0  -H6   9
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MV..\ASG/VS_0&W&B-[<)9/Q1BZTJMW;!D9(T-N5)T5"]@[R+O*L*VT.GS^C
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M&2ZSE^%Z;ADY(Y+'])Z04)S%X@B&BZKB.4,S6&#38!TC%&>Q.(+AHD)YCM$
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MW^_G"YF1T\T6?2-1,O3V#WTKRVM4'Z6?1N,,- 6Z*0Z?F2@=]ADOS\#JWOJ
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M %T"SP34]Q5C\OB2=5!=Z4S_ U!+ P04    " !E@5E5,B_X]] "  !R"0
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MR\2Y6 8AO>BH=4!0OJ:=V8\_F"/CES9_(&$V$N8@82X2YB%A/@C6\-R@]MQ
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MY7D'=7W.F'P[R0/4/W:8_0-02P,$%     @ 98%95282EDK3"   #%<  !D
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MG_09C:69T,_MR7#:K"QHLEY5MILJ@ZIRC6KQ-5U356LKLP3+'";TR1\KU.4
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M]F'6ZMT'9JWQL+D:QH4J,HVBW5RZR%&2JF$R3;#-:<)I>-4NF3:W[%U^:,X
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M;ZJJ_?+%HN,_5O7GO<;E_P!02P,$%     @ 98%957T7;![B @  [0@  !D
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M7Z#1,S)\":?2_J-=;3L*')144O&B >L=%(353WS7Q.$ H'FZ 4$#"%X*&#:
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M(0WV%#=<8]<'91-P?2FEV06VL;3_(]+?4$L#!!0    ( &6!655U;1<@' 4
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M0!_ K^#3XPUX_^X#> >2'-PG:2KO0#GWA"R@DO'6[6!7S6!X8K!'MG<!@1<
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MYGUP<R**??U*=54(463UX8[1#>-5@/Q^6TB_[4GUEK9[*[_\'U!+ P04
M" !E@5E5_X'BNDX#   H#0  &0   'AL+W=O<FMS:&5E=',O<VAE970U.2YX
M;6R]5U%OTS 0_BM60 BDD:1)F[:CC;0VF4!BTK0)>$ \>,FUM4CB8#LM_'O.
M21::-BL%(EY:V[GO.W]W]MF>[;CX*C< BGQ/DTS.C8U2^:5ER6@#*94FSR'#
M+RLN4JJP*]:6S 70N 2EB>78MF>EE&6&/RO';H4_XX5*6 :W@L@B3:GXL8"$
M[^;&P'@<N&/KC=(#EC_+Z1KN07W(;P7VK(8E9BEDDO&,"%C-C:O!93C1]J7!
M1P8[N=<F6LD#YU]UYUT\-VP](4@@4IJ!XM\6EI DF@BG\:WF-!J7&KC??F2_
M+K6CE@<J8<F33RQ6F[DQ,4@,*UHDZH[OWD*M9Z3Y(I[(\I?L*EO/-DA42,73
M&HPS2%E6_=/O=1SV ,C3#7!J@',(&#X!<&N >ZZ'80T8GNMA5 -*Z5:EO0Q<
M0!7U9X+OB-#6R*8;9?1+-,:+97J=W"N!7QGBE']-F2 ?:5( N0$J"P&X")0D
M+P-0E"62.*_(:_+A/B OG[\BSPG+R U+$LRQG%D*)Z!IK*AVMJB<.4\X<\D-
MS]1&DC"+(>[ !Z?QTQ-X"X4WZIU']0OG).$]Y"9Q[0OBV([3,9_E^?!!EYQ_
M\Q[^M?=6,-QF*;@EG_L$WZ*0."(EN8J^%4PRO9$OR!(CSK(U+@K=E"P&0<LM
M_OD]6I-W"E+YI6LI5,Z&W<YT^;N4.8U@;F!]DR"V8/@OG@T\^TU7'OHD"_HD
M"WLB:V5LV&1L>(K=W\M-U,H-2W/<UWHG=V6F(O5*4GV.;'W'Q 6TW0_XL<U@
M9'IMHZ##R#7';:/PV&@XW7/7$CYJA(]."O]5M2[:9>L.HD((C$F7[I.<?[HB
M^R0+^B0+>R)K)<9K$N/]SQKB]9FQ/LF"/LG"GLA:&1LW&1O_?BMMJZWT &N6
M99@IPE<D!\%XUR&]J C'^]M^.C9'!Q7DV,IQ/-,]*"$=5O;TL!J%'5:CJ3GI
M+B*31OGD;.60Q:<U3XY+W71D#@\T'ULY _NP(@9G<86_XZHT6WM7OQ3$NKQS
M2SP.BDQ51W\SVESKK\K;[,'X8G"Y''2,!_@,J&[MO^BK-\0-%;A<)$E@A:YP
M:EAX1'4OKSJ*Y^7%\X$KO,:6S0T^94!H _R^XEP]=K2#YG'D_P102P,$%
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M\U$-%FXQ!CL^.OL^NNXA']W&1_=$'_]7^NX>L(=W>+M[O-C?6&%;N%&#&WT
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M;Q8TNL&X -I?:XU'QR7H_@S2/U!+ P04    " !E@5E5R"(,'6X"   \!@
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MM;["3L^QXRN4,/X)ZRXW"J!HC%55!Z8**B[;-WOJ?-@ Q,,=@*0#)/\+2#M
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MX8<EM7?4+H'6%TK9YXGK(/T/(_\#4$L#!!0    ( &6!657*RJ=B"A(  '(
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M1K40U2)4$Z@F44VAFD:UF-+LI5<F= Z<R=W1,R W=VQ[H%K8:=;TP3\;[TV
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M:""_?\SD";U>*!+LWQ->_ =02P,$%     @ 98%953OWECN+ P  \1   !D
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MDA7>Q&).MU](L:"NY MHS/-OM%5CNWT#!1LN:%* 809)E*I?_%P(40$ 3SW
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MV$S]_$S]W'Z6)]DQ+8L6L>)TW^99(A*O:\[_/OZMWH?R#PGFS_6IO)Q/Z44
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MW9F51S'+&T$WQ5G#>RH$38K+-<$+PG(#^?V24O%XDP^P/Q [^P]02P,$%
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MD7Q25AYRE -!=\57_!45@J;%Y19P#$P!Y/TUE7UM-5 *ZJ.F^;]02P,$%
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M<[%DI=7V?'7"25[N/S\0SDE:'AXPBC M .+['2'\]:08H/F1Q.8_4$L#!!0
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M<?!3W"A^,"<;CUPIGIG+/1#]*9L'Z-^WG*N7FSQ!=?PV^PY02P,$%     @
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M:G%KNY8[''?;A>\B14 =[_#C'OEQC?Q\2$2R(67YP:D0:;6OD$U.RW<Z)BI
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MT0')1^-/0S/MCEXXME)1S4$U%]4\5/-1+4"U$-4B5(M1+4$U@6HII<F=I,U
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M?<MA@N8U4<U!-1?5/%3S42U M1#5(E2+42U!-8%J*:7)G:B-=4ZTB:[ON.5
MYLXN4<U!-1?5O$:3S_7'W8L5<L@ U4+%"Y@,K.[%"CEDC&I)HTGST4^ZUXM"
M\3+[2Z74ELG5V^8E)_IGV7__/0<T#8EJ#JJYJ.8UFG2)VKUB]]$A U0+%2_
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M]9-(ZY)(DW_6N<R+*OUS4S119]''I$Q+99;>W8E"9%,QW#8@-8].(5+34<U
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M]8EZHGS,JRI?KG^<BV0FBN8.]=_O\KQZ^J69X%->_+Y^F+?_!5!+ P04
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M0.U?,749%%]T@O)EP/E_4$L#!!0    ( &6!657!!]T!_@(  -D+   9
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M/T-^'A-@R&)AGFB?V7:[%@JW0K(D!ZL($D*S-W[(\U "*)YJ@)<#O*> ]@N
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M[9(@B"([ IA=01!@".Q&',$4@ 8,"8+B/KAS/_(V]RFO_A?^Z"]02P,$%
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M,9%Y,O)ECZ>#OC*Z9>^5DP<?8TSDGNR%%CX\YBY@[BJ)$^%XC(DLE+U4?7/
MOG%S'^5[0MD,7)DC">4O5NP<]!F;5GV^X8-]?R3&1!+*R2N?1\S_Z$TDH9Q8
M0K! &R@]1Q+*R:?+$.9@.1M)*">6T+-UY';88TRX[$XL(8@Y''0DH9Q80L]A
MWK?'F$A".;&$<&\.[DTDH9Q80A@SSN-R)*&<6$+/S'&,Q,T"6:@@MA#&C-/-
M EFHH%ZM1YB#)[U %BKVL6K_@!D_0@6R4+&?^;=[S,%^)62A@MI"HY@/K3$F
MLE!!;*'GY@GOGZ$8$V[_(K80W!;!7L68R$(%L86V&R,>(]"%N'4=;P8!$^FG
M()]_>]PJ,1[.D76*E]@,X,NR36>J]: C8\02&:<D-@Z<KQZ$\A(9IR0VSKFH
M&FYM/^D6#C+=N5"<W>/'F,@X);%QQJ;5QT8<Z:8DULWXO/H8);)-26P;2,F2
M&!/9IB2VS7#^'T3)$LFF)-]0-D(YH(.;C(D=@Y<IXC2M1*HIB56#,>,TK43.
M*8F=@U=3XMZ<(^_,][KH$_?F''EG_@+S;<]NJ!KH<8Z\,R?VSN.&JM''>XY\
M,Z?>GASM8((A<HY\,^]],^U/MN^.:K&22M3?_#=8WU[QICHS+/P)5TK2+ ^[
M0%==TWST;=_55\WKW3]L[?[9[-V_4$L#!!0    ( &6!6563,;S]@ (  ),Q
M   :    >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'/-VDUNHT 0AN&K6!P@
M[:[JJNZ,XJQFD^TH%T!.^T>QC06,)KG]6,["_M L9A/QK5"#*-X%>H2 IU_U
MT([[[C3L]N=A\7$\G(95LQO'\X\0AO6N'MOAH3O7T^7(INN/[7A9]MMP;M?O
M[;8&62X]]/<SFN>G^YF+U\]S_9^)W6:S7]>?W?KWL9[&?PP.?[K^?=C5.C:+
MU[;?UG'5A(_#;?<0KIOX<)G<+%[>5DW_\A:;,'>00)#,'Z00I/,')0A*\P<9
M!-G\00Y!/G]0AJ \?U"!H#)_T",$/<X?%)<HXY(@:8(U@=81N8X$7D<$.Q*(
M'9'L2&!V1+0C@=H1V8X$;D>$.Q+('9'N2&!W1+PC@=Z">@N!WH)Z"X'>,GG8
M)M!;4&\AT%M0;R'06U!O(=!;4&\AT%M0;R'06U!O(=!;4&\AT%M1;R706U%O
M)=!;46\ET%LG+TL(]%;46PGT5M1;"?16U%L)]%;46PGT5M1;"?16U%L)]$ZH
M=R+0.Z'>B4#OA'HG KT3ZIT(]$Z3E]T$>B?4.Q'HG5#O1*!W0KT3@=X)]4X$
M>B?4.Q'H;:BW$>AMJ+<1Z&VHMQ'H;:BW$>AMJ+<1Z&V3CY4$>AOJ;01Z&^IM
M!'H;ZFT$>AOJ;01Z.^KM!'H[ZNT$>COJ[01Z.^KM!'H[ZNT$>COJ[01Z^^1G
M$P*]'?5V KT=]78"O1WU=@*],^J="?3.J'<FT#NCWIE [XQZ9P*],^J="?3.
MJ'<FT#NCWIE [SSY69! [XQZ9P*],^J="?0NJ'<AT+N@WH5 [X)Z%P*]"^I=
M"/0NJ'?Y3KV'\?-0AUO/UQJO_YU4CY=SZ^WRU^77SLG=>\4YW%<,SW\!4$L#
M!!0    ( &6!657W,"8&)P(  #(P   3    6T-O;G1E;G1?5'EP97-=+GAM
M;,W;36[;,! %X*L8V@86S7^UB+-INVVSZ 58:1P+ED2"9%+G]J7D)$"+U$C@
M GT;"S;)>2,.\.U\_?TQ4%H=QV%*VVJ?<_C(6&KW-+I4^T!36=GY.+I<OL8[
M%EQ[<'?$Q&9C6.NG3%->Y[E&=7/]F7;N?LBK+\?R<^K]M*TB#:E:?3IMG+.V
ME0MAZ%N7RSI[F+H_4M9/"74YN>Q)^SZDJ[*A8J\FS"M_#W@Z]^V!8NP[6MVZ
MF+^ZL>QBQX&E_#A0JL^7>*5'O]OU+76^O1_+D3J%2*Y+>Z(\#O6IZ-7YY%QN
MF$Z?_.+\I<RYP++S-OJ0RL0BO3_N>23SZ74HA2CF_OPKOB26TA>_'\W3[JA[
M8W:YWI\^'I9Y)+8\+K_CWV?\4O^=?0B0/B1('PJD#PW2AP'IPX+TT8#T\0&D
M#[Y!:01%5(Y"*D<QE:.@RE%4Y2BL<A17.0JL'$56@2*K0)%5H,@J4&05*+(*
M%%D%BJP"15:!(JM D56BR"I19)4HLDH4626*K!)%5HDBJT215:+(*E%D52BR
M*A19%8JL"D56A2*K0I%5H<BJ4&15*+(J%%DUBJP:15:-(JM&D56CR*I19-4H
MLFH4636*K!I%5H,BJT&1U:#(:E!D-2BR&A19#8JL!D56@R*K09'5HLAJ462U
M*+):%%DMBJP615:+(JM%D=6BR&I19&U09&U09&U09&U09&W^IZP_O#_\X_CE
M68^NGY[SV?)7@9M?4$L! A0#%     @ 98%950=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !E@5E5
M_H+;O^X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    " !E@5E5F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( &6!65658:]%P 4
M +D>   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    " !E@5E5)N;I+#8(  "/*   &               @($#
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 98%9524&
M=0_)!   CA,  !@              ("!;Q8  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( &6!657X.+UB(P<  .<>   8
M  " @6X;  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !E
M@5E50/]];]@(   A)P  &               @(''(@  >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ 98%95?'LRW<-%0  0C8! !@
M         ("!U2L  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( &6!657MS%ZV&@X   8D   8              " @1A!  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    " !E@5E5C_F2UT('   U$P
M&               @(%H3P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ 98%95<.EG7MF"@  >!H  !@              ("!X%8  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( &6!654\"M74&04
M .(,   9              " @7QA  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ 98%951HQK>BB"0  OAH  !D              ("!
MS&8  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !E@5E5
M\P[>"T -  !\*@  &0              @(&E<   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( &6!654937QD60@  .87   9
M      " @1Q^  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ 98%95?3U+8@_#   KRH  !D              ("!K(8  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    " !E@5E5Q/Q(X+0%   .#@
M&0              @($BDP  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( &6!656%>B?:800  #,*   9              " @0V9  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 98%954.88=(X
M!0   @\  !D              ("!I9T  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    " !E@5E5_5M3V]H&  #L%   &0
M@($4HP  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( &6!
M656;T&OO@ ,  -8'   9              " @26J  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ 98%958%B%3F)!   D0L  !D
M         ("!W*T  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    " !E@5E5/!?PCE (  #2%   &0              @(&<L@  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( &6!656%PGN@0 <  ',4
M   9              " @2.[  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ 98%953'6VA,E&@  7%T  !D              ("!FL(
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    " !E@5E5W@HM
M)2T(  "4%P  &0              @('VW   >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( &6!655E!K.O[A$  +PR   9
M  " @5KE  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M98%952W?=PH# @  G00  !D              ("!?_<  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    " !E@5E5+M3/T]$&  "-$0  &0
M            @(&Y^0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( &6!657KNJA6!0X  .,D   9              " @<$  0!X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 98%95;*70 4G P
M.P<  !D              ("!_0X! 'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    " !E@5E5 )$>Q[ )  ""&0  &0              @(%;
M$@$ >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( &6!654B
MC$H>O@(  /P%   9              " @4(< 0!X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ 98%953%]#R R!   ?@H  !D
M     ("!-Q\! 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
M" !E@5E5?"+$*GH(  !H&   &0              @(&@(P$ >&PO=V]R:W-H
M965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( &6!654@4EYZ-P8  $$2   9
M              " @5$L 0!X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L!
M A0#%     @ 98%95<8*E#%Y!@  QA8  !D              ("!OS(! 'AL
M+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    " !E@5E5@(%V#NH%
M   X$@  &0              @(%O.0$ >&PO=V]R:W-H965T<R]S:&5E=#,V
M+GAM;%!+ 0(4 Q0    ( &6!655 #!S/4 ,  (0'   9              "
M@9 _ 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ 98%9
M54ZUV=@;!   < L  !D              ("!%T,! 'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    " !E@5E5%D1I"&\#  "P!P  &0
M        @(%I1P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( &6!657\=]%O?P8  !X1   9              " @0]+ 0!X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ 98%959Z/AN.W!   D@\
M !D              ("!Q5$! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    " !E@5E58Y"E1%<"  !.!0  &0              @(&S5@$
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( &6!654U\NQM
MD@0  '(?   9              " @4%9 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ 98%957N-9,0^!   VA8  !D
M ("!"EX! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !E
M@5E5O[X=(@X3  #*YP  &0              @(%_8@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( &6!657$.SJ>F00  &46   9
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M970U,"YX;6Q02P$"% ,4    " !E@5E5,B_X]] "  !R"0  &0
M    @(%:B@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M &6!654$ OZ!B@4  /@P   9              " @6&- 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ 98%95282EDK3"   #%<  !D
M             ("!(I,! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    " !E@5E5RW#C5Y$"  !5!@  &0              @($LG $ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( &6!6567ZN@58P\
M 'W5   9              " @?2> 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ 98%957T7;![B @  [0@  !D              ("!
MCJX! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    " !E@5E5
MURZU880"  !3"   &0              @(&GL0$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( &6!655U;1<@' 4  *$?   9
M      " @6*T 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ 98%95?^!XKI. P  * T  !D              ("!M;D! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    " !E@5E5JC#+^(@#  #Z$
M&0              @($ZO0$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( &6!656Z?20\$@<  #(O   9              " @?G  0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ 98%95;7/QM<S
M P  ,@H  !D              ("!0L@! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    " !E@5E5'UG_F@X#  "X"0  &0
M@(&LRP$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( &6!
M655N:!T68P(  !@&   9              " @?'. 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ 98%95<@B#!UN @  / 8  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( &6!654[]Y8[BP,  /$0   9
M  " @8_X 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
M98%951%*FYJA"   O$<  !D              ("!4?P! 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    " !E@5E5M& K4VT&   <*P  &0
M            @($I!0( >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4
M Q0    ( &6!654GF7'.M00  '8:   9              " @<T+ @!X;"]W
M;W)K<VAE971S+W-H965T-S,N>&UL4$L! A0#%     @ 98%95?H-,<.M!
M)QD  !D              ("!N1 " 'AL+W=O<FMS:&5E=',O<VAE970W-"YX
M;6Q02P$"% ,4    " !E@5E5D2S@\T4%   P(0  &0              @(&=
M%0( >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    ( &6!657C
M0.WF^ ,  (D:   9              " @1D; @!X;"]W;W)K<VAE971S+W-H
M965T-S8N>&UL4$L! A0#%     @ 98%953V2FO6-!   BA,  !D
M     ("!2!\" 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( &6!656 ,LUBNP8  !@X   9              "
M@:Y6 @!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%     @ 98%9
M5<$'W0'^ @  V0L  !D              ("!H%T" 'AL+W=O<FMS:&5E=',O
M<VAE970X,RYX;6Q02P$"% ,4    " !E@5E5A\+I,7,'   40P  &0
M        @('58 ( >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+ 0(4 Q0
M   ( &6!657_<&&/=P,  ,\7   -              "  7]H @!X;"]S='EL
M97,N>&UL4$L! A0#%     @ 98%959>*NQS     $P(   L
M ( !(6P" %]R96QS+RYR96QS4$L! A0#%     @ 98%95>>^3YH.!@  \#8
M  \              ( !"FT" 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    (
M &6!6563,;S]@ (  ),Q   :              "  45S @!X;"]?<F5L<R]W
M;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( &6!657W,"8&)P(  #(P   3
M              "  ?UU @!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !<
- %P .QD  %5X @    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>741</ContextCount>
  <ElementCount>393</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>147</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2108103 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2116104 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2120105 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2124106 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2131107 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2139108 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2142109 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2144110 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2146111 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2148112 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2153113 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2156114 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2160115 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2164116 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2168117 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2172118 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2174119 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2176120 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2177121 - Disclosure - Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Dispositions</Role>
      <ShortName>Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2309302 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2317303 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2321304 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2325305 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2332306 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2340307 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2349308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2354309 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2357310 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2361311 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2365312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2369313 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2418410 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2419411 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2422412 - Disclosure - Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1</Role>
      <ShortName>Intangible Assets and Goodwill (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2426414 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2427415 - Disclosure - Fair Value Measurements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual</Role>
      <ShortName>Fair Value Measurements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails</Role>
      <ShortName>Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2429417 - Disclosure - Fair Value Measurements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails1</Role>
      <ShortName>Fair Value Measurements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2430418 - Disclosure - Fair Value Measurements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDetails2</Role>
      <ShortName>Fair Value Measurements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2433419 - Disclosure - Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails</Role>
      <ShortName>Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2434420 - Disclosure - Financial Instruments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails1</Role>
      <ShortName>Financial Instruments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2435421 - Disclosure - Financial Instruments (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails2</Role>
      <ShortName>Financial Instruments (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2436422 - Disclosure - Financial Instruments (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetails3</Role>
      <ShortName>Financial Instruments (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Financial Instruments (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual</Role>
      <ShortName>Financial Instruments (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstrumentsTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2</Role>
      <ShortName>Financial Instruments Financial Instruments (Details Textual 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2441425 - Disclosure - Derivative Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsDetails</Role>
      <ShortName>Derivative Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstrumentsTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2443426 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2445427 - Disclosure - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesDetailsTextual</Role>
      <ShortName>Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Leases</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2447428 - Disclosure - Indebtedness (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessDetails</Role>
      <ShortName>Indebtedness (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Indebtedness</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2450429 - Disclosure - Share Repurchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareRepurchasesDetails</Role>
      <ShortName>Share Repurchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2451430 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2452431 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2455432 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2458433 - Disclosure - Share-Based Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails</Role>
      <ShortName>Share-Based Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2459434 - Disclosure - Share-Based Payments (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsDetails1</Role>
      <ShortName>Share-Based Payments (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/ShareBasedPaymentsTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2462435 - Disclosure - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetailsTextual</Role>
      <ShortName>Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2463436 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxesTables</ParentRole>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2466437 - Disclosure - Other Consolidated Financial Statement Detail (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2467438 - Disclosure - Other Consolidated Financial Statement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual</Role>
      <ShortName>Other Consolidated Financial Statement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2470439 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2471440 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2473441 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2475442 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20220930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2478443 - Disclosure - Dispositions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DispositionsDetailsTextual</Role>
      <ShortName>Dispositions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Dispositions</ParentRole>
      <Position>84</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 11 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityCommonStockSharesOutstanding, us-gaap:AssetImpairmentCharges, us-gaap:DebtInstrumentInterestRateStatedPercentage, us-gaap:FiniteLivedIntangibleAssetUsefulLife, us-gaap:SubsequentEventsTextBlock -  biib-20220930.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="biib-20220930.htm">biib-20220930.htm</File>
    <File>biib-20220930.xsd</File>
    <File>biib-20220930_cal.xml</File>
    <File>biib-20220930_def.xml</File>
    <File>biib-20220930_lab.xml</File>
    <File>biib-20220930_pre.xml</File>
    <File>biib-2022930xex311.htm</File>
    <File>biib-2022930xex312.htm</File>
    <File>biib-2022930xex321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20220930_g1.jpg</File>
    <File>biib-20220930_g10.jpg</File>
    <File>biib-20220930_g11.jpg</File>
    <File>biib-20220930_g12.jpg</File>
    <File>biib-20220930_g13.jpg</File>
    <File>biib-20220930_g14.jpg</File>
    <File>biib-20220930_g15.jpg</File>
    <File>biib-20220930_g16.jpg</File>
    <File>biib-20220930_g17.jpg</File>
    <File>biib-20220930_g18.jpg</File>
    <File>biib-20220930_g19.jpg</File>
    <File>biib-20220930_g2.jpg</File>
    <File>biib-20220930_g20.jpg</File>
    <File>biib-20220930_g21.jpg</File>
    <File>biib-20220930_g22.jpg</File>
    <File>biib-20220930_g23.jpg</File>
    <File>biib-20220930_g3.jpg</File>
    <File>biib-20220930_g4.jpg</File>
    <File>biib-20220930_g5.jpg</File>
    <File>biib-20220930_g6.jpg</File>
    <File>biib-20220930_g7.jpg</File>
    <File>biib-20220930_g8.jpg</File>
    <File>biib-20220930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1553">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>124
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "biib-20220930.htm": {
   "axisCustom": 5,
   "axisStandard": 34,
   "contextCount": 741,
   "dts": {
    "calculationLink": {
     "local": [
      "biib-20220930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20220930_def.xml"
     ]
    },
    "inline": {
     "local": [
      "biib-20220930.htm"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20220930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20220930_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "biib-20220930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 730,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 10,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 16
   },
   "keyCustom": 77,
   "keyStandard": 316,
   "memberCustom": 77,
   "memberStandard": 65,
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20220930",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.biogenidec.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116104 - Disclosure - Inventory",
     "role": "http://www.biogenidec.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2120105 - Disclosure - Intangible Assets and Goodwill",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2124106 - Disclosure - Fair Value Measurements",
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2131107 - Disclosure - Financial Instruments",
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139108 - Disclosure - Derivative Instruments",
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "shortName": "Derivative Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2142109 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2144110 - Disclosure - Leases",
     "role": "http://www.biogenidec.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2146111 - Disclosure - Indebtedness",
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "shortName": "Indebtedness",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2148112 - Disclosure - Equity",
     "role": "http://www.biogenidec.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2153113 - Disclosure - Earnings per Share",
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "shortName": "Earnings per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2156114 - Disclosure - Share-based Payments",
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "shortName": "Share-based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2160115 - Disclosure - Income Taxes",
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2164116 - Disclosure - Other Consolidated Financial Statement Detail",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2168117 - Disclosure - Collaborative and Other Relationships",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "shortName": "Collaborative and Other Relationships",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2172118 - Disclosure - Investments in Variable Interest Entities",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "shortName": "Investments in Variable Interest Entities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2174119 - Disclosure - Litigation",
     "role": "http://www.biogenidec.com/role/Litigation",
     "shortName": "Litigation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2176120 - Disclosure - Subsequent Events",
     "role": "http://www.biogenidec.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": null
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2177121 - Disclosure - Dispositions",
     "role": "http://www.biogenidec.com/role/Dispositions",
     "shortName": "Dispositions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309302 - Disclosure - Revenues (Tables)",
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2317303 - Disclosure - Inventory (Tables)",
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2321304 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2325305 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2332306 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340307 - Disclosure - Derivative Instruments (Tables)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "shortName": "Derivative Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2349308 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2354309 - Disclosure - Earnings per Share (Tables)",
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "shortName": "Earnings per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2357310 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2361311 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2365312 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2369313 - Disclosure - Collaborative and Other Relationships (Tables)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserveAccrualAdjustment1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Revenues - Revenues by product (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "shortName": "Revenues - Revenues by product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id05eb883732b498a834f089684813866_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412406 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i85e08dba5a5d46c48d1d0ba4950b19c1_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "if13532228d6b4faa9945313be54cbe8a_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:ShareOfCoPromotionProfits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Revenues - Other Revenues (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "shortName": "Revenues - Other Revenues (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i7d47538d8dcd446ca3b4284f191efc96_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Revenues - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "shortName": "Revenues - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "INF",
      "lang": "en-US",
      "name": "biib:NumberOfWholesalers",
      "reportCount": 1,
      "unique": true,
      "unitRef": "wholesaler",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418410 - Disclosure - Inventory - Components of Inventory (Details)",
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "shortName": "Inventory - Components of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419411 - Disclosure - Inventory - Narrative (Details)",
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "shortName": "Inventory - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ibf9a5892d99e44d8b1534f84205aaefe_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422412 - Disclosure - Intangible Assets and Goodwill (Details)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsGrossExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423413 - Disclosure - Intangible Assets and Goodwill (Details 1)",
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1",
     "shortName": "Intangible Assets and Goodwill (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426414 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i7c435e88eff34c74b9a309271c43e352_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427415 - Disclosure - Fair Value Measurements (Details Textual)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual",
     "shortName": "Fair Value Measurements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AssetImpairmentCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ic2ccf4f8b82f4fda959e8343a1d3dde5_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428416 - Disclosure - Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
     "shortName": "Fair Value Measurements Fair Value Measurements - Contingent Consideration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ic2ccf4f8b82f4fda959e8343a1d3dde5_I20220930",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2429417 - Disclosure - Fair Value Measurements (Details 1)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
     "shortName": "Fair Value Measurements (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NotesPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430418 - Disclosure - Fair Value Measurements (Details 2)",
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
     "shortName": "Fair Value Measurements (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "if91d142efb024f1784dcfc0a7ba633de_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statement of Equity Statement",
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "if91d142efb024f1784dcfc0a7ba633de_I20201231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433419 - Disclosure - Financial Instruments (Details)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails",
     "shortName": "Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434420 - Disclosure - Financial Instruments (Details 1)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
     "shortName": "Financial Instruments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2435421 - Disclosure - Financial Instruments (Details 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails2",
     "shortName": "Financial Instruments (Details 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2436422 - Disclosure - Financial Instruments (Details 3)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetails3",
     "shortName": "Financial Instruments (Details 3)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2c07337e773d46e6ad996880dd86a2fe_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Financial Instruments (Details Textual)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual",
     "shortName": "Financial Instruments (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2c07337e773d46e6ad996880dd86a2fe_D20220101-20220331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "biib:AverageMaturityOfMarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i0caa15f7fec549d5b6d3e7a3c8450b9e_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Financial Instruments Financial Instruments (Details Textual 2)",
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
     "shortName": "Financial Instruments Financial Instruments (Details Textual 2)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i0caa15f7fec549d5b6d3e7a3c8450b9e_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "biib:StrategicInvestmentPortfolio",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441425 - Disclosure - Derivative Instruments (Details)",
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
     "shortName": "Derivative Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443426 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445427 - Disclosure - Leases (Details Textual)",
     "role": "http://www.biogenidec.com/role/LeasesDetailsTextual",
     "shortName": "Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "icbf7777c4f84426e979a7f5b8e8fa8ce_D20220901-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:OperatingLeaseRightOfUseAssetDerecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i737aacf58c3f4d9b8d3e88a3953abda7_I20150915",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2447428 - Disclosure - Indebtedness (Details)",
     "role": "http://www.biogenidec.com/role/IndebtednessDetails",
     "shortName": "Indebtedness (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i737aacf58c3f4d9b8d3e88a3953abda7_I20150915",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PaymentsForRepurchaseOfCommonStock",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2450429 - Disclosure - Share Repurchases (Details)",
     "role": "http://www.biogenidec.com/role/ShareRepurchasesDetails",
     "shortName": "Share Repurchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "iaec7e30533b342c590bb4d7ffe633982_I20201031",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451430 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ia953e5a0fc224c8c9f234d2c963d4105_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherOperatingIncomeExpenseNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2452431 - Disclosure - Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "role": "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Reclassification out of Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ie8e3376c311a4ab1ba9f36f3d6388b0b_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455432 - Disclosure - Earnings per Share (Details)",
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "shortName": "Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2458433 - Disclosure - Share-Based Payments (Details)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
     "shortName": "Share-Based Payments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2459434 - Disclosure - Share-Based Payments (Details 1)",
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1",
     "shortName": "Share-Based Payments (Details 1)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ic363356bb33f48c5be8d5bb4b72a7bf6_D20220701-20220930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "id7caa4287cd44462b9d9cd33c1545d15_I20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462435 - Disclosure - Income Taxes (Details Textual)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
     "shortName": "Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i54de034401784154b4ba0d3eb7e3d450_I20221231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2463436 - Disclosure - Income Taxes (Details)",
     "role": "http://www.biogenidec.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2466437 - Disclosure - Other Consolidated Financial Statement Detail (Details)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
     "shortName": "Other Consolidated Financial Statement Detail (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2467438 - Disclosure - Other Consolidated Financial Statement (Details Textual)",
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
     "shortName": "Other Consolidated Financial Statement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "biib:PercentageoffuturedevelopmentcostsrelatedtoEisai",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2470439 - Disclosure - Collaborative and Other Relationships - Collaborations (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
     "shortName": "Collaborative and Other Relationships - Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ic1d7c5e3e6ea45b8a521c6d470f1bfa6_D20210701-20210930",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:AdjustmentForAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2471440 - Disclosure - Collaborative and Other Relationships - Equity Method Investments (Details)",
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
     "shortName": "Collaborative and Other Relationships - Equity Method Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "iecc1e7ba25054542bf09508f1c307e7e_I20181107",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromEquityMethodInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2473441 - Disclosure - Investments in Variable Interest Entities (Details)",
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6cac6a36cb7544188ce0dee2256caca4_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i6b06fa1a19ae4126926d8a3e45ba10c4_D20220701-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2475442 - Disclosure - Litigation (Details)",
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "shortName": "Litigation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ia953e5a0fc224c8c9f234d2c963d4105_I20201231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LossContingencyEstimateOfPossibleLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2478443 - Disclosure - Dispositions (Details Textual)",
     "role": "http://www.biogenidec.com/role/DispositionsDetailsTextual",
     "shortName": "Dispositions (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "ibc6bd70fa92347e2a75c9496e8e6e49d_D20220101-20220930",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108103 - Disclosure - Revenues",
     "role": "http://www.biogenidec.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "biib-20220930.htm",
      "contextRef": "i2abaac82076c4b6ca9bdc640eaa5f64a_D20220101-20220930",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 147,
   "tag": {
    "biib_A125BroadwayBuildingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "125 Broadway Building",
        "label": "125 Broadway Building [Member]",
        "terseLabel": "125 Broadway Building"
       }
      }
     },
     "localname": "A125BroadwayBuildingMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "terseLabel": "2.250% Senior Notes due May 1, 2030"
       }
      }
     },
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Share Repurchase Program [Member]",
        "label": "2020 Share Repurchase Program [Member]",
        "terseLabel": "2020 Share Repurchase Program"
       }
      }
     },
     "localname": "A2020ShareRepurchaseProgramMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "terseLabel": "3.150% Senior Notes due May 1, 2050"
       }
      }
     },
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_A3250SeniorNotesDueFebruary152051Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.250% Senior Notes, Due February 15, 2051",
        "label": "3.250% Senior Notes, Due February 15, 2051 [Member]",
        "terseLabel": "3.250% Senior Notes, Due February 15, 2051"
       }
      }
     },
     "localname": "A3250SeniorNotesDueFebruary152051Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ADUHELMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADUHELM",
        "label": "ADUHELM [Member]",
        "terseLabel": "ADUHELM"
       }
      }
     },
     "localname": "ADUHELMMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AVONEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "AVONEX",
        "label": "AVONEX [Member]",
        "terseLabel": "AVONEX"
       }
      }
     },
     "localname": "AVONEXMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AccruedMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Milestone Payments",
        "label": "Accrued Milestone Payments",
        "terseLabel": "Accrued milestone payments"
       }
      }
     },
     "localname": "AccruedMilestonePayments",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdditionalMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional milestone payment.",
        "label": "Additional Milestone Payment",
        "terseLabel": "Additional milestone payment"
       }
      }
     },
     "localname": "AdditionalMilestonePayment",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years.",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "negatedLabel": "Adjustments Relating To Prior Years"
       }
      }
     },
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AdministrativeSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Administrative Space",
        "label": "Administrative Space [Member]",
        "terseLabel": "Administrative Space"
       }
      }
     },
     "localname": "AdministrativeSpaceMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization and Impairment of Acquired Intangible Assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "terseLabel": "Amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Analysis of amount of and change in product revenue reserves.",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "terseLabel": "Analysis of change In reserves"
       }
      }
     },
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents debt securities, at cost, net of adjustments made for accretion, amortization, other-than-temporary impairments, and hedging, if any, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Amortized Cost",
        "verboseLabel": "Due after five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsAmortizedCost",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the fair value of debt securities, which are expected to mature after five years from the balance sheet date and which are categorized neither as held-to-maturity nor trading securities.",
        "label": "Available For Sale Securities Debt Maturities After Five Years Fair Value",
        "verboseLabel": "Due after five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveYearsFairValue",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_AverageMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average remaining time to maturity of marketable debt securities, available-for-sale securities.",
        "label": "Average Maturity Of Marketable Securities",
        "verboseLabel": "Average maturity of marketable securities, months"
       }
      }
     },
     "localname": "AverageMaturityOfMarketableSecurities",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_BENEPALIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BENEPALI [Member]",
        "label": "BENEPALI [Member]",
        "terseLabel": "BENEPALI"
       }
      }
     },
     "localname": "BENEPALIMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111AndBIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 and BIIB112",
        "label": "BIIB111 and BIIB112 [Member]",
        "terseLabel": "BIIB111 and BIIB112"
       }
      }
     },
     "localname": "BIIB111AndBIIB112Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB111Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB111 [Member]",
        "label": "BIIB111 [Member]",
        "terseLabel": "BIIB111"
       }
      }
     },
     "localname": "BIIB111Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BIIB112Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BIIB112 [Member]",
        "label": "BIIB112 [Member]",
        "terseLabel": "BIIB112"
       }
      }
     },
     "localname": "BIIB112Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BYOOVIZMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BYOOVIZ",
        "label": "BYOOVIZ [Member]",
        "terseLabel": "BYOOVIZ"
       }
      }
     },
     "localname": "BYOOVIZMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Basic and diluted earnings per share.",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_BiologicsManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biologics Manufacturing",
        "label": "Biologics Manufacturing [Member]",
        "terseLabel": "Biologics Manufacturing"
       }
      }
     },
     "localname": "BiologicsManufacturingMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biosimilars",
        "label": "Biosimilars [Member]",
        "terseLabel": "Biosimilars"
       }
      }
     },
     "localname": "BiosimilarsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes an overview of the company and its operations.",
        "label": "Business Overview [Policy Text Block]",
        "verboseLabel": "Overview"
       }
      }
     },
     "localname": "BusinessOverviewPolicyTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_CashflowsoperatingexpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, operating expenses [Member]",
        "label": "Cash flows, operating expenses [Member]",
        "terseLabel": "Cash flows, operating expenses"
       }
      }
     },
     "localname": "CashflowsoperatingexpensesMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CashflowsrevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash flows, revenue [Member]",
        "label": "Cash flows, revenue [Member]",
        "terseLabel": "Cash flows, revenue"
       }
      }
     },
     "localname": "CashflowsrevenueMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CentersForMedicareAndMedicaidServiceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Centers for Medicare and Medicaid Service",
        "label": "Centers for Medicare and Medicaid Service [Member]",
        "terseLabel": "Centers for Medicare and Medicaid Service"
       }
      }
     },
     "localname": "CentersForMedicareAndMedicaidServiceMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CollaborationAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement Term",
        "label": "Collaboration Agreement Term",
        "terseLabel": "Collaboration agreement term"
       }
      }
     },
     "localname": "CollaborationAgreementTerm",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_Collaborationexpensesaccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration expenses accrual",
        "label": "Collaboration expenses accrual",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "Collaborationexpensesaccrual",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Collaborationprofitlosssharing": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration profit (loss) sharing",
        "label": "Collaboration profit (loss) sharing",
        "terseLabel": "Collaboration profit (loss) sharing"
       }
      }
     },
     "localname": "Collaborationprofitlosssharing",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContingentCommercializedRightsNumberOfProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Commercialized Rights, Number Of Products",
        "label": "Contingent Commercialized Rights, Number Of Products",
        "terseLabel": "Contingent Commercialized Rights, Number Of Products"
       }
      }
     },
     "localname": "ContingentCommercializedRightsNumberOfProducts",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_ContingentMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Milestone Payments Made To Collaborative Partner",
        "label": "Contingent Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Contingent additional milestone payment"
       }
      }
     },
     "localname": "ContingentMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractOptionExerciseFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Option Exercise Fee",
        "label": "Contract Option Exercise Fee",
        "terseLabel": "Contract Option Exercise Fee"
       }
      }
     },
     "localname": "ContractOptionExerciseFee",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ContractualAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual adjustments.",
        "label": "Contractual Adjustments [Member]",
        "terseLabel": "Contractual adjustments"
       }
      }
     },
     "localname": "ContractualAdjustmentsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate debt securities Current.",
        "label": "Corporate Debt Securities Current [Member]",
        "verboseLabel": "Corporate debt securities Current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CorporateDebtSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Debt Securities Non Current.",
        "label": "Corporate Debt Securities Non Current [Member]",
        "verboseLabel": "Corporate debt securities Non-current"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_CostOfGoodsSoldCapacityCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of Goods Sold, Capacity Charges",
        "label": "Cost of Goods Sold, Capacity Charges",
        "terseLabel": "Idle capacity charges"
       }
      }
     },
     "localname": "CostOfGoodsSoldCapacityCharges",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current provisions to product revenue reserves relating to sales in current year.",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "terseLabel": "Current Provisions Relating To Sales In Current Year"
       }
      }
     },
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption, Amount",
        "label": "Debt Instrument, Redemption, Amount",
        "terseLabel": "Debt Instrument, Redemption, Amount"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionAmount",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DebtInstrumentRedemptionRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Redemption Rate",
        "label": "Debt Instrument, Redemption Rate",
        "terseLabel": "Redemption rate"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionRate",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_DenaliTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Denali Therapeutics Inc",
        "label": "Denali Therapeutics Inc [Member]",
        "terseLabel": "Denali Therapeutics"
       }
      }
     },
     "localname": "DenaliTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_DerivativeMaturityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Axis]",
        "terseLabel": "Derivative Maturity [Axis]"
       }
      }
     },
     "localname": "DerivativeMaturityAxis",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_DerivativeMaturityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Derivative Maturity [Axis]",
        "label": "Derivative Maturity [Domain]",
        "terseLabel": "Derivative Maturity [Domain]"
       }
      }
     },
     "localname": "DerivativeMaturityDomain",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "label": "Derivatives used in net investment hedge, net of tax, excluded component increase (decrease)",
        "terseLabel": "Gains (losses) on net investment hedge, excluded component"
       }
      }
     },
     "localname": "Derivativesusedinnetinvestmenthedgenetoftaxexcludedcomponentincreasedecrease",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DiscreteIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discrete Income Tax Expense (Benefit)",
        "label": "Discrete Income Tax Expense (Benefit)",
        "terseLabel": "Discrete income tax expense (benefit)"
       }
      }
     },
     "localname": "DiscreteIncomeTaxExpenseBenefit",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_DistributorOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor one.",
        "label": "Distributor One [Member]",
        "terseLabel": "Distributor One"
       }
      }
     },
     "localname": "DistributorOneMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DistributorTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Distributor two.",
        "label": "Distributor Two [Member]",
        "terseLabel": "Distributor Two"
       }
      }
     },
     "localname": "DistributorTwoMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_DivestituresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "terseLabel": "Divestitures [Abstract]"
       }
      }
     },
     "localname": "DivestituresAbstract",
     "nsuri": "http://www.biogenidec.com/20220930",
     "xbrltype": "stringItemType"
    },
    "biib_DuefromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivable from anti-CD20 therapeutic programs for our share of the pre-tax co-promotion profits generated from our co-promotion arrangement for sales of RITUXAN.",
        "label": "Due from anti-CD20 therapeutic programs",
        "verboseLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "DuefromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_E2609andBAN2401Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "E2609 and BAN2401 [Member]",
        "label": "E2609 and BAN2401 [Member]",
        "terseLabel": "BAN2401 and Elenbecestat"
       }
      }
     },
     "localname": "E2609andBAN2401Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EffectiveTaxRateReconciliationGILTItax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, GILTI tax",
        "label": "Effective Tax Rate Reconciliation, GILTI tax",
        "terseLabel": "GILTI"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationGILTItax",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationInternationalReorganization": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, International Reorganization",
        "label": "Effective Tax Rate Reconciliation, International Reorganization",
        "terseLabel": "International reorganization"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationInternationalReorganization",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationLitigationAgreement": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Litigation Agreement",
        "label": "Effective Tax Rate Reconciliation, Litigation Agreement",
        "terseLabel": "Litigation settlement agreement"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationLitigationAgreement",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EffectiveTaxRateReconciliationNuerImmuneTaxImpacts": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "label": "Effective Tax Rate Reconciliation, NuerImmune Tax Impacts",
        "terseLabel": "Neurimmune tax impacts"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNuerImmuneTaxImpacts",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "biib_EffectiveTaxRateReconciliationSaleOfSamsungBioepis": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis",
        "label": "Effective Tax Rate Reconciliation, Sale Of Samsung Bioepis",
        "terseLabel": "Sale of Samsung Bioepis"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationSaleOfSamsungBioepis",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EisaiMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Eisai [Member]",
        "label": "Eisai [Member]",
        "terseLabel": "Eisai"
       }
      }
     },
     "localname": "EisaiMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan [Member]",
        "verboseLabel": "Employee stock purchase plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity wide percentage of revenue from major distributors.",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "terseLabel": "Percentage of revenues from major distributors"
       }
      }
     },
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "label": "Equity Method Investment, Ownership Percentage Before Additional Purchase Transaction",
        "terseLabel": "Percentage of stake in entity"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentageBeforeAdditionalPurchaseTransaction",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Method Investments, Expected Profit Share",
        "label": "Equity Method Investments, Expected Profit Share",
        "terseLabel": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_EquitySecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Current",
        "label": "Equity Securities, Current [Member]",
        "terseLabel": "Equity Securities, Current"
       }
      }
     },
     "localname": "EquitySecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "terseLabel": "Equity Securities, Non-Current"
       }
      }
     },
     "localname": "EquitySecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_Equitymethodinvestmentbasisdifferenceamortizationperiod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity method investment basis difference amortization period",
        "label": "Equity method investment basis difference amortization period",
        "terseLabel": "Equity method investment basis difference amortization period"
       }
      }
     },
     "localname": "Equitymethodinvestmentbasisdifferenceamortizationperiod",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones.",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones"
       }
      }
     },
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ExpenseIncurredByCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total expense incurred by collaboration.",
        "label": "Expense Incurred By Collaboration",
        "terseLabel": "Expense Incurred By Collaboration"
       }
      }
     },
     "localname": "ExpenseIncurredByCollaboration",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expenseincurredbythecollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "terseLabel": "Expense incurred by the collaboration"
       }
      }
     },
     "localname": "Expenseincurredbythecollaboration",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "terseLabel": "Expense reflected within statements of income"
       }
      }
     },
     "localname": "Expensereflectedwithinstatementsofincome",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_FAMPYRAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FAMPYRA [Member]",
        "label": "FAMPYRA [Member]",
        "terseLabel": "FAMPYRA"
       }
      }
     },
     "localname": "FAMPYRAMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FLIXABIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FLIXABI [Member]",
        "label": "FLIXABI [Member]",
        "terseLabel": "FLIXABI"
       }
      }
     },
     "localname": "FLIXABIMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FUMADERMMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "FUMADERM [Member]",
        "label": "FUMADERM [Member]",
        "terseLabel": "FUMADERM"
       }
      }
     },
     "localname": "FUMADERMMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Axis]",
        "terseLabel": "Facility Location [Axis]"
       }
      }
     },
     "localname": "FacilityLocationAxis",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "-- None. No documentation exists for this element. --",
        "label": "Facility Location [Domain]",
        "terseLabel": "Facility Location [Domain]"
       }
      }
     },
     "localname": "FacilityLocationDomain",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FacilityTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Axis]",
        "terseLabel": "Facility Type [Axis]"
       }
      }
     },
     "localname": "FacilityTypeAxis",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FacilityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility Type",
        "label": "Facility Type [Domain]",
        "terseLabel": "Facility Type [Domain]"
       }
      }
     },
     "localname": "FacilityTypeDomain",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FumarateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fumarate [Member]",
        "label": "Fumarate [Member]",
        "terseLabel": "Fumarate"
       }
      }
     },
     "localname": "FumarateMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "terseLabel": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesAxis",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Domain]",
        "terseLabel": "Future Contingent Milestone Types [Domain]"
       }
      }
     },
     "localname": "FutureContingentMilestoneTypesDomain",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment, Tenant Allowance",
        "terseLabel": "Tenant allowance"
       }
      }
     },
     "localname": "GainLossOnDispositionOfPropertyPlantEquipmentTenantAllowance",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GainLossOnRestructuringCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (Loss) On Restructuring Charges",
        "label": "Gain (Loss) On Restructuring Charges",
        "terseLabel": "Gain due to lease termination"
       }
      }
     },
     "localname": "GainLossOnRestructuringCharges",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government securities Current.",
        "label": "Government Securities Current [Member]",
        "verboseLabel": "Government securities Current"
       }
      }
     },
     "localname": "GovernmentSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_GovernmentSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Government Securities Non Current.",
        "label": "Government Securities Non-current [Member]",
        "verboseLabel": "Government securities Non-current"
       }
      }
     },
     "localname": "GovernmentSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IMRALDIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMRALDI [Member]",
        "label": "IMRALDI [Member]",
        "terseLabel": "IMRALDI"
       }
      }
     },
     "localname": "IMRALDIMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IncomeLossFromEquityMethodInvestmentsNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income (Loss) from Equity Method Investments, Net of Tax",
        "label": "Income (Loss) from Equity Method Investments, Net of Tax",
        "negatedTerseLabel": "Equity in (income) loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfTax",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InnoCarePharmaLimitedInnoCareAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "InnoCare Pharma Limited (InnoCare) Agreement",
        "label": "InnoCare Pharma Limited (InnoCare) Agreement [Member]",
        "terseLabel": "InnoCare Pharma Limited (InnoCare) Agreement"
       }
      }
     },
     "localname": "InnoCarePharmaLimitedInnoCareAgreementMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets excluding goodwill.",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_InterestInSubsidiary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest in subsidiary.",
        "label": "Interest In Subsidiary",
        "verboseLabel": "Interest in subsidiary (less than given percentage)"
       }
      }
     },
     "localname": "InterestInSubsidiary",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_InterferonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interferon",
        "label": "Interferon [Member]",
        "terseLabel": "Interferon"
       }
      }
     },
     "localname": "InterferonMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, Net Current and Noncurrent",
        "label": "Inventory, Net Current and Noncurrent",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNetCurrentAndNoncurrent",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_Inventorynetcurrentandnoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inventory, net current and noncurrent",
        "label": "Inventory, net current and noncurrent",
        "totalLabel": "Total inventory"
       }
      }
     },
     "localname": "Inventorynetcurrentandnoncurrent",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "verboseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities"
       }
      }
     },
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments In Variable Interest Entities.",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "terseLabel": "Investments in Variable Interest Entities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "nsuri": "http://www.biogenidec.com/20220930",
     "xbrltype": "stringItemType"
    },
    "biib_IonisSangamoDenaliAndSageMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ionis, Sangamo, Denali and Sage",
        "label": "Ionis, Sangamo, Denali and Sage [Member]",
        "terseLabel": "Ionis, Sangamo, Denali and Sage"
       }
      }
     },
     "localname": "IonisSangamoDenaliAndSageMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LecanemabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lecanemab",
        "label": "Lecanemab [Member]",
        "terseLabel": "Lecanemab"
       }
      }
     },
     "localname": "LecanemabMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_LongTermDebtExchangedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long Term Debt, Exchanged, Amount",
        "label": "Long Term Debt, Exchanged, Amount",
        "terseLabel": "Long Term Debt, Exchanged, Amount"
       }
      }
     },
     "localname": "LongTermDebtExchangedAmount",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_MSProductRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MS Product Revenues [Member]",
        "label": "MS Product Revenues [Member]",
        "terseLabel": "MS Product Revenues"
       }
      }
     },
     "localname": "MSProductRevenuesMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MarketStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market stock units.",
        "label": "Market Stock Units [Member]",
        "verboseLabel": "Market stock units"
       }
      }
     },
     "localname": "MarketStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage and other asset backed securities Current.",
        "label": "Mortgage And Other Asset Backed Securities Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_MortgageAndOtherAssetBackedSecuritiesNonCurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Mortgage And Other Asset Backed Securities Non Current.",
        "label": "Mortgage And Other Asset Backed Securities Non Current [Member]",
        "verboseLabel": "Mortgage and other asset backed securities Non-current"
       }
      }
     },
     "localname": "MortgageAndOtherAssetBackedSecuritiesNonCurrentMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NeurimmuneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neurimmune.",
        "label": "Neurimmune [Member]",
        "terseLabel": "Neurimmune"
       }
      }
     },
     "localname": "NeurimmuneMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_NoncontrollingInterestCapitalContribution": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncontrolling Interest, Capital Contribution",
        "label": "Noncontrolling Interest, Capital Contribution",
        "terseLabel": "Capital contribution from noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestCapitalContribution",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_NumberOfSquareFeet": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Square Feet",
        "label": "Number of Square Feet",
        "terseLabel": "Number of square feet"
       }
      }
     },
     "localname": "NumberOfSquareFeet",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "biib_NumberOfWholesalers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Wholesalers",
        "label": "Number of Wholesalers",
        "terseLabel": "Number of wholesalers"
       }
      }
     },
     "localname": "NumberOfWholesalers",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "biib_OperatingLeaseLiabilityDerecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Liability, Derecognized",
        "label": "Operating Lease, Liability, Derecognized",
        "terseLabel": "Lease liabilities derecognized"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityDerecognized",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OperatingLeaseRightOfUseAssetDerecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Right-Of-Use Asset, Derecognized",
        "label": "Operating Lease, Right-Of-Use Asset, Derecognized",
        "terseLabel": "Right-of-use assets derecognized"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetDerecognized",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OtherAssetsCurrentFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Current, Fair Value Disclosure,",
        "label": "Other Assets, Current, Fair Value Disclosure,",
        "terseLabel": "Other current assets, receivable"
       }
      }
     },
     "localname": "OtherAssetsCurrentFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OtherAssetsMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Assets, Measurement Input",
        "label": "Other Assets, Measurement Input",
        "terseLabel": "Risk-adjusted discount rates"
       }
      }
     },
     "localname": "OtherAssetsMeasurementInput",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "decimalItemType"
    },
    "biib_OthercorporaterevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other corporate revenues [Member]",
        "label": "Other corporate revenues [Member]",
        "terseLabel": "Other corporate revenues"
       }
      }
     },
     "localname": "OthercorporaterevenuesMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherresearchanddiscoveryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other research and discovery [Member]",
        "label": "Other research and discovery [Member]",
        "terseLabel": "Other research and discovery"
       }
      }
     },
     "localname": "OtherresearchanddiscoveryMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_OtherrevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "terseLabel": "Other revenues [Abstract]"
       }
      }
     },
     "localname": "OtherrevenuesAbstract",
     "nsuri": "http://www.biogenidec.com/20220930",
     "xbrltype": "stringItemType"
    },
    "biib_OtherrevenuesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues [Table Text Block]",
        "label": "Other revenues [Table Text Block]",
        "terseLabel": "Other revenues"
       }
      }
     },
     "localname": "OtherrevenuesTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_OutLicensedPatentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Out-licensed patents.",
        "label": "Out Licensed Patents [Member]",
        "terseLabel": "Completed technology"
       }
      }
     },
     "localname": "OutLicensedPatentsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PLEGRIDYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PLEGRIDY",
        "label": "PLEGRIDY [Member]",
        "terseLabel": "PLEGRIDY"
       }
      }
     },
     "localname": "PLEGRIDYMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables To Divestiture Of Interest In Joint Venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "terseLabel": "Payables to divestiture of interest in joint venture"
       }
      }
     },
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent",
        "label": "Payables To Divestiture Of Interest In Joint Venture, Contingent Discount on Shares, Percent",
        "terseLabel": "Contingent discount on common shares"
       }
      }
     },
     "localname": "PayablesToDivestitureOfInterestInJointVentureContingentDiscountOnSharesPercent",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "terseLabel": "Payment Due At First Anniversary"
       }
      }
     },
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "terseLabel": "Payment Due At Second Anniversary"
       }
      }
     },
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year.",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year"
       }
      }
     },
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PercentageoffuturedevelopmentcostsrelatedtoEisai": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of future development costs related to Eisai",
        "label": "Percentage of future development costs related to Eisai",
        "terseLabel": "Percentage of future development costs related to Eisai"
       }
      }
     },
     "localname": "PercentageoffuturedevelopmentcostsrelatedtoEisai",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Cash [Member]",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "terseLabel": "Performance stock units settled in cash"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Performance Stock Units Settled in Stock [Member]",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "terseLabel": "Performance stock units settled in stock"
       }
      }
     },
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans.",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "verboseLabel": "Plan assets for deferred compensation"
       }
      }
     },
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential future milestone payments commitment to third party approximately.",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "terseLabel": "Potential future milestone payments commitment to third party"
       }
      }
     },
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "nsuri": "http://www.biogenidec.com/20220930",
     "xbrltype": "stringItemType"
    },
    "biib_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones [Member]",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentAssetDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Domain]",
        "label": "Research and development asset [Domain]",
        "terseLabel": "Research and development asset [Domain]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetDomain",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ResearchAndDevelopmentCostsPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Costs, Percentage",
        "label": "Research and Development Costs, Percentage",
        "terseLabel": "Research and development costs, percentage"
       }
      }
     },
     "localname": "ResearchAndDevelopmentCostsPercentage",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_ResearchanddevelopmentassetAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development asset [Axis]",
        "label": "Research and development asset [Axis]",
        "terseLabel": "Research and development asset [Axis]"
       }
      }
     },
     "localname": "ResearchanddevelopmentassetAxis",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_ReserveforCashDiscountsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reserve for Cash Discounts [Member]",
        "label": "Reserve for Cash Discounts [Member]",
        "terseLabel": "Discounts"
       }
      }
     },
     "localname": "ReserveforCashDiscountsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "terseLabel": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues from anti-cd20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "terseLabel": "Revenue from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_RocheGroupGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Roche group Genentech.",
        "label": "Roche Group Genentech Member",
        "terseLabel": "Genentech"
       }
      }
     },
     "localname": "RocheGroupGenentechMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SPINRAZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINRAZA [Member]",
        "label": "SPINRAZA [Member]",
        "terseLabel": "SPINRAZA"
       }
      }
     },
     "localname": "SPINRAZAMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SageTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sage Therapeutics Inc.",
        "label": "Sage Therapeutics Inc. [Member]",
        "terseLabel": "Sage Therapeutics Inc."
       }
      }
     },
     "localname": "SageTherapeuticsIncMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Samsung bio-similar agreement.",
        "label": "Samsung Biosimilar Agreement [Member]",
        "terseLabel": "Samsung Bioepis"
       }
      }
     },
     "localname": "SamsungBiosimilarAgreementMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SangamoTherapeuticsInc.AgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "label": "Sangamo Therapeutics, Inc. Agreement [Member]",
        "terseLabel": "Sangamo Therapeutics, Inc. Agreement"
       }
      }
     },
     "localname": "SangamoTherapeuticsInc.AgreementMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "terseLabel": "5.200% Senior Notes due 2045"
       }
      }
     },
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "terseLabel": "4.050% Senior Notes due 2025"
       }
      }
     },
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "label": "Senior Notes Three Point Six Two Five Percent Due Twenty Twenty Two [Member]",
        "terseLabel": "3.625% Senior Notes due 2022"
       }
      }
     },
     "localname": "SeniorNotesThreePointSixTwoFivePercentDueTwentyTwentyTwoMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation expense included in costs and expenses.",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "terseLabel": "Share-based compensation expense included in total costs and expenses"
       }
      }
     },
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShareOfCoPromotionProfits": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of co promotion profits.",
        "label": "Share Of Co Promotion Profits",
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA"
       }
      }
     },
     "localname": "ShareOfCoPromotionProfits",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_ShorttermderivativeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short-term derivative [Member]",
        "label": "Short-term derivative [Member]",
        "terseLabel": "Short-term derivative"
       }
      }
     },
     "localname": "ShorttermderivativeMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SolothurnSwitzerlandMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Solothurn, Switzerland [Member]",
        "label": "Solothurn, Switzerland [Member]",
        "terseLabel": "Solothurn, Switzerland"
       }
      }
     },
     "localname": "SolothurnSwitzerlandMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_StrategicInvestmentPortfolio": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investment portfolio.",
        "label": "Strategic Investment Portfolio",
        "verboseLabel": "Strategic investment portfolio"
       }
      }
     },
     "localname": "StrategicInvestmentPortfolio",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_StrategicInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Strategic investments.",
        "label": "Strategic Investments [Member]",
        "terseLabel": "Strategic Investments"
       }
      }
     },
     "localname": "StrategicInvestmentsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets.",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "terseLabel": "Total reserves included in consolidated balance sheets"
       }
      }
     },
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of share-based compensation expense associated with different programs.",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]"
       }
      }
     },
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "biib_SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to Aducanumab Collaboration [Table]",
        "label": "Summary of Activity Related to Aducanumab Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Aducanumab Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoAducanumabCollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration"
       }
      }
     },
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "biib_TECFIDERAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TECFIDERA [Member]",
        "label": "TECFIDERA [Member]",
        "terseLabel": "TECFIDERA"
       }
      }
     },
     "localname": "TECFIDERAMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TGNMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TGN",
        "label": "TGN [Member]",
        "terseLabel": "TGN"
       }
      }
     },
     "localname": "TGNMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TechnologicalAndRegulatorySuccessProbability": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Technological and Regulatory Success, Probability",
        "label": "Technological and Regulatory Success, Probability",
        "terseLabel": "Technological and Regulatory Success, Probability"
       }
      }
     },
     "localname": "TechnologicalAndRegulatorySuccessProbability",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "percentItemType"
    },
    "biib_Termofcollaborationagreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of collaboration agreement",
        "label": "Term of collaboration agreement",
        "terseLabel": "Term of collaboration agreement"
       }
      }
     },
     "localname": "Termofcollaborationagreement",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Time vested restricted stock units.",
        "label": "Time Vested Restricted Stock Units [Member]",
        "verboseLabel": "Time-vested restricted stock units"
       }
      }
     },
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_TysabriProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TYSABRI product [Member]",
        "label": "TYSABRI product [Member]",
        "terseLabel": "TYSABRI"
       }
      }
     },
     "localname": "TysabriProductMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UCBPharmaS.A.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UCB Pharma S.A. [Member]",
        "label": "UCB Pharma S.A. [Member]",
        "terseLabel": "UCB Pharma S.A. [Member]"
       }
      }
     },
     "localname": "UCBPharmaS.A.Member",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Losses) on Foreign Currency Derivatives, Net, before Tax",
        "verboseLabel": "Gain/Loss on fair value of foreign currency forward contracts"
       }
      }
     },
     "localname": "UnrealizedGainLossesOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedGainOnDerivatives": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Gain on Derivatives",
        "label": "Unrealized Gain on Derivatives",
        "terseLabel": "Unrealized Gain on Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainOnDerivatives",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UnrealizedLossOnDerivatives": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrealized Loss on Derivatives",
        "label": "Unrealized Loss on Derivatives",
        "negatedTerseLabel": "Unrealized Loss on Derivatives"
       }
      }
     },
     "localname": "UnrealizedLossOnDerivatives",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total upfront and milestone payments made to collaborative partner.",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "terseLabel": "Upfront and milestone payments made to collaborative partner"
       }
      }
     },
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "biib_VUMERITYMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "VUMERITY",
        "label": "VUMERITY [Member]",
        "terseLabel": "VUMERITY"
       }
      }
     },
     "localname": "VUMERITYMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_VixotrigineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vixotrigine",
        "label": "Vixotrigine [Member]",
        "terseLabel": "Vixotrigine"
       }
      }
     },
     "localname": "VixotrigineMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WarehouseUtilitiesAndSupportSpaceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warehouse, Utilities and Support Space",
        "label": "Warehouse, Utilities and Support Space [Member]",
        "terseLabel": "Warehouse, Utilities and Support Space"
       }
      }
     },
     "localname": "WarehouseUtilitiesAndSupportSpaceMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_WorkforceReductionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Workforce Reduction",
        "label": "Workforce Reduction [Member]",
        "terseLabel": "Workforce Reduction"
       }
      }
     },
     "localname": "WorkforceReductionMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "biib_ZINBRYTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZINBRYTA [Member]",
        "label": "ZINBRYTA [Member]",
        "terseLabel": "ZINBRYTA"
       }
      }
     },
     "localname": "ZINBRYTAMember",
     "nsuri": "http://www.biogenidec.com/20220930",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CAD": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Canada, Dollars",
        "verboseLabel": "Canadian dollar"
       }
      }
     },
     "localname": "CAD",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_CHF": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Switzerland, Francs",
        "terseLabel": "Swiss franc"
       }
      }
     },
     "localname": "CHF",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "verboseLabel": "Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_GBP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "United Kingdom, Pounds",
        "terseLabel": "British pound"
       }
      }
     },
     "localname": "GBP",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_JPY": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Japan, Yen",
        "terseLabel": "Japan, Yen"
       }
      }
     },
     "localname": "JPY",
     "nsuri": "http://xbrl.sec.gov/currency/2021",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r716"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r724"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_ConsolidatedEntitiesAxis": {
     "auth_ref": [
      "r146",
      "r314",
      "r319",
      "r325",
      "r488",
      "r489",
      "r496",
      "r497",
      "r574",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Axis]",
        "terseLabel": "Consolidated Entities [Axis]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidatedEntitiesDomain": {
     "auth_ref": [
      "r146",
      "r314",
      "r319",
      "r325",
      "r488",
      "r489",
      "r496",
      "r497",
      "r574",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidated Entities [Domain]",
        "terseLabel": "Consolidated Entities [Domain]"
       }
      }
     },
     "localname": "ConsolidatedEntitiesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r67",
      "r69",
      "r144",
      "r145",
      "r331",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r216",
      "r402",
      "r406",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r330",
      "r368",
      "r422",
      "r425",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r612",
      "r667",
      "r671",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r330",
      "r368",
      "r422",
      "r425",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r612",
      "r667",
      "r671",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r216",
      "r402",
      "r406",
      "r670"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r213",
      "r402",
      "r404",
      "r614",
      "r666",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r213",
      "r402",
      "r404",
      "r614",
      "r666",
      "r668"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r330",
      "r368",
      "r412",
      "r422",
      "r425",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r612",
      "r667",
      "r671",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r330",
      "r368",
      "r412",
      "r422",
      "r425",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r612",
      "r667",
      "r671",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r68",
      "r69",
      "r144",
      "r145",
      "r331",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r161",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r161",
      "r166",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r214",
      "r215",
      "r402",
      "r405",
      "r669",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r214",
      "r215",
      "r402",
      "r405",
      "r669",
      "r694",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r161",
      "r166",
      "r308",
      "r423",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r587",
      "r589",
      "r592",
      "r709",
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "December 31, 2021"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r49",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Reduction of accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r15",
      "r31",
      "r217",
      "r218"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r28",
      "r620",
      "r646"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Accrued income taxes"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities, Current [Abstract]",
        "verboseLabel": "Accrued Expenses and Other"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "auth_ref": [
      "r53"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered.",
        "label": "Accrued Liabilities [Member]",
        "terseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "AccruedLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Royalties, Current",
        "verboseLabel": "Royalties and licensing fees"
       }
      }
     },
     "localname": "AccruedRoyaltiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r77",
      "r82",
      "r90",
      "r91",
      "r92",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Unfunded status of postretirement benefit plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r47",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r72",
      "r82",
      "r90",
      "r91",
      "r92",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, including the portion attributable to the noncontrolling interest.",
        "label": "Accumulated Foreign Currency Adjustment Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedForeignCurrencyAdjustmentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r92",
      "r93",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r82",
      "r90",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Unrealized gains (losses) on securities available for sale"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r92",
      "r530"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from increase (decrease) in value of excluded component of derivative hedge, including portion attributable to noncontrolling interest.",
        "label": "Accumulated Other Comprehensive Income (Loss), Derivative Qualifying as Hedge, Excluded Component, Including Portion Attributable to Noncontrolling Interest [Member]",
        "terseLabel": "Gains (losses) on net investment hedge"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r34",
      "r80",
      "r81",
      "r82",
      "r648",
      "r676",
      "r677"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "periodEndLabel": "Accumulated other comprehensive income (loss), net of tax ending balance",
        "periodStartLabel": "Accumulated other comprehensive income (loss), net of tax beginning balance",
        "terseLabel": "Balance, January 1, 2018",
        "verboseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r90",
      "r91",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r79",
      "r82",
      "r90",
      "r91",
      "r92",
      "r153",
      "r154",
      "r155",
      "r495",
      "r672",
      "r673",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r72",
      "r82",
      "r90",
      "r91",
      "r92",
      "r495",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Currency translation adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "verboseLabel": "Other Consolidated Financial Statement Detail"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r32",
      "r438",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "verboseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r435",
      "r436",
      "r437",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentForAmortization": {
     "auth_ref": [
      "r129",
      "r278"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.",
        "label": "Amortization",
        "terseLabel": "Amortization"
       }
      }
     },
     "localname": "AdjustmentForAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r427",
      "r432",
      "r439"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "negatedTerseLabel": "Compensation related to share-based payments",
        "verboseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) from increase (decrease) in value of excluded component of derivative hedge.",
        "label": "AOCI, Derivative Qualifying as Hedge, Excluded Component, after Tax",
        "terseLabel": "Derivative qualifying as net investment hedge, excluded component"
       }
      }
     },
     "localname": "AociDerivativeQualifyingAsHedgeExcludedComponentAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r232",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "verboseLabel": "Mortgage and other asset backed securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r129",
      "r284"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r139",
      "r201",
      "r205",
      "r211",
      "r249",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r488",
      "r496",
      "r550",
      "r575",
      "r577",
      "r618",
      "r645"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r16",
      "r17",
      "r65",
      "r139",
      "r249",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r488",
      "r496",
      "r550",
      "r575",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Assets:"
       }
      }
     },
     "localname": "AssetsFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r225"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross unrealized gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r226"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r223",
      "r256"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "verboseLabel": "Summary of Contractual Maturities: Available-for-Sale Securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r230"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r227",
      "r230",
      "r641"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "verboseLabel": "Due after one year through five years, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r227",
      "r229",
      "r640"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due in one year or less, estimated fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r220",
      "r224",
      "r256",
      "r624"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Marketable debt securities",
        "totalLabel": "Estimated Fair Value",
        "verboseLabel": "Fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r222",
      "r256"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r428",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r511",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "125 Broadway Building",
        "verboseLabel": "Building"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r474",
      "r475",
      "r477"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "periodEndLabel": "Fair value, end of period",
        "periodStartLabel": "Fair value, beginning of period",
        "terseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r474",
      "r476"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "verboseLabel": "Contingent consideration obligations"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "verboseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r126",
      "r131",
      "r132"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "auth_ref": [
      "r126",
      "r555"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r44"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashEquivalentsAtCarryingValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Equivalents, at Carrying Value [Abstract]",
        "verboseLabel": "Summary of financial assets with original maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "CashEquivalentsAtCarryingValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r479",
      "r480",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "verboseLabel": "Collaborative and Other Relationships"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r58",
      "r307",
      "r627",
      "r653"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "verboseLabel": "Commitments, contingencies and guarantees"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r533"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r30",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance, shares",
        "periodStartLabel": "Beginning balance, shares"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r30",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock, par value $0.0005 per share"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r86",
      "r88",
      "r89",
      "r101",
      "r633",
      "r661"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r88",
      "r100",
      "r486",
      "r487",
      "r505",
      "r632",
      "r660"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r86",
      "r88",
      "r99",
      "r485",
      "r505",
      "r631",
      "r659"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited_1": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Comprehensive income (loss) attributable to noncontrolling interests, net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "verboseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressGross": {
     "auth_ref": [
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress, Gross",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r413",
      "r420",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "verboseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r106",
      "r614"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r105"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total cost and expense"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "verboseLabel": "Cost and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r135",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r344",
      "r351",
      "r352",
      "r354",
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Indebtedness"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r138",
      "r146",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358",
      "r359",
      "r567",
      "r619",
      "r621",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r327",
      "r356",
      "r357",
      "r565",
      "r567",
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFairValue": {
     "auth_ref": [
      "r342",
      "r356",
      "r357",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable.",
        "label": "Debt Instrument, Fair Value Disclosure",
        "verboseLabel": "Debt instruments, fair value"
       }
      }
     },
     "localname": "DebtInstrumentFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r55",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Senior notes interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r56",
      "r138",
      "r146",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r356",
      "r357",
      "r358",
      "r359",
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r56",
      "r138",
      "r146",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r334",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r353",
      "r356",
      "r357",
      "r358",
      "r359",
      "r383",
      "r386",
      "r387",
      "r388",
      "r564",
      "r565",
      "r567",
      "r568",
      "r643"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1",
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedLabel": "Realized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table Text Block]",
        "terseLabel": "Marketable debt and equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "verboseLabel": "Short-term debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax asset"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r129",
      "r140",
      "r455",
      "r461",
      "r462",
      "r463"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r442",
      "r443"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "terseLabel": "Deferred tax assets, unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r129",
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r129",
      "r198"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "verboseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r513",
      "r594"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Fair Value, Gross Asset",
        "terseLabel": "Derivative asset, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r66",
      "r69",
      "r70",
      "r513",
      "r594"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Fair Value, Gross Liability",
        "terseLabel": "Derivative liability, fair value"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r69",
      "r512",
      "r514",
      "r521",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r532",
      "r536"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "verboseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r510",
      "r512",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet": {
     "auth_ref": [
      "r519",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of gains and losses (net) on derivative instruments designated and qualifying as hedging instruments representing (a) the amount of the hedge ineffectiveness and (b) the amount, if any, excluded from the assessment of hedge effectiveness.",
        "label": "Derivative Instruments, Gain (Loss) Recognized in Income, Ineffective Portion and Amount Excluded from Effectiveness Testing, Net",
        "terseLabel": "Gain (loss) recognized in net income, excluded component"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossRecognizedInIncomeIneffectivePortionAndAmountExcludedFromEffectivenessTestingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, Notional Amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Remaining Maturity",
        "verboseLabel": "Range of durations of foreign currency forward contracts"
       }
      }
     },
     "localname": "DerivativeRemainingMaturity1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "verboseLabel": "Designated as hedging instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed technology"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "verboseLabel": "Effect of dilutive securities:"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disaggregation of Revenue [Abstract]",
        "terseLabel": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r402",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Revenues by product"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "auth_ref": [
      "r13",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "terseLabel": "Dispositions"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Dispositions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DueFromRelatedParties": {
     "auth_ref": [
      "r143",
      "r317",
      "r319",
      "r320",
      "r324",
      "r325",
      "r326",
      "r573",
      "r625",
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.",
        "label": "Due from Related Parties",
        "terseLabel": "Due from Related Parties"
       }
      }
     },
     "localname": "DueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r143",
      "r317",
      "r319",
      "r320",
      "r324",
      "r325",
      "r326",
      "r573",
      "r626",
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties.",
        "label": "Due to Related Parties",
        "terseLabel": "Due to Related Parties"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r102",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r167",
      "r169",
      "r174",
      "r175",
      "r176",
      "r180",
      "r181",
      "r534",
      "r535",
      "r634",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r102",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r169",
      "r174",
      "r175",
      "r176",
      "r180",
      "r181",
      "r534",
      "r535",
      "r634",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r177",
      "r178",
      "r179",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r445"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r141",
      "r445",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r445",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "verboseLabel": "Taxes on foreign earnings"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "auth_ref": [
      "r445",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "verboseLabel": "Purchased intangible assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r445",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r445",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "verboseLabel": "State taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r445",
      "r464"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedLabel": "Credits and net operating loss utilization"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Collaboration expense"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "auth_ref": [
      "r433"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Amount Capitalized",
        "negatedTerseLabel": "Capitalized share-based compensation costs"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Income tax effect"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r90",
      "r91",
      "r92",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r183",
      "r250",
      "r382",
      "r389",
      "r435",
      "r436",
      "r437",
      "r457",
      "r458",
      "r533",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r672",
      "r673",
      "r674",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Amortization of basis differences"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity, ownership interest",
        "verboseLabel": "Percentage of stake in entity maximum"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r103",
      "r104",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis(1)"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r45",
      "r202",
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Investment in Samsung Bioepis"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": 3.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.",
        "label": "Equity Securities, FV-NI, Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r244"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "totalLabel": "Net (gains) losses recognized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLossAlternativeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]",
        "terseLabel": "Equity Securities, FV-NI, Gain (Loss), Alternative [Abstract]"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLossAlternativeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r244",
      "r663"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "terseLabel": "Net gains (losses) realized during the period on equity securities",
        "verboseLabel": "Less: Net (gains) losses realized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r244",
      "r663"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Net gains recognized on the increase in fair value of equity securities",
        "verboseLabel": "Net unrealized (gains) losses recognized on equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Extinguishment of Debt, Amount"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r537",
      "r538",
      "r539",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Fair Value by Asset Class",
        "verboseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r537",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r342",
      "r356",
      "r357",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r538",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r537",
      "r538",
      "r541",
      "r542",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r545"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r342",
      "r413",
      "r414",
      "r419",
      "r420",
      "r538",
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r342",
      "r356",
      "r357",
      "r413",
      "r414",
      "r419",
      "r420",
      "r538",
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r342",
      "r356",
      "r357",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r538",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r543",
      "r546"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "verboseLabel": "Fair value of contingent consideration obligations"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r544"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "negatedLabel": "(Gain) loss on fair value remeasurement of contingent consideration",
        "negatedTerseLabel": "Contingent consideration",
        "terseLabel": "Contingent consideration impairment"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r342",
      "r356",
      "r357",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r545",
      "r547"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring",
        "verboseLabel": "Fair Value, Measurements Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r511",
      "r516",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r232",
      "r233",
      "r241",
      "r242",
      "r243",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r258",
      "r259",
      "r260",
      "r353",
      "r380",
      "r532",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r277"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "Expected future amortization expense, 2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "terseLabel": "Expected future amortization expense, 2019 (remaining three months)"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "Expected future amortization expense, 2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "verboseLabel": "Expected future amortization expense, 2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "Expected future amortization expense, 2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "verboseLabel": "Expected future amortization expense, 2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r272",
      "r274",
      "r277",
      "r281",
      "r615",
      "r616"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Finite-lived Intangible Assets, Fair Value Disclosure"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r277",
      "r616"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r272",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r277",
      "r615"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "verboseLabel": "Derivative contracts"
       }
      }
     },
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r551",
      "r552",
      "r553",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "negatedLabel": "Foreign exchange (gains) losses, net"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r69",
      "r413",
      "r524"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contract"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "verboseLabel": "Gain on interest rate swap"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "terseLabel": "Gain (loss) on sale"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "auth_ref": [
      "r512",
      "r520"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "terseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments"
       }
      }
     },
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security.",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "terseLabel": "Gain (loss) on investments in equity securities"
       }
      }
     },
     "localname": "GainLossOnInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfInvestments": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net realized gain (loss) on investments sold during the period, not including gains (losses) on securities separately or otherwise categorized as trading, available-for-sale, or held-to-maturity, which, for cash flow reporting, is a component of proceeds from investing activities.",
        "label": "Gain (Loss) on Sale of Investments",
        "negatedTerseLabel": "Gain on sale of equity interest in Samsung Bioepis"
       }
      }
     },
     "localname": "GainLossOnSaleOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Gain on sale of building",
        "terseLabel": "Gain on sale of building"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r129",
      "r360",
      "r361"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "terseLabel": "Gain (Loss) on Extinguishment of Debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r264",
      "r265",
      "r577",
      "r617"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "netLabel": "Goodwill",
        "periodEndLabel": "Goodwill, end of period",
        "periodStartLabel": "Goodwill, beginning of period"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r266",
      "r268"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "verboseLabel": "Accumulated impairment losses related to goodwill"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r510",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r129",
      "r282"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r201",
      "r204",
      "r207",
      "r210",
      "r212"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income tax expense and equity in loss of investee, net of tax"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r96",
      "r129",
      "r199",
      "r245",
      "r628",
      "r656"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "negatedTerseLabel": "(Gain) loss on equity method investments",
        "terseLabel": "(Gain) loss on equity method investments",
        "verboseLabel": "Income (loss) from equity method investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents the undistributed income (or loss) of equity method investments, net of dividends or other distributions received from unconsolidated subsidiaries, certain corporate joint ventures, and certain noncontrolled corporations; such investments are accounted for under the equity method of accounting. This element excludes distributions that constitute a return of investment, which are classified as investing activities.",
        "label": "Income (Loss) from Equity Method Investments, Net of Dividends or Distributions",
        "terseLabel": "Loss recorded on Samsung Bioepis joint venture"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetOfDividendsOrDistributions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r421",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r290",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r289",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r448",
      "r449",
      "r451",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r141",
      "r446",
      "r450",
      "r454",
      "r459",
      "r465",
      "r467",
      "r468",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r142",
      "r164",
      "r165",
      "r200",
      "r444",
      "r460",
      "r466",
      "r664"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income Tax Expense (Benefit)",
        "verboseLabel": "Income tax (benefit) expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "terseLabel": "Income tax assets and liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expense and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDueFromRelatedParties": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity.",
        "label": "Increase (Decrease) in Due from Related Parties",
        "negatedLabel": "Due from anti-CD20 therapeutic programs"
       }
      }
     },
     "localname": "IncreaseDecreaseInDueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "auth_ref": [
      "r124",
      "r240"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "negatedLabel": "(Gain) loss on strategic investments"
       }
      }
     },
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in operating assets and liabilities, net:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "negatedLabel": "Other changes in operating assets and liabilities, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "verboseLabel": "Stock units"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r273",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r280"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Cost and Net"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r273",
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "terseLabel": "Total intangible assets, gross"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r271",
      "r275"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Intangible assets, net",
        "verboseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r94",
      "r197",
      "r563",
      "r566",
      "r635"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest Expense",
        "verboseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Interest Income (Expense), Net [Abstract]",
        "verboseLabel": "Other Income (Expense), Net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r263"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r38",
      "r262"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 3.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r14",
      "r63",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "verboseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r40",
      "r262"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 1.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "verboseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r39",
      "r262"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "order": 2.0,
       "parentTag": "biib_Inventorynetcurrentandnoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r261"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Excess and obsolescence charges related to inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r108",
      "r196"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investment Type Categorization [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsAllOtherInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, All Other Investments [Abstract]",
        "terseLabel": "Investments, All Other Investments [Abstract]"
       }
      }
     },
     "localname": "InvestmentsAllOtherInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "verboseLabel": "Summary of contractual maturities: available-for-sale securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.",
        "label": "Investments, Fair Value Disclosure",
        "terseLabel": "Marketable equity securities"
       }
      }
     },
     "localname": "InvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Litigation"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r52",
      "r139",
      "r206",
      "r249",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r489",
      "r496",
      "r497",
      "r550",
      "r575",
      "r576"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r37",
      "r139",
      "r249",
      "r550",
      "r577",
      "r623",
      "r651"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "LIABILITIES AND EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r54",
      "r139",
      "r249",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r489",
      "r496",
      "r497",
      "r550",
      "r575",
      "r576",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r537"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Fair Value Disclosure [Abstract]",
        "verboseLabel": "Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement agreement",
        "verboseLabel": "Litigation agreement in principle"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r27",
      "r341",
      "r355",
      "r356",
      "r357",
      "r621",
      "r647"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "verboseLabel": "Notes payable"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r309",
      "r310",
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss Contingency, Estimate of Possible Loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and Equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsFairValueMeasurementsContingentConsiderationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r62",
      "r139",
      "r249",
      "r314",
      "r319",
      "r320",
      "r321",
      "r325",
      "r326",
      "r550",
      "r622",
      "r650"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "verboseLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r389"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedTerseLabel": "Distribution to noncontrolling interest"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash flow provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r126"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash flow provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r126",
      "r127",
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flow provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flow from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r12",
      "r84",
      "r87",
      "r92",
      "r97",
      "r130",
      "r139",
      "r156",
      "r158",
      "r159",
      "r160",
      "r161",
      "r164",
      "r165",
      "r173",
      "r201",
      "r204",
      "r207",
      "r210",
      "r212",
      "r249",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r535",
      "r550",
      "r629",
      "r657"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "totalLabel": "Net income attributable to Biogen Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Attributable to Parent [Abstract]",
        "verboseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r84",
      "r87",
      "r92",
      "r164",
      "r165",
      "r492",
      "r504"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Net\u00a0income (loss) attributable to noncontrolling interests, net\u00a0of\u00a0tax"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New accounting pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Rest of World"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r389",
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Noncontrolling interest"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not designated as hedging instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NotesPayable": {
     "auth_ref": [
      "r27",
      "r621",
      "r647"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes Payable",
        "verboseLabel": "Notes payable, carrying value"
       }
      }
     },
     "localname": "NotesPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Current portion of notes payable"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "auth_ref": [
      "r51"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of notes payable.",
        "label": "Notes Payable, Fair Value Disclosure",
        "verboseLabel": "Notes payable, fair value"
       }
      }
     },
     "localname": "NotesPayableFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails1"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenseMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations.",
        "label": "Operating Expense [Member]",
        "terseLabel": "Operating expense"
       }
      }
     },
     "localname": "OperatingExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "negatedTerseLabel": "Operating Expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r569"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Operating Leased Assets [Line Items]",
        "terseLabel": "Operating Leased Assets [Line Items]"
       }
      }
     },
     "localname": "OperatingLeasedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r20",
      "r21",
      "r53"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r64",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "verboseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of other assets.",
        "label": "Other Assets, Fair Value Disclosure",
        "terseLabel": "Other assets, receivable"
       }
      }
     },
     "localname": "OtherAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Investments and other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r74",
      "r75",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "verboseLabel": "Unrealized gains (losses) on securities available for sale, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r93",
      "r556",
      "r558",
      "r562"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Reclassifications, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), before reclassifications, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeReclassificationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r73",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r80",
      "r83",
      "r518"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r71",
      "r80"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "negatedTerseLabel": "Cumulative translation loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Currency translation adjustment"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r522"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Gain on derivative used in net investment hedge"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r85",
      "r88",
      "r90",
      "r91",
      "r93",
      "r98",
      "r382",
      "r556",
      "r561",
      "r562",
      "r630",
      "r658"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r85",
      "r88",
      "r485",
      "r486",
      "r494"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "verboseLabel": "Other comprehensive income:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r78",
      "r80"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r511",
      "r528"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Component of accrued expenses and other"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r18",
      "r19",
      "r53",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Total accrued expense and other",
        "verboseLabel": "Accrued expense and other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r109"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedLabel": "Other (income) expense, net",
        "negatedTerseLabel": "Other (income) expense",
        "terseLabel": "Other (income) expense"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringCosts": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.",
        "label": "Other Restructuring Costs",
        "terseLabel": "Other restructuring costs"
       }
      }
     },
     "localname": "OtherRestructuringCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Parent",
        "verboseLabel": "Total share-based compensation expense, net of tax"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r114",
      "r118"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRestructuring": {
     "auth_ref": [
      "r123",
      "r296"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.",
        "label": "Payments for Restructuring",
        "negatedTerseLabel": "Payment"
       }
      }
     },
     "localname": "PaymentsForRestructuring",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r110",
      "r115",
      "r221"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedTerseLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireEquityMethodInvestments": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of or advances to an equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Payments to Acquire Equity Method Investments",
        "terseLabel": "Payments to acquire additional investment in equity method investment"
       }
      }
     },
     "localname": "PaymentsToAcquireEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r116"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflows from the purchase of net carrying value allocated to in-process research and development costs and materials acquired in a business combination.",
        "label": "Payments to Acquire in Process Research and Development",
        "negatedTerseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "PaymentsToAcquireInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r29",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r29",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock, par value $0.001 per share"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets.",
        "label": "Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid research and development expenses"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of Hiller\u00f8d, Denmark manufacturing operations"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "terseLabel": "Proceeds from divestiture of interest in joint venture"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r119",
      "r122"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsToMinorityShareholders": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from (to) a noncontrolling interest. Excludes dividends paid to the noncontrolling interest.",
        "label": "Proceeds from (Payments to) Noncontrolling Interests",
        "terseLabel": "Net (distribution) contribution to noncontrolling interest"
       }
      }
     },
     "localname": "ProceedsFromPaymentsToMinorityShareholders",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r110",
      "r111",
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities and sales"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails3"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "verboseLabel": "Proceeds from sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r112"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "negatedTerseLabel": "Proceeds from sale of equity interest in Samsung Bioepis"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "auth_ref": [
      "r114"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from the sale of investments classified as other.",
        "label": "Proceeds from Sale of Other Investments",
        "terseLabel": "Proceeds from sales of strategic investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r113"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Sales price",
        "verboseLabel": "Proceeds from sale of building"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other.",
        "label": "Product and Service, Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProductAndServiceOtherMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product, net"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r12",
      "r84",
      "r87",
      "r92",
      "r125",
      "r139",
      "r156",
      "r164",
      "r165",
      "r201",
      "r204",
      "r207",
      "r210",
      "r212",
      "r249",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r485",
      "r491",
      "r493",
      "r504",
      "r505",
      "r535",
      "r550",
      "r636"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r47",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r292",
      "r696",
      "r697",
      "r698"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r46",
      "r286"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Fixed assets placed into service"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r23",
      "r24",
      "r288",
      "r577",
      "r642",
      "r652"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r23",
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual",
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of realized gains and losses on investments reported in the statement of income.",
        "label": "Realized Gain (Loss) on Investments [Table Text Block]",
        "verboseLabel": "Proceeds from marketable debt securities"
       }
      }
     },
     "localname": "RealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "auth_ref": [
      "r665"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment.",
        "label": "Realized Investment Gains (Losses)",
        "negatedTerseLabel": "(Gains) losses on investments, net"
       }
      }
     },
     "localname": "RealizedInvestmentGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax": {
     "auth_ref": [
      "r82",
      "r90",
      "r91",
      "r93",
      "r556",
      "r560",
      "r562"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss).",
        "label": "Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax",
        "terseLabel": "Amounts reclassified from accumulated other comprehensive income, net of tax"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "terseLabel": "Repayments of borrowings and premiums paid on debt exchange"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r121"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedTerseLabel": "Repayment of borrowings and premiums paid"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "auth_ref": [
      "r121"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.",
        "label": "Repayments of Senior Debt",
        "terseLabel": "Repayments of Senior Debt"
       }
      }
     },
     "localname": "RepaymentsOfSeniorDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "Overnight reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r441",
      "r613",
      "r711"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r441"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "Acquired in-process research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r294",
      "r296",
      "r299",
      "r305",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r129",
      "r293",
      "r300",
      "r302"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r295",
      "r296",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r296",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Restructuring reserve, ending",
        "periodStartLabel": "Restructuring reserve, beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Accelerated depreciation expense"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAccrualAdjustment1": {
     "auth_ref": [
      "r296",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) which increases (decreases) the restructuring reserve from an adjustment to a previously accrued restructuring liability.",
        "label": "Restructuring Reserve, Accrual Adjustment",
        "terseLabel": "Foreign currency and other adjustments"
       }
      }
     },
     "localname": "RestructuringReserveAccrualAdjustment1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r33",
      "r389",
      "r438",
      "r577",
      "r649",
      "r675",
      "r677"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r250",
      "r435",
      "r436",
      "r437",
      "r457",
      "r458",
      "r533",
      "r672",
      "r674"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r403",
      "r411"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r95",
      "r139",
      "r194",
      "r195",
      "r203",
      "r208",
      "r209",
      "r213",
      "r214",
      "r216",
      "r249",
      "r314",
      "r315",
      "r316",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r325",
      "r326",
      "r550",
      "r636"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "netLabel": "Other Revenues",
        "terseLabel": "Product revenues",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "verboseLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]",
        "terseLabel": "Royalty"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers.",
        "label": "Sales Returns and Allowances [Member]",
        "terseLabel": "Returns"
       }
      }
     },
     "localname": "SalesReturnsAndAllowancesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "verboseLabel": "Accrued expenses and other"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r82",
      "r561",
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesTable": {
     "auth_ref": [
      "r228",
      "r231",
      "r234",
      "r235",
      "r236",
      "r238",
      "r638",
      "r639"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.",
        "label": "Schedule of Available-for-sale Securities [Table]",
        "terseLabel": "Schedule of Available-for-sale Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r470",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "verboseLabel": "Summary of fair and carrying value of debt instruments"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r512",
      "r521",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Summary of fair value and presentation of derivatives"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Basic and diluted earnings per share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r427",
      "r431",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r427",
      "r431",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r12",
      "r139",
      "r248",
      "r249",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r537",
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "verboseLabel": "Summary of assets and liabilities recorded at fair value"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r272",
      "r276",
      "r615"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Summary of roll forward of the changes in goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r22",
      "r41",
      "r42",
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Components of inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r523"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of gains and losses on derivative instruments (and nonderivative instruments) designated and qualifying in net investment hedges recorded in accumulated other comprehensive income (loss) during the term of the hedging relationship and reclassified into earnings during the current period.",
        "label": "Schedule of Net Investment Hedges in Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Summary of the effect of derivatives designated as net investment hedging instruments on our consolidated statement of income"
       }
      }
     },
     "localname": "ScheduleOfNetInvestmentHedgesInAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions.",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue"
       }
      }
     },
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Schedule of Operating Leased Assets [Table]",
        "terseLabel": "Schedule of Operating Leased Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesDetailsTextual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "verboseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r47",
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r295",
      "r296",
      "r297",
      "r298",
      "r302",
      "r303",
      "r304"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r296",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r59",
      "r136",
      "r184",
      "r185",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r371",
      "r375",
      "r380",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfVariableInterestEntitiesTable": {
     "auth_ref": [
      "r488",
      "r489",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.",
        "label": "Schedule of Variable Interest Entities [Table]",
        "terseLabel": "Schedule of Variable Interest Entities [Table]"
       }
      }
     },
     "localname": "ScheduleOfVariableInterestEntitiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Estimated future amortization for acquired intangible assets"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r107"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettlementLiabilitiesCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts payable for money transfers, money orders, and consumer payment service arrangements. Settlement liabilities include amounts payable to intermediaries for global payment transfers.",
        "label": "Settlement Liabilities, Current",
        "terseLabel": "Litigation settlement agreement(1)"
       }
      }
     },
     "localname": "SettlementLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee related costs"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r128"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Abstract]",
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income"
       }
      }
     },
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r426",
      "r429"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r133",
      "r152"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of significant accounting policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r61",
      "r90",
      "r91",
      "r92",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r165",
      "r183",
      "r250",
      "r382",
      "r389",
      "r435",
      "r436",
      "r437",
      "r457",
      "r458",
      "r533",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r562",
      "r672",
      "r673",
      "r674",
      "r725"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ReclassificationoutofAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r153",
      "r154",
      "r155",
      "r183",
      "r614"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailsTextual",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r29",
      "r30",
      "r382",
      "r389",
      "r430"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "terseLabel": "Issuance of common stock under award plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "auth_ref": [
      "r30",
      "r382",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r61",
      "r382",
      "r389"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock under stock award plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "auth_ref": [
      "r29",
      "r30",
      "r382",
      "r389",
      "r391"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock Repurchase Program, Authorized Amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount remaining under 2019 Share Repurchase Program"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedAndRetiredDuringPeriodShares": {
     "auth_ref": [
      "r29",
      "r30",
      "r382",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased and retired during the period.",
        "label": "Stock Repurchased and Retired During Period, Shares",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Programs, at cost, shares"
       }
      }
     },
     "localname": "StockRepurchasedAndRetiredDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r30",
      "r35",
      "r36",
      "r139",
      "r219",
      "r249",
      "r550",
      "r577"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "totalLabel": "Total Biogen Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Biogen Idec Inc. shareholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r91",
      "r139",
      "r153",
      "r154",
      "r155",
      "r157",
      "r163",
      "r249",
      "r250",
      "r389",
      "r435",
      "r436",
      "r437",
      "r457",
      "r458",
      "r483",
      "r484",
      "r503",
      "r533",
      "r550",
      "r556",
      "r557",
      "r562",
      "r673",
      "r674",
      "r725"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "verboseLabel": "Equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r367",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r381",
      "r389",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r578",
      "r580"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "verboseLabel": "Taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "auth_ref": [
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trademarks and Trade Names [Member]",
        "terseLabel": "Trademarks and Trade Names"
       }
      }
     },
     "localname": "TrademarksAndTradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r232",
      "r233",
      "r241",
      "r242",
      "r243",
      "r353",
      "r380",
      "r532",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r610",
      "r611",
      "r717",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsDetails1",
      "http://www.biogenidec.com/role/FinancialInstrumentsFinancialInstrumentsDetailsTextual2"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the cumulative translation adjustment from gain (loss), after tax, on foreign currency derivatives, that are designated as, and are effective as, economic hedges of a net investment in a foreign entity.",
        "label": "Derivatives used in Net Investment Hedge, Net of Tax, Period Increase (Decrease)",
        "terseLabel": "Gains (losses) on net investment hedges, net of tax"
       }
      }
     },
     "localname": "TranslationAdjustmentForNetInvestmentHedgeNetOfTaxPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r60",
      "r391"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockRetiredCostMethodAmount": {
     "auth_ref": [
      "r30",
      "r382",
      "r390"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease of par value, additional paid in capital (APIC) and retained earnings of common and preferred stock retired from treasury when treasury stock is accounted for under the cost method.",
        "label": "Treasury Stock, Retired, Cost Method, Amount",
        "negatedTerseLabel": "Retirement of common stock pursuant to Share Repurchase Progams, at cost"
       }
      }
     },
     "localname": "TreasuryStockRetiredCostMethodAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r30",
      "r382",
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Repurchase of common stock, at cost, shares",
        "terseLabel": "Repurchase of common stock, at cost, shares"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareRepurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r60",
      "r391",
      "r392"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r382",
      "r389",
      "r391"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock, at cost"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCollaborationsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEquityMethodInvestmentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r295",
      "r296",
      "r302",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r413",
      "r637",
      "r678"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "verboseLabel": "Government securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "terseLabel": "Unrealized Gain (Loss) on Derivatives"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax": {
     "auth_ref": [
      "r517"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net unrealized gain (loss) related to the change in fair value of foreign currency exchange rate derivatives designated as cash flow hedging instruments. Recorded in accumulated other comprehensive income to the extent that the cash flow hedge is determined to be effective.",
        "label": "Unrealized Gain (Loss) on Foreign Currency Derivatives, Net, before Tax",
        "terseLabel": "Unrealized gain (loss) on net investment hedges in AOCI"
       }
      }
     },
     "localname": "UnrealizedGainLossOnForeignCurrencyDerivativesNetBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r147",
      "r151"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "verboseLabel": "Investments in Variable Interest Entities"
       }
      }
     },
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableInterestEntityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Variable Interest Entity [Line Items]",
        "terseLabel": "Variable Interest Entity [Line Items]"
       }
      }
     },
     "localname": "VariableInterestEntityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "totalLabel": "Dilutive potential common shares"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r168",
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc.",
        "totalLabel": "Shares used in calculating diluted earnings per share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Weighted-average shares used in calculating:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r167",
      "r176"
     ],
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted average number of common shares outstanding",
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc."
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(23))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3444-108585"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/subtopic&trid=2122178"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1707-109256"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1757-109256"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1500-109256"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8813-108599"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27337-111563"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27340-111563"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583714&loc=SL75117360-209713"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117546-209714"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12317-112629"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123467658&loc=d3e12355-112629"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4613674-111683"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5728-111685"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6759159-111685"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5747-111685"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=SL6228884-111685"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20,22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1),(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121549185&loc=d3e80784-113994"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "http://asc.fasb.org/topic&trid=2229140"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=120253306&loc=d3e28228-110885"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10(3))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(3),(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(25))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.17)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.3)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(21))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04.3(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r712": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r713": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r714": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r715": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r716": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r717": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r718": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r719": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r720": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r721": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r722": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r723": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r724": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e689-108580"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>125
<FILENAME>0000875045-22-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-22-000031-xbrl.zip
M4$L#!!0    ( &6!654IG58YV:8$ -^=-P 1    8FEI8BTR,#(R,#DS,"YH
M=&WLO5M[%$?2+7R_?X4_KE^-\Q!Y"#\SW@\VX)?9"#R [8&;>2(B(Z&Q#DQ+
MPL"O_R*%A,%FQM@6JJYJ&6-W=W57===:F6M%9F3D7__OR_V]SU[H^FAU>/"W
M:_XO[MIG__?+O_Y_.SO__.K^G<]N',K)OAX<?_;U6NE8VV<_K8Z??O9#TZ,?
M/^OKP_W/?CA<_[AZ03L[IY_Y^O#YJ_7JR=/CSX(+X1<'UU_D#@YKS#LUMKX#
MU9<=KHP[A5+O+H,]SO_SY(L>@B0)?H?0NQTHV>T@1]S!C*F4T"K6^C_MB^XE
M:?<%T'>0(,Q8I?9<.+C8[2IVV:?']NOL%QX<_>W:T^/CYU]\_OE//_WTEY_B
M7P[73S[WB/CYR_&>:V_>] 6O5OS>.WEU^$0/5DWE+W*X__GX60ZC.W__R[W5
MP8__^=3CZ/E;C];';]_8Z8A/WV8OCG/Z'>=WHC]_Z^KE\<Z1RGOGM>=_>7+X
MXO/5@9U4!SB?'Z_IX*@?KO?IV,"S\_BTX^H[YY'#DX/C]:NWYWG)Z[VW)SH[
M>'KY\P^<'.T\(7K^Z^]Y=N #W_7D>/W>]SR]QOA(< X_MZ-O;Y4=6/W'MT;[
M84?'="#Z]B8<'4+PY;]]XLT[WKU 6[W_8\_>FS]_<_#G&_R?3NOC.W?X[9F/
M5A_"V$[L/__G[IT'\E3W:>=7/^#E\8>O\M\@#&['A1T?SD_2=/5A^.S *1K_
MAO.W_HJ*[]^M<9CIZ.W7DY/U6@_D/['C[.C/]/ABCPZ>_.V:'NQ\]^":M2RE
M]N5?]_68/AN?W]%_GZQ>_.W:UX<'Q]9?[#Q\]=RN)&^>_>W:L;X\_ORTH7W^
MY?_Y/__GK\>KXSW]<K2VG?,F]=?/W[SXU\_?G)H/VZLO_]I6+SX[.GZUIW^[
MUE9'S_?HU1<'AP=J7V#U\HOQ1EV_>;AJ30].']KQN]9IK5?RYOHOC^]K_]NU
M52 FDAI<R0*<A9";9'!*UOUDH'_=./TJWNC]<S,_H/UQ:5U]<?/ OM^KK^WG
MK&GO]D'3E_]/7UW[;-7LU"U^_XIO'+ZX$^Z_>!1W3]JSFR\>?X//[NT_>OGH
M]?=[CY_=C'=O_/CR\;/[SW;W[ZX>/?L1'KU^NG_W65OM/KO^^O&SW7 GWMU[
M]/KY_NX/N_[Q#X]>WGW]C[3[PR/WZ/7?GSW:OYWN?;,+CY\]BH^>W?YI-SQZ
M?7>ONCOA\:M'/TA^_'#WY>,;3Y\]>O;D];T;/]JU=MWN-[=?[;ZV<WWS]_U[
M/_S#V;G"O1NW7[1O;JWXF^_RHV=_W[_[4-S=\/>G=[^QOS<>KW9_N/5L]_7C
MO<<W;MIU=E_?>_C(OL/NV6>^MVNE@\</GZ]V]Q]Y^W[QT?Y--_[>W;_]\M$/
MNZ_O[G__X^Y#^TVO=]/=9S^^?.3KRSL/;Q[O/G#C_Z_OWK#S_?2O#F1MDFDG
M:#<=B,5T@#CNE.(K&  A<[_VI;-_:DD.TE\_?P_63XGRUZ>\/[ZU.A+:>Z2T
MOGG0;ICR7?OL32NU*[P\_J+9*SO[=MFG.XVN2/";)'CU 1)DE[%!BCL=B7<
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MQH=37NR^_D>X]W#W7\AFWW/,.]HMH(5>@CD[3SO1&KIA%Q.C]2#P>V0!6K*
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M$3PY"HG- X\Z_,EG9[$E->Z%I]C%<*;B,#V6H)[5NJ@:'0(;A"7EQJ$W Y(
MP_*PG"1I;9I=,Z/K+7;%D,Q@-Z':>RO>,R@FT+8\;*=/6IL$: ^!*K$V[*/F
M,I($L,BI%L D&&AY0&];TMHDM-*6)0K[7*F#=208M4#/KD0U\?=U>;3:FJ2U
M:;R&9_318M88'?06N'6?&E/)+I'D,B<^74'[/K0M2C*/,88?1DEV\J8\8*]8
MD->"SBHDN$I:VQ!2)8LKJ7NJF@HH0*68H1#T0N9CSY+69D*JJZ2U#208@NLC
M9XUZR8"C=J#Q+/OHN>7JD)='L"U,6IN$623-%2DN!^=!)%?OF%Q7%W%@[Y?'
MK(5KD41*J8UT&4%HKE?P)>8XJKK%4.A*B^8,;DX@E;M7*!T*((_Y:%#&9@&+
M4#N;J)D_II>;M'9!5>"PYBZ]FE#7#HD245-?<JKBJF HBT'G$I/6+JJX9>DR
M]D]*M6;PZ#DWY\";C>(0K2$M!IJ)DM8NJMIE@EAC!)>:!T?(+E*4(( )>ZBR
M')BF3UJ[J$ZOH$L<V91)P8GI4.BU:([J3)3"<B3ILI/6+@B?H XDE\C !-R5
M+5[$:&"U@$$3+P:?2TU:NZBZL2Y4RMQ[Y  M=.OPJC6DSLYKZ#$N!IS+25J[
M*%2:!<4DJ:EY!*FI6F#<@P.L7J,D6@PJTR2M71!*';V9A*#66 )T7RHTZ>*H
M,.48VYL:?6X!U> N,19R%U8%SI,&UU()V 1  [,R] Q2(GK?^F+0N:Q8Z.*@
MJ<FY*.)['6GL,1LNG;GG6H.@^N4TG"EBH8N#25$SU29<1@/"7'.R8#59CQ?5
MK)PL!Z:)8Z&+@ZR-$ER])FW=0_:9#:>2I.>DQ$[38B"[U%CH O'12C$I=\H"
M:/^"4V_='HY%ICG"8O"YO%CHXL#));16-?>,!<AE,]LAQ: ^^:ZNM,6 <PFQ
MT,6A4DJVP!3-*#@SV YJ82_%PB,OV1'6Q: R02QT<2AARZD%K4G80B*'!#U1
MZB7H2$MQ^6S2SR]GTN_REZ]\;(F*BYOMXQX"FT_WR93*!S&/?CI^5W,U!?.Z
M/%0O:_G*Y6-)V+042:Y0 >L]+3R6L?U00\KF$MWRL)QJ^<KE8]NJ$R7M'DN#
MJ)W-9A;AG-.(KEM<'K8;L7SE\H$68,\Y28PT%A;"V%Z9DV'L,HM(6Q[06[A\
MY?)IE:B:F0:-L1#X%% L1M58-&N-_NUR@P71:IN6KUP^G\Q9N!ZI&6,ZJ(_4
MNSUNY*I%<EQFQ:<K:-\/"4J3/L:M1M5_A<*,PNBR89MRI70%[>R7KUP^J7)N
MFDIS"$$A2^=1+Z&Y[JW;L#[#SXE45\M7-I!@S8*@E#76/C8 PU@%&]0.&513
MS5?#4U?,^H/,<J7E5E%]KAE*B13">"& Q&"N!Y;'K*5KD<\A4/6A%0NQD^=&
MHJ9#%@MY<+XO#]#)EJ]<"K@G!ZLWR)Y]T[=@[9\.+.B;7NOLX/DYSH^=/Q\G
M^=4)#T[&G?C5^<Z^E#W\F+/](F>)V/>>RDCY2TIC<Y,>$+17\:IO$F,VLLSW
MT?KXBP=VQ7:RI_?Z&[[MZO'30^/3"STZ_IF%[[ZJ>I?V]1WQ>$#[1R<'3[Y:
M'1ZM]E=[M+[^9*VG%/ZD\V#APG("25P.-1>/3L%9M.MC=&9G:VAC^+V=56R'
M\XKML'E0OAUY>_7<H+R^7M/!DU,()L+IO5[#D(*/K]0.%R,)T6?5[+N<5C*N
MSK!%16Q1+0IVJ9\U2[^Y4]";@N7[;<Y?4-Z&*[YF+JU+A9AK5>XQJ+-NM(L_
MVVA^(^$YO?^W3HY-'+ZV7V0^?=SUU9YUC2;4 [2C=X#ZEEZ-\]XXT>O'MU;K
MH^/K!P>K%[H^HO6KB[+WBR:*UD;FXT8N28"BCEP)'8N D4,@;C!1/BD\GY"F
M#]0 :!_/TTUA2C3U'B%=:=;AYQX(?&U5@S;16-.Y$=O@JL&;V9#_>+'<MZ[[
MQ_5/O[+<JZ-#"+Y\\?_N__"[/3=+YE9<)PS1.H5 )0D"9JT6\0&V&>VQLRF8
M_]*Q3;#!N.]%F\]1$D,33YFY(7$'P$ZN;VX@M7F6X!:MUM_3WHE^9:<\;53C
MDK?6^N\3/9!7[X\EO'WS.V\]NJ]RLE[;3[FHK_3.R6\?/#\Y'K?E_>_QRW?<
M6!W)X<G!\7TCU)_]%E>Q[MG09T_,/D@'4\D28XVID]@?YBCRUG=O8"/;0&I?
MGL>Z:F6S:F4IU)ZE96M5 *2,(;0@&3V/Q3V:KUK9%:E^-ZF84BECE+FD,%;$
M5N34:@(?(R87SS<Y+E>F]P^;WH^MS75QIC>Y%C/E/(PN1&F<:O.U%HMD*1K8
MIZ#&\T@F;F+T.MKG_0'D&Q#'T]W5P6K_Y$\GW)RV_//YL >B!V3W]>>KG+]R
MZW"M0I\\2SQ^?% 4WX^:_]3,IE $3+%5 &%7LVOB8AU5)C3$N?*#7E[QXV*"
M9NXF"D6@&S]"5BQ(Q3Q^U=JIBIZ) EZB*/R!?A>G&&RP[K6<;K,-D"MKCAD$
M8Z[!>_]FA:+?Y!6*]\WDK$_$@@_S6%\?CF&$9J_I^L6[KN>'P_6/_7 M>M_\
MDXR,@4_J=OR%+4Z,HT8Q(!; "J4SIQ)R0JA8*.-9>OL[0WSQ"JG?W^Y^QR!?
M? ?6/[/I!N6>>\&H3: T5\E4#3IK8*52VUED=(7F[XXRX@65X.G@2P+%5A2J
M4\Z4PJC&,[)9QJY^OTB&V$##L7E(_8ETB OR"1I\*\&BBF:]JG)'46MW(9FU
MK.HP3P#K+.X;JUEO^QDMM@ T"NUU5%.@L1]@K%TV?U)Q<UK!14TK_B* 5M0>
M2BXYP"B;7#)6BC5@\@99G-&HR.8@-?VX2$D-'4?G<H\6V/BJ&&KSU*#UUC!M
M_@CJYJ#Y248CE=2B)@]M#$R,(F-8FBF)14]46HYM!NUNC!%\NSX<]_W>^H$!
MLY)WH7EX\^M;MV_<O'_]0H<IOM&QK.+YTY70WIN+G<Z^K%]]\=V#935ARJ4R
M.VY,$7HVGAAALA*D*D7>1G!7#/E-AKQ3'..[3UVS9A*J--74W2@ZU 5\4))4
MT+RJXY1[DCE,;5P0568)7S)KG*AB3"Z!H\CB.K!W5#Q;_#B'#5HWI*5?@A9,
MM!69-.O\R?X-P*%5"95\UUY-"7R*5PS91"V89F\Q#PP"+)KI=+?GDCFC:\R^
M-:IY>Z@R2_A<"F;\TBB:2J 6Q=48+#[HO:;B0H692/F?ZZ/_+$.^_V[WYOW;
M#Q\MT2PP-7(^^) LL,=J]H ":F  C8B)YT^0W]-%7S'EOPPQB*3 8\?2$LU6
M)DY0.$ -6HHS:SD3IFPI>M'BN91+;A$]0,L&9%!G<D#!@O_29J+C6R$$DS@%
M/^I>QN83D@)Y8B>C8D/.W;E<.,V?( L4@DF84G,3=32V&FY 4CA7U9!\D%(Y
M!)P)4[84O9Z:"Q+-\C4'N5-U/4;#4\F:?I^-C$\K!+=.]FG]VRLT9ND4FD7W
MP7B1(37PDI"A(%1"%!"D.G^"7*80+)DI73E+ZXQ@P 45M,BQE9Q=Z.*,.S-A
MRI:B)S7T+.1*LBA.T=4>((P-)U)NY!S/1,:W0@BF&3OT/G0+!,2'!$D1H4='
M->86A.W0_ FR0"&8A"F9H'K/.8.1I'FJGFDLB:%0<W2IS(0I6XI>*"49-"*B
M#5HT#.VFEBS=@CN,J<]?QJ]_?^_NS7_.?[)XFAD"U"H&5>;@(:LY!FODT'J2
M #7B A*'+H4>B\\:TD3<0L80)8%WODKT''TT&'OHCK:$)[/$+IEJ=X@"P!;)
M8;)8H#2P&ZM!DJ\Z?P%?B@1,,^(KV(JK7I4CA$1$G$A]=S4$I.:NZ+%Q$C!-
M7IG&KL#2E NT&@C&,)"%!%VE5]T6GLP2NQ HI9(@N P0V)IU:8%\8G82M"U@
MV/<2AH.^O7/SF_NW;RPR@\"G./9%;T(U@L4"[&JD5,WJ933W@/,GR&4.!RV9
M*>!C*,&T (,9RUP( $/1C-(L9BP+B!B7C%[W(;O&7G,8<3Y5*?:H^#P&?UU<
MP+#O<H1@FFB \A@7A)$P -K0),#" %>X4\_0YI+_L5U", E3I(WEITVM0\EF
M+(E'61'"6D?)/$D+&%98,GJY-!8+" )+A)(1NUI,X)G08] ^A[7\OX'>Z8;F
M7=>_N<S[$A1GEEZ!$W F;5UX3 $V9)>H>@T"P_O)3"BR(5+PT72<)5> 8K<0
M8,2-#)4*C>PR<@ NJI,T%ZYL+7XHE4,LVBTT ,G,$5*GY'Q+/K"#^8OYDN1@
M$L<0TU@O@-1;1Y":V35JG%IP#I%H+A39-CF89KQ9>R^)F$($R$$K)FJ8Q:DX
M\5%FPI6MQ4^%,CF+Y<1[B+W4YDO+T&/FEK#-I4C(M,-$#U\=$:]79^]8HFLH
M?=0WU)XI.]!.2$YR0@Q0@K@VE['@#9&$Y?.%84P]NIJQ=Y#8N?K"4+Q3[RC/
M8EN%K<?0)T(#JP6?$DB+7#JK!7D!.Q/) @:(ER8-TY26P:Z.O>,>"2B<<J.(
MKQ0:1(8Z?YHL5AHFX0MK@9PJMH(*@;4F: V$2P5Q2>?2K6PUALTY!@?BQ5G4
M0!D=9B7AV 1-X1<P"'CK^NZWCY90F6ZJ):7=M2I4?(1>::P?L@>>G!G!5.8R
MY[0AFO!Q7)PE41(97-%YC$S (T<=4#/$U')0=3H3HFPG>-J*:\X"O-0 4B4*
M8SL9[X/4Y&.;2S&B;5"!25P">&&I'KUH &ZQEH@NL7"B$BO,)8]\JU1@$J*D
M%I70>:^B0"K(W%-KKF@LGM-<<A6W$[RH(S6XJ LFW!Q\==Z0JY0K^AIP+GL6
M3#M,M/O@[.!]?:$')[K(I:51.#BMW'+V,'8I(PT6#9@89/-Z/)>H<4/T8"LH
MTUQ2KC66&!BPCC4KW57,%:J/->>94&;;821NZ#I[XBY M7,F\,57ZPLBQSB7
M2O7;I1$36<$<0U8(.2:0),0.4<@ULX)F$Z_JEUY1YI>4J=6' JF@(X L3,V!
M]34)1R&TYA<0/6P%C* NCOV)M04!SY%:L:Z J.*("&=3L/*_P/C@V]MW[U]_
MO(#AI$E,1*">Q?E"H@XHN-JU01!%PIJMK5\19 ,+6$S"E$R)$;'ZL;0Q.\$B
M;90VC91++VXN0Q)_GBFS1"\D"*AC:^R4 %O#WE)+H53DUG->P'+#Y0C!-'L<
MI- E)Y]*)X@Y< Q2<H$&/5)/X8H@&R@$T^0:C15I55KV$D Z<8.<0;P+V;/3
MN423TPO!).B55&3L8\(FW6"-O#9.):+AV'US,I?QXO^"WE<W[][\]OJ=V_,7
M@FFRS*-7<NJ+5P_>1]9>L(6>VM@/H\QE$XSI";+XB  A5BE5<JT$W)5:)QI[
M:0.ZL8QE:Y@R2_1&1M&H-\)@D?^80L1N85RT/\P#R?G+^'*$8!J?%YLC;XT<
MH()O3)%3K[WGY@5Z]5<$V4 AF"9V1&==2<KHF2 79%^ :NNMH<^$<YF)G%X(
MIFGG(B[7W$JE H%;-=PL(@#HZJO3!2Q#O81YY-N[]Z_?N;%(HY"H&3DH)B6!
MX",6K6. "'/*'7@N<T@;,GN\8*)@8I<DA[%\"4HGAAI3,5]I7;]T7<#ZY 6#
M!PS9&G16NYE (5$9$1V/#8LHB,XE'-@&%9AF=:)*D3'LZUP$CLHAC<HTSM?J
M:YM-39JM4H&)BA=!CQ6(28PHI-@2]UI(>G0-= $SC0L&KU=!'T*!/.I;QXX.
M4V.VEN]]+&4N&Q5-JP*W[MS^Y_6O%ND20O*YJ2?)CDXW1HW>0@)!YWJ/F.>R
MM'1#5&#!1$&CB AK .K0E"B1A8PUQ^@]I[* :<8%@\?)44=??#+PJ%1FPC2P
MJB6G"'.1\&U0@6FJGZ<"I9886VT0M=5BT0%S%>BI)9C+S,!6J< T"T]\#R7W
MD4N0H 6L"-V!&VK "6 !$P,+!B\0NJ3B,EAS;Q0LBA-5;W)>N16W@'HSEZ "
M7SVZ=^_[VX^7Z!(H4\(:+;Y'!E>4P.4JB3&VP!1A_ORX3!58,%'8J;.NGT9!
M:RC4:Y/472C=]5J++F 3]06#EWWD@B&3] 2,E:0X"#64:+&<SB8O?!M48)I*
MI5FZ9+2_,A*%'!LU*-92!*.9O*M*I5=$.4L2ZEF#)@Y1'?18J(91Q H@([K>
MYK(!QG:"%[)H''%^<04X-BZ:$(HU=2XF#0O( ;D,%5@='JWV5WNT7F0ZN%"K
MUKPI!DK@9%0A9M7D4LH.NYM+69E-48)EDR6Z6G,F],&PBQZHN91S*;FXU'V?
MRT3C]@)(&6( "PP@FA#8?Y*OOI)%>:62IKG4*=T619C$-3CQ7F.N58PCG7U%
M:_6]L3//9Q9B+I9OZQ1A&K)4$C$#X2)[Z,Y1Z*-&50]8,$.=RZ3C]@*8S/-A
M<2V'C)!KPYXBU.!9>XM-Y[(<<.)9X^]VK]^X>7]WB98ANK'6W#%H,<L0D20
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M$.]]@N&T3P(.E(I$K8SQ,=!$8]*AB,O!%:+N8?/#P(T#Y^(BONJ0R>RAV!]
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MQ(<R]AJ,%%&K-S_:F:61+K%%7@*0$VSK,,9!(8?8N8-ZI-QC:%$DUX(&[[*
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M_/2PW3YXH6\VX/WUJZJ_*,[U@/:/3@Z>?+4Z/%KMK_9H??W)6C^F8O^5Q_@
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M&4N<$R?'9%3(&C+C3 /C-K*,L0L%L%>5G2^QQAY/GN*GA#$;E2$%*'P!N:2
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M]"A"/.S%4I'S*])7%W:]K<\SJ:%Q2WLG1V$T^&G\-9G*SSX1T^4GLCN?0V]
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M[!R>UE^?B/KK=_CD_=[ER?=WW^KO]VA]YX0.WP/?=?&!OI/U]Q^:'W;VOA[
M>_;?O_I<?[V+/WSZC#\<P]]]^L^G^O$N.?ET@NN?/J3]2_SMS?%N;_\(?]O_
M_A<].-[_1UF=C"(4:>HIXEQJ9).W2"5/(J.:&R'7-LFZD70#S.^/Z^$6UV(:
M$ PI;@HPW(.X)W#K3$AF+K1Z&\G,CDOF<AO3<(D01!FF"4Z$"TJLY90Z&Z/W
MS"67*BXA0RXAA4L6PB7?1[DD$/B?]@%)+SB"B1-(.Q(0UYP0'+S#3(..7Z=8
M;*CIN&1AE%$$RU,5+))[:K%SC"C&.3;.X4A-8 8L'P.R&0@64@3+(DF&C)(,
M-@D++3V2R2;$#67(@5A!S GO$\8N$K&V*=>Q9ANL")8B6.;!)51)$:5D) 3)
M@4$T5QX8Q7N+-? &'0@64@3+(KF$C7*)",(IRC2BE(-,B<(@&S#X0B%YR7R,
M5I+,)5*P#3Y_P?)T(T6#Y=T_>I7+9:)M0,@/-26']2IO#8?27X=#?TF?*R]B
M@E0J)7"*(DAN&YRUA,!BYBEP94S@#XBZ%&ZY,[?4M\<#*]K(0"R-2'$).H5B
MC+0Q# @&A*;67A#!UC8YD1MF957*!"S.'G++9NL920I YYVEAD=B-$G<N>@E
M25%J3A\0G"B0FP9R8_$'%K&,W(%K$ U SGJ!')84/ 5P[8 ;@Z<Z0TXLPI@_
M&%G/V,I%XKR,1 F6$@_.&*P8=LE':YB6BA57?1GP..:J*X5Q,I8B131&'#PB
MI+G02(OL&T4N/,N]D=>IH!NR&,%5,H)8A9"C9IA+P26F3G/L%=:<4*8,3\7A
M709$CCF\H%@(> 8:V;SEQS&UR(5(4>1<LT@M)UY7B.2\.+RSA-9!=FV+*_LS
M2A'&**V3$4D$3L%W2D$'IJB1RN;?%5=V+JQQ-.[*<I:\CYXC'4(.N1,/7JQQ
MB'H7M5-,1>^ -:C9$,6*+YQJIH"<\M+C)%(DV'$EG'6!:>&] < 1PUAQ9><$
MN3%7%@?%3! ).>8DXC$QI(W._X#7(PGS'.>T'*$V='%E5\G*82(P84P3 U8N
M2.X8-2IQ#WK,<<O$ US9 KEI(#?FK2;#I$L<O%4>'.*<1F2-S.!3VHO K(AF
M;9,:5JS<BEDYZ0)U#@?!P,H1J86AC L:I&*"\8=LSA;(30.Y,7?44!.H]>".
M"JO '54".0/@BP$\41LQ9=2O;3*!ITT]79 S2LP*N*+'[5Y5$;-:PP]Q2>]\
MONAI6G+IL$R66&)LY(1*0V70ED4..II@_Y"MUQ("FQ'G-,:=6:J9L#%09$%:
M(^Y!7FM0VPA\6&68(#3HE)-4!=8S,_33G,1;D"*?+Y:73B*8B#F)E!ON.0AT
M$QGEE&&L::1:QI)PO@Q8'O.2C316"6D0]C$'ICQ!ADB/;/0T$F:<L3YC62D]
M=9;%\D.VV.7)N9C66="48'FEYTYZ:USPDN-HK4B2V[)9O Q8'G._"0Y<,,D1
M41A\ :DYLC($I#66N9R7=5JL;:IU2<VT6U/%+J^J7=;2>X>%2&">>9;:&%:)
M\<$+N'5K0]EF7@8LC_GUF!#MK,(H"(D1MQPTM@2[3!+UC'!#N,1KFWJ=<K5T
M=OF)5978;G<'33/ZO7!+>8G[E)=8H=M_NCD4U5)NI^OFSL..._8LMW;L]Z3L
M=SDX.[>-3M5IM.HL-FB7TFCU;.MCU8#7=KNQ5\X6S#? E2?P(+UNMT-WJQ6.
M8N=+P\?N4;L9BL6=PN(>3#AM8(+0F B*I,I'K[UTR"7&4' 8UA0V+BJWMLEE
M2=%8!B9;9&2J@'!6(!P+1SG&%.?<(B.J^@<B(*>40S!G2NJ0K+4 0D%(2=I8
M+4LX\Y#2ST!8'-.9(70LR.2YI9H +IF.#AQ3+,%,*H((L\YHR3V&F=LDZPJK
MF069E@*\3]]0SCQ45# Z%XR.!X],U#CFDPF:&\0CV%,=N<S9QEA8&[U4-&.4
M<S/MJ:%R1N'GA_*[T7;\:>5"W^CF6;SD.:>!]*<!2&?G>A)V^^&[W6'08VL0
MU-AKO>VT@9>ZF:X*]TS#/1-..@3)C+:1(29]U@>>(1N50AI$ @G8<)JR@@?F
MH44=+)RP%IO@45 Z)Y2.UQE4TC%A)<)&@4+@0B+C34#64BL]M5HXLK:I,"WG
M_%?+ECY"ZL8#4%I$_LP@/.:(,RTEA>6'O,BE.G0TR!APQ(&;G38D6!]"%OFR
M'"I<-5/["#D;!<3+ .+QXQLJ,@;2& GF<XDK;Y#U0B"!E5<B8;#&/(-88[*(
M>K]/UU,_BDWXY<?UVL?8BAW;K#QV&\X:K4:WUZF:Z1:G?:Y.^V!&7O?G YAJ
MZX?9&)!589QI"G8>;U5L4['.\3[\[O/W?QP.020?D,KU"+)Y =\<_/7LQGF0
M_RKB[*#+5:[]^RQ5P\P=](+(QT'DY0@B%>5**!F1RR>FN?(9C($@IA*5F%FC
M:5K;E((OX@QG<<:7R!F_*R*+9)\=7.NC!I1Q$.PZ492\4@!7(Y#%+" 7>=0\
M<<))?P=<X6FS5(H)?6*.=P'L @ [:E^-92F8%!$3N4&7LQ%9A2V*/'B@89AR
M6Y7LTUJ6DGVS1-Y6R2I?:M?;-1KNQ<U) H+:NYJB@W0=$!S.SU8U/862IJ*D
MW7$G/,)4&6D\8B&!AJ .(VVI0$:HQ -3!IYD)[Q$[I> QA;A@Q=HS@N:HVI!
M$*T BQZ\<>$1MSH@"Y.(4M*81F<IMN"-$T(V</'&5\ELSLP;+]B<$S;'7&\:
M%'?&2T0#%XCSB,%BZH1<3G3U1IE &6#3X-(19K7LYLP<[X+->6%SU&YB;T#8
M4(NXD0QQ81RR6==:9;4CFC%@W;5-3=BTB9_%Q_[YD>YFT[IVI^]DGW?:J=&K
M_=9L=[N_U[JGM@.W5;SI^7G3/TQ'?S;R7 QFHK#,5"RS-^XX2\-T5)@B+[$>
M'!#-Z>5":PI* 'PN#2S#1=F\7@)N6ICC7% X6Q2.^<A)":FB10E3"2B,'&P]
MIT@;+&U*)$9-UC8I682I+R[R" I_FZ^/W(6;AD<%CX^'QS&_.''K(A44$6,X
M^,6*@E\,\.2Y\0\X5#0J#U9Q4H^XWXM!7$J#.%N/N !PM@ <-8B<!!JTT[D6
M@L[GJ00R028$[,Y(5!HSQ=8V%9]V/Z?XOC^U;*]MH_5[+:_D&J IV4:G]L4V
M+V*M$\^B[5[D'_V]YHPMN,O\#!YV&R'VL? ,?>-I],#,L[Q?P1S]G:=H_WI^
MWC=ZI^]:;0>W\\6Z9MQKG5_TNH<1KL0WFHUJGN#912=SU4O;;73?-*R#5WJ7
M>0&\@>G?:^4S+#FLMVL[+?BS$M";CM/VQUUM@@/UA',0^<0@[GQ"1I* F)&4
MQB#!,\,@\B<DI19-,4\27&2*>('STL)Y+ O. ''CJN>D!XFBA4.6XX TIMYQ
M[KTGN96TF,)'6 K8/F?S//,$\X+G9<7SF,^OP!7TEF+DL,/@<F PSS@J!+Z^
M2#B!XV]R5BN;<&ZTV.<EM<\SSS\O>%Y:/(^= I-"@W=ED0X6Y+8TU2,.H$Z*
M^\0E9G%MDYLI]':)'OPT._TZ_1R=]PL>U#JE@-LRG 6?7*_BJB[%C^=E4N-;
M#.A[[+0+"4U%0G]-\/F)E"'!<%KO@81(8L@R+Q#(3*6"#<E1L[;Y?_Y+4T+_
M+#OL"^>PY:O?5D Z<Y".*H4@L%'8421ME(@GEC/4/4<^L@#<RWS Z9X@70HL
M/F-+.J?R;06DLP;IF'ONP)3&X"R2"8,E%9+E%!F,0"*!?^XPCCG<5BSI"EK2
M.95GNP'2 L;IP#AJ,:EC)D5B$::>Y8+H"L$DPO1(HL&:NJAXKI6H%W&DZ^DZ
MV+"L>YT+W[O(@:2:/[6=C[$<[9Z[)WT]!]O]*2A\,A6?O!MWDY.PRMK<(8S9
MG.[#'-*"6L2XH$IS1D6TU5Y:Z8"R>!I:L(\\ 7Y%<\\&EJ-FWOLH0D@<,9C"
MG/RJD*-1H42H<"(0*Z,JCO%*&L;'<(R+87PH L>\7ANMQI%%Q,$;0EQCB:S+
MI0PCE5@;ZZ7U8!CIU*4,BV5\>CYOL8R/ALNQP]E!,!:)RM%B &>*%%GN%2+*
MT*0)![*G"[2,]_&!5\ !SND2.3$]M]O.2>CNHM$,S_- ]D*3SH=I*P>M(YB)
M@_2VTSZ'\;E\V[2MWN[_7C2J>%MAF:E8YN2&6_S7]_K.'O^'>)<LLPPQ1QE(
M  OZFWB-=/!>.J\M-7AM4^"2D[8ZAG_F+O%=P5BDP&Q >CD"TJBX%(0QY$G,
M=5JT1L:P@(*1'D?E0\"V.,FK:3EG[B47R_DHH*R/6DX:F54AM_#RC" >4PXH
M&XZ4=4JSJ)EWMEC.U;*<,W>9B^6<+TA'+:<B"BB3>"0)L8@[Y9$FPB "<$W)
MQ"CQ(L/+3]2)/NB=QD[MMT;+M\_B[[78+YF_7FO%YYB5O5 _NIJ*@_/JZ'SK
MXUXU(X,6!O585,#]_>=A%0F-30"# 8SB<R.@P)$37J+$@7JL)J#38U45?#Q-
MI8B Y10!,W"?1PHJ%3 ^LI\\/"\MN3;<1"0(-8A['Y"-&B/0 -2)$(+0+$MR
M.FVMX:5 WG.VBS/WD@L4'\D['G;+2#9)$P**P@3$0PK(.2K 14[6,X.=K"J1
M4#*AZF<QC,MI&&?@'1?#.%\W>%C\T^ 0"=?(L)3 #0ZY!&^T2!&B76(,*V;7
M-@UA*]),BY@5\(*/VSW;A#OJ]JJCR0,O^"$.L&MW0NR@7OO\11Z);KO9"+5\
M,ZLJ 1;I&6_#Q'2W6F' ,]W2T6]V%.3''66P'"#8"$9.4: @2QVRPE)$+$@"
MX@*E(=<R6B=,S2P%^VYX69R@GR.<ETU+S'R/NL#Y4>$\7II,&B!DAS03'/0]
MD<@H;A'.+76-]UYJ ?I^G6LU=4?=)4=ML<YS\,\+G!\3SF/NNM8LVB@#RAG?
MB$=,D79*(Y!6007P'JA):YM\'2QXL<Y/WSK/?!^\P/E1X3QJG9EA0C!O4:I:
M[A"+D75,@;'&2GF-L=%X;5.N&ZPF9*<LT#I/%PM8^A! /Y)5<Q%6>ZSU]\-K
M/?MM& SH!P;^]Z+1NX17!U71$SS\$KN]V-\QS[^ MY2XP9+$#?ISFI-Z7G7:
M9]M5D?H+&,-!^++=ZKZLIKO_=\?V6^SN-UKM#LSQ'EQ7!V8V-SC\X5-VJR6P
M'WNG;7@E3WY."RHL.4.6_#@>DK!,&:DL0=PKFLLW.F0#%MF;X8EX9353.23!
M%)G9V;<B>I96],P\)#%7IBAD,!T9C+6#H<G&0!TR@GK$N2;(.(I!,C$>K2?,
M![FV2<WT5+#DB"^B80[AC"(:5I0GQONV>>6,-01AP23B.E=S%X$CK;P-6C$9
M'<V!3Z.G+DU51,/JB8:91TH*4ZPJ4XPJ"E@,*7+&4  W$W&P(<@$)1#UA,2(
MG915Q:EUQO&T35=+$&;Z($P.N_SF8BNF1N_W661C/'T9]$BQ$R"M01SX97\Z
M"M=,Q36?)Q2!]S[P@".2@>1JF4HBR\&/P4H[A8W)"Q94"9-3,TW)N5SY_F^W
M)%T6,,X(C&,U[1S7,0D""\A;Q'DTR)&<^PQS([@3FG@#8!033B&4MFW+:0D?
M*2!0P/=0\(V7LU,">\()LC:!ZM9$(!.]1,QXRH1T3ED GU!ZVK[.Q1*N?J>U
M8@D?%XQC->RD3U%[BAPLI5RX1B 7 T=,,D<]S&>UP\8,GJ)&1O%PQU"T>Y5!
M<'7F_K%2"9Z^J9^9T^L:#??B3H&X>NP=)*"?4@=D%D3T:6O</\;*@O:F% E%
M$N(PJPA\)X8<]SA9;+QDNK1V61Y&6TB']/L M@!S.F".-T;CVD:KD-(Y<"6L
M1=;1A$#7)6X3\2$#<]*F>W&5G_I9_8+'1\?C>(MR9XU-*B!'=<Z$LQ392 D2
M6D=!DQ0QU[.A&[*<VE\5^SBS+>J"Q\?'XUB+<9,S2H1!'@")>.(&N2#!7!H
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M%P?'?^'ZCN?PGJ\G[S\T3H[_<W:P Y_Q^O 4KO7LY/@O,;J+5?^^=7GR_;.
M]^#Z]X_P_I>G'\[^ W]_PNOO]_&'U[N7)_3#:7VGF?8G]!PGX,9*3RC"4C'$
M!?>YL#A#FIL(CFT2X-BN;;)UJ28U-5F58[IW/3RTE'Q\&R$]W8UUZ:V7EDGO
ME."<:.TC#C%2*O(KEE>\0PAEI/#.:O#.6-USF@13F&I$;.ZLG'G'> ],(<"V
MY'1?+&U.1:*23%NE;/ZGHE9)W>W;SN<XB,=$?]%I]!IQ3-D]@P/4"Y!!6U]L
MHYE'_E6[<P3L<70U_CO1]:Z?#1RB0D"S(J#ZA*:J@5$I*25(6,419R(B&Y)#
MEG!NDN+,:)6S=R@3,ZMS6DY0KY1\*'A='%['! .15F#M+0K"N=PH1>5*!Q01
MFHBQGAJ13,:KX%-GVQ7!\#/@;7E?;2S5.M%'$,> AZJF6=$,<]$,@]$_O!K\
M>NP5PIDUX4SHNR8,$T29A&+R!H$F,,A*SA!FB@?OK#.V$@A"ZFGK-A2!\$0$
M0@'G?, YI@84U9'D0D=868NX$@(9&SUR$>0!X3H('/MJP)3PP2Q1MG,1:ZG3
M/JO95J^!MG<HSAF#'7L>+^ Z:^>=]L>./2L!A4<5!Z[1<"]@)O)$Y'G(TW!C
M%H:34%AF&I9IC$L ZQ)U, \H2LP0=\(C*ZA!*DD<I4XQ*+FVR8F8NI%"$0 K
M+0 * !\%@&-FWCI)L(H,24LXXCX&Y$342%&::) JI>0S .FT52&*D?\9DO9:
M7T#!MCN7Q8S/P\>_&F[P'HK;,#,^F9#M$$D *VX9(E$2<!L21]88AX*67G+!
M Y:XZJV@Q 8N)GWA1+0 G[Z \9' .&;<.68F"DZ0]=$AKK%%5EF=Q;9Q5%+"
MO>HW.IFZTV Q[S]#5=4HN.9_2+LMEGX>EKX:^:UJP$N8<,84<S!ADS^"BQ!D
M,BAQ PZ\=Q+\!V\1\1A[QJ(,M.JEQ$W9Y%\&9EJ O9\$R8*Z:5 W9M@3)D98
M;!!Q#KQVXCER3@24?!+)\,@<U6N;BJ] O?,^=,P*&/7C=L\V9VC4GWG#U)GM
MWQ=C_RBT,V'#GG-80C'7-$Q6((Z51-H&@\"9EP(;K&GP:YMF74DQLPW[)2M>
M6!JC/MI6?\'Q(^%X3#ZPI)VC6"&L#<B'P#BR+FD47;!2LX"MM2 ?UK604XOV
MT@"U'!98$>%PQ^3C7/JS^"W3GTDZWAKOVF%CBH1QB@03#/%$ @(BTHA&291E
M5 2#US:UG+[Q<@D6/ T54$#YZ* <+;,K?3 VMPXVRFO$-6?(&2Y1]"8E["7C
MB@,H#9UVQZ[8^S%(O>VTS^&2+M=KYTV;PPBM4!6 .,_U_4K6_]R,_W >WN99
MV&J%W>$<E$W)F=+-A)[E,;>A,38A+5U"7(6$K X141YSTG^BP=-<$(%*6;+^
MEH"R%J ""CKGALY1,2!X\H);@9CV$G$<*;+,8.2(8!Q[@X.R&9V<3(W.(@?&
M$P5@F=M>+@_<C+8;2ZK /%,%AF/_)@_]8;Z8@_2N&ZM 9"&2J8AD0H/.R"@E
M6 OD9;"(LY!3^YU"+&A*&;/**[VVR2DO>0%+0$2+R LH^)LE_D8->0C*2:TM
MHE)PQ*-5R,+:1(%&PD,2+'D/AEQ-?;2FF/$)Z?P]V_K8R%'\O@4OGOP<<_N'
M8]_?00078??;H)77ZW8[?&TTF\5GF!W5[(^;>A\LQDI1A%T"4R]T0LZ!@\^-
MPDE&KEQ0N=08QGK#%&._<+I:2-)_0>F<43HJ")0WBEB.$376(Y[Q:IEFB)E$
M.3.21R.K@H"4+/]AOZ67!,-%743 /$1 H9#94\A?$PR]\$ ;0B+KP), GUX@
MIX%'J)'!*4>CLG%M4ZPK3F;6WK@8^I4R] 6)CX+$46/NJ(V: ?2\H@YQCA5R
M#&NDC+;"&JE%/G<#2)0K4*QOZ8WY3DRQTXFAUK/?^AY^,>OS,.O#<>]WZCZV
MWZZ<AT(OLZ.7=^.&/DBB1#0$*8G!C]?@T6OK"8(9Y#"WD0AM\[$^HDKX?AD(
M:@&&OF!S3M@<]^.3,I@(9#S5B MLD-4Q(<\23S3:I(BOCMP244S_3"KU='M5
M]]TJ6:]='>TO^_0+.=)_,^NW<,RL..9DW/[3Y!E)&B,5<Q:04!%II0/2!&91
M$\N4K#A&$KK"38N*_9_-L?X"RT>"Y5BFODT\,FV05$P@GH/YUOH( "4V4 _(
MI%6)?L/,BA3T6:&3_Y-M_AW/+P^ZQ#*X[="^R(D"PTM_V/'AI]'@<8:#5"34
MK6>K"SG/CIS]N&9R.'CC<$+$L03D+!-RG.32QE8EF$(3L5C;I'Q="SZSW9'9
M(6>N?2*7C!7G8D5N9<4E(;^G*E0+^3T"^8WM1RD3@C8"L:0YXKKJ\R8#L@FS
MJ##W7F@@/[:NE9KZ;/?".>[I-;U_L[?U<N_-WO'>[E%MJ[Y3V_WKW=[QR0\3
M\,0">8/*,K5FP[I&LSI$_N+6 ![[60"O^N_/7P85IH@__.)/GVZAU.&DG+<[
ME3EHIUJKW8O=VKF]S%4 'M0I_NGZ2\7C^97'4\^KZ&U_$4VL*94:WV) WV.G
M78S_-,;_TX2J+A@D&2%2(\LQ1=P%A720 F$F!,')&>GB&MAX30G]<V6CQ7>-
M$"\ET986]_=U'R8R26&,Z1ACU%V@C&.'F4.:Z6H/.\=* D?1"\M28%)YL[9I
MC%G^'>Q5DEO']MOMVJKL7C^&$*F&O-#' ^AC0@D9@2.35G,42 ZU<NV0Q3HB
MR@S0BDD2&Y^C#=.'&I9';I3-Z0<8[8*Z&:!NU&@S8@R+W"'C&,A\S0QR@4HD
MHK"8.F6-SDDABF^H8K0?H3U\L=L+: M?2.0!)#*A+$Q*S 82"!(T,<1-",B:
M (^TQ)$SR@+)U=\T*P?(EH![%MCRO0#O8< ;L]XN:4>Y1];E3DV1$&0ER6GC
M0L>H@"Q#6ML4VDP+O&*]?V&].Q<QU.*W\]C*%=Z&.>3%C,\M>?S-]99?Z2\Q
M<ZZ95! F":VT-4ASX<#(<X:LU0IIG2N\*R(UB;F(),.B%(19 I):5/IX >8C
M W/L[)BQA#!A$78$(YX DY8KC!3#4EK/)/PZUX 13*R(#%BA!'(_GH%2^L<M
M7"$4#GI,#II41,8J;#Q3*%!P/[B7'.E$!.*!XWSHS#HJLS@P=';UWY<L"[IT
MD7LL65'0_,AH'E44402<2$H(&Z(0Y\P@*YU%S!B0%(Y+P4'J\W5J]-01O=)+
M;BJXU7^6.5G""X\B'MJMC\>Q<Y:;4Q6BF1W13"A)0Y7R@L:$=#Y4Q26.R"0M
MD;.*@M'0'GNQMBG7J9HZ@EEB"D_$^!<T/A8:1\V^]2Q9I0AB,K>"UEPCXZ0%
M)>\,#=I+F4P?C;QTC9MM_;EA^."RF/B%U*"[X6+42Z.**:ED0JT9&9E5+#ID
M>*X>CS5!UC"-$L;$$".=BKGC%"VUXY>!BI:ATEQ!X,,0.+8K #9<!( <M\(C
M'BA%VGN#C'61:>$P]^##2S-UK<=BRL</WH)&13T0J;7V2.^W&6T+%,M^OP9P
M0U*Y+*VE[\DL$VJB!*ZUL4F J\X3XC1A9+Q/R ;F87Y<"A+<!";XABZV?>'<
MM/ F< 6#,\#@J'4GB=JDI4?2<88XF'1D8W"(>@-6WR3-K0,,,EP:P3V\GVM5
M';9Y9>.+35]POE\I3?D8+/-QTJZ^E91:C"2/$O&$+=(F)209=9QPP8A45<5X
MHZ<]TUML_1.Q]06;\\'F6$]W%I3.W6&TDX!-(%GD0N3(8&69=S(2XC(V&<7+
M[^&O6M9?R?9;)GUP@WX*Z<R.=#Y/$@0);'VN&>^Y0%P(C!SX_H@$S*G$WF&?
M@'3H.M:JY/F5/+][Y_D5',\4QV,[_409$ H1):44X@1P;)B0R OBHG>&.^HK
M'!NBINX%43+\IBN7V#X[:_2;T:Q7N(*+CRT/(*C.%7Z\L/"-O?@3I?'3PI93
M<.B0Z1['@G_K-EZT&LW_N];K7,11Z-\8A*U6V+XY"@7CO\;X]PD%_*Q7ANH8
M$58B#%I*18Z1CDPP&;QB,F9(C6![1C5/'VG!36-JRH)[W 4W5BXZ4NZYM<C0
M0&'!F2P.N4)$T!"XUU$8<NN">V*DOON_%XW>Y3UK$?\8"%NZ6L1+/_@O&VV
M<FVOY3=JW5/;B:?M)I!1MRI6JOZLQ2<\.:M41N%M9Y@"V>VU_>?UVKGMU+[8
MYD6L_3?>P)C4SF.G/X-EHV4>@92K"3G*\_%WGHE28'DFYG)2/06L(XY&@3ZC
MN?(:SJ<@J$51.F<T9\Q*NOH%ELOFR@,"(@6/CXC',?DJ$C::1F2<4R!?.4%6
MD(04X<R[)+5G^IYX+-64?A4 :;=NT0!8%!$P7Q'0GXZ;C%.890IFF5 < 29#
MAIA3L7-U="Y\0)8;BG0T05JBDG-\;1.7%(HE(*,%6/D"N(<";M24)Z:4BYR!
MEO88<9(,<@Y'I$),B28E%:?W %PQXS\MB@A7GL?0-L&&-P*"C_;VO-&SS6*W
MYU+<^&K\W\+P[[6V^X-?'(:9L,R$X@6!28L]=<BJ(!'WW"''A$!>2!PXE2EH
M51SXY2&H1=0]O@V3!7O386\L@4%08JA("-@S.^O8(BL#02%PEY+&)@J_MBFG
M+D]43/POZAY?G%TT;2\.ZAW#_9V==^)I;'4;7V*M41WFK?W6;'>[OS]#J__;
M7,Q^%^X5'DVHL3Z<G"HI>_OFU/2/6;^!>:G'WD$ZMM\*!TW%01-J'&!,8M#1
M(BIRKX-@)-+..L0T2\Y2ETC,R9"23<B@&D-',?S+ <O[6_X"R\7 <JP-8;*<
M4, A%I[FFF+Y3(0G2":<;-1!*AT!EEA.Z&AT&RR++/@9O@YCS\(O0RW:3@ON
MH1R+G(O#/QSVW<&HWV":G9@:OE&.8,V0:2840A L!&]S<J52&'%&%(*I!*8)
MU$;'4G#9"2%BW1!9@OM+0%0+B  4D,X9I&/;^M8;I0E&26L#2)6Y-YE,*&L!
MYIC*)0\!I Q 2DJ/PYD>E>Q$V[WH7 YW]FT/;K#;>X;B8#YQ@9%NJ8/1ORUU
MJ!#-0XAF0K$$RYP/BE&$+6&()Q60TPQ6<.(6!RRTUU4;%J/4!#%0 @)/+B!0
M\#A7/(X50"0X<"8I\E8#'F6PR$25&R0:Y9@C4@LU/1Y+;81?U4:XV^F+4C9A
MX?&#BHD&D],_KU08:7:,-*%Z HG2I<2 @JSUB.LDD"6*(A*9H219Z7+&/Z'K
M2HEI:[:4Z@E+184+$!@%SH\,YU&!883U F.'A(DDEUDV"";/($J3XX%$3JO(
M E[71I8V28_=)JF50=5I-YNY^'(#\-6)W=YSW(E8:!+"?J/5[@#U[ TFH+#,
M%"Q3WYE0QD$GI7W>7S""8<25U\@)GE# ,$,!GD<#HD%/L9E90@I/P^ 7K#T4
M:Z,676O!J"$,22L9XC%7-B=2(\!;,DI3SG)9),E*0<59!PU*4&!I@P)[+=^\
MR*/WMMW)5['5ZW4:[J*7&U(>MW\47M=45#R/6?'4[H3$ ZR4T,8B8P1'W&N/
M7-0,>>)"H%0&'DD_D"#ES)HPE$#",]$5A0*6D )&I4KN\2 \LT@0;G,"$K@%
M.:W! _\;&D1P-%3!!R/,M&D-2Q9\6#4M<Z,X=%7!<;*VN2/=]N_I!8-A".T+
MP-O51#R,[:8=O[GHG?]>X" 5-?CSBKQ;K5 BS(])\GOC.D]Q'+RB$AEO-?BC
MQB&=J$<:>Z8EPX%*\$<I7]>"SZP_]NPP-1\A^*/16A:^G(N]N94OEX06GZI"
M+K0X5UH<U;Y2:D4< :?7Z=Q<V&%D4B#(,<NTUH8GQX 6V;I6:H/=2_LND/TJ
M<?Q'Y5O!S]#XLODO^&=X?3<^R\?L:@V0M_DOU_EC\^JF[OJVV0*6X%\AEF;$
M'L58LSX?';:MR[Q=UVKW0"OWVK7>:>Q&0+ %;S,?,@;TAMCJ]A]50UV=/4Z-
MEFWY!FCM;@]^455QWKCUW@??S6D_;?J\W:W.Y+_HQ*;M-;[$/[\V0N]TR"8W
MWCA8!/CZ+=;!15ST;G_+4HVS^G%(;OZ;+[DBGT2\B(DH;DCBGOI<>]+K))6C
MF"4F_Z%Z;?BFT\ZU+?X8D>M$^QG9!'?YPC:_VLONVA\_#,99HS6\(";ABD<'
M[=:A2>G>0Z-'1D9-&)D^((&.V[E-)4PKB*#8R7\%UV67ZGIJIYULN?[KU_.D
MP/W,G%%KIUHN9YXQ\:\_[.:D-3#]@H5OMRK<?\'2.PS#VN;+O8/7N_7:7GU[
MH[95WZD=O7MYM+>SMW6XMWOT4&J;SQUL']1W=NM'NSLU>'1T\&9O9^L8GAP=
MPX_]W?KQ4>W@56U[Z^C?M5=O#MZOQCW]=L7'ZS7X7/B:)BS2&P4>1J_^S'8^
M O2SB1255*^,V8B%A5MHVO-N?#%\\&=H=,^;]O)%HU5=0_6F/P>?-:#BS-\C
MQK,:JO[+UP23"T=FDAG$F ;?/'AYHWIIQ.[W7Y-R0S%YZ\MX@]SZVL\^EO -
MJ<V]/O;GKS'-'^5BS=TN:&62B/2&O),O,5D:7MV:N<NM]0&[T)L;PW%U<Z_:
MG2RP:G5XI;8/?W[:K>V"I0FUHW@.*LK%3HWA]1_N_KG-\$]+_U?_3>4 /&Q=
M/#"J>-=UD4.!=QF0:3JZ//1S5@E7.6;P5$ S^0ZW;?>TEIKMK[74:9_5VL/^
M[K7L47^IXB#W[*8Q!:1FVVIC^J]<Q8.Z=V7%>NP-BG<])&=P&3::[GK'4V\U
M+<UFT5WO<(JX*+7.6J\I5M)S)[TU+GC)<;16),GM/SO5=A'!!-VUD4@[-7JY
MKM%JA$(/M@>AT+-W^(36/Y\<__VY3D_X_O>_+N'S&R?'S<_[9R>X_GT//NOP
M[,/.+K\.A?Y]^N']![B&ORX_''_$\/-[%<[\]([6=_[SN?YICYQ\^O"I_ND=
M&PN%OG_5_'!VDO^N>5"%7>MG)V>[E_7C$[Q_]A?=__1WHWZV3^O'(5V%08_P
M-[@N>G"\_T\D+K&(&;*8!,2E4,AZFE!TSFF5!+.&YS..G- 5+D!RU\S@)277
MVZAF:?99'H%1M/3>82%2Q)P32PS&@1L?O(";MC94C$*&C$(*HRR(4;Z/,HH-
M6C###'(^ J-P99$F3"'%M56:2$.4S6WEX7DIGSY;>&V%3Q?=?DO*O!?2B8 H
MWVC&6NM*G>7?YV?^T03Y*K2W(VPEYG,GGL,<-JJ0?I4(9L]R^N3WZA=/ZF#:
M*DC2F[,!CYNQ2F1MA:T;DU*LQQ36HWXTKD<5QAJ'8)"UE".>"$.&.8ZDP30&
MEJ(W;&V3&3UU4_'E4:.K<&9M%11= >3L 3DNYR1C*O>S$QC<0JZ"1S;7J*9>
M84:P"$%G0 JV@5="S*V(Z=\[.[>-3I9R>3N^T>K9UL=&W@.UW6Y\8J?25\'X
M7\_'0=J[FHVM:C+V6B&F!EQ,;#:^Q+#[;7#6Y76[';XVFLO?0&<EN*DQ+A9(
M) QHB2''C =7TU-DM4](*"ZD4XP(YDO_G&6BM47*A8=!N$!U&JB.R8A !8@%
M;U$@/B N7 2H,HL<B<;CY#T7?&U34C-MNFV1$3_#&RSDV.T?(FOGS-/8];'E
M8\V?VL['V*U5&:PQY*A0H_4%H-'N/.@,?=$6]]$6PY%_WP$"VFE_+5[+5'0S
M85LK,.=LT!)YJC3BDDMD.8^(.?!@9!3&10Q>"R4EC+ 4/+5075#@]T#XC0<-
M8K3<*X<8DP:$N>5(*Y,0AFG"U"NO"%A[)E>E#,YJ&/LM_[\7C0Y8\T8+G7?:
ME>7OQ&ZT'7]:28 0O\1F^SQ+X&+DYVSD#P<3L=4*.]?3L-=ZVY^H$B.8 14=
M;(\K :Z%\M0X%#T3B%L5D:&:(@DS":LB*4))B1$L$XTM4@O\$J4%C=.@<4P8
M,,H2]TPBZ5/>WE,,:4<E$H0*HC5QS.NU3:++9L(L$764B^@C9_O'8,_.8ZM;
M4@@6(0*JB7B9YV'[QC045IF&528D#1 =O<5!(*^D!!MO!-)2)L2%]02L/P6[
MD%E%;IABX9> CQ9IX0L$9P'!,<.>O#3 DQ1A8REX_(!#8YU$(0K'6-*>Q]R9
M0IEIJTD6R_XS).5S^G#I.4T@U[=HA-AYOI9]FKKU,S?MKVRC4S7EVJ^Z=%4E
M1=XW>J?O6FT'-_0EGT7?:YU?]+J'@[3<?N(2/+OH=&"\@9,:W6%=H,O7MM'*
MN>K]PIDQ[+6&_3\+54V3H'X\H2!^D,239#%R*E?_H38@1RE!(<'<>V8%U9FK
M6*F(OVAZFP;1,U<*!=%+B^C1>EZ8^9APD,CB2',Y:XZ<#!$9SH0VB6&OXMHF
M-RO0IF\U=,=.3+'3WVKHGRJQW^+S3$J<L^BXI6O.<#[VJNDXMM]VOV7?)KZ,
MK9@:R]/88S489D+!_*0XQT0'%+1BB!.JD)$L("5(C(IJ8D+5!'R2?U-$PU,6
M#061\T'D6*L=*;$@6"*I2=Y*,&#N=1#(4$%=2LK$(-8VE<#%Z,\*6%G"_EYK
M@HBMM?,U=&PO?H3/SJF#@W.GSU(#+(4$ *+)#<+C3NS_!/^B*B5\E-V1ZD#O
MJR_U1N&=J7AG0DEU$IE@&GO$*).(Q[R%F?<QC8C@=X@8?<YD)A)/73BXR('5
MWVPHX)PK.$=% ?')1ZL54@D;Q /@T@D<$-':.6E,\A; J0@NF8>/J SZ_6IJ
M9[%WV@[/7ATL=%NB[W[DN..K3ONL3SK[U;SL74]+X9VI>&=_0C\]S1W&DB+L
M"0910'+'E121=IY[DGCRV*YMT@FG#4IPX"D'!PH8YP#&L<YV%'B31HR\L@QQ
M1PS*M>Z1##"9/%*36,JY"!,:'I7 P'U E:U_%1&P_>X! _O?&#1RS#7?C^Q9
M]Z+UL?:RT8[GC2($YBX$AMN/!ZTCF*5\ OH&XY1Z>+.BH[\F]&"+A!K+-?(,
M2(CCX) EC".I+&6,:JVCR07Q!!8;O.B#YQ0MN"=$R_&@^Z-S5"PP)Y33AJ&H
MI$4\!8:TL181)1ASU I,XSW/!Q71,(UH<!>-9KZ7(@T6+0W>=G(YT-[EVZ9M
M];*74AV"*E0S%=6\NR$$_OH*GR_^"5$F2P/-5$,1#X(CF#N%M ,C8GAB6,JU
M38%+XN'"R6F99,!M<"R*8#8PO1R!*1&)&PD2P!IN$-?YQ# Q%IE$G8PQ,A.*
M(G@,T!WT3F/G69K_I4@@J(:_WF[ETN#]2.4@9:E0RKTM_\#)L-$0ZBE&!N?3
M45I*Y()T*&CKB$VY'7$^<<#5M*>CBOE?-!X?+V>@X''V)GYX7H :PYAP"!/J
M$#?PC\-:HX ]ETP31W/38B)Y21.8Z6G%4]O*50>SXW_=<*(JP%G5)VH.SLHT
M8G<]=ZEXRATH] 9=D:8BWL/H]G(I*1\;U:FG9ZG1%IW&,9(_-IR6PZM9*69A
M*K/@)Z1V<N^9BAQYPR/BW&#D-%9(.>$)XPX[D64:-A/,0@G0/#^%5E#Y&*@<
MVZ$QG'LB X@U[Q&/3"&KE$#:,VJ4"UI5I27$U,[3HL3:RIC^G8O8;P]F6[T&
MV@:<Y/;?'7L>+^!*:^>=]L>./2O)'$L@!V"J<D[98;^>]UO;R2*Z<,]4W/-Q
M7!%0B_-T:.3 -40\X 2*0 6DJ##8,ZDT=6N;DWK?K*8>&+^Z5/WW"#A]WD*A
MX'4F>!U+_4R6<9HPTB2WCQ/*($TY1H0[XBUE7))0E7:9,JYS)UP4#3&ID=6S
M;BNQ9"IA.!F%:Z;EFL\3\CH5X=9A61WR &T0+#P*!'D;-$L!.R&R-F!ZPD'0
MU50'*RL"%GWJH\!P=C <V\N)B5.32[$,*D\*@"'SR MJ P>2QY[D5B_3'+XJ
M5OW7FP*=BQAJL;\CV6\PE6,#M5S[+)>CO+&7\RPM_W(9_L%\O;F>E$(\TQ#/
MIPEE)+74TB9*D2=1(IZW#*Q2&"5I@M7&8BG4VJ9DM!2"6 K.6HZZ4 6;CX'-
M45% -8DL18*LRW7@65#(Y'QK'20@-CJCN5S;I)Q-H<V+*/BEJS^L!7E+4L>S
M% ++42#R5MJYJD\7NV_M9=FQG)I])A2+!/+15A*. L$:<>?!)8G&(4>#4\IP
M[' N%HGQ%"?0BRA8M$R?0V"@8')FF!PK%TFMU9$$E(QR.8N (6L!HBK*X+#1
MB1(!BD"N3&6HE9$%!_VXP)2YG\]2*RRI5*AF\& X:]OVO-&SS7HL1T*G8Z4)
MQ20EL)*WVB*K T<<3 IX+($@:3 S249XPG)N4VE<M114MF3[" 67L\+E^*:"
MI]YH@9C2"G$N+-)8)A0]3&H,W.F<":S5\N\IK(A(@%5;RP>=:JG9_IHS"[\T
M0@PU=UG[[:);]9GX_:9N@*'^\N"0@FMW0NR@7OO\11ZM;KO9"+7A#1<-<8^-
M!YC%;9C$MX/I>WGYKIN]F2N*VKJ:MU)S:G;\-:$>)8G24,HY8B0"?SGM0%=0
MA6+4WG'.'0ZDJCDES,QV)^X,I\5E-\X7\,\@A%$ OR# CPH6JUU(0DMDM.8Y
MO&&05A&C(%CR6D=M7 YOK&M,)FB6GP/^L7$]G:I9*C&C)I]SO1(RU>F)?@'L
M'W7+@XZVWFE&9GON=?JOO(=651MJ-=3JVXN./P47K)L+EYT/ZO.LU\YSA9XJ
MFA6'97J>91AKH5FO;^UE53+QN+WE818Z\8?Z25NM4"J:W<_J3*AK$A@5V@>-
M"%<)<>\# F7ID9 8#(Z3DL0J?,4FQ*_*1M?S"5T53#X>)L>.P&@:9=(!,4XT
MXBQ29)-C2"JL:. Z)9Y "6(YQ2'V!<6N_C][[][4UK&L#W\5%?O4K[*K/&0N
M/3=G%U78.'DYM8'$D+,K_B<UEQZC&"2V).++IW]G%G*,D7"0+4""/B=;%I*6
M-*M[^IFGIWNZUX</C(8),8\O^%ZK:'H1U*K^SK2]3R,*IV'T!B<MG-L;_]7W
MYU$2A'OE!U-=M>-WK<!B19^]"S6]/RA[?ZGH4V<F\ER7AU>_S7((;CA(4(D!
M),[ )F"Q-7#.(97@5=;9I8TM]41PF%,7E:)@CVO#B:SW?JWW*MN(-B;+?61:
M^^H!1&693Y"94RY*FWC2%_M.7+HY?5A7,;%F?4C'Y4T(XA:KN?FP_6?HGS2U
M_#@<-;SZ!$P[&"<$3LL#ISGUO'PI2D1KF/,MBA^L9U%75PA=RA8 M?'J8E-\
M7H(-;5 \X@T*LML[M-NKI *#"TEPR43DJMIM:-V5O6?@?07GI*UI+9;E$V77
MX%#O^O")F4T,ZN6V%CL8!X5:22X#B>;4_XJE&(R)L^!#9H >F),MRJ&Q>*U\
MU-EO;'E/S=Y7 \-6:6OB"V9)K5N68ZY7B8/FH QFR72RH1(' <P+ ":+<JY$
M@:CL>K5N67/V\*B;NJT61Z"0ZU)@Y\/VE<9NK\7O#IV.Z!SSSDL&-HI*$'3E
M"\87C@ >0_57M)OGK1!+>.PLX0N&23QA.0;[_HK!8JQ\7HK"5%&100J*.=,>
MLE&50Q3KM2.>< <\(?>[U-C)^:BC"_]?_^0$1__O'Q+<#_E);P<'+:[1.PV#
M\U*%?SYJ2;338T## >T\W">KV/FDNH/R['Q<!SH>7XVW$FA]I7,SI]ZHL%*D
MA))55<%%J-4IU"S*$KB6MM(.\96@13SCODWU5GG&M:9*)KF825[=;S 6C.4<
MF0%;Z7[;(_19"B:X-B)P5"++C2U*?5A^^=$N2->.!;.S-M''K3W9&,,H'7>)
MEQG_Q)/AXSV!L5(Y$+N#GR]T]'*JHNKD['Q2$#&&I>]+3.&I*E$6G3F+6@4&
MTB/SODJW:-#9><F5U<085@G85BL)XF\-EPST*_<AI@9:81=C0&#*5%X/(5D6
MC0O,1A,$!JB@7 U4N 7Z"Q%UN %U&/>[_8.VY= ?3,+@=;\E3EY4(WN4?&&U
MDB9W_]+)=J<2 IJ%@&9.1=*Z['/O(;#H4HM+!,4"<,>B<AG1!*U-ZXM$69#W
M#4^K1@#($+_-$&=V#+3P@FO/ % Q2(ZS4,V/5?BT*A;T'--BAD@+_N)G,^NZ
M/YZ,P@1?U]_H?\K,>91K_ZH$%"ZBH5U-0TJ66C84S:D]*GWPN;H8+ ?E*AY9
MSIRKFHO.*J$-VA(*[0ZL$I2M2CSA.DLEBUS,(F>KCD:A%!86BV_D #SS0026
M3#5!J#KTR6YL>3&G;0"%$[ZU0CFM_?=5</RCV_'C<'0992[ARY5*@H0S"^#,
MG.J@ >I,CLDQ[:'B#-0'[ZL[HCR6S%7A5:_-"7&TZJ\ .JU$VS*RT5NVT1DN
M$+V5E8FSE'QEYSPA"SE6:T4>91(1.+B-+;YH1O%]=2OQ:T$$;E*%?%XU3ZI"
MODJ;"M<4)9X+4W2.>UD8]LN<TDXVQR!*85Z87'F&D"QXC,PKFZ6'6/^+K0JY
M%79II9VH"OFC"%Q<0U,6,7VR[L6L>Z;0I$T\NZ(8M]XR4"DPEU"W#,@04P'0
M,FQL@18+9"]0K?%OK#5>^H,P2'=1:_RN"XT_\BKCD];SZ7STO@YEF-X\RLVJ
ME4A2J0[P2SR;:N:@/!^>G@X'ATTGM*(LM*+,*05J"A1P/K*ZLG &+7,UR$H?
M==0@DM,J%[^Q935?9$6A3:G[ML5;RU/YDBV28[=$0[U*_81!1.\2$Q:1 9><
M18' ;-!)@3 E &^.G>.+F"J%J?Z&#TRG?6^$)V&"N3<9]OKC\7DE?'B1TE)G
M?IOXO?%Q&"&+H>U9I>'I&0[&W8G97AB-6AO>[FL>;YO=E2 2+R^4>#0\"N_^
MTY\<'P^[2BFMWF#3WK.FO.>7=$>HM1!JS2D':H)+(@G!A"N!@2N6N> <*QES
MZYB V<J-+3TG[$7DXO&1"[+/V[;/F=,PE?8'JRS3")Z!B9)YI8!%Z7T,7-5W
M\\:6FU-JCQC%UQE:9<\7L[VKU34<C89OZ[U<]"XY&^%I__QTW#L+_4PTX:YI
MPE^J&1^4?P\'KX]P=$JEAY>+07,*?@IC4TJV,)^U8B!Y8<%#83'[2A)B3#*[
MYMEP+N=DX1%/>#P\X7H#)1M<S :O\@#I> (I!?.(P$"%Q+RH)HE&&I6%J._Y
M:H-VQ?86<G]\=A+>M^'@EVWSKC[YT :\UERKY19]5V]Z,NK'\S97_]D!U,>_
MVF9.%47WTO#DI$7P/M9<?Y3D:U5.)7TZ$[G7'PQ;GZG._6O>((XHBV 1L-_?
MF7,R&8SU)K8:S1B@=7BHU,M5I\];\,AY#)!$!?MY;(N2D1\\Y;HN&YD,]-8,
M="81V;52)%$P;I-A@-540VQ;,UAQ%RL?\YIO;'E88-N4MF7H/-)ZK/H_#D>=
M,G[\F%9%"81?B2QS#B G'Z1UD;.0DVC5CPJKZFS=VC![+I!K45H\9K86 JW\
MM/*3D=Z*D<ZT5+&0;2R!>=\J!W4K?VDQU,(MYA)%PM:+3:Y^Q9('= 9I7I8O
MG4&ZY_C-8D<2YH(5A7:6A61S3CUG'9.17C//L2&9JHY,P<(P2J&RRY5SI.XT
MDO++J(-&!Y$>,T\AJ[\GJ[_*7ZR0CL=86$'#&7 GF2M%,VXBEQZ%E++K)<N]
MH7-*MTQK^H/43K%@[[LZO;MG[3CU!=MI*2?=D]9P]L\ZY[^Q'-O#I#3WN3_2
M\*S][\4G!;W$%LY*$\SMC>U!_OR%2Y_\N=YP:X)YH?:=J?I?O$LGYTT3]<EQ
M2TQ^&2;XHA1,E.>R1%B<<S0;7%;"5O8CP5A6_^+5P=.&I?JJL[8X:6TC0UK9
M19M7$"-:,>B]SRR9NP8-PH7%<&$FV@,6(Z]H8)3RS4F*U4E2O&WW9 ->H^6\
MTB4-"[>R),:TH-E>3.F6F8O3B=YK)6M[%\_'O>$M,:>U)4>KL=]SH;:#<AF=
M#@;?A(,$:PO!VJ^S="<">JF\9*F$EM:+F;F R(I70B25%?>MXMU"V]@49[IW
M*[Z]_1NRXA6PXIGB^5D;%$*P8GUBX$&S:K^% ?<</ ]:.K.Q!;!:><'KQSR>
M7T<KGO0BONX/!ET;WM*;'&/OK./HCY)O+ !4E6 D$Y1)T>J*5,XEY!E12MW>
M"?#[;L,G(96X17>*ME26ATYSJI>XJ+V.1C(?H#7TJ _U)<$$^HC"!ZU]M],L
MC=@$2FE9 9Q;P("#UPIUX"5)"<DE7Z2"+),W*H/@NC-@3@:\3@9\E5ZX%#T8
M65B 1B]:STSO4F)>9P<.!1;=NO$]46H-*O"O-\W ^NH7"<8-]YHO[O*IJB+/
MP_/6Y._CS7W;5N^B$KTC1O(_]RBF!\;8LDTA@'0V98"*"M'GZE@JE41KGBLN
M /^VHV8$^,L#_#D%8138HH2N/,V5=O8H91:TX\QQ[F1%>VF=W=A23XS5"V]W
MW[[%W0W?^WS[?E7P](Y6J&OQ=$5@<_5XLM?62E^<%<(!E.*\$E88%;.*TB%>
M.+H$F^L$FU=Y,G)3(-A*D:62E2=KQX*I9%FJE'2L*C<*NMP!6+R%S+VC8\>R
MOY^$^J/UW]S_<^M?]>'C^$[#Z'5_T/V\^AS!$K;3VE,SW?I7''V_]=<]?N6W
M+-?8!?\[6Y?-U@\1>R&UHH%A\+[M\PV&$QRWT^F5C(^QVGXXS_U)5UAPD'%P
M46)PT"FB*THXS4T/)W7X]87NA,;FM:*8_K9J0'0VO.C+_;2K;]C_$W]XV\^3
MXX\@=.FJZ?S@GRX)L8[@?'+])2LE9/>Y/"X_MB%WL%1$TEB$!2\*))EBK,ZH
M*\9&R551YG<E-CY>=#SZM(R_1A9'&-ZP4.I=/@TG;\/[\<;WGT_ .ONF P)Y
M<2KRJMRNE4XI7[_>_%U%\RJ<"VNH6#T<=675GE8*A:/VJ3JNL%+CZ1V/VIKW
MC[]756611PU1FD_[O"V778@^;,V;!HO/V?KKP>:OG[/R!F+8V'JV>_#3B_W>
M[O[SS=[V_D[O\-=GA[L[N]LO=U\<7FO>*W4'SP_V=U[L'[[8Z=5GAP?_WMW9
M/JI_'![5?_9>[!\=]@Y^[+WXY=?=H]_6XX:^^PN,G[0\VOHS)W6&CO^Y\.C_
M9KV:=UFW0EY9MNO-GX2S,3[]^.2'CT5>^H-N]-U%/TR7ORF(-_"YLB)WOW?Q
M]A27O-^L3EB#IND&V/2'IZBUV:'6%2XQ?:]>J=RU;_--<?VE7_A:M:GT]5=^
MZ5N__)X">0MC-=:NS5A)KK<Q5MBL+MF:C-5N&@]K,E:]J:5:D[&J3>OTFHP5
M-HU>ESE@-ITT:S)6NZG=NHQ5;PI^L_DZ#8U=<2H%=#N9*Q\NNU&?I_G;)G_=
MF+_)C5V0MY6[M9^K&X6C$38%?ZFWT0+)">LLCHLV)LN31?WH:/CV2TD;ZR&7
M[3K@YH&'D\Y;:66I67_0/4_AK#^IKY.T/DDKI?/3\ZZ$?2>B85=3JA/6\/1L
MA,<X&/?_Q.Z5D^'X^A,#CU!V+W$2ZHL7@L,P:OF.2Q'0.L/2T<T:T#W"Z7(T
MG$PQZ5E_^!H'O=U!VNS^'E^J1/C__N&DL#]<S*G_GO<G[TF&EXZ'?U;ZMA/2
MQ_*W!$USY]J<.32?!DO^>&CP#?J(S@D4KH'>NYJF-[&$&]WWM_1A74_Y;9\.
MSP?75])>;JO:]1013;'5FV+W_M$'IB.:XP]OCJ]/7OR-1/PLG+2&GD]Z_WL^
MP)[B3WHMT7B]2B&I&+Y:2G93?UM28N=TC:_D)181$#D8KK,$&4MT*MJ"/ID4
M!>8T3><V?YN7^*G'\ 66')Q/QI,P:#+\/.VP]-]A9A]P-%R5C,,/>X?3C,,_
M3M[L__2+VMO9A3WYBWBU\_+TU=&S_JO3%_S@/[NP?_3+^[V=9W_L'^T?_Y5Q
M>/K+A]^.?A6__6?OW?[1B_<'.R]/]N3+_JO__*I?_?%_;UX=_7BZ_Y]7IWM_
MO'QS->/PU<[^\?[1_QW_]N&%V#NJW__3KQ]>_?2_)Z^.3NHU]7O^\YMX=?K;
M^_V?7I:]_C3;\)"_V_OPBSPXVOL])ZZ,Q\"2LYR!-8IY0,64U2E%BP&B;:Y!
M=;#E#^M=K.AO3_I=EY]].\;_%>=<[L+VO_:<RQT<8[E7Z)O-QUX6[G6(-]W)
M>M'M/.P.IF68?AZ.VBBV)Q>]C%J*S]'P\_V<W>E6#B'D<A#RPPQ"!IZCRY&9
M9 .#$B-SA7M63-*Z%(<NA<>*D$25%J-*3NGL4DJ UD,=GS=96>6S*HD7T&(Y
M5(D,?A&#%U<-WF:0VKG"5$J6 8^<^>(]$\6FX'W4.L2-+6'\G%HH#]O<B1 1
M(?I2R:@EH=NR"!'AX"(XJ*[BH#?*"N"&%:LK#EHT+ AAF3?.2O1"058;6WS=
M:]@2"A(*+K6Z@3(!%6+D/D/D/#HNZY]")^F#X$!NX3JBH[Z*CD448S7G3*)R
M#1T]<R(JQF6J:JYKGV[-51^G6T@(^?@0<I':HLKI:+QS$8R!K&6HWI8+H7"M
M$816UT/D-25%B3'>2S!AMO4!>FY2S@S!MA+G(K.@"F=.^Y #9"]LKJZSX'.J
M]*U+%RA"0T+#9?)%E8LM6DN7N0"GLFMU/ARV%JVQ2!/NDR^N:'V7]0'(F999
MQB6'23!A,3+(,;#6J9>!4+$21@B51U: A"=>S^N4][!I(T43KB=1<\,)Z.NR
MFCE6^J3! <24(%D=75V"M;&<P@GW8//[,PT25'2>:\^R586!BHF%X#*3-A0M
MC94RZXTMJ>84=").1)SHP7"B13S$KT>V6_80B1TM$2EGV%'T+IL<68G),$#N
MF0<96;?15AEQ$-FT,N_>SNN<1V!)8/E@P'(!K(R80TQ< 08)//&H0N(.I-.6
MQ\@E.9#K"Y$'LYW6985(GYCR@ P<(O-&%&94=L$6R.A;<U'QQ%FYJ1^9 TE
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M1HFU%UR0.6YRP;V">\\#]XQ0BIJD%2&:\Y2T8401R5P @JAC+'SP*8/BS-Z
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M[?CGC)_]^LG#:XG0\+8^)T.? ][#HI[D0>-G1ES:6]M?=C<_JA18TE&C(+A
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M[&3NKG;U&S4% *SX7@:;[&1GEE>=Y+FZY&IKY)KS44]S%D"W#T+-TCRJ\O/
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MDY-,QZ#AZ]1038P5F@@E@V XF:=+M5]51"=S@JRP\-_URMQ<RWR;7D@52G6
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M%X'+BUFX]$3:G.^)O"4"<4(L,LDII)D/D4GKM0'6*>?D@<Y$80I0WADH5V_
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MQ#&U2'-A4!!>2&]LB(2MO3#TWDJ%/ESRX3<?66#GF<&.E4H[A^$E+>-) O@
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MS9(?HX07AM/I>=\@.EHQ1FE?!:<4L^(2@RH5"&T#3] [)= -&"4\0'HU7[#
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MPW/(V(7A]+R,=86<"\8JV8NBL*<]QU:ZDRU'XRD[[AUJ;H*,'>Z =UUMQJ9
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MZFSQJ^6/6;W>W>>]E:V3HWRRQX<K&\>'!Z]?_GE_'O&KY3NHM^D:=^FIM[>
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MR(78Q$J\;9EK5W%?+0LG+H-_Z]JI;]ET6I\Y>[8^I^ 038RYZE(K@.N/\'"
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M# L<)<\EY=X([L+:AGK!R<(33]YW7LF?9ALOX/>\P>^7U4*_2Q3Z,GLN>+A
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MX+2"5^0F!IBU<\4[DI#U:J>3(]-J+5Q=3+&S;=N!L:AL#]H6/@_[-5!>D0H
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MDYC3UF.M'2=)82KLVL5#-[.YR3$WW&77JV#<XN@X#@(; T972B[HM;G)YL(
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M?O;=C\\9M'I3&]@?]H]'D0MIV*M-MLL[$-WZ[GZ\<"D[:%88?U[C?2T/8+\
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MCJUC26/F_-H&H^MTA8"KT)(5=!S<08@+,5F(<$^X#IB%B9(@S5'Z@+@@$>F
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MB+D01&.E,8NCXS6$4$9^'(635]!F)^1_MB_6T3.M5_#'YX];F[QY]/%S<^N
M?-A_BQN?7Q]^W-IF=>3-UHZ Y]#F_@ZY'JW3>-/\TM@ZH!^/&GAWZ^_#YM;;
MT\8_K[\T]KW8W=^$Y[3AF1](X_/?J?D*G]:1.GOX6P.>M[O?^*2U3C!A&CDF
M*.*,!J2EXDA$G1(+.A)M<KD"R>B\YW"6%Y=8H.1)0 F7C$1*"?<Q<4J<)@*6
M60K.:J=]$DN&DB=WZ.3>4 1?1Q%G2$C8JEPV62+N54+6>8&4,U1RJT@@MSUS
M4E"DH,@/443"0L/$N42#YY8'2U04A@%^D!0H9860K#*4T.M08KQ+SF&*)#!*
MQ&-PR$HCD PX1BF3\(P70E*@9!E00JCTU@<G/8M<1&>XE,HPD801/FI;",F*
MH@B_CB(6,XTE$\A@!X2$&8\ 6#CB07$?C&-6/20A>;J.H=%V1AV3$J(;Y*C5
M86\9I=7*I8MR.1+S"-;5JV[O. <53BRKQ:8K7GPFM%73<91:DVPB2B;)-3/9
M 42\8D%(S /6L^JXS:^VU<YR_KK;VP-=M7<^(ULP01=_%;:\,#W7FG3?>9)]
ML"%EM@QZCOI<;31XA(/A0GE*A/%UM5$\=QJ=^V?+SU(>@S#&>DRBY(1[X":*
M2"6D#]AK*4)<KCP6RGE;49SP@3&AM#?!(.&,0=P V[21).293U@$9^'[1^,#
M>Y:B:+D5%*M(O=0<4-5JXIB0D3(%IH1W136NL#Q..))$Q,DKKI AS"'NF$=6
M!X7 LM=&)A,\$T4UKK(\*I<"#C:!/&+.B+ QTB@$X9@IZ+PIJG$U17'"&Q.2
M9))YC+3+HFBX0UG\4%!8)*.)I4D\+F_,H["9WW2A19T<05_LY=MO4B<C- LR
M6*RYCM8&;T54QJAHJ'6JD(*51:+327M96,V4R;F\L+"(,ZN0Q38B(;6GD;-(
M$ZM)@:'KJI""%93'D!B0.A=L/G_I8K*&$,N"D8S@E,C,V[V%%-RO*$[8RUB"
M39P<19HD@K@2#&GA) K [YP)5H2HBKV\RJ*84Z\YX:6+TO$HL"7*NAP1:H5G
M@86B&E=8'B?L98XC"U%:A'G.QQZT1IJ*A)CPT4@:$L6QJ,95ED>A%<,.2^^=
MX]8R9Z01T@K@K2EQ)8MJ7$U1G(Q>"(P3F$&00J,0=\!2#<<)N21#D%IQBEFQ
MEQ<?N]#M#0[L0:Q3NW7SZ<'*YA-:54X\&4,QHF^-3-%QS;D&?6((I]S8;%!3
M:2)FG*6X!*90$&AF!-J=<BPD1>>I8@S8%0N(>QX14'*)4F#,!.I#B/E8R&.(
MP7R6 N==Y,X01@A0<V6XHYJJP(4-!N.HEQSE4:C ;05QPDHFDG,1F4.*2@=6
M,K;(&$M0H#"[*L]@",5*7F51A)FRSB6LB+#<16*YI4H(8Z0B%&2SZ+Z'%;D)
M0QA;;:)4&'0?YH@3%9%6QJ"8O L.!VP5+[IO=07.*ZZ5D\PD2[F46GMKH\'&
M&BV2Y67;>$4%<<(,ICY9HK5!UMN(N 61M(IP1*1UE)C O2E!_$L.XA_G@"ZF
M[T/G2[A(S5[.)"X5B/:F6,.8".:=0Q*('.*86V2E,HA1F:O,>LRIRJYQS/6Z
M*)Q@!:5P4:D&?B:%1=#F$;0):]=0[[2F^?!OU#D;B0#J30*0<&RH55(;EL,S
M-"D[4"LI9HLZBU_$;)%B-KG5*QG#P7E8,P[$3$N"'$D*10!(Z<%HB@*(M99R
MW@J'1<P>U3GU>3AEL6MO*WZ3X=":X) 40R8K.!Z<009[@R@F,5+ME'6/+!SZ
MD=BU6W#7U[KN32U/>42+/?M ]NSK;@]:T'E55T_SIZ_&\U&G1"TZ_VZ@T]C?
M'#2N5S6VS@A%14 B8(QX=!$YT"&(4!J,]%PY14'IXRGURXK.?WBY6Y0%.[?<
M%1*P$'EL7B^3ZZ.5+G&+0M0$6( 5R'#OD#8N:DR"3(J4G=U5%LE%6;M%%2Y9
M]*ZK0B<(,&_'0?=E^]=ID#J7)(K88HZ)TBGPH@I75NX69?X65?@P\CA1,3ZH
M)%-,"<F43^59:9&UB2)IF$S&B$1C,8B7(73_;L-[ZQCG?EU'.,0401AR-X^.
M8Z=?ER(L%O+]6LBNU7(O\\R,RH, 2FV-I^75I5DIQ."N0+0]:2-+@@%JE$!@
M:@G$,4THGV5#07.M+'Q!C%W;8&R=%V*P@I)W5QOY#I)7J,%")'**E8RIC0(D
MTC*02&L"TD)I9#EVSD2"I;;%2EYEH;RKE5S4X;T)WW5UF+0R8&8IA*4CB/N$
MD0F)(:^]9I@;*W-*NZ(.5U3R[FHG%W7XT!(Y82D+&I75AB.839!()@DR@A)D
M)4DBJ,"DI(_+4F9XG3X&4WG6*K@_*04Q<T7+QU\G8O:N/BG47=0&^1AT2ZSW
M,B%V9]('X(.7.2DSHE;E&%2F<[)"A4)2)&C&8]1J;4.\H%2OD_D@=IYRMO=7
MG:9 TE.'I$7%#OP D@KJS(4Z$WX.J1D#:N=R3E1 '6$E<E92)*,5+DCOI8FW
MBGPOF%,PYS&Z?0H-NE] FJ!!7%-O T=26)TSP#!D,$_ A806.I(DG<XT"',Y
MK_NG0%*!I,?H#YL3DHK?Z]9H-!DA E8UDY8BI1A!W  SLB9:I"R)WE(NF+AM
MLMBEH]%\3K%5 )7ZJ2]; WBCGT$$_VI9UVHOH\C?I;EA,/JA.\PY":Y/SF++
MZI5WWOC.IQL(M>"30;-N,:WD6#R_NK]+/M/4/P/(T^(ZN2LW>#OIL-6ASI%'
M82D1#)9*D,AASY$'6]-'I610V76"5_\P<X&-A^_&ZAS)^@EL%%-C(7 RX8F-
M0AK,K$-62#W:8M?,242\I)'&( *3CR;BK"#*PW=C=4Z4%2*R4.2X3D28L\(G
MA9&1=7".Q<A2X9!626OE $D(*T2DP,;*.C8+$7E .)F,]<,I,JLQHI8SQ*VP
MR)I 40!5H )+FEOSN&+]'HDS**][:'JNFPEBUF^%V*LC7:NN@P;6OY:T,0_D
M8OECV(=F]/NOND>NU:GGXF*Z7EV>K7/0*D@T%Q*]GQ(2EQ3CS@6DL7.()T>0
MC4X@&:@W*6%8#8!$%)MY ^+*08!'Y:BXE? 5>K 0H9SP4RC*G67<($>M1URG
M@%R( D7L)+?8Q1C+R;B5%LM%6?M%+!]0+"=V(UBR*1\<-Y@HQ G%R"GE4?0Z
M5Q+7#).'S&51Q/+>K.G_G[UW;VHC2=:'OTH'YST1LQ$44_>+9X,(QC ^S&\E
M=@Q>A_V/HZX@+"16$F/C3_]FM80!-=@2")"@9L_!H&YU5V55/I69E?5D,54?
M7OV:3K,A8)IR@IQD"7')-=(I,20U\\*3((Q^.E.U'(^;,0ESW)V;\E)>7I;F
M(F3QK/!Y4:&$*VEK93ODOE#\H1DUP-1@6#<YTL3G@N(N_X8U"BIYCVW4/'F
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MT5F$_CS%)N/3X^$R[#\^(>PMV]9DU(%23DR4(G+K@R,D))J"# );I^(D_ZO
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M2EDZ /++PG1C[O)Q.W)W_^Y\[8_ &<E\:&!R'P[LR7"!ZOJ$6KF\:T#!BQ7
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ME+S8P^PKFV/S^#0'LW*YKL)Y_I,^-.A;#/]T@U\W7_>'HQED]7,!O# IOAF
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MI6.(F6@2#HK ?VN;3(NG@)JB>,NB>"7&\!#:V(@QX.22E<$CI:+/Q9^R-I*
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MVV[?AA/YW=%(.#^R%,H>Q?-M=VG!7'G@QT8M; /8@!62N+396^-]@J]G2BB
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M:GGP;X:@"'M5V.S_V*5:3P&*&Z3??[42\2(FHK@AB7OJG3/:ZR25HY@E)@_
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MR8+[Y,Y[SSO(-BAO+:=:^< YE]298'Q@S!/!12#BH5ZI:RO>NK9@^+T=\R_
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M9A0(*37E=8;H7\TE&T^&R,&2/)^Z>%6%0GX;O_-Z- _M96(I*^(5W3Z#O>Z
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M G$;* )^%@C.00B)4V(YH1]TU'WY-U=4-4TR7Q%1EK!C4/.#*5U&N>3!;C,
ME;FT42ME68I*6@&2*M('4] 8-'^*XX4U4_4(F9QJ^IE./]MD]^.!98J89 +*
M'8P1USR/D70>:9ISI !0PT&L;1!![FM95CE1;P$"4-N%B[&3)S%F5AY+I9RL
M6H+7Z[FJO^?7^T-_]+I$B26A9;C1[91#=\>7NFI.E2]SE8Y?7N\2^8Z2^J]
M<Y73;\.WX6B*+R"+"<S;_2>.(.JH]&TJ1SP4D2X9OMCI7&[7ZQN^KR=4$HL%
M'K,"(;6>N(O//]+=PP-FL+*&.% 1S "?)P^F,:8H#Q+3S!G-.5G;T%-&;#\0
M>Y1\_21:8E$D5&N)QU#/YXL&: F7NYXR@1(&V,IQ(DB'F!"G#G-"/2>YY0JA
M4X:0W4K9!'C:'E;UR=[WAK%JH#3LG-A6N)3'5:E#[Y*_[]<C-QTUUS3)Z4T_
MQQ2GWUR3+R4QFI%@!::<:&JBT=)::I)0G(T&H\TS^3+G$_=S0G'L-SO3?'XU
M6<Z(_7(@RT"P%RIH0"M"(PXX)@])5$ACI0SVSB@MLROYOI:!=_C[,A5-2KM1
M-\J*B&[G(8]HK=5Y3I_: SQIY2#9N3R3G3#IDKQ9_O1C;LE<4M3-8P%'B=NS
M=GLU\58Y%JT?!X.JT7TU@:W=[Q;'-L2GT94+ET_7=64MCF;'M4I;*N?Q8I8[
M+\080#<*AL"D54BX:,"Z$DYX#5J2W=_]N3NBF]P ^BY%>34&I&W[@ZN7QZQ=
M5OIU.S,@V^#(#JI0P)73"-X<VP7ER 40,\->[X>:["Z<*,?!U>U*=M8T.9TF
M=\\:AP>"6^$Q4"*E"?":Q1ZY9"4B8-L[E0PUN<!$W@?<LE@:"?);(GLR#+ R
M^K!NQGA/,T:RB&:,FM;-&.MFC'4SQKH9XZ_0C)'-;,:X_?'SSOZ79ZW!VQMT
M_?>C;AM$03\W<AF<9^"W=%5Y?/<2&^WB7?KQ+&,;N!;.4_\ Q_ F7&OW>/?\
MR\67"W@-\,\.O8V-=B\^7GS=>G^<>T##[[RQ]>5\]^)0?+GX?)[OW8#K-+9V
MX+Y?R]@98*.0 M/)*&1);G?@O42.!(FL9SXHK[3F\G9_1@>?Y2SRX*SF.F>R
MP3\:,^^TC=JS'ZWB>[$QZD=YPBJ8>Z-DB_YJVMP[G:+I!]U1;QE<PL>W7=LK
MYSMLM0".#KH] +'#P5&W=^D2[![V[''5EN4RV61XDE^8:VY.]"HRP-K,,4Z]
M,-@Y'A1 8IFGF-,RE13X]6;JWY14TI)MKX[B0[6^S<LU5^$.LA*U?B_ V]MG
M>48B \/&(X8]<+:B%%E)0NY,$;P*>?BSG-[)O7 W QU@5!QG-TX^DN)525.W
M6:48'=!O50CTSL\4H0N&=Z>;XYG_Q-+O=G;2JC!;::T#=@&3OU]^_8H:^T6)
MY\:MA.ZX_GC 82\.@-K!AO_\L"^./.7CE\,H9;:\R/0&H%-F;N=K]V^';[10
M7A)#79!<.JH9"RQXGK!,%-Z<V_J_Q1UALQ,^5>O<*KL]? #)T0U[H[6L@&O@
M^5GDXCL]H%+$*(4#QL@#[H*PR'F71V)$J2PQ6%IUUQC1ZZU^YJ,(JF/$.*?=
M@RTB>=+"B> D9X)$%SU^\"R[FB(6"(C&PS#.FUN'>>*8M400:1T2W''$4^#(
MY)$IEG%'-!'&Y%%V;$JRVN5T[>KTITI2.P#%FQU*/Q@;7K1PV>]%"\CX?$12
M)1&]@V7N1E"^JY2/]NPDU-CZ?'&@A?8<<X*<RQYP8/#<AU0@RH,1'+L0R@1\
M@>^=H3+O9/:%"Y6:$A8D3$1C\X  -]HH)0("<8@S:I&60!<>R()*[:.A@,?4
M5+JX%"?7YC3/5T%P<^;[>K'UR N1)P-)>0XA =,!; <,HA;$62) OE9)+*R7
M:I3CHL8Y+O-1;Z7Y-OW_#O-":Z*=*K[V_<5!%-*:J /LAK*(:V^1P<(C,,FQ
M )DA+7:Y?N@),)$W.*?J@H!*/!)F4X+?@\4Z4./4F !(30!/1P"'IP?!2AJ=
MY8AX E!8*@R@&.14 (:DD89D+,W1LONTU],CGX5+C ^C./_[;N\*2N?I"WGM
M)175=#.5;K[ML@-*5;2)&(0#$8A')I!5."&3Q_H)V'Z=U"S]]H.X9]&"8U%T
M\*OYG7*WS -%G0Q)ER7I*<L/ABSQ#D5I&94I)>+*)E.S$D#<.$WR)F#9?/Q\
M2>M\$"PJ[@VWRH.!Y!RA5F<J\2G.&,\PT6]LNDORTS@/[,HW>?69VDMYI[:Y
M-K9V:Y,>.&RIDI[E.;4*S.V8D.:,(2RUQ1'HAF;*F99@>^FQK++R,A+]Q[;:
M92#WH5[#F9,7?JCV]J5B&9O>#X^'[3))I%FFE[S+8Y[C4>ST<__SG2I5Y%7.
MN_WM6>-Q_BB&81O$Z;4EEBN\L<!J?7EU93C^%X[2B=W3 RZIUR9F22J!,[0E
M\)L2*'(; UB/6+LY>F<N6;PJY[FG;KO=/2TMTGS<.7/].'<2N*C&$52I567S
M8GN-L*N\*7^#L$<Y4*_:F;"K%*J<L6O/JA$#HU*J-W.E"Y1KNLIHZH% 0;!%
M;7O2CV_&O_P>6OV3MCU_T^J4SUA^Z??1SH_2H'+ZSC^Q-VB!Q!_=I+Q?]?8H
ML\>8=2U83NX9]."_,+[Q*.]GO<S[^?<@3+['R+HT<N;;>)T\\CW!Z*.^>==B
MS3HU8F76BO'CKEKOZUUK)7B=RYI@%[]6#2+$/.BJ_RZ%3"5H0)1EJ?A_U]C:
M59)BF6OTAIZ<%62L.BK)E=./;DNS2I ]B3:Y-P6P3(A\M=,9.TNOX9K1)MSQ
M?#@_W=J#/CIE*RI-L72;\;F3I^B4*1YED54%]V+_MYP/OY=[PU5#238OP7).
M'<Y#0U\7C4IQ[MNS>A?OV,5WN7#E/6"7XG]B.,R=D%Y@X^[DQ&?/K'[8KDYN
M9=ZXG<X_<52;/GL_%[]DL7YO:B,L>DK:>T;4B*[K25SGP+:L<J%?D=L)GC4C
M'5:GW[XZ_5SRD"UX%SLQM0;76E;6LNAJ"]_E0J2./Z_&.+>KG*G-RX8._5]]
M?_:[ ]N^L0GWX)N1-5?F5I\,BK*RIABO=7G!SX0E73[]VZJF]'6Q%?W(B46J
MJ.T/T,5XHZS_?MCK#CL!C1XIE/_[_<$[B(L%[",5RGKWQ/OXW[>W:W%[</W9
MR\F"2_?PK^:)O"0I@M?>64ZXX]A8G+11.L@89)"V=*V3/('[=L"E#\\*O]WV
M#C[0)P@*H9E ':QZQ.WHR_%9NWF\?=K<S_??Y;MT6S2V/AWOTEW>N C?FEO?
M<>/O_[2^;NW =S^>C;\#]QI^I9_EE_U- =?*_L.++_OPV3_R'0Y9 [[?W/\(
MZ__S^^ZW/[\UMMZGW3U\_M?^]@#^/=N]^$B;^[L'2@0P%(E PAN'>([3&"T3
MBL[;(+6+ >/IT?X)XVIA/)+?G9-7[A!K4];C\O_]7LN[6MZ5#I2'BSMA;#3)
M"!6$SZVW37 T8*=#E,P+I6:+NUK*/:.4P[>E7(I:JI B\H%CQ ,.2!,;4:!2
M$&V5(32L;8C930E^/5E7?>_7EG7S[L%/)>MRC9 U ?M$ I?:.B<HL0;3J)4G
M =>R;BED';TMZW0P01EN4&26(RX81R9I!C^D]2&R*$+(Z>?KDY,%YI5U<_+'
MTLJZ&M?]C+AN'CN6^!"4C< G5'-*@P&QIJU.CG,BJ;T#V-5V[$M(/7Y;ZH48
MC2* \"0M[5BID,6)(P*O$H^%),RL;7 ^!>'5AFPM\'XY@2>D3%8+D&51<LN8
ML]0FRST1-!%*:H&W9 +O;/<=/BN%WOXN;GS[?G&0B.%>.8LB830W-=,(H%^"
M/^%( U4>>Y=[L9@IZ?8K+/*J]=0BKQ9Y\XH\Z:V7EDGOE !8I[6/&& #I2*_
M8WDM\I9-Y+5NB3P*&HI0ZQ 6/E>F83!ML2=()IQLU$$JG><T8#EESL?RB;SY
M$N\J>437J5B!.'3SOKSLPL74K<:OM6V_?SG^8B'Y"_3AD'FFJ%]]<:<\YR8(
MG>.P\%NTG#&C%.=)8I)&(P/N;@8P0^[=)>S>EN?ZZ?:QUC+P,3*P-1FO%5&I
ME"Q8MX+G$1;YMZ0CTI1QEH>)IBC7-JB<,MYQ#@DXR20O;,K^ KP]!VMKB9W2
M(8@ [.RYU5+;2 'OTR1RH>/<?3YJCGXVCIZ(30K-P0)7"DDM+>*!1F24 '@C
M F/22FZP H[&?&$.^YJOEY2OC64F28$3D8G;P%RN:1=&:4-",,37?+V\?#T1
MAQ,DZ.051=98C3@U!!GA*#(I:"HB,4:D<ES0K$F7-5O_)&S- XD)3,K</(<K
MFTS$G-)(HPV2BE"S]1*S]42@22BPI/+8+Z$M / \3<ZR9)!6+&FL#0\^KFWP
MF>V1:JY>9JZ>Q\".)&$X<L>T83QJI46,+AD*Z)P#C'M(M[W:P'YI_IZ,J^@H
ML?<:(ZMR)#E$B8R&,U0ZMS8/@:B0!QB):7B\-K&7FKOG*6QX3*.36F<O"4_?
M#ARDX!*.,B+GM,TMJ22RB7,4C2<@M7/C9P9*&T_QFKV<UOZ)XP-56ZS^-?=_
M'F::Q[C-U=VE#A8L2-HM(%9P>V3B35GV'L[V >'2JKIU4/4JK\7?8\3?^928
M@3/)*:MRPSF/N .[!12;0(80:;WA0G$P6=12";\:U#R%R;* P,$,DZ5F^)=C
M^(F0 O7),!TC(@1KQ"TE"/!KSIB05$5%D])YK,74&H#:A/EIN'T!X82:VY>.
MVR<+?AA-FCJ,I,88<96'V! F$)8^"DU5DH:O;3 ]I6UJS>Q+S>PO&6-8+(M?
M;W^<6F<QH(O8Z]:L/Q_K3P8C$@$@SS$2/M<U)Q\0&- :R9 $<41&K\D:H'A-
M"?V]1O<_MPA80#RBUO++PNJ3<0GKA:662\2XCJ#FB426.H.(< QL>&&X=FL;
M0J^;FM%7D-'GZKKTX\&)&M@O(<M/U#M0[:7E$3F>)[B"Y8[RF'IDI?:8,(V#
M 3O>J'6V',C^$1$+M:Y6(6"1&U#ZBLB+DY+*ER8Z\6,E;:LO#%^FSJ$6<H\0
M<HUWD\$)F8N.DTD(4^(0%U0CJXU#6@)X=9Q&Q<+:!OG!*M;5ZE3RJ[/_LI9"
MU$S_.*:?"% X+**26*' G$><*8&TI_ C&1MCPBIAOK:AIC']S]VCZ%?G_.4(
M;]0R8/$R8")L01UWR:J(>$@)<1X4TDQQ9#2CV9#5U,_J4U8K_I^4_9>UJ*)F
M^L<Q_62;+B\(]B$B8IW,U1,!68$=HE1CQKTE5I%%5D_4C+\:C+_\=1>U"'B<
M")@,9!!#D_(Q(D,4R "J$G(N14199)$JAED$Q6_$E,+(6O'_?_;^M:F-)%L;
MAO]*!?>[(WHB.ID\'^P=1&"#>^AH1-NHQZ_]I2./(%M(;$DTQK_^65D2MJ&$
MC;"0"LC>LS&H2E5YNJYUR)5K%?S?X^[';?#_YW"4&[@]F8QZ[JRN\=D=_FFS
M9[A0PZ+4<'W#0W)9GZ!$EA&+N -^<"YPQ)361F,,ZD'>XY1S]CC;1PT/MK#B
M#VH+-2MDWTMQH2NS-"N?RV JPO L%RJ\[/33SNBW]$%Z7*+"6TV\8 SD@P%C
M@QBC&&.)PJ!9"8ICG?)O$0E14O[=HT284Y[(,T<9M00E&A/B6CGDE/(H^J"I
MUM8G8C>V*/FY^D3+1E%K\SX73BV<^I-^MR0D#89%PCWAQB4M!)76DYB]\89^
MAU(+DZZ021M;;IY9$8G&"%.6TQIH@IPW$3%MJ== K]+AG"Z:+J$&4N'3PJ>%
M3V^YCV$U)AXKK!GAC$AG39*.:4(MYL+9>^/3<B1C&3S;V-;$'C15FB*"J<Q[
MFP)XUD6!G+%6:I&,2FK91S(*TQ:F?:),N]#&$0Z"$IR,=(H+HUV*CG+!-9.*
M>\F+-Z!=W-K8/78LF4BYRZFY%.)64:2C5"B'DF&7N* YI2;'2]PY*IQ:.+5P
MZG>*JD3# W,Q>&:X)=IZ28@)- @K&8NI<&J[.+6Y'1^D=%3D=$!:&\23H;D"
MO$7.$I.HEDYKNK%%&2^L6EBUL.I*6#4H;RVG6OG .9?4F6!\8,P3P44@9=^J
M=:QZ/9+!:$)S&"K2B1+$?>97ZAD21'.IM4@L\8TM(MGC8-4ZUN'?=30,_!MZ
M_VS]+_RX;/@WS_(1EOD(OE;?^Z5GT_9!K_KV=!R?7?[R//3&IWU[\:PWJ %5
M?^GYB1T=]0:7W<W'1Z^UK7[?]/+S\UZ8'#\S9I,3D3USLX",V8NG5\EF[;2[
M-MS3:XQM8J)NO(PWR8W7OOM8LDFP6/YCZ:90^E:/G86G7-XPXRI62[D;A.25
M97;S0KHQN&V!@Z\_N'7^>KN/X!BQ27]$[Q3_S_/3X;B7P?ML%(%E@52?9[ A
MNJF;R]/9<<P/ )E OF!]#6$]-*^CZD4$, U@A"MX*LB&:AQ!%H7J_\[L"*!:
M#5,=XU.=QVHPK/K#P1%\>#SLAVH0)_"=?^)X<I+/11_'<!3'E1WGIUS _:-8
M^?YP'$-UWIL<3Y\-4B4_<7@VJFZ4AX.S'%UTO4*WM8ZD!*M;:"ZBU2'X1 V/
M27L28YPO$MEU0;C[?V>]R<5^G!P/P]Z7MA^<#^)H?-P[_3..,D/9H_A%!"+Z
M,&5@/_[GS<7[M^'442[W/[_^_'[GU<G!SOL3^)UW=MYEV2;>??[K(K^[ \_I
M[.S!>]^G@^[>Y[^3I=*2Z%# .1(O1(JT-QQ906G0REF>W,86-W,B\?ZGBO4@
MP]J ]0,CG!?6H3T9G\$:>]$;QM/>.'^T?3KJ]>NUM5F]&HZJC//\ -N'J]/=
MB;PLAH/&ROGQ\W^M3OL18%:-H@W5"C!6/_59;P((][= 76<XB17]M=H!^39C
M#FCSNKE@,LQ##:.6"0!TPY@)>5"3?)V0.?4&=N![,$'C"7R0D3/>_**L7)?Z
M,S&=>5!>M5[6IP1HP>ZD!)!-:>2=I/7WKPE&EZX#F$UJ[J99K*.M&-_MJ65<
MO]=6@C>Y+ MV^6W50"%F$?WZX85_J_GNB[U!!8_N9TFUE-0VMQJ*J:1HW6#\
M-0"]H@_WA^HWVQN,JU^R]R2._Y6UE</HST8@TD$7WO[']OJUC -]!G24?ORU
MRJF$0(_IVD]E%+\SBB_M^+AZU1^>5_^I[8HR<%\'KCE:>6R^FC-ER+ZWUHZF
MH]?_.GJGV0\*_[HXB*D'0^:@T;7U48;PZQ!.D_SYBZH+3Q[WI];9=OAP-EUT
M2RG=_I#'ISL$Z^_*(/Q !5C$*]LB_> 'Q\-VHI^=#B/UZ3"\A--A*]TK6\EP
MW;A7MIH=KY7T<9$HV(2#=A8+2@S/F6&4<M+G$,H4I>2Z]NYA0ADIIPH:^UP?
MMLG[D]?P[FW>^?P[O/OU16[7^V[_X_YOKWGMW^ON?3K8V>?7][GV=_Y[\GZG
M<[*_<\3V3_[[H;/S>^^@>]P_>/OZ_/W.,?01WOMAE^]_/D[[<\YG\:B8<42A
M/%$Y(LLA$Y1%@5HCM$DQV5PL<>'20NN) B@T]!AI:*'< G5E;I*259K3:'30
MC!%IK3%,<4MNYJ&R\;X.0FJ6/M)8:A4EBD(*Q),$:O)1(*T]\5(E[J4%0IJ;
M6O#&??<UQ23=YK6%JIXJ5>F48B1!^J0M)]Y823F!]>T)%C(25ZBJ7535/"F4
M4L)&1^228(@KXU$^D8 2#\Z+:%D,;F-++Y+_L!!5"T!<B.I:$@X>K?),6VP9
M#U@92U2,*5@3,.A5O!!5NXBJ<>Q&TJ"\4!%Y@17BW.$<')Z0M)'0&+#!C&]L
M2;E(&8IBX!4R6LMY%1J]%([80 -WWIB(4]28:1&]C9$6,FH7&37/J^2#?MH(
MA2)8=(B;I)&5F".2:,#44VUCCDR3BP16%S8J;+0.-K)&L"@L3IY2[K4WB8**
M1+V1+'"PXPH;M8V-KI_S$&"\.>L%PDXDQ&T$(\XYC8@,1G.CC$Q^8XN:5OF;
M[E"GB]!-^A *=1W\J"I7Y6(:CG)@\-5*=TO9OJ9SQW Y>7A;1U[.8$$B9<EB
MS)V31A+M95*@1HDD**_S\)++/+QD27EX7]33=[U.86&T.S%:K[FC1QS7PD2)
M7!WX[PBH5\(GA!6/DG@*FK, 0EO *[5Z!>KQX'$!.#+!J,-<NWQFU 7O$M98
M415EXI'[= LX%A2N"85SLO4%+1FA*&D#1@[8I\@Q39&+42FA&68F;V-QMFB%
MK +&E8"1)FN=-=Y%I7G.6@Z,&B5U0C''B*$%C.T%8V.C!N;."RHTPL%2Q$'#
M02ZEB#P62:9D#39F8XN).?[/@L468-$X(D+4$AO+C?'P/T*UUH1[%T(J@K'%
M6&P6D!+&Q. $<D+:''"6D#$BYU50@3(""BH#>YO-.99:H-@"FU$%S#W8C58K
MR9,++C'ML<<F,JPDP<5F? "@;/KD59)!PO0A2;,7C $JK1&I+MZBP?Q03JF-
M+8T7V"$LB%Q1_63O'18B1<Q!424&X\"-#UY UZT-13BV&8?7O=$,Y]U-$Q%A
M1B+N<D@1@ \)1AC#5ELF (<Y&<[JQ>,C=CIOGPS/!I/Q-S[EG"QA-#RI[-?]
MF&KX(]=T\4 OQEU+<$!?Y:[KS/0*IO 6.VK3@W&3/Z&_PU#(["YD=M%T1&?Y
M(QBH]HP8@3AG%.F '0)37"GXX964^6@)*9I^"[&Y=&]TP>;ZL-EP3[.@*)5*
M("-M1)SDLNTA$&2%X5@JK9,*&UN2%N]T.\WP);BG;S##"TS7!].&XYI8AKEB
M'I'D<A(WAI%3A*-DP,Y+27$CP1S <T1HL<H?E\MZN;!\S*6#5@?79GF+: CC
M7"&)14!<.8*,\ JI0"T6S%FF]!U+!Q7<K@2W2W!O%]RV';=-]S>G5M 8-?(\
M)0"N%PCLGH!LU"(D$VQ]DJ\ M[W 7;H;O.C!ZP3H=;]XDH%X3C2*4N0T)18D
M*Q,.":>Q2CQH;B78JVN)IKJ#7UQMJH?@%L^IT_QT05>G]8I>M0_\YX[0M)/5
MVA^B77CK#KS5>3DG%EOI2(G B&AC@+9"KB7*$S($*ZX235+;^=F5'LA)MR<"
MV;9&<1>@W@VH#7^X),%X'RARA( ! #H%TL$0Q&,$TR FRC%8[A2+116,@M>6
MXW6E@=X%KW?#:\,QKHF4D@F-#&4.!*OC2$<0K#Q2I;U2$FR^.J*;%K@^+KBN
M,A:\P/5N<&TXQADU)G++$*C!N>XS2%9C D?")R\\<UAK?(>@[X+6MMNOZPD7
M+[B]&VZ;CG'B4U0N*>1  \ZUA3ERT63EF >?&*<FD 7CP@MH6RYB5QI1?@G5
M/X>CW*[MR634<V=UA;#N\$^;78\%Q8NB^+KW/'(LDI .!6<MXI[K7"'<(TIQ
M9,1+&DA.\BUIZ])\/]@:3#^HL7 83R>S(@NX+K) EE9DH2T5RU<RH#_(1[7V
MPN1MXW9L)66,>D]#F'H[K &!CC4)@8)*5N>KN@6E+YRFJD0N_#RUSRG?(**+
M7.?80)Z]E=9H9+4S8&=YHX2G\ &]8^#"^FN2%Q8L+'@_&BY.$D?OM%:!NZB,
MS7NKVG&JA=/2W!L+%K9;A.T:NS0\NB!<LH@&11''U"-#B4,^2J>"5(P0L$:I
MO.,F3:&Z0G6/C>J$8LQ;EXQDC$=E@?,DD3HGVN J!ERHKA54U]C@<I;C8)5'
M0C"/N"82P<2!!4\(UIPD&X2NJ4X5JBM4]WBI;J'-AAQ0Q4T*8-AR0J4EG'NF
MG3,T$K![;^:ZDHQY':37V"8DC :N!47!R)PTD1CD;- H.HM)\)(GGNI3J0O'
MRQ6^*WSWZ/@N2F.%<<!ZCG!&J/8B1 9*'2A]U#):^*Y=?-?<7@T62RL#1D&[
M'+PD"+),)P3T9[#T1/"<=@M$V9S(B,)XA?&>&N,9H10U22M"-.<I:<.((I*Y
MP!S5,1;&:QOC7=^*-IP(3#!%BBN#> H).849$EPK'$7"M"[ORNY0_6>-C%=O
M4_^[CEJ ?T/OGZW+QG?.3@ 5OODWW'39_AD<>#X2=CH<]W)GGXTBK$I8A,_/
M>V%R?.GX^>9;L^[BKU^Q#GIV-KGY*]]TRD> U>A>8$_PCW!/<\,8_3*=TP'[
MYN?QZ*O4.(K(C:+]B&R"%C^S_7-[,=[X]Y6.G?0&EP^7:C./X_4AN+&C*2V-
MW]2<?DX7$G#1<%0?(WUV-H"EF.^"=ME6M:<Z'F62_7^]1+R(B2AN<CE:ZL&
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M OL?;VPI5;PX+:"EA7:$!#6612VT9EP(:K$5DG%F="!:*G[W()N"O;MAK^'
M"<DRRKQ%R;F(./,*695+FW$=0)$- :M<484OD+>K%>AZPH*.*V&U#DYX9KC$
MQ$;) A8L"A%PH/,3/Q1!MWRP-;PU >C9*<80E4R M2@(TCXJ) 1/UOB(O<M9
M\CA;N-IGD71K+F]O.04MQF&<!(\^.*X!;U@(21F-4=X]]J& [V[@:[AJ@K!"
M"Z-1]#D$2RB'G)$:*>MLB#1P8@!\4L_1,N]3TCW=2(8O 3U+.(?T!#2 A:+;
MEVWK?IFKF?^XT-%"=#3GD(UT7DMA'>+2Y9T;HI!AB2 E$S-$F^")R9YC_?,1
MH44)>##F;D'=4E'7,'>5$D1@[1$SB>=01X:TRIXG$04CP1J+Y?S]FF+MME36
M+=W<+:C[2=0U[%[F7-!8"B0P =6;,HV<MAJQQ)U2*4J?0/5FFZ+(NH<BZY9@
M\!;4+15U#8-7)248EPKY %CCGB7DF(XH@.)IL8J$YY*JJY9U3]C>77;RC2>@
M"*S5YOW!J:/'7 EZ1;1U,">D7UC,=7:22\_<M+""E88BPQV)0GJ?1+IK)>BB
M-:PWK''I!G*!Z H@VK"B>4[  &H?TB+6%=L-LAX;E)05/$28.<SN"-%6(/&Q
M2=$5F]/E%.\*0-DPLH46B7HPK06-)D=1">2H,X@YKJ0ACG&7LKK?W%HN1G8[
MQ>7R;>R"P"4BL+G#C#G5E >D!,&(2TM!0.(<X\$BS(Z04M$U'89[NE9W.2__
M0#:<;] :RLFE)9#58=/,YOF<4B()*8<3XC1B9$'+ S-;6:J<DMB1C2U5]I\?
MC+JP=.NZ0&\IT&N8SSC7'Z3)(LQCSJ_J.-)<PZPPH4VN!"L-S4DKFMMAQ71N
MLQ"\/].Y('$I2&S8S,D:AR-C"'05C;B(&EE."&(P:T%Q[16.]>F'):0Z;@4\
M'[\47+K17+"W%.PUK&4316(LAV+YG+Y7A8"L40K1%"U-":1@8AM;<HX"6H[.
MM_/4^:/HQ#T=G?]>Y>XUG)\?Q$G5&_P3QY.ZWM[50_3+;Z;8I+=HZ)R:\3F#
M)**;NEF-U=EQG%8?_X5<+ZG\>+Q7)6;D7I4%KQGF.&DB.>8:8ZNH<@+T!-#>
ME7.XQ(RT3Y?8SWK$!?Y4ZQ/=?=SY\/'SW\Y''5B*R N>3>I$D;$:]'K.C,5.
M&E U2M!(>WAMD5QT+ DKB#31!9Z+V@MEA(Q@HE&FM7(E:*2=&.T<7L-HRCE:
M89Y02HXA+HD#8SMAY"UE++)$# \E:N1!RE%K@'%Q#!H+S@.S5F)&J$N*<A.M
M<(N?P2@[U4O%XG5YR1U1(A*+@DL9B\;E^$J,!$Y1,&E-C46F%]VK+L)RS4'0
MU!B/ \$B$=""C)96DN")],P[A7T)&5DO$ ^N"\5(-57<!42\DH@S(9$6*J*\
M:^"I9S0ETLZ8D= ;G_;M16Y3_#Y"RYWW?V=Q63[=3CRR;)\OST:C./ 751>>
M/,Z.0)!YV^'#V=19^1AS?18WW[UJ1083XZ3&7BJP3Y327$AJ4C2$>F\Y+6Z^
M-FI+KYMNOFBD55@'%%)2H"V%B'+:-)2X84Y+PA,VQ<W7'EY;)'HMDD@82UJ$
MQ),/ECN17.**:F6=9L7-UTZ,-MQ\(41.B9.(POPAG@Q'1N<*35($31*GVOKB
MYFN/'%TDPLU8[15G1B49N:3>LH MD4D%%8BBO!P.:PLJKTM.HZ/F1AGD(A6(
M.^^0)<HC0*&DH!HE)M3&EM +Y/DM$G/-&V-$,@;R$6L2N3%)\T"#!CAZ09+T
M9.F^OB(QEX+-A@^01\^BY F%8"*"=2&05A'^),IB'*T0!J]18B[F7JA?H3:5
M> !F=W<XL?UJ%'W?CL>]!$W+(SK^M0Z/&J9\:&P9-OCMBV3_H*;W=,"R5Z\*
MPS/7CW5-W9LK?B^_L/9*-)(;"VO?Z_"T7U-;Q)K2D3$E/2/$<NN(LR8QF5B0
M+,=&NX4]'B  I@+AC^&XI.9:C/+_:CHR3"!!@<A&=EJWCQEDF".(>^&])\+R
M9#>V)%TT^OE>(;(:7>ZR)VVAO)5(HALI;^W,UKK,@](XH#7L*-B<W(5@J8F.
M8&TB80I4I;L7E2D<]S,<UW $ 9^1D!1%).NVW'$+)J<W2$BC!*6.)V,6/5SU
MX%BL:'1%HUO.'A8SAGJ13/"&BR0=#R:[R[5AWCI,%PZQ*VSW4VQW7:-+3$?N
MP72728,1KQA%!J>8B]@QKSE,F/$;6T8M6@JV:'1%HWOD&AT&=<XGSS6-@CN;
MM,21>"])I-YA[>Y>/*EPW,]P7,-1*4ER1I.$(N<><4L"TDY8Q)1VH'QKZ>LC
MN^R!:'2U8_/?$PNONSPZ"#\N6_;-LWR$U3K*D73YWFM-!U3U[>DX/KO\Y?EE
M?%YO4..B_M+S$SLZZ@TN.RJ:!QKK]TTO/S_OA<GQ,V,V.1%939AY7V<OGEXE
MF[4&<6T\I]<83 %1-U[&F^3&:]]]+-DD6"S_L713*'VKQRX>YGAU@5U=1=\N
MI%7%Z376VYK.V])EG+==@W2A>1U5+R* :9!KA\%3)\> R0@B)53_=V9' -7L
MO,]:<'4>J\&PZ@\'1_#A\; ?YI]\KNPX/^4"[A_%RO>'XQBJ\][D>/ILD!KY
MB<.S476C6!N<G3C@B*N2C5CK2$JPNH7F(EH=@D_4\)BT)S'&O_?FZ>KLNAC;
M_;^SWN1B/TZ.AV'O2]L/S@=Q-#[NG?X91YFA[%'\(N(0?9@RKA__\^;B_=MP
MZBB7^Y]??WZ_\^KD8.?]"?S..SOO+O8_'XEWG_^ZR._NP',Z.WOPWO<@K[;I
M_O;?R5)I270H8&)1SD6,--A+R I*@U;.\N0VMKB9L\W]/U6LAQE6!ZP@&..\
MM [MR?@,5MF+WC">]L;YH^W34:]?KZ[-ZM5P5&6DYP?8/ER=;I'FA3$<--;.
MCY__:W7:CP"T:A1MJ%: LOJISWH3P+B_!>XZPTFLZ*_5#DBX&7= F]?-!I-A
M'FH8M4P!>;<Z4_*@IGD[@3]2;V 'O@<3-)[ !W40\>:UE '3Q= Y.X$6^.G?
M&<F]P5D]G5/-H$94(E[$1!0W)'$/&BJH1%XGF9-ZL<3DWUILS%$G9O*_5F4X
M=&LF(5 V7IY1=6G1]'(/)L#!JI8;<X84R(08>><A)=<E@YH[IH1O3LW2YL_=
M[3>=O<YOA]6?NV^JP_]LO]FMK@[FE;&\%K-@G;5>4ZRDYTYZ:USPDN-HK4B2
MST^1=8T,[2@3_QA8[_#8CF(7'OZB/_0?U\QXG<,9XYV\^OBN>]Q[]]FS=]TC
MT,1?\X.==^*@"^S5_6_O???H?'_G"!ALCU]GO'=OWQR#-OZA\SD<'^S\][BS
M<\1!\Q:=#WN?.F]_[Q_L;)\?[/S^8?_#<=J']_]M+:42.XV44<!WWC#D(@LH
M*DI%LL8Z =91!*EPFE7:T5G<N._Y.?0@4\_Z\2!=GZD7=MSSVX.PT^N? 2Z[
M61%ZNK/W%_\[)9O3IC+D<4X_EE@._ AU1GTF$U8.J]28O?F<(J\1".5U",:]
M>  (OA4MU]-=6=#*PG3"JW%>!6.0A1,@XD&FO^HLLS6\M9:/L_52G8*R5M];
M@3;CSV9'0+[]&[X$*EL"BVMX/GYVE7[J'ZNUU C&FWCJT5W45!-R4QE^)YOJ
M^]<$N_FE=[74]*8T=[/_2EL?3UL5OEU[EI]T_,9;S6V.?DW=.&MTE394K9HR
MLA&1387N\2C&:A_N/QY7NT#CH3J,IZ"O@EU9,?SK,D+1'L,X=>#*;8?IP1Z-
MG#\$O^P-*GAT/]M=2\E>_]V#K/5_M_?!_MP26O)^Z_SQRSKK+8;MQUV^S8"N
M9MQ6LN[RMLNZE]O37''+6G2/9-W]@,_OVOUUD?WMW6_U<-0FNYU "]H$QB4G
M5%C#*Q]T]Q_O\8Q.O553E^^QD\FHY\ZF5OUDF/WE1W%0[0W\YD] X:=/=#Z.
M8+O'&S0G'9;)$DN,C9Q0::@,VK+(A;,$>_ZSQR"^/1$W.#M!83A!LZ^W)MKD
MCI[-:;3)A]>?WM&_Q/YO?XF#M_OB8.?UI_W?X#T[1^>=[A&T^PC:]1?OO'W]
M^7JT26?GU8?WW8_G\/_BW>>/O+.S>Y[[=+"S30[@VL%.YP2>0=[O=-+^!;ZX
MGA]>:R\P)AQI1CG*6061S2E=N?(A.*R,46%CB_Q*&-]4#S;7PVU/J[:2H&]B
MF@<6J[8 H2@3,2>1<L,]%YB8"(N3,HPUC53+N'"6BG9&J#T0SL#7.8/0Q*Q*
M#&$B>#Y,99&36B$=B%0\A1"IVMABU,RI@MJRS!-%-WGDNLF=MEJ+;K(.GJ'7
M>48FX;CD'A&;>892AEP0!IGHB<Q5;"2C&UOT5V[DHE7<BFY2=).[$8J6WCLL
M1 (5A6>;!^/ C0\@!4.P-BR<#Z00RGT1"F\4HI,DY?.2"%-F$'=6(8,]0<2#
MF.!>8QY-;>QH-2=TL64I0-K #0MZ5G?B8'C2&ZS&MWKE_%;V]%T[]K 2[^+J
MWOG !^#Q^E??UG_D4"IHF3V*U32&/8<K ^N?@+1I!FR5G+1WDM;3@5RR=[)Q
M3N!R0K>G\]FII_,@U<&7XX.ODUA'YA69O8#,[APV'90Q:IV<C"B0J! G,1=/
MQQ[98'7,E<4$)SF0FF_R!VL"/('$>G.A^;-^O@+-54*SX0=,P@<14D!1.("F
MX@G9""!-,M+H,7.6Y;T#KN><5&V9'[!(S27[S0HT5PG-ANO,).HEH1@%J0CB
MB01DF< (IDDKA9,R269HBJ6E/FL%9I^$U/Q9#U2!YBJAV7!"*>L8\\2C@&5.
M2I@L JH5R',.B!56!.\S-.>=GBTNJ,6 M9M2]'62V?IP5.^?^@C[V:@WZ<7Q
MJEQ0:Z^>], Z42JBK?W.Q^N-Z_9.(LJY'6*H<GJ 4<_79R8G0_^QEKN+%+XJ
M5L2/#'R;A,'62!,M!R/!&>,)8Q8'$'E&A84C _<&?E2G%K#]E[7S=*JD;'\3
MN-H=7AZ#CN%/>Y%OWA[!,!Q-4Q(4_64!_>7@9=,AAZVB%"81::H-XE9KI(GU
MR"46(IC_U'*;:VDN*P-?,2Q6A5;#M+"1"*9"XBZ;_499PR3F/GJJY<)A=P6M
MJT9KPT>G9)*"&(ZHS&BE(B+C ++.RF2\\3&*E-&ZH/.\%:!\VK)5 B:Q9]8'
M'GG4(&IMHIJ!<2F2#Y(L'-E6T+IJM#;<=D$Y#<+5H11)1BO%R%JB$!8Z"(!L
M=%@6V?H092O@DY@06?#4<^V]9LER%H&"D\Q'+Q8.&RMH735:&YX\[T-0&EO$
M/(^@"7N-K)(Y2)5J3;S*:5PS6M<0!?]X#?A]._H8)\5@OQ^:<I%;$H.,PB9.
M.74X!&Y% +L]!!'86@SVEE?$>Q#T-2>RAE+G&64>:1EE+HAGP"H@)&?Q]%K;
M8)(5I<QS>YAOT5U"HDT"$SYAQP473GF=*_HH25U,.!1COO6(;1CS)@8AL!'(
M R,C[K1'SA"/)/<R!\.19&K7&RG&_ .3N]11CY5@"8,Y;PD&9@[6"*Q<"M;3
ML!9COLC=9:"X8>1;'K#D3" 5/$?<)(*,@\'UCCN'&=74W[5T>Y&[:T<RITQS
M18CT7O"\]^6"CR(Z!N2=X,-BZ+<>L4U#WSIKC,*(\1009TJ!IIQKNSN,$Q>"
M:\?7)'<?KZ'_9QS5 FC@X[?6?C6.DTE_FLZX_KB8_\LC+Z&HM%H[Y9SBG#,M
MG)!4XL0,D8G9LE_?;O+:[VY/]GO7ZDD)S2V#V40NT@3LQ06R/EH4<& L< '_
MWL5J*+K&VN%*3*0Q28T3UCS$:#2U7'$JF*':45IL_/;#M?/R&EQM;0%@@1+/
M1<L5X<A(*9"4F 7B"7!T+$;^0Y2N%HC8,9A6$*><!FH)F/V16*L8#3[ALF/_
M .!Z7;K"Y&'N6$1*.H*X!"M!)ZT1B3R)I .V3!;I^A"EJXI,1\R5\: ,>YVL
M2$:#C#786V**)?\0X'IP7;HR(7#R0B!'#2C#*21D#;=(&J<]E=R H?\@3/G6
MV^\[ER=N3H<36+NY,-R5?!<KLMMOG:S\T:H=2T_/._>\X*S<6./0X';X<#:M
MI%G(:R'RVIUCR2<91-0&8:E%#CBR8-,'C*(@FE)I$Q7N#L&\/X^=]1D4JT5W
M&[649>?*+>A>#;J;AC_,HW%1(\SRP>!$(C*6&22)$M2"Z<]MO<L@%T1W^T%<
M9/=]I>$HZ%X7NJ_+;NE-H(P'9,&01-PPA9PV"H'\CI$E(Y-3178_+=F]]%RR
M!=VK07?#K6"I!X)F#M$0<[X=IQ#0=D*!!^J58DFD.VGF]PWB.X0/$+I)'T+\
MP'2]?RE]_*7&\>#H2Z7D9BGDU3HE9L6/Y^1(+9K/JM)VWL2.A1,7XL2]IK<B
MI7R,Q$=$C?6(>XN1CHXCH3TUC@6I19QF[EQ6#K+EP6K=2E%KF*&%6M.JLH86
M9E@2,S0\'4Z9D*CQ2"NF$5="(TL-020'SR9CG*:SQ*%W\W4\: (H.D/KDY86
M9E@6,S1T!D\9 XT/F219CJ80R(!EC)@,R@HJJ)$V,X-<]%!UT1F>M,ZPJIRI
MA1F6Q P-#PMV-#D;,2@)%G0&S"VR*3$D:#(D*+ 54]89Q.+)4=9. +43YM]U
M_ _\&WK_;%WVH"Y%WO-;_PL?7K;WQ(Z.>H.Z.?(2J+U!B(/),\KKHQWW@DJ"
M?P1+FF&Y?0(<.QE7\9/OGX48JC0:GE23X_C5 0-@':9J\+7L=/:^7+ID:O16
M+GI[-H[Y>[U1%>LLKN/J/,(E.YCTT)=LKO5'O<$8!K678( 'DZ^5JG\TD+-V
M\^S,.AV.>[EEST8Q-_&?^/R\%R;'EUSSS;=FZP1__8IUL"2@\3=^Y9O5X&&:
MXFB=$\38M0'ZYF=N<\U.B7@1$U'<D,0]]<X9[762RE',$I-_:[UQ^:7CT5>1
M=121&T7[$: )W7QF^^?V8KSQ[ZOK%Q;OK$52;>;!OSYN-XY.2DL3*FK.X$RQ
M!*P_'-7+]!EH"W&4[X)VV5:UISH>9;GV_WX\4VICJUO7<P?,O<PB<9 SIMBM
MJZM@\=4*[[4J+&^USAN C:T7>P>_[7:JO<[+S6J[LU,=_O7B<&]G;_O-WN[A
MP^A!YZ"[>S@50-V#ZN4!"+[.X>Y._NWPX(^]G>TN_/%JK[/=>;FW_4=UV(4/
M]G<[W0?2O5_.!O8L]("Z?ZTUKM[@+(9_S:.8^2*,\,R^4R&*\C[",ZJN2364
M/YG?1Z$T,?+N?:2WZB,1F],);/X\_,_VFUWT8CO/Z)_;[^J)JZ[V_HH 6H*]
M>E4/W>F-?7\X/AO%@_1R>'(:!^.:*]YD.1;#R^%X,FZ$%(^[T(07_:'_N&9M
M].#E3!O]\!?=/WD'VN#'6OM\]_GU>>?D_7'G\S:%=Y^_W_GKXN"WO_!!=_\"
M-,M^_,^;B_=OPZFC7'9 8WW_X8@?=/<^==[^_J&S ]\YV67[.^]/]KLO/G:Z
M>_Q]%]KR^??4^?#ZXF]FB912$Q2C#8A;&9"+T=1I<' ^J>TMV%81%/;3C+;1
M6=SXC@)VHW.$.;L$\-6/G5=A<?Y2K:<:N3S7U;?+H=K]E'^/JUR:A_XXAK,^
M+,S=D]/^\"+&PSCZI^?CU_7X;1.W^[ @Z]\.TAN0>:#1?885"TT;3I?QTUVT
M[]C?WGB"0\#(^^# _)$::4T=\LF EBVIH K??M&VS6KH@GV0AK  SO/V;&T)
M5>.S$V@T/&0\-0IFJ]I_NZKC=%5G0V)J;4"CAF>CO)1#OI!O']0&FYUF>8=_
M:@+,VM#4^GC6D+-@'$X;<,4^A/'HV]-Q?';YR_/+Q/F]0=VA^DO/9^,\LQ*R
M=GO-]*M'?GKYJ^*[B:?*[VPG?O;FV>7-^M(UJW5Z3<A-9?B-E_$FN>,UP6Y^
MZ?>^^;W&ZDUI1&GK$V^KPK=KSRTC4Y91C\3<YHS-5-5>HQNT(?!KRG@U'-7>
ME2X8A+':A_N/Q]7N('/A83P%MLNE9AG^=1F!+8]AG#IPY;;#]& /9,T?@E_V
M!A4\N@^"<_RO9:R'Q:I/7_6=7G><_MP26O)>Y/SQRWKN+8;MQUU>K(+V?8[;
M2M9=WE IRZTLMW4MMQ_0^"+;.RWB^/F[HF_B.-J1/Z[L(%0A_A/[P]-L\%0_
M <#[/:6SZ#"N).SD_W=OIRT6V!ML7<S-V3A<VU9/V#HC\Z:ZH]P)KC6Q)CDJ
M4Q#!1+/PT>*9$VBV@][P$<V\6*W93;^C*VBZFWZRS^!O>/?['MS']KNO/W5^
M>\<[W=WS=R>O<:>[)_:[>Q?[GS^*Z[OI[SY[L?^Y<](YV6/[._Y39V<7O_]P
M1/:[+WKO=UZ3_0\?/^U_V/M\T.VG_5XS]7>BGAM&$U)*&,2YYTASKI'E0@6)
M V$! Y/R3?$X3R,MY012*P7 C<RU&H):;^A/DZ PQ5:&?(!6<4ZXUR((;6BR
M"1,;F5OX='0AJ/L@J$:F<TEM+F(5D%/P@VM+D0E$HV"2EYIY93S;V")F88)J
M)P\5U:JH5M=CF0V1FF!'=6#<6>M8Q"JS6"0BJ&06/OE=F.L^F*N1W=UI$X03
M 6%I,.*2<61<<B@DK[PG0B;F-K847?AH0U&MBFK5)M4J4HVMS@>;9>)6<FN8
MBL%HEQ0A(+P7/KQ>".H^"*J1S)YXSD+2'(%N3!"W+B%'0T3!J:"EEDP;61/4
MHB<LVG56O?5T<AC[\.'1K]51',21[=<N.QM.>H/>>#*J@Y!+:OLE<97WPG/E
MHP.;@DM+C>5!8* O8"?O].)E[0I7+9^K+II^*D8PZ+\^ 3GEU/6<.F0R5SGM
M3 Q*Y-*I&UM<+LU/U8KS7(_M1%83CX%0C#E7FBB;<:FU)]09D$."4\5X<<NT
M H\-MTRBUFL#LQ(H 3Q*09"FW&8\!AR(TDXQP./"QDTK8/>$Y:/#@0;*8I+6
M<.>I=8P3';'4/B0I%D\S5_!X'WALUHN71A&1&)+1^US:12)MHT:>)6N-C!BF
M;&.+4%,JQC\L 2DYBTPQK;"PG!&BA:?,!DSRS@7EI!C7K0!DP[A../@8N$)>
M  PYU0II 0+2"^L< _LZ"I$!J1;->;0" _HRGAW:%+\/U7+G7>]\O.7Z#L_<
M9#BQ_76G]7\"VMK2$_K?3CATXN0@=>VG(B06$!*=PZ97(S)O6)().<4IXB0R
MI GW*'G&DXPQX"PD%-G$][U%U YU;I58;INBM_3T_07+]XGEAD?$"RTE<"XB
MV2W"Z]15-GD M!;$>:YLCJ23=.'Z7RV';)'+<T(VEIVLOV#Y/K'<\*9X(ZT-
M42'E%6 9PSPY%QU8<%9A:EP,S.?S!633%,'\V 7STG/S%S#?)Y@;GABE'%&&
M!Q2IE8AS!H)9,8*\TB&2G$>2UF#&"VO9]XK91Q;D\-*>UKE+/E^F=IN7Q<'G
M[!X_<T+I"6SF_+)._\!R\K=\LQ:F60(+QRW"<7..\2AIL91.(!^T1UQYCPRA
M%&%M''&6!^PI<-P<AFN<_R[[/NW [M+] 06[K<!N\X2+2[D"/$8NB(0XDQ)I
M:CDB7F!JC>)*DHVM>:;&3=AM!42?LMQ=NOU?L-L*[#8<!9(*;$,$V&97'Q=:
M(T<)1<;!K&(2.0UA8TO-\?D5N=M2N;MT<[]@MQ78;49H4"ZCPQ:I!(HS=Y$B
MD,(.>:&=)(0J:OW&EIP3,'6?<O<1QP4LDKNQCB"H_0'U:8AX+6EIJ3;\$*(*
M7*_GGGW7R;DWF_*]04URVX,PNS N]+8(O<TY,2&9ISXIAX2-H)H0@<&L\ $Q
M#HM-.AEMTD!OYOYC"]J_B_$T-C*6YE$HN%X=KION A+K@&"D(]%@<CB"K+$<
MQ4 T2Q);BA/@&K?NU&:1UVV/-BBX7AVN&ZZ$J #*RBL48I*(IQ"1QI8@ @8I
M8PR3J+(;T"R]2&Z;$?^T!?;27!$%V*L#=L//@"E+,(\,*64H -LJ9 .)B#HK
MLN_?,Y>/9AFVJ5HFL1]9",+>M,C<Q'Z:%9(K@08/.]"@:S^]B(.8>I-7H^%)
M.<7V<]QU\++I1#">>:XH1<3G"DE.&V2D\2BF:)+&% >53[&Q$ECP<#8XUA-8
M4+"Z9*PV' ,$P&@E]8@Y0Q '<P%94!215Y8D08@P+&?*Q"60X.'(U?4$$A2L
M+AFK#6,_<:HH3A&10 &K@2ID*-6(TN0-MYJ;E#:VF"QR]>'(U?4$#A2L+AFK
MS?,#&N-(&$%)!<"J$A+EE"I(2JZT59S&+%>9F..7*X$"]QXH\$WU>#N9C'KN
M;%JS<3*L7O2&1W%0@=F_^1.6_BV]J+,ZCPR&.@S/<@LN!ZND[E[J(+5?P5M
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MCKID;>'*E4BO'Q0N6SLEMFWG;&D>K$*)*Z3$AGO*:FM<2@YASPSBSH$&1Z)
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M]0;6_"I7Y*$_!K+JQX.T>XGE+XLTMR5'K U\K]^KF:W6[Y[PBOW<.?_;,6U
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M9KRJ 6I&@/HZY;AW8A#@DR'CB4#<4?#&)9<H:N"'+E(I@@:*+^=&(>:G4/<
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MW\GW]P"K"D"@9L?G44G8MIJ_:;9=-YA>-5B=0;<($V'%])5K#7RHFG*1OJ(
MN*V>7M5SZ+2K?^ I=M!L)8WHY4:GBZ+YUNDFV2I.H!G=XBR8;GY8]<)>NM-=
MS%NZY9MI#<Z?&/X>-/MG\-6W, S;KQ:GAZ$;BM-0=(-+ZND!_:$W+1AA7[0Z
M/>C6ZGD#7FUOOR*$Y-_AY_0+S3UI=G,63'AY%UZ^5NP/>SG6,)C.WK!UJ7&W
M- Q:U!UKDV_V8(S[H756F-YX'\\?,^41SK3;G7YA0]KQ%YSI]8-?6VXA?K#H
M3I?<ZP6W )O=@7F(K3R/N0VA?WE>0S&6FF5O8'?AGXVWQ8N+3W\KCDV_'[I)
ME'IY,@<@6!ZFIM4YO1"OULVI59=T[C9A%-H'U42D-31?_#TP71B--'II+BYI
MG\GCZT,,W3R#, \&QJJ?IFCOM-G_$;JM-%YPKSDYZ7:^ ZW*>O&/:UG<H.>O
MAN&=<:5AI;-2 (=3R@7L0Z!4I&\,_[*=VD4H(^/,#8FKC&USV$RP$!NID;UW
M36.;:1I#KQ&NI)X",HE\IX^&#SSG<.5R4KA6^/>'L\]_^1-+>=GX\:K5V-SA
MC?W6X<[1)]%X^^G'SG[K:^/HO\W&_L998]/1QH_#PT]''X".;8F=C2]4$14X
M>(6:6(^X-]D_I$AXX:4A/):8W1 PJ"=U$2=5N2@B%AAFD5/$ 2:1CC0BS[$P
M@BGM/5E9YQJOX0E:?4T8 &"IE68>_KL U/_M962PIM?,9G!C\^._M][M5*A>
MF>\*1P$F3@'&#@NXSH>3D$$Q/2L.^H-NQ3LRC ^?L%:,P54$F] _O I7JX4'
MD]M/5L$/'&#4\%'A^PG8!/B]&[Z%-EP"N-5Q39,^ N ZO&CD9;Q+)KQJK&F!
M.3!M%Q84W?X[:NG&J*&U,DQ7AO>X<?I%&H:]P 0)G93!1HV,@K\$"2$HH5G4
M=F6=356&2[*__(8_-KN]_A5% J(V. %);O9Z@Y'05]>F$_B-UYN@)*VL/:!K
MTW4'5 :<YN&9_;GKD9?.&$Z5=)YS7E*KO7:>,4<$%YZ(K$<34>=:C^:H1Q_%
M[OLOUD9LJ$SVA*2][U8@Z^$G(6T4CA!)B5E95^(V-;K [',>?^X^9>]L"NN$
M6]+AJ.S1@9]@+G9\I:^2SS!YT[G#VNQ.$TKX.ED+ T;I7)*S?0!Q!B\.)+GB
MMS'Y $F!S'%GD/R 7HH;5NK0SH0X10F+%\E)_:T _Z+;M(,<>LE7=-I)F+L=
MZ#H\HYD.A(%G"!Y(NC?U.#GAE=N32'EH)X<$?LI1J:QVO3[\4_45KJ]>MPIM
M[@U:_>J98+W2Z%3-R0[]E<9=;=6K9N<@M(OMMEL^3"-TZ(B.84ZS7>GMD*#<
MP8E;+4Y:V>4$EN*+T2 \9G_N'OC*/6QTP.NEX$M?Y-)]BE;>V*;5H2</PW:-
MK":CT0:RU1J3VI]2Q"I];;6,[72'P-+MIG!0%K.,(Q<T>3F$C>A50(2+N!6\
M\K^FV\R8L3W$K6*KW<\>V,\ABS<$Q8<OXR"%?YQT>ED,7F8FU/P6_CAM^O[A
M:#%][*[AH@.^N,58:-&@?_TM8TL++J1A?DZNR,25 1K[^[![L9)Y$) %8?Z*
M3(06OS2M4W/66_G]LG:#:@\?7LJDS1-#<&U'8YS;<HF<TL\*:7RR^EEW7PY
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M1S$ ;HX\MW0T*"^Y@0(51\#%>KZ9W='TFD308CB%=KEPDC_,,8W4Z':G:'6
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M_Z(XY2@_PJM<&'3??*_A:19XFG*<.!4B#HG *T\"P),0R#@B@<\+&6S4C"F
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M.^UFK_CST'2/C0N#/!\]^+CMUHH7^<O?5N'2]H$Y[N2$DYNA#7U*65N/4X+
M?L=]32\P)R?=SO><G1):.$NNTM(Q&;S67FK.I12*^E)C+@35G& C9JXS>5?L
MJ=.63DFUM+_#=C:^Z)2U%&8$@;8 K@A&D (NC&@)N,+*2 U-H3="IVPHNI2X
M]'[I>A=1@R=70\94.&4EO9<&)T&^KP(/-3$IY4A!YZ>5$@M>.F^Y*BV7REM+
M*#$R,,P):"9]-+>HULII6OF1-0Z^"!%TJ3PX.NGX*2>E1L;2B)@37CM51LZ2
M5FIU6SKA^^9@O]:C9]8\9I[7Z3G^-ISK#D#5AGFHLR+D6DJ7>_>XB?KVW&'P
M@U;8C</FO&L:VVQE$<\)+G_AI'T_&AM?L(UI! WR,E7E%(HA(*@E8C#,S&*J
M&%[BI'TC$0QC(E@EODZY?9N]*H7UI1Q[RYU;3ZT)KI<DKQI1:XPO2R+ W-B[
M%;Q:VI,?BY""*_]9PLQ'&QE))EGE? =L^3(;5>.R&=QP6$@>EN=/=G13OO#'
M/TQU<P;_Q\N&?X<R;'@>9=B&O'79$PI@6GH7%G2E\-%CX$_1^1D\7B^=,9PJ
MZ3SGO*16@U/E&7-$<.&)F%[%;M+1O2B0,^8*O!YTN_#)LGNPPX#WQ[.=S4^T
M03\<-8[AW_T/QW"=V/G1.&H<;?%/^;XW1SL_MMG5@'=C?_NTD8+>;W<HM(DT
MWL*S?WS] >^B._N'1\F+@'[\V#D"#V)O<D\8%=;%DF'DM-7@ L> C(-?J<3!
M>:.B8_KFBCIU'H%GYX%U'H$[A<6-*PTKG96"<Z*4"]B'0*E(WQB>X8@0RLA#
MX.BG/EST9# UL76+&AS+X$K$I52(V](B+=(*78S&81EH8.*^AXOJQ (SJ=R'
M\"VT!P&-RJ-U SSG6^CEBF*^V7. ^?VJEII)(1K3=DN<5V#12)7"VAIKL8/_
MI5/IFAD@5)9I%KTFV-Z55/W7M*KZ+!OG<[31]A^&<_G*M-)'-6S- EM3,EU*
MKK LJ49!ZK2=P)3(IHT%48I88J&I,L"NE.#7+OO5)R(7DDSXP#C,'8^"&K!&
MT08.A%F6F&FG0!/O2B9J-7P$-9Q@#R0PII7PB AE$%=4(:.H0*"#W@:O5! 8
MU!#36;<VUO1@0HE>I]45.ZQD-UK'J<W_@L14;+-I7UZ:HE&]6Y-6WI9_2\#3
M8LV4Q$$Z.DN,Y:B,$K!&$(-4D R5DG!B.9.!A95U6N*Y;:.N3?Y2Q ]JU9NS
MZDV8>2PUI40)I$A2/2<LLE@Z!(X1HYS [-AR99VE;0ZUF7]H%*!S9EJY^&%R
M]%M-!Y*<-N^E.NJUM5\0:S_R,H:[:L[GK%X\F1UPIAVH+P5U)"J,?,01<9@<
M9",8_*"YY%02Z85+M8+46EG;^F>'K&=8*Z@5;RZ*-V'II0RX5*5#D9<><2,U
MTI81!'9>*L5I\#B1;%9;^H>KS=;Q2:MS%D+:"Y_X:N78)ZMO0SO$9K^V]XMF
M[T=3]J%:HJFW33P,@*9LF[ ,"\(T1L2FTNE@"9!.-1A4*LL@N8@.>W U"*L#
M^PL 8<]@^6L5G+,*3G  6S)BG56("J6!?$N%C"@-DLK[$&7)E$C>/A<+&-0?
MG3R -H6;E7/QKOQUN[9LS.WRV:V:G"T&.<NS,GFVK38+LYN%W2DQ&16EE9&E
MT*^6*2;#D&'.(\P8UX0JPP1;69>EGCF#0\W,?@IF5NO?//5O,LE>4"&PX!#G
MDH-G1 0RWI3(!^(QU9J45*RL*SIS3/294DX3O026?K_3-ZW"7'=X]M=)*;W0
M!X">/TO6STRI;MN-_Y/EOGA:H)\2 N/,&I@OC)P">@6_1:03T6+&8 %0)$W:
MZ,)6V3UJ_=49 W_VTT?/CX4_,[VML?!1L7""]$:7,J=&A5A0$7'' E(1H%&:
M0+34W#ML5M;IJF _7>+ B8P&*T^=?D7K-4[$?;*O,+:&R=URA,ST6+)&L)C_
M8^F:D&J6C":C"X:8Q+)MNC%GPW#<KQ>D&7)>W/?2Z?)V9Q#?;QZ'7M$(I\6'
MSK%IWS^Q GU(8H7B\7)"W&IZ<B:ES8MD>KT EL87?P],%_0SI?=(M+HX#3GY
M7C=EUS/%23>IX/?"'8(&Y@QYLV2W"Y1X23GX^ KS8*-VP5E.!=="!:S+8>(O
M/DK\5=Y&Z2\R;ER<MQWF)?NI3=D#4MI![PZ^1,4LQBX@'"P#5JXM4MR6"'./
ME:$J8D9O/L\_3!VT6IRT!KTB]/HYVZ'/.SMS2&&T;7FU&!T![7= @%HWYTA)
M%W4#@,JW !?_/6@6?7,\?E.E84ED4]K%MA^X?DKPV.FF#R@F8JUX [\DQ$C7
MFU;1;%>"D.[N5-D>;VE$ZE1.#MD-QC^%BN:G3LO -UUI&YU^@+ZN%A?B_]PX
MLIJ&'X:V%_*LI)GW.1E;,@^58#3;INV:,"&]/GR0TVG>*R%BRA&W6!D1,YDN
MWG7:!PB0\[@8X]7WRL/Z_ GVJAZUSGO4NN@1&(1NF GU'RM^T^BTW2_@MCP@
M%>3&]\;&%QC\DE*#4<G3)J2(#5(Z1E0R:CE)289+N;).5E,"T\D]$*,<<1G3
M9\LO_3B>:CWKM\[ZV<[[+X)YJ1A62-D29AV4#UD?.-+@@3)GRT"(3;/.Z+3J
M]!>S?DW^NV%.\BOIWY*M[YT$ERAPZVPU7]1LN]8@D\?AN@-\T#D.8->_ YCT
MTY)$,N?/ 2C#Y;WMW*#]U)Y:N&X5+K&[\<5( [-I>3JSJ!&GQB-KB49, &7W
M+$B0M)5U(?24C=7/#BCUK-\CI_!IX_T7%6)T(EI46F\1+TN'C+41L5)(3*,!
M7T*OK)?EM#05Q;F_,(X04_A?FO)FN\IV4!&F/-21.!$BD5R3R!UUUFKE5"RE
MI9A%5G[1<N5FED4X,)]A) &E6/A+*J\0+Y0^F4Z[A%1$E_>G75?#"-.))%%K
ME7<U^??KW7?O-E[M?MC8W_[O5K'1V"QV]_^]]:'XL/4./MIM[/U[^\^]XO)X
M/FX*[K%#JM_"1A<&XR"S^LUFS[4ZO4%W<7)PGXWT9?NT\6.'[_SU$7^B\._^
MA^/&_@'__'8KW0.ZX-CG3="CS</657V!][.='P??0<>./L&_C;=P_>;AUT_[
MJ7T?1>.'_PIZ]'7W[7_!R0:]V]S^(H@O,<<":6X]XE8XI&'BD=9"ER"^VFA6
M@1Q(?/ ;"7:" Q"+VE"C'0^"@YP+S8(/REA6>G/WI-V+Y2-M-7NF6;SNK('7
MVO=WJD]QK0\DF*),/&8?IGM%[X(S[7!L;''I@/:2^GA_A>+0Y#"+NY2,XR(6
M<]KL'Q97)JYXD3_X+?G[1YUFN]\Z VL+8-XYR18]E<((W>3G0U.*UOF(O7BU
MT: <D]\2*X3_^DUDCL]:G:;/O]B.'_+%T IM"\0R10E6<[0&&M8J7FV\WBI>
MI.!I,;K/M8+YEKAC:/\X.PZ_ ;,\;-IFO].%^TX[PY:?=#LY2 0-\3D44:4@
M2P\^Z?2AFRDDT>\&DRM\)+:[T?H! P6]^-]>RE26(T$OTO77S/]O:\5V>XPC
M VSJ%#9-O:G:D/.=#;4\O_F@U;'PVC\/T[,93/_ )]<:7C[>_51M))@NC/"4
M)MVOQ,NSBAVAYT P3 8'[D6.QZ4X&W3^0ER&(E7%Y=HI?=S!H&5@:L^*WL >
M-WN]E+=\.(XP0%E4+;0QGS\S[32:KH/&I3%)2B6A"&3BN-,?!;Z'$K(Z-F&'
ME6"EF%4KD\GT.G1LON:'#/J'G6ZS?[8&\]*"Y_7ZO=6AGY.^3ZGN3-<=KH[W
M8K7H 7>L0J,P05]#?OTP2 JO[H:B=PA_@P+\/<A=LJ%_&@)0XMY%PT#2QD>I
M"X+23.-X\<1<>N:;::U>EL#39F[IL.?CBIFNR6].XY#.Z8&^C:KN#)N2Y7LG
M=>E\20!DJBJXDPKD] 8G)]#@"^ 8B_A>O"C"JV%$ 7'.8'AZ.6 (W:M^&:GD
ML6D/(G!&8 ]7!*([.$A3#WK1=E7/\D?#R;M[)'$HC#PM&DZNVYR7:OCG9=,Z
M7/'"%[<8V^NT!OWK;YFVY/EL8,_DE0$:^_NP>['0=A"0!2S\BDR$%K\TK5-S
MUEOY_3*^ +@,'U[*5#)J8@BN[6B,CY>7/BW$Y3'W:;DJ(_/+ <AHMUIM^Y=9
MJ/84A]U$Q/_G=L\&')M<T2;IP^O$X=OI+*U9OQ;_[RAX\%XC_?P$;SKO>[6]
M^W:K46PW7J]EKV7OXZN][<WMC0_;6WO+T8/&[O[67N6$[>\6KW<;FUN-O:W-
M]-/>[KOMS8U]^.7-=F.C\7I[XUVQMP\?[&PU]I>D>R\&;0-V"^!Z]<(5N9KQ
M?^1.CGOGE4]WN[]RV;^1N"1.:Z)X9.!X*EV"=Z6#$V7I@XSJ)H]FP:K59:-X
M5IG$RLHF[M$*_2')NR JN29<\:H)K3MHNE[Q+B?""<4&V,VFJT;SQ:MW&[\-
M5]&*-YL;YR;1. >DL)L-ZLBZ7[*-V3S_9] :-F5T?[KO9-06>'BVF0<P"NFS
M/].2*5"8XD/XU@RG%7\R\#%XE]WF26[19K*O'V%PBC<!VIKJYE5!NL2B4PO^
M \;: ",K<_27+7'1P6N8?6%:O4ZB&-^:B>N,J%0:*IC3:I3NY =M;'[\]]:[
MG>*% ;("HP9O^JUX,?IT]^3"C=AU_<[0B9##%X;OZ4%I036QL\LWY7<E/I9@
M) ?7\RI[&Z;T.J]N)%>YU1-$>[S=PS7S>-'\=-_HE\LCM3%Z_F]+Z)A41<5
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M7C".>0!.BJ.S407IM2'X7KYTK8?STL,))YKZ&(1G'@F24JJJR)'R6B+K!:=
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M(#*VC&%EG6DRZU[#VK>>807\40HJ5IGZ'B-O8NW++X<O7T<FYPJ?4THPDN#
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MQOX^[%X<K#X(R *8?4592UZ:UJDYZZW\?ED+0 6&#R]EDOJ)(;BVHS'.+:G
M-+-6::1/.R7RQ+\$ A^ZZ2IHEUFH]A2'W>0/_T\S$B=")))K$E,*/6NU<BJ6
MTE+,(BN_R)7U_8R3 %:ODRL-E.1?OYOU:U'JCH('[S72ST_PIO.,5]N[;[<:
MQ7;C]5JQT=@L]CZ^VMO>W-[XL+VUMQP]:.SN;^U5_N[^;O%ZM[&YU=C;VDP_
M[>V^V][<V(=?WFPW-AJOMS?>%7O[\,'.5F-_2;KW8M V8 OZ"8^'H!G\;]/0
MX@JJ5B$3<-"DU]+C*"*77FF07."T*923/C0K%P_=2%$8PY1T.L02I)N77NC
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MXMFOKKOA+5ROP_&;>.Z;[?C VW'!@;<#<"<BEIDBP$KL!/YB?N:9W'=YS-V
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M%D#G7I(ZB<53,XU98'JN&YI1ZC(S#5S72E++LQ/Q,*KL>UEE:YL8NGMK81E
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M$S@R31$D7A#'W+,<L 1]Z];DUFQR"YQ@&3IFRS@$9W52CG)^39 %WJ"K>@8
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M8"KN]BX[GW*=&2UK]VE;>C;D@5&WEN^\X7NTMWVX:/#6#;J(L#S3&8&+II7
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M".:)ZA,/5?A,F<8M[?9?OWT\N_D7K#<:43PQ@6(JP#)DI 0\6)/($H."'ST
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MZ7@!L>XKMZN I+9/\"L4ZYN;%^L;,<,XP%$UD8BT7[]>7]Y<??E-&S+;FC)
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M &P89#1P^-0W%C8TV&;(U6UO/ Y8J V?D'*3#\>$Q\GX ?23*0L4/:Q"#\9
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MYQT_T&,P]R9@\)UBE"'./@MT[<L](^L?R0GM1=DB!V[R**>ZA#IAJV1;D&@
M\_&!6QCX*M<#2IL \*5]"J(O1V6:AU(?]E=7JV_1_ P)X85'%,X][.P;0] (
MEU,@3AP+)#YRKAOIFIHX8V8_V0#P%'&DSFA\<($DQNA" %4;\=-8\%YNPJ48
M[EASV2,Q&YNH*2 +GGT'-H3L0*Y7USZB)X80F.+C?NHOL.O/Y%]J9;_@DZ7(
M[D0+=RPO(S+0+BT?K+B57FG@:_@?S?3;=2V+E5BR^7A: O)-Y/@G$&=&(J8>
M2;T)ENH&$UJN-=$"VV&NS:1\U,G!RM<*.M4$N#3'>AZZ?&_\'$8SC]\@SP.Z
M3R(XW_?,C5='AQ1>Z?FLD3+$Q1.V%TU <.8^.G+&8W@&/C?WZ?C,TFN>8'O<
M?1<P$AN2.A.6CO>N)$H02U9"WRF'DN *DJ-P& ;WS@S ]@O=BJ 3.Z"'8^\5
M<9<X=S;!65TYQH>,-V9[/FSI@^$'JX0K%;JSA5,$-LZ"T',1F4^Q0Q@_Q#E[
MYDO T%U2$>#/DWEFT"AVFM/YPJYL$3_[@.;W5U?O#</03D)G"N?4P6$/&L.]
M/\!)M-^0A_+>\ST23E/'JCO^MQS"V /ZB]UL^'%K]& !*Y3" W'9[ RT$]!U
MG=/W%^=GYIO8!SSST'2$MP [959B0SP%L'F \"2: 0,$W@LW6Z$7P%].;C]>
MOFD4B:DI7'=9&/T93:TA:$9$@Z>"PSJQMH'K&'JC)^*,J3?@FMZ?VJA,H0[\
M#V]T]\UQ_QIHDZ?I[-Z;6BFNA?^P9BP*\7T(ZL(%$1F;;5CRV<^7IRVS7;IQ
ML':2GZ>>WP#F[P#N'ADQ5/%^<<2R/GH2WK>PUR5+,;63BT\?C8Y1NI#/H(XX
M;N#A_N& (C&MNY8+!H+1:7!AN6!%K8YVXJ$(&/H 2]<9EB[L^K:N9_U*\,UT
M""]M!T:SL>^A#2Q/6BJ8@T(0M; ,F%%WBV5LV3'74R'W_)<H!H?W"7$+BULB
MY!-EEH<D87E#)@U3O(&PST4$&B>BYR;G*QA^"D)-A(UFSHRRG'3MW_@^>)IV
M&S_ /0ND9BYT*X08LT(P+5QPQF6 VI3/Z ##)P,T0](X<*? R%R&P39X"[_7
M*K1?E2,W=N1VE2-7.7)WE,AT8(<+N4.!-8PHHJV!?9D73L3]4%U"Y4D:6F1/
MKR2H%L;8#I4AQ&WN6]*:/@O-O9YNUGT85[')DQ/6K,AS4:AI9TVH0I_,VU7A
M+_*@3[$HXVTKCY%3HW]8A&#/$+/[;G?YS"NM(PLEPT28++%#FQU0X&W'A<4R
ML"O(]BS0CM\I'!T&1W=@]?D<-]H)(6Q@$I+.)G_"&Z?,3R$)M3J%J,,=)L,
M$]3V0C P0N[5";V)D_'K_.<4OO&-]'FT"$/0T6?.'2KR7K"AG^?@DNA+6FH\
M"JLM[SNQW$SJJ9($!R'>'!;2+LTE'IXUW3I*6%0/C>BC+$&C'84@:+PHR/@E
MI](Q>?[Q\HV2,-7$KF&TRK!;H"_45-SL(:J@[)ZC.$C*[JDMCM:R>Q22ZFOS
M*)5B7PA<$+DNT1MN/UYB[,I+I3S(4.F]-4K5\LV +"@)QPMX7HZES40Z5!!&
M/"!- IAA.56N],^HJ2ZB3-_:' %E^KY4-+8ZY6D7[TI"@O5*XE;DI3PK"KL5
M]ZQ4+C9.&>XJ-+ZFBRA?88!^HH+T8.4FJBQ76,7[-V$V]T8H1GUPA\/.,^</
MSL"465D;2EVD4J1XQR$S]Q6[.J![#4L2UJ]$R+O;:LK#]AFF4SK8$9X@V6%N
M['O3-#:1H\IRXKBHU+*!00+O"V4CL0=>WIFTJ:/;ONJWNF*)2H-3&IRBU)W$
MQE0 H&H*MV+WQZ8!JPK%7(5B3U4HJ@K%?;=:/U24XEKJ_L<1H]AA>^^EYG&Z
M(],RXUBIJ-64KKNRCFL9N>0CL5?NGUL+!G'E:M>T&[-I#'B_<XVR)SD6M;N)
M-P0LRI9CH8^:E=2U<I'L.'I%_>XIB;TH:JU]10F6;VB%@RM\V!YOOM802X%=
M/5#+??K>A%FC[(<RC;.HD_Y=!&2*K=F#:#AU@H!Z?/!=P'J(,8$F=L]YG>M0
M:[A3[)'!?& V$^=/8F4N-F$_!1*>>J$<)B":M/%F+'QY]]8#7AT[V+X,9+2#
MGSN=6M_H)5%X[_E.^*0#&":RUV#2 U+VVFBD=]$0+;3Q&_R$X:WQ]'5L&D.-
MO$8:^R.B+0U9^,B8JT5!LC!= [S^,X*KU%V$+Q9W/*$32[P]!@]- =#>?SR3
M;/_#Q5F,XD5G.D9!73O)G/$FZ(MF*<P/"C#Z!=,3'CW_&VP**87&.R23 8JB
MNM2B!;0F-].@A=,53Q!)SQ5 7-,\!WPYGVGA6X\:+@A/85'70<QYYE0*ZP,B
M&&=:X8T\("SL(>DSFSDT%B$^+1*WM/U'ZH GFMG 4I-N-7)]V/&=UACR_J4A
MG'$\I:4-;^#WAD8J+,^=8/XTD$WI%G(#OCU.Q;"<WSVPW%!YX.\7IS4YP2R!
M.&TG.:]\8[P3'O\B*AKB)-74!X@J'LIRT40QW;+4<Y=SV2 %V 80)NE?/C+9
M?6@G:TK?3V#8:T:_ 09,O@NB%,RI+HB-O6QAZ8)%-=>"L1XH,URD5RTUX$.T
M*Q5=+AT\3]AVZ=B'*+3-N@U1N&4@ K =[,_,I1Z?-#MC!" 6_5<?V!PW6=)A
MO;VDPWJ[J,.Z.6AMN\-ZQ>1S-KMNVS-6 HF_NQ3^K S^8I$E RPC"J9DM *C
MI0]>T[-=W7A-/=E19L+3DZ>"3ITH;DYA;5P^XSC((()'D.5.:#B1&&[%=U(4
MR^$SFJ1!E19ZG+G+-7OCO/[2SFLON&K0:HS<[]E-U$\F&B97[BS<1S0)I7+!
M=?1/YQ?QK"S0@('UN@+&;.( ]HDU<ZXM08L2U;> *@!KD1\W^J>Q>QP/"++0
M<G"TIX84-+4FV?9ZO*ET7+N$.G40%/>%C]5"D!!(^-0[2RIPJ)2+EX#9@DU[
M20]"\SOV=:]I9%=0,W_/8'%N*F&ZN)8+0.Q,AY$?<!61/!1<RT,P.0"AN.,Q
M B,^-.L<?9+ \>@P9[617L[:X[SJBJE_QQTO5P$J5[9QB 6S\5VR^6669XN^
MN GK].%95_;%=="$1>C%H7Y/-+L&1H^V>""]%_!4($L(A5HE[5YYZN,SGWG5
MZN<^/3> )\8M8/ JLK0\LM3?RNC?=D>-_E7QJ",=_;N7";^=)69(IW"L6VL[
M8]UJ(_%PM(*51D5*4^ #*$0L!%46#[NOH_"/IK,8;TX&;TZ"+HO0Q:<W3$F@
M9><;T3?QQKEGQ(2,3 \9,=.Q$0]T3,8]RM&,M)POE^<?KBXN;\ZT$Y_Q\9*/
MGC\9O4EFJ"1YW\GX$$EN<H15/&8*Y.=0B-3:3HW=K>DY-][3RA_M+(G$L)['
M>VX$:(H$4J^0 VGG3<*N.=!;^=FWHJFZ6*Y>Z$:KQA!6B:;#._JR=%)=B*TV
M1GH_WM^E"W6]Z@*QX&RMQ.@Z*S&Z:NRQ6D>KPK2 A_[@0$*N4V$89;C.P8$U
MQ_9 )&\N@<6 K6"!P/T!U.8BMVNKF_\][SM.R?+28H:ROA#I0H?\]M*+-?MZ
MNV"Q8 *LN]CES;I*UOO\YL6*U6[(1>JBNQP<6/-<I+J0>PY_H_R3F,E9V@_M
M=MYDF&,F:7;PX'SW0M^Y0]KB#19[Y0.\\ $VI7B-RR+?FMP!WSKY\O.G-W6U
M*/]-UJ,3XLS/!_+](Q:X[UR,H?+9G>6/4L- T7*D5 [79I3*PR>()MD=8IJH
M'"%,V5J!]#4$/,EF\H1O]*1+ 1-_*%/.FCP%CIHIO#4$4UY>)IZ8S L%[*!/
MR N8%H7.1(:2*-K 8W@:"T*RRH,&_1SCYU&.(HUF/'K$TP*?9&R3^A^F_41P
M MT[)@-GN!@;!"\^B2-N*4O+1PJ,XDF@<%C9@\7'AHL9M%A5Z-E\;3:/);N8
M&,Q\V +1KYB1FMUQG,%-GXX'<A>ZRW+>JF4<*,CX56:P? =[7$F_BN=G(9DZ
M4S+\LPQ@+AP[BDXA&\/1;1PQXXAB/OPITHZ\&?/7<&M5+GGYZO/-_UG3V;L+
MGB<EM#7IMCM/N>UJ%_(7B<QQ$N;"),23& AOTJ.+*3T 9)CV8$TB(CP@$ Z@
MQ5-Z.742Y\440TG J6F"5J%7E-Z$3A9,Q'QBR),M^QZ_)N>+(__3QG"2G"%-
M&-<$<Z?A65)<\T ?)93BB0#1P$\<?,N:$5'\R5<3KRPA (J/)U+;<EW*?Z0Y
MZ/#^7^S0(\W&:,@!?BY.,I:B"Y[F;(:\E[;CV]$4V8!-/W"9A+"+4H+)MGR?
M1!$'L> ] HA31"/!8\C'.N+89& !NE9/4OR%QCY/N*LWWG"&SR7($#!P:/0\
MHRWPB@HY/?K!\AV$1B9/)!88^.:867'&+F>%,A! -F=>R$&!^_.A]K0005HX
MIIO9/+P]!I9(^2DSWQ'IR)2/(AY]8"(A?>X-MN>.@9:TP (1PW.7&;[,LI^2
MH A0K\63-##X3S0>BC3F;-[^F+$1*LX-D?(/9XZ+H$26I0^BJ!42>P86,)0K
MH]\PP']'XW CRKH91RBJ>)4+3[BA-"L;ONXGISU.N,'UXN3>[)I%RV'AYG>!
M^.@@HA(@.Q%,R!_/$/M6*'6P!&MPF\U\5Y06!.EAWH7XIE8C(,&UN2GUE%[!
M[AR\?R&W HQB)8(C"@O2EWPG %"G#K3<.]Z("0]CL-V].)XET<5%B!2:8^0I
M< 1<(8<!\>R[T$5\VC 1A8R)@;;OCL1O"83@_$:PFR>9SPW']XF33:(;I^HP
M<$CZ$Q&WQ$UVM'RN/D4(!UT[3[::Q<D*>I505\2:DZR1_'%^GHIPJ SK7Q-C
MK9Z,]XJKO5(U!.$+ZFM:.J?,T8887TNI@$,LH'&C*?-1M1P!=3\%4HF6^40<
MVY]3S<;Q.)68LF"T$C66W#:"$\^PFQ8(91=8%-F]'C"[^R?MY.+SIS<HB3E[
M0/L/'XGO$$\1!Z+-,/<.F$-<$\+K>;)':,20N*48SN\)?D[;[2MN$989EZVX
MWJ,T7WDY5;I"(<=+LU^+4[8"H<IS/8R&(\OR)9$+AH..>2Z@6;\TU;A]2\K*
MY_C ><H+@86S4XD\1157EC@7(%-EGRW-/ANHO@8JC^PX)R^OQ\8;O#K/2I+G
M*2,@E0%M%;E[,70T[Q9>X 1>09B((@B>M%]=MSI.(\F/%]F>P5J-/2XNDBTP
MZN?+49%VIJ(P(DT$B;J<]_<1?: F<? (#_:I^,%HSF5(6=6E2&'UI%Q9L4)!
ML,4MH9<E9=B0VQ9M-?1283XB.9#2:"6]\A$VCXXJ>$T0+'3H.'%-"_=@H)$[
MB8*4<N*Y=QX^E-5J&NA2"CRPLWW-&0N]W.%<B"6V%KF?&BD7.*:J%;.D%/-)
M]E]/HTQ&_W';(KA>TR#81<+7%U3T4*VV"\?()O76"LFXEAKM[9>S&XT/>4JU
M>"3'27R7^6-+^\_5S=77V_R=)AA9W.DZ98R<DHXO<B>?T)2885%Y0(T3>.ZG
MXQ<N,(BHX0W69T4^6629+ABN\.?$J;*9K&#9(@)-F)0/)^4TIKHEX=*QI6LW
M]EULE)EJY*7X[G-5&GM*,\'?1.^$K+09 K5RUB2["P3+Q Z5)?T)UG]= \Q7
MB86=4>"D@RHF/'3X<@HNIM_LP8K!+ B(4H,7)Q2W!KJ1Q6Q*ERL^4;E (!R*
M:&QAP17Y#=*M"A(/J2@D$Z&7I$V%X]KHF,[N7NPV\;3*DUE75"_O]R!BK\O2
M/98'7.O1!Z+;F*]TH:W^['DCU%8:!U<@M2WV?ZAMHL:JI7O]NC6 .,\4 G\6
MA< ?J1#XEA<"KU-YU5U2>=7=4P.(:K.]\Q4JKY-2&'&0 NT6.'T$E]X['ILY
MP5^U#F@9KY/2<!%0PI<!7\77Y472T/$"!W9E^4&Z.MBZ Q4L:4Z4^P[WI Q7
MJV07S<[^&FCM3F9QO#H\SA7C+9CB\OZLE</BJN0LI,[D.FOJ(]^T&"NK\KHL
M%&@^E<22:I7Q0[NO][1L8XR>H;>U!8IH&.=$+J,O$7CF(>*PL'5 -K?)*ELF
MK*F?7:9I-'5ST3(%K5#P5WMBEB^^QA.>1)1L0Y]5#3*J.<4<7 \H)MGJ>I'*
M#Q.GTZ3-@6"4(D,N2[,'!_\/K9RU65W(5Z.:"'A*OE?0 OY774@B9UX@4^=9
M,0I]%J0E:P6:QZ7EP@\@4[H%'I-!4^\MQ=-J N!(^?_!4;BZ;TY462S35H0J
M2,K*G)\NI8](JJ_NV:3S>'CD9"R 'R@6G 4J_)L%(2;_S:PG4O2GUHA2P#ZQ
M" R-:>2RO H^L2+7OE_0\SKM#"LV!([3);5*"]("\^DXVY(>GO!W[992F442
MU+WF5OI:==JJKY7*1SK2OE8G/UN.^T9#QRG*B@^8N_ KI13<,-$^3\8M$* @
M/_%O\,< *]H)4^OX67M+_*P]U>&*_*PIT*+J0_2,:3DV;-ERXISWPI9/B>-5
M%*4(W4F$ZY(*B;NXSB6<KS9,UV3P>L.X<%94/,G4#V\(X.=+Q24&D7V?_H"=
MWXP()8:9)!DYO20NJZ)2*_H27,!4-G$C%YO%+T]6 LJ^!<O@,I+<TF1H92H/
MYO-T5GUY(Y[!;+EQV8;H+RPWV! =P1*/#<9$3^[HJ$W$44M]WL\?M84+V:"W
MZ9'[%ROALUG4 6;)(KXX4R"<3^Q1N_&FEOM,I?+@$"B-!U#2VC8.8+[KFCA[
MLOHY?CN-I<4::%X %06RHI1_D2<CI-_+*[/2I2=)!41<QL8YU;T#W# ^K((O
M)]DOJ8P.4.1C0W8NM)7.R3R&M(CE7O]J< _%+VK +XS=\XLX?!(D;MJD=A5/
M.M:#4Y+LW& KWC^^DOSBZ%)3NLVZI:;<,-FT''%[SK/UUC&2^DN,I/Y!DE&J
MU4J#9JJ=8S^=6S[_[2II.5]3Z7GE:A?,YCR0\C*1N5Q;8GY<)B\;&0'., M$
MG]F)R&'&67VBX'#1G)/4>!/J,A.PN&L_&BQ#1DF?G%LEO84MK,P=<B]YIKE_
M>I1>S$P%J\+!;& 1VKS.=XVN_XGC/MW]7\B#V-@1SR:L%-]+Y@_85W9*H4L%
MQ45_!9NJ\&T:Y(+?7F5T I< "XK[QX"76O=;_BK'P04LB^""[%X_P]QD*C*&
M$V@0(_9KR _N:\V%=C"F:G3R/TN2E(U4K$7-E7EG#G16R'KG7*GR7%\D=&[P
MYDTSRSFB N;BY"RE6:Z1F9:GUDZ2=B8RT>"$&HM2O$1"P\QGIZ'U?='IR&IQ
MQ-)3(U.R9PX;P%,%?FYAIE&8@V!@ MK2) 12C .:JS3&MJ43[XFQU!FB;'YY
M]GAJ/VG,Z5;DQ?O:Q!GURQP/0;[J/U#!63K.9=FVCU.84H,KA>=M^6>'UH2V
M%=RS51N!5.]<@SJ04*Y4 2B>QDL&:&)WD@%+KD<YK Q'>M(@+?3CH@<T$;,\
MDDL"DM'LT%:SJ;UW7)<]:;<AO"UL:.?6=.@[HSL0N==GVLG<'6\:Z;$[TI!B
MHED0M>6!!<1UQE/K=YK!F[2[DT8/ !<;*W[A\4PL%Q&(U^Z$ESMW CJY4E#9
MJN+1"A)BQ6CV%@DVWL=ZZ:\J,EL2F346PT?%6%6,M<X]'\J3<>9XJF"<4V]$
M9>&\BK 6>3=&0_M(7O>#JWV-;2;6U-20^^!-)MZCZ/C$YKJDR1ZMM@6B%V6R
MR]B(['CMFBQ;J6G8?-PJ!IAYASX^-Q/U-,<F%P.0*>,2')^^B/Q[:]K0/@'L
M[D&#\ 'JKL65O73E*[T7(S'Q4%!8!_E;TPH GS,X92/L99'.99?6/AV,>V]"
MA96^]S!7H"I;UX8<J?(KNG:6;JTB1?LF]2QYJZ&9+ZFF/J$VFZ#W@3HF@HE@
M.YDFO(7ZRU:5[2LWXT/**I""Z?!NJ]R%E)1480L(L)(?4]U8/=+<I?;&'TZ[
MV;E2"@>"^<CW>+DQJJ59N$O4Y[].$,8A"3&,17=D/A(V=N/D/\Q],W@(3KWQ
M:13(1B9ER9X;FOQ5..0)V2I+?XTSRWE#[G21O3MO:_3U?K&ML4/+>.'RY/A4
M!YX*>(Z-E7 US9YXZ-[E-S<2$]_UW-/$S(^9CNA% T89.\7!UOG"_KJ>"VSF
M-XX%8$@J:A!-T7WX)PMD/)'0@SN.NQ(4>6=B[W7:LUUL"JHCN.0(OBT(>PG,
M2$,6#I)_2NGILX"]E7]XES,)Z*%-(EPI@R/TX?^CG#VBTZ4?P]'\M5Y+-XS6
MPLM-W=CH&GRRT]OTR877S);>;BV^G'[MCP0(#@R -R+H[Z]:<4QQAL:+>_?6
MG'W7#'G,.7@G;#P'<@[MG1S\4I.6\'IRY4KO;/ FIC<!A"7[:^+N7JUT:P$H
MN ^E<L#XXH']E@%"";;% 42>#CO42$AIN-9WU:6#.5;4G ^[2Z\R;ZD?QU:Q
MIWYZ6M &=+(PFVDTQ/^^6PVB36T;<#6[(YOM&*X_Y&&U)0"D-T[Z>^5V_G]_
MZ9N&^8XK@KN! EY:$QH;\'#Z1*\&9_B2*ZG;X.+FJU(4E9[':I*EV9-EQ^O2
MI**\A4#]S%/W%>4M ]))5S?G5*P*$)TT%L#B9<LUNN?=65O->7V-B3N$A;ID
M[NE8/$-UJN:!,0V]H]0'I3Y4B2:[37V@U >E/AQ ?3 '>J^*^D-=J>Y#?NA7
M*@0Z^CT*:*Q#H(AR*5$V]4X-:++RM+A,F?PGMNJ1,0&E2VX&X(XI$WV5+JET
MR6K09)*47GT.6AO*4[KD*F*[9>JM&LCMVE"=TB6W0)1&+6BR\K2X3)><3S+9
M?2Q7))RT #LC+\+T%=*>5*1W&^"I_K%N-Y^I>3\+0,_B"3]2XM31-H<8F)WT
MERO5!N)GJF)SM5N+U\J\CYS):,VQ)(,EG2 &A9T@NMU]MLNK9J%D,JF:LK\%
M_'G//(X#4FXFO![<M]DD71-IF!WMO>]9HT?KB7(^J=3R#@=XA_QM.&;1$:WR
MLFG#W69KKG5[/$_;X=,8'T2//2P:Z.?JXIF+P^XM3&+%I%U1'4D[R)9(RH+C
M.T%D<I/YDDE83[Y%.=8K8PX^X"*P>(,(D3D<KU0TLT[**?.?B>&XQXK*6V<*
M +!<YD4!UC7',TXQ_SF9@)G>UV.JD 3 ,>%E+<BMZ<%X%X1E7K<Z!\..WJ'6
M[3%\\J4J(L-<%MKD*T.Z_5Q]-C[GLD=9C.OPED..2$N>KV28+VY=N?IYH<I$
MY=X<FWP^F:RVH441@"0\8R#]$0'O&#M82H6='N6SR1/)(&%Z9P"(P?(.>@0;
M(+KY*HXMCNNM4(7?(IY3DXH^H)#//B(JA#/V>6()=%[^$3FSM%M"%?I5E@)5
MC>DN22\4C3)6)K["#FVJ%T#<"\!<#I]5^\2U5)?V@Z[GB#H(5*ZE(*\-/+DB
M#?J-=BEK^3ZQ< USTFPN-B?EM8.:D]40K*O7A*>'1'&U;RK'.J&BD6]D2M82
MQZ0C,!E79?(N4DFS,S+ @CE+;]Z^D F&0V%=Y";BI#71]D ?['#R3ZDSK2(U
MBPQ4V1#;PF$U?! B5O+C;TJ+QQNIADM81 O8&SZEL,4K36E<U&!^M)&#)C?H
M9L)*14/6TM (%"7M\+I0MG64-?G4=@E[6D<!&;%LXCW64'TUT,5W40;>S+SS
M%:&*VFP48!=(.AR@BS%A4XM#%F0FV)<"G/>V DT*0P^P0$<+K6GZ(:Z9X3X\
M4@<C.Q2CWN 'LVETA/M&K#K=WTP:\DN8P3,\*XO*D@_>@)N07^KI.22#X"LL
M-_!+#VMU+2O:(EE6)D#\8[R1@X-=&?;YAIZE"@@RBLC%[K?4X0)U!.%&S/XD
MG +8,X>Z_<*2A10$_@O,F-R/U-MBKK'-0&]E^V$V]<ZB;IAI?2BW-#'DLVAM
M<SI-V^SJ@]R<Y60^]"9#-KF_LQ!:J08A*:F_(OSG-#;T<LI)%')E2?!@OH&]
MXSXPD5K!]1#LNWCEN0X(JUO0&:VIATOWK1F+0..&7\$&T+43<>T-0>>" 9=R
MJ(DR\J/0X^[;/"H-4^J*LN%NS0_):DKZ"H1(DWF"-_+:YJ>ETT]:Q=(G_F2^
MMY534M<N_X4$=4CBX7/<.\G4=C'+-V%S6V,P IO%'&8UXBU@,-A1;5/^(C@%
M[EARE^5< VAZT,_WZ7X)49MR(['*.E[B/0<:NH#C*US#1S;_=)X05W46=TN&
MBACMA4,O>GUCT-T<2N8*7E;,:R"+[@L8O9]][X$Z**[CZ3.6>/J,(D]?I_G"
MYBQB;THV'G,VKU'S=F*A$\P[I(EA-,R ^#V0+/U;C Y"7G$W\89 I*Y%4Q8%
MTQ#Q;1P%0?)@;-FAYXO9BU/J^ Y I/B;&^)D A CP-*]XJ7(MF_I*4AP;6(]
M N]Y *D@AQ5).3"1HR_D>N!V\K/#VET^Y0-8_9V&>10.,"_M=Q!'P<BQQ6!#
M>@D-7R )@7X+6!Z ]\_,6Q<.PHC]%[R_(UP(TFT[1TDK-7H]J$ .S4I,!C_R
M*\#>X#TD*)-DCKJV<B\>T? LWW*0=2YG)M\5TU+20Y"6 K^JF.32F&1+]2=7
MT<7C[$_.A4XPI_2Z<QE+G!OS/LT/@!($:LH*0C;"60UG\]EA?1DS)-:F8VND
MP7L,9QS]<Z93(U[ ^ZNK]X;!QV+!G_$O)HE/QR?1(SI[<K&;6U@HG/ B E>R
ML%R+5XRX^(QL(2M([S%^3<$K;)S6%>(D(K QF&WA])6:BZ\M!T33/K(%ZH\U
M";PD$!H*\SJ#5Z9]8J#"3*=87WP;#7^!?YW]K)TDO[[1P,0#UAP4A<\2\BIQ
MY]<4=V5A-B,79D/XCMB8T; LQ -O%8RF[Z,3_@F<V.(3L_+^VL%<A!/^ER#A
MKP&];6@%% .3(]X:(GT6CWRL8,8YR".&#7II9*8KAYGSY&NX2[Q!UU);' ,=
MA??Y+38R\S[1P.2OBB>&^3C7/*)<6P\;M(OH7++(+(R2IOIQEG8!1%IS$*D_
M"8T='PR8N3@XS9!W@B"2H.#WHHOET_E%.N):#%$W[919#;K]3L% N=08(J3C
MF#T3]R^@:G@$G;/QT+FDQE%Z*.8?B@6B<+/EELI'UHGA\ZF4;>J+C^G3O*:2
MT@4H<"R-+=EB7SB$13CW!(7@&PWXE^\,(]XV&>_P7!Q[ZWLTMC#V4 5)9C\L
M=_WH<4,DMHNL?HN@PY?#K=3LXO*K>N]X=\REZ,0JE%ZY#*LK=SSAZ+R)YV:>
MV?/9595W;E H]0H6']T!0?-L"CP45S=G-&E"D!K-@)A8CU)=^ZK?<N4)[W.0
MO#B[Q$H%)*B9]$)EYGY:F@%G\350ES_SA-2F^0\DRG&$YC2:\O.#DQHU[& -
MK-=V B[H8\>SSV:1#]I5('6XY'N2I] &X+RC6I6H"YCS(*UB,L+F>OV*8@?F
M A'+$<SR?2,'=@B:FAA-@73O/J'* &_$XSK/% 3Y9T"BP1J*9:>LP%B6YE C
MTNJLY$:O<VY$IX*Y$9U*Y$8<4A4AGE9>\V#C\("A\!V +,:IM&*>#4KA1"&M
M- G&Z3G& */]F?C=K^3U!8E[)>-2EVY(\>AJ9.\\MS;B>&@QD1-8+EH':NM2
M;HF(.K'#1@IY&M[.6%Y]TB=6C6<.*A[/O)1.LJ2(X2,-8!\+%L=X-0/^ .2W
M3JC37!+J-/=4U% ='4U6Q7]@0Q],=1S^9A0-?_O=@S]H#_ K>D-2D]]04J8R
M'3YZ=XY-6=4@=YS@7@X71+'SU)C/B8"7BY!@ _1H-\(0*'T!]'\ ^3=,E'>\
MP(&M6SZJT&AL;5$,'#S'62+@;.8[DQ5:$E!1Q@KI)@C9.;SHAZ^F2&9.IG>6
M7_PCCB/3)AXH9'Z2$"4S0/TX\2WGA,N]YJ_"4".^D03;N7$YQ5G7?Z92\[E#
MA7L=1PY8C-C7BM50Y2 X?Y:5!:%L"3$WWPZH*;BW_-@+5PRLW+RS)&Y11'04
M@*.7"0J=LO#>&XGQENB]0LQC[$@Z!AW2O+%A D9XW/Q"Z%7$/,".MS$\8#U8
MP N&D]P\3-F! O["$N$A2R4F0G@XL?#X?_:^M:EM+%O[KZCZ=)])5QD/YA*@
M<TY7T23I828)&4(Z;_>74[*UC97(DD<7B//KWW7;-TDVA@"V$T_5S 2P==E[
M[75]UK.^*OG5#3[XXSU=84*"#($P-(3)29H17 3O^P8GDC(?2>_06=\U%;S9
M%:"5[#&A9[YY&*23RC0>NSD(B!'=Z3YU :$DCB3K[BEKZ"?+< &F;1C7LK(E
M3N?"/_[8.VAT+SEM9)[T#5NDSKG07FWRK#0=26K9U,^\Q];G<6)URFS5'1;>
M&0YS7^FT'OTU%_5;875ZMQ:M7@TDCM*P,PM]?&^BM[JG5<ORH1Y,X"W.[E&M
M;:&^0G<[. =U\B7N,]GI[LZYV8;*83YL:F\#F]K IAX.-K6"YF+34;#\$'39
MI9'E)WR^HC92M$;:ZR&*O<,.Z"KS8E?LLS%9RKGB>GXQBB>;MA=.$Q_LW) F
MG@E-?9PL\1L?VG)JH2W-U/#,?/#NG'SP;FL^>/]16U^6;K;.[B:&!MC%'W"3
M2U4N_2B)LO9-IXC=LFM(F<!((=5F3(@G[(R!7V%0(TV68\Q:]U6JAC'<**_[
MW.NRR@_.)'1/2#',MMDN4P%+ACZ6A7>CM*@V 0VUHTH78*I9GP+<.HC:!N>[
M.CA?GW^K%7JZI@IM P7>0($? @J\>I)^"]/]D%:9&F"<EN,?>TTF.?A_^"XF
MX2<\-0H_[#3%U-@ D[!*022M9O7@OS>QWO76>#]O%1W[:(CUP TZ4?%M<(/?
M>F3\;<CGFJ )'1E<)33A XO9I@I4JP+MWPNA]X$=[;.I'7V3M:.%\*G;VWM'
M!W=?@P4SCR]/WQR_.3D]?A6<G+UY?GIQ>O:F$[PZ_??[4_CAS^#XS?/@Y/CM
MZ05\X/S%N[/WYR<OWJUIK0#3?U;;H3KDV36(*JO&F ?ZPK"K(2'[BE]N>D_1
M5]S2QVZNT60TX(R\JTFA?M'_>%;+R-"7[I*!=>J.,OW0+TMVZ4^U:6V2YMGM
M]HX.9_YYN]N[X]_V=V??=-XWYSUL;[^[MW.WRR[A87>[1_OKLK)'W?V#G0=X
MUMW#O0=YUL76=6WG@3:T,\]5/4TU/ K"9/5Y &$X9L?1UP&'H&C,7+W+6-K=
M>6-IZ3_UL8S/&F[7;59N9_\@'/0?>.6.[W]FZNWDZ?;K\B@2Q>M2;Q7N?>_+
M\E-P0IFL[WT=?FQ;AQN4ZLQIKOBXJZMQ9TP#-PXB9[M_>20-N] BWD+D%GF6
M[_N6[?>[RY![#K177;)/PH*9*P?X#P3E787)5XZVGRW5"XZSO^U*W;/O<$_C
MP.]OK/>CO-]NY^G!?O?IW29[W\>$[CL)V?V/EG^,4S=+ENYQ$OQCO,9.9^=I
M3S?<+/!*CR,9YJ,[K0JZ54I6<WV?FA$5#[.XRWJOG[[>N&S._1)?H]?9Z^WI
M.=X/>.Z_7;?K-?7^<W+8#E'Y[_\ZW.GM/ O@%[DS6_I^=.#=W;'5]%=ZG9W=
M_1OTXPKY*]^.5>IU]O=ZW=[&ZC_0^C[I'74/&SG<S<)^_<+N;D. \Y K^[T:
MK#1+MS9&:X%E/'RZK3NJ-R;K\:3W\&A'0T4W>O4!].K#:M7O=UU[W8,5,U>]
MHS4P5A=(:T$9[4XCK^U0K]6LV0-FO!<NAGW#Z?#%UV#US?A^Y^#@IL3GUR_$
MHR;2'U=$EYIM>R1)?)1WW.L\/=J[*0NR6@+7YN9_E?"MYL[L[&C^IB5LRQIG
M]F\NS7_C6FC=5%"OLWWP]*ZR?B_Z9VWQG>T+^EN6Y\0A^P@XHX9+L@M[$&45
MNL:/!L'Y3N_YW6&-.$,88-.8\!ZD&4YCG813C,4VD*/O#'(DZ>-UR8=NH ?+
M?XVCHZ--Z?$!2X_80?9 *<<UCDDV1WZ90DEG?L7RX&OB<KVY)__J.RC-/NWL
M'!S= &I;(6?DVS$ZN/![F_+L@ZWO]L9A>KA"T&JB8->H2MLWR:Y-_753?WT,
M6[UBY;!-_76=ZZ\'((F[-QC8%1.X[Z3^^J2W.QL]M:F];FJOWT+M]<G1T6[W
MZ-92OJFZ-I?R0Y9_@N<-!N$$R1TWI==O^9[?:^F5Z4LVA=;OK-!ZU#EXNJ\G
M_*U^;G-3=5G^:QQT#O>?/BS]P'>=.=S9NZ$1[/N-0C;G?JEHSJ/MHX<5S>_$
MUTKBL!\G7]M:]!U47I_L=HYVGG;W9H:QJ^.9?#OVY\E>9^?HL+NS:=Q\@+4]
M?-B^S>]U77</>C<$,9MZZTWUUFL_S?7P15<AL&])^FRJLO>Z2*MOZ/<[A[M'
M7]DV>P\KM8RZ[JJ<@E4HNRQ=V!_'6'7V]P]O(GM9,YF>73I^*/E>S;U]NK=8
MR7\Y&[O&J9^YZS9[T;XG/;GH*JR^O.QT=@YO(A*\CZ7XJD#@[T03\^L=!K8=
M_O!K<TA48U#3UPWF[K5-OEN=X5JWG/H.KQK"[7'F;SR$ETY+IN\9XN"MX%KE
MZC:#N/3 ,1&%+50!,M[2&T*VU3M<[BIA&^3.4W,"EO0<_CKAH#A04#UP8HZZ
MNWK<D![I:W8EF.3958P;VI\&V43AU#P<WSPHXRO*?#[;[-+#[]+1T79SCV!G
M!DI%.*5SH.(K'.J99V,>9QSR<$(< (K46.74S%VFL??AN*A@%W^+,S6)-UOX
M&%NX?[C3?7J7+4S-3O:K.,'K;C;L431C=SOHRW;I8>/C,%)@GMCFY2I2XXDF
M.L -VNT^W=G_"4Q?&L-GN#4/!YI;6]C;9UNXV<%'V,'#;8-O<,Y=25E2.GV\
MJP7MJ#MR^EFPV9Z'WYZ#??"1C4:L<$0U;D0Q"G,\7),J'XS" G<C3*/-ACR"
MQMO?[1XU-\1L!*HYL%C@!);33@"1#.(-TX@\C F>I$7GT<_,4._VPWMX;[IL
MVP#W]EG(9Q"!7<7J>OWF&_?V$=:L@E%X!?\3%V668R293&7@,<XUQOWY/%&#
M$@?"#^!J<0H6"?X]K.!/:+4<KY[&A%'9B+Z$HY*K'/O+\Q@')<.%RU&>59<C
M)T!089["C?0?G"MF:8'AW+5*<*P>.Z.?X2FY.@7?ATO#+P>JZ ;P%GV5Q I>
MY%*EL!(#>-CQ1)4\K!GE\.+%R<O3YR_.CWD\O0K>=]]UZ9EA*<&V?E)3X7V%
M>X(0>V\+QKH:*'H&^^CD;#D/"]=%XTS7I"O0PH9>O!I&("Z%"N+Q!(*@ (T_
M#IBN<*%F7[J[L$59,>EZ7N6X7>21*AR>'?RG"G,()5 9T&)=H[(>8)X&I TD
M!<=;?PY 8^27Y+G^>(2Y$,\,H_*HB@"B$1"K$M6,4H41U11430>NF="?8._"
M $$VE[22\!1EF2CRQL++7/&_:(.++*'= FT$9GSL?HDN1N]!9P!$ 7UO=-+@
M%SO;O?UN<)H&9X,R0R=-OQ9Y>_CF+:]@7$+G.?&C-SPIW>>?%1PDNW81_HF/
MX@T#Y%OS1^/P\Q8GC ZZV[V#G^ )4_G%4_Y%,\/4EKBZ0W)JIY:<6D3+/X[8
M+NZ)=^"DES@A$38)=@GV3J%HI(-X@M- QUD%^X=B[,0#M(OV4LXQX"#NAF!O
MH1AO45NZ:@K#4>3E*"Q]K8\V!\[V]4BEJ-[[,5H.6G_2G*3Y62'4-',HMBH<
M@+4H2"F _X)_@TUB8X?7-P:E$\1#6'0X6U$G0'^RJ(:@P&-1%@5<MAA.??/7
MJ4,G.K" ^#B7L#!@56.TJ!W<55!<N&6B CIM-I.>.%+]$M0 >!<#E Y03+FR
M$0=* /R_*I0BHG*V(21;^N4ZK(:FH$ZSK"!#EDV07:]*<479UN<*OI?R"N*[
MH?\\RI((S!0]!?AO!8@^&\E^5<"B%VCKX [PWE>T6.D@J2).[,%3%FQT\<O@
M0H%"]E-^9*WAJ3HBR?&8G@S_'Q8[*> 9E/KD[1#L.YL1=A)"V?W0T 2J:RPF
M)6$_R^FAK,HLVK:!W\RY@V2YS*H;F0"_(Q=QH@40 8%ERJHDPO6-\>C$( V^
MH<=',HM=3M?U/&*&WEFG. 61&\NZIXN8+#36"MQ_D+,P"AXC;IGIO[>_(6IW
MT,&=X)5YD65&5_1,'3JJZ&QF* D82L&_J'S%^LW,FRY*^ 4K!3Z%\%?R;V/,
M"J+X?9N2IVM!>5Q\*MA4#.A$IFB#00. 9M,^-CK89L$FF:BGS+C=H$.KI*3X
MU-J,E9?;4]CWH'?<7;JPKN+BG(-8!"]A][.\6/X"H5E9P44B"=KM!O^NP&#!
MM]APPK/"+Q+]\_.X&"1907'\<3^KRH!'?06XQ,M?VJ]1>D>KEDHZH8DT-'+]
M16TBC3-?[5US(LV<EZQG,%>@ZO\>I"W1#BTG"<.4W:L*4R.IA#+L:I(36TXG
MXJ[&Z166(4TF!AW@''Z%7^O#DX+_1BJ^8+P N6,E)Q_E+QWT'L<J9W,0@L;'
MW^03=!T5,TYW*#G$$3NN/OK9X-L%EQE$M"DY.'$*;F4E'B;]&M\0'H?S.S8!
M[;BB3K9)UU.W^BJD%(DS<H@\4.?Z^&H0N61YA+XK!SSX_KP48Z;,!@F;@O,/
M7^14&?^F-270$!?9G;T=;J#2)O(7SGM<J6<&E5*+V 5VLVV_$O;!2ZG*V5]Q
M(#80&L B+%,2#Y[.7I]1;C%IEVJK#W[ IZUP"$_\2YA<A]/BA[_[9PX.7&TA
MZVLP\TV'PWN#4K5I%E8 $:;9R+GY!>(IE>.GX+G"E7J>8)2KX?_^\%\W Z@.
M?OCU@HX+G.P3N"&>E/_Y>_CK#4FP!P98^9IWF;(-$<28(QH5#$#/QB4YRUJ]
M^LISYM SQ.V,P=%&9YO">,K';\$;@YH#Y0KZ&^WM$+1-QFYX$L-M"PH-;?I+
M?9Z0#X&)?'@P5&YQ67&. IQZO!E'WXY. YVOUC!XH<4_)H/3!F*[QGI+=.OA
M<UQWIAV83/+L,V6^P1S^N-\]-#@#+'F$N62]_8_!DIB/A?1PS]5 GJU'S];K
M!A>P9V"STDLRPK=^1-C\MC>F[$GC;K 2H5L9BKC0<COT&#W, \.;^![WB;^!
MT#($G4+N3#8<%G E>#\/,0)?H54P5=2O18QTZ#4:Q?&[G2^JBR_S>)T:+>'Z
M5$Q>8Q1<>^JD'R;D114CA1^><19T3I,+.(,PSZ<H>7 &*K.?CJIJD1K,^>\?
M'=F*>+<U!&RV,PWI/\\>>3V#8SB*B:E%H"9)%!6F:@=F#U[IIT6.#1QFYU>O
MLLMX4'2#]VCIZ:+PS3$M$X5M);Q3@0=;LM;F1'EZ;,FP!X@W\91R7"!'=74W
M5>MPU,L8PNL2O:WGRR*OX!KO>FN\PB<GMI63/D9N0Y6C <: ,"BO,PL2 T%?
MM64^[.W4 6ZKN]!HUD"0J>H5YP5"AU)R0L.</<=56]V]W8.U7%W!:;C+2TI:
M&272HK/OSX]8C?7XH*CL2]5(!7%?C*ZNHS&K"?G8J5NA^'&_@?*H)E(D"P<C
MK&F3LX"^G50OG$24J0N#D3P%79%.K>X0W[A"1Q.#,3#$95&&7!2EE,3==\[4
MB%52LPKD+'(<4[?C].!8\"LA0D;!"8/][O9/ 030 PKYX!F36%6D]5A!:L"+
M=6;'.J3D*!%>LAL(-TXRI<?RD !<:_P$OQIE6=3^6,,P3@2G,PX_*:HI)\Y"
M\B+J1^ ;\_)2YG@,#O2:>L0WUVEO%_6L<OEK9]N4;3M8G]#)1WCHI>O]^ZO;
MKN":K^G9N""D##8%DF[@M$4UQL3#%\69*E <N1_=>4V&KK:S85]+B^&O_R.7
M][I3"9HR*=0O^A_/:IE&^M(S641)JF,"N9Y[Q&7E/TL.\NBP>[!'.#HAI/&S
MG%W*<-9:9OEONWO=G?W9?][N]N[T-[CEP>Y=OSGS;SM'W;T[7O;Q'W9WN[NW
MN]@#K2U%=B.KS[Q6IZG.=A0-?JL'XL>>LT9<7[K5*NT\C0;J@5>IF2.]WZ6Z
MWQ5Y#+EII-^\!;GAD"S<X[]"QZ>=[^"Y M<M7L:8HP?@Q[C?D_30,X[NDQKC
M,=Y\;_OP!N[EKUR#U9AM]&WRMJP_,\O^_G;WX&XSC3:C15H\@C"]#,?9VK(
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ME$MHHCE\#DXN3LG+U\_N8=IED"JJ'GH/MT@#?RL%14!NE?U6W^,7!1<9E/^
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M,HV<.8@FS1O_>Y9%UAM_JV%96@ZE(NPV@=0<*J$JJP]<F08GYV>FC<O#7P_
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M E]Y BA=]O99UY5RB=O7D8<@ZH2[:=RS90TI0N*"._UT]6:AQA==F+!-L-/
MWT$2%M2TGZ6-,I =$CFS><MB[)\C7RFE2FQZ@7CH"YOKJ?6%">!?[V[BP?6\
M%+S-)3GVI1CDX'JG4X=,6L ,0Y^,-@G[*M$5C6;B Q\ORL-K]E*;ZS0VU ^Z
MC=#/I0QQ!;QAA8;O Y.3;1MM4EA"^6'X%AQB6KX=CS?0J<^(';^TB?ZK#1>L
ME4=J:0J#IJ:]+&PG7DMZX<YDSTMVQ6>DY$*".A#-O&G)'0O/[I"[XL#VXV'0
M,NP@SB.0L $Q>%Z%</*DHF5;)$RS%R=7X!=RD6I"T0X[B [[<(X,\^SBN^S
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M:5>-AUWH8J.1$6/W,<O(DU/T<VOD-0Z9HDO:7@!'(D1@;>7=!XI@M']9(3;
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M),QG_).)>)AN<02Q7=R979\3Y+I)>IB'%6.!PGYE2_XTK0Y_*_!"'VF4,/6
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M74_!D,3MA@E3*V;T8E:<;T0424YL[7,YVY2[?%SBJM#LWR9KX3D^8<TL43H
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MZ3VH-F#Y>+';]SYON>$/(/RYT,8G@Q?,"?^$K<9HLV(8"8%*Z9"5D. =]HE
M6QR^BKN[11C5F,@9%CWE-!;HKG+G2N)4OW@@V6X-HV+L BDJ>RS73YS3.)9A
MD&1.0XXAQ\*^?[=D8^QEMFPN5\A"ZLT+J*:HRW;9J00B/,22/YFE4,)FZ;C
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M2/C<7E4@(^2?CXC9C'H5 N5XQ>@*LX!@GMWG)(,%P^ZG([';M1(Q_F\/S3Y
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MKB.A'JT)O4R$Y1B#P>!S, 4\ L)TCH1B4W5(6B>P_7 5F"J:U5<R/@_OIL,
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M_]8I_LLQ=(_;"[Q$O_[TOU!+ P04    " !E@5E5*]B%V+\E   X=@$ %0
M &)I:6(M,C R,C Y,S!?8V%L+GAM;.5]:7.;1Y+F]_X56L_7S5;=1\=T3U"2
MW:L(V5+(\GKV$Z*.+!%C$.#@D*7Y]9L%D!1O D05^$KM"(LD".)]JO*IO"HK
MZ]__X_/)Y-DGG"_&L^G??^!_93\\PVF:Y?'TX]]_^.W#3^!^^(]__.4O__Z_
M /[SQ?LWSU[-TNH$I\MG+^<8EIB?_3E>'C_[/>/BCV=E/CMY]OML_L?X4P#X
MQ_J/7LY.O\S''X^7SP03XOIOYW\S13'OI $G<P'EN(7HH@<;="G,*/K>_.^/
M?RM"))T$A^ Y V4- Q^E!V^\ME9DYYU;?^AD//WC;_6?&!;XC 8W7:Q__/L/
MQ\OEZ=^>/__SSS__^CG.)W^=S3\^%XS)Y^?O_N'L[9]OO/]/N7XW]]X_7__V
MXJV+\6UOI(_ES__SYS>_IF,\"3">+I9AFNH#%N._+=8OOIFEL%S/^8.XGMWY
MCOH3G+\-ZDO !4C^U\^+_,,__O+LV68ZYK,)OL?RK'[][?WK*X^,X]E'G(XS
MIK^FV<GS^I;G+V?3C-,%9OIF,9N,<Q7TKTOZMTI^,2NOB2$G^-LTK/*8?D7C
M6C]G^>44__[#8GQR.L'SUX[G6/[^0QR/(U0","]91?=O.S_C^=?QI#!)J\EZ
M^M[0SV=/JM [#PT_+Y'^?C.WYV@FLW3E39,JV=G\_"\G(>)D_>IHM8"/(9R.
M?L'EYC%O9HO%2"29@K8.?.(!5"F.5@#Q&X-4W&%P5K&KLUG'N*!!KLE0PB*N
M&7'VZ<0,P9_C9+DX?Z5./ ?&SXCQ;[?"V,SOX\?T;CXKX^5Z0$[R7!(WH+Q1
MH#!)<"PA2"FTCES:&$.7 7W%<'4TE_AR-$_/9O.,<])U/SS[$ZMF.E-[&T!A
MGFX0Z>JB.WO'\\7JY&3]F4!$.3G_^ZH#6TE[.6LRQQL1$NQ]97QE)$?+Y7P<
M5\L0)_AA]LN,?C%=TL30'W]\/5WB'!?+D0@HM:8QRI0Y*&-(8RO2[LQJSXLK
M/!G?G]O;0-V&,>(K8^ ;H4Q?D35CULO98KDXFN8?/Y]6[;P8><-B+CI"9)90
MJ(@0E5:04Y+"I81!Z2[$N8ZDQ<C>EG_.9KE^ZJ\X_S1.N/AU-LDC\F(B)F6!
MQT!KF.D D>@"2F3MLF184'4;X^V8AJ0W]^+$]7702 S-"/\KKE?=/W&*\S A
M2$?Y9#P=+Y9SFII/>#;FD9)!&*D""*43J7F)$))#,%RGX@F>L;P+1;;#MZ/2
M_';HTD$\S:CSSS">5FW^=OIKF.#;0E[!*<Z77]Y-PG3YXW^OQJ?5E1U%J[.4
MFH,@8T$14Q$0,S.013"I\.@1^YC>[?!M0QUY*'O;E#L=Y+,W=VK\-3HZF<V7
MX__9S/(TOSXY#>-YQ?*V'"7"-<=,7D"8?AR3?W"T6.!R02B#(5?2@2Y25&]
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M!1"%=V1YC=1]"L2;#F/(/LZ3*LSV).B<%SMO^7B*\W5KB3UJA._ZJ#;9L*V
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M-EFP-[N)G_%M_@KD':._I-/I9/$G1:D4")UOX?][/98+!6Z_NO?I:QJ=I\G
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M=M:-/DR[\/OMF(GA(5%C-%BF#>ZIP:)EYF>WR<QZ@G]+6K4W68_J803@-V#
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M*4T!0JG3$T&5MC):0,Q,QZ1Y]&H?U'_0M^[5B+"-T%L4-;KOQ1"=X$9[ ]Z
MRF"SH0RR1*-"X%D QG(*BDMIA5?&Y3:[PCI$1TB(*L+?7P[&^-R=GL3_=SZ9
M%M1T(%*FTG,#3N-&)DJ$V#KE(%KJLV!$$MZFV5(_?$=(F :*:5+OM.+ (]0+
MYDA&AZ3DZQOCP;O@03$;<>D^)=JFP\[]5D;;) *IB.#:2F#:EAH%7XK/O(&H
M8\E^$3S*-JDFCS6)8)</I)5B#IU$T$. LQ@2D_A_HF.9V(QKDIZ@->$2<!<I
MUT):E_>>#OY8@NX;\>%.TVXWO32P\C[BSRV)8!Z%Z@.L:7^;M= .T^.FJB*7
M:Q2K:F&O-(E4<4=3 MR;%>[$FH(K?>Q5<(3GH&-H-+Y[S_2XI^/-8=BQB?!K
MI^#_HQO_GKMQ2.]Q'PU%P/-XL[(A)Y'1O"16@Z J@R49S3L$D[4.42U'C=8D
MWZ][P_[-]TH:Z&J+;W_A^J]I=%Z"L1?_]M^_C+L">Z= ^SW/K!0BWP3Y4G";
MN4@D-9X+$H12UGJK3.(V*.N%$V)P[]-WVW6?#2?NTZ=Q^C0+DQ<"SEYS91#;
MG*-4D8.)I8[=T0A69 [X*)F,XB:F-G&Y^Y#M;LU>"'3@9&8A"@4A*]PW4YFY
MH[( 9T4BGE'!=)MZK@6"_6\V5;5^VQS=0K -PLQK%GEA;V=+B"E5(<Z6]']K
M*6(3 JR+3EF2DA5[I?5>/>&FZJ\F]D.[O>6^^]W%7OMV_ '-K&&X,+0XU]X1
M(B'@68.^6K#@G0M C!':)_R?K)<1N K!H1S:>JKM*HJX<O+(',\$K>LYHLFB
MEW@/4-6SQM;"V7_6V.Z:NJWV2F+>&P=DS%8K-,8#*RR/N#-Z+R.@S>FUCUS$
MU"N2_!!U?T?2V)Y4OXET:SN;KS_,<2WLE[FS%(R1D0@&%!VC,MR3@T60(+62
M6@OM=#;W.2)WO6"_*6&59-]5%EQ%\V^&Z<7YF2OUP',HQI,L<B# ;*3H0D<'
M/CH#Q!NK>=!!+$]M6J/#F\_=G^KJ";JK(Z7:7]_'YT]?O'SV_/W)8DTD:*\"
M Y)]!J%L IMB\2*T$IH%3EV_N0=+#]ZSRG:1<%=)/+55]???7C]___+C/Q?]
M#6F9'6H$)(&GET -@!.()S-",\^&1-WOV[KYW$>JJ!V$4S&78@9EUIPLI_%E
MV$]'8;S'W2&;A&"XUF!I5*"#L41Z%7/HIZGE)S_V?7 G2=56V\G?W[YY_E^+
M*KAHA-#<@%;:@3"ZY&E+"S(0)P27(OG<2V77G[IG=>TFW:Z&:&IO@>]>/?_U
M_<MGBZ^<>VZ4$Q&"$QZ$L^QB:C?AB1I&M;J59;%&2S>?^VCUM(-X:G]-'[]/
MG!\/YQO&HC"16LVRBR!)&8=M<5>V"0%QRWG,)CJ;13_C8L73'[T]O[/(:G]M
M+TY>O_OGI>G#2*(YE'%-UI2\'$+ \*1 2*01(X:R2'LI[\9C'[W6MA=2[4_N
MP[N7;]Z?_/<"BL_.1V\H6,X8?OTI .X>&A+U)EN3'%D>P+U&7S>?^^@5MH.8
M*J9-SJ \&7:3X=GPU(T7IA3N[?ABSR$RAJ84R1Q\&;[GHU1>*V:<4KV4=NO1
MCUYONPFK8E.I"S3/WSQ_=_+JY1R*T])++0*8TC=#>&N01;IX,$BMD%4*D?33
MVXWG[MD2V5'$71WYU#[&7KY^?_+JV0*),I%DB99K,.7]1A)<3,F5MHY'%;)7
MJJ<S=OVQCU=1VTNG]OGUXM7+_SIYLD B*'/9606Q%$((1TL/018@$T\U5YKG
MGL?7C<<^7CUM+YWJI]8_W[[]^\O_ONS&'S@U@I:AGH4Q)=D@E?H5:YB**EG#
M8[^=[_IC'Z^>MI=.[2/JQ6^O3YX]?_]Z <5SFA4/H)3(", 3<$(9<(JBFTDL
M5:I?9/?F<Q^]7;&#F"K.#[F(LSS[[3^?OUH@R0*-3Z09D$R0,9FAC2I"!$4\
M*TT$1 []DBUO//;1ZVM[(348!G+369<*3T^C+; L2OH.VCM66 XJFYQ#D(JD
MI?A&M;F01Q((V5VN:^=[[-C0ZM=41EE_^3P,[G1V"Y^=$21)!HJ+,IZ22#1N
M%0>F,I[-%F&)7L-]-FMJM0SCJ%*2Z@B[=C>KBVRVZY#F!.\#JGXWJW5P#MC-
M:C=U=:UD7;N[T5IP+*JL++I)/@OD.^,"C47&@0K&-*>,!]&K)OHA$J!/1ZL]
MZ'\3$5?4>^C.1]/Q]\%O'P8LH]WOE8<DI"M=%7-I:B\A2<J-%(DQ>E=OA$D*
M?_G4??UE_L0+/<]_,U/S3,%7[]MSQZHZ@N]VDEJ#7/0WW>BWR64,RD9-#-J&
M*1ATZ= 7,Y)$8(9)RRB/-K?I7' -Q&/6ZJXR7?M9-JMHFM7HE694:*W,.#EQ
MHWAR>MK]46;=3.:5/$L7,IN6./5]2>6:IZW6MEP$E7+*/ 8C'!/)>Y]L8F7@
M2PHD!!8&F[]N^^/U[^[T?&9,HB?Q_YV[TV'^7HJVP\7;RFM/N\GY^%JUA!84
M70OKP<E2+>%]!)MC!)I,3CR1Y$6]1I(;P]MUZ[IZX:64KPI/)T_<:?FC@>:Z
MN+H$B"D-!04Z23X%"L%S2U1,3)HV(T9[P=OO=M>60<O;8'W]U$[&?7H^+F-3
MT9?^.BS&W.1C=S.!:P%VUA8!1?6Q^^!.T^3E:/Y?_C.Y\2!YAPX[NMR<H: $
M=11,L 0,TUJ)*)1;-F[7A*&JP#E&1AU(6;7OV:Z:$?7'_FX\[,8%^61@=;:6
M9@%(''XQV]<)SR!'2V@@E'G1[^I[-QQ'2[ ]JJ?VS>"B9=K[-#T?CR8G7[Z<
M#E,\^832G4SO6\KUST-3AN8I8V"#PMV8H.WKN"DD$BGE+)A9KCY=ES!8"='1
MLNT@*JM]T[G3(BZ_G0%Z6E1FJ8$+94$HP<!;18"7YD)!*T66Q_6V8-TEGC\Y
M5T]=#6;5];,K.0*49:B'\Z$,BT@*C%4)/*%$!J&5:300>0N[OXT?>''50(U4
M2><(WI3: YX=D@7M:Z:Y3ZY,?U>]Y%#5!]Q+4X']?5QMM7+H=@/]B%W:!,U"
MVTKE3'(,8(R5((+)8'@FD-&WHTIDHD6;IEC]\.W[/K Q-S;RN;?248..:G>C
MG$=@^V!LVH.O#\K#M.-KH>6-B+2#B@Y%)Z&)LY*4)C_HHPGA/%A-)7C<T[V1
MWCC29FKMX6AT3]N^A\*B3313.R0SAY*[\5,W^7P9NE_4;69MK= !@LNS,=T9
MG.,*DJ5EZIS0GO5+6K_S-?OOLE5?+5T3F5:/]Z)A-'9A>J,Q^ (8#TIY)@-H
M+QGZT08-/T(T9$D9YX9126TO9=_UEF/3=36)-C@69B&ZA:M[_2YN<34;0ADM
MIH$BEE(YF,$S$4 :06-.Q%C=ZW9L\Q;D=P,[(HZT4,7:V.F!;\F7K@W:W)*S
MP]R2+ZUMZ9;<:VZUL#)'$D7*W')T5;075,NDH[8;WY*S'7N'7N9=7;GU.61C
M$J7@+7)6R*C!2,W 1IM\+OX6:]-+\S:6_<2_!/76VT3P^W0.SUF._J0C$GC2
MM(RX98:T6? #N_>NQ(GM+K<W44*#Y*[+-5\$%HS&73:Q!%S8<M6>/?CDBB5&
M?' I6*G:1&9NXMA7,]'*&M]!F \E@C>GY8?/*4U?E9\N4B\^'B4Q.4TL\)A*
MEAI1I4-[!$UC#)8F)W2;,33K$!UL,L8.2NX:"+N!6;P*U]S$ZX.L:<AM/;;#
M!-KJZ+ ',790P)XIPKU(5CM(RN*)%LL7@58>2.J)S8%DF=114..>X-G>F;&!
MW!LP8G%7\3Z%-/Q:]L9%Y1G:_D)9#5P5'U]*M' H=66O=#QKX4AN$U9=AVC_
MEF4MK74-1-[ J+P85WR1@/)JZ/SP%.5[Z<E+XSS7R98A40F$R0&L80)TB%GX
M'*1G;=)M[X1U-*2H)_S]%QM<_+N(ZF0T'3Y]QLA'7(S[DLZGP_!N7$HPSB85
MAZKT?%.342O;K'(IJA)-4,EQ9P-50C'MF61.DLRHL5'&<&L 2\]W-A[+DET(
M2#\!R92^$#%:\(0G",8$[FBT,K=Q,EN-9;GHB?79C=/;_+3DA9YUY07XBSR<
MXGH%S53@1EQFOH/0*N+7ES*@FX#J,U91TB_[>^TK'N 4EDV4?+.W6!4YUKX7
MFNVJXVN?D9M_1M.KS^C+_#,:6$I2*.EDSF9=^C-1\(@<I.&4L:@3):&7PC=Y
MZS%QH)FT&]B]ER.#A-.9VAC 4<[*0'(&EIL,C#,7HB(43^\FV]H#GL6T#0-V
M$FS%M/E>;1J4,99*38"$TLF7EK8:-'J0,J!Q)5,,RRVV?J193+NHOYK8#QU:
M73N#Q'IF#>$>%T$\",(=6&0SE P^'P77G/2:.7Q<LY@V4NU]LY@V$?'>YO#T
M ?7#S6+:2%.]!O)L(^:]<< 0$4E*!%1TI?; <W DH-*T)<$&GX*L5W?]P&<Q
MU5?])M*MGR]XTVP-<:79NDAKH3%Z;0A$:1,(12)X:Q5X%9)6/&@O>2]78:/7
M/I3V9AOIJ=N+D"LZCF7MK]W_Z\9/SR?3[BR-)S.Z:T69MJ6G3Y8$#SABP4@N
M@ 8=!?6.>U*OW.;V^X_JT-]1O)7;G+UQ9^EMOH%I3O0^H*H?^6OA[/_(WU5/
M72LA5S[PUX.CU*+/XR5HR4L7VT1+5^@ .3L20PB>Y'JM#O>L^3L._+TH?A/9
M5C_NN_ Y_3KNSK_\FD;H):;P>=$%5TMJM&=XX+!0JOT]'CA,XUEGDI2<6,+[
M]9Y=^XK]'N.5Y-]5%][:([O1/=4L.KGX387;J)7/JWKG=#_BI9LE9XD14LXR
M%035S :TH8S,^(5FR_)5ON[*)S>^/_(Q<"D)@<R)!B%**K@G''+D*5E&A&ET
M@=SJ_NA6Q-,8GW(*#(+.I: JX@H3LI][XQQ13&C=YH;L 8>2-]'ZVE#R)H)M
MD!AQIPWLHQ4J4 )2F5G?(0;E2@NH$2K27+(*V_16?!2AY%W47TWLAPXE+Q94
M*B_?YI/QV(T^S9X\,ZRDTC(;4B8PZ2(B1\#3@,Z9,CEZ'[)GO>+)&Q-H)9P'
MZ6=NI.RNMM!;9-U=P2GQE3?=R%W]R4?\U<2%(H?+_)\><)OF[VX(^#!)O154
MO9RJMP<]/0!Z*4M*-9XI\37T!#S/8$A*H+B3V<HR@+C-%O0@:'5/0O#A6;6)
M>AJPZ6EWBG_:C7%G_IJN85]P7G)%<6,&1H5 -Q)W:$^\!Z.LUC/SS+3IQW0W
MKOW;PDW5VC732>70^<J[(F:3T(*B\5?R? 2Q#HQ'@Y!Z/-BS,]RI>F&T1W-G
MOHU94T7$E0/HZV^*^H#ZX>[,-])4KXO3;<2\MSMSS24C@2?@L@R"([J4RD8!
MP1G%"7-)I%ZY5@]1]YO>F==7_2;2;9%&V7UWI]/OB[X@+!>GWD&9> K":H++
MTPR2Q97R''2@;1IOW(#Q4*[)-U+-<NAK:[DV2:$.W?A+,3;2(KMW8<)0%SDM
M<SA#,85C*<!.P>(Z=0Z$&,O"TKE^5\KTFK<\9GW6%6&##WB^W*O5SL N6CIQ
MA]\;=T M08!ZADU%,#+G3$(*PK;YGN]"]9CI4%WJE2VY%?>^Q&K+LT??Q"6)
M1JKD8$30Z%DHQKG0WO;+CS^FO)=M#?<=Q5NQR??=-\-]0/U@>2\;Z:E7^L,V
M0MY;WHMG7'G)&1#IRM1ZAA:'\!*,R9XSI3+O=Y7Y$#6_6=Y+?<5O(MO:>2\?
MW-GD?/3I:NKW">YQUR-'@FL;")40T0H!D:,!RXP&AR9*T@3/(2I[673WO>FA
M9,%LI(VNE2AK6^W__?+-D_?__'@RAX)O$ME2#D'0TK 1'0B;3 !*?>#:>^%\
MOQ:8-Y_[Z'6X@YCV76;_I@232[2W0NK2K6=535NZ&^E2RA+GSLTFZ'"!FVG*
M)KL436:,14N%(X.U3VV=KN0M=UHD<,RAC>=L&>0:'#"1M58VZJ#;],/96[H2
M,RDG*2Q^, I/-F4%.&X]4/1>O*+"Y^5ZYQ\@76D#K:]-5]I$L+4W_N>CZ7#Z
M_1_X9;Y#9P</(_<I7:[S!0IDMG^B'*;CH3_'!TT&/(B85#(@$3@(Z3BN/J!?
MZZ-,5"C)E\>YKSD<-G_WD3!@'Y*O;0F^.2^">IO_\1FE-W&G:.\."+(T.IE!
MV3)Q2N$YBHXNA2B)UFC^&K2%>S%AQ<./2=6[RF[?Y>XA"LT8PF)2<[1K) %7
MTK+16O+24/1O4ILND(\C1W&'/;^:V ^=H[CVRBH(@:X+FM54EPQ.)E@96N-
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MDP#>X:^RC1J/)Q*I:+R+K =W/!RII("*$8:9W76);Y2FX6)DC1O%43>:_V9
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M/BS=2*:?NUBP3J:S+F<#3<JL%W10:="XQUD6P <FP D?N5!24]>F<6 O>$=
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M^A&J<&O)K?T**W?@OFS2\#JYTJ%A-NQDA][;=SZO2M?M_HB7^FVGE#CAG(3
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M%RWN>*X.X6MB>#%._SHOEP>S$Y@E&3Q'=X%3IA"B5*57+X-4;CHU)TG11F-
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M0OFT"3_U17@,=&JJE2;=HQ?HWG1%UN[TY*P['TT'T6F>K;*06>E_$? ?WI
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MB5!FWB2#?K@HN<&6 AAEC&%]4.,!JO-EQO.%WV#3V&2;S7?)$*3/ OUK2U5
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MG@4GT"FR[B!KX1P^\MJ"K-V5^K?QZ+*D!!6(OWR+G\O JK3$I;,,V3M-'"+
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M.P=R5-9 @\35S3O;!R@"&XXN[[:XNW^SVNRXXH%SC>XYT^B4>XHB$B(2;]&
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ML\_C>W<L[_X:P63Z>?CEWE0W'6FD4F9B,D<'VN*ZG4)6,\^-I3P&D5K>E':
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M<^:*<2(%?MTV233T5>8>)*/"=9J'U7',W/.1_CA6:*\ZK>@A%=S;<*VF]79
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M.IDZT6??-_^H-&JJH8KQTSG8/[^@&$<S%-#OPRN8SL8C>.^_SX7VNT_P:?Q
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MR)\,QW->,C3>G&>)L%3*_W2>FQ"<Y&!S!"%2H)T:#W<+ &Z"\/.\K:":BNE
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M01)^\M\6U56_H02&5W-W[@^8#5A66A<CF8/0I%"Q+)F3K!1X%(8,T*9_VQ/
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MTK14GY:U3(KG]4S4.UDRJ9<C?3Y>:AS!&\UQ)G/<W(BRE;"UR75[)C=&.&Y
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M9'VT>8\O6YM_\-;1+PZT&.B5.*;12I LM?FP.)@/ZJND!J$CM-DEZ]#4:#5
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M+WNC>63Z(WK%TS%(8L,L!RBZ23DPEH,5 K@XD:INVZYW^ERWQ#2\%2JUIKQ
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M;+=1K[7BRIU2M=NM>C9;CC&0DSH^ADT!3L!&>;L['DZ'*BRVZO0\X_!5384
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MYN!%2T_D,;3(\U(-J;EK]T3594_*HJ9>+ &=SHQPDI9QP4R<+!^-L)%>]:L
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M\BWOWW]F2;KAWGK\V<U3SBI??_:-ZZ-MG^Q/.]@3_J*3W7&P.\_UM<*Q.S>
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M#2X.1U?^AD6X5Z A:,B/[$.%AY;B7W8;-4UFN")1EZB:>(>.C9( S\??)LJ
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MOI7G.>9)6\S7&9S=]J['* M?F[@M6Y$9VC46H:>U-OK;A\PV,NKFE2!I:*?
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M#FWW3IW/]U6!.$X>>8#4)<$8 )8%DLAB?Q1V/ \/"Z^_JH&9<D&S459GE]^
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M(($%_]L=GF-[;09 1 -$"XFDI\!'O?__;?'PZ'7:BXQ2KW^>W<PH/ZK(+-S
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MH;IEUAX+\6)+GOUFGO%/CH=>OYVQ7FSXI/ICQ=6<KRO]^/%O 5&+K]0-;C,
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M9EKS$SQ% 5.H)V1BTT[J82:'BZ2"!2,!USWV+7L@ONAC0?P7QS)/40; Z\6
MT_H+UE%%RCD=J#/P8G6!>?:0C-^*%56: ;ATJ!\ 2VX(B9'1HC(%\PH). B,
M#1$I(;%VUC<HU1?-.:O59=Z*V!S9%;G\2V6SK/PG:,GZB,+4VRPVM'=,>)QJ
M7!@G1M78::G0KP?83U:XO8P&!9;\];9ZLD6+H/LP< 4"N,!?34J$5+]&<9L-
MR;5,L:>9CIAN4Y#BHZL-P$2\.-=XGY=6MTG&G0G9AH,#.ZC)5U,=GL/((40M
M G<?D7"':DN+V3[,[)URUV[%[*]W5AYGS+-+L])^5?'UU("B*2=1DDQA-<<E
M6(OH1$<+"]X!RCX:E?$5^SO@S#G[.W\1*7^A?P6QT2R0J_:*;=*WO>TO3M8R
M_=-3='YQDB;4]KLGND]BR+: "<\[&$?28XF\F&/SC??_;_Y*D0);J$7LPSUY
M8)A=!!-!O,"+YZ'SL#97T(KP''.2R%D0DS<6D9T"-$H[ W!\&4UO82*-?C0)
M$@W:5X23>->NY<5('3H<X/[G-D<Y\)SK%1M.E*?O5V8.6\ER_R1=<3/M\C]!
M'M&I/0NN:C&?=/299)EHFFR\3A.E1<$62N=/:K'W"&>#VB7H@D9WHEZ,U[Q5
M-)'S&AA1X577*W0$94,30JZ3YK% .)3'SK.MY?H(5:>P<FID<N!J^ZS?3U20
M4H_ZDU,[D$&:+XI%2YW42/##=Z&BF@0K(*^""G[P!P")WDBB6-S*"VT:YC3T
M+\SJ,3%2Q<W6]UNUUU<F]OX0WYQ=;O:@<?UZ [H@SV=HVMEF@"":Q=I'V\B.
M](_1X>O(5-A"%A!GKLE+^/TK4V?\>J0V*:Q@^K@^31(V?'2:]4SP&^/7*C.1
MJ3.JSP[ XY:DM&?IBW***Q&=/6F&Y(9=A#?AR9EGVH+WGLN-K,;2RRAR_X8(
MP<,\!R@J3R3==(N9J)K*F8FJ@FWC)VS9*9*Y&TQ<'$E$9_]Y8/$B_1P#L"%-
M%?QS6OF=#F'[-T 8YDOI_=>C5]0=O E=IP:UM<BT]@(:CT50XUQ@[YC63+6B
MD/T0DHKADK<]"<4D1\Z=5=I@>$T&;?]4JK/HRP@.,H]%UM*(Z:;4D213'BZ4
M:8&2%X$[%#R;MX@^9[K_E52VG,38 (?HM^2?%?-6BGAAP07+D/FI?A>O-\>-
M.E!W*KP&S\ZWOF+?ISZ6!)&97TX?.)Y@2L-U;=PCY/HE^CD:15V/(D?OS;F
MZ]!>WHQ_U1!1]J!#<7M!7T*K\8X(*Z6R'"I&9ZJ<\^:+Q!TOW%9'M=Z:S:;
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M>[ =G2-(NHAG;1#F$*:N^GBY[>U7V##1.,N*Y^AV4<?W:P.G;KN<\) >*]J
M_)YY&O*F1?1%N@4EN@X41NVACZE39B+M4@/4BX;J]NI+A[4J;_E*?6/#@MY5
M0\#\.V82SY@98,,B!M:2'.NV9N2.FQRBK&Y^(^HF]."?;'-)D1[$\;Q-#32:
M7&Z4K4C%WYLE?C"I :@'X^H1VX<JW=DP]! ;1AU"D,[(!0#K8EZ+X%81&S99
M-,N&97H361QM4(8D3V"]:"',;C.!GXS5$#H?>/80W88-NVD205A)0(%7-9FW
MQ2B=X#O\28"H2&!Z8#?DKK)A7[PQ\!GX8H N&X88F 0UU2'"F:!K\H43GB0
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M.= '/?!DH[P:$@R_'VP89 ,[:PHQ!#"F]M_/(AG#MS3Q#83MU9*=8TU25-5
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MOSHK8N^/^+@NHCH. -HH;FGK;E#0ZUG_<^_B;=ULY-O(LD?7 3W4>Z\\P98
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M+7:V9ZHI=-?M:_1=&;(Y%'BMDEZ Z7(AC["ATMBNG$D1->8 RNHXI+1]U%Z
M'_&(SW^S*[]DT$VYL*GY66%')A?('"@S655[HM[5V/=M,^Q;]4P72R^NW^A%
MX4).ZE%"U<ZN9=C2?^[ZC-@#L=*_<LRZYK^6#A"R\N%;1Z#@N#B"6/\ R,T"
MJQ?QX!4H5MR56L;2E29!I%P#D28V"LR[^Z/E4&Y +0&^ZKW3 S)/=A&"XVRI
MSDGXUB$2HGX[I>(=&S;E NDX/X,;TJ(U;I;HWSV,Z):0PX=#P02+UF##2FW
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MQM_OCAB%Q1 B"2PHI2$3/)^L.JE.F/U"RM=!SO K#OQ 0!'*MAA0TK44.!7
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MRBQ:&RO6#3O,-RZ>,SYZ/Z=R;9=KFI7@B!NC@:OM ^]D5/;5E!_CG\/DZ!(
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M#SO#XS<Z8[CJ@""]XNL=36]=GU>R845GS[&\\/ITZ IV/Z2S)N<G&9K^ZU!
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M9:1'NM3HMO%B$$\A:E266,IBM+NLR-0"D/LKM6!<M:<X9_R:Q?T?;R7(VRJ
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M9VPH9FK-YW::R_7V/59\-^RF;#:.\_6ERYMWA!NM%A!4F<?9.VB*\1N(9 $
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MVA0O\=<<[W^7=6^)LPO#S@6@O-1Z*.T*W8;" GKXMS>ED5 GL+3 )P?1)6W
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MW;7[N)5>M.]G]>?+MNPK\NA\9.S&X1=TZ3_IB7Z,_"6WOEBJ2Q."+-3SKRE
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M<V>'YK1_+FJ8Y4S[LX_W4W9];6,1_AQ6A&&DEX=C%J1(W]5F.;MG_VA&/ZL
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M>TTIBZ9\A5-IV1,FNS_-9UM0Y*)+#./\*CR?>^*^.FAQ<\"_Q#VP]-\JS$^
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MVO0+S*ZCH%<=;+>C+9\95?'[-*V40C(-73>OJNZSE:G@Z0X[7M)I9QQV^WS
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MB 'OF9LW[+WV;&KWKN8?/]NGM&J[ZU)H9V?GUHC>WD'A!/D#EX5-A75YGP$
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M6<"(,^TK:$K?/Q< NZ^&@"+UNUIJU)*,$)RS8TI4&7&/K(JXMD!_U8(:XX=
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M%G=K+_O=<E"CD!9M*6.0$=')IXOK]9C@L5/=.DISO<@+F!W(;%/* M&/(7U
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M5K*#_^21"N1B3D5?QY;7IG^E;)>AJ.UNKK]=_*)L_RV?W-!59#'A%%;>7];
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MC9_@ZUMV$3?5I<ZL2-VXQ[>EW.+@@J/ 6'P)$[Z DMBW8C_M-@&DKLYDCS2
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MAS)UCJ:)JCYROO$L3R'LSK6IO)GH;'23X_NZ$?>AF-R-F]P\+:LQA,WF'B@
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ME/0]N#)FX@V"2Q4S\0Z+L\G]R.K!E[BU6O"BOV^#,4O8AR$QV>W6F+I/FW&
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MZ98WYHDIW"-:K,C_AJ3? _$7DV#H$">P3*%Z'1!V.V<9[IQC1XI _(D,88B
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MND^3R&3-J!OIJ!0WU+/@:)YH8)7%BZ<2NEA\W=0:6C EH94H!(87Q+(4F:,
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MI.SN_P-_</Q_^X\FS)_^-U!+ P04    " !E@5E5":J!QRS"   U\@  %0
M &)I:6(M,C R,C Y,S!?9S$Q+FIP9^R[!U13W[<N&D1ZB?0F1"F"TI0B2HNH
M-%%!5#H$06HH/T0D2$CHO0C^ $$A" (JO000D$A746G2@A 20*5)@A*VI-WX
M?^^=\W_GG3/&O>_<,=X];]R5,3-6DKWWFG/-M;[Y?<D.:Y:U!#ITR<+: L1Q
M@ /DR7Z 6#] PF:W0[U\0#X@=N-@S8,N@ YP_&E_G@_\:0<Y_SQS'3S(>9";
MBYO['\;#Q\LV'FYN7@%>/OX_C=T3%. 7_//BST7^CU,/<'%R<O'S<//P_P\W
MUAN0".^!] /W.3D400=$.#A%.%@#( C;1ZY_N,<!^C\;QP'.@US</&PW!-@'
M8 ^QW>?D9#O-Q?:8_6D,^W/001$NT:.GS+C%KMWB40P3UXG+?<JK=+ZI5\)^
MG*RLZW4GGH]?4DI:1E;EF*K:\1-Z^J<-SIPUO'#1W,+2ROK2]1LW'1R=G%V\
M;_OX^OD'!(;?C;@7B8BZGY"8E)R2FI:>]_#O_(+"1T7%Y17/*JNJG[]XV=S2
MBFUK[WC5V=<_,#@T_/;=^XG)SU/3,[-S>")I>67UZ[?O:^N4G9^_=JE[P._]
M/W%Q@#@Y_J_V[\8EPH[KP)\<\/R)B^- Y)\#1 YR'3W%+6IVC>=6F)BB3ARO
M^/G<ITV]?$JZ]F0)KSOC_)+*>D05RI_0_A'9?U]@\?^O(ON7P/XU+CQ(D).#
MG3Q.$1 4Q*"7IZN!_BM;0S%NZ26AG05*12\509M1U328ZINWR CB-M@#;T:2
MDZ;?9#R.#&EW/.72KVQ6Y^N<\EB'F^O!\[-RKX8GL+\W6" >6Q;HO1#J%'KF
M6S)N]^CD<\Y%Y"W:172O5;<*T=UR4)(%(E]MX-NPK7:V_JO3(HTR9K+Z=5!S
M]5SSFDB%U6Q?C6&\E8S$+YY$X^L5P'+??5@6TD37NGI#]J[4M(ZAA&^RT_1%
M%=LC^;=ZUV 8"/GZ=CJ&[ R=XZ2Z/Z;F3>+\<^(-/Q8F8S?$I_18("'DB:F[
MSM1%:P;FX,Z5\'J8<N.%R,C@,&53%QE12>YS.G5K4+D(<":A4740-[?M/(GV
M9X%D )H-\)AR:9*X-V B-U1H]R7+(GK!= <1$7TN5ZVQ0&:SUU^SS[55YZUQ
MX]MLD.EH><\A8#6 =AG)#CU^? W=O)A&NX78Z(<*[L+F/NT-&A)2NDVI#A/#
MX9+88-^:@+_:%H,T!L>+'?S^/O$VE9(F;-I)_M9;.('BG$?R4W@&<V0VJC1Y
M:%H;0P;[A-SZA:S'0B/N>&4C+=YO'[/L$M[V?HT]97H*]1DE!431=!&3U"(@
MBDC+49A%:(VX%&Q?)>]N==^Y<CI?<T!J+$U+_I#>=9=1N3M7OS]2\XZ]QP+Y
MCF;^Q1R'MC3$HOWET."VAY#L;HE*1++)\1\7/_JVM^6ZI5Z.<_QP_.O6 C8\
M<\E/XO<:"W3P$Q!1#2@QA0A W LG1"'LM113&," Y[ Q=^ =P04$1XK@I5O.
M3K^#EK_FINA /PR4^@.6)' .I E'%W.DFC">US&A0*$#;OH'4P9 #_;(='9D
M?F]!H)UL;#A\A$H_-HX$RW\0+E2[.&$=<CE[34D%A"J[!GNL &(\P\&A\P;4
M.,;3ZH0W4(55,JX?EMZ9TD\ S=.E*:I)=[MBM):O)D-: PW0^,[*UKT979N3
MN5[%QS4E(6I<]P)X:9Q,OM^DT'GP(+0Y)SF$!0JU3;F&@)/R&_!!=,M0KH^9
M:4C%THOQ-$G=T8-7C \<]U!^D)B[<(X?5,:## 58(-IY!&R9J[!W>VZ&>JN5
M\F6-.+J5(P*7G<F:N= \,6&-EW.Z$).W^D/E4?_=V9L']-M'((M'H"?I:NP%
M,8R:@LBR0'ZP-'0KH3\'4!5*KBRCJU$L7CT%7O9!,\F5M-%G:O"9MFQW?:7\
M WGOBB0PT@)/./=Y8/D0\B7(;W/H5@T+Y%-#FF'FI8,8\HQ"YFDSF@WJ(T28
M!?*?APGWY$@-@ ^L*2CG6.=]OSIM$^,G,1;[5N)BTL&NR&#W^?"X)XX1L (<
MESX+](]TB-90+S!J@_ZDXP:N!Y8LJYV&/!46)C/N1UZLU;B[VY0]ZCOKVQ[_
M5<KU;T6_X@/N"X>'/9XN9_%0BX%Q%H@KCS*SV:2]]8(BU<\""1 9F-8&B=,9
MQ*C-H/K-7;D2%^:X$O:5C3NE3_++^P_S7_VL/H^LAF;%FNZ7XQ2A7@U9.+)]
M WZ9R;?&LZ6_%&-$?3!CJ@1W*$Y GJ0<PY"T.8>)&S>:.XHG/BWNO]^XT09?
M5G<%MXV&!;;(^&#>BIP8S ED5*&#T//1[L 638_Y-A+-W>U'K$,/HX4:Z'Z4
MFGZ<8$2)(%Q \XG#N&FN-_HYP1PNKA[YUT>-L0\SW,J9%T=>?0&ADL=A:JA^
MP^HM8@5S'&5"EAK")"I FP!=K0R_%TC#&90:D-(_T[GX^/FV_[9>$>329ZV5
MKG:EV^11Z+;47E-7CU+#548GTA)-1,?JP/"H\0!R#Q_2IF)^W4,EXQ)\9&U+
M^?,1Z]8M4V7!K_M; BYOO+.=#SY\D7TZI@-$E55?8:\$U6%,*DJ'4<Y.(PLT
MUS5X!ZAKA2:;:I!IP&EM>0_-3PT!WB_][^UEA1J3K!5NB/V>&/YF=#7M3/9Y
M_B /J?YBV)8<I9 I($1IH$93H%N1R[,H*40X,2=9?T-;T'^O (^<;I^9D8U7
MMON"[SW\(J1\8:['6R^S,26_PB'KC2FE0:2#T5PZR>07J6;V.F)XL#;WV* "
M SZ-#A7*EN#FZKVQ/2VMT8BR\Q/?(I945G;(WF\<!:614>09Z@KC.5.=/1AL
M,R""<I]VE0)-Q05"%-@YA TZ:00[VF',R3AJ_CM$2O[*!71D*#PXQ%>$:%U\
MT?Q.I2&,DWZ,XMC+ @%GO/L[N0A#HR*(AOX]='/(ZXBR-:9ZC^O(@DQ.:NO?
MI4?OWKABK&5O #-Y%A&JQSV'O<&Y31!W TI'^_<B307'-R.$;AX]-C1R_;/'
M!-^SS0:="[H64+P(;J+'G;WW@M&]SBAVQ>DU,W:E*"W=>[$4A8(@G8$KI,=;
M<D,$8:Q\H/J:M^2,;>!,P8S(2\TI7(G<P*>7IPUCOQ@'L4!.,ZM2&>BE4IBX
MJ0Y2K(/1@[XE9$_HQ[7B^K3QG*0/B^*O@U1P&:V]RRS0(3TF!+=Z\<&'R@&?
MM[P_^N_P"93Q3!&P4+IX) FWV4*ST.X3:)BM&? P' ,G!^^.U](-IYY]WO7%
M%MYHGW1VO"29_E'YCMNS!MJVQOGZ1=\E):CC#,E@RXB]X:Y/H>$P$($Y"VW^
M-H 3I6L"*4N81(?[!@,0G@ORG>N&W"^9!N,:#:U=36&<5FG-48)WAE>ZA)[E
M*UJEX"$28M0<((U]F18LHR@8%\@"R:Y!!$*A?L>[G6L1KI;%T^-)^(V V[FN
M;KT';'D];^+MMT[ROLU3M.J+-5TKQZDS3[)GT (-'XUG@4#(<!H4  _*#J=V
MA_O1_&>18N243/S,58Q#^X2^NFNPA5RF>ZNDHQ3%3*\MU^2=U:(9YX</-@5[
ML$0I*-D.QHF:601AR;9O<K+0Y.K=&G6:=OH[2O50C_AGS*4.)^,138<^5TV/
MK]O1EZMDZN(?G;[4<-C?;H5SR\3ABKV\#LE=^-,B:=?3.R T\L[8H/(CHYLK
M-^ZD7^7PS#SW+6 -IHWJA9&O,P2H[QAE3#WF.Y0.X J)ZU&BBU $[\G^2(&D
M.=Y(N(9]<-)F(R#QD*[E:RL?__YC0+MGS_CN%906:ORT(ZXQ="O.@"Y9W=N6
M5Y5%1.-M8$ TA6GD](YFF1C!KBD"[PXPMIO=FSODG5?B4.MC/-\+Z1(V3/YK
MY$DFWRW:B5&:-=V,W+JHU/5J)NA7J!#"8=+.QAF;L9$"[71V=[(0%2_V]:I.
M35TWC_X6']KM_0*XVF\')!"[A" NQ2!\<F%5X,<8KM840/1>LI@6M\ZBR\\G
MMP4QPU#@#(HZ0FU@Y*%T4!/WVL-@"&VB:JJQT5)H2N2AM\KQ>TX8MTF_&:S:
M6V)?4,MD[K :%1^?D"84<YP\0I+:TJ8Y,'L)8BS04OD^>LN2A.9!O!R]3LDG
M](<*!^R\Z51-";JK3MLPBE;?,,BLI& VN7[X/"GBP4N?'PNZ_ ^\+&5S-SL8
M_C&;<"2Q*4$W($1S0WTD2.["DA5. %DD:,KUC[=\ H+U6[2Z(CP5IE>NB%WR
MROQRR.&XHI:!>@&/Q/?[52T452J<O373Z.J, LAR81;R)A&<11 R=C]65:HZ
M-1W]&NHT(?SX" Y;(B([_S&9>=O?:YZ_^>*XI<*$-.=:UVB&K H+E-)][052
MOP4M%6@J_CJOWVY<S_6YI#?JP> I+,%H6+3#ND(U/+:K$>7IT+$]:T.MFX2&
M0.>DWF"P51E+[^@F <MU<C2+>?/.;M<T3;OWWR6>W;0;YGL8%_<D/!-3!%U*
MAO+>S4EF@AE/6:#F;F]2W7EU,#YC&&]\"+ZHVHES2"?8\[= 2S=OO_+D_CU;
M!*D1O8+LI<FRXU* WH8"!I;$PJU=XF@.4P5]"*%J.8&5 _.;A\E^U_&'S;\(
M/EVD671>)2!8.1^_FH,7C>0^*ZKG](9GLT[B-Y%V$_6YU 0 TVX [><9C<:W
M**I$7#P6(^.?0?9>#DVL7^T@HS !JTZU^\?:!0]65@[LO;B7_/6'TJ,?PX5Z
MBBH-8_N@WPE,_F#V?N>A#-/%NOH4>"D_'M*,\8AM&TIUSET"SW".+-K7UN\Y
MH34C9#/+3Z=5)D>0N/?BUHY(G@9BFUK)>,V4!.Q_DB!9.$^PL)O_?4.!DKL
M?-E@/K2LR8&;A A^-O%42DC<=64G,7VT)7 UE><->FFU \OFB;=#$QH1#ON?
M9FZ@\0][;:J^K$OFF'0;<,-S-%?3E+.>G9O52/_N=(#S^%F%W6I CLD?4(V\
M18Y,99Y%34+XMWL@ 3OK.:0.)@1I\IJ\.]6SI;,:_,.GT&YJE[<Z_JS5,9-T
MSD<E[2_ERR!7E)ZE*F?UJPO6<#ZPK--$N:)&.V>V\I='9Z]3*QA5QC!:.(+)
M @VB^7H4D998P#'R\/1?\_W"22:][? -_[II@6W]I9U% S/^/E#ZF2>M66SQ
MP@L-@++UA%T./J,?PA]B>F2CE)-\,V=SAAB:BE\L(@HL>\?4!W;21E<MJ8V"
MXW/X83:::F@D6_LJ>.M4#8'V1N>@U/=H/)J$'M).VF-75%O>1>11"A:7$BKF
M\'GKAS(NH%9SV_XOS9%AV4<_Q/B5P]?-WBHLP')APE#_G$PH^2HX#D.VM\T9
M'K*G6U#0;(*5[H"9+9Y^%<P;7?W0?&*K5H$2G*><6Y;M?W#PIG'_P<Q[!<K1
MIXL,Z!*J;[3)[4-0WAYA)(I=C9<I"H\A0R(4@R$%[F">@?L79]W/D_ "5P(M
M)OTR(DN"-)9O*$*U+A;>\^?\I7JMLW3$MI0Z?[5XQ^J67_;$P@-K(Y"5N8Y.
MF1="KLA1-8]'?QG7V+ 5BVD;[C/Q(ST 8#%+O^_"(/ >R<[Q"'D+]1=Y,3I4
MF[/NI2*K\:-R\B_=A#\LP-_2>>KI-QCMT* &/ _Q1SME9DB!EUS86^=M36Y/
MTH,=##RUMJ=#^!)P>C]KJ"'B:-;BTM<?:F5)/X.;N?W2S[- VB8L$/?^'*+E
M*B/-V+D:V!L<!Q+<$Y;W<KRGL=^#*Y+TU;$S(1=GU ][*O(=UDVR$P]Y(RW.
ML:<I?NT<UW_6$ 9T<0.V<B 3F/S7R:++5#]@BF(SA <G[,H]5YUN)7"[S\ZW
M/?,L4DWRR?LZ$<F?-Y1]T$?G1L@7;O5%_S)AL >C%"E%$:-&XQC%/4;K!BR0
MR%TA^/E"*XH@4T.2],VA+?=2^Y,@8ASGEK&Q?R9_\L&3"V[:L6A/] $ 3H(F
M,(_1+8 1"@_)9+N_)FH9B I>7G"80!@;[_0%+Y).P>&<"VZ,DF*1<,2,V DC
M8K^UDD'7M7,*JI$T$<2=#>J7=D8W>(@%DE=-V^J69(KEF%E.L/$,W:Q T5:8
M'0JZ/!>P;/'3>/LD%_ZP8#KUO?HWG R[TE^#>C=P(E(&#*_6D!HDW-=Z#O64
M#@\R3XWUR&YT%J:T&G6<5(W?N-G:DO=)*I6BY3.@+/'@J729( :$[M5$B=(U
M #X*)S6 731'2,E%1#"DIQ$SEP!K+3$V@;^\8KPW77S'UG]-_(Y-N.YVOD^1
M#;)9C51!&:6+$HAL@<)6.K 46!.S@69%MTOI8X$$M5MM&H3=\6[^-3%* 4*<
M 37&6542N9YPQ.PM\5<\'W0<QS!"S". +6FF_R,/J2$6:]ON[W%L/#@B6'+O
M_6V:>>6 NIY.L*=,I-*+7E#F#E>P'4\\;E. F,5#BDQ%G:++ 0R* /%;:C=<
MZ"EE]UOBRH0"1'1AOJ]1A3%81\6$APK-99WOGFYZX\:U4%*3XT.V3/C5 $(X
MC/3):@YN3E.OY4O)YO\J-!!K\AK5:'YK\TY)5U?WE'+!,:Q_&3_JR*1V1(GH
MQJ7);O.H9Z/&*HJ?6W\E5;=YT_U5LZU&P-3QE.?Z.[C-/78]307\:+KT T A
MS8!^EO'"5-N:2$C'9[]X#I3LPK=$26O:$=+31O./5 R==A9ON!VZH)CG?-/I
M1T.=6AFXL#N ?85&(&(9,P=^ VFZ6DVS0EY+Z(,*_=!S1D+# \+*ZVCU#Z:W
MJX;UZJHD(N+JO&XE.MP!/YH0Y)@&(%2)\6XIFB>,B=^#M!H,F/@-WF]("$9J
MOG *K+:0C1AZ'&K<?FC(JWVR/,*G. ISWZKV<J*H([_)1/PY&3V.GRQ0(IM6
ME*+X .?H^@ <1X\QW0J((6J+PO<,/[4L@?G6[_%58A<^)-NTM45G' _56RT:
M,5(I^<!?OTE)G<MPO$)9INH UA02K5?A^*O7T]W:I(;D0IV/9-I0J=AK*WU-
M\*=8,^-K114%,F4%1UXHBPUJV'/9O[WT0A;70MAR)VM3J]#2JKU@2;= '#D>
MT0P30F"V9$VF<EL_+\?+K,1J?KC60C)*S=[E$O[!-WA?$Q2&9L.D&_VDP7YA
M*DH3:!F6_52Y6C?=1=K(L-4S5]C6DEYJ:F_#QIGY*@\>T'U8Z'>BXQL+% 29
M Q.'MZK)]:/$R('00T#&14/+M%\$$2!RP$/TL_V,_?BN*]\ M?W>CO7AW!1+
M>04#>VGZJUZ%%^8@!)ORS@H01S<9-'-$"_4)>72P(;6X(=4XLBJ C!B:@5$4
M;7UJ/)S[/%.NY:DD\7_A=1I<K=!L?N[^X.A%==5$Z*TL<"\46YV%"XI1HL8"
ML8O*E*]Q\ JXH4]_@%"U>8"_ENE0XY >4?&1[%='AP#I%H-MX\'?\,^HX_3K
M9.W>4$X/-ICDU+XNR/?R=E80.%Y?5>RL[%0>+WW$LH 4H'PW^XR799YEQ T'
M7] .% 0-@L2A6TM?-P"ZQ,6F6A?$P[[RA6Y+HK8DPH,%NCC5"GP3]"RV,0)N
M/>I7LYS3>9&5?E+P4B-(P68)!RCGO,'Q @*N9/UO0^!4_(=.S& T+NV^8ZJ^
MO,W5#'OR7GJ];U3UY]ICK4V)1^\5V(V];^Y[IY';ZB/_]W= C,D72:[IP[6Y
M5V]12+@<J 021M&:[QLESNE?00^TC;G:5A7E1;3!KYA.X[FRE,^1SHR+S!4]
M<Y;)<"RGWV4T,P^@/C&/)?3"#F$_>BV[%)H_=ND8IY\BNE]PZ6R>*(_)"Y0Z
MY62F.S_/_3[M-K]\?KZ!3J-"PM*V-'"=!$EL'54 Q ;NN0REU060"0&R;8_O
MM+@NNEZ*(Q4?%\^_>]NS-Z[WH"P(6S/GMNYR\U.)3ZW;VD];SF$)1O'0Q/RI
M@WR'+F4G_;W#6:%E><)28A77K+U96(UZ:PJ>1H++Z,&4X<R@"(S8^GUZRM#D
MVL2[T)CG'A]C[E.P)25-\YH?!R;R@WMM'L192FS<7(5B0[=J:$:HP1Z9R6YK
MRO;@7EM.G9LU=TJ%?S'7U[H7ZZ&R*85O6YK3G5=NV%>N\#6?''E=>&>%<P#-
MQ@) 46HSFG:5;D]A@8;X=K=E$!!GH+H\H#AT0,:8)^I62/%8(RZ>N4@R?]6"
MN4V"PV,F+*[?[^/D+-!<<U'=E*E<@V%W&[::GJ,F<*+ZMM*N"#'FH;VV'EG%
M6=MGCWL17HA;DTI'/RQ!']4VQ+4;(>IGJ,Z,.JA?SKPKD0LSC)Y+(444IM.U
MH\(TFPDN@QHZ9F$R!VRBEHI$7:,*3UR^H]@H6"WM:0LEY<S_I#J3(P?F&Y**
M]W+JEU]-1M"N\+C,'"5O_>K4RJ]9B$+[3M;OZB7.S;N]^SIPT/[2,[VQFN"
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M#/;EGVW2@NF/&N@EUI[9MEJ*+)#?E]RROPBGCHC27=@K)A;U$=J$IHMF]+-
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M=QVZ*+99MP&_FM':]WSJH@,^/33#RE;+D?:$]SMV@G_[1LF\,5T!JLF,'C4
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MTICQ. (BB%#<NS!M?'TYYS#!VF\)#4*X\*Y^WBU2M/OYOMQ9*5W WRZE^&N
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M7!.D_A^NC5Z*:4!(8&["0^3@P?97Q:]UJHD_27UX\KG5&$=9#V(0+S[#EWH
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MTF*F/I3QL)!1"J"^P0=L.KBK/_.!VE&><];OM0C^?+J^IYV&?[QQV'3>&"_
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M-%O01Z&^-G\9G!WRY"OUH'79GE+66<[[22^6S:*^F)F]RI8!W$?(PNVK5/G
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MP6=:'[9L-'NLL#?:<OLKRF*.*OW*KF9KMV$<ZF<N <(I KZ51\6)<XEX)_5
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M4:'X*>OM7!]Y\F*S3XN]NOP"+J]10'!6PCKK.G@M\G!0]C)WB,Y8B#,'JEA
MF>22.4UY@<"+]"SVTI49#C->?K3X,U80U3\>>C-Q?%0^+V#7U6X^'O[D>JZ@
M(*@8P<<YZ SCY2([D(6%$02N4CWCL"VFK9MU\W74_K4)%7-=03_1[ILE3F<'
M+APY5]J:4(5\)CVJ#63J-3$%*AF%Z!N-HNM=PMP4"Z+0SOET22+_./K=79JE
ME^WE3ZX&2Q(J=D4O4<FB 8>^:O&_;Z6;#1@J;<ED6.Y\*;/34+V_09*,!>A[
M2LO 1#):U M7,.)3=2]N8G#4.<S[NT'YLZM)D_/H2K66"%&IQ[=X-I1'+J7
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M0T9W0$/O?:INCW,8MJ':AN 5$0^;'88?%=X8&A6\=4%]T]R=<#9Y]E&7S*M
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M:CM=74E0::QE>_]JCG5M<6K/O][Y]E\[\< .<NDWT\C/ G:>9B2CY[*15UA
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M6$"U("TWL8#(NN5V2*S"H<I>NA8IXY"?N?.0!M]*X=*UTRMGQTXI<?&$\!D
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MBNO9WR]043E(5%%1 4YM0XLA+U$DP^C.)"P'B&TM&?55T,37E%,^/<S6FKK
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M"94M ,X:]$,_7HLYC7GW3HSYJ(?S574$[LA@6CR]&[S<2)- =66*,V*@[A"
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M]NYS'*,+@;8%<U@1Y 5O*4ZKP4"/J@=0H\1V_>&JT/V-@>]7(F:K3FH)/,B
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M%QE$O?@LK^.-#TPXL 9K$M,^:NZ54.:5<_%#O#1^6H!73@YCRXCX@R5:%"_
M[&5[%[1_S^@RF9DV@WG, D15E^[41R./OS;SS$:XGJG2>]5_!YR]FS(S*6&V
M+R$R,='LTMA(DT'R>@@C%27)['?9!_J2,8_6D[H"*-5D 87#E.4D*P^FK%Z]
M%S&)[[/AH%M3N\N!'I\1JDLHY3[I8SU9:-2U0_GB@&<Y)7W4-W/_IWW6\5UG
M*[Q_V$FB%!])NR>^:U\JJ#=T<"W!80ALY+:=K?<06:8FPAWJD0(*WJ80B%D&
MIU>)$-&??MYNP]KA-RE=0?)QI3;5U>ZV,9Q[5<Y)V'-*S5@!SYF\M30]7PA
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MX3P;S8#X(C4L"U#B:;0T%O_U\C_81S^P (J=4"Q,EN")!97A;4*C6NL(L""
M9"$.\A,O+SCX=7I+V)8X2\6DAB&*7R6(N8\?B9 2V7F6RZ('*VJHB&X^C^=@
M1XE:6]2,F._HZLDX<J/I&=#1>R;N=A/S!'CMC>/W>R],.O5J"Z]G$A=_[3K;
M_$SQP7)MRT'8\]V<:_XQ*QIAZ*J@9DST5'E0&-H+)@..G:3X(,J;TR4:@W/
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M\!7-!-4#$??7/T@F<"!\G'TOU%Y0[%SGSQ:^W&LA/GADV^/ZR$O9VTZ]!_*
MS>LQ]"_@,ZHH<X<[18C)]UR(+H8V9^#7X.+S)Y1;QBSD?#-YJ,-$P2-3YH-D
M'<N);E>Q=8AG39B)P'O1Y0<?A<_11R!N2!E&(5X:>8:1SI1F]KD8#J_AMK=1
MM5ID+E:^^8[:.W2M&O$%7Q[YQ8'[2>XSQ>!79SF5XI]PS-^QL8VEWY[&1HUJ
M4B$8I.MKKWLW$UUU-_&OY"OVC/THWI!2OWA,^FNI.M0+'J*3*5]-?3#5 >%I
MRYD8UY=(S\G<7^GH_?HD?WN2M$[Y@=TI/'OU>WFN&5\')<D61%S,":NZ92(4
MXH57+(V<+?K:T%MIYT^.=V^?&R%[<$2:6+UX'+-1W@ZMA+1-14$I-@4:(2A]
M,(^T(!1^F_G182K.W\^_HJ9H)S;8O>![5?O7KYOVCIJ%MJ*9^F\'=3](O?4!
M-JMB*%,C%LP=>VBJS&$8IS\+\$)'P<37>/6U?,F"%A=]%Y9N31Y6K!K\4;BG
M_L$' <N)!T^Z=S)>)P[C?7N?KT>"VS)E8-+5["[%R?_HSO?I:!TB>'BW_-#D
M0W9'K*]6'^\X]G)G2TSN2T342:I+')P,Y?=-O9>*#8(\\T;GCN?T?L!.FIZV
MCJK1OO6W%GS_UD6!2;& =Q/Y+.#S.31#ZM.R=;,O9#NTLO)^D2U3!*VQI*NA
MD;:NNC3>.J.WL0#3:[43<#%\O/>TKG?]?)J%3LCJCGY*$#UNU)81_I(%],4Z
MY](/"&T^1Z\8L8 JZPS(=-3Z19PON_@6BZ\/TF?WK3#;XL;LY#S1\BI?#[A)
M-ZB87,R,+BY=GN>Y;RQF^WWWED5';H'*Z?K*,K8YUD?UKKHX=8A (JM+(Q-;
MPCY86]^ZG[J;8SQ!Y2$#@YY.AI5,M1,^/Y\>*J=&&5,[6@W4%TC+48%>^GHS
ML,>3^X:.<F44[GYRQ#M()O;SQOUX&ZA2^TL@'VA[D$AUG0YJML"X0"SXZ+=!
M* DNXVW9N0]SGNH9M50I>R?!=>?>&M-+XSL#,@\-$V$14'Z\ ,)&8QM= ?1[
MB; X$]I%S&8#]["6(9W=VVP.B%\2#7TG'P&@?$'^=4U0E$P #V#H8A(:7,R/
M3-ZARFX]TG)X(1U"BC,BVMS^W@MS0=Q:&H\U->*]'^U:O;/M5O/AB]+EG2"6
M".74UV4!W"!=ACJ\./7:NQ1Y+=Z"IVM:\.)'<6<4/%K$1R+Z[9F//"^&X;?@
MY/K'7S:@7K:R8C-K"\W8<HW%"<I,1]J4N*$"LP?/VXNTR/>D6;3>TPU?7(+_
M6#F,''N4;:\TC6UHSQF >D)&OIT!LP.H1!-0<+K+0F8B3=?E<"6E,>=>SMB@
MRG*]76M1[4D>M7> #+"1W'[//Y;,QHB&&-(4INY!T==87YJ^+.&AS8E!\WW/
M%WALG@6^]TNR2)C:AUOW2<K^X!ATXYK#N54A4+%[:K'R#7-TJIJ'"!TAV%"6
MZ7N),^+A50X*R0%\CUS-(O58P'[Q8[03+L\?M??-%F][++"#-D-.^^.<#SFD
M/EX8'*;D$ET.]U\.S#A*$)NSV8RHZ^38=DIN;EYJV\V S M:I*EFH; I7F5\
M'7B!$M7"E$R[8B=Y.9F(AU25^98*F LH7MEQ,+DK6N3H1,;;F&R XR0$@Q5K
M@$UC(@@4KYTXR@R9ZV?&F](W<T&30FEG7N358)RJJ$I]9EZ*M!:[QQHJZD<2
M6_OE#GW%=S#28"1X.QH\9+JD6XCT\.-L'>Y#H%L**)4_C01G2RGGZSPWSZ<'
M/^CL-<M_T.CO8"B0V%XFIWH=GTT56DRF'4)4MVX2XAIL:4?H!H,_,U <W(T%
M\PH"I>D+EV,/W'4Z1Y5\=EO.<^?93HU?QLX@AJ;+[(%(%=YIU"(O-\&XP/PQ
MMFHEJ!$>T=6\D>EH $7RB MW.H1)D^/X?A+"CVXV-Y1D]J!YV&'/$RQ_@S:E
MWN%$=0AR#_5YDZ77/1;P"&XXM+N_(V;QH7CM$\!OV[6] ;3R;6T597[*:RK-
MFQWAVCT[QZ9 _LL#Q6L)+K)F%<\LESI2EV05I9BPE+XGH;UY\OE"LO1C8#!5
MJ]D6*XA20@@9;[EF_@#N5R]]TYUT[]IJ;N.-/[O/)FY0_+)8V!&>URX4%A"U
M!N&;LT%)4HJC/=]XIP<6WAU%9>2.*1UV:(D15XP_RF$I?I+C)   +_F?_'9Z
M+]MCWMCRF.1EFO0R"UC+.O=594%(%M4,H3P%>VRI070U=#G:9SY-$NO);)F:
M#2[36IKX%O=YXO&TISR7.PL@UD+G2UG ;",+F!#?=-^YNW//:<T4Y\LP#^=&
MH39-I[VMVII:+[SFQGPGH]!4!7&*!=-<-QR]Z%G" OH?+:R9X(,H%HO"+( W
MZ/$:1A+=,DRS6+?)@P>OHQ?5,N$IBOB)R>"QC)J/.[5ZA_O$5^BFF!;7A2LI
M?+>5,M9\<>FFXQ1_:TQGR:=K,5$JR1=\L!;[M_SY<\-W*E]PH ;71%$:77AF
M/2I]Y>NQ!+IVX^.C\6(2U_,+DL=+@9U?0F$.PVI_WUH=X*06K(\QHAI4V-W@
M>TX[BFX^B=1]BU@EHXD64>D6$3^7V;$OM[XGU=1^^ YDEY>NS=T"M;;*E*4O
MJ93&PO@R4S&?DJ5;]N?.B#%NTT00R>N^C-=H?\BH*5FW]0TE-[JB8(H7O(B.
MN.5[EW(A%Q.Y.A>])ZE-6?9RWW(W6#>Z+=K5*DUVEU!IS^)KFCHD DW)PBR.
M3(M.8Z ?64#X,?!$!TWE0[LN([ES)<@5/SZDR&R&EM1YZ: D+#[7DP[WK]%2
M:TH&3(D96N^JGL4[G)U9T<D6_12RO9<GDHW2(0TJWE0XD^\9A#@57:=)E206
M.;:ZJ/8W\'N3E;S;7T_?_;1\O3_IE+IYRY"A0UMF">^CZ8<P+%:8[D?!DEC
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MO??)VEF!S,SS[-FS?V48.-.<!6"/G;6M-<"SBP>XRGT!G'5@M^7UL&N^@"_
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M_G9ZG;;H$NCN:+2I^ZAJ;\&S\+C,>MR7U2IE:>YUYH\Z 6+*0 %,,D;90C7
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M4:]:VB[>'WF7]H/L(I5LXV0M,ATAK@A^[QV>@5-T\8SK'* WC#W2J35Z?<H
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MRZL[WS/,0NHZ*\CP#RJ+;F.&BG!Q-)GK G[I?$\,*8G[*OA'?9>ATQ6?D4*
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MS@4=FFI$&"5:W?Y6SF4U$E>S]5+?O%/]83]2-WPE5%\G(V8[O[B-C;B-)7
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MC3\\"IIUU]\UKA4<G#'R<;WEO>IS.]_;=.+U;YO/;)A?$L=^A>]KLK3&DT:
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MP9OQ<QR*P?>7<:BH?QZ'^BN>O&\]^&]BG4T,) T5 HGZZ_UH'M7KA6HS!P(
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M)'ODOD[N?$TR=>_\OT!#T=@_WFJ-7^%PND8$G&K4DV/()DKTY4R=+KU&U7F
M>7;TT>0%Z6]50Q7$!T<\X\%TZR[O]$A,X7%E!6])/_G=[-POK87@S/.$@Y_?
M)?NXR?M\0EY.+_Q3@X#>'Q]PE+9@Q(")D]5<Q%U5SF[2N.@,6=@+9X$*7J!8
M]BIG/E /[#JVY0FKL1EMO_26O?IS.\T512=^/@D#%N[C)I%X(ZF#KHGZUA:)
M5X]M*-"(C<)LJ3I1"0DA(]*D"X=7:P;S3NW2JWQA:R;)%]5DGOCPN"DST@O:
M+,HX=DT](-=4/Z"$K,: (@\2F8Y<A$IPS1<N(O@,T'Z:BR@WAT;[&U=65ME"
M3YJ<=]#?0=HD!CIR>433H6..7&0(!$DIZU%("P-2T0-?WS>;UO>1I=9/6N2%
MTV./9ANK6.*;?\M?)AI5B[GFK ,A&AX6#$4>[7@+3'5OI;)[#^;YJJCHMIA7
MEW(^J)0,?_?>KRL;?'X&V&EENQ9VL%7H1GPQFBQSL,7IQ,OTR$-;!W^.%<KD
M/^<B,%CG*6?D6$(%L.NBW-.W\2D)2R/]>U$WG&N9JI*P[WFW<1$\L6#_*#V)
ME6K.P(=OB_PS6UNPQ&#;_:[ERD7<:V9[EA:ZC1_)=!(GI1P-'ER]?^V4C$=[
MD*X/U:3S/NWIO[A!WWG^GYO%"B\7,<H2R_OF&"5 &^RS$GY_[ ? %.?=&_AU
M8U3^CZ]P/D+3>(X[@R]3D3@5>##NZ>^[1F_J_Q\TS](7L:W_I[XP9Q<&DOD1
MY@!1_[H?'_3TP&CF-OOZ-I93-E-_HL89[--?RWCX='*/^<:5VJG]A7\30AQ"
MQ[:?:**^"J^?O/B\.]GR4<;IW$?IO3WI/1(>V;?[HCUC4XA-COL>$A4TBB5V
MOG"PC,HS5>\N-CWNI+[L,?-\7L06]N?Z.BX"=IMU1<K:R1[TFG1IC31^$%4,
M-&)VVX%\'] [:RBYF#7"E1+H8Q7LT9)G*>J/WS[:?V0BYIG4F$4$O(+:2]GA
M#:X7GUD%WWR:=?KMH\L)7S._"AG)W1F-\*P+$[\>JE#EWOG)W?BFAX$"27/8
MNT4VZ\YPIURN6S:L,)8,N_YN.E_IX!D"B\SY+^J&YF*E#J#BI#><%=<U_<..
M<4%ZT=R\CGW2V=4A4FZ#Y&IXXH20;K3G'QKO;-/P7R!^SDL=+Y^Q;I8>SJX3
M)W,K$UPUZ\%9:Y*H63U<1,GR,79C5<$#->+@Z^=.I[]N?<IS#Z5I^ J&[LWX
MWN38^3(Z9=PMTO?G0&OM]9JM.'YZ-%0@2T>&ZMR@=QA45'@=&SYI-TI;M"JY
MNG_B:\/FIK7+-DHF"9B??VW=!LQHK%&A(QOF;9L(I64/\.A19&3L;C!J+&A_
M5[-9ZN:'&;3!?25I_@GI+3;#BO$WC?@4R,?9I\!BUB:V+*<8K\0^ :[!%+#"
M$&OND'0&7W@F<1$[=';2]YM+5F=5,3LU2J,#%6IE!CNP"'V'*R.HN(E/QBWJ
MX60SH%9-!V#IPCI#OL')@>G%2=(@/[!7+FMH4?9A*]*0O%JA^<XKMX,.5K=T
MVZMC?__8>; U&,(\9]_F6<[ZM_<TO*?$ DO;NLFSE; K[J_X1?%\_DD&C[U3
MN0@G"NPEHN-3L&8ZF+O$_B+M"GO#Y%]$IC^9+:(*P8*ZD8M8A6&G^R$)[](_
MW?SW?KHNL S'_R=^</0LR.$BII/Y&$"7*F1R#<T)@?'/K ^&7G(V\D-'=RPH
MG\V&P\P#],(^+B);,)D9N2;/U )/,8:;@&(@3,,<"?6(C4I_F62Y#2R;HNMM
M/M$O+_GBOAX9'7ZA=O/8R/VNZA/0;B["IE?/9Q?4BQ+QN;5**V$(#35 C4)Z
MA&C@F0X0=WVB_(=&;D1[3F.;L%/YZ82 5N7>)S=P/=3MKL63+S)\,Y-[(&CL
M*T7'$95D]2JQ/>MTI&6"\9%'>6:*S^UO):3-,"Q+IW61[K(\\=?Y++%B%\$G
M]-GZ2C)U+X,9Y5*V&%1L':H4Y'>8> 158#BW<O<4PSH[7&/\ZZRT?"6.<T>[
MKR^6)8YONRO=Z4HWUP^JUAL4=L3CL9K8"7P6=049*QGQAF6(-(,%ZH;$ [!E
MRNHES3IZV%+KS@=#*P$MG-9@S-H1MXN<?/15IZW"@8SF^M@8LDN/S3@,#]XY
M^-U K0':U92O4<W$A<:QM;OEWAFN;KYU]/-DU"$$_CMO=[_H^PRV%*A/G0-^
MQRG1)V.T@YZ<*8,YX]0IYQRZ-+]RE:WL+GJF>T7@P]_.(]:Z"XAG%!I P.1(
M9@[UAH9<D%1N5_!:XZ5OE/3D%;%>L"\??*&+-M8X *W:PVN6<X-O'5*XH!?"
M\$ ?T9*DKYSA<!W^RV7L*_&G8EN?0!(=S _]Y70MMC"AP5(QJ$7GU+C#-BWI
M2<<C;.W^SJ>VT\"P^"95JNMC8&4IRPZ8%GJ-&J@Z8PN^SX0OT'G:(A9*VI+=
MAMI9];.\+,^0?Z#R@%"\6A^[S3XQ-J"WRE9C(NI'/GI\Y*3.N,8W##T2&K7O
M9S^ %'%ZG7Z^4/.7!94[')TE-; ?5LM_3O[TKR:-B]MB(^LGP8NL7%N3(5_@
M!],:O8.+L!XQ'Q\O%(;3\@O"NJ<Z%\$+6SB5P$5XI#H01* AB5=67(32,B P
M9#?/W"H@/P-+Q5!-J.L$VXYU#F?54[P*!\H'N2T/R6,"*%1JH+[H#S)CAW\Z
MJC95&[,R$RJ=!*5D[>0B<EZ@56EUONC92<]>]')%O,YE]( 8T[/\L2D-O<VS
MHB?RIFQOE6' O@YBV_[8KK)E8)"7>?D+DQ,U%A9&\3$OM1.,[6@?25Z.5"0(
M-[_PB8J5N]:Q8WQX^,+DF@I6M7PHC(^>)N'84R!BM3A'!6KZV>:-ZXKS2/"V
M%L=1'K('./V&;&U)*!^^4F4T-$M<5H,.B,% O2[.14Q*&7(1"NA(@+8%A(7@
M2=2:#6PS2GJJQ%SRV#,N0D!/'&<3TFP#XQU[V^M910_.<^89X-J>EQ1F-4OR
M[93G%%]J1E>%ZA]^F7,G:Q_^(X;>2J _AH-&'30*C;+DV77XMHD :3^.QI,[
MBR>&)0.G8C]7V3'J[Q63D8QG2F%'GS1V#"[=K*L^'DCR:+5)R1:I[E4MR2^9
M=9EG'Z.G/+J9IE9'*WZT9;TD8&TMVP!K?\NBZL($I:K?T&O=,9'%Y.<DJ<AK
M);O53R]7QO1+V)#\!)$OA>91"6=@D>GBD<4>%>1DZ!UT!UF/]6D92KRSDJ\Z
MIIR[]0%4<X/9L<G)G&?6;RHO))$POF97 %.38'^SU>S@;+[1%T$I+&IK!\RW
M#[>Q+-RK0%MF6W6<6%9-&572))5B=W0W?D/L''%X$0;_6%51G%I_AC-Y2%,K
ML:B N11Q'E]E6V)ASKG[Z2T747VIH#?H>LE^Z&;6EIN UDV@5VH;>O4N&(E_
M%EF$\37ZK+B@DUU+V47VZMCJG]Y$^\$T[ZS2E_7;<MK=62MT.( IM@7;2Z96
MU!SR]P<:&SGW]53LQCDN_H&F(3;6JY_,WDNO%--9D*&3&E335_VY9CCT6)A<
MXZ6K,Y/J+HL^9KYCHU&9N6:*DR)5(2R^XUELJ2YB)O4TEIXE'K2D=PM%O^ S
M&&9\# QS'??AW[G:'(';&;BK@_@TWF:%P!9!,149,;&W=D6S#$$/"0<W_HKH
M;KMXXQ?(Y8?G;,MV\->*-H-<Q!BYEB+V?;4(+*.B0TD&+/6P.QFO'#[?*OGQ
MXQ4Q/3=R;*8GJ^-AGKDAO>]!$L2K< AF;^J*LUH&G?;F@E.6P0T %,'"&BA>
M>N<KM@EX@W8-J--B\/[6HQ5$*9@I:".P)J.]^I]C"86$N?>T/10?4#[=L)(X
M< F+:6MQ;;P,U//A=G23)TQZV';4JJ"..;2H8W/Q]#>U_@DNPH(.D6MC&BR#
MLL.RY6"%8KB# %DA\QBIJ%B!T^F+$MTPBGUPU2>R7S C%1MCY[(9PK!SQ*DQ
MR>!#G]ARC=PWI!UH/NMV%/T=VBM($#H)L\M"2-[]52M'^K4[\ =JSAFM=T+O
M)F!0&?F1+)VP+SR$?? S"E?/"CR6Q<;EE[V3/XUEY(H'=>J^)HO-+H^SW)CK
M7P X M82MOE..!,&DZ-'WCW298]=0'61C\RN#W\GQ9O+0_W>U0IO =OB+$LU
M4C6Y(:E:DF)VA9A7ZO;#KTM8(\:-DYP@\?1K$*GW[+'%N=) $Z]K(R4UWP^F
M1T*EZ)38$O388\J/\^0%V/_+2,R'>)C[:X_K:;E3-L/A[JA$68B.Z;L])JP3
M;=)2G<GTQDE.MM[5+DTW_^9\R:Z:%W#,&Z37,[!T&=J+^9']=(=X/J**(GN!
MT1]R+$.3876XD7JX*/5XH*+QS.>>0_*5#NJ='!)53.2*N%_8,R4]^1T9QU@F
M>=Y$^PP'E7:UH8-$V)5"N[H)DV6<Y!K53YR,J-J-3];:#-F:%XA+IU@'V:XJ
M^.]/:D\8TG +BDOF8-@+EWY!'[MNS(O8+J#?>?=T.#GS*JRFTSKU85[1@$HI
M2I@BV\;XYH50>MV;CO<__#,@B>XF^8><.+T#4Z6W_9NAG@QHW^(NWPS169M(
M]@S?^G1]J@*L:3;U JQ+JT__N;C_8IQ3CC_,WX,$Y5<;;RW%X%M@.='8!=.Y
M!P[0@2&&V' M<&0(8%BO=XW-K0\UH4#MGZ$2N=*Q=UJ! !Z N>NK6Z?O+W6T
MMRCZ *'D!ZX3J#VA<^W"4E;5J2O9TN.%3.)^!M^\).NL$[:_7YXIVY]^U-FX
MZ3C.XJJXP*W'!MHQ"4MLB]KC*W?5>YQ$KZXV4#.Z6;V/@7P[E+[=^J5"Y%+F
MW4E1&A=!)P.>A_0"@8&D\P?OBNOX7 E;4FQ$T:O(V @\UF< ?[JFB&U0<(;P
MRABDK/#IS5IMK;Y1+K=&X^7<:%D_7;E<=YDP^=M/>X=MX19^H!O7"37VT>^S
MU7 &19>#H L_2PWS!*UUXJ",2=@>W*+TL"8^Q3)V!7G<H;^.R$JM);=6(E?J
M%0,M&@#J 3G\[3@&\),7S7G_-RX&D?RK[_K-Q[T%^QTXF3J&.>S?Z.\D#A2K
M#D"#6<,4Y=8S4<<V7-9':)Y7#-S5[/E#@HLP!S<\H%?Q)5@\,6W>=DI+_) ^
MR7@+XZG#HR0/_9*^G!( <2/!G7:L_DBN2%?"W?8#+^RKC70O=WFLFAY(BW94
M'$*/I1&6_*7A'%\>!J4L8!MG_^9'2"'TQ,@4BBD8#B]136,,LZ9<1&;QOX()
M]3+^!:R*8+:>WOT7"?/+]@SREQDDC%4=L-@-X]',O:_ID7\Z5R 2 1KJ,]S8
MHN-C_?,H1F =&4&^1 C3DP4Q\K%7R?1>+B*R1J$]D^)LZN?EXWOKAG ^X7#@
MG>2KDN(FA@H=NQ,Z=UI]1PU$-0$DGY@2U)Y9- D.4:F"U,7P[N:\[2GIX"T[
MB=22H9O3]AXQ8\YKAU/2N\2?5AIDX<BJF9>K)6GR3>00#+_-9K"0X5,O+29V
M,L6%IGQWM.USLU/-K?S%NE>@$6-XC(MH3M%UN0"J,<0,&;HQ#]]Q$:Z>VC$/
MWS3Z74NZ/"3X1*A-^.B1G5\;S)";PG5"3N[Q^D\D3^:T&M!A:4@P=XS5@0!9
M9UGX)\ D)[][7DC_V[6X*YAD39O=MZUJ]QSV_T@\PD6$W<4W<Q'+9X$E\AM@
M21^P .7&?;: 7G4)19\^1P?TI 9<,'OA4;Y4<9OVY&8.7V#M,BF/Z#-%$64?
MI*EHTQ0NLC?96SSP,-AF9F4V<RNA7TDVST.EK'H9?>0[$98Z?MD_RWV_A7$1
MBNOP?[*P1MJ^_)=R'\Q"D\#/>E\D)PPZ4%E/7M_4"(R) &L!:[%LDVQ)X(L!
M"D906$NUGH%^GA!Q * B6>' =-VWZO1"O#1.AP[4$?D&0;X/VH8#ZBE(M;E$
M@GL\1A47+8/K4CO25BEM-'N_:9.7+9VRZ]O -58D8RUMCX99]5W2_BQ7.?&>
MI_'QIIE==P=)02GHO'(?%>(3^@*2QRY;6SVGSM2YO6Z+<F[FO&]6UYWOP9$'
MB03=E_D=8S[L&&%@0!?^PM3SCU:B[Y.7CL%N\/LJ%_&EJUHI!3)X"C3<6TF&
MI9X-;S((W]K]FQ99G<#W1N)NHMLOCSO\B9 !_'UL84_PP/?TTST+S,\&,1/@
M$O*!'[FXK)$P+$@S;U@4&V:;TT<CWF)K^!@U23062Y,^D=@F,UVJ:5-X;J_U
MVJ6(GGT!DXF&GU=-4Z?F;6F4H0UM$/]*WHSTX4X-HYJ#LQ2^:R6IESM.=\NE
M,31&C/L$#WTZ[)!SYW;Y^SM;[CVVO=]X1TE)?O<Q8W9'$A;[>FB&M+3,._-6
MD;8(RD_54< #;O68F*0*OKE5NF)CS0:0@ R-;F8:-N2:WJ18ON]*UH]>5+:Z
MD##N_RG%8A3Y7/!:T*M[:/<^C6D%Z^/6D"<EE_WA(/'GX7,YHULX"372N#V,
MV :,F'_--W1TVO[NK-BQE1%R^!7,3I7* L/7]NZ,WV8832JXQ]-"X<.W8X][
M?6XNXI22D)'K;G-^8WQ@=HZIFY=\)/N06+/)B,2=B'V=0_ZA;YO.GG6?WYIB
MXV>Y85B]X?']:*R4PM/?N\'4TN5A)[^E'N2;-\30&C$VCIY4:QZ)%B\!!OW.
M?U&IXGUC]'*0?8146G.*6JFZ@Q.S9.KM?B6ZZIGZL,F5@HJ*I<BF>($X %!I
M6@]D6E> )U3K)!TPP5R$^&TB:K#6]T@?SBYK]L[JE&7/A(_V3$!FV57]A(G'
M[Z.O%^8J['^K\"9YP,/"%N]T(G=VN"R/Q?-]V4+_%L\?L;1*C;K*CJEPXP3E
M!:8&+0H [WM@R?;]WK\XUXPQ_W7H5!0D8TI$X5SS1V4SW9&1%(Y#?0"&",/E
M!)?YZC#Y]Y9^$\ROE/H'>=[NBUB*R2#AOO]XK:-I$PI6BH,BNL0B9M4H6\;;
MQZV-T:I%5AQBEE8CH[X32]#4+Y25ZX0U.'JM.J'HWWW6R\W9)5P$*Y^<C:9=
MPL'.^HH P5EO*8..!H-K?E8A^2#K#"ZBC1<2V,9%: A"5#0K$.-N&P5]Q!2)
ML8]FLV71C.OD,G)930L7<9A0M"9M"(<\TRLCE9^93:-KXT.*H&V3V;X6D-CP
MZ XVP9KY5"%0Q>YFJ]9DAAG2Z$V+O07V0FE%UR>HDDZ6_03ZW2]XCK]D'E^B
MFZWN(^Z0_&Z"%.4QHKX,A,/Y:RUBM?9/-=64?Y[(_7D^SZ9?ID@HBA_8MER$
MC!G\BDL"Y&4UC$PCY4/6#'Q'U+ZG1X*__YQ20,/A<^P5 &=153B+ E#*?&[C
M[(H)#37GP])B6S,>3L56!=&GYM?A))7$K"3/!WZL:H][AUUJ/OJF;G\,8OK)
M9]/+,$]5HW\6.V71:Y@>]-I^\OMC)M-'/CQ';OG]Z"<#2:&9\Z^,7[RX9-38
M*C*^BS9R9<C+XW9JV5G(B&;.XT\^1E.ZJA=]=XOHVYX75@DF6<??R\X;Y0[.
M7NU=+_XA79WQE\@I?_^?(F?-MY^U]U\BOA=.AQ/-1< (^=#Y<#%C]1Y>BA-B
M4_!#K\6/0PQ03:K1C*ZQ.^!ZW/#21]V;QVLSHO!/I 0(UU^CE>JIA0I9=T4]
MX)4]O9!M9F%F:N,E.UIJ.GRE/I2]B<8FA!?XK_=^/V:1:W;3V%JEYT!F5[4L
MT35KR'8FU@PF _ :5/J7:8\_[Y-25_YT+.:,OSEG':!RSDL^M= / O^ZX6H+
MVPS= OF00+=8C 1$(0DX V^<XKS44:.O3YWM)BTS/A?2JG=[VEB>4F5ZE)9J
MLB35BE_%21ZTEGGRK=[K.C*Q"L,@0 (N6)8'VX=N/E\(OY_3#RF#4R:,-N7F
MAFUGF+=K&-$%Q8$. <KJ R/OIC0);O?'+:2,]\5)'*]/2M/'Y*/'$FM4.;%L
M5_HP;<_BG D+W4'OK].D"&>55M+G1K< VQ4]!3.F#>PRNJ7Y[3OM[.6&SHM=
M\= ^JU@+4\45(GALV+R\HK* BPA^AN,/=IAN6.VJIU^RSI?;F7G:<-_-.9D8
M]9:6H4CM@Z++8FQA+)4XGT<'/J"$?OZIHA"VS9<JIW')Q8A;GIJ0PA?UR<+N
MA1+B7)#*08EC=_:&&UQ*U-R(2M,ZD7(BG*_KWW7TQQ0>?NZCEAG,>HM<Q,O(
M[W]J(;<]P5B$3E7X<?P SD;;6 +\TG1BVX^3 0DB%IBD>X]:(YT&$)N-Y+/\
M8^O,P4.J<\H,RK@4 8'?"77K2?:Q[:/4'*8UB\^2O79Z_]CV+C]8L:#R(F$?
MA6?WLJ5A/MA<EZP5PY9Y"Z(:KE<EWRG.-G<!I"Q+KM';)0W&CCZ^D'#Y*+_,
M&V(BVMLG1$\"'&?I0^T$7FBW_]W/_<[@#89T<[/?4&CJM<+8[?Y8\TCWH0WG
MD8=4W5BZ[ZX_$MAH6;#1X8CS"PUM#<E'B\7]Z44UU3_GC-^_^WDTW4Z<*,.J
M'J _P^DQ-MJ_?N8K."Q:=?^BC+F'KW)67?2'*TITXY2PUN&;F3D;O^&\P4OY
MN$M@H-^8,M^X811ND]QBFVJXCK!<I*>@N(U-S'%596]+I87/RZ?V)VQR,L4Q
M8$L[VFT%J^E@>_:1+J&%@+X^TSL[=3^E9#Y6J7RC,G5M:V&3T8*G]<$JQ=P@
M*^/1'/(7Y+O!!)'* L36>'.$;2(HS^SG)$'[_8FF=."!GJ+#B'F^8[L7M6VU
M>^%5-ZGEU5;7*/.:>#D2V9=_(JNJ:,?.F,.944"I83T%Q;;GQ$$'<4J@%<#T
M$0:?4)G%K_WQP(FVX4#=IX5G?C"*IUPER6''YS&"4"]0TEQ+V(F'21UPA84J
MT\_>O%&1& X@;_L@_15,CSH$F==IIT9S4MJ9X<]Y2#O/>-W:?:?NXSL[P=?V
M9754EW"3P#(O;8_*)5;I[T$LA@\S&#2A:YMJ=M"T(JX&K]JI 5>F[;V?^+ZA
M.&4J2 3(D$HB[9*/)3QMV6L:%VHY5QGJ37A$V6)>AP&=Z2 789)22QF@#+70
M3F!?*><.!N!_3W4ZNL=X27,B[9YP8X!J$YJ7;4WGFT]]"?6.;@.MW_K/&OJ$
M^D'"/25.FYFMBAS-.S7!3,EG?4P:?]HAW.M(Q[/B]B=ND9("Y3\#Q5,1OCX\
M S@T)TD'.Z:,:2SZ[BS'$ M'WF?O5,ZLO]!O:Y-BF<:C.\'LHPP.224Q^^9E
MC'<Y<!%R,I)YXKM#=Z4:&QO-]EN7EBV3$CF+!:A7FF4[1QT,_83*C5RVIU]\
MOGO#T:/O>*SF3LI4Z[U7O4^18"-9IW&:16 &?=V!6##BZ#CTU=YS5Y-@KF";
MQT1I14F:&D'%W2WR8NI-@XEC2H?-'1PMHQZ]L.]%V+K1M2!# ?*<]$]7MA5W
M(GR@K$G!.;< %@[?/9QC8"R5,4;33MYMAUTQEZ<=YP1KM@VKG._DY<O]CVR+
MV7]^/%7U,]W]/.@5?Q,!Q^9O)\$3XS[SI!QPD1E53E]LX"(&%)GQ?7AID-<Q
M!M@^Z!\X-C_23HQ8N2BE?C>A_FSG0FGP28DAJ1U="E_1A[9D=]M/-2.CQ2A%
M56CIFCWX]N02Z$!%":G'"Y*<78URS<E+^?HJ_KB!N$N5P]&EH!=/(I):*&S?
MF65;:^/ES/2GRCY:1#;ZO-Z%WMM<A B^%T4_CWZ D= 1H$\U2JB&0#M!H.'F
MK+,LP^WAHKJ=QHEVRU'!B[>' P._IY<GG#?H%S*97#O9O"5,^;%N5QN-6>W'
M^LV9+0B$2!\*,RVA/[7_A$<G]AW)<#RWNEDX._/^:DJ"Q3?1X7LO)G"5E7<5
MY.U,Y;R$BEC#Y-$!%!H:PFMUX[!T/AKJ@ZXM\S8#B/)-!>K[AYRCJ6WF E^=
M[#R73(7EBCG5YP>'\IDVJCJ%ZG*".PX_K$8RK]&!V!H1Z!.>ER[6A!(RRO<G
MU*=M[E;"F><:UMRIJ0G^?&Q!CF_3I.K^]Y^U-.]>Z0_4E[=93E OJ?X =C-C
M.02\$ML7E Q@_+ %O0(#\QS]L^O]F.1M6\^6[? _6N]83*[H;+AVFE.T('DG
MC::GT[)+T-+I=P.]$);VM/->1O]\#D.-F4A?#-98W [*.]+18>K'Q!KN;OK\
MY%;^3-^MF:,=@<P3Y>-I&C&"E0Z7E.)RGK3M\Y/U-.^\8!,K*F]41Z'O(DS\
M[-J<Y'7[ Z?ZN]4OKNVYW;'.LE_59HT*<1&W<B#53L0?AT4\>_\T2%*3]N>9
MWYJ??TLN$:I#\2\";CY1Z%*Q!D+$J&H92*!6"U_HQR''@U0;5YE>U!;E1,/N
M:]?R+C\[F;M4+_SF](\VI=C4A12M^JYL^_0'6=AIT@J@P;G]>U"[_G6 9T7U
MT2JA6"Q$(S;2WKJ$L&.2+IVJ%3[G/:E94%IR+0,;/A*O=3A[2"O86M*]9<M
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M$.FWJ?W8],B(UI9GE?9E2 .[QIRW@2U2_=AK+V^^Q:]$BO^0D9?H$SB=(/L
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M6M^>.4"[$>_UA2G&F8,V60U1LNE2'&$L,\2*M$I-612B3>+2_VC8SL ?;F[
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M; 8<^,4$!V$%.&:LBY.&([M8$%J?.S+>I9Z>.)E@&A#WX8#E[\R:,+U79-U
M:8[56MC)MY_*=8H7P"PI,_+TH'@6#Y/ "/%<D!P: K@<5QQ44:7)8*/J7*TN
MZ\'?!R3-6H+XA'*VV7^)W195= )TN3T%ZC,R&^>@8S6.LJ>=ZN-H%O1]K+GM
M4KOD(5%WU8GL4A3M]5TEO#\WJNZ'O(KUY3771X^F*\_R(2#H>4)K=B\7-'O;
M4XWX!3\0*O"-"Y)D!0O@:6GSR/%^8X:Q:7![<</WZ6'=U'17.[*1JGWJMCYY
M@<X<MJ!7(-V9H<?.ZC(%:@#J4N1:$6UDT'W)H[(C"*)-T\0^77APSTQMHVY?
MY%S;T8M$7W+L,3"@M<7.[92GA83&8QJFAQRDR*)HQ?9HJ@)0;3<5_$MP(KSX
MI%O(.C547^]-RL*G,V,?Z'&B0>H8;>O+@CT<=?0<X44DY1X]#-8)I#,OL73'
MT.(H5?K9*5&%H>RF;^KTY)0:^8PC43?/R 7F'^'7K@>OP)VL5YCIX4%87)<R
M^@.B<;J'"^*_"A7A2*($:?Z)G4=J['0+6Y-1QTC1]HJ*T_D::2Z%BW)3QT0&
MTS+<'+^<K=K+=U$73'/@ 8D]36_"@GE1D0-H*.6\"/@,2S0]>L7[II#J?-Q^
M_EG#8/<AQ)A>^,*AST%!\[XE"Y5WEBYG/;Y__[J\F-#;%P*W]BHT_G7CHP],
M0V 3$-+F"*8>ZQB[#"*%U&0.R')!C80AK"CJW(2YP9.35]HF;['U[1(GG&Q8
M(?6.5X8\ZR&''<4__3PK. !5PA-?\GX>VHU+BB TE=02'<+< */G/,36GTS&
M)8<'Z_\>X[ IN_IEL)>35G!E&Q<5S_XXT>79/:L]^/+NGS3=/?@K!KM14KS(
M<Q%IP A@/U.?Z#RRA !CKB%;76F#>63%8<5S+[(VG$R\+(_,V>]Z+RX=YIYJ
M&5*K>-KII3E;@PR>$6'LH7MU5 .X?DQ]06_U, +14D+PF-($,%6*[[Y]M;;+
M=V-A#VU6'[S6NB_3AK;!$&,70)2!G:%)>K3?JP/NTHTGZ"L$R4XK#+FBQ55B
M3*B4,U/RN4<Z2#TM9_ "/-K[2NI>%1Y5%DA.$D^^W3I$F/4G5:0_8VD#<'KX
M3WPR1.,*//_SIYEYQ-5\YXMWVG][.)PDDV7;[W=^Z$_UC;2^RCS<B-I') BA
MCM.&L7$L?I*#R:G1IF^H6JC=Z)I/2TMSMOI:UOYNRXOWND%A[N?YEO'-@A0[
M&HQA#EA@Z!U+A$R]6\$R'UPIE/[QP=SOLKG%+]SFJQM2-7.Z+IP[H=2XQ\H/
M(<1.Z=+@#'OI $MUK,MT68H6;7D JP31G1]06E2B^6<$&\637HG LMR"FU)V
M-;;]V+OAEQ_]9.<]SX4VQ0L4,J(,?9 S@@'A X*UQT\";!JTAW.L?GQ]UT!B
M08:Y4="S@> #GD]LQ[Z:" W8*<8**KG >J$SFPQ;-I9E9Y+1Q8]^AQ!#2=5<
M=#,J'JPF@05< UL/SS>6-^GI=>X?E@\839.*<W(\O!V$VN*"!/E'MK>R)/F7
M=*>EU -T;V5TO !A^K]WAQLQ'&X29" [6-+ KU*M1,@Q%IC6FFGXLE)RZ G0
MV,>8RVP_.BAG<SVKE'9L$%F+$P40?9"='_50!X@$L9E !<^,DSIZ)F>:[*.C
M;W&^6\=JB]T&;0<A_KKOM8'AB%72$ D$CK :&9%=YF9(56+IT^')OW!)'(UQ
MJOL4%V0WX3M)T5./CBK?UV.\\?[TLU4%J.M$=A=G%Z#6#=Z%E@3\2;R86RPV
MY$#[D/G8??:;L4( V#]N[&C>95>:(SQ [MBQU7N/)@TRP(VX-2;SY(Q[( :,
MWHXT&9)ID33,-UX\2!MX4J7<^(*OT*@MLU<2]$;N@\XI:\""5M"'%9LF"29W
MR2(C^GKMKDV](47K20HU?4EX]&"@H31EG_J7"'(L]!B>F+BX]Z,_.Q9S]96+
M\M51BC>['*+^SJCWTP';I4.]I-G&V ZA:R4'P\9:>2 L'M%$6-M@FF%Z!#AB
MK)/ $KVJSTMVS!Q**G99@G=,_D*6,4UW>6V].-OR-:S[_%FW-WP6ZOP,:#(7
M=,E@)K[7?<<S$FPG9Y"PLVG8X&+"J=K =DS?\&'%F),'+83- T%N\+U*!]7N
MG+_%\U7^+*F-WL).!2XH$7\I-+XPF-V8W/)JG".W<G98BO_NVY40>=N]2O$G
MP(:8GE=>8O17A#4"/9)12\<D&/P4@<W),M+I\'[LSD#3RK8DLIX,Q]9E\G/&
MCR<6(J_%Z6J#??ON0&/.@OA!WF*Q3B? DIQ9<'/!6C;3";GLR;Z#@C$OH*"T
MZ?A;'4\IG&-738>R=*_YO4K9D]-YY*K&0[>2Z]L6ST!<O?WOP(H/&7-!UJO8
MYNRU5MHRPZ> 43V!UOTF Q:Y-:R^8$%^H+&MU]XR5/O(M?-HMJ]WM5#*P:);
M:!?:RB,'&$>X@^<3UJ=^Z63ZN['CT"*>BYX?-CP7%E!Z8^KY@9[I1SJ,VG3[
M<^VTU!\54E!7F,?0(PB)+@4>[=W.V<=S_WZOB!0-O?'3M))&GO>O/?S&._M=
MK%60;K#T9<.MW=J9U=W=?^LC<24T&]N 'X3.!4*O8E,P39%]\X34+N-QV5Z"
M*%HIH,3PQ<0O<;$ CSD*)<,E][5OU\N KLDH5;^CY^;VQS>X-_U@8[T0M'>,
M?>STKIW(7@)9M@<W*T[")#0S;3_;>X;UJ8#&:PSVP<]E/3/<7?WTBH:MX%U;
M<X5?._^^QFX6NY0CSM)FET($D8U$W-"N'=/.M.S4)L4B\=VSBP==YV:7]LW?
MX()<WFU.G;"P/ML=5SKMXP8Y2@/?Z=($W#>Z"9(H^0H@V7)"[0?U9TR88]KZ
MU)?#8K.J>6Y*OOQQXJ=!@"!GU^6F,0.>LF9"Q3C[[*Z'HJS(RC9PB-9D74AA
M='55XX36>,T8/$)7P#2F\KY$%9]JTL'2G9C>5W#[>QRQ!*"JRN9I][0P4WU%
M^Z/P_9=J;IDI.H\^ZSS^;5I"[B( 4*8I>@3;.)FW6$03(<+B4>+!&-4W,:%$
M+DC4/3#UYO>#"E8MF?QWA7N.#08IS#,,V%EK7?O>T"-&&# @4#Q=X]&P02J9
MIEG2GOX:J1]B"0GTN?-AC7X"_*>0ED%G#!$FCNF!XXF/92%[Z77W?!11IVAW
MW0R,Y,K.^8QIN>UP2U[P/G5;(MZ!AT)"2_\<.Z A<*F(%ERWQ\\ICBSJ , 7
M3*M!3L/,?K)#O0I<.>,E9G9#[V[>W><;<?*\<:^P6&772Y[6Q85@>LQ"?\F'
MIU-GU(A-FV%G_ J_AR:VG[)33UC7?Q_\P[7$SOSK*Y]>+W%:02S*+(CW@MN0
M'HZCMXJ$6!W*!G;U67-S"T>*GTE[:XOF7@>MGE PVABAO&)&H0ZR']8U8>.,
MH;(H\<<L!WIM4RWI06<0621:1UEUTO%->/22;FI1@-W691?)BV\%]I^/RAWX
M:115, "=J6:8 %_(0W3JX,BL :D@(WQVKZWO5*<S\;C9V8Z NY=V#YOK?SDO
M=>>1V 3?.]Z$00L89VC9/=G .6Q#Y."PXA"C2Z8ML-.-'*SF%N\4<\JU*]?^
M777'NZ*;EX/>I?KFDBT%I*6TWJ:,QG]!M#RB_6%TM]FII;F^\%SQ5+2[#*C%
MT.PB,1+W%"W!V@4<8$*!JZ$[4(+ <1(/6&[*UD9![I' XO.!+6,7#Y<9#N]I
M5Y7?.9AV,>-NVI%8[>P_"TR(V0ZR2?8UM#;J)!N+DL AR^V'&*&I1ECAV07$
MG+=W%%QR<,RF&QR>"(KX^2_T:?U_UW_^Y;O:=92&3PJ5Z?.8-$_U.J1:=9>2
MIY[QY7Q6Z:0!X($0Q_^M(J8=!D@C<WC4]_4"#RA[3W!!H[GP/8@]#VZHF EG
M%LM9&Z>W/"-L\,]A2,%_2IW_K:RHQI^RHN@/ZX2S36F<,0<Z3.&-%#'SK;5%
MS^?K0<NW-_&"F-?EE9@98W&V3/,WWZ@/.D>JCT[:N2'L.;5WRJVDX6.Q3E;.
M]!T/HVN^%;B[%/, JV9TBIOJQ,^?B54M/J,?84HY^<JMY09/#?ENIK&&>=;K
MB1SG[(QDWF:)_=EEH/+ ;\]I?</C\%Z\3*<%D:V]"$YP%V7<M*DZG3-DOO+%
M1JU@(?]\+N2!J.GT*]YO]V.(I2I'V3B\7Z@R<IF1CQ )5-D+P.AP+QHXW=SN
ML>/4;\U:S0<?EYU;CG3(E>9H.LK/[(#OC3T9*U[[K69$$)COP>[^*63N1A27
M#2S\FA>&;;SJ?IP5:?R#2*3D&FO/0)*>(NW)F[VAX.^;:#!-:T!<;#7R=_3K
M H:[=>OV]U/#BMHO<]1NOK[PT$) 5 ;T2YIOU,F58P(D$L%)M_?1#?HQ2@$<
M\'A"M?R$T2M''5N35BN"CO9G(M%?:\_M76&6[:/P_ORY@9K"L/F8QP9++YU%
M3K5&/E!2KC3>Z#@Z9,AW-6V(!NV'@E .HU"2)A"\5 SN-PTMH7%! 0&W'\&O
M1Z5OWGN?^C!2-"/C\WF('E!)>]>M2@2H9./X,G9N'V4:,3?7:;SH@'M0OT7]
M>G >_.!MT<B[MM@/MM)\KZS"7 @*$+'%U79XXAI'%^GG"?-L\!B6<DSW; W\
M)1(A[U:: 5GQ4;O[74CM%8K)/(L>PRA"=F%Z;/\<Z#4F2/RT%T_"[F["R</(
MPZ;+UIF:+F--+]<OYU%][R:D&':DG,]60;Q_+RS-]^OXGB(26!Z D@63*2PW
M(G3/2OMB7H1P\\3/]&_KP5]!Q/NYAR^\L%!2F4!V#*+% 0R)F2V#W!BX'9):
MZ0X*:3[N]=LL"&EQ=/OGNXE>MDJ%H+&RY]_:%S/)#JKS_2K*DY30-0-OMQKJ
MM3H95__,I NC$WE7]L8)J4NXWEX>Q,:7R'4P!5,ANH _#,MTNC6BR?1J3>7,
M.?G*S$0*?MC_K1?:>>'.H%"I6&':!SHBG:5%/+YM:0!]C&Y=7!X8D:9 /3>)
M\VEI39"*];(3NB"_]V;T]'M\ Y1B1D\GC["DG1DI )B<G:8@F&HN3*2*(-7@
M  H%K1@2O6[U7+-F?+W8-Z_N8=<[\9%.K7=YEF\$^+^W'U#//5H>>.7Z\])\
MOZ,@L:]=UL LTQ?X"@7V(]:&:3@B? @AM(H00ZNM>NF.FP<^"<B?VFP5#ZL*
MD#5Y4>U5\T%UVX6,!Z,2/[!'&NK=0;^_I_70X0/0))7M4X94,8! AL277U7H
M+/&ZY_-\=;?'\.VMP9ESUKOVC5S94;R4G4K8A99W[XFF:Y%EDDG?0BH.!!FW
M59\*:#PHK_W$Y6R_V/7]_#?3/ALAYJ2(*HE7JKZ[$X;$A=SFOW^4;ZI.QTG.
M#1;D),UY:0:"<B*W'6Z3)^, '?)(+S[5!#X%%>O2 # ([)F[FI5BZ34]MQ@9
MMW7+M'SDB;294K&XM"T,B3K$!65O@FEP Q7.6\A!>DM!#-'3C(C.)%/%5O)-
M=\[;!X:%5Q/<7N;[1:E$S/J)65AN 1D2]WYJ)75IH8SI3UJ?(8-Z"+N;CGN<
M&ZW\T9P)/3/YN"1:]H/QL,*A@&QE.?X3BO==M-(AFJBC-*G#P#)Y1VK9_89<
M^F#M\[[@EEEYB:\0'U'K6O6KB%+]TD<Y+H8$!<#$C5:&I-K00QY&/GYS=?I
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MAE;#\_GU\8XK5>4LV.A5G8TJ#IC.!;D4<T$%!"[H^O0<M"%TB I<_5,3^ 3
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MZ"JT]S%]QM,&GQTCW^Y_>E.MG7V6>C9'JM3+:VK;"X?7P30 R4P20R=Q1]'
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M0[6#])*/P>)#P,\:B\>BQU$!05+=.U[VOO3LLSEFUD:2;8CPWVWBM[X5_F&
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MSG$RKG8/G#Y"?7TU23QJL$-CR+;&5T6V1/M>[RY'+^^3"PCTTK0EFY0\B\F
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MQJ:FAD9J-G]*8/9Z>N-@CF/&59\JK8D3;YA^OB-'8(6(9OUX0BB9R 1<AU1
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MQ\F$7,Q ^<#/-E+3SH7NDM5Y,!U[NCAP G8H<.8+^17.590G-EOP:QQ*0$3
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MA(5$_KSY<Y'_O>L>7FYN7B%^/GZA_^'&?@.("_ R]MSAYE(&]HAS<8MSL?L
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MRH&7R="DEA$E4++OMNM >JT_A>BOT/HPO-EMWNU\/+GXB%3^K9O7NN.[>10
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M!EZ5>JXJU!5X\_1-N!#/2'7O$WD1?[ZD:.@ $&.[+C'G,AS(N]XZHGKA69B
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M-!'\ FD7>6NV_F91[;I*R:@'>ABQ[HW+"7IU4TOS!1MP&#NEI$9W9?7@(>A
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MYT<UQ-L+-J\_]C+BZ!7C'O'0<^&8F^$ZO*/J:'(#FM\"<I_J?M\[B'\UU?3
MA&178C;85]/GIU6]JR7?1W#G#IDM[)([5>"@9 .T V/A% C;O?)-;5*8*R*
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M:FYS]3O7/@P[R880>UX&O:EK[]_.SX=84BLOXX^>M+??6L][8<?QEFL'O1\
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M"W"-!CP: N;T8KAXAK0&QR#L5,-4_20WJC47/J*[[VILAEZJ.MZ[M#JY&OD
M[M,3?__I#>TFV"B&Y@1,DQ<@.QFG@+39^92VY*-YI 5O2Z/ZOO!Z9]FQS2"O
M<4-A3YMYF=TI_9V2>W,K)456B>V6X:Q3S +\Q+@Y.!Q65FY.]GZP,I$4]LJ=
MH$_62\E]&.>Q*5%S.^'4FEM5>/"CT&?)(>D572P"L=)V<8M^ =V7\0'>2!S!
MMIST-#B=--F*C[1(*TG6K"!&E)M#I1F>E4.1<\5NQT)(<L%FYQI^Q.,/=O#.
M,9$22YS@M8OC$D/0Z Z8\"(+C.Z%5VB'URF0=?O#+1<7-A-8'2_5A/3[X^1,
M7)^?)?25>YXY<L#7B0[79HT[B0!2E R: M#\9AXC"*V@8Z,>!M#<FC&N=BMZ
MM\A[C%5+1^QB?W0JXT<FGKV,O!VV]\JI!YD0HV'X\'SEB?D@ET5;K2$UE<K-
M?:8R\L92MC8'3KXXRWWO[%NOS[";F,=H)68B[#8\E.,=,,]1YS0=O3@.#UR>
M)F&#-Q/(31*G?6@_^"S]HN<7:_5OK?8;-7_-<5C%_!'XPH/0H_A5[Z!-IG\9
M&]1;4#11\T]+(RQC7#%;J@W"'#3>#_N&/[^P5D;[M66*3E*E[S%D+*Q?^I?E
MVP?]\6&JQKS=Y1Q"H/5/ZV?W7/Y#_>PBFO_[74A(-,>5>O3C%P_]4NH@*G]B
MV'(XQB7.?]S:C5]7A\NU$C_ES7.\M?I<=C1P\Q\F76R"PXFK<A[XC68VR%63
MM+$,V8.?,N[#+$2POGK-(RV9VQ@2\_+^7YFYP'_7-/,-?!MG7"W A-$" )Y$
MC%#-JNCG6)+ O+1_6%=S:;M@WZB9L*[8KI#PFV:@%[R@(0Y50M]'?X>\[V:(
M3M+RGEYA)K&TO>!\_F P,G]BF!(08Z#:O(L3^C1X:-J),U"92?<AJT-Z+5W$
M5]@H'JW(HH6,2#P76AU0)R&:$7SHC@PA[W4L8%-5J8:/0!D=56%<S748,7-C
MI@;XO;> OCV4D^QS.+8C?LQW?]$^_?AHT-8"+8"9B%:^CAXTT&9^Q'CH.S1/
MMAD<I;Q)(T'V(IV; EZ.#2-]SY6E!^=($&;#=ZLJI,^3S9P,N<^>,Y%^2W"L
M!A-J67R<2,J]#DQ3(LC6V!#8;5PH =.B*HE$V&%-J=XK88?,H!6IM8&AMKT7
MX\J?))*-7M6$WSQ[4*3U4901"%FUZ$M7GL-_X%WT)R$>PWG0^Y$7.JV_UVE[
MUB0\3Y#SV'Z8_R[&/7[^9YZI3'N:DGJRH,KLP81NL32*"4V?NC>5;N2948E8
M4INLM11GF-;TC)ZGM%8FWQG<ACW5</6/-X<:G)9*-WOC;UQ=_R+JJ%IVH:%T
M9$0]ASQB@O-8?=YTR^$%'4QTG2R>=ZCQ2G/!7.G/(5Y'S+[]F<YI1_=,Q9Q%
M)"@:,QFK?,JK56W@$#C%/C:8]FG 0)]A\)3FU,\XG:-1B1'PP^Q?,) +]-MO
M*Q@_?M+!/A>#J'ZV%'\#GR!UHJ71R35C.461*YJ9MLX&80F(QB59, ';(BO=
M7Q=\N$L[,I_B7_[!P\IT33=7/!LS_CHG-O[$*FKE?=F#X9+!?SWYB'Z%LF>#
MXO@WF7/X]=M#L=]YV_ULAU]=_H^\?,LH@S&2B+LQPYZ067BV/XD%XERJCP-O
M<!6X>_]:\U@S#4$R[WFRMB1J!8]]_$]E&Z[]7K:!F79WAQ,O&;\E[:]*Y[/X
M4\7\+W] OAW4 ,JQ('R'X+9B=H/D/Z[[WDRJ8D02$,Q[;-!(+/+1[S'5=KH(
M&X3. ##7>'Y-0*/_*U1%2DQH\<QL&"E]O5Z5 P5#870X_0+9M!+C_BBC<SAS
MUL!A]C2MI/8//B$P:2F-XS?$'X9EV6-\'D4L)OD:K)0%UFXJ/7LTW7X!-,$&
MD:;Q&T:850X67O:$_>V;-3QPA[B=@5]-8(-&W3GQF/.TWG*X^C$XL_*Q/+,0
M,_$AJ/N3ZDAM.T2Z3I>N>_QM =*Y62(E-N%9^B%7,Y?G1UW6=HZ&KS8V&_#I
M&MZ,WN*:X$"8,MH&%=Y2C=9D'&>^\8-'V1N\1^VZ3QZ39^C[J%Q*NO_VQ_'L
ME.M5_(/@ P;NKM7TBT^LZYJ<-.YLB]"> \X3*R-K$P%1'%1C2,U,/4-93O'9
M:/56.&C/L]-5[JMN2);K*#;51W=H9G9)@GX,Z4P["I05LWJ)% L(0<0\1+EH
MA8>91')]JA>@8XD=M<775"+ODNQ^"RPH*%5->!&WE:=7]V#']AK5@<6_D<LX
M3''LCO7GP.F6H*:SJ^UO@,N.\U55>\\J1>TJ3GW_3:V^,O.(C\LWKV]LT$0Z
M&T2Q@T-8/9!2>(2!)NH28 "QI?+DO/NA9VCC@"EUB+6G0HL?0JNN>P\JFD.2
MOSJDJK356/[-(_:: 0-R0XO+*!>.,YN@*$25KT@;%^NWU4^UTF3F[31KUR$G
M7F8I_VQS_V42(;EL4*-/@S[J&#,#9>5-/XJ4L_RNYTAB:@W9#C(L"GX<S1&/
MN[-I)GKOG?"Y@DT):/TUK7-&![Z=N26^\O;WO<[P8]9@7%> 8]U-$$"AO64!
M%PO?;2 BHWWY?#_*@^RMT)Z4)+%I*^PX6A!W,/C(E:)*R2LG@>>2/6=U3]-I
MW9\>H.0!F1R&*;,"K82$D9;?^@:()18=D&A[I+7_<XF@#:755RVRXX;H?$R(
M0^G,8QT$X2F+?XFJP3A/X5WLHUQM%$)ZP:EC TOC^61?C-@BP3CVEK1^?R+5
MPN<V_6*\!4(0<=),6DJ&<%KKKL+B1TZ$0P*O.112#T/70GE1] R.4,&/<7=+
M_-@@D:-9,J]J&F(Q(I\]5*A&/H<EU.IL]UWH4;G_,<K1&8MN),/*X8L=1$'8
M1"9F9\/1A7%-(0#3DF(2B9+P+>K*7PIOOUKMX- I^3KYQ)[&LNHH,[F3?-]=
MTHP@90C.:1RS1N"Q,%$-R/[=>OJ9'BQ9BLL;W-Z,FOU+%P9UBVJ!_J@3%K5.
M9P7V73JRMF\BAQ]$=V#).G#(. =/'(>Q9G)^]PZG^WNKPOZMP7'U_,X:5V!N
MV%%>EL30<S<*G*&,7\Q0L(A?68(16.B'=5Y5B%=I ;.GE_I2MM@@EI0V*W^%
MD8>A$38L1W@G$ QE3+2$#AO$D(=XKVG8W5QM:)V>/-GBF[;$''^]<@9B_LM3
M=C%^Y\:'2O_@UO\9IN)I?PR;\N/@G"6O'\K-C!T<X/0FE0V">SF1_I5,AY<.
ML2DIAVN6H)B-W_]/%ZOF"OXL%F/Q%_&8 ;K.\,XZ<"MF56,>3MOW9_FBA FT
M,J>I^9S_>!_Z2\T^CKPR<64#\T)JW<H(=>(?2_#\SF%3MG^/WC;T%%A,&(55
ML.<+)P0P_BN6^FZP0>W8+5X/XL88&_2BB T29-B1JM$'D&@I_TCKE^?+;:X$
M"?'?OXZ7UJQ7MGG_P4)G^W3TQ>D0V=_X06N<0/18V7-;"TO>HV,AY]1;C"N6
M'YTAC)\I;0-N-BM]>AJR0W9">FUE%ZL=7CK;C'MFG]1.Y&)P4Q(3R$LV!$4?
M_TXPV,%()W0-?<?OV4GUJ.NZ7$G\3\K*G7L+,OE3-B/6(6+N0[(R5(,HC[<>
MFW&2RXN(I41W-\,!QP-BMQ:-;C-. NH4S,2;6(4(]![4,<I0J-]6[IK\!TI;
M&.*6 !ZF9BIT+=WR2(!F;\\9J70U"OQIPV&DYTHC9I^>PANO&OUM[H9>_U2^
MY>(2T1,WCT2?Z9@XP<LM>T:_@.H6PI"9'%-T-]"AI"<77R_^:BO@4G3=Q'=?
MB@)8-/4(-\+$VN6NR_6=)XP\_N;2KG^]M%86) F3NR N-.9PX\W9T2-7>$RD
M0!-/.T0;P!2WIRQ9P+.O,7T'Y4UJUMPVRLDQ_&7.<+NW]]UDA;OWC7<>_*P
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MYS$E:,KY+@]A0Y%#)PM?-A@JX>8M/V$CG-0 !;H:H$U2(90;'*+RAJ)X\SW
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MPL(^4]DKF24,=:Z?'(M#6=R]^*I0=\3.SPQQ)S'*L2K?9GQ17@':%*WXCCL
M7J;*2&*#?NU04)V%9P]L]=%/<L8\AI+$#,]F^6]#X;WINSEF'L/!(W 8;3B=
M=I4A%13V+Y8P:1=^K6'J._]?D_GJQ'D^NSBD.<ZVB4C;5\WQA<+U*W_(=$ J
M,$1S6$9P <SPN4DVZ,P% "&,GXIL"S)A@\RCVE]C/G9.;^5,_3))+#CI%)A0
M"([9A)<AGGLW@"Y\GC2AM)(!C^R;I0+X8Y6!+M7"F'OI7-[=8E2315\/.I35
M!Q%V>4JR:,-1V*!VEG0U)8SV@52/<*@M&RCQ66>>L]NX?GPR4-M3:2Y:H..
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MNH849%SKNUWP"=OUJ.;QPP].5$H8S$TL"*N=8!1S_5O]E2XW=_[3G$7,E\I
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M ^9QM\'!Y$8V&[O7@XCP?,[R&M4-1 #S1"2=:Q,T[L9R1("P2IH-"5EUG-6
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M U5&&+BTT[Z]3-[?7M[ !,$7?Z#)3<OP4Q0XLX.')8W26:Z02L.YPD5^VZ.
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M ']1JF^D7Z0H]&A9P BOG)Y*O/5HN=%LC]%UX_?9;2U6GW;/L7:P(5^)*LQ
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M6/3S6CTYK=I7\-8FY=+%WOR[F7<D_3.+4](?\A84NQ^;.#+O/=P9HF5V9/S
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MZMZ#1RX_>_#"Y-UB1E$SNV$%R@P7X D)6&/&L/HLP-^5V F$&E=$0.!L<AP
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M1VZ-6,NOKK /E$Q^U5W;4)UHY#(XL8M::^8G5/]@IXB>VB>1[W5P6>PP]BA
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M!_=Z6&]Y^5YUT BR;>BF5:)17(!HL4,[9@LO$W$=05G@BZ0+J((U^)N.@U@
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M*S"5EEXT']$77!:0&UC;M:7^U#YIZ6.BPL_D2RPA\A\P0: >L,Q. IU?8>3
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M,(1XFVK M'1KZ\BWAJ'5*<09NX4\._^IQ>)F5(#OGGU6:<;)'RE?GT$X?\%
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M@JYZ$VW&+JJ.Z7\;$5-NUUY_'1D+N6V7__<,M0O<8&K0T D\.$<5?&28D+]
M10\HC+3KP5 1\@,5Z!)/?XLHSI6I2X.:^?=M#XYWWXQ40^H-U!J%>5M!72Z@
M=F+W?D;X;4/2\<#E=/(3"KH/.JM!VPN&452DA+Y@O$^/5%>&+B=[=-@BFYNO
M-2ED,=_&::CL^?=%<O6_HPE=,$07?C:71>"68978AKQA^'ZPYG[!,E&ZW9<I
M9@<^8PI:US4]<AK7:U</NQOTS0.WTA]X%VM=]T'3K]34(UW3)KP6$O7H)6\&
M6<%?0*L&]/11-H7UJ@Q9RM%/'YCDZ;6-,\@2I^9^0=\F%$8?6"5:O'.PN]!Y
M<GU/=\5LQ<8""P]>IY%B4, ==#)'JQ)[:PI[O<2!?7!Z'A,$0X9FFY-/5("9
MEP/-FLD'6Y 6QWWL#QD>.J3M&>,9);4-V7666PI7Y[TCOJU.[3R&U?0P99ZH
MS[GZY*77TA5>4$/L?-EK=_^,^;,O!$:%VF3E8>;/'G6_E$"0IUA#^)F_M'$W
M5C$2N']Y2A^NQW&L 3PM?G66H7<U/@D+D>A[-ZJAD'/Z&WG(RK7G7\C-BU9\
M.QO&@]J#*TSZPB.$&OX&XQ:2G#VHIC]F0 S0EQSKNV>>\FNWP3:DWM2H- "M
M4"8Y_63%QSGX J5I)MBZ1UKF>7<%"U]/9-BR77BSJ'JIAWH\->S=#D"KQU"&
MC#G=<\^W&R\#!MKZH7F]\A.3)7B#5Z_(GIY#P[ ;NZ,;7B;";V;,O!78,K;&
M%K$M0146DUN$OQ9TB9K.>/(:DTM%][<%#KLX?FX/*@BTP"K^/C+PJ36XSL3=
M^2,K46. ^:+2W.3JS7_V))7"L+O89_'=UG@_50V>B!A%PK<;*H<-\V'2J>^9
M8MC ^WBY+RK/#P%4!>6WG1!*;\BK+S\MG4^9W+EZ/)8^W?4 -S&5L(1JO/03
M#S@Y0EE2[>")UU9AU7&MZ<DK[?[P,C3+C5[?5M=X'T.Q\;>?PQQ=C\1HAU<\
M:L:^H-KPHVTQ!P;PP5()*P^>9I\$V_H;6TO3X(>AB9W'@'-;PDFA+TX9O 0&
M)9LT<[ U%4J5^7,"<%?[F-F9"C1K"QP)8YOCNR_H(?R258795_ "N#Z4#,Q:
M\L43WG.6"]GQ77P:+F3/U1-^@IO*29QU\ 53BO6<^PQQC1B' "YTG&85,LU3
M8,Z1Y:#9;YIMO.&WA_5(:=?E)I99MH*96>!>!UGAV=Y9!Q$WJ9GQ<V-KV,T%
MX (7R7K6P9]Y*N[]-F1'IS1N"J</2,5V'@J Z\4/Y-C$*^3OFNC,+:ZDN%[U
MN/7LUF-T^MUPZ;@-C<L9@D["7S9=^A8'\2J=TKP9E SB6H<NZR'39RW^%V)F
MDW,*L$UL4-)'-U2+S'67GXCM?]G<&GTA3+RXU^363Y\,MV Y(Z>'\,#/\..X
M+T01(B6&'VL1E%=(MC.8WK<-490]#WPJ,GM!$XM%2RUE*6YU5#ZL::FS5M+?
M]?G9ZFFQ]!/V]C(G:K2%EWWDF<(#VY DJ +Q&I0\2$E+O\NL'D#M"44D;B%2
M]-O#2L#,[X=Y8^4_W>5R^CM^/?573E9$UWI:!5%G!3QBN?-?)5 (CBCXC>]W
M%[GE_,_08/6##L :'5?"S!U0CF2:QP3KP4Y3FMMW?FX?/MB9%CJ;ZG^(+6NE
M(-R<I8ZK<O=:LK(2V"):8[7X0R@RUQC1"]+$FZK&U,$!DC1'NQ/,8^I(2-&@
ML28+*[/O*@NC%%CKC)T#(K /"=CL-#/^9X39&ME!2/:4P&JEGZBF;4A?.GAH
M*A%GA%EP \S: "U[9M6C5U<Q^6&3]9:)80X,,]9N4^VAN=N/3P8=57C<?MYG
M]U"QSH,H'TJZ*FA)LWFX#1%Q><"Q#GK]LW1K=1A]>R$TR+2A+VOLY0F6HWB"
M'>7I,<T0]PE@C:-22;F/%.5#W"&>XK("[\#DFF2%?[GQ[%).>].1V<A[#>L"
M.XX?V-^;)?8[]\EP!*%AK1^=!-?A-G>*\GIXN\'85Z#E269U?+L]K5IYF:Q2
M;)'ZJ_092[MP3-] U77V3QU*[XG]7MG=%'):[ >(U*ORZA3$;7S"0@.>(]O&
M,@&'F<:GP6XTK1R98***H,PM)NF35]F]#J_G_+<\XYWRHI.G&:NK):TI[UL^
M8M)LL>+V3/QEL(.]B_<953?DCZ@W3.%$4OF[OPW9D_Z@/:( )+-TWP<'+XZN
MH8-^Y5ZLT9K./W[;S2=N3^.P'.=,2A)%<*7U/7,QC:,*$+OOE?4A$^ '&D=#
M'14&'(8O76R/JIGM27++2_\<JJ1)@=CW8R68CUC%S+5NTJRB$X!@9-.E$A$2
MH95HN@*?*HN&T*;B5[^U &9EA97]6=L0B241$2.WJYXPE[>P[+O"^D8W\[RM
MSRXA*#12O+MO*I&2E6\\9<@Y6>UF_S(0I];2$&\W%:ROWAQI.@??8>"=.!'L
MI)<RE"GD?*=*Z-M%"'RQL%.5V\8[A+W(S6B/H)Y #MPS'S"4P9&V?*/1WDQD
M$DYIN<D\7QWHK)\Z29UHT"Z\&Q%Y(VOYR*XS(^KVXI_?[;R/*^ ^:?<H -=8
M*#"2MB;!N9E..YCW.WKS_0'FU\ FGHP@RZ\7)=\U/?K6]^9^^5LZ5ON3()O*
M_YW\H'6T#-:8R<>3!/1:I8DCT_&^7@:"?$/E:<M^2J.M4,>M) B3 #JK(;8A
M+X5YCM;;D'[G!<F_K\0GW#:LVG3,.'U?+I-(OF%Y^9@FQ0RYX^\;_Y>\_ 8_
MQI$$[=EGL8>F<+LXX8!\?"+G(,U#UK_R1\Z_/H4M"8]['Y_6T-T5%J8^,N%V
MMC8:CIW@TZ<,_C9Q0BBS4H]0RG^;6:82]L"5_$>M;H HVC9$R>-#B>>@6'R<
M6,O+^B0>3\[G]#<OK[.I-1%Q_5%>UA!,&>,@6P1[B%O,.0V,#9A?U6.BHAL(
M,>2\?M*C,%3\5O$];.-G3W<5R]P#RH?E/#X(2#].JBJX//##)D ,.>W2JX!H
M].<V,> 6&"[6@1^8#X#'3:X0SD7IA_JTF0<*#=88UXF\QYN6'LV/?4?K&$J"
M_$'][?AFPR.E\\TZ<5X.C&7J#LX?>0M6T(N950T*+>73'A]*,6F(NMVFCO H
M^"=RX'&J0A95M,5)X]OY[Z1JC@$WOZ%: ,PTE,<LLM+!1TRA[T/3O26VM#^;
M[U[6?#%K3Y9\X>V[;[26TWE[6;=<3_JIY>IFCK9@'T^$UW=U'PAE.W)LN:]#
M":D\B\DP4A)AA@AD^;O3?_HB\2OL6XUUZQ?%]A8G?TA,8FJ1)G[G!W:"&T#2
M%'VQ>TT:NW>\/:@2Q'WHV[(>>%&^=%75K) 15)98^,S;W,E1.<OV>MMUC?+]
M&UYA<@(;7_" (^%A-J$6_1!_TU 14]U/7LT >AQUT/%P[?;Q(,8ODJ2G?X:>
M151_PW!>N^C!.--II8SV_@@W;'_XI1\H4=Z.I7G(E"_3);43@5FD"96R@OQ]
M(V@_0W]<'!+R\76MW/Q@:?G/1^<0W8%U:GB\Z%G"J<(',$&J%!]\J(2>Y84X
M13XQK*,35:V!@%$_G/(L9G)KX'J129;C#9\-_3>4K._6]9'J5YHC[]3*IE)=
M0[<A4(0W*1ZJAE,'7>BN3*T$F#I3L-MH[B25H K"EW97,RJ#3R7G'I?YKL2H
MJOPZG7*C.<[YBG6H*#WL7K^< !UGS$W$J7+<N/G8,/9Q3ACS=S(G[#H3:IM[
MCGFEA29Q=O?:]Z;0F]8Q;MV[&LK3[]YTO6:]D.T3[JL_B#7[3UF;XV 8<ZH;
M5?\OL1[5S\ /7)4 8CH5<Z],<=QV$F:W3N8HT>H[TW3]/K^Y='+?@ZZW)JEM
M)&/T-=PS_I<C:88KUE12(K11^!$^2(SO##R+MTSAAR;)#$.KS_6+HP-9C1&=
MMK,',@[61!*&S3[7>)M].[PNM^]R!.IM=?0F*?&J#I@(%-&AZ9W07CKC0AA"
M#0SI;BTI-E-F_'[ZN&-F@W$K?XAF5Y2JF3/@X0^]T8(^(EQ]A__7AJQD;C1?
M"%ICBJ@1":MP?7"LYP@'.D69;%<LQIRL?\=0[XB;#[R9:=U:D_=%+/)K\H<O
MLH&^P6LY9<FL_< FOO$=M\V#GIVVT \%8M)%5*4)9WGO+:S:V;XSG)IKATB$
MC3^=$2_2L\/G=6?]7DH=Y+[%>U?'$QHC'L',J?A]F-Y^-95.P#?U-M:-"I7%
M6%Y(FG4:#0NT?G8@W]CDTAG*(&RDUD&E2"]%=''G3=XGU%M4+W(FF1Z1QK,
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M0=M(]D6S1I<C7NX>)MN0F>>'Y2:9;]5WI@ZUU>8U_.+'"\K"WFW(M3D-.G[
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MN#'MBE1"4KX"V,_4HANF\PX&PG?4M#0 8B#[4ET.0DHLH3VQ-#%(/X@W\@_
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M<&A-^WGRV<VFI/ DAB@:HZ2\^_=A&#&)&(0G;T-<^/;T/) ((!%Q^%TP"=_
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M+[8J!LJZ/L6)-$\TP&I=AT')EQSUHH]];<W!, [XVV<4-*5=;DP@?KSQ\*@
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MM-GWG=C!6$+Z'?<T8Q6'\YDNU)V,^L"8ZLE:K=:FI .W"R]\>M?<]U8WKS5
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M:^.3<6:^9.H<VSK<A-V!61_"6_X'5FJNS69!J>SG_R*CS/^IR:@I>Q)&=3(
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ML/*XVO&7N"YRUX>N8&![IQY%PM;^^"<)LX2UEN]P_.2/P7^IUF5,H\TX3>D
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M8N.5FAP4N7A0D6[2AH7J-K,W)I7KII?'AAINI2-"+G?IGR)+WF8[>*N17R:
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M-HC/\CWC!ZNB+&[0Q/5'\2#&ZN@JK%\5;F9/+ #_M@7TCM)+O^KB.HN566U
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MARH$#R(__?24WO02L]M57375IU_7FR6XW_-'G#-X&<E  >CT"1#F381 ]Z>
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M,KZT3?W= _XQ\G(W'0!-OIGL,- UX4=7KL3GQ4[RT8 \F!!@7S.IF\9Z=O/
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MZ[1&U;NLBHBEN2S['OTVW4.04*6'PRDFMH-W^FV^\3E$<&)P \_)TY,"K"-
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M(NF->&!P]+:J<6AO'N6 66_?$;7U]#[RB:=Y7I65N\JW^FA,/\$-W*?,)"(
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MB<=L56/EFVER)8,Z;5NZ>?[' AP%*H,RQQMO*CU=8@0S[U<P\VTOW';45>$
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M>3/>5-RAK,XXKV/N2#W_=^/=K]](%3S D$5$7I7KQIH=VJ7K;G-Z0/B_9[/
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MY2]F[+/ZG!2L)WTI2N](GX$G'<5Z">%!?0J3KJ,0)X<IN)A9=Y'CXP]2@[&
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M^%G3SGO*:/ []=Q,>>UMU[VRL][8H=5!)SPW1$BNAR_RCT+%@E![%MB"^!;
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MWCSG1_Q-B,X#N.Q79=J8W8QG1VD.#=&D*AN#3]?F%97[_'!OB_ZWM]?1)'%
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ML/.QPZ;K[UT'0_0JWA^_'R6G6',%P6O\Q!Q$_(NM([P_!F?7#['?HZDW>SO
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M1';O%B8)>>66Q5IB</BPY+!!9OKA7!M!1-:.$>V ^\D7I*9:"=;7O--=U%3
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MKK=8M>KY'?H)M9M]EF[<$2'DRP<3S*O7!?F7_3PU)'=7/RORU/8H353>X5!
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M8DZNC1;"[^AGKC;"M^\XXV/^G+I&;*MY:XV<3FJM:.X>"ZS\V3:3P]TZW<'
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M>M1#.VX5U%.3<TVG+[TJ,4_=G#BHDU]Z.S1F%FW0;S1JL.5VDQ]TY2M+'QG
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M>,#EJCW&&46,%@WY(:VP6UQ#XDU"U;13R\WL?6=&9D*4( 1'X.U?(O:1WCP
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MTB.DI58^)6A6(\T8BI5*7<6"VO3RR90AP\-1_ET0G9A7$=D3Y3^>7+K<Z&7
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M\NR]UUE[K=_ZK;W6.4<H[V_F\XOIG$,5RLCME^V:2*GYB=?J$\5N?TI/_N7
M,+TV_\JX[&ZTTQ=AIZ;32Z^1WK:)?\Z.'+!495HBX$7)G48V$4."%2N&8 X
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M;<SZCVYOE9ZF5V,.<0<?M2YL@63.1'D_??>C>D0Q%D"0XLI =YREG,VG.)+
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M-/@]?/5<L"(;0FJNSF1)KM'!A7J. R WB-SUM:XHXVW]1ED]G&*.#0'UPKB
MFH9OQY@"CT5>N$F>6*\[%-A>[Z,P$DV2/KQQ>5KIMO^>O>*KB+_8Q(#79^3\
MO2_EBADNRV^$?OY-I3V_:3T@2#CI/UW)?V&/F72='P]#@9?66V]P_&UW(H1U
MFIW\_AD&\()Z-VCZ3>Y?[XR R,#]V>H?H0MINI2J6 ,]?Q)"$&--31U!UG\<
MEZL82*P)A]J_,G(KB1R_# OXK@YX#RV!@XRXR7B6I/G;S5?1\YDG(J1LGPA9
M)YA_XYR%_W)!W'<6CP#]D.O@G2]\T_CH7<]D7+>>9YRJ&:4;W[[[Z+;7\+VO
MRHN\A26@\G9\9]7*@GAMH5]<<-Z]C),, ZX11MI8(>E@.M<46X+]Y@&C-"'+
M<$P. P1H/A)7P%L;7>M0_H;[<^M4/'BQ0' 7?'4K%<Z2] !!Z+$+J'9QYA_8
M>1XREJ$[.@>&EJ&27WJ<VD$+C2 ZPS:WH/%LR([#;T#P*L?^.I/[D$(FW?P0
MN#]@H*G';X3.8'\7"?[;1!6+OW1L?8/_;??V4V>5/XQQ<&AIF@TYA@!#*JEU
M"+YQ&/?;/ &S0EA7)_CW32P 7G70 ,?:XT[S8D.>RT>!TTR[XQFI)K_/4_MS
M@YCDMQ]M%U@GT7/@&#SCO)A8/1#EUZ+.T%ND@>Z2<8\*2KE#;CSH$G03I.<^
M%PK7LDMAH)<WI1.=8)L*<"%P'-E^*-\%^THGDJ&780,$F@%ET\(5I15Q$R-.
M*8W6.S/"SW7+O?#3Y51I?OG%S&"HV-+&JHE$Y5$J/5_E@__\MT&QU7\%]_K/
M""K^A(?8J41XV3H.8^%/9D-V8XR!)#GF:IAY4@6UO++G:3U,Y5R!\3W([8)M
M09I&[B8\X4V=*8FZ+1NRQ+V&WH#-CY=-,O%U@HR3O88'T,ZMQ)UJZJON+[W=
M=^1/QZ3&^-W>WAQ?M:-F57OUII#UW^USNI=\)S<X)K!#6?A-GL)+UB#</Y*:
M8P: :>7SE*XJ2O9\_08-I$6M_VS/X*82;,V<-9][ 53Q1>+7:-_@KDJ0,RG^
MJZSL[[0'7/AG'53\64%%BUA>AX=0O$M&-./6/_<0$#3CQ?_6Q.%_THSUTN*/
MVM6S_ZJ/<O^/B?R/B?R'F0A!AIG/AGBLC'RG'>N1K09>DM])6'D<"#)N:](W
M>E*5$CM>8V#0N/U2BNY)P1S7+<U94Z]+"J>2EODH"-HCRAH;$F.X#7.ZEV&9
MZQI0Z)J2.)%HN%I9>_EZ\C(^M/*B&5DE\HEJ1<C58ST]!?ET$]'.R>=2B<)=
M:"S9+]+ >IKI1UJ/%/LZ1VD/.QKP566/AUI.K%/<QRK_FJ0X)\24V0MYYO7!
MX&+Z28S(1Y;> KS,.)_*VZHNM9@BNUF71(JO+3GP,KSRG=YHMB7G#8%F3Z4Q
M[W*R_X'QA 7LTW7.LHR:3MHSYBLVQ$E]>/%$*55T69%ZSX)249<O&Y73<B?A
M@Y?O;)ZKK>Y>D\0>CO-?A0H\[9MO.!<"""J*E-2&BDQ!MN#OI>OU8<Q(M6Z3
M7;UK:?L7G,)('$JWFUY8\1?E\A=EFV[=:=&;EY__NLYZ<#1HRN>BY94"A@=@
M#6\>,11P96E4UE&-RLW47F0L/%B_X-KS]FGL5T;B-9<2CN$^(>A#-82PDL;3
M]AT%T7/:ZE$3DA]9!USQ?-J#@>;,NXV!:5RN7K/(\CTZ@C)WDW<F6$1N>U1V
M@"14K:\O[GX;-,]',*.3K'SLN-"76_ O2<R>LX21P1\U\H/_YBK\W]!_])A$
M>%!QN4YR?J=\N-HGM2@WSD*U/?[*'\ \_,\-:$:_6+<+YS_;Z#:<$7+HGVUT
M*XY6^)^1?^\CW2I?DE6M+/9_T:&DD;DJ;U]^-87)39EW*ZD&>>>1[LW5QVS(
M<>TT%,F\)_3[LI E,C9THXT-V>8"(.B.#$X@%N3T8_=H?I2X-/!?G$ ;2<M!
M&,@D\<7@E"_VJA;?>)V@:H)P;"X@NCRJX92+<BS_"A7MA5$0^%$<S8295\,Q
MC<<AR[2&:-[NAFH>)\GJD=II!C9?] W+I/&NKK+6(L"&9---'A6Q@4]Z.TRO
MUDPN)U).TB;[,X"*8@9WOX$$&2$ 3#94T@31HG8I7WII?.W/$W3>5KV-E;7H
M5<[8(ZTAT7[R<\YEZ2::-O,1QIQB0H:W$$:5R>/KD3-48FML0"L;TAQ@?9_T
MQ%7_EH@5_F9E57@.GUQS^)D$\R.R3F9R\.IS>FL%_9D&6RZX)WMX$G<D.)@3
M$CY!-9@A1!<!41*"L6NH"5^1U-Q*=ZBFBK#HS>MW)]U,/P]J%SM>2%XNZIG9
M=Q%_F,_7:=_^Z+WO+\E<UT4O,Z!3.$ )NK1(ANW"V% &J\DK.X&3;>L3.D,^
M3*L#$?;&+JNFY,H8U2=5T;J#$Q.:W_>0ME69]FH&."]9T-48BD-LB&,R\2IT
M%$6ZBR,7HNX'J];VX$VHTNE)@O8V<N^K](V^985$6+]\7=7$'[K_3/*X!$<J
M <RP]K A-ZIA8Z(DYS9L.+',I$F*K[&.OT\[DZPJ,G;,-*>V_Z:[?)]GYJD'
MF=K5QX]P.5F=5!C[XP_;PO"(_01--P9=SBD%4XOY<=B2214)IU0WB']]23\&
M5"^)B(JDBXF\K7J@+7;)L:Q/-<4]<MOD@TPN$S\9B<H#2QONN*UL2)@Y@Z^_
MCA\#H:(>?*8TLZ1Z67(8&RIW;(TJZ4B,(^>\[5'&(DW9Z7XH[>[!4X^?W3:H
M?*UP3.D8:KF)@F7Q[J/&@&$'!"SG%N"0%V7EU,Y))-J/?""W4'E1/T,7[3"K
MLMQ14<-?L+#C&T%AQ]22$?(\,UF%>&OVHV^Q.:UM,%@*ZX% Q\_;HII<4':(
MBHK+#=_E$E95>L]^TXRPO'\Q^BCQT!WT..E^\"9F\&W=VUO% !MRAE\=4(0M
M2Y"[1S1I4D ,=8[$C/X$X$Q[SD\V66H=;Z.EC3=;6=UX0:I__3HJ.GT/OQ]A
M'S-I#D@&,QIRC^$N%L@H8#42I,)4>'3 XL+;W#@?@=.? S]3$UN*JN(V4S^I
MH5*6&FYOZWU&TS>!)<@H7>AC>(';[,3,)U[]8$YS8Y8&[YOGFXZ]^XY8;H"8
M.GKX\I*'^M4ZNA7>>ZNH0&W-TXB!Y#VQRQ(A%P_*P&V8:7!7Y*@,V;F1B:5E
MO:88)K_ *%,%J2IW#?G["6HS5.DW4D6#@T.[^&+0A@U;3Y!=:\+=$[K.B7F)
MJ6<KGHOE/FN!4MX8":S<F%S[R NC6#$]%TG$I31W^JGYA#UKN/#)G9A#9 NE
M8[?/:ML%'LF+6JRT4^Y\?7E'H:+4XL*7C286K_D4O1MG"*&@ED(SZONN8$R
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MB@RR(19]5ROJ*IXZC?/WM.;-WZX]N07.V\N&1,PQXT'#KW6!KV^P(4 *9"U
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M,UWY&;C- &L(_W)R&<S1MJ*!GBG"/;PX0WVZ%NU6)]VSZB'3)%YN[9=I]WK
MX\9+P:P;;YPO9\=+H1-TLT<O<SV'$M@05\1H[O1<PP4R<A=#CQE;@1('K!O$
M7>NHAD4&"%3.^+AQ:4S48[.*E,/B]]IXMJXD3!R^?=W$S_K2FOH]K$@-'_4[
M"1;.TF4<'&!-DKKWH(.[;3^BSMSD'_0[E]6C=Z$C(>[-A78][GB'(W0D1IQ9
MQCH8W)($XV%M93A30%)@@,P#%)<,S'P+71"^7GD=M+R$)O>[:B)']<V@?^#=
M @-+(XR\1"ZD(8 #B&;B/;PH<2J=#>%B8.F&:*6Y)@>^:L _YR1I<L=$]^?.
M[+&&+?6JMH@--\=#0M^QLSGC8"9Z3 1^"S:FU$<SI<HW@.S  :,X:'#:4 UC
MUU?#LZTKT< EY535[4^GU3Y/=K;&>,[D-8P6>3_BO,0L_/$RBUC8=@,C#THG
M#<G$^:X\G-#TD*?;7>R]96#AF&'C:B4@TR+T>&*B%''8?W_RO@CMNZC]5BC5
M"UXT=4% IS%8]4WOBH$EJ?/H"?O=%^Q-3 ,[?1^-C!?=.576%O^M?9>-T,$9
M;L.*+H8?T#?5/?*]W@^V$YS8*]#/X.5EEY0#B;SO\MQ'[X>'5^+=[N,T7"5+
MSYE>E)BY:]HS?DP7-0RCS0/^]" ,%WY:YSY&OAAM=Z['P A+ZI8 X,V4(C^6
MQ.#2,]7QV-;>BZ\\C?FABOL3A&:MFPSW8QMN&-A0G)NE)8 D:BJ-CSH4:0A!
M5S<_33D<0WV[Z%#ZR-AS9J?-I/V"0NN7C@[GFXHJ6;K6)WJ4]5N#\"R>!;JB
M._;5>H.]?[!LQ<,Z/2!U>MRQ;7*7J,4=FI>[?E&CF<=5V2V4L>92V\)'_&&3
M_KQ(EVFX)X'#%62AE=79H#,;8HYLN0+8-C5OJA&IU9<><G*EY5ZV/YYO,]_1
M5+P\0[$[]-!;X'F"]>C-RMV0(+O?/@0 6]:CFX/FA O>"CRFQ3.?&R!%(DEP
MOLO,W(M$'[4VE5VZF48;64_-Q&1..=B,'UNTGPT.P#:T<6AUC_1-P>,82#%4
M9)THLZA&H(!AK0;W@D7VDGT2YY9G-GKM[J7K:)SCS@%26;PZ] L8 ^"0_+(U
M59/%DT8>5R<E%H<,^%IZ3)M+X(47 JS&EP.],PJV(M7@$V9;_>Y8B$=T>%I9
M+KYM6S8O!-@04N0]0UE6*U[@&E#H.OU!G6Y]8B"B1JM86A5^PV/NTX261OF9
M"3>E8Z4U18UG,HK.:]A2<Y=SZ>)H=[)(-D6F#5^.#%/%F'ED7IGX$BS>K_UZ
M*[E7&57^R3,6]Z%R>*,;IK+_2,>2'B$>/C6.X&=<CV%M3YT:0W&Z#:9+O.Y?
MPPLZ8 Q26P(D1Q^*Z)]Y._#^Z6>[RU\]LA+%^!\^/_.'Z4,>A^W<@T000#PR
M6(/I4*K<-'KW>4I2M '?M 21%[W>J%].M5"++[23/:^OTK-;JEE=B/)!J#.$
MVI$5[M%>3:R(;,N#W\2-Q)"AR\I^4V.3@@U3,&XWP[VO>[06+AVHB>L=GT,/
MI.Z[DQ=\2Y+_#\FKC 40J:+M<!R+R'+1I36J7E<F%=5(%)/MKU-&UXG ;E*-
M!@MS;1U&W$2HV[9TJ9=JEV_I5I\)2N4R,Q>36%S9!:".49,BM:';T023JGZM
M6JL.NZ.G&[_NI5X9ZPB7C>JG='2TF!X]KL4QH[^^'.MUC2X/R-"B*=WUA-WN
M$_N F,R%"V@34DZ:W-LOUM;K@UAW._D49].]@LUE!GWMBY)>8QV?II2]X"\)
M#*% >^9SH@M6-+B56.Z\5$O B /5)'5H UD=,-*VOSMD53&PJICS3=3R55U%
ML_?^#P]FSA=8#JO+ZB*RM,5JY*:( I6%A1]R76V-PV_T'?W0*2NR&51CF=9E
M4_IRO[&$?$@!]#A2)[@3STLPU T>GE &X3P5P!N][E-9PW*,HG>3M,/'JT]Z
MJT=DU 1NK)D_&.:*)7B.2RL\XS)W=Q%KK.F6O"I]CXYFC2+YL%?51R*;\>55
M+7;5?O=,JBZO!DG;K54EV?3?O/IT\.!+?K]W^R"/BE]ROCF?YS[L/D4 =#.G
MN.MQ$M@&+98LQH.:U(#8_H6E26E-SFXA$47=@B4J7@]H/?%P>J\Q9F_@=)EC
MQ\;VCAVT->WUXI^/9KER#V2+I'JIQ;IN:R'7?^[E*XR(4)2#+%O'6W8HZFX+
M>PF9<W?D"E#@G,$/K[!X7:?AHS*T2:"0SH5Q8::JUHFA.TEWT]SS-G0,=5@]
MJ)W#5XXH(1>^J)!VC8;.HN*3;<3)6@H2:(M)"=88LER5#5GV)Q-&K&DNS"<^
M<)C)% 'J.HJ+QMCX4X_0E8;,W]9^%Y<Z?$,?\U[MO>4&7?"U8.?N-R>5%#>J
M63L.4PZ_H>MB]E!6&"+.-/_!Y558#+&L-?\FOZBWG=A>JDAD/O+D-</'Z.B.
M&Y'OJW>I?WC"Y5%M>VQQ';:423<$ FEN@'HN ][KFUKL?/YMBKUU2[!"?V+P
M"%GJ^D+-V ?C*8+TC5<))W!/M7C$MYGV'.-^A]S&ADP1L!7$91X*)QFQO),2
MP^*INE;DBN>KN5 ,8!UZ]P,?Q+_H^*6<N^"CZNBA(ILI\*2ST/"@J"ZW-<T;
MM(CBX$%\.7$IZ'GP.$P .Y6\;KL2NK9L2&8)R#?!A3U*:DX,4JZ8;\U1%EM:
MGDXY=NU1D;G7&\J6L/?;_(D,P4[6&3@MAPTI2P 2&1F$,VS(/8_M,,HI5$@6
M?B/T"W837?<<FD.\@1MMFTI:KJ5P'F-F8YV[=]7EDO""C9\YO3ROO2E/UW'Y
M7/$ZZDVT2Y:5R<ETZ[VO'K6E?23>*K1'L7@%"*SZ-I+QRVU=X922SM:V5HUN
MV'#)]3?$IQ\\+G%WP7S."S9/;=SA%WA>U8FG>-:VE)11NFEX*OY>FEV#.+B=
M2=.%; C$''K0(KML-#QAB^XW<^7P-C$K0AV)@KJ_S'#TIO)"=]CD5/OG',^U
M=UOT)+H\[163>ZK -WU V__SU5J.>%P 9 -&^_$NBB+,16:*=0M,N$8/Q)DU
MZDHLBQ\#[Y<OIZZT2,DTB_M6CP8]/2G,H 5<Z::E+@;:"/?:$'VJ,YZ4S#Q\
MASR!GJ.E440CX,[*R%%DH_[=W&D!&9O>(G4#^5RT4[^Y/YF+>$CUX>%W^XP$
M-!&" C+[]U[_IK&_#'H87#K\Q[=_]["$W&$4!#&L%Z2B/$DMW3OL7?6+.TZ)
MJ_.A[RP=K7Q1]"FTD;7P.6Y4\_L5>XV\#9ETTUHB*;<)O@TC!2!)Q/LL@;ZG
M8R<HP9&NV2Z/NAIB:XN+^+:>]/KZ\KG8YD?N#Y-E*(906YN#/K-8E";#+&%#
M'+&"C%U :!':#2N(E@9!1.CR8HI?E,K>VU5\ K/)PTF'//DI@J97*I<\QM<2
M,864SGHK?*7.\D!6\"07!,--(3;:XB."!1UV=C]06Q.[II]3);;B/#O:X'Z+
M*0]S3?;>W2"+O_1S $;N"^X!,^(+N ?$5]W+LY1<VC'@)?W@ LU0!&@KLL@!
MX.0^@%'RAUJF\;6;7CREDP(SSZ)D(KW,I'WX%+><P#L,W<<VF+(AUQ"1>(HE
M<@363"RSCOLZ=K:Z.A;%D".;<M"-0XOM9I=62%=/*LM0&DQ5)=J3)=X]YV*-
M$"NY<41GJ"A#&["C.$]YX)OQ8HPS5('6M&S OL9!*[EXV6,YA3QWWL_=-6GI
MD5)!QTR^5?I62YF.0H<?'ZYO.(MUGQ0,'A.?6X)>HW.BG5F[\5!@RV2K:.\[
M:FD,9Z[%'=5'LL1A^L.Z:[.G.>+\[I9@60+?J%@<T9TX3&PB4L[C1T^VP"D)
M& 00E547:IA#RU!8'9<WK4UO/6+GL_4^_13M._**;EOJT7=[>/@5G@2+8CNZ
MP'W!+O6L8IE'BR'N/S[^2K&"CTG0BH!"*FHJ-XPXE6)EBX@*YET<'#5YN$H4
M9#A'<+O.V3CLOO4NI\9;)DMNH'.OTKSWO;8WK!8\Y1R2(WB()4LE- I<( T]
MJ)-BG ><@P0(.)8XNO8:_6[JG&)@8-[-T F):K,G(G'H9Q%[9-5FQ[\3&+M2
M6>?!U;?QLB&OPJ<FF9H6YX"SG_N0(#)D,FQ\*1L#RS[JPX-=36TKJ Z3 G.R
M7'JOXLM>1Y>>MW-X%:\62) 9W3YXQ(KXRN\A:P?:\#OH^V0$8,>&"*LP=J/\
ML[O%3;+,C]9\C\FONC.?CY(1OB*5-P=7L,JF6P</(L59@NB421)NJ9HNZ3XI
MQKBJ%5KDMFD?&;7D<T15J2$K0<'!?>SS]CX+64V5<\8E'V9,NQPO\4]TDJ%<
M *(E*>7L"S)JA\UD]PLW[*B^5M7=Q7VOJK_=#$%(F[R33S1X]]H[:H]?"6JZ
MNY7(S>H.YL2WC=*2O?.0XPBIB% 2\X!<T,EF\2>I==VYHR]D,"5^5U_RB//(
MQB?HSOA"IN%7L6.1I+EE<&^@+%%D*$:Y&.VY;C&T4G.4S(9L1R=\,LI#^]F^
M>F3B>^VV4.+$_<(M4*4OIN=/Q\"%L1[JX40P<W5'AN-?/DFZN\[2!-*UW?-\
M %2_>8[KH(CFE=J9ER%FUO&[A+B=R+T'Y3MNZL$I"-C(!3OF$Q;WETJ\H-JM
M7.I0,US*7?HH@%-[.ELL>F7 4Z"98I? X7(5H30B&6+OT?0H.QK'P<RN@V"V
M \@?'S-F/C8\@-$"%$FP'<#C5GGR*98:E2N<5&UGONQYJ>?JS81OZ$P;M<MB
MDA'QS\*6 E,@],&_\;7Y4!5F(=81%8JL1-[W(? S;GY<,9J+U'ZPAN5!IQ[O
MSRX=8!S-:UM76RHA[2,]\I%YXM54N$-Y#@RJ%*-JJ!3C&L5D^=I-N@U0UCPI
M6B>&/*X3PC"A!C:-GJW(L:U/]_1P[EM=]-#INO*^Z[%_H1=_08*)PKY[S"8C
M"#J]FGX I,]D^= 2AC851BNAIL5V/RA*5Q=OF=KNH54M8):U38ZN86_D[YN3
M:52I8F<O$UOGQ(;HI5NM3H;C^5@P$!,]GC-@P 62G3VTR6%/[]4^+57I=Z;1
MO8-".]O$9Q)N%^C))OC+)EB@>HYMP[31[;$-APR.@EGJG8\L0W=8):(-N\6M
M3JQ7KH\!=Z0,M=Y-N9D=]H%5YS)0E(75/R?L<&+FR;E[?"U!>J"\54L-=!&0
MVKY:#ZL!$S[H*(+<%N>+%SXM/MTZN:O&6OIEX<C^D[,G!<IQ6UHD+37-E8RO
MW_Q^(/[9P5O6(2 $;;] @G*[ZDS *&T,H4E:?6GI@"]?X;)5;].T0.W;B2N?
MVGNO6,@872VZ$3\2H[OOG5X[N6X^(T399=0PF;2\?^A8CTIF9=G+2O- <Y<(
M$87X$QD<\Q!(D-*'7S*GRS AE@A&#YBDS-D"1E3OAJ?2^RC=#\HW5'QK12^&
MF&\;KWZHH8%_OS-L^U;!8]I$(PCF.)7 VHZ@P*:[ZS7IRL Z+1L8"J*,?CB)
M=F_0QSU87>RTW^5"1A>G*R<OB;,LM]3MTBO).E&P\]X^I:#'4^M+%?3C *I>
MW#D\^$!P_UVK@,A(K7DM//\D8Q]%@!CI4;PZG,DS:^$8I);MKES9_D!9TGT[
M[I;RKIITY]J>8]*^=#W6>Y#X.-G+.%11SHRF9Q<"U<T:BW4:5,0#]6VMV25?
MSN\W'A+=I93!;R+IE64IZV4DZ1;?&GW((<9(B /TVRKU)4L28:R3)$=L0$HP
M/('(J0\B1QT$3M!9PA-E'HZ',SY6 B]>^R_G3O*VBR!4MO&W9U=Y;'F#&"ED
M\91EL[HF156##[KC*PG+VZC&<XC2UU6]JZAH-F3GA8M]M[*?*6E_NFWBL9U^
M[*'9KO:6RJQO(8:W<%GSSZ'[F55@=,9SL2;@95\)="W,:2"6W U%HY N\$K$
M??E7$9\7]J<K]FK*#131A<QV23ZWTMW[QR[EOII#66[B.T+=,[_4*1 'OZJ2
M>=0*\]L\DT3EZ> ?T7NQGV)-I)28O[5K<)#@E'.$82BIFR&41,/6,)_5:3+.
M4TON32U;?>:I&#_2D'3W\$K^QNXV+UYSN0]97X4/1.MLT4A6TO&4M,Y%VY$F
MJDFX\*>3 I/3W%$5$F-V'.ZPF#6%55K_<&AX8IBM:IDIE][!J].RNQ_;@ZM]
M2UKJ!DE6*D5T*95B31:MQ]W'5OBU;NTUE%L4CR,0[-VL-^5:/HG';F;8C]MU
M^+R8K8F^MS?"2/95P<OQ*\0F.+ ?WH0(AY=E)RV%DY!C.%I4),DW\>&@V50U
M5G3!ZG9MUJN:,KN*#SG) L-QQ@D6#<Y;"U_-<0O3BH4XVC%; 1Y*( T)''_.
MV ILFY* \:-/-AT^,634HS6+4ILXVO+LZ76;\;3D"1.5KTOOF\MV!6R"D!;C
M2P3V?P[/9UR@8ENE9%B\"+K5O'Y;G/:]?'0(X$WV2'QROEU(UK+ )!?RTFC/
MSC;8*2.(7W<1YC)(\;!H&+EM"<&]I QO0T2-PB)W) M'E)&#=C>7LB&HQ4</
M4W&5#I_L.C]7])69W6X0ZK!OV"?UB#X ZHI0#P?D#$,IFN3(2$-9-WR5]?*^
M:3J2KZ-W(7T'$$E5.S(ND/U->D^ZN6GQ_EU[JE8>[JZ0/75;(P97D/=+DVX+
M$$52-6\+YNW'R&2AZ3:4VM87MZY9!#8UCBU7)G^A!A6(90@\?%CN\7#FZE1L
M@0)G YB#I&,I/Y[/@E$LL"%6Q#+U!E2TP^&A&JF<<81A5"ZZZVLKJ;S)H!>A
MT2)7D;7CTFSBIRB^J9=CY9)6HI'$J>0Z <K0\E@QMN%D$=P5%VTQ78QML@3\
MSI>ES!E[J)8_FS%S++/#+KTO*(HOC(1^GJF\\O464QE$C\"I;D!F,C)8G'$#
MB*5.DZJ6YZALR#$JK"7HNA2BS5K?LY@TE7+_8Z;)=MY-37]E2<_VC*.OK_CN
M%5\C#B_2>)EI($L<5V]VG!J,+[1?G- :,,Z=QDN@"VU3+PPR3-"<VU*^?;UN
M0XNXFO?"T>+]I>-.\B/SS[?476,68Z>>24LS2X*/S+,AY=+%=">,/T6MF+0L
M;J%S_"7@,6UNH=&-B#LOT!Q?:&-*MJG,2S@Q\RJ#P+MEJ*__''=\<#OQ%5<L
M708(M.LE 2M4';)Q+N&+F6\0&1O-4F8-]3_5)5\FE\=9"IE+U6!K?&//8;YW
M-"<PS@%]])UH[VF_93AECE8\4*<#+)H,&8JH91DH9LWCLF./<KWP?+J>?@?A
MJ/)J(]XX,]GPA$8J5'OYR7_^5_S^C3]N]LC_ U!+ P04    " !E@5E5? ME
MA8AY  #;L@  %0   &)I:6(M,C R,C Y,S!?9S$W+FIP9^R\"3B4[]\W?$EV
MFNQ;F;)$"25+V285DDJ4?9E*ML9224;&#+(OB4(44R1*=H.0L5.2D+V,&23[
MC#*NS/9>_9_G?=__\KN/]W[>]WZ.^WF/Y[X<YQRN[3R_G_-[?C_?S_>Z#,X8
M9QK8><;<TAS@VL8%7(9^ ,XJL,/T6N!53\ 3@#8NSB1P$MC&]6?[\[GMS[:=
M^\\GS_;MW-MY>7AY_];X!/BAQL?+RR_$+R#X9X-^$Q82%/ZS\Z>3_W;K-AYN
M;AY!/EX^P?_AC=,"B/)O>[3M+C>7(K!-E(M;E(O3 < A&WG^9AX7\-\WKFW<
MVWEX^2 SA* +"#LA\[FY(:-Y((NAL^'0>6"[*(_8WL.FO.(V5_@4;TIH1Z8]
MYU<Z4=DJ:3M 53YR]5:4@*"4M(RLG,H^5;7]!W1T]?2/'C,X><K,W.*TY9F+
ME^SL'1R=G#VN>7IY^_A>#[H=?"<$'7KW7G1,;%Q\0F+ZPT<9F5F/LW/R"UX4
MOBPJ?O6ZJKJ&4%M7_[:AK;VCLZN[Y_V'P:$OPR.C8^,39,K,[-SW^1\+B[3U
MG[\VZ)O@[ZT_N+@ ;J[_<_M+7*(0KFU_?,#W!Q?7MI _%XANY]E[F%?,U(;O
MRDUQ1>U(?HD3:<\K6P64CMA2):_>&A"44M8AJ]#^0/L;LG\?L*C_5\C^+V#_
M-ZX)0)B;"W(>MRB  %C,_$0UX/_/K3R'./V:5,<!XG'3V8@J;!$#J=K2@PDF
MK\'<)TPI\C),.]:3D( ZA\/.[<JFI5Y.<4^T>7D>%!^3?]L]2/B]Q 'XK#G
M!Q'L8=SH?"QQ8^]0,?<4Y@KC%*[U=),*V<VB4XH#4,^7"RQ9%SE9WF@P3Z!]
M-I[[WJDQ=[QJ0;3@]%A;B4'4:5G)7WS11A<+P)FVN\@4C/$1RZ(EN=O2(]H&
MDEZQCB.G5*SW9%QI74#BX=2+:XEXJA-BG)ON]H2>/D3T28TRZ,N*)2Q)#.MP
M !',@>';3O0I2Q9^^_JYH#*D<L7)D!#_F\HFSK)B4KS'M4L7$/+!L&12A6HG
M<7S-:0CGPP%D0885^(1V9HB\V6$LWY5UX6N*>=@WDW5T<-CQ-+6*3-GE5A^-
M-I<:[1ZCBI[[@$E_?O-.<,Z7<18#08\:6,!5324PKJ"7VA'"&\CQ3YN=!J2X
M)A.Z_6!WD!3!WZO$]T;ME-_!SH$<>^]'!WKB:0D[3!JH\ZU9@UCN28P@C:\S
M57;II08?0W.I2W^+E%;V+>6)2*_;A+*A)O]\7\J%>SVMWR,.FQS&?L%*@Z&,
M(^@A>C882F:D*HRA-7N=,]?.4S=6FFZ=T\O0Z)#^G*"Y>Z?.1>=^^5OG?SQ6
M\XBXPP&\^I-OL <0U>41.!]Y'*SV(?Q^DV0A.M9X_^JI/J^ZVC37^+.1#A_W
M?U_Y1@A*GO:6_+W  ;9_ H.+0"6V" F,?.6(SD*^DV;O /&P<4+X+52]?R;)
M@29\YHJ3XV^_F>]I<=J(CQUY/J %!98*KR0RQ1WHQJSB4C8"S+(GCJRR94%<
M9[-L0WWRCVHTSM'*BLM3)*^OHM=_]\<=66JG!BT#SMY?4%(!L,]LD$\4 -8+
M(@HQJ4^/9#TONM>"4)BC$MN1B0UQ[21@DBE#4XVYW1BN.7,^%EYS71\WT5!8
MLSEZQ.I0VM6<_1I2<#6>.[[\#&ZVP&]*X"2L$U&5&AO  0*MXVS0*$I&^80?
MTR*0IR\Y :.8=RJ*(76D?_LYHVW[W94?1*=].RX(/./#!((<@'$"C9SAR6I=
M&Q^E7ZFA?5T@]Z^DBJ+D1E-&3U8-#EI.R#N>#$^?6U5YW'Y[S&Z;;ETO?&H/
MXA!3#5H0W=AAN!P'\$8FX&I([:F@JDALX3.F&LW\[7/P=1LBF5K(Z'^AAAJM
MO>^FJY2Q+?U]MB1>1N@I]Q8?,@-./0/_;898*>$ GB64479Z(L#:S<IBZYDR
MK+!]\!T<P&<2N:,Y5;H#MFU!03G5,OW'^1&K<&_)SQ$]DJ=BMC>&^+M-!D4^
M=0A&9A)Y=#G W]PA5D(_R7KC]\<=EXC-R%@YK03,X9LW90>\J5-O#M[>J+S?
M[S7F51?U7=KED:)WSC:W;[NZW9_/I/#1<\ !#L"33AM=KM1:>463;N< 0F06
MOJ9<4B^)'+KL5[:\(9_KS!Y0(KRU<J.U27W]\''RN_?I+[US@2D1)EOY1$7$
MU?(4(M6V?&*&+;# MZ(['6Y(?S!JHH2RS[F'.43;AZ=H<7>3ERY5U><,?IK:
M^K!TJ18UH^X"J^V_>;U:UA/?(WJ@,_4ZZR7.#S<9Y@:N,'38/2$XWB9O<BFN
M&R=2SO2FE;03A8-SA5%"&D_M!TS2/'#%)#.4A'K(C;Z#GS^.\BHGG^I]^Q7
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M:M%?XF146V%2KM>)U"AT%5($C5^1,QY.J_DR$R4[&Z'QT:::8AA_?X-GQZI
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MMM35#ZY.O\WY,3YUJF]7HGVHO8]K_26U"U#=505;\83@&[(J,+XT\W[+ ;8
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MN+:G:,ONXWKZBYT_*S^=NP3=D<?DIZ:N['W.E/U#3\P#U.'<VD+I#BT8NL#
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M$32(V&I]KC6=G_54)_S,S.ESAIU!24Y3HD8<0#2X=-U?)41OLN+MT?<MW,;
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MCVE6&3)Y<Q&,(B_R#5]_R5<4<BOH?*??7(_"U^R#U[\\E.1#>W MB-GVK",
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M58\-.F'J(B'1O85OS.Y)M-J9W;(7'!_(:=P_A@0/SRV]!L;)Q4M=0"V+'PO
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MQF0 #7!>,)WDVGAGZN-3:MXS9BE24-)_0G71W7+UT:.[\5<%(8+%[_7.3NV
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MKWL"G@"KL#%G@-, .]OO\ON5_7?AY/C]RL7)R<')S<7-_1?CX>-E&0\W-Z\
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MO,N%XMB$S6XU:%JK^X)+J4QPO,X-;*%O ]\!ZH6661%R%WMO]G.9KV?[;@1
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M-1\3(_=G52I4CQXP>?KPV6I3I<GRC=-0EA\=NKB S&0F4!^ZU(V+A=57M5?
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MT P7'C$,Y3MW W)E)^QV"5?RB%,HAQ?+6TM^OS&),(.B^.-,X.6(X@/JZGR
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M_.1AOU;OQ%*GY;Q7.EIG1W^0QIMCI\]_>EWRO_>H^_^-@S_\WP!02P,$%
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MB<9&<T$)8;OZE6.VG/"N8]X3#6K]Y,Z;=6,9?6IT8DQLDFCD0>H 169-F^'
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MM%^:@TUEKW2Y2_L6S;Q F]%"8Y>/3'*/&ID8'KQN$#*?^<-&\LCW<\*Q;;K
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M^+&-!:&K#AOC_MX?R[]?Y\VM9$1]'?P7"\$4Y  /%2S_Z<C@1&<<DXUG\W"
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M_[ZY=K?U8%6]-[\O/__>1%-*6_6+YG5FU#IB9=26Q3,>ZG*I>,*+OQOQ]TV
M(,<3O.';.U!X#K!3_S4$ 0TK?SHN_@>5G<_?KS11:6=)S_;@  @HZ&C$#^Y^
M*,J_]:D>^W<%/*'VE&%]A /@H>FH'?\K>@'[3P9G][\)*HXO0A!IRGZO!8D)
M,@(LUCD:31-?3T;^3?-LOX!O6K._E3FN6%_]YVKD(1PZUU5 \()OJR$D(0\I
M;E!Z=MYE/<1^*V1"2W0EA2$=[$[\_^BRXTR-O_#1$$D LW\)+F%\=!Z9F".S
MK3?YNB'A$JUGL*?E%<_U,],)[G?EMG7^^A=/<"_@B/YLH<M0>J/@(GJDW4O(
MNJR"EI?+)$D9\M<.;5$B., ZVKM-;HYPU-G?(%PVW:/LJ/'=_53MN$7G<XL@
M7U96FQ;3"7P^M^9Q#OQ%W3I-[4M'JU1A/5#EUM2A1/C%,<SP^)VFFK<!P<J'
MS_2/;U6+UYY.37?#_%&NQ'Q 0W; 93!*F"GB^IKF7U374;8<ZH$[]<[SB"?:
M/;@DI%3@3SS"3DREL7 ;D^\?\(=B*#' ?;/U>?'AYM1>*3R1,)=#$#5%H ^#
M$33X.=;3MIV^"D(3F]K)889_WC&42=G<BR'29>LK#C^J>>:'6)+1^"$8*PVH
M6_3S[;K!O?1B S>-9]O ^PAT+BQ+U/_3RCM$(/:7+E:! TSR<H"?>H4[5_[F
MV40( 3JY(%^&G0B#$,'\]E]/POD@Q!O[9HS8+01VC'H?I',7[!P7?Q4:OTM6
MJQIH5RM*!O[6U.M >0Z@=(]$AT$^J*=6#LT%,=,EL).08/BI6V5]@ -DE,!I
M^TR\H"4^1?VC)?Y'.U39 GE@-+3]\P$',-/S>[%"V.!NY0!55HB?$L[C;,DW
MN^&F(^92X.2_)D'AYJ?8S[$SDLLW$<LYK)'S55/C[="\=%A(K2CJGS5319HJ
M4R*"+<2-6-.D(>8=.PB@NFU2FYR/J2Y--ZS9-O8G+OZ*=)EO %#;D)8_OK&C
M*$3G7.F%MAL9Q0<L[WPP&:(K@X*,TY@AMC0M.X5AC1D+PTMOO@GJ'7PQ"1(N
M#&OJOLY[OY07V=P^WNA7;5YK[1NU\9&/YXA\;M(O PHA"D*\7&2]P9H)[13$
MYC%EZ(BZ1EI9?*O%,.C1#E%)71BYPLB<NO5 K/;-F.9\:V/Z@JN65][/\/2Z
M^OOK9@*ID1".\333]'$4[>@"Q7HP@';1C3;19:+4EY.'[;251:7896_/7Q[.
M)'ZL<7E+"(_@,5A_=J7KC\74^\3NL/XC2D"DZK]C^*D,FR<Q8V^O;W_G -L"
ME2G_]]6'^L4!F,F'F 1=_EP[<ZE?J'^8TSM8;NS"'X_8'9#R?%(2G#7%%(5J
MJC.(P0]YD+5T@[2A^Y2MS/\2JHKMZG]S0+D\@5W@AP2[>R;VVX&*RVYA[!-A
M^,TE57:,OR&I,^<I]U>B6A%!_E_[73?<WYYA/VDSBO)M$ECV'*#YX">&X>2.
M9+72?_X1W#6&+9(96%=+#6*JD5+8_-34M_,5IO,]HZC9D5(;RZZ1;$9H1:&S
MA.<87\J-A$.O]LW_H32V0H&X6X,_#NME*]G4:8TD&K$%A^;Q1)6$I(;]Y J9
MCCR]N.6IS_F&IQ3=5!;?<P]DJH0[^B),,C,MAG=SQ[.>$;RQTTIT/#A(L;EH
MSX(8R5.5>CZK*I;ZU19,H7H-=3<UTFT"@I3.C%EA8@Q<X@LT>'D2I3A *M<Z
M)#\EP<UK<Z1$=UE6D:DIZA3E0-U3]&GI.X9-T;>CRY:R[YPZ-:J@?JSB=&U*
M9+SE]4?3!TY^#FP'C[(ERY@23>PL6Y  R8GU+A*SJ:H&JFW<-JQS712M"N84
MHQ58R:UF5.Y3.$IK/#S!7:4Z>?P+OZ%"NOO\NQCGZ^9_,MLME;C?'KO>#D0&
M_5=%_H=49"3##&T SM .C'4>9NYB/<&3/S=KI]>ON72/J<:M-=BNL>3$.8#?
M2/]C7&U*U#O3T=Q,$[R:4=I=44FN7Q,,;Q1IGK\#AF,?RJ&0F'N\R=AH.=.*
M<A52=-O>98PP]>;6G2LN+F;Y7[9):SJP>E:Q>B-Y,7%CL<ECDC"7X:Z?0H&J
M(:G@0"Q]N8%5-&J;O*'(M*D=67UY[?7TDV_SJP-2R16-BHS7B<#YD!^!5;(3
M"%]$++8.M^9)"VL/0U)M"(D< *X=U.I.+*VA&9"#.GTVNX)"C'=5CX0*/R*H
MB-#O)WJ8QSAG[3NLGEB\,^MG E.B#.JGF#9]E#5%-=58C*&"*IO[>(1YQM]_
M2!@UUG7PZ;+CT<JT$GBCC;]\L^4;.5W[EZ>4S_:)O(>V._F_:/<_BG9EJJE#
M3.DJ<M/:?II?%]T7#& 8OZ66;O6)^RG(-($/*/F!8W9Y+H]\M+0JKT6H'QP^
M\6/@P,(#C;J*WG&QAY\BM^@J'[$W!VV[V,<?T>>HV)B?2$G5]"G=1%/XC.MG
MWXN^'M9CK:^O%RRKE3[,36OW0GV,=SBA7UB9,^^X%L=09@_FT+<=UZ08]NCC
M5-%/G]T#2IK2T$'72JQT;J3U-UW<[]FOI)0:ZX#P7B?&SLFL.3[Q=]=D/6:K
M?W/7&_ZIB?JV=06"N5 ?[9<'6EQ<(G*< O>%I5]X'KK[>EF"2%F6+A?IW_5^
MXJ_+H^AOGBZZKO<1?O$MD39GH,R+N9MB.8!B,D%[D.O+)3MSC/L_['@W?#OI
MUQZH1JHC(!]\73W_&M'N.ALPT]0X0!+7BBZTQLM_$T$NAY)^<<UB)XKQVX+E
MEQTA!^_O_<JZ:\4!"O,^-%%+OK7_HD-UV/L/2_FW;1_ZEU'JXC4.<(GP/3D4
M\Z$1 K>#4?_\RQ]T+@?@W<DJ0 02B$KS_%U)A*N$:<.AN<8GY$AM-Z0L*ALI
M3/3OF6LV#)NJ$(T;]_!0,E..L>CMX+ZZ,!>%IG* >O[5M]0M>A^X,J>=2J):
MP5(0TILK08G:>A,]D<+T2 7EY(WC-]<\8VTS%S_EF@X&*0M*!F>GME^[OQJ^
ME_\3EFJ#2X+SLE5!=8K6:ZH!_2(-UC&C/TUQ(9) QQX%*-WW[F[X-XS4E_HW
M5K=O<#\]_2*8T9-JQ0S]\1E!/;\.:C?4/[ )X@#\W$O!;[ICK&80GDC16*6X
MRR+="N<_77Z[6GA'ZC<;8V,(#?C5 2J)HI>P-L\X2V1:T[2>T@X$.) HPKZ'
M?0^3?"N*E^Z?QKS=J5B_,2MX78V@=:'Q/'.8?[3AW_,&Z6^?_GW[J_=ECD:T
M=;99<Q@K#,OB<<1! WQ_4=7 CQ/A69)VR)Q_F$%';ZH!VU*0L*KPVP='V;^I
M1_=L2/0JG4503MP=A-8H_S>S_S^2IM^GOR+4N@KFP;N'32.+DM5IU?\J\"3_
M=^[\./DO7(JLJ_B-F5?_Z9<Q7TCU\%7"'($H-#YA]ZAG5I6*3=;MG]*UW0/*
M.!MB*JZ^O#620!QQ[3S#6U'ID<=W]:6'Q@O+XI$3\'UNF'XDU='&=&X2A60+
M2Q39EGF+#5*"IIK.-7^4BI#.'F>/RP0^3I3T?JR0]0W+S0&N:^]".7:/8R6P
M?MI$7"]>KM6Y[%V=[P-4GKJ-D?EH*;)%KS2CK$>J]AVARY@2/I:?6?EEJ.W?
M]7+[-0F'W1 =(ZQ ]/!-L?EO7B1^8$+INA^8SP'^6WO?'=1DM.T;4$$$16D1
M$()2)12EB!0)BE)$C-B0&I%.A*B 1 D)@O0FH* @A**BTCM")'14I",EJ*0H
M*#6AA$]2>/&].W//\9QW[[MSWMRY=^[Y(]_,GLFWO[U^>^VU?FO/VGNY3/'<
MAB1MAJ=(:L7+[ %YSU,2]M_)?Q>JOV9+77_HPO-TW+NA%."!?#6OA]F6?Q?X
MOS8VM7]IB4KF<#M<$T7Q/@7Q[.O_M^-0H@7Y_V)RCOS+;L[\W%6>3CS^3T@=
M^">Z_WGHEF'T&5+%X/8<?B7Z\\FH04VS8,]V4>4[KW'B&A@X#6IS16\3M./+
M_@@+KZ\]?6;RM=^]@V8O?9@](52W4/!I,7Q%'1K"E<0G$W\X9W,W$(S"OVR4
M]^&J R&_5F!L'O][L/?BY24V%":'&WACP%DETBS_JL$,<-\$F7IO@L)Y%&M'
M/,]K1WG3RC? /.O7G,GV^:/)[?V(F_FX":*#N69N=DY$>@D[>!-TXMO4^M F
M* GR1W/B30K[%Y[+P^.=R+\UWD*6P>_]6-U-4 OB%U_4J8!-4%LU8XPCG(Z;
MLN'JX?ZJX34-6YG& 3S7H'"H^*]II^I?=EJZ"8HQW<= W0_^J6^\).)LI%]L
MP:\SH_QP@V6?_^CJX9$5]?,Y!Y5R%[6F'LCGG^*AT&93S&/#^3PU#].$T--F
M>01&S743-&6#>'ZO\M_\@YFLQ&486ZF1R-D!)JX/#6Z"A+3*>4!$+7%6:_C^
M6[[[EVOK->PO7SSGY[A8?:?(V=&2(MLRU/;C6=6:0HICW^N AVGS+8Q_4R\_
MP/YGZ.7+TBG@,M:(1UYOH5@_<5TI?]V:_]S-Q?#,!Q^/&-2U_Y\XI3.E(ZNQ
MX!4]:@8D2JA9 JR#<1L2VKBEY^6C&2W7[:[P9/N+.;#\UXD;WG(MOIO'Y3+M
M>1\XL<[=<(11E#_Q;,RYMSQL,L*/J)7@_K6W0JZ8"X(;)3S%^NGS7_'%IF.A
MY]\T6JG0>T?4>Z,?3=QHGJ[].S<\JW'>\*+2P=\NZ2J8I]^C;UT)A4R>1TJW
M9/!X(&(39.X(6OPCC\KMS\P(D'IT-;5\)W![$W1Z:.W++=+0C//(SN24;1VM
MCLO?CNNW1A_"KL1>S3JSZW9'=YX^EBANJH*Q!;8)LB4/K#/#>"%['=K)D3Z5
MN(8B&5P>:=['MF98-(6X%7P&^%;ESN]4F;094<S2&_:(_C[?$:&21)H^UZMH
M_>;B%F;?:]]&9D*)R]?QGXY/#71^UA_XRME_8\K[<<'[[\VF<_-!_D4/Y. G
MH-.B<:YZHT3R(SS=&B6!GCG'\.Q.7$-$Y?*/E.DEN=LWIRV&W:(3B%?39KW;
M>Y2&>@2SV&E]WZ3(>)7?1YK9<MF_KV[(),_,I] @@L!,]^A752";D@!/. Q
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M2>3@8>X+XB<9D(6=-*?2'3T==X=\-I287#GBB.D8[D"UI5]!GY#5H[8W)Q7
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M#4.U5FM0GQLI8]<K/S)TO)%29R)K[,NPGZ<J+.-@/I#X39 H#%D^,4RU+8K
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MX*E.@539"]>8O;[:T2_JLVTK5KJZ=4Y!$^Z\;X@S]X#DX=RT^3!^/ ?FB1#
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MY8ON"? ,O>4SGEQ?T<>[8"&CX::Y_TARW#]_?WO ?G/B?P%02P,$%     @
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MMA-54Q[1@X%H<7)IEKQXG;R\:RSD?# Y3;*O4)^3HS"*X;5[GV6&2F<X[>;
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M\5WDF+;@*5<Q(04\L\JB##O[P)8-5,0_YJIEP+%=KM@0)%&+G@UV,#112)9
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MC4,2(4LC[ROQ<<27E4A:7&_V#R/6H8R+S8GC]H6F0I5#5?+7\UP.!7WAO42
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M@C"8N^1UWG65;C3^2M^\8Y3<TO1H7V-'SX4>V^%/6<$]UDSQY4M@*,/5C;7
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MAQU#:Y!#KXYM'%K/NRZHZ-"2Y>IR\^WYKE*=?>+[IA=PC?@NK"+K,Q9HQ"7
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MJ7\UOZN_W5GZ>*2Y=E]5K\=AMBO;!6Q=X@Z4-SS0"3\(YSJ$!U7SD*K;$YH
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M>S?70%XXORN))U*:QHZ$&'<6RQG#TJ\TW^LW!9XK-HP_:7EK/[#GV8!?&/_
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MJ]X,W4LLI>,..SWXX OCFJ/98:5?W1HO3MQ.BS8Q[7,JQODJ:SG_:C)#!G#
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M''?K=L%%N[JHA_4N%^ZS,*O,*.=_$;\J\:*EX&W6\=I]Q:G7E3\^4D&3'T5
M_#-#ZLOO8^16NN=&5>PJ$+[]PTEA)! 5>.@G"HAM']*SS.>3CO:X#8D.N",.
M"YQ^$7WR&/&DF*C[[<A8M6,?J5J6AD2?IGZC!0$W5=ZY6[(YN2I2-K$VPDU;
M^.P:8B5EL^V^L0F6^[BI^]UB1VQ]W$HIX>$%J?>Z\@&'7V6G2LA5P/#F<K+8
M%"NQ%)5*7JU2!%;7_9VGG["B9^]R9=+BQ8S Z5N/6OU8]P)WZL4<<Z,)'0V#
M2/V4.2V@4\&@*2Z5^7$%3XB+@CQ\Y7.^U&YEB#LO,"51=H>93=M>H,=?TN#>
MEKK3--F;_/F.D\PGI+K<8M]*18%+RZ:IRT"A)6^Y06G NZYBBC.JCK8<O71X
M:/B2/CX&Z?703TV2?ZIT$J,K@ L8F)HDS_PX922R2VO$_2S.&58<.URQ6*V#
M;!O&>;R]UWPFW_J<MI6&;H&W[D>T\NW@5JV2JIWP9:5GC^$'\,Y>*G>C*3WB
MY6]OCNH]%#4^?,E,=/WFVPEC-\.;S1E1ES^#X78?ZI4YNODM?.,+.D;/<.@O
M17A63@1A"'E%9JV',$.-<3T"ND0]"-FI8[CS"[_45=O\.!,?UH?))6O3024(
MSF_TJ4>]AMI(+TK&'^:[_B]>J#.''()^N] /$B!.<#JG)!0OB!&8J4'>XS0_
M>?2ZD;$Q77!=_3YZQ8T!-."4UCZ"K*4E8C'O;] &IO645KH&@0'DZE,_7@[_
M79EF=0_-TTJX_6_O]:P)_?->C\<O>SU_M)A=3:2]1G_S\[2G5W+00[W)6C]5
M[&@),  DAHPV1ID2!JA!L^@!$'_3/J^ [D0QVJ;^0NA^7K?'FO[*\I^<P?J/
MKUZAG@$K9&"TPS$59C]AWZ_BX]][?2:#?B4J4@H^(@1#X^K#_CQ2*>G$\>2>
M9PS )YTNL8U)-#;41AFC;?\P)( 7Y#T/G#3#2WL(G[YN_/@O1=/Y!1MR"?S(
M?NHZ&>REA"7(?S=/C($8OX7M+/^#RM<$]$3/AOU"-2<:1\#50]K>;H >+H*:
M_T/$W@I<K >YZI%ZZ,8$>MUFH';CYYHNX@ %U GU.ZFK.![<-]T+]&H%VK%_
MVM;$8SHF?_;77\*.=]5/,ZEHU^C/ NN_(+?>1+>!8_O0!HZR!Y2DLQ]RO'\>
M+VYH .W@6PAE%$I2^$J=!UUX-94B^[<4'$VJ *0E:KB%* 8@'97Z^P\X4TM(
M8P'YM>E,>F/'MO28) /(#P!)C&X5RG_@ESID,PAT^S!94"MB"(T!<-/YZ/=F
MP$A(7MNZ]H<GCO_OW0O[F1X@^O]ZS#(RJ:JS;A,,8&SNQZE7]C,W0$>.@0S=
M_AM8R3RG_3OV]E=,KGR0+O<GD_LO9W)_ RNAEV5Q4^T*.]]P+6D9BW\I8OOZ
MFTGWJH_]9Y3_*!'Z]#LI9'S4(%/7)GW.Q&[!J#KJ%%I:L^6)-%;VZU= R.?E
M+A5_*_LZUR"!E7KGRVOP@LZE#<U3"->"!0MWPG>9("%:__IIH5,'.6[.,$]+
M2;M\O'&*CCM(UUWB?YYO6-LVF=/Q/K>[.NOB6!SBTK@^?H<']1M5F3@3J!R/
MU)Y$\S7[[#'E,5DU-W#I&M'I&5:NTQ'*[<F;.O#@K4B\LIS&W@]X3U<8"1I:
M>1E_3[WBL_+@NP+5P^IB]QS?NEA%+K?XJ9Z4'C0*7JD^Y<E;JR5*!%VVD2,
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MT-"E;7 Y/ T[)+$E</M$*YM!TY9SF>J,I$>Z]G#KX[%D;2X3>\,=0UL&(/(
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M X[PE=/[I;_[3])L&DK'A\HE0F!286GHU])-(!5?;)"6$C8/8NH/\ZC?:0[
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MU]B+B$+@AJ$X,]1?9!S<T"_-YW<'+KP'W=LRID(.(4AO@:;:9U#RJ:=0HC)
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M/6+[=J^8GDY8,$0P1%QC+K$TDZ3>7R84OWNK]_F*MIJ#1^#.8\O8'OIEP_:
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M9.4=+*QG>4JRIFUR%ZS7;PSZ+?<<Y%V$@H>YC=Q*[V4,LA.:O9A:+#Z<T&0
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M>&[4<*7_WC9$G"B-UG  N*32GQ!I.G/W:<"JZR*B)O!$\V,5[XT>M1$*Z[+
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M]Y/T1X\ZX]='=GZ^^%(&?O@:5]^3R,8,!/=!T]P/"!VR]WS08@I'#F,.2,:
MB$ZY[OC0%:%:BD1/C9'K1ZT'>Y5+VLCN.P=RPC>]SY_KO@IAILWYK28S#V("
MZ!<5C<&/S*,8$WKPNP )UQ4S-< QCCUUX&:MYE#'Y[<M75 9Q:P*NL:L= OA
MP<S>!D"P"QI#%*-[QEX[3[Y6J HL5+"?&T.$JV7G?=PAD)9Y7LEY/."$F[S"
MU0<\[%ANK&R.1B"D.9JU \%!K+TO;I]&U ;$S[@XG4Y8ZT;MOC!S!KZ8\IS(
ME;RM./(\9Y<!_<)\Z:HC4.S ;M(+U("3S6=--QZPO"/\_TBCKD"%TPJFJ"PM
M@_&L2]:Y2H>IDWNEIK-;(.R=P[C9 AB 2+E"'NQU8M\CBGB8>PEF>HOTMXNH
MCLZ89%8?&?VJ]#7S[MU,#WP;?**?$<7&TRHUB;R8G8!?C%=S-WD.2(NCZ8[@
M%0R2T5_TCT6.?88K8L4Y%)P(QOCV'"H>!SC8A;AG_C6(TC&Q*0H@"@!M[JT!
M#.<KH^O*"DF7K2(D@C_,)CZ+IXJ6W[5#E[+$F7^6U5W$DS<X0NE4V.3S/T*Y
MEF;<6:@$3/^H;)2^CY6X1GO:-;HAO?>^'UI*/B[Q'F]HV<&#,F\N-/#QK@:A
M.$)]W)"00=>NN$D TQBBH-Y+Y'2/3^/[]R#R>:_NY\B:)K?L*]$V?590ECCW
MUQ,H7_U\%),/(Y4ZL_!PRJVTK6^_2DE(;74R1O_8S<)<O<W->3QXF$#+8I[F
M=..KH+1H #GW:!LBO,@N(NK[XZ#-4=1\Y!Y_<ERYD-[OZ9).6K[GY$?-ZZX?
M9X[\6*GV^7"E))_T9[ =PT6]F'Q.*PZP@R7"&^P::'TOU9-8ACC?F\_16BQ!
MZE(M4]YX.GSTL[S+@M15F\6DT:^W,XI?FWSHO*@F=<=L;03GJS,1X@&Z!0'&
M;NQ\$][;LV6'G&SA@M.@49>=MB"R\>.U 9F+J1T'E5ZQCK,?X+PI,3.'D[N1
M@G!?:#Q1;&S_W:>Q+D#_W5"F\-NYRQ>+^O@.4ZU51/?L/$%X@)M];@;A%G 6
MLX==".U&CELQYM_11WXDEK@'F*D :8E8>31FVGVR&_K$M6^V-BTDSD;"HFIZ
M>EXX[7&:W2ANMJA1AR;$-3T%L.J"C^/G+#BE=-YY,[Q4"I#K&]]CNT 72FG^
M&;WW[E/K\K,7^B+;]B=+UA*1G^@^O-_7DBG5I:OOF:>6P_/&NDD332V>!LU#
MU/5R;19REJEUQNW:AM2$O/M?"](J3W8(V.A-?(^42J2F*$ZVS\@-5(32S'HD
MXS]W=4U[Q>\<]K+?"W$\;P2!2/:Q1/ZLRDP@B?Q:VX/Q!,=P\]N0O58[%)P[
M<LBF67<*HY-@/0TU2;I)6JU)Q;=3>=JMP;ZP88BS)#V9$<0NP%U+MG6#DGEG
M83'-8?S)QUW,YV'"K@'^P0B'F&\&.\\)W$S-6M=99=(G&?5T Y8495YZ]>X\
ME!QU<9@HA^:E_DB9LX.>PNV^1D=H;BSPGC(=#D]6;I<5RQ*J^OQU:M%+9X52
MK_V>OGB2_8(# 5%4/ U6AK9M+S2D5Y84HTDVM5]JR[(*9R9/#O^^F'&HDN:#
MWO?Q<E55[R$;^5WEO.<%R]!-##=V+G8_!CY$%$?_9(0":@U4#X732XJR(RQE
MWY#2\;L/=@9]O=\M*@,+LSI3-J<SSH68,_1H1MIK= /#'0Q[[0Z&\P@F_-"#
M\8TCU')%#86"^_<>J8Q2XP\U,NA"WE-4'EME':*N)1'E22-Z\M &_ZV@PB:4
M5F<? 4Y*U;O5#Q-<A! $"S7BZ?#.M"2NE-R&^$^?Q5C0"6T%XK.5!<#[NML$
M/=-@-]S>R>6!F;B\.=_TN&I_F^L]NTOWJ%T6(O^G]MX\',HW_/\>"5DGV;).
M65*AD2QEF[20?*040DQ9LC5-6A@9,_8U>RAB9$F2QB[K8"Q)DB5"S!8B<@\U
MW36+WWB>X_GG>;[__8[??\\<Q_7?'/=UW?=U7N?Y?EW+>06?5.Z4Y&:3?-,3
M3$P7ULF4Z0H:+\8DJ5JKD:G9:A)S"^7N'(W\G7GM2<EE4P13YZ?D5Z71>BX!
MMR. (IK098^@IL?N PXV^XM$TX#/KY;5U1<^X+VE_YK99?6B^B\\G-)@R^%F
M*/QPCX9%UW >@#+T<+LU=<;E"10M%7YI:;?[BH)SQE?;O6;/W6.;-ADN DWG
MCKTSHH!P.H$,2Y)!NG/,P-3B'V,!V6&F6?ZM[2;68Q=PMF?^FW>_@[FE)@EQ
M 5T!=^I2U[ P4HPC ]K3""(!][X6)#50Q/V-_T6T9^\6R"R-DK;;#?EJ?4>D
M_-Z\%C<-[^.@"%8Y,BF/$+[X!*6FEM?]EZ]./H +?G$(Q5;<=@XHVK,1TWAW
M+Z'50@C%N0 FT$A2IQ6BL^GK\>9'Z:D/C1/(.G31TLP7SP")D&IS^+UH'%U_
M264JE>\NU1'^Q!1$(]^7IM/0:W+,<?>F":PKO5!]<<FMO;XV;>:0IOML8I[/
MI<B7SZ6O2+7[9-EJ"GYO$Q=7/=RO>NR_NN29F7FMY/GY73V:YTK%7I7&02 0
M%;'-D41*[<!J$C-^17D]!5]'(N-E1]#W]#[(8-*[_D5L#AAF*?ID_O>IUB5
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M7D8K#5H*^^X_:3^<'2=8O*,SJX6;1/+6&4FHP6JT<S-Y>X=H=NY-K4U ;Y'
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M X+#;TXU;=@IR]>%/C)K77UJL+?RYCK?^"H)>_#4%WQ"17)D;.@.:^,H]KU
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M1? B!9K4-*P&RO3>=.M/KPZDD@*5FQ]>;W2?<3\33RG:)YM_X]J5KO@N?F4
M5SGAL>QV^<-CWRJ/I9_V? -RK*+^T:F#_"([SMQ.OK?!]U3?9K^-W *AP6"U
ML (]: $91T%*F*&T@:R02*S,\BUF:O_8TN@;1.QSK_>QMVBXQX_KI_3>]X[F
MAW;9W8FWD5NYO ##(=8J&:;HO@ZEL79;VGK?5G-.M8>M8.K3@"*!;]4OEA'*
MJ86#C0T9KO.7',OF11H.#+TNO#[/UXOA8@&HKK :PSC/=*1Q@'Z1S74E)-05
MK"@-+$+T*ID)17N'%7VL(R2P9RA6KQJQURC!P;&CUA=O=?/Q%>@MN6FO*I4M
MP7&;M6OUS]&C!&EC>T5WI Q[QU9SA[+Z%_MG#[N05Y'>8QJ[W\W"[E?5QN--
MD35$NBNK&N:?,^5.%L .8"92*9&%&4R#Z'"]!I);GZZA9;@2KUWT[ -I]^C"
M_6>OJ]>)5RA>L8=1<J9^TEVI4;U3M<E%6SDU<Z_&(AGGA-R(NZEKOUKU\RN_
M1F/\QFHVC9(FICS>?.OE=SSSS.AC96A@J3/P<PH":F)6?T<^0UVBKO?FI'M9
MT JPM*A^*61C[^')'T^\P[;1KX6;Y;>+L198_U#SQ[WJH]/6CN>>#BW8:F(]
M0$^&Z8H7/TU7;1]M8$V+)D:1Z$MN//GL).7WK\&2^NDV+TOY!SX!=]\.;?R^
MF^YI>24YJF-M_39,U4*&_9X@;@S+PJJT^R-*P A;%_;$<WO9O+R-T_5]LN&G
MJC5'WV@\"Y0-^O!C^675:;E%4CT'8,I>I-NP6L-05D_1'PC2-0:X6F%[6:^]
MU/Y7)5Y+RC4%OOR]8ZZDD[)=.\6KXL\4/QC<!<2<6Y7^ZCH4++#:/*QY]D6X
ML"--^H#JR<I]&L^GA0?GI?I0*R7<GGT(+7>2BJ!P@$Z#=)BB6<P<20P5TO$9
M@8*7@ZVQ>NV9U99RVD4C:R&[ H2_9"LOY!T^_K;DIQ,A& /NCUH]R8 @GYBI
M,$XQ+W>,;?+7W>8 EU*MJ 45E=EJ;VVNV;5]J\<_""GULQ8=DS/ 9:2(]L9@
MXLVB9H<SU$1'T1K,8S2KV_B2X-8;)MN'Z\L]JL:WFD=+D-^R/]T9?&O)?].(
M9X/4CP4U(*MO: _IXM1"ILQ?*&LPGHQ([I!I;LP*Y(K_)C LTE5OX>=HS*O%
MAOPBIY;W/?>9=1OU5P_&&8<29N_!1'=3[=,[9-XS+)F7[G9YF7^JB82DS4CD
M.(^%5J'L(V],U5Y[4+VJ4?S1$S.$7/7%W0YY=4U/MXH#.(X<5]-BN+&["1!,
M,#8%K0!:5J.L:? $)HP,W;%T:SS?>Q:^NA+)./_0*.)+"N/RX_XOY#Q-W^S#
M^Z92Q _LAZ1AZIHS:8?HCT$$PP692D\"DXHU0/>R('FUG8VX8\=<AE29AVGP
M!W/'POT#^YIT^SQ/&+*_6Q^IO5$:9R9#MF?*K'3"^<Q\:+!^N'"',=/FXQ0E
M)VV=:8DIZZF>'/8N7<8/J\S,N$P-!WUO.#NRSP+Y:,_B1E+,E)DNB6JSGG@1
MTV7*U:$)5Z&3$$H>TRAATO3(O-W7G4$8'[O\5W;P)HS?W)#T<]/FZ/N_[7+[
MN*F!<55)/$::$ !10 ^Q)6B^?<1LE$CY! E\>J;0NC4^=%=KM*.0:UGZU?N'
M+/>RQHZH1/=%DG98[$)JD^WC<9ATK#3JHF\I$F,Y5D88CXP]$RXK?W-D7[36
M33,!49$2B!!-@2ECU^EE3EW,9$.9EUE/++1 ?#=\AW%E[,7^CAU$_29LW7)C
M'_VO2[^5;T2X]VE/>/_4P.=I756<5=J)'Y7[N;C*K0<!6U8Z5QED*-=V&<1S
M #D$O%_9^I'QOO:#%(1HD)OJK^WH*Z5TX4@5I!=29!<BZ_#7H;8P,O8$.,>P
M1ZFSBM>-SD$&N/PHHAI99)=$74]I-R:OO(=?^G1*6+,E3\=N;UE^:;K2V;PU
MX8<?Y274=8#HQ;4_/&L)C.4N+O71S( ,R^  *A:[D8@SU)P,7:9-F0MRS\]S
M>*?/H>(I,\LVK^J+;?9].RSS5]8=D1/'C>/G8. >3#I; _3ZV4G: 9LM@S;Y
M59<&A4<?J[E[N)K<4MH1=\=+Y.PQ]:/IG7N_*PI9^QX5M^0NF017Z%!!18/A
M92AW\"1E*C2BI_63H*>I(T[\";U-XZE&'&WP=JU*_W*MRE.-EPUWS#1ZH%27
M'% ;D\D! K)-Z-XC;(NYWJ)OE?J%Y+:A88GEP]L6>(S*O1@[/4?WR,:V>P<F
M^1WK;NZ^T!A^7/)/>/S=5(,>S,08)6KU32EZ%"Z[YR-:-UAYIH(2,_7FE]/K
MC#F70'?'PQOZ]RL5'Y1')&378;^N5JK)<L^9/^HHB'D*"F)2,6H6&@%>NB!B
M-HVIPB7G:<=B/^1%NK:;*O=KC.G/W;6/T1ET*+6Q+I@HLYE>7O8<BM7P('23
MLC"2;"/78+><'LP._3*A5*8]ALQR<IGS=<&I[,LR.9!P_&N#U37-\'P-LPM"
M2>QA M46-N$\*_B8%F5U+">+&5K!C&@IQJ0K(W*8%[:3.RKT>L7DWJ48NWPR
M^Z([G/#6H\K/2#1S$K6;E?D$M(&DMA_&-A'[#': ]MV!HLB(KF+USZN:34TN
M!_1Z"P^X6L4BU7EN5G]^UYGO2)ZXE!/$K4IGBLGJ23)$'@4GHDV9AT'"'#:E
M>!\M+#>T'#GF0)7;S(/L<)_2J:YON;T]^LVX6#-W1/^)2XV<,-PDJ,0%<V48
MU.9"+;?):MMWO[:9)77J1?01;ZD]I8B]]NBA$*1MGQLWX:7;:W+E@?T+P^\3
M-6:5U*Q5*J?WEO!F_"<:85_3L"I[B@-0+2_3;)([M)C\K2"-L0L./G0B_B(I
M(=6-"WO1 KA/80OMK9D.C=<%UAK>&'WP<U00_S"JOQ"/<0J>MQ=$#Y&H%R')
M&'Y-UF.S?5S*H$63S#9__+D82X'*H\P))MNJSU89H<S[M<S'ME=NV^NK<P#_
MZ=R2OT@'=TDSW;@G)@[]'E:/84IG]G  '&EU/:#C$%6O,.F7G@'9ZT'HS5#N
ML]D]EMX5[NUY>Z[P/. O&T,%RSXX,52WX:7"G5[ ):BP 5@R'(+60!+)^%Z6
M"L6OHUCM<XV%#-+_8D,K]6:9T5GZV%F\B?.)[:[YBV%;BKB#A_H7A*]G3G.A
MCFJ+23C$;8('C.#@'FBJF6]UX"V#E!LQ_%1BEH8+Z4+]YZH?>=L2%_;Q*+&_
M% =;'ZBJHB64S-^JZ%X3HX_&^I])G,/DL*$2)F<SV7LN@K!3;>[9MZZ4G91K
MS1WM5D??S#[[X[SLF3CI3C4I"F9RC,X!:,Y,.;M>:!VT^S$?^7PRV5R;?#DG
M&T,^0FRJMG-JQ6?$,#*-FF-<:M;D77V12G'2ZKW/YYLJ@K!\W' ?H;_ <0I]
M$'"/S=I1Z@Q4*<""!TRG7NQM+E8$'QF%2@>W8:26CB5\&0HU3[2]7ETQ$.6/
M+C]U=PVB-E$J?KV16 +B>Z!-QEO,G4H4DB)[>,:$NO9LTGFUEOPELE82K.F.
M:AS7^T;$Q3ZSYTO%%6FGN\*OO7R[L=NRY=C-OWW^>[=C-XAG*+$_PH50/K2.
M47@ZJ<FBH74QPPPAF#3RQ=7+O>S9K<A'\N5.X?ZA$MGM&JALC6^V(@+=>P4X
MP.046U2")D2_ KZF8NE'VV@5<?:],.C2=GD]Q0 :[ 5M;_YX0T+]S3V5^/*R
ME>%PHP8[6:EN UEY5\U J>,G:QD[V3/%,'")-LPMPAY*)50"F>I"+4X,KD':
M4:")JP8A[3"*G5T"[?ZUVU$M,2J5T9\=3[<O;=GL/]/"7X*E"*TZ,$Z!*Q3G
M[MHI1:8/-3EG )KJAJXH#\KV)3^\1YTA/ OBA<'LD&X+-=Z7D-Y%.ECC"5]G
M'QF-M+N3':I?V"/T5C\<!9(Q.9QL$.E*YK.DCL?OI$_&/CD^+X+0<MV3/^^G
M\DQJ?^G+Y.3[AP9Y:";=,'"? E/6>8 #U OUD::PO1:\H%W%$D&@_23ENS%$
M>"K0[=$8LF'@^"OLFJ.[E\IGY9C[5_*,# 2&'QB%]*E;BYH?7J3_8CTU4R#_
M:<Q-.;T82:0U+(6DAHIX F+LJ?D=N9'R!/+]S<''3969#^>BM%Y/I]@W/J-J
MM9\X=+UKS[V3K1Z(9.Y)MT=,MG42J.>A680Z>B4%D8IW(_2)#2OB<M)#UVN?
M-M=E]EZ?&0KOX MSG?Q:0XT[(IW3?G7JYQ(JC,6='K2>@6W K_ZFJMB.=ZA]
M628)FH7/KDLM%Y7UE\5J=53-J"&+]U[-<A=,\E",]_-#:/H>+S2-$[K+[HG"
M-K.(:\Z,L"_L]QAJ3<B-6)TY)K%Y>,Y3?7OC7,RE6,A9B2NUH5' V)P+.>EA
M@=W=AW6GCJ2EKC(CN*VVBOH#3SU$1]"<NV&00&6A= X0J&3 [M.^O5!PSJ2+
M&A@>-KZG37Y!LSTXNAZQ<R_U]\;IBG=I?FT8@-W/ 9J'.Q'I).5V>ZK8'+2G
MTM-D+BI#H<\0EM:D,E4Y+!QLN$1O=I: %&J&+]_9/]E/>Y;PZ<?@5<MR#RXF
M:)N94\?(F-6?Y>PA#B #MZ15K(YN8:C)8&IO:S0AT2V%/=U3.15TT)IV4*$M
MJUHSI%KVB>KEA-5=\AS UX"+K0-0&4*P*H9N17L]D-Q^[2KU#(CMQLB@>)YZ
M+4V:;U1WXEM&?\R^*OH^,7/J_<X,IVBG (^62WLO<'57 V3-EQN^*:L.%4BS
M'K8=88L@[:U!6QH70KJ4D_#;AVLQ!FDA(?/-)GN^YFU(!1I:[O-],'JMP);?
M3_'4.4WL1>:A.E89>N0YF#JGWT;F J_O1A-" NDE,CX!?5% V9A5NN:W:W]2
MAG&VW0\9Z3(S/%MDA:&'BF05(- &!GU?G;O=D@F]A*QCQ)R09]2%KR.QYC@9
MX+!DXXE2!\54"Z3OC+N:XYP1SZ_+F[AVFHA?G5UJ?/L7J7Q;29XNQVG!^2S:
M>,<>UN/(=1EPG2UV:(ZT$_VQ6!!+)F;IH04F @B2[4I:JR8]O18JYUQ_Z&\6
MM.%]I I,WSS!,[1)\2Y'=?5YH%>1'. \[=O3$DP?CJ9W^T&EY3$[OJ"BZ%>X
M%H<[']]F?">[R*3:.%F+?HF44 $7>X8G["CZ>,8U#M"#8'_LT!FY1C3*X1DF
M0P60]MVT,^-N5H_??W)VQCM.#S?;53Z8F?EJ*=6;:R/_L>;#\'&U&(;(]# %
M ^[37GM*(4A%O%B:,:2FIH8\O5N 'ZUFFH1&\>I'"X^19NQN)Y?YV#"E1)<I
M1+KA>#M/B%U L1A(G"-)@@X<()6QG]B+7PG)P+1DG#TCQ.-S>:?H#PMU]%NX
M2KL&PQ:)IS]FY5IH('U.?F9K(KT&3M,^Y,^IJL6T'6ZKD]%*J1?*W6^"E;W8
M;GB\5ZLW$/BY^V!8+$2 _7Z%H<S-/6R156S!BX*G]A1A4]LUT$7.O0:R2TM(
M&==7A^SUJR,%+^^)-O#/(\]!=8R2C_<+ #%]$3/JHQTJ2!NG#G"!\GFLB9&M
MT[/1%4LQ/Q.N[+)47]]R7VGG6HKN\SQK18F%W==/!>(+6+<W,3G*6ZM=LX_A
M],<;*@-WOSN8I'W#CT[V>MCER=_$^3QTU<S2S.'ARKT?;^+Q? .PV5)LHS]3
M5HA^AP9/:B),%%*(W;'0SE;-].?(S&X.(-5^]/FR"$7"^JA2B7M^4TN2>96F
MU?YN]Y"\K,&:YY7'Y6"S=TF\.(C )#.(]3S,S#B<O :;6^]7^7-;57!/E'PU
M0JLF[^/)T.!((W&>% KU.+$F2= A0KE%LDIH&-M8GEC*Y.Y^HE^'-K*2HEQ5
ME)/%%1CG:+",]478ZV.]A=M]GPHE!["&2KF'[[[]+0Q+Z?C(NM,NQX@&T9@=
M*Q@\K!^;RM9J:Y.O Q%V8"@YYK%A=[?FS[.C;^@ORHM<R_RSKC/DO#U?BAVU
ML*(0P#V(WB%"\HPY*ZM=AE9X>I3-Q[2CA;)K:P(KSCQD1-C6?:HI6G<>T?5U
M/<4[N1RM?_C=4L>,Z9L[FDG6WWG6.$"C;C!MC.X.ZM'L*?2L0O9N>Z'OQ1H_
MP[KT$"_?/TLJ"/$7Z&Q]%/%(87">U^SBK'/W$"0;0W6N38/CA^-71R&BH#M9
M%R:J_IGL84,)O6KN6KLI<B=GLWY"<;;A9[0@ G<*\D.X]ARK#2V!'N< L@3_
M)-"$(<XE3#D]7\\L!X1&ZOG Z]KO6);M)Z]56PQH.EIJQNFBKQ]K#R\X:&C;
M<&J.X),3CZ$ZKJ=X'?B(,F=8,7W W0CJ</?VSH)6^T0VA GK&)VQ/14LT>YH
MOO!IN6!D=Y38#FO]^OE\<6&AY^B1#FWN@D9,!=I6GSFF\\!R#L6)6\_4S=<$
M; 2%Y10<4*5G-)_=N'CN+XUFW&D:7O&#[,$:=[:(*X.;0?H?>A>-VLO*9T95
MEOUH(QN(5;E-U[V[EF'ZIBSO&](G8NMIAFVQ9MB2\B/)_ 5XD_UJ%Q<P VG#
M:S': ^N)6-4.GCYRM>B7*=0Q*NEVNU(5O"/%4]0#[C>SH3A#]_7+>G?I/GG/
MWF81_T.Q^Q@'0'=Z%K6BVSW8?I) \4NF$%0]O*:G@[93DV]$U8V2G>ZDA:Y=
MR2VVRE:72K@6=3-"(ZP+ !Q9+\RB:<1.M.I'?;3P4K$</F6]5P>:U>X]YUZF
MC$@VNH8O#L2)[&*<:_LJ3>OA[<\K5YX_/7 M!+*;J[.HK+I(R)0"&9NU&7O3
M4W+E$A72IQK<=:N@D9R4:_35NZKX<,KVY%&M_-+;P=&S&-TA_7%=_MLM/M"U
M188.RH_U+(PM!S;.8GO?"YW^A%9&6:7VCH&8?F4/8M'ACLQ0,UZ=^^3<G;9B
M9_5W8>YKCFB$#CIQ^]H7$[HYN,C0 K?FY-9SV >0_KUL*)A/V_.SGQZ^Y*54
MW/^#Y-"!Q]FU3+]^][SY^SBIU?(5?3!J\$Q67#2ARV!RF"UJRCB-_@1K@JUN
MDLU59K>2UM"B8$&/_2CNO;WU9^-KXVX_[5*V=:POM>,.-HCPY"WR\ZCOYVJ>
M0_S@96Z.SM$6UP+)!A.D'EBC?7S3.05NH]Z)4GF)?.J)[<M]CZD 3>U'9W2"
M-SYV:;47;AC_>A,J*G*%'Y$[<3,I;([NR;I/"$+$8:&P .AMMVTDGR,'2'Y#
M<5?%G!ZMVISZSFV>_KBQT*;YYB*G1HOK1C=7=N<[B-;MU]C=4&S/V(OIVL<5
MQK43#\GV7:9?=2@5"6,4_\XAS(Y IV--A_'7ERST/N(>]K>UUK4G)16]'[V,
M1Y9G?YNDRA]L&!R)$^8 5\76<R(P76&P0 D->AJ..EW47TB-Z#H\B6XDV[FN
MA6QFRD15VLE];"YV?8:+';65.>5W3S"N[KHBSY8S%RO(]FG']H,1_44[CV5G
MD":],MWCSBBMA?F\BA\4>GSWI$H<4DO04DEN8W&5P)!$C\,E8+-/8-*8,&PV
MH<D^$?<0GJXF,]H4C!7XCM[1FA9X\(M*3F-?:)06:1I^I*T]]^"#A3O)<:%N
M6Y!)(I?JD[(M>%9FI%AW+-21$=T6YI^J^SIR*1C9P%$O]T#OVYJ/O7-8UUZ^
MVNCQY9NMNR)Z!\+'U1,-/?02;O5U,_7!KEGW4^Z0B8INM'IB/UHKWGKJO;L'
M#I]"/#ES\)N1?'?PA+.F%3W3B^?^)ZS$CQJSB]S\?@0K#-) C!#[/5N^@=IN
M/Q*Z*>%SN8A^2:AMR#\HRP;>V _Y*H=EJ/^1CY=K$[8'$MEJ*#N02U+WC)$+
MTM%;7KOJ0<RLIYLYPMGGVUFV[[>GL7^IV6662WN<7QZSZW":4=URKD:%LPH[
MU.'H,67(6B'C"%A[<LP,40%:S'5[[1YE.@0:%=TD/+7]2[_$!JEHRT\G[E[(
ML)(4G?:P'F+TY1V Z',CO.9N8] 'F8*0>75SR(]-Z?<^?7A4]VXD#>LP<J-M
MY;O/M5T5VY??;>0]V_&S_L.Y2]P9Q4QA:L[:[B=,I3_PQ-Q/_?RXN4RAUP""
M?'HLM*$4:=#CIO5V2&][31&OK^%I\=5:[/60@(#Z_0H<^AVT83$-XPN/8VM2
M22E,N#?%(,U+EQB9(P<6]BE79TZY+G=H$GPTSGRT7OTXN7M'9ZY.HU:[5 W]
MB@NSC]I(AW%7_(8R::')S4.Y4GE^FY"UZ=1&L\^^!OI7#E>]%=&1[O7M8!PK
M:[(9PB>^W;@@?L\O6JG38AZLH+(Z]H*0"]1=M($TU!%CX>[#]63/4V[PSK9X
MBTM3+OVG5:)X6GC_LNR"[L)T >T2SY@'6%EF/M0QR]<=K^JIZVM"<RS#MW.7
MVH,S'UQ-]'J5KA8(_U9PXKG8T87[>='&].K1H")THN8MW?"9F:X J](@!6NM
MEGL&;S5S'=X*7C$Y8JVAF6RNLT@"]PRLUM/P])-@Z)Q!*D%Q$RNZG$TQ2._8
M18O-YP I8?KA2I]K%U[G?9XKUN)2BPTY5[['LQMISKH\OT+_,[Z7_W=,#?&4
M_0;&8P295+C >OFK5GAF8([E?,[3U($FAKQ[X69+@[-^0;7,^:L'-!H-K1JO
M'I*_(/+^EI7L!9[_WYC<,/,B6$V=FL7TK#E3"'U<R XL5J'.I(<N+K>.U]ZL
MFYK:<R+[W=>)!Y<O77_WMD3Z^"Y5 ;F?PZM<JB-@P\HB!&+3:JF)G7#9Y(I,
M7R+": W:/;-KK,9HS>ZR78 RQ;U%+\S'UFW:^O;9Y...0(C"\9E,VEWZ,U"%
MJN ^VJY-@_9MB=4$WSEGD4-^#3GY^O.F^^#NJ44/&Q]O<:*$>,P8JANF9U+S
M34D)^*6L4PPZTWS(M0-08(DDV[$#.7>.!DW%!4S\8L%M6UV]'P;?BQS\/K@\
M./C7X/+;S@.[3+W )[,&XLB?/1Q W)@DW8.H!<MUWJ!@Y8;U>30]*35R(1"G
MX:KQYJK%=GQ>^'&57\XZM-0Y_QY('!K" 9)6* ,9SG9C,S],W:\4-'I,>WET
MW'2?FNK,,7[W3BXM0S-JM\N<Z.D*J@8]&]1FG$.>7^S'\G7L<EL9=U*^UWKS
M>6Z?KL*QR%6DH=M7][,OC*N6E6PS+MGPW)L3%P'6GI>VV&>2FDB=\+AB':IS
M/-H =6[LE[D_Q23-^23U_(.(UQ6?:P>'\Y75ZSL%HDR]95L%KWA: C^^EV8
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MQ-D:Y[X$8WHINS%E&#^2I]OY0O4]UUQY<#=]G7P=SZ2$A%F8,F397[%X^[7
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M?K['A( *HYT V$__3<,N_YE6B>"BR$M'ON%6&)4+ 13<[YSK(LJ"_3X?()X
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MWIPPHM!BE^'4J&$D.=DIT4%.@ZS9_?]J^<]4RV4_$I2!I"'G^;R\"KJIBV(
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M&>XIF+%?WAB[N7V'THK2 \@.#5.(J"%(/SJXD'7^H;7,F_B7NO&$)L-XP\Y
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M3@F>>N@3(FR_[U.[^">A73D?WI:UR@MOWI*TZPC!]HJ=E+PTM<)29J(R86[
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MC)"X$*K?W0JG>I\2EN7!5S=+;_3B4LSD">PO)R:S+KQ[8]8QS(7<2310S_,
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M]]O,/^,KR_\/70CNR/\ 4$L#!!0    ( &6!654X;"Z.P]<   4< 0 5
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M=O.249I@_8#,QY*ERLDVTEJ:K:ZY_*:6U$)M<U-CC)F/4M^>X_?S?(^T++.
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M/*L$[C@FZ3ULMR2N0?9W"5CD4>W<E$)N7C3D!FCI$_ANT)T%* WWX*A[&EC
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M7VJ2+$#8;4D,[>\#^[&+!D59P%%#&.@*WX_^YLG69%8X,/5OKZC^I BSH3'
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M&W!P<O'N7+^?GB:+9\GWS3'%F;HFZ8?O7MKS -H R >T* IH&K7RN\E/CR9
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M R)45:[K:6)?^>;8RD4//!TUD;2%2G/V=W".1.<N["AA1-"Y^!R52^FW$[@
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M=<0F0D0VDXYZ:ANY0=P&YA+Q ]VI-DI2/"=?.A6A[6VI"=^/1HPVQ2"U?VM
MG =J-PW5GI0)FR]#G*6,1FUFNE(+*M<..1H67DI2D!CL383#/8BI>O,](I=J
M-4=!#XU/IV<N>,EOVU7[WS]\?[<AKT=C^.-WP*:#%-28X=1H] ;N$.(:,YOQ
MR.M1#NTY:2U&NCYR>-KVXX O7,>F?&#*U^^XV[IE:8X!UYV:%(.+8WV7VK6T
MJ^S0QAR+]#F-[E)>G$*T4W8(G4A>6L(T1.2N^&3R=.CM=A<=<D DPEY=^TZM
M=U1 4<.0?ZU,%*-"?;WJ;3&LNY#P7,[S:YFCTF'[VTF3C8((?UHSQ9 :24E:
M?D)1LR=O_F")?U/O.P02I1F:8BS";0=]7&MKUO=5;HDJ\I;UN6I7!/662TL#
M<*IO0U%4-]I-2L!4 ?.%;W'(&NWR/>];GX80!LI :D1'OO# 9-S\*J"KGGXK
M+N]CIVI*VZ'[$Y@FG['P9LRNJH2 #I$,V5%=4Q+LL+Z[SWL:IBW%4:*PQ$OD
MHM>]0L^]A_2%W#R_*SQ0^IEA^/#K;/'D6Q-[C5/:1;1TF2.5F!/EE3G5UM5E
M26/]W5DNIFD]/MPH+C?JW+@1;G;">'/,S_W=0K +)FN!XAGL7'1YKUSUN6_W
MN3;!S,5V(6A7[Z-BK?-U-<4^_O2*H?C;W 7M]HK)V41%>5/._;CFP(.]&F9S
MVXA*BMZ9]M(O+6Q=;UP&WG;!_"5T]H)!J,]+>:A1_.BGT0DRFO[6@H*,SOXG
MT0];_'\0DO_K[Y#,!B3A]C2":.!1,UH%43G"02B5)?6F\5-F>_;%F<DQK<-:
MZ K/9*ZO$F)[9'1W.8_$D .H@12I)#AVGL"-.*Z7NU)KYJ4:^'"4/UX5N(.[
M[)Q#OOR(9]RIK=SPQ,L4+:=(*Y6+7 58.=IE70(W^ 0, 1C.]5D>3SZ=/=4U
M<V]NMW'J*+BLVDCR04IP[(8HW440O3(XWJL'9=9N;OB4S70SPT$];(#28AU$
M;@-%W1ED&/LEC_SEX*R7!'=T7QU5]IW0[)4/"0GY=**F)DPEYK#\H:*B<]<
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MFF9%-;M0P2_U::>K&VJ'3@>D;ML#\9HY)A5B0DK[+;X1/OQL)<1@#K(![O+
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MJKH2^/6;NIE0P0#P^:..%#E^^*92??JTS[(<70K9G^+YG'&7F58O2))3?_O
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M^0/RPOWB6SL5)%+W>AQ1Y)&)$!\,"CWEH^MYE/] ]3V-TEF!?=Z2QVPB\X1
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M-,-^I"/AN7?V^?39XDD5Y_?5!*IR1@XVC=9!4[&*/_/SI89Z?+=2JH#[A/&
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M?C<YYPL<-^7S7C3AB9["-(L19IYR] ^Q@N!<Y"I@/KN6X,955T'MC#\F9[D
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M)#Q4HS9ZC24W-JD2$X"-+7N>ZW,%+I+CU:UG&4@+XYTU6T]ZKE"%MD1Y#7-
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M(^8<:=GR75=2/1)8@ZK$IKE]DLUS#DR)Q.X*H/Z--AO4Y/B+0S(D1O\><?C
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M&6TU+%]\5F<RR42614JZ+(E/D+ ,#^#.GRBP?:?QR<%&\S[8LI1WS@_U5XL
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M+N*62920%/+T XK(G&=TM7\K<VC>BE$K.C)!'H#05$LKR=I;V5.OK!_8&)I
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MUXSI^JQI"#N4]/@)>N?FK,'HQV'1@95(2-P9=!<\1@<EWXJK8>NON$FNQ99
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MS+ZC>%H#0U=98S@,[]OU[)^U);\N?>@P/HD![;=9E"R]SP5FQ^^<T4"F,NM
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M#I"&GGT$JT.5,^":[>^04>1UB _1BJ(DS[S >AP=CG<[[-FE;E7I[Y'Z6%^
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MQ8$?)P;\\8TY%]-.Q[M]//!M;1H7F34;(/-[B0/P?0*CRD$UMC@)C'_ICBB
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MO+65'6%.L5<Y+_5[I&_1[$SZD;O'14)]Y+H*X6M*M *VJ#BMFGZ'!EN+GIM
MR2$BR9@4HQ4]L<"M?")R##\^KIB@?O8KL6/WR_#BZ<DV7\.LFM2\$M?L=DM:
MM403JZYHE"TB4<[N<,,*XAQN<4$%#GX:["U0?$*8K/+%M=4WW$$\/3ZR&#6K
M,;]!]6UW$Y-'QE#'Z?.L%VPM[F+PU: HVFW&&1HLC1 ,5>'&$-[CKAWF=A9K
M0R70\]XC4O/FK='1$2%AX?X29/O"$S8W2DWAO,Q]-+<.#@ >\>UJYB?U#DH@
MJKNVT'7A;Z.>+K&UVKSZIQ4P:0T/BO;>/.]HKNMB K=X'A5A*#").\^[3I*^
M"!8-=FU%6XH-KT:)7]B[K[?_W&>?$>'GJ]7ZU@:V,*($8:3-FUM[8>@.#Q2W
MXW18F7O1U&9OO9R-04&1'J CY?&:4B]I)TXY6&O)5W;<*7@\?USBE<X7PA.E
M[D^OC$WCOIJ'<@#W\06Y3/1L$5S:4A\IU<1J0U\6=R%U$1H(G7I$7LK'&>FW
MH1J$S(:..0ZPRY -)2R<N/>QM-OOG="/KAO"HD\%OY!P,*9T-(6P6L^PU>L4
MK9ZHZ/8Q'8*DA&T.OV::?GG^>=,?5W >/^KA=DHV8T#]QL7GU8QU[>-5,_ZS
M:C"W<8K)FAFWX,Y]08?  1)[ E:WV$V09.J J;/8)-?;)MU006OEYF53@5=L
MDV'MZH:6VNN\)]/K8L1N],VWB#_/4SV92H3*2-$Q8#KW-/4XUJ,P0C '4%R"
MBD;  @ZT>KQ&>-D5C@TG$U>"KN9X7>S8X21TZ0+19>V0T+M<U9.=<99+Q00M
M]B'N%;1%APPF<   &<F @9 >Q;ZTUL@ 1N $4HJ:FD4</X-UQ8\8:7F%V2IE
M>3?(NLG1K P;<RS>GYRQXOWXT2%_"YXD!Z.>A?.BQF< '-6I'9.-II9O5F@Q
M]#+>T\I[VZ0_8T\UN9OWZ[AV>NGX?%N_<[I,H3+AH?&IZMV!9^=YURQ<'5V4
M]2G>.S_-4#8O^09%1-\8ZE%_:'9A_OR-C#,\E[*.+08MP?50'7#J.98H_3WK
M*=N0_1ZE#WI!X]O4F!(TL5N*/U*AZ6[G$YUQ]PXYK 0E[3*P>WO2+[!K'XB_
MU#:\Z8C210T;NQ%J(M;B39BRY1V-N6799#31 0[>H;'-W-\S[)*BN#U%]/T.
MUGJ==UV3LL=\/&IY2/![ 5/&@2WB3!UE"U]F'!QDV#.MJ TS:BUOQD-_18@C
M7$?/.GC@,E=28<T>WNZVDM*%_E?*T]*6;>XL)D2T^KX$SW2=!1/)+>)0ST*
MF%)0%CP0R]^0"DK>2I'2%="?\?SYUU4Q;!\,/(*B]].K6;DH?=3(+?QU.$*/
MK)EF;C8;D1J]ZYUZPI8[]N)HP#AN_SMR9VC]:$[??CHQ(3%=//8 M9\BMZ;'
M<&5WD*0XP&SQ-GK-CH(61+P:/$?+(W5%[ S::&_63 V]J<58,;NCM6*254K#
MKO+_\/OKD2!1_OA0Z.F_X641E[N=A1,?<PE',I<2M(+BC(NH 9+L)CQ%Y2"8
M38&EGANX[!<49E2OVQ)U265LWE'JU)6LK[M<#ZCJFFCE"\I\OUU63].DAW!+
M,YVIQ<J'SA5D(R^0(=DD<7/O?65%FE_&[KR%N8_L?+R'@'LBH3@UD,*^&GAE
M2J3NQ+"=RH@\[U++8*:B!@=(;75^B32J1\L%6TJ_S>TZ.VSH]4+6%W6OYS".
M9-8GV61?HAD9UU*#NN3:M#[A0*\<A87#)N7:L;BRS-GW3(N@N4HEANV437.K
M5[K.V0_?99Y?.-LG?#\^_J_(+.PCV&P*3.@F)H4-83WC '6MOI3*XUH08F8?
MT7Q7R(QF,\$U@^0B4@\K6KWZYI+ [XE'T I)1V0'0Y'KEPKL*@PTL2,7K&V2
M!S%L#?0NA*;="$X)(F)S7?&[?B!\ZF68\2.=1\<U@L+4\X@+&*)DM,!124/W
M=L'52IG?9,8%U.<B"Q#". _BC[-JS"_3-,F$!!Q6(3"3ZCL7D52UT$1%88,6
MW%]O[\.+\966=F^]O)7R[8?:PQ]]!8:J&M5#V\#O1+9(&+?>!6E]3*F63A4A
MVH_[#',B8MV!5HZY21+LPRBB_9T"7I :,L-7LP/T&Q0P8N2MEY<W)'*U$>OT
M4M9;MBSH\I,"S29<@NR\&'C;5/3)33!DSF0JXFFMJP %$?9\Y)F<N+37_$92
MQF!]\$*:8#MZ=J$)Q^6)5R,2:Q"NVY_&SZ.)]SL<RKXNRV(L6DT$0C Z"^GJ
MV<^/36AG?'??P7O@J,IF.:C$%@DJ1UZF1J>QCZ)&H2+K;="@C64,I8D-15J\
MI6Y^:5O37PC[X5=P]LNF4'G"T9/[+#)X'S[!OU)^"G54>YZFGMVE)5;!>\^N
M4@?EA1IL'E_+FQN<.$<O8969PQF1"#8'Z$$+MZDB[7"@6_3NL6M373N3+3KP
M(2N!E6.BZT:S&S,F5B*=0,:1OQJRN>)%"!8$X^J)LQAB9A=4)-QRSTH1+_4"
M9G6<')%&G'E$%IWSC:T*;F8,+MC1:\2&)XE]7#35UDZQ]U?QU2_K!;8&)V'T
M#V@BFH+NU4O>XG94)Z$9Y%X:CI :(>7Z>>V'.B'HM<ZZRS6=_C[%AS^D1-0C
MEZW>J4S#<^ [88&8+!CU#"0>2W5QPO3UNC!M:6@NP<IPQ4X4CKT)$[I3?M]F
M9.VU"BTL5SWGZ=U OIX+YEU\6;?RU>\8/S)ARFBVZU'QO3"AMIU(%+<;S]%4
M'D-[)6@FO2H"88+=MT],>!^G$$4=@VU' S*CGX1JSYU7A>F>*+@5R/M+T[FY
MJ-^IB#YUIG#CY.6 NR/3]^S-@),V^OI/KR"4'KEIY@H:S1%JJM?BL(U]G18!
ME'L@/';V]TTX-*1-MGDX2ME6ZV5NK#[=X:AWD<1"PJ"2\JN+.S].A[QC"E8Q
MS[/PL-!JHB#Y!YXVWJLB1"WHJ/2UI^*3#>%\P8>7MO1)7X.,M[-[JZ/V9L_,
M?ONQ_VGRS[ Z@8",XQQ SX(#"&Q/(NK/L-+-/<K!K9YA,-$[<6X+XSN&^QY6
MDFRDA1L//S&NM?N2JO!N@^2STN'M\M(\6SK2SL?X_]\.A E3VH2K'*@DML@Y
MJN0</0#\0G/H)4(2-Y5>:(XUD 2\)Z8:GU]ZI)GLE_MM)%HDM_<NGY_^^?"O
M EHS@4]W0GQ814@YFA3]#H%5V&:V;,(!)&Z*AQPO.$D38VO+4A9=&W-.X?\*
M)<?SKIF;!V:)I/ =FKZH%X>^A-X!AE!@B>Q]3%NPGR9(L5COJHB9 V/"YJ9=
M1Q#FYAN=83.4PR$AO-,764\*)2(1XU('S<A=]FHF+<['5#2C&1*(&ROTKWA6
M*Z27 RAKIJ^URK*E,%9V(UP\0]>IT/14)GI#3T\&S=G^-%\_Q$_<+99!_Z"U
M2%#@=GIGF&\U+R*UV_1,!:5:QGNI;5=;45\/^_!0F^)*<T%J@UG3(<V$E0L-
M];F?Y-)HNG[=ZC+WGLD_%<,"Z X=E"13&Q2F\=*#N$VSGY+RB R!MM5@)Q/A
M#4_,+4)>.9IOC17>< I<DK[A$&FPGN?WR %9MY]20AMD2I+(7('"53KP5'@M
MNYIQDGDVM9,#B.DU.%3O]"9>#*R(50L2YPVJ,,\ND\FY%(*8N"S]1O"COML0
M5IR]!W2BC'<-"%*JXW!.^$"??<-A46&R6Q^N,FQ*N[4,]<,N*42KO>P LC;X
MP\X*)A!61<G9@I3H--1AIA+(HHF2%]-:0\2?T387D^9'5*"2TU.=-1JLGDHZ
M-C)"?#+[>.M8;?M%_NDG%1@_JEWBKVH X=K?J:C3LSI&=\Z34\S[56 B57ME
M4+ONG<-[-0,#@\/J^?MP@4]%4'M&]:*>2*Z<&FVUB7D^:*ZA^KGA5W)YHR\S
M4//NR7X(?3CUA=$&876+VT_3P "& 7,'6, P81YEO;34LR>3,HAW7[X GVR&
MK$E2EO2BY,?,IAYJF+IOS)R_N,M:-=?C@ON/ZLK]3R$%K4'<,]2 47/824@[
MM/9,.>,DTCFQ$R;^P] #"8L,NEY<R:BZ-[9>UF=86283%5]YY7*2ZPW(PQ$Q
MGC$02I<9;I5C7(*SB5O0!I-NBX">V]6)84B=E^[!Y;:*4;V/(\SQNWJOX$>+
MH_P*8["W3[X^G23I)F(QDG!,P9#G)P=(XM**(I0PZ'&G*HC TV;./ G&DO4D
M0[9,/]7/0H27;PF7XJ8_IC@T-M[)/!!AN/"HWTSCR4>1JE5:VF2FFR-MCJX/
MVM,HC Z5 V_>CK7J4:I3"O0'J(S>(JFW)XUT()_BK,R='Y7D*SS-W_-27:I'
MVX7?Y=VIEXJ$>M*:-U6/7H:6U^R R%X,)E 3$'5P<01V3='B2T[#Y[D$A?DX
MG8_.]12SM+N;_#M_"/?<U@&NH[DP>9%YR&2[( VE ];W*7XJ7:@<:Z&L9#H9
MVJBLZ\K/UN(;<?%6_NH].PSN%P0<;%KD *'020BY;ZV<6C5(CNZ.V 5FGC"U
M2_]%D@"CNWTD/[N,NPQO>@EWT_&W-NQWYZ3:*:N8N,@SWW2HO+0!$%S*.R%*
M'EQE,6P0]?2_J(,]U6F%U6GFT65!5$3O.)RFZN17X>/1>2G5.5<C6>2KD'O/
M0HE.W0OO>WM/:&DFP2YG0SI@N/)L0FBL&CT.C)M1IWV+#RD),?7K"A(OMPD*
MU+7LK>DU)*L^5/SFYAHD7V^R;M[S.^0SZ@#S'%6O(X+7APLFF-=O\_.N^'JH
MB!ZH*BOT4'<O3I#?8Y=/"5*_>??(%;M<NZCSKO[ !@R A4+CT0U%;ZM! _),
M[6M/Q/W.XNE6.[*>+,*' YSXT@ NBETJ=# #+S_LVF\WJ?\R.^.0V*D:0,5A
ME@"J8]H)0J"H%]5HL1>21OS8C.VY0TB_[99FI.QP)M.%NI51Y1]3_OGUOH;:
MI+VW\L\.?:CK?*^=T^"G_. [*,46CJ96=!(:O<O7:!0"!B:#A--TISH'R9-&
MCNCNQB$OI[)'N5&-(8Z68T3^;/5CE"/#$I./GGLH9+H5,V^RZM@[4)_8^Q([
MX+MP U?F/ ML'GLV#3,/D[VM/9OK1HIC<X/E#KM;&4Q-"7Q(ORJBG)=GHE^C
MDCB[+@^>HT"3&@950*GN6YZ]Z95!5%*08N/C&_5>,UZGXBF%!Z3S;EZ]U!'?
MP:<(X"HF+RY[7OCTQ._UQ:6?3KQ],JS"WI&IPWS"NT[=37ZPP5NB:W?03F:!
M4*>W6E".>F<)&4-"GC+#:'U9H5%8J>7;S-3>T:61]Q&Q+WP&8F_3<$^>U$[I
M#'2/Y(5U.-R+MY-9N;  PT6L53#,4#UM"J.M]K3UGJU&3.5%>X'4DL!"_F^5
M+Y<C%%,+WM7797C,GW<IG1>N.]3_MN#&/&\WFHL%H*K<ZAW&&:8+C0/T"F^N
M*R"@'F!Y<5!A1+>"N6#,Y?#"H1I" GN&8O.F'GN5$A(2.V)[[G8G+V^^SI*G
MYJI"Z1(<MUF]5OL"-4*0-'*2]T)(L7=M-;8IJDXX/7_<@;B"N#RJMO?C+.SA
MZ^IXO!FB:ISNP:J$!6"FO,C\V#[T9"HEJB"#J1=S7:>.Y-FCK6]U76&'0\SL
M(TFOF(*#IV^HUHB5RU]R@E$P4S_I'M3H[JGJY,(M3-7<F]$HAJ.@Y_A>ZMJO
M9MV\BND8M/]HU:9ATN34Q???NOE<3CTW'*H("RIV WY.04!U].KOJ.?(\]3U
M;DRZCR4M'TN+[I5 U'<;$W\\NQR^C7HKU"B[782UQ :$63SI5AWY:NOB6-*_
M8*^.O0AZ,\Q6?/AHVBH':'UK&C11BGA/<KWU<VO*[U_OGM9^;?&QDGWD&WC_
M0__&[_OIWE:7DJ/;UM;OPI0MI=@#!#$C6!96J34@XBD8:>_.GGSA))V;NW&R
MMD?Z^HE*]9'W:L^#I(,__5A^]?JDS"*IE@,PI<_1[5C-X4B;$M0G@F25'JY:
MR$G:9S^U]\U3GR7%JGP_ONY1#Y*U=,=NL=?QIXH>O=L#W'%<E9SVZ _A7VT<
M5#_]\KJ0"TWRD+)UQ0&U%U^%WLU+]"!7GG)[M@%*QIH:0>$ [7KI,'GS.W,D
M461HVY<()+P,;([5:<VLM)+1+!Q>"]T3*#21K;B0:WSLP].?KH00-'@P>M6:
M 4$\,U=BG&!>:!O=Y*NYRP'.I]I0\\LKLE4^V%UU:/E6BW\46NQO*S(JHX?+
M2!'IOH..-X^>'<Q0$1E!J3%-:39W\4]#FF^:;!O7EEU\/;;5./(4\2W[\[UW
M'ZSX;AGR;)!ZL: :9/4][3%=C%K E+J&M 7CR1');5*-]5E!7/'? (9'>>@L
M_!RY\V:Q+J_0M6F@ZR&S9J/VRN$XHS#"[ .8R%ZJ4WJ;U ##BGG^?H>/Q>>J
M*$C:C#C&;33L-=(IZN94]=5'E:MJ14/>Z'[$JA_N;NB;JSK:KSF R_ Q%0V&
M)[N3 $&'8%-0<J!5)=*6!D]@PLC074NWQ_(NS\)75Z(89QX;1DZD,"X\Z9T@
MYZK[91L?F$H1.W00DH:N:<RD&="?@!$,=T0J/0E,*E(#O4J#955VU^-,3=W[
ME9G&-/BC.=/K 4$]#=H]WL?UV=]MCU3?+(XSER([,:56VN&\YKXT6"]<J,V(
M:3<T1<&DK3.MT*5=E<3!R\7+^$&EF1GWJ<'@[W6GAP]8(O[:M[B1=&?*7)M$
MM5M//(?N,./JT(0K4"*$DLLT3"":'9EWF-X=C/9UR'OC &] ^\_U2[XP:XQY
M^-LAIX<;&AA7E<2C)0F!$#E4/UN<YM<SGHT4+ILD@26G"FR;X\/V-,>X"'J4
MIE]Y:&"UGS5Z1"FF)XJTRW(/0I/L%(]#IV,ED>?\BA%HJ]%2PEA4[*GKTK*W
MA@_$:-PRYQ<1?@H1I,DQI1S:?2RHBYEL*/,"ZYFE!HCOA.\RJH@]U]NV:URW
M 5NS7-]#OW;^M^+-2*\>S<G+/]7PN1I7Y&<5=N-'9'XNKG+K@=^>E<Y5!AF*
MU1UZ\1Q )@+>JVC[E]&!UL.4")%@3^5?VS&7BNE"44H('X3PGH@LX^G^EG R
M]C@XQW!"JK**U@T=(7U<?A19B2AT2**NI[0:D5<&X.<_GQ!2;\K5<MA?FE><
MKG Z=TWH\9"LN*H6$+.X]H=G+8&QW,4EALSUR+ ,#J!DN1<1<8J*R=!FVI6Z
M(_;]=,2[?@D32YE9MGM36V1WX)NQU+6L>\+'CQG%S\' ?>ATMAKH\[.=M LV
M6PIM\*\L#KX>8UIUW[B2W%3<%G?/1_BTJ>K1]/;]W^4%;?V.BEEQETR"R[4I
M(6/ ZZ5(+]":,A46V=7\6<#;S 4G]HS>HE:B%D=[=[=:J7>Y6JE$[57=/7.U
M+BC5'0-JHC,Y0&"V"?WR,-MRKKOP6X5N ;FE?U!\V7C;$H]6>G#'0<?%*ZJ^
MY<$A(I]+S:V]9^NO']OYQSV^3JI>%WIRE!*]^KX8-0*7WC>$T@Y1G"FGW)EZ
M_\OU;<:<>Y"7B_&&[L,*^4=ED0G9-=CIU0H5:6Z>!2"/@N@24 "=BE:Q5 OT
MT08C9M.82EQRGF8:^RDWRJ/53+%7;51W[K[3':UWSL5VMOF3I79?EY>]^V/5
M+A(Z25GHG6Q#CQ!/3!=ZEVZI8"K3"4UFN;K/^;GCE YDF1Q*.#9=9W-5_7J>
MFOE9P23V((%J#YMTFQ5X0HNV,<5D,</*F9%-1>ATQ0@,\^QV<ENY3K>HS,<4
M(_?/YA/:@PD?+K[V-Q3))"+WLC*?@7:0U%9C;,-XC]XNT*DS2 01V5&D^F55
MO:'!_9!.=\$A#YM8A"K/K<HO']OS7,B3YS'!W*ITHYBL6I,ALDCX.,J,:0P2
MYK I10=HX3EA98A19ZK,9BYDE]>45F5MT]WMD6]&1>HYP[K/W*MDA. FP4_=
MT9<&04TNU'*;K*93YUN[65*[3F3/^&V5$HKHVXM=%(*D_0NC!KQD:U6.+'!P
M87 @46U60<56J>+K_J<[,OX+!^% PZ R>XH#4*TNT.R2VS28?,T@C;$'#CYV
M'?]%4D"H&A5TH_AQG\,76ILSG>MO\*_5O3?\Y.\B)_9I1'<A'NT:,N\D@.HG
M4<]!DM%\ZJPGY@>XE$&#MC/;XLF7(BP%*HNT()AL*S]?980Q'U8SG]A?NNND
MJ\H! K[F/+U&.KQ'DNG)S9@XU "L%LV4S.SB #C2ZGI@FP%5IR#IEXX>V>=1
MV*TP[KO975:7R[U:<_==XGG$5SJ*#)%^=+R_9L-'B3L]GTM087VP9#@$I888
M)^.[64H4_[8BE2]5EE*(@'-US=1;I8:GZ:.G\29NQ[<[YL^%;\GC#AOT+@C=
MR/S*A3JJ/3K!@-L$#QG"P7W05'._RJ#;>BDW[_!1Q[/4W$EG:[^\_I&[+7[V
M (\">Z(HQ/;0Z]>TA*?SM\L[UT3I([$!IQ+GT!@V5-SD="9[WSD0=J+%*_OV
MI5)KF>:<D4Y5U*WLTS_.2)^*DVQ7D:"@B:-T#D!S8\HX=$-KH)U/>,EGDLD6
MFN0+F&PT^<AX0Z6#:S,^XPXCT[#QCGO5FJR''T(A3E*U^\5\0WDPEI?K[E^H
M"3A.K@<"[K-;.TJ=@2H$6O* Z=1SW8U%\N!?AF&2(2UHB273A(G^,(M$^QN5
MY7W1 :BR$_?7("J3Q6(WZL>?@O@N:(/1%G.W H4DSQZ<,:&N/2>ZK5:3)Z*J
M=X)5G='U8SK?QG&QSYUX4W&%FND>\*NO/FSLM6HRO?6W^[_WV_:">(8">P@N
MB/2EM8W TTD-EG7-BQGF$0))PQ,>/EZESV]'_25;YGH]($P\NU4-F:WVS5Z8
MOW,_/P<@3K%%Q&F"]$O@6RJ6?K2%5A[GU V#+FV7U5+TH"$^T-;&H9OBJN\?
M*,67E:X,7C>L<Y"6Z-23EO50#Y(X9EW-V,V>*8*!2[1!;A%V42J@XHA4=VI1
M8D@5PH$"35S5"VV%41P<$F@/K]Z-;KJC5!'SQ>5DZ]*6W<%337Q/L13!56?&
M"7"%XM99/27/]*4F8_J@J9ZH\K+@;#_RXP?4&<+SX!TPF /"<Z'J\GG$Y4(M
MK-&DGYNOE%K:?6*;\@1[F-[LCZ- ,HB#R7I1'F1>*^I8_&XZ,?;9L7GA" V/
M?7GS_DK/)0X6OTI.?FCPCH=FT@D##\@QI=WZ.$"M8 ]I"MMMN0-T*%\B\+=:
M4[X;082F@CS_&D74]1U[@UUS\?)1^J)XY^&E7$,]_L%'AJ$]JK8B%L:+]%^L
M$G,Y\I_&W(#I1N]$V,)22"K(R&<@VHF:UY83)4L@/]Q\]Z2A(O/Q7+3&VZ\I
M3O7/J1JMQPUN=.Q[8-U\,2*9F^E.$<26=@+U##2+4$.OH$2DXCT)/:*#\CA,
M>MAZ=4EC36;WC9G^ZVV\X1[$Z2IJW!%)3.N5J9]+R' 6=WKP>@:V#K_ZFZID
M/]:F,K%,$C"_/KLNL5Q8VEL:J]'V>D8%4;3_2I:70-)%^7A__PAUOV,%9G&"
M]]E=T=A&UOB:&R-\@CV IE:%WHS5FF..-P[.>:MN;SC>.1\+.2U^J3HL&AB=
M<R<G/<YWN/^XYL21M-159B2WU;ZF_L!3#>@1-+=.&"1(43"= P0IZ+%[-.\N
MY#N:=%"#KH>/[6N175!O#8FIC=B]G_I[XV3YQS3_%C3 [N4 C8/M$>DDQ58G
MJN@<M*O"VV0N.D.N1Q^6UJ T53$H%**_1&]T$X<4J%]?OG>0V$M[GO#YQ[LK
M5F47N9B@:6Y!'26C5W^6L?LY@!3<BE:^.K*%IB:#J=W-,81$SQ3VUZZ*J>##
MMK3#<BU9E>JAE=+/E"\DK.Z1Y0!^>EQL[8-*$4*4T70;VMN^Y-:K5ZBG0&PG
M6@K)4^*S1+38J&S'-XW\F'U3^'URYL3 [@S7&-? BTWG]Y_EZJXZR)H?UWTS
M5@TRB&8[:#_,%D8XV8+V-"Z$="@FX;>-J]%Z::&A\XTF^Z9S-R2"]*T.^#T:
MN9IOS^<O?\)1'7N.:5##*D4-OP!3YW1;R%S@]=MHB!!'^ B/34)?YE,V9A6N
M^N\YF)1AE.WP0TJRU!S/%EYAZ""C6/D1*#V]GFFW3L]D0C<ARW0<$_J<NC ]
M'&N!DP*,=]8?+W:63[5$^,UXJ;C,&?+\NK"):Z4)^]<XI,:W3DCDV>_DZ7#Y
M*C"?11MKV\=Z$K4N!:ZS10WF2+M10T4"6/)XE@Z*?S*0L+-506/5I*O;4LG1
MXX?N9GX+WE<BW^S],SQ#DQ3O?E1;EP=Z!<$!SM"^E3Q%]^!H.G<?55B9.O &
M%\:\P34YWQOZD/&=["Z5:N=J*S(1):X$+G8-3CI0=/&,JQR@*X(]U*8U?'7<
M$,,S2(;R(YPZ::?&/&V>#'QV<\.[?!UL=*AX-#,S;271G6,G.U3U:?"8RAV&
M\-=!"AH\H+E60B%(1+Y<FM&GIJ:&EMS/QX]4,DW"HG?HQ@B-DF8<[B:7^MHQ
M)426*>-T_;%6GE"'P")1<'R.M!-TY@"IC(/CW?B5T QT4\;I4X(\OA=VB_RP
M5$5]@"NUJC'L$7CZ$U:.I1K"U_H+6QWATW>2]BEO3EGE3HMQ2XV41DJM8,Y!
M$ZSTN5;]8]T:W4' S[V'PV,A_.R!%88B-_:P15:1Y0XD/+6K$)O:JH8J=.O6
MDUY:0DAYO#%PTJV,$KBP+T8O()<\!]4R3#[6RP_<Z8F<41UI4T+8N;:!"Y0O
MHPV,;*VNC8Y8BL6IZXKN2[6U30\5=J^E:+_(M9477]A[XT00/I]U=Q.-4=Q:
M[9A] J<_V5#JN__=V23M&WZ$V'W1(5?V%L[WL8=ZECJ&AROW?KR/Q_/VP6:+
ML?4!3&E!^CT:/*F!,%E &>^,A;8WJZ>_0&1V<@")UJ,OEH4IXK9'%9YZY34T
M)5F\5K<YV.D5FIOUKNI%Q3$9V.Q]T@X<A)_(#&:]"#<WNDY>@\VM]RK]>:PJ
MI"M:MC)"HRIWR#HL),I0C">%0CTV7I4DX!RIV+3SM> @MKXLL9C)O?J)_FV:
MB J*XNM"3!978#C28!GKB["WIMT%VSV?"W;V8?45<HSO?_@M!$MI&V+=:Y5A
MQ( H]*X5-![6BTUE:[2TR-: $0Y@&/G.$_W.3O6?IT?>TU^6%7J4!F3=8,A<
M]GXE>M32AD( ]T5T]Q.29RQ86:U2M(*3(VQ>I@,MC%U=%51^ZC$CTK[F<U7A
MNMNPMI_'B1W$Y1A=XX]+;3-F[^^I)]E^YUGC /7:(;11NA>H0W.BT+,*V'N=
M!+\7J?T,[]")>#7P/"D_-("_O?FOR+_DWLWO,#\WZ];9#\E&4]VJT^#XP?C5
M$8@(Z$76AHFH?B%?M*.$7;'PJ-X4OH?9K)V4GZW[&2,0@3L!^2%4[<AJ08FC
MQCB -"$@"31AB'$)$Z9K^M1R8%B4CB^\IO6>5>E!\EJE99^ZBY5ZG#;JAFGK
M]?S#^O9U)^8(OIAX--5E/<7GT!#2@F'#] 7W1E '.[=WYS<[);(A3%C;R(S]
MB1#Q5A>+A<_+^<-[HT5WV>K6SN>)"0F^0 VW:7(7-&3*T;9Z+-#MAY8Q%%=N
M/5,WWQ*PD126:TC@:QW#^>SZ1<=K:HVXDS2\_"?IPU5>;&$/!C>"]#_T+@:Y
MGY7'C*XH_=%"UA-][?FUYN/5#+/WI;G?$+Z16R49]D7JX4N*?^W,6X W.*UV
M< $SB#:X=D>S;ST1J]S&TT.N%)F80II227=;%5[#VU*\12["_6<VY&?H?OY9
M'\\_)._;WR@<8!![@'$(]*)G4<L[O4*<B 2*?S*%H'S1Y^O7X.W4Y)O1-2-D
MUWMI86N7<HILLE4E$JY&WXI4"^\  !?62_,8VG@[2GE(%R6T5"2#3UGOUH)F
MM5Z>\RI5C$@VO(HO"L()[V$XMDQ+TKIV].:6*<Z?[+L:"MG+U5E45DT49$J.
MC,W:C+WEO7/E/!72HQS2<3N_GIR48SA]^761<<HV\:A&7O'=D)A9M':_[I@V
MW]TF7^C:(D,+Z<]Z'LZ6 >MGL=T#@B<_HQ21-JG=HR"Z5_'B>*%Q6V:8^0ZM
MA^2<W?:BIW7WH!^J#ZN%O7/E]K4)$[H%N,C0 +?F9-8Q[$.(@&XV%,RC[?O9
M2[^^Y*-0U/N#Y-R&QSDT?7W[\47C]S%2L]4;^KOH=Z>RXF(('7K$0;:(&>,D
MZC.L ;:Z2;90FMU*6D.)@/E=3B.X 2?;+T97QSQ_.J1L:]F>;\4=KA/FR5WD
MXU$]R-4\!GS@!6Z,'&F+:T%DO4E2%ZS>*;[!48[;J'<CE5XA2KRQ/3D#Z'+0
MS&ED1BMD8ZA#H[5@P^C7^S 1X4M\$3F3MY+"Y^C>K(>$X(@X+!06"+WKN8W@
M=>$ R>\I7LKHDR.O-Z>^<YMG &XTK&&^L="UWO*&X:V5O7G.(C4'U?;6%3DQ
M]J,[#G"%<?7D8[)3A]FT%J4\8902T-Z/WA7D:MI@C+^Q9*DSA'O<V])<TYJ4
M5#@P<@&/*,O^1J3*'JY[-QPGQ &NB*YC(M$=X; @<35Z&H[ZM;"W@!K984Q$
MU9,=/-9"-S.EHBL<9(8:BSR>XV)'[*5.^#\0B*NY(<^SY<;%"K)3FNE!,+*W
M<+=I=@:)Z)/I%7=*82W<]TW\.\$G]ZV5XA : E8*,AN+JP3&3M087!PV^PPF
MB0['9A,:G!)QC^'I*E(C#2%8_N^H7<UI08<GE##U/6'1&J2O\",MK3F''RW<
M2XX+\]R"$,>Y5)^4;<FS,B/!NF>IBHCLM+3X7-G3ED-!2P>-^'@%7;ZK_N0R
MAG7UU9N-+C_>V9I+(O<@O%P]4==%?\JMODZF+M@QZW7""S)9WHE23>Q%:<3;
M3@UX7<3A4\:M9PY_,Y3M#)ET4[>A9_KP//R,%?]197Z.&]\AL%PO#40+L@?8
MLG745J?AL$UQWPN%]/."+?T!P5EV\/I>R+0,EJ'Z1SY>J$[8[DMDJR =0"Y)
MW3=*SD]';?GLJ071L]Z>%A%NOM].L_V^E<1>4W'(+).\>&9YU*'-=49YRZT2
M>9U5T*8*1XTJ0M8*&$? :NM1\XART'*NTV?O"-,YR+#P%J'$_IKN4SN$O#T?
M?7SO0H;-3I&O%VW[&3VYAR"Z7 ^O>MGI]4"F(.0=VACR$S/Z@\^?_JKY.)R&
M=1Z^V;+RW??JGO+M"Q\W<I_O^EG[R?$\=T814XB*6=O[C*GP!YZ8!ZE?GC26
MRG7K01 EIF%UQ0B]+D^-#_TZVVOR>%TU;\MI6]&W_?S\J@_+<:B/T+K%-+0?
M/(ZM3B6E,.&7*7II/MKC41@9L*!'L3)SRF.Y39W@JW9JR'9UB+AW5WN.5KU&
MJT05_9([LX=:3X=Q5_R&-&FBR<Q#N5)Y?IN0M>G:0G/*O@H&5 R^_B"L)=GM
MU\8P+6VPZ\<G?M@X*_; /T:AW7(>+*>RVO:#D+/4/;2^-.01(Z%.XUJR]PE/
M>'M+O.7Y*??>DTK1/$T[KEEU0/>@.X!6\>?,0ZPL<U_JJ-7;MC>UU/4UP3F6
M_H>Y\ZTAF8^N)/J\25<)@G_+/_Y"].C"P]P8(WKE2' A*E']MO;UF9F.0)OB
M8#E;C:8'>A_4<YP_"%PR.6*KIIYLH;5( O?UK=;2\'1K,&Q.+Y4@OXD56<ZF
MZ*6W[:'%YG& E'#=ZPI?JA?>YGZ9*]+@4HL-&0_>)[,;:6[:/+_"_BO^+O\_
M&"H1)>SW,!Y#"%'N+.O5KVJAF;XYEINCMYDS311Q_^RMICHWW?Q*J3-7#JG5
MZ]O47S&0/2L\<-M&^BS/O\9_/"X.]L+3\V$";+D0M+21A7[(5*SLNZ_](;S)
M,<">2U+MYN../LX,KL)[7P)NL=OU.,"S2N"V6ZK1PU8[\@ID5X>H;0'=^:)Z
M^(VSI@( (^L+L1/TY@#J@UT$^HX&#C!\P*L!<+:1_F\:R $NKOFQ<.8V#"'V
MAT-,.'7@V^/2@0IP\3AU8# 3UR_8/,H\$/;"I[252S/WO_._.V,<+?'C[$A,
M\!EA/MZE0BTR;**.05_"@P/E(:;HM<N^M$BR92TM$EY+<RV)(6=&X*UW?!_Y
MZCY-G/'0G])(NO_ZU%F;>^L"[T7>S?Y 39,48$%Z$BBBRD[6?4( =@K31>!9
M>P8&O4"4]ZBHCK<JEX?8N11YGQKI=ZR[:[94+)&K]AE^P]BKGS=H^2DTT/EB
M1+L>'_("&$.M<*!6]P[>E4+:T,R%%B_0;K:IX$:25^HEC3V)&%WIL\>3OZ[U
M.M0:_22L]C%NA!"H9R.R47LBX@ARY@9D3'*;[)?RFA%-7.'8S^XBD_RQ<S(#
MOW9]\-:^F:-O?D#-6AMOICR\]OG -4C5BVHL(8Q U*+H=:WO1FJP"M@"P:Z%
MT7<M#1'-BXYUX]6A8PN&.OLZ>[U83F?=W=?R_5+44V20?8O>)SXIG^_=1/L[
M86#2-S'$?HK)JAIMKF>NN[DOB7GT.=C2X7.HJ%/4X6UDUW92@?%'_'4O52OZ
MXY#^HY2@O7?WS]]U%\I60AVSS"Q^B<"<:QTVMT"_7B+J])9>#_+3'@H:RRKV
M*C^A7;OWBK3!+NFK\;GZ-B@T:AC+A?39"D(-)MM2'C4"5VR#(:3ZV (T4H^R
M7*?E$=#Z&4+('2M>57E-AUS@\+GU6Q,!H7'SW.*K]!1W=:^:..BSS\XV@/3_
M8,@L0/$P9B$,@U[=P0&V%<<KQA^@OG* C4"V!0>H$>4 WT..*3MUP601X=!4
M%6B*]Q69J\,Z,@^*DH[_Y;K(W&<ISP&>?H9N?0E@'JJIC4AI4_&O2[O_C"AY
MVA?[M30<'1#$ 7[.05C;TCQ.;"FH&'HH&,)8QH"GD8<Y@-4+V/JK-ZPGY1Q@
M, NV]=WY[[MG^6'_< R,?)C:QQ+@MO^V5XOT6U@.8'F( Y">V?W#_C%I#O#W
MPUYP@*2^+N@OQ43V=@5VDHAF@ET< )4,_?LN<.X?CBGYNW%5_V#TO^S_E_W_
MLO]?]O]/VU_1APZK)@K23W%[6[D3=7 MM&AW&Q@[1Y+T L]UJW6SO8*&=>8C
M8QQOU+VT5G+<[9S;<US!.M?8#?]WDV6>4)P !*37]?H26X]Z)N?55,^!W/U&
M.L8'AG>7]+IKO00>Y(S"IF\I"S^%]%9/AG00^YA2)FP1F5DTP&Z'-=QLQG:L
M9\!VXPCBB$SZ[=8O9TK#2H*N>XABP9.&6]$QES*T4;3WOP<?O/ZQFX\E#SXF
M#X+[X'T1Q!(?JEZ?4Z+E#II;=Y@!N2?OV[/8.;2 =0QFY]LORZI6UZ.E[!:T
M28'ZZG8+^B_1K;CO<![T%?2D&?WRF-'Z+B8OJX@))7MQ ,EER>D5N69HJDZ8
MW\,W+E=(TL$GCKU0-5\[ERMH-(0\QWH""QB\FT^_A59"\8$FO8>6-@PF;"C5
M8I[!HJ$? ?^LB[9D8>!J5L"..$NN/DZX%C)S: PV^P K8ZY,Q73C\84G+/>
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MIE_K_1,B_G]VO^[?_J\--(,+S4&?":M[3=@I(22M=J8;!U [4\H!+@L3?AG
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M[A!7@E-8B0Q3;O.AXD2 XI-IV<<8([?#LLM6IL0'#+;?JE1XHQWM.?OI8&&
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MS>K."TQODR/,!K>8UY?9XDJ"<^22+K35YYEE[2D.HXR.WK^?("0=_ "X2)_
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MQRD9/')]@2:>;ZYOJ$F76+U9U.GE.3Q6*WH"^1,TO\W%&'88?6FI=SIJ:^5
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M)TCAJ839 I+PO$]L35 ;?6C1AE8G,C)%&."@J:9FLJV?HH_N\WY@>V@*1ON
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MGD9L,F]H^Y%N&LZ7.#+IYNU17G8G\HGT<^<;_J&B61W*R"SE[[:"O-V'>-D
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M,K'#):^2DA[IO>.B&G7#0'49AJ3+ !NHY^\C3F-[S7>!=A5+>-X.2_)/ XC
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M]^!QW:ECJ2FKC @.U591UG$4/5HXU:4;!@F4YT]C X%R.JP^M7N+>?9&793
M&V'C!]NE%U4Z@J/KP_<>HOS9/%WQ,=6O'0VP^ME R]#;\#2B?(<#17@>VE/I
M930?E2[3IPM+;5*8KAP2"-9=HK6XB$+R56XLWS],Z*>6Q7]9?W?5XKDG!Q/4
M3,TH8R3TZJ_GK$$V( &WH%:LCFZC*4E@2F];-#[!/9GUK:=R.NBH-?6H3'MF
MM4I(M>2S?9?B5_=+LP%?'0ZV#D E\,'[T#0KZIN!I(YK5REG0&PW6@+)5>J]
M1##;K'Z+:QU=GWM=^'-J]M2GO>G.T<X!GJU.A\YS^JX&R)HO)WP39ATRD&H]
M9#O"$D0X6(.V5 Z$=,DGXG8,:]$ZJ2$A"RU&!V=R-L4"=2W4?0M&K^79\OC)
MGK)7P5YDZ-4QRU$C+\"4>>UV$@=X?3>;PD41WH+C4]"7>>3-.;EK?OL/)Z8;
M9-FM2XB7F^)8@BMT+60D,R\<I:/3-^/2[9Z$[\5G&D]@0LHHBS,CL6;-$H#A
M[L:3)1=D4\P1OK,>BH[S^ER_+VTU=U %_>KL4N(Z)L5R;7=S=3E^XUO(I(YW
M'F0616Y(@!LL8;UYXE[4<#$?EC21J87BG0K [^Z04UTUZNDU5[!W6]?>RFO'
M^8CEF;Q_AJ.K$>-<CVMJ<T&O(MC .>KWTJ?HOF:JUKV"2@MC.^Z@PNC7S:T7
M[@]_2/])<I5(L7&V%IJ,%%4 ?_0,3=F1M7'T:VR@)YPUW*DQ<FU"'\,U1(+R
M(ARZJ6?&W:V*/GUQ<<$Y?AMJL:LLF)V=L1#KS;:1'J[Y/'1",88N^&V(C ;5
MU=9*R7BQB)=+L[J4E)20T@=YN-%JAE%HU"[M:($QXJS=O:1R'QN&F- R>8*F
M.][!%6(74"P,3LP3=X,7V$ *_?!$+VXE)!W=FG[V##^7SZ6]0NOF2J@/<(4.
M9;HM D<K8F:;*R-\++^R5!#> Z>IGW/G]RG&M!NVUTFH)M?S9Q\VPDI>[- ]
MT:O:&PC\.G T+!;"R_JT0I?GY![V@UELO@L)3^DIQ*9T**,*77IU))>6$!)N
MK_4<M*LC^2X=C-;QSR'-0S7TDT[T\P(Q?1&S2J.="@@;YTYPD?QUK(F>I=&S
MV15+-CMS0]YUJ;Z^]9'<WK5DS1<YUK*BBP=NG@K$Y3'O;:$Q\MNK77-%<%K1
MIL+ @Y\7C%*_XT8)O9YV.=*WFWT>NZEDJF"X..W>^OLX'/< ;*X$V^C/D.2G
MW:?"$YOP4_GDB>Y8Z-LVE;07B(QN-B#6<?S%LB!9U/JXW%./W*;61+,J%:O#
MW1XA.9GO:EY4GI""S3T@[FJ&\!(80<P78:8&-TAKL/F-?H6_OE85W!,E71VN
M6I,S;!D:'*DOPI5,IIR8J$GDNQ AW[J[BG\(V_@\H83!N?H)?IUJB$JR?%4A
M)I/38-A38>D;/V!OC'OS=_J^Y.\>P.K*91L^^/!' );<.<R\WR%%CP91Z#TK
M:!RL'YO"4FUOEZX#P^W 4%),D6YWM\JOLZ/O:2^?%[J5^V?>I$M=\7HE?-S<
MBHP'#X;W#N*39LV8F1T2U/S3HRQNAATUE%5;$UAQYC$]PK;N2TWAALN(IJ_;
MJ5V$Y6AMPX]+G;,F[^^K)%K_Y%IC XV:P=0QF@>H174@TS+S60<<^'\6*_\*
MZ](*?_6I+#$OQ)_W;=N3B"<R[Q9VF5Z<<^D>A&2A*2ZUJ7#<4-SJ*$0(]"!I
MPH24OI(\;<BA5\W<:K<$[V.VZJ=DYQI^1?.%-Y^"K O4VC/;4:*H<38@B?=/
M!(WH(AS!A.F9.;,<$!JIY0.OZ[AO47Z8M%9M/J#B:*%R5Q-UT[CC1MY17=N&
M4_-X'TP<FN*XD>Q]9!AI1K=B^( 'PBE#W3M[\]H<$E@0!JQS=-;V5+!HAZ/9
MXI?EO)$#4<)[K+7K%W)%!/A?H$8ZU3@3ZC-DJ-M]9NBW1Y8Q9&=./5.VWN"Q
M$62F<W! E9;^0E;C#_OKRBW-IZDXV<^21VL\6()N=$X&:7_)NVCD(68N(ZJR
M?+V=I"-<Y?ZM[N.U=)/WY3G?$3X1VZ7IML4J84OR3W;G+L*;'%:[.( 92!U:
MBU$;V$C [NODZB-5"TU.(XTIQ'L=<E7PSF0O(4^XW^RF["S-UR_SH],CTL%#
M+8+^>K'J]".@!RV34M'M$>Q P)/]DLCX?9[>W[X%[:0DW8JJ&R4YWT\-7;N<
M76R5I206?RWJ=H1R6!< .#)?FD93)]ZB]@UKHP26BJ5PR1N]&M#,CBOS'N7R
MX4GZUW#%@<V"^^GV[3/BU)Y=_3G/Y1=.#UP+@1S@]%D49ETD9%J&A,W<BKWM
MM7O%B0+IVQ?<=2>OD928K3]SI:K8,'F'<%PUM^1></0<6G-0>UR3YUZK#W3M
M!UT#Z<<L"V-)@8USV-Y/_*>_H.215BF]8R"Z7]YSHM"P,R/4=)?&(U+V7EOA
ML]K[T8]41I1#WSES>&W2B&8&_J"K@MOS4AL8UA&$?R\+"N92#_[JI]U8\I8K
M[E\G7NC$-=NU?GOS\47+SW%BF\5KVKNH=V<R[T;CNW0(0RPA$_IIU!=8$VQU
MBV2F,+>=N(82 O-Z'$:;/SE8?S6X-N[^RRYY1\/:J:/Y:(,@5\X/'BZEPYR>
M1X\'O,3)D3WUQUH@26>*V -K=(AKLI?A$/5>I,(K1*D7MB_[$[H"-'$8G=4(
MWASN4NW(WS3X_3Y42/ R3WCVU.W$L'F:%_,1/BC\+A8*"X#><]]!<#NR@:3W
M9(]]Z-.C55O3/SGDZ=\\%MJTT%+HW&A^4__VRH'<"T)UAY4/-!0[T ^AN]0Y
MC7'MU&.20Y?)C :Y(GZ,[/]V$+TGT-FXR1!W<\E<:[CY<7][6UU'8F+AI]%+
M.,3SK.\$BO31AG<C=P78P%7A#4P$NBL,%BBJ3$MMIGPK[,^G1'09$E"-)#NW
MM9"M#(FH2CNIX99BM[+FV%%;B5-^#_GNUMV4Y=IVX6 %R2'5^# 8T5^XUS@K
MG4CPSO"X>T9N+<SG==P[_J('E@IW$:I\%G)2FS]6\?3=J'&X*&SN&4P<'8;-
MPC<Y)#0_AJ<I2HPV!6-Y?Z+VM*4&'IU4P#3VA4:I$K_!C[5W9!\M6+R?=#?4
M?1M"F.!(?6*6.=?*K!CSOKD2(J+;W.Q+=5]G-ADM&3CJ[1%XY9Y*T14,\]JK
MUYL]OMQS=9>%[D.X.?U$0P_M*:?ZNAG:8-><QRD/R%1%-THIH1^E&F<]_<G#
MLQF7/&$Y>_2[OG1W\)2+BA4MPYOKT1>LZ'J-Z45.?H?!"IU4$,W/^L22;J!T
M.(R$;HGZ7"JD.?&W#_H'9=K &_LA,U)8NM)?[>.EVOB=@026(M(.Y(C4@V.D
MO#34MO?^>A ]Y^5N%N[B\_TLR_=[:>QU1;N,Y^*>YY;'[#J=9_=MNU0C;S#S
M.Y7@J#%YR%H^_1A8:SEF&EX!FL]W>Q\895P(U"^\C2^UO:[]U 8A:\M#FSBP
MF&ZU6^B;I_4@O2_G"$2;$^$U#QN=/L@TA+1+$T,J,J$]_/+Y2=W'D53LA9%;
M[2L_?:[MK]BY]'$SIVS/K_K/]DX<CV*&  6S=N 90^XO>&(<IGPM:BF7Z=6!
M($J-0QM*$#H][JH?!K5VUF1QVLI>YC/6PF\&>7F5'E4THSY"&WZDHGWA=UDJ
M%&(R WZ%K)/JK3D1B9$"\_ODJS.FW98[5? ^RF>&K5>'"0?VO,W6:%3M$*NA
M779E]%$::3#.C-^11JU4J04HIU5>V,%G;CFW4QVRKH'^E4-5'P0UQ'M].^G&
MY4TV@[B$#YOG11[Z1<N]-5\ *RC,SD,@Y#QE/W4@%7G,0*#;L)[D=<H=_K8]
MSMQIVK7_M$(45^NNZQ9=T/WH+J!#M(QQA)EIZD,9LWC3^;J>LK'&/\_4_3#O
MU!&<47 UP?MUFF(@_'O>R1?"QQ<?Y40;T*I'@PI1"2IW-&_,SG8%6)4$R5BK
MMC[4^:"2?>$#WV6C8];**DEF&C^(X,&!U7HJCF8)AL[KI.!EM[!"RUEDG;3.
M_=387#:0'*9]0^YK[>*;G*_SQ:H<:;$IY<9=-+>9ZJ+)]3OT/^/_\O^!*8:7
MLM[#N/0A!)GSS%>_:P5F!^:9+O9>)A>HPH@'YV^W-KAHYU5+G+MZ1+E1UZKQ
MJI[T><%/=ZPDSW/]T_ZQ>0[UP]/R8'PLF6"TI(&9;O!TK/2[;X/!W$G1P/[+
M$F]-)^R]+] Y'=[[4G";]5:'#3RK!NZXI!@\ZK AK4#V= E;Y],N>*J$W3QO
MS ?0,[\2ND$O-J RU(.G[6IB R/J'DW !2O)_Y+F\A#UC0UL!K#,V$"=,!OX
M&>Q=^_?11L&%\0L%8!3KK3-V1U7C=EVG#/J]'F6#>;<:]ON,\QH@><'JOZ1)
M+4)Q,$8A#(->W<4&=N0G*B?^+N 3^R:Z-_X<1.WC')"J8*6=F:G222)NGF68
ML('+&@Y,\=SV_VW5_'?F#P;W>2M0[Q4=K"5YW9P^WYQROKT^CSQZ^6>^(4[<
MP_/DZ9_4(9'Z(\O5"MSO:N_!YMI0!\'!N?"IQUV=YI2H'HPTHH<TGD*UM'\#
M_B*%<WVS4ZQ^ 5HHM=+/V"RTV:IH&$T5!^3F(P,N35W5S?X.HUBA4_#U%?TF
M16JT/F822NM$(6]>/97?@<I_5Q\O[EE=);V3DO;\]<BZZNB^#ZZ>Y9F'7O4?
M*WKVA!L?\)9_24N*DL_8:T;EI[T'T1R=^ ZL?<'Z2 B/#]57H]A_\3:B:K\A
MV[V+M#,13(U'W*(?"RE6+\]1ESO5X-FWN*ZBL5=LVQS[*9&'#0Q)L4[>/5C2
M:.H?-:\!%0J2P4+T]^DY32@UW1YM6@MVR>D>_7[=W"GONT9,2I+@\HI(6:3
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MB9H;,,Q'6>H,77S*Q>'(1R*$4 Z,7DOY?*(OHL')Q=LI4S>ACR-YZ"N<"]S
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M0HY[?7R>Q&B-7'X;_GX;S_H=WL%['FV]MJNWER_\^.=#SDD/,E_=0'"=V8#
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M#,$\D3"+.<*"KHZ#&'V=#<Q+X6 6BOXI^( <0-)EQ9' 9R-9#F(=7-+$TP^
MV%@6KP<4K@*C,+<E3 T_>* 1[JC Q# P_[D;M;*+M$4FF>W3 L,8H5\!TD)1
MC5358$;(-H:X=&$1BRR%F?D_>3U_.M7O!D/0/(:F-[AZ?)!5H(R'+B1#2"E8
M*O=S$,EA,"^=OP:WG0[<SG\2=X"E=?4(:2B>M.A,6K&Q1[*"-%EJNM#F,@Y"
M4Q0FJ(!<F#*C08,_BX"0_U %^#]4DRPMZ<^B,<1?50#R]]5D3%'_L^C0ZOU'
M-K-[=9^8W==Z_718>/UMP\RB$ YBCSUZ=0D/UQS_'9*Q_O=QFFI':-P6UB((
M=VTI,]B-, X/P&9JF?BY]!>%SZG 4.>2]53%3H!$)54C6UXNP?U$'/?]EU9E
M.7 :]C.2O-6HI2%@T9)<N?3[DG8:F3D"5_IJ\CQ)@#2B>1ZJ4&#OU_12YS/N
M);11?K^4]@^S\]X?O#1GVCB(_?CAP1^V)Z!@3?_O.?/_P&I98S'F!:"1!$Y!
M-3-H#D);ZFW='X:?Y1-H/1LYXBV,9H7) .&HU<NH^";8>"6B&?^4E:&X1<S*
M.E. G VL;LI2-E/G()XJI[.]X>9^%9R/:3< #: 35R")I?]T@[WX:X,E_D^#
M_>\T6&'21&GQDR5[7ZZSG6EE'\I>W"HL+#[7)AOU()/KLEV.+PPRZWMI&LG#
M^,>F%V&7&*J4Q?/$5 '?NTS='B&K+I"1.:%V_1PRKV'8Y:SH9MT:/R?K4WD7
M[ ;E<9VD7:KF]'4U%LA.G(0G-Q9%!;9Y>C"1-3$P\1R9)#J[%I-=5CK.BKS:
M]7Q68GOM^:-[+5^.K%ZE[7S]V-]#>LXA#>^@X-NU9#0! <+1=*N+G4%'3EB=
M-- )*2 >RU0([W#]9OQ>_FJSE+2;S(<^@P4=V4F,7Z(@N''PG6"=$Y_GK;D:
M%4BE.)^V>#*[-RUJ0V%T6'EO]J&;1;=+HL?D)/<4A.?2GJS%QZL)TIKK$@_1
M%((-C6ABSR[;&VHR'.0M;\OO+WK1<R9RPYZ'QQ2#OTIY1);<RRY?NC=0W_->
M5SMK,J?0;L )_7GIW8E!1E2=1MC^U,",:3:S5IMYTNU$H;$!>Y1HG32FW2^1
MF%01RLX[5*YI2SM%\1L47XPM!/-=W4XL/?:RV?O%JEWXM0 /[K#0I^OF=Q68
M;8>XO]U]VT?Q\,.=]'P\A*E<X2!N.6W_9JXIQ1XEU<1VYER-T</,A#;%Y4IP
M6S%0>Y*:G[NOO'0<-#_2G'KH0L;^_DAOV68SVV:XXLBZ1^LSZI0RK/B<\_QN
M95[)T)_/L-/M8:)]>N]/;6:BG.??.MI,8WW4O;EFS#B(+<F0B&$]DI:\2XJ&
M9TF2@:]KO^W<4;RP7?65M^9+V/19.UBS=H/O?6F&)J7T] !7W:WX'7+O0BY\
M43XE]#:Y<_<[A?M/F[+QAR\9;#VP>>SHFG()!=[43<:NHW*\=E/F91XDO0K-
M]LXZ<LWHI=K/22OC0HWGT-'ID@EITRL.@'>3GDF/2O+P!#&-9(]_\I3EP(["
M"6!MP.24R5R6]I>E,(O68:-WG4F%L:8=<I]T^5NJSF6FQE@>.LC4F#NHG[(;
MVVP<_'KW:8MK39,IG84%MJ>-BKR7<6DG!&S-5#Z>[++U.5'GME=F\(6+X<M7
MWZQL%M1+^E6$*B9/O8*EUW,&SR3Q'R'I:L'/>,7F1_HCAZ/15-0E8ALZA#!_
MM1P>;);<<Q#>F[WU#T4KB=(0-\H(]YXBR(1D64=8/6T&ZOST\=G7O]I&@?'$
M?4+-GU4]RD%8<'$0&J>QR#\4^2*Y@0HT"Y6)DJ7;0Q=<45-4#J+CML<S W7?
M#!;TWS.I^/8H)8<0&D]I??#97B X\$+AUQQ'[76-U[<7%C,48)7PV;&9@UB#
M!S]OK.7'_T-)^_^\_G_7Z\Z#!9HL6+.&DZ;UO\ F(M*TARD(B]$)%2L.XD$]
MRQ[/?C7-NJ.VUO-;2W;/,_$=7Y8?WCTK,9UW)[<&6(O#SY_>E@YI/$/5(]D'
MD*T),'.W23,1OA),<>PA6G<&=<Z?@]C)VD"/JNZU#IE1-1TV_JS,[7FMWVOS
M02^5'8U[KS7>N'U>R,TE5\OHFQX*VL)+)^N#]4FLPQVJ!E0VLA:S4U69$A*/
M%@?+SKG%#"SU#A6FB'LCBGGX),8C%/U'';+OV8]-^82$:'>,=7L$:_7=UQ;E
MMU)[%?ZL:5&MHGLSA2)ZP'1U8J8YI_2TRH)]QOQ6OV'#H -C2U,GFF)5I$N?
M);?,\(;$=77JI#W-ZSX<Y5"+/(-KI4_J,D58]]H5RJTI97*:-3M 7U>]HY?I
MR@F%+9-%7RYVKCCK'GS?AVQI$"V51_-3+?AH9):4]^/)(_;>OM&5?H5$1D*O
M6>VI1RB/<:T+S@FISY5"L^:'3^S9W22;F.IVF8]*KLJI6"U>S2=7CKH=]@PU
MM[G27=ZE5R&0T9GNL&24%M_37Z:<^J&:.AB$/47A('K650ZN99VE?E"QH+L3
MAL7.&_E->H=ZM-N87NFFU1V".GF5+EJ]$''9[5AY)*:W5=W)L_O[X#"FFOBX
MA>9$)0>6JR ?895*<?FI]N(RC[6CM+IBYFW3OK1;N=KC3U@<4&UVEGQ0_^[-
MP5>L876'I;&1.3$1@T$SC6[R*)'B(#<.9!WV/^G(#WAMB3YH7GM\X:JAX?78
M=E.GF-9)EKXQ0:6$A:T S9D&T+?2?O)#EELR:%^-D^INYZT5F=:SM?YP0SUN
M]>K6YS4+DI%##\X^=^QK/<)!W,'T+%<"@I#4=Q$5?(62Y_GJ4@$_HES+;#'5
MQI62M>.:YH:L3T>95>7-N7Y:'OQW^D17E/EY>#=33^=H[?_V,O'[\N3$B\[=
ML;P!34;KN(*BC]<].U!9*'Q\?K+-5T%:5,Y5SUSVV[)3;Q_%,3FEMYXN 8O.
M I4J-N[\(1&CAQ1TH(4DU&ZN6*=T_PD?8L\CY4MES_,;)>/C78Y^\-3C,_(,
MSLVYVGJDD#7K/BJTI<=QXW'OZ!,K[MC, _)!4BM%?1Y?8#W\<;'M]X1S?3;,
M:MAIVN>BO3M GT&RRI"S>._"?QAWY,4K.#X@_"KJ"5LO^!>2N!RJ'096N7N
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M<;A,"W*"AS7DA?KZSX)^ZU;MVX$1;OC2+7+AT;HON\M!$#K335B:0D*/#K8
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M@Z?V8"_^)\6PY?\CAL&?Q/ 7 W6L%_/-+\,F_YVT?Y\@@CN)%66_K$#VLZZ
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MQ.-NV5&>Z <(\9[_S :K+ZRC=.L "NA, :VZ]QKI[6HWT9ZX<*#6\:<LM$9
M]=:M J ]9<Q>)NBDV&O)NA/L)J/QGU)OGN&#A],O<U9G$7IZ 18(:TB</_+O
MAPC#G]Z3_/=,O6^!7V7ZY%N#_G4RW_?LA'0.HBT4M3QA\/?#2QM0/[WGYZS4
MX_\DR>C_7/__7/]_W_5GB5*1H>7'2#Q+W7@C_Z\VRV:75 ;4#)W-%7XZY1K
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MX)4;Y(=IX]4YIRPZ"_H\)?**_#;OC3H3V_)<>_=K*VG9S0%['R)1.*!R!W2
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M%?DRD3;6+MQW0 1[F?U&3<9S&!U?I7:,;EUW/(V.J=(>Z?,8FAAJG\Z>[O7
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M6,<X"/]*IHKG &8G>'M0VU;@G:M9GTQ:C*K33G:F4&AFRLRA!V]N-+_,6-=
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M&_C*X(RX'IU812KT3Z]MXV$9LQ-9YJ^^EYZ.>>R;YOF80@@IE.X\I+PY+69
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M3IH6)V8%('T#Z7Z_N]T$(\O_%]0>18, C1R!F/OH?PV@"*0OP+7'* SM'PD
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MA]R>66/131>A&H_QE\\H%\7R-"'*M1IBF?P%R$L>N V09;=3NJ.R_,<"A^J
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MBH2*AJ]-CX-I^@L/Z*#"<N2^,:>_!HRM";E!I(.8*6/4DS@()3X!LK**V?X
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MH!#940D;4[AQYIF9>\[WG6?.W+GSW#/WF3_VYA_R[%]9ZUWONWYEB<=L_SM
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M.-ZP\ '#"IFSE-8Z(>Q?@XP:MDOI]KRA9"L@ZE9X7V[ZQ0AO+^Q?=ZF8+9?
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M:[J%)DVC(L-J%^X:R!+$-'+H8#"01,> %>A1LG "M('#D[H6^?Q:4'/N8'[
M]6\WEXMAFMFF08R/#P;.=SP-S\GA#";O8:23S3B';>:Q55BE)]QM_'"G08U:
MOP5M,)A2=J=%YFJY0DG /I$_U-Q3A2HVU)M]#\-3(']\EY*H<PQ5]B!;!<.'
M\@??!Q7-N[J:A59\(GK/=]=D[JYN/M4D\.0P\N[J\_AFZ[P'EKOC[^5OIIX>
M,#8?TCIGWYH1';GD?+!0FELIF:#>3XC;>S#.</H3K$6XV_Z!B20K#N6X!$N
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M>ZR2<7 &/84^D$.1RW^5[R8CC#UH53M"C5;[<4$@4OL*[MRNCU["/\7GN^_
M '/[V7%'4)EQ OS5]1/ILM;9:M ]G,96H6W%HP[IU37G$5H5BH\+"'AR<:]7
MC9S-4Q$4/E)S8;^TI5P+4SR4[@8&T!SI-_\*T-V+()0T=QHJNJ9@ C#97/I'
M,PTZ#0.S, $1Y8A[N-\(\:*^0&\E:=6)0YG*7Z4AC-?_FJ*^G B3AUF.KTPV
M(58# @)N^-<$!BKSR1TKTQSZ-,/_8I>5$43]%LC+WJ=,VX?',(XR#[&>O9BN
M^5TKA IAE;1# 09ESTO?.R/U?@8-]LH3Z)L/+\+75],_\@B4DY,/*BR_YH@D
M%XZ7%.17LU[IXQOIV?GA+\N%8/8T]Z%GT<))/WZD/KKV<DKIWFWEFZ2RV5.?
MD=)ZWQ=E87ZU\8L-N%3/&M0UFENN=86[;(!*K_U839/LW/;9/.^6QH84YQ7U
MV(;(X.9)Z=O[_, 'C%-,";"8 ;N%K9].12M\RT8*7P4&_,3 0-GS&40-;N%'
M=>=C;QY-D;SAH'_@TEMU#<K?G .\)S,9K<=Q %,DE.*4:@2M0%V@P6)+IE'*
MY#6JWGIB>=6W\/Q*U\XWPS%&^RNVK]*_SWTUN^%S/]?;+3:F!7!=RNR$$37(
MR]CNH#@%V'B[-9FQDGU23TL_H%\Y_5-(Y_<S?B7IDUF4.S5I)<ZFNZ\,I^ /
ML!68PB"BAGD#K*-4N@L33*3'7D\TS=\$L.I#4P=TE-(;1<\X("$Y([OL-)9A
MH*)7=148L33<!17M;.5-0[DS3-=<AM/1TB=OP.[]6)CJEZI253YK>R(7, W?
MVO\C[FJ;BFJ6.?U/!#T6U"'K$$^3[--V(+Z+"@]@=4;!9/=SII/Y@I&I01&!
M@&7?PS-WZD5+ZR C/#IB['%\PT8<WG>"5<%TIT6<'T?+6[UT11Q#XNB A:]R
M>J?BW*<J]%:^4MKA6.=/*14"1\6'T7V++9GK28Q0/R*NA7&$&39F=+T0VN8:
M$#XUZAVW89?5<EMLSDTI]+PL@NIS1M8S0-6_U^HU>@C/U[C(C10@CR-OGDY7
M)5<ZP^Y3M=%>S=EC@U2M@CQ9]^*,LTZ*RV$64EZ73/Q!(2#)^N\V,)X"L)H1
MP#P^7MP U-P#L@?(A6WEQ!Y1J!@RU]BJ-K"$!_E\YDSN5,"Q/E$K3>G!MHK8
M&#C-GI(4B^-CGIPVT49=HFD:PI*,3KVV+4.X%'3J:C6U7W!>O+7KTYV35WB>
MD"!6NUK6?JVQ]YF!T!KF68YE!("+%$/T2*'12.,P?V^)VR I9M>2?9+5M I[
MJLD,\9,>%*%>^S1+U*U7Q&_IYOT:^U6M?YGMVU-:YOK-,*"G,DQN0[Q*6/,!
M J'TL[Y,Z7Z&GF_6F[]?!;B4^ M3(+3,V5HVOQ!#"3V-W6_D##30(T%L:"T8
M_R&G2D%W'-I)+,A9S6GXF"K4U]J<?.Z(G\\N_4/#CT"HQDU8&AQP6)PU(!GT
MV(.^PP_0IZ>JF3YW+T^)G1EC\E3?<K2Z/N0I:7E[?=DI]=/5L]\M]Y7828G
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MTW*[YAGG]M0G2UDOE<I$*QX-Z S^$F0$H#PI.O==X+U!H%;+?;8)!W:*6EI
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M@,Z[/7)OI"&B7#^=F&)B2XM4;]K?/$&%B2@JE%42!A4#/4GX3,U&**^_/;E
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M_.#QAZ8>+P _[FX].+&-LD*%<H;% "QF[$)"Z37-H(%!Y\:^U0BB0EX ^9D
MU:EG,,8O\(>.2)/X7?WPN:)[Q7''5'XIGJC0+]O"S]I[L$I.0!-QFD%SB&X3
MZ#-G8",U3*J8)I%3W)SSVFVUSD)VSD,S9$ U5T8,=\D[S JU+-0$@1JA9Q8;
M8$PQ7S9_.:VA!\]E<A1Q#+1?<NK0.MLC+]R#DZ2I^Z/5QPZ]&Z\.DT6L^9M+
M4^/G/]Y3$CW<)YBFK\OMA"$E8SE8XX]-@7&;J#)5665HS3G4U6;0DX:X OC>
M1VM65ZB# U;-&7*V*F-]1EEM?8+9<1U/I04L:6UO>-^Q>SD\'+^^Q A"PKO8
M>J 8C==JXG>M$++XXIC"]\4KB?:-W?ZJCZ;[#RP'O+K#=DM:ONM >MCY_AR'
M4(B@H2B[T6==<*'VL&)DDKUUTKV-1F,[C;=7+_>L#G1]>IEH[G1*NK:? ^78
M WA/X?L8P 9&Q W3,\>TFFP/#],?T%BU*2CHBUMU,]^=PFLIOYOC%JY:6"1.
M#$;X93=@M6X\_\$C54X?GB%0,NEPIH3]DB\!+X)<^J _CHPG]<:%\0 ;<1L=
M#:ZK-7K(-+^ACIH5ZZ C+C<.*%,L0T75M2 Q"AC2"VR#YF+S6U;\[QW(@WRM
MWG02\*AUH?IV_B?N=6%Z6W1TM*3[K(%CY)CE(:CAJT,IE/.J$WH;*5A!(PU*
M.NP#6PW,?/&M=:HZ<_T])RY>BY.M_/1<6%WU^L_0WGYA/5II2A#Z %*#O8^_
M98(9%$QF':G=@7A]G+-_._'IZ+-GHY3W\0,ZZ;]0J\6!\*\.ABG;:W11UE.V
M#GMBL6&+*EO,C #? 5>GNV5V(-V9XAP*(EN%4T;)O9_<K%8KZ7K@)<-$QHU8
M^,O'-N</9DLM)>SUZSOX\0SL"BJ8)DG>(LA+H\QH&KTN!DF-6V\M11EN$Y3&
MA)+;U#2CJHIK)')H3LK(Z&8!M,OPMLO0O4I7N/,07^+WH;#<4Q E^:I7\1\5
M,R@X+EKF!WLBI@,-9>7?QOMBYJP[82)L/=1I\$J-2H$_#78N?^X"^)*\C:DO
M:BT\)S=NZXM,:44/O!C+]LWYQ*,<##^/Z=!&:R$UEB+6M4B89*PP>Z\M,&>+
M95P8 25<7Q6<<'WF?N'[U-<%/H?=N9_M!7'69?RC4A\%1B#1K'_C3,[_[",7
M1)4D!VCTPAI6,IAB-6 F0Z'W&A!8[AE9R4JO,2$<:,[N^;5]P33O9EU ;-S<
MG;V#: <,H9H#X'\L\>R;&AMLJ]HI^\S%GV>-.*+F9@:'#K^J=_K*@R[X<*E'
M4SG(T^/R]/$Q]7U_,%&B3$UT: ^M8T#<8NYBND7_5NC5:49])H43*]>"9N'L
M;)T=R),4Q@XD&_$M"%3&K'L#KO0PUHO-3%G4*5;E#H1LB&L% KK36BV8!UL,
MX3EB[D1+WU_>3PDWBJ[,IF%U3VW;H0QQ#SA^Y(OIBYC$KU_\NR>]&K$*ICCG
M]&DP;"Y_>1=F>ZF!45ZZ=0+%-A5\YWM"[NA(ZM?1TDMK&V73"T^WY ]<A"=!
M&_[3R!@DXWV$9TN[=R!BU6A]9 ,=">B7+YV6,*^GA1>3-4YMG@XWXT_0+E14
M%W> $ 0AD$J,)!J"VLMZ<3<UAGMIN@.V%USH''+4*LE+91H@RL]Q/_?.TE8,
MNW3G%+<1/_B+S;]%6Z)_ .5I#+H_8+$^R+";!W7LP5[:39T]R&RB/9^_R_-P
MH$_R28M#S.O/'^O3:_;Z>IW.XV^S6Z\E-BSU4B<Y3'P;7 8,.MBG6-5:.%50
M9ZFV6T G*>+B9Z2LW;B1%7EN;A*C>*4^=UZH"N@:8,RL--VI;,F&JW/1<5D,
M&(IGQ.C0*Y3)"'HO>';@#, NW5/\8C6\4*8I8]BV_5X\(32(OT=4VO.ZM-(9
M:<N/AUN,.,R+%W4>&%R)PQU$VMM,WPTXJZ.^ [&:NJW8VO3.)K[9\I5@QG&N
MCMW!<"E,!S_>#TLLIM> O$N+J= FB]YW3'BYWZ)$TP;?M_ 1,,ANO/I&XWA)
MAM*S@"I^JF[V<NJI,WNY3'DR8;1IRA:U-/KO(N8([ 8T:;'9IX6,X4*6DF(6
M,XPJX7M6G9RN2K[Y;HN@(U^_K0^96M[UW%+FC.GVQY,0J ]3GO4,XPN?79CZ
MT4O'@+RDVET=92>C090\&6%[3/N:K]#!YG3NK)R^89>,7OIU5OY=?$HV\^XX
MS#>3VQ5<"/?!]AQ%7AC4<Q:0JT/423ZW,@[Y//UQ!]*\057^>WMLASIS/[81
MF[X#N14#7PK,$=!.#P9J'8&O#TIO&1 +7]3W%O<%Z"4T'E=##(0*5"K%=OVR
M?-&$Z]FX6QN'!YRT[,FJ3,WW</HL$/B49A*C5WL8C! FN/JW0Q'A?>_N?E/Y
M!6LL,0N:?U;R[E)DL(C46:[?+5WV"5A!M([?11!.Z244\';+>!EDS7>7(E,M
M$^F[WZ;ER'6>>OS(,/O"&VEITG0>AE"/)SW#_L[$QD%!_]\8MGEM+D>FE6,;
MIZG+#$-T#ZRAI7LX"2H?V"ZTA)=%;G3@]H/W2MU "YOW+6+?'QYM?];_]E[^
M$4H!\DJP M>EIX<2-N;REK:H9([1U8P:<3-,D:7TZG'T<:2.*_BX&'3L]A"D
M6<16W1V\N#2A?"PU_?B:W<]'PPKS"^?K+.4CY >:8TU*QV D+/R-?=(/3>W?
MT)E4LE!:ZY5QMV\A1)3>& 5Q*N/S@,@UKO2A[@%MX7YCGD#4158VQAN6H:#2
M3*OMP<[FD#=2-Y\I76Z89%XDM<F?_<YS:2^?)DVW;/<NB*)4;2:*FQ9!GP Y
M$,"3"<XR]L.H!37?V#Q 9F>Z05>AA#6<UT\K&A&#OG2TWH:NJ9*H(GK\I<,G
M:>Y31.N?&.""?3(<N"P,JN4QQ30Z\,WWX8##XU%F!,6S<MM0I1)H,W\[8I,;
M53+_ZF+_0U.A$0O7NY_[3GIK=W''-G+]N?+Z6VMX9JGI*W^)_42B2^<;(G'N
MO.A)3P?QBU?.\+^ 0.3^[@44(ZM2O1E_#S]9X*]G)LMDKF\L:=C'XQM;.G7$
MUTR$:;Z)-\>KFK1$-[KR@\^.^/R15I+(V^O4_]C=QE8C4'<O+D!X)I1#@SBS
MD,II\1=6$5N+HV6<X&+,HU32#B1902K3IB$)#I=+<KU8XNI<); W/[I<D6$4
M).U07YIOUV<)8?!2%C]PK +*-"H4!3> H$Z<_EA1WF"F#2TBJ;I)XR[*\TX&
M6=ZT%^734(/QQL_F;I%M8+MT8+[VNZQ)T;Z+0:0^E*(7\;+M\*?F1!UE^T^?
M$]B*:VX;ZT[ +WHY(-DAI,J6U5GZ!:Y1>%B/','[Q-4I"1?TLSL?&EQ=4EV1
M^>=M[A__>.VC(_(:X;9"VQD%1!6[!U:WD<R$%2&MNV#UF017E@;!1I:0[[UQ
M[^YVP.\BOH-SYB./X[/M/_*JU( Z]"NL/+8L2%RBP GX6?P'%^'D'Y2?-4S3
M(M"D?^J/UUP#8OB M:(07INOY^0WN HS$J0R7)&A;(%H((=N#.11C2O\%P69
M8<"B$\V\Z85JXHG(P,-OZR+,6N*^6YMG'0JYJ2F+BD?$+B&/K"\"EW1$.?\*
MXPA)7B269-";;M$A.8V7:#]$'K2EGM R9&E7A<5$]=I@E]M;\KS*Y<>M9(]
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M7=BAQE,JXEJ96CDO]/,-5HYKN0]BQ&#!V/MPX!WF.N81OG'B!1G.RS*9L#H
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MG#E#_F1QOCEE['S^L=SPEG?Z3=^=\@U^0M3Y^>0MN2L0/&.AI62=)8\_Q7Z
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M&(.B%&/B8>I6YLTFV%XPZGP^)21B+=>\+<\OR,F#5^K7T$&?G+X/@3<@<JW
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M']3K-PV1?T.OOW1K!:D7)YBH_XF.6WW!-$0YT./ )+H"(Q00P.-47!I*$%Y
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MZ_<?YA;P=_N?7@(@08'_,OYW]9+EZ[7CGP_ __02V!'S[P!9(>&]!T3D[-S
M5\/E-0\FB2H<SZ]H[!73.G2>KGCM]H2XDK8918?Q3[7_:/9_3K'D_UN:_5?%
M_E>]B*"=@@)\YPG*@J @#OMIEC[H_\L35\8#D2M)^.MO6& DF+*580VA:V R
MB%L#V&Q5ET24#>6MM:/4@]<\D&O6-TIT>XFE_>797BDR>/.@I_"1;4T"%$,F
M-^@->?- R81 8VD*Z>X5.I,0RX(C-=65_3HF4W_'14W9U6:\5%UZ+3:S.^U
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MU+!]8A]^AX='Q5=ZOX,S[_Y@B1.7'6\48=;==>SG3[\#<?)G6M^H'6M5)O[
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ME$>$4]:&<5D84>OX%R$6VT&9*'LZ=J"(&32@U,;J_E \.U>$=Y^3%(WQ_'Q
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M1"#4QM0_5QW0#E.X?4CQV@D:Z$H!: \?"(;8)L , \L5^T4EI<.:27TC>:K
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MC5DWN^/<P6P9N,NK2;0,>CS.KSA0LK4!3TME*!G"X<@^!P5XK?[%2[OW)8)
MMT"XR_\>P1/Z#\]'CT/E6A%W8:J$:WD@9.F@U<9WB\:7ZT3-D? 8S:=#]1LN
MVIK[. H>CS&]^ACR/:@HAOPX;G@ !G&@$WK:N,8,Z !4=@F)@-'?M"3#(6(K
M*X/A@55'WZDJRHKZBYCO3'Q*NSX4+$A3_6_=/O(S;Q'+=88,$Y@"&(XD?.;[
M>^A-S%\SC 8/-"_, _TV?R+UG1+#+H1*\?\@/L4#G:R^.:O<M_E7%ZW.)_V*
M-=S,,\M/=F3I_W?.?9(7SC=-M(SD^)\O'6EK2?K27AAR5/9B\VZ08P\X:=2L
M-/IXF$ZTBWVL'MO298//-.R=>"#]8A+[6AYP$[L XV85<]U,"<!@''1^89@C
M.,T#]>C\3^R]=U13W;HN'D1!!8S2D1(5D"XBQ0(24>DB(DH58J.)@(CTD(4@
M($A1$1 44(IT(EUJI(,*2$=:"*!(DX02%B19^2V_\SMG?_6<?>_>=]Q]QCU_
MK#%686:N.><[G_=YWCG7"Z3+3BV_S$1H[8:OIB"'[.])_.&DY /$4^3Q&.>L
M(:NSXF7%1146KT/8M6&EJ/M6,._R="IY#%U,8/ ITM,P "4"3:H"[(!-6<S&
MV3HF8HH7N.& 6D6:,A&(A(W?_OIKGW72>K"FM,\=4+<50H5=ZMV[V4-9<-5?
M'G=V?OCCFCR+<% 'KTOI5VM7P=UZZJK_^S45=-O"7(&KEP8[E^Z+3,0'R74F
M0C =$LZBFC,1:9FP&S%<@I1TJ6KN3,2I-31Y!_ 8<+;#K.Y!TG>AO_F-\?UW
MK5M?)%S>6=Y!]CV?9EI\3>_GG=+X!"Q<T;:#L'L]VI+4^@!-.A>019.[]*Z$
MIDN7L-8@RNH8T7"=7C.N[K&1:ZK?[3;,T"HOTT/"E*/QEPAJT2)>=D$?KV>&
MI\KZ.Q*G$]?X^):-Z2?EH&P,=(6)8'3H_OK"-FLSO0F],L-$' QC(B1\"?/G
MSS 1:,*R); L-=!GWHXFK^(W7P,;L 1>5T7]YF(N!FY%5RH]"45_#!0<1](A
M6";#E*LMU=H$(\%$-/80YF"/\+6+B1CM WY[E:L!5Z,)+#L"RUI0Z31ZA<9$
M2"8P$0<"7+2QL4P$TH")R!5@(A+03(2'R>^OH6P*DKX!U_8:/M@W>V'DZ5JB
MQV/HX6ME_UEK=7_36-3_H;;VK\;4+ST$R.6:>YU0>]!%4#TC[[8=#36L093;
M]3&*9NX]UJ4U\,Y]0\PIKN>RDLJ&J9=5\SQ!IW-TET?\-U51#8V-)/,O!9I.
MH@J\)K;ZLR&\)J>V_?KPU5V$ZSD8,T6D(0A0:-G<VE=4!9J>A(X!%K8P$9M[
M/[-[DJLA_=0P8&&;$VS#%RN<(T'GB3%9(.S$UB4/+X[O\?FGQPX+'2YP82(:
MD!E 5\<2M*T,<=O$XB?)FT6MK/@S$?===.G[-G7I]''8;5A?8&OFBV$BMFL^
M@?OL* 'D[P/^I^2_>DDS5!,3L7$PY<!/ST:$POUBH=T!XA#.#2 KY/%,F@>K
M9.-$YE<D.T@R:3:[N7KW-"E87V,B8I"7-Q+-H:VUJ&G<#1-M/@8O;OM?Q:EP
M)4- :R1JK1EXG./,UEJ_5[_H >/-"@-&TH\C?I>(OWIQ3"?28WVMJ B3  @S
M$=.E( %JB8*GH,%-?$\7J+4:L[%1"^-B.;X#&4G.K&A!\5NWZ%O0#7&Y%M,3
M5XY-#Q+)[+0Q@(S_!.*.,1%>Z7-,A'A26H3<&NM*X)\FG.I1'*)!1ED-:.HN
M-\;>M8UJS&MB,>;!Z@@3\:6K(<'CB@U;K/'UTU>*8];PGW>"KB>9B"=VBC\_
M#LJG:>Z +Z*,R;CLM3FY0UT-5BY1/3:-[O>LU#Z$55Y'[[&*V]#:=/P7C2#R
MA5'0D'[60\+"-F\8 &PKY)"3 #W6> \PM',)YCRU+F&0QDGS;W88D'L5>+*!
MT>8U7S4!]_U%8)1ELPLV"['#P" ?=#HS.Q\]U8+<G"2T72JC3ZRC >MM.)N?
M6U*?]DXR$;2]JDB&S%."B=SRTA1 CT^%87NH.QN8/1>W3F>!UC%TN15-5#1Z
M+'N3T/;U>UH$XQ1]0CHM O'[0V[UT<]\%+%.Y!A&\ LF0J<6YSHX*[ 0 &-?
M+PE%8S\*1?G]U9BMYDJG$:311O^J_/ M) 6;A I%@!%8"-=J./#U&MT8[D&G
M244:BPUL-PD%;YF(UK!<^B=88VVQC5E&R\%]!46@M_[5SFFTY<+?QH4OC.Y3
MST1<,=_8&4]X*3:S-'\5_Y$0!9NF%1;#1-S0@5UGYA'S.<D_CAS,60+1X_-,
M1 C.H9'22BM#F6^(U/*:8+)1+[?]WA?]/'!/<*W$91?-/7#_> #?!_$=PXP#
MC!C"]#!6G(FX^@WF57@,5RMA63X30C/*4AWJT<M*.1"R7RP.-KNO[+.O__!E
M]>]GC%_M[YQ>*<L8]A#\W@XD(HW%"OC^K&"X 83[3:*KD4#=4@I7*6-=^@\O
MKOT!/T?ST>%P'QII:,,-DR,PN-?*42!Y#9,8!TP8=D.Z7P/@?NK6G;C_%PM7
M[/,G?S4P:? 0QPBBYR.8B/T7!U>"1QF,VWP;WA0"9&C\B(E8<.Q#K[XQ8)S]
MLY'[,RQ,^%_#P@Q,T3K]A?$#8$&$N*DZ3WJW#FD_([0R$>4E"Z 4I*.*KM],
M[\E.BZ"_8JC\87;^?M[@S?'2C$H8U[OI,-I?A6?]YX% =7P(<?D<7?UG;QDS
MN..J+7Z'?/_X]P*-8"H\[+U-&.J6:GC8%:WC?H=]Y; X%1/+6SF"I^_P0[?1
M\7 O;4K3=_\9YOP\& Z_'I8^,Q1EBIWACIF6M8+N^*<2"H((AZ"CL'4Z40!&
MU-XPZ%D[)CON#Z-&@Q!,A#\>XMM(1;:B?O0%8*;OKIIHXU[A[O!>?L$0-NM5
M*%#T%-5TO$X([+"3>'@JY?!"2-^Z\),$S=Q;91)]<9^'G>^D1<@\_)> Q%@2
M_F&919W(]SU2(8=&#X7?8LT[).@KU_&3/QK" /7Y-3SF 0K:OZ.=CJPHB-L&
M X5P$&FSCK"B28 EU>O3Z]"FU5!:H!(309+LA['N NSVZ^)C0'U/8)-7$5C*
M+(B0_I^2_^HEG6$"^;#,4E-DGD)XL+1;+?P>!_\5Y&B%ZI>!W\/F")+NXX?_
M](% EOP.X]1R780T_GLZ^<QG'*</:T-55Y@G$Q&NJ5Q$Z)/''E=X"MR<+9$W
MUDC@/I*GO]]\>=(F3$)&HC@RHI>1M8#;HSU%W"T5E.]66G#]8].Z6465H<O3
M'L?@<JD'N8JQ*YR^NONV'/;))91\"Z'8Z[MAK<GFS5QB^&OR)F..\7=A[+2Q
MJE3/V'-X1.76Z5#,\\C@Z-!:96IQZ;4L,+@9O;N&Y\VL52T^FM.6NS:TV^6'
MI_^^'B'.W./QJEL.2(H_'6IO[^HP:S)(\>6=\?_^-"Z)<#!:4:?">[R#B9!9
MY<V6352_I38W$M5;H99KG55</FBX$6UJ1C[:"(0(=(/LIJ!D#CAB55P2ZL9G
MVYP]VBCZH/A5;%OX54%AOD#%@POE/H+-UT%#4E>#(K?/3!.T_VU?F3-^&^BL
M=R*QPM,"?^B(R<6^\NV8<<W>?2A/?01/JS=-QZ=WJA!/T1ELPFS[-OB:_*V$
M#QZYL&GRQ#-=;_DG.7$92G=6=AP5EYO.OO".E4\@8@EK9T?3GW.GJY);$O+F
M!L6X(WUF&J>N51!2VW1J0TPLW (FU(:61_JC=^VMS+ZN=*0QQ\#KV<0T8SWS
MI6]ARF._T@([@?3:PGMFK\.BO/DX6I3U_1]99SFKY@^$5Q,3;Q7XBT0_>H65
M!8FOYJEB;*"S8LA:!U+[A5FIVG#-X!W;QEV<17H'/\J_.'_Y6:!>/6M$/7F@
M@JS<@.,NKARHX7&?[/!:G':F^=>>=E:WWLKUX.SRG>5JY//RB?3[P>WXBZ#S
MI(^&,"E&P(=H!"H)!-VSP*(]G4\VCZ[S&.?8?@H]IK#GQ_$AH<C([",:;RU>
M[ES!<SBBA7%[9O>Z-0&(8:T NTEAQ:?+7?J/+D0?M#Q\];$AS_;,;5K[/(+K
M-:8*X\Q-^MY,]YE>R>ESJO@P\BCI;D#F3>+8/8]+;UZ]-I$82U6^8&8P*R.M
MRC=FD[G^Y3'=GXQ\@)6NVTO!!.7_**6A>1T-L[GX-P$U:_[QMDO'$34N%=)-
M-R,'%2:,=VA/&>\^%.,Y::.N6V&1XER@>^EYQH66='F?K=5>EUCE];;4HJGQ
MW6L8GB$?X>84\>Z;I93!\ )[&V>#;8W'+./5+;%94NU'9-#[&N@UVV9MK7-
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M!P%+79(6II.P"'- *3O*&>C#09AW9J[ ;OC/[L[5P59%N XTHC[1&V$D7]=
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M&*LGO5KP#*WB%X^26]!T?*Q/*XEK.>]<S@C&VI#GJ3#K# K%]</\MVN1=3)
MO/$H=!)\ELI;)S8.AL[)6=1H9<RI'3[C0;64W*?G<LC%2F:W2.'$G4O?ZII
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M6T\!M'G-]3N]?VI:^DOC8,*".G(%WS/\1[SYBH6!2WPG9H)AN8G9"KR#9;#
M]R#8F0VC(#WV:&#A?!]LPD\-%N1B&*]AFPOTF8&:%HV9"'T)_*,&)J+6E(G@
MIG<5-@/5QMV0[DH87/$:B9YQ#]@)[<$:@B.3W[%<Y+SZ$_&U.1^J.PH3[5=4
MW(-8]6A:0\'B\G?8_ :U:0:XCX @P0Z#&@,%)O$/EA0NJK>3>E6#'0Y8SN4(
M+RI;M\UMC?#1?'6X3:APD'H"Q)-C=,FZT3@$_0K%#$_RQX@99=1F/;H7H#'&
MB#<\/@V4C)[*QTO6U+EUO)U6<?1Z.SN+)E^,"4$+T$].HE!@7B-:\!Z!#WN\
M#JP.<,_Y7G5R15\JK"Q'S*7(1NL 6^CIE.OLITVH:YVC],4KO7S&&M'\7I&B
MB_<82V&7%4/77>XNO8&63V[ZNNY]8RA_3E$FS[;#G\ ?K3[<KNE2MNSP")2B
M\C%RZ_;Y6!M34L-P?$<L;E'"5;SZ55_([?#D/;EW7#@G_>D=?\'^8*\.W]0(
M#85)XZT^$>L-FH<_%Z[6FIY_YZBX2ON^5Z;@JVFHK@XB1VQMO:*U*Q!54K'(
M-P7/O&KJ2T:F"\0%SJTW6GG&A.-0MXITO5SB.3SU4HY?U!)+DCR5?Z!RN.U*
M$7NZK\,B"]D4QO)2Y.+ZY$GTY&#H0?*AL'0GLPI(HO^0&_?*@JU8<6DH7]W1
M'<NC'U5,#C94$E5RDZ./%T/[X_QB1DH3)#(6A>0L,YY9NUP^OS0>5/YHX^D)
MI8V=Z=L63-T2M?W;QV>KVR62#Y:NVR_E069=J0X@*R5B<*()7:HZ&+AT@&S7
MDL5(=</KM149NJ]P1616O/UP;%3 ]7+HW>T%,<&$8O0BDK*D]8YB#IM3&+>M
MDUK%@6$;*YI)^=M2Y2E-@PYO>?>:Y_5#^=9/6@_4KDP"+7;@"&T+77NP-$"8
M)M4X[  3:^0L;L_GR\55M@G;XH;K=P'A;9+3;E-/]87!O*,M: [L-9HM[B-Q
M^P+!GF%JT&?^O@Y5U4,WG<A1G;>62S[!*/R:9'2JU5WBNMZ,;N1&[OF=UXJ"
MH]#E2KFQGI><"(Z37^7>U=_U..3F:S.V3$S4H=T[CRZ^@^N7Q?8+E%S4MS0P
M?A&W3"O\N&C5,?)ML /@A@2P9\"C4\+XGT%)[/Z U_-JUKCN:\"N5I;0RV'V
M9B*A%R]%:ZD&8RQP8W4<O=BCM -8Q(F8J'SLF<F3LES Z7[5*,WO5\Y(F*T?
M_BA::AH9/E5^5 'A*7F4?;M!H/%#J /%"I#\Z-HGSI?E)8LW[E5XEE0123]E
M+O?&Z<Y$AS2T&O5$Q*D_XPF[AVTTATH61L$GMTJZ4NKFVM?8J![B>%E/_UQ\
M_@HE\?;W;W)<AF9]5K6EWR+B7HP8?JGE3^@6JD C-)4LZ8+!U-!JLNBH+6<5
MC (EBV6S0OPRA9K7BBZ54X5TA8,6/QSNU.)K'1P">.N4@88?C,"Z_3YA!MVA
ML23&T<F4^V]\#+5T/CCY7>$_ZKP5L7[;;HP0K2]Q8SUOZD,^7BB\N2$=SR<@
MI&K7;:4@]0UO/Y <_NGM<ZS\+$WHN(RV>EWAHKJON@W&]N<'V=F^6:NM:3 A
MW-L+U<+$\+.V9>ZP(OU^ 7I^ ,W8>CD).IG0U#4O39>6VQADX('IA3IIX,O9
M 1B\ZFY!$7]R\R_BQV,6/:4%IC9]BZLV/$;O:FJJ$Z^5E9:%9,0["9),^+3D
MFQXC6"62\+8O:*)T)_+@PCI-&_2?K(B\5SU2<*1Q\0),?^R//'K'/3G@?,.=
MY;9BLL"+;P?U-A[?/1'SI4A5MJ?Q_+WT#HD7AM6&VBM#]$=<Y^.NG-U_\4J1
MRT':P35 W'0*LR!%.T=G!7W3L.?!$#+!O+RGS$9]\6@O8/\Q2K2CZ6V^P,W"
M_4\>W)H04Y+E_-$FLM2 _.(]16@-D%UO0G-B626_)609'*@;4'1;7+C]^EGD
MP^%O<WJ3Q*!=8R-OM5I5U\*:F8A@,:E^S>W@F29T,?OB&2<\!Q!<E6_UYGZ
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M%T#U1N*V4N/ E&WD@7<I!T#35V"H_P@FXHE-JSM;ULF._M*$)_D7$M0>[6Q
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MZS*CY :YDF*-W=Y7D_F6YNS4L#PT9^@6N1'ZWI#ZZMW,\[Q/FBB?$3/09:H
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MG(B5HEN;-R\JNCG[[Y5@U(I./GP8L[8,W!-??,F&Z$N1L2RQUK^N$ NZL-Z
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MK90Q-J19]RAUF>!:Y,6 OQ\TJ)!1=?W1O+=9X(DC[#27HLY [O]U2O%/Z.3
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MM" FKE;"_1E)0%>&U2VSOYS"RO6N\?8NT#A"[&9#C$?.GABYQ(9H!:RTUH7
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MP]@0UU%+6B/0J;F(HUXDATX:[WY(AHD"L80P?AZWSM9!]9#+BY<L3B8UM7'
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M=[]J7_-*.'$Y7L 'D>6/\3B=)$7=CVU'Z%PP,@%FO8-:?.-^<#[]VWMVFR_
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M;\3_0AD>S[I;74A*3_HJ6G"2T"SHV!;9LM04M%]C#<D0;J4)]8&SWR'>@A=
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M#I6 \]N#^6>H!R*HV!EP)Z3A?"7K+.KBPVZH]$\33Q0T//A.:0VK]O'D1L6
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M8FS'RPF3$3%.=^05[X\>CM*^;R4L(5X"%F4HL>6<._VLZ=_3N1#V5<X+&VT
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MG(FAN]>EP/##<>MC8 G FZP'E=#X2O9QH,!O6'O6;8D_SMIJF%%>;/P5)8+
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MM1[HW5E8Z JR*PU1LM=^^[?A)ZWLBY]$KID?M]?42K36_4X"#@ZL-S#PS-,
MG&J83%#>PDJL9E(,4SOV,V)R>:"D,(,[*E_KEM_G?*46:_.IQ::"IV#1XF:*
MNY[ ;_C_C.?R_QU31Y1Q/T(%3,!$I0N<-[_KQ!8&J!QW%U_+BPQ)Y),+]]\V
MNAODU<B=OW%4L\G(KNF&L>(%\:$'=O(7!/[+_F/S&>Z'I>9!1;A*H1AY4VNC
MT-D8Q0]S@Z&"B5&@_=?D.JVF7/PNLO@*[V,9L,WM-.2!7M2 'K@GFSYM=R"O
M@?=T2=KG,R_Z:(7=O6 A F)E?"5V [X\D-9P#X&YJYD'&CWLW0RZ:"?__X<)
M?$(% 53Z$^9] !/!<*8BLO@3D/YA=K=/OC6I[+# M]QN.ZD0@:B [)F+&B>_
MK)]ZDW/'#\;2PW0Y0V^Z$K=[[[*A@#M#7Y-QS]VK$R&\9A;N&4(9/S]QLR%G
MJT;G3-[Q?:-.36^ROPE=:]0M91#H;H095[Y(*./*(24IHNN!%/AN$@71-9R:
M9V-!KTBFU&,:<7_@-3_A"]V+\5:-C+F.CT9F]?T_MJ->_\*R9069OSG%A*"-
M1Q=0TIQ2&X50J"0TF(_+H009'9A8*'/UVGO<5ROGB)C7IRO]7NG&*+2/5,/C
M$]X_KW[S(Z-3\'<X):MW>!=*$0BE@#,@\BB'W5GD.LD@O%<+X<V<KI'GS&SO
MV-!A,<FC5^R/7_"@@N3BO+,_Y/0W]M^M%KB\JKL(!DZ8+Z+;&.9<<6^&?_]?
M?"EF15\H(&/$<5O#"5;&=RJ[*D,WM7OM%#E+33DTJLJW0[4:]IUS-6FLM?,\
MT&,49*L/\[A$O"J!3J*9TY7Z(9!V!Y8^ *.$83%4'DCL![.U,K7=%/Z^8AP>
MYOI3W6VVP9E^*HR$RTV+[7QN2%QC/F[F8*VD*Z=_%!9G%!LQ\BI,8()>H?AT
MZ1?OD3,+J\OI!K/>09><4U,.%&ALCA0$I'HO0:=Y($? D([E2GI3Z@0 "*6V
MH&XP@J4'Q-1M_3&-C@IKMZUVIOB&43:_N66VO.^MTW3Z$"OD=O7JE:L7!+8)
MO=A4'FBWS6ZDT2^*81]6/5A==>3>LEO'9,2\O:5WD/G1J]):"8?T>@^I?-02
MR#E992/%2$JE;D@1 4)/_/:Z^2NOZ555W[Z_JU^D_3PZIW&VA+H_5^#O))5+
MXFPVHYY3R0/!88">^R,3'DC@1X=D.]U\O;)T90\2X<)8RD=4S@&#5QJ\F00/
M>$,K1<WQ1IR!EH&^U122DKVL;9,-'./'7Q'PYE^]:?Q53CU7.\C=!NPJOJI:
MG$G%2KG<Q;NK^K55DFRP=RIZ5_?X?-@.THR-K4!80'(]F;%@9SYCXP>"G-6/
M$>(.JUL"SRI7%LR C*FR+C^U)]$^J_%C(L7DOS4>IV57F7T_4BFTRU5A?FJ9
M!^JC.71YN;/E)?F<D\: 4; )M:AHRD::C=9[QM]Y-EHM;_$C>N/=%F\\?C ^
MU<4A;FO?)&U63QG/?5%PZ>_:B3NIS /M0>]'ZI(=XDRS4DFR5B[!94A,S\Y-
M8A*N"C;8J&;I<:$]I^W^U:LZ]#=8,1M]M@6P36\["8S3TWL9H7Y*#/O<W>4E
MJR-V&MKSU6]43YSZ\&9183\YUN;K+PC-G($@N])TJ(;*J*,,T5X2V LI1W9Y
MWUNXE?L3)^30BSZ2)FCZOF+@+[]9UX,G2/'J],[8AX$69ECVGC78"&X8T,I:
M_Z.87N/E9YK5_5Z5N 4/<SN-,"+:>^D0SP^ ,EYWJ<@+; 7\]RI/E -MF <Z
MF$4EL4 $;A)N=6L9@H>R"Z%9F/5=/-".ZHAH!+V-ZXA-QJP+\S.X]!(^- ,(
M#:0>!,)+3%3[2E^,ZM_7]<XYN>DN6 /GI/-Y]&^U1AZHTY]K(M!@Y__?[HGY
MK_[_ZO^O_O_1_F\PW'!W'3%R8">KAZ",'H3(H(Z5K*E+,A)::^N"*6NZJ>NX
M-M%QA+YZ7U^;;K_G3XW'3N*;1 5XCK\_:IQUA ?JLB$$(U*@S:0>$K&'.3!B
M)4<^82,%#%+\7BQBP$B;G>\7VB=J47;5I&:\4F1X5YCLJ/ZW6_A$3?W]!=K9
M9=>N0>[\/\Z0S!=,5Q$S3ZA0V@N6*-N6\W>'B",Y/29PH!#*])QH]ZR:(\YZ
M](YI-A-^,)O:JW?MD9,X\>7GT1C(0"&AWUJ3&3 5D;*%$4:>'KB_(-L>NN^T
MVT1%^XC)D-VU.T)3<E;W-QU#&H4"+65:?@I6N%YF&JKQ0"-A@_SZDP6,F29G
M>ES'/=,PVBW]>NW/B&@<RHI3U [AEQD0)QN]+P1+OPR;J>NT.<:X6O-L?FZ&
M!-PI;W!.NI7AYVV+[(#7OTV\D3_X6'R/<T/LD9._AN-A=#O$3/@BF"U?^IW9
M!WBR3K"/TK<3UCM4@XFP1),8I5,>AB9U>P9B8K2_E*OJG3K.'G1..?!+81NK
M]_I"B1P3/-V.X(%LVPS9(E"JP[_>. F!SG,_8YH1G1AB'05!TV8=-HPW73/,
M<&OUX>K2\8]P;4/Z]X8"79L5+X:832FVY/O=NTM\*:Y?-: R'U;;)+V.BV8B
M^>+K'DJ'+KH>\0K]"=KL]JR,??%AO[KF!,J%8>""L(/5K^U\Y580BWI) ??_
MRM;_Z'I8_$:55)1>9\.V80.2Q'UX'P9(8?JS_M7G6!L(\)T'$A+@)+0'LFQ1
M2D <'<NT!"Q?(%V[.K2_&MIH!05V,WJ)G.?$JT/OJP]H)N;X[YM[/)0J$;?\
M4Z@>Q+E#]35D/GO+*6'+O$$*]OF!6X#K\,K54(:HT\3OM>1)0P,O$T7I@"/F
MN:I:<9_C^IWH1N?=7[&4,GF@'^8!/%#L #OHO]T2Y$_H$91^UA70$>UGD120
MU#Y8@VCWO'._C8YWVS.";$B''#Z'$OTG-XL8D'_]QH)_F/['8=,ROAO-G 0V
MGV<(_>2DM2NQ3JQP%>COLU)NWPMU8RQ4DBUOY.TL-+8P3EO_,K;/TGV;*K)]
MH??(DI0[_C^9Q@$S1"3.('L#%^J>8KXAH_]!*UIUXM\_\6XO8_)=>^+ V.#$
MPGB@TUY;#S:S9K%<%\@ @2F X4@'";;^6XF!2_PWY3?H?\Z?2N?P0/SU"1P:
MR(0&#F+WLI4Y!39[3E-=4SK @/DK]LFIBJ\1K];O$7:O9)=W>[M:*D095.2$
M1CEY]9;=[9Y=3C RC@F&/2/1?2#3DO; 'S(IA="BM#[+<@HA27--4*8 Y/4,
MT*)_PFH-(@]<\HY>^9+[:K9%P/&<^XT3^0?-!A7\]]H?!=<3 B#$AWV8YJO;
MC]BF5-+,+Q@07LN&,JR\#M:4AQ(3:T9:L]?A=8K?B*&!]_)F<I;-;$[+*AO9
M?[IB3HVDE=/QBUC:,7HD\_Q$&&T#Y<](]IFHN3=T1'?+<?WV[>9G\Z?@MM0N
M?4661TWGG[M3)X3^W,91870GTNPS_N&:5&@ZK,F!ELVR#N*"@#5Z^(6Q:T#\
M@LJS+V,X5O1:E%;]!/SFB9@<.T$N;>:3P?!36?^LQYRF#A!*C YF*\PRS8"^
M15@\6F84Y4O!IO@9P>2058[T^9J6\JI$^OV75WQ]!I3SJ$*[K/IO7Q!=P'W'
M[+,YQ ZDNWPI( _'P9I^ 53/"<W"J)<3J).M-KG7A>P$?FU(&>,+ESL?'2+?
MG?5IR'2_\]NI&WA2B7+\VJX47<G69*#32X!XC\[Q+<0>)-K7;6R^T<AO4K?*
M/3]C4?R)J-"2U)[=<DQ+3G6[*0N&,OWZSX_H+"_3^]^1$8HAZ@H,0L)6?IIS
MD9Q7PV/MOB9'29/P@ZHG-'.5J[.=U5 O<]4C&55<"5&&)/-^$/H(ZA;G242,
MTN)ZL6[S2&U[E$X*V2*OB%G5VXB?J&U^HAQTVX_BD<0P]M%PJF6N)%U=)BQF
MTB );'%&^F)@YOX<*@7QT,9\E4KYGIK8B;2Z7 ,[#4>WMDN\2D?(M^ 57[64
MW)JS759\<BV7@5G$/W#HK=%DWH6H6H53X#KN@-PB9,^/!4V@CMX_Z!#MZ]_K
M%5'$-E9P<:E$LE]5G WS&O&VG]HUU\=\VK,IP.2@5E@'^27/SDJ%Y8<>)RAB
M GF@72BK"?U[A*3"^ZG1%<C^58:4N@Y^0G7GV)W0/;Z#85KU?SL<OJ%SJK%D
M<T;E'0(X J/!*ME*='P\6B[41A)X$DFN2XUTSP8(O5!I-OAUJ+F;A6GCJ7'B
MH?K,I9;B7\./Y@,L)<Z$O720[5.&'N>/?AP3YAH'DX<N-F%5V_7IXV3#7KC(
M0#]$&B5=#H0,>P#>KU:.!@>7$]?N6LSKU9=.G_$_\EC%K+JZ7/.C<@EX_/WE
MR^._?8VHGE]KQQ8FQT0+OT5Y2^X-*2](70<)\>',/(NP6 .A7P0G8P6WH$18
M+Y1NYRKC :B='X5XPAW<@/D7Q(5GTFW4P/J;YC)?5MT59Z5FIQV:"0H[ K#C
MW!D2XP':DJW&R:1AH@.J@.SV2.JK9$T6N&>SZX[0>>N#DP?'E(+)E+2E:['3
MH.T-\1"OGTUD%V-WAD-R_Y/7\\'TH5<KIWZ<UZL,^OHR>4BBU"7#:0,4UO^7
M<=I(:1KH$-]T^]H=63!,MS5%ER/(5?A>Q%2;@;-)-'@;\X3O].8CXPSJP?<5
M'?I -@^D+<?'P?JO4]Q'(4"QZ="OO95@>P_'S7=FQ:F_?YVC&Z^'Z0H[[<ZH
MGHT<A0X93T').,)J(6:9']CF41Y(NH8'NC+. ^E".17M!]/8VYQP"NP/#\0#
MY?3P0-DV@:QH4QX(BTW ?-A& '#$3@7VCR</1#/!](1B_OD/"Y_XVB>X3KPT
M:VLX%<.'9JXSF'L&BF^"_?D#.+"S[O- 29,\T!L^\.9BN>,.;#,\Y[(KNYH'
M8A;2"P_Q0#Y /A?# RW5\^WT_\*#^;U?!"MBNL,7U\"*,0_7"? $P@Q[GF5S
MXUB;H+6U,,H=YH?BJ\$<ZQ(>:.H%GX(1.WH>&K-GS3X?N=PW\2TM<S+;:]X@
M-=*Z/=VHGWK'*#%X7CLF9[5-Z[[\13OTXY@+__:6EOO?Z#D>:#.(:\T/OR2_
M]H?ZU?W[FW&1,$G"4@$0R>UTP^YHZ]ZO[U#"?#2F\ZMG#?2WDQL-Q#_[?]H4
M?BG1L'S*,$3'TYRCJ#Q02K$T\)U*$ "H U!)4I?Y@T=QM89,^%!\^<83A?F$
M44?I;G'#2CW6F4^UW8<UM)[\ILD++,.:(.L8^B#3&]MGHTE?>$<!RP)- U[/
M+9(?6452]]F%;<'O(J_O\4XM/DY-._XB18P2KTQ-,_TR(?ST>191CJE!_TZ3
M86R0*VG@:C:",96\A4G82:1M)U1;'=_QFJGIFR^;F7,TFIO^O+F!SSM+]SF2
MK'T24?B^,0U$AP&'S-=GJ3#B0S(V":5 )PW8F-/["2^1WUTGF[$R2/,^3>='
MW1[FKW/8@1'+KQSW=7QXTQ^LJ'W0=%[C :RW+E&):_F^9;+=F('HLY&:H)&#
MU"[2>_/" A.*%GP>P[Q]9CO4<L.5GA9<JU68,X?9@:(VUDDL([81)]]*\PW2
MG_PI1,G<Y@!#>I) J<%XM;/.OZA=G=)&L69?_R5XMDMF5^G+.R^#]P:EI)4]
M!LI8HDA1ZJUG2K$=^B@/QA<"?<?::_8")LE])_/%F('70D"Q<F NW&ZKK_5<
M"@\4F+="@:=EU*@FJ%/YL?JN+L+)1^]C_Y/P,2SWH,*D:JXVD/DBJ/#\>T1X
MN)IGGT@ND]"D?,%^WUY.H^]R45SWHL'N&/4TT"\>*)'4A$^VD4?Y ,F,+$?&
M]PQ32U*J:F+F0GEYZ()FWL;YL<+)V?4?A3%M[):4M5]GJXIH#SNO[OJ92C?N
M(NH,U.WACI9N7&AE**6@S"M^&$F^RRYIJ&\L_'DO;7Z7(*1 ?ZGN@%[?I_[C
M,J_V%?VKI=Y'D(4NE8;R\UBUE4_IAF#!_W[7,R"3NY+, \FQLS?G+K(ET'6;
MQX)*T]C/@<[_D+W5V0A@/JJ/8-9&^+D#AQV8FL*""$M90="M'YC?9G4C5I9\
M_*N!T3&T49LG25"2#A?R=5^B_$58/>2O?Y< _^:.SU35U+_+SI/[IKHW_AQ$
M[^/O4*CDICK-5QLFDC;/L?GC7--UY<CFMOWGGX)<9%@O?\&2WY^^T/3DYHC'
MH)9K[/W&%_L7Z5$*#YI0?,S70/,!_]I'/O?V=KLZ>T5K*O"/S$6<"V[ZST.N
M*HR*X.PF_'%IX8&H]S ]SFPX'T.F>*##+21VV%LGW3]45K@%#U12B 7V$CZS
M_S?VOCNJJ>Y--]B09I1>E*A4!40IHH+)9Z&)&!'I0E2D"UA @H1$44%J% 04
MA"A5I$2ITA+I3420&H20@/1 @A .I-TX]\[\OCKS3;EWS5UK_CAK)6=GG[+W
MNY_W>?=;TL(ZQ;<487R3XS[LAR$1\,+$$I?Y[=\/#_- L3^5BS:C@AN!8.<,
M8QA5%/7,7_>&E?*-C!],!"#! ^E6\[$T&>#W.H7G6OL2@1$(O8<'4L!,!_)A
MV+>"_[%(/ I6H8M?%\KCWZV#W? _MX;.W'\Q9NH:?UX<(QRJ,\ ]SC?>BES7
MK.?6#\"$8>>=-J.<&$K<,ZI$'NA*/IZSLX^9^/LS:RV/R0O/,0Q8&T2["?(Q
M=Y8'4I*.4L>W=<4(JV?<^\.Q_F-,AOV4)LBM!7/#^Y9VA0;31;AFS <\D M_
MX9WRYFQL(*[)]_% @MP1B9DCKIPE#(5C-6AE+,426/V#<^D/RNIN[>^V4DL%
M1E '^#K3@T)F"3ABII\5DB;0<D!)PPWV$3I;9VY[OFJD9T'6\EY):@6,<HC>
MPMG"UZZ$-QO/1'7R0 ];&B#+\@^XZYE<"8@HYHLWF#5[3^]- 1DXB^+/PHDW
ML,6W_]/KOT>OWV.3%0\DA V'3>L+<E8<"-H,__#O]*0\R;N-*JGG7JH+YATJ
M<^5KMB!<)CN&+[3"+C' *%]N)ZV7;OR%M;YQ(14!,+'<2NQW>$&JORSRLI/)
MMC+PMUV<M_!?/14W'5N/[>]O_L-280JR5:&R_'7<"UGM0X4PMMDO&&&*X"+A
MIOT''&2#MMCN'IB"*F&JKO! C3R0,HHHB=F RV?'W%7/(*I!#ZK_'V+_ZT-C
MKNL>8LFT%+*^#%M7L&L-7/'_2)28ED8(E5HX%=JJ3UA<D)-=@M[Y"U7$D3HY
MW*0(J4GS]0VT3S<]<MJZ31]-O P=^\-]VF%^F#4]C"(/-+B9/[CZ>#N\.J>2
M3X&[V2'\ 9?AD]'^>X:(<&EI+?I PZ=^*_$ PY/F,;=9SPJ[YFDP+HK_4L23
MQ=#?,<=3G+1<'J@K!K8Z;?6/CQ=[SV^"#9$P;(!O/Z ?0?[QT=+X?[K\/^YB
MZQ]3H"E3+Y^O]6QW[&'4#KX I_LZ2:6.P]8D5OQ96^ \4 ;I?2.FNJN;:Q*(
M>:1M@K(PEK3[L6_MR%]YT5=W%:7E<E)@R[+H,1XHZ50/[A^WLZ9AQDFP]4E8
M(I28FTG/7"E[#V;>X5L&T(,\$/DU0@YE8@-_[+BT]]Z6D@#0QMS%%,)7?#1:
M&=-VFL\RYO7Y>B\SA7B4H<#Y"N:JK2E]!S(!20YBXFJWL=3:4<;]/PM10#BQ
M-Q<7)U"V/%QR//W)=YN%B1#,T*Y-:F7JH_::$@G,N0OAB.4O@[?QY=W'C@UA
M!<"S*-A5/LI$K)C:)AVV>H><I]KN$FX6D-*2M)L7_/9?XM\3H02Q$V#\>PX*
M\XWKT]E^7_[3L1@.!%T^"L!L^?3Q&O^N6OE_ $W;(]C5X'58ZV<\/7NZ*Y)/
M?KEN,+4_U>3\ SI3Q@-A/7F@N>?<B^MN>':(*=] ;EG*'5A>1DNBR\N%@0JJ
M*?N9)8;;8(=8/YI/V_^[$S]P.X@C_)FE8N*AB"C8?7@?UT2+3Y 3<+)_:B7^
M=DHFCOV63JP+1F"6]/.Y8$Z56L^-%M8$#]2PGODN(TJ#N7'A'_N_Q/$Y=!]Z
M7P!=<+XCD((7T>OVZX/N!JKJ5F3G!69VI:=)OE>H9+0%YT3)KJINKB/+WWTD
M*<#@#+#%^:;"(\;Q+K8RU(@'"FOC?KW@HVFA"[C/-3B>2U<H'U9?#CJ?R<K&
M[H+?742#V4:<&HQ'FCO9 GC ^L6>'4"_7J24ONA [RN/IL9JW14ZG11RO4QY
MIU],@X_Z^4_%9UE7_;29*?PK)R)YH#'!!K&@YF-V\]\]BN:.531M!H+I%@UW
M"#H\T%D&X8-?>M^GQ[XG9Y@,<ZD.P^0G\V5/W[VU2B5AW/RCB=+0_4A#^Z]0
M*.IXM]&A<9R0#WEP='\/6Y<JV+M,+M5/*YR_Y73)7%1<1[]V?E/!4R6E9,3+
M_:UCBFG_(4;U?R$BAP\[_-4&[R/.R\&XT=X]!60Y'J@5EX\9U,%PI/OBE#BC
M:.R2;CY[WUU=JB-?0[Z M]7_18X;N,KW7T#EQ<_Z2GR&/7"(G;?".0YY!"DL
M#/O#+ACKS!].L:<:_5?/P@#<!#:9BAVS7L$\C3:6@I]D;(F@AAJR$ U5!3+E
M.<&O9:1[!.$Z^^3WR2A5M<9EW=EOZLW.^#P U?G<U*Z>\>0/T/![ KRVC5 #
M\'6L<L@)'@A_BC\%9>C[%#([UIL'XO_(+W+YY2'N&HS.?3//U\R<>ZQ[OZ8H
M/Q:IQ##H ;8)IZ2,3')B*OW,Q63K,51KQV@75D\BHB'BA/TC,U!TQEX+WQ/+
MG&/]I+'3<Z6DVKE@:[,K@7(Q&K R3)TV6AZ%!J[05ZG0%RQ3U,X>(RG\+$)R
M(5!]/D!;9O88IVQ>U\OQBH'K^5Y,SP&'28DMFB#;V">BN[O2D0E<H5H>:+,
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M]P)R5 UX.%E*G[P+I=MC%!R<RU9F)#\ND_,OTG<6TBJTD*I)74U^=PJ]_JC
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M9A3J<2U=DY[^L"H](I#Y6FK>?.][A\M7PO<KZLA!W5HOF&J<XR2CC!D]?+C
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M\6O<#) 1!P-T6@M%\TY=];4+I4,6P/_+C[0RAG1A*G %;1B%)9L!,NZ&O62
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M^68]ZY;>*-KY@,*R<,2X6Y7I<V2U[/1&FE.SK#RQT )=][EN2'=EUW$Q)4G
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MAXSCRU.4]+P^Y]^@MT!= "A9U0I(.](@636G?ZFSKI&K/FB@2>*BYX+'?;\
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M"L>#7YX\V^N=Y'P[^43*N7R+A4I<1-7M2E].1".SAOZ+(U/_DH/,Q+-9EG]
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M%&.S48(&>K2K0\VRA '!RPUCV],+D3S2KV2\[7\L!&Z6^63=O?<F3S$:T&:
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M#@5GTK!BF@5Y(T(/YE)NZ ..:KZXE_Q%W;B[@K_KQMVT;\R<'@>4R;T$\)H
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MMLV^K-I/4$6%2%/3>=M'8H>BKSFD@G@OO&'[A1;^H]'FWN _F:P](A_J1G%
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M\\K+$7?/) C=N:;%?[U>09'(1',I6$]J'$*3F:.&H6"B7:(>N 1^A0R)*)R
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M29<MM*'CD#D4 U03DE8Z>2G8*YAJ1+L:LXPC2I$'Q62\^SX_$#&5.1XJ-5&
M;&^<%2<Q0$F0N:?XP\URQ$$N[(WA;0BG-Z4Q)?>#D](W9\-3Y0@T?UJ]PJ_/
MI@J&AWF/V3*!XS&B U6WL>I'5:+Y JKSQ]3GZ#5HN EY(X[F0*#.:/?LE85D
MU8E^,CY6TQ8NA^A[Z? T/GTN>A*%^(2Y"YZDTCGXJ/R(MEG^_6B$V#*RJB49
M&UU=6BK&'2\D>7)\6Z1\L/O[SA%"T/C([10S/NP)FXJ#@D9*1V4]#_;2Q&K"
MP@G()R@PTMT/<KV^D81J#\!5]>2Q \B?EL,<SH*SGJ=BIASB9:2QIU>2SAUZ
M KNUA/R$[=B7H]2/(_W$?,R0!+7Q5K!]J,'BU0_QOLH!_N@#AT14AF]&=*&:
M.%UJ'C U.G(2VOYGAX.IE$X*@H1)TN3F6[[A79>#3])S*37F7>G2&5O(<QO;
M*F$[:K]F<[/2.OF AU156#D(GL;TLR%@14HT9-HI"&ZSGZ>G36H<<)I G$V^
M84)"Q229R^S]3*R)R9Q#*6<TBDRO^9TFXCA.9<@_.]8Z2!JAN)#64YEVU=_/
MH:M8MBI%M2,D2?N%:]WKCOK7-\Q3OG??5ZC#@SWKS&KK;&V^/K8;0,@!LLQ&
M>Y&XW"Y8M79L.<9-^3JOVP@=[ "@'<E*GT(]3.XVY<<9>L93XC]+?X=&?K61
M/FPB*K6#3LP39?8RY2:]ZQE@/H=/H8MPISZ.R>9W1"=H/F^J_:8Q4/Q@0MWA
M<M;O 84.^U[_*M435HLJEZ0C'GG$M?)X(24P<[6S? "5-&"9,(N?0W:TP"X#
M&40?TS;1]P6EFE5+>^(I:HLMU6R:*Q70YZK*GPZ\<%E=!K"4,X BL\O>@&$%
M8$<HZGY+U?H%X:P>:%AOMH!T4E''84"L;>:X@P/.S^)P@&;W=%FVT%G!S,XK
MAER$B=7/_[QD8IX)F*FKTO,,$*YHKC6:_)OBU.(L38D )$K! O 3X_,@S<&N
MVYH]&:?/<;-\]_KQ_"Y_?>K]R9O@2A\^HF9OEV[ 8>\;</DA#3^3KHM3,9D>
M1 E;)\73LGK<6IZW7P^9P+*TY(3GSX/ (LP:KXY0\@:3;/?5V\$D:WP\G<N/
MK]/1X+5F40?XL/ZO3-_@:^D./HZC5$O)&^<:*FLXU26JKYM%A_78[^*C\9M5
MF&XP52,<S !!?6Z]99:RJ_L)&$\\(&>W"B9@)@<HT4TDRT+M*+3FD>&:C2,^
M#[,5PP5F]KM7V.XV5$5T]$VP'!F_UW9H,X^+.Q+C IEVZ421[#%"R/9+V\<4
M";YY'&2YCH& 0^UO+\WKFU.OSPJKS#<ZC7_-_J&NSL;?(0P2@;X(>=TF#J'Q
MPBQ&MM" P@Z-7V7ZZL<8G!:01CB=<^[DT?=F&KGQ,@]8R>I5ZI*%+S+Z-<'M
M:W(6^RCDW ]T'.9H*Y]C;Q$00,2OMG@P32[ZJY:==Z;YDD]%[:OL'LU=6Y.(
M6@I(O;DP5V8!O_\:XX(%% )6!ZFWZ$/@:OQ3N"SID&W4/"8A:-!27_TZD%C>
MM:=AJS7L=#DZP^ADB.N]P1W0[0MS"X\QJZI_1G6!UR0/2BR02 U!3""%MC#B
M< _@I8=/X7=SPJ""N;Y8IZALY0Q71E&O8C5:DO3)3.FI1E+"E9C9KP=64=6L
MJU4D#"6=K-H)XX>;5&<YI49CCM\FQ\;"TPNT25,ST\;BSRS;*06GCIPE&X?9
M8A.VN*/P7,'XXX@1R?,Z(;GZJ*?C(S?)6L4*92&.1@70!VU-9/X+ THIQMI^
MSE.;(Q+1\/ _G TXP?R^ .#)B9VGJ1KH-A]4-%V"9UDH3QA E?J8GVHHDXZ-
M<:I?]4NH:6E2:+XF(N)X[5.?<*_HF\-XDA%V:MH>8*&>":V"-9&2>Z.WT D0
M8;C%/)XM5&%Q=!H3LZ5_Y9<6RO7;<8.O>/>4\SF<W*<K1(YROK/+H0^##VWC
M69#MP1@W:&+CSS6V>2P_.MZW]43['0+L^$VOE7>A(<+5H0ML=XX5ON+B$*EM
MKN.%*I991?YT"[>BGIQ$?"<#84YC2/^U0$+&2IUH^JFH=S3Y&&"I-NLT[Z*9
M+,9*+YOWRK"_,$^)B>!0?1\4A1C!5)FLJ9%-*#2 E6H!/S],8Y_E!R[FR3H[
MXIW(%FNU;S\P0#Z31C[4%\21'\EZ&2+(G$N+AU)GMM]P%WWX[YS7]O]__O=_
M2%@F+ER!W$4?#$7?()DDM&J$9UL/U8BL!BO" !--N4W_$VD%:=JR#;:=IT6N
M&_8>3OC* ,46(]J16\X,T.;$&&17$*.,]$'NZN#C\91K->A]E9QF2BLOFF]^
M:>RYM4N!CP<#U _6UYOF$ZE.'YF@8:?P1YD0^:=-"0!]E602C= (+[4>#Q;V
M#9K^TZ;,[XI3:2[)VOKU-@-G1.Z"L#+L.SHTM?UTR,(*0I@!FKHXA-QJ%-W_
MBG[3KZZPFWGZ<\F5KSC8MN_61^&2%Q_,!I5U6?BM;DW-\EO!U)DMW390AOOO
MYR'G7F/X(9[8J7EB>6^TGMV<ZC'S<J^ZT^\<;K4'W55P9",VQERPRK[WF?^V
MZ7DI 2GP5:M;EZB"RV!^/215D&9 3NU636S,:R*B! $.B[$:*"_2W=[)[-C8
MC^<W(&F<6BOL)W5?)RR=:#LPL/.;*:#D-GH@$EA28A?]]'X) ^3] 6Y4W$F&
M](J>>GFJR>O=TNDCN6]"HZX-=Y5D?>ML?N$[[/7N[N="X&C!,V8&5$!Z),^-
MZ]T@:3N3)U;Q1"2;]UYUJWA+;GMC7O&'ET%FZ"PAJN[-05_S\-RO[#*>7^>>
M5/:A_W$8TC/:*>!$&(EO+GO-G.Q#6$#RMZHLQ9\J9'T*-T9-">;9I@:&!Q9W
M[' W>V$UZ](.ITL,:W:%*M>0#FR-"43/IR: CQD(XZ9A\"M _-O0QQQ375J!
M/CG-6O%Z1?DG,I^K!WYS'1]JJ!7$^VH?/<'6/-#L-YVTCKWJ\NK;H5_H-(0J
M?4I2!T*R@DW5$2!M#%!*'L^$@2C-I($<C4JL7N,:GZ6$-(YHN#?&.VZ[WXLP
M_7S5,^WCY"'U(XJPRX@AE$!%ZV$$%J$+$%P(3LDAR".AVM83=X:4V7B7N;V\
ME-OJ+A[H-'69/*?W<>X;JYL1(AQ^%.BDAB-&D!_K8C'^F*E8R@8)G1J,Y/&D
M/,ZKFQ.#Q-H^\')\]*QG9\\M\2*1HKAB_<B*931;[$?TI0X];/8R9-J#LL!$
M*1:X;"H1W0L5GK3?QUC7CNA!WD$_F!S[6OY(C]Q1>:'B0?O5MPNWCZ9H>OBR
MO.&^F]^0[#/OT8[B"O6!DHOB$"JA=SM-QA;LM\H==V!U";CMZ?6RZU5/G^6U
MFPUZ TT]!CP DN## (F';G3KA"3F+X6@ XN7]VI60RBUSSX,F"E].OXAXH%#
MW,$(C0]HZ7VFKO6#1D+JD.V*R%3P(3USG[""&6]M4B?O+>FO'PV1@3['NBJC
M&GETG'9_51SR?>;QS*>59->M&@/A=6U))$QT^;'"_+0"Y*R<A>QB?N'ZL?UR
MSP<KZ_6TN(]$:'^H"$$FXMG*X?YXSG6$?&@(A%?!>)"PJUG/0G(X>O0J"^V+
MEK'!K0=JS@)_V5WU_F/T&ALIRFAT/<@/VDVW&7RW<:P+.;5SK'(LX6-?4E0D
MMW1"%%T4-I?]CVVT&QB@^>#?'MVJNZ=;I1F@C]L_Z2F/V]%]]_60KX:Z+%]Y
MC7SR\U-)I7ETC1&O!BE<45 ;:DVE82LT,#@^PI&:XFE/G$<B;3JW85@LE &J
M6A<*JV*QRA ^)),"%<#9]4 XD OO@4!ZYSAR[[SBZC)5A0][_]&Z9.'5RW=?
M.9IG:HX,5LWT5XGN)I^^DO\?*,%$O;W.*79Y]$L&:.XC6+!5&X&%D"SQ">!J
MCU4RV7:^(T^1)!13.%X]_7Q8"7V[44U ^3#9^9*4_$"]&_L9&?%G[,^XW\NC
MOT+C43R0N?=_!G7F7OYYW6*RA9G>,";?*LB'*U>3>QKFD!+P,R/*6RV6TFX2
MW\?5H'<H87$RM[^D&>Q\)_"C!],H)NU,.HHEI*8BW<$Q#%!U;Q?LN)?!D2H@
M>6Y?VJFJDJQ5=:RR+GWOJV)F#?[TA4W5W#J0:]IPA+YEPMMRH*C30(2T15<A
MR\65:>R?&L=C&T<WT+R*H7=[X#UI<38WD3SG/L EYC&':$9#O7&MX-"!*Q-!
MFU062O*'[F VOY))O-C9GSZ*+OK"DL0(34\T#_!G]<&A_9=(KP <-Q&\ND%"
M$MT3RY8Q7!Z?JL<\*L=O9_I7+":8N<>PV)Z"597D?QYX]DGW1*?QV%I7Q%E+
MT+(%B-]6+K+U%%P;R!#XCN=JE?KU>,_^IK JWFCL;:/@, .$/<]Y=5HL:O.5
MZ.X($=L#304+00+ /(AN_&&ZRL"<$0G9;@X5EKB+-?G4%&YB,ZJZX:>LO&XP
M<;C=[X2@LDPB[[M/8A&'/_!Q'MC6%.@%F#AYB@1K5V;MAM0(-A$L.+K.>-K"
M2#G.2[A<DX+V8@U3%9;FB1-B?>J"/"]!=PL?J-LL[!=!W/N")FM>(CVAA\I?
M;39?FZE+5.IZH!.ME##KS@'Z;"J>W#EZC?6^T7W<SAHWZ5!'L9=<@L'Y4%T+
M)ZIF4R4SB_D<+ZHH3SZK,FDU;.'B$G85E_1Y2T(GPA7GRX_@NV^QD;5095X/
M$QQ'K@^C7>KK7AM*/4\_:Q-C*"XY>N"MT3T4KX%:J"#6J)Z$C370#U4W)*N\
M?:22\7:@;+;]WI'W;]GJJ-JXDU[OK4[R';V'UUFX'0%_2&<+H]X,S9W'T/@.
M$3S6'E*OTPR'UH(#>$.MO0UD)P(X18-S3"=XI2"=XE= -F##5QGI![;6!#:+
M5J.IEC07H([IVN/[!09'0]%$1!01>BA4M?,6ZQ@"#.9>4NL4Y_&N],8:+(V;
M.2[EKGY,_D&!O[Q\]2/$YMN_W>WX?_!A):2N!3! <DYD7?IGP1H&J'#$+F]B
M"=J-!4[^I"E#$F;E@#][Y<M1N %3VJ6PDO!8^O$-[54&R//UC\V=_<J':_CD
M:>/[K[@RL<C..,CR,F2SEP%:7Z81:R_E6E:_*_XUO0+^;7#WO7-2IO'HXQW8
M(CR0*H/L'Z>I,4"?HO,9H*4@3>IK&"><"3B1*LB.,J"<D!J/)PTCF?UZ&MBE
MY5@TB21P;;8.41X-PU21TV+N:R]FJN?/MR_! B=&[E%8!9X4G)M(SGWLC8*>
MPMHI=XYW=ES)KYFT,A+8DGLG\'N')N SATR%>$& 4Q,]&T\P'-6UK<PLI(LM
MA^ $\U"/-W]=P(IS3 <EO3T2.L Y9_=-XQIK/Y)DD3J=2G$A:]/X. B]W8.!
M\T*Q6QQ@%IK.2!!&LKMBN=+1C-!BW#&LZS-@WI69^2;]_-W[-6U*6A\/G\'V
MH-@Q[MB860CSF>(0O7@>A (<7/.IA?QCHQ<&KLTN]U(\-K.6O!.783?$=RU^
M5"^94S3I(1MGVPMW$5Q9++CHEM1^*@/DBA:$6R3.VR5@W+"QCJBD-Z_=H[H;
M8R-]3XW.I]VO&5\BGHT1%C[Q2<VNV8)ZECXXJPED>)"S>R!5&Y&: 4)+/RQB
M$[8A;%/88B<!T.F4I?FS[T&@.S&@-]S1!21LQ'JK!A,(S2 >X9<Z137H[#4D
MIHZZHJ=\WXW/?GI9>U:H0=ONY$$MZ3Z*X&]U$%L:'-O\T.X5P((07;K%Q-%(
M4Z")R/XK9,^#)D6<L!K=?L+>CNU\.2[_+AV:O>]UP"85OS2(2+Q%[X)5(HI*
M5D0I!=03--7Z5C*[P,2&!^G(J\UE;^.C]8%<[H=YSRQLE_923/>?YQ*V8SML
M]U\:2*+8EQSSO1UA,=#(5635ZL:U.RIWZS:;ZQ>MAHVN=5:^X8ZD\P#2\[!>
M%*"(7M._'T8V(5CK-#NJQMP%PM[3+ &G0*(;JEU(]%Z KIGG=J*,N4/ L;[&
MH^E'7LB'"!N5(9.8-:JGABK'-()FLRSI1A>RNO4U66CN.[[F5@KF>,"6!+NS
MN@EI)V)=,UK(\3AW6&BO>5W+=("TQH)L53-W='S5GB[9@_)P'T4W,/((($_,
MP:*:?21?K>(>A]9U"N8\JW&G]JC=%UN5.R3C<JXB$M\AR5=-*@GEG>C8"WHL
M'G*P6\-SM<#)J(;MXX43AVZG>@Q4B=WO4;L ?L4 U1Y#KX:12ND<4U3A94F!
M[(Y;XN3HB1@]/Z[&QC GW*,<&$7Q5.[/:-P9-Y]W49"PLR4_0=P8 P.:_7#K
M01H;&=VK_] \?:^W'<$[6C,](']3\;N1AX]L9\^[R -N21'W'H]K/V& 7/!3
M<H244K<*FM9^%ET<>$R]VI ^;]'RC<9SQTOYW=>25)D ?@67$&L;I7>\_(?:
M!&97=+12B?J2&YVS)X;+T5M4JI?R1EG ;8<[]=&CI;TGS_R7,440PA QRS2P
MT"J9*@F7&H7,52))1E!<2B<!'Z_J\1&3W8;@&9MO)J&Z1NX'BOO<V<\JLW8V
M6TP3O7#@V+/*7FF1&\M00&4T*Z>(QMNXT8,YWGS>H^B[8^A(FU!.SJW5X.'.
MT%)C;797Z0/6@K;^!P[E*2[-J%(N[*=O0>-7R'5&^]D("0=@2.:L7&(YG.^.
MY(<*8PZ.PK@K7+KK%;T]LT=(=ET8-CS 081$;6&.>SJ6-T19#P6W&.@VF?>E
MVO^(L7%-@^[8\UP \]-'_[SW=L7S(R;B29UM69)'F\@)]*^-J[]#J[ISVK([
M&Z'1^.M4Y;&6\G332N<9\X>^+B\4VW_TLF[(GC-U:F2FRFFXX4BK)C/09!$L
MSC[T4U5DV>\P3HW28P&#C>9%O$;^E;N!D6:S G8G=M<?3S3/(+XP31>]O1.M
MJ8N?HK;SW01XS^2QUF=W9/G2):Z!..[VZ.%  L8GIW=,"GWAYX$;I*:Y]2=R
MT08\-*UO>LJ%@V&:"XT!L1JA2GZSB[8S2CWG;*S[U@8,SO:F6X 0:DNS\CE@
M0"NL$W$<N#1OH7X%"5B,3\]?W;LN@M; L-<E;9P8/=44.6Y?P<DA-*"PFY95
M]WOBL<HBV,>0RA6ZB_'"1F D_9 ^ 9%YPO6DYR/MA#5U K1=-UD4*@0@S,]Z
M#.$N$3E>+'SB*;&,[0^.)J9<;H=H3]#9@=.D  *:,@<$DK([=5AI,CN;L-!L
M*I]A70U]O/$9C\R.P755E/3!A[KK+GD6'G!E)KUQWWC2.+@3U\J.P.:QDA!O
M2TRJKF-(=4]7MW8K)D+6/C7S%)AJ!\;(Y7D>^DU;H1OLOT1H>.+HA86 ^3R*
M6:GF\;CA97U6YYH9KWGNF%;UUHD*Y<+DWD') H]C&ZB 3+7O)KZK3_5,W]!S
M)_C>T =A5:AH>+!J-S<G_ #),I?HM>'>C.JRE12HBMDS?UGWJ$JSPUCFK 'E
M^X]/TREF_16XB'\]#L! #2AD@&2UNY 4R68&: AKK[FEFH!TA0)F<.@'()4N
M*)2V_Q:IB<W8SV@:^"U>^WVWX-Q7]2?6$$("<IEYZ0\Q!JC.CC!9P4W4>5&2
MD7Q,//?6E@Z&#$;9]OTVLWF>J2\6[D+WR* I,T#IN00LE=N! ?JU@*XJ[=%3
MIIY$=F@2PW6[D*2/S-97J8 _'+7ZNM4CBU#[<_#<5[57HI3'U*\<GP,YBSAL
MA>L?-)AIEH3KY1JDGFB_>\_:0W2H*J 1F?'G#&=<'LFN'T:ZQ='DI I(]ZYQ
M:_[X<O\$X!,F["4NK]1M8R?7<!<DT7^PM:;"B=C;MA&)DFPVR.,#?I*0';,:
MPP7/S25?$K'<T]Y:2U(]XB;W4M[6B\_K76.=MUNKHW*'VLVA:'S:%$]F@D0
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M0%4XL;R8KD:Q>/,<>-4-32>7TT;*U.!3K9GN>HHY^[+?Y4M@#@H^X]SCA>5
MR!<@O\VAFU4LD'<5:8J9G0IBR#'RF*=,:3:H8<A^%LAO#K8?ER75"]ZW)J^4
M99W][=*D3;2OQ.C]08GS"5SM$4'N<Z$QSQS#8+EX;CT6Z&_A$*VBFC&J _^$
MXQH>!TN4T4Y!GKA]6WK,E[Q0K7%WIR%SQ&?:!QO[5<KUL8)OP3[W^4,#'L^7
M,GBI!< 8"\2=39G::-#>?$F1ZF&!!(D,3'.=Q*DT8N1&8.W&CFRA"W-,L>6-
MC3NE6_++^P]S7WVM/@VMA&3<-]DKP2M ;]9EX,GV=;-+3/XUWDV]Q6A#ZH,I
M$T6X0T$<\CA%!4/2YAP@KE]K?%TP_G%A[_WZM5;XDKHKN'7D=D"3M#=F4.18
M7U8 HP(=B)Z+<@<V:;K,P0@T3X<OL08]@!:NH_M2JGKP0F&%0G!!S6<.8R8/
MO= O".9P<?6(OX8U1C],\2BEGQ]Z\P6$2AR#J:%Z#"HWB:7,,90Q6:H?$R\/
M;0!.:J7YOD0:3*'4@*2>J;:%IR^V_+9T\R$7/FDMMV,5;Y%'H%M2NPWM.,6Z
M2XPVI"6:B+ZO YM%C?F3<?Q(F]*Y[Q[*:1?@0VN;2I\.6S=OFB@)?=W;%'3I
M],ITYGKT,O-4]&L0549]F9T)J@.89)0.HX0=1A9HIKWO#E#3#$TTT2#3@%/:
M<AZ:'^O\O5[YA>]FA!B1K.6OB?T>'U@UO)1R.O.<0*"'5$\!;%.6DL<4%*;4
M4:,HT,V(I6F4%"*4F)6HMZXMY+>;.XN<Q$Y-R<0J7?XRVW7H97#)_ S.2S>]
M/BFGU"&CTX12)_*:T5@TP100J61V.6)X6VS"V: " SZ.].?)%.)G:KU:<$W-
M48CB<^.K88O*R]MDKTY'H8/(2/(4=9GQ@JG.G@RVX1]&N4>[1($FXP,@\NP8
MPOJ<-((<+V/,R7AJSCM$4LZR&3HB!!X4["-"M"XX;WZGW #&25>A.':Q0,!I
MKYXV;D+_B BBKF<7W1C\-JQXC:F.<QV:E\Y*;GY<=.3N-5LC+7M]F'%96(@N
MSTS+-<XM@K@;4#32LQMA(C2V$29\_8A*_]#53Q[C_&4;=3IF)RV@LR+X<9P[
MN_:"T%W.*';'Z3(U<J4H+H:_7(Q$09#.@"WIZ:9L/V%_BUR ^IJ7Y)1=P%3N
ME,@KS<_X0MG>CZ].&=S_8A3( CE-K4BEH1>+8.(F.DBQUPP<VE/8GM"#;\9W
M:\]RDCXLB+\-5,:G-7<ML4 '=)D0_,KY!Q_*>[T'^7[TW.$7+.;]3&B!TL4C
M2/B-)IJ%=K=@W715KX?!*#@Q:&>LFF[PN>S3CD]+WC7LA+/C!<G48:4[;F5U
MM"V-<[4+/HN*4,<IDOZF(;O@KGY&PV$@ G,:VKC:BQ>E:P))BYAXAWOZO1!>
M,[FV[P8\KYCZ8QIUS>T-MSFM4AHCA>X,++<+E^4H6"7-0B3$J%E "OLP32V,
M_"!\  LDLP81#('Z'NUPKD:X6A9,CB7,KOO?>NCJUK7/CN_&]5G[S>-\@]D*
M5MWW3=9*\.K,X^PS:(&&C\2R0"!D* T*@/MD!I([0GUI?M-(,7)2^NS4)8P#
M=EQ/W37(0C;=O5G248IBJMOZT/B=U8(IYX</-KF[L'@I*/DRC!,UM0!J(=MU
M9F6@R94[5>HT[=1WE,I^G/@GS(773D9#F@[=KIH>7[>B+E9(U\0^.76A[I#?
MY67.36,'6WLY'9+[_H\+I)T;7OXA$7=&^Y2>&%Y?OG8G]1+'C?2SJ_YK,&U4
M%XQ\E2%(?<<H9NHRWZ%T %=(#$Z1+D(1"I?YD01)<;P6=Z7EP7&;=?_X R<M
MWUIY^_6H -@;N+$=6Y06:NR4([X^9#-&GRY9V=6:79%!1,_:P( H"M/0Z1W-
M,CZ,W5,$W^UC;#6Z-[Z6<UZ.07T?Y?V61Y>P80I<(4\P^3UIQT9HUG13<O."
M8ON;J<!?(<((AXG+-LXM:>M)T#9G=R<+4?$"GYN5R<G?S:-68T,ZO%X"EWHN
M W'$=F&(2P%H-C&O(F XFKLY"1 -3Q33XM%9</GY[)809@ *G$91AZAUC&R4
M#FH\''L;AM FJB8;&2Z&)$4<&%2*W77"N$WX3K6H#1*[ YLF'@ZH46=CXU*$
MHX^2ATA2F]HT!V8708P%6BS90V]:DM"\B%<C5RDYA)Z0_?[;G6VJ28%WU6GK
MAE'JZ_KIY13,!O</[V?YO+,'SXT&7OP;7A:QN=MEV.Q3-N%(8%."#D"8YH8:
M)DCNP!+ECP$9)&C2U6%/;_\@O2:M]K ;\I/+MF(7;J9_.>!P5$%+7SV75^+;
MO8HFBBH5SB[-%+HZ(Q>RE)>!O$X$9Q"$C=Q5*HI4/T]&O84ZC>]_>AC?4B@B
M,S><R+SE=W-.H/'\F*7\^$'.M?:1-!EE%BBIX\I+I%X36BK 1/QM=L_E,5W7
M%Y)>J =])UH(A@.BKZU+54/OM]>C;CB\WIJVH=9,0(.A,U*=F):*M,5W=&/_
MI1I9FL6<>5N':XKFY???),JN7Q[@?Q03\RPT'9,/74R$\MW-2F2"&<]9H,8.
M+U+-.77P;-K K-$!^()J&]XAE6 OT 0MVKCUY@;/[^E\2)6H+;*+)L/V2QYZ
M"PKH6Q+S-G>((UE,9?0!A*KE>(LL6,#\MLPW'3_8W,N@4_F:^>>4_8.4<F97
MLF9%(WC.B.HZ=?)NU$C\)M*NHSX5&0-@VC4 >XY1;^1)427B8ULPTGYI9*^E
MD/C:E==D%,9_Q:EZ3P4KQ%5>WKO[,CSQZP_%)S\&\G05E.M&]T"_XY@"0>QZ
MYZ4,T,7:N^7Y*#\>T8QF$5LVE,JLNP3>@2P9M(^=[PM"<UKP1H:O3K-TEA!Q
M]Z7GMDBV!F*+6LYXRY0$['^2(!GX&^#];G[W# 0+[P+P)?VYD.(&!QX2(JAL
M_+F4L+CK\G9\ZDA3P$HR;R=Z<>5U"YLGW@J)JT<X['V<NH:>?=1E4_'ENV26
M<8<^#SQ+<R5%*:/L[+1&ZC>G?9Q'S\CO5 *R3 '_2J0G.2*9>08U 1'8PD'\
MM[]GD5XS(4CCM^2=S[A-G96@']YYES_O\%7&GK%2,4[E?%*(?257#+%5+$M6
MRNA1%ZKB?&!9HXER18VT36WF+(U,7Z66,BJ,8+10!),%ZD/SXQ20EBV 8\2A
MR;_F>O8G&'=AX>M^-9."6WJ+VPOZI@+=H-33SYHSV.*%#^H/9>N)RUFS:3T0
M@6"3P^M%G.3K61M3Q)#DV85\HN"25W1M0!MM9,626B\T-C,[P$93#8U$:Q]Y
M+YV*?M#NR R4^AX]BR:A^[43=MD=U8YO 7F$TH)/"A%S^+3Y0PGO7ZVY9?^7
MYM" S),?8@)*H=]-!^7G80]A^Z%^6>E0\B5P#(9L;Y<UT&]/MZ"@V00KU0$S
M73#Y)H@OJO*1^?AFM3PE*%OI87&F'U??=:,>KO3P7*6H4_GZ= G53FTRMA_*
MA]N/1+&[\1)%_BFD7X2BWR_/$\3;>^_\M/LYTJR@;8#%A&]:1&&@QM(U!:C6
M^;QP/\Y?JE?:BH;LBJASEPJVK3Q],\?G'U@;@JS,=72*;R)D\QU5LWGUEO#U
M=9OW,:T#W<:^I < +'KQ]UT8!(Z3;!L+D[-0?YD=K4.U.>->)+(2.R(K]\IM
M_X=Y^""=MY9^C8&%!M;-\A)_8"E3_?)\Y+RN&B]K,C9!%\85<&)M5X?PQ?_4
M7D9_7=B1C(7%KS_4BA-^!C7R^*:>8X&TC5D@GKT91-,E1HJ1<R6PVS<&Q+G'
M+>UF>4VV? LJ3=!3;YD*/C^E?NB& O^ADPF7Q8,[#XIS[&J*7SG+_:\:0I\N
MKL]6#F0"4^ J672)Z@M\IMCTSX+C=F1?J$XV$WC<I^=:RV[DJR9X9W\=CQ#(
M[L_D\M:Y%OR%1WW!KW@_V(-1A)2BB%&C\(P"G.%W?19(Y*XP_%R>%46(J2%)
M6G5H?7@!^RR0&,.Y:63DERZ0R'5\WDW[/OH&>A\ )T'CF"IT"V"(PDLRWNJI
MBEP"(H.6YAW&$49&V]U!"Z03<#CGO!NCL$ D%#$E=LR0V&.MJ-]^Y:R\:@1-
M!'%GG?H%R^@ ][- <JHIFQV23+$L4\MQ-IZA&^4IVO+3_8$79_R7+'X:;1WG
MGCTDE$I]K[Z*EV9W^BM0KSI.1%*OP:4J4IV$^QKN *YHH(]Y8A0GL]Z6E]1L
M^/JX:NSZ]>:F[(]2R10M[UXEB0?/#Q8+84#H+DV4*%T#X*=P4OW937.(E)A/
M!$-P]9B9.%ASH9$Q_)6MT>YDP1T[OS7Q.S:A)[=RO/-MD(UJI%+*"%V40&0+
M%+;2@27!&IAU-"OZY:1N%DA(N]FF;K_[K)M?5;2BOS"G?Y511H7$PQMPQ+2G
M^!O>#SJ.HQAAYF' CC35,\Q+JKO?8H?U\U 9"PH+DMQ]?XMF7MZKKJL3=$,Z
M0O%E%RA]FSOH,F\L?D.0F,%+BDA&G:#+ @R*('$UN0,N_)RRLQJ_/"X/$9V?
MZZY79O354#&A(<(S&><Z)ALZW;CG"ZNRO,F6<;_J0 B'H6X9S;Z-2>J5'"F9
MG%]Y^F(--T<T&@=MWBF>/'GRA%*N2HM?L0#J\(1V6*'H^H6)#O/(LA$C985/
MS;\2*EN]Z'ZJF59#8.I8T@N];?S&+KN?)@.^M)/T?4 >39]^AO'21-N:2$B=
MS7SY BC<@6^*DM:TPPY.&LX]439PVEZXYG; 3"';^;K3C[H:M6)P7H<_^PCU
M0-@29@;<"6FX5$FS0EZ)ZX8*_]!U1D)#_6^7U-!J'TQN50SHUE1(A,74W/2,
M=[@#?C(NQ#$)0*@28QU2M!LPYNPNI%F_U]BW[UY=7!!2\Z530*6%3%C_TQ C
M[('^F]B)DC#O@DC,/:OJB_&BC@+&X[%GI74Y?K) \6Q:483B!YRC:OWQ'#@C
MNA403=06A>\:?&Q:!/-_#^<O;YG_D&C3VAJ5=C1$=R5_R%"Y\(- [08E>2;-
MT9:R1-4!K"DD6I?\T3=O)SNT276)>3K#9%I_D=A;*SU-\,?[ID97\DMSI8MS
M#[]4$NO3L.>V'[SP4@;?1-AT)VM3*] '5;O DFX!>'(LHA$FC,!LRAA_?MC\
M:2E6>OF^YH<K323#Y,P=[OT_^/ON:8)NH]DPZ48_KK^7EXS2!)H&9#Z6K]1,
MMI/6T^QTS>6WM XN-F!;6V),?93Z]IU\E.=[[/4J"Q0(F0$3!S8KR;4CQ(C>
MD - VGD#RY1?!!$@HM=#])/]E/W8CBM_+Q4;OFU]Z&&2I9R\OOU!^ILN^9?F
M( 2;\DX+$D<V&#1S1!/U&7FDKRZYH"[9**+"GXSHGX)1%.R\JSR<NV\D7<E6
M3A#XPN?4MU*JV?C"_<&1\^JJ\5#/#' 7M*4R Q\8K4B]#]Q?4*)\C8&7P@V\
M>_R%*\W]_;1,^NO[=8D*3V2^.CKX'VS2WS+J^PW_A#I*OTK6[@KA]&"#25;U
MV]R<FU[.\H)':RL*G)6<2F(/'K;,)?DKW<T\?=,RVS+LFH,/:!L*@@9"8M#-
M16_K@)/$A89J%\2C[I+Y#DNBMB3"@P4Z_[D96!6Z46!C"'@^Z5&SG-%YF9%Z
M7.A"/4C>9A$/*&5UXOD 05>RWFH_.'GV0QNF+PJ?<L\Q64_.YE*:/7DWM=8G
MLO)3M4IS0_R1\-S+H^\;N]]I/&SVEGO\#1!C\D>0J[KQK>Z5FQ02/@LJ@811
MM.:Z1X@S>K;HWM915[N*_.RP5KBMR>0L=X;26=+I,9&9_#)GZ33'$OI=1B-S
M'^HC4R6N"W:@9?CFDDN>^5.7UV/T$T1W,Y>VQO&2Z.P J1-.IB?GYGC>I]P2
MD,O)T=>IEX];W#H(7"5!XIM'Y &QWG"7_I0:?S+!7Z;UZ9TFUP77"S&D@J/B
M.7=OW>B*Z>*2 ;54S;A]=[G^L="[VFWMIQWG@ 2CH']\[@07_X$+F0F/MSE+
MM2R/64JLX!NU-_(J48,FX$DDN)@>1!E(#PS#B'V_1T_JGU@;?Q<2_<)C./H>
MI:6PL&%.<[AW/">HR^9!C*7$^O45:$O(9A7-$-6'DY[HL*9L]>VV9M6X6?,D
ME?H5<'^M>?D]1"8I;["I,=5Y^9I]^3)_X_&AMWEWECE[T6PL !2D-J)HE^CV
M%!:HGW]G2QH!<08J2_P+0GJEC7@C/8,+1NOQL<P%DOF;)LPM$AP>/6YQ]5XW
M)V>NYIJ+ZH9T^1JL9:=NL^$%:APOJF=WT!4AQCRPVXJ349BV*WO:A;B)\)Q0
M//)A$?JDNBX&:XBHG:(Z,VJ@OEESKD1NS !Z)HD4EI=*UXZ\K=E(<.G3T#&]
M+;W/)G(Q7]0U,N_8Q3L*]4*5!V_804E9<S^ISN2(WKFZA(+=K-JE-Q-A-%M>
MEZDCY,U?;5HY5?.1:)^)VAW=^)DYMW=?>[GL+Y3ICE8%^9<X@G[.@0$E],;O
ML#+D-?)6;U:*APDE%T.)Z!=!-/6>FOWQW#-X#_66KU5RKPAC@O$-,B[L51C_
M8F%O6SJT8JV$<0/<:8;K'EP4#?FCE(%-98H@2;@OH<FLS(ST^]=@<<.7=@]3
MR7POOT?OA[9_/TIQ-[V1$(';W,J$RIF(,8?Q0GK0=(QLAV](,1!J[<2<>6$G
MGIV];=70)W[[?(W2^#O%,G_Q@(\_OK^JMI)8)32P0'3QJU1+1ELPTKP4]1$O
M6JO=4L=G)^ZA1NY_4^RQ)E.;Z\W5.^%,,!/O.B14'7.A*'_P,"C*=D-TWGD(
MSKW1.J)T\>5M/GN*Z'$YLZJCBB^^\ TNB_0AUXO9/?LD2L*,'$)B@3JU4Z '
MC:*6"(+(0-SG$"2L FB+UNQ(JS&54"T8VPP\[,<WG2&SDGWJ[/OBGPYX.!HX
M%K%A1@,CGAO)TL[3K^,F=KCJ,UF@:TGFY-S*J@SY]Y:W;-J_-F#S TM\+ 0F
M)+1;4A,%>J/0,481BR.I\@+C*$6Z <4\$UL,;[NKOW>JH<*M>G*W=;P8\37C
MTX/!]Z9<X;H<VX1^#* (WGA'>4H5(N?1Q?Y"6@ QQ) $G%AK4[H_6_PW \%A
MSIHK/\>CWJPVYA0XO![N>4*OWVZX>>*^7A!^\3%4X C9+@4G-DPSI5][U.5A
M_*DV#)R\()SE.!%4C;0+NSM7=RN_9D.Q:-0=/838\&[)#'QS2U.CF@6R'SLK
MKTQS87;CP6@X)A$E!9C6("THL%@ZE @YL'9O,L=S$;:Q'D:[]%0W=#J1=KVP
M?YJ8K>2=<>KH7*+0\6/@9'1]:QKE)+40"*$Y(9*H\4!\D2+@6AX@*7^HJ<7
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M@!,6E!-2[>DU2H$UXL_EKL=N')9D@;RUV=@Z !'#P^705'/*VX&$CELWR1<
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M8[VO]5[79R,O89)R9E:4EZ?$[XGWFYK&7=@B?CG3*Z)NG=9>*I_WM.X+J*]
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MQU,3YF&A;/A?[AT_[R(DX'Z0!:]P_KAN2J-0:A'I$+/(0 &:_9,_2X2]0WK
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M=X085O/E9_J2_]J#K'XC:*!%^1_KC2WZHUS\<7:$SW#=T_P<$:1*=A*U= 7
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M82'%]E$A3]_*:0]N[M&+6K3U&Q@E+4QZ\8S0GEQ=P1V,&&\[VOC4VU[SZ95
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MY7T#>*Y &?<Z^TD._1UE8-8-N!3:3U@?GF*\T9FC+AP9TO[R)+V@QM6F[H#
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M\)*LZW"A$VZ$VL@C0V][HZUQ:ZFD+!FGR^FEC_%MQXYTVM$CB]C%=;#KOF)
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MJ[ULJ?A$?3A_P/'5'3W2G+_A;F9?;?C!S(7%;S\//T_\%=P@Z)MVE@/2->6
M!'>G$8T76:DFKA7 3N\($.\1O[2#\9K$?0\N2330Q$V%6$QI[KNA*K+O1.(E
MF9 .!1F>'6V9RV<$_K]VA!%3QHCK'*@DMN@5JM02W1>8H-GUS8#CMY5?:4PV
MD00]OLPVE]YXJI'HG?-M-%(TIR^+WUOO:LB<H.:"W_,]8$]6,5*>)DV/)K(*
M"*=_&'% DO<D L_FV]#$V5IRE!6GYNSS^&=!Y%B^#1,3OPS1)/YC\]=U'Z!O
MH'F!0 HLGGV(:04,T(0HIIO=E5%+0%3PTKS3*,+$9*LK>(%R/#"0;_XZJZA
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M0R/!X<%R.Q]O,RS+>C3U]8)O*$:JO>X$96P)!%\2BB.NBY$SA2B1*:CC3&6
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MN".DV7MWF@E*JE\<2@L[$;<0-\?4#GY:A#VIJHW%GT;43-%=6=4P7\RL.UD
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M7NEI+E8 GND'2P6VH257C>.^# 2;QMO>K:[HC_1%E5L\V@"K3+\4O]LX]1S
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MR3A6XF>-R15N?H>!"MT4 "W$'F3+-5#;'4:"MR6\KA70KPJU#?@&9%C#&_O
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M)\J 7CT:4("*A][7NK.PT.EG^3) WDJ]Y;'N1VCVY8^"-XQ.6JE!$TTU5TC
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M7.=EN^B^MB'6TRH5]7+-LLUUTDYL+;)K;N;3Y)B.WH4@VZ.=S6;R3,D*^C+
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M[8^-"84]@O@Q5VG?&E%VVG8I I814W/&[HL9YHLO$'5&"<#B_5,$-_ $!?\
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M6Y_5YUOC*=$!MEU$';1QMSW*1+S_H,;QVG5_1$_$B"@J/F^55>)1C+MU]^P
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MO/?QL WI'S^[;L[[G[+!JR=,@O0URI?$:0S4Y0*&F86IO]1I+)^0(F&7G*W
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M3L#5R/OBS^-&";/Y'"W03S%J.7 ]X[N=4SM:^]2MEX-V.N]>ES[;'F\X=_G
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M-_;>.ZZII=\7C@41"ZB 2)&HH(B 6$! 2FPTV1B1#D*V(E(B M("A,0&2(V
M@( 0:2)2(M*4DM 1$9%>0DOH/:&$!6EW^=QSW\_S;#WGV>_[GG+/O?L/_L@D
MS*R9]?M]R\R:66U EDG72:_=FWMKOI9&.8OL+VR6?YXF_T&/,=Y'CRF/[FU:
M5"(%(K9KB%/GC:GY8;3A6C^SRNPZ; E+'YE.KO;Q.5 +U:*8:(2>>[)\6L*A
M6,T(]>5J6G31J .QU3IG787DOU+X\O;^S3F9Q\L[DKMS]!7$O-MF8CJ*RP8]
M7YB_1.]B9X(IX[0S0<.(%E^U%@/LEHD3ATLX^VSN/VC__$.")W"N*'X_LY.
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M5 -L:(UU6M(5[16&(Z10+;&V^[]7FJ4LF])MB+'G8HXTQ;[T;9>.?OA:3VQ
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MF]NG?CZFEIZHZDK3*B'Y'\D7^]^<? ]R(0*;N)!W!EQ(["*G#7$16WT.YHP
M;&!0Q0H9+F2[(L,UEN(?1BC".JWWD37+YLGCBFO+KQC3B.35U5+6WGC.M5(3
M+J1 <A&,G3RY;RT%%B'CQ78RF14X8^FJ6[(3G?8'9C+*2,NPZV_30EF?V:CU
M6<X./.@B-:F+&T '=H4X1)*26VW]1>$\RH/=@*!BHV$P*G[]0"-+;OF6MI Y
M$=W[JY-B9[B0]ZVLY+5:$E-,@0M)QGSOH:[-G>5"9 )HBYR&,.PDHDB9/J#/
M61: =S*)0ER(1S9'L8WGCWLQRIW_N)$&O:*E%* ,?[0!;<X#A>,=]&D&+TLP
MO8Y43)IKH\(VH^T!>+;S Q1O(T<V0+#^'/1W9,09W\.>9H_']4[DMWW-E%Z'
M\M2\VO9-D2644P/;>K2-*,3" ':T*"T))&D?6M$G&U5*&1#5\^R[779*VVO7
M;YN"Q)]_.']HD_>1YVK2@$,-HE]D%%'5NK<7A:<@ZN9==3YVW!EV.1B7K>1N
MYTT-#ZVVY&LZ@5*;^-0J!)36VZKUY&N8CKH*.HLU9'N3\U<5S%879!(*PBNB
M]WUU@XPQ\KUT;,GX#4R601[TUAP7HI7DPO;2BO_Q>I$9R9.=6C)(_ ?=.D-^
M\C4:/$1#^9U,W4%MI6<NBBM)QUWN?!+!O=4)4PU2LPNLR)9VE-YZ6&>HN [S
M&7.<'8<^2UD4NTR?;914I$T4YEC49CE:-09JP+:]IEE>/2K2%.(0]L77^$L8
M2F;MQK67[ G=ES?1-X$\GY$NP,N+KEYW!@@P-?645<[N_\JC=OV08B%D276D
M1]-T+G]PD.!20?J*0]J+R_4SUU?6H<Z<OJ&#[!@E+@20,:_V!DSI*@V)+^+Z
M2T.X$,I>&X=:,T8-TVLUGHQIOT%AX17'EQB+PS')'_-Y&3&TK!"L(VX3YAOH
M[BW36M\1TT?$73?OM%9M+K+JBF!_2;K;..@01.W_7< TWL<.E[S(,J4&F%_L
M8"ED Y&<R=_:K>ZVKTPO'API= HM>G.\B2SZX)VUHWCH8X]'YJRC= .JZT.E
M05U=FDR=B_^5PB[*4C'21LH\L5^]EZ;3%'=NLW;MJ=H[MW!YQ]M>["LL-R15
M?#(+'UO(332 RTEV,-TSUWZ\LHF'C^X:3-P\'2]YXF-YET*1S3X%,:FSSH:W
M['<GZ>]!$/,8#FZUC[.\W5M01P"L30 :9>(D NN_NSSWN*KFRA"&G6(V5%Z*
M_CB;(HM6I\+WHBY;E]!5GJ[.#BK>^/!"W^&M4P]\*TV5(QVUW5YKY,EO[WN4
M\^2L@NO*; N\7-Z2;11:*MF5M=+T:[D'[<UY'WS\_< IM:T.RAE'*,+"'W3.
M1K]ZE3*?DLF\.W/N/*)>#O[X/,^ AQ-VEY*>AH*KM,#+B?)'*88Z7E*/I3N/
M57C=ZA)54]U6$8EW=W?W=3\Z.+ H_^&3KWU4V-D"->F8)NFU-\;AOK>?9YUT
M.B=DI&TD\]]^>_S_LTW^_\L9E, H9^>/YS,$'F+G3H-$DI9.*.#\_1Y/\T8H
MS;IU?0]ZRX_7=0^SA0_Z^:JPPK-9((;ZBBZR0ITW%%N@R9Y&VIC'F#N_/,W@
M%^@]EKA!YFQO!B'3^AVV%P<:K4RSV.I$[&=B5NKT'?":SV;.8%+!?JZW;40M
M]["$89S?_.N'5^EO0#L54(G1,9_%_Z*PGS;)#">!Q"N-P=;#ED[C /,)4#P3
MT.L?ZO-CLQ%6-@C+WF;Y<T:Y\0_2]KU//__ZKN:CNZ8;4::S\X,&EX# 3$QK
M'EV785;>4=RZ17>D\J0L2^W6F\L^1_.S)!@M?HKS5T\GO^)+3JZ%/,7%7A(<
MP?(JXW:@?V.7@JI#PGE_]WG;,-_1D-4^!<*;T*&AH7ZUC(JEY)=/M7<DJ:E?
MR!>S:+PA&%L4L3&;UI?CV'JIA.?&J\,MN7D=AK;3PR:H5>$%D,FSP*A "@BC
M-4L[B<?0E]O0NA1992,1,EKV'/YHKODC WE!Y30Y.9?F$TVU=G*O[GA =V.1
MT/!A/K2( VV9PK.:'R/2/_ZQ,LHS#/F)L'#G1&I(BLP)X7U*)K84G/K[<Q%6
MA5DM0DE<R'Y\ .FR:%OZ-8+\J^C2I=DU#^M)C^8IPDUV$>8(*JEA6.0(C0L)
M4T8M$BIDT\E3&X$#Y]JN%")T=MJ4],8:AP7'G;HP;G=U&;H+<+6D!S]3T#A-
M8<*UEC:\0K>O\8AJ]N%VO+X3)\T#B;ZPM?O%C%J[<5R\.:?D3([AI<(L$7]U
M%RZ$WRB-&$A/;GV"I02M(OB!8]U#2 5!:F32O;(:\GR\<6P1LSMQ)%IEZUV(
M3K"XW97/0S?Q*>\<NQC9TTAU85M<@;MY91<70OAX/"VTMVH5V^O N<:D#+,C
M0/_SC>2(_)63_W&"LV]PUDS \ [LI\X?+Z)X_,^W31+]H&):B7]MG/S7Y+8$
MMMH5-G:1)L .4L2NF'@Q8/\49N @[D7%PO!CK5(@/$49(K37TY?SP<']#O_Z
M.-<PT]ELPU.LCG$F,^]KM*ZKV^=+>M-%94\&(F;QAK7=9:X/;[#4GHPZ!-X%
MRL5*@\QM2L[WET4'#7\5+WW4!%_<]&V 2DQA9]S7TF#QTWY[P+H0?(V.?>KU
M&:V-?#/K=S?>U2.KUM770<)L'[GL#?F8V=V:5%OAJJ'M,M$E1]OSQ)R<F>6(
M)M_DC^@C>9=,K3_8Q,Z7$&Q$6%!\@Z?Y1TY#J5]ID!(>BEJN23E'6WA"W>G"
MWP'_3JC0]T<*G6[6G+NA]^7D17/7(_WV5692&/>A3[A^K!' SD9U?\'B-NI\
MUFXX.9V,"+C3W6+O=7<L-G$P[T)@VS,U^TFYH'$W!7/7/=/362GE"&U7K8D'
MM6\IL=:5Z**A_O+%++L61T*FUG9,+T*294X_JTVSC:7F:/)6]]_<;)"GU7.A
MX(7%%..ZZ#')>\]%?)8.NR9$6K;>>V3+2]_9X(>K<STXJZ79E7[E4[>7VN*Q
MT--/PS^/EQR?RWFUJ7?3M>2K']Z.JF9FKI&F2-=SKH8[95\R'"2;NA!=27?L
MVL ;7J/8KTM5J8K88M2!V0]WRD(X][CK8]^U9%5[26GO>Q\I9#GJ%>&C-U>W
MJZ!7=6>K#=,<U*L1HP0>0+ :OV]U:G$5Y1G7O:HO"'\\T-#S$>EXM>;9=FO3
MH.MZW^Z_]!8Z'VMJ+VGJT+TQ7YFW-"!\XN23^+,3-@IOF"#?:N+VI87*>;R4
MFW4%I!19R?>SN9#;FL.<6"OS)N5?\,L34*Q%!< OMS=Q(6,.!IWL2^"_+Z>O
M2DT2?C&GV@/[16$QI75-%!O"T0.9+A0[9@>E$5H"A8QLUY<=0-38JJ1@/L+X
M1$5 ,=_P13)/YT;.GTR0+2^G[[@D?W/0JHAVL_Z<F,D-^]]>/U<])#M09?X*
M[=3-V<YR9[_7T,YW+ -H/4^56V[<+>K:EG)5/D5G_UW<XZAFM_*7*4;VTN&/
MY3[?<$K7C52S-+NP-33O8>VAD8VE32S9XJ9=B@JZ1LUF>9A*E865[_/9X9.9
M8LY:,S[%@V7S?>JS2W/^PLG=430L TDG/&1I4R..<"$WZ?F9F9E!L>G.-$1>
MQOYH_;.#!@KE%8X6[T,$O5EGHR'5&EESZP&45@&6?G C1K:\V!J[R\HPA]P_
MJ)<^7^IV&&GM9;RV-N![^(7#V)#[0^2SM&*3@+YCJW%<R -$]!DO-J!4%#GL
M[\?J<[$=K3L_$F/296I/+&]I626_VN:]GO%@DVJ3]"O![LHM-<13[:2[BF&V
MA]X7=U3(T7=\G5Z>1C@[.2#EGF6>CH\3B4A'QYJ%/W<S';.].-ER_%VRLK)#
MJ9VJB>?PF2$F%V(%_6V&5(2OL?%AJ-%E@N6)VU BNIT$-,+E8$F8G9?7Q)'B
MB'8NQ.F(QEP]]?8[ 5GFUU/2H>N)H2<<OP?RW[?-GXBEGZU[L.QIUJ?X^0=I
M3&HB?J((EBT["#NV2 31J[?-E37+""*JA\"&;DUOX'UJ\ M>L/H_O\B?$MR
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M=M!AR@44;/[!V<Q@4 A]@=[Y_S\7)#<G ,CHAF"1V+[T.LQ6H)F&O]$Y1A/
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MNZCZ!+0*4BX7Z7;IM8+HX0LC_(\K<_[K0_D_O_H<1M+?DH-G'SN4N!53-RR
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M&/"A3F4&J)B5G+*5W_?BP=,GM?S!H>UM13F&O+I%WU=6;_'$%KE=./CATI'
MFRF3$',\IPE:C*M6)/N/;'O$O,II33D: *_5.ASX=1MUH-;#2>-^6PO27=!#
MJ$TO-S)8(_^B_6&<>BH&')!AEI X@OT(5Q-Q>V?R3HI-? 0NW#X%5G"SW@.K
M\#_:>\^@IJ)P;32H@( TZ35*1YI212!1D:*HB(4J1 2DA*(4"1*R$94J1$%
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MH_+3"Y:R!JU?<&RXRN J5S&4G33%_(7,H33V/0[9HA3GI[*-I9CQ&.,8B"K
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M4<M)17L^(@\"D$EU'Y$:Y J18SAA\-L]/ [.A:W#"KCR!/=S[\3,4L_$MU0
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MDJ^U2S\ 0KZ4A*:O1%FF6##=T;,F0:T'LI'F^P../%)(W&4\,V!KM;Q\^W2
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M84^[&]U_#/O[4C:">P^ZQW)D>/63("/BRAV.DQMG*S=\'*7.M6]E+10_FH\
M1!*FHLP'?[P.7X]OS8ZZG5Z6G'AK1UI0&C9NF^<B<<(LEZ1H24H%)*S,,D]
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M:K]UU#:_EO,Z/=2K0Y3KTB,UHY>13=,KC9RCD!?;&0KA*.+CISLV<C5YK99
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MG0.?]$MQW-+'5#^-5=ILUZ!S=E)]X)-])S=VMB?0%B$]FS0*C3::IRG/>YZ
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MQ9X8T_4RG#KC)&L'+5&!PW%,$ @13H4"X#ZY@92.<%^JWS1"G)2<,3MU%>V
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M+:L35I*KN$;MK8(JY =3\"0"7$H+)@]D!$6@Q3<>T)+[Q]?'/H9&O_(8BGY
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MJ,3"K$> VK4Q+=WA$Q+)ML7B@])"6M]13U^Y:44ZCD]<XXG[^VL*I IC BW
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MZ&Y*.EUA(79!OL).-^C<LWNQQ8T#,:9M93'\Q_X+?3=[#LVX AG 4=A0=*'
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M395*[7@C%4N+SO(9#/4[S*/9"#),A0-?^,B2B>"UFF8Z *)K&E7H"3XX&>+
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M. .^;%%#C\]Y@J\*)[]U52R>ENEE(^XN]"U= MD(VH4U'^=WLEF!/E*O?\Q
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MLI)@[X/20%+3MHE[_SMW2@GZBV=%B24FS+F\/HG8W.@CK$[Y(&)LF(Y_=<J
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MRALH#I]NX<RP.$NXK$,RM]!OZHS,8$H]0ZP]0/_:"4A&CAV%^(?T)P:>PT<
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M+CPI=BJU1RZNR$KZV<CR\AT3#&OR6*--]Y%FT1LCCH<5N1"M_L[ESUT)*),
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M#]3*_GQ@N/:?7/?^I^O?NV'>Y.\C$W8+:109E1:8A+]^;Q"EY\8I1+.+XM>
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M+"L::LIU&K0*OK]J]%NMYXO21L2E(X:EZ3O6_!]'P16$?.] \(<J"(3,WZ:
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M'#I,O.[YS1:GI<XD*N5]?M^M.XR##<UEBM^T.!>U#!N31%=?%G!/\+9_PBN
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M/ODR6RG#R+ [QX0.NQ=4PN&8S87*\'1+SA:,M,\[=Q]YJ[PR>)O"<@>+\90
M-EN)8\(Z7.HPR=.N0D^$*4R5W&'W%'RY2S9N_$9NR&;FZ^5K[VB\7:/"N&9K
M +^#I/3B=P.E-(,M$(AWEG6W@"XEX=9^^$:)<4?E8$QHK.R*>L/[FOR#O7^N
MR%[%9! "P+.F0]5/*K,)@>MI7@VLVN?N>"557-)-?<%PDNE_]%:*+-?J(/30
M<(MT[T717DI[^-+@>C*AK7+5G(J=*1ELP<H##SE2<#FO4!N5%'OSH?; ZAL6
MM^!VZB<5N[T]S[LTJ&5D[E4A/ZOB'>'?;X7G8%@P4F+<%J@?,>=!#4XR\Y&#
M2ZU@)'D)-.B]F,:PAANESXQV=V+DVLG&=3.CX3%J0Z/6SD<[$5S"LP?H#_!F
M'R%Y [Z*E.;I>Q7LNB-;(+$DY(4/-_[[&,EI!)=.\U\'IV$"2;-%_6"YE\ H
M#3H[T5L"SS;V=7C#]BVCJ1TP/^AU\G3VM..>@BP1.[GYY%%03/2?B9J5SF!F
MZ19(5&D9*H<^1NE[@G1B#/<ZG9#HQ1_\_&+/S'P8.9H5>^=E,>O5K4_HWPIY
MW7O=1M0]OK?Z"87 GS5'WP+=CX"(L8-I:VGT'.GOR=$5R"S'5,[X=2M$:F#
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MQ8(@UU@SP,?U"Y/=SJ\65TQGAA[>L(!)O6UKSIW%%BCDI<:_X8TN9U8^X:=
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MX3<M>5=W'<05J]_KN+#;P\,>Q)=ZAM?X-_<-O%Z344)=W *E0#F)0!Z&CI%
MB71,_@*G$:1^=_Q"=FO=PD44H!Q>^0S&2,;8A U*NGA=T-6]67FD[VCW7 *#
MZH&%^/W/"F-(MQ3;>T#3 #_6NJZ!VC<>76OG_DEE7_GB\OKY5+I'2M/1H9@N
M?XF?R4.[=X#BW6Q?.<>'5UZ]&EIH$!6E+CW%&;4LU+TE=MG0=N[AO<?JP>9_
M-%@/AW$M'OTP8%\E$0L<$LW W$!DH/6 QI=S0-35GNXI5#3&HK3J1W-8VU33
MCW;5J'/AP1Z-Q6.52#)C%''X7-=%DTFH1'BW)_>V8(;2@DFU.<3S9:^GW9%)
MP>N/\[2H6 E >VCS[W8O%;-XGU/AU^\V%.IW%8::B PT%^\[NYHHFS^N"/J]
M#NA/K\;6">; (JTR67@]P$\F>?T711.93/3PTL6W\I\TOGNQ;'JE.8-7U;X>
MXI30E\TH;]D"S65QO@-1W#U(4^)FY^;]WQA%)''89G\:D2)M T:&^X<[#934
M$.XJ\X8N9^J (>URLNJ.[W0*W%D8P+)\Q$-HR''DPE(Z6-4RPUP"DV-CE<D=
MN)!>>;D898O4_)[>>S+P6D!_(L$2)/Z50'UF:LN:%D@D<^5X"*#F&73[52^
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MAX5_$1L3^Q*HZ%=22HUMT;@T'I,:[Z@^K*(3[K'C67[^TWWRF9M_>8U"Z4<
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M0>SR>3/IEWMVK*+M3=ZE10^1,W?]](OD[ X6,.:2-XJ8KY0&XF4 @\L$M>>
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MI00%$IJ40((2/DF;_&=F[LP]YYY94^ZZ9=;966]68'\[>[]Y]W[*%V!/LQ=
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M^.>Y_0\;UUI#%]4]P*VCD2'-<OZ88;%3 ^@09A7J%FHVS@L@T_58PS$HOHY
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MYQ]"RZ,"' )?SK=DA6_F!.JTR*%%B'NO?';$\C3@V[1*9B=+&G#Z18+DX&^
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ME*O]K:6RP#.],/'0=I38FE'2]$B8:;+-[=KJH9A 9-7%1V2PXDR9R.WFJ><
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M5"!49XW6ZB(*+E2)7']XBC!(K4CZNC5\T[S*DX,):B:FE DB:O-7%6N$#9*
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M47_A_L#7PH-#&!VY7(-''_X(0%.[OC ?=DC18P$DZM &"@<=Q*2Q5-O;I1N
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M.]_@(P//,\>#<X8(#2_*O_>1;4]PKT)FA6D\5!39@HKJ@\HCA.FAB$N XVL
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M90IW/C6_[/LDU3S^YI>G=)E:?F5YK8/*ANFZBPQA]_'@CF0Q;Z(4_ HL&2H
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MP5H<<C+7.K>V##ZGRF68KHGN@$/8$+>SC7UH223&NIZZY>5.>?PX0FQN[=9
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M,3[&G&S)HO>8?CEAE?KAW0^BJ,9JPO*@Q5%BX& 36 -0?M8.E.9G785'PTX
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M<T^#<@[+^!ZF+6PU&VS"CC,; "W-'JY%>C=FNATG@7/_[;H+"8(G2#QY&-]
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M@K@%Z>KE U%6<M?S.YH=,J]+'Y*0SUS830]D2#)S]66-QJ5>8G!>V@^KW/(
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MAL>WWIQK[,Y;4H/:J=#CAD'X>@.I T\34XVD5*7;GC8[W9+>N00Z,C4TTT;
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M3$C!N%EYD-P0^<(3A91YY=Y6FL:.\',*6TZE7[4=_&W D03/A%*Z8[ *'&^
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M U/E. U;6)5YO2V;]#L$)P64?.#S ;ZQ/L-;,V_=H47GU"^[#UFKVJF8((H
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MU)<X55[L.9J)0!%BJM$V24L@DTP6OHHS[ %'L:_SNE05N6UX*2^.+)/0O?0
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M3*-0QA+9V :V DR-'#82@WLE: E^F"M91?DC4 MB*=1N,UMFH@3DF61*[[D
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M*GVLP=CQ&WK&*Z]/@M<A*%_DYH=5T,HLXE*PV$]AY.L2CS3T(0Y\!.,PB'"
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M%GTK64=9$:WTH!8?5/+;M*8UGPP#=_XP$ ],>]- UZ;Y[R HC]4 V!7:EDV
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M8+_NTW?UXX_W5<'8=07&._+MABS%C= :J8&J'7\MP*8@P\R+TR#R$@RC1.?
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MRC>8/SZJ_Y25Z!89!XXGLIN"O_/T#$W+C6(Z$61+-?!%@E8Y]1=0J0<:_2[
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MII/DR'W;V$BF-)(>#R".8[4%":0'"<,I3&C( BYQ(M+$V(=X8K"I.04K<2]
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M%7H9J<[R=B*.KQ9<R"H@N8HY?_^-S5=<C?M+GO.OV7P^4YM42DDB8$ YU:G
M!.(HB6&B.UY$!'$>I5:IP&<(,S7#:Z.+CF++-N'ZI%+',A/XG%DR(ZRQL!]Z
M([P#^X$LB8TN32;%#VMU0*O/\0YP]AG$#F!UFU-\CD#C9AD[@&XO[]C%,X>I
MA;?>0K X\?U(<"A1G$*$/ E3&4A(!8H(Y<C'R-)^,QUZ>I;<QZO+-U<?K^ZN
MWM^"R\_OP/O__/7J[N]N*^-9%E$8 LR!2?%PI;Q!*B;8HC-J\;SO4RW!%A+;
M8GJ.=I4ZYU:QW8V85PZ%\B%[>I<_DFPQ\^(D(2Q!"O;4TV9>!%.FMI9^PM,
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M,,@I3SAF.581[1ZDMY5E@9?!'Z,-DBD^1+(2HSU!=LOK :=C8/]W?Q8:Z.
M.WC?S4)7%^9C.PM!Z\)XDA>Z4Z,3AK';-_H0=*:GH]=MW"O=O=5.YNKY[:-<
MZK?=PS^6B[]7W\UHM'J>)4AKGD#:C^"20X2X:0NKW3\<(T3R),:%(+;%[GK&
MF=JKIX4*-EA!"Q9T:.UKWO51VZ]5 0D;6),\N7*J?F?!A'<!O+Y[CU8#S\+
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M]3\79;7ZI_["Z-_/,L*HQ 6%.)4Y1$G.(8DR!7E,%$:$2\:XM58Z#3TU_=R
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M<\QK=AI_>@=J'?P[\- :T,0RTP,3W-[>;O-A]TX?C..!Y6%+[C_VR#W:A=B
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M2NR9S_BNEYZZSLJ?E,FEFZD\DK1@&/(BRB&2>089PP+&)"8*48(CY13<<CS
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MM^80M-R:![X;^QQKG :>6SOGY@5G;&!!N]JZMSW1VUD(&A/O]L.D[\"QI7>
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MFALU&5&!D14886_ 3ESM6S4".QQ.#N%K<90;"+61:68JP!Q.<P,!-]%IKC^
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M]]]!JPQHM %B*T$2H<PEN.:W(391S]%A'MN@.X362 @:'8!6 G1:-'TQ6SU
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M9R<Z:&1WB$K9@F\1_1L!TK&YS0I-G_I%6U@=8GPCP#M1:._*+ZU;),\1IL$
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M<H'3.%>Y:TE.X"V8JB;G,$G;<-ZT&V'W2@X.[L@OYJ-L[1;5;M)C*_7!N*:
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M*CA2,.=1#E&<<TA5AF"28H33@B8I(2ZD-*'L<R.XSM#8Z7X#.NU!HW[[-.\
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M#%<B^YH9ATZ14/0W%X&8<$F('M2F24J<,F >28H>:)R3%GWW&+#*^?&7SZU
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MTH9M3;..%<D)! DEAAI$C  GF0(I3#--!,XRZ$42_</-C2H.K(W8WEP_FKB
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M'BI7LOJBVDK C;I7J[+X:;4XU@_J37UBM*X -)'P%_V#_5HHQF*>"&*03!A
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M-T=N?#0&\B-STZFC,DV15&UVU+%[Q ,R%Y :]V#,N<%?]T#,!4@N'H2Y=/W
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MVZ_'U:.^?7V?'2A,7JR*K?I8_%3R@WF_K>X*0R3UR=//:KN(:8YMZ@,PK!1
M,J. D@0#KF3"A:88,N73][A_.*_G?X(>R)]]&Y!>0-/MZ0^'T<@\4!L**DNC
MO:F[<^)]\/FKD3NA$E:/O'_(:17)G=P_TB1WNVI@Y[OU6OZS6"X7,I9$J528
M@"#- #(A'B L8X B@>PJ.Y<J7JS4UHTBVMLZ?=%W#8ZW(U-!:Y5G3[@6(B(@
M37*B;-_H%*"89H RQ@"3L95@II#E9/&H-L7:<#O;C %5PPDO!QD?LIN(J[MB
M5>VRF)5-;<! '&4&D::"@UCG"4!02\ I8@"J1*:VAX]FHL'QW<JQ _=P%-LA
MIL!0V4,=5Z+G]OX9@L?(;YJ+3Y]_W[X73H9MN-?>?-I.>2]<.FIQ]_+OPVC_
MW2];H_Q4E/<V(V*K ?CV]L&6+B^$5E1!& .=0FZBQ50!(B$!6!(2JUP+E3*?
M->+YH>:V4CRTU#ZHUM:;J+;6[W'M =CM 0X#V\B/]$#$O!_TRV $??1[AIN4
M#"Z[_9(>'*ZX0EWLA/RZ;;?YAI7W[Y?K?]H.FJKMP?E2S_UW98M=?K!?"TDS
M18C$ *;81)K(3 $S[WR08YWI+*<,0^TE<QC,M+D14D]7A+JG[DUD'8RLAU6'
M7%N8M^^X:RMC#CVU49SU-3+.#I!$"S/_;OSW.K,Z,E^^SH0.DW(+BGUX";@P
MYDTO'1<4UI.2<V%'&-CLK%BM;='7AY7A255N%R1)M0DC,4AD;-;.4.: :<U
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M;$L(! '** =<H!@HB2G*4\(R[+UI,A+FX^^HF!%&AEN36!%JOM]""]N6622
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M$FE[RG"[3D$$ IZ*6"6"Q5GF)2I_/,3<WJ(["Z._61NCRDC'@M\>(%W3W]?
M,WHZVPN9 5GI<\X'SC(?#3-QUOB<F\=9X+.?O+:"HZ?Y6;6[O! BQS$G"F"J
M)4 P48!G2H$T%5S'0F"MN<^#[S[TW BANX'?W]6OV9GW) N/2?&MI0@)]81E
M$E>B?$71@RM@(]4S7!S^E4H57&$Y7X7@?(>ABG*[?L\_U>UF8Z50JCVRVY6L
M%.]/__F'^:EDE5I5N7]5XXSF*:<4L#3G-C<+ 84I :FB1"FH60J1GP1=../F
M1HX'OD4=ZZNBM.[O=8^6[3U;18<7#0^S@LZZ&[>^UER.S+Y33>, \;WP> =6
MZPMHX,3R?N&A/=8#'&&,H>?7ZO;@.Y'W=[\>U:I430Y\H0DF!%,!!$EBL])-
M$D")@%9B#.8P%6FJO5:Z%\:;&Y&WYN[4=VS_"]\#;/T(NS%L0-Q&S^$VD'4:
M3S3&1K\UY@9(UWD"$_@$6_^8$Y]@<P+@^ 2;VV4#]KD:=?'2VLI6VT+(-+;O
M1_:HGLQOE8 O>V@/<#(H>"HP!Y!E"J \T8 S>_)!)(SB6"9QZJ1][S_TW,BF
M,;XNB;36@S=OTSCJV!^U#GAL9OC-AL/>TV@8CTQ,K=T=?*WI)_$=(FG@![3'
MMM!H@$^T[^,#?*!]G$&0]6[4^-UQNIV809X>;+4,N\.Y]T)W DV0^H]_^U_M
MOYC_<%:J?_M?_P]02P,$%     @ 98%956;=X2L<X@  &0 * !4   !B:6EB
M+3(P,C(P.3,P7W!R92YX;6SDO=EV6TER+GSOIZC3Y_9$5\Z#E]MG45-;ZY>*
M/)*JV_8-5HX4W" @8U!)?OH_<@,D01"D0& G=U:W>[G$ =P[AB\C(R(C(_[E
M_WZ[FOST-<T7X]GT3W^@?R1_^"E-PRR.IY=_^L.OG]Z ^</__==_^J=_^5\
M__[BP[N?7LW"ZBI-ES^]G">W3/&GW\;+SS_]-:;%WW[*\]G53W^=S?\V_NH
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MSJ9QP\'BU>S*C:>C%#-3'.7 A?3HGGE<*M2AMX:[K"Q!?8B/.31'X>,^&<.
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MG9K;$PD?MIR[<1#WKOD&(M9'V%WW24+>]HK\ ?:IT\H+IG")&P;".X;QAPQ
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M.ZFO'>X/9:#5'.6*,A@O;OJ(_-F-IT49Z[*4HH#K\N*1#(3D4.9;6X2=* -
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M^*R^QL <1&M?)[(W(6UI1WI5+G)V1&_:HI8.I8N.(+]-T TFF7-4:$V >&M
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M9S>_3"4BC%*D$@S&B$(BRH-)"([L<J3<*J&<?@:LK:EI*/'6B\X?!=41"F@
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MC(>^I/>[C4=Q=^)EQ[(+_L5-5FO@3^/_6[G).'\OG7'68X%OFPQ*+Y4-'O=
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M5TDD+J-";P.@\0%4KN+1:$'SR'Q)K&@<5#0X"GAZ*!P91^<#@'2  CJ TO9
M_H )9[_7';9]P&FE)X>#W Y3\]):YSK=.M0=%V2Q*K#2IA9I%T7]P>@0C2\:
MB+\#&+U??\'E593EW2S$V?EF8/J6&1>BM.CK5$\$Y4H"[X0"FW)1L20=19O<
MV)-D35MRT@A0XRFB U1=7_TWSFXA@] AYQ ]U[5_GP6GK0"?/<92$]BBS3.6
MA[1,/%]W/+/H2#%W )1A80S%HX\>&409:%^AI#,U, T2R0.QW C'VF"GXQ3]
M6!@X**ZTCT)>PG.IR[^K<%_-U[,W/PCVB4[C\ TOUK/TZ[(^>OVZ&G'\V\"5
M&@V%.X3/D4;%79'PEBC8%E?^?;;^\N9BM5Y\Q>5U=,'$4C1S B*S!&$,DFX^
MPR%E*96VRH7['??&??3X'(%-1\<9YVCC6@8LU2[FO+9@X3F"UHEN?HTYW6]%
M]Y<?'=<"-WN-D-M')WU,!KL[_\I'X1V3D>AGD9QF&< ;0D M$(Q922L9#L'4
M7W&$W%ZZ?6Z$W#Z"[@,HC[23<DQEAG2_FQQJWBC2-F*)U&P]2SY%3'J\,/]+
M&2&WEV8'C9#;1\Q35X?=-AX"&0\I"[:^,1Z^71D/V[)UGG.TCD'6GOQ5P\A
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M#HS59Y/W,2>I-6-0)*M![MKF/C())4NLWIIRC1H-C%*2-WJ+SN99J%$5T@'
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M;B3M= JXU77M]C8G$96P47/(6(NT"UKP3A%C/@7C-..Q56?O =1U KFQ(#$
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MPPA@NLU4\-/P-VU+MY/X!QT"I8/MLQ>#OX2OV]-'6Y^=S1H$KZ.(HM$0@Y7
M4&:=:M6I;O2RZS""I[4A>\3>_;=>)P#"Y!$]+O3KY2+D/\+W>V9W+HF$E@S4
M+CG$AHUU(JJ$Q#!%P9,+ZEXS]5TAO9UK3-R$^A3Z78PO[ [.R)V7TKOK0M2@
M-2]*9L@\."#3VT$LJM#VLY9))1F+;7KQ/T_;M!TTIPW]'::@#B#W*J6+KQ?G
M];G9#TA$I-EE70=^.\>;A[7+]>S?FY_O%, 9;5TID*Z$[.NC6LT]>!=HOPD;
M0^"E]F-L LRQ..@T^',@LA[.TCZ]FCN ]VUFSYQ6*=?:I%)[*BN;,W@I!(AD
M<WTVXI-IU5'KAHI.XT;CP.Q@<4]ML/UR4>V%]^7CORY(CF_)7#XK,MOBE ?N
ML=1G11P"&;=0C"T\\Y+-P-?U#S^[TYC/<1@80XX=G!AO%IL.%)M7C3_5@_ S
MJ6=%QNQJ=<:8DQAD+4&1'%20%KQ(-5LM6"ADJ+K8YG7!$T1-&U!I?)Z,I8P.
M<+534I?<"!$,,X'<G<#J S.F(+#BZR-:Z8*6T@0\K5T_'%W-;/K&Z!I1)7T
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M/L#S>UC\'UP]8@)U,#HS.E)1$A.L^/KN2A%>CJ9$11Y7$IW@\O3/'WAN:C.
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MT[#PZ4?G'8!T@ )& *6-BW*UJ**\U[BR[1".N:!!G\%4)U85XB@4$I1U/,;
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M[^8^?4^^V:I68VW^\.&92#X$Z^AZQ;5;[VTBQB0Y:C$'44PQ7OA..-KGJYU
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MXL@3XRKK3EM>>KV^#V!DV*E[8S\%8T#/T,'DO4M@8YI6MX\,=VJ9Z&B( <W
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M1KNV /;IR]U: :WJ0>2FY((;[(L0?%^1_QRE94<68IJ;[55<U1YRH*P8*?
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MK]U!O%TYGE34;U7H$,LGMP^K/'3U[<$+C<5GN%[I+WJ>_0%02P,$%     @
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M%T>G*:?WMDA[GN?*M&.H[L)W?LOU+/1EIQQ__;$EZ5$&1<T7.6\G4C->"Q7
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MZ@.#C-$4D1*B)LW.*8PK<+M.^O\YZ9L;';]72(9 M4"D2B^S?_EJTPE[=TO
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M+FAT;5!+ 0(4 Q0    ( &6!6556L/T%71L  ' \ 0 1              "
M 0BG! !B:6EB+3(P,C(P.3,P+GAS9%!+ 0(4 Q0    ( &6!654KV(78OR4
M #AV 0 5              "  93"! !B:6EB+3(P,C(P.3,P7V-A;"YX;6Q0
M2P$"% ,4    " !E@5E55)D[AUVE  #Z'0< %0              @ &&Z 0
M8FEI8BTR,#(R,#DS,%]D968N>&UL4$L! A0#%     @ 98%95:0RP]*CO@
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M+3(P,C(P.3,P7V<Q-"YJ<&=02P$"% ,4    " !E@5E5BYBP)SIR  #/I0
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M,#(R,#DS,%]G,3@N:G!G4$L! A0#%     @ 98%950-GY&O):0  (HP  !4
M             ( !A,(, &)I:6(M,C R,C Y,S!?9S$Y+FIP9U!+ 0(4 Q0
M   ( &6!657T<2#(H4 ! /B3 0 4              "  8 L#0!B:6EB+3(P
M,C(P.3,P7V<R+FIP9U!+ 0(4 Q0    ( &6!6564'$OOL7D  .:=   5
M          "  5-M#@!B:6EB+3(P,C(P.3,P7V<R,"YJ<&=02P$"% ,4
M" !E@5E5.&PNCL/7   %' $ %0              @ $WYPX 8FEI8BTR,#(R
M,#DS,%]G,C$N:G!G4$L! A0#%     @ 98%95:4@B1X(:P  <H\  !4
M         ( !+;\/ &)I:6(M,C R,C Y,S!?9S(R+FIP9U!+ 0(4 Q0    (
M &6!655R4^)CQ&\  .R4   5              "  6@J$ !B:6EB+3(P,C(P
M.3,P7V<R,RYJ<&=02P$"% ,4    " !E@5E5 !)F_6,S 0"*B $ %
M        @ %?FA  8FEI8BTR,#(R,#DS,%]G,RYJ<&=02P$"% ,4    " !E
M@5E548DXXVS4  #2!P$ %               @ 'TS1$ 8FEI8BTR,#(R,#DS
M,%]G-"YJ<&=02P$"% ,4    " !E@5E5&7H0YUK(  #5\P  %
M    @ &2HA( 8FEI8BTR,#(R,#DS,%]G-2YJ<&=02P$"% ,4    " !E@5E5
MTEY7@:AX  #QG@  %               @ $>:Q, 8FEI8BTR,#(R,#DS,%]G
M-BYJ<&=02P$"% ,4    " !E@5E5JY3:63WT   760$ %
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M &)I:6(M,C R,C Y,S!?<')E+GAM;%!+ 0(4 Q0    ( &6!654*MG%.0 @
M $,J   6              "  <CR& !B:6EB+3(P,C(Y,S!X97@S,3$N:'1M
M4$L! A0#%     @ 98%95=7,<JT]"   &2D  !8              ( !//L8
M &)I:6(M,C R,CDS,'AE>#,Q,BYH=&U02P$"% ,4    " !E@5E5K@Q9L)0%
M   ;(0  %@              @ &M QD 8FEI8BTR,#(R.3,P>&5X,S(Q+FAT
7;5!+!08     (  @ %((  !U"1D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
